Annual Meeting Program - Society of Toxicology

Program 

Seattle, Washington 

47 th 

Annual Meeting 

& ToxExpo 

Washington State Convention and Trade Center 

www.toxicology.org


2008 

Dear Colleagues, 

Awards Ceremony 

Sunday, March 16, 

5:15 PM–6:30 PM 

Ballroom 6A 

Welcoming Reception 


6:30 PM–7:30 PM 

Exhibit Hall 4F 

25-Year (or More) 

Member Reception 


7:00 PM–8:00 PM 

Room 601 

SOT Annual Business 

Meeting 

Tuesday, March 18, 

4:30 PM–6:00 PM 

Ballroom 6A 

I invite you to attend the 47 th Annual Meeting of the Society of 

Toxicology in Seattle, Washington. The meeting will highlight 

advancements in science related to the numerous areas of toxicology 

and will continue a familiar structure with many and diverse Symposia, 

Workshops, Roundtables, and Historical Highlight Sessions. 

Presentations will also include detailed results from primary studies in 

the form of over 2,300 posters and platform sessions. The Continuing 

Education program will provide the opportunity for you to learn new 

areas of toxicology. Despite the familiarity of meeting structure, the 

Science of Toxicology continues to change, as will be evident from the 

numerous presentations. 

The Annual Meeting will again provide an important networking forum 

for the exchange of ideas and identification of solutions to the problems 

that you are dealing with in your daily employment. ToxExpo will 

provide the opportunity to investigate the latest in goods and services 

that are important to your career activities. 

I look forward to seeing you in Seattle at another successful Annual 

Meeting of the Society of Toxicology. 

TRIM 

George B. Corcoran, Ph.D., ATS 

2007–2008 SOT President 

47 th Annual Meeting & ToxExpo

Scientific Program Overview 

A page reference follows the session information. 

TRIM 

7:00 AM–7:45 AM 

Sunday, March 16 

Sunrise Continuing education Course 

1. Mini-Pigs as an Alternative Non-Rodent Species in Toxicology 

and Safety Studies (p71) 

8:15 Am–12:00 NOON 

Morning Continuing education Courses 

2. Introduction to Pathology for Toxicologists and Study Directors 

(p72) 

3. Stem Cells and their Multi-Potential Uses and Potential Dangers 

(p72) 

4. Dose-Response Modeling for Occupational and Environmental 

Risk Assessment (p72) 

5. The Use of Transgenic Animal Technology in Toxicological 

Research (p73) 

6. Process-Based Approaches to Modulating Gene and Protein 

Expression In Vivo and In Vitro (p73) 

7. Basic Embryology and Developmental Toxicology (p74) 

1:15 Pm–5:00 PM 

Afternoon Continuing education Courses 


(p74) 

9. Nanotoxicology: The Science of Developing a Safe Technology 

(p74) 

10. Clinical Dose Setting for Biotherapeutics (p75) 

11. Use of Data for Development of Uncertainty Factors in Non- 

Cancer Risk Assessment (p75) 

12. Essential Informatics for Toxicologists: Knowledge Management 

End-to-End (p76) 

13. Epidemiology for Toxicologists: Introduction (p76) 

Thematic Approach 

Session titles related to each theme are color coded in the Program 

overview. 

Developmental Basis of Disease—understanding birth defects and 

how lifelong changes in health and disease may follow the exposure 

to hazardous chemicals during prenatal, infantile, or early childhood 

stages. Recent epidemiological data suggest that chronic diseases such 

as diabetes and hypertension may follow a particular event early in 

life. The cross-cutting goal is to advance scientific understanding of 

the source-disease outcome from intrauterine or childhood exposure 

to hazardous chemicals. 

Nanotechnology—the use of nanomaterials as the building 

blocks for this promising new technology. Currently being utilized 

in many diverse areas such as engineering, information technology, 

and diagnostics, nanomaterials are now routinely produced and 

commercialized. Because little is known about their biology or the 

potential health impacts of these new products, these highlighted 

sessions will explore the potential implication(s) of their use. 

Oxidative Signaling and Redox Biology—the importance of 

reactive oxygen species (ROS) in health and disease has been long 

recognized by toxicologists. In addition to the uncontrolled generation 

of ROS associated with chemical, physical, and biological toxicities, 

the abnormal activation of inflammatory cells is known to play an 

important etiologic role in many degenerative diseases. These sessions 

will explore how altered conditions in the cell can lead to oxidative 

stress, which include: 1) increased levels of transition metals or their 

reactive forms, 2) depletion of non-enzymatic antioxidant defenses, 

3) increased generation of ROS, 4) ionizing radiation, and 5) redox 

cycling. 

Stem Cell Biology and Toxicology—understanding stem cell 

biology and its applications and the intense debates ignited in 

scientific, political, and ethical spheres. The degree to which stem 

cells can be used in toxicological testing to replace other experimental 

models is still in its infancy. Given these facts, this area of research 

has the potential to revolutionize toxicity testing in the academic, 

private, and government setting. The sessions in this theme will 

explore some of the major challenges that must be overcome and 

address new issues as they arise. 

Career Development—providing the tools and resources to 

toxicologists that will enhance their professional and scientific 

development. 

8:15 AM–9:15 AM 

Monday, March 17 

PLENARY OPENING LECTURE 

Perspectives on Science in the 21 st Century 

Lecturer: Nobel Laureate Lee Hartwell (p87) 

9:30 AM–12:15 PM 

SYMPOSIA SESSIONS 

• Metals, Microglia, and Neuroinflammation (p88) 

• Molecular Basis for Susceptibility to Chemical Toxicity 

and Disease (p88) 

• New Developments in Liver Tumor Biology (p89) 

• Particle Interactions with Biomaterials: Beyond Opsonization 

(p89) 

Workshop SESSIONS 

• Current Perspectives on Ocular and Systemic Safety Risks of 

Therapeutics (p90) 

• LLNA: False Positives, False Negatives, and Alternative 

Endpoints (p90) 

PLATFORM SESSIONS 

• Advancing the Science of Risk Assessment (p91) 

• Altered Reproductive Development (p91) 

• Developmental Immunotoxicology, Host Resistance and 

Genomics (p92) 

• Ecotoxicity and Chemical Exposure (p93) 

• Oxidative Stress, DNA Strand Breaks, and Applications of the 

COMET Assay (p93) 

9:30 AM–12:30 PM 

POSTER SESSIONS 

• Animal Models (p102) 

• Bioinformatics and Computational Toxicology (p105) 

• Chemical and Biological Weapons (p97) 

• Endocrine Mechanisms of Toxicity (p94) 

• Immunotoxicology (p99) 

• Inhalants: Oxidative and Redox Mechanisms (p109) 

• Oxidative Stress Mechanisms in Chemical Carcinogenesis (p95) 

• Pesticide Metabolism and Toxicity (p107) 

• Xenobiotic Biotransformation II (p110) 

12:15 PM–1:30 PM 

ROUNDTABLE SESSIONS 

• The Future of Toxicology (p113) 

• Risk Assessment for Biotherapeutics (p112) 

12:30 PM–1:20 PM 

Merit Award Lecture 

The Dose Makes the Toxicologist—Paracelsus as Seen from 

Switzerland 

Lecturer: Hanspeter Witschi (p114) 

1:00 PM–4:30 PM 


• Alternative Ocular and Dermal Models (p114) 

• Apoptosis: Mechanisms and Methods (p116) 

• Biomarkers (p118) 

• Food Safety I (p126) 

• Genetic Polymorphisms (p120) 

• Kidney (p124) 

• Modulators of Cell Proliferation in Chemical Carcinogenesis 

(p129) 

• Nanoparticles: Testing Approaches, Geno- and Ecotoxicity (p122) 

• Receptors (p130) 

• Safety Assessment, Non-Pharmaceutical (p128) 

• Stem Cell Biology and Toxicology (p117)

1:30 PM–4:15 PM 


• Drug-Induced Mitochondrial Toxicity: Novel Insights–Novel Tools (p133) 

• Environmental Influence on Female Puberty and Breast Tumorigenesis 

(p133) 

• Oxidant Air Pollution and Childhood Asthma (IAT) (134) 

• Stem Cells: New Tools for Neurotoxicologists (IAT) (p134) 

WORKSHOP SESSIONS 

• Getting the Most Out of Model Organism Databases: From the Basic 

to the Complex (p135) 

• Mixture Exposures to Metals/Metalloids and Related Health Effects (p136) 

• Where the Rubber Meets the Road: Current Application of Genomic Tools 

in Product Development and Decision Making (p136) 

INFORMATIONAL SESSION 

Future Paths for Puget Sound: Contaminants, Cultures, and Ecosystem Risk 

Characterization—A Special Regional Interest Session (p137) 


• APC’s, B Cells and Haematopoiesis (p137) 

• Disposition/Pharmacokinetics (p138) 

• Frontiers in Liver Toxicology Research (p138) 

4:30 PM–5:50 PM 

ROUNDTABLE SESSION 

Immunotoxicity Testing: Should Elevated Antibody Responses be 

Interpreted as an Indicator of Immunotoxicological Hazard? (p140) 

Historical Highlight Session 

Ozone Toxicology: Historical Perspectives of the Science that Shaped the 

Regulatory Standards (p140) 


Putting Your Best Foot Forward: Job Interviewing Workshop for Early- 

Career Scientists (p141) 

7:30 AM–8:50 AM 

Issues Session 

Tuesday, March 18 

Over-the-Counter Cough and Cold Medications in Children: Efficacy, 

Safety, and Use (p142) 


• Breaking the Log-Jam: Public-Private Partnerships as a Way to Discover 

and Advance Biomarkers of Drug-Induced Toxicity (p143) 

• Reproductive Toxicity Studies: One Generation versus Two Generations 

(p143) 

• The 2007 Pet Food Related Toxic Nephropathy in Dogs and Cats (p144) 


Detection of Biological Free Radicals in Time and Space (p144) 

8:00 AM–8:50 AM 

DEBATE 

SOT/EUROTOX Debate: In Vitro Toxicology Is Useful for Regulatory 

Purposes (p145) 

9:00 AM–11:45 AM 


• Molecular and Genomic Insights into the Nrf2-Regulated Oxidative Stress 

Response: Impact on Carcinogenesis (p146) 

• New Concepts in the Etiology of Breast Cancer: From Genes to Environment 

and Back Again (p146) 


• Drug-Related Torsades de Pointes: Advancements in Preclinical Modeling 

of Potential Cardiac Toxicity (p147) 

• The Allergic March: The Role of Chemicals in the Increasing Prevalence of 

Allergy and Asthma (p147) 

• To Dye or Not to Dye: Safety of Oxidative Hair Dyes (p148) 


Professional Career Development as a Toxicologist (p148) 


• Accelerating Discoveries in Toxicology Through ‘Omics Research (p149) 

• Chemical and Biological Weapons: Molecular Basis for Detection and 

Therapeutic Potential (p150) 

• Developmental Basis of Disease (p150) 

• Health Risks and Food Safety (p151) 

• Manganese Neurotoxicity: From Worms to Primates (p152) 

9:00 AM–12:30 PM 


• Adverse Effects of Natural Products (p152) 

• Alternatives to Mammalian Models (p165) 

• Liver I: In Vivo (p161) 

• Mechanisms and Chemoprevention of PAH and Tobacco-Related 

Carcinogenesis (p164) 

• Particulate Matter and the Cardiovascular System (p153) 

• Persistent Organic Pollutants (POPs) (p158) 

• Regulatory Risk Assessment (p167) 

• Xenobiotic Biotransformation I (p156) 

12:00 NOON–1:20 PM 

Town Hall Meeting 

SOT Strategic Plan —Defining the Future of SOT (p171) 

12:30 PM–1:20 PM 

Distinguished Toxicology Scholar Award Lecture 

Half a Century of Progress in Neurotoxicology: Past, Present, and Future 

Lecturer: Toshio Narahashi (p171) 

1:00 PM–4:30 PM 


• Applications of Biological Modeling (p175) 

• Assessment of Ecological Toxicology (p193) 

• Breast Cancer: Mechanisms, Biomarkers, and Chemoprevention (p180) 

• Inhalation Toxicology (p181) 

• Liver II: In Vitro (p191) 

• Nanoparticles: Target Organs (p177) 

• Pharmacokinetics and Disposition (p172) 

• Regulation/Policy (p174) 

• Reproductive System (p186) 

• Risk Assessment Research (p188) 

• Signal Transduction and Gene Regulation (p183) 

1:30 PM–4:15 PM 


• Endothelial Dysfunction: More Than Just a ‘No NO’ Phenomenon (p195) 

• Neurotoxicant-Induced Alterations in Developmental and Adult 

Neurogenesis: Structure-Function Studies and Clinical Relevance (p196) 

• Novel Biomarkers of Drug-Induced Toxicity: Outcomes of Predtox and the 

Predictive Safety Testing Consortium (p197) 


• Dermal Toxicological Assessment of Nanomaterials and Nanodevices (p197) 

• Host Susceptibility and Chemical Safety Testing: New Approaches to 

Estimate Risks in the Human Population (ITS) (p198) 

• Molecular Mechanisms and Molecular Biology of Metal Carcinogenesis 

(p198) 

• Strategies for Assessing Developmental and Reproductive Toxicology of 

Bio-Pharmaceuticals (p199) 


Human Health Risk Assessment for Pharmaceuticals in the 

Environment (PIE) (p200) 


• Arsenic Toxicity (p200) 

• Mechanisms of Hypersensitivity (p201) 

• Mechanisms of Pesticide Toxicity (p201)

7:30 AM–8:50 AM 


Wednesday, March 19 

• Hazard vs. Risk for Chemical Regulation (p203) 

• Reconciling Scientific and Ethical Concerns in the Use of Animals for 

Toxicological Research (p204) 

• Toxicology Training Needs: New Faces and New Tools for the 21 st Century 

(p204) 

INFORMATIONAL SESSIONs 

• Cross-Cultural Understanding of Asian and Western Cultural Values 

in the Workplace (p205) 

• Toxicological and Public Health Challenges in Africa (p205) 

8:00 AM–8:50 AM 

KEYNOTE MRC LECTURE 

Biological Energy Conversion and its Toxic Consequences 

Lecturer: Nobel Laureate Professor Sir John E. Walker (p206) 

9:00 AM–11:45 AM 


• Developmental Basis of Health and Disease: Persistent Effects of Tobacco 

Smoke Exposure (IAT) (p206) 

• Unusual Manifestations of On-Target and Off-Target Toxicity: Toxicity of 

Kinase Inhibitors (p207) 


• Natural Killer Cells as Targets of Drugs, Toxicants, and Biologicals (p207) 

• Safe Approaches to Topical Product Development (p208) 

• Threshold of Toxicologic Concern: Historical Perspectives and Future 

Applications (p208) 

• Use of Behavioral and Non-Routine Neurological Approaches in Drug 

Discovery Toxicology (p209) 


Globally Harmonized System of Classification and Labelling of Chemicals 

(GHS): A New Language for Toxicologists (p209) 


• Advances in Biological Modeling (p210) 

• Mechanisms of Reproductive Toxicity (p210) 

• Modulating Apoptosis for Beneficial Outcomes (p211) 

• Nanoparticles: Cellular and Organ Disposition (p212) 

9:00 AM–12:30 PM 


• Application of ‘Omics Research Tools in Toxicology (p225) 

• Cardiovascular System: Cardiac Effects (p231) 

• Developmental Toxicology (p221) 

• DNA Damage and Repair: Mechanisms and Agents (p233) 

• Epidemiology and Exposure Assessment (p217) 

• Gene Regulation and Genomic Approaches (p214) 

• Mechanisms of Carcinogenesis (p213) 

• Metals I (p228) 

• Nanoparticles: Inhalation and Respiratory Cell Injury (p219) 

• Respiratory and Skin Hypersensitivity (p215) 

• Skin Penetration and Toxicity (p223) 

12:00 NOON–1:20 PM 


Mentoring 101—How to Mentor, and How to be Mentored (p236) 

MEET THE DIRECTORs: A conversation with the directors 

NIEHS Strategic Plan 

Lecturer: Samuel Wilson (p235) 

1:00 PM–4:30 PM 


• Biomarkers: Methods (p241) 

• Developmental Neurotoxicity (p237) 

• Human Biomarkers (p240) 

• Juvenile Toxicity (p242) 

• Metal Neurotoxicology: Experimental Models and Mechanisms (p248) 

• Neurotoxicity: Miscellaneous Compounds, Models, and Mechanisms (p245) 

• Oxidative Injury and Redox Biology I: In Vivo (p255) 

• Pharmaceuticals (p251) 

• Risk Assessment Applications (p243) 

• Safety Assessment, Pharmaceutical—Liver, Kidney, Immune System (p253) 

1:30 PM–4:15 PM 


• Arsenic and Cardiovascular Disease (p257) 

• Nanomaterial Pharmacokinetics: Where We Are and Where We Need 

to Go (p258) 


• Advances in Technology and Increasing Acceptance for Zebrafish Use in 

Drug Discovery (p258) 

• Chlorotriazine Herbicides and their Common Degradation Products of 

Concern: Disposition and Potential Health Effects (p259) 

• Interdisciplinary Approaches for Improving Chemical Hazard 

Testing Paradigms (p259) 


• Apoptosis: Cardiopulmonary Targets (p260) 

• Immunotoxicology: T Cells (p261) 

• Issues in Regulatory Risk Assessment (p261) 

• New Insights for Developmental Toxicology (p262) 

• Nrf2 Induced Gene Regulation (p262) 

• Selective Dopaminergic Neurotoxicity: Genetics and Mechanisms (p263) 

4:30 PM–5:50 PM 


A Case Study on the Risks and Benefits of Deca-BDE—a Major Brominated 

Flame Retardant (p264) 

INFORMATIONAL SESSIONS 

• Implementation of the ICH S8 Immunotoxicity Testing Guideline (p264) 

• NIEHS Outstanding New Environmental Scientists (ONES) Awardees 

(p265) 

7:30 AM–8:50 AM 

Issues Session 

Thursday, March 20 

2007 National Research Council-National Academy of Sciences Reports: Impact 

on the Future of Toxicology (p266) 


Biofuel Combustion: An Emerging Health Problem? (p266) 

8:30 AM–12:00 NOON 


• AHR Mechanisms (p275) 

• Cardiovascular System: Vascular Effects (p278) 

• Chemoprevention (p276) 

• Fish Alternative Models of Toxicity (p277) 

• Food Safety II (p280) 

• High Throughput, High Content Approaches to Assessing Genotoxicity 

(p282) 

• Metals II (p269) 

• Method Development, Autoimmunity, and Disease Mechanisms in 

Immunotoxicology (p272) 

• Oxidative Injury and Redox Biology II: In Vitro (p266) 

• Pesticide Neurotoxicity (p283) 

• Safety Assessment, Pharmaceutical—Techniques, Pulmonary, 

Cardiovascular (p286) 

9:00 AM–11:45 AM 

Symposia Sessions 

• Cellular Redox Status and Zinc Signaling (p288) 

• Perinatal Exposure to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 

Induces Transplacental Genotoxicity and Mitochondrial Toxicity (p288) 

• Stem Cells in Developmental and Reproductive Biology and Toxicology 

(p289) 


• Genotoxicity Testing from Early Discovery through Regulatory Submission: 

A Comprehensive Primer (p290) 

• Incorporation of Mode-of-Action into Mechanistically-Based 

Quantitative Models (p290) 

• Pulmonary Toxicity Testing of Nanoparticles (p291) 


REACH: Implementation, Chemical Safety, and Information Requirements 

(p291)

47 th Society Annual of Toxicology Meeting 2008 

& ToxExpo 

March 16–20, 2008 

Program Contents 

President’s Letter..................................... Inside Front Cover 

Scientific Program Overview........................... Front Foldout 

Sponsorship 

Sponsorship Opportunities............................................... 352 

2008 Annual Meeting Sponsors 

& The Toxicologist on CD-ROM...........Inside Back Cover 

2008 Annual Meeting Diamond Sponsors...........Back Cover 

Events and Maps 

How to Use this Program.......................................................2 

Daily Pocket Calendar...........................................................3 

Schedule by Event Name.................................................... 17 

Washington State Convention and 

Trade Center Maps......................................................26 

Seattle Hotel Accommodations..........................................30 

Map of Seattle Hotels..........................................................32 

Sheraton Seattle Hotel Map................................................33 

Grand Hyatt Hotel Map......................................................34 

Seattle Restaurants..............................................................35 

Poster Board Surface Maps.................................................36 

Memorabilia.........................................................................54 

Message Boards...................................................................54 

Photography Policy..............................................................54 

Registration Desk Hours.....................................................54 

Safety and Security..............................................................54 

SOT Headquarters Office...................................................55 

Speaker Ready Room..........................................................55 

Sponsorship.........................................................................55 

Transportation.....................................................................55 

Tour Information.................................................................57 

The Toxicologist/Itinerary Planner........................................ 57 

Career Resources and Development 

Career and Development Services.....................................58 

Social Functions 

Social Events........................................................................ 61 

Award and Honor Recipients 

2008 Award Winners..........................................................63 

2008 Honorary Member.....................................................70 

2008 ToxExpo 

ToxExpo Floorplan...........................................................44 

ToxExpo 2008 Exhibitors.................................................46 

Registration 

Registration Information......................................................49 

General Information 

Accessibility for Persons with Disabilities...........................50 

Attire....................................................................................50 

Badges..................................................................................50 

Business Center —FedEx Kinko’s........................................50 

Climate................................................................................50 

Exhibit Hall (Hours/Location)..............................................50 

First Aid and Security..........................................................50 

Food Services...................................................................... 51 

Guest Hospitality Center and Program..............................52 

Housing Information and Reservations...............................52 

Internet Access....................................................................53 

Lost and Found....................................................................53 

Luggage/Coat Check...........................................................53 

Lunch with an Expert Board...............................................53 

Media Support Services.......................................................53 

Meeting Pole........................................................................54 

up-to-date information at www.toxicology.org 1 

Continuing Education 

Continuing Education Courses............................................ 71 

Sessions Index 

Scientific Session Index........................................................77 


Program Description...........................................................85 

Author Index......................................................................294 

SOT Leadership 

2007–2008 Council........................................................... 314 

Officers and Councilors..................................................... 316 

Past Presidents.................................................................. 316 

Elected Committees.......................................................... 317 

Appointed Committees..................................................... 317 

Officers—Regional Chapters............................................320 

Officers—Special Interest Groups....................................322 

Officers—Specialty Sections.............................................323 

SOT References 

SOT Award Descriptions and History..............................325 

Toxicology Specialists........................................................ 337 

SOT Affiliates.....................................................................340 

Headquarters Staff ........................................................... 341 

All text and graphics are © by the Society of Toxicology unless noted. Washington 

photos are courtesy of the Washington State Tourism, Department of Community, 

Trade & Economic Development or Seattle’s Convention and Visitor’s Bureau 

unless otherwise noted. For promotional use only. No advertising use is permitted.

47 th Annual Meeting & ToxExpo 

How to Use this Program 

The Society of Toxicology’s (SOT) Annual Meeting is always an 

exciting opportunity to highlight advancements in the science of 

toxicology. 

In order to maximize the value of your Annual Meeting attendance, 

we offer this overview of the Program publication layout 

and the scientific session reference to assist you. We hope that 

you find this information useful and welcome your comments. 

Program Publication Layout Overview 

Section 

Front Fold-Out 

Cover —Scientific 


Overview 

Event Calendar 

(pages 3–15) 

Schedule by Event 

Name (pages 

17–25) 

Poster Board 

Surface Maps— 

NEW (pages 

36–42) 

Scientific Session 

Index (pages 

77–84) 

Description 

This quick reference guide lists the 

Annual Meeting sessions with page 

numbers to easily find your sessions 

of choice. This year the color-coded 

presentation titles will assist you in 

identifying sessions within each theme. 

A brief description for each theme is 

available as well. 

This at-a-glance calendar is your guide to 

the daily activities of the Annual Meeting 

including special sessions, Specialty 

Sections, Regional Chapters, Special 

Interest Groups, and ancillary functions; 

plus SOT committee meetings. We 

encourage you to tear out the daily guide 

for easy reference. 

This is an alphabetical listing of all 

the functions held during the Annual 

Meeting. You may use this easy-to-read 

schedule to quickly locate an event. 

Please note that for the scientific sessions, 

you must refer to the Scientific Program 

Overview on the front fold out cover or 

Event Calendar on pages 3–15. 

The poster board surface maps are 

displayed with a mock layout of the 

ToxExpo TM Exhibit Hall to assist you 

in finding poster sessions. Each poster 

surface map shows the poster session 

abstract numbers and the poster surface 

locations for each poster session time. 

Posters are displayed in Exhibit Hall 4E 

Monday–Wednesday and Ballroom 6C & 

E on Thursday. 

This index lists the scientific sessions 

by type, date, and time. In addition, this 

information includes the session topics 

with abstract numbers, session locations, 

and corresponding page numbers in the 

Program Description section. 

Scientific Session Reference 

The Program layout is ordered by date and time. Please refer 

to the sample below. Each session includes a session overview 

abstract and list of speakers or the featured presenters. 

Listing 

Session Type and 

Title 

Endorsed by 

Abstract Number 

or Presentation 

Time 

Poster Sessions 

Scientific Session Type Legend 

Description 

Session type and title display in bold type 

and formatted in uppercase. 

This section lists the endorsements from 

SOT Special Interest Groups, Specialty 

Sections, Regional Chapters, or SOT 

Committees. The list of endorsers 

(groups that developed the session) is 

sorted alphabetically and the primary 

endorser is identified by the asterisk (*). 

The first number listed is the abstract 

number, or the SOT final identifying 

number. For scientific sessions (but 

not Continuing Education Courses 

or Poster Presentations), the second 

number is the poster presentation time. 

Individual Abstracts can be found on 

The Toxicologist CD-ROM (free to all 

attendees), The Toxicologist book (available 

for purchase on-site for $20), and on 

the SOT Web site. 

The poster board surface number is 

listed above the title of each individual 

presentation for easy reference. 

Featured Sessions—Plenary and special lectures as well as 

debates 

Symposia Sessions—Cutting-edge science; new areas, 

concepts, or data 

Workshop Sessions—State-of-the-art knowledge in 

toxicology 

Roundtable—Controversial subjects 

Platform Sessions—Oral presentations that cover new 

areas, concepts, or data 

Poster Sessions—Topic specific presentations that cover 

new areas, concepts, or data 

Informational Sessions—Scientific planning or member 

ship development 

Historical Highlights—Review of a historical body of 

science that has impacted toxicology 

Thematic Session—Timely topics of relevance to 

toxicology 

2 

SOT’s 47 th Annual Meeting

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page for a convenient daily calendar _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 

Daily Pocket Calendar 


Society of Toxicology 2008 

For your convenience, please tear out and carry with you. 

Friday March 14, 2008 

Events names are listed alphabetically by 

the event start time. 

Events at the Washington State Convention 

and Trade Center are noted as CC. 

4:00 PM to 7:00 PM 

Council Orientation Meeting 

Sheraton Douglas Room 

7:00 PM to 10:00 PM 

Council Orientation Reception/Dinner 

Sheraton Cedar Room 

Saturday March 15, 2008 

Events are listed alphabetically by the event 

start time. 



8:00 AM to 1:30 PM 

Council Meeting 

Sheraton Issaquah Room 

8:00 AM to 5:00 PM 

ToxExpo Set Up 

CC Exhibit Hall 

8:15 AM to 9:15 AM 

IUTOX Communications Commission 


Sheraton Capitol Hill Room 

8:15 AM to 9:15 AM 

IUTOX Education and Careers Committee 


Sheraton Ballard Room 

9:30 AM to 10:30 AM 

IUTOX Finance Committee Meeting 


9:30 AM to 10:30 AM 

IUTOX Membership Committee Meeting 


10:45 AM to 11:45 AM 

IUTOX Developing Countries Committee 



11:30 AM to 6:00 PM 

Johnson & Johnson Toxicology Interest 

Group Meeting 

Sheraton Greenwood Room 

12:00 NOON to 1:00 PM 

IUTOX Science Committee Meeting 


1:00 PM to 6:00 PM 

ABT Board of Directors Meeting 

Sheraton Ravenna Room 

1:30 PM to 5:30 PM 

IUTOX Executive Committee Meeting I 


2:00 PM to 5:00 PM 

SOT Committee Chair Orientation 

Sheraton Willow A Room 

4:00 PM to 7:00 PM 

E-mail Center/Message Boards 

CC East Lobby, Level 6 

4:00 PM to 7:00 PM 

Housing Desk 

CC South Lobby, Level 4 

4:00 PM to 7:00 PM 

Registration 


4:00 PM to 7:00 PM 

SOT Office 

CC Room 303 

4:00 PM to 7:00 PM 

Speaker Ready Room 

CC Room 213 

4:00 PM to 7:00 PM 

Tour Desk 


5:00 PM to 5:45 PM 

Continuing Education Committee 

Walk-Through 

CC Room 603 

5:30 PM to 8:30 PM 

Fellowship Interviews by Awards 

Committee 

CC Room 308 

5:30 PM to 6:00 PM 

Undergraduate Education Program 

Orientation for SOT Hosts, Peer Mentors, 

and Advisors 

CC Room 305 

6:15 PM to 9:00 PM 

Undergraduate Education Program Lecture 

& Reception 

CC Room 3A 

Sunday March 16, 2008 


start time. 



7:00 AM to 7:45 AM 

Continuing Education Sunrise Mini-Course 

(Ticket Required) 

CC (See Signage for Room Location) 

7:00 AM to 6:00 PM 



7:00 AM to 5:00 PM 

Housing Desk 


7:00 AM to 8:30 PM 

Luggage/Coat Check 

CC Room 454 

7:00 AM to 8:00 PM 

Registration 


7:00 AM to 5:30 PM 

SOT Office 

CC Room 303 

7:00 AM to 5:30 PM 


CC Room 213 

7:30 AM to 2:30 PM 

Concession Stands 

CC Level 6 

7:30 AM to 12:00 NOON 

TEF Board of Trustees Meeting 

Sheraton Leschi Room 

8:00 AM to 10:00 AM 

CRAD Committee Meeting I 

CC Room 209 

8:00 AM to 5:00 PM 

Guest Hospitality Center 


8:00 AM to 4:00 PM 

Tour Desk 


8:00 AM to 5:00 PM 

ToxExpo Set Up 


8:00 AM to 10:35 AM 


CC Room 2A 

8:15 AM to 12:00 NOON 

Continuing Education Courses 



8:30 AM to 12:30 PM 

IUTOX Executive Committee Meeting II 


10:00 AM to 4:30 PM 

CRAD Job Bank Center 

CC Room 205 

10:35 AM to 3:00 PM 


CC Room 2A 

11:45 AM to 1:15 PM 

Continuing Education Luncheon for 

Speakers, Committee, and Students 

(By Invitation Only) 

CC Room 620 

12:00 NOON to 3:00 PM 

Toxicological Sciences Associate Editors 



1:15 PM to 5:00 PM 




2:00 PM to 4:00 PM 

Endowment Fund Board Meeting 

CC Room 212 

3:00 PM to 5:00 PM 

Academic Program Session for 

Undergraduate Students 

CC Room 2A 

4:00 PM to 5:15 PM 

Awards Recipients Photographed 

CC Room 601 

4:45 PM to 5:15 PM 

Awards Ceremony Music Prelude 

Kaley Eaton, Pianist 

CC Ballroom 6A 

5:15 PM to 6:30 PM 


(All Attendees Welcome) 


6:30 PM to 7:30 PM 



CC Exhibit Hall 4F 

6:45 PM to 7:30 PM 

Regional Chapter Graduate Committee 

Introductory Meeting 

Sheraton Aspen Room 

7:00 PM to 8:00 PM 

25–Year (or More) Member Reception 

(By Invitation Only) 

CC Room 601 

7:00 PM to 10:00 PM 

University of Washington Alumni & 

Friends Reception 

Seattle Children’s Orthopedic Hospital 

Research Institute 

7:30 PM to 10:00 PM 

Arizona Night 


7:30 PM to 10:00 PM 

Lovelace Respiratory Research Institute 

Reception for Past and Present Employees 

Sheraton Willow B Room 

7:30 PM to 8:30 PM 

Student/Postdoctoral Fellow Mixer 


Sheraton Grand Ballroom C 

8:00 PM to 10:00 PM 

IUTOX Executive Committee Dinner 

Palomino Restaurant 

Event Calendar



Program Overview by Day & Time 

Sunday March 16, 2008 

7:00 AM–7:45 AM 

Sunrise Continuing education Course 

1. Mini-Pigs as an Alternative Non-Rodent Species 

in Toxicology and Safety Studies 

CE courses held on Level 6. (See signage at the CE 

booth for room assignments.) 

8:15 AM–12:00 NOON 

Morning Continuing education Courses 

2. Introduction to Pathology for Toxicologists and 

Study Directors 

3. Stem Cells and their Multi-Potential Uses and 

Potential Dangers 

4. Dose-Response Modeling for Occupational and 

Environmental Risk Assessment 

5. The Use of Transgenic Animal Technology in 

Toxicological Research 

6. Process-Based Approaches to Modulating Gene 

and Protein Expression In Vivo and In Vitro 

7. Basic Embryology and Developmental 

Toxicology 


1:15 PM–5:00 PM 

Afternoon Continuing education 

Courses 

8. Introduction to Pathology for Toxicologists and 


9. Nanotoxicology: The Science of Developing a 

Safe Technology 

10. Clinical Dose Setting for Biotherapeutics 

11. Use of Data for Development of Uncertainty 

Factors in Non-Cancer Risk Assessment 

12. Essential Informatics for Toxicologists: 

Knowledge Management End-to-End 

13. Epidemiology for Toxicologists: Introduction 

4 







Monday March 17, 2008 


start time. 



6:30 AM to 8:00 AM 

Comparative and Veterinary Specialty 

Section Officers Meeting 

CC Room 304 

6:30 AM to 8:00 AM 

Metals Specialty Section Officers Meeting 

CC Room 305 

7:00 AM to 8:30 AM 

Carcinogenesis Specialty Section Officers 


CC Room 209 

7:00 AM to 8:30 AM 

Continuing Education Committee Meeting 

CC Room 208 

7:00 AM to 6:00 PM 



7:00 AM to 8:30 AM 

Food Safety Specialty Section Officers 


CC Room 310 

7:00 AM to 5:00 PM 

Housing Desk 


7:00 AM to 9:00 AM 

In Vitro and Alternative Methods Specialty 


CC Room 204 

7:00 AM to 8:30 PM 


CC Room 454 

7:00 AM to 9:00 AM 

Mechanisms Specialty Section Officers 


CC Room 214 

7:00 AM to 8:30 AM 

Past Presidents Breakfast 

CC Room 309 

7:00 AM to 8:15 AM 

Postdoctoral Assembly Board Meeting 

CC Room 212 

7:00 AM to 8:30 AM 

Regional Chapter Graduate Committee 

Business Meeting 

CC Room 307 

7:00 AM to 5:00 PM 

Registration 


7:00 AM to 8:00 AM 

Regulatory and Safety Evaluation Specialty 


CC Room 203 

7:00 AM to 9:00 AM 

Risk Assessment Specialty Section Officers 


CC Room 211 

7:00 AM to 5:00 PM 

SOT Office 

CC Room 303 

7:00 AM to 5:00 PM 


CC Room 213 

7:00 AM to 8:00 AM 

Special Interest Group President and 

Officers Meeting 

CC Room 201 

7:15 AM to 8:15 AM 

Program Committee Walk-Through 

CC Room 603 

7:30 AM to 9:30 AM 


CC Level 6 

7:30 AM to 9:00 AM 

Toxicologic and Exploratory Pathology 

Specialty Section Officers Meeting 

CC Room 202 

7:30 AM to 2:00 PM 


CC Room 3A 

8:00 AM to 5:00 PM 



8:00 AM to 9:30 AM 

Poster Set Up 

(See Poster Board Surface Map on 

Page 36) 


8:00 AM to 4:00 PM 

Tour Desk 


8:15 AM to 9:15 AM 

Plenary Opening Lecture: Perspectives on 

Science in the 21 st Century 

Nobel Laureate Lee Hartwell 

CC Exhibit Hall 4F 

9:15 AM to 10:15 AM 

Complimentary Coffee 


9:15 AM to 2:30 PM 



9:15 AM to 4:30 PM 


CC Room 205 

9:15 AM to 4:30 PM 

Hot Zones (Wireless Internet Access) 


9:15 AM to 4:30 PM 

ToxExpo Exhibits Open 


9:30 AM to 11:15 AM 

Poster Session for Visiting Students 


9:30 AM to 12:30 PM 



9:30 AM to 12:15 PM 

Scientific Sessions 

CC (See Program Description for Room 

Locations) 

9:45 AM to 10:45 AM 

Exhibitor Hosted Session: MPI Research: 

Scientific Advances in GLP Bioanalytical 

Analysis 

CC Exhibit Hall 4C-3 

9:45 AM to 10:45 AM 

Exhibitor Hosted Session: Ricerca 

Biosciences, LLC: Biotechnology— 

Both a Business and a Science and 

Biotechnology—Changing Science and 

Service 


11:00 AM to 12:30 PM 

Awards Committee Meeting 

CC Room 304 

11:00 AM to 12:00 NOON 

Exhibitor Hosted Session: Bio-Rad 

Laboratories: SELDI-TOF Strategies for 

Toxicological Biomarker Discovery and 

Application 


11:00 AM to 12:00 NOON 

Exhibitor Hosted Session: Promega 

Corporation: Multiplexing Luminescent 

ADMETox Cell-Based Assays Including 

Applications with Primary Cells and Stem 

Cells 


11:30 AM to 1:30 PM 

Food and Chemical Toxicology Editorial 

Board Meeting 

Sheraton Juniper Room 

11:30 AM to 1:30 PM 

Toxicology and Applied Pharmacology 

Associate Editors Meeting 

Sheraton Madrona Room 

12:00 NOON to 1:00 PM 

HESI-Sponsored Luncheon Seminar 

Sheraton Grand Ballroom B 

12:00 NOON to 1:30 PM 

Nanotoxicology Specialty Section Meeting/ 

Luncheon 

Sheraton Willow Room 

12:00 NOON to 1:30 PM 

Neurotoxicology Specialty Section Officers 

Meeting/Luncheon 

CC Room 214 

12:00 NOON to 1:30 PM 


Specialty Section Meeting/Luncheon 

Sheraton Grand Ballroom D 

12:15 PM to 1:15 PM 

Exhibitor Hosted Session: Phylonix 

Pharmaceuticals, Inc.: Fish First: Zebrafish 

are Increasingly Used for Early Stage 

Assessment of Drug Efficacy, Toxicity, 

and Safety 


12:15 PM to 1:15 PM 

Exhibitor Hosted Session: Strategic 

Applications, Inc. (SAI): Innovations in 

Infusion and Sampling 


12:15 PM to 1:20 PM 

In Vitro Toxicology Lecture and Luncheon 

for Students (Ticket Required) 

Sheraton Grand Ballroom A 

12:15 PM to 1:30 PM 

Regulatory Affairs and Legislative 

Assistance Committee Meeting 

CC Room 209 

12:15 PM to 1:30 PM 



Locations) 

12:30 PM to 1:20 PM 


The Dose Makes the Toxicologist— 

Paracelsus as Seen From Switzerland 

Lecturer: Hanspeter Witschi 

CC Ballroom 6B 

12:30 PM to 1:00 PM 

Poster Set Up 


Page 37) 


1:00 PM to 4:30 PM 



1:30 PM to 2:30 PM 

Exhibitor Hosted Session: Cellular 

Dynamics International, Inc.: Progress in 

Using Human Embryonic Stem Cells in 

Drug Screening, Toxicology, and Drug 

Development 


1:30 PM to 2:30 PM 

Exhibitor Hosted Session: ReachBio 

LLC: Primary Stem Cell Based Assays 

for Toxicology and Other Drug Screening 

Applications 


1:30 PM to 4:15 PM 



Locations) 

1:30 PM to 2:30 PM 

VIP ToxExpo Exhibit Hall Walk- 

Through 


2:45 PM to 3:45 PM 

Exhibitor Hosted Session: GeneGo Inc.: 

Tools for Systems Toxicology—Integrating 

Chemical, Gene Expression, Protein, and 

Metabolic Data into Safety Assessment 


2:45 PM to 3:45 PM 

Exhibitor Hosted Session: National 

Toxicology Program: Public Access to 

the National Toxicology Program: From 

Acrylamide to Zinc 


3:30 PM to 4:30 PM 

Undergraduate Toxicology Faculty Meeting 

CC Room 201 

4:30 PM to 6:00 PM 

ABT Annual Mixer Meeting 


4:30 PM to 7:30 PM 

CAHB and Taconic: Discussion Session 

on Alternative Transgenic Models for 

Carcinogenicity Evaluation 


4:30 PM to 6:00 PM 

K–12 TEAMS Event Volunteers Meeting 

CC Room 309 

4:30 PM to 6:00 PM 

Northern California and Pacific Northwest 

Regional Chapters, UC Davis and UC 

Berkeley Joint Meeting/Reception 

Sheraton Metropolitan B Room 

4:30 PM to 9:30 PM 

Rosetta Biosoftware Hospitality Suite 

Hyatt Blewett Suite 

4:30 PM to 7:00 PM 

Roundtable of Toxicology Consultants 

Meeting/Reception 

Sheraton Willow B Room 

4:30 PM to 5:50 PM 

Scientific Sessions (Sunset) 


Locations) 

4:30 PM to 6:00 PM 

Specialty Section Presidents and Officers 


CC Room 307 

5:00 PM to 8:00 PM 

American Association of Chinese in 

Toxicology Special Interest Group 

Business Meeting, Distinguished Chinese 

Toxicologist Lecture 

Sheraton Grand Ballroom D 

5:00 PM to 6:00 PM 

Gulf Coast and South Central Regional 

Chapters Joint Meeting/Reception 

Gordon Biersch Brewery/Restaurant 

5:30 PM to 7:30 PM 

Elsevier Editors’ Reception 

Hyatt Leonesa 3 Room 

Continued on next page 

Event Calendar





Monday (Continued) March 17, 2008 

5:30 PM to 8:00 PM 

Korean Toxicologist Association in 

America Special Interest Group Meeting/ 

Reception 

Hyatt Leonesa 1 Room 

5:30 PM to 6:30 PM 

Organizational Meeting for a Potential New 

Ocular Toxicology Specialty Section 


6:00 PM to 7:30 PM 

Ethical, Legal, and Social Issues Specialty 

Section Meeting/Reception 

CC Room 601 

6:00 PM to 7:30 PM 

Food Safety Specialty Section Meeting/ 

Reception 

CC Room 619 

6:00 PM to 7:00 PM 

Hispanic Organization for Toxicologists 

Special Interest Group Meeting/Reception 

Sheraton Kirkland Room 

6:00 PM to 7:30 PM 

Mechanisms Specialty Section Meeting/ 

Reception 

CC Room 612 

6:00 PM to 7:30 PM 

Risk Assessment Specialty Section 


CC Room 609 

6:00 PM to 8:00 PM 

St. John’s University 6 th Annual Toxicology 

Alumni Dinner 

Sheraton Ravenna Room 

7:30 PM to 10:00 PM 

North Carolina State University Alumni 

Reception 


6 




8:15 AM–9:15 AM 

PLENARY OPENING LECTURE 

Perspectives on Science in the 21 st Century 

Lecturer: Nobel Laureate Lee Hartwell 

(Exhibit Hall 4F) 

9:30 AM–12:15 PM 


• Metals, Microglia, and Neuroinflammation 

(Room 6A) 

• Molecular Basis for Susceptibility to Chemical 

Toxicity and Disease (Room 605) 

• New Developments in Liver Tumor Biology 

(Room 6C) 

• Particle Interactions with Biomaterials: Beyond 

Opsonization (Room 6B) 

Workshop SESSIONS 

• Current Perspectives on Ocular and Systemic 

Safety Risks of Therapeutics (Room 611) 

• LLNA: False Positives, False Negatives and 

Alternative Endpoints (Room 608) 


• Advancing the Science of Risk Assessment 

(Room 615) 

• Altered Reproductive Development (Room 602) 

• Developmental Immunotoxicology, Host 

Resistance and Genomics (Room 6E) 

• Ecotoxicity and Chemical Exposure (Room 2A) 

• Oxidative Stress, DNA Strand Breaks and 

Applications of the COMET Assay (Room 618) 

9:30 AM–12:30 PM 


(Exhibit Hall — See Poster Board Surface Map on 

Page 36) 

• Animal Models (Exhibit Hall) 

• Bioinformatics and Computational Toxicology 

(Exhibit Hall) 

• Chemical and Biological Weapons (Exhibit Hall) 

• Endocrine Mechanisms of Toxicity 


• Immunotoxicology (Exhibit Hall) 

• Inhalants: Oxidative and Redox Mechanisms 


• Oxidative Stress Mechanisms in Chemical 

Carcinogenesis (Exhibit Hall) 

• Pesticide Metabolism and Toxicity (Exhibit Hall) 

• Xenobiotic Biotransformation II (Exhibit Hall) 

12:15 PM–1:30 PM 


• The Future of Toxicology (Room 602) 

• Risk Assessment for Biotherapeutics (Room 618) 

12:30 PM–1:20 PM 


The Dose Makes the Toxicologist—Paracelsus 

as Seen From Switzerland 

Lecturer: Hanspeter Witschi (Ballroom 6B) 

1:00 PM–4:30 PM 


(Exhibit Hall—See Poster Board Surface Map on 

Page 37) 

• Alternative Ocular and Dermal Models 


• Apoptosis: Mechanisms and Methods 


• Biomarkers (Exhibit Hall) 

• Food Safety I (Exhibit Hall) 

• Genetic Polymorphisms (Exhibit Hall) 

• Kidney (Exhibit Hall) 

• Modulators of Cell Proliferation in Chemical 

Carcinogenesis (Exhibit Hall) 

• Nanoparticles: Testing Approaches, Geno- and 

Ecotoxicity (Exhibit Hall) 

• Receptors (Exhibit Hall) 

• Safety Assessment, Non-Pharmaceutical 


• Stem Cell Biology and Toxicology (Exhibit Hall) 

1:30 PM–4:15 PM 


• Drug-Induced Mitochondrial Toxicity: Novel 

Insights –Novel Tools (Room 6B) 

• Environmental Influence on Female Puberty and 

Breast Tumorigenesis (Room 6E) 

• Oxidant Air Pollution and Childhood Asthma 

(Room 6C) 

• Stem Cells: New Tools for Neurotoxicologists 

(Room 605) 




Monday March 17, 2008 


• Getting the Most Out of Model Organism 

Databases: From the Basic to the Complex 

(Room 615) 

• Mixture Exposures to Metals/Metalloids and 

Related Health Effects (Room 608) 

• Where the Rubber Meets the Road: Current 

Application of Genomic Tools in Product 

Development and Decision Making (Room 611) 


• Future Paths for Puget Sound: Contaminants, 

Cultures, and Ecosystem Risk 

Characterization—A Special Regional Interest 

Session (Room 618) 


• APC’s, B Cells and Haematopoiesis (Room 602) 

• Disposition/Pharmacokinetics (Room 6A) 

• Frontiers in Liver Toxicology Research 

(Room 2A) 

4:30 PM–5:50 PM 


• Immunotoxicity Testing: Should Elevated 

Antibody Responses be Interpreted as an 

Indicator of Immunotoxicological Hazard? 

(Room 615) 


• Ozone Toxicology: Historical Perspectives of the 

Science that Shaped the Regulatory Standards 

(Room 602) 


• Putting Your Best Foot Forward: Job 

Interviewing Workshop for Early-Career 

Scientists (Room 605) 

Event Calendar


Notes 

8 







Tuesday March 18, 2008 


start time. 



6:30 AM to 7:30 AM 

Academy of Toxicological Sciences Board 



6:45 AM to 7:45 AM 

American Board of Veterinary Toxicology 

Diplomate Meeting 

Sheraton Kirkland Room 

7:00 AM to 8:00 PM 


CC Room 454 

7:00 AM to 8:30 AM 

Molecular Biology Specialty Section 


CC Room 304 

7:00 AM to 8:30 AM 

Occupational Toxicology Roundtable 

Planning Meeting 

Hyatt Stevens Boardroom 

7:00 AM to 8:30 AM 

Regional Chapter Presidents and Officers 


CC Room 307 

7:00 AM to 8:00 AM 

Reproductive and Developmental Specialty 


CC Room 309 

7:00 AM to 4:00 PM 

SOT Office 

CC Room 303 

7:00 AM to 4:00 PM 


CC Room 213 

7:00 AM to 8:30 AM 

Specialty Section Graduate Committee 

Business Meeting 

CC Room 211 

7:00 AM to 8:30 AM 

WWW Advisory Committee Meeting 

CC Room 208 

7:15 AM to 8:30 AM 

Animals in Research Committee Meeting 

CC Room 305 

7:30 AM to 9:30 AM 


CC Level 6 

7:30 AM to 8:50 AM 

Issues Session: Over-the-Counter Cough 

and Cold Medications in Children: Efficacy, 

Safety, and Use 


7:30 AM to 8:50 AM 

Scientific Sessions (Sunrise) 


Locations) 

8:00 AM to 6:00 PM 



8:00 AM to 5:00 PM 



8:00 AM to 4:00 PM 

Housing Desk 


8:00 AM to 4:00 PM 

Registration 


8:00 AM to 8:50 AM 

SOT/EUROTOX Debate: In Vitro 

Toxicology Is Useful for Regulatory 

Purposes 


8:00 AM to 4:00 PM 

Tour Desk 


8:30 AM to 2:30 PM 



8:30 AM to 4:30 PM 


CC Room 205 

8:30 AM to 9:30 AM 

Exhibitor Hosted Session: Rosetta 

Biosoftware: Critical Path Analysis 

of Shared Toxicity Data between 

Pharmaceutical Companies Bridges 

Biomarker Discovery 


8:30 AM to 9:30 AM 

Exhibitor Hosted Session: VivoMetrics, 

Inc.: One Year into the Modern Era of Data 

Collection: Successes, Improvements, and 

What’s Next 


8:30 AM to 4:30 PM 



8:30 AM to 12:00 NOON 

K–12 Paracelsus Goes to the Classroom— 

The TEAMS Project: Toxicologists 

Educating and Mentoring Students 

Hyatt E. Anderson Amphitheater 

8:30 AM to 9:00 AM 

Poster Set Up 


Page 38) 


8:30 AM to 4:30 PM 



9:00 AM to 12:30 PM 



9:00 AM to 11:45 AM 



Locations) 

9:15 AM to 10:15 AM 

Complimentary Coffee 


9:45 AM to 10:45 AM 

Exhibitor Hosted Session: Chantest, 

Inc.: Progress in Ion Channel Safety 

Assessments 


9:45 AM to 10:45 AM 

Exhibitor Hosted Session: Charles River 

Laboratories: Building a Global Standard 

GLP Preclinical Research Operation in 

China 


10:00 AM to 11:30 AM 

50 th Year Anniversary Task Force Meeting 

CC Room 209 

10:30 AM to 12:00 NOON 

ToxLearn Work Group Meeting 

CC Room 305 

11:00 AM to 12:00 NOON 

Exhibitor Hosted Session: Data Integrated 

Scientific Systems (D.I.S.S.): The Future 

of Telemetry 


11:00 AM to 12:00 NOON 

Exhibitor Hosted Session: NeuroScience 

Associates (NSA): Key Contemporary 

Concepts in Neurotoxicity Screens 


11:30 AM to 1:30 PM 

Toxicology Editorial Board Meeting 


11:30 AM to 1:30 PM 

Toxicology Letters Editorial Board Meeting 

Sheraton Madrona Room 

11:30 AM to 1:30 PM 

U.S. Environmental Protection Agency: 

Risk Assessment Data Repository—An 

Inter-Agency Collaboration 


12:00 NOON to 2:00 PM 

Central States Regional Chapter 

Meeting/Luncheon 


12:00 NOON to 1:15 PM 

Data Sciences International: Laboratory 

Animal Monitoring—Advanced 

Applications of Jacketed Telemetry: 

Respiration and More (By Invitation Only) 


12:00 NOON to 1:30 PM 

In Vitro and Alternative Methods Specialty 

Section Meeting/Luncheon 


12:00 NOON to 1:30 PM 

Occupational and Public Health Specialty 



12:00 NOON to 1:15 PM 

Postdoctoral Assembly Luncheon 


CC Room 3A 

12:00 NOON to 1:20 PM 

Town Hall Meeting: SOT Strategic Plan— 

Defining the Future of SOT 

CC Ballroom 6E 

12:15 PM to 1:15 PM 

Exhibitor Hosted Session: Affymetrix: 

Affymetrix is Accelerating Toxicology 

Decisions 


12:15 PM to 1:15 PM 

Exhibitor Hosted Session: Thermo Fisher 

Scientific: Cell Based Assays as an 

Alternative to Animal Testing? 


12:30 PM–1:20 PM 

Distinguished Toxicology Scholar Award 

Lecture: 

Half A Century of Progress in 

Neurotoxicology: Past, Present, and Future 

Lecturer: Toshio Narahashi 


12:30 PM to 1:00 PM 

Poster Set Up 


Page 39) 


1:00 PM to 4:30 PM 



1:30 PM to 2:30 PM 

Exhibitor Hosted Session: Covance: 

Outsourcing Preclinical Safety 

Assessment—How to Create a Strategy 

for Success 


1:30 PM to 2:30 PM 

Exhibitor Hosted Session: Metabolon, Inc.: 

Global Metabolomic Analysis in Drug 

Discovery and Development 


1:30 PM to 4:30 PM 

K–12 Paracelsus Goes to the Classroom— 

The TEAMS Project: Toxicologists 

Educating and Mentoring Students 

Hyatt E. Anderson Amphitheater 

1:30 PM to 4:15 PM 



Locations) 

2:00 PM to 3:30 PM 

Special Information Meeting with Ken 

Olden for Students Seeking Postdocs at 

NIEHS 

CC Room 210 

2:45 PM to 3:45 PM 

Exhibitor Hosted Session: Ingenuity 

Systems: Toxicity, Biomarker and 

Metabolomics Workflows Result in 

Efficient Evaluation of Compound 

Toxicity • Safety and the Application of 

IPA Pathway Analysis Tools to Cancer 

Therapeutics 


2:45 PM to 3:45 PM 

Exhibitor Hosted Session: Trevigen: 

Trevigen Standardized CometAssay 

System 


4:30 PM to 6:00 PM 

Annual Business Meeting of the Society 

of Toxicology (SOT Members Only; Full, 

Associate, Postdoctoral, and Student 

Members Invited) 


4:45 PM to 6:00 PM 

ToxExpo 2009 Exhibit Space Selection 



6:00 PM to 8:00 PM 

Association of Scientists of Indian Origin 

in America Special Interest Group Meeting/ 

Reception 


6:00 PM to 8:00 PM 

Axio Research Company: Celebration of 

Seattle 

Sheraton Metropolitan A Room 

6:00 PM to 7:30 PM 

Biological Modeling Specialty Section 


CC Room 308 

6:00 PM to 7:30 PM 

Carcinogenesis Specialty Section Meeting/ 

Reception 

CC Room 606 

6:00 PM to 7:30 PM 

Drug Discovery Toxicology Specialty 


CC Room 616 

6:00 PM to 7:30 PM 

Inhalation and Respiratory Specialty 


CC Room 603 

6:00 PM to 7:30 PM 

Metals Specialty Section Meeting/ 

Reception 

CC Room 619 

6:00 PM to 7:30 PM 

Neurotoxicology Specialty Section 


CC Room 609 

Continued on next page 

Event Calendar



Daily Pocket Calendar (Continued) 


Tuesday (Continued) March 18, 2008 

6:00 PM to 7:30 PM 

Regulatory and Safety Evaluation Specialty 


CC Room 612 

6:00 PM to 9:30 PM 



6:00 PM to 9:00 PM 

Toxicologists of African Origin Special 

Interest Group Meeting/Reception 

Hyatt Princessa 2 Room 

6:30 PM to 8:00 PM 

National Capital Area Regional Chapter 


Wild Ginger Restaurant 

6:30 PM to 8:30 PM 

Pfizer Recruiting/Outreach Effort 

Sheraton Grand Ballroom C 

6:30 PM to 8:30 PM 

Southeastern Regional Chapter Meeting/ 

Reception 

Hyatt Portland Room 

7:00 PM to 8:30 PM 

Kettering Laboratory, University of 

Cincinnati Reception 


7:30 PM to 10:00 PM 

University of Rochester Alumni Reception 


9:00 PM to 11:00 PM 

Michigan State University Environmental 

Toxicology Reception 

Sheraton Wallingford Room 

9:00 PM to 11:00 PM 

Rutgers Joint Graduate Program in 

Toxicology Annual Dessert Reception 


9:00 PM to 10:00 PM 

University of Connecticut Reception 


10 







Tuesday March 18, 2008 

7:30 AM–8:50 AM 

ISSUES SESSION 

• Over-the-Counter Cough and Cold Medications 

in Children: Efficacy, Safety, and Use 

(Ballroom 6B) 


• Breaking the Log-Jam: Public-Private 

Partnerships as a Way to Discover and Advance 

Biomarkers of Drug-Induced Toxicity 

(Room 618) 

• Reproductive Toxicity Studies: One Generation 

versus Two Generations (Room 602) 

• The 2007 Pet Food Related Toxic Nephropathy 

in Dogs and Cats (Room 6C) 


• Detection of Biological Free Radicals in Time 

and Space (Room 611) 

8:00 AM–8:50 AM 

DEBATE 

SOT/EUROTOX Debate: In Vitro Toxicology Is 

Useful for Regulatory Purposes (Ballroom 6A) 

9:00 AM–11:45 AM 


• Molecular and Genomic Insights into the Nrf2- 

Regulated Oxidative Stress Response: Impact on 

Carcinogenesis (Room 605) 

• New Concepts in the Etiology of Breast Cancer: 

From Genes to Environment and Back Again 

(Room 6B) 


• Drug-Related Torsades de Pointes: 

Advancements in Preclinical Modeling of 

Potential Cardiac Toxicity (Room 611) 

• The Allergic March: The Role of Chemicals in 

the Increasing Prevalence of Allergy and Asthma 

(Room 6A) 

• To Dye or Not to Dye: Safety of Oxidative Hair 

Dyes (Room 608) 


• Professional Career Development as a 

Toxicologist (Room 602) 


• Accelerating Discoveries in Toxicology Through 

‘Omics Research (Room 6C) 

• Chemical and Biological Weapons: Molecular 

Basis for Detection and Therapeutic Potential 

(Room 618) 

• Developmental Basis of Disease (Room 6E) 

• Health Risks and Food Safety (Room 615) 

• Manganese Neurotoxicity: From Worms to 

Primates (Room 2A) 

9:00 AM–12:30 PM 


(Exhibit Hall — See Poster Board Surface Map on 

Page 38) 

• Adverse Effects of Natural Products 


• Alternatives to Mammalian Models 


• Liver I: In Vivo (Exhibit Hall) 

• Mechanisms and Chemoprevention of PAH and 

Tobacco-Related Carcinogenesis (Exhibit Hall) 

• Particulate Matter and the Cardiovascular 

System (Exhibit Hall) 

• Persistent Organic Pollutants (POPs) 


• Regulatory Risk Assessment (Exhibit Hall) 

• Xenobiotic Biotransformation I (Exhibit Hall) 

12:00 NOON–1:20 PM 

Town Hall Meeting 

SOT Strategic Plan—Defining the Future of SOT 

(Ballroom 6E) 

12:30 PM–1:20 PM 

Distinguished Toxicology Scholar 

Award Lecture 

Half a Century of Progress in Neurotoxicology: 

Past, Present, and Future 

Lecturer: Toshio Narahashi (Room 6B) 

1:00 PM–4:30 PM 



Page 39) 

• Applications of Biological Modeling 


• Assessment of Ecological Toxicology 


• Breast Cancer: Mechanisms, Biomarkers, and 

Chemoprevention (Exhibit Hall) 

• Inhalation Toxicology (Exhibit Hall) 

• Liver II: In Vitro (Exhibit Hall) 

• Nanoparticles: Target Organs (Exhibit Hall) 

• Pharmacokinetics and Disposition (Exhibit Hall) 

• Regulation/Policy (Exhibit Hall) 

• Reproductive System (Exhibit Hall) 

• Risk Assessment Research (Exhibit Hall) 

• Signal Transduction and Gene Regulation 


1:30 PM–4:15 PM 


• Endothelial Dysfunction: More Than Just a ‘No 

NO’ Phenomenon (Room 605) 

• Neurotoxicant-Induced Alterations in 

Developmental and Adult Neurogenesis: 

Structure-Function Studies and Clinical 

Relevance (Room 611) 

• Novel Biomarkers of Drug-Induced Toxicity: 

Outcomes of Predtox and the Predictive Safety 

Testing Consortium (Room 602) 


• Dermal Toxicological Assessment of 

Nanomaterials and Nanodevices (Room 6C) 

• Host Susceptibility and Chemical Safety Testing: 

New Approaches to Estimate Risks in the 

Human Population (Room 608) 

• Molecular Mechanisms and Molecular Biology 

of Metal Carcinogenesis (Room 6B) 

• Strategies for Assessing Developmental 

and Reproductive Toxicology of Bio- 

Pharmaceuticals (Room 6A) 


• Human Health Risk Assessment for 

Pharmaceuticals in the Environment (PIE) 

(Room 618) 


• Arsenic Toxicity (Room 2A) 

• Mechanisms of Hypersensitivity (Room 6E) 

• Mechanisms of Pesticide Toxicity (Room 615) 

Event Calendar


Notes 

12 







Wednesday March 19, 2008 


start time. 



7:00 AM to 8:30 AM 

Committee on Diversity Initiatives Meeting 

CC Room 305 

7:00 AM to 8:00 AM 

Ethical, Legal, and Social Issues Specialty 


CC Room 209 

7:00 AM to 8:00 PM 


CC Room 454 

7:00 AM to 8:30 AM 

Membership Committee Meeting 

CC Room 208 

7:00 AM to 8:30 AM 

Michigan Regional Chapter Meeting/ 

Breakfast 


7:00 AM to 8:30 AM 

Midwest Regional Chapter 

Meeting/Breakfast 


7:00 AM to 8:30 AM 

NIH Funding Task Force Meeting 

CC Room 304 

7:00 AM to 4:00 PM 

SOT Office 

CC Room 303 

7:00 AM to 4:00 PM 


CC Room 213 

7:00 AM to 8:00 AM 

Student Advisory Council Business 


CC Room 307 

7:30 AM to 9:30 AM 


CC Level 6 

7:30 AM to 9:00 AM 

Drug Discovery Specialty Section Officers 


Sheraton Daily Grill 

7:30 AM to 8:50 AM 



Locations) 

8:00 AM to 9:00 AM 

Dermal Toxicology Specialty Section 


CC Room 309 

8:00 AM to 6:00 PM 



8:00 AM to 5:00 PM 



8:00 AM to 4:00 PM 

Housing Desk 


8:00 AM to 8:50 AM 

Keynote MRC Lecture: Biological Energy 

Conversion and Its Toxic Consequences 

Nobel Laureate Professor 

Sir John E. Walker 


8:00 AM to 4:00 PM 

Registration 


8:00 AM to 4:00 PM 

Tour Desk 


8:30 AM to 2:30 PM 



8:30 AM to 4:30 PM 


CC Room 205 

8:30 AM to 9:30 AM 

Exhibitor Hosted Session: BASi 

(Bioanalytical Systems, Inc.): Automated 

In Vivo Sampling with Culex 


8:30 AM to 9:30 AM 

Exhibitor Hosted Session: Beckman 

Coulter, Inc.: Multiplex Gene Expression 

for Toxicology Screening of Target 

Compounds 


8:30 AM to 4:30 PM 



8:30 AM to 9:00 AM 

Poster Set Up 


Page 40) 


8:30 AM to 4:30 PM 



9:00 AM to 12:30 PM 



9:00 AM to 11:45 AM 



Locations) 

9:45 AM to 10:45 AM 

Exhibitor Hosted Session: Hemogenix Inc.: 

Drug-Drug Interaction Toxicity Screening 

at a Cellular Level 


9:45 AM to 10:45 AM 

Exhibitor Hosted Session: Huntingdon Life 

Sciences: Bioanalysis for Toxicologists: 

Everything You Wanted to Know but Were 

Afraid to Ask 


11:00 AM to 12:00 NOON 

Exhibitor Hosted Session: Numira 

Biosciences: MicroCT Based Virtual 

Histology for Small Animal Imaging 


11:00 AM to 12:00 NOON 

Exhibitor Hosted Session: StemCell 

Technologies, Inc.: Utility of Hematopoietic 

Colony Forming Cell (CFC) Assays in 

Drug Development 


11:30 AM to 1:30 PM 

Finance Committee Meeting 

CC Room 302 

11:30 AM to 1:30 PM 

K–12 Education Committee Meeting 

CC Room 304 

12:00 NOON to 1:30 PM 

Comparative and Veterinary Specialty 



12:00 NOON to 1:30 PM 

Immunotoxicology Specialty Section 


CC Room 208 

12:00 NOON to 1:20 PM 

Meet the Directors: A Conversation with 

the Directors 

NIEHS Strategic Plan, Samuel Wilson 


12:00 NOON to 1:20 PM 

Soapbox Session 


12:15 PM to 1:15 PM 

Exhibitor Hosted Session: Beckman 

Coulter, Inc.: gTox Flow Kit: No-Wash, 

Room-Temperature, Fully Automated Flow 

Cytometric Detection of Murine Peripheral 

Blood Micronucleated Erythrocytes 


12:15 PM to 1:15 PM 

Exhibitor Hosted Session: Covance: Ocular 

Drug Development Selected Preclinical 

Topics—Pharmacokinetic Barriers to 

Ocular Drug Safety and Considerations in 

Species Selection for Safety Studies 


12:30 PM to 1:00 PM 

Poster Set Up 


Page 41) 


1:00 PM to 4:30 PM 



1:30 PM to 2:30 PM 

Exhibitor Hosted Session: Cellumen Inc.: 

CellCiphr Cytotoxicity Profiling for 

Investigational Safety: Cellular Systems 

Biology with 33-Features in HepG2 and 

Primary Rat Hepatocytes 


1:30 PM to 2:30 PM 

Exhibitor Hosted Session: NOTOCORD 

Systems: Evaluation of the Use of an 

Unsupervised ECG Classification Tool in 

Cardiovascular Drug Safety Assessment 


1:30 PM to 4:15 PM 



Locations) 

2:00 PM to 4:00 PM 

Exhibit Liaison Advisory Committee 


CC Room 309 

2:45 PM to 3:45 PM 

Exhibitor Hosted Session: SkinEthic 

Laboratories: An Alternative to Animal 

Use: Today and Prospective 


2:45 PM to 3:45 PM 

Exhibitor Hosted Session: VisualSonics: 

In Vivo Micro-Ultrasound Imaging for 

Quantification of Anatomical, Functional 

and Molecular Biomarkers in Preclinical 



3:00 PM to 5:00 PM 

Board of Publications Committee Meeting 

CC Room 304 

4:30 PM to 6:00 PM 

Education Committee Meeting 

CC Room 208 

4:30 PM to 9:30 PM 



4:30 PM to 5:50 PM 

Scientific Sessions (Sunset) 


Locations) 

5:00 PM - 7:00 PM 

RETHINK: Impact of the Minipig in 

Toxicology Open Meeting 


5:00 PM to 12:00 MIDNIGHT 

ToxExpo Tear Down 


6:00 PM to 7:30 PM 



CC Room 612 

6:00 PM to 7:30 PM 



CC Room 606 

6:00 PM to 7:30 PM 

Mixtures Specialty Section Meeting/ 

Reception 

CC Room 613 

6:00 PM to 7:30 PM 



CC Room 619 

6:00 PM to 7:30 PM 

Reproductive and Developmental 

Toxicology Specialty Section Meeting/ 

Reception 

CC Room 603 

6:00 PM to 7:30 PM 

Women in Toxicology Special Interest 

Group Meeting/Reception 


7:00 PM to 8:30 PM 

President’s Reception (By Invitation Only) 

Sheraton Cirrus Room 

8:00 PM to 9:00 PM 

Academy of Toxicological Sciences 

Reception 


Event Calendar





Wednesday March 19, 2008 

7:30 AM–8:50 AM 


• Hazard vs. Risk for Chemical Regulation 

(Room 618) 

• Reconciling Scientific and Ethical Concerns in 

the Use of Animals for Toxicological Research 

(Room 615) 

• Toxicology Training Needs: New Faces and New 

Tools for the 21 st Century (Room 608) 

INFORMATIONAL SESSIONs 

• Cross-Cultural Understanding of Asian and 

Western Cultural Values in the Workplace 

(Room 602) 

• Toxicological and Public Health Challenges in 

Africa (Room 605) 

8:00 AM–8:50 AM 

KEYNOTE MRC LECTURE 

Biological Energy Conversion and Its Toxic 

Consequences 

Lecturer: Nobel Laureate Professor Sir John E. 

Walker (Ballroom 6A) 

9:00 AM–11:45 AM 


• Developmental Basis of Health and Disease: 

Persistent Effects of Tobacco Smoke Exposure 

(Room 605) 

• Unusual Manifestations of On-Target and Off- 

Target Toxicity: Toxicity of Kinase Inhibitors 

(Room 608) 


• Natural Killer Cells as Targets of Drugs, 

Toxicants, and Biologicals (Room 6B) 

• Safe Approaches to Topical Product 

Development (Room 615) 

• Threshold of Toxicologic Concern: Historical 

Perspectives and Future Applications (Room 6C) 

• Use of Behavioral and Non-Routine Neurological 

Approaches in Drug Discovery Toxicology 

(Room 6A) 


• Globally Harmonized System of Classification 

and Labelling of Chemicals (GHS): A New 

Language for Toxicologists (Room 602) 


• Advances in Biological Modeling (Room 611) 

• Mechanisms of Reproductive Toxicity 

(Room 2A) 

• Modulating Apoptosis for Beneficial Outcomes 

(Room 618) 

• Nanoparticles: Cellular and Organ Disposition 

(Room 6E) 

9:00 AM–12:30 PM 


(Exhibit Hall— See Poster Board Surface Map on 

Page 40) 

• Application of ‘Omics Research Tools in 

Toxicology (Exhibit Hall) 

• Cardiovascular System: Cardiac Effects 


• Developmental Toxicology (Exhibit Hall) 

• DNA Damage and Repair: Mechanisms and 

Agents (Exhibit Hall) 

• Epidemiology and Exposure Assessment 


• Gene Regulation and Genomic Approaches 


• Mechanisms of Carcinogenesis (Exhibit Hall) 

• Metals I (Exhibit Hall) 

• Nanoparticles: Inhalation and Respiratory Cell 

Injury (Exhibit Hall) 

• Respiratory and Skin Hypersensitivity 


• Skin Penetration and Toxicity (Exhibit Hall) 

12:00 NOON–1:20 PM 


• Mentoring 101—How to Mentor, and How to be 

Mentored (Room 615) 

MEET THE DIRECTORs: A Conversation 

with the Directors 

NIEHS Strategic Plan 

Lecturer: Samuel Wilson 

(Ballroom 6B) 

1:00 PM–4:30 PM 



Page 41) 

• Biomarkers: Methods (Exhibit Hall) 

• Developmental Neurotoxicity (Exhibit Hall) 

• Human Biomarkers (Exhibit Hall) 

• Juvenile Toxicity (Exhibit Hall) 

• Metal Neurotoxicology: Experimental Models 

and Mechanisms (Exhibit Hall) 

• Neurotoxicity: Miscellaneous Compounds, 

Models, and Mechanisms (Exhibit Hall) 

• Oxidative Injury and Redox Biology I: In Vivo 


• Pharmaceuticals (Exhibit Hall) 

• Risk Assessment Applications (Exhibit Hall) 

• Safety Assessment, Pharmaceutical—Liver, 

Kidney, Immune System (Exhibit Hall) 

1:30 PM–4:15 PM 


• Arsenic and Cardiovascular Disease (Room 6B) 

• Nanomaterial Pharmacokinetics: Where We Are 

and Where We Need to Go (Room 6C) 


• Advances in Technology and Increasing 

Acceptance for Zebrafish Use in Drug Discovery 

(Room 608) 

• Chlorotriazine Herbicides and their Common 

Degradation Products of Concern: Disposition 

and Potential Health Effects (Room 611) 

• Interdisciplinary Approaches for Improving 

Chemical Hazard Testing Paradigms (Room 6A) 


• Apoptosis: Cardiopulmonary Targets (Room 6E) 

• Immunotoxicology: T Cells (Room 602) 

• Issues in Regulatory Risk Assessment 

(Room 605) 

• New Insights for Developmental Toxicology 

(Room 618) 

• Nrf2 Induced Gene Regulation (Room 615) 

• Selective Dopaminergic Neurotoxicity: Genetics 

and Mechanisms (Room 2A) 

4:30 PM–5:50 PM 


• A Case Study on the Risks and Benefits of Deca- 

BDE—a Major Brominated Flame Retardant 

(Room 608) 

INFORMATIONAL SESSIONS 

• Implementation of the ICH S8 Immunotoxicity 

Testing Guideline (Room 615) 

• NIEHS Outstanding New Environmental 

Scientists (ONES) Awardees (Room 6C) 

14 








Thursday March 20, 2008 


start time. 



7:00 AM to 1:00 PM 


CC Room 454 

7:00 AM to 11:30 AM 

SOT Office 

CC Room 303 

7:00 AM to 11:30 AM 


CC Room 213 

7:30 AM to 12:00 NOON 


CC Level 6 

7:30 AM to 9:30 AM 

CRAD Committee Meeting II 

CC Room 208 

Thursday March 20, 2008 

7:30 AM–8:50 AM 

ISSUES SESSION 

• 2007 National Research Council-National Academy 

of Sciences Reports: Impact on the Future of 

Toxicology (Ballroom 6B) 


• Biofuel Combustion: An Emerging Health 

Problem? (Room 608) 

8:30 AM–12:00 NOON 



Page 42) 

• AHR Mechanisms (Ballroom 6C & E) 

• Cardiovascular System: Vascular Effects 

(Ballroom 6C & E) 

• Chemoprevention (Ballroom 6C & E) 

• Fish Alternative Models of Toxicity 


• Food Safety II (Ballroom 6C & E) 

• High Throughput, High Content Approaches to 

Assessing Genotoxicity (Ballroom 6C & E) 

• Metals II (Ballroom 6C & E) 

• Method Development, Autoimmunity and 

Disease Mechanisms in Immunotoxicology 


7:30 AM to 8:50 AM 

Issues Session: 2007 National Research 

Council-National Academy of Sciences 

Reports: Impact on the Future of 



7:30 AM to 8:30 AM 

Program Committee Meeting 

CC Room 305 

7:30 AM to 8:50 AM 



Locations) 

8:00 AM to 11:30 AM 



8:00 AM to 11:30 AM 



8:00 AM to 11:30 AM 

Housing Desk 


8:00 AM to 8:30 AM 

Poster Set Up 


Pages 42 and 43) 

CC Ballroom 6C & E 

8:00 AM to 11:30 AM 

Registration 


8:00 AM to 11:30 AM 

Tour Desk 


8:00 AM to 12:00 NOON 

ToxExpo Tear Down 


8:30 AM to 12:00 NOON 


CC Ballroom 6C & E 

• Oxidative Injury and Redox Biology II: In Vitro 


• Pesticide Neurotoxicity (Ballroom 6C & E) 

• Safety Assessment, Pharmaceutical— 

Techniques, Pulmonary, Cardiovascular 


9:00 AM–11:45 AM 


• Cellular Redox Status and Zinc Signaling 

(Room 615) 

• Perinatal Exposure to Nucleoside Reverse 

Transcriptase Inhibitors (NRTIs) Induces 

Transplacental Genotoxicity and Mitochondrial 

Toxicity (Room 605) 

• Stem Cells in Developmental and Reproductive 

Biology and Toxicology (Room 611) 


• Genotoxicity Testing from Early Discovery 

through Regulatory Submission: A 

Comprehensive Primer (Room 618) 

• Incorporation of Mode-of-Action into 

Mechanistically-Based Quantitative Models 

(Room 608) 

• Pulmonary Toxicity Testing of Nanoparticles 

(Room 6B) 

9:00 AM to 11:45 AM 



Locations) 

1:00 PM to 4:30 PM 

Satellite Meeting: The Kleinfelder Group: 

Perchlorate Exposures, Iodine Modulation 

of Effect, and Epidemiologic Associations: 

Implications for Risk Assessment 


(Meeting details are on page 292) 

Friday March 21, 2008 

9:00 AM to 3:30 PM 

Satellite Meeting: The Kleinfelder Group: 

Perchlorate Exposures, Iodine Modulation 

of Effect, and Epidemiologic Associations: 



(Meeting details are on page 292) 


• REACH: Implementation, Chemical Safety, and 

Information Requirements (Room 6A) 

Event Calendar


Notes 

16 



Schedule by Event Name 

Event: Date: Time: Location: Room: 

25–Year (or More) Member Reception (By Invitation Only) Sunday, Mar 16 7:00 PM to 8:00 PM Convention Center 601 

50 th Year Anniversary SOT Task Force Meeting Tuesday, Mar 18 10:00 AM to 11:30 AM Convention Center 209 

ABT Annual Mixer Meeting Monday, Mar 17 4:30 PM to 6:00 PM Sheraton Willow A 

ABT Board of Directors Meeting Saturday, Mar 15 1:00 PM to 6:00 PM Sheraton Ravenna 

Academic Program Session for Undergraduate Students Sunday, Mar 16 3:00 PM to 5:00 PM Convention Center 2A 

Academy of Toxicological Sciences Board Meeting Tuesday, Mar 18 6:30 AM to 7:30 AM Sheraton Juniper 

Academy of Toxicological Sciences Reception Wednesday, Mar 19 8:00 PM to 9:00 PM Sheraton Willow 

American Association of Chinese in Toxicology Special Interest 

Group Business Meeting, Distinguished Chinese Toxicologist 

Lecture, 

Monday, Mar 17 5:00 PM to 8:00 PM Sheraton Grand Ballroom D 

American Board of Veterinary Toxicology Diplomate Meeting Tuesday, Mar 18 6:45 AM to 7:45 AM Sheraton Kirkland 

Animals in Research Committee Meeting Tuesday, Mar 18 7:15 AM to 8:30 AM Convention Center 305 

Annual Business Meeting of the Society of Toxicology 

(SOT Members Only; Full, Associates, Postdoctoral, and 

Student Members Invited) 

Tuesday, Mar 18 4:30 PM to 6:00 PM Convention Center Ballroom 6A 

Arizona Night Sunday, Mar 16 7:30 PM to 10:00 PM Sheraton Willow A 

Association of Scientists of Indian Origin in America Special 

Interest Group Meeting/Reception 

Tuesday, Mar 18 6:00 PM to 8:00 PM Sheraton Grand Ballroom A 

Award Ceremony Music Prelude Kaley Eaton, Pianist Sunday, Mar 16 4:45 PM to 5:15 PM Convention Center Ballroom 6A 

Awards Ceremony (All Attendees Welcome) Sunday, Mar 16 5:15 PM to 6:30 PM Convention Center Ballroom 6A 

Awards Committee Meeting Monday, Mar 17 11:00 AM to 12:30 PM Convention Center 304 

Awards Recipients Photographed Sunday, Mar 16 4:00 PM to 5:15 PM Convention Center 601 

Axio Research Company: Celebration of Seattle Tuesday, Mar 18 6:00 PM to 8:00 PM Sheraton Metropolitan A 

Biological Modeling Specialty Section Meeting/Reception Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 308 

Board of Publications Committee Meeting Wednesday, Mar 19 3:00 PM to 5:00 PM Convention Center 304 

CAHB and Taconic: Discussion Session on Alternative Transgenic 

Models for Carcinogenicity Evaluation 

Monday, Mar 17 4:30 PM to 7:30 PM Sheraton Grand Ballroom A 

Carcinogenesis Specialty Section Meeting/Reception Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 606 

Carcinogenesis Specialty Section Officers Meeting Monday, Mar 17 7:00 AM to 8:30 AM Convention Center 209 

Central States Regional Chapter Meeting/Luncheon Tuesday, Mar 18 12:00 NOON to 2:00 PM Sheraton Cedar 

Committee on Diversity Initiatives Meeting Wednesday, Mar 19 7:00 AM to 8:30 AM Convention Center 305 

Comparative and Veterinary Specialty Section Meeting/Luncheon Wednesday, Mar 19 12:00 NOON to 1:30 PM Sheraton Willow 

Comparative and Veterinary Specialty Section Officers Meeting Monday, Mar 17 6:30 AM to 8:00 AM Convention Center 304 

Complimentary Coffee Monday, Mar 17 9:15 AM to 10:15 AM Convention Center Exhibit Hall 

Complimentary Coffee Tuesday, Mar 18 9:15 AM to 10:15 AM Convention Center Exhibit Hall 

Complimentary Coffee Wednesday, Mar 19 9:15 AM to 10:15 AM Convention Center Exhibit Hall 

Concession Stands Sunday, Mar 16 7:30 AM to 2:30 PM Convention Center Level 6 

Concession Stands Monday, Mar 17 7:30 AM to 9:30 AM Convention Center Level 6 

Concession Stands Monday, Mar 17 9:15 AM to 2:30 PM Convention Center Exhibit Hall 

Concession Stands Tuesday, Mar 18 7:30 AM to 9:30 AM Convention Center Level 6 

Concession Stands Tuesday, Mar 18 8:30 AM to 2:30 PM Convention Center Exhibit Hall 

Concession Stands Wednesday, Mar 19 7:30 AM to 9:30 AM Convention Center Level 6 

Concession Stands Wednesday, Mar 19 8:30 AM to 2:30 PM Convention Center Exhibit Hall 

Concession Stands Thursday, Mar 20 7:30 AM to 12:00 NOON Convention Center Level 6 

Continuing Education Committee Meeting Monday, Mar 17 7:00 AM to 8:00 AM Convention Center 208 

Continuing Education Committee Walk-Through Saturday, Mar 15 5:00 PM to 5:45 PM Convention Center 603 

Continuing Education Courses (Ticket Required) Sunday, Mar 16 8:15 AM to 12:00 NOON Convention Center (See Signage for 

Room Location) 


up-to-date information at www.toxicology.org 17



Schedule by Event Name (Continued) 


Continuing Education Courses (Ticket Required) Sunday, Mar 16 1:15 PM to 5:00 PM Convention Center (See Signage for 


Continuing Education Luncheon for Speakers, Committee, and 

Students (By Invitation Only) 

Sunday, Mar 16 11:45 AM to 1:15 PM Convention Center IMP Foyer, 

Level 2 

Continuing Education Sunrise Mini-Course (Ticket Required) Sunday, Mar 16 7:00 AM to 7:45 AM Convention Center (See Signage for 


Council Meeting Saturday, Mar 15 8:00 AM to 1:30 PM Sheraton Issaquah 

Council Orientation Meeting Friday, Mar 14 4:00 PM to 7:00 PM Sheraton Douglas 

Council Orientation Reception/Dinner Friday, Mar 14 7:00 PM to 10:00 PM Sheraton Cedar 

CRAD Committee Meeting I Sunday, Mar 16 8:00 AM to 10:00 AM Convention Center 209 

CRAD Committee Meeting II Thursday, Mar 20 7:30 AM to 9:30 AM Convention Center 208 

CRAD Job Bank Center Sunday, Mar 16 10:00 AM to 4:30 PM Convention Center 205 

CRAD Job Bank Center Monday, Mar 17 9:15 AM to 4:30 PM Convention Center 205 

CRAD Job Bank Center Tuesday, Mar 18 8:30 AM to 4:30 PM Convention Center 205 

CRAD Job Bank Center Wednesday, Mar 19 8:30 AM to 4:30 PM Convention Center 205 

Data Sciences International: Laboratory Animal Monitoring— 

Advanced Applications of Jacketed Telemetry: Respiration and 

More (By Invitation Only) 

Tuesday, Mar 18 12:00 NOON to 1:15 PM Sheraton Grand Ballroom A 

Dermal Toxicology Specialty Section Meeting/Reception Wednesday, Mar 19 6:00 PM to 7:30 PM Convention Center 612 

Dermal Toxicology Specialty Section Officers Meeting Wednesday, Mar 19 8:00 AM to 9:00 AM Convention Center 309 

Distinguished Toxicology Scholar Award Lecture: Half A Century 

of Progress in Neurotoxicology: Past, Present, and Future 

Lecturer: Toshio Narahashi 

Tuesday, Mar 18 12:30 PM to 1:20 PM Convention Center Ballroom 6B 

Drug Discovery Specialty Section Officers Meeting Wednesday, Mar 19 7:30 AM to 9:00 AM Sheraton Daily Grill 

Drug Discovery Toxicology Specialty Section Meeting/ Reception Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 616 

Education Committee Meeting Wednesday, Mar 19 4:30 PM to 6:00 PM Convention Center 208 

Elsevier Editors’ Reception Monday, Mar 17 5:30 PM to 7:30 PM Hyatt Leonesa 3 

E-mail Center/Message Boards Saturday, Mar 15 4:00 PM to 7:00 PM Convention Center East Lobby, 

Level 6 

E-mail Center/Message Boards Sunday, Mar 16 7:00 AM to 6:00 PM Convention Center East Lobby, 

Level 6 

E-mail Center/Message Boards Monday, Mar 17 7:00 AM to 6:00 PM Convention Center East Lobby, 

Level 6 

E-mail Center/Message Boards Tuesday, Mar 18 8:00 AM to 6:00 PM Convention Center East Lobby, 

Level 6 

E-mail Center/Message Boards Wednesday, Mar 19 8:00 AM to 6:00 PM Convention Center East Lobby, 

Level 6 

E-mail Center/Message Boards Thursday, Mar 20 8:00 AM to 11:30 AM Convention Center East Lobby, 

Level 6 

Endowment Fund Board Meeting Sunday, Mar 16 2:00 PM to 4:00 PM Convention Center 212 

Ethical, Legal, and Social Issues Specialty Section Meeting/ 

Reception 

Ethical, Legal, and Social Issues Specialty Section Officers 


Monday, Mar 17 6:00 PM to 7:30 PM Convention Center 601 

Wednesday, Mar 19 7:00 AM to 8:00 AM Convention Center 209 

Exhibit Liaison Advisory Committee Meeting Wednesday, Mar 19 2:00 PM to 4:00 PM Convention Center 309 

Exhibitor Hosted Session: Affymetrix: Affymetrix is Accelerating 

Toxicology Decisions 

Exhibitor Hosted Session: BASi (Bioanalytical Systems, Inc.): 

Automated In Vivo Sampling with Culex 

Exhibitor Hosted Session: Beckman Coulter, Inc.: 

Multiplex Gene Expression for Toxicology Screening of Target 

Compounds 

Tuesday, Mar 18 12:15 PM to 1:15 PM Convention Center Exhibit Hall 4C-3 

Wednesday, Mar 19 8:30 AM to 9:30 AM Convention Center Exhibit Hall 4C-3 


18 





Exhibitor Hosted Session: Beckman Coulter, Inc.: 

gTox Flow Kit: No-Wash, Room-Temperature, Fully Automated 

Flow Cytometric Detection of Murine Peripheral Blood 

Micronucleated Erythrocytes 

Exhibitor Hosted Session: Bio-Rad Laboratories: SELDI-TOF 

Strategies for Toxicological Biomarker Discovery and Application 

Exhibitor Hosted Session: Cellular Dynamics International, 

Inc.: Progress in Using Human Embryonic Stem Cells in Drug 

Screening, Toxicology and Drug Development 

Exhibitor Hosted Session: Cellumen Inc.: CellCiphr Cytotoxicity 

Profiling for Investigational Safety: Cellular Systems Biology with 

33-Features in HepG2 and Primary Rat Hepatocytes 

Exhibitor Hosted Session: Chantest, Inc.: Progress in Ion Channel 

Safety Assessments 

Exhibitor Hosted Session: Charles River Laboratories: Building a 

Global Standard GLP Preclinical Research Operation in China 


Outsourcing Preclinical Safety Assessment—How to Create a 

Strategy for Success 


Ocular Drug Development Selected Preclinical 

Topics—Pharmacokinetic Barriers to Ocular Drug Safety and 

Considerations in Species Selection for Safety Studies 

Exhibitor Hosted Session: Data Integrated Scientific Systems 

(D.I.S.S.): The Future of Telemetry 

Exhibitor Hosted Session: GeneGo Inc.: Tools for Systems 

Toxicology–Integrating Chemical, Gene Expression, Protein and 

Metabolic Data into Safety Assessment 

Exhibitor Hosted Session: Hemogenix Inc.: Drug-Drug Interaction 

Toxicity Screening at a Cellular Level 

Exhibitor Hosted Session: Huntingdon Life Sciences: Bioanalysis 

for Toxicologists: Everything You Wanted to Know but Were 

Afraid to Ask 

Exhibitor Hosted Session: Ingenuity Systems: Toxicity, Biomarker 

and Metabolomics Workflows Result in Efficient Evaluation of 

Compound Toxicity and Safety and the Application of IPA Pathway 

Analysis Tools to Cancer Therapeutics 

Exhibitor Hosted Session: Metabolon, Inc.: Global Metabolomic 

Analysis in Drug Discovery and Development 

Exhibitor Hosted Session: MPI Research: Scientific Advances in 

GLP Bioanalytical Analysis 

Exhibitor Hosted Session: National Toxicology Program: Public 

Access to the National Toxicology Program: From Acrylamide to 

Zinc 

Exhibitor Hosted Session: NeuroScience Associates (NSA): Key 

Contemporary Concepts in Neurotoxicity Screens 

Exhibitor Hosted Session: NOTOCORD Systems: Evaluation of the 

Use of an Unsupervised ECG Classification Tool in Cardiovascular 

Drug Safety Assessment 

Exhibitor Hosted Session: Numira Biosciences: MicroCT Based 

Virtual Histology for Small Animal Imaging 

Exhibitor Hosted Session: Phylonix Pharmaceuticals, Inc.: Fish 

First: Zebrafish are Increasingly Used for Early Stage Assessment 

of Drug Efficacy, Toxicity and Safety 

Exhibitor Hosted Session: Promega Corporation: Multiplexing 

Luminescent ADMETox Cell-Based Assays Including Applications 

with Primary Cells and Stem Cells 

Exhibitor Hosted Session: ReachBio LLC: Primary Stem 

Cell Based Assays for Toxicology and Other Drug Screening 

Applications 

Wednesday, Mar 19 12:15 PM to 1:15 PM Convention Center Exhibit Hall 4C-3 

Monday, Mar 17 11:00 AM to 12:00 NOON Convention Center Exhibit Hall 4C-3 

Monday, Mar 17 1:30 PM to 2:30 PM Convention Center Exhibit Hall 4C-3 


Tuesday, Mar 18 9:45 AM to 10:45 AM Convention Center Exhibit Hall 4C-3 




Tuesday, Mar 18 11:00 AM to 12:00 NOON Convention Center Exhibit Hall 4C-4 






Monday, Mar 17 9:45 AM to 10:45 AM Convention Center Exhibit Hall 4C-3 


Tuesday, Mar 18 11:00 AM to 12:00 NOON Convention Center Exhibit Hall 4C-3 


Wednesday, Mar 19 11:00 AM to 12:00 NOON Convention Center Exhibit Hall 4C-3 


Monday, Mar 17 11:00 AM to 12:00 NOON Convention Center Exhibit Hall 4C-4 








Exhibitor Hosted Session: Ricerca Biosciences, LLC: 

Biotechnology—Both a Business and a Science and Service 

Exhibitor Hosted Session: Rosetta Biosoftware: Critical Path 

Analysis of Shared Toxicity Data between Pharmaceutical 

Companies Bridges Biomarker Discovery 

Exhibitor Hosted Session: SkinEthic Laboratories: An Alternative 

to Animal Use: Today and Prospective 

Exhibitor Hosted Session: StemCell Technologies, Inc.: Utility 

of Hematopoietic Colony Forming Cell (CFC) Assays in Drug 

Development 

Exhibitor Hosted Session: Strategic Applications, Inc. (SAI): 

Innovations in Infusion and Sampling 

Exhibitor Hosted Session: Thermo Fisher Scientific: Cell Based 

Assays as an Alternative to Animal Testing? 

Exhibitor Hosted Session: Trevigen: Trevigen Standardized 

CometAssay System 

Exhibitor Hosted Session: VisualSonics: In Vivo Micro-Ultrasound 

Imaging for Quantification of Anatomical, Functional and 

Molecular Biomarkers in Preclinical Toxicology 

Exhibitor Hosted Session: VivoMetrics, Inc.: One Year into the 

Modern Era of Data Collection: Successes, Improvements, and 

What’s Next 

Monday, Mar 17 9:45 AM to 10:45 AM Convention Center Exhibit Hall 4C-4 



Wednesday, Mar 19 11:00 AM to 12:00 NOON Convention Center Exhibit Hall 4C-4 






Fellowship Interviews by Awards Committee Saturday, Mar 15 5:30 PM to 8:30 PM Convention Center 308 

Finance Committee Meeting Wednesday, Mar 19 11:30 AM to 1:30 PM Convention Center 302 

Food and Chemical Toxicology Editorial Board Meeting Monday, Mar 17 11:30 AM to 1:30 PM Sheraton Juniper 

Food Safety Specialty Section Meeting/ Reception Monday, Mar 17 6:00 PM to 7:30 PM Convention Center 619 

Food Safety Specialty Section Officers Meeting Monday, Mar 17 7:00 AM to 8:30 AM Convention Center 310 

Guest Hospitality Center Sunday, Mar 16 8:00 AM to 5:00 PM Sheraton Greenwood 

Guest Hospitality Center Monday, Mar 17 8:00 AM to 5:00 PM Sheraton Greenwood 

Guest Hospitality Center Tuesday, Mar 18 8:00 AM to 5:00 PM Sheraton Greenwood 

Guest Hospitality Center Wednesday, Mar 19 8:00 AM to 5:00 PM Sheraton Greenwood 

Guest Hospitality Center Thursday, Mar 20 8:00 AM to 11:30 AM Sheraton Greenwood 

Gulf Coast and South Central Regional Chapters Joint Meeting/ 

Reception 

Monday, Mar 17 5:00 PM to 6:00 PM Gordon Biersch 

Brewery/Restaurant 

HESI-Sponsored Luncheon Seminar Monday, Mar 17 12:00 NOON to 1:00 PM Sheraton Grand Ballroom B 

Hispanic Organization for Toxicologists Special Interest Group 


Monday, Mar 17 6:00 PM to 7:00 PM Sheraton Kirkland 

Hot Zones (Wireless Internet Access) Monday, Mar 17 9:15 AM to 4:30 PM Convention Center Exhibit Hall 

Hot Zones (Wireless Internet Access) Tuesday, Mar 18 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Hot Zones (Wireless Internet Access) Wednesday, Mar 19 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Housing Desk Saturday, Mar 15 4:00 PM to 7:00 PM Convention Center South Lobby, 

Level 4 

Housing Desk Sunday, Mar 16 7:00 AM to 5:00 PM Convention Center South Lobby, 

Level 4 

Housing Desk Monday, Mar 17 7:00 AM to 5:00 PM Convention Center South Lobby, 

Level 4 

Housing Desk Tuesday, Mar 18 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Housing Desk Wednesday, Mar 19 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Housing Desk Thursday, Mar 20 8:00 AM to 11:30 AM Convention Center South Lobby, 

Level 4 

Immunotoxicology Specialty Section Meeting/Reception Wednesday, Mar 19 6:00 PM to 7:30 PM Convention Center 606 

20 





Immunotoxicology Specialty Section Officers Meeting Wednesday, Mar 19 12:00 NOON to 1:30 PM Convention Center 208 

In Vitro and Alternative Methods Specialty Section Meeting/ 

Luncheon 

In Vitro and Alternative Methods Specialty Section Officers 


In Vitro Toxicology Lecture and Luncheon for Students 


Tuesday, Mar 18 12:00 NOON to 1:30 PM Sheraton Grand Ballroom B 

Monday, Mar 17 7:00 AM to 9:00 AM Convention Center 204 

Monday, Mar 17 12:15 PM to 1:20 PM Sheraton Grand Ballroom A 

Inhalation and Respiratory Specialty Section Meeting/Reception Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 603 

Issues Session—2007 National Research Council-National 

Academy of Sciences Reports: Impact on the Future of Toxicology 

Issues Session—Over-the-Counter Cough and Cold Medications in 

Children: Efficacy, Safety, and Use 

Thursday, Mar 20 7:30 AM to 8:50 AM Convention Center Ballroom 6B 

Tuesday, Mar 18 7:30 AM to 8:50 AM Convention Center Ballroom 6B 

IUTOX Communications Commission Meeting Saturday, Mar 15 8:15 AM to 9:15 AM Sheraton Capitol Hill 

IUTOX Developing Countries Committee Meeting Saturday, Mar 15 10:45 AM to 11:45 AM Sheraton Ballard 

IUTOX Education and Careers Committee Meeting Saturday, Mar 15 8:15 AM to 9:15 AM Sheraton Ballard 

IUTOX Executive Committee Dinner Sunday, Mar 16 8:00 PM to 10:00 PM Palomino Restaurant 

IUTOX Executive Committee Meeting I Saturday, Mar 15 1:30 PM to 5:30 PM Sheraton Capitol Hill 

IUTOX Executive Committee Meeting II Sunday, Mar 16 8:30 AM to 12:30 PM Sheraton Capitol Hill 

IUTOX Finance Committee Meeting Saturday, Mar 15 9:30 AM to 10:30 AM Sheraton Ballard 

IUTOX Membership Committee Meeting Saturday, Mar 15 9:30 AM to 10:30 AM Sheraton Capitol Hill 

IUTOX Science Committee Meeting Saturday, Mar 15 12:00 NOON to 1:00 PM Sheraton Ballard 

Johnson & Johnson Toxicology Interest Group Meeting Saturday, Mar 15 11:30 AM to 6:00 PM Sheraton Greenwood 

K–12 Education Committee Meeting Wednesday, Mar 19 11:30 AM to 1:30 PM Convention Center 304 

K–12 TEAMS Event Volunteers Meeting Monday, Mar 17 4:30 PM to 6:00 PM Convention Center 309 

K–12 Paracelsus Goes to the Classroom —The TEAMS Project: 

Toxicologists Educating and Mentoring Students 

K–12 Paracelsus Goes to the Classroom —The TEAMS Project: 

Toxicologists Educating and Mentoring Students 

Tuesday, Mar 18 8:30 AM to 12:00 NOON Hyatt E. Anderson 

Amphitheater 

Tuesday, Mar 18 1:30 PM to 4:30 PM Hyatt E. Anderson 

Amphitheater 

Kettering Laboratory, University of Cincinnati Reception Tuesday, Mar 18 7:00 PM to 8:30 PM Sheraton Cedar 

Keynote MRC Lecture: Biological Energy Conversion and its Toxic 

Consequences Lecturer: Nobel Laureate Professor 

Sir John E. Walker 

Korean Toxicologist Association in America Special Interest Group 


Lovelace Respiratory Research Institute Reception for Past and 

Present Employees 

Wednesday, Mar 19 8:00 AM to 8:50 AM Convention Center Ballroom 6A 

Monday, Mar 17 5:30 PM to 8:00 PM Hyatt Leonesa 1 

Sunday, Mar 16 7:30 PM to 10:00 PM Sheraton Willow B 

Luggage/Coat Check Sunday, Mar 16 7:00 AM to 8:30 PM Convention Center 454 

Luggage/Coat Check Monday, Mar 17 7:00 AM to 8:30 PM Convention Center 454 

Luggage/Coat Check Tuesday, Mar 18 7:00 AM to 8:00 PM Convention Center 454 

Luggage/Coat Check Wednesday, Mar 19 7:00 AM to 8:00 PM Convention Center 454 

Luggage/Coat Check Thursday, Mar 20 7:00 AM to 1:00 PM Convention Center 454 

Mechanisms Specialty Section Meeting/Reception Monday, Mar 17 6:00 PM to 7:30 PM Convention Center 612 

Mechanisms Specialty Section Officers Meeting Monday, Mar 17 7:00 AM to 9:00 AM Convention Center 214 

Meet the Directors: A Conversation with the Directors, 

NIEHS Strategic Plan, Samuel Wilson 

Wednesday, Mar 19 12:00 NOON to 1:20 PM Convention Center Ballroom 6B 

Membership Committee Meeting Wednesday, Mar 19 7:00 AM to 8:30 AM Convention Center 208 

Merit Award Lecture: The Dose Makes the Toxicologist— 

Paracelsus as Seen From Switzerland Lecture: Hanspeter Witschi 

Monday, Mar 17 12:30 PM to 1:20 PM Convention Center Ballroom 6B 

Metals Specialty Section Meeting/Reception Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 619 

Metals Specialty Section Officers Meeting Monday, Mar 17 6:30 AM to 8:00 AM Convention Center 305 

Michigan Regional Chapter Meeting/Breakfast Wednesday, Mar 19 7:00 AM to 8:30 AM Sheraton Cedar 







Michigan State University Environmental Toxicology Reception Tuesday, Mar 18 9:00 PM to 11:00 PM Sheraton Wallingford 

Midwest Regional Chapter Meeting/Breakfast Wednesday, Mar 19 7:00 AM to 8:30 AM Sheraton Issaquah 

Mixtures Specialty Section Meeting/Reception Wednesday, Mar 19 6:00 PM to 7:30 PM Convention Center 613 

Molecular Biology Specialty Section Meeting/Reception Wednesday, Mar 19 6:00 PM to 7:30 PM Convention Center 619 

Molecular Biology Specialty Section Officers Meeting Tuesday, Mar 18 7:00 AM to 8:30 AM Convention Center 304 

Nanotoxicology Specialty Section Meeting/Luncheon Monday, Mar 17 12:00 NOON to 1:30 PM Sheraton Willow 

National Capital Area Regional Chapter Meeting/Reception Tuesday, Mar 18 6:30 PM to 8:00 PM Wild Ginger 

Restaurant 

Neurotoxicology Specialty Section Meeting/Reception Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 609 

Neurotoxicology Specialty Section Officers Meeting/Luncheon Monday, Mar 17 12:00 NOON to 1:30 PM Convention Center 214 

NIH Funding Task Force Meeting Wednesday, Mar 19 7:00 AM to 8:30 AM Convention Center 304 

North Carolina State University Alumni Reception Monday, Mar 17 7:30 PM to 10:00 PM Sheraton Cedar 

Northern California and Pacific Northwest Regional Chapters, UC 

Davis and UC Berkeley Joint Meeting/Reception 

Occupational and Public Health Specialty Section Meeting/ 

Luncheon 

Monday, Mar 17 4:30 PM to 6:00 PM Sheraton Metropolitan B 

Tuesday, Mar 18 12:00 NOON to 1:30 PM Sheraton Willow 

Occupational Toxicology Roundtable Planning Meeting Tuesday, Mar 18 7:00 AM to 8:30 AM Hyatt Stevens 

Boardroom 

Organizational Meeting for a Potential New Ocular Toxicology 

Specialty Section 

Monday, Mar 17 5:30 PM to 6:30 PM Sheraton Capitol Hill 

Past Presidents Breakfast Monday, Mar 17 7:00 AM to 8:30 AM Convention Center 309 

Pfizer Recruiting/Outreach Effort Tuesday, Mar 18 6:30 PM to 8:30 PM Sheraton Grand Ballroom C 

Plenary Opening Lecture: Perspectives on Science in the 21 st Century 

Lecturer: Nobel Laureate Lee Hartwell 

Monday, Mar 17 8:15 AM to 9:15 AM Convention Center Exhibit Hall 4F 

Postdoctoral Assembly Board Meeting Monday, Mar 17 7:00 AM to 8:15 AM Convention Center 212 

Postdoctoral Assembly Luncheon (Ticket Required) Tuesday, Mar 18 12:00 NOON to 1:15 PM Convention Center 3A 

Poster Session for Visiting Students Monday, Mar 17 9:30 AM to 11:15 AM Convention Center Exhibit Hall 

Poster Sessions Monday, Mar 17 9:30 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Monday, Mar 17 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Tuesday, Mar 18 9:00 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Tuesday, Mar 18 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Wednesday, Mar 19 9:00 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Wednesday, Mar 19 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Thursday, Mar 20 8:30 AM to 12:00 NOON Convention Center Ballroom 6C & E 

Poster Set Up (See Poster Board Surface Map on Page 36) Monday, Mar 17 8:00 AM to 9:30 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Map on Page 37) Monday, Mar 17 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Map on Page 38) Tuesday, Mar 18 8:30 AM to 9:00 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Map on Page 39) Tuesday, Mar 18 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Map on Page 40) Wednesday, Mar 19 8:30 AM to 9:00 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Map on Page 41) Wednesday, Mar 19 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Map on Pages 42 and 43) Thursday, Mar 20 8:00 AM to 8:30 AM Convention Center Ballroom 6C & E 

President’s Reception (By Invitation Only) Wednesday, Mar 19 7:00 PM to 8:30 PM Sheraton Cirrus 

Program Committee Meeting Thursday, Mar 20 7:30 AM to 8:30 AM Convention Center 305 

Program Committee Walk-Through Monday, Mar 17 7:15 AM to 8:15 AM Convention Center 603 

Regional Chapter Graduate Committee Business Meeting Monday, Mar 17 7:00 AM to 8:30 AM Convention Center 307 

Regional Chapter Graduate Committee Introductory Meeting Sunday, Mar 16 6:45 PM to 7:30 PM Sheraton Aspen 

Regional Chapter Presidents and Officers Meeting Tuesday, Mar 18 7:00 AM to 8:30 AM Convention Center 307 

22 





Registration Saturday, Mar 15 4:00 PM to 7:00 PM Convention Center South Lobby, 

Level 4 

Registration Sunday, Mar 16 7:00 AM to 8:00 PM Convention Center South Lobby, 

Level 4 

Registration Monday, Mar 17 7:00 AM to 5:00 PM Convention Center South Lobby, 

Level 4 

Registration Tuesday, Mar 18 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Registration Wednesday, Mar 19 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Registration Thursday, Mar 20 8:00 AM to 11:30 AM Convention Center South Lobby, 

Level 4 

Regulatory Affairs and Legislative Assistance Committee Meeting Monday, Mar 17 12:15 PM to 1:30 PM Convention Center 209 

Regulatory and Safety Evaluation Specialty Section Meeting/ 

Reception 

Regulatory and Safety Evaluation Specialty Section Officers 


Reproductive and Developmental Toxicology Specialty Section 




Tuesday, Mar 18 6:00 PM to 7:30 PM Convention Center 612 


Wednesday, Mar 19 6:00 PM to 7:30 PM Convention Center 603 

Tuesday, Mar 18 7:00 AM to 8:00 AM Convention Center 309 

RETHINK: Impact of the Minipig in Toxicology Open Meeting Wednesday, Mar 19 5:00 PM–7:00 PM Sheraton Aspen Room 

Risk Assessment Specialty Section Meeting/Reception Monday, Mar 17 6:00 PM to 7:30 PM Convention Center 609 

Risk Assessment Specialty Section Officers Meeting Monday, Mar 17 7:00 AM to 9:00 AM Convention Center 211 

Rosetta Biosoftware Hospitality Suite Monday, Mar 17 4:30 PM to 9:30 PM Hyatt Blewett Suite 

Rosetta Biosoftware Hospitality Suite Tuesday, Mar 18 6:00 PM to 9:30 PM Hyatt Blewett Suite 

Rosetta Biosoftware Hospitality Suite Wednesday, Mar 19 4:30 PM to 9:30 PM Hyatt Blewett Suite 

Roundtable of Toxicology Consultants Meeting/Reception Monday, Mar 17 4:30 PM to 7:00 PM Sheraton Willow B 

Rutgers Joint Graduate Program in Toxicology Annual Dessert 

Reception 

Satellite Meeting: The Kleinfelder Group: Perchlorate Exposures, 

Iodine Modulation of Effect, and Epidemiologic Associations: 


Satellite Meeting: The Kleinfelder Group: Perchlorate Exposures, 

Iodine Modulation of Effect, and Epidemiologic Associations: 


Tuesday, Mar 18 9:00 PM to 11:00 PM Sheraton Grand Ballroom B 

Thursday, Mar 20 1:00 PM to 4:30 PM Sheraton Willow 

Friday, Mar 21 9:00 AM to 3:30 PM Sheraton Willow 

Scientific Sessions Monday, Mar 17 9:30 AM to 12:15 PM Convention Center (See Program 

Description for 

Room Locations) 

Scientific Sessions Monday, Mar 17 12:15 PM to 1:30 PM Convention Center (See Program 



Scientific Sessions Monday, Mar 17 1:30 PM to 4:15 PM Convention Center (See Program 




(Sunset) 


(Sunrise) 

Monday, Mar 17 4:30 PM to 5:50 PM Convention Center (See Program 



Tuesday, Mar 18 7:30 AM to 8:50 AM Convention Center (See Program 



Scientific Sessions Tuesday, Mar 18 9:00 AM to 11:45 AM Convention Center (See Program 



Scientific Sessions Tuesday, Mar 18 1:30 PM to 4:15 PM Convention Center (See Program 










(Sunrise) 

Wednesday, Mar 19 7:30 AM to 8:50 AM Convention Center (See Program 



Scientific Sessions Wednesday, Mar 19 9:00 AM to 11:45 AM Convention Center (See Program 



Scientific Sessions Wednesday, Mar 19 12:00 NOON to 1:20 PM Convention Center (See Program 



Scientific Sessions Wednesday, Mar 19 1:30 PM to 4:15 PM Convention Center (See Program 




(Sunset) 


(Sunrise) 

Wednesday, Mar 19 4:30 PM to 5:50 PM Convention Center (See Program 



Thursday, Mar 20 7:30 AM to 8:50 AM Convention Center (See Program 



Scientific Sessions Thursday, Mar 20 9:00 AM to 11:45 AM Convention Center (See Program 



Soapbox Session Wednesday, Mar 19 12:00 NOON to 1:20 PM Convention Center South Lobby, 

Level 4 

SOT Committee Chair Orientation Saturday, Mar 15 2:00 PM to 5:00 PM Sheraton Willow A 

SOT Office Saturday, Mar 15 4:00 PM to 7:00 PM Convention Center 303 

SOT Office Sunday, Mar 16 7:00 AM to 5:30 PM Convention Center 303 

SOT Office Monday, Mar 17 7:00 AM to 5:00 PM Convention Center 303 

SOT Office Tuesday, Mar 18 7:00 AM to 4:00 PM Convention Center 303 

SOT Office Wednesday, Mar 19 7:00 AM to 4:00 PM Convention Center 303 

SOT Office Thursday, Mar 20 7:00 AM to 11:30 AM Convention Center 303 

SOT/EUROTOX Debate: In Vitro Toxicology Is Useful for 

Regulatory Purposes 

Tuesday, Mar 18 8:00 AM to 8:50 AM Convention Center Ballroom 6A 

Southeastern Regional Chapter Meeting/Reception Tuesday, Mar 18 6:30 PM to 8:30 PM Hyatt Portland 

Speaker Ready Room Saturday, Mar 15 4:00 PM to 7:00 PM Convention Center 213 

Speaker Ready Room Sunday, Mar 16 7:00 AM to 5:30 PM Convention Center 213 

Speaker Ready Room Monday, Mar 17 7:00 AM to 5:00 PM Convention Center 213 

Speaker Ready Room Tuesday, Mar 18 7:00 AM to 4:00 PM Convention Center 213 

Speaker Ready Room Wednesday, Mar 19 7:00 AM to 4:00 PM Convention Center 213 

Speaker Ready Room Thursday, Mar 20 7:00 AM to 11:30 AM Convention Center 213 

Special Information Meeting with Ken Olden for Students Seeking 

Postdocs at NIEHS 

Tuesday, Mar 18 2:00 PM to 3:30 PM Convention Center 210 

Special Interest Group Presidents and Officers Meeting Monday, Mar 17 7:00 AM to 8:00 AM Convention Center 603 

Specialty Section Graduate Committee Business Meeting Tuesday, Mar 18 7:00 AM to 8:30 AM Convention Center 211 

Specialty Section Presidents and Officers Meeting Monday, Mar 17 4:30 PM to 6:00 PM Convention Center 307 

St. John’s University 6 th Annual Toxicology Alumni Dinner Monday, Mar 17 6:00 PM to 8:00 PM Sheraton Ravenna 

Student Advisory Council Business Meeting Wednesday, Mar 19 7:00 AM to 8:00 AM Convention Center 307 

Student/Postdoctoral Fellow Mixer (Ticket Required) Sunday, Mar 16 7:30 PM to 8:30 PM Sheraton Grand Ballroom C 

TEF Board of Trustees Meeting Sunday, Mar 16 7:30 AM to 12:00 NOON Sheraton Leschi 

Tour Desk Saturday, Mar 15 4:00 PM to 7:00 PM Convention Center South Lobby, 

Level 4 

Tour Desk Sunday, Mar 16 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

24 





Tour Desk Monday, Mar 17 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Tour Desk Tuesday, Mar 18 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Tour Desk Wednesday, Mar 19 8:00 AM to 4:00 PM Convention Center South Lobby, 

Level 4 

Tour Desk Thursday, Mar 20 8:00 AM to 11:30 AM Convention Center South Lobby, 

Level 4 

Town Hall Meeting: SOT Strategic Plan—Defining the Future of 

SOT 

Tuesday, Mar 18 12:00 NOON to 1:20 PM Convention Center Ballroom 6E 

ToxExpo 2009 Exhibit Space Selection Meeting Tuesday, Mar 18 4:45 PM to 6:00 PM Convention Center Exhibit Hall 4C-3 

ToxExpo Exhibits Open Monday, Mar 17 9:15 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Tuesday, Mar 18 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Wednesday, Mar 19 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Set Up Saturday, Mar 15 8:00 AM to 5:00 PM Convention Center Exhibit Hall 

ToxExpo Set Up Sunday, Mar 16 8:00 AM to 5:00 PM Convention Center Exhibit Hall 

ToxExpo Tear Down Wednesday, Mar 19 5:00 PM to 12:00 

MIDNIGHT 

Convention Center 

Exhibit Hall 

ToxExpo Tear Down Thursday, Mar 20 8:00 AM to 12:00 NOON Convention Center Exhibit Hall 

Toxicologic and Exploratory Pathology Specialty Section Meeting/ 

Luncheon 

Toxicologic and Exploratory Pathology Specialty Section Officers 


Monday, Mar 17 12:00 NOON to 1:30 PM Sheraton Grand Ballroom D 


Toxicological Sciences Associate Editors Meeting Sunday, Mar 16 12:00 NOON to 3:00 PM Sheraton Issaquah 

Toxicologists of African Origin Special Interest Group Meeting/ 

Reception 

Tuesday, Mar 18 6:00 PM to 9:00 PM Hyatt Princessa 2 

Toxicology and Applied Pharmacology Associate Editors Meeting Monday, Mar 17 11:30 AM to 1:30 PM Sheraton Madrona 

Toxicology Editorial Board Meeting Tuesday, Mar 18 11:30 AM to 1:30 PM Sheraton Juniper 

Toxicology Letters Editorial Board Meeting Tuesday, Mar 18 11:30 AM to 1:30 PM Sheraton Madrona 

ToxLearn Work Group Meeting Tuesday, Mar 18 10:30 AM to 12:00 NOON Convention Center 305 

U.S. Environmental Protection Agency: Risk Assessment Data 

Repository—An Inter-Agency Collaboration 


Orientation for SOT Hosts, Peer Mentors and Advisors 


Lecture & Reception 

Tuesday, Mar 18 11:30 AM to 1:30 PM Sheraton Aspen 

Saturday, Mar 15 5:30 PM to 6:00 PM Convention Center 305 

Saturday, Mar 15 6:15 PM to 9:00 PM Convention Center 3A 

Undergraduate Education Program Sunday, Mar 16 8:00 AM to 10:35 AM Convention Center 2A 

Undergraduate Education Program Sunday, Mar 16 10:35 AM to 3:00 PM Convention Center 2A 

Undergraduate Education Program Monday, Mar 17 7:30 AM to 2:00 PM Convention Center 3A 

Undergraduate Toxicology Faculty Meeting Monday, Mar 17 3:30 PM to 4:30 PM Convention Center 201 

University of Connecticut Reception Tuesday, Mar 18 9:00 PM to 10:00 PM Sheraton Issaquah 

University of Rochester Alumni Reception Tuesday, Mar 18 7:30 PM to 10:00 PM Sheraton Willow A 

University of Washington Alumni & Friends Reception Sunday, Mar 16 7:00 PM to 10:00 PM Seattle Children’s 

Orthopedic Hospital 

Research Institute 

VIP ToxExpo Exhibit Hall Walk-Through Monday, Mar 17 1:30 PM to 2:30 PM Convention Center Exhibit Hall 

Welcoming Reception (All Attendees Welcome) Sunday, Mar 16 6:30 PM to 7:30 PM Convention Center Exhibit Hall 4F 

Women in Toxicology Special Interest Group Meeting/Reception Wednesday, Mar 19 6:00 PM to 7:30 PM Sheraton Grand Ballroom A 

WWW Advisory Committee Meeting Tuesday, Mar 18 7:00 AM to 8:30 AM Convention Center 208 



7th Avenue 

Office Tower 

Garage Ramp 

Down 



To 

Hyatt 

LEVEL 1 

To 

Sheraton 

Pike Street 

Retail 

Retail 

Maps 

Elevators 

Entrance 

SOT 


Entrance Entrance 

Entrance 

14 

Escalators 

Floors 1-4 

and to 

North Lobby 

Retail 

Fountain 

Retail 

8th Avenue 

10 

Galleria 

Up escalators to 

Exhibit Hall and 

Registration (Level 4), 

CE Courses, 

Meeting Rooms, and 

Scientific Sessions (Level 6) 

Retail 

Corridor 

Act 

Retail 

Escalators 

Floors 1-4 

and to 

South Lobby 

ATM 

Convention Place 

SOT 

Tours/Departures 

N 

Exit 

Elevators 

Union Street 

26 



Washington State Convention and Trade Center (Continued) 

LEVEL 2 

Open 

2A 

2B 

Exit 

M 

To/From 

Level 3 

To/From 

Level 1 

W 

292 

290 

Exit 

10 

208 

209 

210 

Retail 

206 

205 

204 

Exit 

CRAD 

CRAD Office 

maps 

Elevators 

Speaker 

Ready Room 

Exit Exit Exit 

211 

212 

213 

214 

Ramp Ramp 

Ramp 

W M 

202 

203 

Exit 

201 




CE Courses, 



LEVEL 3 

Elevators 

To Union Sq. 

Int’l. 


Place 

Open 

To/From 

Level 2 

To/From 

Level 4 

Elevators 

3A 

M 

W 

392 

Public Parking 

390 

Seating Available 

3B 

Exit 

Exit 

10 

To Rows H-L 

To Rows A-G 

Exit 

307 

308 

309 

306 

305 

304 

N 




CE Courses, 



Exit 

Exit 

310 

Elevators 

Galleria 

IMP 

Below 

Exit 

303 

302 

301 

SOT 

Office 


Exit 

Exit 

N 

Exit 



Pine Street (Below) 

Concessions/Deli 

LEVEL 4 

Exit 

8th Avenue 

(Below) 

Hot Zone 

Wireless Internet 

9th Avenue 

(Below) 

Maps 

Restrooms 

Posters 

(See pages 36–43 

for Poster Board 

Surface Maps) 

4E 

ToxExpo Exhibits 

Exit 

Deli 

Welcome 

Reception 

Plenary 

Session 

4F 

Exit 

N-1 

Elevators 

Exhibitor Hosted 

Sessions 

400 

W 

Open 

11 

12 

Exit 

Pike Street 

(Below) 

North 

Lobby 

Exit 

M 

To/From 

Level 3 

490 492 

ToxExpo 

Show Management 

Office 

N 

Elevators 

Luggage/ 

Coat Check 


10 

Exit 

To South Lobby 

Exit 

Exit 

4C-3 4C-2 

4C-4 

401 

To 

North 

Lobby 

Retail 

6 7 

4D 

SOT 

Resource 

Pavilion 

Floors 1 to 4 

UP 

4C 

DOWN 

South 

Galleria 

4C-1 

UP 

W 

454 

Exit 

Exit 

M 

W M 

1 2 


CE Courses, 



Exit 

To/From 

4 & 6 

W 

UP 

Deli 

DOWN 

4B 

M 

498 

W 

South Service Corridor 

Exit 

Exit 

Exit 

Exit 

Exit 

M 

ToxExpo Exhibits 

First Aid 

439 438 

South 

Lobby 

Outdoor Plaza 

Up To 

5 & 6 

4A 

Exit 

Exit 

Exit 

M 

GRAND 

STAIRCASE 

W 

Restrooms 

Exit 

Concessions/Deli 

Hot Zone 

Wireless Internet 

Restrooms 

Soapbox 

Session 

Registration, 

Housing Desk, 

Memorabilia, and 

City Tours 

28 




LEVEL 6 

Exit Exit Exit 

Exit 

Exit 

Restrooms 

10 

Ballroom 

6E 6C 6B 6A 

Awards 

Ceremony 

4 

Restrooms 

maps 

618 617 

M 

W 

610 

605 

W 

M 

Exit 

619 

(6F) 

616 

611 

609 

(6D) 

606 

604 

620 

615 

612 

608 607 

603 

602 

Exit 

Restrooms 

Exit 

M 

Elevators 

W 

West 

Lobby 

Galleria 

(Below) 

E x i t 

Elevators 

614 


Pole 

613 

CE Booth 

East 

Lobby 

South 

Lobby 

(Below) 

Escalators 

Down to Registration and 

Exhibits (Level 4) 

601 

Exit 

E-mail 

Center 

Message 

Boards 


N 



Seattle Hotel Accommodations 

1) Crowne Plaza Seattle 

3) Grand Hyatt Seattle 

6) Mayflower Park Hotel 

SOT Co-Headquarters Hotel 

Maps 

$152 Government Rate or 

$165 Standard Rate 

1113 6 th Avenue 

Seattle, WA 98101 

Tel: (206) 464-1980 

Fax: (206) 340-1617 

Web site: www.cphotelseattle.com 

Club: Priority Club Rewards 

Check in: 4:00 PM— 

Check out: 12:00 NOON 

3 blocks from Convention Center 

Valet parking only 

Internet access at $9.95/day—wireless 

Internet available 

2) The Fairmont Olympic Hotel 

$186 Single/Double 

721 Pine Street 


Tel: (206) 774-1234 

Fax: (206) 774-6120 

Web site: www.grandseattle.hyatt.com 

Club: Hyatt Gold Passport 



1 block from Convention Center 

Self and valet parking 


Internet available for T-Mobile account 

users only 

4) Hilton Seattle 


405 Olive Way 


Tel: (206) 623-8700 

Fax: (206) 382-6996 

Web site: www.mayflowerpark.com 

Club: N/A 





Complimentary high speed Internet in 

guest room and lobby—wireless Internet 

available 

7) Paramount Hotel 


411 University Street 


Tel: (206) 621-1700 

Fax: (206) 682-9633 

Web site: www.fairmont.com/seattle 




Tel: (206) 624-0500 

Fax: (206) 682-9029 

Web site: www.seattlehilton.com 



724 Pine Street 


Tel: (206) 292-9500 

Fax: (206) 292-8610 

Web site: www.paramounthotelseattle.com 

Club: Fairmont’s President Club 





Complimentary high speed Internet in 

guest room—complimentary wireless 

Internet in lobby 

Club: Hilton HHonors 




Self parking 

Internet access at $9.95/day— 

complimentary wireless Internet in lobby 

Club: Coast Rewards 






Internet available 

5) Hotel Max 

8) Pike Street Suites 


620 Stewart Street 


Tel: (206) 728-6299 

Fax: (206) 443-5754 

Web site: www.hotelmaxseattle.com 


$155 One Bedroom Suites 

1011 Pike St. 


Tel: (206) 682-8282 

Fax: (206) 682-5315 

Web site: www.pikestreetsuites.com 

Club: N/A 





Wireless Internet available at 

$11.95/day— 

Club: N/A 



Less then 1 block from Convention Center 

Self parking and valet parking 

Complimentary Internet access— 

wireless Internet available 

30 



Seattle Hotel Accommodations (Continued) 

9) Red Lion Hotel on Fifth Avenue 

11) Roosevelt Hotel 

13) Sheraton Seattle Hotel 

SOT Headquarters Hotel 




Tel: (206) 971-8000 

Fax: (206) 971-8101 

Web site: www.redlion5thavenue.com 

Club: GuestAwards 




Self parking 

Complimentary wireless Internet 

10) Renaissance Hotel Seattle 


515 Madison Street 


Tel: (206) 583-0300 

Fax: (206) 447-0992 

Web site: www.renaissancehotels.com/ 

seasm 





Tel: (206) 621-1200 

Fax: (206) 233-0335 

Web site: www.roosevelthotel.com 

Club: Coast Rewards 





Wireless Internet available at $9.95/day 

12) Sixth Avenue Inn 




Tel: (206) 441-8300 

Fax: (206) 441-9903 

Web site: www.sixthavenueinn.com 




Tel: (206) 621-9000 

Fax: (206) 621-8441 

Web site: www.sheraton.com/seattle 

Club: Starwood Preferred Guest 





Internet access at $9.95/day— 

complimentary wireless Internet in lobby 

14) The Westin Seattle 




Tel: (206) 728-1000 

Fax: (206) 728-2259 

Web site: www.westin.com/seattle 

maps 

Club: Marriott Rewards 

Check in: 4:00 PM 




Internet access at $9.95/day 

The hotel is under construction/ 

remodeling; guest rooms and lobby 

should not be affected. 

Club: N/A 




Self parking 


Internet in lobby 

Club: Starwood Preferred Guest 





Internet access at $9.95/day 

Legend: 

Valet Parking Swimming Pool In-Room Safe Complimentary 

Breakfast 

Self Parking Business Center Gift Shop Restaurant 

Fitness Center In-Room Wireless Concierge All hotels have internet access. 

Hotel sales tax is currently 15.5% 

*Please note that the discounted room rates within the SOT Room Block include a 1090 commission and $3 room rebate 

payable to the Society to offset the expenses associated with the Annual Meeting. 



Map of Seattle Hotels 

Maps 

32 



Sheraton Seattle Hotel Map 

maps 



Grand Hyatt Seattle Map 

FIRST 

FLOOR 

Maps 

THEATER- 

BALLROOM 

LEVEL 

To Convention Center 

SIXTH FLOOR 

SEVENTH FLOOR 

34 



Seattle Restaurants 

Restaurants Within Six Blocks of the Convention Center, Listed Alphabetically 

$ = Under $12 $ = $12–$18 $$ = $18-$30 $$$ = over $30 

94 Stewart 94 Stewart Street (206) 441-5505 $$$ 

Andaluca Restaurant 

& Bar 

407 Olive Way (206) 382-6999 $$$-$$$$ 

Assaggio Ristorante 2010 Fourth Avenue (206) 441-1399 $$-$$$ 

Athenian Inn 1517 Pike Place Market (206) 624-7166 $$-$$$ 

Bambuza 820 Pike Street (206) 219-5555 $-$$ 

Barolo 1940 Westlake Avenue (206) 770-9000 $$-$$$ 

Belle Epicurean Patisserie 1206 Fourth Avenue (206) 262-9404 $ 

Benihana 1200 Fifth Avenue (206) 682-4686 $$$ 

Buenos Aires Grill 220 Virginia Street (206) 441-7076 $$-$$$ 

Cafe Campagne 1600 Post Alley (206) 728-2233 $$$ 

Campagne 86 Pine Street (206) 728-2800 $$$-$$$$ 

Coldwater Bar and Grill 1900 Fifth Avenue (206) 256-7697 $$$ 

Copacabana Cafe 1520 1/2 Pike Place (206) 622-6359 $$ 

Dahlia Lounge 2001 Fourth Avenue (206) 682-4142 $$$ 

Dragonfish Asian Cafe 722 Pine Street (206) 467-7777 $$$ 

Earth & Ocean 1112 Fourth Avenue (206) 264-6060 $$$$ 

Fox Sports Grill 1522 Sixth Avenue (206) 340-1369 $$ 

Geneva 1106 Eighth Avenue (206) 624-2519 $$$ 

Gordon Biersch Brewery 

Restaurant 

600 Pine Street (206) 405-4205 $$ 

Icon Grill 1933 Fifth Avenue (206) 441-6330 $$-$$$ 

IL Bistro 93 Pike Street Suite A (206) 682-3049 $$$ 

Il Fornaio 600 Pine Street (206) 264-0994 $-$$$ 

Ipanema Brazilian Grill 1225 First Avenue (206) 957-8444 $$-$$$ 

Islander Restaurant & Tiki 

Lounge 

96 Union Street (206) 344-8088 $$ 

Juice It Cafe 725 Pike Street #16A (206) 447-6960 $ 

Le Panier French Bakery 1902 Pike Place Market (206) 441-3669 $ 

Lola 2000 Fourth Avenue (206) 441-1430 $$$ 

Lowell’s Restaurant & Bar 1519 Pike Place (206) 622-2036 $ 

Palomino 1420 Fifth Avenue (206) 623-1300 $$-$$$ 

Pellini Ristorante 515 Madison Street (206) 267-2201 $$$$ 

Pike Place Chowder 1530 Post Alley Suite 11 (206) 267-2537 $ 

Purple Cafe & Wine Bar 

1218 Third Avenue 

#900 

(206) 829-2280 $$-$$$ 

Rock Bottom Restaurant 1333 Fifth Avenue (206) 623-3070 $$ 

Ruth‘s Chris Steak House 1809 Seventh Avenue (206) 624-8524 $$$$ 

Sazerac Restaurant 1101 Fourth Avenue (206) 624-7755 $$$ 

Shuckers 411 University Street (206) 621-1700 $$$$ 

Sisters European Snacks 1530 Post Alley #2A (206) 623-6723 $ 

Sound View Cafe 

1501 Pike Place Market 

#501 

(206) 623-5700 $ 

Soups 1420 Fifth Avenue (206) 625-9973 $ 

Specialty’s Café & Bakery 1400 Fifth Avenue (877) 502-837 $ 

Tango Restaurant & 

Lounge 

1100 Pike Street (206) 583-0382 $$ 

Tap House Grill 1506 Sixth Avenue (206) 816-3314 $$$ 

Thai Ginger 600 Pine Street (206) 749-9100 $$ 

The Brooklyn Seafood, 

Steak & Oyster House 

1212 Second Avenue (206) 224-7000 $$$ 

The Cheesecake Factory 700 Pike Street (206) 652-5400 $$ 

The Daily Grill 629 Pike Street (206) 624-8400 $$$ 

The Elephant and Castle 

Pub & Restaurant 

1415 Fifth Avenue (206) 624-9977 $$ 

The Georgian 411 University Street (206) 621-1700 $$$$ 

The Oceanaire Seafood 

Room 

The Pike Brewing 

Company 

1700 Seventh Avenue (206) 267-2277 $$$ 

1415 First Avenue (206) 622-6044 $$ 

The Triple Door 216 Union Street (206) 838-4330 $$ 

Todai 600 Pine Street (206) 749-5100 $$$ 

Top of the Hilton 

Restaurant 

Sixth & University, 

29 th Floor 

(206) 624-0500 $$$ 

maps 

Maximilien in the Market 81 A Pike Street (206) 682-7270 $$$ 

Mexico Cantina y 

Veracruz Cooking 

600 Pine Street (206) 405-3400 $$ 

Morton’s The Steakhouse 1511 Sixth Avenue (206) 223-0550 $$$$ 

P.F. Chang’s China Bistro 400 Pine Street #136 (206) 393-0070 $$-$$$ 

Palace Kitchen 2030 Fifth Avenue (206) 448-2001 $$$ 

Tulio Ristorante 1100 Fifth Avenue (206) 624-5500 $$$ 

Union Restaurant 1400 First Avenue (206) 838-8000 $$$$ 

Union Square Grill 621 Union Street (206) 224-4321 $$-$$$ 

Von’s Grand City Cafe 619 Pine Street (206) 621-8667 $$ 

Wild Ginger Asian 

Restaurant & Satay Bar 

1401 Third Avenue (206) 623-4450 $$-$$$ 



Poster Board Surface Maps 

Monday, March 17—9:30 AM to 12:30 PM—Exhibit Hall 4-E, Level 4 

Poster Set Up—8:00 AM to 9:30 AM 

The abstract final ID# is located to the left of the hyphen (-); the number to the right 

refers to the poster location number, which does not change throughout the week. 

Presenters should ONLY display posters on the assigned date and time communicated 

in your acceptance notice. 

Maps 

Session Title 

Abstract 

Numbers 

Poster Board 

Numbers 

Endocrine Mechanisms of Toxicity 85-108 101-124 

Oxidative Stress Mechanisms in Chemical Carcinogenesis 109-124 125-140 

500's 

600's 

Chemical 

and and Biological Weapons 

125-162 203-240 

Immuntoxicology 

163-200 301-338 

Animal Models 201-235 406-440 

Bioinformatics and and Computational Toxicology 236-263 504-531 

Pesticide Metabolism and Toxicity 264-286 532-554 

Inhalants: Oxidative and Redox Mechanisms 287-300 555-559 AND 604-612 

Xenobiotic Biotransformation II 301-320 614-633 

Visiting Student Poster Session 650-659 AND 704-718 

POSTER SURFACES NOT IN USE—NO POSTERS 

SHOULD BE DISPLAYED ON THESE BOARDS. 

501-562 601-662 

263-531 264-532 318-631 319-632 

262-530 265-533 317-630 320-633 

700's 

261-529 266-534 316-629 634 

701-730 

260-528 267-535 315-628 635 730 

259-527 268-536 314-627 636 729 

258-526 269-537 313-626 637 728 

257-525 270-538 312-625 638 727 

256-524 271-539 311-624 639 726 

255-523 272-540 310-623 640 725 

100's 

200's 

300's 

400's 

101-140 

201-240 

301-340 

401-440 

254-522 273-541 309-622 641 724 

253-521 274-542 308-621 642 723 

104-120 105-121 142-220 143-221 182-320 183-321 215-420 216-421 252-520 275-543 307-620 643 722 

103-119 106-122 141-219 144-222 181-319 184-322 214-419 217-422 251-519 276-544 306-619 644 721 

EXHIBITS 

102-118 107-123 140-218 145-223 180-318 185-323 213-418 218-423 250-518 277-545 305-618 645 720 

101-117 108-124 139-217 146-224 179-317 186-324 212-417 219-424 249-517 278-546 304-617 646 719 

100-116 109-125 138-216 147-225 178-316 187-325 211-416 220-425 248-516 279-547 303-616 647 718 

99-115 110-126 137-215 148-226 177-315 188-326 210-415 221-426 247-515 280-548 302-615 648 717 

98-114 111-127 136-214 149-227 176-314 189-327 209-414 222-427 246-514 281-549 301-614 649 716 

715 

714 

97-113 112-128 135-213 150-228 175-313 190-328 208-413 223-428 245-513 282-550 613 650 713 

96-112 113-129 134-212 151-229 174-312 191-329 207-412 224-429 244-512 283-551 300-612 651 712 

95-111 114-130 133-211 152-230 173-311 192-330 206-411 225-430 243-511 284-552 299-611 652 711 

EXHIBITS 

BACK SURFACE NOT USED 

94-110 115-131 132-210 153-231 172-310 193-331 205-410 226-431 242-510 285-553 298-610 653 710 

EXHIBITS 

93-109 116-132 131-209 154-232 171-309 194-332 204-409 227-432 241-509 286-554 297-609 654 709 

92-108 117-133 130-208 155-233 170-308 195-333 203-408 228-433 240-508 287-555 296-608 655 708 

91-107 118-134 129-207 156-234 169-307 196-334 202-407 229-434 239-507 288-556 295-607 656 707 

90-106 119-135 128-206 157-235 168-306 197-335 201-406 230-434 238-506 289-557 294-606 657 706 

89-105 120-136 127-205 158-236 167-305 198-336 405 231-436 237-505 290-558 293-605 658 705 

88-104 121-137 126-204 159-237 166-304 199-337 404 232-437 236-504 291-559 292-604 659 704 

87-103 122-138 125-203 160-238 165-303 200-338 403 233-438 

EXHIBITS 

86-102 123-139 202 161-239 164-302 339 402 234-439 

85-101 124-140 201 162-240 163-301 340 401 235-440 

Entrance 

36 



Poster Board Surface Maps (Continued) 

Monday, March 17—1:00 PM to 4:30 PM—Exhibit Hall 4-E, Level 4 

Poster Set Up—12:30 PM to 1:00 PM 





Session Title 

Abstract 

Numbers 

Poster Board 

Numbers 

Alternative Ocular & Dermal Models 323-341 101-119 

Apoptosis: Mechanisms and Methods 342-360 121-139 

Stem Cell Biology and Toxicology 361-372 201-212 

Biomarkers 373-399 214-240 

Genetic Polymorphisms 400-422 301-323 

maps 

Nanoparticles: Testing Approaches, Geno- and Ecotoxicity 423-443 330-410 

Kidney 444-473 411-440 

Food Safety I 474-498 501-525 

Safety Assessment: Non-Pharmaceutical 499-518 530-549 

Modulators of Cell Proliferation in Chemical Carcinogenesis 519-532 550-562 AND 601 

Receptors 533-555 609-631 



500's 

600's 

501-562 601-662 

500-531 501-532 555-631 632 

499-530 502-533 554-630 633 

700's 

529 503-534 553-629 634 701-730 

528 504-535 552-628 635 730 

527 505-536 551-627 636 729 

526 506-537 550-626 637 728 

498-525 507-538 549-625 638 727 

497-524 508-539 548-624 639 726 

100's 

200's 

300's 

400's 

101-140 

201-240 

301-340 

401-440 

496-523 509-540 547-623 640 725 

495-522 510-541 546-622 641 724 

494-521 511-542 545-621 642 723 

120 342-121 379-220 380-221 419-320 420-321 453-420 454-421 493-520 512-543 544-620 643 722 

EXHIBITS 

341-119 343-122 378-219 381-222 418-319 421-322 452-419 455-422 492-519 513-544 543-619 644 721 

340-118 344-123 377-218 382-223 417-318 422-323 451-418 456-423 491-518 514-545 542-618 645 720 

339-117 345-124 376-217 383-224 416-317 324 450-417 457-424 490-517 515-546 541-617 646 719 

338-116 346-125 375-216 384-225 415-316 325 449-416 458-425 489-516 516-547 540-616 647 718 

337-115 347-126 374-215 385-226 414-315 326 448-415 459-426 488-515 517-548 539-615 648 717 

336-114 348-127 373-214 386-227 413-314 327 447-414 460-427 487-514 518-549 538-614 649 716 

715 

714 

335-113 349-128 213 387-228 412-313 328 446-413 461-428 486-513 519-550 537-613 650 713 

334-112 350-129 372-212 388-229 411-312 329 445-412 462-429 485-512 520-551 536-612 651 712 

333-111 351-130 371-211 389-230 410-311 423-330 444-411 463-430 484-511 521-552 535-611 652 711 

332-110 352-131 370-210 390-231 409-310 424-331 443-410 464-431 483-510 522-553 534-610 653 710 

EXHIBITS 

331-109 353-132 369-209 391-232 408-309 425-332 442-409 465-432 482-509 523-554 533-609 654 709 

330-108 354-133 368-208 392-233 407-308 426-333 441-408 466-433 481-508 524-555 608 655 708 

329-107 355-134 367-207 393-234 406-307 427-334 440-407 467-434 480-507 525-556 607 656 707 

328-106 356-135 366-206 394-235 405-306 428-335 439-406 468-434 479-506 526-557 606 657 706 

327-105 357-136 365-205 395-236 404-305 429-336 438-405 469-436 478-505 527-558 605 658 705 

326-104 358-137 364-204 396-237 403-304 430-337 437-404 470-437 477-504 528-559 604 659 704 

325-103 359-138 363-203 397-238 402-303 431-338 436-403 471-438 476-503 529-560 603 660 703 

324-102 360-139 362-202 398-239 401-302 432-339 435-402 472-439 475-502 530-561 602 661 702 

323-101 140 361-201 399-240 400-301 433-340 434-401 473-440 474-501 531-562 532-601 662 701 

EXHIBITS 

EXHIBITS 

Entrance 





Tuesday, March 18—9:00 AM to 12:30 PM—Exhibit Hall 4-E, Level 4 






Maps 

Session Title 



Abstract 

Numbers 

Poster Board 

Numbers 

Adverse Effects of Natual Products 

709-725 101-117 

Particulate 

Matter and the Cardiovascular System 

726-753 122-140 AND 201-209 

Xenobiotic Biotransformation I 

754-784 210-240 

Persistent Organic Pollutants (POPs) 

785-821 301-337 

Liver I: In Vivo 822-864 338-340 AND 401-440 

Mechanism and Chemoprevention of PAH and Tobacco-Related 

Carcinogenesis 

865-877 501-513 

Alternatives to Mammalian Models 

878-909 514-545 

Regulatory 

Risk Assessment 

910-942 550-562 AND 601-620 

500's 

600's 

501-562 601-662 

895-531 896-532 631 632 

894-530 897-533 630 633 

700's 

893-529 898-534 629 634 

701-730 

892-528 899-535 628 635 730 

100's 

200's 

300's 

400's 

101-140 

201-240 

301-340 

401-440 

891-527 900-536 627 636 729 

890-526 901-537 626 637 728 

889-525 902-538 625 638 727 

888-524 903-539 624 639 726 

887-523 904-540 623 640 725 

886-522 905-541 622 641 724 

885-521 906-542 621 642 723 

120 121 764-220 765-221 804-320 805-321 844-420 845-421 884-520 907-543 942-620 643 722 

EXHIBITS 

119 726-122 763-219 766-222 803-319 806-322 843-419 846-422 883-519 908-544 941-619 644 721 

118 727-123 762-218 767-223 802-318 807-323 842-418 847-423 882-518 909-545 940-618 645 720 

725-117 728-124 761-217 768-224 801-317 808-324 841-417 848-424 881-517 546 939-617 646 719 

724-116 729-125 760-216 769-225 800-316 809-325 840-416 849-425 880-516 547 938-616 647 718 

723-115 730-126 759-215 770-226 799-315 810-326 839-415 850-426 879-515 548 937-615 648 717 

722-114 731-127 758-214 771-227 798-314 811-327 838-414 851-427 878-514 549 936-614 649 716 

715 

711 

721-113 732-128 757-213 772-228 797-313 812-328 837-413 852-428 877-513 910-550 935-613 650 710 

720-112 733-129 756-212 773-229 796-312 813-329 836-412 853-429 876-512 911-551 934-612 651 709 

719-111 734-130 755-211 774-230 795-311 814-330 835-411 854-430 875-511 912-552 933-611 652 708 

718-110 735-131 754-210 775-231 794-310 815-331 834-410 855-431 874-510 913-553 932-610 653 707 

EXHIBITS 

717-109 736-132 753-209 776-232 793-309 816-332 833-409 856-432 873-509 914-554 931-609 654 706 

716-108 737-133 752-208 777-233 792-308 817-333 832-408 857-433 872-508 915-555 930-608 655 705 

715-107 738-134 751-207 778-234 791-307 818-334 831-407 858-434 871-507 916-556 929-607 656 704 

714-106 739-135 750-206 779-235 790-306 819-335 830-406 859-434 870-506 917-557 928-606 657 703 

713-105 740-136 749-205 780-236 789-305 820-336 829-405 860-436 869-505 918-558 927-605 658 702 

712-104 741-137 748-204 781-237 788-304 821-337 828-404 861-437 868-504 919-559 926-604 659 701 

711-103 742-138 747-203 782-238 787-303 822-338 827-403 862-438 867-503 920-560 625-603 660 

710-102 743-139 746-202 783-239 786-302 823-339 826-402 863-439 866-502 921-561 924-602 661 

709-101 744-140 745-201 784-240 785-301 824-340 825-401 864-440 865-501 922-562 923-601 662 

EXHIBITS 

EXHIBITS 

Entrance 


38 




Tuesday, March 18—1:00 PM to 4:30 PM—Exhibit Hall 4-E, Level 4 






Session Title 

Pharmacokinetics & Disposition 

Abstract 

Numbers 

943-975 

Poster Board Numbers 

101-133 

Regulation/Policy 

976-991 134-140 AND 201-209 

Applications of Biological Modeling 

992-1022 

210-240 

maps 

Nanoparticles: Target Organs 

1023-1056 

301-334 

Breast Cancer: Mechanisms, Biomarkers and Chemoprevention 1057-1070 335-340 AND 401-408 

500's 

600's 

Inhalation Toxicology 

Signal Transduction and Gene Regulation 

1071-1102 

1103-1131 

409-440 

501-529 

501-562 

601-662 

Reproductive System 

Risk Assessment Research 



1132-1161 

1162-1199 

532-561 

601-638 

Liver II: In Vitro 1200-1222 640-662 

Assessment of Ecological Toxicology 

1223-1250 

701-728 

531 1132-532 1192-631 1193-632 

530 1133-533 1191-630 1194-633 700's 

1131-529 1134-534 1190-629 1195-634 701-730 

1130-528 1135-535 1189-628 1196-635 730 

1129-527 1136-536 1188-627 1197-636 729 

1128-526 1137-537 1187-626 1198-637 1250-728 

100's 

200's 

300's 

400's 

101-140 

201-240 

301-340 

401-440 

1127-525 1138-538 1186-625 1199-638 1249-727 

1126-524 1139-539 1185-624 639 1248-726 

1125-523 1140-540 1184-623 1200-640 1247-725 

1124-522 1141-541 1183-622 1201-641 1246-724 

1123-521 1142-542 1182-621 1202-642 1245-723 

962-120 963-121 1002-220 1003-221 1042-320 1043-321 1082-420 1083-421 1122-520 1143-543 1181-620 1203-643 1244-722 

EXHIBITS 

961-119 964-122 1001-219 1004-222 1041-319 1044-322 1081-419 1084-422 1121-519 1144-544 1180-619 1204-644 1243-721 

960-118 965-123 1000-218 1005-223 1040-318 1045-323 1080-418 1085-423 1120-518 1145-545 1179-618 1205-645 1242-720 

959-117 966-124 999-217 1006-224 1039-317 1046-324 1079-417 1086-424 1119-517 1146-546 1178-617 1206-646 1241-719 

958-116 967-125 998-216 1007-225 1038-316 1047-325 1078-416 1087-425 1118-516 1147-547 1177-616 1207-647 1240-718 

957-115 968-126 997-215 1008-226 1037-315 1048-326 1077-415 1088-426 1117-515 1148-548 1176-615 1208-648 1239-717 

956-114 969-127 996-214 1009-227 1036-314 1049-327 1076-414 1089-427 1116-514 1149-549 1175-614 1209-649 1238-716 

1237-715 

1236-714 

955-113 970-128 995-213 1010-228 1035-313 1050-328 1075-413 1090-428 1115-513 1150-550 1174-613 1210-650 1235-713 

954-112 971-129 994-212 1011-229 1034-312 1051-329 1074-412 1091-429 1114-512 1151-551 1173-612 1211-651 1234-712 

953-111 972-130 993-211 1012-230 1033-311 1052-330 1073-411 1092-430 1113-511 1152-552 1172-611 1212-652 1233-711 

952-110 973-131 992-210 1013-231 1032-310 1053-331 1072-410 1093-431 1112-510 1153-553 1171-610 1213-653 1232-710 

EXHIBITS 

951-109 974-132 991-209 1014-232 1031-309 1054-332 1071-409 1094-432 1111-509 1154-554 1170-609 1214-654 1231-709 

950-108 975-133 990-208 1015-233 1030-308 1055-333 1070-408 1095-433 1110-508 1155-555 1169-608 1215-655 1230-708 

949-107 976-134 989-207 1016-234 1029-307 1056-334 1069-407 1096-434 1109-507 1156-556 1168-607 1216-656 1229-707 

948-106 977-135 988-206 1017-235 1028-306 1057-335 1068-406 1097-434 1108-506 1157-557 1167-606 1217-657 1228-706 

947-105 978-136 987-205 1018-236 1027-305 1058-336 1067-405 1098-436 1107-505 1158-558 1166-605 1218-658 1227-705 

946-104 979-137 986-204 1019-237 1026-304 1059-337 1066-404 1099-437 1106-504 1159-559 1165-604 1219-659 1226-704 

945-103 980-138 985-203 1020-238 1025-303 1060-338 1065-403 1100-438 1105-503 1160-560 1164-603 1220-660 1225-703 

944-102 981-139 984-202 1021-239 1024-302 1061-339 1064-402 1101-439 1104-502 1161-561 1163-602 1221-661 1224-702 

943-101 982-140 983-201 1022-240 1023-301 1062-340 1063-401 1102-440 1103-501 562 1162-601 1222-662 1223-701 

EXHIBITS 

EXHIBITS 

Entrance 





Wednesday, March 19—9:00 AM to 12:30 PM—Exhibit Hall 4-E, Level 4 






Maps 

Session Titles 

Mechanisms of Carcinogenesis 

Gene Regulation and Genomic Approaches 

Abstract 

Numbers 

1407-1419 

1420-1433 


101-113 

114-127 

Respiratory 

and Skin Hypersensitivity 

1434-1457 128-140 AND 201-211 

Epidemiology and Exposure Assessment 

1458-1484 

214-240 

500's 

600's 

501-562 601-662 

1594-531 1595-532 1649-631 1650-632 

Nanoparticles: Inhalation and Respiratory Cell Injury 1485-1514 301-330 

1593-530 

1596-533 

1648-630 1651-633 

700's 

Developmental 


1515-1542 331-340 AND 401-418 

Skin Penetration and Toxicity 

1543-1563 

420-440 

Application of 'Omics Research Tools in Toxicology 1564-1606 501-543 

Metals 

I 

1607-1644 546-562 AND 601-621 

Cardiovascular Systems: Cardiac Effects 1645-1667 627-649 

DNA Damage and Repair: Mechanisms and Agents 1668-1689 650-662 AND 701-709 

1592-529 1597-534 1647-629 1652-634 701-730 

1591-528 1598-535 1646-628 1653-635 730 

1590-527 1599-536 1645-627 1654-636 729 

1589-526 1600-537 626 1655-637 728 

1588-525 1601-538 625 1656-638 727 



100's 

101-140 

200's 

201-240 

1587-524 1602-539 624 1657-639 726 

1586-523 1603-540 623 1658-640 725 

1585-522 1604-541 622 1659-641 724 

1584-521 1605-542 1644-621 1660-642 723 

1426-120 1427-121 1464-220 1465-221 1504-320 1505-321 1543-420 1544-421 1583-520 1606-543 1643-620 1661-643 722 

1425-119 1428-122 1463-219 1466-222 1503-319 1506-322 419 1545-422 1582-519 544 1642-619 1662-644 721 

EXHIBITS 

1424-118 1429-123 1462-218 1467-223 1502-318 1507-323 1542-418 1546-423 1581-518 545 1641-618 1663-645 720 

1423-117 1430-124 1461-217 1468-224 1501-317 1508-324 1541-417 1547-424 1580-517 1607-546 1640-617 1664-646 719 

1422-116 1431-125 1460-216 1469-225 1500-316 1509-325 1540-416 1548-425 1579-516 1608-547 1639-616 1665-647 718 

1421-115 1432-126 1459-215 1470-226 1499-315 1510-326 1539-415 1549-426 1578-515 1609-548 1638-615 1666-648 717 

1420-114 1433-127 1458-214 1471-227 1498-314 1511-327 1538-414 1550-427 1577-514 1610-549 1637-614 1667-649 716 

715 

714 

1419-113 1434-128 213 1472-228 1497-313 1512-328 1537-413 1551-428 1576-513 1611-550 1636-613 1668-650 713 

1418-112 1435-129 212 1473-229 1496-312 1513-329 1536-412 1552-429 1575-512 1612-551 1635-612 1669-651 712 

1417-111 1436-130 1457-211 1474-230 1495-311 1514-330 1535-411 1553-430 1574-511 1613-552 1634-611 1670-652 711 

1416-110 1437-131 1456-210 1475-231 1494-310 1515-331 1534-410 1554-431 1573-510 1614-553 1633-610 1671-653 710 

1415-109 1438-132 1455-209 1476-232 1493-309 1516-332 1533-409 1555-432 1572-509 1615-554 1632-609 1672-654 1689-709 

1414-108 1439-133 1454-208 1477-233 1492-308 1517-333 1532-408 1556-433 1571-508 1616-555 1631-608 1673-655 1688-708 

1413-107 1440-134 1453-207 1478-234 1491-307 1518-334 1531-407 1557-434 1570-507 1617-556 1630-607 1674-656 1687-707 

1412-106 1441-135 1452-206 1479-235 1490-306 1519-335 1530-406 1558-434 1569-506 1618-557 1629-606 1675-657 1686-706 

1411-105 1442-136 1451-205 1480-236 1489-305 1520-336 1529-405 1559-436 1568-505 1619-558 1628-605 1676-658 1685-705 

1410-104 1443-137 1450-204 1481-237 1488-304 1521-337 1528-404 1560-437 1567-504 1620-559 1627-604 1677-659 1684-704 

1409-103 1444-138 1449-203 1482-238 1487-303 1522-338 1527-403 1561-438 1566-503 1621-560 1626-603 1678-660 1683-703 

1408-102 1445-139 1448-202 1483-239 1486-302 1523-339 1526-402 1562-439 1565-502 1622-561 1625-602 1679-661 1682-702 

1407-101 1446-140 1447-201 1484-240 1485-301 1524-340 1525-401 1563-440 1564-501 1623-562 1624-601 1680-662 1681-701 

EXHIBITS 

300's 

301-340 

400's 

401-440 

EXHIBITS EXHIBITS 

Entrance 


40 




Wednesday, March 19—1:00 PM to 4:30 PM—Exhibit Hall 4-E, Level 4 







Developmental Neurotoxicity 

Human Biomarkers 

Biomarkers: Methods 

Abstract 

Numbers 

1691-1729 

1730-1746 

1747-1764 


101-139 

201-217 

221-238 

500's 

600's 

maps 

Juvenile Toxicity 

Risk Assessment Applications 

1765-1775 

1776-1803 

301-311 

313-340 

Neurotoxicity: Miscellaneous Compounds, Models and Mechanisms 1804-1843 401-440 

Metal Neurotoxicology: Experimental Models and Mechanisms 1844-1889 501-546 

Pharmaceuticals 

1890-1915 550-562 AND 601-613 

Safety Assessment, Pharmaceutical - Liver, Kidney, Immune System 1916-1943 614-641 

Oxidative Injury and Redox Biology I: In Vivo 1944-1964 642-662 

501-562 601-662 

1874-531 1875-532 1933-631 1934-632 

1873-530 1876-533 1932-630 1935-633 

700's 

1872-529 1877-534 1931-629 1936-634 

701-730 

1871-528 1878-535 1930-628 1937-635 730 

1870-527 1879-536 1929-627 1938-636 729 

1869-526 1880-537 1928-626 1939-637 728 



1868-525 1881-538 1927-625 1940-638 727 

1867-524 1882-539 1926-624 1941-639 726 

1866-523 1883-540 1925-623 1942-640 725 

100's 

200's 

300's 

400's 

101-140 

201-240 

301-340 

401-440 

1865-522 1884-541 1924-622 1943-641 724 

1864-521 1885-542 1923-621 1944-642 723 

1710-120 1711-121 220 1747-221 1783-320 1784-321 1823-420 1824-421 1863-520 1886-543 1922-620 1945-643 722 

1709-119 1712-122 219 1748-222 1782-319 1785-322 1822-419 1825-422 1862-519 1887-544 1921-619 1946-644 721 

EXHIBITS 

1708-118 1713-123 218 1749-223 1781-318 1786-323 1821-418 1826-423 1861-518 1888-545 1920-618 1947-645 720 

1707-117 1714-124 1746-217 1750-224 1780-317 1787-324 1820-417 1827-424 1860-517 1889-546 1919-617 1948-646 719 

1706-116 1715-125 1745-216 1751-225 1779-316 1788-325 1819-416 1828-425 1859-516 547 1918-616 1949-647 718 

1705-115 1716-126 1744-215 1752-226 1778-315 1789-326 1818-415 1829-426 1858-515 548 1917-615 1950-648 717 

1704-114 1717-127 1743-214 1753-227 1777-314 1790-327 1817-414 1830-427 1857-514 549 1916-614 1951-649 716 

715 

712 

1703-113 1718-128 1742-213 1754-228 1776-313 1791-328 1816-413 1831-428 1856-513 1890-550 1915-613 1952-650 711 

1702-112 1719-129 1741-212 1755-229 312 1792-329 1815-412 1832-429 1855-512 1891-551 1914-612 1953-651 710 

1701-111 1720-130 1740-211 1756-230 1775-311 1793-330 1814-411 1833-430 1854-511 1892-552 1913-611 1954-652 709 

1700-110 1721-131 1739-210 1757-231 1774-310 1794-331 1813-410 1834-431 1853-510 1893-553 1912-610 1955-653 708 

1699-109 1722-132 1738-209 1758-232 1773-309 1795-332 1812-409 1835-432 1852-509 1894-554 1911-609 1956-654 707 

EXHIBITS 

1698-108 1723-133 1737-208 1759-233 1772-308 1796-333 1811-408 1836-433 1851-508 1895-555 1910-608 1957-655 706 

1697-107 1724-134 1736-207 1760-234 1771-307 1797-334 1810-407 1837-434 1850-507 1896-556 1909-607 1958-656 705 

1696-106 1725-135 1735-206 1761-235 1770-306 1798-335 1809-406 1838-434 1849-506 1897-557 1908-606 1959-657 704 

1695-105 1726-136 1734-205 1762-236 1769-305 1799-336 1808-405 1839-436 1848-505 1898-558 1907-605 1960-658 703 

EXHIBITS 

EXHIBITS 


1694-104 1727-137 1733-204 1763-237 1768-304 1800-337 1807-404 1840-437 1847-504 1899-559 1906-604 1961-659 702 

1693-103 1728-138 1732-203 1764-238 1767-303 1801-338 1806-403 1841-438 1846-503 1900-560 1905-603 1962-660 701 

1692-102 1729-139 1731-202 239 1766-302 1802-339 1805-402 1842-439 1845-502 1901-561 1904-602 1963-661 

1691-101 140 1730-201 240 1765-301 1803-340 1804-401 1843-440 1844-501 1902-562 1903-601 1964-662 

Entrance 




Thursday, March 20—8:30 AM to 12:00 NOON 

Ballroom 6C & E, Level 6 


The abstract final ID# is located to the left of the hyphen (-); the number to the 

right refers to the poster location number, which does not change throughout 

the week. Presenters should ONLY display posters on the assigned date and 

time communicated in your acceptance notice. 

Maps 


Oxidative Injury and Redox Biology II: In Vitro 

Metals II 

Method Development, Autoimmunity and Disease 

Mechanisms in Immunotoxicology 

AHR Mechanisms 

Chemoprevention 

Fish Alternative Models of Toxicity 

DISPLAYED Cardiovascular ON System: THESE BOARDS. Vascular Effects 

Food Safety II 

High Throughput, High Content Approaches to Assessing 

Genotoxicity 

Pesticide Neurotoxocity 

Safety Assessment, Pharmaceutical - Techniques, 

Pulmonary, Cardiovascular 

Abstract Numbers 

2045-2084 

2085-2122 

2123-2155 

2156-2171 

2172-2183 

2184-2199 

2200-2220 

2221-2241 

2242-2259 

2260-2292 

2293-2326 


101-140 

141-160 AND 201-218 

221-253 

254-260 AND 301-309 

311-322 

325-340 

341-360 AND 401 

403-423 

426-443 

446-460 AND 501-518 

520-553 



2054-110 2055-111 2074-130 2075-131 2094-150 2095-151 2114-210 2115-211 2132-230 2133-231 2152-250 2153-251 310 2172-311 2189-330 2190-331 2209-350 221 

2053-109 2056-112 2073-129 2076-132 2093-149 2096-152 2113-209 2116-212 2131-229 2134-232 2151-249 2154-252 2171-309 2173-312 2188-329 2191-332 2208-349 221 

2052-108 2057-113 2072-128 2077-133 2092-148 2097-153 2112-208 2117-213 2130-228 2135-233 2150-248 2155-253 2170-308 2174-313 2187-328 2192-333 2207-348 221 

2051-107 2058-114 2071-127 2078-134 2091-147 2098-154 2111-207 2118-214 2129-227 2136-234 2149-247 2156-254 2169-307 2175-314 2186-327 2193-334 2206-347 221 

2050-106 2059-115 2070-126 2079-135 2090-146 2099-155 2110-206 2119-215 2128-226 2137-235 2148-246 2157-255 2168-306 2176-315 2185-326 2194-335 2205-346 221 

BALLROOM E 

2049-105 2060-116 2069-125 2080-136 2089-145 2100-156 2109-205 2120-216 2127-225 2138-236 2147-245 2158-256 2167-305 2177-316 2184-325 2195-336 2204-345 221 

2048-104 2061-117 2068-124 2081-137 2088-144 2101-157 2108-204 2121-217 2126-224 2139-237 2146-244 2159-257 2166-304 2178-317 324 2196-337 2203-344 221 

2047-103 2062-118 2067-123 2082-138 2087-143 2102-158 2107-203 2122-218 2125-223 2140-238 2145-243 2160-258 2165-303 2179-318 323 2197-338 2202-343 221 

2046-102 2063-119 2066-122 2083-139 2086-142 2103-159 2106-202 219 2124-222 2141-239 2144-242 2161-259 2164-302 2180-319 2183-322 2198-339 2201-342 221 

2045-101 2064-120 2065-121 2084-140 2085-141 2104-160 2105-201 220 2123-221 2142-240 2143-241 2162-260 2163-301 2181-320 2182-321 2199-340 2200-341 221 

42 




Thursday, March 20—8:30 AM to 12:00 NOON 

Ballroom 6C & E, Level 6 


The abstract final ID# is located to the left of the hyphen (-); the number to the 

right refers to the poster location number, which does not change throughout 

the week. Presenters should ONLY display posters on the assigned date and 

time communicated in your acceptance notice. 

maps 


Oxidative Injury and Redox Biology II: In Vitro 

Metals II 

Method Development, Autoimmunity and Disease 

Mechanisms in Immunotoxicology 


Chemoprevention 

Fish Alternative Models of Toxicity 

DISPLAYED Cardiovascular ON System: THESE BOARDS. Vascular Effects 

Food Safety II 

High Throughput, High Content Approaches to Assessing 

Genotoxicity 

Pesticide Neurotoxocity 

Safety Assessment, Pharmaceutical - Techniques, 


Abstract Numbers 

2045-2084 

2085-2122 

2123-2155 

2156-2171 

2172-2183 

2184-2199 

2200-2220 

2221-2241 

2242-2259 

2260-2292 

2293-2326 


101-140 

141-160 AND 201-218 

221-253 

254-260 AND 301-309 

311-322 

325-340 

341-360 AND 401 

403-423 

426-443 

446-460 AND 501-518 

520-553 



89-330 2190-331 2209-350 2210-351 2228-410 2229-411 2246-430 2247-431 2264-450 2265-451 2284-510 2285-511 2304-531 2305-532 2326-553 

88-329 2191-332 2208-349 2211-352 2227-409 2230-412 2245-429 2248-432 2263-449 2266-452 2283-509 2286-512 2303-530 2306-533 2325-552 

87-328 2192-333 2207-348 2212-353 2226-408 2231-413 2244-428 2249-433 2262-448 2267-453 2282-508 2287-513 2302-529 2307-534 2324-551 

86-327 2193-334 2206-347 2213-354 2225-407 2232-414 2243-427 2250-434 2261-447 2268-454 2281-507 2288-514 2301-528 2308-535 2323-550 

85-326 2194-335 2205-346 2214-355 2224-406 2233-415 2242-426 2251-435 2260-446 2269-455 2280-506 2289-515 2300-527 2309-536 2322-549 

2299-526 2310-537 2321-548 

BALLROOM C 

2298-525 2311-538 2320-547 

2297-524 2312-539 2319-546 

84-325 2195-336 2204-345 2215-356 2223-405 2234-416 425 2252-436 445 2270-456 2279-505 2290-516 2296-523 2313-540 2318-545 

BACK SURFACE NOT IN USE 

324 2196-337 2203-344 2216-357 2222-404 2235-417 424 2253-437 444 2271-457 2278-504 2291-517 2295-522 2314-541 2317-544 

323 2197-338 2202-343 2217-358 2221-403 2236-418 2241-423 2254-438 2259-443 2272-458 2277-503 2292-518 2294-521 2315-542 2316-543 

83-322 2198-339 2201-342 2218-359 402 2237-419 2240-422 2255-439 2258-442 2273-459 2276-502 519 

82-321 2199-340 2200-341 2219-360 2220-401 2238-420 2239-421 2256-440 2257-441 2274-460 2275-501 2293-520 


47 th th Annual Meeting & ToxExpo 

ToxExpo Floor Plan 

Exhibit Hall 4-E 

Exhibit Hours: 

LOUNGE 

Monday 

9:15 AM–4:30 PM 

Tuesday 

8:30 AM–4:30 PM 

Toxexpo 

Poster Boards 100s 











Wednesday 

8:30 AM–4:30 PM 



To 

Exhibit Hall 4A-B 

44 


Poster Bo 

Poster Bo 


ToxExpo Floor Plan (Continued) 

Toxexpo 

Poster Boa 




Exhibit Hall 4A-B 


To Exhibit Hall 4-E and Posters 

To General Session/Welcoming Reception 

Escalator to Level 6 


ENTRANCE 

To 

Registration 

REGISTRATION

47 th th Annual Society Meeting of Toxicology & ToxExpo 

2008 

ToxExpo 2008 Exhibitors 

Toxexpo 

(As of January 7, 2008) 

Please visit www.ToxExpo.com or the ToxExpo TM Directory for product/ 

service descriptions, a map of booth locations, and other information. 

2008 Annual Meeting sponsors are in bold. 

See listing of complete sponsors on Inside Back Cover and Back Cover. 

Company Name 

Booth Number 

AAALAC International..........................................................................................................705 

AAAS/SCIENCE..................................................................................................................2448 

ABC Laboratories, Inc..........................................................................................................2036 

AbD Serotec.............................................................................................................................538 

Accelera.................................................................................................................................2512 

Access Technologies...............................................................................................................612 

ADMET Group...................................................................................................................... 2214 

ADMET Technologies..........................................................................................................2248 

Advinus Therapeutics, Pvt. Ltd............................................................................................2443 

Advion......................................................................................................................................948 

AEgis Technologies Group................................................................................................... 2111 

Affymetrix......................................................................................................................... 2143 

AIT Laboratories................................................................................................................... 2611 

Alabama Research & Development...................................................................................... 1743 

Alpha Genesis, Inc................................................................................................................ 2147 

ALZET Osmotic Pumps/DURECT Corp..............................................................................504 

American Board of Toxicology, Inc. (ABT)........................................................................1720 

American College of Medical Toxicology.............................................................................509 

American College of Toxicology (ACT)...............................................................................533 

American Conference of Governmental Industrial Hygienists (ACGIH ® )..........................745 

American Industrial Hygiene Association (AIHA)...............................................................743 

American Radiolabeled Chemicals, Inc...............................................................................2048 

Americans for Medical Progress (AMP)................................................................................530 

Amnis Corporation..................................................................................................................837 

Ani Lytics, Inc......................................................................................................................2028 

Aniara Corporation/Xenometrix AG....................................................................................532 

AniClin Preclinical Services................................................................................................2343 

Anilab, LLC...........................................................................................................................2505 

Animal Identification and Marking System (AIMS)...........................................................1929 

Antech Diagnostics GLP.......................................................................................................2246 

AppTec Laboratory Services................................................................................................ 1747 

APTUIT, Inc..........................................................................................................................2404 

ART Advanced Research Technologies...............................................................................1639 

Assay Depot.............................................................................................................................853 

AstraZeneca, LP....................................................................................................................859 

Austrian Research Centers GmbH - ARC.............................................................................. 914 

AVA Biomedical, Inc.........................................................................................................2540 

Axio Research Company, LLC...............................................................................................507 

Azopharma...............................................................................................................................423 

Baker Company, The............................................................................................................. 1710 

BASF Aktiengesellschaft......................................................................................................2446 

BASi (Bioanalytical Systems, Inc)....................................................................................2215 

Battelle...................................................................................................................................2521 

BD Biosciences..................................................................................................................2242 

Beckman Coulter, Inc..............................................................................................................815 

Bio Medic Data Systems, Inc................................................................................................ 2411 

Bioagri Pharma......................................................................................................................1948 

BioBubble, Inc.........................................................................................................................539 

BioDuro (Beijing) Co., Ltd.....................................................................................................421 

BioDynamics Research Ltd....................................................................................................703 

BioLife Solutions, Inc...........................................................................................................1946 

Biological Test Center (BTC)...............................................................................................1828 

Biomedical Photometrics Inc.................................................................................................. 417 

Biopredic International...........................................................................................................523 

Bio-Rad Laboratories............................................................................................................ 1718 

BioReliance ® .........................................................................................................................1905 

Bio-Serv, Inc.......................................................................................................................... 1913 

BioStat Consultants, Inc.........................................................................................................928 

Biotechnics, LLC...................................................................................................................1808 

Biotrin International..............................................................................................................2245 

BRI Biopharmaceutical Research, Inc...................................................................................505 

Bridge Laboratories............................................................................................................2335 

Bristol-Myers Squibb Company (BMS).............................................................................528 

Britz & Company...................................................................................................................2632 

Brooks Rand Labs...................................................................................................................737 

Burdock Group......................................................................................................................2510 

Buxco Electronics, Inc............................................................................................................902 

Caliper Life Sciences, Inc....................................................................................................... 910 

Calvert Laboratories, Inc...................................................................................................1729 

CANTEST Ltd.......................................................................................................................2144 

CANTOX HEALTH SCIENCES INTERNATIONAL....................................................... 1919 

Carl Zeiss MicroImaging, Inc.................................................................................................405 

Carter2 Systems, Inc.............................................................................................................2609 

Cayman Chemical...................................................................................................................723 

CeeTox, Inc.............................................................................................................................. 814 

Cellular Dynamics International, Inc...................................................................................2612 

Cellumen Inc............................................................................................................................529 

CellzDirect...............................................................................................................................904 

ChemInsight............................................................................................................................ 614 

Cerep...................................................................................................................................... 2511 

CH Technologies (USA), Inc. (CHT)...................................................................................1928 

Company Name 

Booth Number 

ChanTest, Inc.........................................................................................................................2504 

Charles River Laboratories Clinical Services.....................................................................2529 

Charles River Laboratories Library.....................................................................................2328 

Charles River Laboratories Preclinical Services.................................................................2329 

Charles River Laboratories Research Models & Services............................................2429 

Chemical Solutions Ltd...........................................................................................................809 

ChemRisk ® , Inc.......................................................................................................................733 

Chenomx Inc............................................................................................................................403 

CIIT at the Hamner Institutes for Health Sciences........................................................2212 

Cirrus BioSystems.................................................................................................................2615 

CIT......................................................................................................................................... 1931 

ClearH2O, Inc........................................................................................................................1647 

Cogenics...................................................................................................................................808 

Colorado Histo-Prep............................................................................................................. 1911 

Comparative Biosciences......................................................................................................1836 

Comparative Ophthalmic Research Laboratories...............................................................2010 

Constella Group.......................................................................................................................515 

CorDynamics...........................................................................................................................803 

Cosmetic Ingredient Review (CIR)..................................................................................... 2444 

Covance.................................................................................................................................2011 

Covance Research Products, Inc..........................................................................................2029 

Crown Bioscience Inc.............................................................................................................813 

Crystal Import Corporation....................................................................................................936 

CXR BIOSCIENCES LIMITED..........................................................................................2639 

Data Integrated Scientific Systems (D.I.S.S.)......................................................................1703 

Data Sciences International (DSI)....................................................................................1821 

Dataworks Development, Inc.................................................................................................. 510 

Definiens..................................................................................................................................429 

Detroit R&D, Inc...................................................................................................................2442 

Development Center for Biotechnology...............................................................................2506 

Diagnositc Hybrids..................................................................................................................908 

DiLab ® , Inc............................................................................................................................2542 

DMetrix, Inc............................................................................................................................ 431 

Dojindo Molecular Technologies, Inc.................................................................................... 517 

Dow Corning Corporation......................................................................................................735 

Ecogenomics, Inc....................................................................................................................632 

Ellegaard Göttingen Minipigs ® ............................................................................................ 2314 

Elm Hill Breeding Labs, Inc.................................................................................................1949 

Elsevier..................................................................................................................................2209 

emka TECHNOLOGIES, Inc.................................................................................................620 

Enthalpy Analytical, Inc.........................................................................................................836 

EPL Archives, Inc.................................................................................................................2308 

EPL, Inc. (Experimental Pathology Laboratories)........................................................2304 

Esoterix Clinical Trials Services..........................................................................................2022 

Eurofins | Product Safety Labs (EPSL)............................................................................... 2004 

EUROTOX...............................................................................................................................848 

Experimur..............................................................................................................................2441 

Expert Publishing, LLC........................................................................................................2538 

Exponent, Inc.........................................................................................................................1941 

Foundation for Biomedical Research.....................................................................................806 

Fraunhofer ITEM.....................................................................................................................820 

Frontier BioSciences, Inc......................................................................................................2014 

Fulcrum Pharma Developments, Inc......................................................................................812 

Genedata Inc............................................................................................................................807 

GeneGo, Inc.............................................................................................................................502 

Genesis Midwest Laboratories, LLC....................................................................................2607 

Gentronix, Limited................................................................................................................1849 

GenWay Biotech, Inc...............................................................................................................940 

GlobalTox...............................................................................................................................2043 

GMK Bio Services................................................................................................................2637 

Gradient Corporation.........................................................................................................1708 

GraphPad Software, Inc........................................................................................................2546 

H&T Corporation..................................................................................................................1947 

Hamilton Company................................................................................................................. 514 

Hamilton Thorne Research................................................................................................... 2132 

Harlan...................................................................................................................................2119 

HemoGenix Inc.....................................................................................................................2610 

HistoTox Labs, Inc...................................................................................................................628 

HSRL (Histo-Scientific Research Laboratories)................................................................2628 

Hugo Sachs Elektronik/Harvard Apparatus..........................................................................839 

Humana Press........................................................................................................................ 2142 

Huntingdon Life Sciences...................................................................................................2311 

Hurley Consulting Associates, Ltd......................................................................................2208 

iAdvantage Software, Inc.....................................................................................................2046 

ICT-XII.....................................................................................................................................845 

IDEXX Preclinical Research Services................................................................................... 811 

IIT Research Institute (IITRI)..............................................................................................2030 

ILSI Health and Environmental Sciences Institute (HESI)..................................................535 

iMET Research Inc................................................................................................................1848 

Immunology Consultants Laboratory, Inc...........................................................................1645 

In Vitro Technologies, Inc. (IVT).........................................................................................2231 

Ina Research, Inc...................................................................................................................2346 

Informa Healthcare...............................................................................................................2021 

Ingenuity Systems.................................................................................................................2104 

INphoton................................................................................................................................2613 

Instech Solomon....................................................................................................................2006 

Instem.................................................................................................................................2421 

Institute for In Vitro Sciences, Inc. (IIVS)...........................................................................2336 

46 


47 th th Annual Society Meeting of Toxicology & ToxExpo 

2008 

ToxExpo 2008 Exhibitors (Continued) 

Company Name Booth Number Company Name Booth Number 

Institute for Laboratory Animal Research (ISLAR).............................................................747 

Integrated Laboratory Systems, Inc.....................................................................................2513 

International Institute for the Advancement of Medicine (IIAM).......................................749 

International Society of Regulatory Toxicology & Pharmacology (ISRTP).......................842 

In-Tox Products........................................................................................................................437 

IPS Therapeutique.................................................................................................................2018 

ISIS BioComp........................................................................................................................1705 

ISIS Services..........................................................................................................................1744 

ITR Laboratories Canada, Inc..............................................................................................2237 

IUTOX.....................................................................................................................................845 

Jai Research Foundation International (JRF)......................................................................2536 

Kent Scientific Corporation....................................................................................................520 

Kibron Inc................................................................................................................................536 

Kinder Scientific Company...................................................................................................1830 

Kleinfelder Group, The........................................................................................................... 741 

Korea Environmental and Merchandise Institute (KEMTI)..............................................2348 

Korea Institute of Toxicology (KIT)....................................................................................2045 

Lab Manager Magazine ® /ALN Magazine........................................................................2619 

LAB Products, Inc.............................................................................................................2005 

LAB Research, Inc..............................................................................................................2321 

LABCAT................................................................................................................................ 2316 

Lablogic Systems, Ltd........................................................................................................... 2614 

Leadscope, Inc.......................................................................................................................2548 

Leyden Group, The................................................................................................................ 2517 

LHASA, Limited.....................................................................................................................846 

Lifeline Cell Technology.......................................................................................................1734 

Lomir Biomedical, Inc.......................................................................................................... 1915 

Lonza......................................................................................................................................1936 

Lovelace Respiratory Research Institute (LRRI)................................................................ 1735 

Lutronic North America........................................................................................................2604 

Luxcel Biosciences, Ltd........................................................................................................2249 

RCC (now Harlan)................................................................................................................. 2119 

ReachBio................................................................................................................................1722 

Redshift Technologies, Inc.....................................................................................................721 

Regulatory & Toxicology Solutions, Inc.............................................................................. 1714 

Research Diets, Inc................................................................................................................2243 

Ricerca Biosciences, LLC.....................................................................................................1805 

Ridglan Farms, Inc................................................................................................................ 2616 

Risk Assessment Summer School (RASS)............................................................................843 

Roche.....................................................................................................................................1535 

Rosetta Biosoftware............................................................................................................2210 

RTC, Research Toxicology Centre S.p.A.............................................................................2342 

RTI International...................................................................................................................2232 

Safepharm (now Harlan)....................................................................................................... 2119 

SafetyCall International, PLLC............................................................................................2238 

SAGE...................................................................................................................................... 1841 

San Diego Instruments, Inc..................................................................................................1923 

Scientists Center for Animal Welfare....................................................................................844 

SCIREQ, Inc. (Scientific Respiratory Equipment)..............................................................1838 

Seahorse Bioscience................................................................................................................638 

Sequani Limited.................................................................................................................... 2113 

Shared Enterprises..................................................................................................................707 

Sibata Scientific Technology Ltd............................................................................................630 

Siemens Medical Solutions USA..........................................................................................2537 

Sinclair Research Center, Inc. (SRC)...................................................................................1937 

Singulex, Inc..........................................................................................................................2623 

SkinEthic Laboratories...........................................................................................................602 

Smiths Medical MD, Inc....................................................................................................... 2135 

SNBL USA, LTD................................................................................................................... 1811 

Society of Quality Assurance (SQA)......................................................................................954 

Society of Toxicologic Pathology (STP).............................................................................511 

SOT Resource Pavilion 

Maccine Pte Ltd.......................................................................................................................805 . • Animals In Research....................................................................................................1203 

Marshall Bioresources.......................................................................................................... 2310 . • Endowment Fund..........................................................................................................1200 

MB Research Labs, Inc.........................................................................................................1843 . • K–12 and Public Outreach Materials........................................................................1201 

MDS Pharma Services..........................................................................................................2035 . • Member Services..........................................................................................................1200 

Med Associates, Inc..............................................................................................................1940 . • Regulatory Affairs and Legislative Assistance........................................................1202 

Merck & Co., Inc. (Publishing Group)...................................................................................841 

Meso Scale Discovery..........................................................................................................1541 

Metabolon, Inc..................................................................................................................... 616 

Metabometrix, Ltd................................................................................................................1847 

metanomics Health................................................................................................................2635 

Midwest BioResearch, LLC (MBR).....................................................................................2345 

Midwest Research Institute (MRI).......................................................................................1707 

Millipore Corporation.............................................................................................................634 

MitoSciences Inc...................................................................................................................2021 

Moltox...................................................................................................................................... 610 

MPI Research....................................................................................................................... 1717 

MultiCASE, Inc.....................................................................................................................2437 

National Biosafety & Biocontainment Training Program..................................................2633 

National Library of Medicine.................................................................................................521 

National Research Center for New Drug Safety Evaluation (Shenyang).............................938 

National Shanghai Center for New Drug Safety Evaluation & Research..........................2447 

National Toxicology Program............................................................................................1831 

NCEH/ATSDR Information Center (Centers for Disease Control)......................................508 

NeuroScience Associates (NSA)............................................................................................522 

NIEHS/Office of Communications Public Liaison.............................................................1829 

NIH Rapid Access to Interventional Development...............................................................503 

Northwest Life Science Specialties, LLC..............................................................................709 

NOTOCORD Systems.............................................................................................................729 

NOTOX B.V........................................................................................................................... 1810 

NUCRO-TECHNICS............................................................................................................2207 

Numira Biosciences...............................................................................................................2631 

Olympus America Inc.............................................................................................................739 

Oxford Biomedical Research, Inc........................................................................................1746 

Oxford University Press..........................................................................................................944 

Pacific BioLabs......................................................................................................................2012 

Partek Incorporated.................................................................................................................804 

Pathology Data Solutions, Inc..............................................................................................2320 

Pathology Experts LLC.........................................................................................................2645 

Perceptive Instruments......................................................................................................... 2148 

Perry Scientific......................................................................................................................2621 

Pfizer Global Research and Development........................................................................1832 

Pharma Algorithms.............................................................................................................2020 

Pharmalytica Services...........................................................................................................2649 

PharmaNet Development Group...........................................................................................1842 

Pharmatek Laboratories, Inc...................................................................................................934 

Pharmoptima, LLC..................................................................................................................854 

Phylonix Pharmaceuticals, Inc.............................................................................................2439 

Popper & Sons, Inc................................................................................................................2049 

PreClinOmics, Inc.................................................................................................................2507 

Prevalere Life Sciences.........................................................................................................2236 

Primate Products, Inc. (PPI).................................................................................................2230 

Progenix Research Sdn Bhd...................................................................................................958 

Promega Corporation..............................................................................................................821 

Puracyp, Inc............................................................................................................................. 415 

Southern Research Institute..............................................................................................2221 

Southwest Research Institute................................................................................................1643 

Spring Valley Laboratories, Inc...........................................................................................1846 

Springborn Smithers Labs(SSL)/Synomics Pharma Services (SPS)..................................2405 

SRI International...................................................................................................................2128 

STARR Life Sciences............................................................................................................1637 

StemCell Technologies, Inc....................................................................................................713 

Stillmeadow, Inc....................................................................................................................2229 

Stoelting.................................................................................................................................1738 

Strategic Applications, Inc. (SAI)........................................................................................ 2131 

Suburban Surgical Company, Inc.........................................................................................2106 

Summit plc...............................................................................................................................952 

SuperArray Bioscience...........................................................................................................942 

Syracuse Research Corporation........................................................................................... 1748 

Sysmex..................................................................................................................................... 711 

Systems Pathology Company, LLC...................................................................................2338 

Taconic.....................................................................................................................................922 

Tecniplast...............................................................................................................................2643 

Thermo Fisher Scientific.........................................................................................................715 

TNO........................................................................................................................................1837 

Toxicology Education Foundation (TEF).............................................................................. 531 

Toxicology Excellence for Risk Assessment (TERA).......................................................537 

Toxicology Regulatory Services (TRS)...............................................................................1921 

Toxicology Research Laboratory (TRL)................................................................................802 

Toxikon Corporation.............................................................................................................2105 

Tox Monitor/BSR Inc............................................................................................................2109 

TOXSA/7CTDC......................................................................................................................845 

ToxServices, LLC................................................................................................................1537 

Trevigen, Inc............................................................................................................................608 

TSE Systems, Inc................................................................................................................... 1739 

TSI Incorporated.....................................................................................................................912 

Union Biometrica.................................................................................................................. 1716 

U.S. Environmental Protection Agency...............................................................................1740 

Vanny Resources Holdings Limited.....................................................................................1634 

Veritox, Inc...........................................................................................................................2040 

VisualSonics..........................................................................................................................2247 

VITROCELL Systems GmbH..............................................................................................1932 

Vitron, Inc.............................................................................................................................. 1733 

VivoMetrics, Inc......................................................................................................................930 

WIL Research Laboratories, LLC....................................................................................1804 

Wildlife International, Ltd....................................................................................................2205 

World Precision Instruments, Inc......................................................................................... 1635 

Worthington Biochemical Corp............................................................................................. 411 

Xenobiotic Detection Systems..............................................................................................2038 

XenoBiotic Laboratories, Inc................................................................................................2349 

XenoTech, LLC......................................................................................................................1938 

Xybion Medical Systems....................................................................................................... 2137 

ZF BIOLABS...........................................................................................................................439 

Zygogen....................................................................................................................................849 

Purina Mills LabDiet.............................................................................................................2305 

QTest Labs............................................................................................................................. 2617 

Toxexpo 

Admittance to the Exhibit Hall is limited to attendees with full registration. Children under the age of 15 years of age are not allowed in the Exhibit Hall. 

Photography is prohibited in the Exhibit Hall. Special requests can be brought to he Show Manager. The Show Management Office is located in the Exhibit Hall (see map on page 28). 



ToxExpo TM 

ToxExpo Floor Plan (Continued) 

Toxexpo 

You probably know ToxExpo TM as the 

exhibition associated with the Society 

of Toxicology’s Annual Meeting—it’s 

that—but it’s also a great deal more. 

ToxExpo TM is: 

• A unique environment to research 

products and services of exhibiting companies 

and keep you informed of new cutting-edge 

science and technology. 

• A Comprehensive approach to organizing the 

wealth of ideas and insights in cross-disciplinary 

areas of toxicology. 

• The toxicology marketplace—your 

source for product information and resources to 

keep your lab competitive. 

• The place where professionals will 

learn how to explore a rapidly changing science. 

• A chance to think outside the box— 

find out how your work relates to research in 

other disciplines. 

• Up-to-date information on state-of-the-art 

research equipment, technology, and the latest 

publications. 

• A 24/7 comprehensive on-line resource, 

searchable by company name or by product or 

service. Available at www.toxexpo.com. 

Looking for a particular product 

or service? Check the category 

listing on 

www.toxexpo.com 

to see which companies offer the 

best product or service for 

your needs. 

It all adds up to an uncommonly rich 

resource for the scientist, 

the toxicologist, the policy maker, 

the educator, the student— 

anyone looking for the best products and 

services that toxicology has to offer! 

www.toxexpo.com 

48 



Registration 

Annual Meeting Registration Fees: 

On-Site 

SOT Member........................................................$375 

Non-Member........................................................$650 

SOT Retired Member...........................................$145 

Postdoctoral SOT Member...................................$160 

Postdoctoral Non-Member...................................$240 

Graduate Student SOT Member...........................$140 

Graduate Student Non-Member...........................$200 

Undergraduate Student.........................................$140 

SOT Affiliate............................................................$0 

Press..........................................................................$0 

Guest (Non-Scientist)...........................................$100 

(Guests do not have access to the Scientific Sessions or 

the Exhibit Hall.) 

Continuing Education Sunrise 

Mini-Course Fees: 

(includes continental breakfast) 

On-Site 

SOT Member/Corp Affiliate................................$105 

Retired..................................................................$105 

Non-Member........................................................$125 

Postdoctoral (SOT Member or Non-Member).....$105 

Graduate or Undergraduate Student.......................$75 

Press..........................................................................$0 

Continuing Education Course Fees: 

(per AM or PM course) 

(Only Annual Meeting Registrants may enroll in 

CE Courses) 

On-Site 

SOT Member/SOT Corp Affiliate........................$165 

Retired..................................................................$160 

Non-Member........................................................$280 

Postdoctoral (SOT Member or Non-Member)...........$140 

Graduate or Undergraduate Student 

(SOT Member or Non-Member)..................................$95 

Press..........................................................................$0 

Annual Meeting Registration Includes: 

• Awards Ceremony, Sunday, March 16 from 

5:15 PM–6:30 PM. 

• Welcoming Reception, Sunday, March 16 from 

6:30 PM–7:30 PM. 

• Plenary Opening Lecture, Monday, March 17 from 

8:15 AM–9:15 AM. 

• All Scientific Sessions (see program descriptions 

beginning on page 85) 9:30 AM, Monday, March 17 

through 11:45 AM, Thursday, March 20. 

• ToxExpo Exhibit Hall, 9:15 AM–4:30 PM Monday, 

March 17; 8:30 AM–4:30 PM Tuesday, March 18 and 

Wednesday, March 19. 

Participants are also encouraged to register for the 

Continuing Education Courses. These are available during 

three time intervals on Sunday, March 16: the Sunrise Mini- 

Course is from 7:00 AM–7:45 AM, morning courses are 

8:15 AM–12:00 NOON, and afternoon courses are from 

1:15 PM –5:00 PM. 

Registration Desk 

Registration Desk will be located on the Level 4, South 

Lobby. 

Registration Desk Hours: 

Saturday......................................................4:00 PM–7:00 PM 

Sunday...................................................... 7:00 AM–8:00 PM 

Monday......................................................7:00 AM–5:00 PM 

Tuesday..................................................... 8:00 AM–4:00 PM 

Wednesday............................................... 8:00 AM–4:00 PM 

Thursday.................................................. 8:00 AM–11:30 PM 

Registration Materials 

Register before January 25, 2008, and your badge, Program 

and The Toxicologist on CD-ROM will be sent to you 

prior to the Annual Meeting. Your 2008 Annual Meeting 

Registration badge must be presented to obtain access to 

SOT functions. 

When you arrive at the Washington State Convention and 

Trade Center, please go to the registration area on the 4 th 

floor to pick up your ToxExpo Directory and registration 

badge. If you already have your registration badge and 

CE course tickets, there is no need to stand in a registration 

line. Simply stop by the handout table in the registration 

area and present your badge to obtain the other registration 

materials (i.e., The Toxicologist on CD-ROM, the ToxExpo 

Directory and other supplementary materials). 

Registration 



General Information 

General Info 

Accessibility for Persons with Disabilities 

The Washington State Convention and Trade Center and most 

of the SOT hotels are accessible to persons with disabilities. 

If you require special services, please mark the appropriate 

box on the Housing Request Form and the Registration 

Form. If you require more information about disabled 

access, please contact Heidi Prange at SOT Headquarters: 

(703) 438-3115 ext. 1424 or e-mail: heidi@toxicology.org. 

Attire 

The official attire for the Annual Meeting is business casual. No 

coat or tie is required! We encourage you to bring comfortable 

clothing and shoes. Because meeting rooms may seem cold, 

please bring a sweater or jacket and/or dress in layers. 

Badges 

Annual Meeting attendees who have registered before 

January 25, 2008, will receive badges and registration 

materials in the mail. If you already have your 2008 Annual 

Meeting badge you do not need to wait in a registration line. 

If you have registered and have NOT received your badge by 

mail or need a replacement badge, go to the “Badge Pick Up 

Only” registration counter to pick up your badge. 

If you have not registered for the meeting, please complete 

the on-site registration form found at the kiosks in the registration 

area and proceed to the appropriate registration line. 

Business Center—FedEx Kinko’s 

FedEx Kinko’s is a full-service business center offering 

FedEx shipping, high-speed duplication, binding, posters, 

signs, banners, fax service, instant passport photos, lamination, 

Mac and PC rentals, Internet access, and free pick-up 

and delivery. E-mail your documentation preparation 

requests right from your computer. FedEx Kinko’s is located 

on Level 1. Hours: 7:00 AM Monday to 9:00 PM Friday 

and on Saturday and Sunday from 9:00 AM to 6:00 PM. 

Telephone: (206) 467-1767; e-mail: usa5161@fedexkinkos. 

com. 

Climate 

Seattle is known for its remarkable beauty and climate. The 

lush green hills and gardens are a result of seasonal, gentle 

rains brought by Pacific air currents. The resulting maritime 

climate keeps Seattle’s temperatures moderate. It rarely 

freezes or snows in the winter and the days are mild in the 

summer. According to a study by WeatherBill, Inc. (May 

2007), Seattle is ranked number 42 for average annual rainfall, 

lower than New Orleans, Houston, Miami, New York 

City, Memphis, and Washington, D.C. Daytime temperatures 

in the winter months are typically in the 40s or 50s and 

seldom drop below freezing. Average temperature for March: 

highs in the mid 50s °F and lows in the upper 30s °F. 

Exhibit Hall (Hours/Location) 

Exhibit hours at the Convention Center are as follows: 

Monday......................................................9:15 AM–4:30 PM 

Tuesday......................................................8:30 AM–4:30 PM 

Wednesday................................................8:30 AM–4:30 PM 

A map of the Exhibit Hall is located on page 44. Exhibitor 

personnel may enter the hall one hour before the Exhibit 

Hall opens with appropriate identification. Poster presenters 

may enter the hall at the poster set up times specified in the 

Events Calendars. 

Exhibit Space Meeting 

Exhibiting companies should plan on attending the 2009 

Space Selection Meeting on Tuesday, March 18 at 4:45 PM in 

Exhibit Hall 4C-3 on Level 4. 

Exhibit Hall Policy 

Admittance to the Exhibit Hall is limited to attendees with 

full registration. Guest Registrants and children under the 

age of 15 are not allowed in the Exhibit Hall. 

Photography is prohibited in the Exhibit Hall. Special 

requests can be brought to the Show Manager. The Show 

Office is located in Room 401. 

First Aid and Security at the 


If an emergency should occur while at the Washington State 

Convention and Trade Center, proceed directly to the nearest 

house phone, located throughout the facilities, and dial 5127. 

You will be connected to the Security Control office. From 

any phone that is not a house phone, dial (206) 694-5127. Red 

“hot line” phones are also located around the facility and 

ring directly into the Security Control office. Alternatively, 

any uniformed WSCTC personnel with a two-way radio can 

contact the Security Control office if needed. 

SOT will provide a First Aid Room that will be open during 

exhibit move-in, exhibit move-out, and scientific session 

hours. The First Aid Room will be located in the South 

Lobby Level 4 near the entrance of the exhibit hall. 

50 



General Information (Continued) 

Food Services 

Coffee Breaks 

The exhibiting companies are pleased to sponsor 

complimentary coffee in the Exhibit Hall between 9:15 AM– 

10:15 AM, Monday through Wednesday. See Exhibit Hall 

signage for locations. 

Concessions 

Concession stands are available in the Exhibit Hall Monday 

9:15 AM–2:30 PM, and Tuesday and Wednesday from 8:30 

AM–2:30 PM. Breakfast and lunch items will be available, 

as well as coffee, soda, bottled water, and snacks for 

purchase. Concession stands will also be available near Level 

6 meeting rooms. Seating is available in the Concession area 

in Exhibit Hall 4E. 

Restaurants—Food and Drink at the Convention 

Center 

Bambuza—offers fresh and delicious international cuisine 

for lunch and dinner. Daily happy hour with drink and 

appetizer specials from 4:00 PM to 6:00 PM. Located at Pike 

and Ninth. Lunch: Monday–Saturday from 11:00 AM to 

3:00 PM, or try quick sandwich service Monday–Friday, 

10:00 AM to 3:00 PM. Dinner: Monday–Thursday from 

5:00 PM to 9:30 PM and Friday and Saturday, 5:00 PM 

to 10:30 PM. Reservations are accepted. Telephone: 

(206) 219-5555. 

Crêpes Voilá—is a sidewalk café specializing in fresh, 

European-style fast food. Delicate, golden crêpes folded 

around your choice of twenty different fillings for breakfast, 

lunch, dinner and dessert. Located outside under the arch on 

Pike. Hours: Monday–Thursday from 8:00 AM to 8:30 PM, 

Friday from 8:00 AM to 9:30 PM, Saturday from 9:30 AM to 

9:30 PM and Sunday from 9:30 AM to 8:30 PM. Telephone: 

(206) 447-2737. Web site: www.lacreperievoila.com. 

Cyber Dogs—Internet Café—Enjoy gourmet international 

hot dogs, espresso, teas and beverages. T1 high-speed 

Internet service is available. Located just across Convention 

Place on Pike Street. Hours: Open daily from 10:00 AM to 

12:00 Midnight. Telephone: (206) 405-3647. 

Web site: www.cyber-dogs.com. 

Espresso Caffé Dior—offers specialty coffee drinks, teas, 

beverages, a large variety of tasty pastries and freshly made 

sandwiches. Located on Level 1. Hours: Monday–Friday 

from 7:00 AM to 5:00 PM and Saturday 8:00 AM to 

2:00 PM. Sunday hours are based on the Convention Center 

event schedule. Telephone: (206) 624-0814. 

Juice It Café—specialty is freshly squeezed fruit and 

vegetable juice, brown rice bowls, salads, sandwiches, and 

soups. Energy bars, vitamins, and supplements are also 

available. Located in the Level 1 corridor near Gold’s Gym. 

Hours: Monday–Friday, 8:00 AM to 7:00 PM and Saturday, 

10:00 AM to 4:00 PM. Telephone: (206) 447-6960. 

Moby’s Restaurant and Lounge—is a full service restaurant 

featuring grilled steaks, burgers, seafood, and microbrews. 

Open for lunch, dinner, and happy hour. Level 1, near the 

Union Street entrance. Hours: Monday from 11:00 AM to 

3:00 PM, Tuesday–Friday from 11:00 AM to 8:00 PM 

and weekends from 12:00 NOON to 8:00 PM. Telephone: 

(206) 447-0507. Web site: www.mobysrestaurant.tk. 

Subway Sandwiches—offers sandwiches, salads and 

breakfast items. Subway has two convenient locations at the 

Center: Under the arch on Pike and on Level 4 next to Tully’s 

Coffee. Hours: Subway on Level 4 is open daily from 8:00 

AM to 5:30 PM and the Pike Street location is open daily from 

8:00 AM to 9:00 PM. Telephone: Level 4—(206) 505-6498, 

Pike Street—(206) 694-5149. 

Taco Del Mar—Seattle’s biggest and best mission-style 

burritos, made fresh to order. Try famous fish tacos, enchiladas, 

Baja bowls and other delicious Mexican dishes. 

Located on Level 1. Hours: Monday–Saturday, 10:00 AM to 

8:00 PM and Sunday, 12:00 NOON to 6:00 PM. Telephone: 

(206) 628-8982. 

Tully’s Coffee—Enjoy a cup of Seattle’s world-famous 

handcrafted coffee, made fresh by an expert barista. Tully’s 

also offers refreshing cold drinks, teas, pastries, ice cream, 

and more. Located on Level 4 of the South Galleria. Hours: 

Open Monday–Friday from 7:00 AM to 5:00 PM. Weekend 

schedule is based on Convention Center event activity. 

Telephone: (206) 694-5371. 

Unconventional Pizza & Salad—Freshly made pizzas by the 

slice or the whole pie, calzone, salads, and several varieties 

of pasta. Unconventional Pizza is located on Level 1, next 

to FedEx Kinko’s. Hours: Monday–Saturday, 10:00 AM to 

6:00 PM. Hours may be extended for convention event 

activity. Telephone: (206) 625-0102. 

Take a Break! 

Grab a bite! Check e-mail! Plenty of seating is available 

in the Hot Zones in Exhibit Halls 4A and 4E and in the 

Concessions area in Exhibit Hall 4E. 

General Info 




General Info 

Citywide Concierge & Visitor Center 

The Citywide Concierge & Visitor Center can assist with 

everything from tour bookings and sightseeing suggestions 

to dining reservations and local travel information. Operated 

as a complimentary service by Seattle’s Convention and 

Visitors Bureau, the Citywide Concierge & Visitor Center 

is located on Level 1 in the corridor adjacent to Lotte 

Salon. Hours: Open 9:00 AM to 5:00 PM, Monday–Friday. 

Telephone: (206) 461-5888. 

A full listing of restaurants by cuisine and price is on page 

35. 

Guest Hospitality Center and Program 

The SOT Guest Hospitality Center provides guest participants 

(non-scientists) with a place to meet and socialize with 

other guests. To visit the Hospitality Center, guests must 

register for the Annual Meeting with the person they are 

accompanying. Guests are welcome to attend the Welcoming 

Reception, but will not have access to the scientific sessions 

or the Exhibit Hall. Please remember to wear your badge to 

all SOT events. 

The Guest Hospitality Center will be located in the Sheraton 

Hotel, Greenwood room. 

Guest Hospitality Center hours: 

Sunday....................................................... 8:00 AM–5:00 PM 

Monday...................................................... 8:00 AM–5:00 PM 

Tuesday...................................................... 8:00 AM–5:00 PM 

Wednesday................................................ 8:00 AM–5:00 PM 

Thursday.................................................. 8:00 AM–11:30 AM 

Housing 

Housing Desk 

The deadline for housing reservations is February 20, 2008. 

You may continue to make new reservations, changes, or 

cancellations with the Housing Bureau until February 28; 

however the SOT room rate may not be available. Beginning 

February 29, you may call the hotels directly for any housing 

requests. For information regarding your hotel room reservation, 

please visit the SOT Housing Desk located in the South 

Lobby, Level 6 of the Convention Center. 

Housing Desk hours: 

Saturday......................................................4:00 PM–7:00 PM 

Sunday.......................................................7:00 AM–5:00 PM 

Monday......................................................7:00 AM–5:00 PM 

Tuesday..................................................... 8:00 AM–4:00 PM 


Thursday................................................. 8:00 AM–11:30 AM 

Housing desk hours are subject to change. 

Hotel Reservations 

Make your hotel reservations through the Seattle Housing 

Bureau on the SOT Annual Meeting Web site. 

If you are logged on to the SOT Web site and you have 

already registered for the Annual Meeting, your address 

information will be pre-populated when you proceed to the 

hotel reservation service. 

The Society of Toxicology has reserved and made arrangements 

for SOT Annual Meeting attendee discounted room 

rates at various Seattle hotels—known as the SOT hotel 

block. This block includes discounted room rates at many 

premier hotel chains and details can be found on page 30. 

The Room Sharing program will be continued for 2008 SOT 

Annual Meeting Registrants. Access this option from the 

Annual Meeting section of the SOT Web site. 

Did you know that your choice of hotel for the SOT Annual 

Meeting has direct impact on Society’s Strategic initiatives? 

Although we understand that making your reservations 

outside of the SOT block can sometimes be more economical, 

it decreases the money available to the Society to carry 

out its strategic goals and may cause the Society to have 

to pay attrition fees for unutilized rooms. In addition, the 

Society is unable to assist you if you have any difficulties 

with your room reservation, such as the hotel over-booking 

or misplacing your reservation. 

SOT depends on the Annual Meeting revenue to fund other 

programs throughout the year and to keep future registration 

fees low. Please assist the Society by making your hotel 

reservation through the Seattle Housing Bureau. 

A note about calling the hotel directly: please do not call 

your hotel “to be sure” until after Friday, February 29, 2008. 

Please understand that processing your reservations from the 

Housing Bureau into the hotel system will take a few days. 

Rest assured that if you have received a confirmation number 

from the Housing Bureau, the hotel will honor your booking. 

Thank you for your consideration. 

Methods for Making Housing Reservations 

ON-LINE: www.toxicology.org 

TELEPHONE: 

Toll-Free (USA and Canada): (888) 877-0255 

International: (206) 461-5881 

FAX: (206) 461-5853 

52 




MAIL: 

Seattle Housing Bureau 

701 Pike Street, Suite 800 

Seattle, Washington 98101 

United States 

E-MAIL: hotelres@visitseattle.org 

Internet Access 

SOT knows the importance of staying connected to your 

daily activities while attending the Annual Meeting and 

provides you several ways to access the Internet. 

Job Bank users will have the option to send messages to the 

Annual Meeting E-mail Center mailboxes. E-mail Center 

users will have the option to send messages to Job Bank 

registrant mailboxes by name or position number or resume 

number. 

Additionally, the E-mail Center provides extended communication 

permitting members and CRAD registrants who do 

not attend the meeting to communicate with attendees. Even 

colleagues and family members can e-mail messages into 

the Center 

Lost and Found 

Computers Available at the Convention Center 

SOT will provide computers you can use to access the 

Internet. These computers are available to attendees in the 

E-mail Center, located on Level 6 of the Convention Center. 

“Hot Zone” Wireless Access 

“Hot Zone” designated areas in the Exhibit Hall will be 

clearly marked for laptop and handheld users to access the 

Internet via the Wi-Fi network at the Convention Center. 

Internet E-mail Center 

The SOT Annual Meeting E-mail Center is provided to help 

you stay connected to your colleagues during the Annual 

Meeting. SOT members, 2008 Annual Meeting attendees 

including exhibitors, and CRAD Job Bank registrants can 

access the E-mail Center on the SOT Web site to send and 

receive e-mail messages during the 2008 Annual Meeting— 

just like a standard e-mail application. The difference? The 

2008 SOT Annual Meeting E-mail Center gives you a unique 

mailbox without having to provide your personal e-mail 

address to correspondents. 

The service will send you an e-mail alert when you receive a 

message. Use the communication preference to forward your 

incoming messages to your standard e-mail address or PDA. 

Available 24/7, access to the E-mail Center is available any 

time of day and from any computer with an Internet connection, 

before, during and after the 2008 Annual Meeting 

(March 1 through April 1). Simply visit the SOT Web site 

and follow the E-mail Center link from the homepage. 

To log into your mailbox, use your e-mail address and password 

or Annual Meeting badge number. If you don’t know 

your login, you can use the SOT password retrieval request 

from the login on the SOT Web site or ask the Annual 

Meeting registration staff or E-mail Center attendant for 

assistance. 

Lost and found articles may be taken to the SOT Headquarters 

Office, Room 303, of the Washington State 

Convention and Trade Center. Any items left in the SOT 

Headquarters Office after 11:30 AM, Thursday, March 20 

will be deposited in the Security Office at the Convention 

Center. 


For your convenience, a complimentary luggage/coat check 

will be available in the Washington State Convention and 

Trade Center in Room 454 on Level 4. Laptop computers 

will not be accepted. The luggage/coat check will be open 

from Sunday, March 16 through Thursday, March 20. 

Hours of operation: 

Sunday.......................................................7:00 AM–8:30 PM 

Monday......................................................7:00 AM–8:30 PM 

Tuesday..................................................... 7:00 AM–8:00 PM 


Thursday....................................................7:00 AM–1:00 PM 

Luggage/coat check hours are subject to change. 

Lunch with an Expert Board 

The Specialty Section Graduate Committee coordinates 

Lunch with an Expert. The poster containing the Expert 

groups will be located on Level 6 of the Convention Center 

in the West Lobby past Room 614. Experts and students meet 

at the Lunch with an Expert board at the designated time to 

go to the chosen restaurant. 

Media Support Services 

The Society of Toxicology welcomes accredited representatives 

of Media Organizations. Journalists may receive 

complimentary credentials for all meeting sessions, as well 

as a complete media kit, by contacting Clarissa Wilson, 

Media Contact at SOT Headquarters: (703) 438-3115 or 

General Info 




General Info 

e-mail: clarissa@toxicology.org. On-site, media kits can be 

picked up at the SOT Headquarters Office, Room 303, in the 

Washington State Convention and Trade Center. 

Meeting Pole 

In order to facilitate attendees in locating friends and new 

acquaintances, a centralized meeting location has been 

designated on Level 6 in the Washington State Convention 

and Trade Center. The meeting pole tower of the Space 

Needle makes it easy to locate colleagues and will also 

present a great photo opportunity. 

Memorabilia 

Shirts, portfolios, and other items customized for SOT are 

available for sale at the Annual Meeting in the Memorabilia 

Booth on Level 4, South Lobby of the Washington State 

Convention and Trade Center. 

Message Boards 

The pen is still mighty. Leave a quick note on the message 

boards. Note pads and push pins will be available to post 

messages on the message boards. SOT Message Boards 

will be located across from the E-mail Center computers on 

Level 6 of the Washington State Convention and Trade 

Center. 

Photography Policy During Scientific 

Sessions 

Photography of scientific presentations and poster 

presentations is prohibited without the specific consent 

of the presenter(s)/author(s). Session chairs are asked to 

strictly enforce this policy and individuals who do not 

comply will be asked to leave the session. In addition, 

cameras and recording devices are prohibited in the 

Exhibit Hall. If you have any questions regarding this 

policy, please contact SOT Headquarters or stop by the 

SOT Office in Room 303 on Level 3. 

Registration 

Full registration details may be found on page 49. 

Registration Desk Hours 

The Annual Meeting Registration Desk is located in the 

Washington State Convention and Trade Center, Level 4, 

South Lobby. 

Registration Desk hours: 

Saturday......................................................4:00 PM–7:00 PM 

Sunday...................................................... 7:00 AM–8:00 PM 

Monday......................................................7:00 AM–5:00 PM 

Tuesday..................................................... 8:00 AM–4:00 PM 


Thursday................................................. 8:00 AM–11:30 AM 

Safety and Security 

The possibility of demonstrators is very real given the nature 

of our conference. Events of this nature range from verbal 

confrontations, protests, strikes, to riots. We recommend the 

following procedures in the event of demonstrations: 

• Have your name badge available upon entering the 

Convention Center. Wear your name badge in the 

Convention Center. When leaving the facility, remove it 

so as to blend with other people. 

• If you see a demonstration or protest beginning, please 

contact any member of the SOT Annual Meeting staff 

and they will initiate an SOT response. If you see actions 

that appear threatening, notify the nearest security 

officer. 

• Do not engage, defend either side, or subdue person(s) 

in any type of disturbance. Demonstrators are usually 

trying to attract media attention. Don’t help them! 

• SOT representatives will respond to media inquires. Do 

not participate in interviews or other media responses. 

• In the unlikely event that outsiders disrupt a scientific 

session or other event, SOT security officials have 

developed a contingency plan. Please follow directions 

from the chairperson and avoid becoming involved in 

the situation. 

Safety Tips 

Walk “smart” when you leave the Convention Center: 

• Know your destination and the best way to reach it. 

• Travel along sidewalks in lighted areas at night, and 

don’t walk alone. 

• Establish a “buddy” system with another delegate to the 

convention. 

• Share schedules and check up on each other periodically. 

• Build your awareness of unknown surroundings by 

reviewing local information. 

• Laptop computers are attractive, easy targets for thieves. 

Be sure your laptop is in a secure place. 

54 




• Jackets with pockets provide a convenient alternative for 

women to reduce the chance for lost or stolen handbags. 

Our first priority is safety. The best way to stay safe is to 

be aware of your surroundings and to avoid situations where 

you feel uncomfortable. 

SOT Headquarters Office 

The SOT Headquarters Office is located in the Washington 

State Convention and Trade Center, Room 303 on Level 3. 

SOT Headquarters Office hours: 

Saturday......................................................4:00 PM–7:00 PM 

Sunday.......................................................7:00 AM–5:30 PM 

Monday......................................................7:00 AM–5:00 PM 

Tuesday..................................................... 7:00 AM–4:00 PM 


Thursday................................................. 7:00 AM–11:30 AM 


The Speaker Ready Room will be located in Room 213 and 

is available during the SOT Headquarters Office hours listed 

above. 

Sponsorship 

The Society would like to invite your organization to be a 

proud sponsor of the 2008 Annual Meeting. SOT appreciates 

the generous contributions of sponsors that make the SOT 

Annual Meeting possible. Sponsor names are prominently 

displayed on the Annual Meeting and ToxExpo TM Web sites, 

as well as in print materials that are distributed before and 

during the Annual Meeting. Sponsorship is recognized 

through signage displayed around the Convention Center 

during the Annual Meeting. 

There are five levels of sponsorship available: Diamond (over 

$10,000), Platinum ($5,000–$9,999), Gold ($2,500–$4,999), 

Silver ($1,000–$2,499), and Contributor ($999 or below). 

You will find a complete menu of sponsorships designed to 

assist your organization in establishing a leadership position 

at the SOT 2008 Annual Meeting on the Web site at 

www.toxicology.org and promotional opportunities can be 

reviewed at www.ToxExpo.com. 

For detailed information about SOT sponsor and promotional 

opportunities, please contact Liz Kasabian at SOT 

Headquarters: (703) 438–3115 or e-mail: liz@toxicology.org. 

For a listing of sponsors at the print deadline, see the inside 

back cover and the back cover. 

Transportation 

Air Transportation 

The Seattle-Tacoma International Airport (Sea-Tac) is located 

approximately 20 miles away from the Washington State 

Convention and Trade Center and downtown Seattle. The 

airport provides almost 30 million passengers a year with nonstop 

service to 87 domestic and international locations. These 

flights are provided by 8 major domestic carriers as well as 

several regional and international airlines. For more information, 

call (206) 433-5388 or visit www.portseattle.org/seatac. 

Ground Transportation 

The Seattle-Tacoma International Airport (Sea-Tac) is served 

by taxi, shuttle, and bus services. The airport is 20 miles 

south of downtown Seattle. 

From baggage claim, follow the signs directing you to ground 

transportation which is located on the 3 rd floor of the parking 

garage—the same level as baggage claim. 

Once in the garage, proceed to the transportation booth by 

following the group transportation check-in signs. You will 

find booths alongside the Sea-Tac ground transportation 

information center. For more information on ground transportation 

to and from the airport, visit www.portseattle.org/ 

seatac/ground. For airport information, call (206) 433-5388. 

From the Airport—Shuttles and Buses 

Shuttle Express 

• Share and Ride Door-to-Door Shuttle Express is $21. 

• Private, Direct Service Express Car is $50 for 1–3 

guests. 

• Private, Exclusive Van for 7 or less passengers is $61. 

• Private, Exclusive Van for 10 or less passengers is $70. 

• Kids under 12 ride free per paying adult. 

• Board the Shuttle Express at the inner drive curb on the 

third floor of the parking garage. 

• Reservations: Call (425) 981-7000. 

• On-line reservations: www.shuttleexpress.com. 

Downtown Airporter (Gray Line of Seattle) 

• Adults One-Way Fare is $10.25; Roundtrip is $17. 

• Children (2–12 years) One-Way Fare is $7.25; Roundtrip 

is $12. 

• Kids under 2 years old travel at no charge. 

• Operates from 5:30 AM–11:00 PM. 

General Info 




General Info 

Board the Downtown Airporter at the south end of the 

baggage claim level. Follow signs for Scheduled Airporters, 

located at Door 00, just beyond baggage claim carousel #1. 

Direct Downtown Airporter service is provided to and from 

the following locations: Crowne Plaza, Fairmont Olympic, 

Hilton, Sheraton, Hyatt, Westin. 

For more information or to purchase tickets, call 

(206) 626-6088 or (800) 426-7532. 

E-mail: info@graylineseattle.com 

www.graylineofseattle.com 

Metro Transit 

One-Way Fare to downtown is between $1.50 and $2 (exact 

change required). 

Board the Metro Transit buses outside door 6 by 

baggage carousel No. 5, on the baggage claim level. 

http://transit.metrokc.gov 

Taxi Service 

Taxis are readily available at Seattle-Tacoma International 

Airport (Sea-Tac). Cost of a taxi from the airport to downtown 

is approximately $30–35 one-way and most downtown 

hotels are a 30 minute drive. 

Taxis can also be an efficient way to get around town, 

although other means of public transportation may be 

equally, if not more, efficient and less costly. A trip within 

the downtown area will cost $5 to $10 depending on the 

distance. Taxis are readily available at the Colman Dock 

Ferry Terminal and at the cruise ship terminals. Elsewhere, 

call for a taxi or ask your concierge. 

Public Transportation 

The best way to see downtown is on foot. Most of the dining, 

shops, and entertainment centers are within walking distance 

of the Convention Center. However, Seattle offers a number 

of other efficient and interesting ways of getting around. 

Buses 

Metro operates Seattle’s bus system and provides on-line 

tools to help riders. Between 6:00 AM and 7:00 PM 

daily, no fares are required when riding downtown in 

the Ride Free Area, bordered on the north by Battery 

Street, on the South by S. Jackson Street, on the east by 

Sixth Avenue and on the west by the Seattle Waterfront. 

To see your Metro travel options in greater detail, visit 

http://transit.metrokc.gov. 

The Greyhound bus station is located at 811 Stewart 

St. Tickets are available on-line, by phone, at the 

station or at King Street (Amtrak) Station. Go to 

www.greyhound.com for more information. 

Trains 

The Seattle Center Monorail is an excellent transportation 

option, providing a quick, convenient and fun ride 

to the best attractions in town. Costing only $1.50, it 

travels between Westlake Mall in downtown Seattle and 

the Seattle Center and takes two minutes to go the 1.2 

miles to the Center House near the Space Needle. Visit 

www.seattlemonorail.com for more information. 

Three Amtrak trains arrive and depart at historic King Street 

Station (303 S Jackson St.), providing service to Vancouver, 

B.C., Tacoma, Portland, Spokane and other destinations. King 

Street Station is located between the International District 

and Pioneer Square, just north of Qwest Field. Tickets may 

be purchased on-line or at the station. Greyhound tickets 

are also sold at the station. Call (800) USA-RAIL, or visit 

www.amtrak.com for more information. 

The Sounder is a commuter train running from Seattle 

to Everett and from Seattle to Tacoma. The trains are 

boarded at King Street Station. Call (206) 398-5000, or 

visit www.soundtransit.org for more information. 

Ride Share 

SOT is offering a Ride Sharing program in conjunction with 

the Annual Meeting. For those who live close enough to the 

Seattle area or those that do not wish to fly, you may want to 

consider the Ride Share Program. Avoid airport hassles by 

driving and make it easier for other scientists to attend by 

sharing rides. Students especially appreciate ways to make 

the meeting even more economical. 

Once you have registered for the Annual Meeting, you can 

access the Ride Sharing program from the Annual Meeting 

section of the Web site. You can indicate whether you want 

to drive or be a passenger, and then see a list of others who 

have signed up. It will be up to you to match your plans with 

someone else whom is registered, and then to remove your 

names when you have travel plans in place. 

Car Rental 

Avis Rent A Car System is the official car rental company for 

the 47 th Annual Meeting. SOT discounted rates, including 

unlimited mileage, begin at $43.99 per day. These special 

group rates are good one week before and after the SOT 

Annual Meeting so you can take in the sights and explore the 

surroundings at your own pace. To reserve your car on-line, 

56 




go to www.avis.com. You may also call Avis directly at 

(800) 331-1600 to reserve your car. Be sure to mention the 

SOT Avis Worldwide Discount Number: (AWD) T534999. 

Tour Information 

For tour information, visit the Tour Desk located in the 

Registration area, Level 4, South Lobby. 

Tour Desk hours: 

Saturday, March 15....................................4:00 PM–7:00 PM 

Sunday, March 16.................................... 8:00 AM–4:00 PM 

Monday, March 17................................... 8:00 AM–4:00 PM 

Tuesday, March 18.................................... 8:00 AM–4:00 PM 

Wednesday, March 19.............................. 8:00 AM–4:00 PM 

Thursday, March 20............................... 8:00 AM–11:30 AM 

Tour desk hours are subject to change. 

2. Non-member registrants in the U.S. who register after 

January 25 will receive the printed Program and The 

Toxicologist on CD-ROM (with Itinerary Planner) at the 

registration area on-site. 

3. The Annual Meeting Itinerary Planner will be available 

on the SOT Web site January–March. 

4. International members who do not attend the Annual 

Meeting may contact the Headquarters office to 

request a copy of the printed 2008 Program and The 

Toxicologist on CD-ROM. These items will be mailed 

following the Annual Meeting. 

5. The Toxicologist will be available on the SOT Web site 

after March 1, 2008. 

NOTE: Please bring your copy of the Program with you to 

the Annual Meeting. 

If you are interested in signing up in advance for tours, 

please visit the SOT Web site or call Seattle Hospitality at 

(206) 623-2090. The deadline date to sign up in advance 

is February 29, 2008, with the exception of the Victoria 

BC excursion which has a deadline of February 1, 2008. 

All cancellations must be received by February 8, 2008, in 

writing, faxed to (206) 623-2540. There will be no cancellations 

on-site. Tour buses will be departing from Convention 

Place on Level 1 of the Washington State Convention and 

Trade Center. 

Tour Tickets 

Tickets can be picked up on-site at the Tour Desk and will 

not be mailed in advance. 

The Toxicologist/Itinerary Planner 

(Print and CD-ROM) 

All Annual Meeting registrants receive a copy of this 

Program and The Toxicologist on CD-ROM, a special issue 

of Toxicological Sciences that includes all meeting abstracts. 

Special software on the CD, the Itinerary Planner, allows the 

meeting attendee to search the meeting abstracts and develop 

a personalized schedule for the meeting. 

1. SOT members in the U.S. and Canada will receive 

the Program and The Toxicologist on CD-ROM (with 

Itinerary Planner) prior to the meeting, as will U.S. and 

Canadian non-members who pre-register by January 

25, 2008. A printed version of The Toxicologist will be 

available on-site in the registration area for a fee of $20. 

Registrants may reserve a copy by signing up on the 

Registration form or may purchase a copy on-site, while 

supplies last. 

General Info 



Career Resources and Development Services 

The Society of Toxicology’s Career Resource and 

Development (CRAD) Services include an on-line Job Bank, 

special Job Bank activities at the Annual Meeting, career 

development seminars and resources, and employer ads in 

SOT’s newsletter, the Communiqué, which reach the entire 

SOT membership and beyond. 

of candidates available for career opportunities, ranging from 

junior- to senior-level positions. There are between 150 and 

250 candidate profiles posted on the Job Bank at any time. 

The Job Bank helps streamline the process for candidates 

and employers. Candidates can gain access to a variety of 

positions suited to their experience, areas of expertise, and 

desired geographical location. In addition, job seekers can 

see which sectors are hiring and stay abreast of new and 

emerging areas. Employers from corporate, university, 

governmental, and nonprofit organizations can attract 

potential candidates in a targeted and cost-effective manner 

through this SOT service. By having access to detailed candidate 

resumes, employers can determine the right match for a 

specific position and expedite the recruitment process. SOT 

Affiliate Members receive a reduced rate in appreciation 

for supporting the Society in achieving its objectives. 

Job Seeker Registration 

for SOT On-Line Job Bank 

SOT’s Job Bank Services 

Candidate Types 

Fees 

All SOT Members $ 0 

Non-SOT Members $80 

Non-SOT Members—Postdoctoral $45 

Non-SOT Members—Student $30 

Career Services 

On-Line Job Bank and On-Site Job Bank Center 

Are Free to SOT Members! 

The Society’s on-line SOT Job Bank makes it easy for 

candidates and employers alike to access this resource 

year-round, any time, any place via the SOT Web site at 

www.toxicology.org. 

This forum links job candidates with employment positions 

in toxicology and related biological sciences. The SOT Job 

Bank allows you to: 

• Register as an employer or candidate, 

• Post employment positions, 

• Search the Job Bank database, 

• Contact candidates or employers. 

The on-line Job Bank includes more than 100 positions 

available at corporations, academic institutions, government 

agencies, and private research organizations. Employers rely 

on this on-line service to provide them with a robust database 

Employer Registration 

for SOT On-Line Job Bank 

Employer Types 

Fees 

Corporate Affiliate $200 

Corporation $400 

University or Governmental $110 

Nonprofit Organizations $110 

58 



Career Resources and Development Services (Continued) 

Annual Meeting On-Site Job Bank Center— 

We’ve Gone Electronic 

Located in the Washington State Convention and Trade 

Center, the on-site Job Bank Center provides Annual 

Meeting attendees with access to the CRAD Job Bank 

system as well as assistance in facilitating interviews at the 

SOT Annual Meeting. All users with current registrations 

at the time of the Annual Meeting will be permitted to 

use this service. 

For the first time this year, the Job Bank Center is nearly 

paperless. There will be no posted positions nor envelopes 

for candidates to deposit resumes. For your convenience, 

printers will be available for producing paper copies of 

candidate profiles and position descriptions. If you are a 

candidate attending the Annual Meeting, you should 

bring multiple copies of your personal resume for interested 

interviewers. All candidates and positions will be 

sought on-line. 

Employers recognize and appreciate that the Annual Meeting 

On-Site Job Bank Center provides a cost-effective and efficient 

way to interview a distinguished pool of candidates. 

Therefore, interview rooms are available on a first-come, 

first-served basis. 

To ensure privacy for candidates, the SOT Job Bank Center is 

located away from the scientific sessions. It is up to the registrants 

of this service to exercise the confidentiality options 

that are offered. SOT is not responsible if any information 

contained in the Job Bank database is released. 

Although you are encouraged to pre-register before entering 

the Job Bank Center, you can register on-site in Room 205. 

Follow the signage that will lead you to the Job Bank Center 

Registration Office as well as to Room 206, which has 

multiple spaces available to hold interviews. 

The center is available during the following 

hours of operation: 


Monday, March 17 

Tuesday, March 18 

10:00 AM–4:30 PM 

9:15 AM–4:30 PM 

8:30 AM–4:30 PM 

Wednesday, March 19 8:30 AM–4:30 PM 

On-line Job Bank access will be available—as always— 

through your personal computer and at the Annual Meeting 

E-mail Center. Access to the on-line Job Bank in the center is 

limited to short searches for updates or new information. Be 

advised that all career service activities at the SOT Annual 

Meeting will be carried out at the SOT Job Bank Center. 

For additional information, contact Kristy Rand at 

SOT Headquarters: (703) 483-3115 ext. 1429 or e-mail: 

kristy@toxicology.org. 

Employer Ads in SOT Communiqué 

The Society’s newsletter, the Communiqué, is published four 

times annually. It includes career opportunity advertisements 

for employers from corporate, university, governmental, and 

nonprofit organizations wishing to reach the entire SOT 

membership and beyond. For more information, contact 

Marcia Lawson at SOT Headquarters: (703) 438-3115 ext. 

1446 or e-mail: marcia@toxicology.org. 

SOT’s Career Development Program Track 

To help you develop your near-term and long-term career 

pathway, plan on attending the sessions in this year’s 

program that will be of special interest to you, including the 

following: 

• Toxicology Training Needs: New Faces and New Tools 

for the 21 st Century—Roundtable Session 

• The Future of Toxicology—Roundtable Session 

• Putting Your Best Foot Forward: Job Interviewing 

Session for Early-Career Scientists— 

Informational Session 

• NIEHS Outstanding New Environmental Scientists 

(ONES) Awardees—Informational Session 

• Mentoring 101—How to Mentor, How to Be Mentored— 


• Professional Career Development as a Toxicologist— 


Career Services 



Social Event 

60 



Social Events 

Awards Ceremony Music Prelude 


Sunday, March 16, 4:45 PM–5:15 PM 


Ballroom 6A 

Kaley Eaton, a versatile musician, is 

currently pursuing a Bachelor of Arts 

in Vocal Performance with a minor in 

French and German at Whitman 

College. She sings with the Whitman 

Chorale and Chamber Singers (directed 

by. Dr. Robert Bode), is a frequent solo 

recitalist, and most recently appeared 

in Harper Joy Theater’s production of 

Mozart’s Cosi Fan Tutte. Along with 

her vocal endeavors, Kaley is also an 

experienced classical pianist, composer, guitarist, actor, 

cook, and extreme music theory geek. She would like to 

thank her father, Dr. David Eaton, and SOT for the wonderful 

opportunity to share in the gift of music! 



Ballroom 6A 


Join us as SOT honors our prestigious award winners at 

the SOT Awards Ceremony. Please refer to the Awards and 

Fellowships section of the SOT Web site for complete details 

and the nominating form for next year. 

(Open to all attendees) 





Continue the celebration by attending the Welcoming 

Reception following the Awards Ceremony. The Welcoming 

Reception is a great opportunity to renew old friendships 

and to make new acquaintances. Please join the Society in 

this kick-off of the Annual Meeting. 

25–Year (or More) Member Reception 


Room 601 


Have you been a member of the Society of Toxicology for 25 

years (or more)? If so, please join your colleagues in celebration 

and recognition of the scientists who established the 

Society. 



Grand Ballroom C 

Sheraton Seattle Hotel 

All students and postdoctoral fellows are invited to attend 

this reception. Refreshments will be provided by SOT and 

sponsors. A cash bar will also be available. Ticket and 

Meeting Badge are required. 


Tuesday, March 18, 12:00 NOON–1:15 PM 

Room 3A 


Amidst scrambling to attend all of the symposia, poster 

sessions, and social events at the meeting, this will be time 

for postdocs to kick back and relax! All postdoctoral fellows 

are invited to a casual, fun-filled luncheon organized by 

the Postdoctoral Assembly (PDA). We will announce the 

recipients of the Best Postdoctoral Publication Awards and 

acknowledge the postdocs who received awards this year 

from Specialty Sections and Regional Chapters. The PDA 

Board members will present a short overview of accomplishments 

and future directions for the PDA and will introduce 

the newly elected board members for 2008–2009. This is 

a great opportunity for you to meet and congratulate your 

postdoctoral colleagues and check out opportunities to 

volunteer and assume leadership roles within SOT. There 

will be a drawing for prizes. Postdocs can reserve a ticket 

when registering for the Annual Meeting. 

Regional Chapter Receptions 

Monday, March 17 through Wednesday, March 19, 

Various Times 

(Refer to the Annual Meeting Daily Pocket Calendar for 

more details.) 

Many of the SOT Regional Chapters meet during the SOT 

Annual Meeting. A list of Regional Chapter receptions is 

listed in the Daily Pocket Calendar beginning on page 3. 

Social Events 



Social Events 

Social Events (Continued) 

Special Interest Group Receptions 


Various Times 



Each of the 6 Special Interest Groups will hold a meeting/ 

reception during the SOT 2008 Annual Meeting at the 

Sheraton or Hyatt Hotels or at a local venue. All current 

and prospective SOT Special Interest Group members are 

encouraged to attend. The Daily Pocket Calendar beginning 

on page 3 has a listing of locations and function times. 

Specialty Section Receptions 


Various Times 



Each of the 21 SOT Specialty Sections will hold either a 

luncheon or early evening meeting/reception during the SOT 

2008 Annual Meeting. All current and prospective SOT 

Specialty Section members are encouraged to attend. Please 

check the Daily Pocket Calendar beginning on page 3 for a 

listing of meeting and reception times. 

62 


47 th Annual Society Meeting of Toxicology & ToxExpo 2008 

SOT 2008 Award Winners(Continued)) 

Achievement Award 

Arnold J. Lehman Award 

Ivan 

Rusyn 

Ivan Rusyn, M.D., Ph.D., is recognized 

by the Society of Toxicology for 

his outstanding research in elucidating 

the mechanisms of adverse health 

effects of environmental agents. His 

M.D. was earned at Ukrainian State 

Medical University, and the University 

of North Carolina conferred the Ph.D. 

He has been a major contributor to the 

Toxicogenomics Consortium where 

his research led to a better understanding 

of the molecular basis of the 

hepatotoxicity of acetaminophen. Dr. Rusyn’s early work 

with Dr. Thurman stands as a classic in teasing out the 

pathway of toxicity of non-genotoxic rodent liver carcinogens 

related to oxidative stress. His recent work has 

focused on systems biology, toxicogenetics and the use of 

computational approaches to elucidate and predict toxicity 

of xenobiotics. Dr. Rusyn is the exemplar of the spirit of 

the Achievement Award. He is an outstanding mentor, 

facilitator, and educator, as well as the director of several 

toxicology courses and the toxicology seminar series at 

UNC-Chapel Hill. He is an active member of the SOT, 

serving on the Program Committee. In addition, Dr. Rusyn 

has been the recipient of the Leon and Bertha Golberg 

Memorial Postdoctoral Fellowship at UNC, an NIEHS TIP 

Award and is a Principal Investigator or Co-Principal 

Investigator on multiple grants funded by NIH and the 

U.S. EPA. It is an honor to recognize Dr. Ivan Rusyn as the 

Society of Toxicology’s 2008 Achievement Award 

recipient. 

Vicki 

Dellarco 

Vicki Dellarco, Ph.D., has provided 

strong leadership within the U.S. EPA 

and the international community for 

risk assessments that utilize the best 

scientific information available. 

Dr. Dellarco, a senior science advisor 

in the Office of Pesticide Programs, 

has worked effectively to develop 

methods for mode of action analyses 

in risk assessment and to implement 

those methods through case studies 

and Agency assessments for specific 

chemicals. She has promoted revisions of toxicity testing 

guidelines including the thyroid developmental toxicity 

study guidance, development of toxicity testing strategies 

for improving and refining approaches to health risk 

assessment, development of common mechanism policy 

decisions and cumulative risk assessment methods and 

guidance. Her energy, enthusiasm, and collaborative skills 

have greatly enriched the work of Agency and international 

scientific and risk assessment groups. 

Awards & honors 

SOT Sponsored Awards 



SOT 2008 Award Winners (Continued) 

Awards & Honors 

Best Postdoctoral Publication 

Award 

The Postdoctoral Assembly recognizes these three 

recipients of their 2008 awards: 

Joshua P. 

Gray 

Christie M. 

Sayes 

Khristy J. 

Thompson 

Joshua P. Gray, University of 

Medicine and Dentistry of New 

Jersey 

Paraquat Increases Cyanide- 

Insensitive Respiration in 

Murine Lung Epithelial Cells by 

Activating an NAD(P)H:Paraquat 

Oxidoreductase: Identification of the 

Enzyme as Thioredoxin Reductase, 

The Journal of Biological Chemistry, 

Vol. 282, No. 11, pp. 7939–7949, 

(March 16, 2007). 

Christie M. Sayes, DuPont Haskell 

Laboratory for Health and 

Environment 

Assessing Toxicity of Fine and 

Nanoparticles: Comparing In Vitro 

Measurements to In Vivo Pulmonary 

Toxicity Profiles, Toxicological 

Sciences 97(1), 163–180 (2007). 

Khristy J. Thompson, 

Elizabethtown College 

Olfactory Uptake of Manganese 

Requires DMT1 and is Enhanced by 

Anemia, The FASEB Journal Vol. 21, 

223–230 (January 2007). 

Board of Publications Award for 

the Best Paper in Toxicological 

Sciences 

The Board of Publications has unanimously 

selected the paper entitled 

“Sequential Exposure to Cytokines 

Reflecting Embryogenesis: The key for 

In Vitro Differentiation of Adult Bone 

Marrow Stem Cells into Functional 

Hepatocyte-like Cells” as the best 

paper published in Toxicological 

Sciences in the past year (December 

2006; 94:330-341). The authors of the paper, comprising 

an international research team, are Sarah Snykers, Tamara 

Vanhaecke, Peggy Papelue, Aernout Luttun, Yuehua Jiang, 

Yvan Vander Heyden, Catherine Verfaillie, and Vera 

Rogiers. 

The plasticity of stem cells renders them capable of overcoming 

germ lineage restrictions to develop molecular 

characteristics of cells from a different tissue. It has 

previously been shown that adult bone marrow stem cells 

(BMSC) can differentiate into hepatocyte-like cells when 

exposed to a cocktail of cytokines and growth factors. 

However, in the recognized paper, Snykers and colleagues 

applied basic knowledge of liver embryogenesis and 

development to design an experimental paradigm in which 

BMSC were treated sequentially with liver-specific factors 

that regulate hepatocyte differentiation in a manner that 

reflected their temporal expression during in vivo hepatogenesis. 

They evaluated the morphological, molecular and 

functional characteristics of the resulting hepatocyte-like 

cells and compared these features to BMSCs treated 

simultaneously to the cocktail of differentiation factors. 

Their innovative approach produced poylgonal cells that 

presented with many features of differentiated hepatocytes 

which included binucleated morphology, expression 

of α-fetoprotein early in the course of the culture that then 

disappeared, expression of maximal levels of albumin 

and cytokeratin 18, markers of later stage differentiated 

hepatocytes, only after 18 days in culture, and evidence 

for constitutive and inducible cytochrome P450 1A1/2 

and 2B1/2. These features comprise a profile that is 

consistent with the array of developmental stages that is 

comparable with liver development, whereas the simultaneous 

exposure paradigm induced an aberrant pattern of 

differentiation. 

The use of stem cells in clinical and preclinical research 

is an important, timely and controversial topic. As such, 

the work by Snykers et al. is a major scientific achievement 

relative to the development of a method that yields 

64 



SOT 2008 Award Winners (Continued)) 

hepatocyte-like cells from BMSC and represents a significant 

contribution to the field of stem cell research. The 

model provides important new methods for the purification 

and culture of pluripotent stem cells from nonembryonic 

origin. Furthermore, the work offers new opportunities 

to study fundamental biological processes involved in 

development and differentiation, and it yields an unlimited 

source of hepatocyte-like cells for pharmacology and toxicology 

research. 

Toshio 

Narahashi 


Award 

Toshio Narahashi, D.V.M., Ph.D., is 

the John Evans Professor of 

Pharmacology in the Department of 

Molecular Pharmacology and 

Biological Chemistry, Feinberg 

School of Medicine, Northwestern 

University. Since the 1950s his 

discoveries have elucidated the modeof-action 

of important toxicants that 

impact human lives across the globe. 

Dr. Narahashi has been considered as 

the person responsible for driving the 

field of the effects of chemicals on excitable cell membrane 

function. Some of his publications are listed as Citation 

Classics. His studies have added immeasurably to our 

understanding of basic neuronal physiology and the action 

of a variety of neurotoxicants and drugs on axonal and 

junctional physiology. He is respected around the world 

and has received numerous scientific honors. 

Steven 

Cohen 

Education Award 

Steven D. Cohen, M.S., D.Sc., ATS, 

has contributed to the field of toxicology 

in education by developing 

new scientists and leaders in toxicology, 

providing professional 

leadership, and fostering the scientific 

growth of toxicology. He has received 

international recognition for his scientific 

contributions to understanding 

the mechanisms of acetaminopheninduced 

hepatotoxicity. 

Dr. Cohen joined the University of Connecticut Storrs 

in 1972. In the early 1980s he founded the Center for 

Biochemical Toxicology and the Interdepartmental 

Graduate and Postdoctoral Research Training Program 

in Environmental Toxicology at the University of 

Connecticut at Storrs. He directed both for nearly 20 years 

until leaving the University in 2000 as Emeritus Professor 

of Toxicology. The Center was supported by the State of 

Connecticut as a “Center for Excellence” and became a 

statewide resource for toxicology expertise and training. 

The Toxicology Program was supported by funds from 

the University, the State, the chemical and pharmaceutical 

industry and importantly, by an Environmental Toxicology 

Research Training Grant from the National Institute of 

Environmental Health Sciences. Over 50 alumni of the 

Connecticut program are making important contributions 

to toxicology through their professional positions in 

academia, industry and government. His career contributions 

in toxicology education were recognized with the 

establishment in 2004 of an endowed graduate fellowship 

at the University of Connecticut (Rosenberg/Cohen 

Graduate Fellowship in Pharmacology and Toxicology) 

in his honor. In 2007 the School of Pharmacy Alumni 

Association further honored him with the Distinguished 

Emeritus Professor Award. 

In 2000 Dr. Cohen joined the Leadership Team for establishment 

of the Massachusetts College of Pharmacy and 

Health Sciences School of Pharmacy –Worcester where he 

is Professor of Pharmacology and Toxicology and Chair 

of the Department of Pharmaceutical Sciences. For his 

dynamic leadership in toxicology education, his guidance 

of toxicology programs for over 30 years, and his 

outstanding example as a scientist-educator, the Society 

of Toxicology honors Dr. Steven D. Cohen with the 2008 

Education Award. 




SOT 2008 Award Winners (Continued) 


John 

Doull 

Founders Award 

John Doull, M.D., Ph.D., ATS, is the 

recipient of the first Founders Award 

for his illustrious career in toxicology 

with more than 50 years of productive 

contributions to teaching, research, 

and the application of toxicological 

principles to safety evaluation in the 

support and enhancement of public 

health. Dr. Doull is trained and experienced 

both as a physician and as a 

scientist. He obtained his Ph.D. in 

pharmacology and his M.D. from the 

University of Chicago, spent several years at the Univeristy 

of Chicago, then more than 40 years at the University of 

Kansas where he is currently Professor Emeritus of 

Pharmacology and Toxicology. Dr. Doull has had the 

experience of diagnosing and treating individuals who 

have been poisoned and has counseled many individuals 

who were concerned that they may have been poisoned. 

He has had far-reaching influence on the development and 

application of the safety evaluation of chemicals through 

his extensive research (with particular emphasis on modes 

of action) as evidenced by his numerous high quality 

publications. Particularly noteworthy has been his leadership 

in promulgating a most authoritative source of 

toxicology principles presented in the serial publication of 

Casarett and Doull’s Toxicology: The Basic Science of 

Poisons. Furthermore, he has advanced the safety evaluation 

of chemicals through his formal participation in 

numerous national and international authoritative groups 

including the National Academy of Sciences, the 

International Life Sciences Institute, and the National 

Institute of Environmental Health Sciences. Dr. Doull has 

served on numerous governmental and non-governmental 

committees, and has been a leader in promoting use of the 

best science to understand problems and how to deal with 

them. In the face of emotionally-charged issues, Dr. Doull 

has been a source of reason in objectively approaching the 

issues and using common sense in decision-making, typically 

resulting in a report that is highly regarded and 

respected. His contributions to the use of sound science in 

safety evaluations have led to major improvements in 

governmental and non-governmental initiatives aimed at 

protecting and enhancing public health. 

One of Dr. Doull’s outstanding contributions in toxicology 

is the training and guidance that he has provided to many 

productive scientists. At the University of Chicago and the 

University of Kansas, Dr. Doull helped train many young 

and aspiring toxicologists in the sound, fundamental principles 

of toxicology and the application of these principles 

to real-world toxicological problems in both medicine and 

the environment. In addition, Dr. Doull has served as a role 

model, mentor, colleague, and friend to many scientists in 

the field of toxicology. Those fortunate to have learned 

from his scientific creativity and insights have greatly 

expanded the field, and have helped to provide toxicology 

with a high degree of respect and recognition. 

Dr. Doull displayed great foresight in 1961 when he joined 

the group that founded the fledgling Society of Toxicology. 

Since that time, he has fostered the aims of the Society by 

engaging in major leadership roles including serving ably 

as its President. He has been a major force in molding the 

future of the Society and in having it recognized worldwide 

as the central organization in the field of toxicology 

and in the enhancement of public health. The Society of 

Toxicology is pleased to recognize Dr. John Doull as the 

recipient of the first Founders Award for his leadership and 

integrity as a premier scientist and physician. 

66 



SOT 2008 Award Winners (Continued)) 

Hanspeter 

Witschi 

Merit Award 

Hanspeter Witschi, M.D., is Professor 

Emeritus, University of California 

–Davis. Dr. Witschi was an enthusiastic 

proponent of the value of 

mechanistic toxicology in contributing 

to risk assessment. He 

represented the thinking man’s 

pathologist. As an experimentalist, 

Dr. Witschi put much thought into the 

design of a study and what the 

outcomes could be. Consequently, his 

studies were precise, economical, and 

always produced results. His studies were a stimulus to 

himself and others to reveal a greater understanding of 

the phenomenon under investigation. He published 

seminal articles in pulmonary toxicology, adaptation to 

toxicant exposure, second-hand smoke, and lung carcinogenesis. 

He made an enormous contribution to teaching 

and education, and was the recipient of the SOT Education 

Award in 1991. His service to toxicology has been exceptional 

as he served on many local, regional, and national 

offices. He is considered a complete scientist—always 

interested in discussing the dilemmas of toxicology and 

never tempted to arrive at the quick and easy conclusion. 

AstraZeneca Traveling Lectureship Award 

José 

Manautou 

Jose Manautou, Ph.D., Associate 

Professor of Toxicology at the 

University of Connecticut, receives 

the 2008 AstraZeneca Traveling 

Lectureship Award. The award recognizes 

excellence in research and 

service in toxicology and enables a 

lecture tour of Europe to promote 

collaboration between European and 

North American toxicologists. 

Dr. Manautou’s research in the fields 

of hepatotoxicity and drug transporters 

has gained international recognition for excellence. 

In addition to an impressive publication record, he has 

been Associate Editor of Toxicology and Applied 

Pharmacology and a member of an NIH study section. 

Dr. Manautou has been a contributor to SOT programs 

since 1998, serving as a member of several committees, as 

principal investigator of the SOT’s NIH grant that supports 

its undergraduate educational program and as SOT 

Councilor. Dr. Manautou’s planned visits to Switzerland, 

Portugal, France, Hungary, and England will expand his 

collaborative network and bring new perspectives to his 

research efforts. 


Sayed Bakry (Egypt) 

SOT/AstraZeneca IUTOX 

Fellowship 

Phillip Burcham (Australia) 

Kemal Buyukguzel (Turkey) 

Jin-Ho Chung (Korea) 

Hande Gurer-Orhan (Turkey) 

Lyndy McGaw (South Africa) 

Gafer Rageh Ahmed (Egypt) 

Zdravko Paskalev (Bulgaria) 



SOT 2008 2008 Award Award Winners Winners (Continued) (Continued) 


Colgate-Palmolive Awards for Student 

Research Training in Alternative Methods 

Kimberly A. Hays, Oklahoma State 

University 

Project Title: AFLP-Based Assessment 

of Small Mammal Populations from a 

Metal Contaminated Superfund Site 

Host Institution: Tarleton State 

University 

Haitian Lu, Michigan State University 

Project Title: Gene Microarray Analysis 

of the 2, 3, 7, 8-Tetrachlorodibenzop-Dioxin 

(TCDD) Effects on Ex Vivo 

Activated Human Peripheral Blood B 

Lymphocytes 

Host Institution: The Hamner Institutes 

for Health Sciences 

Colgate-Palmolive Traveling Lectureship in 

Alternative Methods in Toxicology Award 

George 

Michalopoulos 

George Michalopoulos, M.D., Ph.D., 

is the Professor and Head of the 

Department of Pathology, University 

of Pittsburgh School of Medicine. 

Dr. Michalopoulos is an eminent 

researcher and an authority on hepatocyte 

culture techniques and their 

use in research. His current areas of 

research focus are growth factors and 

receptors in hepatocytes, mechanisms 

of liver regeneration, growth regulation 

in human hepatocytes, and 

hepatic carcinogenesis. He will be hosted by the Toxicology 

program at University of Louisiana—Monroe College of 

Pharmacy where he will demonstrate the newest hepatocyte 

culture techniques, present liver toxicity and in vitro 

techniques lectures, and participate in hepatobiology and 

carcinogenesis discussion forums. 

Colgate-Palmolive Grants for Alternative 

Research 

Daniel Cerven, MB Research 

Laboratories 

Project Title: Pre-Validation of 

the Porcine Corneal Opacity and 

Reversibility Assay (PorCORA) 

Duncan Ferguson, University of Illinois 

at Urbana-Champaign 

Project Title: Human Neural Stem Cell 

Line in Defined Medium as a Screen for 

Neurodevelopmental Toxins 

Shashi Ramaiah, Texas A&M University 

Project Title: Evaluation of Osteopontin 

as a Potential In Vitro Biomarker 

for Chemically-Mediated Hepatic 

Inflammation 

68 



SOT 2008 2008 Award Award Winners Winners (Continued) (Continued)) 

Pfizer Undergraduate Student Travel 

Award 

Amy DeMicco 

Rutgers University 

Tharu Fernando 

Wright State University 

Yamel Perdomo 

Medgar Evers College 

2007 Fellowship Recipients 

These scientists were selected for Fellowships at the 2007 

SOT Annual Meeting. Visit their presentations at this 

Meeting to see the outstanding work from their 2006–2007 

Fellowship year. 

2007 Novartis Graduate Fellowship 

Atrayee 

Banerjee 

Atrayee Banerjee, Texas A&M 

University, College Station, TX 

Abstract Number: 846 

Poster Board Number: 422 

Abstract Title: Osteopontin 

Mediated b1 and b2 Integrin 

Signaling: A Mechanism for Higher 

Hepatic Neutrophil Infiltration and 

Liver Injury in Female Alcoholic 

Liver Disease 


Amy Yi Hsan Saik 

University of Western Australia 

Kelly Sullivan 

Colorado State University 

2007 Colgate-Palmolive Postdoctoral 

Fellowship Award in In Vitro Toxicology 

Aaron 

Rowland 

Aaron Rowland, University of Utah, 

Salt Lake City, UT 

Abstract Number: 784 

Poster Board Number: 240 

Abstract Title: Mechanisms 

Regulating Lung-Selective Basal 

and Induced Cytochrome P450 2S1 

Expression. 

Nominations for 2009 awards are due October 9, 2008. 

Visit the SOT Web site for award details at… 

www.toxicology.org 



SOT 2008 Honorary Members 


Lee Hartwell 

Lee Hartwell has made important 

contributions to our understanding of 

cell division and cancer through his 

study of genes that control cell division 

in yeast. For this work Hartwell has 

received many scientific awards, 

including the 2001 Nobel Prize in 

Physiology or Medicine. Other honors 

include the Albert Lasker Basic 

Medical Research Award, the Gairdner 

Foundation International Award and 

the Alfred P. Sloan Award in cancer 

research. 

Many of the genes that control yeast division also control 

cell division in humans and often are the site of alteration in 

cancer. Hartwell discovered a new class of gene responsible 

for accurate cellular reproduction: the “checkpoint” gene. 

These genes halt cell division when mistakes are made 

during cellular reproduction so that repair can take place. 

His insights into cell-cycle control are being used to develop 

treatments for cancer and other diseases. In collaboration 

with Steve Friend, Hartwell explored the potential to 

identify cancer therapeutics using a panel of yeast mutants 

defective in DNA repair. He and Lee Hood have founded 

a company to use transcript profiles and yeast mutants to 

identify new therapeutic targets. 

As part of his efforts to use the enormous knowledge 

that has accumulated over the last 50 years in genetics 

and biochemistry to benefit cancer patients, he strives to 

improve molecular diagnostics to identify individuals at 

high risk for disease, detect cancer and other diseases at 

an early stage when they can be cured, provide prognostic 

information, and monitor therapeutic response. Proteins 

will likely provide the best diagnostic information because 

of their greater diversity and because their state reflects 

biological function. The technology for protein diagnostics, 

however, is in its infancy. He is involved in national and 

international projects to increase the number of laboratories 

working in protein diagnostics, develop more team science, 

improve the availability of informatics for data sharing, 

provide standardized reagents, and stimulate new technology 

development. He and Michael Birt organized the 

first international Pacific Health Summit held in June 2005. 

Hartwell earned a Ph.D. from the Massachusetts Institute 

of Technology under the mentorship of Boris Magasanik. 

He engaged in postdoctoral work at the Salk Institute for 

Biological Studies with Renato Dulbecco. He then joined the 

University of Washington faculty and has been a genetics 

professor there since 1973. In 1996 he joined the faculty of 

Seattle’s Fred Hutchinson Cancer Research Center and in 

1997 became its president and director. He is a member of 

the National Academy of Sciences. 

H. Robert 

Horvitz 

Pioneering studies by H. Robert Horvitz 

have made him one of the central figures 

in research on programmed cell death 

(apoptosis). He discovered key genes 

that control cell death in C. elegans. For 

this work and for his studies concerning 

organ development in C. elegans, 

Horvitz won the 2002 Nobel Prize in 

Physiology or Medicine, an award he 

shared with Sydney Brenner and John 

Sulston. 

Horvitz’s work with C. elegans began 

during a postdoctoral fellowship in Brenner’s laboratory in 

Britain in the 1970s. There, Horvitz teamed with Sulston to 

trace the ultimate fate of each cell as it developed from an 

embryo into an adult. Their work revealed that cell division 

in the worm produces many more cells than survive to make 

up the mature animal. 

In the mid-1980s at the Massachusetts Institute of Technology, 

Horvitz identified the first “cell death” genes, called ced-3 and 

ced-4. “Discovering that programmed cell death is specified 

by particular genes established that programmed cell death 

is a basic biological process, much like cell division, cell 

migration, and cell differentiation,” Horvitz explained. Later, 

Horvitz showed the gene ced-9 protects against cell death by 

regulating both ced-3 and ced-4. 

Horvitz’s graduate studies at Harvard were under the guidance 

of James Watson and Walter Gilbert (who developed a 

method to determine the exact sequence of the nucleotides in 

DNA). Both men are also Nobel laureates. 

“As a graduate student, I came away with two beliefs that 

have driven my research career,” Horvitz said. “First, do the 

‘doable.’ I recognized early on that working on an important 

but intractable problem would not suit me. Second, it is no 

harder to work on an important problem than one that is not 

important; this bit of advice, from Jim Watson, was engraved 

in me.” 

Horvitz has also identified many additional apoptosis genes. 

His studies may improve the understanding of neurological 

disorders such as amyotrophic lateral sclerosis (ALS), a 

disease that killed Horvitz’s father. Horvitz collaborated in 

identifying a gene involved in the inherited form of ALS, and 

he is pursuing other genes involved in the disease. 

He has also worked to understand how genes control other 

aspects of development and behavior and has discovered 

genes that are involved, again using C. elegans. His work 

reveals specific pathways shared by both worms and humans 

that are involved in a variety of human diseases. 

Dr. Horvitz is a David H. Koch Professor of Biology at the 

Massachusetts Institute of Technology and Neurobiologist 

and Geneticist at Massachusetts General Hospital, in Boston. 

70 



Continuing Education 


The Continuing Education Program offers a wide range of courses that 

cover state-of-the-art knowledge in toxicology, as well as new developments 

in toxicology and related disciplines. Courses can be applied 

toward certifying and licensing board requirements and may also be used 

for recertification with the American Board of Toxicology (ABT). Both 

basic and advanced course topics are offered. The basic course is intended 

to provide a broad overview of an area or to assist individuals in learning 

new techniques or approaches. The advanced course is intended to be of 

interest to individuals with previous knowledge of the subject or already 

working in the field. 

All courses will be held on Sunday, March 16, 2008, at the Washington 

State Convention and Trade Center. Please check the signage in the registration 

area and at the CE Booth for room assignments. Note: Your course 

materials will be available in the room immediately prior to the course 

(they will not be available at the registration area). If you have your 

course ticket, go directly to the assigned course room. If you have not 

received your course ticket or have not registered, please go to the registration 

area on Saturday afternoon/evening or on Sunday morning. If you 

have misplaced your ticket, please go to one of the Continuing Education 

Booths, Level 6, at the Convention Center on Sunday. The booth will be 

open from 6:30 AM–5:15 PM. 

*Indicates the Primary Special Interest Group (SIG), Specialty Section 

(SS), or Regional Chapter (RC) endorser. 

7:00 AM–7:45 AM Sunrise (SR) Continuing Education 

Course: 

1. Mini-Pigs as an Alternative Non-Rodent Species in Toxicology and 

Safety Studies 

8:15 AM–12:00 NOON Morning (AM) Continuing 

Education Courses: 


3. Stem Cells and their Multi-Potential Uses and Potential Dangers 

4. Dose-Response Modeling for Occupational and Environmental 


5. The Use of Transgenic Animal Technology in Toxicological 

Research 

6. Process-Based Approaches to Modulating Gene and Protein 

Expression In Vivo and In Vitro 

7. Basic Embryology and Developmental Toxicology 

1:15 PM–5:00 PM Afternoon (PM) Continuing Education 

Courses: 


9. Nanotoxicology: The Science of Developing a Safe Technology 

10. Clinical Dose Setting for Biotherapeutics 

11. Use of Data for Development of Uncertainty Factors in 

Non-Cancer Risk Assessment 


7:00 AM–7:45 AM 

Level 6 (See signage at CE Booth for room locations) 

Mini-Pigs As an Alternative Non-Rodent Species in 

Toxicology and Safety Studies 

SR01 

Basic 

Chairperson(s): Glenn Washer, LAB Research Inc., Montreal, Quebec, 

Canada and Andrew Makin, LAB Research Denmark (Scantox), 

Copenhagen, Denmark 

Endorsed by: 

Animals in Research Committee* 

Comparative and Veterinary Specialty Section 


This course will focus on the regulatory acceptability and utility of 

mini-pigs as an alternative to traditional non-rodent species for nonclinical 

studies of pharmaceuticals. Attention will be given to their use in 

general toxicology and safety studies, including non-routine routes and 

embryofetal development studies. 

The choice of non-rodent species for safety assessment of new pharmaceuticals 

is becoming increasingly important. For many years researchers 

have adopted the paradigm that we use the dog, and if the dog is no 

good, then we use the primate. With the ever increasing ethical concerns 

relating to the use of primates, and other groups concerned with the use 

of “man’s best friend”, attention has been increasingly focussed on the 

potential of the pig and mini-pig. An increasing appreciation of the similarities 

between man and the pig in structure of skin, gastrointestinal tract, 

urogenital system, and metabolism is the principal reason for the increased 

popularity. There are 13 species of pig, however, biomedical research has 

been largely restricted to the domestic pig derived from the Eurasian wild 

boar (Sus scofa) and the warthog (Phacochoerus africanus). Smaller 

strains (“mini-pigs”) have increasingly come to prominence in non-clinical 

testing and are now widely employed as non-rodent alternatives for 

regulatory-driven safety programs. For pharmaceutical compounds whose 

route is dermal in man, there is a growing realization that the mini-pig is a 

valid model. Pig skin has been shown to be anatomically, physiologically, 

biochemically, and immunologically similar to human skin. Although 

the use of the mini-pig in the development of dermal products is well 

accepted by regulators, its suitability for a wide range of other study 

types has been somewhat overlooked although in many ways it is more 

representative of man than other species. The mini-pig is now recognized 

as a suitable non-rodent species for efficacy and safety studies of many 

types of pharmaceutical products. Mini-pigs are suitable experimental 

models using many of the commonly applied techniques used in other 

species, and they have also been used as alternative non-rodent species for 

embryofetal studies. 

• Introduction, Glenn Washer, LAB Research Inc., Montreal, Canada 

• Practical Considerations of the Use of Mini-Pigs in Toxicology and 

Safety Studies, Andrew Makin, LAB Research Denmark (Scantox), 

Copenhagen, Denmark 

• The Mini-Pig in Non-Clinical Toxicology—a Regulatory 

Perspective, Abigail Jacobs, U.S. FDA, Silver Spring, MD 

CE 

12. Essential Informatics for Toxicologists: Knowledge Management 

End-to-End 

13. Epidemiology for Toxicologists: Introduction 



Continuing Education (Continued) 

CE 


8:15 AM–12:00 NOON 


Introduction to Pathology for Toxicologists and 


AM02 

Chairperson(s): Laurene M. Fomby, Battelle, Columbus, OH and Pat 

Haley, Incyte Corp, Wilmington, DE 

BASIC 

Endorsed by: 

Comparative and Veterinary Specialty Section* 

Toxicologic and Exploratory Pathology Specialty Section 

Today, even with the promise of ‘omic’ technologies, pathology plays 

a critical role in the evaluation of chemicals and drugs. Toxicological 

pathology uses specialized terms and methods and can generates complex 

interpretative problems. Effective communication between the toxicologist 

and the study pathologists will allow the toxicologist to better 

integrate pathology data into their reports and optimize the scientific 

content of the study. In this basic course, experienced toxicological 

pathologists will introduce important concepts in pathology to toxicologists 

as study directors in order to help the study director appreciate the 

role of pathology in toxicological studies. The course will begin with a 

discussion of basic concepts and the role of the toxicological pathologist 

followed by a discussion of global regulations as they relate to pathology 

endpoints. Later lectures will discuss the lesions and interpretation of 

pathology data in non-oncogenicity studies and oncogenicity studies. 

By the end of the session, the study director should have a better understanding 

of pathology and a basic background that will allow for effective 

communication with a study pathologist. 

• Introduction, Pat Haley, Incyte Corp, Wilmington, DE 

• Basic Concepts in Morphologic Pathology and the Roles of the 

Toxicological Pathologist, Sarah Hale, EPL, Raleigh, NC 

• Important Induced Lesions, and Interpretation of Pathology Data 

in Non-Oncogenicity Studies, Paul Howroyd, MDS Pharma, Lyon, 

France 

• Pathology Endpoints in Routine Repeated Dose Toxicology Studies: 

A Review of Global Regulations, Ken Schafer, Vet Path Services, 

Mason, OH 

• An Introduction to Pathology in Carcinogenicity Studies, 

Dianne Creasy, Huntingdon Life Sciences, East Millstone, NJ 


8:15 AM–12:00 NOON 


Stem Cells and Their Multi-Potential Uses and 

Potential Dangers 

AM03 

Chairperson(s): David Lawrence,Wadsworth Center, Albany, NY and 

Marc J. Pallardy, University of Paris, Chatenay Malabry, France 

BASIC 

Endorsed by: 

Immunotoxicology Specialty Section* 

Mechanisms Specialty Section 

Metals Specialty Section 


Stem cells can theoretically divide without limit to replenish cells and 

each daughter cell has the potential to remain a stem cell or develop into 

a fully functional differentiated cell. Therefore, stem cells have the potential 

to develop into many cell types that could benefit the health status of 

many individuals but the types of cells that could differentiate from stem 

cells must be considered in that certain growth and differentiation factors 

could give rise to conditions that could be harmful including development 

of a cancer stem cell. Additionally, environmental factors can skew 

the developmental patterns of stem cells leading to harmful deficiencies 

or expansions of certain types of progenitors. This course is designed 

as a basic level course to provide an overview of the field of stem cell 

biology, touch upon the differences of adult versus embryonic stem cells 

and provide a foundation for understanding the implications of the use of 

stem cells in toxicological research. Presentations will cover in vitro and 

in vivo proliferation and differentiation of stem cells and the influences 

of toxicants on these processes. Quantification of normal and aberrant 

immunophenotypic changes with development, mechanisms that influence 

proliferation, differentiation, and functional changes, and in vivo 

control of progenitors in their developmental niche will be discussed. The 

effect of environmental toxicants on a single molecular pathway controlling 

cell signaling and development of the CNS will be presented. Finally, 

the challenges in pharmacologically regulated cell therapy including the 

ability to regulate the fate of engineered cells will be deliberated. 

• Analysis and Use of CD34+ Stem Cells from Human Cord Blood, 

David Lawrence, Wadsworth Center, Albany, NY 

• Human Dendritic Cells Derived from Hematopoietic Progenitors 

for Detecting Sensitizing Molecules, Marc J. Pallardy, University of 

Paris, Chatenay Malabry, France 

• Pharmacologically Regulated Cell Therapy, Anthony C. Blau, 

University of Washington, Seattle, WA 

• The Critical Interaction between Hematopoietic Progenitor Cells 

(HPC) and the Bone Marrow Microenvironment in Normal 

Hematopoiesis and Hematopoietic Toxicology, David W. Pyatt, 

Summit Toxicology, LLP, Colorado and University of Colorado Health 

Sciences Center, Schools of Pharmacy and Medicine 

• Redox Modulation of Neural Progenitor Cell Function by 

Environmental Toxicants, Mark Noble, University of Rochester, 

Rochester, NY 


8:15 AM–12:00 NOON 


Dose-Response Modeling for Occupational and 

Environmental Risk Assessment 

AM04 

advanCED 

Chairperson(s): David G. Dolan, Amgen Inc., Thousand Oaks, CA and 

Andrew Maier, Toxicology Excellence for Risk Assessment, Cincinnati, OH 

Endorsed by: 

Occupational and Public Health Specialty Section* 


The development noncancer exposure guidance values—whether for environmental 

or occupational sources of exposure—is rooted in the ‘critical 

adverse effect’ concept. Thus, derivation of such guidance values requires 

understanding the methods and approaches for estimating thresholds for 

the onset of adverse effects. This course will describe the history of the 

development of methods to develop ‘safe’ exposure limits using adverse 

effect level estimation. The lecture will focus on current methods and 

issues for using dose-response modeling for developing potency and point 

of departure estimates for limit-setting. Each lecture will include presentations 

followed by hands-on application of key elements from the lecture 

as applied to model toxicological datasets. The participants are expected 

to obtain sufficient knowledge to estimate critical effect levels for risk 

72 




assessment using a variety of modeling techniques and addressing key 

considerations of current interest. 

• Introduction to Identifying Critical Effects for Quantitative 

Risk Assessment, Andrew Maier, Toxicology Excellence for Risk 

Assessment, Cincinnati, OH 

• Dose-Response Modeling Techniques, Qiyu (Jay) Zhoa, U.S. EPA, 

Risk Assessment, Cincinnati, OH 

• Dose-Response Estimation and Critical Effect Selection: 

Application for Occupational and Environmental Health Settings, 

David G. Dolan, Amgen Inc., Thousand Oaks, CA 

• Dose-Response Estimation and Critical Effect Selection—Special 

Issues, Robert Sussman, SafeBridge Inc., New York, NY 


8:15 AM–12:00 NOON 


The Use of Transgenic Animal Technology in 

Toxicological Research 

AM05 

BASIC 

Chairperson(s): Daniel K. Ness, Elan Pharmaceuticals, Inc., South San 

Francisco, CA and Roy Forster, CIT, Evreux, France 

Endorsed by: 


Drug Discovery Toxicology Specialty Section 


The ability to direct genetic changes at the molecular level in vivo has 

resulted in a revolution in biology. Nowhere has this been more apparent 

than in the production of transgenic animals. A host of techniques has 

been used to effect change in gene expression and develop new toxicological 

testing paradigms. Genetically modified animals are commonly 

produced and often yield important information relevant to safety/toxicological 

assessment. This session will help guide the toxicologist in the 

use and interpretation of data derived from transgenic models. The first 

speaker will introduce this topic and set the stage for subsequent speakers. 

The second speaker will review the history of genetic engineering technologies 

leading to the development of loss-of-function, gain-of-function 

modeling technologies across mammalian platforms. Transgenic animals 

have provided us with powerful tools to explore cellular and physiological 

processes in vivo. Current technologies allow us to modify cell-, tissue-or 

organ-specific gene expression in controlled temporal and spatial fashion. 

Accordingly, experimental considerations including strain-specific variability 

impacting experimental outcomes will be explored. The third 

speaker will cover current practice and previous experience gained in the 

regulatory use of transgenic animals in testing new products. In the area 

of safety evaluation, transgenic models have been used in the testing of 

biotechnology products (homologous models), in carcinogenicity testing, 

and in early toxicology screening. The presentation will cover the use of 

transgenics from the point of view of theory, the concrete practical aspects 

of putting such studies in place and new developments in this area. From 

gene-targeting, gene-trapping, and conditional expression modeling, gene 

knockout technology in mice is employed as an integrated platform to 

study physiological and behavioral functions and pharmaceutical utility 

of targeted genes. The fourth speaker will present recent data comparing 

pharmacological inhibition of selected targets, with a focus on differentiating 

between mechanism and nonmechanism-based toxicity and in 

determining on-target versus off-target toxicity for drug candidates. The 

final speaker will discuss how the lack of practical methods for the study 

of mutagenesis using endogenous genes stimulated the development of 

alternative mutation assays. These mutation analytical systems, developed 

first in rodents, and subsequently in fish share a similar general approach. 

Transgenic mutation models provide opportunities for comparative studies 

of complex processes of mutagenesis simply not possible otherwise. The 

introduction of a mutation model based on a transgenic fish, here the 

transgenic medaka, builds upon the knowledge and experience gained 

from the rodent models, and expands opportunities for increasing the 

understanding of fundamental mechanisms of mutagenesis. 

• Introduction, Daniel K. Ness, Elan Pharmaceuticals, Inc., South San 

Francisco, CA 

• Overview of Transgenic Animal Technology, Carl A. Pinkert, Auburn 

University, Auburn, AL 

• Current Use of Transgenics in Screening and Regulatory 

Toxicology, Roy Forster, CIT, Evreux, France 

• Using Mouse Knockouts to Predict Mechanism-Based Toxicity, 

Brian P. Zambrowicz, Lexicon Pharmaceuticals, The Woodlands, TX 

• From Transgenic Rodent to Fish Modeling: Enhancing Insights 

into Shared Mechanisms of Mutagenesis, Richard N. Winn, 

University of Georgia, Athens, GA 


8:15 AM–12:00 NOON 


Process-Based Approaches to Modulating Gene and 

Protein Expression In Vivo and In Vitro 

AM06 

BASIC 

Chairperson(s): Richard S. Pollenz, University of South Florida, Tampa, 

FL and Robert Tanguay, Oregon State University, Corvallis, OR 

Endorsed by: 


Molecular Biology Specialty Section* 

The mechanistic analysis of cellular responses to xenobiotics 

requires the ability to modulate important genes involved in specific 

pathways. Such genes include those that encode receptors that 

associate with xenobiotics as well as the enzymes involved in xenobiotic 

metabolism. The ability to modulate these genes and proteins 

in vitro and in vivo has become accessible to more laboratories with the 

refinement of techniques such RNA interference (RNAi), viral gene 

delivery, morpholino-mediated gene knock down and targeted gene 

disruption. However, the ability to utilize these techniques and generate 

reproducible results requires a detailed understanding of the advantages 

and applications of each procedure. Thus, the goal of this course is to 

provide the investigator with an overview of experimental design and the 

use of proper controls for four cutting-edge techniques. The first talk will 

focus on experimental design and analysis of RNAi to reduce endogenous 

target proteins in culture cells with emphasis on controls and endpoint 

analysis. The second presentation will move to the zebrafish model system 

and discuss the use of morpholino-mediated gene knock down to reduce 

the expression of specific proteins in embryos. The third presentation 

will discuss gene delivery utilizing the adenovirus system for reduction 

of gene expression in mice. The fourth presentation will detail the use 

or transgenic approaches in mouse models to modulate the expression of 

specific target genes or knock-in genes from other species. This course 

should be of broad interest to laboratories considering a mechanistic 

approach to understanding signal transduction pathways, gene expression 

and protein-protein interactions as well as those currently investigating 

these endpoints. 

• Use of siRNA Technology to Modulate Gene Expression in Culture 

Cells, Richard S. Pollenz, University of South Florida, Tampa, FL 

• Use of Morpholinos to Modulate Gene Expression in Zebrafish, 

Robert Tanguay, Oregon State University, Corvallis, OR 

CE 




CE 

• Adenovirus-Mediated Gene Delivery to Modulate Protein 

Expression In Vivo, Cornelius Elferink, UTMB, Galveston, TX 

• Transgenic Approaches to Modulate Gene Expression in Mouse 

Models, Frank Gonzalez, NCI, Bethesda, MD 


8:15 AM–12:00 NOON 


Basic Embryology and Developmental Toxicology 

AM07 

BASIC 

Chairperson(s): Lori A. Dostal, Ann Arbor, MI and John M. Rogers U.S. 

EPA, Research Triangle Park, NC 

Endorsed by: 

Reproductive and Developmental Toxicology Specialty Section* 

Embryonic and fetal prenatal development in mammalian species is a 

complex process which is sensitive to the effects of maternal and environmental 

factors. The timing of development of major organ systems varies 

between humans and various test species used in assessment of developmental 

toxicity of xenobiotics. This basic course will cover normal 

development from fertilization through early stages of implantation and 

embryogenesis, through development of the major organ systems (cardiovascular, 

central nervous system, craniofacial, skeletal, urogenital). The 

effects of known human and animal teratogens on fetal development will 

be presented as examples, including etiologies of abnormal development. 

Current requirements and study designs for developmental toxicology 

studies required for new chemicals and new drugs will be covered in the 

context of the biological concepts of organ systems described in the initial 

lectures. 

• Introduction and Overview, Lori A. Dostal, Ann Arbor, MI 

• Cleavage, Implantation, Gastrulation, Neurulation Gastrulation, 

E. Sidney Hunter, U.S. EPA, Research Triangle Park, NC 

• Cardiovascular and Craniofacial/Pharyngeal Development, 

Kathleen K. Sulik, University of North Carolina, Chapel Hill, NC 

• Development of the Skeletal System Including Limbs, and the 

Urogenital System, John M. Rogers, U.S. EPA, Research Triangle 

Park, NC 

• Developmental Toxicology Testing and Interpretation, 

Rochelle W.Tyl, RTI International, Research Triangle Park, NC 


1:15 PM—5:00 PM 


Introduction to Pathology for Toxicologists 

and Study Directors 

PM08 

BASIC 

Chairperson(s): Laurene M. Fomby, Battelle, Columbus, OH and Pat 

Haley, Incyte Corp, Wilmington, DE 

Endorsed by: 



Today, even with the promise of ‘omic’ technologies, pathology plays 

a critical role in the evaluation of chemicals and drugs. Toxicological 

pathology uses specialized terms and methods and can generates complex 

interpretative problems. Effective communication between the toxicologist 

and the study pathologists will allow the toxicologist to better 

integrate pathology data into their reports and optimize the scientific 

content of the study. In this basic course, experienced toxicological 

pathologists will introduce important concepts in pathology to toxicologists 

as study directors in order to help the study director appreciate the 

role of pathology in toxicological studies. The course will begin with a 

discussion of basic concepts and the role of the toxicological pathologist 

followed by a discussion of global regulations as they relate to pathology 

endpoints. Later lectures will discuss the lesions and interpretation of 

pathology data in non-oncogenicity studies and oncogenicity studies. 

By the end of the session, the study director should have a better understanding 

of pathology and a basic background that will allow for effective 

communication with a study pathologist. 

• Introduction, Pat Haley, Incyte Corp, Wilmington, DE 

• Basic Concepts in Morphologic Pathology and the Roles of the 

Toxicological Pathologist, Sarah Hale, EPL, Raleigh, NC 

• Important Induced Lesions, and Interpretation of Pathology Data 

in Non-Oncogenicity Studies, Paul Howroyd, MDS Pharma, Lyon, 

France 

• Pathology Endpoints in Routine Repeated Dose Toxicology Studies: 

A Review of Global Regulations, Ken Schafer, Vet Path Services, 

Mason, OH 

• An Introduction to Pathology in Carcinogenicity Studies, 

Dianne Creasy, Huntingdon Life Sciences, East Millstone, NJ 


1:15 PM—5:00 PM 


Nanotoxicology: The Science of Developing a Safe 

Technology 

PM09 

BASIC 

Chairperson(s): Justin G. Teeguarden, Pacific Northwest National 

Laboratory, Richland, WA and Christie M. Sayes, DuPont Haskell Labs, 

Newark, DE 

Endorsed by: 

Inhalation and Respiratory Specialty Section 

Nanotoxicology Specialty Section* 

Occupational and Public Health Specialty Section 


The objective of this course is to prepare toxicologists and risk assessors 

to meet the rapidly growing need to understand and evaluate the risks 

that engineered nanomaterials may pose to human health. Toxicological 

and risk assessment of nanomaterials requires an understanding of the 

unique differences between these ‘new’ materials and their chemical and 

large-particle predecessors. Few currently have the multidisciplinary 

understanding (toxicology, nanoscience, applied physics, dosimetry) to 

effectively approach the problem of risk and safety assessment of these 

materials. This basic course will provide an overview of the state of the 

science of the field of nanotoxicology and develop the scientific basis for 

evaluating and characterizing exposure, toxicity and the risks associated 

with engineered nanomaterials. Nanoscience and nanomaterials will be 

described with a focus on how they may be different than chemicals and 

previous studied particulates. A summary of current evidence regarding 

important routes of exposure and materials humans are exposed to will be 

presented. Current methods for, and challenges to toxicological testing of 

nanomaterials will be covered with specific examples relating the toxicity 

of nanoscale TiO2 to more well characterized particulates (e.g. crystalline 

silica). Guidelines for testing have been proposed by several groups 

and will be summarized. Finally, the dosimetric basis for extrapolating 

the results of toxicology studies to humans will then be developed and 

presented. This course promotes the application of best scientific practices 

74 




in the toxicological evaluation and risk assessment of this rapidly growing 

family of new materials. 

• Introduction and Course Overview, Justin G. Teeguarden, Pacific 

Northwest National Laboratory, Richland, WA 

• Nanomaterials and Nanomaterial Properties, Christie M. Sayes, 

DuPont Haskell Labs, Newark, DE 

• Consumer and Occupational Exposure to Nanomaterials, Annette 

Santamaria, ENVIRON, Houston, TX 

• Nanomaterial Toxicology and Hazard Testing, David B. Warheit, 

DuPont Haskell Labs, Newark, DE 

• Nanomaterial Dosimetry and Risk Assessment, Justin G. 

Teeguarden, Pacific Northwest National Laboratory, Richland, WA 


1:15 PM—5:00 PM 


Clinical Dose Setting for Biotherapeutics 

PM10 

BASIC 

Chairperson(s): James D. Green, Biogen Idec, Inc., Cambridge, MA and 

Shawn M. Heidel, Eli Lilly and Company, Indianapolis, IN 

Endorsed by: 

Regulatory and Safety Evaluation Specialty Section* 

Women in Toxicology Special Interest Group 

Preclinical development programs that are designed to support the safe 

clinical use of biopharmaceuticals have considerations that are very 

different from programs designed to support the development of small 

molecule drugs. The International Conference of Harmonization ICH 

S6 document provides guidance regarding scientific and regulatory 

consensus for key preclinical study design elements. Since the adoption of 

ICH S6 considerable experience has been developed across a wide variety 

of biological drug and antibody constructs. This experience has indicated 

that if ICH S6 guidance is followed and expert assessment of data sets is 

provided, the safety considerations for first in human and later stage clinical 

trials has been assured. However, the recent experience involving the 

humanized monoclonal antibody TGN1412 has raised questions regarding 

the adequacy of current nonclinical approaches. This session will review 

the following: 1. current and proposed regulatory guidance documents that 

determine safe starting doses, 2. basic and advanced concepts in PK and 

PD that support preclinical and clinical dosimetry, 3. basic and advanced 

concepts of toxicology that are involved in the assessment of safety of 

biotherapeutics and 4. the current approaches will be illustrated by several 

case studies across a wide range of product classes. The course attendee 

will learn key concepts and design considerations for successful preclinical 

programs that support the initiation of safe human clinical trials. 

• Introduction, James D. Green, Biogen Idec, Inc., Cambridge, MA 

• Review of Current Regulatory Guidances That Determine 

First Dose in Human, Mark C. Rogge, Biogen Idec, Inc., 

Cambridge, MA 

• PK and PD Principles Supporting the Determination of First in 

Human Dosing, Jenn Visich, Genetech, South San Francisco, CA 

• Toxicology Considerations Supporting Safe Clinical Development, 

Shawn M. Heidel, Eli Lilly and Company, Indianapolis, IN 

• Application of PK/PD and Toxicology Principles to Support 

the Determination of Safe Clinical Dosing: Case Studies, 

Laura Andrews, Genzyme, Framingham, MA 


1:15 PM—5:00 PM 


Use of Data for Development of Uncertainty 

Factors in Non-Cancer Risk Assessment 

PM11 

advanCED 

Chairperson(s): John C. Lipscomb, U.S. EPA, Cincinnati, OH and Lynne 

T. Haber, Toxicology Excellence for Risk Assessment, Cincinnati, OH 

Endorsed by: 



Risk Assessment Specialty Section* 

Promoting clarity and objectivity is a primary concern when advancing 

the technical basis for human health risk assessment. Default values for 

uncertainty factors are intended to serve as place-holders, to be replaced 

when relevant data become available. The default values for the uncertainty 

factors for inter and intraspecies extrapolation were established 

before many toxicologists were born, and methods for incorporation of 

chemical-specific or categorical data continue to evolve. To understand the 

rationale for these uncertainty factors and methods for their replacement, 

this course will present a continuum of approaches to develop non-default 

values for uncertainty factors, culminating in the application of advanced 

toxicokinetic methods to quantify differences in internal dosimetry. The 

course will describe the history of the development of default values for 

uncertainty factors, including their recent subdivision into toxicokinetic 

and toxicodynamic components; methods that make use of generallyapplicable 

species differences in anatomy and physiology and allometric 

scaling; specific instruction in the Chemical Specific Adjustment Factor 

(CSAF) methodology developed by the International Programme on 

Chemical Safety (IPCS); and the application of physiologically based 

pharmacokinetic (PBPK) modeling to develop quantitative data for use 

in replacing default assumptions for inter and intraspecies differences in 

tissue dosimetry. The concluding lecture will present a series of examples 

to illustrate how the various approaches introduced in the course can 

be applied to derive non-default uncertainty factors for environmental 

contaminants and pharmaceutical compounds. 

• Introduction, John C. Lipscomb, U.S. EPA, Cincinnati, OH 

• Overview and History of Default Values for Uncertainty Factors, 

Lynne T. Haber, Toxicology Excellence for Risk Assessment, 

Cincinnati, OH 

• Categorical Default Approaches to Uncertainty Factor 

Development, John C. Lipscomb, U.S. EPA, Cincinnati, OH 

• Development of Chemical Specific Adjustment Factors (CSAF): 

Guidance from the International Programme on Chemical Safety, 

Bette Meek, Health Canada, Ottawa, Ontario, Canada 

• PBPK Models for Developing Chemical-Specific Adjustment 

Factors, Kannan Krishnan, University of Montreal, Montreal, Quebec, 

Canada 

• Examples Illustrating the Use of Data to Replace Default 

Uncertainty Factors, Bruce D. Naumann, Merck & Company, Inc., 

Whitehouse Station, NJ 

CE 




CE 


1:15 PM—5:00 PM 


Essential Informatics for Toxicologists: 

Knowledge Management End-to-End 

PM12 

BASIC 

Chairperson(s): William B. Mattes, The Critical Path Institute, Rockville, 

MD and Lyle D. Burgoon, Toxicogenomic Informatics and Solutions, LLC, 

Lansing, MI 

Endorsed by: 



The combination of the Internet, automated data acquisition, and genomic 

information has transformed the role of the computer in the modern scientist’s 

life. A familiarity with word processing and simple spreadsheets 

is simply not adequate preparation for dealing with large datasets such 

as those generated by large toxicology studies, toxicogenomics or highthroughput 

screens. Increasingly, the software tools used to deal with such 

data require an understanding of basic concepts in computer science, database 

design, bioinformatics and statistics. This ‘basic’ level course hopes 

to provide the beginnings of such an understanding. Thus the first lecture 

will cover some of the essential concepts of operating systems, file and 

data concepts and programming concepts. This will be followed by a talk 

discussing the essentials of database design and use, contrasting flat-file 

and relational databases. A third lecture will provide an overview of the 

information necessary so that data may be integrated, e.g. pathology with 

genomics. The final lecture will cover concepts of visual analysis of large 

data sets, and contrast some of the various approaches used. Hopefully 

after this course the student will be conversant in informatics to the level 

of effectively interacting with computer scientists, as well as collecting 

and manipulating datasets with reasonable skill. 

• Basics of Operating Systems, Data, and Data Handling, 

William B. Mattes, The Critical Path Institute, Rockville, MD 

• Database Essentials for Toxicologists, Lyle D. Burgoon, 

Toxicogenomic Informatics and Solutions, LLC, Lansing, MI 

• Annotating Data With Study and Subject Details—How, Why, 

What to Include, Jennifer Fostel, NIEHS, Research Triangle 

Park, NC 

• What Do I Do with All This Data? Joseph F. Sina, Merck & Co Inc, 

West Point, PA 


1:15 PM—5:00 PM 


Over the course of the last 50 years, epidemiology has gained respect as 

an established scientific discipline. Whereas epidemiologic results were 

once greeted with scorn and skepticism they are now accorded some 

degree of respect and in some instances perhaps too much respect. This 

course will begin by providing an overview of the terminology used to 

describe the techniques used to measure and quantify disease in populations. 

Toxicologist will become familiar the with the various study designs 

used in epidemiologic research to generate and evaluate hypotheses 

regarding disease occurrence. Next, the distinction between experiments 

and observational studies will be made with an overview on epidemiologic 

study designs, and bias in epidemiologic data. We will cover the 

types of observational study designs characterized according to whether 

the unit of observation is a group, the individual, or some hybrid of the 

two. A summary will provide the audience with some general guidelines 

regarding the tendency of the different types of epidemiologic studies to 

provide unbiased results. 

Both toxicologists and epidemiologists contribute to the answers, and 

confusion, by providing information for use in hazard identification and 

dose response which is then cited in the risk characterization process. 

Toxicologists provide data through experimental descriptive and mechanistic 

studies with relevancy sometimes becoming an issue (e.g., PPAR 

mediated liver tumors in rats). Epidemiologists identify opportunistic 

areas to address the study question but have historically provided answers 

with exposure disappointingly defined. Many questions arise from toxicologists 

when trying to understand epidemiology including confusion 

about study bias, statistical inference, representativeness, and generalization. 

In this era of biomonitoring, can both disciplines be more effectively 

understood by each other, let alone others? Our objective is to compare 

and contrast methodologic strengths and weaknesses of the two disciplines 

as they attempt to address the public’s question, ‘is it safe?’ At the 

conclusion of this course, the presenters will reference presentations and 

discuss examples of a number of areas where epidemiology is misused, 

misinterpreted, and over-interpreted. The panelists will include examples 

of the misapplication of biomarkers in assessing risk ratios, the use of 

a minimum risk ratio of two to establish causation in the Texas court 

system, and the misuse of statistical analyses by both epidemiologists and 

toxicologists, among others. 

• Setting the Stage, Richard A. Parent, Consultox Ltd, 

Damariscotta, ME 

• Overview and Terminology, J. Michael Sprafka, Procter & Gamble 

Company, Cincinnati, OH 

• Epidemiolgy Study Designs and Bias in Epidemiologic Data, 

Matthew P. Longnecker, NIEHS, Research Triangle Park, NC 

• Toxicology and Epidemiology—Improving our Mutual 

Understanding, Geary W. Olsen, 3M Corporation, St. Paul, MN 

• Uses and Misuses of Epidemiology, All panel members will 

participate 

Epidemiology for Toxicologists: Introduction 

PM13 

BASIC 

Chairperson(s): Richard A. Parent, Consultox Ltd, Damariscotta, ME 

and Geary Olsen, 3M Corporation, St. Paul, MN 

Endorsed by: 

Carcinogenesis Specialty Section 

Regulatory and Safety Evaluation Specialty Section 


This course is intended to provide participants with insight into epidemiology, 

a critical component of the discipline of toxicology This course 

will be presented by accomplished epidemiologists from government and 

industry. 

76 



Scientific Session Index 

All sessions will be held at the Washington State Convention and Trade Center. 

General Scientifc Sessions 

(Listed by type, then date and time) 


Monday 

Date/Time Topic/Abstract # Room Page 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Workshop Sessions 

Metals, Microglia, and 

Neuroinflammation 

#13–17 

Molecular Basis for 

Susceptibility to Chemical 

Toxicity and Disease 

#18–22 

New Developments in Liver 

Tumor Biology #23–28 

Particle Interactions with 

Biomaterials: Beyond 

Opsonization #29–34 

Room 

6A 

Room 

605 

Room 

6C 

Room 

6B 


Monday 

9:30 AM 

Monday 

9:30 AM 

Platform Sessions 

Current Perspectives on 

Ocular and Systemic Safety 

Risks of Therapeutics 

#35–40 

LLNA: False Positives, False 

Negatives, and Alternative 

Endpoints #41–46 

Room 

611 

Room 

608 


Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Advancing the Science of 

Risk Assessment #47–55 

Altered Reproductive 

Development #56–63 

Developmental 

Immunotoxicology, Host 

Resistance and Genomics 

#64–70 

Ecotoxicity and Chemical 

Exposure #71–78 

Oxidative Stress, DNA 

Strand Breaks, and Applications 

of the COMET Assay 

#79–84 

Room 

615 

Room 

602 

Room 

6E 

88 

88 

89 

89 

90 

90 

91 

91 

92 

Room 2A 93 

Room 

618 

93 


*Attended 9:30 AM–11:00 AM; otherwise attended 11:00 AM– 

12:30 PM. 

Date/Time Topic/Abstract #/ 

Poster 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Roundtable Sessions 

* Endocrine Mechanisms of 

Toxicity #85–108 

Poster Boards 101–124 

Oxidative Stress Mechanisms 

in Chemical 

Carcinogenesis #109–124 


* Chemical and Biological 

Weapons #125–162 


Immunotoxicology 

#163–200 


* Animal Models #201–235 


Bioinformatics and 

Computational Toxicology 

#236–263 


* Pesticide Metabolism and 



Inhalants: Oxidative 

and Redox Mechanisms 

#287–300 

Poster Boards 555–559 and 

604–612 

* Xenobiotic Biotransformation 

II #301–320 

Poster Boards 614-633 

Room 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Page 

94 

95 

97 

99 

102 

105 

107 

109 

110 


Monday 

12:15 PM 

Monday 

12:15 PM 

Risk Assessment for 

Biotherapeutics #321 

The Future of Toxicology 

#322 

Room 

618 

Room 

602 

113 

113 

Session index 



Scientific Session Index (Continued) 

Session index 


*Attended 1:00 PM–2:45 PM; otherwise attended 2:45 PM–4:30 PM. 


Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 


* Alternative Ocular and 

Dermal Models #323–341 


Apoptosis: Mechanisms 

and Methods #342–360 


* Stem Cell Biology and 

Toxicology #361–372 


Biomarkers #373–399 


* Genetic Polymorphisms 

#400–422 


Nanoparticles: Testing 

Approaches, Geno- and 

Ecotoxicity #423–443 


401–410 

* Kidney #444–473 


Food Safety I #474–498 


* Safety Assessment, 

Non-Pharmaceutical 

#499–518 


Modulators of Cell 

Proliferation in Chemical 



601 

* Receptors #533–555 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

114 

116 

117 

118 

120 

122 

124 

126 

128 

129 

130 


Monday 

1:30 PM 

Monday 

1:30 PM 

Monday 

1:30 PM 

Monday 

1:30 PM 

Drug-Induced Mitochondrial 

Toxicity, Novel 

Insights, Novel Tools 

#556–561 

Environmental Influence 

on Female Puberty and 

Breast Tumorigenesis 

#562–567 

Oxidant Air Pollution 

and Childhood Asthma 

#568–575 

Stem Cells: New Tools 

for Neurotoxicologists 

#576–580 

Room 

6B 

Room 

6E 

Room 

6C 

Room 

605 

133 

133 

134 

134 



Monday 

1:30 PM 

Monday 

1:30 PM 

Monday 

1:30 PM 


Getting the Most Out of 

Model Organism Databases: 

From the Basic to the 

Complex #581-585 

Mixture Exposures to 

Metals/Metalloids and 

Related Health Effects 

#586-590 

Where the Rubber Meets 

the Road: Current Application 

of Genomic Tools in 

Product Development and 

Decision Making #591-596 

Room 

615 

Room 

608 

Room 

611 

135 

136 

136 


Monday 

1:30 PM 


Future Paths for Puget 

Sound: Contaminants, 

Cultures, and Ecosystem 

Risk Characterization—A 

Special Regional Interest 

Session #597–603 

Room 

618 

137 


Monday 

1:30 PM 

Monday 

1:30 PM 

Monday 

1:30 PM 

Roundtable Session 

APC's, B Cells and 

Haematopoiesis #604–610 

Disposition/Pharmacokinetics 

#611–618 

Frontiers in Liver 

Toxicology Research 

#619–627 

Room 

602 

Room 

6A 

Room 

2A 

137 

138 

138 


Monday 

4:30 PM 

Immunotoxicity Testing: 

Should Elevated Antibody 

Responses be Interpreted as 

an Indicator of Immunotoxicological 

Hazard? #628 

Room 

615 

140 

78 






Monday 

4:30 PM 


Ozone Toxicology: 

Historical Perspectives of 

the Science that Shaped the 

Regulatory Standards #629 

Room 

602 

140 


Monday 

4:30 PM 

Putting Your Best Foot 

Forward: Job Interviewing 

Workshop for Early-Career 

Scientists #630 

Room 

605 

141 



Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Drug-Related Torsades de 

Pointes: Advancements 

in Preclinical Modeling of 

Potential Cardiac Toxicity 

#647–651 

The Allergic March: The 

Role of Chemicals in the 

Increasing Prevalence 

of Allergy and Asthma 

#652–657 

To Dye or Not to Dye: 

Safety of Oxidative Hair 

Dyes #658–663 

Room 

611 

Room 

6A 

Room 

608 

147 

147 

148 


Tuesday 


Tuesday 

7:30 AM 

Tuesday 

7:30 AM 

Tuesday 

7:30 AM 


Breaking the Log-Jam: 

Public-Private Partnerships 

as a Way to Discover 

and Advance Biomarkers 

of Drug-Induced Toxicity 

#631 

Reproductive Toxicity 

Studies: One Generation 

versus Two Generations 

#632 

The 2007 Pet Food Related 

Toxic Nephropathy in Dogs 

and Cats #633 

Room 

618 

Room 

602 

Room 

6C 

143 

143 

144 


Tuesday 

7:30 AM 

Detection of Biological Free 

Radicals in Time and Space 

#634 

Room 

611 

144 



Tuesday 

9:00 AM 


Professional Career Development 

as a Toxicologist 

#664–668 

602 148 


Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Accelerating Discoveries in 

Toxicology Through ‘Omics 

Research #669–676 

Chemical and Biological 

Weapons: Molecular Basis 

for Detection and Therapeutic 

Potential #677-684 

Developmental Basis of 

Disease #685–692 

Health Risks and Food 

Safety #693–701 

Manganese Neurotoxicity: 

From Worms to Primates 

#702–708 

Room 

6C 

Room 

618 

Room 

6E 

Room 

615 

Room 

2A 

149 

150 

150 

151 

152 

Session index 



Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Molecular and Genomic 

Insights into the 

Nrf2-Regulated Oxidative 

Stress Response: Impact on 


New Concepts in the 

Etiology of Breast 

Cancer: From Genes to 

Environment and Back 

Again #641–646 

Room 

605 

Room 

6B 

146 

146 



12:30 PM. 


Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

* Adverse Effects of Natural 

Products #709–725 


Particulate Matter and the 

Cardiovascular System 

#726–753 


201–209 

Exhibit 

Hall 

Exhibit 

Hall 

152 

153 




Session index 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 


* Xenobiotic Biotransformation 

I #754–784 


Persistent Organic 

Pollutants (POPs) #785–821 


* Liver I: In Vivo #822–864 


401–440 

Mechanisms and Chemoprevention 

of PAH and 

Tobacco-Related Carcinogenesis 

#865–877 


* Alternatives to Mammalian 

Models #878–909 


Regulatory Risk Assessment 

#910–942 


601–620 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 


156 

158 

161 

164 

165 

167 


Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

* Pharmacokinetics and 

Disposition #943–975 


Regulation/Policy 

#976–991 


201–209 

* Applications of Biological 

Modeling #992–1022 

Poster Board 210–240 

Nanoparticles: Target 

Organs #1023–1056 


* Breast Cancer: Mechanisms, 

Biomarkers, 

and Chemoprevention 

#1057–1070 


401–408 

Inhalation Toxicology 

#1071–1102 


* Signal Transduction 

and Gene Regulation 

#1103–1131 


Reproductive System 

#1132–1161 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

172 

174 

175 

177 

180 

181 

183 

186 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 


* Risk Assessment Research 

#1162–1199 


Liver II: In Vitro 

#1200–1222 


* Assessment of Ecological 



Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

188 

191 

193 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 


Endothelial Dysfunction: 

More Than Just a "No NO" 

Phenomenon #1251–1258 

Neurotoxicant-Induced 

Alterations in Developmental 

and Adult 

Neurogenesis: Structure- 

Function Studies and 

Clinical Relevance 

#1259–1263 

Novel Biomarkers of 

Drug-Induced Toxicity: 

Outcomes of Predtox 

and the Predictive Safety 

Testing Consortium 

#1264–1271 

Room 

605 

Room 

611 

Room 

602 

195 

196 

197 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Dermal Toxicological 

Assessment of Nanomaterials 

and Nanodevices 

#1272–1277 

Host Susceptibility and 

Chemical Safety Testing: 

New Approaches to 

Estimate Risks in the 

Human Population 

#1278–1283 

Molecular Mechanisms and 

Molecular Biology of Metal 


Strategies for Assessing 

Developmental and 

Reproductive Toxicology 

of Bio-Pharmaceuticals 

#1290–1295 

Room 

6C 

Room 

608 

Room 

6B 

Room 

6A 

197 

198 

198 

199 

80 






Tuesday 

1:30 PM 

Human Health Risk 

Assessment for Pharmaceuticals 

in the Environment 

(PIE) #1296–1301 

Room 

618 

200 

Wednesday 

9:00 AM 


Unusual Manifestations of 

On-Target and Off-Target 

Toxicity: Toxicity of Kinase 

Inhibitors #1338–1343 

Room 

608 

207 




Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Arsenic Toxicity 

#1302–1309 

Mechanisms of Hypersensitivity 

#1310–1316 

Mechanisms of Pesticide 


Room 

2A 

Room 

6E 

Room 

615 

200 

201 

201 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Natural Killer Cells 

as Targets of Drugs, 

Toxicants, and Biologicals 

#1344–1348 

Safe Approaches to Topical 

Product Development 

#1349–1354 

Threshold of Toxicologic 

Concern: Historical 

Perspectives and Future 

Applications #1355–1360 

Room 

6B 

Room 

615 

Room 

6C 

207 

208 

208 


Wednesday 


Wednesday 

9:00 AM 

Use of Behavioral and 

Non-Routine Neurological 

Approaches in Drug 

Discovery Toxicology 

#1361–1366 

Room 

6A 

209 

Wednesday 

7:30 AM 

Wednesday 

7:30 AM 

Wednesday 

7:30 AM 

Hazard vs. Risk for 

Chemical Regulation #1326 

Reconciling Scientific and 

Ethical Concerns in the 

Use of Animals for Toxicological 

Research #1327 

Toxicology Training Needs: 

New Faces and New Tools 

for the 21 st Century #1328 

Room 

618 

Room 

615 

Room 

608 

203 

204 

204 



Wednesday 

9:00 AM 

Globally Harmonized 

System of Classification 

and Labelling of Chemicals 

(GHS): A New Language for 

Toxicologists #1367–1372 

Room 

602 

209 

Informational Sessions 


Wednesday 

7:30 AM 

Wednesday 

7:30 AM 


Cross-Cultural Understanding 

of Asian and 

Western Cultural Values in 

the Workplace #1329 

Toxicological and Public 

Health Challenges in Africa 

#1330 

Room 

602 

Room 

605 

205 

205 




Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Advances in Biological 

Modeling #1373–1381 

Mechanisms of Reproductive 

Toxicity 

#1382–1389 

Modulating Apoptosis 

for Beneficial Outcomes 

#1390–1397 

Nanoparticles: Cellular 

and Organ Disposition 

#1398–1406 

Room 

611 

Room 

2A 

Room 

618 

Room 

6E 

210 

210 

211 

212 

Session index 

Wednesday 

9:00 AM 

Developmental Basis 

of Health and Disease: 

Persistent Effects of 

Tobacco Smoke Exposure 

#1331–1337 

Room 

605 

206 




Session index 



12:30 PM. 


Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

* Mechanisms of Carcinogenesis 

#1407–1419 


Gene Regulation and 

Genomic Approaches 

#1420–1433 


* Respiratory and Skin 

Hypersentivity #1434–1457 


201–211 

Epidemiology and 

Exposure Assessment 

#1458–1484 


* Nanoparticles: Inhalation 

and Respiratory Cell Injury 

#1485–1514 


Developmental Toxicology 

#1515–1542 


401–418 

* Skin Penetration and 



Application of ‘Omics 

Research Tools in 



* Metals I #1607–1644 


601–621 

Cardiovascular System: 

Cardiac Effects #1645–1667 


* DNA Damage and Repair: 

Mechanisms and Agents 

#1668–1689 


701–709 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

213 

214 

215 

217 

219 

221 

223 

225 

228 

231 

233 




Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 


* Developmental Neurotoxicity 

#1691–1729 


Human Biomarkers 

#1730–1746 


* Biomarkers: Methods 

#1747–1764 


Juvenile Toxicity 

#1765–1775 


* Risk Assessment Applications 

#1776–1803 


Neurotoxicity: Miscellaneous 

Compounds, 

Models, and Mechanisms 

#1804–1843 


* Metal Neurotoxicology: 

Experimental Models and 

Mechanisms #1844–1889 


Pharmaceuticals 

#1890–1915 


601–613 

* Safety Assessment, 

Pharmaceutical—Liver, 

Kidney, Immune System 

#1916–1943 


Oxidative Injury and 

Redox Biology I: In Vivo 

#1944–1964 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

237 

240 

241 

242 

243 

245 

248 

251 

253 

255 




Wednesday 

12:00 

NOON 

Mentoring 101—How to 

Mentor, and How to be 

Mentored #1690 

Room 

615 

236 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Arsenic and Cardiovascular 

Disease #1965–1969 

Nanomaterial Pharmacokinetics: 

Where We Are 

and Where We Need to Go 

#1970–1975 

Room 

6B 

Room 

6C 

257 

258 

82 






Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 


Advances in Technology 

and Increasing Acceptance 

for Zebrafish Use in Drug 

Discovery #1976–1980 

Chlorotriazine Herbicides 

and their Common 

Degradation Products of 

Concern: Disposition and 

Potential Health Effects 

#1981–1986 

Interdisciplinary 

Approaches for Improving 

Chemical Hazard Testing 

Paradigms #1987–1992 

Room 

608 

Room 

611 

Room 

6A 

258 

259 

259 


Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 


Apoptosis: Cardiopulmonary 

Targets 

#1993–2001 

Immunotoxicology: T Cells 

#2002–2007 

Issues in Regulatory Risk 

Assessment #2008–2016 

New Insights for Developmental 


#2017–2025 

Nrf2 Induced Gene 

Regulation #2026–2033 

Selective Dopaminergic 

Neurotoxicity: 

Genetics and Mechanisms 

#2034–2040 

Room 

6E 

Room 

602 

Room 

605 

Room 

618 

Room 

615 

Room 

2A 

260 

261 

261 

262 

262 

263 


Wednesday 

4:30 PM 


A Case Study on the Risks 

and Benefits of Deca-BDE— 

a Major Brominated Flame 

Retardant #2041 

Room 

608 

264 


Wednesday 

4:30 PM 

Wednesday 

4:30 PM 

Implementation of the ICH 

S8 Immunotoxicity Testing 

Guideline #2042 

NIEHS Outstanding New 

Environmental Scientists 

(ONES) Awardees #2043 

Room 

615 

Room 

6C 

264 

265 


Thursday 


Thursday 

7:30 AM 


Biofuel Combustion: An 

Emerging Health Problem? 

#2044 

Room 

608 


12:00 NOON. 

266 


Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

* Oxidative Injury and 

Redox Biology II: In Vitro 

#2045–2084 


Metals II #2085–2122 


201–218 

* Method Development, 

Autoimmunity, and Diseas 

Mechanisms in Immuno- 




#2156–2171 


301–309 

* Chemoprevention 

#2172–2183 


Fish Alternative Models of 



* Cardiovascular System: 

Vascular Effects 

#2200–2220 


401 

Food Safety II #2221–2241 


* High-Throughput, High 

Content Approaches to 

Assessing Genotoxicity 

#2242–2259 


Pesticide Neurotoxicity 

#2260–2292 


501–518 

* Safety Assessment, Pharmaceutical—Techniques, 


#2293–2326 


Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

Ballroom 

6C & E 

266 

269 

272 

275 

276 

277 

278 

280 

282 

283 

286 

Session index 






Thursday 

9:00 AM 

Cellular Redox Status and 

Zinc Signaling #2327–2331 

Room 

615 

288 

Thursday 

9:00 AM 

Perinatal Exposure to 

Nucleoside Reverse 

Transcriptase Inhibitors 

(NRTIs) Induces Transplacental 

Genotoxicity and 

Mitochondrial Toxicity 

#2332–2336 

Room 

605 

288 

Thursday 

9:00 AM 

Stem Cells in Developmental 

and Reproductive 

Biology and Toxicology 

#2337–2341 

Room 

611 

289 



Thursday 

9:00 AM 

Genotoxicity Testing from 

Early Discovery through 

Regulatory Submission: 

A Comprehensive Primer 

#2342–2347 

Room 

618 

290 

Thursday 

9:00 AM 

Incorporation of 

Mode-of-Action into 

Mechanistically-Based 

Quantitative Models 

#2348–2353 

Room 

608 

290 

Thursday 

9:00 AM 

Pulmonary Toxicity 

Testing of Nanoparticles 

#2354–2358 

Room 

6B 

291 

Session index 



Thursday 

9:00 AM 

REACH: Implementation, 

Chemical Safety, and 

Information Requirements 

#2359–2363 

Room 

6A 

291 

84 



Program Description 

All scientific and special events will be held in the Washington State 

Convention and Trade Center unless otherwise noted. 

* Indicates the Primary Endorser. 

Scientific Session TypeS 

Featured Sessions 



Roundtable 


SATURDAY 



Historical Highlights 

Thematic Session 

Exhibitor Hosted Sessions are not approved by the SOT Program Committee. 

Saturday, March 15 

2:00 PM to 5:00 PM 

Sheraton 

Willow A Room 

SOT Committee Chair Orientation 

If you will be a Committee Chairperson in 2008–2009, please make 

plans to attend the Committee Chairperson Meeting scheduled for 

2:00 PM–5:00 PM, Saturday, March, 15. With new committee assignments 

taking effect on May 1, 2008, the meeting is intended to provide new (and 

current, if desired) chairpersons with a basic tutorial on the SOT structure, 

operation, and strategic direction. For additional information, please contact 

SOT Headquarters. 

Saturday, March 15 

5:30 PM to 9:00 PM 

Room 305 


Chairperson(s): Vicente Santa Cruz, CDI Chair, Chevron Phillips 

Chemical Company, LP, The Woodlands, TX, and Charles Miller, III, 

Tulane University, New Orleans, LA 

Sponsored by: 

Committee for Diversity Initiatives 

This event is for undergraduate students and advisors receiving MARC and 

SOT travel funding, and the SOT program volunteers. 

5:30 PM–6:00 PM Orientation for SOT Hosts, Peer Mentors, 

and Advisors 

6:00 PM–6:15 PM Registration for Students 

6:15 PM–7:00 PM Opening Event 

7:00 PM–7:45 PM Dinner 

7:45 PM–8:30 PM Opening Lecture: “What is Toxicology?” 

Craig Marcus, University of New Mexico, 

Albuquerque, NM 

8:30 PM–9:00 PM Dessert and Networking 

6:15 PM–7:00 PM Opening Event 


8:00 AM to 5:00 PM 

Room 2A 

SUNDAY 



Chemical Company LP, The Woodlands, TX, and Charles Miller, III, 

Tulane University, New Orleans, LA 

Sponsored by: 


The Sunday program is open to undergraduate students who registered for 

this event on the Annual Meeting Registration Form, the undergraduate 

students and advisors receiving MARC, SOT, and Pfizer travel funding, 

and the SOT program volunteers. 

All Participants: 

8:00 AM–8:15 AM Introductions 

8:15 AM–8:50 AM Maternal Smoking and Cancer: Are your 

Children Paying the Price? Judy Zelikoff, New 

York University School of Medicine, Tuxedo, 

NY 

8:50 AM–9:10 AM Questions and Discussion 

9:10 AM–9:20 AM Break 

9:20 AM–9:55 AM Nano-a-Nano: The Good, the Bad, and the 

Ugly, Martin Philbert, University of Michigan, 

Ann Arbor, MI 

9:55 AM–10:20 AM Questions and Discussion 

10:20 AM–10:35 AM Undergraduates and Research: Development 

of Breast Cancer in Hamsters as a Model 

to Test Oncolytic Virotherapy, (Room 3A), 

Malari Coburn, Centenary College of Louisiana, 

Shreveport, LA 

10:35 AM–11:30 AM Interactive Session: Receptor-Mediated 

Toxicity, Charles Miller, III, Tulane University, 

New Orleans, LA 

11:30 AM–12:30 PM Lunch and Networking 

For Students: Breakout Sessions (Rooms 307, 308, 309) 

12:30 PM–1:55 PM 40 minutes concurrent sessions, 

each offered at 12:30 PM–1:10 PM and 

1:15 PM–1:55 PM 

A. What is Graduate School and What 

Can I Expect? TBA 

B. How to Get into Graduate School: An 

Academic Advisor’s Perspective, TBA 

Advisors Sessions: (Room 305) 

12:30 PM–1:15 PM Tips for Advising Prospective Graduate 

Students, TBA 

1:15 PM–1:55 PM Best Practices: Idea Sharing about Keeping 

Students on a Science Path, TBA 

sat/sun 



Program Description (Continued) 

All Participants: (Room 3A) 

2:00 PM–2:40 PM Career Opportunities in Toxicology—Panel 

Discussion 

Academia: Alice Villalobos, Texas A&M 

University, College Station, TX 

2:40 PM–3:00 PM Break 


3:00 PM to 5:00 PM 

Room 2A 

industry: Vanessa Silva, Procter & Gamble, 


government: Marquea King, U.S. EPA, 

Washington, DC 

Academic Program Session for Undergraduate 

Students 

Open time with Academic Toxicology Program Directors and 

Internship Sponsors 


7:00 PM–8:00 PM 

Room 601 

25–Year (Or More) Member Reception 

Have you been a member of the Society of Toxicology for 25 years (or 

more)? If so, please join your colleagues in celebration and recognition of 

the scientists who established the Society. (By Invitation Only) 


7:30 PM to 8:30 PM 

Sheraton Seattle Hotel 

Grand Ballroom C 


All students and postdoctoral fellows are invited to attend this reception. 

Refreshments will be provided by SOT and sponsors. A cash bar will also 

be available. Ticket and Meeting Badge are required. 


4:45 PM to 5:15 PM 

Ballroom 6A 

Award Ceremony Music Prelude 



5:15 PM to 6:30 PM 

Ballroom 6A 


Join us as SOT honors our prestigious award winners at the SOT Awards 

Ceremony. Please refer to the Awards and Fellowships section of the 

SOT Web site for complete details and the nominating form for next year. 



6:30 PM to 7:30 PM 



Continue the celebration by attending the Welcoming Reception following 

the Awards Ceremony. The Welcoming Reception is a great opportunity 

to renew old friendships and to make new acquaintances. Please join the 

Society in this kick-off of the Annual Meeting. (All Attendees Welcome) 

sat/sun 

86 




Monday 

Monday Morning, March 17 

7:30 AM to 2:00 PM 

Room 3A 

MONDAY MORNING 


Chairperson(s): Vicente Santa Cruz, CDI chair, Chevron Phillips 

Chemical Company, LP, The Woodlands, TX, and Mari Stavanja, RTR 

Tobacco Company, Winston-Salem, NC 

Sponsored by: 


This event is for undergraduate students and advisors receiving MARC and 

SOT travel funding, and SOT program volunteers. 

7:30 AM–8:10 AM Meeting for Students, Advisors, Peer Mentors, 

and SOT Hosts 

8:15 AM–9:15 AM Plenary Lecture (Exhibit Hall 4F) 

9:30 AM–11:15 AM Poster Session for Visiting Students 


11:15 AM–12:15 PM Selected Scientific Sessions 

12:15 PM–1:30 PM In Vitro Luncheon: Development of In Vitro 

Screening Tools to Test for Drug-Induced 

Mitochondrial Toxicities, Yvonne Will, Pfizer, 

Inc., San Diego, CA 

1:30 PM–2:00 PM Closing Session (Room 3A) 


8:15 AM to 9:15 AM 


Plenary Opening Lecture: Perspectives on Science 

in the 21 st Century 

Lecturer: Nobel Laureate Lee Hartwell, Fred Hutchinson Cancer 

Research Center, Seattle, WA 

Dr. Lee Hartwell didn’t realize as a boy that his 

youthful predilection for chasing butterflies hinted at 

his future as a geneticist. Nor did his teen-age 

tinkering on auto engines give him a clue that he 

would win a Nobel Prize. But today, his career’s work 

in cell genetics has changed the way we think about 

life itself. 

Early in his research career, Hartwell set out to find 

an organism simple enough to experiment on, yet 

complex enough to provide insight into humans. He 

made a risky choice: to use yeast, the same single-celled fungus that makes 

bread dough rise. At the time, most scientists thought yeast was not a good 

model for understanding the complexity of human cells. 

Hartwell persisted, and a series of experiments over several years led to 

a landmark discovery. He discovered the genes that control cell divisiongenes 

that turned out to be the universal machinery for cell growth in 

organisms from fungi to frogs to humans. 

This discovery in yeast not only showed the unity of all life, it also had 

practical applications for human health. 

By identifying “checkpoint” genes that determine whether a cell is dividing 

normally, Hartwell provided important clues to cancer, which arises from 

abnormal, uncontrolled cell growth. Hartwell’s discoveries have led him 

and other scientists to explore ways to stop abnormal cells from dividing. 

Researchers hope this work will lead to new and better ways to prevent, 

diagnose, and treat cancer. 

For his insightful discoveries, Hartwell received the 2001 Nobel Prize in 

Physiology or Medicine. 


9:30 AM to 11:15 AM 

Exhibit Hall 

Poster Session for Visiting Students 


Chemicals International N.V., Brussels, Belgium, and Mari Stavanja, 

RJR Tobacco Company, Winston Salem, NC 

Sponsored by: 


This poster session is part of the Undergraduate Education Program. All 

are welcome to view the specially selected presentations which provide an 

overview of research in toxicology and demonstrate the diversity within the 

discipline. 



Monday 


Abstract # Abstract # 


9:30 AM to 12:15 PM 

Room 6A 


9:30 AM to 12:15 PM 

Room 605 

SYMPOSIUM SESSION: METALS, MICROGLIA, AND 

NEUROINFLAMMATION 

Chairperson(s): David Lawrence, Wadsworth Center, Albany, NY and 

Michael Aschner, Vanderbilt University Medical Center, Nashville, TN. 

Endorsed by: 

Metals Specialty Section* 


The major immune cell that permanently resides within the brain parenchyma 

is the microglial cell. Current consensus suggests that microglia are 

derived from the hematopoietic monocyte lineage and that blood monocytes 

differentiate into perivascular macrophages which develop into microglia as 

they traffic into multiple brain regions. Another hematopoietic cell residing 

in the brain is the mast cell. Most other immune cells only transiently 

migrate through the brain. A major question that continues to be debated 

is whether neurotoxic metals directly activated immune cells within the 

brain that subsequently induce neuronal damage or whether metal toxicants 

induce neuronal damage, which subsequently activates the immune cells 

(mainly microglia) leading to exacerbated neuronal damage. An alternative 

hypothesis is that microglia are neuroprotective but metals cause loss 

of microglial protective factors because of microglial degeneration and/or 

elevated production of potential cytotoxicants. Numerous cytokines have 

been implicated in the neuroinflammation and neurodegeneration, but their 

cellular sources have not been fully delineated. The various neuroimmune 

mechanisms posited to regulate neuroinflammation, neuroprotection, and 

neuronal degeneration will be discussed. 

#13 9:30 METALS, MICROGLIA, AND 

NEUROINFLAMMATION. D. Lawrence. 

Wadsworth Center, Albany, NY. 

#14 9:40 ROLE OF MICROGLIA IN METAL 

NEUROTOXICITY. M. Aschner. Pediatrics, 

Vanderbilt University Medical Center, Nashville, TN. 

#15 10:15 POTENTIAL ROLE OF MICROGLIA IN 

MANGANESE NEUROTOXICITY. N. M. 

Filipov, P. L. Crittenden and S. Lee. CEHS, Basic 

Sciences, Mississippi State University, Mississippi 

State, MS. 

#16 10:50 LEAD AND MERCURY INDUCED 

NEUROIMMUNE CHANGES IN THE BRAIN. 

D. Lawrence 1 , J. Kasten-Jolly 1 , D. Gao 1 , T. Mondal 1 

and C. Hudson 2 . 1 Wadsworth Center, Albany, NY and 

2 

SUNY Upstate Medical University, Syracuse, NY. 

#17 11:25 MICROGLIAL ACTIVATION OR 

MICROGLIAL DEGENERATION? W. J. Streit. 

Neuroscience, University of Florida, Gainesville, FL. 

Sponsor: D. Lawrence. 

12:00 QUESTIONS FROM THE AUDIENCE. 

SYMPOSIUM SESSION: MOLECULAR BASIS FOR 

SUSCEPTIBILITY TO CHEMICAL TOXICITY AND DISEASE 

Chairperson(s): Ronald Hines, Medical College of Wisconsin, 

Milwaukee, WI and Jim MacGregor, Toxicology Consulting Services, 

Arnold, MD. 

Endorsed by: 





The completion of the Human Genome Project in 2003, and more recently, 

the first phase of the International HapMap project, have provided valuable 

tools which we are still learning how to use effectively in our goal to 

improve human health and prevent disease. For example, the cost-effective 

and rigorous ability to perform whole genome association studies for 

complex diseases has only been achieved within this past year. Although 

exciting and of clear utility in identifying multiple genetic loci whose variability 

will contribute to disease risk, such association studies still must be 

followed-up with more detailed analyses to understand the causative variants 

that contribute to differential susceptibility. Further, there now is widespread 

acceptance that most if not all complex disease arises because of an interaction 

between our genome and the environment. Thus, a careful assessment 

and definition of phenotype, including environmental exposure, is critical. 

We also now have clear examples wherein epigenetic changes caused by 

environmental factors, including transgenerational epigenetics changes, can 

also have a significant impact on disease risk. This symposium will provide 

state-of-the-art updates on our understanding of the molecular basis for individual 

differences in susceptibility to chemical toxicity and disease. Topics 

to be covered include how regulatory polymorphisms resulting in variation 

in gene expression can impact risk, chemical-induced epigenetic changes 

and their impact on susceptibility, the use of genetic variation to predict risk 

and efficacy during drug development and the use of pathway analyses to 

understand complex disease risk using Parkinson’s disease as an example. 

Thus, this symposium will span from fundamental, mechanistic studies, 

to translational investigations and clinical applications, demonstrating the 

strengths of an interdisciplinary approach to environmental health issues. 

#18 9:30 MOLECULAR BASIS FOR SUSCEPTIBILITY 

TO CHEMICAL TOXICITY AND DISEASE. R. 

Hines. Medical College of Wisconsin & Children’s 

Research Institute, Milwaukee, WI. 

#19 9:35 REGULATORY POLYMORPHISMS AND 

THEIR IMPACT ON SUSCEPTIBILITY. R. N. 

Hines. Pediatrics, Medical College of Wisconsin & 

Children’s Research Institute, Milwaukee, WI. 

#20 10:15 EPIGENETICS AND ITS IMPORTANCE IN 

TOXICOLOGY. R. L. Jirtle. Radiation Oncology, 

Duke University Medical Center, Durham, NC. 

#21 10:55 THE USE OF GENETIC VARIATION TO 

PREDICT RISK AND EFFICACY DURING 

DRUG DEVELOPMENT. A. D. Roses. Joseph 

and Kathleen Bryan Alzheimer’s Disease Research 

Center, Durham, NC. Sponsor: R. Hines. 

#22 11:35 A GENOMIC PATHWAY APPROACH 

TO COMPLEX DISEASES: PROMISE, 

PITFALLS, AND REMEDIES. D. Maraganore. 

Mayo Clinic College of Medicine, Rochester, MN. 

Sponsor: R. Hines. 

88 




Abstract # 


9:30 AM to 12:15 PM 

Room 6C 

SYMPOSIUM SESSION: NEW DEVELOPMENTS IN LIVER 

TUMOR BIOLOGY 

Chairperson(s): Ruth Roberts, AstraZeneca, UK, Macclesfield, United 

Kingdom and Yvonne Dragan, AstraZeneca Pharmaceuticals LP, 

Wilmington, DE. 

Endorsed by: 

Carcinogenesis Specialty Section* 



The liver is one of the most widely studied organs in cancer biology since 

it provides a flexible model for analysis of tumor biology that is amenable 

to in vitro and in vivo correlative approaches. Because of this, many 

other fields of cancer biology have been informed by data emerging from 

studies of the liver. Over the last decade, the inter-related roles between 

the pathways of apoptosis, cell survival and cell proliferation and their 

relevance to toxicology have been more rigorously described. Key to this 

is the interplay between ligand-activated transcription factors such as the 

peroxisome proliferators activated receptor α (PPARα) and the constitutively 

active/androstane receptor (CAR) and the networks that initiate and 

execute apoptosis. Against this background of knowledge, several new findings 

are particularly resonant. Specifically, increasing evidence suggests a 

pivotal role for epigenetic modification of DNA and its impact on survival 

and proliferation. Also of great relevance is the role played by the WNTsignalling 

pathway in cell signalling and tumorigenesis. Another recent and 

informative approach involves the use of comparative genomics of human 

and model organism hepatocellular carcinoma to identify aberrant phenotypes, 

reflecting molecular pathways that are evolutionarily conserved. This 

is further illustrated by use of a systems toxicology approach to analysis 

of liver tumors. This symposium brings together leading experts in human 

cancer biology and liver toxicology to provoke cross-fertilization of ideas 

and will be of interest both to non-experts looking to gain a greater understanding 

of tumor biology and those with a specific interest in the liver and 

mechanisms of carcinogenesis. 

#23 9:30 NEW DEVELOPMENTS IN LIVER TUMOR 

BIOLOGY. R. Roberts 1 and Y. Dragan 2 . 1 R&D 

Safety Assessment, AstraZeneca, Macclesfield, 

United Kingdom and 2 R&D Safety Assessment, 

AstraZeneca, Wilmington, DE. 

#24 9:35 THE ROLE OF CELL SURVIVAL 

SIGNALLING IN NORMAL AND TUMOR 

CELL BIOLOGY: LESSONS FROM LIVER. 

R. Roberts. Safety Assessment, AstraZeneca, 

Macclesfield, United Kingdom. 

#25 10:05 THE ROLE OF THE WNT PATHWAY AND 

b-CATENIN IN NORMAL AND TUMOR 

CELL BIOLOGY. S. A. Aaronson. Department 

of Oncological Sciences, Mount Sinai School of 

Medicine, New York. Sponsor: R. Roberts. 

#26 10:35 ORPHAN NUCLEAR RECEPTOR 

CONSTITUTIVE ACTIVE/ANDROSTANE 

RECEPTOR (CAR)-MEDIATED 

ALTERATIONS IN DNA METHYLATION 

DURING PHENOBARBITAL (PB) 

PROMOTION OF LIVER TUMORIGENESIS. 

J. I. Goodman 1 and J. M. Phillips 2 . 1 Pharmacology 

and Toxicology, Michigan State University, East 

Lansing, MI and 2 Biochemistry and Mollecular 

Biology, Michigan State University, East Lansing, 

MI. 

Abstract # 

#27 11:05 GENOMIC DECODING OF HUMAN LIVER 

CANCER. S. S. Thorgeirsson. Laboratory of 

Experimental Carcinogenesis, NCI, Bethesda, MD. 

Sponsor: R. Roberts. 

#28 11:35 SYSTEMS TOXICOLOGY: APPLICATIONS 

TO RAT MODELS OF CARCINOGENESIS. 

Y. Dragan 1 , R. Beger 2 , R. Edmondson 2 , J. Fuscoe 2 , 

H. Fang 2 and W. Tong 2 . 1 Safety Assessment-U.S., 

AstraZeneca, Wilmington, DE and 2 Systems 

Toxicology, NCTR/FDA, Jefferson, AR. 



9:30 AM to 12:15 PM 

Room 6B 

Nanotechnology 

SYMPOSIUM SESSION: PARTICLE INTERACTIONS WITH 

BIOMATERIALS: BEYOND OPSONIZATION 

Chairperson(s): JeanClare Seagrave, Lovelace Respiratory Research 

Institute, Albuquerque, NM and David Barber, University of Florida, 

Gainesville, FL. 

Endorsed by: 

Inhalation and Respiratory Specialty Section* 

Nanotoxicology Specialty Section 

Concern is increasing regarding the potential adverse health effects of 

materials in the nanoscale range, including both ambient air pollutants 

and manufactured nanoparticles. The extremely high surface area of these 

materials relative to their mass suggests the potential for interactions with 

biological molecules, resulting in either inactivation or local concentration 

of the biological materials. Nanomaterial surface properties, including 

charge, reactivity, hydrophobicity, and granularity, vary as a function of the 

source and chemical composition. There is, therefore, potential for some 

degree of selectivity in the interactions with biological materials, which may 

influence subsequent responses to the particles. This symposium focuses on 

recent investigations into these interactions and their biological implications. 

#29 9:30 INTRODUCTION. D. S. Barber. University of 

Florida, Gainesville, FL. 

#30 9:45 THE ADSORPTION OF BIOLOGICAL 

MACROMOLECULES BY COMBUSTION- 

DERIVED NANOPARTICLES. K. BéruBé 1 and 

T. Jones 2 . 1 School of Biosciences, Cardiff University, 

Cardiff, United Kingdom and 2 School of Earth, 

Ocean and Planetary Sciences, Cardiff University, 

Cardiff, United Kingdom. Sponsor: J. Seagrave. 

#31 10:15 USING PROTEOMIC ANALYSIS TO 

DETERMINE COMPETITIVE BINDING 

OF PROTEINS TO NANOPARTICLES. S. 

C. Wasdo. University of Florida, Gainesville, FL. 

Sponsor: D. Barber. 

#32 10:45 SURFACE PROPERTIES CONTROL 

INTERACTIONS WITH CYTOSKELETAL 

ELEMENTS. J. L. McGrath. Biomedical 

Engineering, University of Rochester, Rochester, NY. 

Sponsor: D. Barber. 

#33 11:15 MECHANISMS AND IMPLICATIONS OF 

PARTICLE/CHEMOKINE INTERACTIONS. 

J. Seagrave. Lovelace Respiratory Research Institute, 

Albuquerque, NM. 

Monday 



Monday 



#34 11:45 ROLE OF IRON SEQUESTRATION IN HOST 

RESPONSE TO PARTICLES AND FIBERS. A. 

J. Ghio. Human Studies Division, National Health 

and Environmental Effects Research Laboratory, 

U.S. Environmental Protection Agency, Research 

Triangle Park, NC. 


9:30 AM to 12:15 PM 

Room 611 

WORKSHOP SESSION: CURRENT PERSPECTIVES ON 

OCULAR AND SYSTEMIC SAFETY RISKS OF THERAPEUTICS 

Chairperson(s): Michael Aleo, Pfizer Global Research & Development, 

Groton, CT and Christopher Somps, Pfizer Global Research & 

Development, Groton, CT. 

Endorsed by: 



Ophthalmic safety risks can occur from systemically administered therapeutics 

while systemic safety risks can occur from ophthalmic therapeutics. 

Such adverse safety effects identified during the research, development, and 

marketing phase of a new therapeutic agent may drastically limit further 

progression or marketing depending upon: the nature and severity of the 

finding, the stage of development, the proposed indication for the new drug, 

therapeutic index, and relevance of the lesion to humans based on mechanistic 

elucidation. The goal of this symposium is to present the Yin and 

Yang of managing ocular safety risks of systemic therapeutics and systemic/ 

ocular safety risks of ophthalmic therapeutics in the pharmaceutical industry 

and potential methods for managing risks through mechanistic evaluation. 

Specific emphasis will be placed on the following concepts: 1) unexpected 

lenticular toxicity associated with therapeutic agents intended for systemic 

administration along with ways to screen potential back-up candidates 

and risk assessment strategies, 2) unintended systemic toxicity associated 

with therapeutic agents intended for ophthalmic administration, 3) newest 

concepts and challenges associated with the development of antisense, 

nanotechnology, and biologic-based therapeutics for ophthalmic indications, 

implantable ophthalmic delivery devices and special formulations for 

ophthalmic delivery and 4) a perspective on how such cases may be viewed 

by medical reviewers for regulatory agencies. As a workshop this course 

will promote interaction with the audience to share experiences in managing 

ocular/systemic safety risks in a pharmaceutical setting. 

#35 9:30 CURRENT PERSPECTIVES ON OCULAR 

AND SAFETY RISKS OF THERAPEUTICS. 

M. D. Aleo and C. A. Somps. Drug Safety R&D, 

Pfizer Global R&D, Groton, CT. 

#36 9:40 LENTICULAR TOXICITY OF SYSTEMIC 

THERAPEUTICS IN THE RAT: CASE STUDY 

AND MECHANISM-BASED SCREENING 

APPROACHES. M. D. Aleo. Drug Safety R&D, 

Pfizer Global R&D, Groton, CT. 

#37 10:10 LENTICULAR TOXICITY OF SYSTEMIC 

THERAPEUTICS IN THE DOG: CASE 

STUDY AND MECHANISM-BASED 

SCREENING APPLICATIONS. C. J. Somps. 

Drug Safety R&D, Pfizer, Groton, CT. 

#38 10:40 SYSTEMIC CONSIDERATIONS WITH 

OCULAR PHARMACOLOGIC THERAPIES. 

R. B. Bhisitkul. Department of Ophthalmology, 

UCSF, Beckman Vision Center, San Francisco, CA. 

Sponsor: M. Aleo. 

#39 11:10 NONCLINICAL STUDIES FOR 

OPHTHALMIC DRUG DEVELOPMENT. Z. 

Chen. U.S. FDA, Silver Spring, MD. Sponsor: M. 

Aleo. 

#40 11:40 STRATEGIES FOR NONCLINICAL SAFETY 

ASSESSMENT OF NOVEL OCULAR 

PRODUCTS. D. J. Kornbrust. Preclinsight, Reno, 

NV. Sponsor: M. Aleo. 


9:30 AM to 12:15 PM 

Room 608 

WORKSHOP SESSION: LLNA: FALSE POSITIVES, FALSE 

NEGATIVES, AND ALTERNATIVE ENDPOINTS 

Chairperson(s): David Basketter, DABMEB Consultancy, Bedford, United 

Kingdom and Ian Kimber, The University of Manchester, Manchester, 

United Kingdom. 

Endorsed by: 

Dermal Toxicology Specialty Section* 


The local lymph node assay (LLNA) is being used increasingly in the identification 

of skin sensitising chemicals for regulatory purposes. In the context 

of new chemicals legislation (REACH) in Europe, it is the preferred assay, 

as it is for an increasing number of regulations and regulatory agencies. An 

important part of the rationale for this is that the LLNA offers a quantitative 

and objective approach to skin sensitisation testing allied with the important 

animal welfare benefits. However, as with certain guinea pig sensitisation 

tests before it, this increasing use also brings experience with an increasingly 

diverse range of industrial and non-industrial chemicals where the 

outcome of the assay does not always necessarily meet with the expectations 

of those conducting it. Sometimes, the result appears to be a false negative, 

but recently more common has been the suggestion that some chemicals 

represent false positives. Typically, this situation can arise when the chemistry 

and guinea pig test history with similar materials suggests possible 

overestimation of the hazard. Against this background this session aims to 

review instances where false positive and false negative results have been 

described and will attempt to reconcile science with expectation. The consequences 

of confusion surrounding this subject will be considered in relation 

to efforts to produce valid non-radioactive endpoints for the LLNA as well 

as in the context of integrating potency measurement and risk assessments 

into classification and labelling schemes whose aim is to manage potential 

risks to human health. 

#41 9:30 THE LLNA, FALSE POSITIVES, FALSE 

NEGATIVES AND ALTERNATIVE 

ENDPOINTS. D. Basketter. St John’s Institute of 

Dermatology, St Thomas’ Hospital, London, United 

Kingdom. 

#42 9:45 THE LOCAL LYMPH NODE ASSAY: 

INTRODUCTION, CONDUCT AND 

PERFORMANCE. I. Kimber. Central Toxicology 

Laboratory, Syngenta, Cheshire, United Kingdom. 

#43 10:15 ALTERNATIVE METHODS AND 

ENDPOINTS IN “ENHANCED” LOCAL 

LYMPH NODE ASSAYS AND THE PHOTO- 

LLNA. G. L. DeGeorge. MB Research Laboratories, 

Spinnerstown, PA. 

#44 10:45 USE OF THE LOCAL LYMPH NODE 

ASSAY FOR SENSITIZATION HAZARD 

IDENTIFICATION: A FIVE-YEARS 

EXPERIENCE FROM A REGULATOR’S 

POINT OF VIEW. A. Oberemm, H. B. Richter- 

Reichhelm and U. Gundert-Remy. Safety of 

Substances and Preparations, Federal Institute for 

Risk Assessment, Berlin, Germany. Sponsor: D. 

Basketter. 

90 




Abstract # 

#45 11:15 DISCORDANT RESULTS BETWEEN 

THE LLNA AND GUINEA PIG TESTS: 

SPECIFICITY VS. SELECTIVITY. A. Mehling 2,9 , 

N. Ball 1,9 , H. Certa 8,9 , D. Eigler 6,9 , H. Esch 4,9 , C. 

Haux 3,9 , R. Kreiling 7,9 , K. Skirda 9 and G. Veenstra 5,9 . 

1 

Dow Europe GmbH, Horgen, Switzerland, 2 Cognis 

GmbH, Düsseldorf, Germany, 3 Akzo Nobel Surface 

Chemistry AB, Stenungsund, Sweden, 4 BASF AG, 

Ludwigshafen, Germany, 5 Shell International BV, 

The Hague, Netherlands, 6 Goldschmidt GmbH, 

Essen, Germany, 7 Clariant Produkte (Deutschland) 

GmbH, Sulzbach, Germany, 8 SASOL Germany 

GmbH, Marl, Germany and 9 CESIO, Brussels, 

Belgium. Sponsor: D. Basketter. 

#46 11:45 WHERE ARE WE NOW: TRUE AND FALSE 

POSITIVES AND NEGATIVES. D. A. Basketter. 

St John’s Institute of Dermatology, St Thomas’ 

Hospital, London, United Kingdom. 


9:30 AM to 12:15 PM 

Room 615 

PLATFORM SESSION: ADVANCING THE SCIENCE OF RISK 

ASSESSMENT 

Chairperson(s): Lynne Haber, Toxicology Excellence for Risk Assessment, 

Cincinnati, OH and Martha Moore, NCTR, AR. 

#47 9:30 COMPUTATIONAL TOOLS AND TESTING 

METHODS: DELIBERATIVE AND 

JUDICIOUS USE IN RISK ASSESSMENT. M. 

Mumtaz 1 , P. Ruiz 1 , W. Stokes 2 , H. Hansen 1 and C. De 

Rosa 1 . 1 Division of Toxicology and Environmental 

Medicine, ATSDR/CDC, Atlanta, GA and 

2 

NICEATM, NIEHS, RTP, NC. 

#48 9:49 MODULATION OF GENE EXPRESSION BY 

BTEX: RISK ASSESSMENT IMPLICATIONS. 

D. A. Sarigiannis, G. Cimino-Reale, E. Marafante, 

A. Collotta and A. Gotti. Institute for Health and 

Consumer Protection, European Commission - Joint 

Research Centre, Ispra, Italy. Sponsor: L. Birnbaum. 

#49 10:08 EXPLORING THE BOUNDARIES OF 

ADDITIVITY: MIXTURES OF NADH- 

QUINONE OXIDOREDUCTASE 

INHIBITORS. J. W. Boyd, J. B. Patrone, N. T. 

Boggs, H. T. Le and M. L. Theodore. Eisenhower 

Research Center, Johns Hopkins University Applied 

Physics Lab, Laurel, MD. Sponsor: M. Trush. 

#50 10:27 OPENREP: A COMMUNITY-BASED 

DELIBERATION PLATFORM FOR 

DEBATING DIOXIN AND DIOXIN-LIKE 

CHEMICAL TOXIC EQUIVALENCY DATA 

AND ASSIGNED FACTORS. L. D. Burgoon and 

T. R. Zacharewski. Toxicogenomic Informatics & 

Solutions, LLC, Lansing, MI. 

#51 10:46 A FRAMEWORK TO EVALUATE CHILD- 

ADULT DIFFERENCES IN INHALATION 

DOSIMETRY OF GASES: APPLICATION 

TO SELECTED SYSTEMICALLY-ACTING 

VOLATILE ORGANIC COMPOUNDS 

(VOCS). L. T. Haber 1 , R. Gentry 2 , T. Adamou 3 and 

K. Krishnan 3 . 1 TERA, Cincinnati, OH, 2 Environment 

Monroe, LA and 3 U Montreal, Montreal, QC, 

Canada. 

Abstract # 

#52 11:05 AGE-RELATED DIFFERENCES IN 

SUSCEPTIBILITY TO CARCINOGENESIS 

III. TENTATIVE CLASSIFICATION 

FOR AGENTS WITH PUTATIVE NON- 

GENETIC MODES OF ACTION, AND 

USE FOR ANALYSIS OF AGE-RELATED 

SUSCEPTIBILITY DIFFERENCES. D. Hattis 1 , 

M. Chu 2 and R. L. Goble 1 . 1 George Perkins Marsh 

Institute, Clark University, Worcester, MA and 

2 

NCEA, U.S. Environmental Protection Agency, 

Washington, DC. 

#53 11:24 TUMORS DERIVED FROM MANY 

DIFFERENT TISSUES MAY HAVE 

POLYCLONAL ORIGIN: EVIDENCE AND 

IMPLICATIONS. B. L. Parsons. Division of 

Genetic and Reproductive Toxicology, National 

Center for Toxicological Research, U.S. FDA, 

Jefferson, AR. 

#54 11:43 MODE OF ACTION (MOA) UNCERTAINTY 

FOR “DUAL MODE” CARCINOGENS: 

IMPACT ON RISK ESTIMATED FROM 

NAPHTHALENE-INDUCED NASAL 

TUMORS IN RATS. K. T. Bogen. Exponent Health 

& Environmental, Oakland, CA. Sponsor: G. Brorby. 

#55 11:59 RESEARCH STRATEGY TO BETTER 

INFORM THE DECISION AS TO WHETHER 

A CARCINOGEN IS A “MUTAGENIC 

CARCINOGEN” M. Moore, M. Manjanatha and R. 

Heflich. DGRT, NCTR, Jefferson, AR. 


9:30 AM to 12:15 PM 

Room 602 

Developmental Basis of Disease 

PLATFORM SESSION: ALTERED REPRODUCTIVE 

DEVELOPMENT 

Chairperson(s): Vickie Wilson, U.S. EPA, Research Triangle Park, NC. 

#56 9:30 FETAL TESTOSTERONE LEVELS ARE 

DIFFERENTIALLY AFFECTED IN MALE 

SPRAGUE DAWLEY AND WISTAR 

RATS AFTER IN UTERO EXPOSURE 

TO DIETHYLHEXYL PHTHALATE: A 

DOSE RESPONSE STUDY. V. S. Wilson, K. L. 

Howdeshell, C. S. Lambright, J. Furr and L. Gray. 

Reproductive Toxicology Division, U.S. EPA, ORD, 

NHEERL, RTP, NC. 

#57 9:54 INTERACTIVE EFFECTS OF DI-(2- 

ETHYLHEXYL) PHTHALATE AND 

DI-BUTYL PHTHALATE ON MALE RAT 

REPRODUCTIVE DEVELOPMENT: 

EFFECTS ON ANDROGENIC STATUS. A. J. 

Andrade 1 , G. Botelho 1 , G. Müller 2 , R. Morais 2 and 

P. Dalsenter 1 . 1 Pharmacology, Federal University of 

Paraná, Curitiba, Brazil and 2 Physiology, Federal 

University of Paraná, Curitiba, Brazil. Sponsor: E. 

Silbergeld. 

#58 10:18 DI-BUTYL PHTHALATE TARGETS 

MULTIPLE SIGNALING MECHANISMS TO 

DOWN-REGULATE FETAL TESTOSTERONE 

BIOSYNTHESIS. A. Kuhl and K. Gaido. The 

Hamner Institutes, Research Triangle Park, NC. 

Monday 



Monday 



#59 10:42 VINCLOZOLIN (V) INDUCES 

REPRODUCTIVE MALFORMATIONS AND 

INFERTILITY WHEN ADMINISTERED 

DURING SEXUAL BUT NOT GONADAL 

DIFFERENTIATION. L. E. Gray and J. Furr. 

ENDOCRINOLOGY BRANCH, NHEERL, ORD, 

U.S. EPA, Research Triangle Par, NC. 

#60 11:06 THE EFFECTS OF SUBACUTE ORAL 

EXPOSURE TO VINCLOZOLIN 

AND SEXUAL MATURITY 

ON 11b-HYDROXYSTEROID 

DEHYDROGENASE 2 ACTIVITY IN THE 

PORCINE TESTIS. T. J. Evans 1 , S. Talatum 2 , 

E. Walters 1 , Y. Agca 1 and V. Ganjam 2 . 1 Veterinary 

Pathobiology, University of Missouri, Columbia, MO 

and 2 Biomedical Sciences, University of Missouri, 

Columbia, MO. 

#61 11:29 AKT1 PARTICIPATES IN THYROID- 

DEPENDENT GROWTH OF THE 

PERIPUBERTAL TESTIS. M. Hixon, J. Santos 

Ahmed and T. Rasoulpour. Pathology, Brown 

University, Providence, RI. 

#62 11:52 PRENATAL AND LACTATIONAL 

EXPOSURE TO ETHINYLESTRADIOL, BUT 

NOT BISPHENOL A, ADVERSELY AFFECTS 

REPRODUCTIVE MORPHOLOGY AND 

SPERM PRODUCTION IN THE MALE LONG 

EVANS HOODED RAT. K. L. Howdeshell 1 , J. 

Furr 1 , C. R. Lambright 1 , V. S. Wilson 1 , B. C. Ryan 2,1 , 

A. K. Hotchkiss 2,1 and L. Gray 1 . 1 Reproductive 

Toxicology Division, U.S. EPA, Research Triangle 

Park, NC and 2 North Carolina State University/U.S. 

EPA Coop. #CT826512010, Raleigh, NC. 

#63 12:15 METABOLOMICS: APPLICATION 

TO THE STUDY OF PHTHALATES IN 

REPRODUCTION AND DEVELOPMENT. 

S. J. Sumner, R. Snyder, J. Burgess, C. Myers, R. 

Tyl, C. Sloan and T. Fennell. Health Sciences, RTI 

International, Research Triangle Park, NC. 


9:30 AM to 12:15 PM 

Room 6E 


PLATFORM SESSION: DEVELOPMENTAL 

IMMUNOTOXICOLOGY, HOST RESISTANCE AND GENOMICS 

Chairperson(s): Kathleen Gilbert, ACRHI/University of Arkansas for 

Medical Sciences, Little Rock, AR and Wimolnut Auttachoat, Virginia 

Commonwealth University, Richmond, VA. 

#64 9:30 IMMUNOSUPPRESSION BY TBTO 

REVEALED BY GENE EXPRESSION 

PROFILING IN VIVO AND IN VITRO. K. 

Baken 1,2 , J. Pennings 2 , H. van Steeg 2,3 and H. van 

Loveren 1,2 . 1 Health Risk Analysis and Toxicology 

(GRAT), Maastricht University, Maastricht, 

Netherlands, 2 Laboratory for Health Protection 

Research, National Institute for Public Health and the 

environment (RIVM), Bilthoven, Netherlands and 

3 

Toxicogenetics, Leiden University Medical Center 

(LUMC), Leiden, Netherlands. 

#65 9:54 OVERLAPPING GENE EXPRESSION 

PROFILES OF IMMUNOTOXIC MODEL 

COMPOUNDS. H. Van Loveren 1,2 , K. Baken 1,2 , J. 

Pennings 1 , H. Van Steeg 1,3 and T. Breit 4 . 1 Laboratory 

for Health Protection Research, National Institute 

for Public Health and the Environment (RIVM), 

Bilthoven, Netherlands, 2 Health Risk Analysis 

and Toxicology (GRAT), Maastricht University, 

Maastricht, Netherlands, 3 Toxicogenetics, Leiden 

University Medical Center (LUMC), Leiden, 

Netherlands and 4 MicroArray Department (MAD), 

University of Amsterdam, Amsterdam, Netherlands. 

#66 10:18 COMBINING TRANSCRIPTOMICS 

AND METABOLOMICS TO 

DELINEATE IMMUNOTOXICITY OF 

TRICHLOROETHYLENE. K. Gilbert 1 , B. 

Przybyla 1 , J. Fuscoe 2 , T. Han 2 , L. Schnackenberg 2 , 

N. Pumford 4 , J. Doss 3 , L. Macmillan-Crow 3 and S. 

Blossom 1 . 1 Arkansas Children’s Hospital Research 

Institute/ University of Arkansas for Medical 

Sciences, Little Rock, AR, 2 FDA-National Center for 

Toxicological Research, Jefferson, AR, 3 University of 

Arkansas for Medical Sciences, Little Rock, AR and 

4 

University of Arkansas, Fayetteville, AR. 

#67 10:42 JUVENILE DEVELOPMENTAL 

IMMUNOTOXICITY TESTING (DIT) IN SD 

RATS: EFFECT OF DEXAMETHASONE 

ON INFLUENZA VIRAL CLEARANCE, 

NK ACTIVITY, CTL ACTIVITY AND 

T-DEPENDENT VIRAL-SPECIFIC IGM AND 

IGG ANTIBODY PRODUCTION (TDAR). G. R. 

Burleson 1 , F. G. Burleson 1 and R. R. Dietert 1,2 . 1 BRT- 

Burleson Research Technologies, Inc., Morrisville, 

NC and 2 Cornell University, Ithaca, NY. 

#68 11:06 DEVELOPMENTAL AND EARLY LIFE 

EXPOSURE TO TRICHLOROETHYLENE 

PROMOTES AN AUTISTIC PHENOTYPE 

IN MRL+/+ MICE: POTENTIAL ROLE OF 

OXIDATIVE STRESS IN NEUROIMMUNE 

DYSFUNCTION. S. Blossom 1 , S. James 2 , S. L. 

Jernigan 2 and S. Melnyk 2 . 1 Pediatrics, Arkansas 

Children’s Hospital Research Institute, Little Rock, 

AR and 2 Pediatrics, Autism Metabolic and Genomics 

Laboratory at Arkansas Children’s Hospital Research 

Institute, Little Rock, AR. 

#69 11:30 BETA-NAPHTHOFLAVONE CAUSES 

AN AHR-DEPENDENT INHIBITION 

OF INVASION AND INTRACELLULAR 

MULTIPLICATION OF LISTERIA 

MONOCYTOGENES IN MURINE 

HEPATOCYTES. L. Z. Shi 1 , C. R. Jefcoate 2 

and C. J. Czuprynski 1 . 1 Pathobiological Sciences, 

University of Wisconsin-Madison, Madison, WI and 

2 

Phamacology, University of Wisconsin-Madison, 

Madison, WI. 

#70 11:53 A DEVELOPMENTAL IMMUNOTOXICITY 

STUDY IN THE JUVENILE RAT WITH 

CYCLOSPORIN. P. Barrow, F. Horand, P. Fant, J. 

Briffaux and L. Allais. MDS Pharmacology Services, 

St Germain sur l’Arbresle, France. 

92 




Abstract # 


9:30 AM to 12:15 PM 

Room 2A 

PLATFORM SESSION: ECOTOXICITY AND CHEMICAL 

EXPOSURE 

Chairperson(s): Chris Pritsos, University of Nevada, Reno, NV and Louis 

Trombetta, St. Johns University, New York, NY. 

#71 9:30 CHEMICAL TOXICITY DISTRIBUTIONS 

OF TRADITIONAL AND ALTERNATIVE 

ENDPOINTS: PARABEN EFFECTS TO 

AQUATIC ORGANISMS. L. Dobbins, T. W. 

Valenti, Jr, S. Usenko and B. W. Brooks. Baylor 

University, Waco, TX. 

#72 9:51 SYNERGY OF MALATHION AND DIAZINON 

MIXTURES IN RAINBOW TROUT. M. 

Hooper 1 , K. A. King 2 and C. E. Grue 2 . 1 Texas 

Tech University, Lubbock, TX and 2 University of 

Washington, Seattle, WA. Sponsor: T. Kavanagh. 

#73 10:12 CHOLINESTERASE INHIBITOR PESTICIDE 

EFFECTS ON REPRODUCTION AND 

NEONATAL DEVELOPMENT IN NON- 

TARGET AVIAN SPECIES. J. K. Moye 2 and 

C. A. Pritsos 1,2 . 1 Nutrition, University of Nevada, 

Reno, NV and 2 Environmental Sciences and Health 

Graduate Program, University of Nevada, Reno, NV. 

#74 10:33 MALE RAINBOW TROUT EXPOSED IN 

VIVO TO 17a–ETHYNYLESTRADIOL 

PRODUCE ANEUPLOID OFFSPRING. K. 

H. Brown 1,2 , J. G. Cloud 1,2 , I. R. Schultz 3 and J. J. 

Nagler 1,2 . 1 Biological Sciences, University of Idaho, 

Moscow, ID, 2 Center for Reproductive Biology, 

University of Idaho, Moscow, ID and 3 Marine 

Science Laboratory, Battelle PNNL, Sequim, WA. 

#75 10:54 CONGENER DISTRIBUTION OF 

POLYBROMINATED DIPHENYL ETHERS 

IN CHINOOK SALMON, LAKE TROUT, 

AND LAKE WHITEFISH FROM LAKE 

MICHIGAN. Y. Kuo 1 , M. Sepulveda 2 , T. Sutton 3 , 

H. Ochoa-Acuña 4 and I. Hua 1 . 1 School of Civil 

Engineering, Purdue University, West Lafayette, 

IN, 2 Department of Forestry and Natural Resources, 

Purdue University, West Lafayette, IN, 3 School of 

Fisheries and Ocean Sciences, University of Alaska 

Fairbanks, Fairbanks, AK and 4 Department of 

Comparative Pathobiology, Purdue University, West 

Lafayette, IN. Sponsor: G. Carlson. 

#76 11:15 IMPACT OF THIAMETHOXAM ON THE 

SERUM BIOCHEMICAL PARAMETERS 

IN CHANNA PUNCTATUS. V. R. Chintalapani. 

Biochemistry, Chaitanya Degree and P.G. College, 

Warangal, Andhrapradesh, India. Sponsor: C. chetty. 

#77 11:35 PARENTAL AND TRANSGENERATIONAL 

EFFECTS OF EXPOSURE TO 

ENVIRONMENTAL STEROIDS IN TROUT. I. 

R. Schultz 1 , K. Brown 2 and J. Nagler 2 . 1 Battelle PND, 

Sequim, WA and 2 Biological Sciences, Unversity of 

Idaho, Moscow, ID. 

#78 11:55 PHYSICO-CHEMICAL 

CHARACTERIZATION METHODS 

RELEVANT FOR TOXICOLOGICAL AND 

ECO-TOXICOLOGICAL EVALUATIONS OF 

NANOMATERIALS. C. M. Sayes, R. A. Hoke and 

D. B. Warheit. DuPont Haskell Laboratory, Newark, 

DE. 

Abstract # 


9:30 AM to 12:15 PM 

Room 618 

Oxidative Signaling AND Redox Biology 

PLATFORM SESSION: OXIDATIVE STRESS, DNA STRAND 

BREAKS, AND APPLICATIONS OF THE COMET ASSAY 

Chairperson(s): Jing Shi, Bioreliance, Rockville, MD and April Luke, 

University of North Carolina Chapel Hill, Chapel Hill, NC. 

#79 9:30 OXIDATIVE DNA DAMAGE AND ITS 

REPAIR IN THE SPLEENS OF RATS 

EXPOSED TO ANILINE. H. Ma 1 , J. Wang 1 , S. 

Abdel-Rahman 2 , P. Boor 1 and M. Khan 1 . 1 Pathology, 

University of Texas Medical Branch, Galveston, TX 

and 2 Preventive Medicine and Community Health, 

University of Texas Medical Branch, Galveston, TX. 

#80 9:58 CYTOTOXICITY, OXIDATIVE STRESS, 

AND GENOTOXICITY IN HUMAN LIVER 

CARCINOMA (HEPG2) CELLS EXPOSED 

TO DINITROTOLUENES. K. Y. Glass and P. 

B. Tchounwou. Biology, Jackson State University, 

Greenwood, MS. 

#81 10:26 3-METHYLINDOLE-INDUCED DNA 

DAMAGE IN PRIMARY NORMAL HUMAN 

BRONCHIAL EPITHELIAL CELLS. J. M. 

Weems and G. S. Yost. University of Utah, Salt Lake 

City, UT. 

#82 10:54 ASSESSMENT OF DNA DOUBLE-STRAND 

BREAKS AND gH2AX INDUCED BY THE 

TOPOISOMERASE II POISONS ETOPOSIDE 

AND MITOXANTRONE IN V79 CELLS. 

D. J. Smart 1 , K. Brunnemann 1 , D. Halicka 1 , Z. 

Darzynkiewicz 1 , G. Schmuck 2 and G. M. Williams 1 . 

1 

Department of Pathology, New York Medical 

College, Valhalla, NY and 2 Bayer HealthCare, 

Wuppertal, Germany. 

#83 11:21 DETECTION OF SINGLE STRAND BREAKS 

BY AN IMPROVED HYDROXYLAMINE 

COUPLED ALKALINE GEL 

ELECTROPHORESIS ASSAY. A. M. Luke 1 , J. 

A. Swenberg 1,2 and J. Nakamura 2 . 1 Curriculum in 

Toxicology, University of North Carolina, Chapel 

Hill, NC and 2 Department of Environmental Science 

and Engineering, University of North Carolina, 

Chapel Hill, NC. 

#84 11:48 COUPLING CYTOTOXIC BIOMARKERS 

WITH GENOTOXICITY TESTS. J. Shi, S. 

Bruce, M. Scherer, J. Sly, K. Pant and P. Escobar. 

Genetic Toxicology, BioReliance Corporation, 

Rockville, MD. Sponsor: S. Shah. 

Monday 



Monday 




9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: ENDOCRINE MECHANISMS OF TOXICITY 

Chairperson(s): Tammy Stoker, U.S. EPA, Research Triangle Park, NC 

and Karen Porter, U.S. Army, Frederick, MD. 

Displayed: 9:30 AM–12:30 PM 

Attended: 9:30 AM–11:00 AM 

#85 Poster Board Number.......................................101 

SODIUM DIMETHYLDITHIOCARBAMATE 

(DMDC) EFFECTS ON GNRH NEURONAL 

ACTIVATION AND THE LUTEINIZING 

HORMONE SURGE. J. M. Goldman, A. S. Murr, 

R. L. Cooper and A. R. Buckalew. Endocrinol. Br., 

RTD, NHEERL, ORD, U.S. EPA, Res. Triangle Pk., 

NC. 


DECREASED INSULIN SECRETION IN 

MURINE PANCREATIC BETA CELLS 

EXPOSED TO FLUORIDE. E. A. García- 

Montalvo and L. M. Del Razo. Toxicology, 

Cinvestav-IPN, Mexico D.F, Mexico. 


DEVELOPMENT OF A RAT PRIMARY 

LEYDIG CELL ASSAY FOR DETECTION OF 

POTENTIAL ENDOCRINE SIDE EFFECTS. 

R. Hernandez 1 , A. Fosdick 2 , R. Hu 1 , M. Higgins 1 , 

B. Han 2 , H. Hamadeh 1 , C. Afshari 1 and R. T. Dunn 1 . 

1 

Investigative Toxicology, Amgen Inc, Thousand 

Oaks, CA and 2 Toxicology, Amgen Inc, Thousand 

Oaks, CA. 


THE EPIDERMAL GROWTH FACTOR 

RECEPTOR AS A POTENTIAL TARGET FOR 

OBESITY. M. Weed 1,2 , C. W. Barrick 1,2 , T. Lee 2 

and D. W. Threadgill 2,1 . 1 Curriculum in Toxicology, 

University of North Carolina, Chapel Hill, NC 

and 2 Department of Genetics, University of North 

Carolina, Chapel Hill, NC. 


ENDOCRINE TOXICITY OF NITRATE/ 

NITRITE. B. S. Reeves and G. A. LeBlanc. 

Environmental and Molecular Toxicology, North 

Carolina State University, Raleigh, NC. 


IPRODIONE DELAYS MALE RAT 

PUBERTAL DEVELOPMENT, REDUCING 

SERUM TESTOSTERONE AND EX VIVO 

TESTOSTERONE PRODUCTION. C. R. 

Blystone 1,2 , C. S. Lambright 2 , M. C. Cardon 2 , J. Furr 2 , 

V. S. Wilson 2 and L. E. Gray 2 . 1 Molecular Biomedical 

Sciences, NC State University, Raleigh, NC and 

2 


NHEERL, Research Triangle Park, NC. 


MICROPLATE EDGE EFFECTS IN RANGE 

FINDING STUDIES USING THE LUMI- 

CELL ® ER BIOASSAY: INCREASING ASSAY 

THROUGHPUT. J. D. Gordon 1 , M. S. Denison 2 , 

A. C. Chu 1 , M. D. Chu 3 , C. M. Matherly 1 and G. 

C. Clark 1 . 1 Xenobiotic Detection Systems, Inc., 

Durham, NC, 2 Department of Environmental 

Toxicology, University of California Davis, Davis, 

CA and 3 Analytical Perspectives, Wilmington, NC. 


EVALUATING DRUG-INDUCED THYROID 

EFFECTS AND SPECIES DIFFERENCES 

USING IN VITRO THYROID CULTURE 

MODELS IN RAT AND HUMAN. J. R. Sinclair 1 , 

S. R. Morris 1 , J. T. Heale 1 , W. Way 1 , R. L. Fisher 2 and 

A. E. Vickers 1 . 1 Allergan, Inc., Irvine, CA and 2 Vitron 

Inc., Tucson, AZ. 


TRICLOSAN ALTERS THYROID HORMONE 

HOMEOSTASIS VIA UP-REGULATION 

OF HEPATIC CATABOLISM. K. B. Paul 1 , 

J. M. Hedge 2 , K. M. Crofton 2 and M. J. DeVito 3 . 

1 

Curriculum in Toxicology, University of North 

Carolina, Chapel Hill, NC, 2 Neurotoxicology 

Division, NHEERL, ORD, U.S. EPA, RTP, NC and 

3 

Experimental Toxicology Division, NHEERL, ORD, 

U.S. EPA, RTP, NC. 


EFFECT OF TRICLOSAN ON 

THYROID FUNCTION AND PUBERTAL 

DEVELOPMENT IN THE MALE WISTAR 

RAT. L. Zorrilla 2,1 , R. Cooper 1 , S. Jeffay 1 , E. Gibson 1 

and T. Stoker 1 . 1 Endocrinology, U.S. EPA, Research 

Triangle Park, NC and 2 North Carolina State 

University, Raleigh, NC. 


EFFECT OF A PERI-JUVENILLE EXPOSURE 

OF 2, 4-DICHLOROPHENOXYACETIC ACID 

(2, 4-D) ON THYROID FUNCTION AND 

REPRODUCTIVE DEVELOPMENT IN THE 

MALE WISTAR RAT. T. Stoker 1 , L. Zorrilla 2,1 , S. 

Jeffay 1 , R. Cooper 1 and E. Gibson 1 . 1 Endocrinology 

Branch, U.S. EPA, Research Triangle Park, NC and 

2 

North Carolina State University, Raleigh, NC. 


EFFECTS OF ATRAZINE (ATR), 

DEISOPROPYLATRAZINE (DIA), AND 

DIAMINOCHLOROTRIAZINE (DACT) 

ON THE HYPOTHALAMIC-PITUITARY- 

ADRENAL (HPA) AXIS IN FEMALE RATS. M. 

P. Fraites, S. C. Laws, J. Ferrell, A. Buckalew and R. 

Cooper. ORD, NHEERL, U.S. EPA, RTP, NC. 


EFFECT OF ACRYLAMIDE ON THE 

HYPOTHALAMIC-PITUITARY-THRYOID 

AXIS: GENOMIC, HORMONAL, AND 

HISTOLOGICAL INVESTIGATIONS IN 

MALE F344 RATS. D. R. Doerge 1 , J. F. Bowyer 2 , 

J. R. Latendresse 3 , L. Muskhelishvili 3 and E. 

Tareke 4 . 1 Biochem. Toxicol., NCTR, Jefferson, 

AR, 2 Neurotoxicology, NCTR, Jefferson, AR, 

3 

Toxicologic Pathology Associates, NCTR, Jefferson, 

AR and 4 Personalized Nutrition and Medicine, 

NCTR, Jefferson, AR. 

94 




Abstract # 


THYROID HORMONE STATUS IN 

ADULT RATS AFTER AN ORAL DOSE 

OF PERFLUOROBUTYRATE (PFBA). S. 

Chang 1 , J. A. Hart 1 , D. J. Ehresman 1 , T. N. John 2 , 

A. T. Eveland 2 , J. D. Zitzow 2 and J. L. Butenhoff 1 . 

1 

3M Company, St. Paul, MN and 2 Pace Analytical 

Services, Inc., Minneapolis, MN. 


THE EFFECT OF SULFATHIAZOLE ON 

THYROID-PITUITARY HORMONAL 

SYSTEM IN PREPUBERTAL RATS AND IN 

RAT PITUITARY AND HELA-TRE CELLS. S. 

Jeong, B. Choi, J. Jang, E. Kim, J. Kang, G. Chung, 

H. Kang and J. Cho. Toxicology, Nat’l Vet Res & 

Quarant Service, Anyang, South Korea. 


IN VITRO METABOLISM OF THYROID 

HORMONES BY RECOMBINANT HUMAN 

UDP-GLUCORONOSYLTRANSFERASES 

AND SULFOTRANSFERASES. V. Richardson 

and M. DeVito. U.S. EPA, RTP, NC. 


EFFECTS ON HEPATIC DEIODINASE 1 

AND THYROID HORMONE LEVELS IN 

PERINATALLY EXPOSED RATS TO A PBDE 

COMMERCIAL MIXTURE. D. T. Szabo 1,2 , V. M. 

Richardson 2 , J. J. Diliberto 2 , D. Ross 2 , P. Kodavanti 3 

and L. S. Birnbaum 2,1 . 1 Curriculum in Toxicology, 

University of North Carolina - Chapel Hill, Durham, 

NC, 2 ORD/NHEERL/ETD, U.S. EPA, RTP, NC and 

3 

ORD/NHEERL/NTD, U.S. EPA, RTP, NC. 


A 10-DAY STUDY COMPARING 

THE EFFICACY AND TOXICITY OF 

GLYCOPEGYLATED AND NON- 

GLYCOPEGYLATE HGH FOLLOWING 

SUBCUTANEOUS ADMINISTRATION IN 

HYPOPHYSECTOMIZED FEMALE RATS. S. 

Matalonis 2 , C. Bowe 2 , A. Scott 2 , R. Xing 2 , B. Wu 2 , 

K. Johnson 2 , S. DeFrees 2 , D. Zopf 2 , S. Godin 1 and E. 

Koo 1 . 1 Bridge Global Pharmaceutical Services, Inc., 

Gaithersburg, MD and 2 Neose Technologies, Inc., 

Horsham, PA. 


EFFECTS OF 4-TERT-OCTYLPHENOL ON 

XENOPUS TROPICALIS IN A LONG TERM 

EXPOSURE. K. Porter 1 , A. W. Olmstead 2 , D. 

M. Kumsher 1 , W. E. Dennis 1 , G. W. Holcombe 2 , 

J. J. Korte 2 , A. Lindberg-Livingston 2 and S. J. 

Degitz 2 . 1 U.S. Army Center for Environmental 

Health Research, Fort Detrick, MD and 2 U.S. EPA 

National Health and Environmental Effects Research 

Laboratory, Mid-Continent Ecology Division, 

Duluth, MN. 


EFFECT OF ARSENIC ON ESTROGEN 

STIMULATED PROLIFERATION IN HUMAN 

BREAST TUMOR-DERIVED T47D CELLS. 

Y. Zang, W. H. Watson and J. D. Yager. Department 

of Environmental Health Sciences, Division of 

Toxicology, Johns Hopkins Bloomberg School of 

Public Health, Baltimore, MD. 

Abstract # 


MEASUREMENT OF MULTIPLE TYPES OF 

ENDOCRINE ACTIVITIES IN WATER. M. 

Heringa 1 , S. van der Linden 2 , B. van der Burg 2 and 

L. Puijker 1 . 1 Kiwa Water Research, Nieuwegein, 

Netherlands and 2 BioDetection Systems, Amsterdam, 

Netherlands. 


DEVELOPMENT OF AN AMPHIBIAN 

LIFE CYCLE ASSAY FOR ENDOCRINE 

DISRUPTOR TESTING. A. W. Olmstead, J. 

Korte, G. Holcombe, P. Kosian, B. Bennett, K. 

Woodis, S. Ostazeski, A. Lindberg-Livingston, 

I. Leland and S. Degitz. Mid-Continent Ecology 

Division, U.S. EPA, NHEERL, Duluth, MN. 

Sponsor: M. Hornung. 


USE OF A NOVEL MICROPLATE 

READER-BASED HIGH-THROUGHPUT 

ESTROGEN RECEPTOR BINDING ASSAY 

IN PREDICTING COMBINATION EFFECTS. 

H. Gurer-Orhan 1 , T. Backhaus 2 and J. N. Meerman 3 . 

1 

Toxicology, Ege University, Faculty of Pharmacy, 

Izmir, Turkey, 2 Biology and Chemistry, Institute 

for Cell Biology, University of Bremen, Bremen, 

Germany and 3 Pharmacochemistry, LACDR, 

Division of Molecular Toxicology, Vrije Universiteit, 

Amsterdam, Netherlands. Sponsor: A. Karakaya. 


IN VITRO EFFECTS OF ESTRADIOL 

PRESENT IN COW’S MILK DETERMINED 

WITH MICROARRAYS AND A CO-CULTURE 

SYSTEM OF CACO-2 AND MCF-7 CELLS. 

D. Scholten 1 , M. Heneweer 2 , V. J. Schulz 1,2 , M. van 

den Berg 1 , A. A. Bergwerff 1 and M. B. van Duursen 1 . 

1 

Toxicology division, Institute for Risk Assessment 

Sciences, Utrecht, Netherlands and 2 Rikilt Institute of 

Food Safety, Wageningen, Netherlands. 


9:30 AM to 12:30 PM 

Exhibit Hall 


POSTER SESSION: OXIDATIVE STRESS MECHANISMS IN 

CHEMICAL CARCINOGENESIS 

Chairperson(s): Jill Harvilchuck, Purdue University, West Lafayette, IN. 


Attended: 11:00 AM–12:30 PM 


COMPARISON OF ACRYLONITRILE- 

INDUCED OXIDATIVE DNA DAMAGE 

IN CULTURED RAT AND HUMAN 

ASTROCYTES. X. Pu, L. M. Kamendulis and J. 

E. Klaunig. Pharmacology and Toxicology, Indiana 

University, Indianapolis, IN. 


GENDER DISPARITY IN EARLY 

OCHRATOXIN A MEDIATED RENAL 

TOXICITY. D. R. Dietrich and K. Stemmer. Human 

and Environmental Toxicology, University of 

Konstanz, Konstanz, Germany. 

Monday 



Monday 




EXPRESSION OF CYCLINS AND CYCLIN- 

DEPENDENT KINASES IN RAT SPLEEN 

FOLLOWING ANILINE EXPOSURE. J. Wang, 

G. Wang and M. Khan. Pathology, University of 

Texas Medical Branch, Galveston, TX. 


PROPICONAZOLE-INDUCED 

CARCINOGENESIS: ROLE OF OXIDATIVE 

STRESS. M. E. Bruno, P. Chen, T. Moore, S. 

Nesnow and Y. Ge. EPA, Research Triangle Park, 

NC. 


MECHANISTIC STUDY ON 

HEPATOCARCINOGENESIS OF PIPERONYL 

BUTOXIDE IN MICE. M. Kawai, Y. Saegusa, 

M. Jin, J. Nishimura, Y. Dewa, M. Shibutani and 

K. Mitsumori. Laboratory of veterinary pathology, 

Tokyouniversity of agriculture and technology, 

Fucyu city, Tokyo, Japan. Sponsor: M. Takahashi. 


PROTEIN DAMAGE FROM OXIDATIVE 

STRESS ACCUMULATES IN LUNGS OF 

MICE EXPOSED TO ELECTROPHILIC 

TUMOR PROMOTERS DERIVED FROM 

BHT. C. T. Shearn and J. Thompson. Pharmaceutical 

Sciences, UCHSC, Denver, CO. 


ALTERATION OF AIRWAY EPITHELIAL 

HOMEOSTASIS BY VANADIUM PENTOXIDE 

(VO). Y. Zhao 1 , L. Zhu 1 , D. M. Walters 2 , S. 

Kleeberger 2 and Y. Chen 1 . 1 Translational biology, 

Institutes for Health Sciences, Research Triangle 

Park, NC and 2 National Institute of Environmental 

Health Sciences, RTP, NC. 


LUNG TUMOR PROMOTION BY 

CURCUMIN. M. S. Miller, S. T. Dance, N. D. 

Kock, J. E. Moore, R. B. D’Agostino, Jr., L. J. 

Mosley and A. J. Townsend. Wake Forest University 

School of Medicine, Winston-Salem, NC. 


CC10 mRNA AND PROTEIN EXPRESSION 

IN CLARA CELLS OF CD-1 MICE 

FOLLOWING EXPOSURE TO STYRENE OR 

ITS METABOLITES STYRENE OXIDE OR 

4-VINYLPHENOL. J. Harvilchuck, R. Zurbrugg 

and G. Carlson. Health Sciences, Purdue University, 

West Lafayette, IN. 


EFFECTS OF ESTRADIOL ON TCDD- 

INDUCED OXIDATIVE STRESS IN LIVER 

CELLS. M. Goettel 1 , M. Chagnon 2 and D. Schrenk 1 . 

1 

Food Chemistry and Toxicology, University of 

Kaiserslautern, Kaiserslautern, Germany and 2 Food 

Toxicology, ENSBANA, University of Burgundy, 

Dijon, France. 


CHEMOPREVENTION OF 

GASTROESOPHAGEAL REFLUX-INDUCED 

ESOPHAGEAL ADENOCACINOMA BY 

a-TOCOPHEROL, N-ACETELCYSTEINE, 

AND OMEPRAZOLE IN RAT MODEL. J. 

Hao 1 , B. Zhang 2 , B. Liu 1 , M. Li 1 , X. Chen 2 and 

C. Yang 1 . 1 Joint Graduate Program in Toxicology, 

Department of Chemical Biology, Ernest Mario 

School of Pharmacy, Rutgers, the State University of 

New Jersey, Piscataway, NJ and 2 Cancer Research 

Program, L. Chambers Biomedical/Biotechnology 

Research Institute, North Carolina Central 

University, Durham, NC. 


CHARACTERIZATION OF GLUTATHIONE 

S-TRANSFERASE ALPHA 4 (GSTA4) AS 

A MODIFIER OF TUMOR PROMOTION 

SUSCEPTIBILITY IN THE MOUSE TWO- 

STAGE SKIN CARCINOGENESIS MODEL. 

E. L. Abel, J. M. Angel, P. K. Riggs, L. Elizondo and 

J. DiGiovanni. Carcinogenesis, The University of 

Texas MD Anderson Cancer Center—Science Park- 

Research Division, Smithville, TX. 


THE ROLE OF KUPFFER CELLS IN 

ETHANOL-INDUCED HEPATOCELLULAR 

GROWTH. S. M. Corthals, S. E. Owumi, Z. Wang, 

J. E. Klaunig and L. M. Kamendulis. Pharmacology 

and Toxicology, Indiana University School of 

Medicine, Indianapolis, IN. 


LONG-TERM, LOW-LEVEL 

EXPOSURE OF UROTSA CELLS TO 

MONOMETHYLARSONOUS ACID 

PRODUCES PROTEIN CARBONYL 

MODIFICATIONS AND OXIDATIVE 

DAMAGE TO DNA. S. M. Wnek, K. E. Eblin, D. 

W. Cromey and A. J. Gandolfi. Pharmacology and 

Toxicology, University of Arizona, Tucson, AZ. 


CHRONIC EXPOSURE TO 

MONOMETHYLARSONOUS ACID INDUCES 

CHANGES IN HUMAN UROTSA CELLS 

CONSISTENT WITH UROTHELIAL 

TUMORIGENESIS. S. Buffington, K. Eblin, 

X. Zheng and A. Gandolfi. University of Arizona, 

Tucson, AZ. 


PROTECTIVE EFFECTS OF BLACK TEA ON 

OXIDATIVE DAMAGE IN HUMANS. Z. Wang, 

J. Meng, Z. Jiao, Y. Xu, L. M. Kamendulis and J. 

E. Klaunig. Pharmacology and Toxicology, Indiana 

University School of Medicine, Indianapolis, IN. 

96 




Abstract # 


9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: CHEMICAL AND BIOLOGICAL WEAPONS 

Chairperson(s): Alan Brimfield, USAMRICD, Aberdeen Proving Ground, 

MD and Heather Floyd, U.S. EPA, Research Triangle Park, NC. 


Attended: 9:30 AM –11:00 AM 


KINETICS OF SUBCUTANEOUS EXPOSURE 

TO SUB-LETHAL VX, GF AND GB DOSES 

IN GUINEA PIG. C. E. Whalley 1 , L. A. 

Lumley 2 , J. M. McGuire 1 , C. Robison 2 , T. Ward 2 , 

B. Somsamayvong 2 , E. M. Jakubowski 1 , R. J. 

Mioduszewski 1 , T. M. Shih 2 and S. A. Thomson 1 . 

1 

ECBC, APG, MD and 2 USAMRICD, APG, MD. 


POST-EXPOSURE PROTECTION AGAINST 

SOMAN-INDUCED LETHALITY WITHOUT 

CARBAMATE PRETREATMENT IN GUINEA 

PIGS. S. DeBus, D. Spriggs and F. Chang. 

USAMRICD, Edgewood, MD. Sponsor: W. Smith. 


PHYSIOLOGICALLY-BASED MODELING 

OF NEUROTHERAPEUTICS. E. A. Merrill, 

P. J. Robinson and J. M. Gearhart. AFRL, Applied 

Biotechnology Branch, HJF, Wright-Patterson AFB, 

OH. 


SIMULATION OF VX EXPOSURE 

IN MULTIPLE SPECIES BY 

MEANS OF A PHYSIOLOGICALLY 

BASED PHARMACOKINETIC/ 

PHARMACODYNAMIC MODEL (PBPK/PD). 

J. Gearhart 1 , P. Robinson 1 , C. Whalley 2 , J. McGuire 2 , 

R. Evans 2 , S. Hulet 2 , C. Byers 2 and E. Jakubowski 2 . 

1 

AFRL/HEPB, Henry M. Jackson Foundation, 

Wright-Patterson Air Force Base, OH and 2 U.S. 

Army ECBC, Edgewood, MD. 


A PHYSIOLOGICALLY-BASED 

DEPOSITION, CLEARANCE, AND 

SYSTEMIC BIOKINETIC MODEL OF 

INHALED BACILLUS ANTHRACIS SPORES. 

E. Hack 1 , B. Gutting 3 , P. Robinson 1 , T. Nichols 2 , G. 

Andrews 3 and J. Gearhart 1 . 1 HJF AFRL, Wright- 

Patterson AFB, OH, 2 U.S. EPA, Cincinnati, OH and 

3 

NAVSEA, Dahlgren, VA. 


COMPARATIVE HEMATOTOXICITY 

OF HEXAHYDRO-1, 3, 5-TRINITRO-1, 

3, 5-TRIAZINE (RDX) VS. MONO- AND 

TRI-NITROSO ENVIRONMENTAL 

DEGRADATION PRODUCTS MNX AND TNX. 

M. S. Wilbanks 1 , S. Reeves 1 , L. Escalon 2 , E. J. 

Perkins 3 and S. A. Meyer 1 . 1 Toxicology, University 

Louisiana-Monroe, Monroe, LA, 2 SpecPro, 

Vicksburg, MS and 3 ERDC, U.S. Army Corps of 

Engineers, Vicksburg, MS. 

Abstract # 


KINEMATIC EVALUATION OF MOTOR 

IMPAIRMENT AND RECOVERY OF 

FUNCTION FOLLOWING SOMAN 

EXPOSURE IN A RAT MODEL. L. Lumley, C. 

Robison, S. Estes, S. Parylak, J. Kraft, T. Ward, K. 

Kamberger, S. Johnson and T. Shih. USAMRICD, 

Aberdeen Proving Ground, MD. 


PREDICTABILITY AND RELIABILITY 

OF THE UP-AND-DOWN METHOD 

FOR DETERMINING LD50 VALUES 

FOR CHEMICALS WITH STEEP DOSE- 

RESPONSE CURVES: AN ANALYSIS OF 

INTRAVENOUS VX TOXICITY IN THE 

GOTTINGEN MINIPIG. S. W. Hulet, D. R. 

Sommerville, B. J. Benton, J. A. Scotto, D. C. 

Burnett, R. J. Mioduszewski and S. A. Thomson. 

Toxicology, U.S. Army ECBC, Aberdeen Proving 

Grounds, MD. 


EFFICACY OF NOVEL PYRIDINIUM 

OXIMES TO REACTIVATE RAT 

BRAIN AND RED BLOOD CELL 

ACETYLCHOLINESTERASE INHIBITED 

BY ORGANOPHOSPHATES. E. C. Meek 1 , H. 

W. Chambers 2 , J. S. Manion 1 and J. E. Chambers 1 . 

1 

Center for Environmental Health Sciences, 

Mississippi State University, Mississippi State, MS 

and 2 Department of Entomology, Mississippi State 

University, Mississippi State, MS. 


A SULFUR MUSTARD AND THERMAL 

SUPERFICIAL DERMAL INJURY PIG 

MODEL. F. M. Reid 1 , R. C. Kiser 1 , W. E. Hart 1 , 

E. E. McGuinness 1 , J. Mann 1 and J. S. Graham 2 . 

1 

Biomedical Research Center, Battelle, West 

Jefferson, OH and 2 Medical Toxicology Branch, 

U.S. Army Medical Research Institute of Chemical 

Defense, APG, MD. 


MECHANISM OF INHIBITION OF 

THIOREDOXIN REDUCTASE IN LUNG 

EPITHELIAL CELLS BY THE VESICANT 

2-CHLOROETHYL ETHYL SULFIDE. Y. 

Jan 1 , J. P. Gray 1 , A. T. Black 1 , D. R. Gerecke 1 , 

R. P. Casillas 2 , D. L. Laskin 1 and J. D. Laskin 3 . 

1 

Pharmacology & Toxicology, Rutgers University, 

Piscataway, NJ, 2 Biomedical Science and 

Technology, Battelle Biomedical Research Center, 

Columbus, OH and 3 Environmental & Occupational 

Medicine, UMDNJ-Robert Wood Johnson Medical 

School, Piscataway, NJ. 


RADIATION PROTECTION AGAINST 

EARLY AND LATE EFFECTS OF IONIZING 

RADIATION BY GENISTEIN. M. R. Landauer 1 , 

M. Barshishat-Kupper 2 , S. R. Mog 1 , E. A. McCart 1 , 

P. G. Prasanna 1 , T. A. Davis 3 and R. M. Day 2 . 1 Armed 

Forces Radiobiology Research Institute, Bethesda, 

MD, 2 Uniformed Services University, Bethesda, MD 

and 3 Naval Medical Research Center, Bethesda, MD. 

Monday 



Monday 




ACUTE TOXIC EFFECTS OF VX VAPOR 

IN RATS – INTERACTIONS OF EXPOSURE 

CONCENTRATION AND DURATION. L. Foo, 

W. Sew, M. Ho and W. Loke. Defence Medical & 

Environmental Research Institute, DSO National 

Laboratories, Singapore, Singapore. Sponsor: T. Shih. 


QUANTITATION OF THE 

BIOMARKER ETHYL 

METHYLPHOSPHONOFLUORIDATE IN 

RED BLOOD CELLS FOLLOWING AN 

ACCIDENTAL EXPOSURE TO THE NERVE 

AGENT VX. J. McGuire, J. T. Taylor, C. Byers, E. 

M. Jakubowski and S. Thomson. U.S. Army ECBC, 

APG, MD. 


EFFICACY COMPARISON OF RSDL, 

M291 SDK, 0.5% BLEACH AND 1% SOAPY 

WATER CHALLENGED WITH SOMAN, 

CYCLOSARIN, VX, AND RUSSIAN VX. E. H. 

Braue, B. F. Doxzon, K. A. Hanssen, H. L. Lumpkin, 

M. A. Sigler and E. Clarkson. Analytical Toxicology 

Division, U.S. Army Medical Research Institute of 

Chemical Defense, Aberdeen Proving Ground, MD. 

Sponsor: A. Sciuto. 


DEVELOPMENT OF SELECTIVE 

NANOPOROUS SORBENTS FOR 

RADIONUCLIDE DEPORPORATION. W. 

Yantasee, R. S. Addleman, G. E. Fryxell and C. 

Timchalk. Pacific Northwest National Laboratory, 

Richland, WA. 


SUB-ACUTE SARIN EXPOSURE 

TRIGGERS NEUROCHEMICAL AND 

NEUROPATHOLOGICAL CHANGES IN THE 

RAT BRAIN. M. B. Abou-Donia 1 , A. K. Shetty 2 and 

A. A. Abdel-Rahman 1 . 1 Pharmacology and Cancer 

Biology, Duke University Medical Center, Durham, 

NC and 2 Department of Surgery, Duke University 

Medical Center, Durham, NC. 


EFFECTIVENESS OF RSDL TOPICAL 

SKIN DECONTAMINANT AT REDUCING 

MORTALITY IN RATS WHOLE-BODY 

EXPOSED TO VX VAPOR. B. J. Benton 1 , D. 

R. Sommerville 2 , R. J. Mioduszewski 1 and S. A. 

Thomson 1 . 1 Operational Toxicology, Edgewood 

Chemical and Biological Center, Aberdeen Proving 

Ground, MD and 2 Modeling Simulation and 

Analysis, Edgewood Chemical and Biological 

Center, Aberdeen Proving Ground, MD. 


RICIN STABILITY AND BIO-ACTIVITY 

AFTER TREATMENT AS DETERMINED 

BY A NEUTRAL RED UPTAKE ASSAY. J. S. 

Madren-Whalley 1 , V. H. Bevilacqua 2 , J. S. Rice 2 , 

A. M. Schenning 3 and L. M. Reilly 2 . 1 Molecular 

Engineering Team, Edgewood Chemical Biological 

Center, Aberdeen Proving Ground, MD, 2 Chemical 

Methodology Team, Edgewood Chemical Biological 

Center, Aberdeen Proving Ground, MD and 3 SAIC, 

Gunpowder, MD. Sponsor: J. Weeks-Sekowski. 


STUDIES ON THE EFFECT AND 

MECHANISM OF LONG-TERM EXPOSURE 

TO DEPLETED URANIUM ON BONE 

METABOLISM AND BONE MINERAL 

INJURY. Z. Guo-ying, W. Jin-hai, X. Xi-qiao and 

C. Xiao. Institute of Radiation Medicine, Fudan 

University, Shanghai, China. Sponsor: G. Nordberg. 


MACHINE LEARNING ALGORITHMS 

IDENTIFY EXPOSURE AND POTENTIAL 

MECHANISMS OF GF VAPOR TOXICITY 

IN RAT BRAIN. J. W. Sekowski 1 , A. Jensenius 2 , A. 

Brodzik 2 , C. Whalley 1 , J. Horsmon 1 , M. Horsmon 1 , 

M. Orehek 1 , M. Vahey 3 , M. Nau 3 , W. Muse 1 , D. 

Miller 1 , R. Mioduszewski 1 , J. Valdes 1 and O. Peters 2 . 

1 

ECBC, U.S. Army, APG-EA, MD, 2 MITRE, 

McClean, VA and 3 Gene Array Facility, WRAIR, 

Rockville, MD. 


UPREGULATION OF THE 

5-LIPOXYGENASE LEUKOTRIENE 

BIOSYNTHETIC PATHWAY BY THE 

VESICANT 2-CHLOROETHYL ETHYL 

SULFIDE IN MOUSE KERATINOCYTES. A. 

T. Black 1 , L. B. Joseph 1 , J. P. Gray 1 , D. R. Gerecke 1 , 

R. P. Casillas 2 , D. L. Laskin 1 and J. D. Laskin 3 . 

1 


Piscataway, NJ, 2 Biomedical Science & Technology, 

Battelle Biomedical Research Center, Columbus, 

OH and 3 Environmental & Occupational Medicine, 

UMDNJ-Robert Wood Johnson Medical School, 

Piscataway, NJ. 


THIOREDOXIN REDUCTASE REDUCES 

SULFUR MUSTARD IN VITRO TO YIELD 

CARBON-BASED FREE RADICALS. 

A. A. Brimfield 1 and S. Soni 2 . 1 Pharmacology, 

USAMRICD, Aberdeen Proving Ground, MD and 

2 

Analytical Toxicology, USAMRICD, Aberdeen 

Proving Ground, MD. 


EFFECTS OF VX ON ACOUSTIC STARTLE 

RESPONSE AND OPERANT BEHAVIOR IN 

RATS. J. L. Langston, N. Connis, T. Shih and L. A. 

Lumley. U.S. Army Medical Research Institute of 

Chemical Defense, Aberdeen Proving Ground, MD. 


NITRITE-MEDIATED ANTAGONISM OF 

CYANIDE INHIBITION OF CYTOCHROME 

C OXIDASE. H. B. Leavesley, L. Li, K. 

Prabhakaran, L. Zhang, X. Zhang, J. L. Borowitz 

and G. E. Isom. Medicinal Chemistry and Molecular 

Pharmacology, Purdue University, West Lafayette, 

IN. 


TREATMENT WITH TERTIARY OXIMES 

PREVENTS SEIZURES AND IMPROVES 

SURVIVAL FOLLOWING SARIN 

INTOXICATION. T. Shih, A. G. Yahyavi, M. 

T. Scott, J. W. Skovira and J. H. McDonough. 

Pharmacology Branch, U.S. Army Med Res Inst 

Chem Defn, Aberdeen Proving Ground, MD. 

98 




Abstract # 


SULFUR MUSTARD ANALOG-CAUSED 

ACTIVATION OF SIGNALING CASCADES 

IN SKH-1 HAIRLESS MOUSE SKIN. A. Pal 1 , C. 

Agarwal 1 , S. Rana 1 , M. Gu 1 , N. Tewari-Singh 1 , C. W. 

White 2 and R. Agarwal 1 . 1 Pharmaceutical Sciences, 

UCDHSC, Denver, CO and 2 National Jewish 

Medical and Research Center, Denver, CO. Sponsor: 

V. Vasiliou. 


IMAGING EARLY PATHWAYS OF SULFUR 

MUSTARD TOXICITY. R. J. Werrlein, C. R. 

Braue, C. S. Phillips and J. F. Dillman. Cell and 

Molecular Biology Branch, USAMRICD, Aberdeen 



PROTEOMIC ANALYSIS OF TYROSINE- 

PHOSPHORYLATED PROTEINS FROM 

RAT HIPPOCAMPUS FOLLOWING SOMAN 

EXPOSURE. L. N. Bottalico, G. D. Minsavage 

and J. F. Dillman. Cell and Molecular Biology, 

USAMRICD, Aberdeen Proving Ground, MD. 


PHYSIOLOGICAL CHANGES IN C3H/ 

HEJ MICE AFTER MICROINSTILLATION 

INHALATION EXPOSURE TO 

STAPHYLOCOCCAL ENTEROTOXIN B. 

J. J. Yeager, E. C. Troxell, R. K. Gordon and M. P. 

Nambiar. Biochemical Pharmacology, Walter Reed 

Army Institute of Research, Silver Spring, MD. 


SULFUR MUSTARD INDUCED CHANGES 

IN LAMININ-332 IN THE MOUSE EAR 

VESICANT MODEL (MEVM). D. R. Gerecke 1 , 

C. L. Sabourin 2 , K. K. Svoboda 3 , S. Lou 4 , M. 

K. Gordon 1 , R. P. Casillas 2 and Y. Chang 1 . 

1 


Piscataway, NJ, 2 Battelle Biomedical Research 

Center, Columbus, OH, 3 Biomedical Sciences, 

Baylor College of Dentistry, Dallas, TX and 

4 

Biostatistics, UMDNJ School of Public Health, 



DEVELOPMENT OF HUMAN IN VITRO 

3D LUNG MODELS TO ASSESS LUNG 

INJURY AND EVALUATE THERAPEUTICS 

AGAINST SOMAN AND SOMAN SIMULANT 

EXPOSURE. P. Dhoieam 1 , B. F. Curtin 1 , X. Shi 1 , 

A. M. Scuito 2 , R. K. Gordon 1 and M. P. Nambiar 1 . 

1 

WRAIR, Silver Spring, MD and 2 USAMRICD, 

Aberdeen, MD. 


POST-EXPOSURE PROPHYLAXIS WITH 

A COMBINATION VACCINE-ANTIBIOTIC 

REGIMEN INCREASES SURVIVAL 

OF RABBITS CHALLENGED WITH 

AEROSOLIZED B. ANTHRACIS SPORES. P. 

Sabourin, D. S. Read, J. M. Mott, K. H. Clement and 

G. V. Stark. Battelle, Columbus, OH. 


RAPID ASSESSMENT OF THE EFFECTS 

OF RADIATION EXPOSURE VIA FLOW 

CYTOMETRIC ANALYSIS OF WHOLE 

BLOOD. J. C. Bemis 1 , Y. Chen 2 , S. M. Bryce 1 , 

O. Hyrien 2 , J. Palis 2 and S. D. Dertinger 1 . 1 Litron 

Laboratories, Rochester, NY and 2 University of 

Rochester Medical Center, Rochester, NY. 

Abstract # 


SIMULTANEOUS DETERMINATION 

OF CYANIDE, THIOCYANATE AND 

2-AMINOTHIAZOLINE-4-CARBOXYLIC 

ACID (ATCA) BY HPLC. D. M. Hinkens and 

B. A. Logue. Chemistry and Biochemistry, South 

Dakota State University, Brookings, SD. 


AEOL 10150 RESCUES THE LUNG FROM 

HALF-MUSTARD (2-CHLOROETHYL 

ETHYL SULFIDE)-INDUCED INJURY. N. 

Gould 2,3 , H. O’Neil 2,4 , R. Rancourt 4 , J. Loader 4 , T. 

Hendry-Hofer 4 , C. W. White 1,4 and B. J. Day 1,2,3 . 

1 

Medicine, University of Colorado Health Sciences 

Center, Denver, CO, 2 Pharmaceutical Sciences, 

University of Colorado Health Sciences Center, 

Denver, CO, 3 Medicine, National Jewish Medical 

and Research Center, Denver, CO and 4 Pediatrics, 

National Jewish Medical and Research Center, 

Denver, CO. 


SURFACE ENHANCED RAMAN 

SPECTROSCOPY AS A FIELD SENSOR FOR 

THE DETECTION OF CYANIDE EXPOSURE. 

C. V. Vinnakota 1 and B. Logue 2 . 1 Chemistry, 

South Dakota State University, Brookings, SD 

and 2 Chemistry, South Dakota State University, 

Brookings, SD. 


STERICALLY STABILIZED LIPOSOMES 

ENCAPSULATING RHODANESE FOR 

CYANIDE ANTAGONISM. I. Petrikovics 1,3 , M. 

Budai 2 , P. Grof 2 , K. M. Beigel 3 , B. J. Schapiro 3 , 

J. Childress 1 , G. A. Rockwood 3 and S. I. Baskin 3 . 

1 

Chemistry, Sam Houston State University, 

Huntsville, TX, 2 Pharmaceutics, Semmelweis 

University, Budapest, Hungary and 3 Analytical 

Toxicology Division, U.S. Army Medical Research 

Institute of Chemical Defense, APG, MD. 


9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: IMMUNOTOXICOLOGY 

Chairperson(s): Courtney Sulentic, Wright State University, Dayton, OH 

and Timothy Pastoor, Syngenta Crop Protection, Greensboro, NC. 




2, 3, 7, 8-TETRACHLORODIBENZO-P- 

DIOXIN-MEDIATED IMPAIRMENT OF 

B CELL DIFFERENTIATION THROUGH 

DEREGULATION OF PAIRED BOX GENE 

5 (PAX5). M. A. Manzan 2 , D. Schneider 2,1 and N. 

E. Kaminski 1,2 . 1 Center for Integrative Toxicology, 

Michigan State University, East Lansing, MI and 

2 

Pharmacology and Toxicology, Michigan State 

University, East Lansing, MI. 

Monday 



Monday 




A COX-2 METABOLITE OF 

2-ARACHIDONYL GLYCEROL IS 

INVOLVED IN THE SUPPRESSION OF 

IL-2 SECRETION IN ACTIVATED JURKAT 

T CELLS. P. Raman 1,2 , C. E. Rockwell 3 , B. L. 

Kaplan 1,2 and N. E. Kaminski 1,2 . 1 Pharmacology 

and Toxicology, Michigan State University, East 

Lansing, MI, 2 Center for Integrative Toxicology, 

Michigan State University, East Lansing, MI 

and 3 Pharmacology, Toxicology, & Therapeutics, 

University of Kansas Medical Center, Kansas City, 

KS. 


ROLE OF NF-kB/REL PROTEINS IN 

MEDIATING THE REPRESSIVE EFFECTS 

OF TCDD ON 3’IgHRR ACTIVATION. 

R. Salisbury, E. J. Romer and C. E. Sulentic. 

Pharmacology & Toxicology, Wright State 

University, Dayton, OH. 


3, 4-DICHLOROPROPANANILIDE ALTERS 

T CELL ACTIVATION BY INHIBITING THE 

CA2+ INFLUX PATHWAY. T. L. Lewis 1,2 , K. 

M. Brundage 1,2 , R. Brundage 1,2 and J. B. Barnett 1,2 . 

1 

Microbiology, Immunology and Cell Biology, West 

Virginia University, Morgantown, WV and 2 Center 

for Immunopathology & Microbial Pathogenesis, 

West Virginia University, Morgantown, WV. 


TCDD-INDUCED MODULATION OF THE 

HUMAN POLYMORPHIC HS1, 2 ENHANCER 

WITHIN THE 3’IgH REGULATORY 

REGION. T. Fernando, R. Fecher and C. E. 

Sulentic. Pharmacology & Toxicology, Wright State 



EFFECT OF TCDD ON THE 

TRANSCRIPTIONAL ACTIVITY OF THE 

3’IgHRR ENHANCER ELEMENTS HS3A 

AND HS1, 2. T. Fernando and C. E. Sulentic. 

Pharmacology & Toxicology, Wright State 



EVALUATION OF POSSIBLE MODES OF 

ACTION FOR PFOS-INDUCED HUMORAL 

IMMUNOSUPPRESSION. M. Peden-Adams 1,2 , 

M. Mollenhauer 1 , E. Driscoll 2 , S. G. Bradshaw 1 , 

J. Berger 4 , P. A. Fair 3 and D. E. Keil 4 . 1 MUSC, 

Charleston, SC, 2 College of Charleston, Charleston, 

SC, 3 NOS/NOAA, Charleston, SC and 4 UNLV, Las 

Vegas, NV. 


DRUG METABOLISM AND IMMUNE 

RESPONSE CROSSTALK: THE ROLE OF 

PREGNANE X RECEPTOR IN MHC-II 

TRANSCRIPTIONAL REGULATION. E. 

Fuentes-Mattei 1,2 and B. D. Jimenez 1,2 . 1 Biochemistry, 

School of Medicine, UPR Medical Sciences Campus, 

San Juan, PR and 2 Center for Environmental and 

Toxicological Research, UPR Medical Sciences 

Campus, San Juan, PR. 


METALLOTHIONEIN GENE DOSE 

INFLUENCES CYTOKINE SECRETION 

PROFILE. X. Yin, D. W. Unfricht, G. Jin, K. 

Zaffuto and M. Lynes. Molecular and Cell Biology, 

University of Connecticut, Storrs, CT. 


MECHANISMS OF DITHIOCARBAMATE 

IMMUNOMODULATION: ALTERED 

CELLULAR RED-OX STATUS. S. B. Pruett 1,2 , 

R. Fan 2 and B. Cheng 2 . 1 Department Basic Sciences, 

College Vet. Med., Mississippi State U., Mississippi 

State, MS and 2 Cellular Biology & Anatomy, LSU 

Health Sciences Center, Shreveport, LA. 


ALTERATIONS IN POLY I:C-INDUCED 

CYTOKINE PRODUCTION BY ACUTE 

ETHANOL ADMINISTRATION: ROLE OF 

NEUROENDOCRINE MEDIATORS. M. Glover 1 

and S. B. Pruett 1,2 . 1 Department Basic Sciences, 

College Vet. Med., Mississippi State U., Mississippi 

State, MS and 2 Celluar Biology & Anatomy, LSU 



IMMUNE FUNCTION IN INTACT AND 

PPARa KNOCKOUT MICE EXPOSED TO 

PFOA. J. DeWitt 1 , C. B. Copeland 2 and R. W. 

Luebke 2 . 1 Curriculum in Toxicology, UNC-CH, RTP, 

NC and 2 Immunotoxicology Branch/ETD/NHEERL/ 

ORD, U.S. EPA, RTP, NC. 


HISTOLOGIC FEATURES OF THE 

DEVELOPING IMMUNE SYSTEM OF 

RATS. G. A. Parker 1 , C. A. Picut 1 , K. L. Scully 1 

and D. J. Veney 2 . 1 Pathology, WIL Research- 

Biotechnics, Hillsborough, NC and 2 Developmental 

& Reproductive Toxicology, WIL Research, Ashland, 

OH. 


EFFECTS OF GLUTATHIONE DEPLETION 

ON PULMONARY AND SPLENIC 

INFLAMMATORY CELLS FOLLOWING 

EXPOSURE TO DIESEL EXHAUST. H. Neff- 

LaFord, L. M. Corey, C. C. White, J. Stewart, J. 

D. Kaufman, M. E. Rosenfeld and T. J. Kavanagh. 

Environmental & Occupational Health Sciences, 

University of Washington, Seattle, WA. 


IMMUNOTOXIC EFFECTS AFTER UTERO 

AND LACTATIONAL EXPOSURE TO 

ENDOSULFAN IN LYMPH NODES, SPLEEN 

AND THYMUS OF IMMATURE RATS. A. 

Lafuente 1 , T. Cabaleiro 1 , A. Caride 1 , A. Romero 1 

and A. Anadon 2 . 1 Toxicology Laboratory, Faculty 

of Sciences, Vigo University, Orense, Spain and 

2 

Department of Toxicology and Pharmacology, 

Faculty of Veterinary Medicine, Universidad 

Complutense, Madrid, Spain. 


METALLOTHIONEIN EXPRESSION 

AFFECTS THE INNATE IMMUNE 

RESPONSE TO INFECTION. G. Marusov 1 , 

X. Yin 1 , R. Emeny 2 , D. A. Lawrence 2 and M. 

Lynes 1 . 1 Molecular and Cell Biology, University of 

Connecticut, Storrs, CT and 2 Wadsworth Center, 

Albany, NY. 

100 




Abstract # 


EXPOSURE TO ENVIRONMENTAL 

BACTERIA IS ASSOCIATED WITH TNF- 

ALPHA AND IL-6 PRODUCING CAPACITY 

IN INFANCY. M. H. Lappalainen 1 , M. Roponen 1 , 

A. Hyvärinen 1 , A. Nevalainen 1 , O. Laine 1 , J. 

Pekkanen 1,2 and M. Hirvonen 1,3 . 1 Department of 

Environmental Health, National Public Health 

Institute, Kuopio, Finland, 2 School of Public Health 

and Clinical Nutrition, University of Kuopio, 

Kuopio, Finland and 3 Department of Environmental 

Science, University of Kuopio, Kuopio, Finland. 

Sponsor: M. Viluksela. 


DICHLORVOS SIGNIFICANTLY 

DECREASES THE EXPRESSION OF 

GRANZYME B AND GRANZYME 3/K IN 

HUMAN NK CELLS. Q. Li, M. Kobayashi and 

T. Kawada. Hygiene and Public Health, Nippon 

Medical School, Tokyo, Japan. 


PRENATAL EXPOSURE TO CIGARETTE 

SMOKE SUPPRESSES CYTOTOXIC 

T-LYMPHOCYTE (CTL) ACTIVITY IN THE 

OFFSPRING POSSIBLY VIA INCREASED 

NUMBERS OF T-REGULATORY CELLS. S. 

P. Ng 1 , A. E. Silverstone 2 , Z. Lai 2 and J. T. Zelikoff 1 . 

1 

Department of Environmental Medicine, New York 

University School of Medicine, Tuxedo, NY and 

2 

Department of Microbiology & Immunology, SUNY 

Upstate Medical University, Syracuse, NY. 


COMPARISON OF 28S RRNA CLEAVAGE 

BY RICIN AND TRICHOTHECENE 

DEOXYNIVALENOL IN RAW 264.7 

MACROPHAGES. M. Li 1,2 and J. Pestka 1,2,3 . 

1 

Department Food Science and Human Nutrition, 

MIchigan State University, East Lansing, MI, 

2 

Department Microbiology molecular genetics, 

Michigna State University, East Lansing, MI and 

3 

Center for Integrative Toxicology, Michigna State 



TOXICOLOGICAL EFFECTS OF 

NAPHTHALENE ON INNATE IMMUNITY 

OF FISH (CENTROPOMUS PARALLELUS). 

EVALUATION BY FLOW CYTOMETRY. L. C. 

Sá-Rocha, V. M. Sá-Rocha, D. Kinoshita and S. F. 

Affonso. Pathology, School of Veterinary Medicine 

- São Paulo University, São Paulo, Brazil. Sponsor: 

S. Barros. 


EARLY TOXICITY OF T-2 TOXIN: EFFECTS 

ON HUMAN MONOCYTE, MACROPHAGE 

AND DENDRITIC CELL. D. Parent-Massin, N. 

Hymery and Y. Sibiril. UFR Sciences et techniques, 

Food Toxicology Laboratory EA 3880, West Brittany 

University, Brest, France. Sponsor: N. Claude. 


LESSONS FROM THE 

IMMUNOTOXICOLOGY BENCH: A MULTI- 

PLATFORM APPROACH TO INNATE 

IMMUNE EVALUATION OF POTENTIAL 

IMMUNOTOXICITIES. W. J. Freebern, T. J. 

Bigwarfe, K. A. Bello, K. D. Price, T. P. Reilly and 

H. G. Haggerty. Drug Safety Evaluation, Bristol- 

Myers Squibb, Syracuse, NY. 

Abstract # 


ARSENITE EXPOSURE DECREASES 

FUNCTIONAL ACTIVATION RESPONSE 

AND BACTERICIDAL CAPABILITY OF 

LPS-STIMULATED J774A.1 MURINE 

MACROPHAGES. L. C. Acosta-Saavedra 1 , P. C. 

Conde 1 , I. Estrada 2 and E. S. Calderon-Aranda 1 . 

1 

Toxicologia, Cinvestav, Mexico, DF, Mexico 

and 2 Departamento de Inmunologia, ENCB, IPN, 

Mexico, D.F., Mexico. Sponsor: L. Del Razo. 


IMMUNOTOXIBASE: A FREE-ACCESS 

DATABASE ON THE IMMUNOTOXICITY OF 

DRUGS AND CHEMICALS. J. Descotes. Poison 

Center, Lyon, France. 


EXPOSURE TO CARBON BLACK 

NANOPARTICLES ACTIVATES ANTIGEN- 

PRESENTING CELLS IN VIVO AND IN 

VITRO. E. Koike 1 , H. Takano 1 , K. Inoue 1 , R. 

Yanagisawa 1 , M. Sakurai 1 and T. Kobayashi 2 . 

1 

Environmental Health Sciences Division, National 

Institute for Environmental Studies, Tsukuba, 

Ibaraki, Japan and 2 Integrated Research Institute, 

Tokyo Institute of Technology, Yokohama, Japan. 

Sponsor: J. Yonemoto. 


SUPPRESSION OF B CELL 

DIFFERENTIATION BY 2, 3, 7, 8- 

TETRACHLORODIBENZO-P-DIOXIN. J. E. 

Suárez 1 and N. E. Kaminski 2 . 1 University of Puerto 

Rico at Cayey, Guayama, PR and 2 Department 

of Pharmacology & Toxicology, Michigan State 



SUBCELLULAR LOCALIZATION OF 

THE AMIDE CLASS HERBICIDE 3, 

4-DICHLOROPROPIONANILIDE (DCPA) 

IN T CELLS. M. L. Hanson 1 , C. J. Peer 2 , K. 

M. Brundage 1 , R. Schafer 1 , S. A. Eremin 3 and J. 

B. Barnett 1 . 1 Microbiology, Immunology & Cell 

Biology, West Virginia University, Morgantown, 

WV, 2 Basic Pharmaceutical Sciences, West Virginia 

University, Morgantown, WV and 3 Chemical 

Enzymology, Moscow State University, Moscow, 

Russian Federation. 


EVALUATION OF VIRAL REACTIVATION 

BY MURINE IFNb AND AN a4 INTEGRIN 

MONOCLONAL ANTIBODY IN A MCMV 

HOST RESISTANCE MODEL. N. G. Wehner 2 , 

G. Burleson 3 , J. Clarke 1 and C. Hurst 1 . 1 Biogen Idec, 

Cambridge, MA, 2 Elan, South San Francisco, CA and 

3 

Burleson Research Technologies, Morrisville, NC. 


AUGMENTATION OF INFLAMMATORY 

MEDIATORS IN AQUEOUS HUMOR AND 

DIFFERENTIAL REMODELING OF THE 

CORNEAL STROMA IN RESPONSE TO 

SULFUR MUSTARD EXPOSURE. D. Milhorn 1 , 

M. R. Nelson 1 , K. A. Whitten 2 and T. A. Hamilton 2 . 

1 

Research, USAMRICD, Aberdeen Proving Grounds, 

MD and 2 Comparative Medicine, USAMRICD, 

Aberdeen Proving Grounds, MD. Sponsor: W. Smith. 

Monday 



Monday 




EFFECT OF TARGETED ANTI- 

INFLAMMATORY AGENTS IN A RAT 

STREPTOCOCCAL HOST RESISTANCE 

MODEL: IL-1RA, ANTI-TNF, OR COMBINED 

IL-1RA AND ANTI-TNF. W. J. Komocsar 1 , F. G. 

Burleson 2 , P. S. Struve 2 and D. Wierda 1 . 1 Investigative 

Toxicology - Immunomodulation Group, Eli 

Lilly and Company, Greenfield, IN and 2 Burleson 

Research Technologies, Inc., Morrisville, NC. 


IN VITRO IMMUNOTOXIC EFFECTS OF 

MERCURY DEPEND ON ACTIVATION OF 

HUMAN PBMCS. R. M. Gardner, J. F. Nyland, 

S. Evans, S. Wang, K. M. Doyle, D. M. Ansari and 

E. K. Silbergeld. Environmental Health Sciences, 

Johns Hopkins Bloomberg School of Public Health, 

Baltimore, MD. 


DEVELOPMENT OF TOLERANCE TO 

D9-THC-INDUCED SUPPRESSION OF 

IN VIVO AND IN VITRO HUMORAL 

IMMUNE RESPONSES. C. M. Sheth and K. 

L. White. Pharmacology & Toxicology, Virginia 

Commonwealth University, Chesterfield, VA. 


A CONSTITUTIVELY ACTIVE AHR 

EXPRESSED IN T CELLS INCREASES 

PERCENTAGE OF CD25 + CD4 + T CELLS 

BUT DOES NOT SUPPRESS ANTIBODY 

PRODUCTION UPON OVA-IMMUNIZATION 

OF MICE. K. Nohara 1,2 , K. Ao 1 , Y. Miyamoto 1 , K. 

Inouye 1 , X. Pan 1 , H. Motohashi 2 , M. Yamamoto 2 and 

C. Tohyama 3 . 1 National Institute for Environmental 

Studies, Tsukuba, Japan, 2 University of Tsukuba, 

Tsukuba, Japan and 3 University of Tokyo, Tokyo, 

Japan. 


ENHANCED HOST RESISTANCE TO 

LISTERIA MONOCYTOGENES (LM) 

FOLLOWING EXPOSURE TO THE POTENT 

IMMUNOSUPPRESSIVE COMPOUNDS 

BENZO(A)PYRENE AND DIBENZ(A, H) 

ANTHRACENE IN FEMALE B6C3F1 MICE. 

W. Auttachoat, D. Roesh, R. D. Brown and K. 

L. White. Pharmacology & Toxicology, Virginia 

Commonwealth University, Richmond, VA. 


THE EFFECTS OF PERFLUOROOCTANE 

SULFONATE EXPOSURE ON 

INFLAMMATION IN B6C3F1 MICE. M. 

Mollenhauer 1 , J. A. Cook 1 , P. A. Fair 2 and M. Peden- 

Adams 1 . 1 MUSC, Charleston, SC and 2 NOS/NOAA, 

Charleston, SC. 


HPLC/DAD STUDY ON COVALENT 

BINDINGS OF SENSITIZING CHEMICAL 

SUBSTANCES TO SERUM ALBUMIN. T. Isse, 

O. Tsunehiro, T. Pham and T. Kawamoto. Department 

of Environmental Health, School of Medicine, 

University of Occupational and Environmental 

Health, Kitakyushu, Fukuoka, Japan. 


AN ELECTROPHORETIC STUDY ON 

COVALENT BINDINGS OF SENSITIZING 

CHEMICAL SUBSTANCES TO ALBUMIN. 

T. Kawamoto, T. Oyama, T. Isse and T. Pham. 

Department of Environmental Health, University of 

Occupational and Environmental Health, Kitakyushu, 

Japan. 


9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: ANIMAL MODELS 

Chairperson(s): Joshua Gray, Rutgers University, Piscataway, NJ and 

Wei Zou, Michigan State University, East Lansing, MI. 




EVALUATION OF THE EFFECTS OF 

NYLABONES ® ON RAT SUBCHRONIC 

TOXICITY STUDY ENDPOINTS. S. A. 

MacKenzie, G. P. Sykes, N. E. Everds and L. A. 

Malley. DuPont Haskell Global Centers for Health 

and Environmental Sciences, Newark, DE. 


OCULAR PHOTOTOXICITY: ROLE 

OF PIGMENTATION AND OBSERVED 

PHOTOTOXICITY INDUCED BY 

8-METHOXYPSORALEN. C. P. Sambuco 1 , D. 

B. Learn 1 , J. D. Wilson 2 , P. D. Forbes 1 , S. Bistner 2 , 

K. Frazier 1 and A. M. Hoberman 1 . 1 Center for 

Photobiology, Charles River Laboratories Preclinical 

Services, Horsham, PA and 2 GlaxoSmithKline, King 

of Prussia, PA. 


CHRONIC INTERMITTENT EXPOSURE 

TO SOLAR-SIMULATED ULTRAVIOLET 

AND VISIBLE RADIATION INDUCES 

OCULAR CHANGES IN ALBINO BUT 

NOT PIGMENTED MICE. D. B. Learn 1 , J. 

D. Wilson 2 , C. P. Sambuco 1 , P. D. Forbes 1 , S. 

Bistner 2 , K. Frazier 2 , W. R. Brown 3 and A. M. 

Hoberman 1 . 1 Center for Photobiology, Charles 

River Laboratories Preclinical Services, Horsham, 

PA, 2 GlaxoSmithKline, King of Prussia, PA and 

3 

Research Pathology Services, New Britain, PA. 


DEVELOPING IN VIVO CEES-INDUCED 

SKIN TOXICITY MOUSE MODELS. S. Rana 1 , 

N. Tewari-Singh 1 , M. Gu 1 , D. J. Orlicky 1 , C. W. 

White 2 and R. Agarwal 1 . 1 Pharmaceutical Sciences, 

UCDHSC, Denver, CO and 2 National Jewish 

Medical and Research Center, Denver, CO. Sponsor: 

V. Vasiliou. 


DEVELOPMENT OF AN ANIMAL MODEL 

OF ABRADED SKIN. P. Glerup, C. Skytte and A. 

Makin. LAB Research (Scantox), Lille Skensved, 

Denmark. Sponsor: G. Washer. 

102 




Abstract # 


TEMPORAL CHANGES IN 

MITOCHONDRIAL STRUCTURE, 

FUNCTION, AND MUTATIONS FOLLOWING 

IN UTERO EXPOSURE OF FEMALE 

CD-1 MICE TO AZT, 3TC, OR AZT/3TC. 

S. M. Torres 1 , R. L. Division 2 , C. L. McCash 1 , 

T. Einem 2 , D. M. Walker 3 , M. C. Poirier 2 and V. 

Walker 1 . 1 Lovelace Respiratory Research Institute, 

Albuquerque, NM, 2 National Cancer Institute, 

Bethesda, MD and 3 BioMosaics, Burlington, VT. 


OZONE EXPOSURE DYSREGULATES KEY 

ENDOTHELIAL TRANSCRIPTS IN THE APO 

E (-/-) MOUSE. J. Maresh 1 , B. Johnson 2 and M. 

Dohm 2 . 1 Medicine, University of Hawaii, Honolulu, 

HI and 2 Chaminade University, Honolulu, HI. 

Sponsor: M. Campen. 


CONTRIBUTION OF LOCUS COERULEUS 

DEGENERATION TO THE PARKINSONIAN 

SYMPTOMS IN VMAT2 DEFICIENT MICE. 

T. N. Taylor 1,2 , W. M. Caudle 1,2 , M. Z. Wang 1,2 , J. 

R. Schank 3 , H. A. Mitchell 3 , D. Weinshenker 3 and 

G. W. Miller 1,2 . 1 Environmental and Occupational 

Health, Emory University, Atlanta, GA, 2 Center 

For Neurodegenerative Disease, Emory University, 

Atlanta, GA and 3 Department of Human Genetics, 

Emory University, Atlanta, GA. 


IMMUNOCYTOCHEMICAL AND 

BEHAVIORAL EVIDENCES OF THE 

NEUROPROTECTIVE EFFECTS OF 

MELATONIN IN A PARKINSON’S DISEASE 

MODEL. A. Gutierrez-Valdez, L. Colin-Barenque, 

J. Ordonez-Librado, V. Anaya-Martinez, R. Garcia 

and M. Avila-Costa. Neuroscience, UNAM, Mexico, 

Mexico. 


OZONE DYSREGULATES CARDIAC AND 

PULMONARY TRANSCRIPTS IN THE APO 

E (-/-) MOUSE. M. Dohm 2 , J. Maresh 1 , B. Johnson 2 

and A. Machado 2 . 1 Medicine, University of Hawaii, 

Honolulu, HI and 2 Biology, Chaminade University, 

Honolulu, HI. Sponsor: M. Campen. 


RESPIRATPORY SAFETY 

PHARMACOLOGY: RELEVANT 

PARAMETERS. C. Petit-Turcotte 1 , S. Authier 1,2 , 

M. Legaspi 1,2 and E. Troncy 2 . 1 Toxicology, LAB 

Research Inc., Laval, QC, Canada and 2 Faculty 

of Veterinary Medicine, University of Montreal, 

St-Hyacinthe, QC, Canada. Sponsor: G. Washer. 


RESPIRATORY SAFETY PHARMACOLOGY: 

COMPARISON OF CONSCIOUS BEAGLE 

DOGS, CYNOMOLGUS MONKEY AND 

SPRAGUE-DAWLEY RATS. S. Authier 1,2 , M. 

Legaspi 1,2 , S. Fournier 1 and E. Troncy 2 . 1 Veterinary 

Services, LAB Preclinical Research, Laval, QC, 

Canada and 2 Faculty of Veterinary Medicine, 

Montreal University, St-Hyacinthe, QC, Canada. 

Sponsor: G. Washer. 

Abstract # 


OPTIMIZATION OF ACCLIMATION AND 

EXPERIMENTAL PROCEDURES FOR 

HEAD-ONLY INHALATION EXPOSURE 

OF TRIAMCINOLONE ACETONIDE IN 

CYNOMOLGUS MONKEYS. J. T. Weinberg, D. 

T. Kirkpatrick, E. A. Anderson, B. M. Golias and M. 

S. Cockburn. Toxicology Department, WIL Research 

Laboratories, LLC, Ashland, OH. 


MICROARRAY ANALYSIS OF MURINE 

LUNGS FOLLOWING PULMONARY 

EXPOSURE TO DIESEL EXHAUST 

PARTICLES. R. Yanagisawa 1 , H. Takano 1,2 , K. 

Mizushima 2 , K. Inoue 1 , E. Koike 1 and T. Yoshikawa 2 . 

1 

National Institute for Environmental Studies, 

Tsukuba, Japan and 2 Kyoto Prefectural University of 

Medicine, Kyoto, Japan. Sponsor: J. Yonemoto. 


NOSE-ONLY INHALATION EXPOSURE CAN 

DEPLETE LIVER GLUTATHIONE LEVELS. 

L. D. Fechter, A. Nelson-Miller, C. Gearhart and S. 

Fulton. Research (151), Loma Linda VA Medical 

Center, Loma Linda, CA. 


BISPHENOL A (BPA) DOES NOT 

EXACERBATE IGE-MEDIATED ASTHMA 

WHEN EVALUATED IN A RELEVANT 

MOUSE EXPOSURE MODEL. V. L. Peachee 

and K. L. White. Virginia Commonwealth University, 

Richmond, VA. 


IS TOLUENE DIAMINE (TDA) A 

SENSITIZER AND IS THERE CROSS- 

REACTIVITY BETWEEN TOLUENE 

DIAMINE (TDA) AND TOLUENE 

DIISOCYANATE (TDI)? J. A. Vanoirbeek, V. De 

Vooght, N. Synhaeve, B. Nemery and P. H. Hoet. 

Research Unit for Lung Toxicology, K.U.Leuven, 

Leuven, Belgium. 


KNOCKDOWN OF GAMMA- 

GLUTAMYLCYSTEINE SYNTHETASE IN 

RAT CAUSES ACETAMINOPHEN-INDUCED 

HEPATOTOXICITY. T. Yokoi, S. Akai, H. 

Hosomi, K. Minami, M. Katoh and M. Nakajima. 

Graduate School of Medical Science, Kanazawa 

University, Kanazawa, Ishikawa, Japan. 


GENE EXPRESSION IN VARIOUS 

BIOLOGICAL PATHWAYS IN FLUTAMIDE- 

TREATED RATS AND CHIMERIC MICE 

WITH HUMANIZED LIVER. S. Nagatsuka 1 , K. 

Matsumura 1 , S. Ninomiya 1 , M. Kakuni 2 , T. Shimada 2 

and Y. Yamazoe 3 . 1 R&D Department, ADME/TOX 

Research Institute, Daiichi Pure Chemicals, Co., 

Ltd., Tokai-mura, Ibaraki, Japan, 2 Chimeric Mice 

Business Division, PhoenixBio Co., Ltd., Higashi- 

Hiroshima, Hiroshima, Japan and 3 Graduate School 

of Pharmaceutical Sciences, Tohoku University, 

Sendai, Miyagi, Japan. Sponsor: T. Miyaoka. 

Monday 



Monday 




INFLAMMATION-MEDIATED LIVER 

INJURY IN RATS COTREATED WITH 

SULINDAC AND LIPOPOLYSACCHARIDE. 

W. Zou 1 , S. S. Devi 1 , H. S. Younis 2 , R. A. Roth 1 and P. 

E. Ganey 1 . 1 Michigan State university, East Lansing, 

MI and 2 Pfizer Global Research and Development, 

San Diego, CA. 


MODIFIED ALCOHOL LIQUID DIET 

MODEL FOR LIVER INJURY IN MICE. B. 

Bradford 1 , O. Kosyk 1 , H. Kono 2 , S. Shymonyak 1 , P. 

Ross 1 and I. Rusyn 1 . 1 Environmental Sciences and 

Engineering, UNC Chapel Hill, Chapel Hill, NC and 

2 

Surgery, U. Yamanashi, Yamanashi, Japan. 


A NOVEL “PATIENT-LIKE” MODEL OF 

CHOLANGIOCARCINOMA PROGRESSION 

BASED ON BILE DUCT INOCULATION OF 

TRANSFORMED RAT CHOLANGIOCYTES 

OVEREXPRESSING ERBB2. A. E. Sirica, D. 

J. Campbell and Z. Zhang. Pathology, Virginia 

Commonwealth University School of Medicine, 

Richmond, VA. 


MONITORING A MOUSE WHICH 

EXPRESSES A YELLOW FLUORESCENT 

PROTEIN IN MONOCYTES WITH 

INTRAVITAL MICROSCOPY. T. Kampfrath, J. 

Anderson, Q. Sun, S. Parthasarathy, M. Ostrowski 

and S. Rajagopalan. Ohio State University, 

Columbus, OH. 


LIVER-SELECTIVE EXPRESSION OF 

FUNCTIONAL HUMAN ARYLAMINE 

ACETYLTRANSFERASE NAT2 IN 

TRANSGENIC MICE. K. S. Sugamori, D. 

Brenneman and D. M. Grant. Pharmacology and 

Toxicology, University of Toronto, Toronto, ON, 

Canada. 


TOXICOLOGICAL RESPONSES TO 1, 

2-DICHLORO-4-NITROBENZENE IN 

GLUTATHIONE S-TRANSFERASE M1 

KNOCKOUT MICE. W. Takasaki, S. Arakawa, K. 

Fujimoto, T. Maejima, Y. Shibaya, T. Yamaguchi, H. 

Miida, R. Kawai, Y. Ando, T. Yamoto and S. Manabe. 

Medicinal Safety Res Labs, Daiichi-Sankyo Co., 

Ltd., Fukuroi, Shizuoka, Japan. 


A NOVEL TRANSGENIC MOUSE MODEL 

EXPRESSING A HUMAN ENZYME FOR 

REPAIR OF OXIDATIVE DNA DAMAGE. S. L. 

Ondovcik 1 , T. J. Preston 1 , S. K. Ho 1 , J. T. Henderson 1 , 

K. Lam 2 and P. G. Wells 1,2 . 1 Pharmaceutical Sciences, 

University of Toronto, Toronto, ON, Canada and 

2 

Pharmacology and Toxicology, University of 

Toronto, Toronto, ON, Canada. 


CARCINOGENIC COMPARATIVE STUDY 

ON CB6F1 TG RASH2 MICE PRODUCED BY 

TWO BREEDING FACILITIES. K. Urano, K. 

Machida, M. Yoshimura, K. Kikuchi, T. Nomura and 

T. Usui. Central Institute for Experimental Animals, 

Kawasaki, Japan. 


A NOVEL PARADIGM FOR ASSESSING 

EFFICACIES OF POTENTIAL ANTIDOTES 

AGAINST NEUROTOXINS IN MICE. D. 

L. Crankshaw 1,2,3 , D. J. Goon 1,2 , J. E. Briggs 1 , D. 

DeLong 2 , M. Kuskowski 2 , S. E. Patterson 1 and H. T. 

Nagasawa 1,2 . 1 Center for Drug Design, University of 

Minnesota, Minneapolis, MN, 2 VA Research Service 

151, VA Medical Center, Minneapolis, MN and 

3 

Department Food Science and Nutrition, University 

of Minnesota, St. Paul, MN. Sponsor: P. Hanna. 


NON-INVASIVE MOUSE GENOTYPING 

USING DNA ISOLATED FROM FECAL 

SAMPLES. M. M. Ralston, K. D. Bongiovanni and 

C. V. Smith. Seattle Children’s Hospital Research 

Institute, Center for Developmental Therapeutics, 

Seattle, WA. 


UNANTICIPATED ANTICOAGULANT 

RESPONSE TO UNFRACTIONATED 

HEPARIN IN CYNOMOLGUS MONKEYS 

MEASURED BY ACTIVATED CLOTTING 

TIME. P. Beaumier, M. Bauman, T. Dawe, J. Tilton, 

R. Coxen and D. Hayward. Safety Assessment, 

SNBL USA, Everett, WA. Sponsor: M. Osier. 


INTRACELLULAR ACIDIFICATION 

PROMOTES ALLOXAN-INDUCED 

TOXICITY IN PANCREATIC ISLETS. J. P. 

Gray 1 , E. Heart 2 , K. Fussell 1 , S. Jamil 3 , P. J. Smith 2 

and J. D. Laskin 3 . 1 Pharmacology & Toxicology, 

Rutgers University, Piscataway, NJ, 2 Biocurrents 

Research Center, Marine Biological Laboratory, 

Woods hole, MA and 3 Environment & Occupational 


School, Piscataway, NJ. 


THE QUANTIFICATION OF STRUCTURAL/ 

FUNCTIONAL IMPAIRMENT IN THE 

EXPERIMENTAL DOG OSTEOARTHRITIS 

MODEL IS A USEFUL TOOL FOR DRUG 

TESTING. E. Troncy 1,3 , M. Moreau 1 , M. D’Anjou 1 , 

F. Duguay 2 , S. Authier 2,1 , C. Boileau 1,3 , J. Martel- 

Pelletier 1,3 , F. Abram 3 , J. Raynauld 1,3 and J. 

Pelletier 1,3 . 1 Université de Montréal, Saint-Hyacinthe, 

QC, Canada, 2 LAB Research Inc., Laval, QC, 

Canada and 3 ArthroLab Inc., Montreal, QC, Canada. 



TOXICITY OF INTRAVENOUSLY 

ADMINISTERED ACIDIC AND ALKALINE 

VEHICLE FORMULATIONS IN MICE. S. 

A. Shah, L. S. Krsmanovic, P. I. Atkins and E. A. 

Zahalka. Mammalian Toxicology, BioReliance, 


104 




Abstract # 


THE LOW DOSE EFFECTS OF PCB126 ON 

RAT LIVER METABOLISM IN RATS GIVEN 

A CONTROLLED DIETARY LEVEL OF 

SELENIUM. I. Lai 1,2 , B. Prather 1,2 , B. Wang 1,2 , 

M. Coleman 3 , D. Spitz 1,3 , Y. Chai 4 , B. Wels 4 , D. 

Simmons 4 , G. Ludewig 1,2 and L. Robertson 1,2 . 

1 

Interdisciplinary Program in Human Toxicology, 

University of Iowa, Iowa City, IA, 2 Occupational 

and Environmental Health, University of Iowa, 

Iowa City, IA, 3 Free Radical and Radiation Biology, 

University of Iowa, Iowa City, IA and 4 University 

Hygienic Laboratory, University of Iowa, Ankeny, 

IA. 


COMPARISON OF 

ELECTROCARDIOGRAPHIC EFFECTS 

IN NONHUMAN PRIMATES: CONSCIOUS 

UNRESTRAINED VERSUS PHYSICALLY 

OR CHEMICALLY RESTRAINED. A. C. 

Jenkins, A. Mitchell, C. Foley and R. Sarazan. Safety 

Pharmacology, Covance Laboratories Inc., Madison, 

WI. 


9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: BIOINFORMATICS AND COMPUTATIONAL 

TOXICOLOGY 

Chairperson(s): Hao Zhu, University of North Carolina at Chapel Hill, 

Chapel Hill, NC and Richard Judson, U.S. EPA, Research Triangle Park, 

NC 




THE TOXICITY DATA LANDSCAPE FOR 

ENVIRONMENTAL CHEMICALS. R. Judson 1 , 

A. Richard 1 , D. Dix 1 , K. Houck 1 , M. Martin 1 , R. 

Kavlock 1 , D. Vicki 2 , T. Holderman 3 , S. Tan 3 , T. 

Carpenter 4 and E. Smith 5 . 1 NCCT/ORD, U.S. EPA, 

RTP, NC, 2 OPP/OPPTS, U.S. EPA, Arlington, VA, 

3 

OPPT/OPPTS, U.S. EPA, Washington, DC, 4 OW/ 

OGWDW, U.S. EPA, Washington, DC and 5 GLNPO, 

U.S. EPA, Chicago, IL. 


TOXCAST: DEVELOPING PREDICTIVE 

SIGNATURES OF CHEMICALLY INDUCED 

TOXICITY. R. J. Kavlock, D. J. Dix, K. Houck, 

R. Judson, T. Knudsen, M. Martin, A. Richard and 

W. Setzer. U.S. Environmental Protection Agency, 

Research Triangle Park, NC. 


TOXREFDB: CLASSIFYING TOXCAST 

PHASE I CHEMICALS UTILIZING 

STRUCTURED TOXICITY INFORMATION. 

M. T. Martin 1 , R. Judson 1 , K. McLaurin 1 , D. Rotroff 1 , 

V. Dellarco 2 , E. Mendez 2 , M. Reaves 2 and D. J. Dix 1 . 

1 

National Center for Computational Toxicology 

(NCCT), U.S. EPA, Research Triangle Park, NC 

and 2 Office of Pesticide Programs (OPP), U.S. EPA, 

Arlington, VA. 

Abstract # 


A COMPUTATIONAL FRAMEWORK 

FOR SYSTEMS-BASED ANALYSIS OF 

DEVELOPMENTAL TOXICITY. T. B. Knudsen 1 , 

A. V. Singh 2 , R. J. Kavlock 1 , D. J. Dix 1 , R. S. 

Judson 1 , M. T. Martin 1 , V. L. Dellarco 3 , E. Mendez 3 

and E. Reaves 3 . 1 National Center for Computational 

Toxicology, Office of Research and Development, 

U.S. EPA, Research Triangle Park, NC, 2 Lockheed 

Martin, Research Triangle Park, NC and 3 Office of 

Pesticide Programs, U.S. EPA, Washington, DC. 


UNDERSTANDING TOXICITY THROUGH 

THE ANALYSES OF A WELL DESIGNED 

TOXML DATABASES. A. Storaska 1,2,5 , K. 

Arvidson 2 , R. Benz 3 , R. Brown 1,3,6 , D. Bower 1 , E. 

Lee 1,2 , C. Marchant 4 , G. Sun 1 , J. Wood 1,2,6 and C. 

Yang 1 . 1 Leadscope, Inc., Columbus, OH, 2 Center 

for Food Safety and Applied Nutrition, U.S. FDA, 

College Park, MD, 3 Center for Drug Evaluation and 

Research, U.S. FDA, Silver Spring, MD, 4 Lhasa, Ltd, 

Leeds, United Kingdom, 5 University of Maryland, 

College Park, CA and 6 University of California, 

Berkeley, CA. 


USING THE COMPARATIVE 

TOXICOGENOMICS DATABASE TO 

IDENTIFY CHEMICAL-GENE-DISEASE 

ASSOCIATIONS: ARSENIC AS A CASE 

STUDY. C. Mattingly 1 , M. C. Rosenstein 1 , T. 

Wiegers 1 , C. Murphy 1 , J. L. Boyer 2 and A. P. Davis 1 . 

1 

MDIBL, Salisbury Cove, ME and 2 Yale University, 

New Haven, CT. Sponsor: W. Toscano. 


ADVERSE EFFECTS OF 

PHARMACEUTICALS: A. CONSTRUCTION 

OF A RELATIONAL DATABASE OF ADVERSE 

CARDIOLOGICAL EFFECTS USING FDA 

ARCHIVES, PHARMAPENDIUM, AND 

PUBLIC SOURCES. A. A. Frid, E. J. Matthews, 

N. L. Kruhlak, R. Benz and J. F. Contrera. CDER / 

OPS / ICSAS, Food and Drug Administration, Silver 

Spring, MD. 


LEVERAGING HISTORICAL 

INFORMATION IN PRECLINICAL 

TOXICOLOGY STUDIES: THE 

HEPATOTOXICITY KNOWLEDGEBASE. 

S. Matis 1 , I. Dix 3 , M. Firth 3 , A. Ganguri 1 , S. 

Jagannathan 1 , G. Kenna 2 , J. Kozlovsky 4 , Y. Li 1 , 

N. Mian 3 , E. Pichler 4 and D. Cook 2 . 1 Discovery 

Information, Astra Zeneca Pharmaceuticals, 

Wilmington, DE, 2 Global Safety Assesssment, Astra 

Zeneca Pharmaceuticals, Alderley Park, Cheshire, 

United Kingdom, 3 Discovery Information, Astra 

Zeneca Pharmaceuticals, Alderley Park, Cheshire, 

United Kingdom and 4 Discovery Information, Astra 

Zeneca Pharmaceuticals, Waltham, MA. 


QSAR MODELING OF HUMAN LIVER 

ADVERSE EFFECTS DATABASE USING kNN 

METHOD. A. D. Rodgers 1 , H. Zhu 2 , I. Rusyn 1,3 and 

A. Tropsha 1,2 . 1 Curriculum in Toxicology, University 

of North Carolina, Chapel Hill, Chapel Hill, NC, 

2 

Division of Medicinal Chemistry and Natural 

Products, University of North Carolina, Chapel Hill, 

Chapel Hill, NC and 3 Department of Environmental 

Sciences and Engineering, University of North 

Carolina, Chapel Hill, Chapel Hill, NC. 

Monday 



Monday 




TWO-STEP QUANTITATIVE STRUCTURE 

ACTIVITY RELATIONSHIP MODELING 

OF IN VIVO TOXICITY USING IN VITRO 

CYTOTOXICITY DATA. H. Zhu 1,2 , L. Ye 2 , 

I. Rusyn 3 , A. Richard 4 , A. Golbraikh 2 and A. 

Tropsha 1,2 . 1 Carolina Environmental Bioinformatics 

Center, Chapel Hill, NC, 2 Division of Medicinal 

Chemistry and Natural Products, UNC-CH, Chapel 

Hill, NC, 3 Department of Environmental Sciences 

and Engineering, UNC-CH, Chapel Hill, NC and 

4 

National Center for Computational Toxicology, 

EPA, RTP, NC. 


IN SILICO STUDIES OF THE TOXCAST 

CHEMICALS INTERACTING WITH 

BIOMOLECULAR TARGETS. M. R. Goldsmith, 

S. B. Little, K. A. Houck, D. J. Dix and J. R. 

Rabinowitz. National Center for Computational 

Toxicology, U.S. -Environmental Protection Agency, 



APPLICATION OF IN SILICO TOXICANT- 

TARGET APPROACH TO SCREENING 

A CHEMICAL LIBRARY FOR 

ESTROGENICITY. J. Rabinowitz, S. Little and 

M. Goldsmith. National Center for Computational 

Toxicology, U.S. EPA, Research Trianlge Park, NC. 


A QSTR ANALYSIS OF CWAS USING 

COMMERCIAL QSTR MODELS: DEREK 

AND TOPKAT. C. J. Moudgal 1 and M. Sparks 2 . 

1 

ORD/NHSRC, U.S. EPA, Kansas City, KS and 

2 

University of Missouri, Columbia, MO. 


ADVERSE EFFECTS OF 

PHARMACEUTICALS: B. PREDICTION 

OF ADVERSE CARDIOLOGICAL EFFECTS 

USING MC4PC, LEADSCOPE, BIOEPISTEME, 

AND MDL-QSAR SOFTWARE PROGRAMS. 

E. J. Matthews, A. A. Frid, N. L. Kruhlak, R. Benz 

and J. F. Contrera. CDER / OPS / ICSAS, Food and 

Drug Administration, Silver Spring, MD. 


GENERATION AND VALIDATION OF 

MULTI-GENE VALIDATED BIOMARKERS 

FOR PREDICTION AND DIAGNOSIS OF 

BILE DUCT HYPERPLASIA IN RATS. B. D. 

Jeffy 1 , E. Blomme 2 and Y. Yang 2 . 1 Molecular and 

Investigative Toxicology, Entelos, Inc., Foster City, 

CA and 2 Cellular and Molecular Toxicology, Abbott 

Laboratories, Abbott Park, IL. 


THIRD-PARTY BIOMARKER VALIDATION 

AND HYPOTHESIS GENERATION IN 

A VERY LARGE TOXICOGENOMIC 

DATABASE. J. Gollub, B. Jeffy, D. N. Halbert and 

A. Roter. Entelos, Inc., Foster City, CA. 


USE OF PROTEOMICS-BASED 

MATHEMATICAL BIODESCRIPTORS IN 

CHARACTERIZING CHEMICAL TOXICITY. 

S. C. Basak 1 , B. Gute 1 and F. Witzmann 2 . 1 Center for 

Water and the Environment, University of Minnesota 

Duluth/NRRI, Duluth, MN and 2 Department 

of Cellular and Integrative Physiology, Indiana 

University School of Medicine, Indianapolis, IN. 


COMPUTATIONAL INFORMATICS 

SYSTEMS FOR SCREENING THE TOXICITY 

OF NATURAL PRODUCTS. L. G. Valerio 1 , R. 

F. Chanderbhan 1 and M. Diaz 2 . 1 Center for Food 

Safety and Applied Nutrition, U.S. Food and Drug 

Administration, College Park, MD and 2 Department 

of Chemical Engineering, University of Puerto Rico, 

Mayaguez, PR. 


THE RELATIONSHIP BETWEEN THE 

AROMATIC RING CLASS CONTENT AND 

REPEAT-DOSE AND DEVELOPMENTAL 

TOXICITIES OF PETROLEUM 

SUBSTANCES BOILING ABOVE 

APPROXIMATELY 300∞F. B. Simpson 2 , W. 

Dalbey 3 , J. Fetzer 4 , J. Murray 5 , M. Nicolich 3 , R. 

Roth 1 , M. Saperstein 6 , R. White 7 and T. Gray 7 . 

1 

Roth Toxicology Consulting, Westlake Village, 

CA, 2 Simpson Toxicology Consulting, Whitfield, 

United Kingdom, 3 EMBSI, Annandale, NJ, 4 Fetzpahs 

Consulting, Pinole, CA, 5 Murray & Associates, 

San Jose, CA, 6 BP Corporation, La Palma, CA and 

7 

American Petroleum Institute, Washington, DC. 


UNCERTAINTY AND VARIABILITY IN 

PREDICTING PHYSICAL PROPERTIES 

OF EMERGING MATERIALS AND 

PHARMACEUTICALS USING 

COMMERCIAL QSAR MODELS. E. Bennett 1 , 

J. Clausen 3 , E. Linkov 1 and I. Linkov 2,1 . 1 Intertox Inc., 

Seattle, WA, 2 Carnegie Mellon University, Brookline, 

MA and 3 ERDC-CRREL, U.S. Army Corps of 

Engineers, Hanover, NH. 


NOVEL CHIRALITY INDICES TO 

MODEL BIOACTIVITY/TOXICITY OF 

DIASTEREOMERS. R. Natarajan 1,2 and S. C. 

Basak 1 . 1 University of Minnesota Duluth, Natural 

Resources Research Institute, Duluth, MN and 

2 

Department of Chemical Engineering, Lakehead 

University, Thunder Bay, ON, Canada. 


AN IN SILICO APPROACH TO ASSESSING 

RISK OF 1-BROMO-2-CHLOROETHANE. 

N. Y. Wang and J. C. Lambert. National Center for 

Environmental Assessment, U.S. Environmental 

Protection Agency, Cincinnati, OH. 


AN INTELLIGENCE NETWORK FOR 

DRUG-INDUCED LIVER INJURY. D. Cook 2 , 

G. Kenna 2 , P. Bradley 1 , N. C. Day 1 , J. Z. Reed 1 , 

J. Reynolds 3 and J. C. Barnes 1 . 1 Biowisdom Ltd, 

Cambridge, Cambridgshire, United Kingdom, 

2 

AstraZeneca, Macclesfield, Cheshire, United 

Kingdom and 3 JAReynolds and Associates, Madison, 

CT. 


THE GENETIC AND ENVIRONMENTAL 

PATHWAYS TO COMPLEX DISEASES. J. M. 

Gohlke 1 , R. Thomas 1 , Y. Zhang 2 , M. C. Rosenstein 3 , 

A. P. Davis 3 , C. Murphy 3 , C. J. Mattingly 3 , K. G. 

Becker 2 and C. J. Portier 1 . 1 Laboratory of Molecular 

Toxicology, NIEHS, Research Triangle Park, NC, 

2 

Gene Expression and Genomics Unit, National 

Institute of Aging, Baltimore, MD and 3 Department 

of Bioinformatics, Mount Desert Island Biological 

Laboratory, Salisbury Cove, ME. 

106 




Abstract # 


IDENTIFICATION OF POSITIONALLY 

CONSERVED DIOXIN RESPONSE 

ELEMENTS IN ORTHOLOGOUS HUMAN, 

MOUSE, AND RAT GENES. A. Cabunoc 1,2,3 , L. D. 

Burgoon 1,2,3 and T. R. Zacharewski 1,2,3 . 1 Biochemistry 

& Molecular Biology, Michigan State University, 

East Lansing, MI, 2 National Food Safety & 

Toxicology Center, Michigan State University, East 

Lansing, MI and 3 Center for Integrative Toxicology, 

Michigan State University, East Lansing, MI. 


VALIDATING ALERTS FOR THE 

PREDICTION OF MUTAGENICITY. C. A. 

Marchant, E. M. Covey-Crump, K. Langton, R. T. 

Naven and R. V. Williams. Lhasa Limited, Leeds, 

United Kingdom. Sponsor: N. Greene. 


ANALYSIS OF TRANSCRIPTION FACTOR 

BINDING MOTIFS IN UPSTREAM 

REGIONS OF CO-REGULATED GENES: A 

METHOD FOR CREATING REGULATORY 

NETWORKS. L. M. Munsie 1 , S. Lewin-Koh 2 , 

J. J. Lowinger 1 and M. A. Davis 1 . 1 Investigative 

Toxicology, Eli Lilly and Company, Greenfield, IN 

and 2 Toxicology/ADME Statistics, Eli Lilly and 

Company, Greenfield, IN. 


THE USE OF GENE EXPRESSION DATA 

FROM MULTIPLE EXPOSURE TIMES 

FOR THE DEVELOPMENT OF GENOMIC 

BIOMARKERS OF CARCINOGENIC 

POTENTIAL. R. R. Shah 2 , S. S. Auerbach 1 and R. 

D. Irwin 1 . 1 National Toxicology Program, National 

Institute of Environmental Health Science, NIH, 

Durham, NC and 2 Constella Group, Durham, NC. 


9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: PESTICIDE METABOLISM AND TOXICITY 

Chairperson(s): Lesley Mills, U.S. EPA, Narragansett, RI. 




STRUCTURAL REQUIREMENTS FOR 

ORGANOPHOSPHORUS INSECTICIDES 

TO INHIBIT IN VIVO KYNURENINE 

FORMAMIDASE IN CHICKEN EMBRYOS 

AND MICE. J. Seifert. PEPS, University of Hawaii, 

Honolulu, HI. 


PURIFICATION AND CHARACTERIZATION 

OF RECOMBINANT HUMAN 

PARAOXONASE FROM ESCHERICHIA 

COLI. R. C. Stevens 1 , S. M. Suzuki 1 , R. Richter 1 , T. 

B. Cole 1,2 and C. E. Furlong 1 . 1 Medical Genetics and 

Genome Sciences, University of Washington, Seattle, 

WA and 2 Environmental and Occupational Health 

Sciences, University of Washington, Seattle, WA. 

Abstract # 


IDENTIFICATION OF CYTOCHROME 

P450 SUBFAMILIES INVOLVED IN 

ORGANOPHOSPHOROUS PESTICIDES 

BIOTRANSFORMATION IN MALE 

REPRODUCTIVE TRACT OF MICE. B. 

Quintanilla-Vega, Y. Palacios-Gil and A. Sierra- 

Santoyo. Toxicology Section, CINVESTAV, Mexico 

City, D.F., Mexico. 


CYP-SPECIFIC PBPK/PD MODELS 

FOR ASSESS HUMAN RISK TO 

ORGANOPHOSPHOROUS PESTICIDES. R. J. 

Foxenberg, J. B. Knaak, B. P. McGarrigle and J. R. 

Olson. Pharmacology and Toxicology, University at 

Buffalo, Buffalo, NY. 


EVALUATION OF A WEIGHTED TEST IN 

THE ANALYSIS OF ORDINAL GAIT SCORES 

IN AN ADDITIVITY MODEL FOR FIVE OP 

PESTICIDES. A. Robinson 1 , C. Gennings 1 and 

V. Moser 2 . 1 Biostatistics, VCU, Richmond, VA and 

2 

NTD, NHEERL, ORD, U.S. EPA, RTP, NC. 


CUMULATIVE RISK ESTIMATION USING 

EXPOSURE AND DOSE MODELS TO THREE 

N-METHYL CARBAMATES: CARBARYL, 

ALDICARB, AND CARBOFURAN. X. Zhang 1 , 

M. S. Okino 2 , J. B. Knaak 3 , A. M. Tsang 1 , J. Xue 4 , 

L. S. Harrison 1 , N. E. Heravi 1 , R. W. Gerlach 1 , J. 

C. Johnson 2 , R. Tornero-Velez 4 , V. G. Zartarian 4 

and C. C. Dary 2 . 1 General Dynamics Information 

Technology, Henderson, NV, 2 National Exposure 

Research Laboratory, U.S. Environmental 

Protection Agency, Las Vegas, NV, 3 Department of 

Pharmacology and Toxicology, The State University 

of New York at Buffalo, Buffalo, NY and 4 National 

Exposure Research Laboratory, U.S. Environmental 

Protection Agency, Research Triangle Park, NC. 


REPEATED DOSE TWENTY-ONE DAY 

DERMAL TOXICITY STUDY WITH 

CARBOFURAN, A CARBAMATE 

INSECTICIDE. J. D. McCarty 1 and A. M. 

Hoberman 2 . 1 FMC Corporation, Princeton, NJ and 

2 

Charles River Laboratories Preclinical Services, 

Horsham, PA. 


AN EMPIRICAL APPROACH TO 

SUFFICIENT SIMILARITY IN DOSE- 

RESPONSIVENESS IN A MIXTURE OF 11 

PYRETHROIDS. S. Marshall 1 , C. Gennings 1 , 

L. Stork 2 , L. Teuschler 3 , J. Lipscomb 3 , M. DeVito 4 

and K. Crofton 4 . 1 Biostatistics, VCU, Richmond, 

VA, 2 Monsanto, St. Louis, MO, 3 U.S. EPA/NCEA, 

Cincinnatti, OH and 4 U.S. EPA/NHEERL, Research 



RATIONALE FOR THE USE OF THE 

CIS:TRANS ISOMER RATIO OR TOTAL 

ISOMER CONTENT OF CYPERMETHRIN, 

ZETA CYPERMETHRIN, AND 

PERMETHRIN FOR HUMAN HEALTH RISK 

ASSESSMENT. M. Maynard, M. L. Weiner and S. 

F. Elaggar. FMC Corporation, Princeton, NJ. 

Monday 



Monday 




ENANTIOSELECTIVE ESTROGENIC 

ACTIVITY OF PYRETHROID 

INSECTICIDES. D. Schlenk, M. Nillos and J. 

Gan. Environmental Sciences, University California- 

Riverside, Riverside, CA. 


ESFENVALERATE ACTS AT THE 

HYPOTHALAMUS TO SUPPRESS THE 

AFTERNOON RISE OF LUTEINIZING 

HORMONE IN PREPUBERTAL FEMALE 

RATS. M. Pine and J. K. Hiney. Veterinary 

Integrative Biosciences, Texas A&M University, 

College Station, TX. 


PYRETHROID EXPOSURE OF ZEBRAFISH 

(DANIO RERIO) EMBRYOS RESULTS IN 

ABNORMAL DEVELOPMENT. A. Green 1 , A. 

DeMicco 1 , K. R. Cooper 1 , J. R. Richardson 2 and L. 

A. White 1 . 1 Biochemistry and Microbiology, Rutgers 

University, New Brunswick, NJ and 2 Toxicology 

Division, EOHSI, Piscataway, NJ. 


EVALUATION OF VASCULAR TOXICITY OF 

PERMETHRIN IN HUMAN ENDOTHELIAL 

CELL AND MOUSE ES CELL. S. Imanishi, 

J. Yonemoto and H. Sone. National Institute for 

Environmental Studies, Tsukuba, Japan. 


EVIDENCE FOR LACK OF GENOTOXICITY 

OF ZETA-CYPERMETHRIN. W. Luo, J. 

D. McCarty, M. L. Weiner and M. S. Maynard. 

Toxicology, FMC Corporation, Princeton, NJ. 


EFFECTS OF ATRAZINE ON BLOOD 

PHYSIOLOGY IN ADULT FEMALE WISTAR 

RATS. R. R. Brown 2 , C. D. Foradori 2 , L. R. Hinds 2 , 

G. Dooley 1 , W. H. Hanneman 1 and R. J. Handa 2 . 

1 

Environmental and Radiological Health Sciences, 

Colorado State University, Fort Collins, CO and 

2 

Biomedical Sciences, Colorado State University, 

Fort Collins, CO. 


REVERSAL OF ATRAZINE DEPENDENT 

EFFECTS ON GNRH NEUROENDOCRINE 

FUNCTION IN WISTAR RATS. C. D. Foradori 2 , 

L. R. Hinds 2 , W. H. Hanneman 1 and R. J. Handa 2 . 

1 

Environmental Health, Colorado State University, 

Fort Collins, CO and 2 Biomedical Sciences, Colorado 

State University, Fort Collins, CO. 


ATRAZINE INHIBITS THE PULSATILE 

LH RELEASE WITHOUT ALTERING 

PITUITARY SENSITIVITY TO A GNRH 

RECEPTOR ANTAGONIST IN FEMALE 

WISTAR RATS. R. J. Handa 2 , L. R. Hinds 2 , W. 

H. Hanneman 1 , M. E. Legare 1 , C. M. Clay 2 and 

C. D. Foradori 2 . 1 Environmental Health, Colorado 

State University, Fort Collins, CO and 2 Biomedical 

Sciences, Colorado State University, Fort Collins, 

CO. 


DIFFERENCES IN METABOLISM AND 

AROMATASE ACTIVITY IN A FISH AND A 

RAT SPECIES TREATED WITH ATRAZINE. 

L. J. Mills 1 , R. Gutjahr-Gobell 1 , S. Jayaraman 1 , 

G. Zaroogian 1 and S. Laws 2 . 1 NHEERL, Atlantic 

Ecology Division, U.S. EPA, Narragansett, RI and 

2 

NHEERL, Reproductive Toxicology Division, U.S. 

EPA, Research Triangle Park, NC. 


CHARACTERIZATION OF CYPS IN THE 

METABOLISM OF ALL TRANS RETINOIC 

ACID BY LIVER MICROSOMES FROM 

MICE TREATED WITH CONAZOLES. P. 

Chen 1,2 , W. T. Padgett 1 , M. Tanya 1 , W. Winnik 1 , S. 

Thai 1 , S. D. Hester 1 and S. Nesnow 1 . 1 Environmental 

Carcinogenesis Division, U.S. EPA, Research 

Triangle Park, NC and 2 Department of Agricultural 

Chemistry, National Taiwan University, Taipei, 

Taiwan. 


GENDER- AND SPECIES-MEDIATED 

DIFFERENCES IN THE IN VITRO 

METABOLISM OF TRIADIMEFON BY 

RODENT HEPATIC MICROSOMES. S. Ritger 1 , 

M. Henderson 2 , J. F. Kenneke 2 , C. S. Mazur 2 and J. 

W. Fisher 1 . 1 Interdisciplinary Toxicology Program, 

College of Public Health, University of Georgia, 

Athens, GA and 2 Ecosystems Research Division, 

United States Environmental Protection Agency, 

Athens, GA. 


RISK TO HUMANS FROM DIETARY 

EXPOSURE TO THE NEONICOTINOID 

INSECTICIDE IMIDACLOPRID. S. E. 

Koshlukova, N. R. Reed, K. Pfeifer and J. Gee. 

Pesticide Regulation, CalEPA, Sacramento, CA. 


DETERMINANTS OF HUMAN EXPOSURE 

TO PET PEST PRODUCTS: FIPRONIL. M. M. 

Bigelow, Y. Li, Z. Chen, H. Vega and R. I. Krieger. 

Environmental Toxicology Graduate Program/ 

Entomology, PCEP, University of California- 



CHLORPYRIFOS ALTERS METHYLATION 

STATUS OF PROMOTER-CPG ISLANDS IN 

PLACENTAL CHORIOCARCINOMA CELLS. 

M. D. Saulsbury, S. O. Heyliger, Q. Chen, K. 

Wang, J. Morse and D. J. Johnson. Pharmaceutical 

Sciences, Hampton University, Hampton, VA. 

108 




Abstract # 


9:30 AM to 12:30 PM 

Exhibit Hall 


POSTER SESSION: INHALANTS: OXIDATIVE AND REDOX 

MECHANISMS 

Chairperson(s): Nabil Elsayed, Celgene Corporation, Summit, NJ and 

Rodney Rouse, Louisiana State University, Baton Rouge, LA. 




BASIC COMPONENTS OF WOOD 

SMOKE PARTICULATE MATTER CAUSE 

OXIDATIVE STRESS AND CASPASE- 

DEPENDENT APOPTOSIS IN RAW 264.7 

CELLS. K. A. Fay, C. D. Simpson, R. L. Dills, 

M. H. Paulsen, C. C. White and T. J. Kavanagh. 

Environmental and Occupational Health, University 

of WA, Seattle, WA. 


UPREGULATION OF POLYAMINE 

BIOSYNTHESIS IN RAT LUNG FOLLOWING 

BLEOMYCIN ADMINISTRATION. N. 

M. Elsayed 1,2 and D. F. Tierney 3 . 1 Early Drug 

Development, Toxicology, Celgene Corp, Summit, 

NJ, 2 Anatomy and Cell Biology, Medical College, 

SUNY Downstate Medical Center, Brooklyn, NY and 

3 

Pulmonary Disease, UCLA School of Medicine, Los 

Angeles, CA. 


INTERMEDIATE FILAMENT PROTEINS 

AS TARGETS FOR REACTIVE CARBONYL 

COMPOUNDS. A. Y. Saik. Pharmacology and 

Anaesthesiology Unit, University of Western 

Australia, Nedlands, WA, Australia. Sponsor: P. 

Burcham. 


CARBONYL SCAVENGERS SUPPRESS 

THE TOXICITY OF POLYETHYLENE 

PYROLYSIS PRODUCTS. P. C. Burcham. 

Pharmacology Unit, University of Western Australia, 

Nedlands, WA, Australia. 


A GENETIC BASIS FOR THE HEIGHTENED 

SENSITIVITY OF THE NEONATAL MOUSE 

LUNG TO OZONE. E. M. Vancza, K. Galdanes 

and T. Gordon. New York University School of 

Medicine, Tuxedo, NY. 


THE INORGANIC FRACTION OF PM 10 

AND PM 2.5 

INDUCES OXIDATIVE STRESS IN 

HUMAN LUNG CELLS. R. García-Dominguez 1 , 

M. Uribe-Ramirez 1 , V. Mugica-Alvarez 3 , A. Eiguren- 

Fernandez 4 , J. Froines 4 , A. Osornio-Vargas 2 and A. 

De Vizcaya-Ruiz 1 . 1 Toxicology, CINVESTAV-IPN, 

México D.F., Mexico, 2 Investigación Básica, INCan, 

SSA, Mexico D.F., Mexico, 3 Química Aplicada, 

UAM-A, Mexico D.F., Mexico and 4 COEH-SCPC, 

UCLA, LA, CA. 

Abstract # 


AIRBORNE PARTICULATE MATTER 

DEPLETES GLUTATHIONE AND INDUCES 

CELL DEATH ON HUMAN ALVEOLAR 

CELLS. G. Alvarez-Labastida 1 , M. Uribe-Ramirez 1 , 

A. Osornio-Vargas 2 and A. De Vizcaya-Ruiz 1 . 

1 

Toxicology, CINVESTAV-IPN, México D.F., 

Mexico and 2 Investigación Básica, INCan, SSA, 

Mexico D.F., Mexico. 


GENE PROFILING OF LIBBY AMPHIBOLE 

ASBESTOS COMPARED TO CROCIDOLITE 

ASBESTOS IN HUMAN MESOTHELIAL 

CELLS. J. M. Hillegass 1 , A. Shukla 1 , M. 

MacPherson 1 , V. Alexeeva 1 , A. van der Vliet 1 , M. 

E. Gunter 2 and B. T. Mossman 1 . 1 Department of 

Pathology, University of Vermont, Burlington, VT 

and 2 Department of Geological Sciences, University 

of Idaho, Moscow, ID. 


MITOCHONDRIAL OXIDATIVE AND 

ENZYMATIC DAMAGE IN ACUTE 

CARBON MONOXIDE POISONING: 

LIPID PEROXIDATION AND COMPLEX 

IV ACTIVITY IN LYMPHOCYTES AND 

ITS MODIFICATION AFTER OXYGEN 

THERAPY. F. Cardellach 1 , G. Garrabou 1 , J. 

M. Inoriza 2 , M. J. Marti 2 , G. Oliu 2 and O. Miro 1 . 

1 

Hospital Clínic of Barcelona. IDIBAPS. University 

of Barcelona, Barcelona, Spain and 2 Hospital of 

Palamós, Palamós, Spain. Sponsor: J. Domingo. 


BIOMARKERS OF SULFUR MUSTARD 

EXPOSURE IN HUMAN CELL LINES. J. 

Seagrave, W. Weber, C. Irvin, L. Herrera, D. Palucki, 

G. Herbert, J. D. McDonald and G. R. Grotendorst. 

Lovelace Respiratory Research Institute, 



GAS-PARTICLE PARTITIONING IN URBAN 

AIR MIXTURES AND ITS EFFECT ON 

HUMAN EPITHELIAL LUNG CELLS. S. 

Ebersviller 1 , K. G. Sexton 1 , K. de Bruijne 1 , R. 

Woodside 1 , C. Olenick 1 , I. Jaspers 2,1 and H. Jeffries 1 . 

1 

Environmental Sciences and Engineering, UNC 

Chapel Hill, Chapel Hill, NC and 2 CEMALB, UNC 

Chapel Hill, Chapel Hill, NC. 


INHALATION OF COMBUSTION- 

DERIVED NANOPARTICLES STIMULATES 

EXPRESSION OF NRF2 MEDIATED 

OXIDATIVE STRESS RESPONSE GENES 

IN MURINE LUNG. R. Rouse, G. Murphy and A. 

Penn. CBS, SVM, LSU, Baton Rouge, LA. 


IMPAIRMENT OF MACROPHAGE 

FUNCTION UNDER MODERATE 

CONCENTRATIONS OF OXYGEN. L. 

Mantell 1,2 , T. Entezari-Zaher 1 , E. J. Miller 2 , K. 

Degenhardt 1 and A. Pathak 1 . 1 Pharmaceutical 

Sciences, St. John’s University College of Pharmacy, 

Queens, NY and 2 Cardiopulmonary Research, The 

Feinstein Institute for Medical Research, Manhasset, 

NY. 

Monday 



Monday 




DOES SANDBLASTED METAL ATTENUATE 

OR ENHANCE THE TOXICITY OF FRESHLY 

FRACTURED SILICA? M. Pacurari, V. Robinson, 

V. Castranova, S. S. Leonard, F. Chen, V. Vallyathan 

and M. Barger. CDC/NIOSH/HELD, Morgantown, 

WV. 


9:30 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: XENOBIOTIC BIOTRANSFORMATION II 

Chairperson(s): David Williams, Oregon State University, Corvallis, OR. 




FROM XENOBIOTICS TO ENDOBIOTICS: 

EFFICIENT HYDROLYSIS OF 

THE ENDOCANNABINOID 

2-ARACHIDONYLGLYCEROL BY HUMAN 

CARBOXYLESTERASES 1 AND 2. M. Ross 1 , 

A. Borazjani 1 , S. Xie 1 and P. M. Potter 2 . 1 Center for 

Environ Health Sci, Mississippi State University, 

Mississippi State, MS and 2 St. Jude Children’s 

Research Hospital, Memphis, TN. 


METHYLATION OF DIMETHYLTIN IN 

MICE AND RATS. K. Furuhashi 1 , M. Ogawa 2 , 

Y. Suzuki 2 , Y. Endo 2 , Y. Kim 3 and G. Ichihara 1 . 

1 

Occupational and Environmental Health, Nagoya 

University Graduate School of Medicine, Nagoya, 

Japan, 2 Clinical Research Center for Occupational 

Poisoning, Tokyo Rosai Hospital, Tokyo, Japan and 

3 

Occupational and Environmental Medicine, Ulsan 

University Hospital, University of Ulsan Colledge of 

Medicine, Ulsan, South Korea. 


EFFECT OF OSMOTIC STRESS ON THE 

EXPRESSION OF FLAVIN-CONTAINING 

MONOOXYGENASE mRNA, PROTEIN AND 

CATALYTIC ACTIVITY IN RAT KIDNEY. D. 

Schlenk 1 , G. Rodriguez-Fuentes 1 , C. Coburn 2 and 

M. Curras-Collazo 2 . 1 UC- Riverside, Riverside, CA 

and 2 Cell Biology & Neuroscience, University Cal. 



MECHANISM OF METHYLMERCURY 

BIOTRANSFORMATION IN HUMAN CELL 

LINES. M. Nagano 1 , A. Yasutake 1 and K. Miura 2 . 

1 

National Institute for Minamata Disease, Minamata, 

Kumamoto, Japan and 2 Wako University, Machida, 

Tokyo, Japan. Sponsor: M. Yamamoto. 


PURIFICATION AND CHARACTERIZATION 

OF FLAVIN-CONTAINING 

MONOOXYGENASE ISOFORM 3 (FMO3) 

FROM MALE RAT KIDNEYS. R. Novick and 

A. A. Elfarra. University of Wisconsin-Madison, 

Madison, WI. 


EFFECT OF MICROBIALLY INDUCED 

TRANSFORMATIONS OF BROMINATED 

FLAME RETARDANTS AND TOXICITY IN 

ZEBRAFISH. J. M. McCormick, K. R. Cooper, M. 

M. Haggblom and L. A. White. Biochemistry and 

Microbiology, Rutgers, The State University of New 

Jersey, New Brunswick, NJ. 


BIOTRANSFORMATION OF 2, 3, 3, 

3-TETRAFLUOROPROPENE IN RATS. P. 

Schuster 1 , R. Bertermann 2 , G. M. Rusch 3 and W. 

Dekant 1 . 1 Department of Toxicology, University 

of Würzburg, Würzburg, Germany, 2 Department 

of Inorganic Chemistry, University of Würzburg, 

Würzburg, Germany and 3 Honeywell Inc., 

Morristown, NJ. 


IDENTIFICATION OF A TRYPTANTHRIN 

METABOLITE IN RAT LIVER 

MICROSOMES BY LC-ESI MS. Y. Seo 1 , S. 

Lee 2 , G. Kim 1 , D. Kim 2 , M. Kang 1 , Y. Jahng 1 and T. 

Jeong 1 . 1 College of Pharmacy, Yeungnam University, 

Gyeongsan, South Korea and 2 Bioanalysis and 

Biotransformation Research Center, KIST, Seoul, 

South Korea. 


EFFECTS OF RUTAECARPINE 

ON PHARMACOKINETICS OF 

ACETAMINOPHEN IN RATS. J. Kim 1 , S. Lee 2 , 

S. R. Bista 1 , M. Kang 1 , Y. Jahng 1 and T. Jeong 1 . 

1 

College of Pharmacy, Yeungnam University, 

Gyeongsan, South Korea and 2 BBRC, KIST, Seoul, 

South Korea. 


METABOLISM OF FPP-3, AN ANTI- 

INFLAMMATORY PROPENONE 

COMPOUND, IN RATS. T. Jeong 1 , S. Lee 2 , J. 

Kim 1 , Y. Seo 1 , H. Jeong 3 , M. Kang 1 and E. Lee 1 . 

1 

College of Pharmacy, Yeungnam University, 

Gyeongsan, South Korea, 2 BBRC, KIST, Seoul, 

South Korea and 3 College of Pharmacy, Chosun 

University, Gwangju, South Korea. 


METABOLISM OF [ 14 C]CUMENE IN F344 

RATS AND B6C3F1 MICE: FORMATION OF 

ALPHA-METHYLSTYRENE. L. C. Ferguson, 

Z. Gao, H. B. Hoffman, B. M. Hedtke and K. J. 

Dix. Lovelace Respiratory Research Institute, 



SPECIFICITY OF RAT 

SULFOTRANSFERASES FOR 

HYDROXYLATED POLYCHLORINATED 

BIPHENYLS AND ITS MODIFICATION 

BY OXIDIZED GLUTATHIONE. Y. Liu 1 , H. 

Lehmler 2 , L. W. Robertson 2 and M. W. Duffel 1 . 

1 

Division of Medicinal and Natural Products 

Chemistry, College of Pharmacy, University of Iowa, 

Iowa City, IA and 2 Department of Occupational and 

Environmental Health, College of Public Health, 

University of Iowa, Iowa City, IA. 

110 




Abstract # 


DETERMINATION OF THE SITES OF 

HYDROLYSIS AND IN VITRO RATE 

CONSTANTS FOR METABOLIC AND NON- 

METABOLIC CLEARANCE MECHANISMS 

OF SULFURYL FLUORIDE IN THE RAT. 

E. R. Lowe 1 , D. L. Rick 1 , T. S. McMullin 1 , M. J. 

Bartels 1 and D. L. Eisenbrandt 2 . 1 Toxicology and 

Environmental Research and Consulting, The 

Dow Chemical Company, Midland, MI and 2 Dow 

AgroSciences LLC, Indianapolis, IN. Sponsor: S. 

Saghir. 


REACTIONS OF SINGLET OXYGEN WITH 

FUROSEMIDE: POSSIBLE FORMATION 

OF REACTIVE ELECTROPHILIC 

INTERMEDIATES. B. M. King 1 , R. M. Uppu 1,2 

and M. O. Fletcher Claville 2,1 . 1 Environmental 

Toxicology, Southern University and A&M College, 

Baton Rouge, LA and 2 Chemistry, Southern 

University and A & M College, Baton Rouge, LA. 


CHARACTERIZATION OF CYTOCHROME 

P450 ISOFORMS INVOLVED IN 

VINCLOZOLIN BIOTRANSFORMATION 

IN RAT LIVER. A. Sierra-Santoyo, L. Lopez- 

Gonzalez and E. Angeles-Soto. Toxicology Section, 

CINVESTAV-IPN, Mexico City, D.F., Mexico. 


BASE-CATALYZED HYDROLYSIS OF 

ARTIMISININ TO A HYDROPEROXIDE 

DERIVATIVE: IMPLICATIONS TO 

MECHASIM OF ACTION OF ARTEMISININ 

AND ITS DERIVATIVES. R. M. Uppu and A. C. 

Raghavamenon. Environmental Toxicology and the 

Health Research Center, Southern University and 

A&M College, Baton Rouge, LA. 


RESVERATROL INDUCTION OF DRUG 

TRANSPORTER EXPRESSION IN MOUSE 

LIVER. S. R. Kulkarni, Q. Cheng and A. L. 

Slitt. Biomedical and Pharmaceutical Sciences, 

University Of Rhode Island, Kingston, RI. Sponsor: 

J. Manautou. 


HESPERETIN INDUCTION OF 

SULFOTRANSFERASES IN HEP G2 CELLS 

AND RAT TISSUES. C. Huang and G. Chen. 

Physiological Sciences, Oklahoma State University, 

Stillwater, OK. 


RECEPTOR-MEDIATED REGULATION 

OF HUMAN CYP450, PHASE II, AND 

TRANSPORTER GENE EXPRESSION BY 

SELECTIVE ACTIVATORS ASSESSED BY 

QUANTITATIVE RNASE PROTECTION 

ASSAYS. S. S. Ferguson, C. Black, C. Baucom and 

E. L. LeCluyse. CellzDirect, Durham NC. Sponsor: 

O. Hankinson. 


POTENTIAL ROLES OF NF-KAPPAB AND 

NFE2L2 IN REGULATION OF HUMAN 

HEPATIC MRP4 GENE EXPRESSION. S. 

Campion, X. Gu and J. E. Manautou. Department of 

Pharmaceutical Sciences, University of Connecticut, 

Storrs, CT. 


9:45 AM to 10:45 AM 

Exhibit Hall 4C-3 

Exhibitor Hosted Session: Scientific Advances in 

GLP Bioanalytical Analysis 

Presented by: MPI Research 

Scientific advances on assay reproducibility for incurred samples and 

related bioanalytical techniques will be presented. Current industry trends 

and the latest regulatory recommendations regarding sampling methodology, 

randomization, reporting, and acceptance criteria will also be 

discussed. 


9:45 AM to 10:45 AM 


Exhibitor Hosted Session: Biotechnology—Both 

a Business and a Science and Biotechnology— 

Changing Science and Service 

Presented by: Ricerca Biosciences, LLC 

Pharmaceutical research has changed over the past 30–40 years. The business 

economics have evolved from ‘re-investment of profit’ to external 

investment in the process by those looking for high return. The concept of 

a CRO has also evolved in both scope and service with new opportunities 

for CROs to offer Drug Discovery through IND-enabling studies. 


11:00 AM to 12:00 NOON 


Exhibitor Hosted Session: SELDI-TOF Strategies 

for Toxicological Biomarker Discovery and 

Application 

Presented by: Bio-Rad Laboratories 

Bio-Rad’s SELDI Application Scientists and Biomarker Research Centers 

have used SELDI ProteinChip technologies in collaborations with the U.S. 

EPA, the European Union PredTox Consortium, and multiple pharmaceutical 

companies to discover and characterize biomarkers of toxicity from 

crude biological samples. Examples from some of these collaborations will 

be presented. 

Monday 



Monday 



11:00 AM to 12:00 NOON 


Exhibitor Hosted Session: Multiplexing 

Luminescent ADMETox Cell-Based Assays 

Including Applications with Primary Cells and 

Stem Cells 

Presented by: Promega Corporation 

Combining luminescent assay sensitivity with the ability to multiplex 

increases experimental efficiency and reduces the number of cells required 

for ADMET studies with primary cells or stem cells. Requirements for 

multiplexing luminogenic viability assay chemistries will be presented 

along with examples including: multiplexing CYP450 activity and hepatocyte 

viability, and GSH levels and cytotoxicity. 

MONDAY AFTERNOON 

Monday Afternoon, March 17 

12:00 NOON to 1:30 PM 

See Daily Pocket Calendar on page 6 for room listings 

Specialty Section Meetings/Lucheons: 

Nanotoxicology, Neurotoxicology, Toxicology 

and Exploratory Pathology 


12:15 PM to 1:20 PM 

Sheraton Hotel 

Grand Ballroom A 

In Vitro Toxicology Lecture AND LUNCHEON for 

Students 

Lecturer: Yvonne Will, Pfizer, Inc., San Diego, CA 

Development of In Vitro Screening Tools to Test 

for Drug-Induced Mitochondrial Toxicities 

(ticket required) 

Sponsored by: 

The Colgate-Palmolive Company 

Organized by: 

The Animals in Research Committee 

It is estimated that only 50% of the animal studies 

predict human efficacy and more importantly human 

toxicity. In addition, the use of animals should be minimized 

as much as possible for ethical reasons. Today, 

there are vigorous, ongoing national and international 

research and policy efforts to develop alternatives to 

animal testing. The efforts focus on both in vitro and in 

silico approaches and methods. For example, the 

National Toxicology Program (NTP) at the National 

Institute of Environmental Health Sciences (NIEHS) 

created the NTP Interagency Center for the Evaluation 

of Alternative Toxicological Methods (NICEATM) in 1998. 

Mitochondrial dysfunction is a common mechanism of drug-induced 

toxicity for a variety of therapeutics, such as certain antiviral drugs, lipidlowering 

drugs, NSAIDs and certain cancer chemotherapeutics. Therefore, 

the early identification of drug candidates that potentially disrupt mitochondrial 

function is of significant importance in drug discovery. In the past few 

years we have developed organelle and cell based in vitro screens to detect 

potential mitochondrial toxicities. These include oxygen sensors to measure 

mitochondrial respiration in isolated mitochondria and cells, immunocapture 

of individual electron transport chain proteins that can identify 

inhibitors of mitochondrial electron transport, and metabolic profiling using 

oxygen and pH measurements. We discuss the strength and limitations of 

new applicable high throughput screens and provide recommendations of 

where to position these assays within the drug development process. 

112 




Abstract # 


12:15 PM to 1:30 PM 

Room 618 

Abstract # 


12:15 PM to 1:30 PM 

Room 602 

Monday 

ROUNDTABLE SESSION: RISK ASSESSMENT FOR 

BIOTHERAPEUTICS 

Chairperson(s): Leigh Ann Burns Naas, Pfizer Global Research and 

Development, San Diego, CA and Laura Andrews, Genzyme Corporation, 

Framingham, MA. 

Endorsed by: 





The evaluation of nonclinical safety of potential new drugs underpins 

the design and execution of their clinical development plans. Nonclinical 

safety evaluation for biotherapeutics is similar in principle to that for small 

molecules; however, the very nature of these molecules requires special 

considerations that are likely to be unique for each new entity. To make 

the nonclinical assessment even more challenging, newer biotherapeutics 

are becoming much more refined (species specific and potent) and diverse 

in nature. Additionally, with the merger of certain aspects of CBER into 

CDER, and in the aftermath of TeGenero and the report from Professor 

Duff’s Expert Working Group, it is clear that regulatory expectations are 

changing. Specifically, at the writing of this abstract FDA is drafting a guidance 

document intended to supplement ICH S6 in the nonclinical assessment 

of biotherapeutics, EMEA has released draft guidance on the requirements 

to support first in human dosing (including a recommendation for dose 

setting in FIH studies), and ICH is considering whether to open the ICH 

S6 guidance for biologics for maintenance. These evolutions in science and 

regulatory policy present ever increasing challenges in the safety assessment 

of biotherapeutics. This roundtable will present information and raise 

questions for discussions related to increasing confidence in safety during 

biotherapeutics discovery, when and how surrogate models for safety assessment 

of biotherapeutics may be appropriate, how to use pharmacological 

data to help select appropriate doses for nonclinical safety assessment, and 

key considerations for dose selection in human studies. 

#321 12:15 RISK ASSESSMENT FOR 

BIOTHERAPEUTICS. L. Burns Naas 1 , L. 

Andrews 2 , J. Bussiere 3 , C. Horvath 4 , M. Dempster 5 

and T. Determined 6 . 1 Drug Safety Research 

& Development, Pfizer, Inc., San Diego, CA, 

2 

Department of Pharmacology and Toxicology, 

Genzyme Corporation, Framingham, MA, 

3 

Department of Toxicology, Amgen, Thousand Oaks, 

CA, 4 Toxicology, Archemix Corporation, Cambridge, 

MA, 5 GlaxoSmithKline, Herts, United Kingdom and 

6 

U.S. Food and Drug Administration, Washington, 

DC. 

12:20 TARGET LIABILITY ASSESSMENT: 

WHAT’S IN YOUR WALLET? Jeanine Bussiere 

12:34 WHEN THE USUAL SUSPECTS JUST 

WON’T WORK: SURROGATE MODELS IN 

NONCLINICAL SAFETY TESTING. Laura 

Andrews 

12:48 USING PHARMACOLOGY DATA TO 

SELECT DOSES FOR TOXICOLOGY 

STUDIES. Christopher Horvath 

1:02 ISSUES IN DOSE SELECTION FOR FIRST- 

IN-HUMAN STUDIES. Maggie Dempster 

1:16 REGULATORY PERSPECTIVE. TBD 


Career Development 

ROUNDTABLE SESSION: THE FUTURE OF TOXICOLOGY 

Chairperson(s): Boris Zhivotovsky, Karolinska Institutet, Stockholm, 

Sweden and Ivan Rusyn, University of North Carolina Chapel Hill, 


Endorsded by: 

Education Committee 

Mechanisms Specialty Section* 

Toxicology benefits greatly from recent advances in biomedical sciences and 

technology that provide new opportunities to facilitate our understanding of 

the chemical and biological mechanisms of toxicity. However, the discipline 

is facing something of an identity crisis. Toxicology as a scientific discipline 

has traditionally combined fundamental and applied research. Unfortunately, 

during the past decade the balance has shifted in favor of applied research. 

This roundtable will consider the future directions in toxicological research 

and highlight some of the examples of how fundamental science can be 

used successfully to address applied issues of toxicological relevance. 

For example, cell death research can serve as an important link between 

basic science and toxicology and as an area of cross-fertilization between 

disciplines. Cell death is the result of toxicity, and analysis of signaling pathways 

is essential for verification of the targets and mechanisms of toxins 

action. Furthermore, novel molecular, biochemical, genetic and genomics 

approaches are increasingly used to understand the mechanisms of environmental 

toxicants. New data which combines knowledge of the toxicity 

mechanisms, gene expression profiling and the information on the genetic 

diversity in the mammals makes it possible to determine what genetic variants 

correlate with susceptibility or resistance to toxicity and disease, thus 

potentially helping to identify a susceptible population for each exposure. In 

addition, uncovering the mechanisms by which agents cause adverse effects 

allows for a more refined assessment of dose-response, and therefore better 

predictions regarding thresholds for toxicity. Such information is critical for 

medical practice, drug development and setting environmental and occupational 

exposure limits. Finally, the public expects that the time frame from 

fundamental toxicological research to practical application must shorten 

commensurable with the urgency to deliver adequate risk assessment on 

issues relevant to public health and safety. Hence, tight interactions between 

fundamental and applied research is the future of toxicology. 

#322 12:15 THE FUTURE OF TOXICOLOGY. B. 

Zhivotovsky. Institute of Environmental Medicine, 

Division of Toxicology, Karolinska Institutet, 

Stockholm, Sweden. 

12:19 DOES IT MATTER HOW CELLS DIE? Boris 

Zhivotovsky 

12:30 GENETICAL GENOMICS AND 

MECHANISTIC TOXICOLOGY. Ivan Rusyn 

12:40 METABOLIC ACTIVATION AND 

DRUG DESIGN: CHALLENGES AND 

OPPORTUNITIES IN CHEMICAL TOXICITY. 

Thomas Baillie 

12:50 MECHANISTIC RESEARCH AND DRUG 

SAFETY ASSESSMENT: CHALLENGES AND 

OPPORTUNITIES. James Stevens 

1:00 THE SYSTEMS BIOLOGY APPROACH IN 

TOXICOLOGY. Dean Jones 

1:10 DISEASE-ORIENTED TOXICOLOGY: NIEHS 

STRATEGIC PLAN FOR 2006–2011. Samuel 

Wilson 

1:20 THE ROLE OF MECHANISTIC 

TOXICOLOGY IN SUPPORTING 

TRANSLATIONAL SCIENCE-BASED 

MEDICINE. Terrance J. Kavanaugh


Monday 



12:15 PM to 1:15 PM 


Exhibitor Hosted Session: Fish First: Zebrafish 

are Increasingly Used for Early Stage Assessment 

of Drug Efficacy, Toxicity, and Safety 

Presented by: Phylonix Pharmaceuticals, Inc. 

We have developed in vivo zebrafish assays for assessing drug toxicity 

and safety. Conventional sample handling instrumentation can be used to 

perform quantitative assays. Models for most major diseases, including: 

heart, neuronal, liver and other organs, eye, and cancers have been generated 

and studies show a striking correlation between results in zebrafish 

and results in mammals. 


12:15 PM to 1:15 PM 


Exhibitor Hosted Session: Innovations in Infusion 

and Sampling 

Presented by: Strategic Applications, Inc. (SAI) 

This session will address the integration of Wi Fi and infusion pump 

technology and its potential impact on pharmaceutical research and development. 

We will also discuss the products designed to enhance the quality 

and efficiency of preclinical infusion and sampling procedures and technological 

advancements in catheter design and customization. 


12:30 PM to 1:20 PM 

Ballroom 6B 

Merit Award Lecture: The Dose 

Makes the Toxicologist—Paracelsus 

As Seen From Switzerland 

Lecturer: Hanspeter Witschi, University of California 

Davis, Emeritus, Bandon, OR 

Theophrastus Bombastus von Hohenheim—as he 

called himself throughout his life—was born in Switzerland 

(1493) where he lived with his parents during 

the first few years of his childhood and, later, some 5 years in Basel, 

St. Gall and its surroundings. The rest of his unruly life he spent traveling; 

the last few years in Austria where he died in 1541. He is best remembered 

for the saying “the dose makes the poison”, but his impact on contemporary 

and later medicine was much broader. Joseph F. Borzelleca gives 

a vivid description of Paracelsus’ accomplishment in his most readable: 

“Paracelsus—Head of Modern Toxicology” (ToxSci. 53, 2–4, 2000). In 

1993, the Swiss historian Pirmin Meier wrote a book never translated into 

English “Paracelsus—Arzt und Prophet”, highlighting Paracelsus’ activity 

in Switzerland. It served as primary source material for adding some details 

to the work and life of Paracelsus, such as interesting information on his 

name, on how he looked at disease in a new and holistic manner, his preoccupation 

with the “invisible diseases”, his “Hippocratic oath” and why he 

was banned from publishing by the City of Nuremberg in 1530 (most of 

his voluminous writing was published only after his death in 1541). A few 

personal reflections on Paracelsus and his role in toxicology will be added. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: ALTERNATIVE OCULAR AND DERMAL 

MODELS 

Chairperson(s): Frank Barile, Saint Johns University, Queens, NY. 

Displayed: 1:00 PM–4:30 PM 

Attended: 1:00 PM–2:45 PM 


THE UTILIZATION OF THE EPIOCULAR TM 

HUMAN TISSUE MODEL TO ASSESS AND 

COMPARE THE IRRITATION POTENTIAL 

OF MULTIPLE SURFACTANT SYSTEMS 

USED IN SHAMPOOS AND FACIAL 

CLEANSERS. P. Vavilikolanu 1 , C. Lazaro 1 , G. 

Mun 2 , A. Hilberer 2 , M. Hyder 2 , H. Raabe 2 and R. 

D. Curren 2 . 1 Alberto-Culver Company, Melrose 

Park, IL and 2 Institute for In Vitro Sciences, Inc., 

Gaithersburg, MD. 


COMPARISON OF THE EPIOCULAR ASSAY 

WITH HUMAN CLINICAL USE STUDIES 

AND POST-MARKET CONSUMER DATA. C. 

Gomez 1 , A. Dang 1 , S. Steele Fisher 2 and J. Harbell 3 . 

1 

Product Safety, Mary Kay Inc., Dallas, TX, 

2 

Technical Information, Mary Kay Inc., Dallas, TX 

and 3 Clinical and Consumer Evaluation, Mary Kay 

Inc., Dallas, TX. 


THE DEVELOPMENT AND UTILIZATION 

OF AN IN VITRO SAFETY TESTING 

PROGRAM FOR HAIR CONDITIONERS. 

C. Lazaro 1 , P. Vavilikolanu 1 , G. Mun 2 , A. Hilberer 2 , 

M. Hyder 2 , H. Raabe 2 and R. D. Curren 2 . 1 Alberto- 

Culver Company, Melrose Park, IL and 2 Institute for 

In Vitro Sciences, Inc., Gaithersburg, MD. 


EXPANDED UTILIZATION OF THE 

EPIOCULAR HUMAN CORNEAL TISSUE 

MODEL FOR OCULAR IRRITATION 

TESTING. M. Klausner, L. d’Argembeau-Thornton, 

H. Kandarova, P. Hayden and Y. Kaluzhny. MatTek 

Corporation, Ashland, MA. 


THE PORCINE CORNEAL OPACITY 

AND REVERSIBILITY ASSAY IS AN 

ALTERNATIVE ASSAY THAT PROVIDES 

EVIDENCE OF REVERSIBLE EYE 

IRRITANCY. A. C. Gilotti, M. Piehl, A. L. Ball 

and D. R. Cerven. MB Research Laboratories, 



CONFOCAL MICROSCOPY OF 

REVERSIBILITY IN EXCISED PORCINE 

CORNEAS. M. Piehl, A. C. Gilotti, A. Ball 

and D. R. Cerven. MB Research Laboratories, 


114 




Abstract # 


AN INTER-LABORATORY STUDY OF 

SHORT TIME EXPOSURE(STE) TEST 

FOR PREDICTING EYE IRRITATION 

POTENTIAL OF COSMETIC INGREDIENTS 

AND FINAL PRODUCTS. Y. Takahashi 1 , T. 

Hayashi 2 , S. Watanabe 3 , M. Koike 1 , H. Sakaguchi 1 , 

S. Ebata 3 , H. Kuwahara 2 , T. Nakamura 3 and N. 

Nishiyama 1 . 1 Kao Corporation, Tochigi, Japan, 

2 

Kanebo Cosmetics INC., Kanagawa, Japan and 

3 

Lion Corporation, Kanagawa, Japan. Sponsor: J. 

Avalos. 


EVALUATION OF THE CHICKEN 

ENUCLEATED EYE TEST FOR ITS ABILITY 

TO PREDICT EYE IRRITATION POTENTIAL 

OF ZINC PYRITHIONE-BASED ANTI- 

DANDRUFF SHAMPOO FORMULAS. A. A. 

Pérez-Rivera 1 , P. M. McNamee 2 , R. Roggeband 3 , 

C. Faller 4 , K. Smith 2 , D. A. Roberts 1 , K. D. Acuff 1 

and K. Schutte 3 . 1 Central Product Safety, Procter 

& Gamble Company, Cincinnati, OH, 2 Central 

Product Safety, Procter & Gamble Company, Egham, 

United Kingdom, 3 Central Product Safety, Procter & 

Gamble Company, Brussels, Belgium and 4 Central 

Product Safety, Procter & Gamble Company, Marly, 

Switzerland. Sponsor: J. Skare. 


IN VITRO EVALUATION OF 

PHOTOREACTIONS IN THE SKIN USING 

EPIDERMAL SKIN TEST 1000 (EST-1000). J. 

Hoffmann 1 , E. Heisler 2 , S. Weimans 2 , A. Thiemann 2 , 

A. Schnurstein 2 and H. Fuchs 1 . 1 CellSystems 

Biotechnologie Vertrieb GmbH, St. Katharinen, 

Germany and 2 EVONIK Stockhausen GmbH, 

Krefeld, Germany. Sponsor: R. Curren. 


MICROFLUIDIC HEK CULTURES AS 

ALTERNATIVES TO MAMMALIAN 

MODELS. A. O’Neill 1 , N. Monteiro-Riviere 2,1 

and G. Walker 1 . 1 Biomedical Engineering, North 

Carolina State University, Raleigh, NC and 

2 

Center for Chemical Toxicology Research and 

Pharmacokinetics, North Carolina State University, 

Raleigh, NC. 


PREDICTING SKIN IRRITATION: IN VIVO 

RABBIT TEST VS. 4H HUMAN PATCH 

TEST AND IN VITRO HUMAN SKIN MODEL 

TEST. H. Bendová 1 , D. Basketter 2 , H. Kandarova 3 , 

D. Jírová 1 , M. Marriott 4 , K. Kejlová 1 , E. Spiller 3 

and M. Liebsch 5 . 1 National Institute of Public 

Health, Prague, Czech Republic, 2 St. John’s Inst 

of Dermatology, St.Thomas Hospital, London, 

United Kingdom, 3 MatTek Corporation, Ashland, 

MA, 4 Unilever Colworth Laboratory, Safety and 

Environmental Assurance Center, Bedford, United 

Kingdom and 5 Federal Institute for Risk Assessment, 

ZEBET, Berlin, Germany. 


PERFORMANCE STANDARDS FOR 

THE USE OF IN VITRO TISSUES IN A 

REGULATED ENVIRONMENT. M. Klausner, P. 

Hayden, Y. Kaluzhny, H. Kandarova, J. Kubilus and 

J. Sheasgreen. MatTek Corp, Ashland, MA. 

Abstract # 


EVALUATION OF EPIDERM FULL 

THICKNESS-300 (EFT-300) AS AN IN VITRO 

MODEL FOR SKIN IRRITATION. M. S. 

Sachdeva 1 , R. Mallapati 1 , P. Hayden 2 , M. Klausner 2 , 

R. R. Patlolla 1 and R. J. Babu 3 . 1 College of Pharmacy, 

Florida A&M University, Tallahassee, FL, 2 MatTek 

Corporation, Ashland, MD and 3 Harrison School of 

Pharmacy, Auburn University, Auburn, AL. 


DEVELOPMENT AND USE OF AN IN VITRO 

SAFETY TESTING PROGRAM FOR BATH 

AND BODY WASH PRODUCTS. D. Orak 1 , N. 

Barnes 2 , H. Raabe 2 , N. Wilt 2 and T. A. Re 1 . 1 Safety 

Evaluation, L’Oreal USA, Clark, NJ and 2 Institute for 

In Vitro Sciences, Inc., Gaithersburg, MD. 


IN VITRO MODEL WITH DISCRIMINATIVE 

POWER FOR SKIN SENSITIZERS BASED 

ON GENE EXPRESSION PROFILES OF 

HUMAN DENDRITIC CELLS. J. Hooyberghs 1 , 

N. Lambrechts 1,2 , E. Schoeters 1 , K. Hollanders 1 , I. 

Nelissen 1 , R. Van Den Heuvel 1 , H. Witters 1 and G. 

Schoeters 1,2 . 1 Environmental Toxicology, VITO N.V., 

Mol, Belgium and 2 Department Biomedical Sciences, 

University of Antwerp, Antwerp, Belgium. Sponsor: 

R. Pieters. 


DEVELOPMENT OF AN ORAL PHOTO- 

LLNA TO IDENTIFY PHOTOALLERGENS. 

M. Kirk 1 , Y. Broomhead 1 , G. L. DeGeorge 1 , J. 

R. Piccotti 2 and T. T. Kawabata 2 . 1 MB Research 

Laboratories, Spinnerstown, PA and 2 Pfizer Global 

Research & Development, Ann Arbor, MI. 


EFFECT OF GROWTH FACTORS 

AND EXTRACELLULAR MATRIX 

COMPONENTS ON GENE EXPRESSION 

AND DIFFERENTIATION OF MOUSE 

EMBRYONIC STEM CELLS. A. R. Calabro and 

F. A. Barile. Pharmaceutical Sciences, St. John’s 

University College of Pharmacy, Queens, NY. 


IN VITRO ASSESSMENT OF THE SKIN 

IRRITATION POTENTIAL OF HAIR DYES 

WITH A RECONSTRUCTED HUMAN 

EPIDERMIS (RHE) MODEL BY VIABILITY 

MEASUREMENT (MTT) AND HISTOLOGY. 

C. Faller 1 , P. Aeby 1 and C. Goebel 2 . 1 Central Product 

Safety, Procter & Gamble Co, Cosmital SA, Marly, 

Switzerland and 2 Procter & Gamble Co, Wella 

Service GmbH, Darmstadt, Germany. Sponsor: F. 

Gerberick. 


HEALING OF DERMAL BURN WOUNDS IN 

THE EPIDERM-FT IN VITRO HUMAN SKIN 

MODEL. P. J. Hayden, G. Stolper, C. Cooney and 

M. Klausner. MatTek Corp., Ashland, MA. 

Monday 



Monday 




1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: APOPTOSIS: MECHANISMS AND 

METHODS 

Chairperson(s): Alvaro Puga, University of Cincinnati, Cincinnati, OH 

and Rachel Murrell, North Carolina State University, Greenville, NC. 




HIGH THROUGHPUT, MULTI- 

PARAMETRIC MONITORING OF 

APOPTOSIS IN CELLS USING HIGH 

CONTENT SCREENING CELL BASED 

ASSAYS. R. N. Ghosh and B. S. Mandavilli. 

Research and Development, Thermo fisher scientific, 

Rockford, IL. Sponsor: A. Barchowsky. 


AH RECEPTOR INTERACTION WITH E2F1 

BLOCKS E2F1-INDUCED APOPTOSIS. A. 

Puga 1 , J. Marlowe 1 , Y. Fan 1 , C. Ma 1 , C. Mayhew 2 

and E. Knudsen 2 . 1 Department of Environmental 

Health, University of Cincinnati, Cincinnati, OH and 

2 

Cell and Cancer Biology, University of Cincinnati, 

Cincinnati, OH. 


1-NITROPYRENE (1-NP) INDUCES 

APOPTOSIS, NECROSIS AND PARAPTOTIC 

LIKE CELL DEATH IN HEPA1C1C7 CELLS. 

J. A. Holme 1 , N. Asare 1 , N. Landvik 1 , D. Lagadic- 

Gossmann 2 , M. Rissel 2 , X. Tekpli 2 , P. E. Schwarze 1 

and M. Låg 1 . 1 Division of Environmental Medicine, 

Norwegian Institute of Public Health, Oslo, Norway 

and 2 Inserm U620, Université Rennes 1, Rennes, 

France. Sponsor: E. Dybing. 


1, 3-BUTADIENE INDUCED APOPTOSIS IN 

LNCAP CELLS IS MEDIATED IN PART BY 

REGULATION OF BCL2/BAX EXPRESION 

LEVELS. S. Koppula 1 , R. Solipuram 1 , A. Hurst 1 

and W. Gray 1,2 . 1 Environmental Toxicology, Southern 

University, Baton Rouge, LA and 2 Chemistry, 

Southern University, Baton Rouge, LA. 


ENHANCEMENT OF CYTOKINE-INDUCED 

APOPTOSIS BY BENZENE METABOLITES 

IS UNIQUE TO TNFa P. Kerzic 1,2 , S. Gross 3 , A. 

Le 3 and R. Irons 1,2,3 . 1 Cinpathogen, Inc, Boulder, 

CO, 2 School of Public Health, Fudan University, 

Shanghai, China and 3 Molecular Toxicology 

Program, University of Colorado Health Sciences 

Center, Denver, CO. 


BREVETOXIN 2 ALTERS JURKAT E6-1 

APOPTOSIS RELATED GENE EXPRESSION. 

R. N. Murrell 1,4 , D. G. Baden 2,3 , A. J. Bourdelais 2 

and J. E. Gibson 4,1 . 1 Department of Environmental 

and Molecular Toxicology, NCSU, Raleigh, NC, 

2 

Center for Marine Science, UNCW, Wilmington, 

NC, 3 Chemistry, UNCW, Wilmington, NC and 

4 

Pharmacology and Toxicology, ECU, Greenville, 

NC. 


TNF-a-MEDIATED DISRUPTION OF 

SPERMATOGENESIS IN RESPONSE TO 

SERTOLI CELL INJURY IS PARTIALLY 

REGULATED BY MMP-2. P. Yao 1 , Y. Lin 2 , J. 

Cobarrubia 1 and J. H. Richburg 1,2 . 1 Institute for 

Cellular and Molecular Biology, the University 

of Texas at Austin, Austin, TX and 2 Division of 

Pharmacology and Toxicology, College of Pharmacy, 

the University of Texas at Austin, Austin, TX. 


APOPTOSIS PRECEDES MULTI-ORGAN 

INFLAMMATION IN MRL+/+ MICE 

CHRONICALLY EXPOSED TO TCE. S. 

Kondraganti 1 , P. J. Boor 2 , F. M. Khan 2 , R. Konig 3 , 

B. S. Kaphalia 2 and G. A. Ansari 1,2 . 1 biochemistry 

and Molecular Biology, UTMB, Galveston, 

TX, 2 pathology, UTMB, Galveston, TX and 

3 

microbiology and immunology, UTMB, Galveston, 

TX. 


ETHANOL IS APOPTOTIC TO NEURAL 

CREST BECAUSE IT ABERRANTLY 

ACTIVATES SIGNALS THAT NORMALLY 

GOVERN NEURAL CREST APOPTOSIS. S. 

M. Smith 1,2 , A. Garic-Stankovic 1 , M. Hernandez 1 and 

G. Flentke 1 . 1 Department of Nutritional Sciences, 

University of Wisconsin-Madison, Madison, WI and 

2 

Waisman Center, University of Wisconsin-Madison, 

Madison, WI. Sponsor: C. Jefcoate. 


MULTIDRUG RESISTANCE-ASSOCIATED 

PROTEIN 1, MRP1, MEDIATES 

GLUTATHIONE RELEASE DURING 

APOPTOSIS. R. Marchan, C. L. Hammond and N. 

Ballatori. Environmental Medicine, University of 

Rochester, Rochester, NY. 


P38 MAP KINASE MEDIATES APOPTOSIS 

THROUGH ACTIVATION OF FOXO3A AND 

INDUCTION OF BIM TRANSCRIPTION. B. 

Cai and Z. Xia. University of Washington, Seattle, 

WA. 


ARSENIC INDUCES DIFFERENT CELL 

SIGNALING PATHWAYS LEADING TO 

APOPTOSIS AND CELL CYCLE ARREST IN 

P53 +/+ AND P53-/- CELLS. Z. Guerrette, X. Yu, 

S. Hong, E. Kim and E. M. Faustman. Department 

of Environmental and Occupational Health Sciences, 



TITANIUM DIOXIDE NANOPARTICLES 

INDUCE JB6 CELL APOPTOSIS THROUGH 

ACTIVATION OF THE CASPASE-8/BID 

PATHWAY. J. Zhao 1 , L. Bowman 1 , X. Zhang 2 and 

M. Ding 1 . 1 Pathology and Physiology Research 

Branch, National Institute for Occupational Safety 

and Health, Morgantown, WV and 2 Graduate Center 

for Toxicology, University of Kentucky, Lexington, 

KY. Sponsor: V. Castranova. 


A COMPARATIVE EFFECT OF CADMIUM 

ON NON-TUMOR AND TUMOR DERIVED 

OSTEOBLASTIC CELLS. A. E. McCartney, W. 

A. Harvey, L. E. Delana and S. J. Heggland. Biology, 

Albertson College of Idaho, Caldwell, ID. 

116 




Abstract # 


LEAD INDUCES APOPTOSIS IN HUMAN 

LEUKEMIA (HL-60) CELLS VIA OXIDATIVE 

STRESS. C. G. Yedjou and P. B. Tchounwou. 

Biology, Jackson State University, Jackson, MS. 


MECHANISMS OF CHEMICALLY-INDUCED 

DNA DAMAGE BY CHLORPYRIFOS IN 

THE ETIOLOGY OF INFANT LEUKEMIA. 

S. C. Tilton 1 , J. S. Shao 1 , C. C. White 1,2 , T. J. 

Kavanagh 1,2 and E. P. Gallagher 1,2 . 1 Environmental 

and Occupational Health Sciences, University 

of Washington, Seattle, WA and 2 Center for 

Ecogenetics and Environmental Health, University of 

Washington, Seattle, WA. 


INHIBITION OF CA 2+ -INDEPENDENT 

PHOSPHOLIPASE A 2 

-INDUCES P53- 

DEPENDENT PROSTATE CANCER 

CELL DEATH. B. Sun and B. S. Cummings. 

Pharmaceutical and Biomedical Sciences, University 

of Georgia, Athens, GA. 


ROLE OF CALCIUM-INDEPENDENT 

PHOSPHOLIPASE A 2 

IN SIGNAL 

TRANSDUCTION DURING CYTOSTASIS 

AND CELL DEATH IN PROSTATE CANCER 

CELLS. X. Zhang, S. Talathi, J. H. Hurst, S. B. 

Hooks and B. S. Cummings. Pharmaceutical and 

Biomedical Sciences, University of Georgia, Athens, 

GA. 


CHRONIC EXPOSURE OF CADMIUM 

RESULTS IN AN INCREASED CELL 

SURVIVAL AND ACQUISITION OF 

APOPTOTIC RESISTANCE OF TM3 CELLS. 

C. L. Pevey, K. Singh and J. W. DuMond. Texas 

Southern University, Houston, TX. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Stem Cell Biology AND Toxicology 

POSTER SESSION: STEM CELL BIOLOGY AND TOXICOLOGY 

Chairperson(s): Fanny Casado-Pena, University of Rochester, 

Rochester, NY. 




ROLE OF CX32 IN STEADY- 

STATE HEMATOPOIESIS AND 

LEUKEMOGENESIS: STUDY IN THE 

CX32-KNOCKOUT MICE. Y. Hirabayashi 1 , 

B. Yoon 1 , I. Tsuboi 1 , Y. Kodama 1 , J. Kanno 1 , J. 

E. Trosko 2 and T. Inoue 3 . 1 Cellular & Molecular 

Toxicology Division, Center for Biological Safety 

& Research, National Institute of Health Sciences, 

Tokyo, Japan, 2 Department of Pediatrics and Human 

Development, Michigan State University, College of 

Human Medicine, East Lansing, MI and 3 Center for 

Biological Safety & Research, National Institute of 

Health Sciences, Tokyo, Japan. 


EFFECT OF METHYLMERCURY ON 

NEURAL STEM CELLS DIFFERENTIATION 

DERIVED FROM CYNOMOLGUS MONKEY 

EMBRYONIC STEM CELLS. M. Yamamoto 1 , 

T. Okuno 2 and Y. Kondo 2 . 1 Department of Basic 

Medical Sciences, National Institute for Minamata 

Disease, Minamata City, Japan and 2 Advanced 

Medical Research Laboratory, Mitsubishi Tanabe 

Pharmacology Corporation, Osaka City, Japan. 


BIOLOGICAL EFFECTS OF BENZO[A] 

PYRENE AND CHLORINATED BENZO[A] 

PYRENE IN MOUSE EMBRYONIC STEM 

CELLS. T. Nishimura 1 , K. Shimizu 1 , R. Kubota 1 , 

M. Tahara 1 , M. Ema 2 and H. Tokunaga 1 . 1 Division 

of Environmental Chemistry, National Institute of 

Health Sciences, Tokyo, Japan and 2 Division of Risk 

Assessment, Biological Safety Research Center, 

National Institute of Health Sciences, Tokyo, Japan. 


HUMAN EMBRYONIC STEM CELLS 

AS A MODEL OF DEVELOPMENTAL 

TOXICITY—A TOXICOGENOMICS 

APPROACH. M. Jergil 1 , R. Strehl 2 , R. Söderlund 1 , 

M. Fernandes 3 , H. Nau 3 , J. Hyllner 2 , L. Dencker 1 

and M. Stigson 1 . 1 Pharmaceutical Biosciences, 

Uppsala University, Uppsala, Sweden, 2 Cellartis AB, 

Göteborg, Sweden and 3 Food toxicology, Veterinary 

Medical University, Hannover, Germany. 


ARYL HYDROCARBON RECEPTOR 

ROLE IN HEMATOPOIETIC STEM CELL 

FUNCTION. F. L. Casado, K. P. Singh and T. A. 

Gasiewicz. Environmental Medicine, University of 


Monday 



Monday 




DIFFERENTIAL INFLAMMATORY GENE 

EXPRESSION IN YOUNG AND AGED MICE 

DURING CHEMICAL INJURY-INDUCED 

HIPPOCAMPAL NEUROGENESIS. C. A. 

McPherson 1,2 , M. Aoyama 1,3 , S. F. Grissom 1 , 

J. Gohlke 1 and G. J. Harry 1 . 1 Laboratory of 

Neurobiology, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC, 

2 


Carolina at Chapel Hill, Chapel Hill, NC and 

3 

Department of Molecular Neuroscience, Nagoya 

City University Graduate School of Medical 

Sciences, Nagoya, Japan. Sponsor: H. Tilson. 


PERSISTENT ARYL HYDROCARBON 

RECEPTOR ACTIVATION RESULTS IN 

ALTERED NUMBERS AND FUNCTION OF 

HEMATOPOIETIC STEM/PROGENITOR 

CELLS. K. P. Singh 1 , A. Wyman 2 , F. Casado 1 , 

R. Garrett 3 and T. A. Gasiewicz 1 . 1 Environmental 

Medicine, University of Rochester, School 

of Medicine and Dentistry, Rochester, NY, 

2 

Mathematics and Science, Seattle Community 

College District, Seattle, WA and 3 Department of 

Medicine, University of Pennsylvania, School of 

medicine, Philadelphia, PA. 


COMPARISON OF THREE IN VITRO 

STEM CELL HEMOTOXICITY, ATP- 

BASED, CYTOTOXIC ASSAYS FOR DRUG 

DISCOVERY AND DEVELOPMENT AND 

XENOBIOTIC TESTING. K. M. Hall and I. Rich. 

HemoGenix, Inc, Colorado Springs, CO. 


THE ROLE OF MITOCHONDRIAL 

AND OXIDATIVE INJURY IN BDE 47 

TOXICITY TO HUMAN FETAL LIVER 

HEMATOPOIETIC STEM CELLS. J. Shao, 

C. C. White, M. J. Dabrowski, T. J. Kavanagh, 

M. L. Eckert and E. P. Gallagher. University of 



QUANTITATIVE MICROARRAY ANALYSIS 

BY “PERCELLOME” METHOD OF 

MURINE EMBRYONIC STEM CELLS AND 

EMBRYOID BODIES. A. Takagi 1 , S. Kitajima 1 , 

N. Nakatsu 1 , K. Igarashi 1 , K. Aisaki 1 , M. Ema 2 

and J. Kanno 1 . 1 Division of Cellular & Molecular 

Toxicology, National Institute of Health Sciences, 

Tokyo, Japan and 2 Division of Risk Assessment, 



THE EFFECTS OF POLYCYCLIC 

AROMATIC HYDROCARBONS ON GAP 

JUNCTION FUNCTION IN AN ADULT 

HUMAN LIVER STEM CELL LINE. B. L. 

Upham 1,2 , P. Babica 1,2 , J. Park 1,2 , I. Sovadinova 1,2 , J. 

E. Trosko 1,2 and C. Chang 1,2 . 1 Pediatrics & Human 

Development, Michigan State University, East 

Lansing, MI and 2 and National Food Safety & 


Lansing, MI. 


AHR PATHWAY GENES ARE EXPRESSED 

IN HUMAN EMBRYONIC STEM CELLS. E. 

A. Bolterstein 1 and B. Allen-Hoffmann 1,2 . 1 Molecular 

and Environmental Toxicology Center, University 

of Wisconsin, Madison, WI and 2 Department of 

Pathology, University of Wisconsin, Madison, WI. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: BIOMARKERS 

Chairperson(s): Ivan Rusyn, University of North Carolina Chapel 

Hill, Chapel Hill, NC and Joel Pounds, Pacific Northwest National 

Laboratory, Richland, WA. 




THE MECHANISM OF GALACTOSAMINE 

TOXICITY AND IDIOSYNCRATIC 

RESPONSE; A METABONOMIC STUDY. M. 

Coen 1 , T. A. Clayton 1 , E. Want 1 , C. M. Rhode 2 , Y. S. 

Hong 1 , E. Holmes 1 , J. C. Lindon 1 , M. D. Reily 2 , D. 

G. Robertson 2 and J. K. Nicholson 1 . 1 Biomolecular 

Medicine, Imperial College London, London, United 

Kingdom and 2 Metabonomics Evaluation Group, 

Pfizer Global R&D, Ann Arbor, MI. 


PHENOTYPIC ANCHORING OF 

GENE EXPRESSION DATA FROM 

ACETAMINOPHEN HEPATOTOXICITY 

STUDIES IN THE MOUSE MODEL OF 

THE HUMAN POPULATION REVEALS 

BIOMARKERS OF RESPONSE. A. Hege 1 , P. 

Ross 2 , D. Threadgill 1,3 and I. Rusyn 1,2 . 1 Curriculum 

in Toxicology, UNC-Chapel Hill, Chapel Hill, 

NC, 2 Department of Environmental Sciences and 

Engineering, UNC Chapel Hill, Chapel Hill, NC and 

3 

Department of Genetics, UNC Chapel Hill, Chapel 

Hill, NC. 


EVALUATION OF INDIVIDUAL BILE ACIDS 

AS BIOMARKERS OF HEPATOTOXICITY. J. 

Colangelo 1 , C. Fritz 1 and R. Schneider 2 . 1 Drug Safety, 

Pfizer Global Research & Development, Groton, 

CT and 2 Translational and Molecular Medicine, 

Pfizer Global Research & Development, Groton, CT. 

Sponsor: M. Aleo. 


DETERMINATION OF BIOMARKER GENES 

FOR THE EXPOSURE OF ARISTOLOCHIC 

ACID IN RAT KIDNEY. T. Chen, N. Mei and L. 

Guo. National Center for Toxicological Research, 

U.S. Food and Drug Administration, Jefferson, AR. 

118 




Abstract # 


BIOMARKER DOSE RESPONSE PROFILING 

TO THE NEPHROTOXIN d-SERINE IN 

FISHER 344 RATS. C. Mauzy 1 , J. Frey 1 , E. 

Fleming 1 , D. Todd 1 , D. Mahle 1 , N. DelRaso 1 and 

R. Rietcheck 2 . 1 Applied Biotechnology-Human 

Effectiveness Directorate, Air Force Research 

Laboratory (AFRL), Wright Patterson Air Force 

Base (Wright-Patterson AFB ), OH and 2 Army 

Comparative Medicine-Pathology, AFRL, Wright- 

Patterson AFB, OH. Sponsor: J. Schlager. 


KIDNEY INJURY MOLECULE 1 (KIM-1) AS 

AN EARLY BIOMARKER OF CADMIUM 

NEPHROTOXICITY: COMPARISON 

WITH URINARY CADMIUM AND ALPHA- 

GLUTATHIONE-S-TRANSFERASE 

(ALPHA-GST). W. C. Prozialeck 1 , J. Edwards 1 , 

P. C. Lamar 1 , V. S. Vaidya 2 and J. V. Bonventre 2 . 

1 

Pharmacology, Midwestern University, Downers 

Grove, IL and 2 Renal Division, Brigham and 

Women’s Hospital, Harvard Medical School, Boston, 

MA. 


DETECTION OF MULTIPLE GLOBIN 

MONO-ADDUCTS AND CROSS- 

LINKS AFTER EXPOSURE OF 

RAT ERYTHROCYTES TO S-(1, 

2-DICHLOROVINYL)-L-CYSTEINE 

SULFOXIDE BOTH IN VITRO AND IN VIVO. 

N. Barshteyn and A. A. Elfarra. Pharmaceutical 

Sciences, University of Madison, Wisconsin, 

Madison, WI. 


PSTC VXDS#2: NOVEL URINARY 

BIOMARKERS THAT DETECT KIDNEY 

TUBULAR HISTOPATHOLOGIC 

ALTERATIONS OUTPERFORM OR ADD 

VALUE TO BUN AND SERUM CREATININE. 

J. S. Ozer 1 , V. Vaidya 2 , D. Holder 1 , S. Troth 1 , N. 

Muniappa 1 , H. Jin 1 , Y. Yu 1 , D. Thudium 1 , W. White 1 , 

D. McCausland 1 , H. Duong 1 , M. Lease 1 , M. Topper 1 , 

W. Bailey 1 , D. Gerhold 1 , J. Bonventre 2 and F. 

Sistare 1 . 1 Safety Assessment, Merck, West Point, PA 

and 2 Harvard Medical School, Brigham and Women’s 

Hospital, Boston, MA. 


EVALUATION OF RAT GST-ALPHA 

AND OSTEOPONTIN AS MARKERS OF 

PROXIMAL TUBULAR INJURY. S. Altman- 

Hamamdzic, D. Gerhold, W. J. Bailey, W. E. Glaab, 

C. B. Frederick and A. Galijatovic-Idrizbegovic. 

Department of Safety Assessment, Merck Research 

Laboratories, West Point, PA. 


BIOMARKERS OF FURAN EXPOSURE BY 

METABOLITE PROFILING OF RAT URINE 

WITH LC-TANDEM MASS SPECTROMETRY 

AND PRINCIPAL COMPONENT ANALYSIS. 

M. Kellert, S. Wagner, U. Lutz and W. K. Lutz. 

Toxicology, University of Würzburg, Würzburg, 

Germany. 

Abstract # 


DIFFERENTIAL EXPRESSION OF 

LIVER GENES IN MICE EXPOSED TO 

ACRYLAMIDE IN DRINKING WATER. L. 

Guo 1 , M. M. Manjanatha 1 , S. Dial 1 , R. Liu 1 , J. Tseng 2 , 

W. Liao 2 and N. Mei 1 . 1 NCTR, Jefferson, AR and 

2 

PhalanxBio, Inc, Palo Alto, CA. 


EVALUATION OF CALPROTECTIN AS 

A BIOMARKER FOR DRUG-INDUCED 

VASCULAR INJURY IN THE RAT. C. Drupa, 

J. Colangelo, E. Floyd, M. Lawton, P. Lee and K. 

Navetta. DSRD, Pfizer, Groton, CT. 


ASSAY OF VE-CADHERIN GENE 

EXPRESSION TO MEASURE CIRCULATING 

ENDOTHELIAL CELLS AS A BIOMARKER 

OF VASCULAR INJURY IN DOGS. J. Cai, M. 

Lawton, E. Floyd, S. Kamerling, D. Gallagher and 

W. Carter. Pfizer Grobal Research and Development, 

Groton, CT. 


EVALUATION OF CANDIDATE 

BIOMARKERS OF DRUG-INDUCED 

VASCULITIS IN RATS. H. W. Smith, D. Sun, D. 

Shoufler and D. Wierda. Investigative Toxicology, 

Eli Lilly and Company, Greenfield, IN. 


CHARACTERIZATION AND UTILITY OF 

TWO NOVEL PEPTIDE MARKERS OF 

EXOCRINE PANCREATIC TOXICITY. J. L. 

Walgren, M. D. Mitchell, L. O. Whiteley and D. C. 

Thompson. Drug Safety Research and Development, 

Pfizer, Inc., St. Louis, MO. 


PLASMA VON WILLEBRAND FACTOR 

(VWF) AS A POTENTIAL PRECLINICAL 

DRUG-INDUCED VASCULAR INJURY 

(DIVI) BIOMARKER. A. Katein 1 , D. Brott 1 , 

R. J. Richardson 2 and C. Louden 3 . 1 Global Safety 

Assessment (GSA), AstraZeneca Pharmaceuticals 

(AZ), Wilmington, DE, 2 Department of 

Environmental Health Sciences, University of 

Michigan, Ann Arbor, MI and 3 GSA, AZ, Alderley 

Park, United Kingdom. 


IDENTIFICATION OF NOVEL SAFETY 

BIOMARKERS FOLLOWING EXPOSURE 

TO THE MODEL PANCREATIC TOXIN 

CYANOHYDROXYBUTENE. D. C. Thompson, 

M. D. Mitchell, L. O. Whiteley and J. L. Walgren. 

Drug Safety Research and Development, Pfizer, Inc., 

St. Louis, MO. 


EVALUATION OF SERUM TROPONIN I AND 

URINARY MYOGLOBIN AS PRECLINICAL 

BIOMARKERS OF SKELETAL MUSCLE 

TOXICITY IN RATS. J. D. Vassallo 1 , D. Wescott 1 , 

E. B. Janovitz 1 , C. Chadwick 2 and L. D. Lehman- 

Mckeeman 1 . 1 Discovery Toxicology, Bristol-Myers 

Squibb, Princeton, NJ and 2 Life Diagnostics, West 

Chester, PA. 

Monday 



Monday 




EARLY CYTOKINE CHANGES AS 

SURROGATE MARKERS OF LOW DOSE 

IRRADIATION. J. N. Finkelstein 1,2,3 , J. P. 

Williams 2 , E. Hernady 2 , C. Reed 1 and C. Johnston 1 . 

1 

Pediatrics, University of Rochester, Rochester, 

NY, 2 Radiation Oncology, University of Rochester, 

Rochester, NY and 3 Environmental Medicine, 

University of Rochester, Rochester, NY. 


BIOMARKER LEVELS IN DOGS AFTER 

28-DAY ORAL TREATMENT WITH SR16157. 

L. L. Rausch 1 , P. Catz 1 , S. LeValley 1 , K. Steinmetz 1 , 

C. Green 1 , J. Tomaszewski 2 , K. Schweikart 2 , 

N. Zaveri 1 and J. Mirsalis 1 . 1 toxicology, SRI 

International, Menlo Park, CA and 2 Developmental 

Theraputics Program, National Cancer Institute, 

Bethesda, MD. 


TEMPORAL PATTERN OF SKELETAL 

MUSCLE GENE EXPRESSION FOLLOWING 

PROLONGED ENDURANCE EXERCISE 

IN ALASKAN SLED DOGS. M. A. Peters 1 , 

E. P. Brass 3 , K. W. Hinchcliff 4 and R. G. Ulrich 2 . 

1 

Rosetta Biosoftware, Seattle, WA, 2 Calistoga 

Pharmaceuticals, Seattle, WA, 3 UCLA, Torrance, CA 

and 4 University of Melbourne, Victoria, Australia. 


A PROTEOMIC APPROACH TO IDENTIFY 

POTENTIAL TARGET PROTEINS OR 

BIOMARKERS INDUCED BY THE HSP90 

INHIBITOR 17-DMAG IN KASUMI-1 

LEUKEMIA CELLS. S. Qin, D. Zhou, J. Ye, X. 

Zhang, L. Li and J. Barsoum. Synta Pharmaceuticals 

Corp., Lexington, MA. Sponsor: E. Kitayama. 


IDENTIFICATION OF RNS/ROS-MODIFIED 

PROTEINS AS BIOMARKERS FOR 

CHRONIC INFLAMMATORY STRESS IN 

MOUSE LUNG. C. A. Sacksteder 1 , J. M. Jacobs 1 , 

K. M. Lee 2 , K. M. Waters 1 , D. J. Bigelow 1 and J. G. 

Pounds 1 . 1 Pacific Northwest National Laboratory, 

Richland, WA and 2 Battelle Toxicology Northwest, 

Richland, WA. 


USING PHARMACOKINETIC DATA TO 

INTERPRET METABOLOMIC CHANGES 

IN CD-1 MICE TREATED WITH TRIAZOLE 

FUNGICIDES. W. M. Henderson 1,2 , J. F. Kenneke 1 , 

T. W. Collette 1 and S. E. Ritger 2 . 1 Office of Research 

and Development, National Exposure Research 

Laboratory, U.S. Environmental Protection 

Agency, Athens, GA and 2 College of Public Health, 

Interdisciplinary Toxicology Program, University of 

Georgia, Athens, GA. 


INVESTIGATING THE EFFECTS OF 

DIFFERENT HEPATOTOXINS ON 

SERUM BILE ACID AND PHOSPHOLIPID 

PATTERNS. E. J. Want 1 , M. Coen 1 , C. Rohde 2 , E. 

Holmes 1 , J. Lindon 1 , M. D. Reily 2 , D. Robertson 2 

and J. K. Nicholson 1 . 1 Biomolecular Medicine, 

Imperial College, London, United Kingdom and 

2 

Metabonomics Evaluation Group, Pfizer Global R & 

D, Ann Arbor, MI. 


THE HSP90 INHIBITOR 17-DMAG 

SUPPRESSES LPS-INDUCED 

UP-REGULATION OF MULTIPLE 

CYTOKINES IN HUMAN PBMC IN VITRO 

AND IL-12 PRODUCTION IN A MOUSE 

SEPTIC SHOCK MODEL. D. Zhou, L. Li, 

J. Chu, J. Ye, X. Zhang, S. Qin, Y. Wada and J. 

Barsoum. Synta Pharmaceuticals Corp., Lexington, 

MA. Sponsor: E. Kitayama. 


PSTC VXDS #3: URINARY BIOMARKER 

TO MONITOR DRUG- INDUCED 

GLOMERULAR TOXICITY IN RATS. F. 

Dieterle, E. Perentes, D. R. Roth, A. Cordier, 

G. Maurer and J. Vonderscher. Pharmacology 

Development, Novartis, Basel, Switzerland. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: GENETIC POLYMORPHISMS 

Chairperson(s): Timothy Fennell, RTI International, Research Triangle 

Park, NC and David Hein, University of Louisville, Louisville, KY. 




COMPARISON OF 

COPROPORPHYRINOGEN OXIDASE 

(CPOX) AND ITS GENETIC VARIANT 

(CPOX4) IN HUMAN LIVER. T. Li and J. 

S. Woods. Environmental Health, University of 



POLYMORPHISMS IN THYMIDYLATE 

SYNTHASE GENE ARE ASSOCIATED 

WITH INCREASED RISK FOR NON- 

SMALL CELL LUNG CANCER AND 

THERAPEUTIC OUTCOME IN A 

PORTUGUESE POPULATION. A. Lima 1,2 , V. M. 

Seabra 1 , A. Coelho 2 , A. Araújo 2 and R. Medeiros 2 . 

1 

Pharmaceutical Sciences, ISCS-Norte, Gandra, 

PRD, Portugal and 2 Molecular Oncology, IPO, Porto, 

Portugal. 


GSTM1 AND GSTT1 POLYMORPHISMS, 

RESPONSE TO CHEMOTHERAPY AND 

SURVIVAL IN LUNG CANCER PATIENTS. 

M. Iscan 1 , A. O. Ada 1 , S. C. Kunak 2 , F. Hancer 1 , 

S. H. Suzen 1 , S. Alpar 3 , M. Gulhan 3 and B. Kurt 3 . 

1 

Toxicology, Ankara University, Faculty of 

Pharmacy, Ankara, Turkey, 2 Internal Medicine, 

Ankara Hospital, Ankara, Turkey and 3 Pulmonary 

diseases, Ataturk PulmonaryDiseases and Thoracic 

Surgery Hospital, Ankara, Turkey. Sponsor: A. 

Karakaya. 


IMPACT OF GST POLYMORPHISMS ON 

HEMOGLOBIN ADDUCTS IN SMOKERS 

AND NON SMOKERS. T. R. Fennell and R. W. 

Snyder. RTI International, Research Triangle Park, 

NC. 

120 




Abstract # 


ASSOCIATION OF THE OGG1 SER326CYS 

POLYMORPHISM WITH LUNG CANCER 

RISK IN A TURKISH POPULATION. A. 

E. Karakaya 1 , B. Karahalil 1 , E. Emerce-Tufan 1 , 

B. Kocer 2 , S. Han 2 and N. Alkis 3 . 1 Department 

of Toxicology, Gazi University, Ankara, Turkey, 

2 

Numune Training and Research Hospital, Ankara, 

Turkey and 3 Ankara Oncology Training and Research 

Hospital, Ankara, Turkey. 


GENE-ENVIRONMENT INTERACTION 

BETWEEN HOGG1 SER326CYS 

POLYMORPHISM AND SMOKING ON 

LUNG CANCER SUSCEPTIBILITY. R. Yoshida. 

National institute of Occipational Safety and Health, 

Kawasaki, Japan. 


GENETIC RISK FACTORS IN 

PROGRESSIVE MASSIVE FIBROSIS IN 

COAL MINERS. B. Yucesoy 1 , V. J. Johnson 1 , K. 

Fluharty 1 , M. L. Kashon 2 , J. Slaven 2 , G. Kissling 4 , 

D. Germolec 5 , V. Vallyathan 3 and M. I. Luster 1 . 

1 

Toxicology and Molecular Biology Branch, CDC/ 

NIOSH, Morgantown, WV, 2 Biostatistics and 

Epidemiology Branch, CDC/NIOSH, Morgantown, 

WV, 3 Pathology and Physiology Research Branch, 

CDC/NIOSH, Morgantown, WV, 4 Biostatistics 

Branch, NIEHS, Research Triangle Park, NC and 

5 

Toxicology Operations Branch, NIEHS, Research 



RELATIONSHIP BETWEEN ARSENIC- 

SKIN LESIONS AND THE MET287THR 

POLYMORPHISM IN AS3MT GENE. O. L. 

Valenzuela 1 , Z. Drobná 2 , G. G. Garcia-Vargas 3 , V. 

H. Borja-Aburto 4 , M. Styblo 2 and L. M. Del Razo 1 . 

1 

Toxicology, Cinvestav-IPN, Mexico D.F, Mexico, 

2 

Department of Nutrition, and CEMALB, UNC at 

Chapel Hill, Chapel Hill, NC, 3 Medicina, UJED, 

Gomez Palacio, Durango, Mexico and 4 IMSS, 

Mexico, D.F., Mexico. 


AMINOLEVULINIC ACID DEHYDRATASE 

(ALAD) POLYMORPHISM IS ASSOCIATED 

WITH BLOOD LEAD LEVEL AND 

HYPERTENSION IN THE NATIONAL 

HEALTH AND NUTRITION EXAMINATION 

SURVEY (NHANES III). F. Scinicariello 1,3 , B. A. 

Fowler 1,3 , A. Yesupriya 2,3 and M. Chang 2,3 . 1 DTEM, 

ATSDR, Atlanta, GA, 2 NOPHG, CDC, Atlanta, 

GA and 3 for the CDC/NCI NHANES III Genomics 

Working Group, Atlanta, GA. 


GENETIC VARIANTS IN FOUR METAL- 

REGULATORY GENES IN AUTISM. S. E. 

Owens 1 , M. L. Summar 2 , K. K. Ryckman 2 , J. L. 

Haines 2 and M. Aschner 1 . 1 Pediatrics, Vanderbilt 

University Medical Center, Nashville, TN and 

2 

Center for Human Genetics Research, Vanderbilt 

University Medical Center, Nashville, TN. 

Abstract # 


ASSOCIATIONS BETWEEN THE 5-HTTLPR 

POLYMORPHISM AND MERCURY FOR 

MOOD AND BEHAVIOR IN HUMANS. 

D. Echeverria 1,2 , J. S. Woods 2 , N. Heyer 1 , D. 

Rholman 3 , F. Farin 2 and T. Li 2 . 1 Center for Public 

Health Research and Evaluation, Battelle CPHRE, 

Seattle, WA, 2 Department of Environmental Health, 

University of Washington, Seattle, WA and 3 3Center 

for Research on Occupational and Environmental 

Toxicology, Oregon Health and Science University, 

Portland, OR. 


MULTIPLE LOCI SURROUNDING THE 

APOE GENE ARE ASSOCIATED WITH APOE 

LEVELS IN POSTMORTEM ALZHEIMER’S 

DISEASE BRAIN. L. M. Bekris 1,2 , N. Galloway 2 , 

T. J. Montine 5 , G. D. Schellenberg 2,3,4 and C. Yu 1,2 . 

1 

Medicine, University of Washington, Seattle, WA, 

2 

Geriatric Research, Education and Clinical Center, 

Veterans Affairs Puget Sound Health Care System, 

Seattle, WA, 3 Neurology, University of Washington, 

Seattle, WA, 4 Pharmacology, University of 

Washington, Seattle, WA and 5 Pathology, University 

of Washington, Seattle, WA. 


IDENTIFICATION OF SINGLE 

NUCLEOTIDE POLYMORPHISMS IN 

THE HUMAN AHR FROM SIX ETHNIC 

POPULATIONS. J. Rowlands 1 , R. Budinsky 1 , 

B. Gollapudi 1 , K. Drinkwater 2 and M. Storck 2 . 

1 

The Dow Chemical Company, Midland, MI and 

2 

Functional Biosciences, Inc., Madison, WI. 


N-ACETYLTRANSFERASE 2 GENETIC 

POLYMORPHISM INCREASES BREAST 

CANCER RISK AMONG WOMEN SMOKERS 

IN NEW MEXICO. T. J. Schlierf 1 , D. Yang 2 , M. 

A. Doll 1 , K. B. Baumgartner 2 and D. W. Hein 1 . 

1 


Louisville, Louisville, KY and 2 Epidemiology 

and Population Health, University of Louisville, 

Louisville, KY. 


INVESTIGATION OF THE MECHANISM 

OF INCREASED N-ACETYLTRANSFERASE 

1 (NAT1) EXPRESSION IN ESTROGEN 

RECEPTOR POSITIVE BREAST CANCER. 

X. Zhang 1 , D. F. Barker 1 , M. A. Doll 1 , R. C. 

Martin 1 , J. States 1 , C. M. Klinge 2 and D. W. Hein 1 . 

1 


Louisville, Louisville, KY and 2 Biochemistry 

& Molecular Biology, University of Louisville, 



FUNCTIONAL EFFECT OF 

N-ACETYLTRANSFERASE 1 (NAT1*10) 

POLYMORPHISM IN DNA ADDUCT 

FORMATION AND MUTAGENESIS 

FOLLOWING EXPOSURE TO AROMATIC 

AND HETEROCYCLIC AMINE 

CARCINOGENS. L. M. Millner, J. Bendaly, M. 

A. Doll, D. F. Barker, J. States and D. W. Hein. 


Louisville, Louisville, KY. 

Monday 



Monday 




ROLE OF HUMAN CYTOCHROME 

P4501A1 AND N-ACETYLTRANSFERASE 

2 GENETIC POLYMORPHISM ON 

THE MUTAGENICITY AND DNA 

DAMAGE OF THE ENVIRONMENTAL 

CARCINOGENS 2-AMINO-1-METHYL-6- 

PHENYLIMIDAZO[4, 5-B]PYRIDINE AND 

4- AMINOBIPHENYL. J. Bendaly, S. Zhao, 

K. J. Metry, M. A. Doll, J. States, N. B. Smith, 

W. M. Pierce and D. W. Hein. Pharmacology and 

Toxicology, University of Louisville, Louisville, KY. 


ROLE OF HUMAN 

N-ACETYLTRANSFERASE 2 

ACETYLATION POLYMORPHISM IN 

MUTAGENESIS AND DNA ADDUCT 

FORMATION BY THE AROMATIC AMINE 

CARCINOGENS 2-AMINOFLUORENE AND 

4-AMINOBIPHENYL. K. J. Metry, M. A. Doll, 

N. B. Smith, S. Zhao, J. States, W. McGregor, 

W. M. Pierce and D. W. Hein. Pharmacology and 



ANALYSIS OF TRICHLOROETHYLENE 

METABOLISM IN A GENETICALLY 

DIVERSE PANEL OF MOUSE INBRED 

STRAINS. S. Kim 1 , M. C. DeSimone 2,3 , D. 

Harbourt 2 , G. Boysen 1 , L. Collins 1 , T. M. O’Connell 4 , 

A. Gold 1 , L. M. Ball 1 , S. Waidyanatha 1 , B. Bradford 1 , 

D. Threadgill 2,3 and I. Rusyn 1,2 . 1 Envr Sci Eng, UNC- 

CH, Chapel Hill, NC, 2 Curriculum in Toxicology, 

UNC-CH, Chapel Hill, NC, 3 Genetics, UNC-CH, 

Chapel Hill, NC and 4 Devision of Molecular 

Pharmaceutics, UNC-CH, Chapel Hill, NC. 


THE ROLE OF PARAOXONASE (PON1) 

IN MODULATING TOXICITY OF OP 

MIXTURES. K. L. Jansen 1 , T. B. Cole 1,2 , W. 

Li 3 , S. Park 1 , C. E. Furlong 2 and L. G. Costa 1 . 

1 

Environmental and Occupational Health Sciences, 

University of Washington, Seattle, WA, 2 Medical 

Genetics, University of Washington, Seattle, WA and 

3 

Environmental Health and Occupational Medicine, 

National Health Research Institutes, Zhunan Town, 

Taiwan. 


SUBCELLULAR LOCALIZATION OF 

SOLUBLE EPOXIDE HYDROLASE 

REGULATES ENZYME STABILITY AND 

ACTIVITY. B. Luo, A. E. Enayetallah and D. F. 

Grant. Department of Pharmaceutical Sciences, 



EXPLORING GENETIC POLYMORPHISMS 

IN XENOBIOTIC METABOLIZING 

ENZYMES THAT MAY AFFECT RESPONSE 

TO ENVIRONMENTAL TOXICANTS. 

D. Johns 1 , K. Z. Guyton 2 , B. Sonawane 2 and G. 

Ginsberg 3 . 1 NCEA, ORD, U.S. EPA, Research 

Triangle Park, NC, 2 NCEA, ORD, U.S. EPA, 

Washington, DC and 3 Connecticut Department of 

Public Health, Hartford, CT. 


QUANTITATION OF NAT1, NAT2 AND NAT3 

mRNA IN THE RAT: INVESTIGATION OF 

TISSUE, GENDER AND AGE-SPECIFIC 

EFFECTS ON GENE EXPRESSION. D. F. 

Barker, J. M. Walraven, E. H. Ristagno, M. A. Doll 

and D. W. Hein. Pharmacology and Toxicology, 

University of Louisville, Louisville, KY. 


1:00 PM to 4:30 PM 

Exhibit Hall 


POSTER SESSION: NANOPARTICLES: TESTING 

APPROACHES, GENO- AND ECOTOXICITY 

Chairperson(s): Amy Ringwood, University of North Carolina Charlotte, 

Charlotte, NC and Richard Peterson, University of Wisconsin Madison, 

Madison, WI. 


Attended: 2:45 PM– 4:30 PM 


SIZE-DEPENDENT TOXICITY AND 

UPTAKE OF FLUORESCENT SILICA 

NANOPARTICLES INTO CELLS. L. Davis 1 , C. 

M. Grabiniski 1,2 , A. M. Schrand 1 , R. C. Murdock 1 , 

L. K. Braydich-Stolle 1 , B. Gu 3 , J. J. Schlager 1 and 

S. M. Hussain 1 . 1 Applied Biotechnology Branch, 

RHPB, Air Force Research Labs, Wright Patterson, 

OH, 2 Department of Chemical and Materials 

Engineering, University Of Dayton, Dayton, OH 

and 3 Environmental Sciences Division, Oak Ridge 

National Laboratory, Oak Ridge, TN. 


ANALYSIS OF SERUM PROTEIN AND 

NANOMATERIAL INTERACTIONS AND 

THE EFFECT ON IN VITRO TOXICOLOGY 

STUDIES. R. C. Murdock, L. K. Braydich-Stolle, 

A. M. Schrand, D. R. Mattie, J. J. Schlager and S. M. 

Hussain. Applied Biotechnology Branch, RHPB, Air 

Force Research Labs, Wright Patterson, OH. 


EFFECTS OF TEMPERATURE, TIME, 

AND SOLVENT ON NANOPARTICLE 

AGGLOMERATION. M. C. Moulton, K. O. Yu, 

A. M. Schrand, D. R. Mattie, J. J. Schlager and S. M. 

Hussain. Applied Biotechnology Branch, RHPB, Air 

Force Research Labs, Wright Patterson, OH. 


DEVELOPMENTAL TOXICITY OF 

QUANTUM DOTS IN ZEBRAFISH: 

INFLUENCE OF SURFACE CHEMISTRY. R. 

E. Peterson 1,2 , T. C. King Heiden 1 , A. Mangham 3 , 

P. Wiecinski 1 , K. M. Metz 4 , D. Nesbit 2 , J. A. 

Pedersen 1,4 , R. J. Hamers 3 and W. Heideman 1,2 . 

1 

Molecular and Environment Toxicol. Center, 

UW-Madison, Madison, WI, 2 School of Pharmacy, 

UW-Madison, Madison, WI, 3 Department of 

Chemistry, UW-Madison, Madison, WI and 

4 

Environment Chem. and Technol. Program, 

UW-Madison, Madison, WI. 

122 




Abstract # 


ZEBRAFISH AS AN ALTERNATIVE 

MODEL TO ASSESS BIOMATERIAL 

NANOTOXICITY. O. Bar-Ilan, R. M. Albrecht, 

R. E. Peterson and D. Y. Furgeson. Pharmaceutical 

Sciences, University of Wisconsin-Madison, 

Madison, WI. 


DIFFERENTIAL TOXICITY OF METALLIC 

NANOPARTICLES TO AQUATIC SPECIES. 

J. Griffitt 1 , J. Luo 1 , N. D. Denslow 1 , K. Powers 2 and 

D. S. Barber 1 . 1 Center for Environmental and Human 

Toxicology, University of Florida, Gainesville, 

FL and 2 Particle Engineering Research Center, 

University of Florida, Gainesville, FL. 


A COMPARISON OF BULK AND NANO- 

SIZED ALUMINUM OXIDE (AL 2 

O 3 

) 

ECOTOXICITY TO HYALELLA AZTECA AND 

TUBIFEX TUBIFEX IN SPIKED SEDIMENT. 

J. K. Stanley. U.S. Army Research and Devlopment 

Center, Vicksburg, MS. Sponsor: J. Steevens. 


THE EFFECTS OF METAL 

NANOPARTICLES AND FULLERENES ON 

OYSTER HEPATOPANCREAS CELLS AND 

EMBRYOS. A. H. Ringwood 1 , M. McCarthy 1 , T. 

Changela 1 , D. Carroll 2 and N. Levi 2 . 1 Biology, UNC 

- Charlotte, Charlotte, NC and 2 Physics, Wake Forest 

University, Winston-Salem, NC. 


DIFFERENTIAL AQUATIC TOXICITY 

RESPONSES OF GREEN ALGAE TO 

VARIOUS NANOPARTICLE-TYPES. C. M. 

Sayes, B. D. Ferrell, R. A. Hoke and D. B. Warheit. 

DuPont Haskell Laboratory, Newark, DE. 


FATE OF FULLERENE NANOPARTICLES 

AND THEIR INTERACTIONS WITH 

ORGANIC MATTERS IN AQUATIC 

ENVIRONMENTS. Y. Xia 1 , X. Q. Kong 2 and 

X. Xia 2 . 1 Dalian University of Technology, Dalian, 

China and 2 North Carolina State University, Raleigh, 

NC. 


AN EZ METRIC FOR EVALUATING 

NANOMATERIAL-BIOLOGICAL 

INTERACTIONS. S. L. Harper 1 , S. Lee 2 and 

R. L. Tanguay 1,3 . 1 Environmental and Molecular 

Toxicology, Oregon State University, Corvallis, OR, 

2 

iFusion Laboratory, Department of Engineering, 

Oregon State University, Corvallis, OR and 

3 

Environmental Health Sciences Center, Oregon 

State University, Corvallis, OR. 


SCREENING ASSAYS FOR ASSESSING 

NANOPARTICLE TOXICITY. G. Oberdörster 2 , 

E. K. Rushton 2 and J. N. Finkelstein 1,2 . 1 Pediatrics, 

University of Rochester, Rochester, NY and 

2 

Environmental Medicine, University of Rochester, 


Abstract # 


LIVE-CELL ATTENUATED TOTAL 

REFLECTION - FOURIER TRANSFORM 

INFRARED SPECTROSCOPY (ATR-FTIR) 

OF THE CELLULAR RESPONSE ON 

EXPOSURE TO NANOMATERIALS. S. K. 

Sundaram, T. J. Weber, B. J. Riley, B. M. Webb- 

Robertson and R. S. Addleman. Pacific Northwest 

National Laboratory, Richland, WA. Sponsor: J. 

Pounds. 


INTEGRATION OF MICROARRAY AND 

PROTEOMIC DATA REVEALS PATHWAY- 

SPECIFIC INFLAMMATORY MARKERS OF 

NANOPARTICLE EXPOSURE TO MOUSE 

MACROPHAGES. S. Bandyopadhyay, L. 

Masiello, N. Karin, J. Jacobs, J. Pounds, B. Thrall 

and K. M. Waters. Environmental Biomarkers 

Initiative, PNNL, Richland, WA. 


CORRELATING TOXICITY OF 

NANOMATERIAL WITH PHYSICAL 

CHARACTERIZATION USING AN 

OXIDATIVE STRESS MODEL. M. Kovochich, 

T. Xia and A. E. Nel. Medicine, UCLA, Los Angeles, 

CA. 


NANOMATERIALS TOXICITY: 

CLASSIFICATION USING MULTI-CRITERIA 

DECISION ANALYSIS. I. Linkov 1 , T. Tervonen 2 , 

J. R. Figueira 2 , J. Steevens 3 and J. Kim 3 . 1 Carnegie 

Mellon University, Brookline, MA, 2 Technical 

University Lisbon, Lisbon, Portugal and 3 U.S. 

Army Corps of Engineers, Engineer Research and 

Development Center, Vicksburg, MS. 


ANALYSIS OF SIZE-DEPENDENT 

CELLULAR RESPONSES TO SILICA 

NANOPARTICLES FROM INTEGRATED 

GENOMIC AND PROTEOMIC DATA. 

B. Thrall, K. M. Waters, L. M. Masiello, B. J. 

Terasavich and R. C. Zangar. Pacific Northwest 

National Laboratory, Richland, WA. 


ENHANCED CYTO- AND GENOTOXIC 

EFFECTS OF FE(III) NANOPARTICLES 

COMPARED TO FE(III) FINE PARTICLES 

IN HUMAN LUNG CELLS. K. Bhattacharya 1 , E. 

Hoffmann 2 , C. Albrecht 3 , R. Schins 3 , G. Alink 4 and 

E. Dopp 1 . 1 Institute of Hygiene and Occupational 

Medicine, University of Duisburg-Essen, Essen, 

Germany, 2 Institute of Cell Biology, University 

of Rostock, Rostock, Germany, 3 Institut fuer 

Umweltmedizinische Forschung (IUF), Duesseldorf, 

Germany and 4 Wageningen University, Wageningen, 

Netherlands. 


SINGLE-WALLED CARBON NANOTUBES: 

GENO- AND CYTO-TOXIC EFFECTS IN 

LUNG FIBROBLAST V79 CELLS. E. Kisin 1 , 

A. Murray 1 , M. Keane 2 , X. Shi 2 , D. Schwegler- 

Berry 1 , O. Gorelik 3 , S. Arepalli 3 , V. Castranova 1,4 , 

W. Wallace 2 , V. Kagan 4 and A. Shvedova 1 . 1 PPRB, 

NIOSH, Morgantown, WV, 2 EAB, NIOSH, 

Morgantown, WV, 3 NASA-JSC, Houston, TX and 

4 

University of Pittsburgh, Pittsburgh, PA. 

Monday 



Monday 




A 28-DAYS REPEATED DOSE AND 

GENOTOXICTY STUDY OF SILVER 

NANOPARTICLES. Y. Kim 1 , J. Kim 1 , J. Kim 1 , J. 

Park 2 , H. Chang 3 , R. Im 2 , M. Song 1 , Y. Chung 4 and 

I. Yu 1 . 1 Biosafety Evaluation Headquarter, KEMTI, 

Incheon, South Korea, 2 College of Medicine, Chung- 

Ang University, Seoul, South Korea, 3 College of 

Medine, Kosin University, Busan, South Korea 

and 4 Center for Occupational Toxicology, KOSHA, 

Daejeon, South Korea. 


LIMITATIONS OF THE STANDARD IN 

VITRO GENOTOXICITY PROTOCOLS 

FOR TESTING OF NANOMATERIALS. M. 

Schulz 1 , W. Wohlleben 2 , B. van Ravenzwaay 1 and R. 

Landsiedel 1 . 1 Experimental Toxicology and Ecology, 

BASF, Ludwigshafen am Rhein, Germany and 

2 

Polymer Physics, BASF, Ludwigshafen am Rhein, 

Germany. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: KIDNEY 

Chairperson(s): Peter Goering, U.S. FDA, Silver Spring, MD. 




ALTU-237: A 14-DAY ORAL TOXICITY 

STUDY IN BEAGLE DOGS. E. Koo 1 , G. 

Gesswein 1 , C. Godin 1 and K. Loveday 2 . 1 Bridge 

Global Pharmaceutical Services, Inc., Gaithersburg, 

MD and 2 Toxicology & Pharmacology, Altus 

Pharmaceuticals, Cambridge, MA. 


MECHANISTIC ASPECTS OF PROPANIL 

NEPHROTOXICITY IN VITRO. C. Racine 2 , A. 

Sweeney 1 , A. Kraynie 1 , S. Baksi 1 , D. Anestis 1 and 

G. O. Rankin 1 . 1 Pharmacology, Marshall University, 

Huntington, WV and 2 Davis & Elkins College, 

Elkins, WV. 


DETECTION OF ENDOTOXIN-INDUCED 

ACUTE KIDNEY INJURY IN RATS. R. P. 

Brown 1 , V. S. Vaidya 3 , B. C. Beach 1 , M. C. Toal 1 , S. 

T. Loftin 1 , J. Zhang 2 , F. B. Collings 3 , J. V. Bonventre 3 

and P. L. Goering 1 . 1 CDRH, U.S. FDA, Silver Spring, 

MD, 2 CDER, U.S. FDA, Silver Spring, MD and 

3 

Brigham and Women’s Hospital, Harvard Medical 

School, Boston, MA. 


ROLES OF MITOCHONDRIAL 

DYSFUNCTION, CASPASES, AND FAS 

RECEPTOR IN S-(1, 2-DICHLOROVINYL)- 

L-CYSTEINE (DCVC)-INDUCED 

CYTOTOXICITY IN HUMAN PROXIMAL 

TUBULAR (HPT) CELLS. L. H. Lash, F. Xu, D. 

A. Putt and I. Papanayotou. Pharmacology, Wayne 

State University Sch. Med., Detroit, MI. 


MITOCHONDRIAL GLUTATHIONE 

TRANSPORT IN DIABETIC NEPHROPATHY. 

Q. Zhong and L. H. Lash. Pharmacology, Wayne 

State University Sch. Med., Detroit, MI. 


PUROMYCIN TREATMENT RESULTED IN 

DIFFERENTIAL EXPRESSION OF GENES 

INVOLVED IN PATHWAYS ASSOCIATED 

WITH GENE/PROTEIN EXPRESSION 

PROCESS. A. R. Stapleton 1 and V. T. Chan 2 . 1 HJF, 

Wright-Patterson AFB, OH and 2 AFRL/HEPB, 

Wright-Patterson AFB, OH. Sponsor: J. Gearhart. 


ATTENUATION OF N-(3, 

5-DICHLOROPHENYL)-2- 

HYDROXYSUCCINIMIDE-O-SULFATE 

(NSC)-INDUCED NEPHROTOXICITY IN 

PRIMARY CULTURES OF RAT RENAL 

PROXIMAL TUBULE CELLS. G. O. Rankin, 

C. Cook, S. L. Miles, S. K. Hong and D. K. Anestis. 

Pharmacology, Physiology & Toxicology, Marshall 

University, Huntington, WV. 


URINARY KIDNEY INJURY MOLECULE-1 

AND N-ACETYL b-D-GLUCOSAMINIDASE 

AS BIOMARKERS FOR AMINOGLYCOSIDE 

AND CISPLATIN-INDUCED 

NEPHROTOXICITY IN PATIENTS. V. S. 

Vaidya, S. S. Waikar, F. B. Collings, K. Sunderland 

and J. V. Bonventre. Medicine-Renal, Brigham and 

Women’s Hospital, Harvard Medical School, Boston, 

MA. 


MODULATION OF OXIDATIVE STRESS BY 

RESVERATROL AND ATTENUTATION OF 

CISPLATIN IN VITRO RENAL TOXICITY. 

M. Valentovic and M. V. Terneus. Pharmacology, 

Physiology and Toxicology, Marshall University 

School of Medicine, Huntington, WV. 


GENE EXPRESSION ANALYSIS REVEALS 

NEW POSSIBLE MECHANISMS 

OF VANCOMYCIN-INDUCED 

NEPHROTOXICITY. H. H. Ng, C. Dieterich, A. 

Puey, S. Lin, R. Swezey, A. Furimsky, D. Fairchild 

and J. C. Mirsalis. BioSciences, SRI International, 

Menlo Park, CA. 


CHARACTERIZATION OF PROPIVERINE 

EFFECTS ON RAT PPARS. A. H. Heussner 1 , 

M. M. Baldock 1 , B. Manfred 2 and D. R. Dietrich 1 . 

1 

Human and Environmental Toxicology, University 

of Konstanz, Konstanz, Germany and 2 Preclinical 

and Clinical Safety, APOGEPHA GmbH, Dresden, 

Germany. 


THE POTENTIAL EFFECT OF MT-AB 

ON RENAL DYSFUNCTION WITHIN A 

CHINESE DIABETIC POPULATION. L. Lei 1,2 , 

L. Chen 1,2 , T. Jin 1,2,4 , M. Nordberg 3 and G. Nordberg 4 . 

1 

Occupational Health, Fudan University, Shanghai, 

China, 2 Toxicology, Fudan University, Shanghai, 

China, 3 Enviromental Medicine, Karolinska Institute, 

Stockholm, Sweden and 4 Public Health and Clinical 

Medicine, Umea University, Umea, Sweden. 

124 




Abstract # 


CHANGES IN THE RENAL EXPRESSION 

OF RPA-1, RPA-2, AND KIM-1 FROM 

SPONTANEOUSLY HYPERTENSIVE RATS 

(SHR) GIVEN DOXORUBICIN (DXR) 

OR MITOXANTRONE (MTX), WITH OR 

WITHOUT DEXRAZOXANE (DRZ). J. Zhang 1 , 

M. Shaw 2 , J. Keenan 2 , C. Kilty 2 , S. E. Lipshultz 3 , A. 

Knapton 1 , V. S. Vaidya 4 , J. V. Bonventre 4 and E. H. 

Herman 1 . 1 CDER, FDA, Silver Spring, MD, 2 Biotrin 

Intl Ltd, Dublin, Ireland, 3 Miller School of Medicine, 

University of Miami, Miami, FL and 4 Renal Division 

Department of Med. Brigham & Women’s Hosp., 

Harvard Medical School, Boston, MA. 


SPONTANEOUS OCCURENCE OF A 

DISTINCTIVE AMPHOPHILIC-VACUOLAR 

RENAL TUBULE TUMOR PHENOTYPE 

IN RAT CARCINOGENICITY STUDIES 

CONDUCTED BY THE NATIONAL 

TOXICOLOGY PROGRAM. G. C. Hard 1 , J. 

C. Seely 2 , G. E. Kissling 3 and L. J. Betz 4 . 1 Private 

Consultant, Tairura, New Zealand, 2 Experimental 

Pathology Labs., Inc., Research Triangle Park, NC, 

3 

National Institute of Environmental Health Sciences, 

NIH, Research Triangle Park, NC and 4 Constella 

Health Sciences, Durham, NC. Sponsor: J. Hardisty. 


UPREGULATION OF GLYCERALDEHYDE 

3 PHOSPHATE DEHYDROGENASE 

(GAPDH) AND GLUCOSE 6 PHOSPHATE 

DEHYDROGENASE (G6PDH) DURING THE 

EARLY STAGES OF CADMIUM-INDUCED 

RENAL INJURY. J. Edwards, P. C. Lamar and 

W. C. Prozialeck. Pharmacology, Midwestern 

University, Downers Grove, IL. 


THE QUANTITATIVE DETERMINATION 

OF GENTAMICIN-, INDOMETHACIN- AND 

AMPHOTERICIN-INDUCED RENAL INJURY 

USING AN ETHIDIUM HOMODIMER- 

BASED IN SITU VIABILITY ASSAY. M. V. 

Kowal, J. Edwards, E. A. Diamantakos and W. C. 

Prozialeck. Pharmacology, Midwestern University, 

Downers Grove, IL. 


PATHWAYS OF r-NONYLPHENOL (NP)- 

INDUCED RENAL TOXICITY SUGGESTED 

BY GLOBAL GENE EXPRESSION 

PROFILES. L. Camacho 1 , T. Han 2 , X. Fu 3 , S. 

Cooper 1 , J. Fuscoe 2 and K. Delclos 1 . 1 Division of 

Biochemical Toxicology, NCTR, FDA, Jefferson, 

AR, 2 Division of Systems Toxicology, NCTR, 

FDA, Jefferson, AR and 3 Division of Reproductive, 

Abdominal and Radiological Devices, ODE, CDRH, 

FDA, Rockville, MD. 


ZINC SUPPLEMENTATION PARTIALLY 

PREVENT DIABETIC NEPHROPATHY. Y. 

Tang 1 , Q. Yang 2 and L. Cai 1 . 1 Medicine, University 

of Louisville, Louisville, KY and 2 Pathophysiology, 

Guiyang Medical College, Guiyang, Guizhou, China. 

Abstract # 


IDENTIFICATION OF A RAT SPECIFIC 

MECHANISM FOR ANTISENSE 

OLIGONUCLEOTIDE (ASO) INDUCED 

KIDNEY INJURY. L. Shen, R. Louhead, R. Fey, 

G. Hung and S. P. Henry. ISIS Pharmaceuticals, Inc, 

Carlsbad, CA. 


THE POTENTIAL ROLE OF THE SODIUM 

IODIDE SYMPORTER IN BROMATE- 

INDUCED KIDNEY CELL DEATH AND 

DNA DAMAGE. D. De Silva 1 , R. J. Bull 2 , O. 

Quinones 3 , S. A. Snyder 3 , J. A. Cutruvo 4 , J. Fisher 5 

and B. S. Cummings 1 . 1 Pharmacology and Biomed. 

Sci., University of Georgia, Athens, GA, 2 MoBull 

Consulting, Richland, WA, 3 Southern Nevada Water 

Authority, Henderson, NV, 4 Joseph Curtruvo & 

Associates, Washington, DC and 5 Environment 

Health Sci., University of Georgia, Athens, GA. 


CADMIUM INHIBITS LACTATE 

GLUCONEOGENESIS IN HUMAN RENAL 

PROXIMAL TUBULES. G. Baverel, H. Faiz, 

S. Renault, B. Ferrier, G. Martin, M. Boghossian, 

M. Martin, A. Duplany-Conjard and R. Nazaret. 

Metabolomics, INSERM U820, Lyon Cedex 08, 

France. 


METHYL ISOBUTYL KETONE (MIBK) 

INDUCED a2u-GLOBULIN (a2u) 

NEPHROPATHY IN MALE AND FEMALE 

F344 RATS. G. C. Hard 1 , N. Berdasco 2 , R. 

Gingell 2 , S. Green 2 , W. Gulledge 2 and S. Borghoff 3 . 

1 

Pathologist, Tairua, New Zealand, 2 America 

Chemistry Council Ketones Panel, Arlington, VA and 

3 

ILS, Inc, Research Triangle Park, NC. 


COMBINATION OF RENAL 

FUNCTION INVESTIGATION WITH 

PLETHYSMOGRAPHY IN RATS: 

REFINEMENT OF THE CORE BATTERY. 

A. Bétat, P. Lainée, G. Froget and R. Forster. CIT, 

Evreux, France. 


LINDANE-INDUCED APOPTOSIS IN 

MDCK CELLS CORRELATES WITH 

DOWN-REGULATION OF BCL-XL UNDER 

CONDITIONS OF HYPERTONIC STRESS. 

A. L. Piskac and M. Smith. Environmental and 

Occupational Health Sciences, The University of 

Texas School of Public Health, Houston, TX. 


CHEMICAL-INDUCED POST- 

TRANSLATIONAL MODIFICATIONS 

AND THE CONSEQUENT STRUCTURAL 

AND FUNCTIONAL ALTERATIONS. A. A. 

Fisher 1 , S. Lau 1 , M. T. Labenski 1 , S. Malladi 2 , M. 

Chen 3 , X. Shen 3 , S. B. Bratton 2 and T. J. Monks 1 . 

1 

Pharmacology and Toxicology, The University of 

Arizona, Tucson, AZ, 2 Division of Pharmacology 

and Toxicology, University of Texas, Austin, TX and 

3 

Carcinogenesis, UT MD Anderson Cancer Center, 

Smithville, TX. 

Monday 



Monday 




TUBEROUS SCLEROSIS-2 AND THE 

REGULATION OF 8-OXOGUANINE DNA 

GLYCOSYLASE. I. L. Druwe, S. Lau, A. Wenx 

and T. J. Monks. Pharmacology and Toxicology, The 

University of Arizona, Tucson, AZ. 


MALDI TISSUE IMAGING OF RENAL 

TUMORS THE IN EKER RAT. S. Lau, B. 

D. Leinweber, G. T. Tsaprailis and T. J. Monks. 

Pharmacology and Toxicology, The University of 

Arizona, Tucson, AZ. 


STRAIN DIFFERENCE OF URINARY 

OXALATE AND ELECTROLYTES IN 

ETHYLENE GLYCOL TREATED WISTAR 

AND F344 RATS. K. McMartin, B. Lieblong and Y. 

Li. Pharmacology, Toxicology & Neuroscience, LSU 



A METABONOMIC INVESTIGATION 

INTO THE DIURETIC EFFECTS OF 

BROMOETHANAMINE. A. J. Campbell 1 , 

C. Muireann 1 , G. H. Cantor 2 , N. Aranibar 2 , J. T. 

Pearce 1 , E. J. Want 1 , M. Sanders 2 , J. D. Vassallo 2 , L. 

Lehman-McKeeman 2 , E. Holmes 1 , J. C. Lindon 1 and 

J. K. Nicholson 1 . 1 Biomolecular Medicine, Imperial 

College London, London, United Kingdom and 

2 

Discovery Toxicology, BMS, Lawrenceville, NJ. 


IDENTIFICATION OF PROBABLE 

GENOMIC AND URINARY PROTEIN 

NEPHROTOXICITY BIOMARKERS IN 

MICE. Y. Gu, E. Wang, R. J. Smith, W. Feng, 

J. Petrulis and R. D. Snyder. Drug Safety and 

Metabolism, Schering-Plough, Summit, NJ. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: FOOD SAFETY I 

Chairperson(s): Scott Belcher, University of Cincinnati, Cincinnati, OH 

and Bruce Hammond, Monsanto Company, St. Louis, MO. 




WATER ARSENIC AND DAIRY FOOD 

SAFETY. M. Murphy 1 , J. Kashman 1 , J. Linn 3 , B. 

Liukkonen 3 , V. Crary 3 , Z. Kassa 2 , M. Campbell 2 

and G. Horvath 2 . 1 Veterinary Populatin Medicine, 

University of Minnesota, St. Paul, MN, 2 Laboratory 

Services, Minnesota Department of Agriculture, 

St. Paul, MN and 3 Department of Animal Science, 

University of Minnesota, St. Paul, MN. 


FISH CONSUMPTION ADVISORIES: 

TOXICOLOGICAL RISK AND 

NUTRITIONAL BENEFIT MESSAGES TO 

SENSITIVE POPULATIONS. A. C. Scherer 1,2 , A. 

Tsuchiya 1,2 , L. R. Younglove 1,2 , T. M. Burbacher 1 and 

E. M. Faustman 1,2 . 1 Department of Environmental 

and Occupational Health Sciences, University of 

Washington, Seattle, WA and 2 Institute for Risk 

Analysis and Risk Communication, Seattle, WA. 


NATURAL IS NOT ALWAYS SAFE: A 

LESSON FROM THE LITERATURE ON THE 

USE OF HERBAL PRODUCTS. A. Vitalone 1 and 

L. Costa 1,2 . 1 University of Parma, Parma, Italy and 

2 



IDENTIFICATION AND 

CHARACTERIZATION OF TOXICITY OF 

CONTAMINANTS IN PET FOOD LEADING 

TO AN OUTBREAK OF RENAL TOXICITY. 

G. Daston, R. Dobson, S. Motlagh, M. Quijano, T. 

Cambron, T. Baker, A. Pullen, B. Regg, A. Bigelow- 

Kern, T. Vennard, A. Fix, G. Overmann and Y. Shan. 

Procter & Gamble, Cincinnati, OH. 


DISPOSITION OF MELAMINE IN PIGS. R. 

E. Baynes, G. Smith, S. E. Mason, E. Barrett, B. 

M. Barlow and J. E. Riviere. Center for Chemical 

Toxicology Research and Pharmacokinetics, North 



ACRYLAMIDE: TOXICOKINETICS IN 

HUMANS. E. Kopp and W. Dekant. Department 

of Toxicology, University of Würzburg, Würzburg, 

Germany. 


A 12-WEEK TOXICOLOGICAL STUDY OF 

ORALLY ADMINISTERED ACRYLAMIDE 

IN JUVENILE RATS. T. Imai, S. Takami, Y. Cho, 

M. Hirose and A. Nishikawa. Division of Pathology, 



DIET BASED EXPOSURE TO ACRYLAMIDE 

IN FINLAND. K. Peltonen, S. Eerola and K. 

Hollebekkers. Department of Chemistry and 

Toxicology, Finnish Food Safety Authority EVIRA, 

Helsinki, Finland. 


RELATIVE AMOUNTS OF THE 

MYCOTOXIN DEOXYNIVALENOL IN 

FOODS PREPARED FROM WHEAT FLOUR 

UNDER COMMERCIALLY RELEVANT 

CONDITIONS. K. A. Voss 1 , M. E. Snook 1 , W. 

Li 2 , B. Strouts 3 and J. Barach 4 . 1 Toxicology & 

Mycotoxin Research Unit, ARS-USDA, Athens, GA, 

2 

Department of Food Safety and Nutrition, Frito- 

Lay Inc., Plano, TX, 3 American Institute of Baking, 

Manhattan, KS and 4 Grocery Manufacturers/Food 

Products Association, Washington, DC. 

126 




Abstract # 


IN VITRO CHARACTERIZATION OF 

MYCOTOXIN BINDING AGENTS 

INCLUDED IN ANIMAL FEEDS IN MEXICO. 

A. G. Marroquin-Cardona 1,3 , C. T. Hallmark 2 , 

J. Taylor 1 , E. Afriyie-Gyawu 1 , A. Robinson 1 , N. 

Johnson 1 and T. D. Phillips 1 . 1 Veterinary Integrative 

Biosciences, Texas A&M University, College Station, 

TX, 2 Soil and Crop Sciences, Texas A&M University, 

College Station, TX and 3 Universidad Autonoma de 

Nuevo Leon, San Nicolas de los Garza, Mexico. 


EVIDENCE FOR FUMONISIN- 

CORN MATRIX BINDING DURING 

NIXTAMALIZATION. T. D. Burns 1 , M. 

E. Snook 2 , T. R. Mitchell 2 and K. A. Voss 2,1 . 

1 

Interdisciplinary Toxicology Program, University of 

Georgia, Athens, GA and 2 Toxicology & Mycotoxin 

Research Unit, ARS-USDA, Athens, GA. 


COMPARATIVE AND COMBINATIVE 

CYTOTOXIC EFFECTS OF AFLATOXIN 

B1 AND FUMONISIN B1 ON HUMAN 

ESOPHAGEAL CELLS. V. Kolli, L. Tang and J. S. 

Wang. Texas Tech University, Lubbock, TX. 


DEVELOPMENT OF ADSORPTIVE 

MATERIALS FOR THE REMEDIATION 

OF FUMONISIN B1 CONTAMINATED 

FOODSTUFFS. A. Robinson, J. Taylor, N. Johnson, 

A. Marroquin-Cardona, H. Huebner, N. Sarpong, E. 

Afriyie-Gyawu and T. Phillips. Veterinary Integrative 

Biosciences, College of Veterinary Medicine and 

Biomedical Sciences, Texas A&M University, 

College Station, TX. 


ACCUMULATION OF SPHINGOID 

BASES, THE STRUCTURAL SPHINGOID 

BASE ANALOG FTY720 AND THEIR 

PHOSPHORYLATED METABOLITES 

IN BLOOD, PLASMA AND DECIDUA OF 

SWV AND LMBC MICE TREATED WITH 

FUMONISIN B1 OR FTY720. R. T. Riley 1 , K. 

A. Voss 1 , J. R. Maddox 2 , J. Wilberding 2 and J. B. 

Gelineau-van Waes 2 . 1 Toxicology and Mycotoxin 

Research Unit, USDA-ARS, Athens, GA and 

2 

Department of Genetics, Cell Biology and Anatomy, 

University of Nebraska Medical Center, Omaha, NE. 


ESTIMATION OF OCHRATOXIN A IN 

TURKISH POPULATION: AN ANALYSIS 

IN URINE AS A SIMPLE, SENSITIVE AND 

RELIABLE BIOMARKER. A. Karakaya 1 , C. 

Akdemir 2 , A. Basaran 2 , O. C. Ulker 1 and S. Ozkaya 2 . 

1 

Department of Toxicology, Ankara University 

Faculty of Pharmacy, Ankara, Turkey and 2 Ministry 

of Agriculture and Rural Affairs, Ankara Provincial 

Control Laboratory, Ankara, Turkey. Sponsor: A. 

Karakaya. 


MONOCLONAL ANTIBODIES AGAINST 

OTB: POTENTIAL FUTURE APPLICATIONS. 

S. T. Auslaender, A. H. Heussner and D. R. Dietrich. 

Human and Environmental Toxicology, University of 

Konstanz, Konstanz, Germany. 

Abstract # 


NOVASIL CLAY INTERVENTION IN 

GHANAIANS AT HIGH RISK FOR 

AFLATOXICOSIS: IMMUNE PARAMETERS 

AS BIOMARKERS OF EFFECT. L. Xu 1 , E. 

Afriyie-Gyawu 2 , Y. Jiang 3 , L. Tang 1 , H. J. Huebner 2 , 

N. A. Ankrah 4 , D. Ofori-Adjei 4 , W. O. Ellis 5 , P. E. 

Jolly 3 , J. H. Williams 6 , J. S. Wang 1 and T. D. Phillips 2 . 

1 

Texas Tech University, Lubbock, TX, 2 Texas A&M 

University, College Station, TX, 3 University of 

Alabama, Birmingham, AL, 4 University of Ghana, 

Accra, Ghana, 5 KNUST, Kumasi, Ghana and 6 The 

University of Georgia, Griffin, GA. 


SAFETY EVALUATION OF CARRAGEENAN 

FOR USE IN INFANT FORMULA. M. L. Weiner 

and S. Alcasey. Toxicology, FMC Corporation, 

Princeton, NJ. 


EXPRESSION OF CU/ZN SUPEROXIDE 

DISMUTASE AND CATALASE BY 

ALTERATION OF PPARg AND NF-kB DNA 

BINDING ACTIVITIES. Y. Nakamura and S. 

T. Omaye. Nutrition, University of Nevada, Reno, 

Reno, NV. 


EFFECTS OF GACINIA CAMBOGIA 

EXTRACT (HYDROXYCITRIC ACID) ON 

SERUM SEX HORMONES IN OVERWEIGHT 

SUBJECTS: A DOUBLE-BLIND, 

RANDOMIZED, PLACEBO-CONTROLLED 

TRIAL. K. Hayamizu 1 , H. Tomi 1 , I. Kaneko 1 , 

M. Shen 1 , M. G. Soni 2 and G. Yoshino 3 . 1 FANCL 

Research Institute, Yokohama, Kanagawa, Japan, 

2 

Soni & Associates Inc., Vero Beach, FL and 3 Toho 

University School of Medicine, Ohta-ku, Tokyo, 

Japan. 


SAFETY ASSESSMENT OF SDA SOYBEAN 

OIL. J. Lemen 1 , G. Ahmed 1 , J. Kirkpatrick 2 , W. 

Harris 3 and B. Hammond 1 . 1 Product Safety Center, 

Monsanto Company, St. Louis, MO, 2 WIL Research 

Laboratories, Ashland, OH and 3 Department 

Research Metabolic Disease, University South 

Dakota, Sioux Falls, SD. 


EFFECTS OF T-2 TOXIN ON HEPATIC 

DRUG METABOLIZING ENZYMES AND 

THE BINDING ACTIVITY OF AFLATOXIN 

B1 TO DNA IN RATS. Y. Sugita-Konishi 1,2 , A. 

Kubosaki 1 , K. Sugiyama 1 , A. Poapolathep 2 , K. Dong 2 

and S. Kumagai 2 . 1 Div of Microbiology, National 

Institute of Health Sciences, Tokyo, Japan and 

2 

Graduate School of Agricultural and Life Sciences, 

The University of Tokyo, Tokyo, Japan. 


HEAT STABILITY OF ANTIBIOTICS 

CHARACTERIZED BY CHANGES IN 

CHROMATOGRAPHIC PROFILES, 

ULTRAVIOLET SPECTROMETRY, 

ANTIMICROBIAL ACTIVITY AND 

GENOTOXICITY. C. Chou 1 , Y. Huang 1 , C. 

Shyu 1 , J. Liao 2 and S. Chang 3 . 1 Veterinary Medicine, 

National Chung-Hsing University, Taichung, Taiwan, 

2 

Graduate Institute of Veterinary Pathology, National 

Chung-Hsing University, Taichung, Taiwan and 

3 

Veterinary Medicine, National Taiwan University, 

Taipei, Taiwan. 

Monday 



Monday 




EFFECTS OF SYNEPHRINE, BITTER 

ORANGE, AND CAFFEINE ON 

PHYSIOLOGICAL AND CARDIOVASCULAR 

VARIABLES IN FEMALE SPRAGUE- 

DAWLEY RATS. P. Duffy 1 , G. White 1 , S. Appana 1 , 

L. Pellicore 2 , V. Francos 2 and D. Hansen 1 . 1 National 

Center for Toxicological Research, FDA, Jefferson, 

AR and 2 Center for Food Safety and Applied 

Nutrition, FDA, College Park, MD. 


EFFECT OF DEOXYNIVALENOL ON LPS 

SIGNALING IN MACROPHAGE. K. Sugiyama 1 , 

M. Muroi 1 , K. Tanamoto 2 , M. Nishijima 3 and Y. 

Sugita-Konishi 1 . 1 Division of Microbiology, National 

Institute of Health Sciences, Tokyo, Japan, 2 Division 

of Food Additives, National Institute of Health 

Sciences, Tokyo, Japan and 3 Department of Food and 

Health Science, Jissen Women’s University, Tokyo, 

Japan. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: SAFETY ASSESSMENT, 

NON-PHARMACEUTICAL 

Chairperson(s): Evans Afriyie-Gyawu, Texas A&M University, College 

Station, TX. 




APPLICATION OF A TOXICOLOGICAL 

SURROGATE EVALUATION FRAMEWORK: 

ALKYL AMMONIO ACETATES AS A CASE 

STUDY. A. Maier 1 , R. Venkatapathy 1 and G. Simon 2 . 

1 

Toxicology Excellence for Risk Assessment, 

Cincinnati, OH and 2 Rhodia, Inc., Raleigh, NC. 


EFFECTS OF OCCUPATIONAL EXPOSURE 

TO CHEMICALS ON HEARING - A WEIGHT 

OF EVIDENCE APPROACH. A. Vyskocil 1 , G. 

Truchon 2 , T. Leroux 3 , F. Lemay 2 , S. Lim 1 , F. Gagnon 1 

and C. Viau 1 . 1 Environmental and Occupational 

Health, Université de Montréal, Montreal, QC, 

Canada, 2 Institut de recherche Robert-Sauvé en santé 

et en sécurité du travail, Montreal, QC, Canada and 

3 

École d’orthophonie et d’audiologie, Université de 

Montréal, Montreal, QC, Canada. 


SAFE DRINKING WATER FROM 

LONG-LIFE, POINT-OF-USE 

HOUSEHOLD TREATMENT BASED 

ON BROMINE CHARGING OF 

POLYSTYRENEHYDANTOIN BEADS 

(HALOPURE). S. C. Himley, M. Bridges and J. F. 

Williams. HaloSource, Inc., Bothell, WA. Sponsor: 

S. Gilbert. 


PROPOSAL FOR SAFETY EXPOSURE 

LEVEL OF NITROBENZENE THROUGH 

FOODS AND DRINKING WATER. M. Hirata- 

Koizumi, R. Hasegawa, A. Hirose and M. Ema. 



EVALUATION OF CLIMBAZOLE 

GENOTOXICITY IN A BATTERY OF IN 

VITRO AND IN VIVO MUTAGENICITY 

TESTS. J. F. Nash, M. J. Aardema and A. A. Pérez- 

Rivera. Central Product Safety, Procter & Gamble 

Company, Cincinnati, OH. Sponsor: J. Skare. 


21-DAY DERMAL TOXICITY STUDY OF 

EUCALYPTUS ESSENTIAL OIL IN FEMALE 

RATS. C. Wang, H. Chen, S. Hsu, Y. Yang, C. 

Tseng, C. Chen and H. Chu. Development Center for 

Biotechnology, Taipei, Taiwan. 


CUTANEOUS LOCAL TOLERANCE OF 

DIPHOTéRINE® IN HUMAN VOLUNTEERS 

AFTER A UNIQUE OCCLUSIVE 

APPLICATION DURING 48 HOURS. L. 

Mathieu 1 , F. Burgher 1 , A. H. Hall 2 and H. I. 

Maibach 3 . 1 Prevor Laboratory, Valmondois, France, 

2 

Preventive Medecine, UCHSC, Denver, CO and 

3 

Medical Center, UCSF, San Francisco, CA. 


SUBCHRONIC TOXICITY OF DIMYRCETOL 

IN RATS. C. Letizia, A. Api and V. Politano. RIFM, 

Woodcliff Lake, NJ. 


NOVASIL CLAY DOES NOT AFFECT 

BIOAVAILABILITY AND UTILIZATION 

OF VITAMINS A AND E AND NUTRIENT 

MINERALS IN GHANAIANS AT HIGH RISK 

FOR AFLATOXICOSIS. E. Afriyie-Gyawu 1 , Z. 

Wang 2 , N. Johnson 1 , L. Xu 2 , N. Ankrah 3 , T. Lili 2 , 

H. Huebner 1 , P. Jolly 4 , J. Williams 5 , J. Wang 2 and 

T. Phillips 1 . 1 Veterinary Integrative Biosciences, 

Texas A&M University, College Station, TX, 

2 

Environmental Toxicology/The Institute of 

Environmental and Human Health, Texas Tech 

University, Lubbock, TX, 3 Noguchi Memorial 

Institute for Medical Research, University of Ghana, 

Legon, Accra, Greater Accra, Ghana, 4 Epidemiology/ 

School of Public Health, University of Alabama, 

Birmingham, AL and 5 Peanut Collaborative Research 

Support Program, University of Georgia, Griffin, 

GA. 


METHYL TERTIARY BUTYL ETHER 

(MTBE) 13-WEEK DRINKING WATER 

STUDY IN WISTAR RATS. E. Bermudez, H. D. 

Parkinson and D. E. Dodd. The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC. 


SCREENING LEVEL RISK EVALUATIONS 

FOR OCCUPATIONAL EXPOSURES TO 

CHLOROPRENE DIMERS. R. Valentine and B. 

Szostek. DuPont Haskell Global Centers for Health 

and Environmental Sciences, Newark, DE. 


NASAL EPITHELIAL LESIONS IN RATS 

FOLLOWING AN ACUTE INHALATION 

EXPOSURE TO NAPHTHALENE VAPOR AT 

LOW CONCENTRATIONS. D. E. Dodd 1 , R. A. 

James 1 , E. A. Gross 1 , R. A. Miller 2 , V. J. Piccirillo 3 

and B. A. Wong 1 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, 2 Experimental 

Pathology Laboratories, Research Triangle Park, NC 

and 3 VJP Consulting, Inc., Ashburn, VA. 

128 




Abstract # 


IMPAIRED GLUCOSE TOLERANCE IN 

RODENTS ADMINISTERED HIGH DOSES 

OF GLUCOSAMINE ARE NOT RELEVANT 

TO HUMANS. R. R. Simon, L. A. Haighton and N. 

J. Baldwin. Cantox Health Sciences International, 

Mississauga, ON, Canada. 


PRELIMINARY PALATABILITY TESTING 

OF IONIC LIQUIDS IN WISTAR HAN 

RATS AND B6C3F1 MICE. J. W. Algaier 1 , 

C. R. Croutch 1 , E. Luxford 1 , A. B. Astroff 1 , A. P. 

Clark 1 , R. K. Harris 1 , C. S. Smith 2 , M. J. Hooth 2 

and B. Jayaram 2 . 1 Product Sciences Division, 

Midwest Research Institute, Kansas City, MO and 

2 

Environmental Toxicology Program, NIEHS, 



QUARTZ-CONTAINING CERAMIC 

DUSTS: IN VITRO SCREENING OF 

THE CYTOTOXIC AND GENOTOXIC 

POTENTIAL OF 5 FACTORY SAMPLES. 

C. Ziemann 1 , P. Jackson 2 , R. Brown 3 , G. Attik 4 , B. 

Rihn 4 and O. Creutzenberg 1 . 1 Genetic Toxicology, 

Fraunhofer Institute of Toxicology and Experimental 

Medicine, Hannover, Germany, 2 CERAM, Stoke-on- 

Trent, United Kingdom, 3 TOXSERVICES, Stretton, 

United Kingdom and 4 Pharmacy, UHP, Nancy, 

France. Sponsor: H. Muhle. 


QUARTZ-CONTAINING CERAMIC DUSTS: 

IN VIVO STUDY ON INFLAMMATORY 

EFFECTS OF TWO FACTORY SAMPLES 

IN LUNGS AFTER INTRATRACHEAL 

INSTILLATION IN A 28-DAY STUDY WITH 

RATS. O. H. Creutzenberg 1 , C. Ziemann 1 , T. 

Hansen 1 , H. Ernst 1 , P. Jackson 2 and R. Brown 3 . 

1 

Inhalation Toxicology, Fraunhofer Institute of 

Toxicology and Experimental Medicine, Hannover, 

Lower Saxony, Germany, 2 CERAM, Stoke-on-Trent, 

United Kingdom and 3 TOXSERVICES, Stretton, 

United Kingdom. Sponsor: H. Muhle. 


CARCINOGENESIS STUDIES OF CRESOLS 

IN RATS AND MICE. J. M. Sanders 1 , J. R. 

Bucher 1 , J. C. Peckham 1 , G. E. Kissling 1 , M. 

R. Hejtmancik 2 and R. S. Chhabra 1 . 1 National 

Toxicology Program, NIEHS, RTP, NC and 2 Battelle, 

Columbus, OH. 


TOXICITY AND CARCINOGENICITY OF 

CHROMIUM FOLLOWING CHRONIC ORAL 

EXPOSURE: DEPENDENCE ON VALENCE 

STATE AND TISSUE UPTAKE. M. D. Stout 1 , 

B. J. Collins 1 , R. A. Herbert 1 , A. Nyska 2 , G. E. 

Kissling 1 , K. Levine 3 , G. T. Ross 3 , C. D. Hébert 4 , G. 

S. Travlos 1 , J. R. Bucher 1 and M. J. Hooth 1 . 1 NIEHS, 

Research Triangle Park, NC, 2 ILS, Research Triangle 

Park, NC, 3 RTI International, Research Triangle Park, 

NC and 4 SRI, Birmingham, AL. 

Abstract # 


TISSUE DISTRIBUTION OF CHROMIUM IN 

MALE FISCHER 344 RATS AND FEMALE 

B6C3F1 MICE EXPOSED TO SODIUM 

DICHROMATE DIHYDRATE IN DRINKING 

WATER FOR 2 YEARS. B. J. Collins 1 , K. Levine 2 , 

G. T. Ross 2 , R. Fernando 2 , T. R. Fennell 2 , G. E. 

Kissling 1 , M. D. Stout 1 and M. J. Hooth 1 . 1 National 

Institute of Environmental Health Sciences, Research 

Triangle Park, NC and 2 RTI International, RTP, NC. 


TISSUE DISTRIBUTION OF CHROMIUM IN 

MALE FISCHER 344 RATS AND FEMALE 

B6C3F1 MICE EXPOSED TO CHROMIUM 

PICOLINATE MONOHYDRATE IN THE 

DIET FOR 2 YEARS. R. Fernando 1 , K. Levine 1 , 

B. J. Collins 2 , G. E. Kissling 2 , M. J. Hooth 2 , T. 

R. Fennell 1 , G. T. Ross 1 and M. D. Stout 2 . 1 RTI 

International, RTP, NC and 2 National Institute of 

Environmental Health Sciences, Research Triangle 

Park, NC. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: MODULATORS OF CELL PROLIFERATION 

IN CHEMICAL CARCINOGENESIS 

Chairperson(s): Brinda Mahadevan, Schering-Plough Research Institute, 

Summit, NJ. 




MODIFYING EFFECTS OF TROGLITAZONE 

ON THE VASCULAR TUMORIGENESIS 

INITIATED WITH URETHANE IN RASH2 

MICE. M. Jin 1,2 , Y. Dewa 1 , J. Nishimura 1 , S. 

Matsumoto 1 , Y. Saegusa 1 , K. Hasumi 2 and K. 

Mitsumori 1 . 1 Laboratory of Veterinary Pathology, 

Tokyo University of Agriculture and Technology, 

Japan, Fuchu, Tokyo, Japan and 2 Department of 

Applied Biological Scinece, United Graduate School 

of Agricultural Sciences, Tokyo University of 

Agriculture and Techonology, Fuchu, Tokyo, Japan. 

Sponsor: M. Takahashi. 


EVALUATION OF POSSIBLE 

CYTOTOXICITY AND MITOGENESIS IN 

HUMAN MICROVASCULAR ENDOTHELIAL 

CELLS TREATED WITH THE PPARg 

AGONIST, TROGLITAZONE. S. Kakiuchi- 

Kiyota, R. Singh, S. Suzuki, K. L. Pennington, 

M. Nascimento, L. L. Arnold and S. M. Cohen. 

Pathology and Microbiology, University of Nebraska 

Medical Center, Omaha, NE. 


ROLE OF KUPFFER CELL IN 

WYETH-14, 643-INDUCED HEPATOCYTE 

PROLIFERATION IN NAÏVE C3H MICE. B. 

K. Philip, C. Rice, L. Kamendulis and J. Klaunig. 

Pharmacology and Toxicology, Indiana University 

School of Medicine, Indianapolis, IN. 

Monday 



Monday 




GENE EXPRESSION PROFILES OF 

PERFLUOROOCTANOIC, -NONANOIC 

AND -DECANOIC ACIDS AND 8:2 

FLUOROTELOMER ALCOHOL IN 

RAINBOW TROUT, A MODEL FOR HUMAN 

HEPATOCARCINOGENESIS. A. D. Benninghoff 

and D. E. Williams. Department of Environmental 

and Molecular Toxicology and the Environmental 

Health Sciences Center, Oregon State University, 

Corvallis, OR. 


MECHANISMS OF INHIBITION OF 

GAP JUNCTION INTERCELLULAR 

COMMUNICATION THROUGH DIFFERENT 

MOLECULAR PATHWAYS. J. Park 1,2 , I. 

Sovadinova 1,2 , P. Babica 1,2 , A. Wilke 1,2 , H. Boke 1,2 , 

L. Kleinow 1,2 , E. Kumar 1,2 , J. E. Trosko 1,2 and B. 

L. Upham 1,2 . 1 Pediatrics & Human Development, 

Michigan State University, East Lansing, MI 

and 2 National Food Safety & Toxicology Center, 



MECHANISM OF GENOMIC 

HYPOMETHYLATION DURING 

HEPATOCARCINOGENESIS INDUCED BY 

PEROXISOME PROLIFERATORS IN RATS. 

V. Tryndyak 1 , A. Boureiko 1 , S. Melnyk 2 , I. Rusyn 3 and 

I. Pogribny 1 . 1 Division of Biochemical Toxicology, 

National Center for Toxicological Research, 

Jefferson, AR, 2 Department of Pediatrics, UAMS, 

Little Rock, AR and 3 Department of Environmental 




ROLE OF C-MYC IN NICKEL-INDUCED 

HISTONE MODIFICATION ALTERATIONS. 

Q. Li, T. Suen, H. Chen and M. Costa. Environmental 

Medicine, New York University School of Medicine, 

Tuxedo, NY. 


PHENOBARBITAL (PB) ALTERS THE 

METHYLATION STATUS OF KEY 

GENES DURING EARLY PHASES OF 

TUMORIGENESIS. J. M. Phillips 1 and J. I. 

Goodman 2 . 1 Biochem. & Mol. Biol., Mich. State U., 

East Lansing, MI and 2 Pharmacology & Toxicology, 

Mich. State U., East Lansing, MI. 


CHRONIC EXPOSURE TO HIGH-FAT DIET 

CAUSES RENAL PATHOLOGY IN NON- 

DIABETIC RATS. K. Stemmer 1 , P. T. Pfluger 2 , 

D. Perez-Tilve 2 , M. H. Tschöp 2 and D. R. Dietrich 1 . 

1 

Human and Environmental Toxicology, University 

of Konstanz, Konstanz, Germany and 2 Department 

of Psychiatry, Obesity Research Centre - Genome 

Research Institute, University of Cincinnati – 

College of Medicine, Cincinnati, OH. 


ABERRANT EXPRESSION OF KEY 

REGULATORS OF MITOSIS AND 

CHROMOSOME SEGREGATION IN RAT 

KIDNEY FOLLOWING EXPOSURE TO 

OCHRATOXIN A. M. Adler, K. Mueller, E. 

Rached, W. Dekant and A. Mally. Department of 

Toxicology, University of Wuerzburg, Wuerzburg, 

Germany. 


PROPYLENE OXIDE: BIOMARKERS 

OF EXPOSURE, NASAL CELL 

PROLIFERATION, AND CANCER MODE- 

OF-ACTION IN RATS AND MICE EXPOSED 

VIA INHALATION. L. H. Pottenger 1 , J. A. 

Hotchkiss 1 , S. M. Krieger 1 , J. R. Harkema 2 , M. I. 

Banton 3 and J. A. Swenberg 4 . 1 TERC, The Dow 

Chemical Company, Midland, MI, 2 Michigan State 

University, East Lansing, MI, 3 Lyondell, Houston, 

TX and 4 University of North Carolina, Chapel Hill, 

NC. 


CONSTITUTIVE ACTIVATION AND 

TARGETED DISRUPTION OF SIGNAL 

TRANSDUCER AND ACTIVATOR OF 

TRANSCRIPTION 3 (STAT3) IN MOUSE 

EPIDERMIS REVEAL ITS CRITICAL ROLE 

IN UVB-INDUCED SKIN CARCINOGENESIS. 

D. J. Kim and J. DiGiovanni. Department of 

Carcinogenesis, The University of Texas M.D. 

Anderson Cancer Center, Science Park-Research 

Division, Smithville, TX. 


USE OF MECHANISTIC DATA IN 

ASSESSMENT OF CARCINOGENICITY 

OF IPROVALICARB. M. J. Iatropoulos 1 , G. M. 

Williams 1 , D. L. Van Goethem 2 , V. Payraudeau 3 , E. 

Hartmann 4 and L. Schladt 4 . 1 New York Medical 

College, Valhalla, NY, 2 Bayer CropScience, Stilwell, 

KS, 3 Bayer CropScience, Sophia Antipolis, France 

and 4 Bayer HealthCare AG, Wuppertal, Germany. 


MODE OF ACTION FOR THE SYNTHETIC 

PYRETHROID METOFLUTHRIN-INDUCED 

RAT LIVER TUMORS: CONSTITUTIVE 

ANDROSTANE RECEPTOR (CAR) 

ACTIVATION AND ASSOCIATED LIVER 

CHANGES. T. Yamada, Y. Duguchi, Y. Hirose, H. 

Nagahori, T. Sukata, M. Kushida, K. Sumida, Y. 

Tomigahara, T. Yoshioka, S. Uwagawa, S. Kawamura 

and Y. Okuno. Environmental Health Science 

Laboratory, Sumitomo Chemical Company, Ltd., 

Osaka, Japan. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: RECEPTORS 

Chairperson(s): Mary Walker, University of New Mexico, Albuquerque, 

NM and Matthew Stoner, University of Rhode Island, Kingston, RI. 




INTERACTIONS BETWEEN ARYL 

HYDROCARBON RECEPTOR AND 

ESTROGEN RECEPTOR ALPHA: ROLE 

OF AF2 DOMAIN. L. M. MacPherson and J. 

Matthews. Pharmacology, University of Toronto, 

Toronto, ON, Canada. 

130 




Abstract # 


CHIP-ON-CHIP ANALYSIS OF TCDD- 

DEPENDENT ARYL HYDROCARBON 

RECEPTOR BINDING TO HUMAN 

PROMOTER TILING ARRAYS REVEALS 

AHR RECRUITMENT TO ESTROGEN 

RECEPTOR ALPHA PROMOTER AND 

ENHANCER REGIONS. J. Matthews, S. Ahmed, 

L. M. MacPherson, A. Pansoy and A. Forgacs. 


University of Toronto, Toronto, ON, Canada. 


EFFECT OF ENVIRONMENTAL 

ENDOCRINE DISRUPTORS ON 

3-METHYLCHOLANTHRENE-DEPENDENT 

INDUCTION OF ARYL HYDROCARBON 

RECEPTOR ACTIVITY AND 

RECRUITMENT OF ESTROGEN RECEPTOR 

ALPHA TO AHR TARGET GENES. A. Forgacs, 

J. Matthews, L. M. MacPherson, S. Ahmed and 

A. Pansoy. Department of Pharmacology and 

Toxicology, University of Toronto, Toronto, ON, 

Canada. 


PHYTOESTROGENS REGULATE PS2 AND 

PROGESTERONE RECEPTOR (PGR) GENE 

EXPRESSION AT THE CHROMATIN LEVEL 

THROUGH ESTROGEN RECEPTOR IN 

MCF-7 CELLS. S. Sankella 1 , S. Naragoni 1 and W. 

G. Gray 1,2 . 1 Environmental Toxicology, Southern 

University, Baton Rouge, LA and 2 Chemistry, 

Southern University, Baton Rouge, LA. 



(AHR) ACTIVATION DECREASES 

PROLIFERATION BUT DOES NOT 

INCREASE APOPTOSIS IN MAMMARY 

EPITHELIAL CELLS. B. J. Lew 1 , L. Collins 1 , 

M. O’Reilly 2 and B. Lawrence 1 . 1 Environmental 

Medicine, University of Rochester, Rochester, NY 

and 2 Pediatrics, University of Rochester, Rochester, 

NY. 


OVEREXPRESSION OF ARNT DOES NOT 

ALTER CROSSTALK BETWEEN THE 

ARYL HYDROCARBON RECEPTOR AND 

HYPOXIA PATHWAYS IN PLHC-1 CELLS. 

C. R. Fleming, S. Billiard, D. E. Hinton and R. T. Di 

Giulio. Integrated Toxicology and Environmental 

Health Program, Duke University, Durham, NC. 


INTEGRATED REGULATION OF 

CYTOCHROME P450 1A1 mRNA 

EXPRESSION BY HYPOXIA AND AHR 

SIGNALING PATHWAYS IN HUMAN 

PULMONARY MICROVASCULAR 

ENDOTHELIAL CELLS. N. Zhang and M. K. 

Walker. Pharmacy, University of New Mexico, 


Abstract # 


REGULATION OF PEROXISOME 

PROLIFERATOR ACTIVATED RECEPTORS 

(PPARS) BY E6-ASSOCIATED PROTEIN 

(E6AP). L. Gopinathan 1 , D. B. Hannon 2 and J. P. 

Vanden Heuvel 2,1 . 1 The Huck Institutes of the Life 

Sciences, Pennsylvania State University, University 

Park, PA and 2 Veterinary and Biomedical Sciences, 

Pennsylvania State University, University Park, PA. 


COMPARISON OF THE ACTIVITIES OF 

CARBOXYLATES AND SULFONATES OF 

PERFLUOROALKYL ACID (PFAA) OF 

VARIOUS CARBON CHAIN LENGTHS 

ON MOUSE AND HUMAN PEROXISOME 

PROLIFERATOR-ACTIVATED RECEPTOR- 

ALPHA (PPARa) IN COS-1 CELLS. C. J. Wolf, 

M. L. Takacs, J. E. Schmid, C. Lau and B. D. Abbott. 

Reproductive Toxicology Division, NHEERL, ORD, 

U.S. EPA, Research Triangle Park, NC. 


SPECIES DIFFERENCE IN THE HEPATIC 

RESPONSE TO PERFLUOROCTANOIC 

ACID (PFOA). J. P. Vanden Heuvel 1 , S. R. Frame 2 , 

J. L. Butenhoff 3 , G. L. Kennedy 2 , S. E. Loveless 2 , R. 

W. Rickard 2 and J. M. Peters 1 . 1 Center for Molec. 

Toxic. & Carcinogenesis, Penn. State University, 

University Park, PA, 2 Dupont Haskell Global Centers 

of Health and Environmental Sciences, Newark, NJ 

and 3 3M Comp., St. Paul, MN. 


ROLE OF DISCOIDIN DOMAIN RECEPTOR 

1 ON NITRIC OXIDE-INDUCED APOPTOSIS 

IN MACROPHAGES. S. Lee and S. Kim. 

Pharmacology, Kyungpook National University 

Medical School, Daegu, South Korea. 


IDENTIFICATION OF BORIC ACID- 

RESPONSIVIE RYANODINE RECEPTOR 

ISOFORMS IN TUMOR AND NON-TUMOR 

PROSTATE CELL LINES. S. E. Kobylewski 1 , C. 

Eckhert 2 and K. Henderson 1 . 1 Molecular Toxicology, 

UCLA, Los Angeles, CA and 2 Environmental Health 

Sciences, UCLA, Los Angeles, CA. 


REACTIVE CYSTEINES C1040 AND C1303 

OF RYANODINE RECEPTOR TYPE 1 

INFLUENCE RESPONSES TO CELLULAR 

OXIDATIVE STRESS AND GLUTATHIONE 

DEPLETION. D. Bose 1 , C. F. Perez 2 , N. 

Yamaguchi 3 , G. Meissner 3 , P. D. Allen 2 and I. 

N. Pessah 1 . 1 Veterinary Molecular Biosciences, 

University of California, Davis, Davis, CA, 

2 

Department of Anesthesia Research, Brigham and 

Women’s Hospital, Boston, MA and 3 Department of 

Biochemistry and Biophysics, University of North 


Monday 



Monday 




COMPARISON OF METHAMPHETAMINE, 

COCAINE, AND APOMORPHINE-INDUCED 

BEHAVIORAL SENSITIZATION IN 

MU-OPIOID RECEPTOR KNOCKOUT 

MICE. T. Ma 1 , X. Shen 1 , L. Tien 1 , I. A. Paul 2 , H. H. 

Loh 3 and I. K. Ho 1 . 1 Pharmacology & Toxicology, 

University of Mississippi Medical Center, Jackson, 

MS, 2 Psychiatry & Human Behavior, University 

of Mississippi Medical Center, Jackson, MS and 

3 

Pharmacology, University of Minnesota Medical 

School, Minneapolis, MN. 


GABAA AND PERIPHERAL 

BENZODIAZEPINE RECEPTOR LIGANDS 

ACTIVATE LIVER NUCLEAR RECEPTORS. 

L. D. Hamel 1,2 and M. A. Stoner 1,2 . 1 Biomedical & 

Pharmaceutical Sciences, University of Rhode Island, 

Kingston, RI and 2 Rhode Island IDeA Network of 

Biomedical Research Excellence (RI-INBRE) Center 

for Molecular Toxicology, Kingston, RI. 


UNIQUE TRANSCRIPTION START SITES 

AND DISTINCT PROMOTER REGIONS 

DIFFERENTIATE THE PREGNANE X 

RECEPTOR (PXR) ISOFORMS PXR 1 AND 

PXR 2. A. D. Wallace 1 , L. M. Tompkins 1 and T. L. 

Sit 2 . 1 Environmental and Molecular Toxicology, 

North Carolina State University, Raleigh, NC and 

2 

Department of Plant Pathology, North Carolina State 



THE CIRCADIAN RHYTHM OF 

ENTEROHEPATIC CIRCULATION OF BILE 

ACIDS IN MICE. Y. Zhang and C. D. Klaassen. 

Department of Pharmacology, Toxicology and 

Therapeutics, University of Kansas Medical Center, 

Kansas City, KS. 


TRANSCRIPTIONAL REGULATION OF 

PREGNANE X RECEPTOR BY PROTEIN 

ARGININE METHYLTRANSFERASES. Y. 

Xie 1 , S. Ke 1 , X. Gu 4 , D. Liu 1 , W. Xie 3 , M. Bedford 2 

and Y. Tian 1 . 1 Texas A&M University, College 

Station, TX, 2 M.D. Anderson Cancer Center, houston, 

TX, 3 University of Pittsburgh, pittsburgh, PA and 

4 

University of Connecticut, storrs, CT. 


CROSSTALK BETWEEN THE AHR AND 

CAR PATHWAYS IN HEPATOCYTES. R. T. 

Taylor, S. S. Ferguson, A. Currier, J. Hill and E. L. 

LeCluyse. CellzDirect, Austin, TX. 


CHARACTERIZATION OF AH RECEPTOR 

AND ARNT PROTEIN EXPRESSION IN 

YEAST. S. Wilson, K. H. Schmidt and R. S. Pollenz. 

Cell Biology, Microbiology and Molecular Biology, 

University of South Florida, Tampa, FL. 


INTER-SPECIES AND –ISOFORM 

DIFFERENCES IN FUNCTIONS OF TWO 

ARYL HYDROCARBON RECEPTORS (AHR1 

AND AHR2) FROM AVIAN SPECIES. E. Kim 1 , 

H. Iwata 1 , T. Yasui 1 , N. Inoue 1 , J. Lee 1 , D. G. Franks 2 , 

S. I. Karchner 2 , M. E. Hahn 2 and S. Tanabe 1 . 1 Center 

for Marine Environmental Studies, Ehime University, 

Matsuyama, Japan and 2 Biology Department, Woods 

Hole Oceanographic Institution, Woods Hole, MA. 


UNIQUE STRUCTURAL DETERMINANTS 

CONFER LOW TCDD RESPONSIVENESS 

TO AN ARYL HYDROCARBON RECEPTOR 

FROM THE FROG XENOPUS LAEVIS. S. A. 

Holzman and W. H. Powell. Biology Department, 

Kenyon College, Gambier, OH. 


DIFFERENTIAL FACTORS AFFECTING 

BINDING OF SILICA AND TITANIUM 

DIOXIDE (TIO 2 

) PARTICLES TO THE 

SCAVENGER RECEPTOR CYSTEINE- 

RICH (SRCR) DOMAIN OF MACROPHAGE 

ASSOCIATED RECEPTOR WITH 

COLLAGENOUS DOMAIN (MARCO). S. A. 

Thakur 1 , T. Pikkarainen 2 and A. Holian 1 . 1 Center 

of Environmental Health sciences, Department 

of Biomedical and Pharmaceutical Sciences, The 

University of Montana, Missoula, MT and 2 Division 

of Matrix Biology, Karolinska institute, Stockholm, 

Sweden. 


1:30 PM to 2:30 PM 


Exhibitor Hosted Session: Progress in Using 

Human Embryonic Stem Cells in Drug Screening, 

Toxicology and Drug Development 

Presented by: Cellular Dynamics International, Inc. 

Cellular Dynamics (CDI) is making differentiated cells from human embryonic 

stem cells for use in all phases of drug development. The first cell type 

available and in commercial sale and use today from CDI is human cardiomyocytes. 

CDI will show that cardiomyocytes produced from hES cells 

exhibit electrophysiology characteristics useful in drug safety screening. 

CDI will also show data on the use of human cardiomyocytes in in vitro 

tests of acute toxicity. 


1:30 PM to 2:30 PM 


Exhibitor Hosted Session: Primary Stem Cell 

Based Assays for Toxicology and Other Drug 

Screening Applications 

Presented by: ReachBio LLC 

New initiatives such as Stem Cells for Safer Medicine suggest the need 

for more predictive screening assays early in drug development. We will 

discuss the validated bone marrow (CFU-GM) and other in vitro biological 

assays that utilize primary cells. Donor variability, assay sensitivity and 

choice of cells will be discussed. 

132 




Abstract # 


1:30 PM to 4:15 PM 

Room 6B 

SYMPOSIUM SESSION: DRUG-INDUCED MITOCHONDRIAL 

TOXICITY: NOVEL INSIGHTS–NOVEL TOOLS 

Chairperson(s): Yvonne Will, Pfizer, Inc., San Diego, CA and Urs 

Boelsterli, University of Connecticut School of Pharmacy, Storrs, CT. 

Endorsed by: 



Mitochondria have been increasingly recognized as a target of drug toxicity 

resulting in disruption of bioenergetics and causing oxidant stress in sensitive 

organs including CNS, heart, and skeletal muscle. In addition, there is 

increasing awareness that mitochondria are key mediators of drug toxicity 

in a number of other organs including liver and kidney, often causing 

mitochondrial outer membrane permeabilization and release of cell death 

proteins. Furthermore, certain underlying disease states like diabetes, infections, 

or neurodegenerative diseases can greatly alter mitochondrial function 

and make the mitochondria more vulnerable to drug toxicity. Conventional 

in vitro approaches in drug discovery and development have often failed to 

detect mitochondrial dysfunction, and there are few animal models which 

would readily reveal mitochondrial liability. This symposium will focus on 

new approaches to detect, understand, and predict mitochondrial toxicity. 

These novel approaches include transcriptional fingerprinting of mitochondrial 

changes, transgenic mouse models, and novel in vitro tools. 

#556 1:30 DRUG-INDUCED MITOCHONDRIAL 

TOXICITY: NOVEL INSIGHTS–NOVEL 

TOOLS. Y. Will 1 and U. A. Boelsterli 2 . 1 Drug Safety 

Research and Development, Pfizer, San Diego, 

CA and 2 Department of Pharmaceutical Science, 


#557 1:45 TRANSCRIPTIONAL SIGNATURE OF 

MITOCHONDRIAL TOXICITIES. K. B. 

Wallace. Biochemistry & Molecular Biology, 

University of Minnesota Medical School, Duluth, 

MN. 

#558 2:15 MITOCHONDRIA IN DRUG-INDUCED 

LIVER INJURY (DILI). U. A. Boelsterli. 


Storrs, CT. 

#559 2:45 INHIBITION OF ETHANOL EFFECTS BY 

MITOCHONDRIAL THIOREDOXIN-2. J. 

Hansen. School of Medicine, Emory University, 

Atlanta, GA. Sponsor: Y. Will. 

#560 3:15 LINKING MITOCHONDRIAL 

DYSFUNCTION TO HYPERGLYCEMIA: 

IMPACT OF MITOCHONDRIAL FIDELITY 

AND OXIDATIVE STRESS ON DIABETES 

AND ITS COMPLICATIONS. C. M. Palmeira. 

IMAR, Mitochondrial Research Group, Department 

of Zoology, University of Coimbra, Coimbra, 

Portugal. 

#561 3:45 STRATEGIES TO REDUCE NCE ATTRITION 

DUE TO MITOCHONDRIAL TOXICITY- 

DESIGNING NOVEL SCREENING 

METHODS. Y. Will. Drug Safety Research and 

Development, Pfizer, San Diego, CA. 

Abstract # 


1:30 PM to 4:15 PM 

Room 6E 


SYMPOSIUM SESSION: ENVIRONMENTAL INFLUENCE ON 

FEMALE PUBERTY AND BREAST TUMORIGENESIS 

Chairperson(s): Elizabeth Maull, NIEHS, Research Triangle Park, 

NC and Coral Lamartiniere, University of Alabama at Birmingham, 

Birmingham, AL. 

Endorsed by: 





Breast cancer is a complex disease, resulting from both genetic and environmental 

influences. Environmental exposures during critical windows 

of mammary gland development may be responsible for altering tissue 

susceptibility resulting in increased risk of future breast cancer. The pubertal 

hypothesis suggests that exogenous agents such as endocrine disrupting 

chemicals or other dietary factors, may mimic estrogen or influence their 

levels, such that the period of rapid development of the mammary gland is 

extended, putting the gland at higher risk for a transition to carcinogenesis. 

The NIEHS and NCI established the Breast Cancer and the Environment 

Research Centers (BCERC) Network, a unique multidisciplinary, translational 

grant program that includes basic biology, epidemiology, and 

community outreach and translation components to address the pubertal 

hypothesis. A primary objective of the BCERC Network is to explore the 

influence of a select set of exposures and activities on the onset of breast 

development and progression through puberty, early onset of puberty being 

among the most reliable risk factors for future beast cancer. Research within 

the Network spans a spectrum of biological organization: molecular mechanisms 

controlling regulation of differentiation of gland stem cells; insights 

into genomic and proteomic pre-disposition for disease; the impact of environmental 

exposures (including diet and obesity) at sensitive windows of 

development on gland development and the future risk of developing breast 

cancer as well as a cohort study of puberty designed to look at both environmental 

and genetic factors, and when possible their interactions, evaluating 

the impact of environmental exposures (broadly defined to include dietary, 

endocrine disruptors, consumer product use and socioeconomic factors) on 

progression to and through puberty in young girls. The aim of this symposium 

is to present the latest findings relating early environmental exposures 

with alterations in pubertal milestones that predispose towards breast cancer. 

#562 1:30 ENVIRONMENTAL INFLUENCE ON 

FEMALE PUBERTY AND BREAST 

TUMORIGENESIS. E. A. Maull 1 , S. Lynch 2 , 

D. Winn 2 , G. Collman 1 and L. Reinlib 1 . 1 National 

Institute of Environmental Health Sciences, RTP, NC 

and 2 National Cancer Institute, Rockville, MD. 

#563 1:45 THE EFFECT OF ENVIRONMENTAL 

EXPOSURES ON MAMMARY STEM CELLS 

DURING PUBERTY. M. Barcellos-Hoff 1 , I. 

Illa-Bochaca 1 , C. Lamartiniere 2 and Z. Werb 3 . 

1 

Lawrence Berkeley National Laboratory, Berkeley, 

CA, 2 University of Alabama, Birmingham, AL 

and 3 University of California, San Francisco, San 

Francisco, CA. 

#564 2:15 PRENATAL EXPOSURE TO BISPHENOL A 

(BPA) INDUCES GENOMIC ALTERATIONS 

IN THE RAT MAMMARY GLAND. J. Russo 1 , 

J. Pereira 1 , R. Moral 1 , C. Lamartiniere 2 and I. H. 

Russo 1 . 1 Fox Chase Cancer Center, Philadelphia, 

PA and 2 University of Alabama at Birmingham, 

Birmingham, AL. 

Monday 



Monday 



#565 2:45 NEONATAL/PREPUBERTAL BISPHENOL 

A EXPOSURE ALTERS THE MAMMARY 

PROTEOME, DECREASES APOPTOSIS 

AND INCREASES SUSCEPTIBILITY FOR 

CHEMICALLY-INDUCED MAMMARY 

CANCER IN RATS. C. Lamartiniere. University of 

Alabama at Birmingham, Birmingham, AL. 

#566 3:15 THE ENVIRONMENTAL IMPACT 

OF DIET AND OBESITY ON BREAST 

CARCINOGENESIS. D. Clegg 1 , R. Gear 1 , J. 

Schneider 1 , M. Mistry 1 , K. Olson 2 and S. Haslam 2 . 

1 

University of Cincinnati, Cincinnati, OH and 

2 


Sponsor: E. Maull. 

#567 3:45 THE BREAST CANCER AND THE 

ENVIRONMENT RESEARCH CENTERS: A 

NOVEL TRANSDISCIPLINARY APPROACH 

TO UNDERSTANDING THE CAUSES AND 

MECHANISMS OF BREAST CANCER. D. 

Winn 1 , E. A. Maull 2 , G. Collman 2 , L. Reinlib 2 and S. 

Lynch 1 . 1 National Institute of Environmental Health 

Sciences, Research Triangle Park, NC and 2 National 

Cancer Institute, Rockville, MD. 


1:30 PM to 4:15 PM 

Room 6C 


SYMPOSIUM SESSION: OXIDANT AIR POLLUTION AND 

CHILDHOOD ASTHMA (iat) 

Chairperson(s): Laura Van Winkle, University of California Davis, Davis, 

CA and Jack Harkema, Michigan State University, East Lansing, MI. 

Endorsed by: 





Ozone is one of the primary constituents of smog. Under the Clean Air 

Act, the EPA has set protective health-based standards for ozone. However, 

in 2005, 98 million people lived in U.S. counties with ozone concentrations 

above the 8 hr National Ambient Air Quality Standard of 0.08. There 

continues to be concern about the long term sequelae of widespread ozone 

exposures in sensitive populations, particularly children. This concern has 

been heightened by a recent surge in asthma prevalence in children, with 

disproportionately higher morbidity and mortality due to asthma for inner 

city children. The lung continues to grow and differentiate into adulthood. 

Interaction with air pollutants, such as ozone, during postnatal development 

of the respiratory system may alter the normal pattern of either growth or 

differentiation in such a way as to predispose to disease. Recent research 

has defined several important features regarding ozone exposure in children 

including: 1) critical windows of susceptibility to ozone for both the structural 

and immune components of the respiratory tract, 2) genetic markers for 

increased risk for decrements in lung function due to ozone exposure and 3) 

interaction effects with allergic sensitization and preexisting inflammation. 

The purpose of this session is to bring together the most current basic and 

applied research on the influence of ozone on the development of the lung. 

#568 1:30 OXIDANT AIR POLLUTION AND 

CHILDHOOD ASTHMA. L. S. Van Winkle 1 and J. 

R. Harkema 2 . 1 Center for Health & the Environment; 

Vet Med: Anatomy, Physiology and Cell Biology, UC 

Davis, Davis, CA and 2 Department of Pathobiology, 


#569 1:40 OXIDANT AIR POLLUTION AND 

CHILDHOOD ASTHMA: GENE, 

ENVIRONMENT AND GENE- 

ENVIRONMENT INTERACTION. T. S. Islam 

and F. D. Gilliland. Preventive medicine, University 

of Southern California, Los Angeles, CA. Sponsor: L. 

Van Winkle. 

#570 2:00 GENETIC MECHANISMS OF 

SUSCEPTIBILITY TO OZONE-INDUCED 

LUNG INJURY: NEW INSIGHTS. S. R. 

Kleeberger. NIEHS, Research Triangle Park, NC. 

Sponsor: L. Van Winkle. 

#571 2:20 EFFECTS OF OXIDANT EXPOSURE ON 

IMMUNE SYSTEM DEVELOPMENT 

IN EARLY LIFE. L. A. Miller. University of 

California, Davis, Davis, CA. Sponsor: L. Van 

Winkle. 

#572 2:40 CRITICAL TIMEPOINTS FOR POSTNATAL 

DEVELOPMENT OF INFLAMMATORY AND 

EPITHELIAL DEFENSE MECHANISMS: 

OZONE AND LPS EXPOSURE. C. J. Johnston 

and J. N. Finkelstein. Pediatrics and Environmental 

Medicine, University of Rochester, Rochester, NY. 

#573 3:00 OZONE-INDUCED INJURY IN THE 

IMMATURE/DEVELOPING NASAL 

AIRWAYS OF INFANTS. J. R. Harkema 1 , S. 

A. Carey 1 , J. G. Wagner 1 and E. M. Postlethwait 2 . 

1 

Pathobiology, Michigan State University, East 

Lansing, MI and 2 Environmental Health Sciences, 

University of Alabama at Birmingham, Birmingham, 

AL. 

#574 3:30 OZONE-INDUCED CHANGES IN 

CONDUCTING AIRWAYS IN NON-HUMAN 

PRIMATES. M. V. Fanucchi. School of Veterinary 

Medicine, University of California, Davis, CA. 

#575 3:50 STRUCTURAL AND FUNCTIONAL 

CONSEQUENCES OF OZONE INHALATION 

ON ALVEOLAR MORPHOGENESIS. D. M. 

Hyde, N. K. Tyler, L. F. Putney and M. V. Avdalovic. 

California National Primate Research Center, 

University of California, Davis, CA. Sponsor: L. Van 

Winkle. 

4:10 KEY POINTS REGARDING OZONE AND 

ASTHMA STRUCTURAL CHANGES. Panel 

Discussion 


1:30 PM to 4:15 PM 

Room 605 


SYMPOSIUM SESSION: STEM CELLS: NEW TOOLS FOR 

NEUROTOXICOLOGISTS (iat) 

Chairperson(s): Timothy Shafer, U.S. EPA, Research Triangle Park, NC 

and Jeff Johnson, University of Wisconsin Madison, Madison, WI. 

Endorsed by: 

In Vitro and Alternative Methods Specialty Section 


Neurotoxicology Specialty Section* 


In the last decade, significant progress has been achieved in developing 

models of neuronal stem and precursor cells. These efforts have been 

134 




Abstract # 

directed primarily towards treatment of neurodegenerative disorders, restorative 

therapy for spinal cord injuries and other clinically-oriented issues. 

Stem and neuroprogenitor cells provide a readily available supply of human 

neurons, glia and oligodendrocytes, and may represent more accurate models 

of neuronal function and developmental processes than tumor-derived cell 

lines. As such, they have many potential uses for toxicologists, including 

mechanistic studies, safety pharmacology, and predictive toxicity screening. 

To date, the use of neural stem and progenitor cells for toxicity studies has 

been limited, but will continue to grow as these model systems become 

more readily available. This symposium will focus on uses of stem and 

neuroprogenitor cells in toxicology, including as models for investigative or 

mechanistic toxicology studies of developmental toxicity and potential uses 

in high-throughput screening of drugs and chemicals for neurotoxicity. This 

is an abstract for a proposed presentation, and does not represent Agency 

policy. 

#576 1:30 STEM CELLS: NEW TOOLS FOR 

NEUROTOXICOLOGISTS. T. J. Shafer. 

Neurotoxicology Division, NHEERL, ORD, U.S. 


#577 1:35 STEM CELL ASSAY FOR DEVELOPMENTAL 

NEUROTOXICITY. D. M. DeGroot 1 , S. 

Schulpen 1 , H. Wortelboer 1 , A. Freidig 1 , J. Lammers 1 , 

A. Wolterbeek 1 , R. Westerink 2 , A. Seiler 3 and 

J. Burgsteden 1 . 1 TNO Quality of Life, Zeist, 

Netherlands, 2 IRAS, Utrecht, Netherlands and 

3 

ZEBET, Berlin, Germany. Sponsor: V. Feron. 

#578 2:15 HUMAN NEUROSPHERES IDENTIFY 

THREADS FOR BRAIN DEVELOPMENT. 

E. Fritsche, J. E. Cline, K. Gassmann, J. Heinrichs, 

M. Moors, T. D. Rockel, T. Schreiber and J. Abel. 

Toxicology, Institut für umweltmedizinische 

Forschung, Düsseldorf, Germany. Sponsor: T. Shafer. 

#579 2:55 EFFECTS OF NEUROTOXICANTS ON 

PROLIFERATION AND VIABILITY OF 

IMMORTALIZED HUMAN CORTICAL 

NEURAL PROGENITOR CELLS. J. M. 

Breier 1,2 , W. R. Mundy 2 and T. J. Shafer 2 . 1 Toxicology, 

University of North Carolina, Chapel Hill, NC and 

2 

Neurotoxicology Division, U.S. EPA, Research 


#580 3:35 THE NRF2-ARE PATHWAY: 

IDENTIFICATION OF NEUROTOXIC AND/ 

OR NEUROPROTECTIVE CHEMICALS. J. 

Johnson 1,2,3 , D. Johnson 1,2 , J. Li 1 , M. Calkins 2 , M. 

Vargas 1 and M. Emborg 4 . 1 Pharmaceutical Sciences, 

University of Wisconsin, Madison, WI, 2 Molecular 

and Environmental Toxicology Center, University 

of Wisconsin, Madison, WI, 3 Neuroscience Training 

Program, University of Wisconsin, Madison, WI 

and 4 Wisconsin National Primate Research Center, 

University of Wisconsin, Madison, WI. 


1:30 PM to 4:15 PM 

Room 615 

WORKSHOP SESSION: GETTING THE MOST OUT OF 

MODEL ORGANISM DATABASES: FROM THE BASIC TO THE 

COMPLEX 

Chairperson(s): Michael Carvan, University of Wisconsin Milwaukee, 

Milwaukee, WI and Susan Bello, The Jackson Laboratory, Bar Harbor, 

ME. 

Endorsed by: 


Model organisms are surrogates for studying normal and disease-related 

biology as well as extrapolating to potential human responses to toxicants. 

Abstract # 

The selection of a model depends on the species’ or strains’ characteristics 

and relies on in-depth knowledge of the model’s biology. Today, the amount 

of data available for any one model organism greatly exceeds the amount 

of time researchers have to spend tracking down these data. This is especially 

true for those organisms (zebrafish, rat and mouse) with significant 

biological knowledge bases that are the subject of whole genome sequencing 

and large-scale projects in mutagenesis, gene expression and biological 

networks. To deal with the data overload, model organism databases have 

been developed to capture and integrate these data, provide quick access to 

fundamental data on genes and strains and enable complex biological questions 

to be addressed. The integration of phenotypic, functional, and genetic 

data combined with data mining and visualization tools allows users to 

quickly extract information that would otherwise have taken days or weeks 

to find. However, the differences between databases complicates the process 

of extracting this information. The types of data as well as the balance and 

emphasis of similar data types differs between databases, reflecting the 

different research strengths of each model organism. In addition, each database 

has its own unique set of data mining and visualization tools designed 

to help analyze and understand the data from that species. Thus, determining 

how to use a specific database to address your question, whether it is to find 

out what is known about a gene in that species, identify the best strain or 

mutant line for an experiment or generate a list of potential candidate genes, 

may be a daunting task. A researcher armed with knowledge about their 

model organism database’s strengths and weaknesses is better able to extract 

the answers needed to push the research forward. Overviews of the represented 

databases will be given and Internet access will allow participants to 

work through example searches or try queries relevant to their own research 

with experts on hand to answer questions. 

#581 1:30 GETTING THE MOST OUT OF MODEL 

ORGANISM DATABASES: FROM THE 

BASIC TO THE COMPLEX. S. M. Bello. Mouse 

Genome Informatics, The Jackson Laboratory, Bar 

Harbor, ME. 

#582 1:35 ZFIN, THE ZEBRAFISH MODEL ORGANISM 

DATABASE. M. Westerfield and the ZFIN Staff. 

ZFIN, University of Oregon, Eugene, OR. Sponsor: 

S. Bello. 

#583 1:55 THE RAT GENOME DATABASE: 

INTEGRATED DATA PLATFORM FOR 

RESEARCH. M. Shimoyama, V. Petri, S. 

Laulederkind, J. Smith, R. Nigam, G. Kowalski, D. 

Li, J. DuPons, S. Twigger, A. Kwitek and H. J. Jacob. 

Human and Molecular Genetics Center, Medical 

College of Wisconsin, Milwaukee, WI. Sponsor: S. 

Bello. 

#584 2:15 THE MOUSE GENOME DATABASE: A 

SHORT USER’S GUIDE. S. M. Bello, C. L. Smith, 

H. Dene, D. L. Burkart, L. L. Washburn, I. Lu, M. 

Tomczuk, A. Anagnostopoulos, B. Richards-Smith, 

M. Updegraff, H. Onda, R. Babiuk, M. Knowlton and 

J. T. Eppig. Mouse Genome Informatics, The Jackson 

Laboratory, Bar Harbor, ME. 

#585 2:35 MOUSE PHENOME DATABASE (MPD): A 

RESOURCE AND RESEARCH TOOL. M. A. 

Bogue, T. P. Maddatu, C. J. Bult and S. C. Grubb. 

Mouse Phenome Project, The Jackson Laboratory, 

Bar Harbor, ME. Sponsor: S. Bello. 

2:55 TUTORIAL AND QUESTIONS FROM THE 

AUDIENCE. 

Monday 



Monday 




1:30 PM to 4:15 PM 

Room 608 

WORKSHOP SESSION: MIXTURE EXPOSURES TO METALS/ 

METALLOIDS AND RELATED HEALTH EFFECTS 

Chairperson(s): Bruce Fowler, CDC Agency for Toxic Substances 

& Disease Registry, Atlanta, GA and Monica Nordberg, Karolinska 

Institutet, Stockholm, Sweden. 

Endorsed by: 


Mixtures Specialty Section 

Exposure of human populations to mixtures of metals (lead, cadmium, 

mercury) and metalloids (arsenic) are common under both occupational and 

environmental situations such as Superfund sites. The routes of exposures 

to these mixtures may include inhalation, ingestion or absorption across the 

skin and result in a number of deleterious health effects. Particle exposures 

of rodents to binary semiconductor compounds such as gallium arsenide 

and indium arsenide have demonstrated a number of compound – specific 

changes in proteomic and metabolomic biomarkers. Studies of human 

populations in China with combined exposures to cadmium and arsenic have 

demonstrated marked increases in renal toxicity with regard to proteinuria 

biomarkers. Factorial design studies in rats exposed to low dose mixtures 

lead, cadmium and arsenic have shown increased oxidative stress in kidneys 

and changes in a number of other target organ system biomarkers as a function 

of duration of exposure. Interaction studies between lead and dietary 

calcium have demonstrated a strong influence of calcium intake on the 

gastrointestinal absorption of lead and hence risk of toxicity. Selenium exposure 

has been shown to influence the toxicity of inorganic mercury but not 

methyl mercury. Data from these studies provide clear evidence for the need 

to understand interactions among components of metallic mixture exposures 

in order to improve human health risk assessments. 

#586 1:30 MIXTURE EXPOSURE TO METALS/ 

METALLOIDS AND RELATED HEALTH 

EFFECTS. M. Nordberg 2 and B. A. Fowler 1 . 

1 

Division of Toxicology and Environmental 

Medicine, ATSDR, Atlanta, GA and 2 Environmental 

Medicine, Karolinska Institute, Stockholm, Sweden. 

#587 1:35 INTERACTIVE EFFECTS ON MOLECULAR 

BIOMARKERS FOLLOWING EXPOSURE 

TO BINARY III-V SEMICONDUCTOR 

COMPOUNDS: AN OVERVIEW OF IN VIVO 

AND IN VITRO STUDIES. B. A. Fowler 1 , E. A. 

Conner 2 and H. Yamauchi 3 . 1 Division of Toxicology 

and Environmental Medicine, ATSDR, Atlanta, 

GA, 2 Laboratory of Experimental Caricnognesis, 

NCI, Bethesda, MD and 3 Pharmaceutical Sciences, 

Kitasato University, Kitasato, Japan. 

#588 2:15 MIXED EXPOSURES TO CADMIUM 

AND ARSENIC AND RELATED DOSE- 

RESPONSE RELATIONSHIPS IN HUMANS. 

G. F. Nordberg 1 , T. Jin 2 , F. Hong 3 , A. Zhang 3 , J. P. 

Buchet 4 and A. Bernard 4 . 1 Environmental Medicine, 

University of Umea, Umea, Sweden, 2 Occupational 

Health, Fudan University, Shanghai, China, 

3 

Toxicology, Guiyang Medical College, Guiyang, 

China and 4 Industrial Toxicology, Universite 

Catholique de Louvain, Brussels, Belgium. 

#589 2:55 EXPOSURE TO PB, CD, AND AS MIXTURES 

POTENTIATES THE PRODUCTION OF 

OXIDATIVE STRESS PRECURSORS: 30-DAY, 

90-DAY, AND 180-DAY DRINKING WATER 

STUDIES IN RATS. M. H. Whittaker 1 , G. Wang 2 , 

X. Chen 1 , M. M. Lipsky 3 , D. Smith 4 , R. Gwiazda 4 and 

B. A. Fowler 5 . 1 ToxServices, Washington, DC, 2 MD 

Anderson Cancer Center, Houston, TX, 3 University 

of Maryland School of Medicine, Baltimore, MD, 

4 

Environmental Toxicology, University of California 

-Santa Cruz, Santa Cruz, CA and 5 Division of 

Toxicology and Environmental Medicine, ATSDR, 

Atlanta, GA. 

#590 3:35 MULTIPLE CONTAMINANT METALS 

AND NUTRITION. K. R. Mahaffey. Exposure 

Assessment and Coordination and Policy, U.S. EPA, 



1:30 PM to 4:15 PM 

Room 611 

WORKSHOP SESSION: WHERE THE RUBBER MEETS THE 

ROAD: CURRENT APPLICATION OF GENOMIC TOOLS IN 

PRODUCT DEVELOPMENT AND DECISION MAKING 

Chairperson(s): George Daston, Procter & Gamble Company, 

Cincinnati, OH and Russell Thomas, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC. 

Endorsed by: 



The use of genomic tools to broadly survey the transcriptional response of 

an organism or cell began over a decade ago. The toxicology community 

initially embraced the technology with the hope that it would allow rapid 

hazard identification and provide mechanistic insights into how environmental 

chemicals and pharmaceuticals exert their adverse effects. However, 

the direct application of genomic technology has proven to be challenging 

for the both toxicology and regulatory communities. Issues such as reproducibility, 

the ability to link transcriptional changes to phenotypic effects, 

and the conservative nature of safety assessment have all hindered the 

acceptance and wide-spread application of genomic tools. With the maturation 

of the technology, the toxicology and regulatory communities now have 

a better grasp on how these tools can be applied in product development and 

decision making in the context of safety assessment. The purpose of this 

symposium is to offer practical examples of how genomic technologies are 

being applied within a broad range of industries together with perspectives 

from the EPA and FDA on how these data are currently being used in regulatory 

decision-making. 

#591 1:30 WHERE THE RUBBER MEETS THE ROAD: 

CURRENT APPLICATION OF GENOMIC 

TOOLS IN PRODUCT DEVELOPMENT AND 

DECISION MAKING IN THE CONSUMER 

PRODUCT, PHARMACEUTICAL, AND 

CHEMICAL INDUSTRIES. R. S. Thomas 1 and 

G. P. Daston 2 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 Central 

Product Safety Evaluation, Procter & Gamble, 


#592 1:45 GENOMIC TECHNOLOGY AND ANALYSIS 

FOR ASSESSING TOXICITY AND RISK IN 

THE CONSUMER PRODUCTS INDUSTRY. G. 

Daston and J. Naciff. Miami Valley Labs, Procter & 

Gamble, Cincinnati, OH. 

136 




Abstract # 

#593 2:15 APPLICATION OF GENOMICS TESTING 

TO NEW PRODUCT DEVELOPMENT. G. M. 

Rusch. Toxicology & Risk Assessment, Honeywell 

International, Morristown, NJ. 

#594 2:45 THE USE OF GENOMIC INFORMATION, 

KNOWLEDGE TOOLS AND INTELLIGENCE 

NETWORKS FOR PRECLINICAL DECISION 

MAKING IN THE PHARMACEUTICAL 

INDUSTRY. J. A. Reynolds 1,3,2 . 1 JAReynolds 

& Associates, Madison, CT, 2 Safety Sciences & 

Translational Research, The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC and 

3 

BioWisdom Ltd, Cambridge, United Kingdom. 

#595 3:15 AN ARRAY OF TOXICOGENOMICS 

EFFORTS AT FDA. W. Tong. NCTR, Jefferson, 

AR. Sponsor: R. Thomas. 

#596 3:45 USE OF GENOMICS DATA AT THE U.S. 

EPA FOR PREDICTIVE AND MECHANISTIC 

TOXICOLOGY. D. J. Dix. National Center for 

Computational Toxicology, U.S. Environmental 



1:30 PM to 4:15 PM 

Room 618 

INFORMATIONAL SESSION: FUTURE PATHS FOR PUGET 

SOUND: CONTAMINANTS, CULTURES, AND ECOSYSTEM 

RISK CHARACTERIZATION—A SPECIAL REGIONAL 

INTEREST SESSION 

Chairperson(s): Annie Jarabek, NIEHS, Research Triangle Park, NC and 

Roseanne M. Lorenzana, U.S. EPA, Seattle, WA. 

Endorsed by: 


The Puget Sound Georgia Basin ecosystem, extending from the Campbell 

River in Northern British Columbia, Canada to the Nisqually River in 

Central Western WA in the U.S. is one of the most ecologically diverse in 

North America. The health of this ecosystem is a cornerstone of the region’s 

quality of life and vibrant economy. Current population in this region is 

over 6 million people with projections that by 2020 to over 10 million. The 

area is ethnically diverse with increasing representation of Asian, Latin and 

European cultures. The area is also home to many First Nation communities 

(Canada) and Tribal Nations (U.S. side) with long established cultural, 

social, religious and resource-based traditions and customs within these local 

areas. However, this uniquely valuable region faces increasing pressures and 

the vital relationship between ecosystem health, human health and ocean are 

at risk. Of particular challenge to the scientific community is the complexity 

and interrelatedness of these pressures for predicting and protecting human 

and ecosystem health. This symposium will explore these relationships. Case 

examples from the region will describe ecosystem challenges in relationship 

to persistent organic pollutants and marine mammal health and characterize 

risks for high fish and shellfish consuming human populations. The regional 

public health risk assessment dilemmas for encouraging consumption of 

“heart and brain healthy” seafoods will be discussed in relationship with 

risk messages warning of eating contaminated seafoods that may contain 

neurodevelopmentally toxic or cancer causing substances. The importance 

of understanding the dynamics of naturally produced toxins such as those 

from harmful algal blooms, the significance of microbial contaminants (such 

as vibrio) and presence of persistent environmental pollutants that bioaccumulate 

will illustrate the need for integrated public health relevant risk 

assessments and prevention measures for this region. 

#597 1:30 FISH: BRAIN FOOD OR BRAIN POISON? A 

SPECIAL REGIONAL INTEREST SESSION. 

E. Faustman 1 and R. Lorenzana 2 . 1 Institute for Risk 

Analysis and Risk Communication, Seattle, WA and 

2 

U.S. EPA, Seattle, WA. 

Abstract # 

#598 1:35 STATE OF THE PUGET SOUND. W. 

Ruckelshaus. Puget Sound Nearshore Ecosystem 

Restoration Project, Salmon Recovery Funding 

Board, Seattle, WA. Sponsor: E. Faustman. 

#599 1:45 OCEANS AND HUMAN HEALTH: LESSONS 

LEARNED FROM THE PUGET SOUND. 

E. Faustman. Institute for Risk Analysis and Risk 

Communication, Seattle, WA. 

#600 2:15 MARINE ECOSYSTEMS AND HUMAN 

HEALTH IN PUGET SOUND. U. Varanasi, J. 

Stein, T. Collier, W. Dickhoff and T. Hom. NW 

Fisheries Science Center, NOAA Fisheries, Seattle, 

WA. Sponsor: E. Faustman. 

#601 2:45 MERCURY EXPOSURE IN A GROUP OF 

PUGET SOUND AREA ASIAN-AMERICAN 

WOMEN OF CHILD-BEARING AGE. 

K. Marien. Department of Health, Office of 

Environmental Health Assessments, Olympia, WA. 

Sponsor: E. Faustman. 

#602 3:15 DEFINING CULTURAL WELL-BEING 

FOR TRIBAL NATIONS: GOING BEYOND 

ACCEPTABLE LEVELS OF RISK. J. Donatuto. 

Office of Planning and Community Development, 

Swinomish Indian Tribal Community, LaConner, 

WA. 

#603 3:45 BALANCING THE HEALTH BENEFITS AND 

RISKS OF SEAFOOD CONSUMPTION. D. 

Bellinger. Neurology-Children’s Hospital, Harvard 

Medical School, Boston, MA. Sponsor: E. Faustman. 


1:30 PM to 4:15 PM 

Room 602 

PLATFORM SESSION: APC’S, B CELLS AND 

HAEMATOPOIESIS 

Chairperson(s): David Shepherd, CEHS, Missoula, MT. 

#604 1:30 INNATE CONTROL OF ADAPTIVE 

IMMUNITY: DENDRITIC CELLS AND 

TCDD. J. Bankoti 1,2 , B. Rase 1 and D. M. 

Shepherd 1,2 . 1 Center for Environmental Health 

Sciences, University of Montana, Missoula, MT and 

2 

Biomedical & Pharmaceutical Sciences, University 

of Montana, Missoula, MT. 

#605 1:54 MECHANISMS OF ETHANOL MEDIATED 

SUPPRESSION OF MACROPHAGE 

ACTIVATION. K. von Maltzan 2 and S. B. Pruett 1,2 . 

1 

Department Basic Sciences, College Vet. Med., 

Mississippi State U., Mississippi State, MS and 

2 

Cellular Biology & Anatomy, LSU Health Sciences 

Center, Shreveport, LA. 

#606 2:18 AHR ACTIVATION REDUCES DENDRITIC 

CELL FUNCTION BUT NOT MIGRATION 

IN INFLUENZA VIRUS-INFECTED MICE. 

G. Jin 1 , J. J. Neumiller 2 , J. A. Cundiff 2 and B. 

Lawrence 1,2 . 1 Environmental Medicine, University 

of Rochester, Rochester, NY and 2 Pharmaceutical 

Sciences, Washington State University, Pullman, 

WA. 

#607 2:42 ACTIVATION AND TRAFFICKING OF 

PERITONEAL B1A B CELLS IN RESPONSE 

TO ASBESTOS. J. C. Pfau, K. M. Hurley and 

S. Li. Biomedical and Pharmaceutical Sciences, 

University of Montana, Missoula, MT. 

Monday 



Monday 



#608 3:06 EFFECTS OF THE HEAVY METALS 

MERCURY AND LEAD ON IL-33-INDUCED 

MAST CELL CYTOKINE SECRETION. C. A. 

Hudson 1 , P. T. Massa 1 and D. Lawrence 2 . 1 Upstate 

Medical University, Syracuse, NY and 2 Wadsworth 

Center, Albany, NY. 

#609 3:30 CONTRIBUTION OF P53 AND BCL-2 

FAMILY MEMBERS IN PROSTAGLANDIN 

AND PHTHALATE-INDUCED PRO/ 

PRE-B CELL APOPTOSIS. J. Schlezinger, 

S. L. Bissonnette, J. E. Teague and D. H. Sherr. 

Environmental Health, Boston University School of 

Public Health, Boston, MA. 

#610 3:53 BENZO(A)PYRENE AND 7, 

12-DIMETHYLBENZ(A)ANTHRACENE 

DIFFERENTIALLY DISRUPT 

HAEMATOPOIESIS IN BONE MARROW 

AND LYMPHOID ORGANS. A. N’jai 1,2 , L. Shi 1 , 

M. Larsen 3 , C. Jefcoate 2,3 and C. Czuprynski 1,2 . 1 PBS, 

University of Wisconsin Madison, Madison, WI, 

2 

Mol. & Env. Toxicology University of Wisconsin 

Madison, Madison, WI and 3 Pharmacology, 

University of Wisconsin, Madison, WI. 


1:30 PM to 4:15 PM 

Room 6A 

PLATFORM SESSION: DISPOSITION/PHARMACOKINETICS 

Chairperson(s): Rakesh Dixit, MedImmune, Gaithersburg, MD and 

Gabriel Knudsen, University of Arizona, Tucson, AZ. 

#611 1:30 ORGANIC CATION TRANSPORTERS 1 

AND 2 MEDIATE PRALIDOXIME RENAL 

SECRETION. M. Kayouka 1 , P. Houze 1 , P. Risede 1 , 

C. Monier 1 , S. Cisternino 1 , C. Pope 2 and F. J. 

Baud 1 . 1 INSERM U705 - UMR CNRS/INSERM 

7157, Université Paris V - VII, Paris, France and 

2 

Department of Physiological Sciences, Oklahoma 

State University, Stillwater, OK. 

#612 1:51 PBPK MODELING OF DELTAMETHRIN 

IN RATS. S. J. Godin 1 , R. Tornero-Velez 2 , E. J. 

Scollon 4 , D. G. Ross 4 , M. F. Hughes 4 , R. Conolly 3 and 

M. DeVito 4 . 1 Curriculum In Toxicology, UNC-CH, 

Chapell Hill, NC, 2 ORD/NERL, U.S. EPA, Durham, 

NC, 3 ORD/NCCT, U.S. EPA, Durham, NC and 

4 

ORD/NHEERL, U.S. EPA, Durham, NC. 

#613 2:12 EFFECT OF NICOTINE EXPOSURE ON IN 

VITRO CYP450S-MEDIATED METABOLISM 

OF CHLORPYRIFOS (CPF) IN SPRAGUE- 

DAWLEY (S-D) RATS. S. Lee, T. S. Poet, A. L. 

Busby and C. Timchalk. Pacific Northwest National 


#614 2:33 DISPOSITION OF NOVEL NANOPARTICLE 

CONSTRUCTS IN JUVENILE SWINE. S. 

W. Casteel 1 , G. M. Fent 1 , K. Branson 2 , K. Katti 3 , 

R. Kannan 3 , K. K. Katti 3 , S. Nune 3 , E. Boote 4 , J. 

C. Waldrep 5 , J. Guo 5 and R. Dhand 5 . 1 Veterinary 

Pathobiology, University of Missouri, Columbia, 

MO, 2 Veterinary Medicine and Surgery, University 

of Missouri, Columbia, MO, 3 Medical Radiology, 

University of Missouri, Columbia, MO, 4 Physics and 

Astronomy, University of Missouri, Columbia, MO 

and 5 Pulmonary, Critical Care and Environmental 

Medicine, University of Missouri, Columbia, MO. 

#615 2:54 THE ORGANIC SOLUTE TRANSPORTER 

ALPHA AND BETA, A POTENTIAL STEROID 

HORMONE CONJUGATE TRANSPORTER 

IN STEROIDOGENIC TISSUES. F. Fang and 

N. Ballatori. enviomental medicine, university of 

rochester, Rochester, NY. 

#616 3:15 UPTAKE OF PERFLUOROOCTANOIC ACID 

BY FRESHLY ISOLATED HEPATOCYTES 

FROM MALE AND FEMALE RATS. X. Han, 

C. Yang, S. I. Snajdr, D. L. Nabb and R. T. Mingoia. 

DuPont Haskell Global Centers for Health & 

Environmental Sciences, Newark, DE. 

#617 3:35 EFFECT OF NRF2 ACTIVATION ON 

BILIARY EXCRETION OF BSP AND DBSP. 

I. L. Csanaky, S. A. Reisman, R. L. Yeager and C. D. 

Klaassen. Department of Pharmacology, Toxicology 

and Therapeutics, University of Kansas Medical 

Center, Kansas City, KS. 

#618 3:55 TISSUE DISTRIBUTION OF THE 

MACROCYCLIC TRICHOTHECENE 

SATRATOXIN G FOLLOWING 

INTRANASAL INSTILLATION IN THE 

MOUSE. C. J. Amuzie 1,2 , Z. I. Islam 2 , J. R. 

Harkema 1,2 and J. J. Pestka 1,2 . 1 Comparative 

Medicine and Integrative Biology, Michigan 

State University, East lansing, MI and 2 Center for 

Integrative Toxicology, Michigan State University, 

East Lansing, MI. 


1:30 PM to 4:15 PM 

Room 2A 

PLATFORM SESSION: FRONTIERS IN LIVER TOXICOLOGY 

RESEARCH 

Chairperson(s): Michael Cunningham, NIEHS, National Toxicology 

Program, Research Triangle Park, NC and Jose Manautou, University of 

Connecticut, Storrs, CT. 

#619 1:30 DEVELOPMENT OF PREDICTIVE IN 

VITRO ASSAYS FOR THE DETECTION 

OF STEATOSIS IN PRIMARY RAT 

HEPATOCYTES. L. M. Rice, H. Garside, J. 

Pilling, E. Ainscow and M. Sullivan. Advanced 

Science and Technology Laboratory, AstraZeneca, 

Loughborough, Leicestershire, United Kingdom. 

Sponsor: M. Graham. 

#620 1:49 USE OF RAT AND HUMAN SANDWICH- 

CULTURED HEPATOCYTES AND A 

CASSETTE DOSING APPROACH TO ASSESS 

INHIBITION OF BILE ACID TRANSPORT. K. 

K. Wolf 1 , S. Vora 1 , L. O. Webster 2 , G. T. Generaux 2 , 

J. W. Polli 2 and K. Brouwer 1 . 1 School of Pharmacy, 


2 

GlaxoSmithKline Inc., Research Triangle Park, NC. 

#621 2:08 MICROFLUIDIC ARRAY FOR HIGH 

THROUGHPUT PRIMARY HEPATOCYTE 

CULTURE AND ANALYSIS. P. J. Lee and P. J. 

Hung. CellASIC Corp., San Leandro, CA. Sponsor: 

P. Help. 

138 




Abstract # 

#622 2:27 TOXICOGENOMIC ASSESSMENT 

OF SPECIES- AND SEX- 

DEPENDENT MECHANISMS OF 

HEPATOCARCINOGENICITY USING 3-D 

LIVER TISSUE CO-CULTURES. L. New, D. R. 

Applegate, K. Liu and B. A. Naughton. RegeneMed 

Inc, San Diego, CA. 

#623 2:45 TROVAFLOXACIN ENHANCES THE 

INFLAMMATORY RESPONSE TO A 

GRAM-NEGATIVE OR A GRAM-POSITIVE 

STIMULUS, RESULTING IN NEUTROPHIL- 

DEPENDENT LIVER INJURY IN MICE. P. J. 

Shaw, P. E. Ganey and R. A. Roth. Pharmacology & 

Toxicology, Michigan State University, East Lansing, 

MI. 

#624 3:03 CENTRILOBULAR INDUCTION OF MRP4 

DURING ALLYL ALCOHOL TOXICITY IS 

NOT DEPENDENT ON KUPFFER CELL 

FUNCTION. S. N. Campion 1 , L. M. Augustine 2 , 

M. J. Goedken 3 , N. J. Cherrington 2 and J. E. 

Manautou 1 . 1 Department of Pharmaceutical Sciences, 

University of Connecticut, Storrs, CT, 2 Department 

of Pharmacology and Toxicology, University of 

Arizona, Tucson, AZ and 3 Schering-Plough Research 

Institute, Lafayette, NJ. 

#625 3:21 ROLE HYPOXIA-INDUCIBLE FACTOR- 

1ALPHA IN THE DEVELOPMENT OF 

LIVER FIBROSIS. B. L. Copple and J. Moon. 

Pharmacology, Toxicology and Therapeutics, 


KS. 

#626 3:39 MECHANISMS OF PROTECTION AGAINST 

ACETAMINOPHEN HEPATOTOXICITY BY 

GLUTATHIONE AND N-ACETYLCYSTEINE. 

C. Saito 1 , C. Zwingmann 2 and H. W. Jaeschke 1 . 

1 

Pharmacology, Toxicology & Therapeutics, 


KS and 2 Centre de recherche, Centre hospitalier 

de l’Universite de Montreal, Hopital Saint-Luc, 

Montreal, ON, Canada. 

#627 3:57 COX-2 KO MICE ARE SUSCEPTIBLE TO 

SPLA2-MEDIATED PROGRESSION OF 

ACETAMINOPHEN HEPATOTOXICITY. H. 

M. Mehendale 1 , V. S. Bhave 1 , S. Donthamsetty 1 , J. R. 

Latendresse 3 and M. Cunningham 2 . 1 University of 

Louisiana at Monroe, Monroe, LA, 2 NIEHS, RTP, 

NC and 3 NCTR, Jefferson, AR. 


2:45 PM to 3:45 PM 


Exhibitor Hosted Session: Tools for Systems 

Toxicology–Integrating Chemical, Gene 

Expression, Protein and Metabolic Data into 

Safety Assessment 

Presented by: GeneGo, Inc. 

This session will address a critical issue facing Safety Assessment groups 

today—how to efficiently integrate and interpret data generated by the 

many different types of computational and molecular analyses performed 

during compound discovery and development. A brief introduction to the 

systems toxicology tools available from GeneGo will be followed by a case 

study presentation by Dr. Ethan Xu of Merck & Co., with new insights into 

two classic nephrotoxicants—cisplatin and gentamicin. 


2:45 PM to 3:45 PM 


Exhibitor Hosted Session: Public Access to the 

National Toxicology Program: From Acrylamide 

to Zinc 

Presented by: National Toxicology Program 

Learn about the NTP’s research and risk assessment activities and how you 

can be a part; from nominating substances for toxicity testing to the postdoctoral 

training program, and even how to get free information from an 

extensive archive of data, reports and biological specimens. 


3:30 PM to 4:30 PM 

Room 201 

Undergraduate Toxicology Faculty Meeting 

Interested in Undergraduate Toxicology education? The Education 

Committee invites all faculty who teach toxicology or interested in 

including toxicology at the undergraduate level to meet and provide feedback. 

The Education Committee is moving forward on recommendations 

resulting from the Undergraduate Faculty Focus Group held last fall. Some 

of the initiatives include establishing a subcommittee for undergraduate 

education, providing support for faculty, including increasing undergraduate 

research opportunities and developing curricular resources, and increasing 

communication among these SOT members. Attend to hear about these 

plans, provide your input, and network. 

Monday 



Monday 




4:30 PM to 6:00 PM 

Room 309 

K–12 TEAMS Event Volunteers Meeting 

Volunteers for the Toxicologists Educating and Mentoring Students 

(TEAMS) sponsored by the Committee on K–12 Education will meet for 

an orientation to the Tuesday activity. 


4:30 PM to 5:50 PM 

Room 615 

ROUNDTABLE SESSION: IMMUNOTOXICITY 

TESTING: SHOULD ELEVATED ANTIBODY 

RESPONSES BE INTERPRETED AS AN INDICATOR OF 

IMMUNOTOXICOLOGICAL HAZARD? 

Chairperson(s): Robert Luebke, U.S. EPA, Research Triangle Park, NC 

and Michael Holsapple, ILSI Health and Environmental Sciences Institute 

HESI, Washington, DC. 

Endorsed by: 




The current EPA Office of Prevention, Pesticides and Toxic Substances draft 

Health Effects Test Guidelines (OPPTS 870.7800 Immunotoxicity) were 

designed to meet testing requirement of the Toxic Substances Control Act 

and the Federal Insecticide, Fungicide and Rodenticide Act. The guidelines 

require evaluation of the antibody response to sheep red blood cells (SRBC) 

to determine whether repeated exposure to a pesticide causes immunotoxicity. 

The purpose of OPPTS 870.7800 is “to provide information on 

suppression of the immune system”. Although many immunotoxicants 

suppress the primary antibody response, certain pesticides (e.g., propanil and 

malathion), drugs (cocaine) and other chemicals of environmental concern 

(T-2 toxin, cadmium, lead and methyl mercury) have been reported to cause 

increased responses to T-dependent antigens. It can be argued that increased 

antibody production in response to immunization should not be interpreted 

as adverse ‘per se’ because current vaccination protocols typically rely on 

chemical adjuvants that stimulate antibody production. However, in some 

cases, elevated antibody synthesis following xenobiotic exposure has been 

associated with increased production of autoantibodies or worsening of 

disease in autoimmune-prone animal models. The current language of the 

immunotoxicity testing guidelines identifies suppression, rather than modulation, 

of the antibody response as the outcome of concern, and in essence 

ignores an increased antibody response to SRBC as a signal of potential 

immunotoxicity. This Roundtable will address whether considering only 

suppression of the antibody response may compromise hazard identification 

and risk assessment. 

#628 4:30 IMMUNOTOXICITY TESTING: SHOULD 

ELEVATED ANTIBODY RESPONSES BE 

INTERPRETED AS AN INDICATOR OF 

IMMUNOTOXICOLOGICAL HAZARD? R. W. 

Luebke 1 and M. P. Holsapple 2 . 1 Immunotoxicology 

Branch, U.S. EPA, ORD, NHEERL, ETD, Research 

Triangle Park, NC and 2 Health and Environmental 

Sciences Institute, ILSI, Washington, DC. 

4:35 THE BACKGROUND: ELEVATED 

ANTIBODY RESPONSES FOLLOWING 

EXPOSURE TO PESTICIDES. Rosana Shafer 

4:40 THE ISSUE, PART I: ELEVATED 

ANTIBODY RESPONSES ALONE CAN BE 


IMMUNOTOXICOLOGICAL HAZARD. Henk 

van Loveren 

4:45 THE ISSUE, PART II: ELEVATED ANTIBODY 

RESPONSES ALONE SHOULD NOT BE 


IMMUNOTOXICOLOGICAL HAZARD. Mary 

Jane Selgrade 

4:50 THE REACTION: AN INDUSTRY 

PERSPECTIVE. Michael Woolhiser 

4:55 THE REACTION: AN EPA PERSPECTIVE. 

Vicki Dellarco 

5:00 PANEL DISCUSSION. 


4:30 PM to 5:50 PM 

Room 602 

HISTORICAL HIGHLIGHT SESSION: OZONE TOXICOLOGY: 

HISTORICAL PERSPECTIVES OF THE SCIENCE THAT 

SHAPED THE REGULATORY STANDARDS 

Chairperson(s): Michael Madden, U.S. EPA, Chapel Hill, NC and 

Richard Schlesinger, Pace University, Pleasantville, NY. 

Endorsed by: 




Ozone (O3) is a ubiquitous air pollutant that has been the focus of intense 

study for decades. O3 is a criteria pollutant requiring the U.S. EPA to 

reevaluate new findings on public health periodically to determine if the 

National Ambient Air Quality Standard (NAAQS) should be revised. Early 

studies demonstrated human lung physiological changes in healthy adults. 

Panel studies with populations exposed to O3 for several hours provided 

further evidence of ozone-induced physiological changes with ambient 

exposures. O3-induced changes in human lung cell populations and soluble 

mediator production in lavage fluids were also documented. In vitro O3 

exposures performed with lung cells allowed mechanistic examination of 

how this pollutant exerted effects. Studies with nonhuman animal models 

also provided valuable insights into the toxicity. Chief among those types 

of studies were subchronic and chronic exposure studies, and assessment of 

whole lung pathobiology. With advances in genetics and molecular biology, 

the role of genetic polymorphisms in mediating the effects of O3 has been 

studied, in part to identify possible susceptible individuals. Epidemiological 

studies continue to examine possible effects of long term ozone exposures, 

as well as the role of O3 in modifying the effects of other air pollutants, e.g., 

particulate matter. The reactions of O3 with other airborne components may 

induce some health effects. O3 has remained a major air pollutant of concern 

in the U.S. and globally despite regulation and extensive study. For instance, 

under a recent court ordered decision, the U.S. EPA has until March 12, 

2008 to decide to retain or revise the O3 standard. The lessons learned from 

O3 research have helped optimize current investigations examining the role 

of other air pollutants in human health effects, have assisted in strategies 

for performing risk assessment especially with possible sensitive populations, 

and given guidance in management of health risks. Mort Lippmann, 

Rich Schlesinger, and Harvey Richmond will present these findings. [This 

abstract may not reflect EPA policy.] 

#629 4:30 OZONE TOXICOLOGY: HISTORICAL 

PERSPECTIVES OF THE SCIENCE THAT 

SHAPED THE REGULATORY STANDARDS. 

M. C. Madden. ORD, NHEERL, HSD, Clinical 

Research Branch, U.S. EPA, Chapel Hill, NC. 

140 




Abstract # 

4:35 HUMAN HEALTH EFFECTS STUDIES WITH 

OZONE FROM WHOLE POPULATIONS TO 

SENSITIVE INDIVIDUALS. Morton Lippmann 

5:00 USE OF ANIMAL MODELS TO BETTER 

ASSESS THE HEALTH EFFECTS AND THE 

MECHANISMS LEADING TO TOXICITY 

FROM OZONE EXPOSURE. Richard 

Schlesinger 

5:25 HISTORICAL PERSPECTIVE AND RECENT 

DEVELOPMENTS CONCERNING U.S. AND 

INTERNATIONAL HEALTH-BASED AMBIENT 

STANDARDS FOR GROUND LEVEL OZONE. 

Harvey Richmond 


4:30 PM to 5:50 PM 

Room 605 


INFORMATIONAL SESSION: PUTTING YOUR BEST FOOT 

FORWARD: JOB INTERVIEWING WORKSHOP FOR EARLY- 

CAREER SCIENTISTS 

Chairperson(s): Kristen Mitchell, University of Texas Medical Branch, 

Galveston, TX and Nick Radio, U.S. EPA, Research Triangle Park, NC. 

Endorsed by: 

Career Resource and Development Committee 

Postdoctoral Assembly* 

Student Advisory Council 

You’ve finished graduate school and maybe completed one or two stints 

as a postdoctoral fellow. You may know how to conduct research, write 

manuscripts and present seminars, but do you know what it takes to land 

that first job? This interactive workshop is designed to provide novice job 

seekers with timely and valuable information about how to successfully 

navigate the hiring process. Listen as hiring managers from government and 

industry discuss what they look for when reviewing job applications and get 

the straight facts about what can make or break a job interview. Find out 

what to say and how to present yourself during the interview so that hiring 

managers know that YOU are the person for the job. Furthermore, listen 

to the firsthand experience of an early-career scientist who recently landed 

an academic position. Watch and learn as experts and audience members 

participate in skits and mock interviews. Join us for a dynamic, informative 

and interactive workshop designed to put you in the driver’s seat of your 

career development! 

#630 4:30 PUTTING YOUR BEST FOOT FORWARD: 

JOB INTERVIEWING WORKSHOP FOR 

EARLY-CAREER SCIENTISTS. K. A. Mitchell 1 , 

N. Radio 2 , L. S. Birnbaum 3 and L. Burns Naas 4 . 

1 


University of Texas Medical Branch, Galveston, 

TX, 2 Neurotoxicology Division, U.S. EPA, Research 

Triangle Park, NC, 3 Experimental Toxicology 

Division, U.S. EPA, Research Triangle Park, NC 

and 4 Drug Safety Research and Development, Pfizer 

Global Research and Development, San Diego, CA. 

4:35 INTERVIEWING FOR A POSITION IN 

GOVERNMENT. Linda Birnbaum 

4:50 INTERVIEWING FOR A POSITION IN 

INDUSTRY. Leigh Ann Burns Naas 

5:05 WHAT TO EXPECT WHILE INTERVIEWING 

FOR AN ACADEMIC POSITION. Kristen 

Mitchell 

5:20 SKITS AND MOCK INTERVIEWS. Nick Radio 

Abstract # 


4:30 PM to 6:00 PM 

Room 307 

Specialty Section Presidents and officers 


If you will be a President or a Vice President of a Specialty Section in 

2008–2009, please make plans to attend the Specialty Section President 

meeting scheduled for 4:30 PM–6:00 PM on Monday, March 17. The 

agenda for the meeting will include an overview of the SOT Long-Range 

Plan. If you have long-range planning ideas that you would like added to 

the agenda, please send a message to Marcia Lawson at SOT Headquarters. 

The agenda will include information on the scientific session selection 

process, budgetary guides, a review of 2007–2008 activities, and plans for 

the future. 


4:30 PM to 6:00 PM 

Sheraton 

Metropolitan B Room 

Northern california and pacific northwest 

Regional chapters, UC Davis and Uc berkeley joint 

meeting/reception 


5:00 PM to 6:00 PM 

Gordon Biersch Brewery/Restaurant 

Regional Chapters Meeting/Reception: GUlf 

coast and south central chapters joint meeting/ 

reception 


5:00 PM to 8:00 PM 

Sheraton 

Grand Ballroom D 

Special Interest Group Meeting/Reception: 

American Association of Chinese in toxicology 


5:30 PM to 8:00 PM 

Hyatt 

Leonesa 1 Room 

Special Interest Group Meeting/Reception: 

Korean Toxicologist Association in America 


5:30 PM to 6:30 PM 

Sheraton 

Capitol Hill Room 

Specialty Section Meeting: Organizational 

Meeting for a Potential New Ocular Toxicology 

Specialty Section 

Monday 



Monday 


Monday Evening, March 17 

6:00 PM to 7:00 PM 

Sheraton 

Kirkland Room 

MONDAY EVENING 

Special Interest Group Annual Meeting/Reception: 

Hispanic Organization for Toxicologists 

Monday Evening, March 17 

6:00 PM to 7:30 PM 


Specialty Section Meetings/RECEPTIONS: Ethical, 

Legal and Social Issues, Food Safety, Mechanisms, 


Tuesday Morning, March 18 

7:00 AM to 8:30 AM 

Room 307 


7:30 AM to 8:50 AM 

Ballroom 6B 

TUESDAY MORNING 

Regional Chapters Presidents and Officers 


If you will be a President or a Vice President of a Regional Chapter in 

2008–2009, please make plans to attend the Regional Chapters Presidents 

meeting scheduled for 7:00 AM–8:30 AM Tuesday, March 18. The agenda 

for the meeting will include an overview of the SOT Long-Range Plan. 

If you have long-range planning ideas that you would like added to the 

agenda, please send a message to Marcia Lawson at SOT Headquarters. 

The agenda will include Headquarters administrative support information, 

budgetary guides, a review of 2007–2008 activities, and plans for the future. 

Issues SESSION: Over-the-Counter Cough and 

Cold Medications in Children: Efficacy, 

Safety, and Use 

Chairpersons: Charles Vincent Smith, Seattle Children’s Hospital 

Research Institute, Seattle, WA and Sid Nelson, University of Washington, 

Seattle, WA 

Endorsed by: 

SOT Presidential Chain 

Parents spend around $500 million each year in the U.S. to purchase 95 

million boxes containing almost 4 billion doses of over-the-counter (OTC) 

pediatric cough and cold products, despite the absence of any published 

evidence of efficacy of these formulations from randomized, doubleblind, 

placebo-controlled studies in children or infants. Both the American 

Academy of Pediatrics and the American College of Chest Physicians have 

published statements on the lack of efficacy of these products in children. 

Nevertheless, many parents, including many parents trained as biomedical 

scientists, believe that these OTC products provide beneficial effects in 

their children. Decongestants (alpha-1 agonists) have been linked to cardiac 

arrhythmias and hypertension, antihistamines with sedation and visual 

hallucinations, and antitussives with depressed levels of consciousness and 

encephalopathy, particularly in children under the age of 6 years. A Food 

and Drug Administration (FDA) review identified 123 deaths in children 

less than 6 years of age over the last several decades associated with use 

of OTC cough and cold products. This number has been questioned due to 

inclusion of examples in which oter factors may have been dominant and, 

conversely, the identification of true cases may be incomplete. Whatever 

the true measure, the number of deaths has been interpreted either as small, 

relative to the millions of children dosed, or as unjustifiable, in absence of 

evidence of efficacy. Additional concerns are that virtually nothing is known 

of potentially adverse effects of these products on child development. An 

advisory panel convened by the FDA in October 2007 produced a vigorous 

discussion of the need for better data on risks and benefits in children of 

OTC cough and cold medications. In addition to the direct importance of the 

topic, this controversy serves as an example of several core issues relevant to 

toxicologists, regulatory personnel, and consumers. One issue is the recognition 

that children are not simply small adults, and differences from adults 

in physiologies and susceptibilities to pharmacological and environmental 

exposures need to be considered and studied, so that rational judgments and 

risk/benefit assessments can be made. A second consideration arises from 

the broader question of how best to use incomplete data for evidence-based 

risk/benefit evaluations and decision-making processes that can be applied 

in timely and useful policies. Discussion of these principles will enhance our 

efforts to identify the most important questions to be addressed by ongoing 

and future research. 

142 




Abstract # 

Efficacy and Toxicity Concerns of Current Cough and Cold Products 

in Children, Wayne Snodgrass, University of Texas Medical Branch at 

Galveston, Galveston, TX 

Cough Cold Efficacy Studies, Philip D. Walson, University of Cincinnati, 


Abstract # 


7:30 AM to 8:50 AM 

Room 602 


Making Decisions Without Sufficient Data: OTCs in Children As an 

Example, Richard C. Dart, Rocky Mountain Poison and Drug Center, 

Denver Health, Denver, CO 


7:30 AM to 8:50 AM 

Room 618 

ROUNDTABLE SESSION: BREAKING THE LOG-JAM: PUBLIC- 

PRIVATE PARTNERSHIPS AS A WAY TO DISCOVER AND 

ADVANCE BIOMARKERS OF DRUG-INDUCED TOXICITY 

Chairperson(s): William Mattes, Critical Path Institute, Rockville, MD 

and Friedlieb Pfannkuch, Hoffmann La Roche, Inc., Basel, Switzerland. 

Endorsed by: 


The drug-development process entails an interaction between the industrial 

(private) sector and public regulatory agencies. Likewise, changing 

this process through the use of innovative new safety tests also requires an 

interaction between the public and private sectors. Two unique and parallel 

efforts are the Innovative Medicines Initiative and the Predictive Safety 

Testing Consortium. The former, under the auspices of the European Union, 

brings together academics and companies in a combined effort to discover 

and qualify new ʻomics-based markers of toxicity. The latter, under the 

direction of the non-profit Critical Path Institute, brings together companies 

to comprehensively qualify new safety biomarkers for both non-clinical and 

clinical applications. Both efforts directly involve members of the regulatory 

agencies so that the processes are not just transparent to regulatory agencies, 

but result in assays that are accepted by the general scientific, industrial 

and regulatory communities. This Roundtable will provide an overview of 

these processes with particular attention to the interaction between scientific 

approaches and regulatory input, and allow discussion of how these partnerships 

achieve their goals. 

#631 7:30 BREAKING THE LOG-JAM: PUBLIC- 

PRIVATE PARTNERSHIPS AS A WAY TO 

DISCOVER AND ADVANCE BIOMARKERS 

OF DRUG-INDUCED TOXICITY. W. B. Mattes 1 , 

F. Pfannkuch 2 , J. Vidal 3 and F. M. Goodsaid 4 . 

1 

Toxicology, The Critical Path Institute, Rockville, 

MD, 2 Pharmaceuticals Division, F. Hoffmann-La 

Roche Ltd., Basel, Switzerland, 3 Safety Working 

Party, EMEA, London, United Kingdom and 4 Office 

of Clinical Pharmacology, CDER, U.S. FDA, Silver 

Spring, MD. 

7:40 The EU FP6 Predtox (Predictive Toxicology) 

Project and Biomarker Identification Using An 

Integrative ‘Omic Approach. Friedlieb Pfannkuch, 

Hoffmann La Roche Inc., Basel, Switzerland 

7:58 Scientific Strategies of the Predictive Safety 

Testing Consortium. William B. Mattes, The 

Critical Path Institute, Rockville, MD 

8:16 EMEA Oversight of European and U.S. Efforts 

for Biomarker. Jean-Marc Vidal, European 

Medicines Agency, London 

8:34 The USFDA's Role in Biomarker Qualification. 

Federico M. Goodsaid, Silver Spring, MD 

ROUNDTABLE SESSION: REPRODUCTIVE TOXICITY 

STUDIES: ONE GENERATION VERSUS TWO GENERATIONS 

Chairperson(s): Susan Makris, U.S. EPA, Washington, DC and Carole 

Kimmel, Private Consultant, Southern Shores, NC. 

Endorsed by: 




As an outcome of an international effort to develop an alternative protocol 

for hazard and dose-response characterization for agricultural chemicals, 

a life stage oriented testing paradigm was proposed (Cooper et al., 2006). 

The screening protocol as described in this manuscript incorporates multiple 

endpoints that might traditionally be assessed in completely separate studies; 

it thereby strives to reduce the number of animals used in testing and to 

refine the testing paradigm through more efficient utilization of animals. An 

important and controversial aspect of this study design is the use of a single 

generation of rodents to assess reproductive toxicity. Questions and concerns 

have been expressed regarding the adequacy of using a one-generation study 

for the characterization of reproductive hazard and dose response, rather 

than the traditionally accepted two generations. A previous EPA workshop 

(Francis and Kimmel, 1988) had concluded that two-generations were 

optimal and that one would be insufficient. However, a preliminary review 

of historical evidence available at the time of the Cooper et al. publication 

suggested that this conclusion may not be universally supported. More 

rigorous retrospective reviews of reproductive toxicity study outcomes 

and their use in risk assessment have been conducted since the time of the 

publication and will be presented in this session. Some of the issues for 

consideration and discussion include: What has been learned through the 

retrospective review of reproductive toxicity study data? How might hazard 

and dose-response characterization be affected by assessment of only one 

generation? What would trigger the conduct of a second generation, and how 

confident could one be that this decision would be applied appropriately and 

consistently? What role might chemical class or mode of action information 

play in directing the testing paradigm on a chemical-specific basis? How 

will testing and validation of this approach be conducted? 

#632 7:30 REPRODUCTIVE TOXICITY STUDIES: 

ONE GENERATION VERSUS TWO 

GENERATIONS. S. Makris 1 , C. Kimmel 2 , L. 

James 3 , E. Mendez 4 and A. Piersma 5 . 1 ORD/NCEA, 

U.S. EPA, Washington, DC, 2 Private Consultant, 

Southern Shores, NC, 3 The Weinberg Group, 

Washington, DC, 4 OPP/HED, U.S. EPA, Washington, 

DC and 5 RIVM, Bilthoven, Netherlands. 

7:35 PROGRESS TOWARD IMPROVING 

THE QUALITY OF SCIENTIFIC 

INFORMATION ON REPRODUCTIVE AND 

DEVELOPMENTAL TOXICOLOGY AND 

AGRICULTURAL CHEMICAL SAFETY 

ASSESSMENT. James Lamb 

7:55 RETROSPECTIVE ANALYSIS OF MULTI- 

GENERATION REPRODUCTION STUDIES 

DATABASE: WHAT IS THE IMPACT OF 

THE SECOND GENERATION IN HAZARD 

ASSESSMENT FOR PESTICIDES? Elizabeth 

Mendez 

8:15 A RETROSPECTIVE ANALYSIS OF THE 

TWO-GENERATION STUDY: WHAT IS 

THE ADDED VALUE OF THE SECOND 

GENERATION? Aldert Piersma 

8:35 ROUNDTABLE DISCUSSION. 

Tuesday 






7:30 AM to 8:50 AM 

Room 6C 


7:30 AM to 8:50 AM 

Room 611 

Tuesday 

ROUNDTABLE SESSION: THE 2007 PET FOOD RELATED 

TOXIC NEPHROPATHY IN DOGS AND CATS 

Chairperson(s): Jim Riviere, North Carolina State University, Raleigh, 

NC and Ramesh Gupta, Murray State University, Hopkinsville, KY. 

Endorsed by: 


Food Safety Specialty Section 


The focus of this Roundtable will be to provide an up-to-date overview 

of the pet food related toxic nephropathy that swept across the United 

States and Canada in 2007. This episode was unique in both the breadth 

and rapidity of its occurrence as well as to the unique nature of its toxicological 

manifestations. It exposed the public to a large-scale toxicological 

investigation in progress, and has had significant impact on assessing safety 

of imported foods for both animal and human consumption. This Roundtable 

will review the epidemiology, clinical manifestations, pathology and 

potential mechanisms of action, as well as the regulatory response and 

management of the crisis. 

#633 7:30 THE 2007 PET FOOD RELATED TOXIC 

NEPHROPATHY IN DOGS AND CATS. J. 

Riviere 1 and R. Gupta 2 . 1 College of Veterinary 

Medicine, North Carolina State University, Raleigh, 

NC and 2 Murray State University, Hopkinsville, KY. 

7:40 EPIDEMIOLOGY OF THE 2007 PET FOOD 

RECALL: VETERINARY COMMUNITY 

PERSPECTIVE. Sharon Gwaltney-Brant 

7:55 MENU FOOD MYSTERY BEGINNING 

INVESTIGATION. Karyn Bischoff 

8:10 PET FOOD SAFETY: MORPHOLOGIC 

FINDINGS AND IMPLICATIONS FOR 

PATHOGENESIS. Wanda Haschek-Hock 

8:25 REGULATORY RESPONSE. Stephen Sundlof 

8:40 SUMMARY AND LESSONS LEARNED. 

Ramesh C. Gupta 

Oxidative Signaling AnD Redox Biology 

INFORMATIONAL SESSION: DETECTION OF BIOLOGICAL 

FREE RADICALS IN TIME AND SPACE 

Chairperson(s): Michael Waalkes, NCI at NIEHS, Research Triangle 

Park, NC and Ron Mason, NIEHS, Research Triangle Park, NC. 

Endorsed by: 



The accurate and sensitive detection of biological free radicals in a reliable 

manner is a requirement to define the mechanistic roles of such species in 

toxicology. Most of the techniques currently available are either not appropriate 

to detect free radicals in cells and tissues due to sensitivity limitations 

(electron paramagnetic resonance, EPR) or subject to artifacts that make 

the validity of the results questionable (flourescent probe based analysis). 

The recently introduced immuno-spin trapping technique is based on the 

fact that amino acid derived radicals react with the spin trap 5, 5-dimethyl- 

1-pyrroline-N-oxide (DMPO) to form protein-DMPO nitroxide radical 

adducts. These adducts have limited stability and decay producing the very 

stable protein-DMPO-nitrone product. The formation of protein-DMPOnitrone 

adducts is based on the selective reaction of free radical addition to 

the spin trap and is thus not subjected to artifacts frequently encountered 

with ordinary methods for free radical detection. Rabbit polyclonal anti- 

DMPO nitrone antiserum has been developed and validated. Immuno-spin 

trapping is proving to be a potent, sensitive, and accessible method to 

detect low levels (e.g. nanomolar) of protein-derived radicals produced in 

vitro and in vivo. Moreover, it has been established that anti-DMPO nitrone 

antibodies can be utilized for the detection of DNA-derived radicals in the 

form of DNA-DMPO nitrone adducts, and such technique has been applied 

to models of metal carcinogenesis. Most recently, immunofluorescence and 

immunochemistry have been used to determine the distribution of free radicals 

in cells and tissues. In summary, the advances the immuno-spin trapping 

technique affords in accurate and sensitive determination of biological free 

radicals is having a major impact on our understanding of the role of such 

radicals in toxic response and mechanism. 

#634 7:30 DETECTION OF BIOLOGICAL FREE 

RADICALS IN TIME AND SPACE. M. Waalkes 1 , 

R. Mason 2 and V. Kagan 3 . 1 LPC, NIEHS, Research 

Triangle Park, NC, 2 LCC, NCI at NIEHS, Research 

Triangle Park, NC and 3 University of Pittsburgh, 

Pittsburgh, PA. 

7:35 USING ANTI-5, 5-DIMETHYL-1- 

PYRROLINE-N-OXIDE (ANTI-DMPO) TO 

DETECT PROTEIN AND DNA RADICALS 

IN TIME AND SPACE WITH IMMUNO-SPIN 

TRAPPING. Ron Mason 

8:00 CYTOCHROME C ACTS AS A CARDIOLIPIN 

OXYGENASE REQUIRED FOR RELEASE 

OF PROAPOPTOTIC FACTORS. Valerian 

Kagan 

8:25 OXIDATIVE DNA DAMAGE INDUCED 

BY INORGANIC ARSENITE DETECTED 

USING THE IMMUNO-SPIN TRAPPING 

METHOD: DELAYED DAMAGE AT 

ENVIRONMENTALLY RELEVANT 

EXPOSURE LEVELS. Michael P. Waalkes 

144 





8:00 AM to 8:50 AM 

Ballroom 6A 


8:30 AM to 9:30 AM 


SOT/EUROTOX Debate 

MOTION: In Vitro Toxicology is Useful for 

Regulatory Purposes 

Endorsed by: 

Society of Toxicology (SOT) 

European Societies of Toxicology (EUROTOX) 

Debaters: 

SOT: George Daston, Procter & Gamble Company, 

Cincinnati, OH (con) 

EUROTOX: Thomas Hartung, European Centre for the 

Validation of Alternative Methods, Ispra, Italy (pro) 

Each year the SOT Annual Meeting includes a debate that continues a 

tradition that originated in the early 1990s in which leading toxicologists 

advocate opposing sides of an issue of great toxicological importance. 

This year, our debaters will address the proposition: In Vitro Toxicology is 

Useless for Regulatory Purposes. 

In vitro toxicity assays have been in use for a long time and have a large 

number of applications, but in regulatory settings they are still used largely 

as preliminary screens rather than as the definitive basis for chemical 

regulation. A number of reasons underlie the current status of in vitro tests, 

including that they often do not provide information that is directly usable 

in risk assessment. Addressing the question of regulatory utilization of in 

vitro tests is becoming urgent as laws such as the European Union’s 7 th 

Amendment to the Cosmetics Directive come into force, which will not 

allow ingredients tested in animals after 2013 to be used in personal care 

products. The debate will present some of the challenges to the use of in 

vitro toxicity assays as the basis for chemical regulation. 

Regardless of framework differences and personal convictions, each 

scientific delegate will present relevant evidence and compelling scientific 

arguments to persuade and appeal to the response of the audience in order 

to obtain the approval or refusal of the motion. 

Exhibitor Hosted Session: Rosetta Biosoftware: 

Critical Path: Analysis of Shared Toxicity Data 

Between Pharmaceutical Companies Bridges 

Biomarker Discovery 

Presented by: Rosetta Biosoftware 

In 2006 the Critical Path Initiative’s Predictive Safety Testing Consortium 

licensed the Rosetta Resolver ® system as a mechanism for collaboration 

and analysis of toxicity data from multiple technologies such as: nonclinical 

data, metabolomics and transcriptomics. This workshop will illustrate 

how such data is shared across organizations and analyzed by the Resolver 

system. 


8:30 AM to 9:30 AM 


Exhibitor Hosted Session: One Year Into the 

Modern Era of Data Collection: Successes, 

Improvements, and What’s Next 

Presented by: VivoMetrics, Inc. 

In this session we will discuss recent developments to the LifeShirt Preclinical, 

a wireless telemetry system that non-invasively monitors in real-time 

a broad range of cardiopulmonary parameters in preclinical settings unlike 

any other available system. We will review historical background, context 

for development and a description of how the LifeShirt works in both 

human and animal research. Opportunities, challenges and exciting next 

steps will also be included in the discussion. 

Tuesday 

In addition to being a featured session at the Annual Meeting, this debate 

will again take place from October 5–8 at the 45 th Congress of EUROTOX 

in Rhodes, Greece. 


8:30 AM to 12:00 NOON 

Hyatt 

E. Anderson Amphitheater 

K–12 Paracelsus Goes to the Classroom—The TEAMS 

Project: Toxicologists Educating and Mentoring 

Students 

Chairperson(s): Katie Sprugel, Amgen, Seattle, WA and Vanessa 

Fitsanakis, King College, Bristol, TN 

Continuing the tradition of providing public outreach in conjunction 

with the Annual Meeting, the Committee on K–12 Education will host a 

symposium for high school students by videoconferencing from the Annual 

Meeting to classrooms around the state of Washington. Twelve groups of 

students will present their projects to one another and to a panel of toxicologists 

in a morning and an afternoon session. Other students will have 

the opportunity to submit an electronic version of their project for a virtual 

poster session. The presentations will educate other students about a health 

or environmental health issue of importance to the students or their community. 

Toxicologists from SOT will also serve as mentors in the months 

preceding the meeting as the students develop their presentations. 






9:00 AM to 11:45 AM 

Room 605 


#640 11:15 KEAP1-NRF2 SIGNALING AS A TARGET 

FOR CANCER CHEMOPREVENTION: PRE- 

CLINICAL AND CLINICAL PERSPECTIVES. 

T. W. Kensler. Environmental Health Sciences, Johns 

Hopkins University, Baltimore, MD. 

Tuesday 

SYMPOSIUM SESSION: MOLECULAR AND GENOMIC 

INSIGHTS INTO THE NRF2-REGULATED OXIDATIVE STRESS 

RESPONSE: IMPACT ON CARCINOGENESIS 

Chairperson(s): Chris Corton, U.S. EPA, Research Triangle Park, NC 

and Thomas Kensler, Johns Hopkins Bloomberg School of Public Health, 


Endorsed by: 




The transcription factor Nrf2 plays a significant role in protecting cells from 

endogenous and exogenous stresses. Mice lacking Nrf2 are more sensitive 

to the hepatic, pulmonary, ovarian, and neurotoxic consequences of acute 

exposures to environmental agents and drugs as well as chronic exposures 

to cigarette smoke and other carcinogens. Under quiescent conditions, 

Nrf2 interacts with the actin-anchored protein Keap1, leading to low basal 

expression of Nrf2-regulated genes. However, upon recognition of chemical 

signals imparted by oxidative and electrophilic molecules, Nrf2 is released 

from Keap1, escapes proteasomal degradation, translocates to the nucleus, 

and trans-activates the expression of several dozen cytoprotective genes that 

enhance cell survival. This symposium will highlight recent exciting findings 

in the field including different mechanisms by which chemical exposure 

can activate Nrf2, the role of Nrf2 in modifying chemical carcinogenesis and 

how cancer cells can highjack this protective system to increase survival. 

#635 9:00 MOLECULAR AND GENOMIC INSIGHTS 

INTO THE NRF2-REGULATED OXIDATIVE 

STRESS RESPONSE: IMPACT ON 

CARCINOGENESIS. C. Corton 1 and T. Kensler 2 . 

1 

NHEERL, U.S. EPA, Research Triangle Park, NC 

and 2 Johns Hopkins University, Baltimore, MD. 

#636 9:15 FUNCTION AND SIGNAL TRANSDUCTION 

OF NRF2 FROM A METAL’S PERSPECTIVE. 

Q. Ma and X. He. Toxicology and Molecular Biology 

Branch, Health Effects Laboratory Division, National 

Institute for Occupational Safety and Health, Centers 

for Disease Control and Prevention, Morgantown, 

WV. 

#637 9:45 REDOX REGULATION OF NRF2: IN 

VITRO SIGNALING CIRCUITRY AND 

IN VIVO CARCINOGENESIS/ANTI- 

CARCINOGENESIS FUNCTIONS. T. Kong. 

The State University of New Jersey, Piscataway, NJ. 

Sponsor: C. Corton. 

#638 10:15 NRF2-MEDIATED SIGNALING: ROLE 

IN LUNG INFLAMMATION AND 

TUMORIGENESIS. S. R. Kleeberger 1 , A. K. 

Bauer 2 , X. Wang 1 and D. A. Bell 1 . 1 NIEHS, Research 

Triangle Park, NC and 2 Michigan State University, 

East Lansing, MI. Sponsor: C. Corton. 

#639 10:45 DYSFUNCTIONAL KEAP1-NRF2 

INTERACTIONS IN LUNG CANCER AND 

IMPLICATIONS FOR OTHER CANCERS. S. 

Biswal. Johns Hopkins University, Baltimore, MD. 

Sponsor: C. Corton. 


9:00 AM to 11:45 AM 

Room 6B 

SYMPOSIUM SESSION: NEW CONCEPTS IN THE ETIOLOGY 

OF BREAST CANCER: FROM GENES TO ENVIRONMENT AND 

BACK AGAIN 

Chairperson(s): David Eaton, University of Washington, Seattle, WA and 

Stephen Safe, Texas A&M University, College Station, TX. 

Endorsed by: 




This ‘all-star’ cast of breast cancer researchers will present new research 

that provides important new insights into the etiology of breast cancer. One 

out of eight woman living in the U.S. today will get breast cancer sometime 

in her lifetime. Although mortality from breast cancer has declined somewhat 

over the past 10 years due to earlier diagnosis and better treatment, 

some studies indicate that the incidence increased in this same period. The 

discovery of the BRCA1 gene by Mary-Claire King and others over 15 years 

ago has led to the identification of additional, but generally less penetrant, 

breast cancer genes, such as CHEK2, ATM, NBS1, RAD50, BRIP1, and 

PALB2. However, most breast cancer is non-familial and the etiology is 

multifactorial. Although lifestyle factors that influence hormonal regulation 

are undoubtedly important, environmental factors such as organochlorine 

pesticides, phyto-estrogens, and diurnal rhythm have also been hypothesized 

to contribute to the etiology of breast cancer. This symposium will present 

new data on ‘established’ risks factors, as well as explore new concepts 

and approaches to unraveling the genetic and environmental causes of this 

disease. The symposium will be geared to a general audience, but will also 

provide new information on emerging environmental risk factors for this 

important disease. 

#641 9:00 NEW CONCEPTS IN THE ETIOLOGY OF 

BREAST CANCER: FROM GENES TO 

ENVIRONMENT AND BACK AGAIN. D. 

L. Eaton. Env. Occup. Health Sci., University of 


#642 9:15 NEW INSIGHTS INTO HORMONAL, 

HISTOLOGICAL, AND MOLECULAR 

ASPECTS OF BREAST CANCER ETIOLOGY. 

C. I. Li. Epidemiology, Fred Hutchinson Cancer 

Research Center, Seattle, WA. Sponsor: D. Eaton. 

#643 9:45 CIRCADIAN DISRUPTION AND THE 

RISK OF BREAST CANCER. S. Davis 1,2 . 

1 

Epidemiology, University of Washington, Seattle, 

WA and 2 Division of Public Health Sciences, Fred 

Hutchinson Cancer Research Center, Seattle, WA. 

Sponsor: D. Eaton. 

#644 10:15 GENOMIC ANALYSIS OF INHERITED 

BREAST CANCER. M. King. Genome Sciences, 

University of Washington, Seattle, WA. Sponsor: D. 

Eaton. 

146 




Abstract # 

#645 10:45 THE ONCOGENIC MICRORNA-27A 

TARGETS GENES THAT REGULATE 

SPECIFICITY PROTEIN (SP) 

TRANSCRIPTION FACTORS AND 

ESTROGEN RECEPTOR a IN BREAST 

CANCER CELLS. S. Safe 1,2 , S. U. Mertens- 

Talcott 1 , S. Chintharlapalli 2 and X. Li 1 . 1 Veterinary 

Physiology & Pharmacology, Texas A&M University, 

College Station, TX and 2 Institute of Biosciences 

& Technology, Texas A&M Health Science Center, 

Houston, TX. 

#646 11:15 NETWORKS OF PROTEIN-PROTEIN 

INTERACTIONS NECESSARY FOR 

UBIQUITINATION OF ESTROGEN 

RECEPTOR ALPHA BY BRCA1/BARD1. C. M. 

Eakin 1 , M. J. MacCoss 2 , D. E. Christensen 1 and R. 

E. Klevit 1 . 1 Biochemistry, University of Washington, 

Seattle, WA and 2 Genome Sciences, University of 

Washington, Seattle, WA. Sponsor: D. Eakin. 


9:00 AM to 11:45 AM 

Room 611 

WORKSHOP SESSION: DRUG-RELATED TORSADES DE 

POINTES: ADVANCEMENTS IN PRECLINICAL MODELING OF 

POTENTIAL CARDIAC TOXICITY 

Chairperson(s): Alan Bass, Schering-Plough Research Institute, 

Kenilworth, NJ and Jean-Pierre Valentin, AstraZeneca, Macclesfield, 


Endorsed by: 



Safety Pharmacology Society 

Drug-induced delay in cardiac ventricular repolarization (QT/QTc prolongation) 

serves as a sensitive surrogate of the potential life-threatening 

cardiac arrhythmia, torsades des pointes (TdP), but importantly lacks the 

specificity to know if, when & under what circumstances TdP may be elicited 

in the clinical population. Identification of better preclinical models 

of drug-related TdP is a significant challenge for the scientific community, 

and was thoroughly debated at an ILSI/HESI workshop convened in 

November 2005 at which recommendations for further study were proposed 

(www.hesiglobal.org/Events/TdPWorkshop.htm). Advancements in three 

key areas of investigation will be judged in terms of progress in each of 

these areas of model development. They include: cellular and molecular 

biology of drug-induced TdP, attempts to directly link drug exposure to 

TdP; understanding the dynamics of periodicity (beat to beat variability in 

the electrocardiogram) from preclinical and clinical investigations; and in 

vitro and in vivo modeling of drug-induced TdP. The timing of the 2008 

SOT workshop is important as 2009/2010 was selected for a followup two 

day ILSI/HESI meeting at which those areas of scientific pursuit holding 

the greatest promise of providing better predictors of TdP arrhythmia will be 

considered and possibly prioritized. The 2008 workshop will be an important 

interim assessment of advancements in each of the three areas of study 

since the 2005 program and also serve to advocate further investigation by 

toxicology scientists in preparation for the important debate in 2009/2010. 

Drug-induced TdP remains a serious public health issue in rapidly bringing 

safe new pharmaceutical agents to the marketplace for diseases for which 

there are no acceptable alternative therapies. As a result, accurate identification 

of those drugs posing a risk of cardiac toxicity using the best preclinical 

models is of paramount importance. This workshop is being co-sponsored 

by Society of Toxicology and Safety Pharmacology Society. 

Abstract # 

#647 9:00 DRUG-RELATED TORSADES DES POINTES: 

ADVANCEMENTS IN PRECLINICAL 

MODELING OF POTENTIAL CARDIAC 

TOXICITY. A. S. Bass 1 and J. Valentin 2 . 

1 

Investigational & Regulatory Safety Pharmacology, 

Schering-Plough, Kenilworth, NJ and 2 Drug 

Safety, AstraZeneca, Macclesfield, Chesire, United 

Kingdom. 

#648 9:17 CELLULAR AND MOLECULAR BIOLOGY 

OF DRUG-INDUCED TDP: THE ROLE 

OF POTASSIUM CHANNELS, OTHER 

PROTEINS, AND DOWNSTREAM EVENTS. 

D. Roden. Oates Institute for Experimental 

Therapeutics, Vanderbilt University School of 

Medicine, Nashville, TN. Sponsor: A. Bass. 

#649 9:54 CELLULAR AND MOLECULAR BIOLOGY 

OF DRUG-INDUCED TORSADE DE POINTES 

(TDP) IN THE LONG QT SYNDROME: ROLE 

OF CALCIUM CHANNEL MODULATION IN 

TRIGGERING TDP. G. Salama. Cell Biology and 

Physiology, University of Pittsburgh, Pittsburgh, PA. 

Sponsor: A. Bass. 

#650 10:31 DYNAMICS OF PERIODICITY: 

PRECLINICAL AND CLINICAL EVIDENCE 

OF PROARRHYTHMIA POTENTIAL. A. A. 

Fossa. Translational and Molecular Medicine, Pfizer 

Global Research and Development, Groton, CT. 

Sponsor: A. Bass. 

#651 11:08 ADVANCES IN NON-CLINICAL MODELS 

FOR DETECTING DRUG-INDUCED 

TORSADES DE POINTES (TdP). J. Valentin 1 , 

C. Lawrence 1 , C. E. Pollard 1 , G. Duker 2 and T. G. 

Hammond 1 . 1 Safety Assessment UK, AstraZeneca 

R&D, Alderley Park, Macclesfield, United Kingdom 

and 2 Integrative Pharmacology, AstraZeneca R&D, 

Molndal, Sweden. 


9:00 AM to 11:45 AM 

Room 6A 

WORKSHOP SESSION: THE ALLERGIC MARCH: THE ROLE 

OF CHEMICALS IN THE INCREASING PREVALENCE OF 

ALLERGY AND ASTHMA 

Chairperson(s): Ian Kimber, The University of Manchester, Manchester, 

United Kingdom and Ian Gilmour, U.S. EPA, Research Triangle Park, NC. 

Endorsed by: 


It is now well-established that during the last four decades there has been in 

industrialized western societies a substantial increase in the prevalence of 

asthma and atopic allergic disesae. These changes are acknowledged to have 

been too rapid to be accounted for by alterations in the gene pool, and for 

this reason there has been considerable interest in the roles played by environmental 

influences and acquired host factors on susceptibility to allergy 

and asthma. In this context there has been speculation that increased exposure 

to certain specific chemicals and/or chemical pollution more generally, 

may impact on the development of allergy and asthma. We will here explore 

whether and to what extent chemical exposure is implicated in susceptibility 

to allergic disease, and in addition what other environmental factors may be 

influential 

Tuesday 




Tuesday 


#652 9:00 THE ALLERGIC MARCH: THE ROLE 

OF CHEMICALS IN THE INCREASING 

PREVALENCE OF ALLERGY AND ASTHMA. 

I. Kimber 1 and I. Gilmour 2 . 1 Central Toxicology 

Laboratory, Syngenta, Cheshire, United Kingdom 

and 2 Experimental Toxicology, EPA, Research 


#653 9:15 INTRODUCTION: THE CHANGING FACE 

OF ALLERGY AND ASTHMA. J. Vanoirbeek. 

Department of Public Health, Research Unit for Lung 

Toxicology, Katholieke University Leuven, Leuven, 

Belgium. Sponsor: P. Hoet. 

#654 9:45 THE INFLUENCE OF PARTICULATE 

AIR POLLUTANTS ON ALLERGIC 

SENSITIZATION IN ANIMAL MODELS. M. 

Gilmour. NHEERL, U.S. EPA, RTP, NC. 

#655 10:15 THE “HYGIENE HYPOTHESIS” AND 

BEYOND. I. Kimber. Central Toxicology 

Laboratory, Syngenta, Cheshire, United Kingdom. 

#656 10:45 PARTICULATES, ALLERGY AND ASTHMA. 

M. Lovik 1,2 , T. Alberg 1 , M. Samuelsen 1 , J. S. 

Hansen 1 , U. Nygaard 1 and A. Nilsen 2 . 1 Department 

of Environmental Immunology, Norwegian Institute 

of Public Health, Oslo, Norway and 2 Department of 

Cancer Research and Molecular Medicine, Faculty 

of Medicine, Norwegian University of Science and 

Technology, Trondheim, Norway. 

#657 11:15 PHTHALATES AND ATOPIC ALLERGY : IS 

THERE AN EFFECT? R. J. Dearman. University 

of Manchester, Manchester, United Kingdom. 


9:00 AM to 11:45 AM 

Room 608 

WORKSHOP SESSION: TO DYE OR NOT TO DYE: SAFETY OF 

OXIDATIVE HAIR DYES 

Chairperson(s): Madhu Soni, Soni & Associates, Vero Beach, FL and 

Gerhard Nohynek, L, Asnieres, France. 

Endorsed by: 





During the past decades, the safety of oxidative hair dyes has been repeatedly 

questioned. Oxidative hair dyes contain aromatic amines, a chemical 

family that includes known human carcinogens. Therefore, the association 

of hair dye exposure and neoplastic diseases in consumers and professionals 

handling hair dyes has been the subject of numerous epidemiological and 

toxicological investigations. During the past years several investigators have 

undertaken major research efforts to investigate the safety of oxidative hair 

dyes in depth, in particular the systemic exposure of consumers, the metabolism 

of hair dyes in different human NAT2 genotypes, hair dye metabolism 

in animal models after dermal application, human skin and hepatocytes, 

including their capacity to form electrophilic and potentially carcinogenic 

metabolites. In addition, several recent epidemiologic investigations have 

implicated oxidative hair dyes, especially the permanent type, in the development 

of bladder cancer, leukaemia and non-Hodgkin’s lymphoma. The 

objectives of the session are (1) Present and discuss the recent findings 

from human studies and animal studies; (2) Use of animal data in safety 

assessment of oxidative hair dyes for human use; (3) Role of genetic polymorphism 

and hair dye toxicity; and (4) regulatory stipulations with respect 

to health and safety. 

#658 9:00 TO DYE OR NOT TO DYE: SAFETY OF 

OXIDATIVE HAIR DYES. M. G. Soni 1 and G. 

J. Nohynek 2 . 1 Soni & Associates and Vero Beach 

Hematology Oncology, Vero Beach, FL and 2 Global 

Safety Department, L’OREAL Research and 

Development, Asnieres, France. 

#659 9:15 EPIDEMIOLOGY STUDIES ON HAIR DYES 

AND CANCER. K. J. Helzlsouer 1,2 , D. E. Rollison 3 

and S. M. Pinney 4 . 1 Prevention and Research Center, 

Mercy Medical Center, Baltimore, MD, 2 Department 

of Epidemiology, Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD, 3 H. Lee Moffitt 

Cancer Center & Research Institute, Tampa, FL 

and 4 University of Cincinnati College of Medicine, 

Cincinnati, OH. Sponsor: M. Soni. 

#660 9:45 HUMAN EXPOSURE TO [14C]-PARA- 

PHENYLENEDIAMINE-CONTAINING 

OXIDATIVE HAIR DYES. G. J. Nohynek 1 , F. 

Hueber-Becker 1 , E. K. Dufour 1 , W. J. Meuling 2 , 

A. T. de Bie 2 and H. M. Bolt 3 . 1 Global Safety, 

L’Oreal R&D, Asnieres, France, 2 TNO Quality 

of Life, TNO, Zeist, Netherlands and 3 Institut 

für Arbeitsphysiologie, University of Dortmund, 

Dortmund, Germany. 

#661 10:15 METABOLISM OF OXIDATIVE HAIR 

DYES —A KEY CONSIDERATION FOR 

SAFETY ASSESSMENT. J. A. Skare 1 , R. Powrie 2 , 

W. Meuling 4 , D. W. Hein 3 , D. Duche 5 and G. J. 

Nohynek 5 . 1 Central Product Safety, Procter & Gamble 

Company, Cincinnati, OH, 2 CXR Biosciences, 

Ltd, Dundee, United Kingdom, 3 Department of 


Louisville, Louisville, KY, 4 TNO Quality of Life, 

TNO, Zeist, Netherlands and 5 Global Safety, 

L’OREAL R&D, Asnieres, France. 

#662 10:45 CARCINOGENICITY HAZARD 

ASSESSMENT OF HAIR DYES: IS THERE 

A BIOLOGICALLY PLAUSABLE CANCER 

RISK? J. I. Goodman. Pharmacology and 


MI. 

#663 11:15 CURRENT SAFETY CONCERNS ABOUT 

OXIDATIVE HAIR DYES: EUROPEAN 

PERSPECTIVE. T. Platzek. Federal Institute for 

Risk Assessment, Berlin, Germany. Sponsor: M. 

Soni. 


9:00 AM to 11:45 AM 

Room 602 


INFORMATIONAL SESSION: PROFESSIONAL CAREER 

DEVELOPMENT AS A TOXICOLOGIST 

Chairperson(s): Vishal Vaidya, Brigham & Women, Boston, MA and 

B. Bhaskar Gollapudi, Dow Chemical Company, Midland, MI. 

Endorsed by: 

Career Resource and Development Committee* 


Postdoctoral Assembly 


The overall objective of the symposium is to foster career development of 

a toxicologist by providing education and knowledge about different facets 

of a toxicology career. The goals of this session are: 1. To provide insights 

148 




Abstract # 

into various facets of a successful career in toxicology. 2. To highlight qualities 

necessary to develop these career characteristics. 3. To provide a path 

forward towards developing a career as an academic, industrial or entrepreneurial 

toxicologist. This session will have three parallel components. 

Firstly, it will be targeted towards the career development of early career 

toxicologists including graduate students, postdoctoral fellows and young 

investigators who are at the crossroads of deciding a suitable path forward 

in toxicological sciences. The presentation will give an in-depth perspective 

about career as an industrial toxicologist, toxicologist in drug development, 

academic toxicologist, clinical toxicologist, forensic toxicologist, ecotoxicologist, 

regulatory toxicologist, or occupational toxicologist. The second 

component is targeted towards educating the toxicologists about developing 

adequate skill set necessary to manage a laboratory in academics or in 

industry and secondly towards applying for potential funding opportunities 

to support the laboratory. The third component is geared towards an entrepreneurial 

toxicologist desiring to start a company at any stage of his/her 

career. This presentation will lay out different steps involved from having 

the initial idea to starting a company, including approaching the venture 

capitalist, strategy design, implementation and execution, etc. 

#664 9:00 PROFESSIONAL CAREER DEVELOPMENT 

AS TOXICOLOGIST. V. S. Vaidya 1 , D. A. Keller 2 , 

J. Popp 3 , V. McGovern 4 , P. J. Mastin 5 and S. B. Farr 6 . 

1 

Medicine-Renal, Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA, 2 Sanofi- 

Aventis, Malvern, PA, 3 Stratoxon LLC, Lancaster, 

PA, 4 Burroughs Wellcome Fund, Research Triangle 

Park, NC, 5 NIEHS, Research Triangle Park, NC and 

6 

Vista Therapeutics, Santa Fe, NM. 

#665 9:05 CAREERS IN TOXICOLOGY. J. Popp. 

Stratoxon LLC, Lancaster, PA. 

#666 9:45 MANAGING A LABORATORY. V. McGovern. 

Burroughs Wellcome Fund, Research Triangle Park, 

NC. Sponsor: V. Vaidya. 

#667 10:25 NIH GRANT OPPORTUNITIES IN 

TOXICOLOGY. P. J. Mastin. NIEHS, Research 

Triangle Park, NC. Sponsor: V. Vaidya. 

#668 11:05 STARTING A COMPANY. S. B. Farr. Vista 

Therapeutics, Santa Fe, NM. Sponsor: V. Vaidya. 


9:00 AM to 11:45 AM 

Room 6C 

PLATFORM SESSION: ACCELERATING DISCOVERIES IN 

TOXICOLOGY THROUGH ‘OMICS RESEARCH 

Chairperson(s): Helmut Zarbl, University of Medicine and Dentistry of 

New Jersey, Piscataway, NJ. 

#669 9:00 A NOVEL METHOD FOR DERIVING 

MECHANISTICALLY-ANCHORED GENE 

EXPRESSION BIOMARKERS. R. J. Brennan, 

W. Shi, A. Bugrim, Y. Nikolsky and T. Nikolskya. 

GeneGo Inc, San Diego, CA. 

#670 9:21 INDEPENDENTLY PUBLIC 

TOXICOGENOMICS STUDIES VALIDATE 

THE TRANSSULFUATION PATHWAY AS 

POTENTIAL LIVER TOXICITY PATHWAY. 

M. Chen 1,2 , L. K. Schnackenberg 1 , R. Holland 1 , 

R. D. Beger 1 , S. Isukapalli 2 , P. G. Georgopoulos 2 , 

W. J. Welsh 2 and W. Tong 1 . 1 Division of Systems 

Toxicology, FDA’s National center for toxicology 

research, Jefferson, AR and 2 Departments 

of Pharmacology and of Environmental and 

Occupational Medicine, UMDNJ-RWJMS, 


Abstract # 

#671 9:42 PHENOTYPIC ANCHORING OF 

CARCINOGEN-INDUCED GENE 

EXPRESSION REVEALS A COINCIDENCE 

BETWEEN THE NO TRANSCPTIONAL 

EFFECT LEVEL (NOTEL) AND THE NO 

DETECTABLE ADDUCT LEVEL (NODAL): 

IMPLICATIONS FOR RISK ASSESSMENT? 

H. Zarbl 1 , R. C. Sullivan 1 , J. Glick 2 and P. Vouros 2 . 

1 

Environmental And Occupational Health Sciences 

Institute, Robert Wood Johnson Medical School, 

UMDNJ, Piscataway, NJ and 2 Department of 

Chemistry and Chemical Biology and The Barnett 

Institute, Northeastern University, Boston, MA. 

#672 10:03 TRANSCRIPT PROFILING REVEALS 

DIVERGENT REGULATION OF 

MITOCHONDRIAL METABOLISM IN 

HUMAN AND MOUSE MODELS IN 

RESPONSE TO XENOBIOTICS. K. M. 

Olsavsky 1 , M. Johnson 1 , S. Strom 2 , H. Zarbl 3 and 

C. Omiecinski 1 . 1 Department of Veterinary and 

Biomedical Sciences, Pennsylvania State University, 

University Park, PA, 2 Department of Pathology, 

University of Pittsburgh, Pittsburgh, PA and 3 Fred 

Hutchinson Cancer Research Center, Seattle, WA. 

#673 10:24 DIFFERENCES IN GENE EXPRESSION 

PROFILES FROM TCDD-, 4-PECDF- OR 

TCDF-TREATED PRIMARY RAT AND 

HUMAN HEPATOCYTES. J. Rowlands 1 , R. A. 

Budinsky 1 , B. Gollapudi 1 , D. Boverhof 1 , S. Ferguson 3 , 

R. F. Novak 2 , D. Cukovic 2 , S. Salagrama 2 and A. 

Dombkowski 2 . 1 The Dow Chemical Company, 

Midland, MI, 2 Institute of Environmental Health 

Sciences, Detroit, MI and 3 CellzDirect, Inc., 

Pittsboro, NC. 

#674 10:45 COMPARATIVE METABOLOMIC ANALYSIS 

OF HEPATOTOXICITY EXPERIMENTS IN 

RATS AND MICE. G. L. Jahns 1 , N. V. Reo 2 , M. N. 

Kent 2 , M. K. Makley 2 , A. Kopec 3 , D. R. Boverhof 3 , 

L. Burgoon 3 , T. R. Zacharewski 3 and N. DelRaso 4 . 

1 

Advanced Information Technologies, BAE Systems, 

San Diego, CA, 2 Department Biochemistry & 

Molecular Biology, Boonshoft School of Medicine, 

Wright State University, Dayton, OH, 3 Department 

Biochemistry & Molecular Biology, National 

Food Safety & Toxicology Center, Michigan 

State University, East Lansing, MI and 4 Human 

Effectiveness Directorate, Air Force Research 

Laboratory, Wright-Patterson AFB, OH. 

#675 11:05 APPLICATION OF A SYSTEMS 

TOXICOLOGY APPROACH TO 

INVESTIGATE TROGLITAZONE 

HEPATOTOXICITY IN THE RAT. E. Troesken 1 , 

A. Gruhler 2 , E. Boitier 1 , J. Marchandeau 1 , K. 

Arnold 3 , B. Bidlingmaier 1 , A. Brandenburg 4 , 

M. Kurz 1 , A. Pfenninger 1 , J. Schnieders 1 , I. 

Stammberger 1 , M. Stolte 1 and A. Amberg 1 . 1 Sanofi- 

Aventis, Hattersheim, Germany, 2 Novo Nordisk 

A/S, Bagsværd, Denmark, 3 Boehringer Ingelheim 

Pharmacology GmbH & Co KG, Biberach, Germany 

and 4 Genedata AG, Basel, Switzerland. Sponsor: M. 

Bonnefoi. 

Tuesday 




Tuesday 


#676 11:25 INTEGRATED TRANSCRIPTOMIC 

AND PROTEOMIC EVALUATION OF 

GENTAMICIN NEPHROTOXICITY IN 

RATS. E. Com 1 , E. Boitier 1 , J. Marchandeau 1 , M. 

Courcol 1 , J. Leonard 1 , M. Duchesne 2 , B. Genet 2 , S. 

Schroeder 3 , M. Wendt 4 and J. Gautier 1 . 1 Drug Safety 

Evaluation, sanofi aventis, Vitry sur Seine, France, 

2 

Biological Sciences, sanofi aventis, Vitry sur Seine, 

France, 3 Nycomed GmbH, Barsbüttel, Germany 

and 4 Genedata AG, Basel, Switzerland. Sponsor: E. 

Harpur. 


9:00 AM to 11:45 AM 

Room 618 

PLATFORM SESSION: CHEMICAL AND BIOLOGICAL 

WEAPONS: MOLECULAR BASIS FOR DETECTION AND 

THERAPEUTIC POTENTIAL 

Chairperson(s): Gunda Reddy, U.S. Army Center for Health Promotion 

and Preventive Medicine, Aberdeen Proving Ground, MD and Charles 

Timchalk, Pacific Northwest National Laboratory, Richland, WA. 

#677 9:00 TOXIGENIC PHASE OF ANTHRAX 

INFECTION: BIOLOGICALLY-BASED 

MODELING OF MODULATION OF MAP 

KINASE SIGNALING PATHWAY. D. J. 

Schneider 2 , P. J. Robinson 1 , J. M. Gearhart 1 , C. 

Hack 1 , G. A. Andrews 3 and B. W. Gutting 3 . 1 HEPB, 

Air Force Research Laboratory, Wright-Patterson 

AFB, OH, 2 Air Force Institute of Technology, 

Wright-Patterson AFB, OH and 3 Naval Surface 

Warfare Center, Dahlgren, VA. 

#678 9:23 BIOLOGICAL AND MOLECULAR 

MARKERS FOR SULFUR MUSTARD 

ANALOG CEES-INDUCED SKIN INJURY 

IN MOUSE AND HUMAN EPIDERMAL 

KERATINOCYTES. N. Tewari-Singh 1 , S. Rana 1 , 

M. Gu 1 , C. Agarwal 1 , C. W. White 2 and R. Agarwal 1 . 

1 

Pharmaceutical Sciences, UCDHSC, Denver, CO 

and 2 National Jewish Medical and Research Center, 

Denver, CO. Sponsor: V. Vasiliou. 

#679 9:46 NANOPARTICLE-BASED 

ELECTROCHEMICAL IMMUNOSENSOR 

FOR DETECTION OF PHOSPHORYLATED 

ACETYLCHOLINESTERASE ADDUCT: 

AN EXPOSURE BIOMARKER OF 

ORGANOPHOSPHATE PESTICIDES AND 

NERVE AGENTS. Y. Lin 1 , G. Liu 2 , J. Wang 1 , 

C. Timchalk 1 , P. L. Gassman 1 , R. C. Barry 1 , A. L. 

Busby 1 and H. Wang 1 . 1 Pacific Northwest National 

Laboratory, Richland, WA and 2 North Dakota State 

University, Fargo, ND. 

#680 10:09 TRANSCRIPTIONAL RESPONSES IN 

PORCINE SKIN FOLLOWING SULFUR 

MUSTARD AND THERMAL BURNS. J. Price 1 , 

J. Rogers 1 , J. McDougal 2 , F. Reid 1 and J. Graham 3 . 

1 

Battelle, Columbus, OH, 2 Wright State University, 

Dayton, OH and 3 USAMRICD, APG, MD. 

#681 10:32 GENE EXPRESSION PROFILING OF 

PORCINE SKIN EXPOSED TO SULFUR 

MUSTARD. C. S. Phillips 1 , J. S. Graham 2 and J. F. 

Dillman 1 . 1 Cell and Molecular Biology, USAMRICD, 

Aberdeen Proving Ground, MD and 2 Medical 

Toxicology Branch, USAMRICD, Aberdeen Proving 

Ground, MD. 

#682 10:55 REAL-TIME PCR QUANTITATION OF 

SINGLE-BASE SUBSTITUTIONS IN 

RNA, AND ITS APPLICATION TO THE 

DETECTION OF RICIN AND OTHER 

RIBOSOME-INACTIVING PROTEINS. W. B. 

Melchior and W. H. Tolleson. NCTR, Jefferson, AR. 

#683 11:17 DIFFERENTIAL GENE EXPRESSION IN 

SULFUR MUSTARD TREATED MURINE 

SKIN AFTER TREATMENT WITH MMP-2/ 

MMP-9 INHIBITOR I. Y. Chang 1 , R. P. Casillas 2 , 

C. C. Sabourin 2 , J. D. Laskin 3 , M. K. Gordon 1 and D. 

R. Gerecke 1 . 1 Pharmacology & Toxicology, Rutgers 

University, Piscataway, NJ, 2 Battelle Biomedical 

Research Center, Columbus, OH and 3 Environmental 

& Occupational Medicine, UMDNJ-Robert Wood 

Johnson Medical School, Piscataway, NJ. 

#684 11:39 BIODEGRADABLE MICROSPHERE 

DELIVERY SYSTEM FOR 

BUTYRYLCHOLINESTERASE TO 

PROTECT AGAINST ORGANOPHOSPHATE 

TOXICITY. B. R. Coleman, W. Bahar, J. Yeager, 

R. K. Gordon and M. Nambiar. Walter Reed Army 

Institute of Research, Silver Spring, MD. 


9:00 AM to 11:45 AM 

Room 6E 


PLATFORM SESSION: DEVELOPMENTAL BASIS OF DISEASE 

Chairperson(s): Mary Walker, University of New Mexico, Albuquerque, 

NM and David Threadgill, University of North Carolina Chapel Hill, 


#685 9:00 MODULATION OF OSTEOBLAST 

DIFFERENTIATION BY A MECHANISM 

INVOLVING THE ARYL HYDROCARBON 

RECEPTOR. E. P. Ryan 1 , J. D. Holz 1 , T. Sheu 2 , 

T. A. Gasiewicz 1 and J. Puzas 2,1 . 1 Environmental 

Medicine, University of Rochester, Rochester, NY 

and 2 Orthopedics and Center for Musculoskeletal 

Research, University of Rochester, Rochester, NY. 

#686 9:21 NEW INSIGHTS INTO HOW SUSTAINED 

AHR ACTIVATION DURING 

DEVELOPMENT CAUSES LONG-LASTING 

ALTERATIONS IN IMMUNE FUNCTION. 

A. J. Moore 1 , J. Hogaboam 2 and B. Lawrence 1,2 . 

1 


Rochester, NY and 2 Pharmaceutical Sciences, 

Washington State University, Pullman, WA. 

#687 9:42 IN UTERO AND LACTATIONAL TCDD 

EXPOSURE ALTERS LIPID METABOLISM 

IN MALE C57BL/6 MOUSE OFFSPRING 

FED A HIGH-FAT DIET. E. Sugai, W. Yoshioka 

and C. Tohyama. Division of Environmental 

Health Sciences, CDBIM, The University of Tokyo 

Graduate School of Medicine, Tokyo, Japan. 

150 




Abstract # 

#688 10:03 OBESITY AND PERINATAL TCDD 

EXPOSURE INCREASES MAMMARY 

TUMORS IN FVB MICE. M. La Merrill 1,2,3 , L. S. 

Birnbaum 4 , R. D. Cardiff 5 and D. W. Threadgill 1,2,3 . 

1 

Curriculum in Toxicology, UNC-CH, Chapel 

Hill, NC, 2 Department of Genetics, UNC-CH, 

Chapel Hill, NC, 3 Center for Environmental and 

Health Susceptibility, UNC-CH, Chapel Hill, NC, 

4 

NHEERL, U.S. EPA, RTP, NC and 5 Center for 

Comparative Medicine, Department of Pathology and 

Laboratory Medicine, UCD, Davis, CA. 

#689 10:24 DEVELOPMENTAL EXPOSURE 

OF THE MOUSE TO 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN 

(TCDD) INCREASES THE SUSCEPTIBILITY 

TO HYPERTENSION AND CARDIAC 

HYPERTROPHY IN ADULTHOOD. M. K. 

Walker, A. C. Aragon and M. Goens. Pharmacy, 

University of New Mexico, Albuquerque, NM. 

#690 10:45 IDENTIFICATION OF GENES 

DEVELOPMENTALLY REPROGRAMMED 

IN THE UTERUS BY NEONATAL EXPOSURE 

TO XENOESTROGENS. K. L. Greathouse 1 , 

J. D. Cook 3 , K. Lin 1 , B. J. Davis 2 , T. Berry 1 , T. 

Bredfeldt 1 and C. L. Walker 1 . 1 Carcinogenesis, UT 

MD Anderson Cancer Center, Smithville, TX, 

2 

Millennium Pharmaceuticals, Cambridge, MA and 

3 

Dana-Farber Cancer Institute, Boston, MA. 

#691 11:06 DISPARITIES IN LEARNING, MEMORY 

AND BEHAVIOR AS A RESULT OF 

ENVIRONMENTAL CONTAMINANT 

EXPOSURE DURING GESTATION. D. B. 

Hood 1 , M. M. McCallister 1 , S. Liu 1 , M. Maguire 1 , 

F. F. Ebner 2 , P. Levitt 4 and M. Aschner 3 . 1 Center 

for Molecular and Behavioral Neuroscience, 

meharry medical college, Nashville, TN, 2 Center for 

Cognitive and Integrative Neuroscience, Vanderbilt 

University, Nashville, TN, 3 Center in Molecular 

Toxicology, Vanderbilt University, Nashville, TN and 

4 

Kennedy Center for Research in Child and Human 

Development, Vanderbilt University, Nashville, TN. 

#692 11:26 FETAL EXPOSURE TO CIGARETTE SMOKE 

ALTERS OFFSPRING RESPIRATORY 

FUNCTION: A MOUSE MODEL. J. Grabowski, 

C. Hoffman, E. Brush, S. P. Doherty and J. T. 

Zelikoff. Environmental Medicine, New York 

University School of Medicine, Tuxedo, NY. 


9:00 AM to 11:45 AM 

Room 615 

PLATFORM SESSION: HEALTH RISKS AND FOOD SAFETY 

Chairperson(s): John Garst, Consultant, Alamogordo, NM and Ronald 

Riley, U.S. Department of Agriculture, Athens, GA. 

#693 9:00 FISH INTAKE GUIDELINES: N-3 FATTY 

ACID INTAKE AND CONTAMINANT 

EXPOSURE IN THE KOREAN AND 

JAPANESE COMMUNITIES. A. Tsuchiya 1,2 , 

J. Hardy 3 , T. M. Burbacher 1 , F. M. Elaine 1,2 and 

K. Mariën 3 . 1 Department of Environmental and 

Occupational Health Medicine Sciences, University 

of Washington, Seattle, WA, 2 Institute for Risk 

Analysis and Risk Communication, University of 

Washington, Seattle, WA and 3 Washington State 

Department of Health, Olympia, WA. 

Abstract # 

#694 9:19 SAMPLE SELECTION PROCESS FOR USDA/ 

FSIS NATIONAL RESIDUE PROGRAM. J. 

Vodela 1 , H. L. Walker 1 and K. Dearfield 2 . 1 Residue 

Branch, USDA/FSIS, Washington DC, DC and 

2 

USDA/FSIS, Residue branch, Washington DC, DC. 

#695 9:38 CRITICAL FOLATE PROBLEM WITH 

“LIFETIME” ASPARTAME AND RELATED 

STUDIES. J. E. Garst. consultant, Alamogordo, 

NM. 

#696 9:57 DETERMINATION OF MULTI-CLASS, 

MULTI-RESIDUE SULFUR-CONTAINING 

ANTIBIOTICS IN ANIMAL TISSUES USING 

INTEGRATED PULSED AMPEROMETRIC 

DETECTION FOLLOWING 

HIGH-PERFORMANCE LIQUID 

CHROMATOGRAPHY. S. R. Vavilala and W. 

R. Lacourse. Department of Chemistry, UMBC, 


#697 10:15 ASSESSMENT OF THE HEALTH RISKS 

POSED BY BENZENE IN CERTAIN SOFT 

DRINKS. M. Harris 1 , J. A. Tachovsky 2 , E. S. 

Williams 1 , D. J. Paustenbach 3 and L. C. Haws 2 . 

1 

ChemRisk, Houston, TX, 2 ChemRisk, Austin, TX 

and 3 ChemRisk, SanFrancisco, CA. 

#698 10:33 THE IMPORTANCE OF ENDOTOXIN 

CONTAMINATION OF COMMERCIAL 

PROTEIN PREPARATIONS IN THE 

CELLULAR EFFECTS OF ADVANCED 

GLYCATION ENDPRODUCTS. T. M. Buetler, 

H. Latado, A. Baumeyer, T. Delatour and B. Schilter. 

QS, Nestlé Research Center, Lausanne, Switzerland. 

#699 10:51 MODE OF EXPOSURE FOR PHOTOTOXIC 

COUMARINE DERIVATIVES FROM FOOD 

AND DRUG EXTRACTS. J. B. Schulze. Office 

of the Dean, Johann Wolfgang Goethe-University, 

Frankfurt/Main, Germany. 

#700 11:09 INDIVIDUAL AND COMBINED EFFECTS 

OF OCHRATOXIN A AND FUMONISIN B1. E. 

E. Creppy 1 , S. Moukha 1,2 , B. Sangare-Tigori 1,3 , J. H. 

Kouadio 1,3 , T. Mobio 1 and M. Carratu 4 . 1 Toxicology, 

University Bordeaux 2, Bordeaux, France, 2 INRA, 

Centre de Recherches de Bordeaux Aquitaine, 

UPR 1264, Villenave d’Ornon, France, 3 Faculty of 

Pharmacy, University of Abidjan, Abidjan, Cote 

d’Ivoire and 4 Pharmacology, Medical School, 

University of Bari, Bari, Italy. 

#701 11:27 VALIDATION OF URINARY FREE 

FUMONISIN B1 AS A BIOMARKER OF 

EXPOSURE. J. S. Wang 1 , L. Xu 1 , Q. Cai 1 , L. Tang 1 , 

G. Sun 2 , X. Hu 3 and J. Su 4 . 1 Texas Tech University, 

Lubbock, TX, 2 Southeast University, Nanjing, China, 

3 

Chuzhou CDC, Huaian, China and 4 Guangxi Cancer 

Inst., Nanning, China. 

Tuesday 




Tuesday 



9:00 AM to 11:45 AM 

Room 2A 

PLATFORM SESSION: MANGANESE NEUROTOXICITY: FROM 

WORMS TO PRIMATES 

Chairperson(s): Tomas Guilarte, Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD and Dejan Milatovic, Vanderbilt 

University, Nashville, TN. 

#702 9:00 NEUROTOXIC EFFECTS OF MANGANESE 

ON THE DOPAMINERGIC INNERVATION 

OF THE GILL OF THE BIVALVE MOLLUSC, 

CRASSOSTREA VIRGINICA. K. Martin, C. 

King, T. Huggins, M. A. Carroll and E. J. Catapane. 

Biology, Medgar Evers College, Brooklyn, NY. 

Sponsor: C. Miller. 

#703 9:24 POTENTIATION OF PROINFLAMMATORY 

CYTOKINES BY MANGANESE IN LPS- 

ACTIVATED MICROGLIA IS ASSOCIATED 

WITH DECREASED EXPRESSION AND 

ACTIVITY OF MITOGEN ASSOCIATED 

PROTEIN KINASE PHOSPHATASE-1. P. L. 

Crittenden, S. Lee and N. M. Filipov. CEHS, Basic 


State, MS. 

#704 9:48 NF-kB-DEPENDENT EXPRESSION 

OF NITRIC OXIDE SYNTHASE 2 IN 

ASTROCYTES IS POTENTIATED BY 

MANGANESE VIA ACTIVATION OF 

SOLUBLE GUANYLATE CYCLASE AND 

EXTRACELLULAR REGULATED KINASE 

SIGNALING PATHWAYS. J. Moreno 1,2,3 , K. 

A. Sullivan 1 , D. Carbone 1,3 and R. B. Tjalkens 1,2,3 . 

1 

Environmental Radiological and Health Sciences, 

Colorado State University, Fort Collins, CO, 

2 

Program in Cell and Molecular Biology, Colorado 

State University, Fort Collins, CO and 3 Program in 

Molecular, Cellular, and Integrative Neuroscience, 

Colorado State University, Fort Collins, CO. 

#705 10:12 MANGANESE PRIMARILY ACCUMULATES 

IN NUCLEUS OF CULTURED BRAIN CELLS. 

K. Kalia 1 , W. Jiang 2 and W. Zheng 2 . 1 Biosciences, 

Sardar Patel University, Anand, Gujarat, India and 

2 

School of Health Sciences, Purdue University, West 

Lafayette, IN. 

#706 10:36 DEVELOPMENTAL VULNERABILITY TO 

MANGANESE-INDUCED BEHAVIORAL 

DYSFUNCTION. C. Yeomans 1 , J. A. Moreno 1,2,3 , K. 

A. Sullivan 1 and R. B. Tjalkens 1,2,3 . 1 ERHS, Colorado 

State University, Fort Collins, CO, 2 Program in 

Cellular and Molecular Biology, Colorado State 

University, Fort Collins, CO and 3 Program in 



#707 11:00 EFFECTS OF CHRONIC MANGANESE 

EXPOSURE ON GLUTAMATERGIC 

MARKERS IN THE NON-HUMAN PRIMATE 

BRAIN. N. C. Burton 1 , J. S. Schneider 2 and T. R. 

Guilarte 1 . 1 Environmental Health Sciences, Johns 

Hopkins University Bloomberg School of Public 

Health, Baltimore, MD and 2 Pathology, Anatomy, 

& Cell Biology, Thomas Jefferson University, 

Philadelphia, PA. 

#708 11:23 MANGANESE EXPOSURE IN 328 SMELTING 

WORKERS: RELATIONSHIP AMONG 

EXTERNAL/ INTERNAL MARKERS 

AND NEUROLOGICAL/PSYCHOMOTOR 

EXAMINATIONS. D. M. Cowan 1 , Q. Fan 2 , Y. 

Zou 2 , X. Shi 3 , F. S. Rosenthal 1 , M. Aschner 4 and 

W. Zheng 1 . 1 Health Sciences, Purdue Univeristy, 

West Lafayette, IN, 2 Preventative Medicine, Zunyi 

Medical College, Zunyi City, Guizhou, China, 

3 

Guizhou Institute of Occupational Safety and 

Health, Zunyi City, Guizhou, China and 4 Pediatrics, 

Vanderbilt University Medical Center, Nashville, TN. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: ADVERSE EFFECTS OF NATURAL 

PRODUCTS 

Chairperson(s): David McCormick, IIT Research Institute, Chicago, IL 

and Ira Richards, Consultant, Lutz, FL. 




HEPATOTOXIC REACTION ASSOCIATED 

WITH A PRODUCT CONTAINING “BLACK 

COHOSH”: ONE CASE OF MISTAKEN 

IDENTITY. S. Jordan 1 , M. Murty 1 , S. Perwaiz 1 , 

R. Bertrand 2 and J. Griffiths 1 . 1 Marketed Health 

Products Directorate, Health Canada, Ottawa, ON, 

Canada and 2 Health Products and Food Branch 

Inspectorate, Health Canada, Ottawa, ON, Canada. 

Sponsor: G. Bondy. 


USNIC ACID-INDUCED CHANGES IN 

THE TRANSCRIPTIONAL PROFILE OF 

MITOCHONDRIAL GENES IN MOUSE 

LIVER. V. G. Desai 1 , A. Joseph 2 , T. Lee 3 , C. L. 

Moland 1 , W. S. Branham 1 , J. C. Fuscoe 1 , S. M. 

Lewis 4 and J. E. Leakey 4 . 1 Center for Functional 

Genomics, Division of Systems Toxicology, NCTR, 

Jefferson, AR, 2 The University of Abertay, Dundee, 

Scotland, United Kingdom, 3 Division of Personalized 

Nutrition and Medicine, NCTR, Jefferson, AR and 

4 

Office of Scientific Coordination, NCTR, Jefferson, 

AR. 


CARDIOPROTECTIVE ACTIVITY OF 

RESVERATROL IN RATS. D. L. McCormick 1 , 

W. D. Johnson 1 , R. L. Morrissey 2 , I. M. Kapetanovic 3 

and J. A. Crowell 3 . 1 IIT Research Institute, Chicago, 

IL, 2 Pathology Associates, Chicago, IL and 3 National 

Cancer Institute, Bethesda, MD. 


CYTOTOXICITY SCREENING OF 

AYURVEDIC HERBAL EXTRACTS USING 

IN VITRO TECHNIQUES AND SCANNING 

ELECTRON MICROSCOPY. J. R. Placido 

and S. Zito. Pharmaceutical Sciences, St. John’s 

University, Jamaica, NY. 

152 




Abstract # 


CYTOTOXICITY OF STILBENE 

COMPOUNDS IN TRANSFORMED CELLS. 

D. Hardej, V. Radkar, C. Lau-Cam and B. Billack. 

Pharmaceutical Sciences, St. John’s Univeristy, 

Jamaica, NY. 


OXYMATRINE REDUCES DMSO-INDUCED 

TOXICITY IN H4IIE CELLS. P. Lee, W. Chim 

and J. Ho. Biochemistry, CUHK, Shatin, China. 


SUBCHRONIC SAFETY EVALUATION 

OF A UNIQUE COMPOSION OF 

DEFIND EXTRACTS OF SCUTELLARIA 

BAICALENSIS AND ACACIA CATECHU. 

M. A. Yimam, Y. Zhao, W. Ma and Q. Jia. Unigen 

Pharmaceuticals Inc., Lacey, WA. Sponsor: P. 

Marone. 


TOXICITY EVALUATION OF 

PHYLLANTHUS AMARUS SCHUM 

&THONN EXTRACTS. E. E. Creppy 1 , P. 

S. Lawson-Evi 2,1 , K. C. Eklu-Gadegbeku 2,1 , A. 

Agbonon 2 , K. Aklikokou 2 , S. Moukha 1 and M. F. 

Gbeassor 2 . 1 Toxicology, University Bordeaux 2, 

Bordeaux, France and 2 Laboratory of Physiology, 

University of Lome, Lome, Togo. 


THE EFFECTS OF CHRONIC ALOE 

VERA ADMINISTRATION ON COLONIC 

PROTEIN EXPRESSION AND GLOBAL DNA 

METHYLATION IN THE FISHER-344 RAT. 

M. Pogribna, F. A. Beland, V. Tryndyak and M. D. 

Boudreau. Division of Biochemical Toxicology, 


Jefferson, AR. Sponsor: W. Tolleson. 


PURIFICATION AND TOXICITY 

CHARACTERIZATION OF SATRATOXIN 

G AND RORIDIN L2 FROM THE BLACK 

MOLD STACHYBOTRYS CHARTARUM. 

Z. Islam 1,2 , J. R. Harkema 1,3 and J. J. Pestka 1,2 . 

1 

Center for INtegrative Toxicology, Michigan 

State University, East Lansing, MI, 2 Department of 

Microbiology and Molecular Genetics, Michigan 

State University, East Lansing, MI and 3 Food Science 

and Human Nutrition, Michigan State University, 



ACUTE HEPATOTOXICITY OF USNIC ACID 

IN FISHER 344 RATS AND B6C3F1 MICE. A. 

A. Ali 1 , S. M. Lewis 1 , M. Mukherjee 1 , G. Olson 2 , W. 

T. Allaben 1 and J. E. Leakey 1 . 1 Office of Scientific 

Coordination, NCTR, Jefferson, AR and 2 TPA inc., 



SUBCHRONIC TOXICITY OF PULEGONE 

ADMINISTERED BY GAVAGE TO 

FISCHER344 RATS. D. K. Gerken 1 , M. J. Ryan 1 , 

A. J. Skowronek 1 , S. W. Graves 1 , J. M. Durnford 1 , 

M. R. Hejtmancik 1 and P. Chan 2 . 1 TOXBC, Battelle 

Memorial Institute, Columbus, OH and 2 NIEHS, 


Abstract # 


THE ESSENTIAL OIL OF LIPPIA ALBA 

PROTECTS AGAINST THE CYTOTOXIC 

AND GENOTOXIC EFFECTS OF CADMIUM. 

R. Baldiris 1,2 , J. Guette 1,2 , E. Stashenko 2 , B. 

Jaramillo 1,2 , M. Quintero 3 , M. Florian 3 , G. 

Caballero 1 , A. Patiño 1 , L. Molina 1 and J. Olivero 1,2 . 

1 

Environmental and Computational Chemistry 

Group, Universidad de Cartagena, Cartagena, 

Colombia, 2 CENIVAM, Bucaramanga, Colombia and 

3 

Universidad del Atlántico, Barranquilla, Colombia. 


TOXICITY OF THE LICHEN 

XANTHOPARMELIA CHLOROCHROA. M. 

Raisbeck 1 , R. N. Dailey 1 , D. Montgomery 1 , J. T. 

Ingram 2 , R. S. Siemion 1 and M. Vasquez 1 . 1 University 

of Wyoming, Laramie, WY and 2 Clinical Sciences, 



SAFETY ASSESSMENT OF MALE 

ENHANCEMENT DIETARY SUPPLEMENTS. 

A. Schauss 1 , I. Financsek 2 , Y. Smitasiri 3 , C. Chen 4 , 

W. Lin 5 and J. Kababick 6 . 1 AIBMR Life Sciences, 

Puyallup, WA, 2 PCDL, Budapest, Hungary, 3 Mae 

Fah Luang University, Muang Chiangrai, Thailand, 

4 

CTPS, Xizhi City, Taiwan, 5 MPITDC, Taipei Hsien, 

Taiwan and 6 Flora Res., Grants Pass, OR. 


THE EFFECT OF HIGH DELTALINE 

CONCENTRATION ON THE TOXICITY OF 

METHYLLYCACONITINE IN MICE. K. Welch, 

K. Panter, D. Gardner, B. Green, J. Pfister and D. 

Cook. Poisonous Plant Research Laboratory, USDA- 

ARS, Logan, UT. 


PUERARIN STIMULATES HEME 

OXYGENASE-1 EXPRESSION THROUGH 

PI3K AND NRF-2 PATHWAY. H. Jeong 1,2 and Y. 

Hwang 1,2 . 1 Pharmacy, Chosun University, Kwangju, 

South Korea and 2 Research Center for Proteineous 

Materials, Chosun University, Gwangju, South 

Korea. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: PARTICULATE MATTER AND THE 

CARDIOVASCULAR SYSTEM 

Chairperson(s): Michael Kleinman, University of California Irvine, 

Irvine, CA and Urmila Kodavanti, U.S. EPA, Research Triangle Park, NC. 




ATHEROGENIC AND PULMONARY 

RESPONSE OF APOE- AND LDL 

RECEPTOR-DEFICIENT MICE TO 

CIGARETTE SMOKE. S. Han 1 , D. Howatt 2 , A. 

Daugherty 2 and C. Gairola 1 . 1 Graduate Center for 

Toxicology, University of Kentucky, Lexington, KY 

and 2 Cardiovascular Research Center, Gill Heart 

Institute, University of Kentucky, Lexington, KY. 

Tuesday 




Tuesday 



EXACERBATION OF ATHEROSCLEROSIS 

FOLLOWING EXPOSURE TO VARIOUS 

COMBUSTION SOURCE PARTICLES. H. 

S. Floyd, N. Haykal-Coates and K. L. Dreher. 

NHEERL, U.S. EPA, Research Triangle Park, NC. 


INHALED NICKEL NANOPARTICLES 

INDUCE SYSTEMIC INFLAMMATION 

AND ACCELERATE ATHEROSCLEROTIC 

PLAQUE FORMATION IN APOPROTEIN 

E (APOE) KNOCKOUT MICE. G. Kang, P. 

Gillespie, Q. Li, M. Zhong, T. Gordon and L. Chen. 

Environmental Medicine, New York University, 

Tuxedo, NY. 


HEALTH EFFECTS OF TRAFFIC RELATED 

PARTICULATE MATTER. M. Gerlofs-Nijland 1 , 

A. Campbell 2 , M. Miller 3 , K. Donaldson 3 and F. 

Cassee 1 . 1 National Institute for Public Health and 

the Environment, Bilthoven, Netherlands, 2 Western 

University of Health Sciences, Pomona, CA and 

3 

University of Edinburgh, Edinburgh, United 

Kingdom. 


WILL THE GASEOUS DIESEL EXHAUST 

SYNERGISTICALLY EXACERBATE 

CONCENTRATED AMBIENT PARTICLES 

INDUCED PROGRESSION OF 

ATHEROSCLEROSIS PLAQUE IN APOE-/- 

MICE? C. Quan, X. Jin, M. Zhong, M. Lippmann 

and L. Chen. Environmental Medicine, New York 

University, Tuxedo Park, NY. 


ALTERATION OF CARDIAC FUNCTION 

BY URBAN AND RURAL CONCENTRATED 

AMBIENT PM. Q. LI, X. Jin, M. Zhong, M. 

Lippmann and L. Chen. Environmental Medicine, 

New York University School of Medicine, Tuxedo 

Park, NY. 


FINE PARTICULATE MATTER EXPOSURE 

EXACERBATES ATHEROSCLEROSIS IN 

GENETICALLY SUSCEPTIBLE (APOE 

KNOCKOUT) MICE. M. T. Kleinman 1 , D. 

Meacher 1 , G. Gookin 1 , K. Salazar 1 , P. Willett 1 , X. 

Jin 2 , Q. Li 2 and L. Chen 2 . 1 Community and Env. 

Med., University California, Irvine, Irvine, CA and 

2 

Environment Med., New York University School of 

Med., Tuxedo, NY. 


ULTRAFINE PM AFFECTS CNS 

INFLAMMATORY PROCESSES AND 

MAY ACT VIA MAP KINASE SIGNALING 

PATHWAYS. M. T. Kleinman 1 , J. Araujo 3 , A. Nel 2 , 

C. Sioutas 4 , P. Q. Cong 1 and S. C. Bondy 1 . 1 Commun. 

& Environment Med., University California, Irvine, 

Irvine, CA, 2 NanoMedicine, University California, 

Los Angeles, Los Angeles, CA, 3 Medicine, 

Cardiology Division University California, Los 

Angeles, Los Angeles, CA and 4 Civil/Environmental 

Engineering, University Southern California, Los 

Angeles, CA. 


CHRONIC EXPOSURE OF APOLIPROTEIN 

E KNOCKOUT MICE TO FINE PARTICLES 

INDUCED HEART RATE CHANGES 

BUT NOT CHANGES IN TIME DOMAIN 

MEASUREMENTS OF HEART RATE 

VARIABILITY. K. Salazar, D. Meacher, G. 

Gookin, P. Willett and M. Kleinman. Community and 

Env. Med., University California, Irvine, Irvine, CA. 


EXPOSURE TO PARTICULATE MATTER 

POTENTIATES INSULIN RESISTANCE 

ASSOCIATED WITH MACROPHAGE 

ACCUMULATION IN ADIPOSE TISSUE. Q. 

Sun 1 , C. N. Lumeng 2 , A. Wang 1 , X. Jin 3 , Y. Cai 1 , 

M. Zhong 3 , M. Lippmann 3 , A. R. Saltiel 2 , L. Chen 3 

and S. Rajagopalan 1 . 1 The Ohio State University, 

Columbus, OH, 2 University of Michigan, Ann Arbor, 

MI and 3 New York University, Tuxedo, NY. 


ADVERSE CARDIOVASCULAR EFFECTS 

WITH ACUTE PARTICULATE MATTER AND 

OZONE EXPOSURES: THE ROLE OF TOLL- 

LIKE RECEPTOR 4. A. Hamade, R. Rabold and 

C. G. Tankersley. Environmental Health Sciences, 

Johns Hopkins University, Baltimore, MD. 


DIESEL EXHAUST EXPOSURE AUGMENTS 

ENDOTHELIN CONSTRICTOR 

SENSITIVITY AND DIMINISHES 

ACETYLCHOLINE MEDIATED DILATION 

IN RAT CORONARY ARTERIES. T. Cherng 1 , 

N. Kanagy 1 , M. Campen 2 and B. Walker 1 . 1 University 

of New Mexico, Albuquerque, NM and 2 Lovelace 

Respiratory Research Institute, Albuquerque, NM. 


INHALED COMPLEX COMBUSTION 

EMISSIONS UPREGULATE 

TRANSCRIPTION AND ACTIVITY 

OF SYSTEMIC MATRIX 

METALLOPROTEINASE-9 (MMP9): 

EVIDENCE IN MURINE AND HUMAN 

MODELS. M. J. Campen 1 , A. K. Lund 1 , M. C. 

Madden 2 , J. Lucero 1 , S. Lucas 1 , T. L. Knuckles 1 , M. 

Doyle-Eisele 1 , S. Allen 1 , J. D. McDonald 1 , M. D. 

Reed 1 , J. Seagrave 1 and J. L. Mauderly 1 . 1 Toxicology, 

Lovelace Respiratory Research Institute, 

Albuquerque, NM and 2 NHEERL, HSD, U.S. EPA, 



GASOLINE ENGINE EMISSIONS 

EXPOSURE RESULTS IN 

UPREGULATION OF ENDOTHELIN-1 

– MEDIATED VASCULAR MATRIX 

METALLOPROTEINASE ACTIVITY. A. K. 

Lund, J. Lucero, S. Lucas, T. L. Knuckles and M. J. 

Campen. Lovelace Respiratory Research Institute, 



CARBON NANOTUBE ACUTE LUNG 

EXPOSURE INDUCES PLASMINOGEN 

ACTIVATOR INHIBITOR 1. A. Erdely, T. 

Hulderman, R. Salmen, A. Liston, P. C. Zeidler- 

Erdely and P. Simeonova. NIOSH, Morgantown, WV. 

154 




Abstract # 


THE AORTA, BUT NOT LUNG OR HEART, 

IS THE TARGET OF SUBCHRONIC DIESEL- 

INDUCED INJURY AND INFLAMMATION. 

R. Thomas 1 , M. C. Schladweiler 1 , A. D. Ledbetter 1 , J. 

Shannahan 2 , J. Wallenborn 3 , A. Nyska 4 , D. Malarkey 5 , 

J. H. Richards 1 , R. Jaskot 1 and U. P. Kodavanti 1 . 

1 

ETD/NHEERL, U.S. EPA, RTP, NC, 2 Curriculum 

in Toxicology, UNC, Chapel Hill, NC, 3 SPH, UNC, 

Chapel Hill, NC, 4 Toxicologic Pathology, Timrat, 

Israel and 5 NTP, NIEHS, RTP, NC. 


CHANGES IN ENDOTHELIAL TUBE CELL- 

CELL BORDERS IN RESPONSE TO DIESEL 

EXHAUST PARTICLES. M. Chao 1 , P. Po 1 , J. 

Koslosky 2 , D. R. Gerecke 1 , R. Laumbach 3 and M. K. 

Gordon 1 . 1 Pharmacology and Toxicology, Rutgers 

University, Piscataway, NJ, 2 Molecular and Cell 

Biology, Bristol-Myers-Squibb, New Brunswick, 

NJ and 3 Environmental and Occupational Medicine, 

UMDNJ, Robert Wood Johnson Medical School, 



EXACERBATION OF ATHEROSCLEROSIS 

BY URBAN AND RURAL CONCENTRATED 

AMBIENT PM. L. Chen 1 , Q. Li 1 , C. Prophete 1 , 

X. Jin 1 , M. Zhong 1 , Q. Sun 2 , S. Rajagopalan 3 and 

M. Lippmann 1 . 1 Environmental Medicine, New 

York University School of Medicine, Tuxedo, 

NY, 2 Environ Health Sci, Ohio State University, 

Columbus, OH and 3 Davis Heart and Lung Institute, 

Ohio State University, Columbus, OH. 


LIPOIC ACID PREVENTS VASCULAR 

DYSFUNCTION AND INFLAMMATION 

IN PARTICULATE AIR POLLUTION 

EXPOSURE. S. Rajagopalan 1 , C. N. Lumeng 3 , A. 

Wang 1 , X. Jin 2 , M. Zhong 2 , Y. Cai 1 , A. R. Saltiel 3 , 

L. Chen 2 and Q. Sun 1 . 1 The Ohio State University, 

Columbus, OH, 2 New York University, Tuxedo, NY 

and 3 University of Michigan, Ann Arbor, MI. 


EFFECTS OF FRESHLY-GENERATED LOW- 

AND ULTRALOW-SULFUR FUEL EMISSION 

AEROSOLS IN INSULIN-RESISTANT, 

OBESE RATS. A. Elder 1 , N. Corson 1 , R. Gelein 1 , P. 

Mercer 1 , A. Rinderknecht 1 , W. Watts 2 , D. Kittelson 2 , 

R. Phipps 1 , M. Frampton 3 , M. Utell 3 , J. Finkelstein 4 

and G. Oberdörster 1 . 1 Environmental Medicine, 

University of Rochester, Rochester, NY, 2 Mechanical 

Engineering, University of Minnesota, Minneapolis, 

MN, 3 Adult Critical Care Medicine, University of 

Rochester, Rochester, NY and 4 Pediatrics, University 

of Rochester, Rochester, NY. 


REPEATED EXPOSURE EFFECT OF 

TRAFFIC RELATED AIR POLLUTANTS ON 

THROMBOGENICITY. E. Kilinc 1 , H. Spronk 1 , H. 

ten Cate 1 , R. van Oerle 1 , F. Cassee 2 and M. Gerlofs- 

Nijland 2 . 1 Laboratory for Clinical Thrombosis and 

Haemostasis, Maastricht University, Maastricht, 

Netherlands and 2 National Institute for Public Health 

and the Environment, Bilthoven, Netherlands. 

Abstract # 


PARTICLE-INDUCED RELEASE 

OF CYTOKINES IN MONO- AND 

CO-CULTURES OF PRIMARY LUNG AND 

HEART CELLS. A. I. Totlandsdal 1 , M. Refsnes 1 , T. 

Skomedal 2 , J. Osnes 2 , P. E. Schwarze 1 and M. Låg 1 . 

1 

Division of Environmental Medicine, Norwegian 

Institute of Public Health, Oslo, Norway and 

2 

Department of Pharmacology, University of Oslo, 

Oslo, Norway. Sponsor: E. Dybing. 


ACUTE EXPOSURE TO PARTICULATE 

MATTER (PM) IN A RAT MODEL OF HEART 

FAILURE. A. P. Carll 1,2 , N. Haykal-Coates 2 , D. 

W. Winsett 2 , W. H. Rowan 2 , A. D. Ledbetter 2 , J. 

H. Richards 2 , A. K. Farraj 2 , D. L. Costa 3 and W. P. 

Watkinson 2 . 1 Environmental Sciences & Engineering, 

University of North Carolina School of Public 

Health, Chapel Hill, NC, 2 Experimental Toxicology 

Division, U.S. EPA, RTP, NC and 3 ORD, U.S. EPA, 

RTP, NC. 


DIFFERENTIAL CARDIAC ARRHYTHMIA 

PROFILES IN HYPERTENSIVE AND 

NORMAL RATS AFTER EMISSION SOURCE 

PARTICULATE EXPOSURE. A. K. Farraj 1 , 

D. W. Winsett 1 , N. Haykal-Coates 1 , M. S. Hazari 2 , 

A. P. Carll 3 , A. D. Ledbetter 1 and D. L. Costa 4 . 

1 

Experimental Toxicology Division, U.S. EPA, 

Durham, NC, 2 Curriculum in Toxicology, University 

of North Carolina, Chapel Hill, NC, 3 Environmental 


Carolina, Chapel Hill, NC and 4 Office of Research 

and Development, U.S. EPA, Durham, NC. 


DOSE INDEPENDENT CHANGES IN HEART 

RATE AND HEART RATE VARIABILITY 

FOLLOWING INHALATIONAL EXPOSURE 

TO DIESEL EXHAUST. L. M. Corey, C. Baker, 

J. Stewart, D. L. Luchtel, J. D. Kaufman, T. J. 

Kavanagh and M. E. Rosenfeld. Environmental 




ALTERATIONS OF HEART RATE 

VARIABILITY AND CARDIOVASCULAR 

RISK FACTORS IN RATS EXPOSED 

TO COARSE AND FINE PARTICULATE 

MATTER. T. Cheng and C. Chang. National Taiwan 

University, Taipei, Taiwan. Sponsor: L. Chen. 


ACUTE EFFECTS OF TOBACCO, INCENSE, 

AND CANDLE SMOKE ON PORCINE 

BLOOD GASES AND CARDIOVASCULAR 

FUNCTION. A. Al-Dissi 1 , J. Marit 2 , T. German 2 

and L. P. Weber 1,2 . 1 Toxicology, University of 

Saskatchewan, Saskatoon, SK, Canada and 

2 

Veterinary Biomedical Sciences, University of 

Saskatchewan, Saskatoon, SK, Canada. 


CHANGES IN CARDIAC PHYSIOLOGY 

AFTER CHRONIC EXPOSURE TO 

CONCENTRATED AMBIENT PARTICLES IN 

AGED RATS. G. Gookin, K. Salazar, P. Willett, D. 

Meacher and M. T. Kleinman. Community and Env. 

Med., University California, Irvine, Irvine, CA. 

Tuesday 




Tuesday 



9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: XENOBIOTIC BIOTRANSFORMATION I 

Chairperson(s): Aaron Rowland, University of Utah, Salt Lake City, UT 

and Nathan Cherrington, University of Arizona, Tucson, AZ. 




PATHWAY AND SPECIES DIFFERENCE 

IN THE BIOACTIVATION OF TRICYCLIC 

ANILINES CATALYZED BY P450 ENZYMES. 

Y. Hu, S. Yang, B. Shilliday, D. Thompson, P. 

Chiang, B. Heyde, J. Gard, S. Selness and A. 

Thurston. PGRD, Pfizer, Inc., St. Louis, MO. 


CYTOCHROME P450 2E1 PHENOTYPING 

IN HUMANS: DOSE-DEPENDENT 

METABOLISM OF CHLORZOXAZONE MAY 

CAUSE UNRELIABLE RESULTS. L. Ernstgård, 

G. Johanson and M. Warholm. Work Environment 

Toxicology, Institute of Environmental Medicine, 

Karolinska Institutet, Stockholm, Sweden. 


EFFECT OF TROGLITAZONE ON 

INDUCTION OF CYTOCHROME P450 1A1 

AND BENZO[A]PYRENE-DNA ADDUCT 

FORMATION IN HEPA-1C1C7 CELLS. 

H. Kim 1,2 and H. Jeong 1,2 . 1 Pharmacy, Chosun 

University, Kwangju, South Korea and 2 Research 

Center for Proteineous Materials, Chosun University, 

Gwangju, South Korea. 


A COMPARATIVE STUDY FOR 

LIVER-TOXICITY INDUCED 

WITH ACETAMINOPHEN AND ITS 

REGIOISOMER, N-ACETYL-M- 

AMINOPHENOL IN RATS. M. Kobayashi, T. 

Yamamoto, T. Tomari, Y. Inoue, T. Ohta, Y. Ikeda 

and A. Sugiyama. Mitsubishi Tanabe Pharmacology, 

Kisarazu-shi, Japan. Sponsor: J. Sugimoto. 


PARTICIPATION OF MICRORNA IN 

THE REGULATION OF HUMAN CYP3A4 

EXPRESSION. A. Miyajima-Tabata 1 , S. 

Ishida 1 , S. Ozawa 2 and K. Nakazawa 1 . 1 Division 

of Pharmacology, National Institute of Health 

Sciences, Setagaya, Tokyo, Japan and 2 Department 

of Pharmacodynamics and Molecular Genetics, Iwate 

Medical University, Yahaba, Iwate, Japan. Sponsor: 

M. Ema. 


INDUCTION OF P4504A1 ACTIVITY AND 

PEROXISOMAL PROLIFERATION BY 

LAMBDA-CYHALOTHRIN. M. R. Martinez- 

Larrañaga, V. Castellano, M. A. Martinez, M. 

Martinez, M. J. Diaz, V. Caballero and A. Anadon. 





ACTIVATION OF ARISTOLOCHIC ACID 

TO MUTAGENIC METABOLITES BY 

HUMAN CYP1A1, 1A2 AND 3A4. E. C. 

Peck 1 , P. L. Stapleton 1 , A. P. Grollman 2 and D. L. 

Eaton 1 . 1 Environmental and Occupational Health 

Sciences, University of Washington, Seattle, WA and 

2 

Pharmacological Sciences, State University of New 

York at Stony Brook, Stony Brook, NY. 


AROMATASE EXPRESSION AND 

TRANSCRIPTIONAL REGULATION BY 

BENZO(A)PYRENE AND INHIBITOR 

FADROZOLE. W. Dong 1 , L. Wang 1 , C. Thornton 1 , 

B. Scheffler 2 and K. L. Willett 1 . 1 Department of 

Pharmacology and Environmental Toxicology 

Research Program, School of Pharmacy, University 

of Mississippi, University, MS and 2 USDA-ARS- 

CGRU MSA Genomics Laboratory, Stoneville, MS. 


CLONING, EXPRESSION AND PARTIAL 

CHARACTERIZATION OF CYTOCHROME 

P450 3A37 FROM TURKEY LIVER THAT 

OXIDIZES AFLATOXIN B1. S. Rawal and R. A. 

Coulombe. Toxicology Graduate Program, Utah State 

University, Logan, UT. 


TEMPORAL CHANGES IN MOUSE CYP 

mRNA WITH CLASSIC INDUCERS. E. Wang 1 , 

G. Mandakas 1 , J. Palamanda 2 , X. Lin 2 , P. Kumari 2 , I. 

Chu 2 , G. Zairov 1 , R. J. Smith 1 , R. D. Snyder 1 and Y. 

Gu 1 . 1 Toxicology, Schering-Plough, Summit, NJ and 

2 

DMPK, Schering-Plough, Kenilworth, NJ. 


TESTICULAR CYP1B1 REGULATION IN 

MOUSE MA-10 AND RAT R2C LEYDIG 

CELLS. S. M. Bandiera and S. Deb. Faculty of 

Pharmaceutical Sciences, University of British 

Columbia, Vancouver, BC, Canada. 


HUMAN METABOLISM IN VITRO OF 

ATRAZINE AND CHLOROTHALONIL. 

E. Hodgson, H. Joo and K. Choi. Environmental 

and Molecular Toxicology, North Carolina State 



ADRENOCORTICAL TOXICITY 

FOLLOWING CYP11A1 METABOLISM OF 

A KINASE INHIBITOR. O. Flint, J. Lubinski, R. 

Mulvey, D. Zhang, R. Westhouse, A. Bellamine, L. 

Wang, A. Gupta and W. G. Humphreys. Discovery 

Toxicology, Bristol-Myers Squibb, Princeton, NJ. 


METABOLISM OF DI- AND TRI- 

HALOACETIC ACIDS IN RODENTS AND 

HUMANS: ISOFORM SPECIFICITY AND 

IMPACT OF GENETIC POLYMORPHISMS. I. 

Schultz 1 , R. Shangraw 2 and S. Saghir 3 . 1 Battelle PND, 

Sequim, WA, 2 Oregon Health Sciences University, 

Portland, OR and 3 Dow Chemical, Midland, MI. 

156 




Abstract # 


MUTATIONS IN THE PXR GENE AFFECT 

BASAL EXPRESSION AND INDUCIBILITY, 

BUT DO NOT PREVENT THE ABILITY OF 

SULFORAPHANE TO INHIBIT LIGAND 

BINDING TO PXR. E. M. Poulton and D. L. 

Eaton. DEOHS, University of Washington, Seattle, 

WA. 


NONYLPHENOL ACTIVATES THE 

CONSTITUTIVE ANDROSTANE RECEPTOR 

AND CAUSES SEXUALLY DIMORPHIC 

CHANGES IN P450 EXPRESSION. J. P. 

Hernandez 1 , L. M. Mota 2 and W. S. Baldwin 2 . 

1 

Biological Sciences, The University of Texas at El 

Paso, El Paso, TX and 2 Environmental Toxicology, 

Clemson University, Pendleton, SC. 


TETRAMETHOXYSTILBENE (TMS), 

A POTENT CYTOCHROME P450 (CYP) 

1A1/1B1 INHIBITOR, ENHANCED BENZO(A) 

PYRENE (BP)-DNA ADDUCT FORMATION 

IN MCF-7 CELLS. T. L. Einem, R. L. Division , Y. 

Chu and M. C. Poirier. Carcinogen-DNA Interactions 

Section, Laboratory of Cancer Biology and Genetics, 

National Cancer Institute, NIH, Bethesda, MD. 


METABOLISM OF INHALED 

GLUCOCORTICOIDS BY CYTOCHROME 

P450 3A ENZYMES. C. R. Orton and G. S. Yost. 

Pharmacology and Toxicology, University of Utah, 

Salt Lake City, UT. 


MICE LACKING THE GENES FOR 

CYTOCHROME P450 (CYP)1A1 OR 

1A2 DISPLAY INCREASED LEVELS OF 

LIPID PEROXIDATION PRODUCTS 

AND ENHANCED SUSCEPTIBILITY TO 

HYPEROXIC LUNG INJURY IN VIVO. B. 

Moorthy 1 , L. Wang 1 , X. Couroucli 1 , F. M. Khan 2 and 

W. Jiang 1 . 1 Pediatrucs, Baylor College of Medicine, 

Houston, TX and 2 Pathhology, UTMB, Galveston, 

TX. 


CYTOCHROME P4501A1 AND ARSENIC 

IN BENZO(A)PYRENE-INDUCED 

CARCINOGENESIS. K. Burwinkel 1 , D. 

Thompson 1 and G. Mayer 2 . 1 Northern Kentucky 

University, Highland Heights, KY and 2 University of 

Maine, Orono, ME. 


BIOLUMINESCENT ASSAYS FOR IN 

VITRO ADMET STUDIES. J. J. Cali, M. P. 

Valley, M. Sobol, D. Ma and J. Shultz. Research 

and Development, Promega Corp., Madison, WI. 

Sponsor: R. Bulleit. 


FICZ, A SUGGESTED NATURAL AHR 

LIGAND AND A SUPER SUBSTRATE FOR 

HUMAN CYP1 ENZYMES. E. Wincent 1 , A. 

Rannug 2 and U. Rannug 1 . 1 Genetics, Microbiology 

and Toxicology, Stockholm University, Stockholm, 

Sweden and 2 Karolinska Institutet, Institute of 

Environmental Medicine, Stockholm, Sweden. 

Abstract # 


DOCKING STUDIES OF A FAMILY OF 

METHOXYFLAVONES. M. Foroozesh, C. K. 

Stevens and P. Jin. Chemistry, Xavier University of 

Louisiana, New Orleans, LA. Sponsor: N. Hopkins. 


WHOLE ZEBRAFISH CYTOCHROME P450 

MICROPLATE ASSAYS FOR ASSESSING 

DRUG METABOLISM AND DRUG SAFETY. 

C. Li, W. L. Seng and P. McGrath. Phylonix, 

Cambridge, MA. Sponsor: C. Zhang. 


CHARACTERIZATION OF DRUG- 

METABOLIZING ENZYMES (DME) AND 

RECEPTORS IN THE HEPATOMA CELL 

LINES HEPG2 AND H4IIE, AND PRIMARY 

RAT HEPATOCYTES. Y. Fery 1 , S. O. Mueller 2 

and D. Schrenk 1 . 1 food chemistry and toxicology, 

University of Kaiserslautern, Kaiserslautern, 

Germany and 2 Institute of Toxicology, Merck KGaA, 

Darmstadt, Germany. 



(AHR)-DEPENDENT INDUCTION 

OF FLAVIN-CONTAINING 

MONOOXYGENASES. T. Celius 1 , S. Roblin 1,2 , 

P. A. Harper 1,2 , P. C. Boutros 1 , I. D. Moffat 1 , J. 

Matthews 1 , D. Wendelin 3 , R. Pohjanvirta 3,4 and A. 

B. Okey 1 . 1 Pharmacology, University of Toronto, 

Toronto, ON, Canada, 2 The Hospital for Sick 

Children, Toronto, ON, Canada, 3 Department of Food 

and Environmental Hygiene, University of Helsinki, 

Helsinki, Finland and 4 Finnish Food Safety Authority 

EVIRA, Kuopio Research Unit, Kuopio, Finland. 


STRUCTURAL AND FUNCTIONAL 

ANALYSIS OF THE RAINBOW TROUT 

(ONCORHYNCHUS MYKISS) FMO GENE. 

R. Aparicio-Fabre and D. Schlenk. Environmental 

Sciences, University of California Riverside, 

Riverside, CA. 


ANALYSIS OF A PUTATIVE FOXA1 

BINDING SITE IN THE DANIO RERIO 

CYP1A1 PROMOTER/ENHANCER REGION. 

G. ZeRuth and R. S. Pollenz. Cell Biology, 

Microbiology and Molecular Biology, University of 

South Florida, Tampa, FL. 


CHARACTERIZATION OF TCDD-INDUCED 

HISTONE MODIFICATIONS TO STUDY 

THE DIFFERENTIAL REGULATION OF 

THE HUMAN CYP1A1 AND CYP1B1 GENES. 

S. R. Beedanagari, R. T. Taylor and O. Hankinson. 

Molecular Toxicology, UCLA, Los Angeles, CA. 


SUSCEPTIBILITY DIFFERENCES OF THE 

KOREN PEARS (PYRUS PYRIFOLIA VAR.) 

INDUCED ALCOHOL DETOXIFICATION 

IN ALDH2 KNOCKOUT MICE. M. Yang 1 , H. 

Lee 1 , T. Isse 2 and T. Kawamoto 2 . 1 Department of 

Toxicology, SookmyungWomen’s University College 

of Pharmacy, Seoul, South Korea and 2 Department of 

Environemental Health, University of Occupational 

and Environmental Health, Kitakyushu, Japan. 

Tuesday 




Tuesday 



MECHANISMS REGULATING LUNG- 

SELECTIVE BASAL AND INDUCED 

CYTOCHROME P450 2S1 EXPRESSION. 

A. M. Rowland, S. Cutler and G. S. Yost. Pharm/ 

Toxicology University of Utah, Salt Lake City, UT. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: PERSISTENT ORGANIC POLLUTANTS 

(POPS) 

Chairperson(s): Anne Chappelle, Sunoco, Inc., Marcus Hook, PA and 

Janis Hulla, U.S. Army, Corps of Engineers, Sacramento, CA. 




CURRENT LEVELS OF POLYBROMINATED 

DIPHENYL ETHER (PBDE) FLAME 

RETARDANTS IN THE USA: HUMANS, 

FOOD, ENVIRONMENTAL SAMPLES AND 

DAILY INTAKE. A. J. Schecter 1 , T. R. Harris 2 , 

N. C. Shah 1 and O. Paepke 3 . 1 Environmental and 

Occupational Health Sciences, U. Texas School 

of Public Health, Dallas Campus, Dallas, TX, 

2 

Biostatistics, Univ of Texas School of Public Health, 

Dallas, Dallas, TX and 3 Eurofins-ERGO, Hamburg, 

Germany. 


OCTYLPHENOL AND NONYLPHENOL- 

INDUCED APOPTOSIS IN MOTOR 

NEURON IS RELATED TO FAS-FAS 

LIGAND PATHWAY. L. Kyungjin 1,2 and H. 

Jeong 1,2 . 1 Pharmacy, Chosun University, Kwangju, 



Korea. 


TRIBUTYLTIN INDUCED APOPTOSIS IN 

RAT LEYDIG CELL LINE, R2C, THROUGH 

THE FAS/FAS L PATHWAY. K. Lee 1,2 and H. 




Korea. 


O, P’-DDT INDUCE MAST CELL 

DEGRANULATION AND ENHANCE IGE- 

MEDIATED RELEASE OF ALLERGIC 

MEDIATORS. H. Eunhee 1,2 and H. Jeong 1,2 . 

1 

Pharmacy, Chosun University, Kwangju, South 

Korea and 2 Research Center for Proteineous 


Korea. 


STRUCTURE-ACTIVITY RELATIONSHIPS 

FOR PEFLUOROCARBON-MEDIATED 

TRANSCRIPTIONAL RESPONSE IN RAT 

AND HUMAN HEPATOCYTES. J. A. Bjork 1 , 

J. L. Butenhoff 2 , S. Chang 2 and K. B. Wallace 1 . 

1 

Biochemistry & Molecular Biology, University of 

Minnesota, Duluth, MN and 2 Medical Department, 

3M, St. Paul, MN. 


GLUTATHIONE LEVELS MODULATE THE 

NEUROTOXICITY OF POLYBROMINATED 

MIXTURE DE-71 IN MOUSE NEURONS. 

L. G. Costa 1,2 , T. J. Kavanagh 1 and G. Giordano 1 . 

1 


University of Washington, Seattle, WA and 2 Human 

Anatomy, Pharmacology and Forensic Medicine, 

University of Parma Medical School, Parma, Italy. 


LUNG MORPHOLOGY AND 

RESPIRATORY MECHANICS ARE 

SIGNIFICANTLY ALTERED IN RATS 

GESTATIONALLY EXPOSED TO 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN. 

K. M. Kransler, B. P. McGarrigle and J. R. Olson. 

Pharmacology & Toxicology, University at Buffalo, 

The State University of New York, Buffalo, NY. 


XENOBIOTIC GEOMETRY AND MEDIA PH 

DETERMINE CYTOTOXICITY THROUGH 

SOLUBILITY. G. Luthe 1,2,3 , R. Garica 1 , J. 

Jacobus 1,2 , B. J. Smith 1 , A. Rahaman 1 , L. W. 

Robertson 1,2 and G. Ludewig 1,2 . 1 Occupational and 

Environmental Health, University of Iowa, Iowa 

City, IA, 2 Interdisciplinary Graduate Program in 

Human Toxicology, University of Iowa, Iowa City, 

IA and 3 Institute for Inorganic & Physical Chemistry, 

University of Bremen, Bremen, Germany. 


DISPARITY IN THE INDUCTION OF 

OXIDATIVE DNA DAMAGE AND REPAIR 

BY POLYCHLORINATED BIPHENYLS 

(PCBs ) IN HUMAN MCF-7 AND MDA- 

MB-231 BREAST CANCER CELLS. P. Lin, 

C. Lin, C. Huang and M. Chuang. Department of 

Environmental Engineering, National Chung Hsing 

University, Taichung, Taiwan. 


ENHANCED POTENCY OF PBDE 

METABOLITE 6-OH-BDE47 TO AFFECT 

CA 2+ HOMEOSTASIS AND EXOCYTOSIS IN 

PC12 CELLS. M. M. Dingemans 1 , A. de Groot 1 , R. 

G. van Kleef 1 , . Bergman 2 , M. van den Berg 1 , H. P. 

Vijverberg 1 and R. H. Westerink 1 . 1 Institute for Risk 

Assessment Sciences - Toxicology Division, Utrecht 

University, Utrecht, Netherlands and 2 Department of 

Environmental Chemistry - Wallenberg Laboratory, 

Stockholm University, Stockholm, Sweden. 


FREE RADICAL FORMATION 

BY UV IRRADIATION OF DECA- 

BROMODIPHENYL ETHER (DECA-BDE). 

Y. Suh 1 , G. R. Buettner 2 , L. W. Robertson 1 and G. 

Ludewig 1 . 1 Occupational and Environmental Health, 

University of Iowa, Iowa City, IA and 2 Free Radical 

and Radiation Biology & ESR Facility, University of 

Iowa, Iowa City, IA. 


POLYBROMINATED DIPHENYL ETHERS 

(PBDES) IN LEACHATES FROM SELECTED 

LANDFILL SITES IN SOUTH AFRICA. A. 

D. Odusanya 1 , J. O. Okonkwo 1 and B. M. Botha 2 . 

1 

Department of Environmental Science, Water & 

Earth Sciences, Tshwane University of Technology, 

Pretoria, Gauteng, South Africa and 2 Department 

of Chemistry, Tshwane University of Technology, 

Pretoria, Gauteng, South Africa. 

158 




Abstract # 


EFFECTS OF THE BROMINATED 

FLAME RETARDANT HBCD ON CA 2+ 

HOMEOSTASIS IN PC12 CELLS. H. J. 

Heusinkveld 1 , M. M. Dingemans 1 , . Bergman 2 , M. 

van den Berg 1 and R. H. Westerink 1 . 1 Cellular and 

Molecular Toxicology, Institute for Risk Assessment 

Sciences - Utrecht University, Utrecht, Netherlands 

and 2 Department of Environmental Chemistry, 

Wallenberg Laboratory, Stockholm University, 



PERFLUOROOCTANOIC ACID ALTERS 

T LYMPHOCYTE PHENOTYPES AND 

CYTOKINE EXPRESSION IN MICE 

FOLLOWING 21-DAY ORAL EXPOSURE. 

H. Son, S. Lee, H. Lee and S. Kim. Pharmacology, 

Kyungpook National University Medical school, 

Daegu, South Korea. 


IN VITRO HEPATIC METABOLISM OF PBDE 

CONGENERS 99 AND 209 BY CHINOOK 

SALMON. E. P. Browne 1 , S. Tilton 1 , H. Stapleton 2 

and E. Gallagher 1 . 1 Environmental and Occupational 

Health Sciences, University of Washington, Seattle, 

WA and 2 Nicholas School of the Environment and 

Earth Sciences, Duke University, Durham, NC. 


INVESTIGATION OF 4-CHLOROBIPHENYL 

(4-CB) AND ITS PHASE I METABOLITES AS 

SUBSTRATES OF HUMAN RECOMBINANT 

PROSTAGLANDIN H SYNTHASE-2. O. 

Wangpradit 1 , L. Teesch 2 , M. Duffel 1 , K. Norstrom 3 , L. 

Robertson 1 and G. Luthe 1 . 1 Interdisciplinary Graduate 

Program in Human Toxicology, University of Iowa, 

Iowa city, IA, 2 High Resolution Mass Spectrometry 

Facility, University of Iowa, Iowa city, IA and 3 Civil 

and Environmental Engineering, University of Iowa, 

Iowa city, IA. 


RESIDUAL PAHs, PCBs, PCDDs, AND PCDFs 

IN SOIL AND HOUSE DUST FOLLOWING 

AN INDUSTRIAL CHEMICAL RELEASE 

AND FIRE. P. Nony 1,2 , D. W. Gaylor 3 , G. C. 

Millner 1 , A. C. Nye 1 and J. Gandy 1,2 . 1 Center for 

Toxicology and Environmental Health, LLC, North 

Little Rock, AR, 2 Department of Environmental and 

Occupational Health, University of Arkansas for 

Medical Sciences, Little Rock, AR and 3 Gaylor and 

Associates, LLC, Eureka Springs, AR. 


THE EFFECT OF PRENATAL 2, 3, 7, 


EXPOSURE ON CYP1A1, CYP2E1, EGF, 

AND EGFR EXPRESSION IN ADULT AHR 

CONGENIC MICE. C. D. Landon, Y. M. Huet- 

Hudson, N. Steuerwald and L. J. Leamy. Biology, 

University of North Carolina at Charlotte, Charlotte, 

NC. Sponsor: L. Birnbaum. 

Abstract # 


IN VITRO ANTI-ANDROGENICITY 

OF PBDES, HBCD, TBP AND AND 

HYDROXYLATED AND METHOXYLATED 

PBDES BASED ON A YEAST BIOASSAY. 

R. F. Cantón 1 , M. van den Berg 1 , T. Bovee 2 , A. 

Bergman 3 , F. Daamen 1 and M. B. van Duursen 1 . 

1 

Institute for Risk Assessment Sciences (IRAS), 

Utrecht University, Utrecht, Netherlands, 2 RIKILT 

- Institute for Food Safety, Wageningen University 

and Research Center, Wageningen, Netherlands 

and 3 Department of Environmental Chemistry 

and Analytical Chemistry, Stockholm University, 



2, 2’, 3, 3’, 6, 6’-HEXACHLOROBIPHENYL 

(PCB 136) ATROPISOMERS BIND 

ENANTIOSELECTIVELY TO HEPATIC 

MICROSOMAL CYTOCHROME P450 

ENZYMES. H. Lehmler 1 , I. Kania-Korwel 1 , 

E. Hrycay 2 and S. M. Bandiera 2 . 1 1Department 

of Occupational and Environmental Health, 

University of Iowa, Iowa City, IA and 2 Faculty 

of Pharmaceutical Sciences, University of British 



IDENTIFYING A UNIQUE HEPATIC GENE 

EXPRESSION SIGNATURE FOR EXPOSURE 

TO DIOXIN- LIKE COMPOUNDS. C. Ellison 1 , 

B. Ovando 2 , K. Kransler 1 and J. Olson 1 . 1 University 

at Buffalo, Buffalo, NY and 2 Procter & Gamble, 



DIETHYLSTILBESTROL-LIKE EFFECT OF 

METABOLITES OF LOWER CHLORINATED 

BIPHENYLS ON WNT7A GENE 

EXPRESSION IN A HUMAN ENDOMETRIAL 

CELL LINE. L. Lehmann 1 , J. Wagner 1 and L. W. 

Robertson 2 . 1 University of Karlsruhe, Karlsruhe, 

Germany and 2 The University of Iowa, Iowa City, 

IA. 


LOWER CHLORINATED NON-DIOXIN- 

LIKE PCBs ACT AS PARTIAL AGONIST 

ON THE GABA A 

RECEPTOR AND INHIBIT 

AROMATASE ACTIVITY. E. Antunes Fernandes, 

M. B. van Duursen, F. E. Daamen, R. G. van Kleef, 

M. van den Berg and R. H. Westerink. Cellular and 

Molecular Toxicology, Institute for Risk Assessment 

Sciences, Utrecht University, Utrecht, Netherlands. 


INTERACTION OF POTASSIUM 

PERFLUOROALKYL ACID(PFAA) WITH 

MODEL AND CELL MEMBRANES: 

FLUORESCENCE ANISOTROPY STUDY. 

W. Xie 1 , K. Wang 2 , H. Lehmler 1 and G. Ludewig 1 . 

1 

Occupatioanl and Environmental Health, The 

University of Iowa, Iowa City, IA and 2 Biostatistics, 

The University of Iowa, Iowa City, IA. 


CYTOCHROME P450 MEDIATED 

BIOTRANSFORMATION OF 2, 2¢, 4, 

4¢-TETRABROMODIPHENYL ETHER. 

S. M. Bandiera and P. R. Edwards. Faculty of 

Pharmaceutical Sciences, University of British 


Tuesday 




Tuesday 



PARAOXONASE (PON1) ACTIVITY 

IN RATS AFTER EXPOSURE TO 

POLYCHLORINATED BIPHENYLS (PCBs 

). H. Shen 1,2 . 1 Interdisciplinary Graduate Program 

in Human Toxicology, University of Iowa, Iowa 

City, IA and 2 Department of Occupational and 


City, IA. Sponsor: L. Robertson. 


INTERACTIONS OF NON-DIOXIN-LIKE 

2, 2’, 4, 4’, 5, 5’-HEXACHLOROBIPHENYL 

(PCB 153) WITH MEMBRANE-ASSOCIATED 

AND INTRACELLULAR SIGNALING 

PATHWAYS IN LIVER EPITHELIAL CELLS. 

M. Machala 1 , P. Simeckova 1 , V. Paderova 1 , J. 

Slavik 1 , K. Pencikova 1 , J. Neca 1 , L. Umannova 1,2 , 

Z. Andrysik 1 , J. Hofmanova 2 and J. Vondracek 1,2 . 

1 

Veterinary Research Institute, Brno, Czech Republic 

and 2 Institute of Biophysics, Brno, Czech Republic. 


DECACHLOROBIPHENYL (PCB209) LACKS 

ENZYME INDUCTION POTENTIAL, 

GENETIC TOXICITY, AND ENDOCRINE 

ACTIVITY. J. O’Connor 1 , M. Donner 1 , X. Han 1 , 

J. Clarke 2 , D. Nabb 1 , R. Mingoia 1 , S. Snajdr 1 , L. 

Ford 1 and M. Kaplan 1 . 1 Investigative Toxicology, 

DuPont Haskell Global Center for Human Health 

& Environmental Sciences, Newark, DE and 

2 

BioReliance Corporation, Rockville, MD. 


3, 3’, 4, 4’-TETRACHLOROBIPHENYL 

(PCB77) ALTERS DIETARY FATTY 

ACID ACTIVATION OF PEROXISOME 

PROLIFERATOR ACTIVATED RECEPTOR- 

ALPHA (PPARa) AND INDUCTION OF ITS 

RESPONSE GENES IN MOUSE LIVER. X. 

Arzuaga 1 , E. P. Black 2 , A. J. Stromberg 3 , L. A. 

Cassis 5 , M. J. Toborek 4 and B. Hennig 1 . 1 Animal 

Sciences, University of Kentucky, Lexington, KY, 

2 

Pharmaceutical Sciences, University of Kentucky, 

Lexington, KY, 3 Statistics, University of Kentucky, 

Lexington, KY, 4 Neurosurgery, University of 

Kentucky, Lexington, KY and 5 Nutritional Sciences, 

University of Kentucky, Lexington, KY. 


ANALYTICAL METHOD DEVELOPMENT 

FOR THE SIMULTANEOUS EXTRACTION 

AND ANALYSIS OF BISPHENOL A (BPA), 

BIS-GMA, BADGE, BPAHPE, BPADM AND 

TEGDMA IN HUMAN URINE AND SALIVA. 

P. J. Schebler 1 , K. E. Brackman 1 , T. M. O’Neill 1 , L. 

L. Haney 1 , A. P. Clark 1 , R. K. Harris 1 , J. W. Algaier 1 , 

B. Jayaram 2 and C. S. Smith 2 . 1 Product Sciences 

Division, Midwest Research Institute, Kansas City, 

MO and 2 Enviromental Toxicology Program, NIEHS, 

Research Triangle PArk, NC. 


PBDE CONGENERS ARE CAR ACTIVATORS. 

E. Pacyniak 1 , G. Guo 1 , C. Klaassen 1 and K. Kramer 2 . 

1 

Pharmacology, Toxicology & Therapeutics, 


KS and 2 Puracyp, Inc., Carlsbad, CA. 


CONGENER CLASS AND CONGENER- 

SPECIFIC RELATIVE POTENCY VALUES 

FOR DIOXIN AND DIOXIN-LIKE 

CHEMICALS DETERMINED IN NORMAL 

HUMAN EPIDERMAL KERATINOCYTES. 

J. B. Silkworth 1 , C. Sutter 2 and T. R. Sutter 2 . 

1 

Environmental Programs, General Electric, 

Niskayuna, NY and 2 Feinstone Center for Genomic 

Research, University Memphis, Memphis, TN. 


DIVERGENT DISRUPTION OF SEXUALLY 

DIMORPHIC BASAL EXPRESSION OF 

STEROID METABOLISM GENES IN PCB 

AND DIOXIN EXPOSED SPRAGUE-DAWLEY 

RATS. E. A. Carlson 1 , T. R. Sutter 2 , S. Goodwin 2 , C. 

McCulloch 1 , K. Illouz 1 and J. B. Silkworth 1 . 1 Global 

Research, General Electric, Niskayuna, NY and 

2 

Feinstone Center for Genomic Research, University 

Memphis, Memphis, TN. 


MUTAGENICITY OF 

3-METHYLCHOLANTHRENE, 

4-MONOCHLOROBIPHENYL (PCB3), 

AND ITS METABOLITE 4-OH-PCB3 IN 

THE LUNG OF MALE TRANSGENIC 

BIGBLUE ® RATS. C. Maddox 1 , B. Wang 1 , P. A. 

Kirby 3 , K. Wang 2 and G. Ludewig 1 . 1 Department 

of Occupational and Environmental Health, the 

University of Iowa, Iowa City, IA, 2 Department of 

Biostatistics, the University of Iowa, Iowa City, IA 

and 3 Department of Pathology, the University of 

Iowa, Iowa City, IA. 


AGE DEPENDENT CARDIOTOXICITY OF 2, 

3, 7, 8 TETRACHLORODIBENZO-P-DIOXIN 

IN ZEBRAFISH. K. A. Lanham 1 , S. Severson 2 , 

R. E. Peterson 2 and W. Heideman 1,2 . 1 Biomolecular 

Chemistry, UW Madison, Madison, WI and 2 School 

of Pharmacy, UW Madison, Madison, WI. 


CHLORDECONE PRETREATMENT 

PROMOTED UP-REGULATION OF 

SCAVENGER RECEPTOR B2 IN MOUSE 

HEPATIC MICROSOMES. R. C. Scheri 1 , J. Lee 1 , 

D. F. Barofsky 2 and L. R. Curtis 1 . 1 Environmental 

and Molecular Toxicology, Oregon State University, 

Corvallis, OR and 2 Chemistry, Oregon State 

University, Corvallis, OR. 


NOVEL HYDROPHOBICITY RULER 

APPROACH FOR DETERMINING 

THE OCTANOL/WATER PARTITION 

COEFFICIENTS OF VERY HYDROPHOBIC 

COMPOUNDS VIA THEIR POLYMER/ 

SOLVENT SOLUTION DISTRIBUTION 

COEFFICIENTS. X. Q. Kong, D. Shea and X. Xia. 

North Carolina State University, Raleigh, NC. 

160 




Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: LIVER I: IN VIVO 

Chairperson(s): Jeff Waring, Abbott Laboratories, Abbott Park, IL and 

Christine Powell, University of North Carolina Chapel Hill, Chapel Hill, 

NC. 




HEPATIC TRANSPORTER AND DRUG 

METABOLISM ENZYME EXPRESSION IN 

HUMANS WITH NON-ALCOHOLIC FATTY 

LIVER DISEASE. C. D. Fisher, A. J. Lickteig, L. 

M. Augustine and N. J. Cherrington. Department 




ISOFORMS OF ALANINE 

AMINOTRANSFERASES IN HUMAN 

TISSUES AND SERUM. B. Glinghammar 1 , P. 

Thulin 2 , I. Rafter 1 , A. Ulf 1 , P. Lindblom 1 and C. 

Ian 1 . 1 Molecular Toxicology, Safety Assessment, 

Södertälje, Sweden and 2 Atherosclerosis Research 

Unit, Center for Molecular Medicine, Karolinska 

Institutet, Stockholm, Sweden. 


ADAPTIVE REGULATION AFTER 

HEPATOCYTE-SPECIFIC LOSS OF NADPH- 

CYTOCHROME P450 REDUCTASE (CPR) 

IN MICE. X. Cheng 1 , J. Gu 2 and C. D. Klaassen 1 . 

1 

Pharmacology, KUMC, Kansas City, KS and 

2 

Wadsworth Center, Albancy, NY. 


CHARACTERIZATION OF MICE NULL FOR 

LIVER-SPECIFIC UPTAKE TRANSPORTER 

ORGANIC ANION TRANSPORTING 

POLYPEPTIDE 1B2 (OATP1B2). H. Lu 1 , S. 

Choudhuri 2 , K. Ogura 3 , I. Csanaky 1 , P. Song 1 , X. 

Cheng 1 , X. Lei 1 and C. D. Klaassen 1 . 1 University of 

Kansas Medical Center, Kansas City, KS, 2 Food and 

Drug Administration, College Park, MD and 3 Tokyo 

University of Pharmacy and Life Science, Tokyo, 

Japan. 


ROLE OF HEPATIC LIPASE IN ACROLEIN- 

INDUCED DYSLIPIDEMIA IN MICE. O. A. 

Barski, A. Bhatnagar and D. J. Conklin. Inst. Mol. 

Card., University of Louisville, Louisville, KY. 


INDUCTION OF BILE ACID 

TRANSPORTERS AND NUCLEAR 

RECEPTORS BY BILE ACIDS. P. Song 

and C. Klaassen. Pharmacology, toxicology and 

therapeutics, University of Kansas Medical Center, 

Kansas city, KS. 

Abstract # 


GENDER- AND AGE-DEPENDENT HEPATIC 

GENE EXPRESSION DUE TO RXRa 

DEFICIENCY. M. Guo 1 , G. Lei 2 , L. Lehman- 

McKeeman 2 and Y. Wan 1 . 1 Pharmacology, KUMC, 

Kansas City, KS and 2 Bristol-Myers Squibb 

Company, New York. 


ANIT-TREATED FXR-NULL MOUSE 

LIVERS EXHIBIT MORE SINGLE CELL 

DEGENERATION DUE TO IMPAIRED 

INDUCTION OF EFFLUX TRANSPORTERS. 

Y. Cui 1 , L. M. Aleksunes 1 , Y. Tanaka 1 , M. J. Goedken 2 

and C. D. Klaassen 1 . 1 Department of Pharmacology, 

Toxicology and Therapeutics, University of Kansas 

Medical Center, Kansas City, KS and 2 Department 

of Pathology, Schering-Plough Research Institute, 

Lafayette, NJ. 


UPREGULATION OF EARLY GROWTH 

RESPONSE FACTOR-1 BY BILE ACIDS 

REQUIRES EGF RECEPTOR ACTIVATION. 

K. Allen and B. Copple. Pharmacology, Toxicology 

and Therapeutics, University of Kansas Medical 



TIME-COURSE COMPARISON OF 

GENE EXPRESSION SIGNATURES OF 

XENOBIOTIC ACTIVATORS OF CAR AND 

PPARa IN MOUSE LIVER. P. K. Ross 1 , C. G. 

Woods 2,3 , B. U. Bradford 1 , O. Kosyk 1 and I. Rusyn 1 . 

1 

UNC-CH, Chapel Hill, NC, 2 Hamner Institutes 

for Health Sciences, RTP, NC and 3 ExxonMobil 

Biomedical Sciences, Annandale, NJ. 


ACTIVATION OF THE ARYL 

HYDROCARBON RECEPTOR PROMOTES 

HEPATIC LIPOGENESIS. J. Torres 1 , J. Hoon 2 

and W. Xie 2 . 1 Chemistry, University of Puerto Rico at 

Cayey, Cayey, PR and 2 Center for Pharmacogenetics 

and Department of Pharmaceutical Sciences, 

University of Pittsburgh School of Pharmacy, 

Pittsburgh, PA. Sponsor: R. Ross. 


MECHANISMS OF HEPATOPROTECTION 

DURING LCA-INDUCED CHOLESTASIS: 

ROLE OF APOTOTIC SIGNALING. L. 

D. Beilke 1 , A. L. Slitt 2 and N. J. Cherrington 1 . 

1 

Pharmacology/Toxicology, University of Arizona, 

Tucson, AZ and 2 Biomedical and Pharmaceutical 

Sciences, University of Rhode Island, Kingston, RI. 


GENE EXPRESSION PROFILING OF 

XENOBIOTIC METABOLIZING ENZYMES 

(XMES) THROUGH THE LIFE STAGES OF 

THE MALE C57BL/6 MOUSE. J. S. Lee, W. 

Ward, H. Ren, R. Grindstaff, M. George, D. Delker 

and J. C. Corton. NHEERL, U.S. EPA, Durham, NC. 


ONCOTIC NECROSIS AND APOPTOSIS 

MEDIATE LIVER INJURY IN RESPONSE TO 

SUPEROXIDE FORMATION IN VIVO. J. Hong 

and H. W. Jaeschke. Pharmacology, Toxicology & 



Tuesday 




Tuesday 



ROLE OF APOPTOSIS-INDUCING FACTOR 

IN ACETAMINOPHEN-INDUCED LIVER 

CELL NECROSIS. H. W. Jaeschke 1 , M. Lebofsky 1 , 

J. J. Lemasters 2 and M. Bajt 1 . 1 Pharmacology, 

Toxicology & Therapeutics, University of Kansas 

Medical Center, Kansas City, KS and 2 Medical 

University of South Carolina, Charleston, SC. 


ROLE OF TISSUE FACTOR AND 

PROTEASE ACTIVATED RECEPTOR-1 

IN ACETAMINOPHEN-INDUCED 

HEPATOTOXICITY IN MICE. J. P. Luyendyk 1 , 

P. E. Ganey 2 , S. W. Newport 2 , T. M. Eagle 2 , J. F. 

Maddox 2 , N. Mackman 1 and R. A. Roth 2 . 1 Department 

of Immunology, The Scripps Research Institute, La 

Jolla, CA and 2 Department of Pharmacology and 


MI. 


EFFECT OF SAME TREATMENT 

GIVEN AFTER ACETAMINOPHEN 

(APAP) OVERDOSE ON HEPATIC 

TRANSMETHYLATION SUBSTRATES. J. 

Brown and M. Valentovic. Pharmacology, Physiology 

and Toxicology, Marshall University School of 

Medicine, Huntington, WV. 


CAVEOLIN-1 IS REQUIRED FOR HIGH 

MOBILITY GROUP BOX PROTEIN-1 

(HMGB1)-INDUCED MACROPHAGE 

ACTIVATION AND NITRIC OXIDE 

PRODUCTION DURING ACETAMINOPHEN- 

INDUCED HEPATOTOXICITY. A. Dragomir, C. 

R. Gardner, L. B. Joseph and D. L. Laskin. Rutgers 

University, Piscataway, NJ. 


AUTOPROTECTION AGAINST 

ACETAMINOPHEN HEPATOTOXICITY: 

CLUES FROM A GENE EXPRESSION 

PROFILE ANALYSIS. M. A. O’Connor 1 , P. 

Koza-Taylor 2 , L. M. Aleksunes 3 , S. N. Campion 1 , 

M. Lawton 2 and J. E. Manautou 1 . 1 Department of 

Pharmaceutical Sciences, Univeristy of Connecticut, 

Storrs, CT, 2 Pfizer Inc., Groton, CT and 3 Department 

of Pharmacology, Toxicology and Therapeutics, 


KS. 


MECHANISMS OF PROTECTION BY 

SAPONINS DERIVED FROM ROOTS OF 

PLATYCODON GRANDIFLORUM AGAINST 

CARBON TETRACHLORIDE-INDUCED 

LIVER DAMAGE IN MICE. C. H. Jaeho 1 , K. 

Lee 1 , Y. Chung 2 and H. Jeong 1 . 1 Pharmacy, Chosun 

University, Kwangju, South Korea and 2 Division of 

Food Science, Jinju International University, Jinju, 

South Korea. 


METHYL-DONOR ENRICHMENT 

ATTENUATES ALCOHOL-INDUCED LIVER 

INJURY:MECHANISMS OF PROTECTIVE 

ACTION. C. Craig 1 , C. L. Powell 2 , I. Pogribny 3 , 

S. Melnyk 4 , M. Tsuchiya 1 , B. U. Bradford 1 , D. 

W. Threadgill 2 and I. Rusyn 1 . 1 Department of 

Environmental Sciences & Engineering, University 

of North Carolina, Chapel Hill, NC, 2 Department of 

Genetics, University of North Carolina, Chapel Hill, 

NC, 3 Division of Biochemical Toxicology, National 

Center for Toxicological Research, Jefferson, AR and 

4 

Department of Pediatrics, University of Arkansas for 

Medical Sciences, Little Rock, AR. 


PROTECTIVE EFFECTS OF IN 

VIVO S-ADENSOYLMETHIONINE 

ADMINISTRATION ON CHRONIC 

ALCOHOL INDUCED MITOCHONDRIAL 

DYSFUNCTION. A. L. King, S. K. Mantena, H. 

B. Eccleston, K. K. Andringa and S. M. Bailey. 

Environmental Health Sciences, University of 

Alabama at Birmingham, Birmingham, AL. Sponsor: 

T. Kimmel. 


CYTOKINE AND CHEMOKINE 

EXPRESSION ASSOCIATED WITH 

STEATOHEPATITIS AND HEPATOCYTE 

PROLIFERATION IN RATS FED ETHANOL 

VIA TOTAL ENTERAL NUTRITION. M. J. 

Ronis 1 , A. Butura 2 , S. Korourian 1 , K. Shankar 1 , C. 

Jo 1 , P. Simpson 1 , E. Albano 3 , M. Ingelman-Sundberg 2 

and T. M. Badger 1 . 1 Pharmacology & Toxicology, 

UAMS, Little Rock, AR, 2 Karolinska Institute, 

Stockholm, Sweden and 3 Universita de Torino, 

Novara, Italy. 


THE INFLUENCE OF SEX STEROIDS IN 

ALCOHOLIC LIVER INFLAMMATION. R. 

Gallucci, E. Lee and B. Mickle. Pharmaceutical 

Sciences, University of Oklahoma HSC, Oklahoma 

City, OK. 


OSTEOPONTIN –MEDIATED B1 AND B2 

INTEGRIN SIGNALING: A MECHANISM 

FOR HIGHER HEPATIC NEUTROPHIL 

INFILTRATION AND LIVER INJURY IN 

FEMALE ALCOHOLIC LIVER DISEASE. 

A. Banerjee 1,2 and S. K. Ramaiah 1,2 . 1 Toxicology, 

Texas A&M University, College Station, TX and 

2 

Pathobiology, Texas A&M University, College 

Station, TX. 


COEXPOSURE OF MICE 

TO TROVAFLOXACIN AND 

LIPOPOLYSACCHARIDE RESULTS IN A 

UNIQUE GENE EXPRESSION PROFILE 

AND VASCULAR ENDOTHELIAL GROWTH 

FACTOR (VEGF)-DEPENDENT LIVER 

INJURY. R. A. Roth 1 , P. J. Shaw 1 , A. C. Ditewig 2 , 

J. F. Waring 2 , M. J. Liguori 2 , E. A. Blomme 2 , D. 

M. Briscoe 3 and P. E. Ganey 1 . 1 Pharmacology & 


MI, 2 Mol. and Cell. Toxicol., Abbott Laboratories, 

Abbott Park, IL and 3 Children’s Hospital, Harvard 

Medical School, Boston, MA. 

162 




Abstract # 


HEMOSTATIC SYSTEM ACTIVATION 

CONTRIBUTES TO HEPATOTOXICITY IN 

MICE TREATED WITH TROVAFLOXACIN 

AND LIPOPOLYSACCHARIDE. A. M. 

Fullerton, P. J. Shaw, P. E. Ganey and R. A. Roth. 


Center for Integrative Toxicology, Michigan State 



ROLE OF P38 MAPK KINASE IN TNF-a 

PRODUCTION AND LIVER INJURY 

IN HEPATOTOXIC INTERACTION OF 

LIPOPOLYSACCHARIDE AND RANITIDINE. 

X. Deng 1 , J. Lu 1 , L. Lehman-McKeeman 2 , E. Malle 3 , 

P. Ganey 1 and R. Roth 1 . 1 Michigan State University, 

East Lansing, MI, 2 Bristol-Myers Squibb, Princeton, 

NJ and 3 Medical University Graz, Graz, Austria. 


DETERMINANTS OF SENSITIVITY TO 

HALOTHANE-INDUCED HEPATOTOXICITY 

IN MICE. C. M. Dugan 1 , R. A. Roth 2 and P. E. 

Ganey 2 . 1 Cellular and Molecular Biology Program, 


2 

Pharmacology and Toxicology, Michigan State 



POSSIBLE ROLE OF OSTEOPONTIN IN TH1 

IMMUNE RESPONSE AND LYMPHOCYTIC 

INFILTRATION DURING NON-ALCOHOLIC 

STEATOHEPATITIS IN A DIETARY MURINE 

MODEL. N. Banerjee 1 , A. Banerjee 1 , M. Shinohara 2 

and S. K. Ramaiah 1 . 1 Toxicology, Texas A&M 

University, College Station, TX and 2 Harvard 



EFFECTS OF TCDD ON LIVER LIPID 

METABOLISM – MOUSE VERSUS RAT. M. K. 

Makley 1 , M. N. Kent 1 , N. V. Reo 1 , G. L. Jahns 2 , N. J. 

DelRaso 3 , D. Boverhof 4 , L. Burgoon 4 , D. Jump 4 and 

T. Zacharewski 4 . 1 Biochem & Mol Biol, Wright St 

University Dayton, OH, 2 BAE Systems, San Diego, 

CA, 3 AFRL/RHPB, Wright-Patterson AFB, Dayton, 

OH and 4 Biochem & Mol Biol, National Food Safety 

& Toxicol Ctr, Ctr Integrative Toxicol, Michigan St 

University East Lansing, MI. 


DIOXIN ALTERS INFLAMMATORY 

RESPONSES TO LIPOPOLYSACCHARIDE. P. 

E. Ganey, J. T. Olivero and R. A. Robert. Department 

of Pharmacology and Toxicology. Center for 

Integrative Toxicology, Michigan State University, 



THE CONTRIBUTION OF PPAR-ALPHA 

TO HEPATIC RESPONSES IN A MOUSE 

MODEL OF INFLAMMATION-DIOXIN 

INTERACTION. J. T. Olivero, G. Hayley, R. Roth 

and G. E. Patricia. Department of Pharmacology 

and Toxicology. Center for Integrative Toxicology, 


Abstract # 


PERFLUOROOCTANESULFONATE 

CONCENTRATIONS IN ADULT RAT LIVERS 

AFTER FIVE ORAL DOSES – COMPARISON 

BETWEEN LOBES. J. A. Hart 1 , D. J. Ehresman 1 , 

T. N. John 2 , A. T. Eveland 2 , J. D. Zitzow 2 , S. Chang 1 

and J. L. Butehoff 1 . 1 3M Company, St. Paul, MN and 

2 

Pace Analytical Services, Inc., Minneapolis, MN. 


HEPATIC GENE EXPRESSION ANALYSES 

REVEAL ALTERATIONS IN CHOLESTEROL 

METABOLISM IN TR- RATS. L. W. Lecureux, 

D. M. Nelson and L. D. Lehman-McKeeman. 

Discovery Toxicology, Bristol-Myers Squibb, 



HEPATIC ALT 1 & 2 PROTEINS ARE 

DIFFERENTIALLY EXPRESSED 

FOLLOWING DEXAMETHASONE 

TREATMENT IN MICE. W. Reagan 1 , S. Park 2 , R. 

Goldstein 1 , D. Brees 1 , F. Rajamohan 1 , R. Yang 2 and 

D. Gong 2 . 1 Drug Safety Research & Development, 

Pfizer, Groton, CT and 2 Division of Endocrinology, 

Diabetes, and Nutrition, University of Maryland, 

Baltimore, MD. Sponsor: M. Lawton. 


ATYPICAL HEPATOTOXICITY CAUSED BY 

PHOSPHOPHIORATE OLIGONUCLEOTIDE 

ISIS-147420 IS MEDIATED BY AN 

INTERFERON TYPE I RESPONSE. S. Burel, 

T. Machemer, W. Gaarde, G. Hung and S. P. Henry. 

ISIS Pharmaceuticals, Inc, Carlsbad, CA. 


INVESTIGATION OF THE DIFFERENTIAL 

HEPATIC CONCENTRATION OF AN ANTI- 

INFLAMMATORY COMPOUND AND ITS 

ASSOCIATION WITH PHOSPHOLIPIDOSIS 

IN RODENTS. H. Powell 1 , J. Eakins 1 , A. Bigley 1 , 

A. Marsden 1 , J. Bunch 2 , C. McLeod 2 , J. Evans 1 and 

P. A. Duffy 1 . 1 Global Safety Assessment, AstraZeneca 

Pharmaceuticals, Macclesfield, Cheshire, United 

Kingdom and 2 Centre for Analytical Sciences, 

University of Sheffield, Sheffield, South Yorkshire, 



EFFECTS OF SYNTHETIC ANDROGENS 

ON LIVER FUNCTION USING THE RABBIT 

AS A MODEL. S. A. Hild, B. J. Attardi, B. A. Till, 

S. Koduri, J. Engbring and J. R. Reel. Reproductive 

Endocrinology & Toxicology, BIOQUAL, Inc., 



CLINICAL AND HISTOPATHOLOGIC 

EFFECTS OF ORAL FURAN EXPOSURE IN 

FISCHER-344 RATS. S. Gill, M. Kavanagh, G. 

Bondy, D. E. Lefebvre, R. Mehta, S. Aziz, M. Barker, 

E. Vavasour and G. M. Cooke. Bureau of Chemical 

Safety, Health canada, Ottawa, ON, Canada. 


EFFECTS OF ORAL FURAN 

ADMINISTRATION ON LIVER GENE 

EXPRESSION AND PROTEIN EXPRESSION 

IN FISHER-344 RATS. I. Curran, S. Gurofsky, 

V. Liston, A. Nunnikhoven, S. Gill and R. Mehta. 

Health Canada, Ottawa, ON, Canada. 

Tuesday 




Tuesday 



HIGH DIETARY INORGANIC PHOSPHATE 

AFFECTS LIVER DEVELOPMENT 

THROUGH ALTERING PROTEIN 

TRANSLATION, CELL CYCLE, AND 

ANGIOGENESIS IN DEVELOPING MICE. 

C. Xu and M. Cho. Lab of Toxicology, College of 

Veterinary Medicine, Seoul National University, 

Seoul, South Korea. 


GLUTATHIONE DEPLETION FOLLOWING 

INTRAPERITONEAL INJECTION OF 

2-CHLOROACRYLONITRILE. P. E. Malichky, 

J. M. Mostowy, F. W. Fochtman, J. Bricker and D. A. 

Johnson. Mylan School of Pharmacy, Department of 

Pharmacology and Toxicology, Duquesne University, 



9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: MECHANISMS AND CHEMOPREVENTION 

OF PAH AND TOBACCO-RELATED CARCINOGENESIS 

Chairperson(s): Lu Wang, University of Mississippi, University, MS. 




CYTOTOXICITY AND CRM1 

DOWN-REGULATION OF 

4-(METHYLNITRO-SAMINO)-1-(3- 

PYRIDYL)-1-BUTANONE IN HUMAN 

BRONCHIAL EPITHELIAL CELL LINE. L. 

Chen, C. Shao, Q. Tian, L. Tang, J. Wang and W. 

Gao. Texas Tech University, Lubbock, TX. 


DIETARY FAT MODULATION OF BENZO(A) 

PYRENE-INDUCED ADENOMAS IN COLON 

OF APC MIN MICE. D. L. Harris 1 , A. Ramesh 1 , 

M. K. Washington 2 and J. D. Morrow 3 . 1 Cancer 

Biology, Meharry Medical College, Nashville, 

TN, 2 Pathology, Vanderbilt University, Nashville, 

TN and 3 Pharmacology and Division of Clinical 

Pharmacology, Vanderbilt University, Nashville, TN. 


CYP1C1 AND CYP1A EXPRESSION IN PAHs 

INDUCED FUNDULUS LIVER TUMORS. 

L. Wang 1 , W. Dong 1 , C. Thornton 1 , A. M. Hailey 1 , 

A. Camus 2 and K. L. Willett 1 . 1 Pharmacology and 

Environmental Toxicology, University of Mississippi, 

University, MS and 2 Pathology, College of Veterinary 

Medicine, University of Georgia, University, GA. 


EFFECT OF METHYL SUBSTITUTION ON 

TOXIC EVENTS ELICITED BY BENZ[A] 

ANTHRACENE DERIVATIVES IN LIVER 

CELL LINES. J. Topinka 1 , S. Marvanová 2 , J. 

Vondráček 2,3 , K. Pěnčíková 2 , L. Trilecová 2 , P. 

Krčmár 2 , Z. Nováková 1 , A. Milcová 1 and M. 

Machala 2 . 1 Genetic Ecotoxicology, Institute of 

Experimental Medicine ASCR, v.v.i., Prague, Czech 

Republic, 2 Chemistry and Toxicology, Veterinary 

Research Institute, Brno, Czech Republic and 

3 

Cytokinetics, Institute of Biophysics, Brno, Czech 

Republic. Sponsor: H. Autrup. 


CARCINOGENICITY OF 

4-AMINOBIPHENYL IN ARYLAMINE 

N-ACETYLTRANSFERASE NAT1/NAT2 

NULL MICE. D. M. Grant, K. S. Sugamori and 

D. Brenneman. Pharmacology and Toxicology, 



BENZO[A]PYRENE-7, 8-QUINONE FORMS 

COVALENT-DNA ADDUCTS IN VITRO 

BUT NONE WERE DETECTED IN THE 

LUNGS OR LIVERS OF STRAIN A/J MICE 

IN VIVO. S. Nesnow, W. Padgett, G. Nelson, W. 

Winnik, G. Lambert, M. H. George and J. A. Ross. 

Environmental Carcinogenesis Division, U.S. EPA, 

Research Triangle Park, NC. Sponsor: S. Hester. 


CURCUMIN LOWERS THE THRESHOLD 

OF P53 ACTIVATION AND SUBSEQUENT 

INDUCTION OF DNA DAMAGE 

RECOGNITION PROTEINS XPC AND 

DDB2. E. N. Rogers 1 , G. Jiang 1 and J. States 1,2 . 

1 

Pharmacology & Toxicology, University of 

Louisville, Louisville, KY and 2 Ctr Environmental 

Genomics & Integrative Biology, U. Louisville, 



FURAN-2-YL-3-PYRIDIN-2-YL-PROPENONE 

INHIBIT 7, 12-DIMETHYLBENZ[A] 

ANTHRACENE-INDUCED GENOTOXICITY 

IN MCF-7 CELLS. Y. Hwang 1,2 , E. Han 1,2 and H. 




Korea. 


ORAL CANCER CHEMOPREVENTION 

BY LYOPHILIZED STRAWBERRIES IN 

HAMSTER CHEEK POUCHES. B. M. Warner, 

B. C. Casto, T. J. Knobloch and C. M. Weghorst. 

College of Public Health and Comprehensive Cancer 

Ctr, Ohio State University, Columbus, OH. 


INHIBITION OF MMP SECRETION, 

INVASION AND GROWTH OF TONGUE 

CANCER CELL LINE SC-255 BY A 

NUTRIENT MIXTURE. M. Roomi, N. Roomi, 

V. Ivanov, M. Rath and A. Niedzwiecki. Dr. Rath 

Research Institute, Santa Clara, CA. 

164 




Abstract # 


THE EFFECT OF CIGARETTE SMOKE 

AND THE ANTIOXIDANTS RESVERATROL 

AND CURCUMIN ON A TWO-STAGE CELL 

TRANSFORMATION ASSAY. D. M. Breheny 1 , 

T. Tai 1 , Y. Xu 2 and M. Gaca 1 . 1 R&D Centre, British 

American Tobacco, Southampton, United Kingdom 

and 2 Covance Laboratories Inc, Vienna, VA. Sponsor: 

J. Seagrave. 


CHEMOPREVENTION OF MURINE LUNG 

TUMOR PROGRESSION BY SULINDAC. S. 

T. Dance, N. D. Kock, J. E. Moore, R. B. Agostino, 

Jr., L. J. Mosley and M. S. Miller. Wake Forest 

University School of Medicine, Winston-Salem, NC. 


3-METHYLTHIO-PROPIONIC ACID ETHYL 

ESTER ENHANCED DIFFERENTIATION IN 

WELL-DIFFERENTIATED HUMAN COLON 

CANCER CELLS. Y. Nakamura 1 , Y. Nakayama 1 , 

A. Tanaka 2 , T. Matsuo 3 , S. Okamoto 4 , B. L. Upham 5 , 

C. Chang 5 , J. E. Trosko 5 , E. Park 1 and K. Sato 1 . 1 Food 

Science, Kyoto Prefectural University, Kyoto, Japan, 

2 

Vegetable Division, Kyoto Prefectural Agricultural 

Research Institute, Kameoka, Japan, 3 Biochemical 

Science and Technology, Kagoshima University, 

Kagoshima, Japan, 4 Agricultural Science, Kagoshima 

University, Kagoshima, Japan and 5 Pediatrics & 

Human Development, Michigan State University, 



9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: ALTERNATIVES TO MAMMALIAN 

MODELS 

Chairperson(s): Ron Hardman, Duke University, Durham, NC and Judy 

Strickland, Integrated Laboratory Systems, Inc., Research Triangle Park, 

NC. 




MODELING THE EFFECTS OF 

CHLORPYRIFOS ON CAENORHABDITIS 

ELEGANS GROWTH AND DEVELOPMENT. 

W. A. Boyd 1 , M. V. Smith 2 , G. E. Kissling 1 , S. J. 

McBride 3 , J. R. Rice 1 , D. W. Snyder 1 , C. J. Portier 1 

and J. H. Freedman 1,3 . 1 NIEHS, Research Triangle 

Park, NC, 2 Constella Group, Durham, NC and 3 Duke 



TOXICITY OF DOXORUBICIN AND 

ISOPROTERENOL DEPENDS ON THE 

DIFFERENTIATION STAGE OF H9C2 

MYOBLASTS. S. Pereira 1 , V. Sardão 1 , A. Branco 1 , 

J. Holy 2 , C. Oliveira 1 , K. Wallace 2 and P. Oliveira 1 . 

1 

Ctr for Neurosciences and Cell Biology, University 

Coimbra, Coimbra, Portugal and 2 Univ Minnesota, 

Duluth, Duluth, MN. 

Abstract # 


IDENTIFICATION OF HYPOXIA RESPONSE 

INDUCERS USING QUANTITATIVE HIGH- 

THROUGHPUT SCREENING. M. Xia, R. 

Huang, M. Cho, J. Inglese and C. Austin. NIH 

Chemical Genomics Center, Bethesda, MD. Sponsor: 

R. Tice. 


ETHANOL TERATOGENESIS IN JAPANESE 

MEDAKA: EFFECTS AT THE CELLULAR 

LEVEL. A. K. Dasmahapatra 1,2 , M. Wu 2,1 , A. 

Chaudhary 2 and I. A. Khan 1 . 1 National Center for 

Natural Product Research, University of Mississippi, 

University, MS and 2 Department of Pharmacology, 

University of Mississippi, University, MS. 


FROM YEAST TO HUMANS: FUNCTIONAL 

GENOMICS IN THE MODELING OF 

ARSENIC AND HEAVY METAL TOXICITY 

IN YEAST AND ITS RELEVANCE TO 

HUMANS. W. J. Jo 1 , A. Loguinov 1 , X. Ren 2 , M. 

Chang 1 , P. Wong 1 , H. Wintz 1 , L. Zhang 2 , M. T. 

Smith 2 and C. D. Vulpe 1 . 1 Nutritional Sciences and 

Toxicology, University of California Berkeley, 

Berkeley, CA and 2 School of Public Health, 

University of California Berkeley, Berkeley, CA. 


GENOTOXICITY TESTING USING THE 

MICRONUCLEUS ASSAY IN THE HUMAN 

EPIDERM 3D SKIN MODEL. Y. Kaluzhny 1 , 

V. Karetsky 1 , R. Curren 2 , M. Aardema 3 , P. Hayden 1 , 

T. Hu 3 and M. Klausner 1 . 1 MatTek Corporation, 

Ashland, MA, 2 Institute for In Vitro Science, Inc., 

Gaithersburg, MD and 3 Procter & Gamble Co., 



GERM-LINE STEM CELLS-GONOCYTES 

AS AN IN VITRO MODEL FOR MALE 

DEVELOPMENTAL TOXICITY: 

COMPARISON FROM CYTOTOXICITY TO 

GENOMIC RESPONSES TO PHTHALATES. 

X. Yu, S. Hong and E. M. Faustman. Environmental 

Health, IRARC, UW, Seattle, WA. 


INTERLABORATORY VALIDATION OF 

PRECISION CUT LUNG SLICES AS PRE- 

STUDY TEST SYSTEM FOR INHALATION 

STUDIES. S. N. Boehn 1 , K. Sewald 2 , H. G. Kamp 1 , 

A. Braun 2 , B. van Ravenzwaay 1 and R. Landsiedel 1 . 

1 

Experimental Toxicology and Ecology, BASF, 

Ludwigshafen am Rhein, Germany and 2 Fraunhofer 

Institute for Toxicology and Experimental Medicine, 

Hannover, Germany. 


GENE EXPRESSION PROFILING OF THE 

HUMAN MACROPHAGE TRANSCRIPTOME 

IN RESPONSE TO THE RESPIRATORY 

SENSITIZER HEXAMETHYLENE 

DIISOCYANATE. S. Verstraelen 1 , R. Van 

Den Heuvel 1 , J. Hooyberghs 1 , I. Nelissen 1 , H. 

Witters 1 , P. Van Cauwenberge 2 and G. Schoeters 1 . 

1 

Environmental Toxicology, Flemish Institute 

for Technological Research, Mol, Belgium and 

2 

Department of Otorhinolaryngology, Ghent 

University, Ghent, Belgium. Sponsor: R. Pieters. 

Tuesday 




Tuesday 



GLOBAL GENE EXPRESSION ANALYSIS 

OF ORGANOPHOSPHATE INTOXICATION. 

J. A. Lewis 1 , M. Szilagyi 2 , E. Gehman 3 , E. Clegg 1 

and D. A. Jackson 1 . 1 U.S. Army Center for 

Environmental Health Research, Ft. Detrick, MD, 

2 

U.S. Environmental Protection Agency, Washington, 

DC and 3 Battelle National Biodefense Institute, 

Frederick, MD. 


A GENETIC APPROACH TO ARSENIC 

SUSCEPTIBILITY. J. G. Muniz, D. Kane and I. 

Cartwright. Molecular Genetics, Biochemistry and 

Microbiology, University of Cincinnati, Cincinnati, 

OH. Sponsor: M. Genter. 


EPIGENETIC CYTOTOXICITY OF METALS 

ON MOUSE EMBRYONIC STEM CELLS. D. I. 

Gazarian and F. A. Barile. Pharmaceutical Sciences, 

St. John’s University College of Pharmacy, Queens, 

NY. 


DEVELOPMENT OF NORMAL HUMAN 

COLON CELL CULTURES TO IDENTIFY 

UNREGULATED DISINFECTION 

BY-PRODUCTS (DBPS) WITH 

CARCINOGENIC POTENTIAL. C. Jones 1 , S. 

Thai 1 , W. Ward 1 , M. Moyer 2 and A. DeAngelo 1 . 1 U.S. 

EPA, Research Triangle Park, NC and 2 INCELL 

Corporation, San Antonio, TX. 


ICCVAM RECOMMENDATIONS ON 

THE USE OF FIVE IN VITRO PYROGEN 

TEST METHODS FOR ASSESSING 

THE POTENTIAL PYROGENICITY OF 

PHARMACEUTICALS AND OTHER 

PRODUCTS. R. McFarland 1 , M. Wind 2 , J. Kulpa- 

Eddy 3 , R. Tice 4 and W. Stokes 4 . 1 FDA, Washington, 

DC, 2 CPSC, Bethesda, MD, 3 USDA, Riverdale, MD 

and 4 NICEATM, NIEHS/NIH/DHHS, Research 



UTILIZATION OF A RAT 

CARDIOMYOCYTE MODEL TO IDENTIFY 

HEART-SPECIFIC TOXICITY USING 

MULTIPLE ACUTE BIOCHEMICAL 

ENDPOINTS AND GENE EXPRESSION 

MARKERS. P. C. Wilga, D. K. Petrella, S. A. 

Thompson, A. J. Swanson, J. F. Pregenzer, K. L. 

Rutherford-Root, S. B. Ouellette and J. M. McKim. 

CeeTox, Kalamazoo, MI. 


PREDICTING ACUTE ORAL TOXICITY 

(LD50) WITH AN IN VITRO CELL-BASED 

SYSTEM. J. F. Pregenzer, K. L. Rutherford-Root, 

D. K. Petrella, S. B. Ouellette, A. J. Swanson, S. A. 

Thompson, P. C. Wilga and J. M. McKim. CeeTox, 

Kalamazoo, MI. 


EVALUATION OF MORPHOLOGICAL 

CHARACTERISTICS AND NEURONAL 

FUNCTION USING HIGH CONTENT 

ANALYSIS. A. M. Peters, D. M. Miller, G. Lin 

and J. R. Haskins. Integrative Technologies, Thermo 

Fisher Scientific, Pittsburgh, PA. Sponsor: A. 

Barchowsky. 


DRUG METABOLIZING ENZYME 

ACTIVITY IN HUMAN IN VITRO DERMAL 

(EPIDERM) AND AIRWAY (EPIAIRWAY) 

EPITHELIAL MODELS. P. J. Hayden, J. 

Bolmarcich, G. R. Jackson, G. Stolper and M. 

Klausner. MatTek Corp., Ashland, MA. 


WHEN ACCOUNTING FOR 

BIOAVAILABILITY IN VITRO MATTERS. 

N. I. Kramer, B. J. Blaauboer and J. M. Hermens. 

Institute for Risk Assessment Sciences, Utrecht 

University, Utrecht, Netherlands. 


THE TEMPORAL AND DOSE GENOMIC 

RESPONSE OF A HUMAN PROSTATE 

CARCINOMA CELL LINE TO 5 ALPHA- 

DIHYDROTESTOSTERONE. J. M. Naciff, Z. S. 

Khambatta, T. D. Reichling, G. J. Carr, J. P. Tiesman 

and G. P. Daston. Procter & Gamble Company, 



IN VITRO CYTOTOXICITY TEST METHODS 

FOR ESTIMATING RAT ACUTE ORAL 

TOXICITY: PREDICTION OF GHS ACUTE 

ORAL HAZARD CATEGORIES. M. Paris 1,3 , 

J. Strickland 1,3 , S. Casati 2 , R. Tice 3 and W. Stokes 3 . 

1 

NICEATM, ILS, Inc., RTP, NC, 2 ECVAM, Joint 

Research Center, Ispra, Italy and 3 NICEATM, 

NIEHS, RTP, NC. 


AN ALTERNATIVE USE OF IN VITRO 

CYTOTOXICITY TEST DATA TO 

DETERMINE WHEN RAT ACUTE ORAL 

TOXICITY TESTING SHOULD START 

WITH THE LIMIT TEST. J. Strickland 1 , M. 

Paris 1 , D. Allen 1 , R. Tice 2 and W. Stokes 2 . 1 ILS, Inc., 

NICEATM, RTP, NC and 2 NICEATM, NIEHS/NIH/ 

DHHS, RTP, NC. 


COMPARISON OF HUMAN AND RODENT 

3-D LIVER TISSUE CO-CULTURES IN 

ADMET ASSESSMENT OF NEW DRUG 

CANDIDATES. R. D. Applegate, K. Liu, L. New 

and B. A. Naughton. RegeneMed, Inc., San Diego, 

CA. 


NON INVASIVE HIGH RESOLUTION 

IN VIVO IMAGING OF ALPHA- 

NAPTHYLISOTHIOCYANATE (ANIT) 

INDUCED HEPATOBILIARY TOXICITY IN 

STII MEDAKA. R. Hardman, S. Kullman and D. 

E. Hinton. Nicholas School of the Environment and 

Earth Sciences, Duke University, Durham, NC. 

166 




Abstract # 


EFFECT OF SORAFENIB, SUNITINIB, 

IMATINIB AND DASATINIB ON 

MITOCHONDRIAL FUNCTION IN 

ISOLATED RAT LIVER AND HEART 

MITOCHONDRIA AND IN HEPG2 AND 

H9C2 CELLS. J. A. Dykens 3 , S. Nadanaciva 2 , 

J. Jamieson 3 , B. Hirakawa 3 , L. D. Marroquin 3 , 

J. Hynes 4 , B. Jessen 3 , R. Capaldi 2 and Y. Will 1 . 

1 

Exploratory Safety Differentiation, Pfizer Global 

Research & Development, Groton, CT, 2 Mitosciences 

LLC, Eugene, OR, 3 DSRD, Pfizer Global Research 

& Development, San Diego, CA and 4 Luxcel 

Biosciences, Cork, Ireland. 


BIGUANIDE-INDUCED MITOCHONDRIAL 

DYSFUNCTION INCREASES LACTATE 

PRODUCTION AND REDUCES VIABILITY 

OF AEROBICALLY POISED HEPG2 AND 

HUMAN HEPATOCYTES IN CULTURE. 

L. D. Marroquin 2 , J. A. Dykens 2 , S. Nadanaciva 3 , 

J. Jamieson 2 and Y. Will 1 . 1 Exploratory Safety 

Differentiation, Pfizer Global Research & 

Development, Groton, CT, 2 DSRD, Pfizer Research 

& Develoment, San Diego, CA and 3 Mitosciences, 

Eugene, OR. 


ANALYSIS OF MITOCHONDRIAL 

FUNCTION BY MONITORING 

INTRACELLULAR OXYGEN 

CONSUMPTION. T. O’Riordan 2 , J. Hynes 2 , 

D. Papkovsky 2 and Y. Will 1 . 1 Exploratory Safety 

Differentiation, Pfizer Global Research & 

Development, Groton, CT and 2 Luxcel Biosciences, 

Cork, Ireland. 


A NOVEL METHOD FOR IDENTIFYING 

DRUG-INDUCED MTDNA DEPLETION AND 

MTDNA-ENCODED PROTEIN DEPLETION 

IN MITOCHONDRIA. R. Capaldi 2 , S. 

Nadanaciva 2 , J. H. Willis 2 , M. Barker 2 and Y. 

Will 1 . 1 Exploratory Safety Differentiation, Pfizer 

Global Research & Development, Groton, CT and 

2 

Mitosciences LLC, Eugene, OR. 


MITOCHONDRIAL LIABILITIES- 

A POSSIBLE EXPLANATION FOR 

IDIOSYNCRATIC HEPATOTOXICITY 

OBSERVED WITH NEFAZODONE, BUT NOT 

WITH BUSPIRONE AND TRAZODONE. S. 

Nadanaciva 2 , J. A. Dykens 3 , L. D. Marroquin 3 , J. D. 

Jamieson 3 , R. Capaldi 2 and Y. Will 1 . 1 Exploratory 

Safety Differentiation, Pfizer Global Research & 

Development, Groton, CT, 2 MitoSciences, Inc, 

Eugene, OR and 3 DSRD, Pfizer Global Research & 

Development, San Diego, CA. 


EFFECT OF MAINSTREAM CIGARETTE 

SMOKE GAS/VAPOR PHASE AND WET 

TOTAL PARTICULATE MATTER ON THE 

METABOLIC PATHWAYS OF HUMAN 

LUNG EPITHELIAL CELLS: THE 

‘METABOLOMIC’ APPROACH. S. V. Vulimiri 1 , 

M. Misra 1 , J. T. Hamm 1 and A. Berger 2 . 1 A.W. Spears 

Research Center, Lorillard Tobacco Company, 

Greensboro, NC and 2 Metabolon Inc., Durham, NC. 

Abstract # 


CHARACTERIZATION OF A WHOLE 

SMOKE IN VITRO EXPOSURE SYSTEM, 

THE MIMIC SMOKER BURGHART -01 

(MSB-01). M. J. Scian 1 , W. J. McKinney 2 and J. 

S. Edmiston 2 . 1 Philip Morris USA Post-Graduate 

Research Program, Richmond, VA and 2 Philip Morris 

USA, Richmond, VA. 


IMPROVEMENT OF MONKEY (MACACA 

FASCICULARIS) HEMATOPOIETIC 

CLONOGENIC ASSAYS FOR 

TOXICOLOGICAL STUDIES. D. Parent- 

Massin 1 , G. Le Borgne 1 , N. becourt-Lhote 2 , B. 

Jehannin 1 , Y. Sibiril 1 and N. Claude 2 . 1 UFR Sciences 

et techniques, Food Toxicology Laboratory, Brest, 

France and 2 Institut de recherches Internationales, 

Servier, Courbevoie, France. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: REGULATORY RISK ASSESSMENT 

Chairperson(s): Patty Wong-Yim, CAL/EPA, Sacramento, CA and Steven 

Kueberuwa, U.S. EPA, Washington, DC. 




INTEGRATED RISK INFORMATION 

SYSTEM HEALTH ASSESSMENT OF PBDE 

CONGENERS. J. M. Donohue 1 , H. Galal- 

Gorchev 1 and S. J. Jones 2 . 1 Office of Water, U.S. 

EPA, Washington DC, DC and 2 Office of Research 

and Development, U. S. Environmental Protection 

Agency, Washington, DC. 


RECENT DEVELOPMENTS IN THE U.S. 

EPA ’S INTEGRATED RISK INFORMATION 

SYSTEM (IRIS) PROGRAM. A. M. Kadry, K. 

Hammerstrom, J. Strong and J. Vandenberg. Office 

of Research and Development, National Center for 

Environmental Assessment, U.S. Environmental 

Protection Agency, Washington, DC. 


CURRENT CHALLENGES FOR 

CARCINOGEN RISK ASSESSMENT. K. 

Hammerstrom, L. Flowers, K. Hogan, C. Keshava, 

R. Sams, D. Wong, A. M. Kadry and J. Vandenberg. 

Office of Research and Development, National 

Center for Environmental Assessment, U.S. 

Environmental Protection Agency, Washington, DC. 


UNDERSTANDING MODE OF ACTION 

DATA AND UNCERTAINTY IN THE 

CHARACTERIZATION OF CANCER RISK 

ASSOCIATED WITH NAPHTHALENE- 

INDUCED TOXICITY. G. S. Backus 1 , P. 

McClure 2 , C. Keshava 1 and L. Flowers 1 . 1 ORD/ 

NCEA/IRIS, U.S. EPA, Washington, DC and 

2 

Syracuse Research Corporation, Syracuse, NY. 

Tuesday 




Tuesday 



ADDRESSING UNCERTAINTY IN THE 

ESTIMATION OF HUMAN RISKS FROM 

TETRACHLOROETHYLENE EXPOSURE. 

K. A. Hogan, S. Barone, R. C. Brown, W. Chiu, K. 

Z. Guyton, L. Kopylev, S. Makris, R. McGaughy, C. 

Siegel Scott, B. Sonawane, R. Subramaniam and P. 

White. ORD/NCEA, U.S. EPA, Washington, DC. 


A COMPARISON OF ANIMAL AND 

HUMAN DATA USED IN DERIVING A 

CARBON TETRACHLORIDE REFERENCE 

CONCENTRATION. S. Rieth, C. S. Scott and 

G. S. Cooper. National Center for Environmental 

Assessment, U.S. EPA, Washington, DC. Sponsor: 

A. Kadry. 


RATS, MONKEYS, AND HUMANS: 

COMPARING POINTS OF DEPARTURE 

FOR USE IN THE DERIVATION OF A 

REFERENCE CONCENTRATION FOR 

2-HEXANONE. A. S. Persad, T. O. Berner and 

T. Stedeford. National Center for Environmental 

Assessment, Office of Research and Development, 

U.S. Environmental Protection Agency, Washington, 

DC. 


EVALUATION OF TOXICITY 

ASSOCIATED WITH ORAL EXPOSURE 

TO CHLORDECONE: COMPARISON OF 

POINTS OF DEPARTURE FOR USE IN THE 

DERIVATION OF AN ORAL REFERENCE 

DOSE (RFD). K. Newhouse 1 , T. Berner 1 , D. 

Mukerjee 2 and M. Follansbee 3 . 1 IRIS/NCEA/ORD, 

U.S. EPA, Washington, DC, 2 NCEA/ORD, U.S. 

EPA, Cincinnati, OH and 3 Syracuse Research Co., 

Syracuse, NY. 


U.S. EPA INTEGRATED RISK INFORMATION 

SYSTEM (IRIS) REASSESSMENT OF 1, 1, 2, 

2-TETRACHLOROETHANE. G. W. Patton and 

T. Berner. ORD/NCEA/IRIS Program, U.S. EPA, 



U.S. EPA INTEGRATED RISK INFORMATION 

SYSTEM (IRIS) ASSESSMENT OF CERIUM 

OXIDE AND CERIUM COMPOUNDS. M. 

W. Gehlhaus, A. Rooney and J. Strong. U.S. EPA, 



MICROCYSTIN-LR: SUGGESTIVE 

EVIDENCE OF CARCINOGENICITY. B. 

S. Hawkins. National Center for Environmental 

Assessment, U.S. Environmental Protection Agency, 



CONSIDERATION OF THERAPEUTIC AND 

TOXICITY DATA FOR ORAL COBALT 

ASSESSMENT. H. Choudhury 1 , J. C. Lambert 1 and 

J. Klotzback 2 . 1 ORD/NCEA, U.S. EPA, Cincinnati, 

OH and 2 Toxicology, Syracuse Research Corporation, 

Syracuse, NY. 


SCREENING-LEVEL HAZARD 

CHARACTERIZATION OF HIGH 

PRODUCTION VOLUME CHEMICALS. 

M. Sonawane, T. Henry, M. Townsend and O. 

Hernandez. U.S. EPA, Washington, DC. Sponsor: L. 

Scarano. 


DEVELOPMENT OF RISK 

CHARACTERIZATIONS UNDER THE 

U.S. HIGH PRODUCTION VOLUME (HPV) 

CHALLENGE PROGRAM. M. Szilagyi, J. Seed, 

T. Henry, L. Scarano, N. Nguyen, D. Locke, C. 

Fehrenbacher, M. Townsend and O. Hernandez. U.S. 

EPA, Washington, DC. 


DATA FOR THE DEVELOPMENT OF 

DRINKING WATER HEALTH ADVISORY 

FOR N-NITROSODIMETHYLAMINE. S. S. 

Kueberuwa 1 , K. A. Davidson 2 and D. M. Opresko 3 . 

1 

Office of Water, U.S. EPA, Washington, DC, 

2 

SUMMITEC Corporation, Oakridge, TN and 3 Oak 

Ridge National Laboratory, Oakridge, TN. 


PROVISIONAL ADVISORY LEVEL (PAL) 

DEVELOPMENT FOR HCL AND HBR. 

C. Wood 1 , D. Gardner 2 , M. McClanahan 3 , E. 

McConnell 4 , L. Koller 5 and F. Adeshina 6 . 1 Oak Ridge 

Nat Lab, Oak Ridge, TN, 2 Inhalation Toxicology 

Associates, Savannah, GA, 3 Retired; Centers for 

Disease Control and Prevention, Chamblee, GA, 

4 

ToxPath, Inc., Raleigh, NC, 5 Environmental Health 

and Toxicology, Corvallis, OR and 6 U.S. EPA, 



PROVISIONAL ADVISORY LEVELS (PALS) 

FOR RED PHOSPHORUS SMOKE. K. 

Davidson 1 , D. Gardner 2 , C. Weese 3 and F. Adeshina 4 . 

1 

Oak Ridge National Laboratory, Oak Ridge, TN, 

2 

Inhalation Toxicology Associates, Savannah, GA, 

3 

USA CHPPM, Aberdeen Proving Ground, MD and 

4 

U.S. EPA, Washington, DC. 


PROVISIONAL ADVISORY LEVEL 

(PAL) DEVELOPMENT FOR 

PERFLUOROISOBUTYLENE (PFIB). P. 

B. Selby 1 , D. Dorman 2 , E. E. McConnell 3 and 

F. Adeshina 4 . 1 Oak Ridge National Laboratory, 

Oak Ridge, TN, 2 North Carolina State University, 

Raleigh, NC, 3 ToxPath Inc., Raleigh, NC and 4 U.S. 



PROVISIONAL ADVISORY LEVELS 

(PALs) DEVELOPMENT FOR 

POLYTETRAFLUOROETHYLENE (PTFE), 

TETRAFLUOROETHYLENE (TFE), AND 

CARBONYL DIFLUORIDE (COF 2 

). J. L. 

Rayner 1 , F. Adeshina 5 , D. Dorman 2 , G. Henningsen 3 

and P. McGinnis 4 . 1 ORNL, Oak Ridge, TN, 2 NCSU, 

Raleigh, NC, 3 H&H Scientific Services, LLP, 

Evansville, IN, 4 Syracuse Research Corp, Syracuse, 

NY and 5 U.S. EPA, Washington, DC. 

168 




Abstract # 


PROVISIONAL ADVISORY LEVELS (PALS) 

FOR PHOSGENE. D. F. Glass 1 , L. Koller 2 , M. 

McClanahan 3 and F. Adeshina 4 . 1 Oak Ridge National 

Laboratory, Oak Ridge, TN, 2 Environmental Health 

and Toxicology Consultant, Corvallis, OR, 3 Retired: 

Centers for Disease Control and Prevention, 

Chamblee, GA and 4 U.S. EPA, Washington, DC. 


USE OF GENETIC TOXICITY TEST 

BATTERY IN HAZARD IDENTIFICATION 

FOR POTENTIAL CARCINOGENICITY 

OF VETERINARY DRUGS AND FEED 

INGREDIENTS. D. Jagannath 1 and T. Zhou 2 . 

1 

DHHS, FDA/CVM, Rockville, MD and 2 DHHS, 

FDA/CVM, Rockville, MD. 


MINIMAL RISK LEVELS FOR ORGANIC 

ARSENICALS. S. Chou 1 and L. Ingerman 2 . 

1 

Division of Toxicology and Environmental 

Medicine, Agency for Toxic Substances and Disease, 

Atlanta, GA and 2 Syracuse Research Corporation, 

Syracuse, NY. Sponsor: B. Fowler. 


ATSDR’S CHRONIC MINIMAL RISK LEVEL 

(MRL) FOR STYRENE. L. Ingerman 1 , Z. 

Rosemond 2 and S. Chou 2 . 1 Syracuse Research Corp, 

Poughkeepsie, NY and 2 Agency for Toxic Substances 

and Disease Registry, Altanta, GA. Sponsor: P. 

McGinnis. 


INHALATION MINIMAL RISK LEVELS 

(MRLS) FOR ETHYLBENZENE. H. G. Abadin 1 , 

J. B. Taylor 1 and J. M. Klotzbach 2 . 1 Toxicology and 

Environmental Medicine, ATSDR, Atlanta, GA and 

2 

Environmental Science Center, Syracuse Research 

Corporation, Syracuse, NY. 


AIR TOXICS HOT SPOTS PROGRAM 

RISK ASSESSMENT GUIDELINES, PART 

II: TECHNICAL SUPPORT DOCUMENT 

FOR DESCRIBING AVAILABLE CANCER 

POTENCY FACTORS. J. D. Budroe, A. G. Salmon 

and M. A. Marty. Air Toxicology and Epidemiology 

Branch, Office of Environmental Health Hazard 

Assessment (OEHHA), Oakland, CA. 


A REVIEW OF THE ROLE OF PEROXISOME 

PROLIFERATORS AS MEDIATIORS OF 

ENVIRONMENTAL TOXICANTS DURING 

DEVELOPMENT. P. Iyer, J. M. Donald, L. 

Zeise and M. S. Golub. OEHHA, California EPA, 

Sacramento, CA. 


ESTIMATING ACCEPTABLE LEVELS OF 

EXPOSURE TO AIRBORNE SENSORY 

IRRITANTS USING THE RD 50 

. G. V. Alexeeff, 

M. A. Marty and A. Salmon. OEHHA, Cal/EPA, 

Oakland, CA. 

Abstract # 


AN APPROACH FOR TOLUENE CHRONIC 

AND 8-HOUR REFERENCE EXPOSURE 

LEVELS WITH BENCHMARK DOSE 

ANALYSIS FOR COLOR VISION 

IMPAIRMENT AND PBPK MODELS FOR 

ADULT-CHILD VARIABILITY. A. A. Wang, D. 

Dodge and R. Blaisdell. Office of Environmental 

Health Hazards Assessment, California 

Environmental Protection Agency, Sacramento, CA. 


DEVELOPMENT OF A CANCER POTENCY 

FACTOR FOR STYRENE. J. F. Collins, J. P. 

Brown, A. J. Dunn, R. A. Howd and G. V. Alexeeff. 

OEHHA, CalEPA, Oakland, CA. 


SELENIUM - DEVELOPMENT OF A 

HEALTH PROTECTIVE CONCENTRATION 

IN DRINKING WATER. A. M. Fan, Y. Wang 

and R. A. Howd. Office of Environ Health Hazard 

Assessment, Cal/EPA, Oakland, CA. 


CARBOFURAN: TOXICITY PROFILE AND 

NON-DIETARY RISK EVALUATION. A. 

L. Rubin 1 , S. Beauvais 2 and K. Pfeifer 1 . 1 Medical 

Toxicology Branch, Department of Pesticide 

Regulation, Cal-EPA, Sacramento, CA and 2 Worker 

Health & Safety Branch, Department of Pesticide 

Regulation, Cal-EPA, Sacramento, CA. 


HUMAN HEALTH RISK ASSESSMENT 

FOR EXPOSURE TO POLYCHLORINATED 

BIPHENYLS IN CONTAMINATED 

BUILDINGS. P. Wong-Yim, M. Wade, B. Davis, K. 

DiBasio and T. Taras. Toxic Substances Control, Cal/ 

EPA, Sacramento, CA. 


RESIDENTIAL PESTICIDE STUDY: 

EVALUATION OF RESIDUAL 

ORGANOCHLORINE PESTICIDES 

AROUND RESIDENTIAL PROPERTIES IN 

CALIFORNIA. W. Bosan 1 , J. Jones 3 , D. Oudiz 1 , 

R. Morris 2 , J. Hinojosa 1 and S. Fair 1 . 1 Department 

of Toxic Substances Control, California EPA, 

Sacramento, CA, 2 California Air Resources Board, 

California EPA, Sacramento, CA and 3 Camp, Dresser 

& McKee, Los Angeles, CA. 


9:45 AM to 10:45 AM 


Exhibitor Hosted Session: Progress in Ion Channel 

Safety Assessments 

Presented by: ChanTest, Inc. 

Drug-induced ion channel dysfunction results in widespread adverse 

reactions. ChanTest provides toxicity screening, secondary confirmatory 

screening and selectivity profiling using Human Ion Channel Panels ® and 

two automated patch clamp methods, FASTPatch ® and SuperFASTPatch ® . 

The ChanTest platform facilitates mechanistic studies and SARs to aid 

decision-making in drug development. 

Tuesday 




Tuesday 


9:45 AM to 10:45 AM 


Exhibitor Hosted Session: Building a Global 

Standard GLP Preclinical Research Operation in 

China 

Presented by: Charles River Laboratories 

The presentation will cover Charles River Laboratories’ initiative to 

establish a global standard GLP preclinical research operation in China. 

In recent years, China, particularly Shanghai, has experienced tremendous 

growth in the pharmaceutical and biotech industry. Charles Rivers’ objective 

is to support these companies’ research and development needs by 

providing preclinical services. The unique challenges and opportunities of 

operating a GLP preclinical operation in China will be discussed. 


11:00 AM to 12:00 NOON 


TUESDAY AFTERNOON 

Tuesday Afternoon, March 18 

12:00 NOON to 1:15 PM 

Room 3 



Amidst scrambling to attend all of the symposia, poster sessions, and 

social events at the meeting, this will be time for postdocs to kick back and 

relax! All postdoctoral fellows are invited to a casual, fun-filled luncheon 

organized by the Postdoctoral Assembly (PDA). We will announce the first 

recipients of the Best Postdoctoral Publication Awards and acknowledge 

the postdocs who received awards this year from Specialty Sections and 

Regional Chapters. The newly elected PDA Board members for 2008-2009 

will also be introduced and will present a short overview of accomplishments 

and future directions for the PDA. This is a great opportunity for you 

to meet and congratulate your postdoctoral colleagues and check out opportunities 

to volunteer and assume leadership roles within SOT. There will be 

a drawing for prizes. 

Exhibitor Hosted Session: The Future of 

Telemetry 

Presented by: Data Integrated Scientific Systems (D.I.S.S.) 

Welcome to the future! A look at the newest products and options for the 

highest quality telemetry systems available. Come hear about systems that 

can accommodate both implanted and non-invasive telemetry, alarm notification, 

networking, remote control, database organization, new sensors 

and more 


11:00 AM to 12:00 NOON 


Exhibitor Hosted Session: Key Contemporary 

Concepts in Neurotoxicity Screens 

Presented by: NeuroScience Associates (NSA) 

The most fundamental objective in a neurotoxicity assessment is to assess 

for potential cell death (neurodegeneration) which is an excellent, but 

elusive indicator of neurotoxicity. This session will focus on the proper 

application of contemporary assessment principles (sacrifice schedules and 

sampling) that can efficiently expose neurodegeneration, enabling accurate 

safety screens. 


12:00 NOON to 1:30 PM 


Specialty Sections meetings/Luncheons: In Vitro 

and Alternative Methods, Occupational and 

Public Health 


12:00 NOON to 2:00 PM 

Sheraton 

Cedar Room 

Regional Chapter meeting/luncheon: Central 

States 

170 





12:00 NOON to 1:20 PM 

Ballroom 6E 


12:15 PM to 1:15 PM 


Town Hall Meeting: SOT Strategic Plan—Defining 

the Future of SOT 

Chairperson(s): George B. Corcoran, Wayne State University, Detroit, 

MI and Kenneth S. Ramos, University of Louisville, Louisville, KY 

The future of toxicology is being debated on multiple fronts. As such, 

it is imperative for the Society to assess the needs and responsibilities 

of the membership in leading the evolution of the science and practice 

of toxicology. In 2005, Council determined that an in-depth review of 

our direction and organizational structure was warranted and that such 

an assessment should include broad representation of the membership. 

Between the summer of 2005 and January 2006, three strategy committees 

were established to advise Council on future directions in three major areas 

of Society activities and interests: Science, Communications, and Membership. 

These groups conducted strategy sessions and carefully reviewed the 

work of past groups including, the Liaison Task Force, the Recruitment 

and Retention Task Force, and the Communications Committee. The final 

reports of the three Strategy Committees were received by Council in April 

2007, following member input on-line, at the 2007 Town Hall Meeting, and 

via correspondence. During the spring, summer and fall of 2007, over four 

2-day meetings, Council consolidated strategy reports and member input 

and developed steps for implementation of a 3-year plan. In addition, areas 

of diverse opinion have been identified and slated for additional member 

input. The consolidated Council Strategic Plan, which has been posted on 

the SOT web site for comment, will be presented at the 2008 Town Hall 

Meeting. Join members of Council for the official roll-out of the plan to 

learn what to expect from SOT in 2008–2009 and to share your thoughts on 

how toxicologists can work together toward creating a safer and healthier 

world by advancing the science of toxicology. 

Gathering Information and Putting the Plan to Paper, George 

Corcoran, Wayne State University, Detroit, MI 

From Plan to Reality: What to Expect in 2008–2009, Kenneth Ramos, 

University of Louisville, Louisville, KY 


12:15 PM to 1:15 PM 


Exhibitor Hosted Session: Affymetrix is 

Accelerating Toxicology Decisions 

Presented by: Affymetrix 

Affymetrix GeneChip ® products provide a complete Toxicogenomics 

solution to help researchers reduce pharmaceutical candidate attrition and 

discover new biomarkers predictive of toxic outcomes. 

This seminar will highlight whole product solutions that enable faster and 

more informed development decisions. In this session, you will learn how 

to use gene expression data to identify mechanisms of toxicity. You will 

also learn how to accelerate Toxicogenomics analysis to provide timely 

answers. 

Exhibitor Hosted Session: Cell Based Assays as an 

Alternative to Animal Testing? 

Presented by: Thermo Fisher Scientific 

The session will explore the debate relating to cell based assays and the 

study of toxicity pathways as an alternative to animal testing. Using a 

series of case studies using High Content Analysis, in toxicology profiling, 

predictive toxicology and genotoxicity, we will provide evidence to sway 

the debate in favor of in vitro cell based assays. 


12:30 PM–1:20 PM 

Ballroom 6B 


Award Lecture: Half a Century of 

Progress in Neurotoxicology: Past, 

Present, and Future 

Lecturer: Toshio Narahashi, Northwestern 

University Feinberg School of Medicine, Chicago, 

IL. 

Progress in neurotoxicology has come a long way. 

This presentation highlights the progress in our laboratories during 59 

years of my scientific careers. Studies of the mechanism of action of 

insecticides began flourishing in 1950s when many synthetic insecticides 

were developed. Our study in 1952 showed that DDT prolonged the depolarizing 

after-potential of the nerve, suggesting the sodium channel as a 

target site. This discovery eventually led to voltage clamp studies of DDT 

and pyrethroids demonstrating the prolonged openings of sodium channels 

being responsible for their toxic action (1967~). Only 1% of sodium channels 

needs to be modified by pyrethroids to cause hyperactivity of animals 

(1994–96). DDT and pyrethroids are unique in that they are more potent in 

killing insects and in modulating the nervous system at low temperatures 

than at higher temperatures (1954), and the mechanism lies in the temperature 

dependence of sodium channel prolongation (1996). Glutamate-gated 

chloride channels, which are present in insects but not in mammals, are a 

decisive factor in the selective toxicity of fipronil in insects over mammals 

(2003-05). We previously demonstrated that the reduced sensitivity of 

the nerve to insecticides played a significant role in the resistance of 

insects to insecticides (1958-65). This discovery led to the concept of kdr 

strains of insects, and eventually to the molecular identification of sodium 

channel mutations in pyrethroid resistance by many investigators. Another 

important development occurred in 1960 and 1964 when we discovered 

the selective and potent sodium channel blocking action of the pufferfish 

toxin, tetrodotoxin (TTX). This discovery caused explosive uses by many 

of TTX and other toxins/chemicals as tools for the studies of ion channels, 

a concept that was almost inconceivable before that time. It eventually led 

to the development of neuroreceptor/channel-based mechanistic studies 

of a wide variety of chemicals including neuroactive therapeutic drugs 

and environmental toxicants (1974). This field now represents one of the 

most important and popular research subjects in biomedical and toxicological 

sciences. For example, our recent studies of Alzheimer’s drugs 

have shown that they stimulate not only the cholinergic system but also 

the NMDA system, both of which are known to be down-regulated in the 

brain of Alzheimer’s disease patients (2001-07). Neurotoxicology is now 

progressing toward the molecular mechanisms of drug action. The role of 

environmental toxicants in causing certain neurodegenerative disorders is 

receiving much attention these days. 

Tuesday 




Tuesday 



1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: PHARMACOKINETICS AND DISPOSITION 

Chairperson(s): Sophia Fang, University of Rochester, Rochester, NY and 

Stephen Godin, University of North Carolina Chapel Hill, Chapel Hill, 

NC. 




FEXOFENADINE AS A PROBE DRUG 

FOR TRANSPORTER ACTIVITY: 

DEVELOPMENT AND VALIDATION OF 

AN HPLC-MS/MS METHOD. C. A. Flynn, Y. 

Alnouti, B. Hagenbuch and G. Reed. Pharmacology, 

Toxicology, and Therapeutics, University of Kansas 

Medical Center, Kansas City, KS. 


DETERMINANTS OF TRAFFICKING 

AND FUNCTIONAL ACTIVITY OF THE 

HETEROMERIC ORGANIC SOLUTE 

TRANSPORTER, OSTa-OSTb N. Li and N. 

Ballatori. Environmental Medicine, University of 

Rochester School of Medicine, Rochester, NY. 


ABSORPTION AND DISTRIBUTION OF 

51 

CHROMIUM(VI) AND 51 CHROMIUM(III) 

IN MALE RATS AND MICE. K. J. Dix, Z. 

Gao, H. B. Hoffman, K. M. Pacheco and L. C. 

Ferguson. Lovelace Respiratory Research Institute, 



TOXICITY AND TISSUE DISTRIBUTION 

OF TITANIUM DIOXIDE (TIO2) 

NANOPARTICLES IN SUBCUTANEOUSLY 

AND INTRAVENOUSLY INJECTED MICE 

OVER 6 MONTHS. T. Umbreit 1 , P. L. Goering 1 , 

T. J. Miller 2 , J. L. Weaver 2 , S. Francke-Carroll 3 , N. 

Sadrieh 2 , J. Kauffman 5 , J. Guthrie 4 , J. Robertson 4 

and M. E. Stratmeyer 1 . 1 CDRH/OSEL, FDA, Silver 

Spring, MD, 2 CDER/DAPR, FDA, Silver Spring, 

MD, 3 CFSAN/OCD, FDA, College Park, MD, 4 Univ 

of Missouri, Columbia, MO and 5 CDER/DPA, FDA, 

St. Louis, MO. 


CHARACTERIZATION OF PRESYSTEMIC 

ELIMINATION OF TRICHLOROETHYLENE 

(TCE) IN RATS FOLLOWING 

ENVIRONMENTALLY-RELEVANT 

EXPOSURES. Y. Liu 1 , M. G. Bartlett 1 , C. A. 

White 1 , S. Muralidhara 1 , J. V. Bruckner 1 and J. 

W. Fisher 2 . 1 Department of Pharmaceutical & 


GA and 2 Interdisciplinary Program in Toxicology, 

University of Georgia, Athens, GA. 


INHALATION KINETICS OF JET FUEL 

COMPONENTS IN THE RAT. S. A. Martin 1,2 , 

K. Flynt 2 , C. Kendrick 2 , R. T. Tremblay 1,2 and J. W. 

Fisher 1,2 . 1 Interdisciplinary Toxicology Program, 

University of Georgia, Athens, GA and 2 Department 

of Environmental Health Science, University of 



THE EFFECT OF ANAESTHETICS 

AND DOSE FORMULATIONS ON THE 

PRODUCTION OF TOXICOKINETIC DATA. 

G. T. Smith, R. R. Brodie, I. A. Crawford, T. A. 

Bates and R. M. Major. Bioanalysis, Huntingdon 

Life Sciences, Huntingdon, Cambridgeshire, United 

Kingdom. Sponsor: E. Moore. 


PHARMACOKINETIC MODEL OF 

CARISOPRODOL AND MEPROBAMATE 

METABOLISM IN HUMANS. T. A. 

Lewandowski 1,2 . 1 Gradient Corporation, Seattle, 

WA and 2 Health and Nutrition Sciences, Brooklyn 

College, CUNY, New York. 


PHARMACOKINETIC EVALUATION 

OF EXPOSURE TO ECOLOGICALLY 

RELEVANT CONCENTRATIONS OF 2, 

3, 7, 8-TCDF AND 2, 3, 4, 7, 8-PECDF IN 

MINK (MUSTELA VISON). L. L. Aylward 1 , 

M. Zwiernik 2 , S. Bursian 2 , D. Kay 3 , J. Moore 2 , J. 

Rowlands 5 , K. Woodburn 5 , J. Khim 4 , J. Giesy 4 and R. 

Budinsky 5 . 1 Summit Toxicology, LLP, Falls Church, 

VA, 2 Michigan State University, East Lansing, 

MI, 3 ENTRIX, Inc., Okemos, MI, 4 University of 

Saskatchewan, Saskatoon, SK, Canada and 5 The 

Dow Chemical Company, Midland, MI. 


DOSE-DEPENDENT DISTRIBUTION AND 

ELIMINATION OF CIS- AND TRANS- 

PERMETHRIN IN THE RAT. E. J. Scollon 1 , J. 

M. Starr 2 , M. F. Hughes 1 , R. Tornero-Velez 2 , H. M. 

Wheeler 3 , D. G. Ross 2 and M. J. DeVito 1 . 1 ORD/ 

NHEERL, U.S. EPA, Research Triangle Park, NC, 

2 

ORD/NERL, U.S. EPA, Research Triangle Park, NC 

and 3 SSC, Raleigh, NC. 


ALTERATION OF PERMETHRIN 

PHARMACOKINETICS FOLLOWING 

A SINGLE DERMAL DOSE OF DEET (N, 

N-DIETHYL-M-TOLUAMIDE), ALONE OR 

IN COMBINATION WITH AN ORAL DOSE 

OF PYRIDOSTIGMINE BROMIDE (PB) IN 

MALE RATS. A. W. Abu-Qare 2 , M. B. Abou-Donia 1 

and A. A. Abdel-Rahman 1 . 1 Pharmacology and 

Cancer Biology, Duke University Medical Center, 

Durham, NC and 2 Bioanalytical R&D, Drug Safety 

and Metabolism, Wyeth Research, Pearl River, NY. 


IN VIVO DERMAL ABSORPTION OF 

PYRETHROIDS IN THE RAT. M. F. Hughes and 

B. C. Edwards. ORD/NHEERL, U.S. EPA, Research 



ONTOGENY OF METABOLISM OF 

VOLATILE ORGANIC COMPOUNDS (VOCS) 

IN SPRAGUE-DAWLEY (S-D) RATS. B. T. 

McPhail 1 , S. Muralidhara 1 , J. D. Wilson 2 , C. A. 

White 1 and J. V. Bruckner 1 . 1 PBS / Interdisciplinary 

Toxicology, University of Georgia, Athens, GA 

and 2 Division of Toxicology, Agency for Toxic 

Substances and Disease Registry, Atlanta, GA. 

172 




Abstract # 


SODIUM PERFLUOROHEXANOATE 

PHARMACOKINETICS IN RATS DURING 

AND AFTER 90-DAY ORAL GAVAGE 

ADMINISTRATION. M. W. Himmelstein 1 , B. 

P. Slezak 1 , R. C. Buck 1 , S. H. Korzeniowski 1 and 

E. Decker 2 . 1 E.I. DuPont de Nemours & Co. Inc., 

Wilmington, DE and 2 MPI Research, State College, 

PA. 


8-2 FLUOROTELOMER ALCOHOL: LIVER 

GLUTATHIONE STATUS, METABOLITE 

KINETICS IN TISSUES, AND EXCRETION 

AND METABOLISM WITH DAILY ORAL 

DOSING. W. Fasano 1 , M. P. Mawn 1 , D. L. Nabb 1 , X. 

Han 1 , B. Szostek 1 and M. L. Gargas 2 . 1 Investigative 

Sciences, DuPont-Haskell, Newark, DE and 2 The 

Sapphire Group, Inc., Beavercreek, OH. 


EVALUATION OF BIOPERSISTENCE 

POTENTIAL AMONG CLASSES OF 

POLYFLUORINATED CHEMICALS USING A 

MAMMALIAN SCREENING METHOD. T. L. 

Serex, M. W. Himmelstein, C. Carpenter, R. C. Buck 

and S. H. Korzeniowski. E.I. DuPont de Nemours & 

Co. Inc., Wilmington, DE. 


EFFECT OF LOW TO MODERATE DOSES 

OF ETHYL ALCOHOL ON REACTION 

TIMES. F. B. Swann, D. H. Petroni and W. J. 

George. Division of Toxicology, Tulane University 

School of Medicine, New Orleans, LA. 


DISPOSITION OF DICLOFENAC AND ITS 

METABOLITES IN WILD-TYPE AND MRP3- 

NULL MICE. R. J. Scialis 1,2 , J. E. Manautou 1 , L. 

M. Aleksunes 3 , I. L. Csanaky 3 and C. D. Klaassen 3 . 

1 

University of Connecticut, Storrs, CT, 2 Pfizer Global 

Research and Development, Pfizer Inc., Groton, CT 

and 3 University of Kansas Medical Center, Kansas 

City, KS. 


STEREOSELECTIVITY IN DISPOSITION OF 

BROMOCHLOROACETIC ACID (BCA) IN 

FISCHER 344 RATS AND B6C3F1 MICE. S. 

Hong 1 , J. D. Johnson 1 , S. Graves 1 , V. Godfrey 2 and 

C. Smith 2 . 1 Battelle Memorial Institute, Columbus, 

OH and 2 NIEHS, NIH, Research Triangle Park, NC. 


SINGLE ADMINISTRATION GAVAGE 

TOXICOKINETIC STUDY OF 2 

METHYLTETRAHYDROFURAN (MTHF) IN 

FISCHER 344/N RATS AND B6C3F1 MICE. J. 

D. Johnson 1 , S. P. Hong 1 , B. Harritos 1 , S. Graves 1 , V. 

Godfrey 2 and C. Smith 2 . 1 Battelle, Columbus, OH and 

2 

NIEHS, NIH, Research Triangle Park, NC. 


APPROACHES FOR SETTING AN 

ANALYTICAL ASSAY LLOQ IN PRE- 

CLINICAL TOXICOKINETIC STUDIES. D. 

M. Grant, J. Gremminger, M. Miller, J. Margolis 

and L. Kendall. Pharmacokinetics, Dynamics and 

Metabolism, Pfizer Inc, Groton, CT. 

Abstract # 


ABSORPTION, DISPOSITION, AND 

ELIMINATION OF 1-BUTYL-3- 

METHYLPYRROLIDINIUM CHLORIDE 

(BMPY-CL) FOLLOWING IV, ORAL OR 

DERMAL ADMINISTRATION IN MALE 

F-344 RATS. G. A. Knudsen, R. K. Kuester and I. G. 

Sipes. University of Arizona, Tucson, AZ. 


BIODISTRIBUTION OF 3 H-PIGMENT 

YELLOW 74, A TATTOO INK PIGMENT, 

FOLLOWING INTRADERMAL 

ADMINISTRATION IN MICE TO MIMIC 

TATTOOING. L. H. Couch, N. V. Gopee and P. C. 

Howard. Biochemical Toxicology, National Center 

for Toxicological Research, U.S. FDA, Jefferson, 

AR. 


USE OF A PHYSIOLOGICALLY-BASED 

PHARMACOKINETICS (PBPK) MODEL TO 

PREDICT INTERNAL DOSIMETRY OF ZINC 

PYRITHIONE (ZPT) IN RATS AND HUMANS. 

G. L. Diamond 1 and J. F. Nash 2 . 1 Syracuse Research 

Corporation, Syracuse, NY and 2 Procter & Gamble 

Co., Cincinnati, OH. 


PHYSIOLOGICALLY BASED 

PHARMACOKINETIC MODEL 

DEVELOPMENT AND SIMULATIONS 

FOR ETHYLENE DICHLORIDE (1, 

2-DICHLOROETHANE) IN RATS. M. 

Gargas and L. Sweeney. The Sapphire Group, Inc., 

Beavercreek, OH. 


ABSORPTION, DISTRIBUTION, 

METABOLISM AND EXCRETION 

OF INTRAVENOUSLY AND ORALLY 

ADMINISTERED BIS-2-(BROMOMETHYL) 

PROPANE-1, 3-DIOL IN MALE FISCHER-344 

RATS. S. I. Hoehle, G. A. Knudsen, L. M. Jacobs, R. 

K. Kuester and I. Sipes. Pharmacology, University of 



STUDY OF THE AGGREGATE EFFECTS OF 

INGESTION, INHALATION AND DERMAL 

EXPOSURE TO THE INTERNAL DOSE OF 

TOLUENE IN RATS. M. Gagné, G. Charest- 

Tardif, K. Krishnan and R. Tardif. GRIS - Santé 

environnementale et santé au travail, Université de 

Montréal, Montréal, QC, Canada. 


PHARMACOKINETICS OF BIS- 

METHYLSALICYLATE CARBONATE 

(BMSC) AND ITS HYDROLYSIS TO 

METHYLSALICYLATE (MS) AND 

SALICYLIC ACID (SA) AFTER A SINGLE 

ORAL (GAVAGE) DOSE TO RATS. D. I. 

Draganov 1 , T. L. Johnson 1 , S. S. Dimond 2 and J. Van 

Miller 3 . 1 Metabolism, WIL Research Laboratories, 

LLC, Ashland, OH, 2 GE Plastics, Pittsfield, MD and 

3 

TRS, Charlottesville, VA. 

Tuesday 




Tuesday 



SINGLE INTRAVENOUS ADMINISTRATION 

TOXICOKINETIC STUDY (TKS) OF 

GLYOXYLIC ACID MONOHYDRATE (GXA) 

USING MALE AND FEMALE FISCHER 

344 RATS. S. Graves 1 , J. Merrill 1 , S. P. Hong 1 , 

B. Burback 1 , J. D. Johnson 1 , V. Godfrey 2 and C. 

Smith 2 . 1 Battelle, Columbus, OH and 2 NIEHS, NIH, 



EFFECT OF DRINKING WATER PRE- 

CONDITIONING ON TOXICOKINETICS OF 

BROMOCHLOROACETIC ACID (BCA) IN 

FISCHER 344 RATS AND B6C3F1 MICE. V. 

Godfrey 2 , S. Hong 1 , J. D. Johnson 1 , S. Graves 1 and 

C. Smith 2 . 1 Battelle Memorial Institute, Columbus, 

OH and 2 NIEHS, NIH, Research Triangle Park, NC. 


HUMAN GLUTATHIONE S-TRANSFERASE 

OMEGA IS INHIBITED BY TOCOPHEROL 

ESTERS. A. Sampayo-Reyes 1 , A. Hernandez 3 and 

R. A. Zakharyan 2 . 1 Toxicology and Pharmacology, 

Centro de Investigaciones Biomedicas, Monterrey, 

Nuevo León, Nuevo León, Mexico, 2 Department of 

Molecular and Cellular Biology,, The University of 

Arizona, Tucson, AZ, AZ and 3 Grup de Mutagènesi, 

Departament de Genética i de Microbiología, 

Universitat Autónoma de Barcelona., Barcelona, 

Spain. 


KINETICS FOR ETHYLENE DICHLORIDE 

(EDC) AND ITS EFFECTS ON LIVER, 

KIDNEY AND LUNG GLUTATHIONE (GSH) 

IN RATS FOLLOWING INHALATION OR 

ORAL ADMINISTRATION. S. A. Saghir, A. J. 

Clark, M. M. Goeddeke, M. S. Carr, S. M. Krieger 

and D. L. Rick. The Dow Chemical Company, 

Midland, MI. 


IN VITRO METABOLISM OF 

NIMESULIDE: INVESTIGATION OF ITS 

HEPATOTOXICITY. F. Li, M. Chordia and T. 

Macdonald. Chemistry, University of Virginia, 

Charlottesville, VA. Sponsor: C. Holstege. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: REGULATION/POLICY 

Chairperson(s): Petra Begemann, ENVIRON, Arlington, VA. 




EVALUATION AND ACCREDITATION OF 

INTERNATIONAL ANIMAL CARE AND 

USE PROGRAMS. J. Swearengen. AAALAC 

International, Frederick, MD. Sponsor: L. Koller. 


THE USE OF “CLEAN” FUELS TO 

IMPROVE AIR QUALITY. T. W. Hesterberg 1 , C. 

A. Lapin 2 and W. B. Bunn 1 . 1 International Truck and 

Engine Corporation, Warrenville, IL and 2 Lapin and 

Associates, Glendale, CA. 


THE APPROPRIATENESS OF THE USE OF 

THERAPEUTIC DRUGS ON REGULATORY 

TOXICOLOGY STUDIES AND ETHICAL 

CONSIDERATIONS. W. Ruddock, B. G. 

Procter and O. Jumanca. General Toxicology, ITR 

Laboratories Canada Inc., Baie d”Urfé, QC, Canada. 


MANGANESE AND THE DEVELOPMENT 

OF REFERENCE EXPOSURE LEVELS 

TO PROTECT AGAINST 8-HOUR AND 

CHRONIC EXPOSURES. B. Winder 1 , D. Morry 2 , 

A. Salmon 2 and M. Marty 2 . 1 OEHHA, CalEPA, 

Sacramento, CA and 2 OEHHA, Cal/EPA, Oakland, 

CA. 


THE DEVELOPMENT OF REFERENCE 

EXPOSURE LEVELS TO PROTECT 

AGAINST ACUTE, 8-HOUR AND CHRONIC 

EXPOSURES TO ACROLEIN. A. Salmon 1 , 

B. Winder 2 , J. Brown 1 and M. Marty 1 . 1 OEHHA, 

CalEPA, Oakland, CA and 2 OEHHA, Cal/EPA, 



IMPLEMENTING THE CALIFORNIA SAFE 

COSMETICS ACT OF 2005. M. J. DiBartolomeis, 

A. Ritieni, A. Le and B. Materna. DEODC, CA 

Department of Public Health, Richmond, CA. 

Sponsor: G. Alexeeff. 


CHEMICALS RISK ASSESSMENT 

UNDER THE NEW EUROPEAN REACH 

REGULATION. T. Petry and F. R. Tencalla. 

ToxMinds BVBA, Hoeilaart, Belgium. 


INTEGRATION OF LIFE-STAGE AND 

EXPOSURE DURATION ASSESSMENTS 

INTO DERIVATION OF STANDARDS. H. 

Goeden, P. Moyer and C. Greene. Minnesota 

Department of Health, St. Paul, MN. 


TOXICOLOGY CONSIDERATIONS FOR 

PRECLINICAL DEVELOPMENT OF 

ANTICANCER DRUGS. P. Colombo, M. Cattoni, 

R. Pulci and M. Brughera. Accelera, Preclinical 

Development, Nerviano Medical Sciences, Nerviano, 

Milano, Italy. 


PROGRESSING FROM THE MOUSE 

BIOASSAY FOR SHELLFISH TOXIN 

TESTING IN CANADA. A. Guy and G. Griffin. 

Canadian Council on Animal Care, Ottawa, ON, 

Canada. Sponsor: A. Goldberg. 

174 




Abstract # 


EXTRAPOLATING HUMAN EFFECT 

THRESHOLDS FROM ANIMAL TOXICITY 

DATA FOR THE DERIVATION OF 

IMMEDIATELY DANGEROUS TO LIFE AND 

HEALTH VALUES. A. Parker 1 , A. Maier 1 , G. 

Dotson 2 and C. L. Geraci 2 . 1 Toxicology Excellence 

for Risk Assessment, Cincinnati, OH and 2 EID, 

CDC/NIOSH, Cincinnati, OH. 


DEVELOPMENT OF AN IMPROVED 

STRATEGY FOR THE DERIVATION OF 

SKIN NOTATIONS. G. Dotson 1 , A. Maier 2 , B. 

Gadagbui 2 and C. L. Geraci 1 . 1 EID, CDC/NIOSH, 

Cincinnati, OH and 2 Toxicology Excellence for Risk 

Assessment, Cincinnati, OH. 


THE NICEATM-ICCVAM FIVE YEAR PLAN: 

CREATING A PATH FORWARD TO REDUCE, 

REFINE AND REPLACE ANIMAL TESTING. 

A. Poland 1 , M. Wind 2 , W. Stokes 3 , D. Allen 4 , S. 

Fitzpatrick 5 , J. Kulpa-Eddy 6 , D. Hattan 7 , A. Jacobs 8 , 

D. McCarley 3 , A. Rispin 9 , M. Snyder 10 , C. Sprankle 4 , 

R. Tice 3 and D. Winters 4 . 1 NCI, NIH/DHHS, 

Bethesda, MD, 2 CPSC, Bethesda, MD, 3 NICEATM, 

NIEHS, RTP, NC, 4 ILS, Inc., NICEATM, RTP, NC, 

5 

FDA, Rockville, MD, 6 USDA, Riverdale, MD, 

7 

FDA, College Park, MD, 8 FDA, Silver Spring, 

MD, 9 EPA, Washington, DC and 10 OD, NIH/DHHS, 

Bethesda, MD. 


CREATION AND IMPLEMENTATION 

OF DATA RESOURCES SUPPORTING 

INTEGRATED SCIENCE ASSESSMENTS OF 

CRITERIA AIR POLLUTANTS. G. M. Woodall 1 , 

E. Lorang 2 , T. Luben 1 , L. B. Wichers 1 , M. Ross 1 , L. 

D. White 1 , B. Hassett-Sipple 3 and D. Walsh 1 . 1 NCEA, 

U.S. EPA, Research Triangle Park, NC, 2 NHEERL, 

U.S. EPA, Research Triangle Park, NC and 3 OAQPS, 



THE USE OF HEALTH-BASED 

OCCUPATIONAL EXPOSURE LIMITS AS 

REACH DERIVED NO EFFECT LEVELS. R. 

S. Skoglund, N. Pechacek, L. Milchak and R. Roy. 

Medical Department, 3M, St. Paul, MN. 


SYSTEMIC TESTING BY THE DERMAL 

ROUTE CAN BE PRECLUDED BY IN 

VITRO OR IN SILICO PERCUTANEOUS 

ABSORPTION STRATEGIES. K. M. Stoick 1 , K. 

Nitschke 2 and C. Sandusky 1 . 1 Physicians Committee 

for Responsible Medicine, Washington, DC and 

2 

Dow Chemical Company, Inc., Midland, MI. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: APPLICATIONS OF BIOLOGICAL 

MODELING 

Chairperson(s): Kannan Krishnan, University of Montreal, Montreal, 

QC, Canada. 




AUTOMATED SELF-SIMILARITY 

ANALYSIS OF AIRWAYS IN THE SPRAGUE 

DAWLEY RAT. B. Neradilak 2 , D. R. Einstein 1 , 

C. Wallis 3 , N. Pollisar 2 , J. Carson 1 , A. Kuprat 1 and 

R. Corley 2 . 1 Biological Monitoring and Modeling, 

Pacific Northwest National Laboratory, Richland, 

WA, 2 The Mountain-Whisper-Light Statistical 

Consulting, Seattle, WA and 3 Primate Center, 

University of Davis, Davis, WA. 


SIMULATION OF INSPIRATORY AIRFLOW 

IN THE B6C3F1 MOUSE NASAL PASSAGES. 

J. S. Kimbell, E. A. Gross and J. D. Schroeter. The 

Hamner Institutes for Health Sciences, Research 



DOSIMETRY PREDICTIONS OF INHALED 

HEXAMETHYLENE DIISOCYANATE IN 

THE HUMAN RESPIRATORY TRACT. J. 

D. Schroeter, B. Asgharian, J. S. Kimbell and M. 

E. Andersen. The Hamner Institutes for Health 



NANOPARTICLE DEPOSITION IN THE RAT 

NASAL CAVITY: PREDICTION OF DOSE TO 

THE OLFACTORY EPITHELIUM. G. J. Garcia, 

K. Nazridoust and J. S. Kimbell. Computational 

Biology Division, The Hamner Institutes for Health 



A MODEL OF NANOPARTICLE TRANSPORT 

AND DEPOSITION IN THE NASAL AND 

LUNG AIRWAYS OF HUMANS AND RATS. 

B. Asgharian 1 , O. T. Price 1 , B. A. Wong 2 and E. 

Tewksbury 2 . 1 Division of Computational Biology, 

The Hamner Institutes for Health Sciences, Research 

Triangle Park, NC and 2 Division of Biological 

Sciences, The Hamner Institutes for Health Sciences, 



EVALUATION OF PHYSIOLOGICAL 

PARAMETERS IN ADULT RATS AND MICE 

FOR POPULATING AN ACCESS DATABASE. 

B. R. Sonawane 1 , D. Johns 2 , C. Thompson 1 , H. 

Barton 3 , D. Hattis 4 , R. Tardif 5 and K. Krishnan 5 . 

1 

ORD, NCEA, U.S. EPA, Washington, DC, 2 ORD, 

NCEA, U.S. EPA, Research Triangle Park, NC, 

3 

ORD, NCCT, U.S. EPA, Research Triangle 

Park, NC, 4 Clark University, Worcester, MA and 

5 

University of Montreal, Montreal, QC, Canada. 

Tuesday 




Tuesday 



A HIERARCHIAL ALGORITHM FOR 

COMPUTING DISTRIBUTIONS OF HUMAN 

BLOOD: AIR PARTITION COEFFICIENTS 

(PB) OF TOLUENE. P. Thomas and K. Krishnan. 

SEST, Université de Montréal, Montréal, QC, 

Canada. 


PREDICTING NERVE AGENT 

TISSUE:BLOOD PARTITION 

COEFFICIENTS USING ALGORITHMS 

ACCOUNTING FOR ACCESSIBLE TISSUE 

FRACTION. T. R. Sterner and P. J. Robinson. HJF, 

Wright-Patterson AFB, OH. 


EVALUATION OF POTENTIAL 

BIOACCUMULATION OF 

UNMETABOLIZED COMPOUNDS BY DE 

NOVO ESTIMATION OF MAMMALIAN 

PHYSIOLOGICALLY-BASED 

PHARMACOKINETICS. M. Bartels 1 , D. L. Rick 1 , 

E. R. Lowe 1 , T. McMullin 2 , S. E. Erhardt 1 and K. 

Woodburn 1 . 1 Toxicology, Dow Chemical, Midland, 

MI and 2 Toxicology, Dow Corning, Midland, MI. 


SCANNING TUNNELING MICROSCOPY 

OF INDOLO[2, 1-B]QUINAZOLIN-6, 

12-DIONE (TRYPTANTHRIN) ANALOGUES: 

EVIDENCE OF ADSORPTION-INDUCED 

STEREOISOMERIZATION. M. J. Novak*, J. 

A. Olson, J. W. Buhrow and C. J. Baum. Chemistry, 

Florida Institute of Technology, Melbourne, FL. 

Sponsor: A. Brimfield. 



PHARMACOKINETIC MODELING OF 

BROMOCHLOROACETIC ACID. J. L. 

Matthews 1 , M. R. Easterling 1 , R. L. Melnick 2 and G. 

E. Kissling 2 . 1 Constella Group, LLC, Durham, NC 

and 2 NIEHS, RTP, NC. Sponsor: S. Atwood. 


DEVELOPMENT OF A PHYSIOLOGICALLY- 

BASED PHARMACOKINETIC (PBPK) 

MODEL FOR THE INHALATION OF 2, 2, 

4-TRIMETHYLPENTANE (TMP) IN LONG 

EVANS RATS. H. A. El-Masri, J. Simmons, R. A. 

Pegram, R. A. Harrison, J. Yavanhxay, S. Dowd and 

M. V. Evans. NHEERL, U.S. EPA, Research Triangle 

Park, NC. 




P-TERT-OCTYLPHENOL IN MALE AND 

FEMALE SPRAGUE-DAWLEY RATS. G. 

Hamelin, K. Krishnan and R. Tardif. GRIS, Santé 


Montréal, Montréal, QC, Canada. 


PBPK MODELING OF CHLORZOXAZONE 

AND ITS 6-HYDROXY METABOLITE 

IN HUMANS. K. Krishnan 1 , T. Adamou 1 , L. 

Ernstgard 2 , M. Warholm 2 and G. Johanson 2 . 1 SEST, 

University of Montreal, Montreal, QC, Canada and 

2 

Karolinska Institutet, Stockholm, Sweden. 


ASSESSMENT OF DICHLOROMETHANE 

PBTK MODEL PERFORMANCE IN THE 

RAT. M. Lumpkin 1 , P. R. McClure 1 , G. L. Diamond 1 , 

P. Schlosser 2 and G. S. Cooper 2 . 1 Environmental 

Science, Syracuse Research Corp., Acworth, GA and 

2 

National Center for Environmental Assessment, U.S. 



SEQUENTIAL BAYESIAN ANALYSIS OF 

THE FORMALDEHYDE CANCER MODEL, 

PART 2: CALIBRATION OF RAT CLONAL 

GROWTH MODEL. Y. Yang 1 , B. Allen 2 , Y. Tan 1 

and H. Clewell 1 . 1 The Hamner, Research Triangle 

Park, NC and 2 Bruce Allen Consulting, Chapel Hill, 

NC. 


A QUANTITATIVE MODEL FOR 

XENOBIOTIC METABOLIZING ENZYME 

(XME) INDUCTION REGULATED BY THE 

PREGNANE X RECEPTOR (PXR). N. S. Luke 1 , 

M. J. DeVito 1 , I. Shah 2 and H. El-Masri 1 . 1 ORD/ 

NHEERL/ETD, U.S. EPA, Research Triangle Park, 

NC and 2 ORD/NCCT, U.S. EPA, Research Triangle 

Park, NC. 


ASSESSING FACTORS IMPORTANT FOR 

TISSUE ACCUMULATION OF MANGANESE 

IN MONKEYS BY PHARMACOKINETIC 

MODELING. A. Nong 1 , D. C. Dorman 1,2 , H. J. 

Clewell 1 and M. E. Andersen 1 . 1 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC 

and 2 College of Veterinary Medicine, North Carolina 

State University, Raleigh, NC. 


UNDERSTANDING THE COMPLEXITY IN 

KINETICS OF PERFLUOROOCTYLACIDS 

IN MONKEYS AND RATS USING A 

PHARMACOKINETIC MODEL. Y. Tan, H. J. 

Clewell and M. E. Andersen. The Hamner Institutes, 

Research Trianlge Park, NC. 


ENHANCING THE MODELING OF PFOA 

PHARMACOKINETICS WITH BAYESIAN 

ANALYSIS. J. F. Wambaugh, H. A. Barton and 

W. Setzer. National Center for Computational 

Toxicology, U.S. EPA, Research Triangle Park, NC. 


MODELING THE PHARMACOKINETICS 

OF PERFLUOROOCTANOIC ACID DURING 

GESTATION AND LACTATION IN MICE. C. 

E. Rodriguez and H. A. Barton. National Center for 

Computational Toxicology, U.S. EPA, RTP, NC. 


A BIOLOGICALLY BASED DOSE- 

RESPONSE MODEL FOR DIETARY IODIDE 

AND THE ADULT RAT THYROID AXIS: 

APPLICATION TO IODIDE DEFICIENCY 

AND PERCHLORATE EXPOSURE. E. D. 

McLanahan 1 , M. E. Andersen 2 and J. W. Fisher 1 . 

1 

Environmental Health Science/Interdisciplinary 

Toxicology Program, University of Georgia, Athens, 

GA and 2 Division of Computational Biology, The 

Hamner Institutes for Health Sciences, RTP, NC. 

176 




Abstract # 


PREDICTING LACTATIONAL AND 

EARLY POST-WEANING EXPOSURES 

IN RATS USING BIOLOGICALLY BASED 

PHARMACOKINETIC MODELING. M. 

Yoon 1 and H. A. Barton 2 . 1 Research Associateship 

Program, National Research Council, RTP, NC and 

2 

National Center for Computational Toxicology, U.S. 

Environmental Protection Agency, RTP, NC. 


UTILIZING PK/PD RELATIONSHIPS FOR 

INHIBITION OF SOD1 EXPRESSION IN 

BRAIN AND SPINAL CORD (CNS) OF RATS 

AND MONKEYS TO PREDICT HUMAN ASO 

DOSE. R. S. Geary 1 , G. Hung 1 , S. P. Henry 1 , R. 

Boyd 2 and F. Bennett 1 . 1 ISIS Pharmaceuticals, Inc, 

Carlsbad, CA and 2 Northern Biomedical Research, 

Inc., Muskegon, MI. 



PHARMACOKINETIC MODELING OF AN 

ALKYLBENZENE MIXTURE IN CHILDREN 

OF VARIOUS AGE GROUPS. T. Adamou 2 , S. 

Haddad 1 and K. Krishnan 2 . 1 Biological sciences, 

Université du Québec à Montréal, Montreal, QC, 

Canada and 2 GRIS/TOXHUM, Université de 

Montréal, Montreal, QC, Canada. 


PBPK MODELS FOR MIXTURES OF 

DIOXIN-LIKE CHEMICALS. M. Easterling 1 , 

N. J. Walker 2 , F. M. Parham 2 and C. J. Portier 2 . 

1 

Constella Group, Durham, NC and 2 National 

Institute of Environmental Health Sciences, RTP, 

NC. 


EFFECT OF DYNAMIC BLOOD 

PARTITIONING DURING LATE GESTATION 

ON CHLORPYRIFOS DOSIMETRY. T. S. 

Poet 1 , E. Lowe 2 , J. L. Mattsson 2 , M. J. Bartels 2 and 

C. Timchalk 1 . 1 Biological Monitoring and Modeling, 

Pacific Northwest Nat’l Lab, Richland, WA and 2 The 

Dow Chemical Company, Midland, MI. 


A DISCRETE TIME MODEL TO ANALYZE 

THE EFFECTS OF TOXICANTS ON THE 

GROWTH OF C. ELEGANS NEMATODES 

IN A MEDIUM THROUGHPUT SETTING. M. 

Smith 1 , W. Boyd 2 , S. McBride 3 , G. Kissling 2 , J. H. 

Freedman 2,3 and C. Portier 2 . 1 Constella, Durham, 

NC, 2 National Institutes of Health (NIH)/National 

Institute of Environmental Health Sciences(NIEHS)/ 

Laboratory of Molecular Toxicology, Research 

Triangle Park, NC and 3 Duke University/Nicholas 

School of the Environment and Earth Sciences, 

Durham, NC. 


THE DEVELOPMENT OF A MULTISCALE 

CARDIAC MODEL OF NANOPARTICLE 

DRIVEN ATHEROSCLEROSIS. J. P. Carson, D. 

R. Einstein, A. P. Kuprat and K. R. Minard. Pacific 

Northwest National Laboratory, Richland, WA. 

Sponsor: C. Timchalk. 

Abstract # 


DIMENSIONAL ANALYSIS TO PREDICT 

THE SPECIFIC ISOFORMS INVOLVED IN 

BINDING CYP SUBSTRATES. B. Reisfeld 1,3 , 

P. N. Ciesielski 2 and A. N. Mayeno 3 . 1 Chemical and 

Biological Engineering, Colorado State University, 

Fort Collins, CO, 2 Interdisciplinary Program in 

Materials Science, Vanderbilt University, Nashville, 

TN and 3 Environmental and Radiological Health 


CO. 


AN UPDATED METHODOLOGY TO 

PREDICT RATES OF CYTOCHROME 

P450 MEDIATED HYDROXYLATION OF 

ALIPHATIC SUBSTRATES. A. N. Mayeno 1 , 

R. Yang 1 and B. Reisfeld 2,1 . 1 Environmental and 

Radiological Health Sciences, Colorado State 

University, Fort Collins, CO and 2 Chemical and 

Biological Engineering, Colorado State University, 



1:00 PM to 4:30 PM 

Exhibit Hall 


POSTER SESSION: NANOPARTICLES: TARGET ORGANS 

Chairperson(s): Margaret Kraeling, U.S. Food and Drug Adminstration, 

College Park, MD. 




ANALYSIS OF DERMAL PENETRATION 

OF TITANIUM DIOXIDE (TIO2) 

FROM SUNSCREEN FORMULATIONS 

CONTAINING MICRON- AND NANO- 

SCALE PARTICLES OF TIO2. N. Sadrieh 1 , 

A. M. Wokovich 2 , N. V. Gopee 3 , P. H. Siitonen 3 , 

C. R. Cozart 3 , P. C. Howard 3 , W. H. Doub 2 and L. 

F. Buhse 2 . 1 FDA/CDER/OPS, Silver Spring, MD, 

2 

FDA, Saint Louis, MO and 3 FDA, Jefferson, AR. 


THE TOXICITY AND BIOCOMPATIBILITY 

OF NANOMATERIALS IN HUMAN 

KERATINOCYTES (HACAT CELLS). N. 

M. Schaeublin 1 , J. J. Schlager 1 , S. M. Hussain 1 , 

J. M. Miller 2 , G. R. Johnson 3 and D. M. Eby 3 . 

1 

Applied Biotechnology Branch, RHPB, Air Force 

Research Labs, Wright Patterson, OH, 2 Department 

of Chemistry, University Of Oregon, Eugene, OR 

and 3 Airbase Sciences Branch, Materials Science 

Directorate, Air Force Research Labs, Tyndall, FL. 


THE ROLE OF SIZE IN TITANIUM DIOXIDE 

DERMAL NANOTOXICITY. S. M. Hussain 1 , 

L. K. Braydich-Stolle 1 , N. M. Schaeublin 1 , R. 

C. Murdock 1 , D. R. Mattie 1 , A. M. Schrand 1 , J. 

J. Schlager 1 , J. Jiang 2 and P. Biswas 2 . 1 Applied 

Biotechnology Branch, RHBP, Air Force Research 

Labs, Wright Patterson, OH and 2 Department Of 

Chemical Engineering, Washington University in St. 

Louis, St. Louis, MO. 

Tuesday 




Tuesday 



STUDIES ON SIO 2 

NANOPARTICLE 

CHARACTERIZATION AND ITS 

RELATIONSHIP TO TOXICITY IN 

KERATINOCYTES. K. O. Yu 1 , A. M. Schrand 1 , 

M. C. Moulton 1 , J. Harber 1 , L. K. Braydich-Stolle 1 , 

N. M. Schaeublin 1 , W. Wang 2 , B. Gu 2 , J. J. Schlager 1 

and S. M. Hussain 1 . 1 Applied Biotechnology Branch, 

RHPB, Air Force Research Labs, Wright Patterson, 

OH and 2 Oak Ridge National Laboratory, Oak Ridge, 

TN. 


BIOLOGICAL INTERACTIONS OF 

QUANTUM DOT NANOPARTICLES IN 

SKIN AND IN HUMAN EPIDERMAL 

KERATINOCYTES. L. W. Zhang 1 , W. W. 

Yu 2 , V. L. Colvin 2 and N. A. Monteiro-Riviere 1 . 

1 



Raleigh, NC and 2 Department of Chemistry, Rice 

University, Houston, TX. 


ION-PAIRING EFFECTS ON SKIN 

ABSORPTION OF CHARGED 

NANOPARTICLES. X. Xia, N. A. Monteiro-Riviere 

and J. E. Riviere. Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina State 



EVALUATION OF QUANTUM DOT 

NANOPARTICLE PENETRATION IN 

HUMAN SKIN. N. A. Monteiro-Riviere and A. O. 

Inman. Center for Chemical Toxicology Research 

and Pharmacokinetics, North Carolina State 



COMPARISON OF NINE VIABILITY 

METHODS IN HUMAN EPIDERMAL 

KERATINOCYTES TREATED WITH 

DIFFERENT NANOPARTICLES. A. O. Inman 

and N. A. Monteiro-Riviere. Center for Chemical 

Toxicology Research and Pharmacokinetics, North 



INDUCTION OF AP-1-MAPKS AND NF-KB 

SIGNAL PATHWAYS BY TUNGSTEN 

CARBIDE-COBALT PARTICLES. M. Ding, 

J. Zhao, L. Bowman, S. Leonard, Y. Lu, E. Kisin, 

A. Murray, V. Vallyathan, V. Castranova and A. 

Shvedova. Pathology and Physiology Research 


and Health, Morgantown, WV. 


IN VITRO PENETRATION OF DENDRIMER 

NANOPARTICLES INTO HUMAN SKIN. M. 

E. Kraeling 1 , O. A. Ogunsola 1 and R. L. Bronaugh 2 . 

1 

Office of Regulatory Science, U.S. FDA, College 

Park, MD and 2 Office of Cosmetics and Colors, U.S. 

FDA, College Park, MD. 


INTRAVENOUS ADMINISTRATION 

OF GADOLINIUM MODIFIED 

NANOPARTICLES TO SPRAGUE-DAWLEY 

RATS. K. L. Steinmetz, L. Rausch and B. MacQueen. 

Biosciences and Physical Sciences Divisions, SRI 

International, Menlo Park, CA. 


INDUCTION OF MATRIX 

METALLOPROTEINASE 2 AND 9 BY 

HUMAN MONOCYTES IN RESPONSE 

TO DIFFERENT TYPES OF METAL 

NANOPARTICLES. Q. Zhang, R. Wan, Q. 

Yang, Y. Mo and D. J. Tollerud. Environmental 




ASSESSMENT OF THE TOXICITY OF 

SILVER NANOPARTICLES IN VITRO: A 

MITOCHONDRIAL PERSPECTIVE. J. P. 

Teodoro 1 , F. V. Duarte 1 , A. M. Simões 1 , A. P. Rolo 1 , 

S. M. Hussain 2 and C. M. Palmeira 3,1 . 1 Center for 

Neurosciences and Cell Biology, Department of 

Zoology, University of Coimbra, Coimbra, Portugal, 

2 

Applied Biotechnology, Air Force Research 

Laboratory/HEPB-Wright Patterson Air Force 

Base, AFB, Dayton, OH and 3 IMAR, Mitochondrial 

Research Group, Department of Zoology, University 

of Coimbra, Coimbra, Portugal. 


INVOLVEMENT OF ENDOCYTOSIS IN 

UPTAKE OF PHOSPHATIDYLSERINE- 

COATED SINGLE-WALLED 

CARBON NANOTUBES BY RAW 264.7 

MACROPHAGES. W. Feng 1 , N. V. Konduru 1 , Y. 

Y. Tyurina 1 , K. Clark 3 , D. B. Stolz 3 , H. Bayir 2 , B. 

Fadeel 4 , A. A. Shvedova 5 and V. E. Kagan 1 . 1 Center 

for Free Radical and Antioxidant Health, Department 

.of EOH, University of Pittsburgh, Pittsburgh, PA, 

2 

Department .of Critical Care Medicine, University 

of Pittsburgh, Pittsburgh, PA, 3 Department .of Cell 

Biology & Physiology, University of Pittsburgh, 

Pittsburgh, PA, 4 Institute of Environmental 

Medicine, Karolinska Institute, Stockholm, Sweden 

and 5 Division of Pathology/Physiology, NIOSH, 

Morgantown, WV. 


INHALED MULTIWALLED CARBON 

NANOTUBE INDUCTION OF 

IMMUNOMODULATORY CYTOKINES AND 

STRESS ASSOCIATED ENZYMES IN VIVO. 

L. Mitchell 1,2 , F. Lauer 2 , A. Gigliotti 1 , R. Vander Wal 3 , 

S. Burchiel 2 and J. McDonald 1 . 1 Lovelace Respiratory 

Research Institute, Albuquerque, NM, 2 College of 

Pharmacy, University of New Mexico, Albuquerque, 

NM and 3 NCMR, NASA-Glenn Research Center, 

Cleveland, OH. 


ACID-FUNCTIONALIZED SINGLE- 

WALLED CARBON NANOTUBES ENHANCE 

CARDIAC ISCHEMIC/REPERFUSION 

INJURY. H. Tong, M. Gilmour, M. Daniels, E. 

Boykin, U. P. Kodvanti, R. B. Devlin and R. K. 

Saxena. U.S. EPA, RTP, NC. 


CYTOTOXIC EFFECT OF SILICA 

NANOPARTICLES IN HUMAN 

IMMUNOLOGICAL CELLS. J. A. Torres- 

Hernandez 1 , D. A. Lawrence 2 and J. G. Ault 2 . 1 Texas 

Southern University, Houston, TX and 2 Wadsworth 

Center New York State Department of Health, 

Albany, NY. 

178 




Abstract # 


STUDY OF HEPATOTOXICITY 

BIOMARKERS IN SWISS-WEBSTER MICE 

TREATED WITH CARBON NANOTUBES. 

A. K. Patlolla, B. Knighten, D. McAllister and P. 

Tchounwou. Jackson State University, Jackson, MS. 


ASSESSING IN VITRO RESPONSES OF 

MURINE SPLENOCYTES TO DANSYL- 

SILOXANE NANOPARTICLES THROUGH 

FLOW CYTOMETRIC METHODS. J. F. 

Nyland 1 , J. Bai 2 , H. E. Katz 2 and E. K. Silbergeld 1 . 

1 

Environmental Health Sciences, Johns Hopkins 

Univ SPH, Baltimore, MD and 2 Materials Science, 



NEUROTOXICITY ASSESSMENT OF 

SILVER-25 NANOPARTICLES: AN IN 

VITRO AND IN VIVO STUDY. M. F. Rahman 1 , 

J. Wang 1 , T. A. Patterson 1 , H. M. Duhart 1 , G. D. 

Newport 1 , S. M. Hussain 2 , J. J. Schlager 2 and S. 

F. Ali 1 . 1 Neurochemistry Laboratory, Division of 

Neurotoxicology, NCTR/FDA, Jefferson, AR and 

2 

Applied Biotechnolgy Branch, Human Toxicological 

Research, Air Force Research Laboratory, Wright- 

Patterson AFB, OH. 


EXPRESSION CHANGES OF 

DOPAMINERGIC SYSTEM-RELATED 

GENES IN PC12 CELLS INDUCED BY MN, 

AG, OR CU NANOPARTICLES. J. Wang 1 , M. 

F. Rahman 1 , H. M. Duhart 1 , G. D. Newport 1 , T. A. 

Patterson 1 , S. M. Hussain 2 , J. J. Schlager 2 and S. F. 

Ali 1 . 1 Division of Neurotoxicology, NCTR, Jefferson, 

AR and 2 Applied Biotechnology Branch, Air Force 

Research Laboratory, Wright-Patterson AFB, OH. 


TRANSCRIPT PROFILES OF METAL 

OXIDE NANOPARTICLE-TREATED COLON 

CANCER CELLS. P. J. Moos, M. Honeggar, 

K. Olszewski, N. Cutler and J. M. Veranth. 

Pharmacology & Toxicology, University of Utah, 



ENHANCEMENT OF PLATELET 

ACTIVATION AND THROMBUS 

FORMATION BY SILVER NANOPARTICLES. 

E. Jun, O. Bae, K. Lim, J. Noh and J. Chung. College 

of Pharmacy, Seoul National University, Seoul, 

South Korea. 


CYTOTOXICITY OF MICRO AND NANO 

METALLO-OXIDE: A COMPARATIVE 

STUDY. B. Viviani, A. Facchi, F. Bresciani, M. 

Boraso, S. Bartesaghi, E. Corsini, C. L. Galli and 

M. Marinovich. Department of Pharmacological 

Sciences, University of Milan, Milan, Italy. 


INTERACTIONS OF NANO- AND MICRO- 

SIZED MESOPOROUS SILICA PARTICLES 

WITH PRIMARY HUMAN MONOCYTE- 

DERIVED MACROPHAGES. B. Fadeel 1 , 

E. Witasp 1 and A. Garcia-Bennett 2 . 1 Institute of 

Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden and 2 Department of Engineering 

Sciences, Uppsala University, Uppsala, Sweden. 

Sponsor: V. Kagan. 

Abstract # 


TOXICITY OF SILICON NANOPARTICLES 

AND MICROPARTICLES. J. Choi 1,2,3 , Q. Zhang 1 , 

V. M. Hitchins 1 , M. E. Stratmeyer 1 , P. L. Goering 1 , 

R. Vytas 2 and N. Wang 3 . 1 Center for Devices 

and Radiological Health, U.S. Food and Drug 

Administration, Silver Spring, MD, 2 Biochemical 

Science Division, National Institute of Standards and 

Technology, Gaithersburg, MD and 3 Department of 

Chemical and Biomolecular Engineering, Univ of 

Maryland, College Park, MD. 


EFFECT OF CARBON NANOPARTICLE 

EXPOSURE ON RENAL BARRIER 

EPITHELIAL CELLS IN VITRO. F. A. 

Witzmann 1 , A. D. Amos 2 , E. A. Chernoff 2 , D. 

Hong 1 , X. Lai 1 , H. N. Ringham 1 and B. L. Blazer- 

Yost 2 . 1 Cellular & Integrative Physiology, Indiana 

University School of Medicine, Indianapolis, IN and 

2 

Biology, Indiana University Purdue University - 

Indianapolis, Indianapolis, IN. 


ACTIVATION OF AUTOPHAGY IN PORCINE 

KIDNEY CELLS BY QUANTUM DOTS. S. 

T. Stern, B. S. Zolnik, J. Zheng and S. E. McNeil. 

Nanotechnology Characterization Laboratory, 

National Cancer Institute, Frederick, MD. Sponsor: 

N. Walker. 


INDUCTION OF METALLOTHIONEIN IN 

PORCINE KIDNEY CELLS BY QUANTUM 

DOTS. C. B. McLeland, S. E. McLeland and S. T. 

Stern. Nanotechnology Characterization Laboratory, 

National Cancer Institute, Fredrick, MD. Sponsor: 

N. Walker. 


TOXICITY OF CARBON AND METAL 

BASED NANOPARTICLES IN HEPG2 CELLS. 

R. C. Casabar 1 , P. Phadke-Gupta 1 , A. Wallace 2 , 

J. J. Schlager 1 and S. M. Hussain 1 . 1 Applied 

Biotechnology Branch, RHPB, Air Force Research 

Labs, Wright Patterson, OH and 2 Department of 

Environmental and Molecular Toxicology, North 



SILVER NANOPARTICLES DISRUPT GDNF 

SIGNALING IN MALE GERM-LINE STEM 

CELLS. L. K. Braydich-Stolle 1 , B. Lucas 2 , R. C. 

Murdock 1 , A. M. Schrand 1 , T. Lee 2 , J. J. Schlager 1 , 

S. M. Hussain 1 and M. Hofmann 2,3 . 1 Applied 


Labs, Wright Patterson, OH, 2 Department Of 

Veterinary Biosciences, University Of illinois at 

Urbana Champaign, Urbana, IL and 3 Institute for 

Genomic Biology, University Of illinois at Urbana 

Champaign, Urbana, IL. 


SILVER NANTOXICITY IS MEDIATED BY 

2-MERCAPTOETHANOL IN JURKAT T 

CELLS. K. Szczublewski 1,3 , S. LeMay 2 , E. Romer 3 , 

C. Sulentic 3 , J. Schalger 1 and S. Hussain 1 . 1 Applied 


Labs, Wright Patterson, OH, 2 Avetec, Springfield, 

OH and 3 Pharmacology and Toxicology, Wright State 

University, Springfield, OH. 

Tuesday 




Tuesday 



FUNCTIONALLY CHARGED NANOSIZE 

PARTICLES DIFFERENTIALLY ACTIVATE 

BV2 MICROGLIA. B. Veronesi 1 , L. Liu 2 , S. 

Hester 1 , W. Ward 1 , J. Tajuba 3 , M. Pooler 4 , C. 

Swartz 3 , N. Saleh 5 , G. V. Lowry 5 and S. A. Simon 2 . 

1 

NHEERL, U.S. EPA, RTP, NC, 2 Neurobiology 

Department, Duke University, Durham, NC, 3 School 

of Public Health, UNC, Chapel Hill, NC, 4 Toxicology 

Program, NCSU, Raleigh, NC and 5 Department of 

Civil and Environmental Engineering, Carnegie 

Mellon University, Pgh, PA. 


QUANTITATIVE DETERMINATION OF 

C60 FULLERENE BY LC-MS/MS AND ITS 

TISSUE DISTRIBUTION FOLLOWING 

ORAL ADMINISTRATION TO RATS. R. 

Kubota 1 , M. Tahara 1 , K. Shimizu 1 , H. Tokunaga 1 , 

A. Hirose 2 , M. Ema 2 and T. Nishimura 1 . 1 Division 

of Environmental Chemistry, National Institute of 

Health Sciences, Tokyo, Japan and 2 Division of Risk 

Assessment, Biological Safety Research Center, 



1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: BREAST CANCER: MECHANISMS, 

BIOMARKERS, AND CHEMOPREVENTION 

Chairperson(s): Melanie Flint, University of Pittsburgh Cancer Institute, 

Pittsburgh, PA and Thu Nguyen, Kansas State University, Manhattan, KS. 




THE EQUINE ESTROGEN METABOLITE, 

4-HYDROXYEQUILENIN, ACTIVATES 

ESTROGEN RECEPTOR-MEDIATED 

GENE TRANSCRIPTION AND ENHANCES 

GENOTOXICITY IN ER ALPHA(+) CELLS. 

K. Peng 1 , Z. Wang 1 , M. Chang 2 , J. Frasor 3 , B. 

Dietz 1 , G. R. Thatcher 1 and J. L. Bolton 1 . 1 Medicinal 

Chemistry, University of Illinois at Chicago, 

Chicago, IL, 2 Metabolism and Pharmacokinetics, LG 

Life Sciences, Daejeon, South Korea and 3 Physiology 

and Biophysics, University of Illinois at Chicago, 

Chicago, IL. 


ESTROGEN RECEPTOR ALPHA 

SELECTIVELY MEDIATES OXIDATIVE 

DNA DAMAGE INDUCED BY THE 

EQUINE CATECHOL ESTROGEN 

4-HYDROXYEQUILENIN IN ER ALPHA 

POSITIVE BREAST CANCER CELLS. Z. 

Wang, L. Yuan, K. Peng, B. Dietz, G. R. Thatcher, 

R. B. van Breemen and J. L. Bolton. Department of 

Medicinal Chemistry & Pharmacognosy, University 

of Illinois at Chicago, Chicago, IL. 


MECHANISM OF ESTROGEN 

CARCINOGENESIS: DEPURINATING 

DNA ADDUCTS AND CELLULAR 

TRANSFORMATION FROM REACTIVITY 

OF ELECTROPHILIC OXIDATIVE 

METABOLITES. I. Kastrati, P. D. Edisiringhe, J. 

L. Bolton and G. R. Thatcher. Medicinal Chemistry, 

University of IL at Chicago, Chicago, IL. 


COMBINED EFFECTS OF ESTROGEN AND 

IONIZING RADIATION ON EPIGENETIC 

PROCESSES IN RAT MAMMARY GLAND. 

K. Kutanzi 1 , V. Tryndyak 2 , I. Pogribny 2 and O. 

Kovalchuk 1 . 1 University of Lethbridge, Lethbridge, 

AB, Canada and 2 NCTR, Jefferson, AR. 


ROLE OF THE ARYL HYDROCARBON 

RECEPTOR IN MAMMARY TUMOR 

PROGRESSION. S. Narasimhan 1 and D. H. 

Sherr 1,2 . 1 Department of Pathology and Laboratory 

Medicine, Boston University Medical Center, 

Boston, MA and 2 Department of Environmental 

Health, Boston University School of Public Health, 

Boston, MA. 


EXPOSURE TO SERUM FROM 

SOY-FED RATS RESULTS IN 

PROTEASOME-MEDIATED DEGRADATION 

OF ARYL HYDROCARBON RECEPTOR IN 

FGC-4 CELLS. R. Singhal 1 , T. M. Badger 2 and M. 

J. Ronis 1 . 1 Pharmacology & Toxicology, UAMS, 

Little Rock, AR and 2 Physiology & Biophysics, 

UAMS, Little Rock, AR. 


MOLECULAR DETERMINATION OF 

STRESS HORMONE-MEDIATED DRUG 

RESISTANCE TO PACLITAXEL IN BREAST 

CANCER. M. Flint 1 , B. L. Hood 1 , G. Kim 1 , J. 

N. Sutton 1,2 and T. P. Conrads 1 . 1 Pharmacology, 

University of Pittsburgh Cancer Institute, Pittsburgh, 

PA and 2 BRIMS center, Cambridge, MA. 


EPIGENETIC DYSREGULATION 

IN ESTROGEN-INDUCED BREAST 

CARCINOGENESIS. O. Kovalchuk 1 , K. 

Kutanzi 1 , V. Tryndyak 2 and I. Pogribny 2 . 1 University 

of Lethbridge, Lethbridge, AB, Canada and 

2 

Biochemical Toxicology, NCTR, Jefferson, AR. 


COMPARISON OF BIOMARKERS IN 

HUMAN BREAST CANCER CASES AND RAT 

MAMMARY TUMORS. P. Krishnan 1,3 , K. Yan 1,3 , 

J. Tubbs 2,3 , B. Li 2,3 and H. Kleiner 1,3 . 1 Pharmacology, 

Toxicology and Neuroscience, LSU Health Sciences 

Center, Shreveport, LA, 2 Department of Surgical 

Oncology, LSU Health Sciences Center, Shreveport, 

LA and 3 Feist Weiller Cancer Center, LSU Health 

Sciences Center, Shreveport, LA. 

180 




Abstract # 


DEVELOPMENT OF BREAST CANCER 

IN HAMSTERS AS A MODEL TO TEST 

ONCOLYTIC VIROTHERAPY. M. Coburn 1,3 , 

J. Podduturi 2,3 , J. M. Mathis 2,3 and H. E. Kleiner 1,3 . 

1 

Pharmacology, Toxicology and Neuroscience, LSU- 

HSC Shreveport, Shreveport, LA, 2 Cellular Biology 

and Anatomy, LSU-HSC Shreveport, Shreveport, 

LA and 3 Feist-Weiller Cancer Center, LSU-HSC 

Shreveport, Shreveport, LA. 


MODULATION OF XENOBIOTIC- 

METABOLIZING ENZYMES 

BY CHEMOPREVENTIVE AND 

CHEMOTHERAPEUTIC COMPOUNDS TO 

SUPPRESS MAMMARY DNA ADDUCTS 

AND TUMORS. S. R. Kondraganti, L. Wang, W. 

Jiang, K. Muthiah and B. Moorthy. Pediatrics, Baylor 

College of Medicine, Houston, TX. 


ANTI-TUMOR EFFECT OF SUBSTITUTED 

QUINOLINES. T. A. Nguyen, S. Kim and T. Ohira. 

Diagnostic Medicine, Kansas State University, 

Manhattan, KS. 


THE MAMMARY EPITHELIAL CELL 

SPECIFIC ROLE OF PEROXISOME 

PROLIFERATOR-ACTIVATED RECEPTOR 

(PPAR)g IN DMBA-MEDIATED BREAST 

TUMOURIGENESIS. C. J. Nicol 1,2,3 , J. M. 

Roche 1,3 and N. Peterson 1,3 . 1 Pathology & Molecular 

Medicine, Queen’s University, Kingston, ON, 

Canada, 2 Pharmacology & Toxicology, Queen’s 

University, Kingston, ON, Canada and 3 Division 

of Cancer, Biology & Genetics, CRI, Queen’s 

University, Kingston, ON, Canada. 


EXPOSURE TO TCDD DURING 

PREGNANCY DELAYS DEVELOPMENT OF 

DMBA-INDUCED MAMMARY TUMORS. 

B. A. Vorderstrasse and T. Wang. Pharmaceutical 

Sciences, Washington State University, Pullman, WA. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: INHALATION TOXICOLOGY 

Chairperson(s): James Wagner, Michigan State University, East Lansing, 

MI and Jon Hotchkiss, The Dow Chemical Company, Midland, MI. 




COMPARATIVE EFFECTS OF 

SUBCHRONIC INHALATION EXPOSURE 

OF RODENTS TO DIESEL AND GASOLINE 

ENGINE EMISSIONS, HARDWOOD SMOKE, 

AND SIMULATED DOWNWIND COAL 

EMISSIONS. J. L. Mauderly 1 , E. G. Barrett 1 , M. 

J. Campen 1 , A. P. Gigliotti 1 , J. D. McDonald 1 , J. 

Seagrave 1 , M. D. Reed 1 and S. K. Seilkop 2 . 1 Lovelace 

Respiratory Reserch Institute, Albuquerque, NM and 

2 

SKS Consulting Services, Siler City, NC. 

Abstract # 


SUBCHRONIC EPISODIC EXPOSURE OF 

RATS TO DIESEL PLUS OZONE INDUCES 

MINIMAL CARDIOPULMONARY EFFECTS. 

M. C. Schladweiler 1 , A. D. Ledbetter 1 , J. Shannahan 2 , 

J. Wallenborn 3 , A. Nyska 4 , D. Malarkey 5 , J. 

Richards 1 , H. Tong 1 , R. B. Devlin 1 and U. P. 

Kodavanti 1 . 1 NHEERL/ETD, U.S. EPA, Durham, 

NC, 2 Curriculum in Toxicology, UNC, Chapel Hill, 

NC, 3 SPH, UNC, Chapel Hill, NC, 4 Toxicologic 

Pathology, Timrat, Israel and 5 NTP, NIEHS, Durham, 

NC. 


INHIBITION OF TYROSINE PHOSPHATASE 

ACTIVITY INITIATES RECEPTOR 

SIGNALING IN AIRWAY EPITHELIAL 

CELLS EXPOSED TO DIESEL EXHAUST 

PARTICLES. T. Tal 1 , P. A. Bromberg 2 , R. 

Silbajoris 3 and J. M. Samet 3,1 . 1 Curriculum in 

Toxicology, UNC Chapel Hill, Chapel Hill, NC, 

2 

CEMALB, UNC Chapel Hill, Chapel Hill, NC and 

3 

NHEERL, U.S. EPA, Chapel Hill, NC. 


LUNG INJURY IS INDUCED BY INSOLUBLE 

AND TOTAL BUT NOT SOLUBLE 

PARTICULATE MATTER (PM) COLLECTED 

IN MEXICO CITY. A. De Vizcaya-Ruiz 1 , A. 

Osornio-Vargas 2 , M. C. Schladweiler 3 , A. D. 

Ledbetter 3 , J. H. Richards 3 , J. McGee 3 , R. H. Jaskot 3 

and U. P. Kodavanti 3 . 1 Toxicology, CINVESTAV- 

IPN, México D.F., Mexico, 2 Investigación Básica, 

INCan, SSA, México D.F., Mexico and 3 NHEERL, 

ETD, U.S. EPA, Research Triangle Park, NC. 


URBAN PARTICULATE MATTER 

ACTIVATES CALPAIN AND TRIGGERS 

THE UNFOLDED PROTEIN RESPONSE. T. 

L. Watterson 1 , B. Hamilton 1 , R. Martin 2 and R. A. 

Coulombe 1 . 1 Toxicology Graduate Program, Utah 

State University, Logan, UT and 2 Department of 

Civil and Environmental Engineering, Utah State 

University, Logan, UT. 


90-DAY INHALATION TOXICITY STUDY 

WITH DISK-SHAPED MAGNESIUM 

POTASSIUM TITANATE PARTICLES 

(TERRACESS PS) IN RATS. S. Sakai 1 , K. Inada 1 , 

A. K. Tanaka 1 , D. P. Kelly 2 , G. Sykes 3 and K. P. 

Lee 4 . 1 Otsuka Chemical Co, Osaka, Japan, 2 Haskell 

Laboratory, DuPont Co., Newark, DE, 3 PharmPath, 

West Grove, PA and 4 Path.Conslt., Newark, DE. 

Sponsor: S. Loveless. 


CLASSIFICATION OF AEROSOLIZED 

MINERAL BASE OILS UNDER THE 

GLOBALLY HARMONIZED SYSTEM OF 

CLASSIFICATION AND LABELING OF 

CHEMICALS (GHS). W. Dalbey, F. Whitman and 

M. Amoruso. ExxonMobil Biomedical Sciences, Inc., 

Paulsboro, NJ. 

Tuesday 




Tuesday 



IN VIVO EVALUATION OF LUNG 

STRUCTURE BY MAGNETIC RESONANCE 

IMAGING (MRI) FOLLOWING ELASTASE 

INDUCED EMPHESEMA IN RATS. R. E. 

Jacob 1 , K. M. Gideon 2 , K. R. Minard 1 and C. 

Timchalk 1 . 1 Pacific Northwest National Laboratory, 

Richland, WA and 2 Battelle Toxicology NW, 

Richland, WA. 


PROGRESSIVE PULMONARY AND 

PLEURAL EFFECTS OF INDIUM 

PHOSPHIDE IN B6C3F1 MICE: 

PARTICULATE INDUCED PLEURAL 

FIBROSIS AND PROLIFERATION. P. Kirby 1 , 

C. Shines 1 , G. Taylor 2 , R. Bousquet 2 , H. Price 2 , J. 

Everitt 3 and D. Morgan 1 . 1 Respiratory Toxicology, 

NIEHS, Durham, NC, 2 Alion, Durham, NC and 

3 

Consultant, Durham, NC. 


TOXICOLOGICAL CHARACTERIZATION 

OF INHALED CUSTOM PEPTIDES. K. 

McInally 1 , A. S. Aslam 1 , E. Devemy 2 and O. 

Blaschuck 2 . 1 Inhalation Toxicology, ITR Laboratories 

Canada Inc., Baie D’Urfe, QC, Canada and 2 Urology 

Department, McGill University, Montreal, QC, 

Canada. Sponsor: B. Procter. 


INHALATION OF STAINLESS STEEL 

WELDING FUME RESULTS IN DISSIMILAR 

INFLAMMATORY RESPONSES IN THE 

LUNGS OF A/J AND C57BL/6J MICE. P. C. 

Zeidler-Erdely, S. Stone, M. Donlin, A. Moseley, J. 

Cumpston, B. T. Chen, D. G. Frazer, S. Young and J. 

M. Antonini. HELD, NIOSH, Morgantown, WV. 


BERYLLIUM-INDUCED SENSITIZATION 

AND GRANULOMATOUS LUNG DISEASE 

IN MURINE MODELS. L. M. Tarantino 1 , A. F. 

Hubbs 2 , M. D. Hoover 2 , D. L. Delano 3 , T. Wiltshire 3 

and T. Gordon 1 . 1 Environmental Medicine, New 

York University School of Medicine, Tuxedo, NY, 

2 

NIOSH, Morgantown, WV and 3 Genomic Institute 

of the Novartis Research Foundation, San Diego, 

CA. 


USE OF A MOUSE MODEL TO EVALUATE 

PULMONARY INFLAMMATION CAUSED 

BY FLOOR DUST FROM A WATER- 

DAMAGED BUILDING. S. Young, J. M. 

Cox-Ganser, M. Wolfarth, J. M. Antonini, V. 

Castranova and J. Park. NIOSH, Morgantown, WV. 


REFINEMENT OF TRADITIONAL 

RESTRAINED WHOLE-BODY 

PLETHYSMOGRAPHY (WBP): 

DEVELOPMENT OF A MODULAR 

RESTRAINED WBP CHAMBER FOR NOSE- 

ONLY INHALATION EXPOSURE STUDIES 

IN MICE. S. M. Krieger, T. J. Cawley, W. M. 

Snellings, M. J. Filary, S. G. Walker and J. A. 

Hotchkiss. The Dow Chemical Company, Midland, 

MI. 


DIFFERENTIAL PHYSICOCHEMICAL 

PROPERTIES OF PARTICLES FROM WOOD 

COMBUSTION AND TRAFFIC DETERMINE 

PRO-INFLAMMATORY POTENTIAL. P. 

Schwarze 1 , A. Kocbach 1 , J. I. Herseth 1 and T. 

Sandström 2 . 1 Air Pollution and Noise, Norwegian 

Institute of Public Health, Oslo, Norway and 

2 

University of Umeå, Umeå, Sweden. Sponsor: E. 

Dybing. 


THE PROTECTIVE EFFECT OF THE UPPER 

AIRWAYS AGAINST WATER SOLUBLE 

IRRITANT GAS EXPOSURE – A CASE 

STUDY OF ACUTE AMMONIA EXPOSURE. 

J. Kind, P. Nony and D. Hewitt. Center for 

Toxicology and Environmental Health, North Little 

Rock, AR. 


LUNG RESPONSE TO COARSE PM: 

BIOASSAY IN MICE. T. C. Wegesser and J. A. 

Last. Pulmonary and Critical Care Medicine, School 

of Medicine, CCRBM, University of California, 

Davis, CA. 


OZONE EXPOSURE EXACERBATES 

EOSINOPHILIC AND EPITHELIAL 

CELL RESPONSES IN SINUS AND 

NASOLACRIMAL DUCT AIRWAYS IN 

ALLERGIC RATS. J. G. Wagner 1 , M. E. Swinkey 1 , 

J. R. Harkema 1 and D. B. Peden 2 . 1 Michigan State 

University East Lansing, MI and 2 Univ N Carolina, 



EFFECTS OF IN VITRO EXPOSURE OF 

HUMAN RESPIRATORY EPITHELIAL 

CELLS TO FORMALDEHYDE. C. R. 

O’Lenick 1 , K. G. Sexton 1 , K. DeBruijne 1 , S. 

Ebersviller 1 , S. Casper 1 , I. Jaspers 1,2 and H. Jeffries 1 . 

1 

Environmental Science Engineering, UNC-CH, 

Chapel Hill, NC and 2 CEMALB, UNC-CH, Chapel 

Hill, NC. 


NASAL UPTAKE OF DIACETYL AND 

BUTYRIC ACID VAPORS. J. B. Morris 1 and 

A. F. Hubbs 2 . 1 Toxicology Program, University 

of Connecticut, Storrs, CT and 2 NIOSH, CDC, 



COMPARING THE TOXICITY OF FRESH 

AND AGED DIESEL EXHAUST USING 

SEPARATE PARTICLE AND GASEOUS 

EXPOSURE SYSTEMS. K. de Bruijne 1 , 

S. Ebersviller 1 , K. G. Sexton 1 , C. Olenick 1 , R. 

Woodside 1 , S. Casper 1 , I. Jaspers 1,2 and H. Jeffries 1 . 

1 

Envr Sciences & Eng, University of North Carolina, 

Chapel Hill, NC and 2 CEMALB, University of North 

Carolina at Chapel Hill, Chapel Hill, NC. 


NASAL UPTAKE OF NAPHTHALENE IN 

THE F344 RAT. B. Simmons 1 , J. B. Morris 1 and 

A. Buckpitt 2 . 1 Toxicology Program, University of 

Connecticut, Storrs, CT and 2 Mol Biosciences, UC 

Davis, Davis, CA. 

182 




Abstract # 


AMBIENT PARTICULATE MATTER 

SUPPRESSES ALVEOLAR MACROPHAGE 

CYTOKINE RESPONSE TO 

LIPOPOLYSACCHARIDE. K. Sawyer 1 , M. C. 

Madden 2 and A. J. Ghio 2 . 1 Environmental Science 

and Engineering, University of North Carolina at 

Chapel Hill, Chapel Hill, NC and 2 National Health 

Effects Research Laboratory, U.S. EPA, RTP, NC. 


THE ROLE OF SPARC IN ASBESTOS- 

INDUCED PULMONARY FIBROSIS. A. M. 

Smartt, M. Brezinski, A. Brave Rock and E. A. 

Putnam. Biomedical & Pharmaceutical Sciences/ 

Center For Environmental Health Sciences, 

University of Montana, Missoula, MT. Sponsor: M. 

Pershouse. 


TOXICOLOGIC EFFECTS OF ACUTE 

1, 2-DICHLOROETHANE (ETHYLENE 

DICHLORIDE; EDC) INHALATION IN F344 

RATS. J. A. Hotchkiss, K. A. Johnson, A. K. Andrus, 

S. M. Krieger and J. P. Maurissen. Toxicology, 

Environmental Research and Consulting, The Dow 

Chemical Company, Midland, MI. 


BIOAEROSOL EMISSIONS FROM 

COMPOSTING GROUNDS INDUCE 

CYTOTOXICITY AND INFLAMMATORY 

RESPONSES IN RAW264.7 MACROPHAGES. 

M. Roponen 1 , K. Huttunen 1 , H. Rintala 1 , P. 

Kaarakainen 1 , A. Nevalainen 1 and M. Hirvonen 1,2 . 

1 

Department of Environmental Health, National 

Public Health Institute, Kuopio, Finland and 

2 

Department of Environmental Science, University of 

Kuopio, Kuopio, Finland. Sponsor: M. Viluksela. 


COMPARISON OF LUNG INJURY FOR JP-8 

VERSUS S-8 JET FUELS AT THRESHOLD 

CONCENTRATIONS. M. McLaughlin, J. Vargas, 

R. Camponovo, S. S. Wong, K. Le and M. Witten. 

Center for Toxicology & Department of Pediatrics, 

The University of Arizona, Tucson, AZ. 


EXTRAPULMONARY TISSUE 

DISTRIBUTION OF METALS FOLLOWING 

REPEATED LUNG EXPOSURES TO 

WELDING FUMES WITH DIFFERENT 

ELEMENTAL PROFILES. J. M. Antonini, 

J. R. Roberts, K. Sriram, S. A. Benkovic, J. P. 

O’Callaghan and D. B. Miller. NIOSH, Morgantown, 

WV. 


DESIGN OF AN INHALATION EXPOSURE 

SYSTEM TO STUDY SPOT WELDING FUME 

CHARACTERISTICS AND BIOLOGICAL 

EFFECTS. A. A. Afshari, J. M. Antonini, V. 

Castranova, R. Boylstein, R. Kanwal and D. G. 

Frazer. NIOSH, Morgantown, WV. 

Abstract # 


A NOVEL METHOD FOR THE CHEMICAL 

CHARACTERIZATION OF GENERATED 

JET FUEL VAPOR AND AEROSOL FOR 

ANIMAL STUDIES. R. T. Tremblay 1 , S. 

A. Martin 1 , L. D. Fechter 2 and J. W. Fisher 1 . 

1 

Environmental Health Science Department, 

University of Georgia, Athens, GA and 2 Loma Linda 

VA Medical Center, Loma Linda, CA. 


SELECTIVITY OF NEUROPEPTIDE 

RELEASE FROM PULMONARY 

CAPSAICIN-SENSITIVE AFFERENTS 

IN RELATION TO DIESEL EXHAUST 

EXPOSURE. S. S. Wong 1 , N. N. Sun 1 , I. Keith 3 , 

C. Lantz 2 and M. Witten 1 . 1 Center for Toxicology & 

Department of Pediatrics, The University of Arizona, 

Tucson, AZ, 2 Center for Toxicology and Department 

of Cell Biology & Anatomy, The University of 

Arizona, Tucson, AZ and 3 School of Veterinary 

Medicine, University of Wisconsin-Madison, 

Madison, WI. 


DETERMINATION OF CELL 

PROLIFERATION, APOPTOSIS AND 

CYTOKERATIN EXPRESSION IN THE 

EPITHELIUM OF THE DOG LARYNX. A. 

Postoyalko and C. M. Bray. Covance Laboratories 

Ltd, Harrogate, United Kingdom. Sponsor: D. 

Everett. 


1:00 PM to 4:30 PM 

Exhibit Hall 


POSTER SESSION: SIGNAL TRANSDUCTION AND GENE 

REGULATION 

Chairperson(s): Heekyong Bae, Michigan State University, East Lansing, 

MI and Stacey Harper, Oregon State University, Corvallis, OR. 




CIGARETTE SMOKE CONDENSATE 

DOWNREGULATION OF LYSYL OXIDASE 

TRANSCRIPTION MEDIATED BY 

INACTIVATION OF NUCLEAR FACTOR 

I. W. Li, S. Gao, Y. Zhao, P. Toselli and P. Stone. 

Biochemistry, Boston University School of Medicine, 

Boston, MA. 


COX-2 REGULATES NF-kB ACTIVATION 

VIA THE RHO-A/JNK/AP-1 SIGNALING 

AXIS IN RENAL TUBULE CELLS. M. E. Ellis, 

W. W. Polk, P. L. Simmonds, J. V. Kushleika and 

J. S. Woods. Environmental Health, University of 


Tuesday 




Tuesday 



P38 MAP KINASE REGULATES SULFUR 

MUSTARD-INDUCED CYTOKINE 

PRODUCTION INDEPENDENT OF NF-kB 

AND P53 SIGNALING BUT DOES NOT 

REGULATE SULFUR MUSTARD-INDUCED 

CELL DEATH. A. L. Ruff and J. F. Dillman. Cell 

and Molecular Biology, USAMRICD, Aberdeen 



PROTECTIVE EFFECT OF CAFFEIC ACID 

PHENETHYL ESTER ON TERT-BUTYL 

HYDROPEROXIDE-INDUCED OXIDATIVE 

HEPATOTOXICITY. Y. Chung 1 , J. Choi 2,3 , K. 

Lee 2,3 and H. Jeong 2,3 . 1 Division of Food Science, 

Jinju International University, Jinju, South Korea, 

2 




Korea. 


METALLOTHIONEIN-III ENHANCES 

VASCULAR ENDOTHELIAL GROWTH 

FACTOR EXPRESSION THROUGH THE 

ACTIVATION OF HIF-1ALPHA. H. H. Kim 1,2 

and H. Jeong 1,2 . 1 Pharmacy, Chosun University, 

Kwangju, South Korea and 2 Research Center for 

Proteineous Materials, Chosun University, Gwangju, 

South Korea. 


OSTEOPONTIN REGULATES MOUSE 

VASCULAR SMOOTH MUSCLE 

CELL DIFFERENTIATION VIA AN 

EXTRACELLULAR SIGNALING 

TRANSDUCTION PATHWAY. H. Gao 1 , M. C. 

Steffen 1 , T. Fan 2 and K. S. Ramos 1 . 1 Biochemistry, 

University of Louisville, Louisville, KY and 

2 

Chemistry, University of Louisville, Louisville, KY. 


GENE EXPRESSION DIFFERENCES IN P53- 

DEFICIENT DAY-9 MOUSE EMBRYOS. H. 

Hosako, G. S. Martin, M. Barrier, S. H. Safe and P. 

E. Mirkes. Veterinary Physiology & Pharmacology, 

Texas A&M University, College Station, TX. 


TCDD DISRUPTS THE WNT SIGNALING 

PATHWAY IN THE DEVELOPING MOUSE 

KIDNEY. E. MacAulay 1,2 , P. C. Boutros 3 and P. 

A. Harper 2,3 . 1 Pharmaceutical Sciences, University 

of Toronto, Toronto, ON, Canada, 2 Development 

& Stem Cell Biology, Hospital for Sick Children, 

Toronto, ON, Canada and 3 Pharmacology, University 

of Toronto, Toronto, ON, Canada. Sponsor: D. Grant. 


TCDD ALTERS VASCULAR REMODELING 

IN RAT PLACENTA. R. Ishimura 2 , T. Kawakami 2 , 

S. Ohsako 1,2 and C. Tohyama 1,2 . 1 Division of 

Environment Health Sciences, CDBIM, The 

University of Tokyo, Graduate School of Medicine, 

Tokyo, Japan and 2 Environmental Health Sciences 

Division, National Institute for Environmental 

Studies, Tsukuba, Japan. 


EPIGALLOCATECHIN-3-GALLATE 

PREVENTS OBESITY-RELATED FATTY 

LIVER BUT IS HEPATOTOXIC AT HIGH 

DOSES. J. D. Lambert 1 , M. Bose 1 , S. Sang 1 , J. Ju 1 , 

K. R. Reuhl 2 and C. S. Yang 1 . 1 Chemical Biology, 

Rutgers, The State University of New Jersey, 

Piscataway, NJ and 2 Pharmacology and Toxicology, 

Rutgers, The State University of New Jersey, 



TOXIC ENDOVANILLOID ACCUMULATION 

IN THE LUNG LEADS TO TRPV1- 

MEDIATED ER STRESS AND ACUTE LUNG 

INJURY. K. C. Thomas, C. E. Deering, G. S. Yost 

and C. A. Reilly. Pharmacology and Toxicology, 

University of Utah, Salt Lake City, UT. 


EFFECT OF OLEANDRIN ON BINDING AND 

ACTIVITY OF NA-K-ATPASE IN CRUDE 

CARDIAC MEMBRANE PREPARATION. A. 

K. Tiwary 1,2,3 , B. Puschner 1,2,3 and I. N. Pessah 1,3 . 

1 

Graduate Group in Pharmacology and Toxicology, 

University of California, Davis, CA, 2 California 

Animal Health and Food Safety Laboratory, 

University of California, Davis, CA and 3 Veterinary 

Molecular Biosciences, University of California, 

Davis, CA. 


CHANGES IN MITOGEN-ACTIVATED 

PROTEIN KINASE IN CEREBELLAR 

GRANULE NEURONAL CULTURES BY 

POLYBROMINATED DIPHENYL ETHERS. 

C. Fan 2,1 and P. R. Kodavanti 1 . 1 Neurotoxicology 

Division, U.S. EPA, RTP, NC and 2 Curriculum in 


Hill, NC. 


EFFECT OF GINSENOSDIES RD AND 

RF ON ALTERING INTRACELLULAR 

GLUTATHIONE METABOLISM OF C6 

GLIOMA CELLS. W. Y. Ng and M. S. Yang. 

Biology, Hong Kong Baptist University, Kowloon, 

Hong Kong, China. 


BREVETOXIN-INDUCED 

BRONCHOCONSTRICTION AND 

ANTAGONISM IS MODULATED BY 

THE ANTIPARALLEL CHARACTER 

OF SYNTHETIC SIDE CHAINS: 

CHARACTERISTICS FOR SUCCESSFUL 

PULMONARY DRUG DESIGN. D. Baden 1 , S. 

Michelliza 1 , M. Wolf 1 , H. Jacocks 1 and W. Abraham 2 . 

1 

Center for Marine Science, UNCW, Wilmington, NC 

and 2 Department of Research, Mount Sinai Medical 

Center, Miami Beach, FL. 


COMPARISON OF GENE EXPRESSION 

PROFILES IN LIVER OF RATS TREATED 

WITH RIDDELLIINE AND COMFREY. N. 

Mei 1 , L. Guo 2 , S. L. Dial 2 , J. C. Fuscoe 2 and T. Chen 1 . 

1 

Division of Genetic and Reproductive Toxicology, 


Jefferson, AR and 2 Division of Systems Toxicology, 


184 




Abstract # 


RED TIDE TOXIN PRODUCES IN VITRO 

DEPOLARIZATIONS OF HUMAN AIRWAY 

SMOOTH MUSCLE. I. Richards and M. M. 

Bourgeois. Environmental and Occupational Health, 



BIPHASIC REGULATION OF IL2 GENE 

EXPRESSION IN NAïVE CD4+ T CELLS: 

RATE LIMITING ROLES FOR TNF-a 

RECEPTOR SIGNALING AND CHROMATIN 

STRUCTURE. S. C. Mckarns and R. H. Schwartz. 

Laboratory of Cellular and Molecular Immunology, 

NIAID/NIH, Bethesda, MD. 


REGULATION OF TUMOR NECROSIS 

FACTOR-a AND INTERLEUKIN-1b- 

MEDIATED TNF RECEPTOR EXPRESSION 

AND PROINFLAMMATORY RESPONSES 

IN LUNG EPITHELIAL CELLS. S. Saperstein 1 , 

G. S. Pryhuber 1,2 and J. N. Finkelstein 1,2,3 . 

1 


Rochester, NY, 2 Pediatrics, University of Rochester, 

Rochester, NY and 3 Radiation Oncology, University 



INHIBITORY EFFECT OF THE SAPONINS 

DERIVED FROM ROOTS OF PLATYCODON 

GRANDIFLORUM ON ANAPHYLACTIC 

REACTION AND MAST CELL ACTIVATION. 

E. Han 1,2 , Y. Chung 3 and H. Jeong 1,2 . 1 Pharmacy, 

Chosun University, Kwangju, South Korea, 

2 

Research Center for Proteineous Materials, Chosun 

University, Gwangju, South Korea and 3 Division of 

Food Science, Jinju International University, Jinju, 

South Korea. 


IN VIVO AND IN VITRO MECHANISTIC 

ANALYSES OF LIPOPOLYSACCHARIDE 

(LPS)-INDUCED HEPATOTOXICITY 

DEMONSTRATE SIMILAR TOXICITY 

PATTERNS. B. Ganter 1 , N. Zidek 2 , P. Hewitt 2 , D. 

Müller 3 , D. L. Abramovitz 1 , D. N. Halbert 4 and A. 

Vladimirova 1 . 1 Ingenuity Systems, Redwood City, 

CA, 2 Merck KGaA, Darmstadt, Germany, 3 Institute 

of Pharmacology and Toxicology, University of Jena, 

Jena, Germany and 4 Entelos, Foster City, CA. 


SUPPRESSIVE EFFECTS OF PHORBOL- 

12-MYRISTATE-ACETATE ACTIVATED 

CYCLOOXYGENASE-2 EXPRESSION 

BY DIHYDROARTEMISININ IN 

MACROPHAGES. H. Park 1,2 , E. Han 1,2 and H. 




Korea. 

Abstract # 


DEOXYNIVALENOL-INDUCED MAP 

KINASE ACTIVATION MEDIATED VIA 

THE RIBOSOME CAN INDUCE ROBUST 

PROINFLAMMATORY GENE EXPRESSION 

AND APOPTOSIS IN MONONUCLEAR 

PHAGOCYTES. H. Bae 1,2 and J. J. Pestka 1,2,3 . 

1 

Food Science and Human Nutrition, Michigan State 

University, East Lansing, MI, 2 Center for Integrative 


MI and 3 Microbiology and Molecular Genetics, 



UNFOLDED PROTEIN RESPONSE 

INDUCED IN MACROPHAGES BY THE 

TRICHOTHECENE DEOXYNIVALENOL. 

Y. Shi 1,2 and J. J. Pestka 1,2,3 . 1 Food Science and 

Human Nutrition, Michigan State University, East 

Lansing, MI, 2 Center for Integrative Toxicology, 


3 

Microbiology and Molecular Genetics, Michigan 

State University, East Lansing, MI. 


SUPPRESSION OF MAST CELL-MEDIATED 

ALLERGIC REACTION BY AMOMUM 

XANTHIODES. S. Kim. Pharmacology, 

Kyungpook National University Medical School, 

Daegu, South Korea. 


HIGH-THROUGHPUT SCREEN FOR SMALL 

MOLECULE HEDGEHOG SIGNALING 

INHIBITORS RELEVANT TO HUMAN 

EXPOSURE. R. J. Lipinski 1,2 and W. Bushman 2,1 . 

1 

Molecular and Environmental Toxicology Center, 

University of Wisconsin-Madison, Madison, WI 

and 2 Surgery, University of Wisconsin-Madison, 

Madison, WI. 


TRANILAST INHIBITS TRANSCRIPTIONAL 

ACTIVITY OF HYPOXIA INDUCIBLE 

FACTOR. A. Lulla and S. Park. Pharmaceutical 

Sciences, St. John’s University, Queens, NY. 


THE ROLE MAP3K1 IN NICKEL-INDUCED 

LUNG INJURY. M. Mongan, Z. Tan, Z. Peng, G. 

Leikauf and Y. Xia. Environmental Health, University 

of Cincinnati, Cincinnati, OH. 


PRETREATMENT WITH LOW 

CADMIUM CONCENTRATION AND THE 

ANTIOXIDANT ALPHA-LIPOIC ACID 

AFFORDS PROTECTION TO A HIGHER 

CADMIUM CONCENTRATION ON HEPG2 

CELLS BY MODULATION OF THE 

ANTIOXIDANT AND INFLAMMATORY 

GENE EXPRESSION. F. Siller, J. Macias, S. 

Huerta and J. Armendariz. Biologia Molecular y 

Genomica, Universidad de Guadalajara, Guadalajara, 

Jal, Mexico. Sponsor: B. Quintanilla. 

Tuesday 




Tuesday 



1:00 PM to 4:30 PM 

Exhibit Hall 


POSTER SESSION: REPRODUCTIVE SYSTEM 

Chairperson(s): Marion Miller, University of California Davis, Davis, CA 

and Erin Hines, U.S. EPA, Durham, NC. 




VALIDATION OF INHININ B ELISA. R. Kuk 

and D. J. Stanislaus. Reproductive Toxicology, Safety 

Assessment, GlaxoSmithKline, King of Prussia, PA. 

Sponsor: S. Lerman. 


OXIDATIVE STRESS DAMAGE CAUSED 

BY FLUORIDE EXPOSURE DECREASED 

THE IN VITRO FERTILIZATION IN RAT 

SPERMATOZOA. J. A. Izquierdo-Vega 1,2 , 

M. Sanchez-Gutierrez 3 and L. M. Del Razo 1 . 

1 

Toxicology, Cinvestav-IPN, Mexico D.F, Mexico, 

2 

FES-Cuautitlan, UNAM, State of Mexico, Mexico 

and 3 Academic Area of Medicine, UAEH, Pachuca, 

Hidalgo, Mexico. 


DETERMINATION OF PEAK HORMONE 

LEVELS FOLLOWING A SINGLE 

INTRAMUSCULAR INJECTION OF HUMAN 

CHORIONIC GONADOTROPHIN (HCG) 

IN DOGS. B. Han 1 , R. T. Dunn 1 , M. A. Kuhlman 1 , 

A. Mould 2 , J. Wisler 1 , J. Bussiere 1 and I. Pyrah 1 . 

1 

Amgen, Thousand Oaks, CA and 2 Covance, 

Madison, WI. 


EFFECTS OF RESTRICTED FEEDING ON 

PREGNANCY OUTCOME AND BLOOD 

PARAMETERS IN RABBITS. Y. Asano. Bozo 

Research Center, Tagata-gun, Shizuoka, Japan. 

Sponsor: S. Tsuda. 


POSTNATAL DEVELOPMENT AND 

EVALUATION OF THE IMMUNE SYSTEM 

IN THE CYNOMOLGUS MONKEY MODEL 

(MACACA FASCICULARIS). G. Weinbauer, W. 

Frings and A. Fuchs. Covance Laboratories GmbH, 

Muenster, Germany. 


THE EFFECTS OF IN VIVO EXPOSURE 

OF METHOXYCHLOR TO IMMATURE 

RATS ON SERUM PROGESTERONE AND 

ESTRADIOL LEVELS AND THE EX VIVO 

FORMATION OF PROGESTERONE BY 

THECA-INTERSTITIAL CELLS. Y. Akgul 1,2 , 

R. C. Derk 2 and E. P. Murono 2,1 . 1 Physiology 

and Pharmacology, West Virginia University, 

Morgantown, WV and 2 PPRB, NIOSH, Morgantown, 

WV. Sponsor: V. Castranova. 


ANALYSIS OF CYTOGENETIC AND 

DEVELOPMENTAL EFFECTS ON PRE- 

IMPLANTATION MOUSE EMBRYOS 

AFTER MATERNAL EXPOSURE TO 

TRICHLORFON. Y. Tian 1,2 , Z. Shufang 1 , G. Yu 1 , S. 

Li 1 , S. Rong 1 , Z. Yijun 1 , H. Song 3 and S. Xiaoming 2 . 

1 

Environmental Health Department, Shanghai Jiao 

Tong University School of Medicine, Shanghai, 

China, 2 Shanghai Institute for Pediatric Research, 

Shanghai XinHua Hospital affiliated to Shanghai 

Jiaotong University School, Shanghai, China and 

3 

Department of Epidemiology,, Shenyang Medical 

College, Shenyang, China. 


CONSEQUENCES OF PRENATAL PFOA 

EXPOSURE ON MOUSE MAMMARY 

GLAND GROWTH AND DEVELOPMENT 

IN F1 AND F2 OFFSPRING. S. S. White 1,2 , E. P. 

Hines 2 , J. P. Stanko 2 and S. E. Fenton 2 . 1 Curriculum 

in Toxicology, University of North Carolina, 

Chapel Hill, NC and 2 U.S. EPA, ORD, NHEERL, 

Reproductive Toxicology Division, RTP, NC. 


NEONATAL EXPOSURE TO DES INDUCES 

DOSE-DEPENDENT DELAYED EFFECTS AT 

DOSES SHOWING ESTROGENIC ACTIVITY 

IN FEMALE DONRYU RATS. M. Yoshida 1 , 

A. Maekawa 2 and A. Nishikawa 1 . 1 Department of 

Pathology, National Institute of Health Sciences, 

Tokyo, Japan and 2 Chemical Management Center, 

National Institute of Technology and Evaluation, 

Tokyo, Japan. 


OVARIAN FOLLICLE COUNTING USING 

PROLIFERATING CELL NUCLEAR 

ANTIGEN (PCNA) AND SEMI-AUTOMATED 

IMAGE ANALYSIS IN SPRAGUE DAWLEY 

RATS. A. K. Remick 1 , C. L. Swanson 1 , K. 

L. Scully 1 , V. C. Roseman 2 and C. A. Picut 1 . 

1 

WIL Research Laboratories-Biotechnics, LLC, 

Hillsborough, NC and 2 Media Cybernetics, Bethesda, 

MD. Sponsor: G. Parker. 


TRIMETHYL NONANOL: A COMBINED 

REPEATED DOSE TOXICITY STUDY WITH 

THE REPRODUCTION/DEVELOPMENTAL 

TOXICITY SCREENING TEST IN 

CRL:CD(SD) RATS. R. Rasoulpour, N. M. 

Berdasco, E. W. Carney, C. L. Zablotny, A. K. 

Andrus and K. E. Stebbins. Developmental and 

Reproductive Toxicology, The Dow Chemical 

Company, Midland, MI. 


ORAL BIOAVAILABILITY AND KINETICS 

OF BENZO(A)PYRENE DISPOSITION IN 

OVARIAN TISSUES OF F-344 RATS. A. 

Ramesh 1 and A. E. Archibong 2 . 1 Cancer Biology, 

Meharry Medical College, Nashville, TN and 

2 

Obstetrics & Gynecology, Meharry Medical 

College, Nashville, TN. 

186 




Abstract # 


MODULATION OF INTRATESTICULAR 

FUNCTION IN F-344 RATS BY BENZO(A) 

PYRENE. A. E. Archibong 1 , M. S. Niaz 1 , C. M. 

Brooks 1 , S. I. Roberson 1 , A. Ramesh 2 and D. D. 

Lunstra 3 . 1 Obstetrics & Gynecology, Meharry 

Medical College, Nashville, TN, 2 Cancer Biology, 

Meharry Medical College, Nashville, TN and 

3 

Animal Reproduction Division, USDA Meat Animal 

Research Center, Clay Center, NE. 


EVALUATION OF OVOTOXICITY INDUCED 

BY 7, 12-DIMETHYLBENZ[A]ANTHRACENE 

AND ITS 3, 4-DIOL METABOLITE 

UTILIZING A RAT IN VITRO OVARIAN 

CULTURE SYSTEM. Y. Igawa 1,3 , I. Sipes 1 and P. 

B. Hoyer 2 . 1 Pharmacology, University of Arizona, 

Tucson, AZ, 2 Physiology, University of Arizona, 

Tucson, AZ and 3 Biopharma Center, Asubio 

Pharmacology Co., Ltd., Gunma, Japan. 


CIGARETTE SMOKE AND BENZO(A) 

PYRENE CAUSE FOLLICLE LOSS IN VIVO 

AND IN VITRO AT PHYSIOLOGICALLY 

RELEVANT CONCENTRATIONS. A. Mulligan 

Tuttle and W. G. Foster. McMaster University, 

Hamilton, ON, Canada. 


GLUCOCORTICOID RECEPTOR 

ACTIVATION RESTRAINS THE GROWTH- 

PROMOTING EFFECT OF TCDD ON 

MAMMARY EPITHELIAL CELLS. T. 

Wang 1 , B. Lawrence 2 and B. A. Vorderstrasse 1 . 

1 

Pharmaceutical Sciences, Washington State 

University, Pullman, WA and 2 Department of 




EFFECTS OF MOTORCYCLE EXHAUST 

AND COTREATMENT WITH VITAMIN E ON 

SPERM CONTENT AND INTERLEUKIN-6 

EXPRESSION IN RAT TESTIS. T. Ueng, Y. Liu 

and P. Chan. Institute of Toxicology, National Taiwan 

University, Taipei, Taiwan. 


DOES BUTYL ISOCYANATE PLAY A ROLE 

IN THE TUBULIN DEPOLYMERIZING 

ACTION OF THE FUNGICIDE BENOMYL? 

A. Rodriguez and M. G. Miller. Environmental 

Toxicology, UC Davis, Davis, CA. 


ASSESSMENT OF THE EFFECTS OF 

MONOETHYLHEXYLPHTHALATE (MEHP) 

AND MONOBUTYL PHTHALATE (MBP) ON 

GENE EXPRESSION IN FETAL RAT TESTES 

EXPLANT CULTURES BY TRANSCRIPTION 

PROFILING. S. Plummer 1 , F. Chauvigne 2 , B. 

Jégou 2 and C. Elcombe 1 . 1 CXR Biosciences Ltd, 

Dundee, United Kingdom and 2 Inserm, Campus de 

beaulieu, Rennes, France. 

Abstract # 


THE EFFECT OF INDIVIDUAL VS GROUP 

HOUSING ON GROWTH, ONSET OF 

PUBERTY, AND REPRODUCTIVE ORGAN 

DEVELOPMENT IN MICE. S. S. Dimond 1,2 . 

1 

Department of Environmental Health and 

Toxicology, State University of New York at Albany, 

Albany, NY and 2 Environmental, Health and Safety 

Department, SABIC Innovative Plastics, Bedford, 

NH. 


EFFECT OF METHOXYCHLOR 

METABOLITE HPTE IN RAT OVARIAN 

GRANULOSA CELLS. C. N. Harvey 1 , M. Esmail 2 , 

M. Uzumcu 1,2 and R. Zachow 3 . 1 Joint Graduate 

Program of Toxicology, Rutgers University/UMDNJ, 

Piscataway, NJ, 2 Department of Animal Sciences, 

Rutgers University, New Brunswick, NJ and 

3 

Department of Physiology and Biophysics, Robert 

Wood Johnson Medical School, Piscataway, NJ. 


CELL CYCLE REGULATORS IN MOUSE 

OVARIAN ANTRAL FOLLICLES ARE 

ALTERED BY METHOXYCHLOR 

EXPOSURE. R. K. Gupta, H. H. Yao and J. A. 

Flaws. Veterinary Biosciences, University of Illinois, 

Urbana, IL. 


DOSE DEPENDENT EFFECTS OF SERTOLI 

CELL TOXICANTS 2, 5-HEXANEDIONE, 

CARBENDAZIM, AND MONO-(2- 

ETHYLHEXYL) PHTHALATE IN ADULT 

RAT TESTIS. J. S. Moffit, B. H. Bryant, C. L. 

Auriemma, R. T. Glenn, H. Yamasaki, M. A. 

Sandrof, S. J. Hall and K. Boekelheide. Pathology & 

Laboratory Medicine, Brown University, Providence, 

RI. 


REPRODUCTIVE AND DEVELOPMENTAL 

EFFECTS OF GESTATIONAL EXPOSURE 

TO PERFLUOROOCTANOIC ACID IN 

MALE CD-1 MICE. J. P. Stanko 1 , E. P. Hines 1 , S. 

S. White 2,1 , G. R. Klinefelter 1 , L. F. Strader 1 , J. D. 

Suarez 1 and S. E. Fenton 1 . 1 NHEERL, U.S. EPA, 

Research Triangle Park, NC and 2 Curriculum in 


Hill, NC. 


ADULT OUTCOMES OF GESTATIONAL 

OR ADULT EXPOSURE TO 

PERFLUOROOCTANIC ACID (PFOA) IN 

FEMALE CD-1 MICE. E. P. Hines 1 , S. S. White 2 , 

J. P. Stanko 1 and S. E. Fenton 1 . 1 Reproductive 

Toxicology, DBB, ORD, NHEERL, U.S. EPA, 

Durham, NC and 2 Curriculum in Toxicology, UNC, 



EVALUATION OF TWO- 

GENERATION REPRODUCTIVE 

TOXICITY OF FLAME RETARDANT 

HEXABROMOCYCLODODECANE (HBCD) 

IN RATS. M. Ema 1 , S. Fujii 2 , M. Hirata-Koizumi 1 

and M. Matsumoto 1 . 1 Division of Risk Assessment, 

National Insitute of Health Sciences, Tokyo, 

Japan and 2 Safety Research Institute for Chemical 

Compounds Co., Ltd., Sapporo, Japan. 

Tuesday 




Tuesday 



EFFECTS OF IN UTERO AND 

LACTATIONAL EXPOSURE TO 2, 3, 7, 


(TCDD) ON REPRODUCTIVE FUNCTION 

IN MALE RHESUS MONKEYS. A. Arima 1,5 , 

T. Tateishi 1 , K. Hanaki 1 , Y. Nishida 1 , J. Okayama 1 , 

T. Iahara 1 , R. Nagata 1 , S. Kubota 2 , T. Fukusato 3 , 

H. Sumida 4 , M. Yasuda 4 and S. Kamimura 5 . 

1 

Drug Safety Research Laboratories, Shin Nippon 

Biomedical Laboratories, Ltd., (SNBL), Kagoshima, 

Japan, 2 Department of Life Science, Graduate School 

of Arts and Sciences, University of Tokyo, Himeji, 

Japan, 3 Department of Pathology, Teikyo University 

School of Medicine, Tokyo, Japan, 4 Department 

of Clinical Radiology, Faculty of Health Sciences, 

Hiroshima International University, Higashihiroshima, 

Japan and 5 Laboratory of Theriogenology, 

Faculty of Agriculture, University of Miyazaki, 

Miyazaki, Japan. Sponsor: R. Nagata. 


ATSDR’S ACUTE MINIMAL RISK LEVEL 

FOR HEPTACHLOR. Z. A. Rosemond 1 , L. 

Ingerman 2 and C. V. Smith 1 . 1 Division Of Toxicology 

and Environmental Medicine, Agency for Toxic 

Substances and Disease Registry, Atlanta, GA and 

2 

Environmental Science Center, Syracuse Research 

Corporation, Syracuse, NY. Sponsor: R. Williams. 


ABSENCE OF DEVELOPMENTAL 

TOXICITY IN EMBRYOFETAL AND 

PRE- AND POSTNATAL DEVELOPMENT 

STUDIES IN CYNOMOLGUS MACAQUES 

FOLLOWING ANTAGONISM OF IL-12/23 

ACTIVITY WITH USTEKINUMAB (CNTO 

1275). C. Sachs 1 , N. Imai 2 , S. Oneda 2 , H. Tsusaki 2 , 

A. Schantz 1 , J. Marini 1 , D. Graden 1 , G. Treacy 1 and P. 

Martin 1 . 1 Centocor R&D Inc, Radnor, PA and 2 Shin 

Nippon Biomedical Laboratories, Kagoshima, Japan. 


SUBLETHAL TCDD EXPOSURE DURING 

EARLY STAGES OF DEVELOPMENT 

INDUCES CRANIOFACIAL, CARDIAC, AND 

REPRODUCTIVE TOXICITY IN ADULT 

ZEBRAFISH. T. King Heiden 1 , J. Spitsbergen 2 , 

K. M. Xiong 3 , W. Heideman 1,3,4 and R. E. 

Peterson 1,4 . 1 Molecular and Environ Toxicol Center, 

UW-Madison, Madison, WI, 2 Center for Fish Disease 

Research, Oregon State University, Corvallis, OR, 

3 

Depart Biomed Chem, UW-Madison, Madison, WI 

and 4 School of Pharmacy, UW-Madison, Madison, 

WI. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: RISK ASSESSMENT RESEARCH 

Chairperson(s): Gunda Reddy, U.S. Army Center for Health Promotion 

and Preventive Medicine, Aberdeen Proving Ground, MD and Jane Ellen 

Simmons, U.S. EPA, Research Triangle Park, NC. 




THE PHTHALATE ESTERS: 

PHARMACODYNAMIC (PD) VS. 

PHARMACOKINETIC (PK) FACTORS 

AFFECTING POTENCY IN TESTOSTERONE- 

MEDIATED DEVELOPMENTAL EFFECTS. 

R. A. Clewell 1 , J. Campbell 2 , H. Clewell 2 , K. Gaido 2 

and M. Andersen 2 . 1 Environmental Sciences and 

Engineering, University of North Carolina at Chapel 

Hill, Research Triangle Park, NC and 2 The Hamner 

Institutes, Research Triangle Park, NC. 


SODIUM PERFLUOROHEXANOATE: 

ORAL REPEATED DOSE SUBCHRONIC, 

ONE-GENERATION REPRODUCTION, 

GENOTOXICITY, AND DEVELOPMENTAL 

TOXICOLOGY. B. P. Slezak, T. L. Serex, S. E. 

Loveless, R. C. Buck and S. H. Korzeniowski. E.I. 

DuPont de Nemours & Co Inc., Wilmington, DE. 


TOXICOLOGY AND SENESCENCE: 

BASELINE VARIABILITY AND TOLUENE 

EFFECTS ON MOTOR FUNCTION IN 

AGING BROWN NORWAY RATS. R. C. 

MacPhail, J. D. Farmer and K. A. Jarema. NHEERL, 



VALIDATION OF A MORBIDITY SCORE 

IN A STUDY OF BOTULINUM TOXIN A. R. 

Ellis 1 , C. Gennings 1 , J. Benson 2 and B. Tibbetts 2 . 

1 

Biostatistics, Virginia Commonwealth University, 

Richmond, VA and 2 Lovelace Respiratory Research 

Institute, Albuquerque, NM. 


DNA ADDUCT FORMATION OF LOW DOSE 

13C2H2 LABELED METHYLMETHANE 

SULPHONATE. E. F. Tita, G. Boysen, V. Afonin, L. 

Collins and J. A. Swenberg. Environmental Science 

and Engineering, UNC Chapel Hill, Chapel Hill, NC. 


IN VITRO ASSESSMENT OF HUMAN SKIN 

METABOLISM OF AROMATIC AMINE HAIR 

DYES. C. Goebel 1,3 , G. Kunze 2,3 , G. Waterval 2,3 , T. 

Sieber 2,3 , A. Zeller 2,3 and S. Pfuhler 2,3 . 1 CPS, Wella 

Service GmbH, Darmstadt, Germany, 2 CPS, Wella- 

Cosmital, Marly, Switzerland and 3 CPS, Procter 

& Gamble Company, Cincinnati, OH. Sponsor: F. 

Gerberick. 

188 




Abstract # 


HUMAN AND RAT PRIMARY HEPATOCYTE 

CULTURES FOR THE STUDY OF 

PEROXISOME PROLIFERATOR-ACTIVED 

RECEPTOR a (PPARa) AGONISTS 

ACTIVITY IN ENVIRONMENTAL 

CHEMICALS. R. Poon, J. Jiao, M. Rigden and R. 

Bose. Safe Environment Program, Health Canada, 

Ottawa, ON, Canada. Sponsor: I. Chu. 


AN IN VIVO PHOTOCARCINOGENESIS 

STUDY DEMONSTRATING THE VALIDITY 

OF THE SCUP-M ACTION SPECTRUM FOR 

UVR-INDUCED SKIN CANCER. P. D. Forbes, 

D. B. Learn, C. P. Sambuco, M. Arocena and A. M. 

Hoberman. Center for Photobiology, Charles River 

Laboratories Preclinical Services, Horsham, PA. 


ORAL BIOAVAILABILITY OF 

CYCLOTRIMETHYLENETRINITRAMINE 

(RDX) FROM CONTAMINATED SITE SOILS 

IN RATS. L. C. Crouse, M. W. Michie, M. A. 

Major, G. J. Leach and G. Reddy. U.S.Army Center 

for Health promotion and Preventive Medicine, 

Aberdeen Proving Ground, MD. 


IN VIVO BIOAVAILABILITY OF ARSENIC 

IN COAL COMBUSTION BY-PRODUCTS. L. 

J. Bradley 1 , G. M. Fent 2 and S. W. Casteel 2 . 1 ENSR, 

Westford, MA and 2 Veterinary Medical Diagnostic 

Laboratory, University of Missouri, Columbia, MO. 


REDUCTION OF STRAWBERRY PESTICIDE 

RESIDUES USING CALYX REMOVAL AND 

A WATER RINSE. Y. Li, M. M. Bigelow, Z. Chen, 

H. Vega and R. I. Krieger. Environmental Toxicology 

Program, PCEP, Department Entomology, University 

of California, Riverside, Riverside, CA. 


REDUCING ANIMAL USE IN REGULATORY 

TOXICOLOGY: A REVIEW OF CURRENT 

WAIVER SUBMISSIONS UNDER THE EU 

BIOCIDES DIRECTIVE. S. Warren. Centre for 

Chemical Regulation and Food Safety, Exponent 

International, Harrogate, United Kingdom. 


PHASE I TO II CROSS-INDUCTION OF 

XENOBIOTIC METABOLIZING ENZYMES: 

A POTENTIAL SOURCE FOR HORMETIC 

RESPONSES. Q. Zhang 1 , J. Pi 2 and M. E. 

Andersen 1 . 1 Computational Biology, The Hamner 

Institutes for Health Sciences, RTP, NC and 

2 

Translational Biology, The Hamner Institutes for 

Health Sciences, RTP, NC. 


INTEGRATION OF BENCHMARK DOSE 

ANALYSIS WITH GENOMIC DATA TO 

ASSESS THE FUNCTIONAL EFFECTS OF 

CHEMICAL EXPOSURE. B. C. Allen 1 , A. Nong 2 , 

L. Yang 2 , H. J. Clewell 2 , M. E. Andersen 2 and R. S. 

Thomas 2 . 1 Bruce Allen Consulting, Chapel Hill, NC 

and 2 The Hamner Institutes for Health Sciences, 


Abstract # 


ACUTE INHALATION TOXICITY: 

PHYSIOLOGICAL TIME AND SPECIES- 

SPECIFIC HALF-LIFE AS DETERMINANTS 

OF ANIMAL-TO-HUMAN EXTRAPOLATION 

OF TOXICOLOGICALLY EQUIVALENT 

COMBINATIONS OF AIR CONCENTRATION 

AND DURATION. L. R. Rhomberg. Gradient 

Corporation, Cambridge, MA. 


BENCHMARK DOSES FOR CHEMICAL 

MIXTURES: EVALUATION OF A MIXTURE 

OF 18 PHAHS. E. Nyirabahizi 1 , C. Gennings 1 , W. 

W. Piegorsch 2 , S. Yeatts 3 , M. J. DeVito 4 and K. M. 

Crofton 4 . 1 Biostatistics, Virginia Commonwealth 

University, Richmond, VA, 2 BIO5 Institute, Univ of 

Arizona, Tucson, AZ, 3 Biostatistics, Medical Univ of 

South Carolina, Charleston, SC and 4 NHEERL, U.S. 



DEVELOPMENT OF WEIGHTED 

DISTRIBUTIONS OF REPS FOR DIOXIN- 

LIKE COMPOUNDS: IMPLICATIONS FOR 

RISK ASSESSMENT. L. C. Haws 1 , M. J. DeVito 2 , 

J. N. Walker 3 , L. S. Birnbaum 2 , K. M. Unice 4 , P. 

Scott 4 , M. A. Harris 5 , J. A. Tachovsky 1 , W. H. 

Farland 6 , B. Finley 7 and D. F. Staskal 1 . 1 ChemRisk, 

Austin, TX, 2 U.S. EPA, RTP, NC, 3 NIEHS, RTP, NC, 

4 

ChemRisk, Pittsburgh, PA, 5 ChemRisk, Houston, 

TX, 6 Colorado State University, Fort Collins, CO and 

7 

ChemRisk, SanFrancisco, CA. 


VALUE OF INFORMATION ANALYSIS 

INTEGRATING DIVERSE INFORMATION 

SOURCES TO ESTIMATE VARIABILITY 

OF GENOTYPES AND PHENOTYPES OF 

CYP450 ENZYMES IN METABOLISM OF 

CHLORPYRIFOS. W. C. Griffith, E. M. Vigoren 

and E. M. Faustman. Univ of Washington, Seattle, 

WA. 


ASSESSING THE ADEQUACY OF 

THE DEFAULT INTERINDIVIDUAL 

VARIABILITY FACTOR (IVF) USING A 

PHYSIOLOGICALLY-BASED STEADY- 

STATE (PBSS) ALGORITHM. M. Valcke 1,2 and 

K. Krishnan 1 . 1 Université de Montréal, Montréal, 

QC, Canada and 2 Institut national de santé publique 

du Québec, Montreal, QC, Canada. 


TUMOUR DATA FROM HAN WISTAR 

RAT DIETARY AND ORAL GAVAGE 

TUMORIGENICITY STUDIES, COMPLETED 

OVER THE PERIOD OF 1994 TO 2006. W. N. 

Hooks 1 , C. J. Groom 1 , M. Laurent 1 and I. Taylor 2 . 

1 

Division of Toxicology, Huntingdon Life Sciences, 

Huntingdon, Cambridgeshire, United Kingdom 

and 2 Department of Pathology, Huntingdon Life 

Sciences, Huntingdon, Cambridgeshire, United 

Kingdom. Sponsor: C. Hardy. 


RAT STRAIN DIFFERENCES IN NASAL 

TISSUE RESPONSE AND METABOLISM. 

M. Mannix, A. N. Bachman, L. K. Low, J. Lewis 

and M. G. Bird. ExxonMobil Biomedical Sciences, 

Annandale, NJ. 

Tuesday 




Tuesday 



DOSE-RESPONSE COMPARISONS OF 

SINGLE VS. REPEATED EXPOSURES IN 

DEVELOPMENTAL TOXICITY STUDIES. J. 

A. Davis 1 , J. S. Gift 1 , G. M. Woodall 1 , M. Narotsky 2 

and G. L. Foureman 1 . 1 NCEA, U.S. EPA, Research 

Triangle Park, NC and 2 NHEERL, U.S. EPA, 



RETROSPECTIVE ANALYSIS OF 

MULTIGENERATION REPRODUCTION 

TOXICITY STUDIES: WHAT IS THE 

IMPACT OF THE SECOND GENERATION IN 

HAZARD ASSESSMENT FOR PESTICIDES? 

M. E. Reaves 1 , R. Cooper 3 , V. Dellarco 1 , D. Dix 2 , 

M. Martin 2 , E. Mendez 1 and T. Stoker 3 . 1 OPP, U.S. 

EPA, Washington, DC, 2 NCCT-ORD, U.S. EPA, 

Washington, DC and 3 NHEERL-ORD, U.S. EPA, 



THE IMPORTANCE OF ASBESTOS FIBER 

LENGTH AS A PREDICTOR OF POTENCY 

FOR ASBESTOS-RELATED DISEASE. A. D. 

Phelka 1 , J. A. Clarke 2 , D. J. Paustenbach 2 and B. L. 

Finley 2 . 1 ChemRisk, Boulder, CO and 2 ChemRisk, 

San Francisco, CA. 


SKIN SENSITIZATION TO HAIR DYE 

ACTIVES: USE OF SKIN PENETRATION 

DATA IN A QUANTITATIVE RISK 

ASSESSMENT APPROACH. C. Goebel 1 , C. 

Ryan 3 , P. Kern 3 , K. Smith 3 , T. Sieber 2 , H. Rothe 1 

and G. F. Gerberick 3 . 1 CPS, Wella Service GmbH, 

Darmstadt, Germany, 2 Wella-Cosmital, Marly, 

Switzerland and 3 Procter & Gamble Co., Cincinnati, 

OH. 


A NOVEL FRAMEWORK FOR ASSESSING 

RISK FROM FORMALDEHYDE- 

RELEASING BIOCIDES. N. M. Berdasco, S. 

M. Arnold, P. J. Spencer and B. D. Landenberger. 

Toxicology and Environmental Research and 

Consulting, The Dow Chemical Company, Midland, 

MI. 


EVALUATING THE TOXICOLOGICAL 

SIGNIFICANCE OF ENDPOINTS FROM 

HUMAN AND ANIMAL STUDIES: USING 

PERFLUORINATED COMPOUNDS (PFCS) 

AS AN EXAMPLE. A. Lewis, L. A. Beyer and B. D. 

Beck. Gradient Corporation, Cambridge, MA. 


CASE STUDIES FOR THE DEVELOPMENT 

OF A PATHOPHYSIOLOGICAL 

PROGRESSION MODEL. D. G. Dodge 1 , L. T. 

Haber 2 , E. Kopras 3 , J. E. Goodman 4 , I. Pagan 5 , 

J. S. Gift 5 and L. R. Rhomberg 4 . 1 Gradient Corp, 

Seattle, WA, 2 TERA, Cincinnati, OH, 3 University 

of Cincinnati, Cincinnati, OH, 4 Gradient Corp, 

Cambridge, MA and 5 U.S. EPA NCEA, Research 



REMOVING CENSORSHIP BIAS FROM 

CORRELATION ESTIMATES OF DATA SETS 

CENSORED BY LIMITS OF DETECTION. 

E. M. Vigoren, F. Krogstad, W. C. Griffith and E. 

M. Faustman. Institute for Risk Analysis and Risk 

Communication, University of Washington, Seattle, 

WA. 


THE POWER TO DETECT A DIFFERENCE: 

DETERMINING SAMPLE SIZE 

REQUIREMENTS FOR EVALUATION OF 

REPRODUCTIVE/DEVELOPMENTAL 

EFFECTS FROM EXPOSURE TO 

COMPLEX MIXTURES OF DISINFECTION 

BYPRODUCTS. J. Simmons 1 , C. Dingus 2 , L. 

K. Teuschler 3 , G. E. Rice 3 and M. G. Narotsky 1 . 

1 

NHEERL/ORD, U.S. EPA, Research Triangle Park, 

NC, 2 Battelle, Columbus, OH and 3 NCEA/ORD, U.S. 

EPA, Cincinnati, OH. 


GEOSPATIAL CONSIDERATIONS IN 

CALCULATING 95% UPPER CONFIDENCE 

LIMITS ON THE MEAN. M. E. Schuck 1 , K. 

Goff 2 , S. M. Roberts 2 and J. K. Tolson 1,2 . 1 GeoSyntec 

Consultants, Tampa, FL and 2 University of Florida, 



ASSESSMENT OF THE RELEVANCE 

OF CARBOXIN SOIL METABOLITES. E. 

Freeman 1 , V. Clayton 2 , S. Long 1 , U. Wanner 1 , C. 

Pratt 1 and R. Cardona 1 . 1 Chemtura Corporation, 

Middlebury, CT and 2 Crop Protection, Chemtura 

Europe Limited, Slough, United Kingdom. 


BIOAVAILABILITY ADJUSTMENT OF RISK- 

BASED SOIL CLEANUP LEVELS. C. Liu, D. 

Keil and N. Luke. Camp Dresser & McKee, Edison, 

NJ. 


BIOREACTIVITY OF LEACHATE FROM 

MUNICIPAL SOLID WASTE LANDFILLS 

— ASSESSMENT OF TOXICITY. L. Koshy 1 , 

T. Jones 2 and K. BeruBe 1 . 1 School of Biosciences, 

Cardiff University, Cardiff, United Kingdom and 

2 

School of Earth, Ocean and Planetary Sciences, 

Cardiff University, Cardiff, United Kingdom. 

Sponsor: T. Gordon. 


XENOBIOTIC METABOLISM RESEARCH 

AND ITS APPLICATION TO HUMAN AND 

ECOLOGICAL EXPOSURE AND RISK 

ASSESSMENT. J. F. Kenneke 1 , C. S. Mazur 1 , W. 

M. Henderson 1 , A. W. Garrison 1 , S. E. Ritger 2 , T. J. 

Sack 3 , C. C. Brown 3 and J. K. Avants 3 . 1 of Research 

& Development, National Exposure Research 

Laboratory, U.S. Environmental Protection Agency, 

Athens, GA, 2 Student Services Authority, Athens, GA 

and 3 Senior Service America Incorporated, Athens, 

GA. 


BIOMONITORING EQUIVALENTS: CASE 

STUDIES. D. W. Pyatt 2 , L. L. Aylward 1 and S. M. 

Hays 3 . 1 Summit Toxicology, LLP, Falls Church, 

VA, 2 Summit Toxicology, LLP, Lafayette, CO and 

3 

Summit Toxicology, LLP, Lyons, CO. 

190 




Abstract # 


A FRAMEWORK FOR EVALUATING 

SERUM DIOXIN DATA DERIVED FROM 

BIOMONITORING STUDIES. J. D. Urban 1 , L. 

C. Haws 1 , L. F. Scott 2 , P. S. Scott 3 , D. F. Staskal 1 , 

J. A. Tachovsky 1 , K. M. Unice 3 and M. A. Harris 2 . 

1 

ChemRisk, Austin, TX, 2 ChemRisk, Houston, TX 

and 3 ChemRisk, Pittsburgh, PA. 


BIOMONITORING EQUIVALENTS: 

TECHNICAL ISSUES AND GUIDELINES – 

REPORT FROM THE EXPERT WORKSHOP. 

S. M. Hays 2 and L. L. Aylward 1 . 1 Summit Toxicology, 

LLP, Falls Church, VA and 2 Summit Toxicology, 

LLP, Lyons, CO. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: LIVER II: IN VITRO 

Chairperson(s): Craig Thomas, Lilly Research Labs, Greenfield, IN and 

Blair Bradford, University of North Carolina Chapel Hill, Chapel Hill, 

NC. 




COMPARISON OF HUMAN CYP 

INDUCTION BETWEEN IN VIVO AND IN 

VITRO STUDIES USING PXB MICE ® WITH 

HIGHLY REPOPULATED HUMANIZED 

LIVER. M. Kakuni 1 , C. Yamasaki 1 , A. Tachibana 1 , 

Y. Yoshizane 1 , S. Ninomiya 2 and C. Tateno 1 . 1 Study 

Service Department, PhoenixBio Co., Ltd., Higashihiroshima, 

Japan and 2 ADME-TOX Research 

Institute, Daiichi Pure Chemicals, Co., Ltd., Tokai, 

Japan. Sponsor: T. Miyaoka. 


DEVELOPMENT AND VALIDATION OF 

A HEPATOCYTE ASSAY THAT DETECTS 

REACTIVE METABOLITE CYTOTOXICITY. 

D. D. Baker 1 , Y. LaForge 2 , M. Hickman 1 , M. 

Abbasian 1 , O. Laskin 1 , A. P. Li 2 and P. J. Lapinskas 1 . 

1 

Exploratory Toxicology, Signal Pharmaceuticals, 

LLC, a wholly owned subsidiary of Celgene Corp., 

San Diego, CA and 2 In Vitro ADMET Laboratories, 

LLC., Rockville, MD. 


FUNCTIONAL STABILITY OF HUMAN 

HEPATOMA HEPARG CELLS AND THEIR 

USE FOR CHRONIC TOXICITY AND 

GENOTOXICITY STUDIES. R. Josse 1 , C. 

Aninat 1 , D. Glaise 1 , J. Poul 3 , R. Li 4 , C. Gugen- 

Guillouzo 2 and A. Guillouzo 1 . 1 INSERM U. 620, 

Université de Rennes 1, Rennes, France, 2 INSERM 

U. 522, Hôpital de Pontchaillou, Rennes, France, 

3 

Agence Française de Sécurité Sanitaire des 

Aliments, Fougères, France and 4 BIOPREDIC 

International, Rennes, France. Sponsor: B. 

International. 

Abstract # 


APPLICATION OF A NEW HEPATOCYTES 

PRESERVATION TECHNOLOGY USING 

A UNIQUE MATRIX TO IN VITRO 

TOXICOLOGY ASSAYS. T. Yamamoto 1 , M. 

Kobayashi 1 , T. Tomari 1 , B. Griffiths 2 , A. Watson 2 , K. 

Suzuki 3 , T. Ebihara 3 , P. Evans 4 , N. Ishii 5 , N. Tashiro 5 

and N. Tsutsui 1 . 1 Mitsubishi Tanabe Pharmacology 

Corporation, Kisarazu, Chiba, Japan, 2 Abcellute 

Limited, Cardiff, United Kingdom, 3 GeneFrontier 

Corporation, Chuo-ku, Tokyo, Japan, 4 Cardiff School 

of Biosciences, Cardiff University, Cardiff, United 

Kingdom and 5 Kashima Laboratory, Mitsubishi 

Chemical Safety Institute LTD, Sunayama, Ibaraki, 

Japan. Sponsor: J. Sugimoto. 


CYTOTOXICITY OF DEOXYNIVALENOL IN 

RAT LIVER CLONE-9 CELLS IN CULTURE. 

S. C. Sahu, L. H. Garthoff, M. G. Robl, S. J. 

Chirtel, D. I. Ruggles, T. J. Flynn and T. J. Sobotka. 

Toxicology, U.S. Food and Drug Administration, 

Laurel, MD. 


THE IN VITRO AND IN VIVO FUNCTIONAL 

EFFECTS OF A LIPOPHILIC ANTI- 

INFLAMMATORY COMPOUND ON 

BILIARY CLEARANCE IN THE RAT. P. 

A. Duffy, J. Eakins, J. Barber, C. Summers, A. 

Marsden, A. Bigley, J. Evans and H. Powell. Global 

Safety Assessment, AstraZeneca Pharmaceuticals, 

Macclesfield, Cheshire, United Kingdom. 


AN IN VITRO SCREENING APPROACH 

FOR PREDICTING HEPATOTOXICITY. R. 

J. Ochalski, S. Culp, G. Kenna, Y. Dragan and M. 

Otieno. AstraZeneca, Wilmington, DE. 


SCREENING FOR MECHANISM OF 

HEPATOTOXICITY: PHOSPHOLIPIDOSIS, 

STEATOSIS, APOPTOSIS AND 

INFLAMMATORY MARKERS. R. Keyser, 

Y. Ovechkina and C. O’Day. MDS Pharmacology 

Services, Bothell, WA. Sponsor: L. KIng. 


MICROARRAY ANALYSIS OF 

TROVAFLOXACIN-INDUCED GENE 

EXPRESSION CHANGES IN HUMAN 

HEPATOCYTES COMPARED TO 

HEPATOCYTES ISOLATED FROM RATS 

TREATED WITH LPS. E. Sparkenbaugh 1 , P. 

Shaw 1 , P. E. Ganey 1 , R. A. Roth 1 , A. Ditewig 2 , E. G. 

Blomme 2 , M. Liguori 2 and J. F. Waring 2 . 1 Department 

of Pharmacology and Toxicology, Michigan State 

University, East Lansing, MI and 2 Cellular and 

Molecular Toxicology, Abbott Laboratories, Abbott 

Park, IL. 


GENE EXPRESSION AND PATHWAY 

ANALYSIS TO STUDY THE EFFECT OF 

CELLULAR STRESS ON IDIOSYNCRATIC 

DRUG INJURY IN RAT PRIMARY 

HEPTOCYTES. M. Mukai, R. A. Jolly, X. Zhang, 

J. P. Stutz, G. H. Searfoss and C. E. Thomas. Eli Lilly 

& Co., Greenfield, IN. 

Tuesday 




Tuesday 



ROLE OF HYDRAZINE IN ISONIAZID- 

INDUCED HEPATOTOXICITY IN A 

HEPATOCYTE INFLAMMATION MODEL. S. 

Tafazoli and P. J. O’Brien. Pharmaceutical Sciences, 



CHOLOROACETONITRILE-INDUCED 

CYTOTOXICITY AND OXIDATIVE STRESS 

IN ISOLATED RAT HEPATOCYTES. O. S. 

El-Tawil 1 , A. H. Abou-Hadeed 2 , A. A. Shalaby 3 and 

S. M. Mouneir 4 . 1 Department of Toxicology and 

Forensic Medicine, Faculty of Veterinary Medicine, 

Cairo University, Giza, Cairo, Egypt, 2 Department 

of Forensic Medicine and Toxicology, Faculty of 

Veterinary Medicine, Zagazig University, Zagazig, 

Egypt, 3 Department of Biochemistry, Faculty of 

Veterinary Medicine, Suez Canal University, Ismalia, 

Egypt and 4 Department of Pharmacology, Faculty of 

Veterinary Medicine, Cairo University, Giza, Cairo, 

Egypt. Sponsor: A. Kadry. 


4-HYDROXYNONENAL AND 

4-OXONONENAL MAY CONTRIBUTE TO 

HEPATOSTEATOSIS BY DISRUPTING 

CELLULAR MICROTUBULES. B. Stewart and 

D. Petersen. University of Colorado at Denver and 

Health Sciences Center, Denver, CO. 


MITOCHONDRIALLY-TARGETED 

DELIVERY OF A STABLE NITROXIDE 

PROTECTS HUMAN HEPATOCYTES FROM 

TROGLITAZONE- OR DICLOFENAC- 

INDUCED CELL INJURY. U. A. Boelsterli 1,2,3 , P. 

L. Lim 2 , W. Siu 2 , J. Liu 3 and M. Go 3 . 1 Pharmaceutical 

Sciences, University of Connecticut, Storrs, CT, 

2 

Pharmacology, NUS, Singapore, Singapore and 

3 

Pharmacy, NUS, Singapore, Singapore. 


PROBING THE ROLE OF REACTIVE 

OXYGEN SPECIES ON ACQUISITION 

OF HEPATITIS B VIRUS HOTSPOT 

MUTATIONS IN VITRO. S. S. Iyer 1 , S. Kuang 1 , 

T. Nilles 1 , W. G. Nelson 2 and J. D. Groopman 1 . 

1 

Johns Hopkins Bloomberg School of Public Health, 

Baltimore, MD and 2 Johns Hopkins School of 

Medicine, Baltimore, MD. 


APPLICATION OF STEATOSIS ASSAY 

FOR THE ASSESSMENT OF HUMAN 

HEPATOTOXICITY : ONO-NT-126, 

A THROMBOXANE RECEPTOR 

ANTAGONIST, INHIBITS MITOCHONDRIAL 

BETA-OXIDATION AND INDUCES 

STEATOSIS. S. Neki 1 , H. Oida 1 , A. Hashimoto 1 , 

N. Matsumoto 2 , M. Konishi 1 and Y. Aze 1 . 1 Safety 

Research Laboratories, Ono Phamaceutical CO., 

LTD., Fukui, Japan and 2 Discovery Technology 

Laboratory, Medicinal Chemistry Research 

Laboratories, Ono Phamaceutical CO., LTD., Osaka, 

Japan. 


3, 3’, 4, 4’, 5-PENTACHLOROBIPHENYL 

(PCB 126) DEREGULATES PROLIFERATION 

OF CONTACT-INHIBITED RAT LIVER 

EPITHELIAL ‘STEM-LIKE’ CELLS VIA 

ARYL HYDROCARBON RECEPTOR – 

EFFECTS ON CELL CYCLE REGULATORS, 

CELL-TO-CELL COMMUNICATION AND 

INTERACTIONS WITH OTHER SIGNALING 

PATHWAYS. J. Vondracek 1,2 , J. Zatloukalova 1,2 , L. 

Umannova 1,2 , V. Bryja 1 , P. Krcmar 2 , A. Kozubik 1 , C. 

Dietrich 3 and M. Machala 2 . 1 Institute of Biophysics, 

Brno, Czech Republic, 2 Veterinary Research Institute, 

Brno, Czech Republic and 3 Institute of Toxicology, 

Johannes Guttenberg University, Mainz, Germany. 


ROLE OF PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR-a( IN OROTIC 

ACID-INDUCED HEPATIC STEATOSIS. E. 

Jung, S. Jang, J. Chung and B. Lee. Seoul National 

University, Seoul, South Korea. 


SEX-RELATED DIFFERENCES IN 

METHIONINE TOXICITY IN FRESHLY 

ISOLATED MOUSE HEPATOCYTES AND 

EVIDENCE FOR TRANSAMINATION, BUT 

NOT TRANSMETHYLATION, PLAYING A 

KEY MECHANISTIC ROLE. J. T. Dever and A. 

A. Elfarra. Molecular and Environmental Toxicology 

Center, University of Wisconsin-Madison, Madison, 

WI. 


MECHANISMS FOR ENHANCED TNFa 

EXPRESSION BY WYETH 14, 643 IN RAT 

KUPFFER CELLS. Z. Wang. Pharmacology and 

Toxicology, Indiana University School of Medicine, 

Indianapolis, IN. Sponsor: L. Kamendulis. 


PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR a (PPARa) 

AGONISTS SUPPRESS ETHANOL-INDUCED 

OSTEOPONTIN EXPRESSION IN BILIARY 

EPITHELIAL CELLS. J. Lee, M. M. Wallace 

and S. K. Ramaiah. Pathobiology, Texas A&M 

University, College station, TX. 


EFFECT OF 2, 3, 7, 


(TCDD) ON THE EXPRESSION OF 

APOPTOSIS-RELATED GENES IN MOUSE 

LIVER AND PRIMARY RAT HEPATOCYTES. 

M. Chopra, M. Chopra and D. Schrenk. 

Food Chemistry & Toxicology, University of 

Kaiserslautern, Kaiserslautern, Germany. 


PRECLINICAL MECHANISTIC 

INVESTIGATION FOR RAT SPECIFIC 

HYPERBILIRUBINEMIA INDUCED BY 

MLN8054. C. Q. Xia, L. Gan, V. J. Kadambi, Y. Li, 

N. Liu, V. Uttamsingh, R. Gallegos, M. N. Milton, 

J. Wu, S. R. Prakash, C. L. Alden, F. W. Lee and 

S. K. Balani. Millennium Pharmaceuticals, Inc., 

Cambridge, MA. 

192 




Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: ASSESSMENT OF ECOLOGICAL 

TOXICOLOGY 

Chairperson(s): Louis Trombetta, St. Johns University, New York, NY and 

Michael Hemmer, U.S. EPA, Gulf Breeze, FL. 




EFFECTS OF DILTIAZEM AND 

LANTHANUM ON COPPER INHIBITION 

OF MITOCHONDRIAL O 2 

CONSUMPTION 

OF GILL OF THE AMERICAN OYSTER, 

CRASSOSTREA VIRGINICA. K. McCoy, M. A. 

Carroll and E. J. Catapane. Biology, Medgar Evers 

College, Brooklyn, NY. Sponsor: C. Miller. 


THE TOXIC EFFECTS OF MARINE 

BIOCIDE COPPER PYRITHIONE (COPPER 

2-PYRIDINETHIOL-1-OXIDE) ON 

JUVENILE BROOK TROUT, SALVELINUS 

FONTINALIS. D. A. Borg and L. D. Trombetta. 

Pharmaceutical sciences, St. Johns University, New 

York. 


THE EFFECTS OF COPPER- 

DIMETHYLDITHIOCARBAMATE 

ON MITOCHONDRIAL-DEPENDENT 

APOPTOSIS AND HEAT SHOCK PROTEIN 

60 IN RAT HIPPOCAMPAL ASTROCYTES. A. 

C. Solanki and L. D. Trombetta. St. Johns University, 

New York. 


EFFECTS OF CADMIUM ON GROWTH AND 

METAMORPHOSIS OF AFRICAN CLAWED 

FROG. B. Sharma 1 and R. Patiño 2 . 1 Natural 

Resource Management, Texas Tech University, 

Lubbock, TX and 2 USGS Texas Cooperative Fish 

and Wildlife Research Unit, Texas Tech University, 

Lubbock, TX. 


BIOACCUMULATION OF MERCURY FROM 

MERCURY CONTAMINATED SOILS BY THE 

EARTHWORM LUMBRICUS TERRESTERIS. 

A. C. Nichols, D. A. Steffy and A. J. McLaughlin. 

Physical and Earth Sciences, Jacksonville State 

University, Jacksonville, AL. 


TIERED TESTING APPROACH TO 

DETERMINE POTENTIAL ANDROGENIC 

RECEPTOR EFFECTS OF THE HUMAN 

PHARMACEUTICAL, INSPRA ® IN FISH. M. 

A. Moen 1 , L. A. Constantine 1 , J. F. Ericson 1 , J. C. 

Cook 2 and D. B. Huggett 3 . 1 PDM - Environmental 

Sciences, Pfizer, Inc., Groton, CT, 2 DSRD - 

Investigative Toxicology, Pfizer, Inc., Groton, CT 

and 3 Department of Biological Sciences, University 

of North Texas, Denton, TX. 

Abstract # 


PROTEOMICS IN ECOTOXICOLOGY: 

PROTEIN EXPRESSION PROFILING TO 

SCREEN CHEMICALS FOR ANDROGENIC 

ACTIVITY. M. J. Hemmer 1 , K. A. Salinas 1 , P. A. 

Harris 1 , J. W. Ng 1 and C. C. Walker 2 . 1 Gulf Ecology 

Division, NHEERL, ORD, U.S. Environmental 

Protection Agency, Gulf Breeze, FL and 2 National 

Marine Fisheries Service, NOAA, Pascagoula, MS. 

Sponsor: W. Benson. 


PROTEOMIC RESPONSES IN THE 

GILL AND MUSCLE OF ZEBRAFISH 

FOLLOWING IBUPROFEN EXPOSURE. P. 

Adhikari, B. Venables and D. B. Huggett. University 

of North Texas, Denton, TX. 


PROTEOMIC AND GENE EXPRESSION 

CHANGES IN THE FATHEAD MINNOW 

LIVER IN RESPONSE TO FLUTAMIDE AND 

TRENBOLONE WATERBORNE EXPOSURE. 

C. J. Martyniuk 1 , D. Villeneuve 2 , G. T. Ankley 2 and N. 

D. Denslow 1 . 1 Center for Environmental and Human 

Toxicology, University of Florida, Gainesville, FL 

and 2 U.S. EPA, Duluth, MN. 


HEPATIC GENE EXPRESSION IN RAINBOW 

TROUT (ONCORHYNCHUS MYKISS) 

EXPOSED TO DIFFERENT HYDROCARBON 

MIXTURES. S. Hook 1 , M. A. Lampi 2 , E. J. Febbo 2 , 

J. A. Ward 1 and T. F. Parkerton 2 . 1 Battelle, PNWD, 

Sequim, WA and 2 2. ExxonMobil Biomedical 

Sciences, Annandale, NJ. 


SPECIFIC AHR AND ERALPHA IN VITRO 

TOXICITY OF CRUDE AND REFINED 

PETROLEUM PRODUCTS. C. Vrabie 1 , A. 

J. Murk 2,3 , M. O. Jonker 1 and M. van den Berg 1 . 

1 

Institute for Risk Assessment Sciences, Utrecht 

University, Utrecht, Netherlands, 2 Toxicology, 

Wageningen University, Wageningen, Netherlands 

and 3 Wageningen Imares, Wageningen, Netherlands. 


EFFECT OF MICROCYSTIS AERUGINOSA 

LIPOPOLYSACCHARIDE (LPS) ON 

NEONATAL RAT BRAIN MICROGLIA 

RELEASE OF SUPEROXIDE ANION, 

THROMBOXANE B 2 

, TUMOR 

NECROSIS FACTOR-a AND MATRIX 

METALLOPROTEINASE-9. A. M. Mayer 1 , M. 

A. Holland 1 , M. L. Hall 1 , P. B. Jacobson 2 and J. P. 

Berry 3 . 1 Pharmacology, Midwestern University, 

Downers Grove, IL, 2 Abbott Laboratories, Abbott 

Park, IL and 3 Chemistry and Biochemistry, Florida 

International University, Miami, FL. 


EFFECTS OF BENZO[A]PYRENE ON 

MITOCHONDRIAL DNA DAMAGE IN THE 

KILLIFISH (FUNDULUS HETEROCLITUS). 

D. Jung, J. Meyer and R. Di Giulio. Nicholas School 

of the Environment and Earth Sciences, Duke 


Tuesday 




Tuesday 



EFFECTS OF POLYBROMINATED 

DIPHENYLETHER (DE-71) EXPOSURE ON 

STEROIDOGENSIS IN JUVENILE XENOPUS 

(SILURANA) TROPICALIS. D. J. Fort 1 , R. 

L. Rogers 1 , P. D. Guiney 2 and J. A. Weeks 2 . 1 Fort 

Environmental Laboratories, Stillwater, OK and 2 S.C. 

Johnson & Son, Racine, WI. 


MONITORING OF ENVIRONMENTAL 

POLYCYCLIC AROMATIC 

HYDROCARBONS (PAH) IN FISH, 

VEGETATION AND SOIL FROM THE 

CUCHARILLAS MARSHLAND, CATANO, 

PUERTO RICO. P. Nieves 1,2 , J. Marengo 1 , W. 

L. Lopez 1 , C. Velez 1 and B. Zayas 1 . 1 School of 

Environmental Affairs, Universidad Metropolitana, 

San Juan, PR and 2 School of Science and 

Technology, Universidad Metropilitana, San Juan, 

PR. Sponsor: D. Herreno. 


ASSESSMENT OF PERFLUORINATED 

CHEMICALS (PFCS) DEVELOPMENTAL 

TOXICITY USING EMBRYONIC 

ZEBRAFISH. L. Duong 1 , A. Benninghoff 2 and R. 

Tanguay 1,2 . 1 Environmental Science, Oregon State 

University, Corvallis, OR and 2 Environmental and 

Molecular Toxicology, Oregon State University, 



THE DISPOSITION AND REPRODUCTIVE 

TOXICITY OF PBDE-47 AND 

PERFLUOROCTANOIC ACID IN FISH 

AFTER ORAL DOSING. I. R. Schultz 1 , D. 

Haskell 1 , S. Lema 2 and P. Swanson 2 . 1 Battelle PND, 

Sequim, WA and 2 NOAA NWFSC, Seattle, WA. 


COMPARISON OF PREDICTED AND 

EXPERIMENTALLY DERIVED VALUES 

FOR THE DURATION OF THE EXPOSURE 

PHASE IN FISH BIOCONCENTRATION 

STUDIES. K. Barrett 1 , W. Davies 1 , A. D. 

Langford-Pollard 2 and D. Kirkpatrick 1 . 1 Programme 

Management, Huntingdon Life Sciences, 

Huntingdon, Cambs, United Kingdom and 

2 

Enviornmental Sciences, Huntingdon Life Sciences, 

Huntingdon, Cambs, United Kingdom. Sponsor: S. 

Dean. 


COMPARING THE TOXICITY AND 

BIOACCUMULATION POTENTIAL OF 

BULK AND NANO ALUMINUM OXIDE 

USING EISENIA FETIDA. J. Coleman, D. R. 

Johnson, A. J. Bednar and J. A. Steevens. U.S. 

Army Engineer Research and Development Center, 

Vicksburg, MS. 


DIALLYL SULFIDE INCREASES 

DIETHYLSTILBESTROL EXPOSED MCF10A 

CELL VIABILITY AND REDUCES DNA 

SINGLE STRAND BREAKS. M. McCaskill, A. 

Aboyade-Cole, O. Newell, A. Tucker and R. Thomas. 

College of Pharmaceutical Sciences, Florida A&M 

University, Tallahassee, FL. 


EFFECT OF THE CYP1A INHIBITOR 

FLUORANTHENE ON THE 

BIOTRANSFORMATION OF BENZO[A] 

PYRENE IN TWO POPULATIONS OF 

FUNDULUS HETEROCLITUS WITH 

DIFFERENT EXPOSURE HISTORIES. L. 

Battle 1 , S. Zhu 2 , K. Willett 2 and R. Di Giulio 1 . 

1 

Duke University, Durham, NC and 2 University of 

Mississippi, University, MS. 


INVESTIGATION OF THE LACK 

OF CYTOCHROME P450 1A1 GENE 

EXPRESSION IN PADDLEFISH (POLYODON 

SPATHULA). L. Sardinia, R. Fitzmorris and 

D. Gundersen. Environmental Science, Pacific 

University, Forest Grove, OR. 


REPRODUCTIVE TOXICITY OF 

NORETHINDRONE TO JAPANESE 

MEDAKA. J. V. Storey, P. Paulos, T. LaPoint and D. 

B. Huggett. University of North Texas, Denton, TX. 


CHARACTERIZATION OF METABOLIC 

ENZYMES AND METABOLIC STABILITY 

IN RAINBOW TROUT CRYOPRESERVED 

HEPATOCYTES AND S9 LIVER FRACTIONS. 

K. M. Johanning 1 , J. Sahi 1 , J. Rebecca 1 , J. Wright 1 , 

I. Schultz 2 , J. Hill 1 , M. Shaw 1 and L. Dungan 1 . 

1 

CellzDirect, Inc., Austin, TX and 2 Battelle, Pacific 

Northwest National Laboratory, Sequim, WA. 


TOXICOGENOMIC RESPONSES OF 

RAINBOW TROUT EXPOSED TO 

CONTAMINANTS. S. E. Hook and I. R. Schultz. 

Battelle PND, Sequim, WA. 


SIMULTANEOUS ANALYSIS OF DOMOIC 

ACID KINETICS AND ELISA ASSAYS TO 

GUIDE PUBLIC HEALTH DECISIONS 

FOR MULTIPLE SHELLFISH SPECIES. F. 

Krogstad, E. Dusek, E. M. Vigoren, M. S. Parker, W. 

C. Griffith, C. A. Simenstad and E. M. Faustman. 



BIOMARKERS OF EXPOSURE AND 

TOXICITY IN ECOLOGICAL RECEPTORS. 

M. A. Kelley 1 , A. Gillespie 1 , B. Duncan 2 , T. 

McDonald 1 , G. Zhou 1 and K. C. Donnelly 1 . 1 Texas 

A&M University, College Station, TX and 2 U.S. EPA 

Region 10, Seattle, WA. 


AN EXAMINATION OF HYPOTHESES FOR 

THE MECHANISM OF TRIBUTYLTIN- 

INDUCED IMPOSEX. R. M. Sternberg, A. 

K. Hotchkiss and G. A. LeBlanc. Environmental 



194 





1:30 PM to 4:30 PM 

Hyatt 

E. Anderson Amphitheater 

K–12 Paracelsus Goes to the Classroom—The TEAMS 

Project: Toxicologists Educating and Mentoring 

Students 

Chairperson(s): Katie Sprugel, Amgen, Seattle, WA and Vanessa 

Fitsanakis, King College, Bristol, TN 

Continuing the tradition of providing public outreach in conjunction 

with the Annual Meeting, the Committee on K–12 Education will host a 

symposium for high school students by videoconferencing from the Annual 

Meeting to classrooms around the state of Washington. Twelve groups of 

students will present their projects to one another and to a panel of toxicologists 

in a morning and an afternoon session. Other students will have 

the opportunity to submit an electronic version of their project for a virtual 

poster session. The presentations will educate other students about a health 

or environmental health issue of importance to the students or their community. 

Toxicologists from SOT will also serve as mentors in the months 

preceding the meeting as the students develop their presentations. 


1:30 PM to 2:30 PM 


Exhibitor Hosted Session: Covance: Outsourcing 

Preclinical Safety Assessment—How to Create a 

Strategy for Success 

Presented by: Covance 

The consideration to outsource your preclinical safety assessment studies 

cannot be approached without consideration of many factors—your 

strengths and resources, identifying what you need in an outsourcing 

partner, your timelines and options to successfully meet your milestones, 

and deciding on the right combination of available options. Learn more 

about critical considerations that will contribute to your success in developing 

the right outsourcing strategy for your program. 


1:30 PM to 2:30 PM 


Exhibitor Hosted Session: Global Metabolomic 

Analysis in Drug Discovery and Development 

Presented by: Metabolon, Inc. 

Small molecule biomarkers are the most common approach to diagnose and 

monitor human disease. Detection of endogenous biochemicals and xenobiotics 

also provides solutions for compound profiling and optimization, 

toxicology, drug discovery, and drug safety. Metabolon’s analytical mass 

spectrometry platform and proprietary data analysis software provides a 

method for the detection and identification of small molecules across a 

wide array of sample types. An overview of the technology and numerous 

case study examples will be provided. 

Abstract # 


1:30 PM to 4:15 PM 

Room 605 


SYMPOSIUM SESSION: ENDOTHELIAL DYSFUNCTION: 

MORE THAN JUST A ‘NO NO̓ PHENOMENON 

Chairperson(s): Matthew Campen, Lovelace Respiratory Research 

Institute, Albuquerque, NM and Daniel Conklin, University of Louisville, 


Endorsed by: 



Various environmental and anthropomorphic toxins can cause direct or 

indirect injury to the vasculature, resulting in endothelial cell dysfunction. 

Endothelial dysfunction is thought to be an early marker of vascular injury 

and precedes overt macro- and microvascular pathology (e.g., atherosclerosis, 

peripheral artery disease, angiopoathy), and may even be a crucial 

factor in end-stage lung disease. Endothelial dysfunction has been measured 

in many forms such as decreased endothelium-dependent relaxation, 

increased expression of endothelial cell adhesion molecules (e. g., ICAM-1, 

VCAM-1, selectins, etc), increased circulating endothelial-derived products 

(e.g., sICAM-1, ET-1, vWF, etc…), and increased vascular permeability. 

Endothelial dysfunction is often linked to a generalized decrease in bioavailable 

or bioactive nitric oxide (NO), which could result from diminished 

eNOS expression, decreased eNOS activity due to decreased co-factor availability 

or protein uncoupling, and/or increased superoxide production, which 

can sequester NO to form peroxynitrite. In addition, as toxicants combine 

with pre-existing disease conditions to amplify vascular oxidative stress, 

endothelial dysfunction is typically evidenced by increased superoxide 

production, increased iNOS and cytokine expression, and increased protein 

modification by peroxynitrite, which could result in protein inactivation. 

Despite inconsistencies among methodologies across laboratories, and some 

variation among findings, data largely indicate that a variety of inhaled and 

ingested xenobiotics can adversely impact endothelial function, especially in 

the setting of pre-existing disease. 

#1251 1:30 ENDOTHELIAL DYSFUNCTION: MORE 

THAN JUST A ‘NO NO̓ PHENOMENON. 

M. J. Campen 1 and D. J. Conklin 2 . 1 Cardiovascular 

and Respiratory Physiology, Lovelace Respiratory 

Research Institute, Albuquerque, NM and 2 Institute 

of Molecular Cardiology, University of Louisville, 


#1252 1:41 MECHANISMS OF ENDOTHELIAL 

DYSFUNCTION: RELEVANCE TO INHALED 

PM. S. Rajagopalan. Ohio State University Medical 

Center, Columbus, OH. Sponsor: D. Conklin. 

#1253 2:03 EFFECTS OF INHALED DIESEL EXHAUST 

ON VASCULAR OXIDATIVE STRESS 

AND ENOS FUNCTION. T. L. Knuckles 1 , S. 

Lucas 1 , A. Lund 1 , T. Cherng 2 , N. Kanagy 2 and M. 

Campen 1 . 1 Lovelace Respiratory Research Institute, 

Albuquerque, NM and 2 University of New Mexico, 


#1254 2:25 REGULATION OF ENDOTHELIAL CELL 

ADHESION MOLECULES BY ACROLEIN, 

AN ENVIRONMENTAL ALDEHYDE. S. E. 

D’Souza 1 , S. D. Sithu 1 , E. N. Vladykovskaya 2 , 

D. J. Conklin 2 , A. Bhatnagar 2 and S. Srivastava 2 . 

1 

Physiology, University of Louisville, Louisville, KY 

and 2 Molecular Cardiology, University of Louisville, 


Tuesday 




Tuesday 


#1255 2:47 ULTRAFINE PARTICULATE MATTER 

INHALATION ATTENUATES 

MICROVASCULAR ENDOTHELIAL NITRIC 

OXIDE PRODUCTION. T. R. Nurkiewicz 1 , D. 

W. Porter 2 , A. F. Hubbs 2 , B. T. Chen 2 , D. G. Frazer 2 

and V. Castranova 2 . 1 Center for Interdisciplinary 

Research in Cardiovascular Sciences, West Virginia 

University, Morgantown, WV and 2 PPRB/HELD, 

National Institute for Occupational Safety and 

Health, Morgantown, WV. 

#1256 3:09 DIESEL EXHAUST EXPOSURE INCREASES 

BLOOD PRESSURE, SYMPATHETIC 

ACTIVITY, AND CORONARY ARTERY 

CONSTRICTOR FUNCTION. N. L. Kanagy 1 , 

M. J. Campen 2 , T. W. Cherng 1 and B. R. Walker 1 . 

1 

University of New Mexico, Albuquerque, NM 

and 2 Lovelace Respiratory Research Institute, 


#1257 3:31 ENDOTHELIAL DYSFUNCTION AND 

ENVIRONMENTAL ALDEHYDES: ACROSS 

SPECIES COMPARISONS. D. J. Conklin. 

Cardiology, University of Louisville, Louisville, KY. 

#1258 3:53 ADENOSINE RECEPTOR INVOLVEMENT 

IN THE CONSTRICTOR RESPONSES 

FOLLOWING ULTRAFINE PARTICULATE 

MATTER EXPOSURE. C. J. Wingard 1 , M. 

R. Van Scott 1 , A. Bofferding 1 , T. Martin-Nims 1 , 

W. E. Cascio 2 , R. B. Devlin 3 and R. M. Lust 1 . 

1 

Physiology, Brody School of Medicine at East 

Carolina University, Greenville, NC, 2 Medicine 

Division of Cardiology, Brody School of Medicine 

at East Carolina Univeristy, Greenville, NC and 

3 

National Health and Enviromental Effects Research 

Laboratory, United States Environmental Protection 

Agency, Research Triangle Park, NC. Sponsor: M. 

Campen. 


1:30 PM to 4:15 PM 

Room 611 


SYMPOSIUM SESSION: NEUROTOXICANT-INDUCED 

ALTERATIONS IN DEVELOPMENTAL AND ADULT 

NEUROGENESIS: STRUCTURE-FUNCTION STUDIES AND 

CLINICAL RELEVANCE 

Chairperson(s): Donald Fox, University of Houston, Houston, TX and 

Tomas Guilarte, Johns Hopkins Bloomberg School of Public Health, 


of neurogenesis - especially the coordination of proliferation and cell fate 

specification - and will address the adverse effects of known neurotoxicants 

on neurogenesis in the brain and retina. The speakers will provide an integrated 

overview of these processes and molecular mechanisms in several 

different brain regions; present the molecular mechanisms of how low-level 

gestational lead exposure produces a selective increase in neurogenesis and 

cell proliferation of late-born retinal neurons (rods and bipolar cells), but not 

glial cells, which results in both a novel retinal phenotype and function in 

children and adult animals; discuss the mechanisms of how ethanol exposure 

during different life stages produces long-term changes in hippocampal 

neurogenesis, survival and cognitive function; describe the mechanisms of 

chronic lead exposure during early life on cell proliferation, survival and 

phenotypic differentiation of progenitor cells in the hippocampus and how 

these changes compromise synaptic plasticity and cognition. 

#1259 1:30 NEUROTOXICANT-INDUCED 

ALTERATIONS IN DEVELOPMENTAL AND 

ADULT NEUROGENESIS: STRUCTURE- 

FUNCTION STUDIES AND CLINICAL 

RELEVANCE. D. A. Fox 1 and T. R. Guilarte 2 . 

1 

College of Optometry, University of Houston, 

Houston, TX and 2 Environmental Health Sciences, 

Johns Hopkins, Baltimore, MD. 

#1260 1:35 REGULATION AND SPECIFICATION 

OF NEUROGENESIS AND CELL FATE 

DURING CENTRAL NERVOUS SYSTEM 

DEVELOPMENT AND ADULTHOOD: 

AN OVERVIEW, CHALLENGES AND 

QUESTIONS. M. A. Dyer. Developmental 

Neurobiology, St. Jude Childrens’ Research Hospital, 

Memphis, TN. Sponsor: D. Fox. 

#1261 2:15 GESTATIONAL LEAD EXPOSURE (GLE) 

UPREGULATES CELL CYCLE GENES 

AND PROLONGS RETINAL PROGENITOR 

CELL (RPC) PROLIFERATION RESULTING 

IN INCREASED ROD PHOTORECEPTOR 

AND BIPOLAR CELLS. D. A. Fox. College of 

Optometry, University of Houston, Houston, TX. 

#1262 2:55 ALCOHOL DYSREGULATION OF ADULT 

NEUROGENESIS: EFFECTS ACROSS THE 

LIFESPAN. K. Nixon. Pharmaceutical Sciences, 

University of Kentucky, Lexington, KY. Sponsor: D. 

Fox. 

#1263 3:35 ADULT NEUROGENESIS IN THE 

HIPPOCAMPUS: ALTERATIONS BY 

LEAD EXPOSURE AND LONG-TERM 

IMPLICATIONS FOR SYNAPTIC 

PLASTICITY AND COGNITION. T. R. Guilarte. 


University Bloomberg School of Public Health, 


Endorsed by: 




Neurotoxicology Specialty Section* 

The orderly formation of the CNS requires a multitude of complex, integrated 

and simultaneously occurring processes. Neural progenitor cells 

expand through proliferation, commit to different cell fates, exit the cell 

cycle, and generate different neuronal and glial cell types. New neurons 

then migrate to specified areas and establish synaptic connections. A similar 

neurogenic process has been identified in certain regions of the adult brain. 

Gestational, postnatal and/or adult exposure to well-known environmental 

toxicants, pharmacological agents and drugs of abuse produce persistent 

alterations in behavioral, cognitive, sensory and motor functions that likely 

reflect a disruption of these processes of CNS development. This symposium 

will provide a framework for understanding the orchestrated events 

196 




Abstract # 


1:30 PM to 4:15 PM 

Room 602 

SYMPOSIUM SESSION: NOVEL BIOMARKERS OF DRUG- 

INDUCED TOXICITY: OUTCOMES OF PREDTOX AND THE 

PREDICTIVE SAFETY TESTING CONSORTIUM 

Chairperson(s): I Rosenblum, Rosenblum Consulting, LLC, Newton, NJ 

and Denise Robinson-Gravatt, Pfizer, Inc., Groton, CT. 

Endorsed by: 




There is general agreement regarding the potential for safety biomarkers to 

provide earlier and more sensitive or specific indicators of preclinical and 

clinical safety, to improve understanding of mechanisms of toxicity, and to 

speed up and/or reduce the cost of preclinical drug safety evaluation. It is 

also increasingly recognized that the path to establishing new biomarkers is 

time and resource intensive, and will be more efficiently progressed through 

collaborative approaches. To this end, several consortia have been created 

to jointly develop the necessary data to advance novel safety biomarkers. 

The European Commission’s PredTox Project, involving pharmaceutical 

companies, universities and regulatory agencies in Europe has focused on 

the usefulness of “ʻomic” technologies in preclinical safety testing, and the 

value of combining results from omics technologies with the results from 

more conventional toxicology methods. Likewise, the Predictive Safety 

Testing Consortium (PSTC) has been established as a collaboration between 

the pharmaceutical industry, the FDA, and the Critical Path Institute, with 

the mission to efficiently qualify new biomarkers of drug-induced toxicity 

for application in drug development and regulatory decision-making. Both 

of these efforts have made use of the combined resources of the participants 

to rapidly discover (PredTox) and qualify (PSTC) new safety biomarkers. 

The involvement of regulatory scientists assures progress toward predictive 

biomarkers that are relevant for preclinical and investigative clinical 

application and regulatory decision-making. The Symposium will showcase 

progress of the working groups of PredTox and the PSTC toward novel 

assays of nephrotoxicity, hepatotoxicity, vascular injury, and non-genotoxic 

carcinogenicity, as well as an overview of the regulatory review process for 

these assays within the Pilot Process for Biomarker Qualification initiative 

at the FDA. 

#1264 1:30 NOVEL BIOMARKERS OF DRUG-INDUCED 

TOXICITY: OUTCOMES OF PREDTOX 

AND THE PREDICTIVE SAFETY TESTING 

CONSORTIUM. D. Robinson-Gravatt 1 and I. Y. 

Rosenblum 2 . 1 Drug Safety R&D, Pfizer, Groton, 

CT and 2 Non-clinical Drug Development, Kyowa 

Pharmaceutical Inc., Princeton, NJ. 

#1265 1:40 FIRST REGULATORY SUBMISSION 

OF NEWLY QUALIFIED ACCESSIBLE 

BIOMARKERS OF NEPHROTOXICITY 

VIA A NEW ROLLING QUALIFICATION 

PROCESS. J. P. Vonderscher 1 and F. D. Sistare 2 . 

1 

Exploratory Development, Novartis, Basel, 

Switzerland and 2 Safety Assessment, Merck, White 

House Station, NJ. 

#1266 2:00 NOVEL BIOMARKERS OF 

HEPATOTOXICITY. P. Wier 1 and K. 

Kolaja 2 . 1 Safety Assessment, GlaxoSmithKline 

Pharmaceuticals, King of Prussia, PA and 

2 

Investigative Toxicology, Roche, Palo Alto, CA. 

#1267 2:20 QUALIFYING NOVEL BIOMARKERS OF 

VASCULAR INJURY. M. Lawton 1 and R. Snyder 2 . 

1 

Investigative Toxicology, Pfizer Global Research 

and Development, Groton, CT and 2 Genetic and 

Molecular Toxicology, Schering-Plough Research 

Institute, Summit, NJ. 

Abstract # 

#1268 2:40 VALIDATION OF RAT HEPATIC mRNA 

SIGNATURES FOR NONGENOTOXIC 

HEPATOCARCINOGENS. B. Car 1 and P. G. 

Lord 2 . 1 Bristol-Myers Squibb Co., Princeton, NJ and 

2 

GPCD, J&J PRD LLC, Raritan, NJ. 

#1269 3:00 ʻOMICS IN HEPATOTOXICITY 

PREDICTION. A. Mally. Department of 

Toxicology, University of Wuerzburg, Wuerzburg, 

Germany. Sponsor: F. Pfannkuch. 

#1270 3:20 AN INTEGRATED ʻOMICS APPROACH 

TOWARDS A BETTER UNDERSTANDING OF 

DRUG-INDUCED NEPHROTOXICITY AND 

USEFUL BIOMARKERS. F. Staedtler. Biomarker 

Development, Novartis Pharmacology AG, Basel, 

Switzerland. 

#1271 3:40 A YEAR OF BIOMARKER QUALIFICATION 

SUBMISSIONS THROUGH THE 

PILOT PROCESS FOR BIOMARKER 

QUALIFICATION AT THE FDA. F. M. 

Goodsaid. Genomics/OCP/OTS/CDER/FDA/HHS, 

Silver Spring, MD. Sponsor: I. Rosenblum. 



1:30 PM to 4:15 PM 

Room 6C 


WORKSHOP SESSION: DERMAL TOXICOLOGICAL 

ASSESSMENT OF NANOMATERIALS AND NANODEVICES 

Chairperson(s): Dave Hobson, H&H Scientific Services, LLP, Boerne, TX 

and Robert Osterberg, Aclairo Pharmaceutical Development Group, Inc., 

Vienna, VA. 

Endorsed by: 


Nanotoxicology Specialty Section 


Developments in nanotechnology are creating a rapidly increasing number 

and variety of engineered nanomaterials and nanodevices with potential 

for dermal applications in topical drug and cosmetic product formulations. 

Dermal exposures associated with various industrial applications, occupations 

and environmental releases related to these developments may also 

occur. The small size and large surface area of nanomaterials provides for 

unique properties of these materials in addition to their chemical composition 

that allow them to advance or enhance technology in an expanding 

number and variety of applications such as consumer goods (foods, household 

goods, cosmetics, textiles, etc.), drugs and drug delivery systems and 

diagnostic systems. Dermal exposures to nanomaterials have potential to 

enhance or modify the efficacy of therapeutics and skin protectants as well 

as show toxicity that is differential to that expected due to chemical composition 

and from materials that normally could not gain entrance to the body 

via dermal routes that are relatively unique to nanomaterials. While some 

nanomaterials appear to be safe at this time, it is becoming evident that 

nanomaterials may become differentially activated biologically and exhibit 

pharmacologically and toxicologically significant properties that are not 

evident in micro or macroparticulate forms for the same materials that must 

be taken into account in the design of dermal toxicological studies. The 

results of different investigations being conducted internationally clearly 

indicate that the biological activity and pharmacokinetics of nanoparticles 

are different from non-nanoparticles. These differences can change the 

protein binding, cellular uptake, distribution and the pathologies of materials 

for which toxicities are already understood and may make prediction of 

dermal toxicity even more difficult and complex than presently exists with 

current testing methodologies. Current data demonstrate that nanomaterials 

should be tested using specific modifications to existing procedures or using 

Tuesday 




Tuesday 


new methods specifically developed to optimize the assessment of toxicological 

effects of these nanomaterials. 

#1272 1:30 DERMAL TOXICOLOGICAL ASSESSMENT 

OF NANOMATERIALS AND NANODEVICES. 

D. Hobson 1 and R. Osterberg 2 . 1 H&H Scientific LLP, 

Boerne, TX and 2 Aclairo PDG Inc., Vienna, VA. 

#1273 1:45 SAFETY CONSIDERATIONS FOR THE 

DEVELOPMENT OF NANOMATERIALS 

AND NANODEVICES WITH TOPICAL 

EXPOSURE POTENTIAL. D. Hobson. H&H 

Scientific LLP, Boerne, TX. 

#1274 2:15 FDA PERSPECTIVE ON TOPICAL 

NANOMATERIALS IN COSMETICS. R. 

Bronaugh. FDA, College Park, MD. 

#1275 2:45 CHPA PERSPECTIVES FOR 

NANOTECHNOLOGY DERIVED 

CONSUMER PRODUCTS. H. Schneider. 

Consumer Healthcare Products Association, 


#1276 3:15 STUDY DESIGN CONSIDERATIONS FOR 

THE EVALUATION OF SKIN EXPOSURES 

AND BIODISTRIBUTION TO ENGINEERED 

NANOPARTICLES. N. A. Monteiro-Riviere. North 


#1277 3:45 ASSESSMENT OF THE DERMAL 

PENETRATION AND TOXICITY OF 

NANOPARTICULATE METALS. S. M. Roberts, 

K. W. Powers and S. C. Wasdo. University of 

Florida, Gainesville, FL. 


1:30 PM to 4:15 PM 

Room 608 

WORKSHOP SESSION: HOST SUSCEPTIBILITY AND 

CHEMICAL SAFETY TESTING: NEW APPROACHES TO 

ESTIMATE RISKS IN THE HUMAN POPULATION (ITS) 

Chairperson(s): Ivan Rusyn, University of North Carolina Chapel Hill, 

Chapel Hill, NC and John French, NIEHS, Research Triangle Park, NC. 

Endorsed by: 


Drug Discovery Toxicology 

Regulatory and Safety Evaluation 


The focus of classical toxicology is on dose-response relationships and 

mode-of-action paradigms. Yet, the effects of many drug and environmental 

chemical exposures are context dependent, with genetic diversity between 

individuals a major variable that is usually overlooked in safety testing. 

Recent advances in our basic understanding of the genetic diversity of the 

human genome, as well as genomes of model organisms used in toxicity and 

safety assessment testing, not only provide an improved basis for species 

comparisons, but also serve as a lead into designing new approaches for 

understanding and estimating the risks in a genetically diverse population. 

The presentations and discussion in this session will highlight 1) new initiatives 

being considered for improvement of chemical testing at the National 

Toxicology Program based on host susceptibility and high throughput testing 

systems; 2) the use of genetic differences between isogenic mouse strains to 

develop knowledge applicable to human populations studies with regard to 

assessment of organ-specific toxicity of xenobiotics; 3) experimental models 

that explore the relationship between highly conserved mouse and human 

genes that affect responses to environmental agents; 4) the utility of denselygenotyped 

mouse and human lymphoblast cell lines to discover genetic 

polymorphisms that may be critical to population-wide responses to environmental 

agents; and 5) a perspective for introducing the aspect of genetic 

diversity and the relative value into drug safety evaluation of pharmaceuticals. 

Improved approaches and methods based on the rapid developments in 

genetics and genetic tools should lead to improvements in the use of experimental 

models for the identification of the genes and their allelic forms 

associated with phenotypes of interest for extrapolation to humans and to 

aid in the identification of orthologous human genes in genetically diverse 

human populations. 

#1278 1:30 HOST SUSCEPTIBILITY AND CHEMICAL 

SAFETY TESTING: NEW APPROACHES 

TO ESTIMATE RISKS IN THE HUMAN 

POPULATION. I. Rusyn 1 and J. E. French 2 . 

1 

Environmental Sciences and Engineering, The 

University of North Carolina at Chapel Hill, Chapel 

Hill, NC and 2 Laboratory of Molecular Toxicology, 

NIEHS, NIH, Research Triangle Park, NC. 

#1279 1:45 GENETIC VARIATION AND INDIVIDUAL 

SUSCEPTIBILITY TO ENVIRONMENTAL 

EXPOSURE AND DISEASE. J. E. French. Host 

Susceptibility Branch, NIEHS, NIH, Research 


#1280 2:15 MOUSE MODELS FOR HUMAN 

POPULATIONS AND DISEASE: BUILDING 

A HUMAN-TO-MOUSE-TO-HUMAN 

CHEMICAL SAFETY TESTING PARADIGM. 

D. Threadgill 1,2 , I. Rusyn 2 and A. Hege 2 . 1 Genetics, 


2 



#1281 2:45 THE GENETIC BASIS FOR 

SUSCEPTIBILITY TO ENVIRONMENTAL 

LUNG DISEASES IN MOUSE AND HUMANS. 

S. R. Kleeberger. NIEHS, Research Triangle Park, 

NC. Sponsor: J. French. 

#1282 3:15 GENETICS OF VARIATION IN HUMAN 

GENE EXPRESSION AT BASELINE AND IN 

RESPONSE TO GENOTOXIC AGENTS. V. G. 

Cheung. Departments of Pediatrics and Genetics, 

University of Pennsylvania, Philadelphia, PA. 

Sponsor: J. French. 

#1283 3:45 UNDERESTIMATING THE IMPACT 

OF RODENT GENETICS ON 

PHARMACEUTICAL SAFETY ASSESSMENT. 

F. D. Sistare. Safety Assessment, Merck & Co., Inc., 

West Point, PA. 


1:30 PM to 4:15 PM 

Room 6B 

WORKSHOP SESSION: MOLECULAR MECHANISMS AND 

MOLECULAR BIOLOGY OF METAL CARCINOGENESIS 

Chairperson(s): Joseph Landolph, Keck School of Medicine, University 

of Southern California, Los Angeles, CA and Max Costa, New York 


Endorsed by: 





Specific compounds of the metals, nickel, chromium, cadmium, and lead, 

and the metalloid, arsenic, are human carcinogens. Mechanisms of metal/ 

metalloid carcinogenesis include uptake of ions into cells by cellular transport 

systems - anion transport carriers for soluble Cr(VI)compounds or 

phagocytosis for insoluble Ni or Cr compounds, followed by dissolution of 

metal ions inside cells. Intracellular Ni(II) and Cr(III) ions bind to proteins. 

198 




Abstract # 

Reduction of protein-bound metal/metalloid ions [Ni or Cr(VI)ions] inside 

cells leads to oxygen radical generation, and 8-OH-dG, which leads to mutagenesis 

and gene amplification. Low doses of Pb, Cd, and As also interact 

to induce oxidative protein damage and 8-hydroxy-dG damage in DNA. 

Studies of metal ions in yeast cells indicate that many metal ions cause 

substantial global de-regulation of gene expression in yeast. In mammalian 

cells, Ni(II)ions cause chromosome aberrations and amplification of 

onocogenes, leading to over-expression of proto-oncogene mRNAs and 

proteins and expression of mutated oncogene protein products. Ni(II)ions 

also cause chromatin condensation and inhibition of histone demethylases. 

This then leads to DNA methylation and silencing of many genes, including 

tumor suppressor genes. The combinationn of activation of oncogenes and 

inactivation of tumor suppressor genes by metal ions, leads to loss of transcription 

of genes controlled by actively transcribed tumor suppressor genes 

and aberrantly high expression of genes controlled by proto-oncogenes, 

in mammalian cells. This results in global disruption of gene expression 

in cells. Approximately 150 genes are aberrantly expressed in Ni(II)transformed 

cell lines. The resultant global disruption in cellular gene expression 

leads to neoplastic transformation of cells, hence carcinogenesis. 

#1284 1:30 MOLECULAR MECHANISMS AND 

MOLECULAR BIOLOGY OF METAL 

CARCINOGENESIS: CHEMISTRY, 

MOLECULAR GENETICS, EPIGENETICS, 

AND ABERRATIONS IN GENE 

EXPRESSION. J. R. Landolph 1,2,3 . 1 Department 

of Molecular Microbiology and Immunology, 

University of Southern California, Los Angeles, 

CA, 2 Department of Pathology, University of 

Southern California, Los Angeles, CA and 3 USC/ 

Norris Comprehensive Cancer Center, University of 

Southern California, Los Angeles, CA. 

#1285 1:35 MOLECULAR TOXICOLOGY OF 

TRANSITION METALS: FROM YEAST TO 

MAN. J. H. Freedman. LMT, NIEHS, NIH, DHHS, 


#1286 2:05 CHEMISTRY AND BIOLOGY OF 

CHROMIUM CARCINOGENESIS. A. 

Zhitkovich. Brown University, Providence, RI. 

#1287 2:35 INSOLUBLE NICKEL COMPOUNDS 

INDUCE GENOTOXIC AND EPIGENETIC 

EVENTS, GLOBAL DISRUPTION OF GENE 

EXPRESSION, AND MORHOLOGICAL/ 

NEOPLASTIC TRANSFORMATION OF 

10T1/2 MOUSE EMBRYO CELLS. J. R. 

Landolph 1,2,3 , A. DeSilva 2,3 , H. K. Lee 1,2 , N. 

Garg 1,2 and D. Fleck 1,2 . 1 Department of Molecular 

Microbiology and Immunology, University of 

Southern California, Los Angeles, CA, 2 Department 

of Pathology, University of Southern California, 

Los Angeles, CA and 3 USC/Norris Comprehensive 

Cancer Center, University of Southern California, 

Los Angeles, CA. 

#1288 3:05 EPIGENETIC MECHANISMS OF NICKEL 

ION CARCINOGENESIS BY INHIBITION 

OF HISTONE DEMETHYLASES ( H3K9). 

M. Costa 1,2 and H. Chen 1 . 1 Env Med, New York 

University School of Medicine, New York and 

2 

Pharmacology, New York University Cancer 

Institute, New York University Schoolx of Medicine, 

New York. 

#1289 3:35 INTERACTIONS AMONG ARSENIC, 

CADMIUM, AND LEAD IN CAUSING 

TOXICITY AND CARCINOGENESIS. B. A. 

Fowler 1 , G. Wang 2 and M. H. Whittaker 3 . 1 Agency 

for Toxic Substances and Disease Registry, Atlanata, 

GA, 2 M. D. Anderson Cancer Center, Houston, TX 

and 3 ToxServices LLC, Washington, DC. 


Abstract # 


1:30 PM to 4:15 PM 

Room 6A 


WORKSHOP SESSION: STRATEGIES FOR ASSESSING 

DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY OF 

BIO-PHARMACEUTICALS 

Chairperson(s): Mark Hurtt, Pfizer, Inc., Groton, CT and Barbara Davis, 

Millennium Pharmaceutical, Inc., Cambridge, MA. 

Endorsed by: 


The current ICH Guidance (S6 Preclinical Safety Evaluation of Biotechnology-Derived 

Pharmaceuticals, July 1997) for reproductive performance 

and developmental toxicity studies describes a case-by-case situation for 

every new entity. “The need for reproductive/developmental toxicity studies 

is dependent upon the product, clinical indication and intended patient 

population. The specific study design and dosing schedule may be modified 

based on issues related to species specificity, immunogenicity, biological 

activity, and/or a long elimination half-life.” In addition to the lack of 

specific guidance, development of monoclonal antibodies and other biological 

modalities for therapy presents some challenges to traditional practices 

for assessing developmental and reproductive toxicity. The characteristics of 

target specificity without off-target toxicity attributed to this type of therapy 

brings into question the rationale and approaches for standard testing protocols, 

including the choice of nonclinical test species. Of particular concern 

is the increased emphasis on using non-human primates as a primary test 

species in reproductive studies. Working groups are addressing the scientific 

and ethical concerns of using non-human primates and developing 

strategies for standard toxicology testing (Chapman K, Pullen N, Graham 

M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance 

of species relevance. Nat Rev Drug Discov. 2007:120-6). A focused 

discussion of the strategies for testing bio-pharmaceuticals for potential 

reproductive and developmental toxicity is merited. This workshop will 

bring together experts in the fields of reproductive and developmental toxicology, 

biologics, and regulatory agencies to discuss relevant reproductive 

testing strategies for bio-pharmaceuticals. 

#1290 1:30 STRATEGIES FOR ASSESSING 

DEVELOPMENTAL AND 

REPRODUCTIVE TOXICOLOGY OF BIO- 

PHARMACEUTICALS. M. Hurtt 1 and B. Davis 2 . 

1 

Drug Safety, Pfizer, Groton, CT and 2 Millennium 

Pharmaceutical Inc, Cambridge, MA. 

#1291 1:45 ISSUES IN DEVELOPMENTAL 

AND REPRODUCTIVE TESTING 

OF BIOPHARMACEUTICALS AND 

COMMUNICATION OF HUMAN RISK. J. 

Cavagnaro. Access BIO, Boyce, VA. 

#1292 2:15 FDA REGULATORY PERSPECTIVE ON 


TESTING FOR BIOPHARMACEUTICALS. H. 

Ghantous. CDER/DAVP, U.S. -FDA, Silver Spring, 

MD. 

#1293 2:45 EU REGULATORY PERSPECTIVE ON 

TOXICITY TESTING FOR REPRODUCTIVE 

AND DEVELOPMENTAL TOXICITY. J. W. 

van der Laan. Centre for Biological Medicines and 

Medical Technology, RIVM, Bilthoven, Netherlands. 

Sponsor: M. Hurtt. 

#1294 3:15 APPROACHES TO TESTING FOR 


TOXICITY: USE OF NONHUMAN 

PRIMATES. G. J. Chellman. Preclinical Services, 

Charles River Laboratories, Sparks, NV. 

Tuesday 




Tuesday 


#1295 3:45 APPROACHES TO TOXICITY TESTING FOR 


TOXICITY: USE OF SURROGATES. J. L. 

Bussiere. Toxicology, Amgen, Inc., Thousand Oaks, 

CA. 


1:30 PM to 4:15 PM 

Room 618 

ROUNDTABLE SESSION: HUMAN HEALTH RISK ASSESSMENT 

FOR PHARMACEUTICALS IN THE ENVIRONMENT (PIE) 

Chairperson(s): Hal Zenick, U.S. EPA, Research Triangle Park, NC and 

Daniel Caldwell, Johnson & Johnson, New Brunswick, NJ. 

Endorsed by: 

Mixtures Specialty Section 



Numerous studies have documented the presence of low levels of mixtures 

of emerging contaminants, including human and veterinary medicines, in 

surface water. These findings are gaining increasing attention. Scientists and 

the media are questioning the potential impact of these substances on human 

health and on environmental species. Several issues need to be considered. 

For example, what are the pathways of entry of human and veterinary medicines 

to the environment and how can potential exposures be derived from 

monitoring and modeling data. Significant water reuse in certain regions of 

the U.S. and the current state of water treatment underscore the importance 

of valid exposure assessments related to PIE. Preclinical and clinical toxicology, 

pharmacology and metabolic data generated during the process of 

drug development and registration can be used to support human health risk 

assessments. The Federal Interagency PIE Working Group has been formed 

to identify some of the key definitional issues, data gaps, research priorities 

and collaborations. Additionally, there are U.S. EPA mandates and regulations 

that could be applied and critical considerations need to be defined. 

The session addresses these issues and provides an interactive discussion. 

#1296 1:30 HUMAN HEALTH RISK ASSESSMENT 

FOR PHARMACEUTICALS IN THE 

ENVIRONMENT (PIE). D. J. Caldwell 2 , 

E. Hayes 1 and H. Zenick 3 . 1 Corporate Quality 

Environment Health and Safety, Bristol-Myers 

Squibb Company, New Brunswick, NJ, 2 Worldwide 

Environmental Affairs, Johnson & Johnson, New 

Hope, PA and 3 National Health and Environmental 

Effects Research Laboratory, Office of Research 

and Development, U.S. Environmental Protection 

Agency, Research Triangle Park, NC. 

#1297 1:35 DEVELOPMENT OF PHARMACEUTICALS 

IN THE ENVIRONMENT AS AN ISSUE 

AND CONSIDERATIONS FOR EXPOSURE 

ASSESSMENT. R. T. Williams. Pharmaceutical 

Sciences, Pfizer Global Research and Development, 

Groton, CT. Sponsor: F. Mastrocco. 

#1298 2:00 TREATMENT AND TREATABILITY 

OF PHARMACEUTICALS IN WATER 

TREATMENT PLANTS. D. Sedlak. Civil and 

Environmental Engineering, University of California, 

Berkeley, CA. Sponsor: E. Hayes. 

#1299 2:25 INTERAGENCY PRIORITIES AND 

COLLABORATION IN ADDRESSING 

PHARMACEUTICALS IN THE 

ENVIRONMENT. H. Zenick. National Health and 

Environmental Effects Research Laboratory, Office 

of Research and Development, U.S. Environmental 


#1300 2:50 HUMAN HEALTH RISK ASSESSMENT 

OF PHARMACEUTICALS IN THE 

ENVIRONMENT: A REGULATORY 

PERSPECTIVE. E. Ohanian and O. Conerly. 

Health and Ecological Criteria Division, Office 

of Science and Technology, Office of Water, U.S. 


#1301 3:15 HAZARD IDENTIFICATION AND 

HUMAN HEALTH RISK ASSESSMENTS 

RELATED TO PHARMACEUTICALS IN 

THE ENVIRONMENT. E. Hayes 1 , J. Cook 2 , F. 

Mastrocco 3 and R. Meyerhoff 4 . 1 Corporate Quality 

Environment Health and Safety, Bristol-Myers 

Squibb Company, New Brunswick, NJ, 2 Safety 

Sciences, Pfizer, Inc., Groton, CT, 3 Corporate 

Environment Health and Safety, Pfizer, Inc., New 

York and 4 Lilly Research Laboratories, Eli Lilly & 

Company, Indiannapolis, IN. 



1:30 PM to 4:15 PM 

Room 2A 

PLATFORM SESSION: ARSENIC TOXICITY 

Chairperson(s): Susan Makris, U.S. EPA, Washington, DC. 

#1302 1:30 ARSENIC IMPAIRS PANCREATIC BETA- 

CELL FUNCTION: INVOLVEMENT OF 

OXIDATIVE STRESS RESPONSE. J. Pi 1 , J. Fu 2 , 

Q. Zhang 1 , C. G. Woods 1 , G. Sun 2 , M. E. Andersen 1 

and S. Collins 1 . 1 The Hamner Institutes for Health 

Sciences, RTP, NC and 2 China Medical University, 

Shenyang, China. 

#1303 1:52 ABERRANT CYTOKERATIN EXPRESSIONS 

ASSOCIATED WITH ARSENIC-INDUCED 

MALIGNANT TRANSFORMATION OF 

HUMAN KERATINOCYTES. Y. Sun, J. Pi, J. Liu 

and M. Waalkes. Inorganic Carcinogenesis Section, 

LCC, NCI at NIEHS, Research Triangle Park, NC. 

#1304 2:14 ARSENIC ALTERS FOCAL ADHESION 

COMPLEXES LEADING TO CHRONIC 

STIMULATION OF FAK – SRC MEDIATED 

PATHWAYS. M. D. Pysher 1 , R. R. Vaillancourt 2 and 

Q. M. Chen 1 . 1 Pharmacology, University of Arizona, 

Tucson, AZ and 2 Pharmacology and Toxicology, 


#1305 2:35 ARSENIC INHIBITS LXR-MEDIATED 

TRANS-ACTIVATION, BUT NOT TRANS- 

REPRESSION IN MACROPHAGES. A. M. 

Padovani, W. H. Miller and K. K. Mann. Lady Davis 

Institute for Medical Research, McGill University, 

Montreal, QC, Canada. 

#1306 2:55 g-GLUTAMYL TRANSFERASE (GGT1) 

EXPRESSION LEVEL IS ASSOCIATED 

WITH ARSENIC RESISTANCE IN NORMAL 

HUMAN LYMPHOBLASTS: A MICROARRAY 

STUDY. T. G. Rossman, E. V. Komissarova, A. 

Nadas and A. N. Uddin. Environmental Medicine, 

New York University School of Meicine, Tuxedo, 

NY. 

200 




Abstract # 

#1307 3:15 POTENTIAL GENERATION OF CANCER 

STEM CELLS DURING ARSENIC-INDUCED 

MALIGNANT TRANSFORMATION OF 

HUMAN UROGENITAL PROGENITOR 

CELLS. E. J. Tokar 1 , M. M. Webber 2 and M. 

Waalkes 1 . 1 Inorganic Carcinogenesis Section, LCC, 

NCI at NIEHS, Research Triangle Park, NC and 

2 


#1308 3:35 CHRONIC LOW-DOSE ARSENIC 

EXPOSURE ALTERS KEY REGULATORS 

OF INNATE IMMUNE RESPONSE IN VIVO. 

C. D. Kozul 1,2 , T. H. Hampton 1,2 , J. C. Davey 1,2 , J. A. 

Gosse 1,2 , A. P. Nomikos 1,2 , L. A. Warnke 3 , M. A. Ihnat 3 

and J. W. Hamilton 1,2 . 1 Department of Pharmacology 

& Toxicology, Dartmouth Medical School, Hanover, 

NH, 2 Center for Environmental Health Sciences, 

Dartmouth College, Hanover, NH and 3 Department 

of Cell Biology, University of Oklahoma Health 

Sciences Center, Oklahoma City, OK. 

#1309 3:55 INTERPLAY BETWEEN CELLULAR 

METHYL METABOLISM AND ADAPTIVE 

EFFLUX DURING CHRONIC ARSENIC 

EXPOSURE IN HUMAN CELLS. J. Coppin and 

M. Waalkes. Inorganic Carcinogenesis Section, LCC, 

NCI at NIEHS, Research Triangle Park, NC. 


1:30 PM to 4:15 PM 

Room 6E 

PLATFORM SESSION: MECHANISMS OF HYPERSENSITIVITY 

Chairperson(s): Jean Regal, University of Minnesota Medical School 

Duluth, Duluth, MN and Rebecca Dearman, Manchester University, 

Manchester, United Kingdom. 

#1310 1:30 THE IMPACT OF GLYCOSYLATION 

ON IGE ANTIBODY RESPONSES. R. 

Almond 1 , R. J. Dearman 2 , B. F. Flanagan 1 and 

I. Kimber 2 . 1 University of Liverpool, Liverpool, 

United Kingdom and 2 Faculty of Life Sciences, 

Manchester University, Manchester, GREATER 

MANCHESTER, United Kingdom. 

#1311 1:54 LIMITING ALLERGEN EXPOSURE DURING 

DEVELOPMENT: DIFFERENTIAL EFFECT 

ON ASTHMA SYMPTOMS IN A MOUSE 

MODEL. J. F. Regal 1 , A. L. Greene 1 , M. S. 

Rutherford 2 , R. R. Regal 3 , M. Duan 3 , V. Haynes 1 

and M. Mohrman 1 . 1 Biochemistry & Molecular 

Biology, University of Minnesota Medical School 

Duluth, Duluth, MN, 2 Veterinary & Biomedical 

Sciences, University of Minnesota, St. Paul, MN and 

3 

Mathematics & Statistics, University of Minnesota, 

Duluth, MN. 

#1312 2:18 LOCAL ANTIBODY CLASS SWITCHING 

IN THE NASAL MUCOSA OF MICE WITH 

TDI RHINITIS. V. J. Johnson 1 , K. Fluharty 1 , J. S. 

Reynolds 2 , M. I. Luster 1 and B. Yucesoy 1 . 1 Toxicology 

and Molecular Biology Branch, NIOSH/CDC, 

Morgantown, WV and 2 Pathology and Physiology 

Research Branch, NIOSH/CDC, Morgantown, WV. 

#1313 2:42 EVALUATION OF IRRITANCY AND THE 

SENSITIZATION POTENTIAL OF METAL 

WORKING FLUIDS AND METAL WORKING 

FLUID COMPONENTS. S. Anderson 1 , K. Brown 2 , 

L. Butterworth 1 , A. Fedorowicz 1 , D. Beezhold 1 , A. E. 

Munson 1 and B. J. Meade 1 . 1 NIOSH, Morgantown, 

WV and 2 NIOSH, Cincinnati, OH. 

Abstract # 

#1314 3:06 EVALUATION OF A GENOMIC APPROACH 

TO THE LOCAL LYMPH NODE ASSAY 

(LLNA). D. R. Boverhof, B. B. Gollapudi, J. A. 

Hotchkiss and M. R. Woolhiser. Toxicology and 



#1315 3:30 HEME-OXYGENASE 1 AND NADPH 

QUINONE OXIDOREDUCTASE 1: 

NEW TARGET GENES TO PREDICT 

THE SENSITIZING POTENTIAL OF 

CHEMICALS? M. Pallardy 1 , N. Ade 1 , L. Bochet 1 , 

H. Assaf-Vandecasteele 1 , S. Kerdine-Römer 1 and 

J. Ourlin 2 . 1 Toxicologie, INSERM UMR-S 749, 

Universite Paris-Sud 11, Chatenay-Malabry, France 

and 2 Direction des laboratoires et des controles, 

AFSSAPS, Vendargues, France. 

#1316 3:53 ZINC DIETHYLDITHIOCARBAMATE 

ALLERGENICITY: POTENTIAL 

HAPTENATION MECHANISMS. I. Chipinda 1 , 

J. M. Hettick 1 , R. H. Simoyi 2 and P. D. Siegel 1 . 

1 

NIOSH/HELD, CDC, Morgantown, WV and 

2 

Chemistry, Portland State University, Portland, OR. 


1:30 PM to 4:15 PM 

Room 615 

PLATFORM SESSION: MECHANISMS OF PESTICIDE 

TOXICITY 

Chairperson(s): David Dix, U.S. EPA, Research Triangle Park, NC and 

Mary Beth Genter, University of Cincinnati, Cincinnati, OH. 

#1317 1:30 ATROPINE BUT NOT METHYLATROPINE 

CORRECTS PARAOXON-INDUCED 

RESPIRATORY DISTURBANCES. H. Pascal 1 , 

L. Pronzola 1 , M. Kayouka 1 , C. Pope 2 and F. 

Baud 1 . 1 INSERM U705 - UMR CNRS/INSERM 

7157, Université Paris V - VII, Paris, France and 

2 

Department of Physiological Sciences, Oklahoma 


#1318 1:49 TISSUE CHOLINESTERASE ACTIVITIES 

DO NOT EXPLAIN REBUND OF PAROXON- 

INDUCED RESPIRATORY TOXICITY AFTER 

PRALIDOXIME IN RATS. C. Martin 3 , P. Houze 1 , 

T. Duarte 3 , C. Pope 2 and F. J. Baud 1 . 1 INSERM 

U705, UMR CNRS/INSERM 7157, Université Paris 

V - VII, Paris, France, 2 Department of Physiological 

Sciences, Oklahoma State University, Stillwater, OK 

and 3 Animalerie Centrale, Faculté de Pharmacie Paris 

V, Paris, France. 

#1319 2:08 ALL ORGANOPHOSPHATES ARE NOT THE 

SAME: DEVELOPMENTAL EXPOSURES 

TO DIAZINON OR PARATHION 

PRODUCE DIFFERENT CELL SIGNALING 

OUTCOMES. A. A. Adigun, F. J. Seidler and T. A. 

Slotkin. Pharmacology & Cancer Biology, Duke Univ 

Med Ctr, Durham, NC. 

#1320 2:27 CRITICAL MOLECULAR PATHWAYS OF 

NEUROGENESIS IN CHLORPYRIFOS 

RESPONSE. M. Vredevoogd, X. Yu, S. Hong and 

E. M. Faustman. Environmental and Occupational 


WA. 

Tuesday 



Tuesday 


Abstract # 

#1321 2:45 EFFECTS OF ATRAZINE ON 

NEUROENDOCRINE FUNCTION IN 

WISTAR RATS. C. D. Foradori 2 , L. R. Hinds 2 , 

W. H. Hanneman 1 , M. E. Legare 1 , C. M. Clay 2 and 

R. J. Handa 2 . 1 Environmental Health, Colorado 

State University, Fort Collins, CO and 2 Biomedical 


CO. 

#1322 3:03 PROTEOMIC ANALYSIS OF 


ADDUCTS IN WISTER RAT PITUITARY 

GLANDS AND LbT2 RAT PITUITARY 

CELLS. G. Dooley 1 , K. Reardon 2 , J. Prenni 3 , M. 

Legare 1 , C. Foradori 4 , J. Tessari 1 and W. Hanneman 1 . 

1 

Enviromental and Radiological Health Sciences, 

Colorado State University, Fort Collins, CO, 

2 

Chemical and Biological Engineering, Colorado 

State University, Fort Collins, CO, 3 Macromolecular 

Resources, Colorado State University, Fort Collins, 

CO and 4 Biomedical Sciences, Colorado State 

University, Fort Collins, CO. 

#1323 3:21 HEPATIC TOXICOGENOMIC RESPONSES 

TO TRIAZOLE ANTIFUNGALS 

CONSERVED BETWEEN RODENTS AND 

HUMANS. A. K. Goetz, D. J. Dix and I. Shah. U.S. 

Environmental Protection Agency, Research Triangle 

Park, NC. 

#1324 3:39 TRANSCRIPTIONAL RESPONSES IN 

THYROID TISSUES FROM RATS TREATED 

WITH A TUMORIGENIC AND A NON- 

TUMORIGENIC TRIAZOLE CONAZOLE 

FUNGICIDE. S. Hester and S. Nesnow. 

Environmental Carcinogenesis Division, U.S. EPA, 

Durham, NC. 

#1325 3:57 CHLORACETANILIDE HERBICIDE 

STRUCTURE-ACTIVITY STUDY 

USING BIOCHEMICAL AND GENOMIC 

APPROACHES. M. Genter, B. M. Warner, M. 

Medvedovic and M. A. Sartor. Environmental Health, 

University of Cincinnati, Cincinnati, OH. 


2:45 PM to 3:45 PM 


Exhibitor Hosted Session: Toxicity, Biomarker 

and Metabolomics Workflows Result in Efficient 

Evaluation of Compound Toxicity • Safety and 

The Application of IPA Pathway Analysis Tools to 

Cancer Therapeutic 

Presented by: Ingenuity Systems 

Toxicity, Biomarker, and Metabolomics Workflows Result in Efficient 

Evaluation of Compound Toxicity and Safety—System-wide perspective 

and analysis of ‘omics data (transcriptomic, proteomic and metabolomic 

data) through Ingenuity’s user-friendly molecular pathway and network 

analysis tools. 

The Application of IPA Pathway Analysis Tools to Cancer Therapeutics—Pathway 

context and gene network analysis, performed within the 

IPA platform, enables predictive modeling of the effects of chemotherapeutic 

agents on individual patients and tumors. 


2:45 PM to 3:45 PM 


Exhibitor Hosted Session: Trevigen Standardized 

CometAssay System 

Presented by: Trevigen 

In a typical comet assay, electrophoresis methods and differences in cell 

preparations create a significant source of variation in comet tail parameters. 

Trevigen’s set of stable control cell populations are being used to 

analyze critical electrophoresis parameters. A standardized electrophoresis 

system to control variation in comet parameters will be discussed. 


4:30 PM to 6:00 PM 

Ballroom 6A 

SOT Annual Business Meeting 

Chairperson(s): George B. Corcoran 

(SOT Members Only; Full, Associate, Postdoctoral, and Student 

Members Invited) 

Members are invited and encouraged to attend the 47 th Annual SOT Business 

Meeting. If you have long-range planning ideas that you would like 

added to the agenda, please send them to Shawn Lamb at SOT Headquarters. 

The agenda includes a discussion of the Council 2008 strategic 

planning session, financial summary, a review of the 2007–2008 activities, 

and plans for the future. 

202 




TUESDAY EVENING 

Abstract # 

WEDNESDAY MORNING 

Tuesday Evening, March 18 

6:00 PM to 9:00 PM 

See Daily Pocket Calendar on pages 9 and 10 for room 

listings 

Special Interest Group Meetings/Receptions: 

Association of Scientists of Indian Origin in 

America, Toxicologists of African Origin 

Wednesday Morning, March 19 

7:00 AM to 8:30 AM 


Regional Chapter Meetings/Breakfasts: Michigan, 

midwest 


6:00 PM to 7:30 PM 

See Daily Pocket Calendar on pages 9 and 10 for room 

listings 

Specialty Section Meetings/Receptions: 

Biological Modeling, Carcinogenesis, 

Drug Discovery Toxicology, Inhalation 

and Respiratory, Metals, Neurotoxicology, 

Regulatory and Safety Evaluation 


6:00 PM to 8:30 PM 


Regional Chapter Meetings/Receptions: National 

Capital Area, Southeastern 


7:30 AM to 8:50 AM 

Room 618 

ROUNDTABLE SESSION: HAZARD VS. RISK FOR CHEMICAL 

REGULATION 

Chairperson(s): George Daston, Procter & Gamble Company, 

Cincinnati, OH and Robert Lindenschmidt, Procter & Gamble Company, 


Endorsed by: 





Different governmental organizations, and even different industries, have 

taken different approaches to decision-making about the safety of chemicals. 

U.S. and Canadian regulatory agencies take a risk-based approach to chemical 

regulation, whereas the E.U. approach is hazard-based. Many retailers of 

products that contain chemicals, such as WalMart, are also starting to adopt 

a hazard-based expectations for their suppliers. Both approaches have their 

supporters, and both have positive and negative aspects. They may lead to 

very different decisions regarding acceptability based on the same data set. 

Since these decisions have important public health and economic impliations, 

it is important to understand more about them. The purpose of this 

Roundtable will be to present the current lay of the land in chemical regulation, 

and to highlight the differences in decisions that are often made by the 

two approaches, as well as their consequences. 

Wednesday 

#1326 7:30 HAZARD VS. RISK FOR CHEMICAL 

REGULATION. G. Daston and R. Lindenschmidt. 


7:35 HAZARD-BASED CLASSIFICATION 

SYSTEMS AND PRODUCT SUBSTITUTION. 

Lauren Zeise 

7:40 HAZARD-BASED BINNING AS A BASIS FOR 

DECISION MAKING. Barbara Beck 

7:45 THE NEW DRIVING FORCE FOR HAZARD- 

BASED APPROACHES - THE RETAIL 

TRADE. Thomas Osimitz 

7:50 THE IMPORTANCE OF DOSE-RESPONSE 

AND EXPOSURE ASSESSMENT IN 

CHEMICAL REGULATION. James Bus 

7:55 VCCEP AS AN EXAMPLE OF AN 

EFFECTIVE RISK-BASED REGULATORY 

PROCESS. Michael Dourson 

8:00 LIMITATIONS IN THE USE OF DATA 

ON INTERMEDIATE STEPS FOR 

QUANTIFYING HUMAN RISK. Kenny Crump 







7:30 AM to 8:50 AM 

Room 615 


7:30 AM to 8:50 AM 

Room 608 

Wednesday 

ROUNDTABLE SESSION: RECONCILING SCIENTIFIC 

AND ETHICAL CONCERNS IN THE USE OF ANIMALS FOR 

TOXICOLOGICAL RESEARCH 

Chairperson(s): Mara Seeley, Environmental Health & Engineering, 

Newton, MA and Thomas Lewandowski, Gradient Corporation, Seattle, 

WA. 

Endorsed by: 

Animals in Research Committee 

Ethical, Legal, and Social Issues Specialty Section* 


This roundtable will explore the tension between scientific necessity and 

ethical concerns regarding the use of animals in toxicological research. At 

present, scientific research depends on animal studies to address questions 

about efficacy and safety of potential drugs, and the potential hazards of 

chemicals. The Society of Toxicology and other societies have addressed 

ethical issues of using animals in research, and government regulations 

specifically address the scientific and ethical treatment of animals. In addition, 

there are ongoing efforts to develop alternative methods that could 

replace, refine, or reduce the use of experimental animals in toxicological 

research. For example, new methods with more specific and less variable 

endpoints may enable experimental designs that require fewer animals. 

Following a summary of recent trends in the use of animals in research, this 

roundtable will discuss the report recently released by the National Research 

Council regarding efforts to develop alternatives to animal testing, and how 

these alternatives can be implemented. We will then examine how advances 

in disciplines such as genomics might contribute to reductions in animal 

use. We will also consider refinement alternatives as well as approaches for 

recognizing and minimizing distress that animals may experience in toxicity 

studies. Finally, this roundtable will discuss limitations on the use of animal 

alternatives for toxicity testing in the regulatory arena – both for drug safety 

testing and for support of human health risk assessments. 

#1327 7:30 RECONCILING SCIENTIFIC AND ETHICAL 

CONCERNS IN THE USE OF ANIMALS 

FOR TOXICOLOGICAL RESEARCH. T. A. 

Lewandowski. Gradient Corporation, Seattle, WA. 

7:35 TOXICITY TESTING IN THE TWENTY- 

FIRST CENTURY. Mel Andersen 

7:41 ALTERNATIVES TO ANIMAL TESTS IN 

TOXICOLOGY - MORE THAN WISHFUL 

THINKING. Thomas Hartung 

7:47 RECOGNITION AND ALLEVIATION OF 

DISTRESS IN LABORATORY ANIMALS. 

Joanne Zurlo 

7:53 HUMANE SCIENCE: REFINEMENT 

ALTERNATIVES. Alan Goldberg 

7:59 DRUG SAFETY EVALUATION AND 

ALTERNATIVE TEST METHODS: 

CHALLENGES AND OPPORTUNITIES. 

Lynnda Reid 

8:05 PHASING OUT ANIMAL TESTING AS NEW 

TEST STRATEGIES DEVELOP. Lauren Zeise 



ROUNDTABLE SESSION: TOXICOLOGY TRAINING NEEDS: 

NEW FACES AND NEW TOOLS FOR THE 21 ST CENTURY 

Chairperson(s): William Slikker, National Center for Toxicological 

Research, Jefferson, AR and John Bucher, U.S. Department of Health & 

Human Services, Rockville, MD. 

Endorsed by: 

Academy of Toxicological Sciences 

Career Resource and Development Committee* 

Postdoctoral Assembly 


There is growing concern within the discipline of toxicology with regard 

to the projected retirement of experienced toxicologists and the toxicology 

training pipeline from both a numbers and depth of training perspective. 

This problem is only becoming more acute due to budgetary constraints, 

regulatory and policy shifts and the advent of new chemical and biological 

challenges resulting from innovative and technology driven product development. 

Toxicologists are being asked to address safety issues for novel 

nanotechnology products, plant-made pharmaceuticals and industrials, 

combination therapeutics and concerns related to potential chemical and 

biological terror agents in a timely and cost effective manner. To address 

these issues, the next generation of toxicologists will need new tools and 

cutting edge training, and they must be produced in sufficient numbers to 

effectively replace the current cadre of toxicologists as they retire. A necessary 

first step in assuring the availability of qualified toxicologists is to 

begin a dialogue among the various potential employers on projected current 

and future needs in toxicology and what type of training experience would 

be most advantageous as the discipline moves into the 21 st century. There is 

also a need to develop a clear picture of the number of new toxicologists that 

will be needed over the next 10 years. This session will focus on the number 

of toxicologists and the required skill sets needed as discussed by representatives 

from the industry, academic, research, consulting and government 

sectors and will be a positive step forward by addressing these needs at 

a meeting where most of the concerned toxicologists and many of those 

responsible for training and hiring toxicologists will be in attendance. 

#1328 7:30 TOXICOLOGY TRAINING NEEDS: NEW 

FACES AND NEW TOOLS FOR THE 21 ST 

CENTURY. W. Slikker 1 and J. Bucher 2 . 1 Office 

of the Director, FDA / NCTR, Jefferson, AR and 

2 

Associate Director NTP, NIEHS / NIH, Research 


7:34 TRAINING NEEDS FOR TOXICOLOGISTS: 

A VIEW FROM EUROPE AND THE 

PHARMACEUTICAL INDUSTRY. Ruth 

Roberts 

7:53 TRAINING NEEDS FOR TOXICOLOGISTS: 

A VIEW FROM THE ACADEMIA 

TRENCHES. David Eaton 

8:12 THE ACADEMIC TRAINING NEEDS 

FOR TOXICOLOGIST: A GOVERNMENT 

PERSPECTIVE. Bruce Fowler 

8:31 TOXICOLOGY TRAINING TO MEET 

THE NEEDS OF THE BIOTECHNOLOGY 

INDUSTRY. John A. Wisler 

204 




Abstract # 


7:30 AM to 8:50 AM 

Room 602 

Abstract # 


7:30 AM to 8:50 AM 

Room 605 

INFORMATIONAL SESSION: CROSS-CULTURAL 

UNDERSTANDING OF ASIAN AND WESTERN CULTURAL 

VALUES IN THE WORKPLACE 

Chairperson(s): Thomas Kawabata, Pfizer Global Research and 

Development, Groton, CT and Diana J. Auyeung-Kim, Charles River 

Laboratories Preclinical Services Nevada, Sparks, NV. 

Endorsed by: 

Association of Scientists of Indian Origin Special Interest Group 


Korean Toxicologists Association in America Special Interest 

Group* 

The competition in developing your career as a scientist can be daunting at 

times. It is clear that being productive through hard work alone is not the 

answer. In order to meet your career goals, scientists must also develop leadership 

and people skills. The mastering of these skills may be particularly 

challenging for those scientists reared with cultural values that differ from 

their western workplace culture. The differences in cultural values may be 

manifested in misunderstanding and barriers or “glass ceilings” in the development 

of one’s career. Asian scientists and their co-workers and managers 

need to better understand how Asian and Western cultural values differ and 

how such cultural values are directly connected to behavior and practices in 

the workplace. Many Asians for example, are taught to respect authority, not 

to toot their own horn and value harmony of the team. It is also important 

to understand of how different behaviors are perceived by their non-Asian 

managers and co-workers in the Western workplace and the potential 

impact that may ensue when behaviors are misunderstood. For instance, not 

speaking up in team meetings may be perceived as being not interested or 

having nothing valuable to add to the discussion. These misperceptions may 

result in organizations underutilizing their Asian employees and decreased 

team effectiveness. In addition, Asian scientists may experience limited 

upward mobility and lower job satisfaction. This background information 

will be covered by Sally Huang-Nissen, a consultant and trainer with 

extensive experience in the area of cross-cultural effectiveness and diversity 

training. This will be followed by a roundtable discussion by a panel of 

SOT members from different backgrounds and with different career paths 

(academia, industry, government). The roundtable discussion will focus on 

their personal experiences and how these scientists addressed these cultural 

differences in their careers. 

#1329 7:30 CROSS CULTURAL UNDERSTANDING OF 

ASIAN AND WESTERN VALUES IN THE 

WORKPLACE. T. Kawabata 1 and D. Auyeung- 

Kim 2 . 1 Pfizer, Groton, CT and 2 Charles River 

Laboratories, Sparks, NV. 

7:35 INDIAN PERSPECTIVE. Madhu Soni 

7:45 UNDERSTANDING ASIAN CULTURAL 

VALUES AND POTENTIAL IMPACT IN THE 

WESTERN WORKPLACE. Sally Huang-Nissen 

7:55 KOREAN PERSPECTIVE. Byong Han Chin 

8:05 CHINESE PERSPECTIVE. Fengju Bai 

8:15 PERSPECTIVES FROM A NON-ASIAN THAT 

WORKED IN ASIA. Karen Blackburn 


INFORMATIONAL SESSION: TOXICOLOGICAL AND PUBLIC 

HEALTH CHALLENGES IN AFRICA 

Chairperson(s): Sanmi Areola, Nashville Metro Public Health 

Department, Nashville, TN and Abdel Razak Kadry, U.S. EPA, 


Endorsed by: 



Paucity of data and lack of information exchange present major challenges 

to identifying feasible risk management options for toxicological challenges 

in Africa. The associated consequences are typified by current global health 

initiatives that are unintentionally excluding toxicological and public health 

concerns pertinent to the African continent. For example, concerns about 

nanoproducts may not be as relevant to Africans as would exposure to 

cyanide from widespread consumption of cassava as a staple food source. 

Two-thirds of the 900 million sub-Saharan Africans live in rural areas 

and rely on agriculture and other natural resources for sustenance causing 

shrinkage in the environmental resource base of the region. The resultant 

decline in biodiversity imposes an enormous strain on food safety, which 

frequently leads to dependence on food sources tainted with toxicants. In 

addition, large volumes of industrial chemicals associated with growth in 

the petro-chemical, agro-chemical, textile, mining, and food preservation 

industries raise concerns on their short- and long-term effects. Oil pollution 

is an important and controversial subject of discussion in Africa. The 

public health impacts of new pharmaceuticals such as anti-retroviral drugs, 

new classes of anti-malarial drugs, and the growing problems of illicit drug 

dumping in Africa are largely unknown. Most countries lack the resources 

needed to conduct relevant human health risk assessment and for making 

environmental risk management decisions. This session provides a platform 

to bridge the gaps by highlighting some specific toxicological problems 

facing the continent, engaging scientists conducting global health researches, 

and bringing to the table individuals who have been part of risk management 

practices in the developed countries. It is hoped that feasible approaches 

that take into consideration Africa’s geopolitical and cultural divides will be 

identified, discussed and prioritized to guide future interventions. 

#1330 7:30 TOXICOLOGICAL AND PUBLIC HEALTH 

CHALLENGES IN AFRICA. S. Areola. Metro 

Public Health Department, Nashville, TN. 

7:32 TOXICOLOGY IN THE AFRICAN CONTEXT. 

Peter Spencer 

7:42 MYCOTOXINS IN AFRICA: WHAT DO WE 

KNOW? Edmond Creppy 

7:52 EFFECTS OF URBANIZATION AND RAPID 

INDUSTRIAL DEVELOPMENT ON HEAVY 

METAL LEVELS IN WATER, PLANT, AND 

FISH AROUND GREATER CAIRO, EGYPT. 

Osama El-Tawil 

8:02 THE ENVIRONMENTAL, POLITICAL, AND 

SOCIOECONOMIC CONSEQUENCES OF 

OIL PRODUCTION IN THE NIGER DELTA 

REGION OF NIGERIA. Chuck Okereke 

8:12 IDENTIFYING AND PRIORITIZING 

OPTIONS FOR ADDRESSING 

TOXICOLOGICAL CHALLENGES IN 

AFRICA. Sanmi Areola 

Wednesday 




Abstract # 


8:00 AM to 8:50 AM 

Ballroom 6A 


8:30 AM to 9:30 AM 


Wednesday 

Keynote Medical Research Council 

(MRC) Lecture: Biological Energy 

Conversion and its Toxic 

Consequences 

Lecturer: Nobel Laureate Sir John E. Walker, MRC 

Dunn Human Nutrition Unit, Cambridge, UK 

Energy in foodstuffs is released by respiration 

(controlled burning), consuming in the process most 

of the oxygen that we have breathed in. Of the 1000 

or so proteins that are involved, about 100 of them are organized into the 

respiratory enzyme complexes in mitochondria that function as molecular 

machines to convert the redox energy derived from food-stuffs into 

adenosine triphosphate (ATP), the energy currency of biology. The final 

synthetic step is achieved by a remarkable molecular machine that has a 

mechanical rotary action. An important toxic by-produce of energy conversion 

is the production of ROS reactive oxygen species (ROS). ROS are 

generated during the process of electron transfer, but where and how they 

are generated remains controversial. The ROS can react with nucleic acids, 

proteins and phospholipids causing damage to biological processes that 

may lead to diseases and contribute to ageing. Hence, there is a need to 

develop drugs to prevent the toxic effects of ROS. All of these issues will 

be discussed in the lecture. 


8:30 AM to 9:30 AM 


Exhibitor Hosted Session: Automated 

In Vivo Sampling with Culex 

Presented by: BASi (Bioanalytical Systems, Inc.) 

Culex is a modular system for programmed blood and bile sampling, 

microdialysis, infusions and physiological measurements. This presentation 

will outline the basics of automated sampling and how the Culex, a unique 

instrument, gets the job done 24/7, using freely-moving animals. You will 

learn the differences between manual and automatic sampling and dosing, 

and how multiple data streams from a single animal can be obtained at one 

time. 

Exhibitor Hosted Session: Multiplex Gene 

Expression for Toxicology Screening of Target 

Compounds 

Presented by: Beckman Coulter, Inc. 

Detection of cellular response in toxicological studies requires a comprehensive 

detection platform that can analyze multiple relevant pathways in a 

cost-effective manner. Multiplex gene expression can be employed to look 

at various metabolic, cell signaling, or user defined pathways simultaneously. 

The Beckman Coulter GeXP Genetic Analysis platform delivers high 

throughput gene expression using a simplified chemistry to allow same day 

sample to answers. 


9:00 AM to 11:45 AM 

Room 605 


SYMPOSIUM SESSION: DEVELOPMENTAL BASIS OF HEALTH 

AND DISEASE: PERSISTENT EFFECTS OF TOBACCO SMOKE 

EXPOSURE (iat) 

Chairperson(s): Laura Van Winkle, University of California Davis, Davis, 

CA and Kent Pinkerton, University of California Davis, Davis, CA. 

Endorsed by: 





Children are exposed to tobacco smoke. In a study of 5, 400 U.S. school 

aged children, 85% had measurable cotinine levels in their blood. Whether 

it is prenatal exposure to mainstream smoke or postnatal exposures to sidestream 

smoke, childhood exposures are most often involuntary exposures 

and can result in adverse health effects. This is not surprising as tobacco 

smoke contains a complex mixture of compounds with toxic and/or bioactive 

effects. Yet the long term outcomes of childhood exposures are still 

not well understood. The purpose of this session is to bring together the 

latest research on the effect of tobacco smoke on development of the neural, 

immune and respiratory systems and to highlight potential areas of future 

research. There is recent concern about the possibility of persistent adverse 

health effects of tobacco smoke exposure that continue into adulthood after 

exposures during development in either the pre or postnatal period. Persistent 

effects have been described for the lung, the immune system and for 

both behavior and neurobiology. 

#1331 9:00 DEVELOPMENTAL EFFECTS OF HEALTH 

AND DISEASE: PERSISTENT EFFECTS OF 

TOBACCO SMOKE EXPOSURE. L. S. Van 

Winkle 1,3 and K. E. Pinkerton 1,2,3 . 1 Center for Health 

& the Environment, UC Davis, Davis, CA, 2 Med: 

Pediatrics, UC Davis, Davis, CA and 3 Vet:Med 

Anatomy, Physiology and Cell Biology, UC Davis, 

Davis, CA. 

#1332 9:05 EFFECTS OF ENVIRONMENTAL TOBACCO 

SMOKE ON THE DEVELOPING IMMUNE 

SYSTEM OF INFANT MONKEYS. K. E. 

Pinkerton, L. Wang and J. P. Joad. Center for Health 

and the Environment, University of California, 

Davis, Davis, CA. 

206 




Abstract # 

#1333 9:30 ETS AND GENDER EFFECTS ON ALLERGIC 

ASTHMA. L. J. Gershwin 1 , V. L. Mitchell 1,2 and 

L. S. Van Winkle 2 . 1 Pathology, Microbiology, & 

Immunology, University of California, Davis, Davis, 

CA and 2 Center for Health and the Environment, 

University of California, Davis, CA. 

#1334 9:55 PRENATAL EXPOSURE TO TOBACCO 

SMOKE INDUCES ASTHMA-RELATED 

RESPONSES IN NON-SENSITIZED FEMALE 

OFFSPRING LATER IN LIFE. J. T. Zelikoff, 

S. Doherty, C. Hoffman and E. Brush. School of 

Medicine, Department Environment Med., New York 

University, Tuxedo, NY. 

#1335 10:20 ENVIRONMENTAL TOBACCO SMOKE 

(ETS) AS A RISK FACTOR IN CHILDHOOD 

BEHAVIORAL DISORDERS. M. Golub 1,2 . 

1 

California EPA, Sacramento, CA and 2 Department of 

Environmental Toxicology, UC Davis, Davis, CA. 

#1336 10:45 MATERNAL SMOKING AND FETAL LUNG 

DEVELOPMENT. E. R. Spindel. Division of 

Neuroscience, Oregon National Primate Research 

Center, Oregon Health & Science University, 

Beaverton, OR. Sponsor: L. Van Winkle. 

#1337 11:10 SEX DIFFERENCES IN ADULT 

SUSCEPTIBILITY TO TOXIC CHALLENGE: 

ROLE OF NEONATAL ETS EXPOSURES. L. S. 

Van Winkle 1 , K. Sutherland 1 , P. Edwards 1 , G. Baker 2 , 

M. Shultz 1 and D. Nguyen 1 . 1 UC Davis, Davis, CA 

and 2 Battelle Toxicology Northwest, Richland, WA. 



9:00 AM to 11:45 AM 

Room 608 

SYMPOSIUM SESSION: UNUSUAL MANIFESTATIONS OF 

ON-TARGET AND OFF-TARGET TOXICITY: TOXICITY OF 

KINASE INHIBITORS 

Chairperson(s): Kyle Kolaja, Roche Palo Alto, Palo Alto, CA and Bruce 

Car, Bristol-Myers Squibb Company, Princeton, NJ. 

Endorsed by: 

Drug Discovery Toxicology Specialty Section* 

Abstract: In recent years, several relatively selective tyrosine and serinethreonine 

kinase inhibitors have been discovered and developed for 

therapeutic applications in oncology and immunology. In addition the 

kinome is being explored for targeted inhibition in a much wider variety 

of disease areas. Typically, small molecules or antibodies are used to 

target a kinase proximal or otherwise key to a signal transduction cascade 

leading to endpoints such as tissue inflammation or cell proliferation. In 

addition to toxicity mediated by biotransformation to toxic intermediates 

(e.g. hepatic and renal toxicity), a particularly broad and novel variety of 

adverse behavioral or tissue-based changes are noted with kinase inhibitors 

from memory loss (MEK), and extreme neuropathic pain (Ret), to failure of 

growth plate closure (VEGFR2), clastogenicity (many kinase inhibitors), 

cardiotoxicity, hematopoetic toxicity, and teratologic outcomes (Wnt kinases 

and many others). These effects may be mediated either by inhibition of 

targeted kinases, closely related kinases or ostensibly nonhomologous 

kinases to those targeted or a combination of on- and off-target effects. As 

more data are collected, an emerging trend is that the inhibition of kinases 

by parent molecules and their metabolites is the causative factor leading 

to the panoply of untoward toxicity. Substantial efforts requiring novel 

approaches in predictive toxicology, risk assessment and monitoring have 

been employed to adequately avoid, understand, and manage the outcomes 

of kinase inhibition. This Symposium summarizes the different experiences 

of several pharmaceutical companies in managing a challenging new area of 

the toxicology of pharmaceutical agents. 

Abstract # 

#1338 9:00 UNUSUAL MANIFESTATIONS OF 

ON-TARGET AND OFF-TARGET TOXICITY: 

TOXICITY OF KINASE INHIBITORS. B. Car 2 

and K. L. Kolaja 1 . 1 Discovery and Investigative 

Safety, Roche, Palo Alto, CA and 2 Discovery 

Toxicology, BMS, Princeton, NJ. 

#1339 9:15 INCREASED ORGAN CHEMICAL BURDEN 

AS A CONTRIBUTOR TO THE TOXICITY 

MECHANISM OF A RECEPTOR TYROSINE 

KINASE INHIBITOR IN RATS. H. Hamadeh. 

Toxicology, Amgen Inc, Thousand Oaks, CA. 

#1340 9:45 KINASES OF TOXICOLOGICAL CONCERN: 

DEVELOPMENT OF IN VITRO – IN VIVO 

CORRELATIONS FOR KINASE INHIBITION 

AND TOXICITY. K. L. Kolaja. Discovery and 

Investigative Safety, Roche, Palo Alto, CA. 

#1341 10:15 DISCOVERY AND IN VIVO APPROACHES 

TO EVALUATION OF DIVERSE KINASE 

INHIBITOR TOXICITIES. B. D. Car, B. 

Gemzik, A. K. Gupta, P. C. Levesque, D. Li and R. 

A. Westhouse. Bristol-Myers Squibb Company, 


#1342 10:45 EVALUATING MECHANISM- AND NON- 

MECHANISM-BASED TOXICITY OF 

KINASE INHIBITORS: P38 MAP KINASE 

INHIBITORS AS A CASE STUDY. D. Morris. 

Drug Safety R&D, Pfizer Global Research & 

Development, Chesterfield, MO. 

#1343 11:15 SPECIES-SPECIFIC TOXICITIES 

OBSERVED WITH KINASE INHIBITORS: 

IMPACT ON THE PRECLINICAL SAFETY 

PLAN AND REGULATORY STRATEGY. J. W. 

Davis. DSRD, PGRD, Chesterfield, MO. 


9:00 AM to 11:45 AM 

Room 6B 

WORKSHOP SESSION: NATURAL KILLER CELLS AS 

TARGETS OF DRUGS, TOXICANTS, AND BIOLOGICALS 

Chairperson(s): Jeanine Bussiere, Amgen, Inc., Thousand Oaks, CA and 

Stephen Pruett, Louisiana State University, Shreveport, LA. 

Endorsed by: 



NK (natural killer) and NK-T cells are immunologically important cells 

involved at the interphase of innate and adaptive immunity and respond to 

physiopathological processes. They may even be more sensitive than some 

of the other commonly used immunotoxicity tests. Suppression of NK 

cell activity by environmental contaminants is well known e.g., organotins. 

NK cell activity is one of the initial screening study end points for 

immunotoxicity testing under European drug regulatory guidelines. The 

pharmacological activation of NK cells in anti-viral and anti-tumor therapies 

has been emerging for approved therapeutics and those under clinical trial. 

Imiquimod, a TLR7/8 ligand that induces NK-activating cytokines is an 

approved agent for genital warts caused by papilloma virus. NK cell modulations 

are known during Herpes virus and Cytomegalovirus infections. 

Studies showing NK or NK-T cells being recruited into the liver after viral 

infection, NK cells moving into the lymph nodes in response to immunization 

or tumors, participation of NK / NK-T cells in inflammatory responses 

in liver and lungs are noteworthy. The therapeutic activity of monoclonal 

antibodies against human cancer cells may involve antibody-mediated cellmediated 

cytotoxicity, one of NK cells’ known functions. Several natural 

product extracts modulate NK cells. Thus, the effects of immunotoxicants, 

immunotherapeutics or small molecules on NK cells, the modulations of NK 

cells in anti-infectives / vaccine development are of interest to toxicologists 

Wednesday 




Wednesday 


and drug discovery groups. A brief overview of the functions, and concepts 

of NK cells will be followed by some of the cutting edge results from in 

vitro and in vivo data from different species. 

#1344 9:00 NATURAL KILLER CELLS AS TARGETS OF 

DRUGS, TOXICANTS, AND BIOLOGICALS. 

R. Krishnaraj. Pharmacology, University of Illinois 

at Chicago, Chicago, IL. 

#1345 9:25 ENVIRONMENTAL IMMUNOTOXICANTS 

ON HUMAN NK CELLS. M. Whalen. Chemistry, 

Tennessee State University, Nashville, TN. Sponsor: 

R. Krishnaraj. 

#1346 10:00 NATURAL KILLER CELLS AT THE 

INTERPHASE OF INNATE AND ADAPTIVE 

IMMUNITY. C. Munz. Laboratory of Viral 

Immunobiology, The Rockefeller University, New 

York. Sponsor: R. Krishnaraj. 

#1347 10:35 DIRECT AND INDIRECT EFFECTS OF 

ETHANOL ON ACTIVATION OF NK CELLS 

THROUGH TLR3. S. B. Pruett. Department Basic 

Sciences, Coll. Vet. Med., Mississippi State U., 

Mississippi State, MS. 

#1348 11:10 SUBTYPE MARKERS DEFINE THE 

TISSUE SPECIFIC EFFECTS OF CHRONIC 

ALCOHOL CONSUMPTION ON NK CELLS. 

G. G. Meadows and H. Zhang. Cancer Prevention 

& Research Center, Washington State University, 

Pullman, WA. 


9:00 AM to 11:45 AM 

Room 615 

WORKSHOP SESSION: SAFE APPROACHES TO TOPICAL 

PRODUCT DEVELOPMENT 

Chairperson(s): Dave Hobson, H&H Scientific Services, LLP, Boerne, TX 

and William Reifenrath, Stratacor, Inc., Richmond, WA. 

Endorsed by: 


Topical products are applied to the skin, eyes, or mucosal membranes 

for purposes that vary from altering appearance, to combating disease 

or to protecting against environmental assaults. Topical formulations are 

usually complex mixtures that may contain one or more pharmacologically 

active agents, a vehicle to facilitate application, components to improve 

user acceptability, agents to promote or retard penetration or evaporation, 

stabilizers or preservatives, as well as other materials depending on the ultimate 

use. Most topical drug products are formulated with commonly used 

excipients that are included in FDA’s Inactive Ingredients Guide. But some 

new products may need novel ingredients that offer benefits not available 

with commonly used excipients. The potential of a formulation to produce 

untoward effects is governed by the properties of each ingredient and the 

presentation of those ingredients to a site of action. However, simple addition 

of individual ingredient toxicities has proven inadequate for predicting 

the toxic potential of the formulation. Good toxicological judgment and critical 

testing thus play an important role in eliminating formulation problems 

well before they become significant clinical issues. Safety considerations 

are paramount for products intended for damaged tissue, and products for 

wound care or healing or for aging populations have unique requirements. 

Inclusion of in vitro studies to include skin penetration and distribution 

assessment, corrosion assays, and skin culture tests can aid in early stage 

toxicological decisions. The primary test systems for predicting skin corrosion 

or irritation have been the human cornified tissue constructs. The skin 

corrosion and basic irritation endpoints have recently completed formal validation. 

Assessment of eye irritation potential uses a range of test systems, 

with some systems tailored to demonstrate the required mildness of formulation. 

In summary, the judicious choice of excipients, the proper design 

of formulation, and the information gained from critical pre-clinical tests 

combine to make the difference between success and failure for a promising 

topical product. 

#1349 9:00 SAFE APPROACHES TO TOPICAL 

PRODUCT DEVELOPMENT. W. G. Reifenrath. 

Stratacor, Inc., Richmond, CA. 

#1350 9:05 THE ROLE OF TOXICOLOGY IN TOPICAL 

DRUG DEVELOPMENT. L. Mutter. Preclinical, 

Regulatory Affairs, Dow Pharmaceutical Sciences, 

Inc., Petaluma, CA. 

#1351 9:35 TOXICOLOGICAL CONSIDERATIONS FOR 

THE USE OF EXCIPIENTS IN TOPICAL 

DRUG PRODUCTS AND FDA’S EXCIPIENT 

GUIDANCE. R. E. Osterberg. Aclairo PDG Inc., 

Chevy Chase, MD. 

#1352 10:05 IN VITRO APPROACHES FOR PREDICTING 

IRRITATION POTENTIAL OF TOPICAL 

EXPOSURES TO THE SKIN AND EYES. J. W. 

Harbell. Mary Kay Inc., Addison, TX. 

#1353 10:40 SAFETY AND MECHANISTIC 

CONSIDERATIONS IN SKIN TRANSPORT 

OF TOPICAL PRODUCTS. W. G. Reifenrath. 

Stratacor, Inc., Richmond, CA. 

#1354 11:15 TOXICOLOGICAL CONSIDERATIONS IN 

THE FORMULATION AND DEVELOPMENT 

OF WOUND HEALING AND TISSUE REPAIR 

PRODUCTS. D. W. Hobson. H&H Scientific 

Services LLP, Boerne, TX. 


9:00 AM to 11:45 AM 

Room 6C 

WORKSHOP SESSION: THRESHOLD OF TOXICOLOGIC 

CONCERN: HISTORICAL PERSPECTIVES AND FUTURE 

APPLICATIONS 

Chairperson(s): Susan Felter, Procter & Gamble Company, Cincinnati, 

OH and Karen Blackburn, Procter & Gamble Company, Cincinnati, OH. 

Endorsed by: 




The Threshold of Toxicological Concern (TTC) approach was developed by 

the U.S. FDA in the 1980s as a means to more efficiently address questions 

related to the safety of food packaging materials that have some potential to 

migrate to foodstuffs, but at levels that would result in exceedingly small 

human exposures. The approach is based on the fundamental premise that 

there is an exposure to untested chemicals below which adverse health 

effects will be negligible or absent. TTC-based exposure limits are established 

based on the distribution of potencies of chemicals for which toxicity 

data exist, with a tiered approach being developed that includes both cancer 

and non-cancer endpoints. For an untested chemical, a TTC-based exposure 

limit is then determined by placing the chemical into the appropriate tier 

based on evaluation of chemical structure, the presence of structural alerts, 

and other available data. This session will provide an overview of the history 

of TTC; the scientific basis behind the tiered TTC exposure limits; current 

regulatory acceptance of TTC; and future opportunities for the continued 

expansion of this risk assessment tool. 

#1355 9:00 THRESHOLD OF TOXICOLOGICAL 

CONCERN: HISTORY, CURRENT USES AND 

FUTURE OPPORTUNITIES. S. P. Felter and 

K. L. Blackburn. Central Product Safety, Procter & 

Gamble, Cincinnati, OH. 

208 




Abstract # 

#1356 9:15 HISTORY AND OVERVIEW OF THE 

THRESHOLD OF TOXICOLOGICAL 

CONCERN (TTC) CONCEPT. A. McDougal. 

CFSAN, U.S. FDA, College Park, MD. Sponsor: K. 

Blackburn. 

#1357 9:45 APPLICATION OF THRESHOLD OF 

TOXICOLOGICAL CONCERN (TTC) 

TO THE SAFETY EVALUATION OF 

FLAVORING SUBSTANCES. T. Adams. The 

Roberts Group, Washington, DC. Sponsor: S. Felter. 

#1358 10:15 USE OF THRESHOLD OF TOXICOLOGICAL 

CONCERN (TTC) FOR GENOTOXIC 

IMPURITIES IN FOOD. I. C. Munro and B. 

Danielewska-Nikiel. CANTOX Health Sciences 

International, Mississauga, ON, Canada. 

#1359 10:45 USE OF THRESHOLD OF TOXICOLOGICAL 

CONCERN (TTC) APPROACH IN 

ASSESSMENT OF GENOTOXIC 

IMPURITIES IN PHARMACEUTICALS. R. 

Mauthe. Global Research and Development, Pfizer, 

Ann Arbor, MI. 

#1360 11:15 THE THRESHOLD OF TOXICOLOGICAL 

CONCERN (TTC) – FUTURE 

OPPORTUNITIES. A. G. Renwick. School of 

Medicine, University of Southampton, Southampton, 

United Kingdom. Sponsor: S. Felter. 


9:00 AM to 11:45 AM 

Room 6A 

WORKSHOP SESSION: USE OF BEHAVIORAL AND NON- 

ROUTINE NEUROLOGICAL APPROACHES IN DRUG 

DISCOVERY TOXICOLOGY 

Chairperson(s): Brian Gemzik, Bristol-Myers Squibb Company, 

Princeton, NJ and Karen Steinmetz, SRI International, Menlo Park, CA. 

Endorsed by: 



Novel pharmaceutical targets, including kinase inhibitors for inflammatory 

diseases and oncology, have been evaluated for their potential as therapeutic 

interventions in recent years. Unusual considerations for the toxicologist 

may include unwanted neurobehavioral effects, and deficits in learning and 

memory acquisition. In addition, interactions of chemical structure types 

with biogenic amine (e.g., serotonergic and dopaminergic) receptors and 

their metabolism and uptake mechanisms are relatively common off-target 

effects. Toxicologists in the drug discovery environment are confronted with 

the adverse neurobiology of small molecules and are required to place these 

effects in a broad risk-assessment perspective. Bridging pharmacology and 

toxicology, this expertise is of growing interest in the toxicology community 

- this session focuses the current knowledge and awareness in an area 

traditionally considered peripheral to the issues that most toxicologists are 

asked to address. The goal of this session is to raise awareness to the role of 

toxicologists in defining adverse neurological effects, particularly within the 

discovery and target selection environment, through illustration of this field, 

the techniques employed, and with specific examples of risk assessment for 

neurobehavioral and related toxicity. 

#1361 9:00 USE OF BEHAVIORAL AND NON-ROUTINE 

NEUROLOGICAL APPROACHES IN DRUG 

DISCOVERY TOXICOLOGY. B. Gemzik 1 and 

K. Steinmetz 2 . 1 Discovery Toxicology, Bristol-Myers 

Squibb Co, Princeton, NJ and 2 SRI international, 

Menlo Park, CA. 

Abstract # 

#1362 9:15 NOVEL CNS PHARMACOLOGIC TARGETS: 

CONSIDERATIONS FOR EVALUATING 

ADVERSE BIOLOGY. S. Lelas, Neurobiology, 

Microbia Inc, Cambridge, MA. Sponsor: B. Gemzik. 

#1363 9:45 LEVERAGING NEUROBEHAVIORAL 

ASSESSMENT OF ADVERSE CNS EFFECTS 

TO IMPROVE CANDIDATE SELECTION. M. 

J. Kallman. Investigative Toxicology Lilly Research 

Labs, Greenfield, IN. 

#1364 10:15 THE EFFECTS OF KINASE INHIBITORS 

ON LONG-TERM POTENTIATION 

AND MEMORY. C. A. Miller and D. Sweatt. 

Neurobiology, University of Alabama, Birmingham, 

AL. Sponsor: B. Gemzik. 

#1365 10:45 MAXIMIZING SENSITIVITY AND 

EFFICIENCY IN THE DETECTION 

OF PROCONVULSANT LIABILITY IN 

RODENTS. M. Bell. Safety Assessment, 

AstraZeneca Pharmaceuticals, Wilmington, PA. 

Sponsor: P. Ciaccio. 

#1366 11:15 THE PHENOTYPIC EVALUATION OF 

NEUROBEHAVIORAL ACTIVITY IN 

KNOCKOUT MOUSE MODELS. T. Lanthorn. 

Lexicon Pharmacenticals, The Woodlands, TX. 

Sponsor: B. Gemzik. 


9:00 AM to 11:45 AM 

Room 602 

INFORMATIONAL SESSION: GLOBALLY HARMONIZED 

SYSTEM OF CLASSIFICATION AND LABELLING 

OF CHEMICALS (GHS): A NEW LANGUAGE FOR 

TOXICOLOGISTS 

Chairperson(s): Patricia Weideman, Schering-Plough Corporation, 

Union, NJ and Heather Burleigh-Flayer, PPG Industries Inc, Pittsburgh, 

PA. 

Endorsed by: 




The United Nations has issued a system for the classification and labeling of 

chemicals known as the Globally Harmonized System of Classification and 

Labeling of Chemicals (GHS). The intent of the GHS system is to provide a 

consistent foundation for classification and labeling of chemicals that takes 

into account the extensive global trade of chemicals and the need for the 

development of national programs to deal with the safe supply, use, transport, 

and disposal of chemicals. This system is being adopted by countries 

around the world, as well as the newly adopted European chemical legislation, 

REACH. The challenges that will be faced include the following: 1) 

available toxicology data used for classification may vary in quality and 

consistency between countries and companies, 2) lack of a universal rating 

system recommended for evaluating the quality of the toxicology data, 3) 

knowledge and expertise of individuals determining hazard classifications 

may vary widely, and 4) different countries are not uniformly adopting the 

GHS, nor the “building blocks” of GHS. Despite the intention of harmonization, 

it is inevitable that toxicologists will encounter differing classification 

outcomes for a given chemical because of differences in the availability 

of information, the evaluation of information, the expertise of the professional 

(or the regulatory body) performing the evaluation, and differences in 

implementation of the GHS by various countries or regions. Consistent use 

by toxicology experts of the criteria and interpretation of data with respect to 

select endpoints is critical to the success of the GHS and provides for scientific 

soundness of this hazard communication system. Furthermore, scientists 

from all disciplines, including those from academia, industry, or government, 

need to be aware of the GHS and utilize the criteria when applying 

Wednesday 




Wednesday 


terminology to chemicals if we are to “speak the same language” and reduce 

confusion amongst the public and ourselves about chemical hazards. 

#1367 9:00 GLOBALLY HARMONIZED SYSTEM OF 

CLASSIFICATION AND LABELING OF 

CHEMICALS (GHS): A NEW LANGUAGE 

FOR TOXICOLOGISTS. P. A. Weideman 1 and H. 

D. Burleigh-Flayer 2 . 1 Schering-Plough Corporation, 

Union, NJ and 2 PPG Industries Inc., Allison Park, 

PA. 

#1368 9:05 THE HISTORY, DEVELOPMENT, AND 

VALUE OF THE GHS. M. R. Sullivan. MRS 

Associates, Arlington, VA. Sponsor: P. Weideman. 

#1369 9:35 GHS IMPLEMENTATION IN THE 

AMERICAS: ACCEPTANCE AND 

TIMELINES. D. A. Deeds. Industrial Health & 

Safety Consultants, Inc., Woodbridge, CT. Sponsor: 

P. Weideman. 

#1370 10:05 GHS IMPLEMENTATION IN THE ASIA/ 

PACIFIC RIM: VARIATIONS AND 

CHALLENGES. A. M. Johnson. 3M Company, St. 

Paul, MN. 

#1371 10:35 GHS AND REACH: MEETING THE 

CHALLENGES OF TWO CHEMICAL 

MANAGEMENT REQUIREMENTS. R. Warner. 

Chemwise Associates, Oxford, United Kingdom. 

Sponsor: P. Weideman. 

#1372 11:05 TOXICOLOGICAL CHALLENGES OF GHS 

IMPLEMENTATION. A. R. Schatz. Global 

Safety & Environmental Affairs, Schering-Plough 

Corporation, Union, NJ. 



9:00 AM to 11:45 AM 

Room 611 

PLATFORM SESSION: ADVANCES IN BIOLOGICAL 

MODELING 

Chairperson(s): Hugh Barton, U.S. EPA, Research Triangle Park, NC and 

Thomas Webster, Boston University School of Public Health, Boston, MA. 

#1373 9:00 MULTI-MODAL VALIDATION OF 

COMPUTATIONAL PULMONARY AIRFLOW 

SIMULATIONS IN THE RAT. D. R. Einstein 1 , 

T. H. Robertson 2 , S. Kabilan 1 , A. P. Kuprat 1 , K. 

Minard 1 , R. Jacobs 1 , J. P. Carson 1 , C. Timchalk 1 and 

R. Corley 1 . 1 Biological Monitoring and Modeling, 


WA and 2 Pulmonary & Critical Care Medicine, 


#1374 9:19 COMPARING PHARMACOKINETIC 

MODELS FOR PERFLUOROOCTANOIC 

ACID IN MICE. H. A. Barton 1 , I. Lou 2,1 , C. Lau 3 , 

R. G. Hanson 3 , A. B. Lindstrom 4 , M. J. Strynar 4 

and R. W. Setzer 1 . 1 ORD National Center for 

Computational Toxicology, U.S. Environmental 

Protection Agency, Research Triangle Park, NC, 

2 

CEMLB, University of North Carolina, Chapel Hill, 

NC, 3 Reproductive Toxicology Division, U.S. EPA, 

RTP, NC and 4 HEASD, NERL, U.S. EPA, RTP, NC. 

#1375 9:38 PBPK MODELING OF THE MAJOR 

CHLORPYRIFOS METABOLITE 

TRICHLOROPYRIDINOL: A POTENTIAL 

BIOMONITORING STRATEGY. C. Timchalk, A. 

L. Busby and T. S. Poet. Pacific Northwest National 


#1376 9:57 UNCERTAINTY ANALYSIS OF HUMAN 

EXTRAPOLATIONS BY USE OF A PBPK 

MODEL FOR 1, 2-DICHLOROETHANE 

(DCE). P. M. Schlosser 1 and H. A. Barton 2 . 1 NCEA, 

U.S. EPA, RTP, NC and 2 NCCT, U.S. EPA, RTP, NC. 

#1377 10:16 A PBPK MODELING APPROACH FOR IN 

VITRO-IN VIVO EXTRAPOLATION OF 

DRUG-DRUG METABOLIC INTERACTIONS. 

S. Haddad 1 and C. Funk 2 . 1 Biological sciences, 

Université du Québec à Montréal, Montreal, QC, 

Canada and 2 PRBN, Roche Pharmaceuticals, Basel, 

Basel Stadt, Switzerland. 

#1378 10:35 MIXTURES OF AHR FULL AGONISTS, 

PARTIAL AGONISTS, AND ANTAGONISTS: 

IMPLICATIONS FOR TEFS. T. F. Webster, 

G. J. Howard and J. J. Schlezinger. Department 

Environmental Health, Boston University School of 

Public Health, Boston, MA. 

#1379 10:54 BIOLOGY-BASED DOSE-RESPONSE 

MODELS FOR RISK ASSESSMENT OF 

CHEMICAL MIXTURES. D. A. Sarigiannis 

and A. Gotti. Institute for Health and Consumer 

Protection, European Commission - Joint Research 

Centre, Ispra, Italy. Sponsor: L. Birnbaum. 

#1380 11:12 MATHEMATICAL MODELING WITH VIRAL 

CARCINOGENESIS AND ANTI-ONCOGENE 

KNOCKOUT MICE. A. O. Chiu 1 , N. H. Chiu 2 , J. 

Lenz 3 , N. Copeland 4 and D. J. Gilbert 4 . 1 NCEADC, 

U.S. EPA, Washington, DC, 2 OW, U.S. EPA, 

Washington, DC, 3 Albert Einstein College of 

Medicine, Yeshiva University, New York and 4 Mouse 

Cancer Genetics Program, National Cancer Institute, 

Frederick, MD. Sponsor: D. Singh. 

#1381 11:29 DEVELOPMENT OF A BIOLOGICALLY 

BASED DOSE RESPONSE (BBDR) MODEL 

FOR ARSENIC INDUCED CANCER. Y. Zhao 1 , 

S. Edwards 2 , D. Wolf 2 and R. Conolly 2 . 1 National 

Research Council, Washington, DC and 2 U.S. EPA, 



9:00 AM to 11:45 AM 

Room 2A 


PLATFORM SESSION: MECHANISMS OF REPRODUCTIVE 

TOXICITY 

Chairperson(s): Ulrike Luderer, University of California Irvine, Irvine, 

CA and Aileen Keating, University of Arizona, Tucson, AZ. 

#1382 9:00 OVOTOXICITY OF 

4-VINYLCYCLOHEXENE 

DIEPOXIDE MEDIATED THROUGH 

PHOSPHATIDYLINOSITOL 3-KINASE 

SIGNALING. A. Keating 1 , N. Sen 1 , I. Sipes 2 and 

P. B. Hoyer 1 . 1 Department of Physiology, University 

of Arizona, Tucson, AZ and 2 Department of 

Pharmacology, University of Arizona, Tucson, AZ. 

210 




Abstract # 

#1383 9:21 OOCYTE INJURY CAN BE DETECTED 

AFTER IN VITRO EXPOSURE TO 

BI-FUNCTIONAL TOXICANTS. S. K. Petrillo 1 , 

P. Desmeules 1 , A. Keating 2 , P. B. Hoyer 2 and P. J. 

Devine 1 . 1 INRS-Institut Armand-Frappier, Institut 

national de la recherche scientifique, Pointe-Claire, 

QC, Canada and 2 Department of Physiology, The 


#1384 9:42 SEXUAL MATURITY-RELATED CHANGES 

IN OVARIAN FOLLICLE GROWTH IN ARYL 

HYDROCARBON RECEPTOR-DEFICIENT 

MICE. I. Hernández-Ochoa, R. K. Gupta, B. N. 

Karman and J. A. Flaws. Veterinary Biosciences, 

University of Illinois, Urbana, IL. 

#1385 10:03 OVEREXPRESSION OF GLUTAMATE 

CYSTEINE LIGASE PROTECTS 

GRANULOSA CELLS AGAINST OXIDANT 

AND RADIATION-INDUCED CELL DEATH. 

M. M. Cortes 1 , E. Giedzinski 2 , C. L. Limoli 2 and 

U. Luderer 1,3 . 1 Developmental and Cell Biology, 

University of California Irvine, Irvine, CA, 

2 

Radiation Oncology, University of California Irvine, 

Irvine, CA and 3 Medicine, University of California 

Irvine, Irvine, CA. 

#1386 10:24 OVEREXPRESSION OF ESTROGEN 

RECEPTOR ALPHA INCREASES 

SENSITIVITY TO METHOXYCHLOR IN 

THE MOUSE OVARY. T. Paulose and J. A. 

Flaws. Veterinary Biosciences, University of Illinois, 

Urbana, IL. 

#1387 10:45 CONCENTRATION DEPENDENT 

EFFECTS OF GENISTEIN IN NOVEL 

MODELS OF ESTROGEN-STIMULATED 

ENDOMETRIUM. B. P. Sampey 1,2 , C. Barbier 1 , E. 

Wilson 1 and D. G. Kaufman 1 . 1 Pathology, University 

of North Carolina at Chapel Hill, Chapel Hill, NC 

and 2 Nutrition, University of North Carolina at 

Chapel Hill, Chapel Hill, NC. 

#1388 11:05 IN VIVO METABOLITES OF DE-71 ARE 

ESTROGENIC IN VITRO. M. Mercado- 

Feliciano 1 and R. M. Bigsby 2 . 1 Department 

Pharmacology & Toxicology, Indiana University, 

Indianapolis, IN and 2 Department Obstetrics and 

Gynecology, Indiana University, Indianapolis, IN. 

#1389 11:25 EFFECTS OF NUTRITION RELEVANT 

MIXTURES OF PHYTOESTROGENS ON 

STEROIDOGENESIS AND ON AROMATASE, 

ESTROGEN, AND ANDROGEN ACTIVITIES. 

A. Elleby 1 , K. Sonne-Hansen 2 , E. Bonefeld- 

Jørgensen 3 , A. Vinggaard 1 , A. Lykkesfeldt 2 and C. 

Nellemann 1 . 1 Department of Toxicology and Risk 

Assessment, Technical University of Denmark, 

Søborg, Denmark, 2 Department of Tumor 

Endocrinology, Danish Cancer Society, Copenhagen, 

Denmark and 3 Department of Environmental and 

Occupational Medicine, University of Aarhus, 

Aarhus, Denmark. Sponsor: L. Gray. 

Abstract # 


9:00 AM to 11:45 AM 

Room 618 

PLATFORM SESSION: MODULATING APOPTOSIS FOR 

BENEFICIAL OUTCOMES 

Chairperson(s): Rhonda Rosengren, Univeristy of Otago, Dunedin, New 

Zealand and Armin Wolf, Novartis AG, Basel, Switzerland. 

#1390 9:00 A TRIPLE BIOFLAVONOID MIXTURE 

MODULATES PRO- AND ANTI- 

APOPTOTIC GENE EXPRESSION DURING 

STREPTOZOCIN (STZ)-INDUCED 

OXIDATIVE STRESS IN THE MOUSE 

LIVER. M. Parmar 1 , I. Syed 1 , S. J. Stohs 2 and S. 

D. Ray 1 . 1 Pharmaceutical Sciences, Arnold & Marie 

Schwartz Coll of Pharmacology & HScs, Brooklyn, 

NY and 2 R & D, AdvoCare International, Carrollton, 

TX. 

#1391 9:21 EFFECT OF SPECIFIC GENE SILENCING 

ON SDZ IMM125-INDUCED CASPASE-3 

AND -7 ACTIVATION IN CULTURED RAT 

HEPATOCYTES. C. Strupp 1 , M. Dong 1 , O. 

Grenet 1 , W. E. Trommer 2 and A. Wolf 1 . 1 Investigative 

Toxicology, Novartis Pharmacology AG, Basel, 

Switzerland and 2 Department of Chemistry, 

University of Kaiserslautern, Kaiserslautern, 

Germany. 

#1392 9:42 MODIFIED CARDIOLIPIN HOMOLOGUES 

AS INHIBITORS OF PRO-APOPTOTIC 

PEROXIDASE FUNCTION OF 

CYTOCHROME C. G. G. Borisenko 3 , A. 

Kapralov 1,2 , V. A. Tyurin 1,2 and V. E. Kagan 1,2 . 1 Center 

for Free Radical and Antioxidant Health, University 

of Pittsburgh, Pittsburgh, PA, 2 EOH, University of 

Pittsburgh, Pittsburgh, PA and 3 Research Institute 

of Physico-Chemical Medicine, Moscow, Russian 

Federation. 

#1393 10:03 STRUCTURE ACTIVITY OF METHOXY 

SUBSTITUTED PHENOLS: CYTOTOXICITY 

TOWARD ESTROGEN RECEPTOR 

NEGATIVE HUMAN BREAST CANCER 

CELLS. T. J. Somers-Edgar and R. J. Rosengren. 

Pharmacology & Toxicology Otago Univeristy, 

Dunedin, New Zealand. 

#1394 10:24 A NUTRIENT MIXTURE INDUCES 

APOPTOSIS IN HUMAN RENAL CELL 

CARCINOMA 786-0 AND HUMAN 

MELANOMA A2058. A. Niedzwiecki, M. Roomi, 

N. Roomi, V. Ivanov and M. Rath. Dr. Rath Research 

Institute, Santa Clara, CA. 

#1395 10:45 ASPIRIN-INDUCED CELL CYCLE ARREST, 

MITOCHONDRIAL DYSFUNCTION, 

OXIDATIVE STRESS AND APOPTOSIS IN 

HEPATOMA HEPG2 CELLS. H. Raza 1 , A. 

John 1 , S. Benedict 2 and A. Al-Otaiba 1 . 1 Biochemistry, 

Faculty of Medicine and Health Sciences, Al Ain, 

United Arab Emirates and 2 Internal Medicine, 

FMHS, Al Ain, United Arab Emirates. 

Wednesday 




Wednesday 


#1396 11:05 CARBACHOL PREVENTS OXIDATIVE 

STRESS-MEDIATED APOPTOSIS INDUCED 

BY DOMOIC ACID IN CEREBELLAR 

GRANULE CELLS. G. Giordano 1 , L. Li 1 , T. 

Kavanagh 1 and L. Costa 1,2 . 1 Environmental and 

Occupational Health Sciences, University of 

Washington, Seattle, WA and 2 Human Anatomy, 

Pharmacology and Forensic Science, University of 

Parma Medical School, Parma, Italy. 

#1397 11:25 THE EFFECTS OF JS-K AND PABA/NO, 

NOVEL ANTI-TUMOR NITRIC OXIDE 

RELEASING PRODRUGS, IN HUMAN 

HEPATOMA HEPB3 CELLS. J. Liu 1 , Q. Wu 2 , L. 

K. Keefer 3 , J. E. Saavedra 4 and M. Waalkes 1 . 1 ICS, 

LCC, NCI at NIEHS, Research Triangle Park, NC, 

2 

Zunyi Medical College, Zunyi, China, 3 CS, LCC, 

NCI at Frederick, Frederick, MD and 4 SAIC, NCI at 

Frederick, Frederick, MD. 


9:00 AM to 11:45 AM 

Room 6E 


PLATFORM SESSION: NANOPARTICLES: CELLULAR AND 

ORGAN DISPOSITION 

Chairperson(s): Nancy Monteiro-Riviere, North Carolina State 

University, Raleigh, NC and Owen Moss, The Hamner Institutes of Health 


#1398 9:00 GOLD NANOPARTICLES IN RATS AFTER 

INHALATION EXPOSURE. L. E. Yu 2 , W. Ong 1 , 

L. Yung 3 , C. Ong 4 , Y. Tan 1 , K. Balasubramanian 2 , 

D. Hartono 3 , G. Shui 5 and M. R. Wenk 5 . 1 Anatomy, 

National University of Singapore, Singapore, 

Singapore, 2 Environmental Science & Engineering, 


Singapore, 3 Chemical & Biomolecular Engineering, 


Singapore, 4 Community Occupational and Family 

Medicine, National University of Singapore, 

Singapore, Singapore and 5 Biochemistry, National 

University of Singapore, Singapore, Singapore. 

Sponsor: U. Boelsterli. 

#1399 9:19 USE OF LABELED SINGLE WALLED 

CARBON NANOTUBES TO STUDY ACUTE 

TRANSLOCATION FROM THE LUNGS. R. 

R. Mercer, J. F. Scabilloni, L. Wang, L. A. Battelli 

and V. Castranova. HELD, National Institute for 

Occupational Safety and Health, Morgantown, WV. 

#1400 9:38 SHORT-TERM INHALATION TESTS WITH 

EIGHT NANO-MATERIALS IN RATS. R. 

Landsiedel 1,2 , L. Ma-Hock 1 , S. Burkhard 1 , V. Strauss 1 , 

A. O. Gamer 1 , K. Wiench 2 and B. van Ravenzwaay 1 . 

1 

Experimental Toxicology and Ecology, BASF, 

Ludwigshafen am Rhein, Germany and 2 Product 

Safety, BASF, Ludwigshafen am Rhein, Germany. 

#1401 9:57 ADSORBED PROTEINS INFLUENCE THE 

BIOLOGICAL ACTIVITY AND MOLECULAR 

TARGETING OF NANOMATERIALS. T. 

Weber 1 , D. Dutta 2 , S. K. Sundaram 1 , J. Teeguarden 1 , 

B. Riley 1 , L. Fifield 1 , J. Jacobs 1 , S. Addleman 1 , 

G. Kaysen 3 and B. Moudgil 2 . 1 Cell Biology and 

Biochemistry Group, Pacific Northwest National 

Laboratory, Richland, WA, 2 Department of Materials 

Science and Engineering, University of Florida, 

Gainesville, FL and 3 Department of Medicine and 

the Department of Biochemistry and Molecular 

Medicine, University of California Davis, Davis, CA. 

#1402 10:15 PHARMACOKINETIC MODELLING AND 

IMPLICATIONS OF PERIODICITY IN 

ARTERIAL EXTRACTION OF QUANTUM 

DOT NANOPARTICLES. H. A. Lee, M. Imran, S. 

E. Mason, N. A. Monteiro-Riviere and J. E. Riviere. 



Raleigh, NC. 

#1403 10:33 COMPARATIVE BIODISTRIBUTION 

OF COATED AND UNCOATED NANO- 

AND MICRON-SIZED TITANIUM 

DIOXIDE FOLLOWING INTRADERMAL 

ADMINISTRATION IN MICE. N. V. Gopee 1 , C. 

Cozart 1 , P. H. Siitonen 1 , C. S. Smith 2 , N. J. Walker 2 

and P. C. Howard 1 . 1 Biochemical Toxicology, 

National Center for Toxicological Research, U.S. 

FDA, Jefferson, AR and 2 National Toxicology 

Program, National Institute for Environmental Health 


#1404 10:51 BIOKINETICS OF AU NANOPARTICLES 

RELATIVE TO SIZE, SURFACE COATING 

AND PORTAL OF ENTRY. A. Rinderknecht 1 , R. 

Prud’homme 2 , R. Poreda 3 , R. Gelein 1 , N. Corson 1 , 

A. Pidruczny 4 , J. Finkelstein 5 , G. Oberdörster 1 and 

A. Elder 1 . 1 Environmental Medicine, University of 

Rochester, Rochester, NY, 2 Chemical Engineering, 

Princeton University, Princeton, NJ, 3 Earth & 

Environmental Sciences, University of Rochester, 

Rochester, NY, 4 Center of Neutron Activation, 

McMaster University, Hamilton, ON, Canada and 

5 

Department of Pediatrics, University of Rochester, 


#1405 11:09 NANOMATERIAL WITH A SPECIFIC SET 

OF PROPERTIES CAN ENTER THE CELL 

VIA MULTIPLE PATHWAYS. G. Orr, D. J. 

Panther, J. L. Phillips, B. J. Tarasevich and J. G. 

Pounds. Pacific Northwest National Laboratory, 

Richland, WA. 

#1406 11:27 MACROPHAGE UPTAKE OF 26 NM AND 

250 NM PSL IS MEDIATED BY SEPARATE 

MECHANISMS. O. R. Moss, V. A. Wong, P. M. 

Radcliffe and E. Bermudez. Toxicology, The Hamner 

Institutes for Health Sciences, Research Triangle 

Park, NC. 

212 




Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: MECHANISMS OF CARCINOGENESIS 

Chairperson(s): Burra Madhukar, Michigan State University, East 

Lansing, MI and Lori White, U.S. EPA, Research Triangle Park, NC. 




CIGARETTE SMOKE (CS) CAUSES 

FORMATION OF REGIONS OF ALTERED 

DNA METHYLATION (RAMS) IN SENCAR 

MOUSE LUNG. J. I. Goodman 1 , J. M. Phillips 2 , 

G. M. Curtin 3 and D. J. Doolittle 3 . 1 Pharmacology 

& Toxicology, Mich. State U., East Lansing, MI, 

2 

Biochem. & Mol. Biol., Mich. State U., East 

Lansing, MI and 3 Research and Development, R. J. 

Reynolds Tobacco Co., Winston-Salem, NC. 


VARIABLE HISTONE MODIFICATIONS AT 

THE A VY METASTABLE EPIALLELE. D. C. 

Dolinoy and R. L. Jirtle. Department of Radiation 

Oncology, Duke University, Durham, NC. 


MEASUREMENT OF CIGARETTE 

SMOKE CONDENSATE-INDUCED 

STRUCTURAL AND FUNCTIONAL 

ALTERATIONS IN BRONCHIAL CELLS 

USING QUANTITATIVE HIGH CONTENT 

SCREENING. C. A. Carter, K. D. Ergle and J. T. 

Hamm. Life Sciences, Lorillard Tobacco Company, 

Greensboro, NC. 


IDENTIFICATION OF EARLY MOLECULAR 

EVENTS UPON PEROXISOME 

PROLIFERATOR EXPOSURE IN THE 

RODENT LIVER. H. Ren, B. Vallanat and J. C. 

Corton. ORD/NHEERL/ECD, U.S. EPA, Durham, 

NC. 


THE ROLE OF TUMOR PROMOTER- 

INDUCED PKC ACTIVATION IN THE 

REGULATION OF HUMAN EQUILIBRATIVE 

NUCLEOSIDE TRANSPORTER 1 

EXPRESSION AND ACTIVITY. S. Jones 1 , 

A. V. Leisewitz 2 and L. M. Graves 2,1 . 1 Curriculum 

in Toxicology, University of North Carolina- 

Chapel Hill, Chapel Hill, NC and 2 Department of 

Pharmacology, University of North Carolina-Chapel 

Hill, Chapel Hill, NC. 


CONSTITUTIVELY ACTIVE B-RAF DOES 

NOT REGULATE CYCLIN D1 IN 2, 3, 5-TRIS- 

(GLUTATHION-S-YL) HYDROQUINONE 

TRANSFORMED, TUBEROUS SCLEROSIS-2 

NULL CELLS. J. D. Cohen, M. T. Labenski, T. J. 

Monks and S. S. Lau. Pharmacology and Toxicology, 


Abstract # 


PROAPOPTOTIC INTERACTIONS OF NON- 

PLANAR PCBs IN RAT LIVER EPITHELIAL 

CELLS: ROLE OF MITOGEN-ACTIVATED 

PROTEIN KINASES. B. V. Madhukar and G. 

Chen. Pediatrics/Human Development, Michigan 



17a-ETHINYLESTRADIOL ESPOSURE 

HINDERS HEPATIC NUCLEOTIDE 

EXCISION REPAIR IN ZEBRAFISH. G. Mayer 

and E. G. Notch. University of Maine, Orono, ME. 


INTERACTION BETWEEN THE ARYL 

HYDROCARBON RECEPTOR (AHR) 

AND THE RAS/RAF SIGNALING 

PATHWAYS IS REQUIRED FOR AHR- 

INDUCED EXPRESSION OF MATRIX 

METALLOPROTEINASES. K. A. Murphy and L. 

A. White. Rutgers University, New Brunswick, NJ. 


MICRORNAOME CHANGES AND BREAST 

CANCER DRUG RESISTANCE. J. Filkowski 1 , 

V. Tryndyak 2 , I. Pogribny 2 and O. Kovalchuk 1 . 

1 

University of Lethbridge, Lethbridge, AB, Canada 

and 2 NCTR, Jefferson, AR. 


OLD NSAID BUT NEW ANTICANCER 

AGENT: TOLFENAMIC ACID INHIBITS 

PANCREATIC CANCER GROWTH AND 

SENSETIZES TUMOR TO RADIOTHERAPY 

THROUGH DOWNREGULATION OF SP 

PROTEINS. M. Abdelrahim 1,2 , S. Konduri 1 , S. 

Safe 3 and J. Colon 1 . 1 Cancer Research Institute, M. 

D. Anderson Cancer Center Orlando, Orlando, FL, 

2 

Burnett College of Biomedical Sciences, University 

of Central Florida, Orlando, FL and 3 Veterinary 

Physiology and Pharmacology, Texas A&M 

University, College Station, TX. 


BORIC ACID AS A NOVEL ENDOPLASMIC 

RETICULUM MODULATOR AND CALCIUM 

RELEASE ANTAGONIST IN DU-145 

PROSTATE CANCER CELLS. K. A. Henderson, 

S. Kobylewski and C. Eckhert. Molecular Toxicology 

IDP, UCLA, Los Angeles, CA. 


EFFECT OF SODIUM ARSENITE ON 

METALLOTHIONEIN 1/2 AND P53 

PROTEIN LEVELS AND ITS POTENTIAL 

RELATIONSHIP WITH CELL CYCLE 

ALTERATIONS IN MCF-7 CELLS. A. D. 

Ríos-Pérez 1 , M. E. Cebrián 1 , R. Ruiz-Ramos 2 

and L. T. Lopez-Carrillo 2 . 1 Toxicology, Centro de 

Investigación y de Estudios Avanzados del Instituto 

Politécnico Nacional, Mexico City, DF, Mexico 

and 2 Centro de Investigacion en Salud Poblacional, 

Instituto Nacional de Salud Publica, Cuernavaca, 

Morelos, Mexico. 

Wednesday 




Wednesday 



9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: GENE REGULATION AND GENOMIC 

APPROACHES 

Chairperson(s): Yue Wern Huang, University of Missouri, Rolla, MO. 




AHR PROTEIN INTERACTIONS: 

BUILDING A COMPREHENSIVE PROTEIN 

INTERACTION NETWORK. D. M. 

Tappenden 1,4 , L. Yang 2 , R. S. Thomas 2 and J. J. 

LaPres 1,3,4 . 1 Biochemistry, MSU, East Lansing, MI, 

2 

The Hamner Institutes for Health Sciences, Research 

Triangle Park, NC, 3 The National Food Safety and 

Toxicology Center, MSU, East Lansing, MI and 

4 

Center for Integrative Toxicology, MSU, East 

Lansing, MI. 


IDENTIFYING THE MECHANISM OF 

AHR-MEDIATED OFF-TARGET EFFECTS 

INDUCED BY A-277249 USING CHIP-ON- 

CHIP TECHNOLOGY. Y. Yang, R. Ciurlionis, 

E. A. Blomme and J. F. Waring. R463, Abbott 

Laboratories, Abbott Park, IL. 


TEMPORAL AND DOSE-DEPENDENT AHR- 

MEDIATED GENE EXPRESSION ANALYSIS 

IN HUMAN LIVER ADULT STEM CELLS. 

S. Kim 1,2,3 , E. Dere 1,2 , L. D. Burgoon 1,2 , C. C. 

Chang 2,4 and T. R. Zacharewski 1,2,3 . 1 Department of 

Biochemistry & Molecular Biology, Michigan State 

University, East Lansing, MI, 2 National Food Safety 

& Toxicology Center, Michigan State University, 

East Lansing, MI, 3 Center for Integrative Toxicology, 


4 

Department of Pediatrics & Human Development, 



CHARACTERIZATION OF GENE 

EXPRESSION RESPONSES ELICITED BY 

TOXIC AND NON-TOXIC AHR LIGANDS 

IN MURINE HEPA1C1C7 CELLS. E. Dere 1,2 , 

A. W. Lee 1,2 , M. S. Kiewitt 1,2 , L. D. Burgoon 1,2 and 

T. R. Zacharewski 1,2 . 1 Department of Biochemistry 

and Molecular Biology, Michigan State University, 

East Lansing, MI and 2 National Food Safety and 


Lansing, MI. 


CONSERVED AND DIVERGENT GENE 

EXPRESSION PROFILES DURING 

ETHYNYLESTRADIOL, TAMOXIFEN AND 

O, P’-DDT INDUCED UTEROTROPHY 

IN THE RAT UTERUS. J. C. Kwekel 1,2 , K. J. 

Williams 2,3 and T. R. Zacharewski 1,2 . 1 Biochemistry 

and Molecular Biology, Michigan State University, 

East Lansing, MI, 2 Center for Integrative Toxicology 

and National Food Safety and Toxicology Center, 


3 

Department of Pathobiology and Diagnostic 

Investigation, Michigan State University, East 

Lansing, MI. 


STEROIDOGENIC ACUTE REGULATORY 

PROTEIN AS A TARGET FOR 

ORGANOCHLORINE PESTICIDES IN 

LARGEMOUTH BASS (MICROPTERUS 

SALMOIDES). M. S. Prucha 1 , W. Rees 2 , D. 

Barber 2 and N. D. Denslow 2 . 1 Pharmacology and 

Therapeutics, University of Florida, Gainesville, FL 

and 2 Physiological Sciences, University of Florida, 



STRESS ASSAY ENSEMBLE RESPONSE 

TO ENVIRONMENTAL CHEMICALS IN 

DIFFERENT HUMAN CELL TYPES. S. 

Simmons and R. Ramabhadran. NHEERL, U.S. 

EPA, Durham, NC. 


EVALUATION OF ESTROGENIC ACTIVITY 

OF PHTHALATE ESTERS BY DNA 

MICROARRAY ANALYSIS. M. Parveen 1 , A. 

Inoue 2 , R. Ise 1 , M. Tanji 2 and R. Kiyama 1,2 . 1 Signaling 

Molecules Research Laboratory, National Institute 

of Advanced Industrial Science and Technology, 

Tsukuba, Japan and 2 InfoGenes Co., Ltd, Kashiwa, 

Japan. Sponsor: M. Sato. 


FULL-GENOME ANALYSIS OF 

ALTERNATIVE SPLICING IN MOUSE 

LIVER AFTER HEPATOTOXICANT 

EXPOSURE. B. Vallanat, J. S. Lee, W. Ward, 

H. Ren, M. Rosen, S. Hester, S. Nesnow, C. Lau, 

D. Delker and J. C. Corton. NHEERL, U.S. EPA, 

Durham, NC. 


NON-LINEAR LOW DOSE RESPONSE 

IN METHYL METHANESULFONATE 

(MMS)-TREATED RATS AS MEASURED 

BY MULTIPLE ENDPOINTS. M. J. LeBaron, 

H. L. Kan, D. R. Geter, L. H. Pottenger, F. Zhang, 

M. R. Schisler, M. J. Bartels and B. B. Gollapudi. 

Toxicology & Environmental Research & 


MI. 


ACRYLAMIDE AND GLYCIDAMIDE- 

INDUCED MITOCHONDRIAL GENE 

EXPRESSION PROFILES IN BIG BLUE 

TRANSGENIC MICE. M. G. Manjanatha 1 , C. 

L. Moland 2 , W. S. Branham 2 , S. D. Shelton 1 , E. 

Tareke 3 , T. Lee 3 , A. Aidoo 1 , J. C. Fuscoe 2 and V. G. 

Desai 2 . 1 Genetic Toxicology, FDA/NCTR, Jefferson, 

AR, 2 Division of Systems Toxicology, National 

Center for Toxicological Research, Jefferson, AR 

and 3 Personalized Medicine and Nutrition, National 

Center for Toxicological Research, Jefferson, AR. 

Sponsor: B. Parsons. 


GENE EXPRESSION CHANGES IN BLOOD 

LEUKOCYTES INDICATIVE OF D-SERINE 

EXPOSURE. A. Soto 1 , M. Davison 2 , N. DelRaso 1 

and V. Chan 1 . 1 HEPB, AFRL, Dayton, OH and 

2 

ORISE, Dayton, OH. Sponsor: D. Mattie. 

214 




Abstract # 


APPLICATION OF IN VITRO 

TOXICOGENOMICS DURING 

INTERMEDIATE STAGES OF COMPOUND 

PROGRESSION. J. F. Waring 1 , M. J. Liguori 1 , 

S. E. Warder 1 , P. J. Hajduk 2 and E. A. Blomme 1 . 

1 

Cellular and Molecular Toxicology, Abbott 

Laboratories, Abbott Park, IL and 2 Protein NMR, 

Molecular Modeling, and Cheminformatics 

Research, Abbott Laboratories, Abbott Park, IL. 


MICROARRAY ANALYSIS OF MOUSE 

LIVER TRANSCRIPTS FOLLOWING 

LOW DOSE ARSENIC/DEXAMETHASONE 

EXPOSURE. J. C. Davey 1 , J. A. Gosse 1 , C. D. 

Kozul 1 , T. H. Hampton 1 , A. Nomikos 1 , L. A. Warnke 2 , 

J. E. Thorpe 3 , J. E. Bodwell 2 , M. A. Ihnat 2 and J. W. 

Hamilton 1 . 1 Pharmacology/Toxicology, Dartmouth 

Medical School, Hanover, NH, 2 Physiology, 

Dartmouth Medical School, Lebanon, NH and 3 Cell 

Biology, University of Oklahoma Health Sciences 

Center, Oklahoma City, OK. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: RESPIRATORY AND SKIN 

HYPERSENTIVITY 

Chairperson(s): Marc Pallardy, University of Paris, Chatenay Malabry, 

France and Victor Johnson, NIOSH/CDC, Morgantown, WV. 




ANTI-INFLAMMATORY EFFECT OF 

SAPONINS ISOLATED FROM THE ROOTS 

OFPLATYCODON GRANDIFLORUM IN 

A MOUSE MODEL OF ALLERGIC LUNG 

INFLAMMATION. J. Choi 1,2 and H. Jeong 1,2 . 

1 




Korea. 



PLATYCODON GRANDIFLORUM INHIBITS 

INFLAMMATORY CYTOKINE EXPRESSION 

IN RAT MAST CELLS. C. Youngchul 1 , E. Han 2 

and H. Jeong 2 . 1 Division of Food Science, Jinju 

International University, Jinju, South Korea and 

2 


Korea. 


UP-REGULATION OF 

CYCLOOXYGENASE-2 EXPRESSION 

BY SERINE PROTEASE, SUBTILISIN, IN 

MACROPHAGES. J. Hyepark 1,2 , E. H. Han 1,2 and 

H. Jeong 1,2 . 1 Pharmacy, Chosun University, Kwangju, 



Korea. 

Abstract # 


ALCALASE-MEDIATED GENE 

EXPRESSION PROFILE CHANGE IN 

HUMAN AIRWAY EPITHELIAL CELL 

LINE A549 GROWN IN AN AIR/LIQUID 

INTERFACE. T. Hu 1 , M. Baccam 1 , T. Reichling 1 , 

G. Carr 1 , E. Roggen 2 and K. Sarlo 1 . 1 Central Product 

Safety, Procter & Gamble, Cincinnati, OH and 

2 

Pharmacology Protein Development, Novozymes, 

Bagsvaerd, Denmark. 


A DRAINING LYMPH NODE ASSAY (DLNA) 

AS A POTENTIAL FIRST TIER FOR 

ASSESSING THE SENSITIZING POTENTIAL 

OF PROTEINS. M. R. Woolhiser, B. B. Gollapudi, 

J. A. Hotchkiss and D. R. Boverhof. The Dow 



IMMUNOGLOBULIN E IN ASTHMATIC 

HUMAN SERA IS REACTIVE AGAINST 

MOLD EXTRACTS. Y. Chung 1 , M. D. Ward 1 , 

E. Svendsen 2 , K. Yeatts 3 , D. Peden 3 , L. Neas 4 and 

R. Devlin 4 . 1 U.S. EPA, Research Triangle Park, 

NC, 2 University of South Carolina, Columbia, SC, 

3 


4 

U.S. EPA, Chapel Hill, NC. 


IMMUNOLOGIC SKEWEDNESS 

TOWARD TYPE-2 RESPONSE PRONE TO 

RESPIRATORY ALLERGY IN PUBLIC 

SERVICE FACILITY EMPLOYEES. Y. Heo 1 , 

H. Kim 2 , S. Lee 1 and S. Kim 3 . 1 Occupational 

Health, Catholic University of Daegu, Kyongsan, 

South Korea, 2 Preventive Medicine, The Catholic 

University of Korea, College of Medicine, Seoul, 

South Korea and 3 Internal Medicine, TEulji 

University School of Medicine, Seoul, South Korea. 


MIXED AIR POLLUTION, ALLERGY AND 

INFLAMMATION. A. Nilsen 1 , T. Alberg 2 , 

J. S. Hansen 2 , U. C. Nygaard 2 and M. Lovik 1,2 . 

1 

Department of Cancer Research and Molecular 

Medicine, Norwegian University of Science and 

Technology, Trondheim, Norway and 2 Division of 

Environmental Medicine, Norwegian Institute of 

Public Health, Oslo, Norway. 


AN ANIMAL MODEL OF PLATINUM (PT) 

HYPERSENSITIVITY. E. H. Boykin 1 , J. R. 

Lehmann 2 , D. L. Doerfler 1 , S. H. Gavett 2 and M. K. 

Selgrade 1 . 1 ITB/ETD, U.S. EPA, Research Triangle 

Park, NC and 2 PTB/ETD, U.S. EPA, Research 



IDENTIFICATION OF RESPIRATORY 

SENSITIZING CHEMICALS OF LOW 

MOLECULAR WEIGHT USING 

BRONCHOALVEOLAR LAVAGE FLUID 

CYTOKINES AND SERUM IGE. M. Ota, T. 

Mori, K. Nishioka and H. Kaneko. Environmental 

Health Science Lab., Sumitomo Chemical Co.Ltd, 

Osaka, Japan. 

Wednesday 




Wednesday 



EVALUATION OF RESPIRATORY 

CHEMICAL ALLERGENS IN THE PEPTIDE 

REACTIVITY ASSAY. H. Rothe 3 , K. Sarlo 1 , 

F. Gerberick 1 , L. Foertsch 1 , R. Dearman 2 and I. 

Kimber 2 . 1 Procter & Gamble, Cincinnati, OH, 

2 

University of Manchester, Manchester, United 

Kingdom and 3 Procter & Gamble, Darmstadt, 

Germany. 


CARBON NANOTUBES ENHANCE 

ALLERGIC RESPONSES IN MICE. U. C. 

Nygaard, J. S. Hansen and M. Lovik. Environmental 

Immunology, Norwegian Institute of Public Health, 

Oslo, Norway. 


ACTIVITY OF CHEMICAL RESPIRATORY 

SENSITIZERS IN A NON-STANDARD LOCAL 

LYMPH NODE ASSAY (LLNA). R. J. Dearman 1 , 

D. A. Basketter 2 , H. F. McGarry 3 and I. Kimber 1 . 

1 

Faculty of Life Sciences, Manchester University, 

Manchester, Greater Manchester, United Kingdom, 

2 

St John’s Institute of Dermatology, St Thomas’ 

Hospital, London, United Kingdom and 3 Health and 

Safety Executive, Bootle, United Kingdom. 


EVALUATION OF THE POTENTIAL AND 

STRENGTH OF SKIN SENSITIZATION 

USING IN VITRO SKIN SENSITIZATION 

TEST - HUMAN CELL LINE ACTVATION 

TEST (H-CLAT). Y. Nukada 1 , T. Ashikaga 2 , N. 

Kosaka 1 , S. Sono 2 , H. Sakaguchi 1 , H. Itagaki 2 and N. 

Nishiyama 1 . 1 Kao Corporation, Tochigi, Japan and 

2 

SHISEIDO CO., LTD., Kanagawa, Japan. 


INVESTIGATION OF FALSE-NEGATIVE 

CONTACT ALLERGENS IN THE IN VITRO 

SKIN SENSITIZATION TEST; HUMAN CELL 

LINE ACTIVATION TEST (H-CLAT). N. 

Kosaka, Y. Nukada, H. Sakaguchi and N. Nishiyama. 

Kao Corporation, Tochigi, Japan. Sponsor: J. Avalos. 


EXAMINATION OF A HUMAN CELL 

LINE ACTIVATION TEST (H-CLAT) FOR 

PREDICTING SKIN SENSITIZATION 

POTENTIAL: OUTCOME OF THE THIRD 

RING TRIAL. C. Ryan 1 , H. Sakaguchi 2 , T. 

Ashikaga 3 , J. Ovigne 4 and D. Eschrich 5 . 1 Procter 

& Gamble Company, Cincinnati, OH, 2 Kao 

Corporation, Safety Science Laboratories, Tochigi, 

Japan, 3 Shiseido Co., Ltd., Quality Assurance Center, 

Kanagawa, Japan, 4 L’Oreal, Advanced Research, 

Aulnay sous Bois, France and 5 Phenion-Henkel, 

Dusseldorf, Germany. 


INTRA- AND INTERLABORATORY 

EVALUATION OF THE LLNA-DA METHOD: 

A NON-RI MODIFIED LLNA IN WHICH ATP 

CONTENT IS USED AS THE ENDPOINT. K. 

Idehara, G. Yamagishi and K. Yamashita. Analysis 

Service Center, Daicel Chemical Industries, LTD., 

Himeji, Japan. Sponsor: M. Takahashi. 


INTER-LABORATORY VALIDATION OF A 

NON-RADIOISOTOPE VERSION OF THE 

LLNA*. H. Kojima 1 , M. Takeyoshi 2 , T. Omori 3 , 

T. Sozu 4 , K. Arima 5 , K. Idehara 6 , Y. Ikarashi 1 , Y. 

Kanazawa 7 , E. Maki 8 , N. Nakagiri 9 , M. Tanaka 10 , A. 

Yuasa 11 and I. Yoshimura 12 . 1 NIHS, Tokyo, Japan, 

2 

Chemical Evaluation and Research, Saitama, Japan, 

3 

Kyoto University, Kyoto, Japan, 4 Osaka University, 

Osaka, Japan, 5 Taisho Pharmaceutical Co., Saitama, 

Japan, 6 Daicel Chemical Industries, Ltd., Hyogo, 

Japan, 7 Food and Drug Safety Center, Kanagawa, 

Japan, 8 Biosafety Research Center, Foods, Drugs and 

Pesticides, Shizuoka, Japan, 9 Otuka Pharmaceutical 

Co., Ltd., Tokushima, Japan, 10 Meiji Seika Kaisha, 

Ltd., Yokohama, Japan, 11 Fiji Photo Film Co., 

Kanagawa, Japan and 12 Tokyo University of Science, 

Tokyo, Japan. Sponsor: T. Inoue. 


TESTING WATER SOLUBLE ALLERGENS 

VIA THE EAR CANAL IN THE LOCAL 

LYMPH NODE ASSAY. N. Berg, U. Festersen, 

C. Rasmussen, T. Kjaer and E. Roggen. Safety & 

Toxicology, Novozymes A/S, Bagsvaerd, Denmark. 


SENSITIZATION POTENTIAL OF 

VETIVERYL ACETATE EVALUATED USING 

THE LOCAL LYMPH NODE ASSAY. L. Jones, 

R. Foxenberg, J. Lalko, C. Letizia and A. Api. Human 

Health Sciences, Research Institute for Fragrance 

Materials, Woodcliff Lake, NJ. 


IMPACT OF OLIVE OIL AND DMSO AS 

VEHICLES ON MURINE LOCAL LYMPH 

NODE ASSAY (LLNA) ESTIMATED BY 

TWO SETS OF ENDPOINTS. W. Wang-Fan, 

E. Deparade and L. G. Ullmann. Business Unit 

Pharmacology, RCC Ltd, Itingen, Switzerland. 

Sponsor: S. Corney. 


PERFORMANCE CHARACTERISTICS OF 

THE LOCAL LYMPH NODE ASSAY (LLNA) 

LIMIT DOSE PROCEDURE. W. Stokes 1 , D. 

Allen 2 , T. Burns 2 , N. Choksi 2 , J. Matheson 3 , A. 

Jacobs 4 and R. Tice 1 . 1 NICEATM, NIEHS/NIH/ 

DHHS, RTP, NC, 2 ILS, Inc., NICEATM, RTP, NC, 

3 

CPSC, Bethesda, MD and 4 FDA, Silver Spring, MD. 


THE CHEMICAL ALLERGEN NICKEL 

SULFATE TRIGGERS THE PRODUCTION 

OF THE BIO-ACTIVE FORM OF 

INTERLEUKIN-12 BY HUMAN DENDRITIC 

CELLS. M. Pallardy, D. Antonios, S. Kerdine- 

Römer, N. Ade and A. Larangé. Toxicologie and 

Inserm UMR-S 749, Universite Paris-Sud 11, 

Chatenay-Malabry, France. 


THE EFFECTS OF ASCORBATE AND 

GLUTATHIONE DEFICIENCY ON THE 

TOXICITY AND IMMUNOGENICITY OF 

SULFAMETHOXAZOLE NITROSO IN 

GUINEA PIGS. S. Bhusari 1 , M. Padilla 1 , M. 

Pinkerton 2 and L. Trepanier 1 . 1 Department of Medical 

Sciences, School of Veterinary Medicine, University 

of Wisconsin, Madison, WI and 2 Department of 

Pathobiological Sciences, School of Veterinary 

Medicine, University of Wisconsin, Madison, WI. 

216 




Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: EPIDEMIOLOGY AND EXPOSURE 

ASSESSMENT 

Chairperson(s): Ellen Silbergeld, Johns Hopkins Bloomberg School of 

Public Health, Baltimore, MD and Annette Rohr, Electric Power Research 

Institute, Palo Alto, CA. 




A STUDY OF AIRBORNE CHRYSOTILE 

CONCENTRATIONS ASSOCIATED 

WITH HANDLING, UNPACKING, AND 

REPACKING BOXES OF AUTOMOBILE 

CLUTCH DISCS (CIRCA 1950-1980). B. L. 

Finley, A. K. Madl, D. M. Murbach, K. A. Fehling, 

D. J. Paustenbach and G. C. Jiang. ChemRisk, Inc., 

San Francisco, CA. 


PREDICTING THE IMPACTS OF 

AGGREGATE AND CUMULATIVE 

EXPOSURES ON HUMAN HEALTH. P. S. 

Price, D. Fontaine and L. McFadden. Toxicology & 

Environmental Research & Consulting, The Dow 



TAPE STRIPPING FOR THE ASSESSMENT 

OF DERMAL PYRENE EXPOSURE: A 

VOLUNTEER STUDY. C. Viau 1 , K. Deroy 1 , 

R. Thuot 1 and A. Maitre 2 . 1 Chair of Toxicological 

Risk Analysis & Management, Department of 

Environmental & Occupational Health, University of 

Montreal, Montreal, QC, Canada and 2 Equipe EPSP 

Environnement, University of Grenoble, Grenoble, 

Isere, France. 


ASSOCIATIONS BETWEEN ASTHMA 

EMERGENCY DEPARTMENT VISITS AND 

DIESEL EMISSIIONS IN TACOMA, WA. J. Q. 

Koenig 1 , T. F. Mar 1 and J. Primomo 2 . 1 environmental 

health, university of washington, Seattle, WA 

and 2 Nursing Progamng Program, university of 

washington, Tacoma, WA. 


EVALUATION OF KEY INFORMATION 

FORMING THE BASIS OF EPA’S NEW 

RECOMMENDED OZONE STANDARD. 

L. A. Beyer, T. M. Slayton, J. E. Goodman, G. I. 

Greenberg, T. C. Hudson and B. D. Beck. Gradient 

Corp., Cambridge, MA. 

Abstract # 


NEUROLOGICAL SYMPTOMS AND 

NEUROPATHOLOGICAL ANTIBODIES 

IN POULTRY WORKERS EXPOSED TO 

CAMPYLOBACTER JEJEUNI. L. B. Price 1,2,3 , 

A. Roess 1 , J. Graham 1 , S. Baqaar 4 , R. Vailles 1 , 

L. Lackey 1 , K. A. Sheikh 2 and E. K. Silbergeld 1 . 

1 


Univ SPH, Baltimore, MD, 2 Johns Hopkins 

University School of Medicine, Baltimore, MD, 

3 

Northern Arizona University, Flagstaff, AZ and 

4 

U.S. Naval Medical Research Center, Silver Spring, 

MD. 


EVALUATION OF POTENTIAL 

INHALATION HAZARDS OF PETROLEUM-, 

SYNTHETIC- AND BIO-FUELS USING 

GC/MS ANALYSIS OF VAPORS UNDER 

EQUILIBRIUM CONDITIONS. C. K. Kendrick 1 , 

S. A. Martin 2 , J. W. Fisher 2 , T. T. Adams 3 and R. 

T. Tremblay 2 . 1 Environmental Health Science, 

University of Georgia, Athens, GA, 2 Interdisciplinary 

Toxicology Program, University of Georgia, Athens, 

GA and 3 Engineering Outreach Service, University of 



NITRATE TOXICITY RISK ASSESSMENT: 

FROM FIELD SAMPLING TO REMOTE 

SENSING AND BEYOND. S. Tawde and D. Van 

Der Merwe. Diagnostic Medicine/Pathobiology, 

Kansas State University, Manhattan, KS. 


EXAMINATION OF THE CURRENT 

GEOGRAPHIC RELATIONSHIP BETWEEN 

BLOOD LEAD LEVELS AND AIR LEAD 

LEVELS IN THE UNITED STATES. R. Mattuck 

and T. S. Bowers. Gradient Corporation, Cambridge, 

MA, MA. Sponsor: B. Beck. 


EFFECTS OF DEMOGRAPHIC, 

ENVIRONMENTAL, AND POLYMORPHIC 

FACTORS ON EMERGENCY DEPARTMENT 

VISITATION IN ASTHMATIC CHILDREN. 

G. G. Goodrich 1 , P. H. Goodman 2 and C. A. Pritsos 1 . 

1 

Environmental Sciences and Health, University 

of Nevada, Reno, NV and 2 Internal Medicine, 

University of Nevada, Reno, NV. 


DETAILED ASBESTOS FIBER SIZE 

AND MORPHOLOGY ANALYSES OF 

AUTOMOBILE CLUTCH DISCS, BRAKE 

PADS, AND BRAKE SHOES. G. C. Jiang, 

A. K. Madl, D. J. Paustenbach and B. L. Finley. 

ChemRisk, Inc., San Francisco, CA. 


ASSOCIATION OF THE CYP1A1 G184C 

POLYMORPHISM WITH LUNG CANCER 

RISK. D. Ryu 1 , M. Huang 2 , C. Park 1 , R. Im 2 

and J. Park 2 . 1 College of Veterinary Medicine, 

Seoul Natinal University, Seoul, South Korea and 

2 

Preventive Medicine, College of Medicine, Chung- 

Ang University, Seoul, South Korea. 


CASE STUDIES OF NON-PAINT SOURCES 

OF LEAD EXPOSURES IN THE UNITED 

STATES. V. Coluccio and K. Vetrano. TRC, 

Windsor, CT. 

Wednesday 




Wednesday 



OCCUPATIONAL EXPOSURE TO BENZENE 

THE EXXONMOBIL REFINERY IN JOLIET, 

ILLINOIS (1977-2006). M. L. Kreider 1 , K. 

M. Unice 1 , J. M. Panko 1 , T. E. Widner 2 , D. J. 

Paustenbach 2 , L. E. Booher 3 , R. H. Gelatt 4 and S. H. 

Gaffney 2 . 1 ChemRisk, Pittsburgh, PA, 2 ChemRisk, 

San Francisco, CA, 3 ExxonMobil Corporation, 

Fairfax, VA and 4 ExxonMobil Biomedical Sciences 

Inc., Clinton, NJ. 


CANCER MORTALITY IN CHINESE 

POPULATIONS SURROUNDING AN ALLOY 

PLANT WITH CHROMIUM SMELTING 

OPERATIONS (1960–1978). B. D. Kerger 1 , W. 

J. Butler 2 , D. J. Paustenbach 3 , J. Zhang 4 and S. Li 5 . 

1 

Health Science Resource Integration, Tallahassee, 

FL, 2 Environmental Risk Analysis, San Mateo, CA, 

3 

ChemRisk, San Francisco, CA, 4 JinZhou Disease 

Control and Prevention Station, JinZhou, LaioNing, 

China and 5 Benxi Disease Control and Prevention 

Station, Benxi, LaioNing, China. 


INHIBIN B IS A POTENTIAL MARKER 

OF TESTICULAR DAMAGE PRODUCED 

BY OCCUPATIONAL EXPOSURE TO 

ORGANOPHOSPHATE PESTICIDES. M. 

M. Morales 1 , J. Blanco-Muñoz 2 , M. E. Cebrián 1 , 

S. Bassol 3 , C. Aguilar-Garduño 4 , C. Hernández 

Morales 3 , R. Arenas-Hernández 1 and M. Lacasaña 5 . 

1 

Toxicology, CINVESTAV, Mexico City, Mexico, 

2 

Occupational Health, INSP, Cuernavaca, Mexico, 

3 

Biology of the Reproduction, UAC, Torreon, 

Mexico, 4 Investigaciones Médicas, San Cecilio 

Hospital Universidad, Granada, Spain and 5 Escuela 

Salud Pública de Andalucía, Granada, Spain. 


COMPARING GENE EXPRESSION 

PATTERNS IN BLOOD AND LUNG TISSUE 

OF IMMUNOLOGICALLY-CHALLENGED 

RATS EXPOSED TO CONCENTRATED 

AIRBORNE PARTICULATES. D. Reif 1 , B. 

Heidenfelder 2 , E. Hubal 1 , J. R. Harkema 3 and J. 

Gallagher 2 . 1 National Center for Computational 

Toxicology, U.S. Environmental Protection Agency, 

Research Triangle Park, NC, 2 Human Studies 

Division, U.S. Environmental Protection Agency, 

Research Triangle Park, NC and 3 Department of 

Pathobiology and Diagnostic Intervention, Michigan 



HIGHER POLYCHLORINATED BIPHENYL 

(PCB) LEVELS AND RATIOS IN SKIN LIPIDS 

RELATIVE TO ADJACENT SUBCUTANEOUS 

ADIPOSE LIPIDS. R. C. James 1 , B. D. Kerger 2 , 

S. M. Roberts 1 , A. F. Payer 3 , D. J. O’Hehir 4 and A. P. 

DeCaprio 5 . 1 University of Florida, Gainesville, FL, 

2 


FL, 3 Florida State University, Tallahassee, FL, 4 State 

University of New York, Albany, NY and 5 University 

of Massachusetts, Amherst, MA. 


PILOT STUDY OF VAPOR REACTION 

PRODUCTS FROM MIXING DIACETYL 

AND CHLORINE BLEACH. M. J. Fedoruk 1 , 

B. D. Kerger 2 , L. Israel 1 , S. Hoyt 3 , J. Britt 4 and R. 

C. James 4 . 1 University of California, Irvine, CA, 

2 


FL, 3 Environmental Analytical Services, San Luis 

Obispo, CA and 4 TERRA, Tallahassee, FL. 


INDOOR ENVIRONMENT, ASTHMA, 

ALLERGIES, SICK BUILDING SYNDROME 

(SBS) IN THE SWEDISH POPULATION- A 

LONGITUDINAL COHORT STUDY FROM 

1989-1997. B. Sahlberg, Y. Mi and D. Norbäck. 

Department of Occupational and Environmental 

Medicine, Uppsala, Sweden. 


URINARY 1-HYDROXYPYRENE: A 

BIOMARKER OF POLYCYCLIC AROMATIC 

HYDROCARBON EXPOSURE IN A 

GHANAIAN POPULATION. N. M. Johnson 1 , 

A. Cardona 1 , A. Robinson 1 , J. Taylor 1 , E. Afriyie- 

Gyawu 1 , H. Huebner 1 , L. Xu 2 , L. Tang 2 , N. A. 

Ankrah 3 , D. Ofori-Adjei 3 , J. H. Williams 4 , J. S. Wang 3 

and T. D. Phillips 1 . 1 College of Veterinary Medicine, 

Texas A&M University, College Station, TX, 2 The 

Institute of Environmental and Human Health, Texas 

Tech University, Lubbock, TX, 3 Noguchi Memorial 

Institute for Medical Research, University of Ghana, 

Accra, Ghana and 4 Peanut Collaborative Research 

Support Program, The University of Georgia, Griffin, 

GA. 


ENVIRONMENTAL HEALTH & 

COMMUNITY REVIEW BOARD (EHCRB): 

SUPPLEMENTING THE TRADITIONAL IRB. 

S. G. Gilbert 1 and T. E. McHugh 2 . 1 INND, Seattle, 

WA and 2 Groundwater Service, Inc., Houston, TX. 


ESTIMATION OF TOTAL DIETARY INTAKE 

OF PERCHLORATE AND IMPACTS ON 

SETTING A MAXIMUM CONTAMINANT 

LEVEL FOR DRINKING WATER. E. J. Martin 

and C. D. Sandau. TRIUM Environmental Solutions 

Inc., Cochrane, AB, Canada. 


ASSESSING POTENTIAL EXPOSURE TO 

TRANSFERABLE INSECTICIDE RESIDUES 

FROM THE FUR OF DOGS TREATED WITH 

A SPOT-ON FLEA CONTROL PRODUCT 

CONTAINING THE PYRETHROID 

INSECTICIDE PERMETHRIN. M. K. Davis, M. 

Russak, M. K. Ross and J. E. Chambers. Center for 

Environmental Health Sciences, Mississippi State 


218 




Abstract # 


CADMIUM EXPOSURE ASSESSMENT 

USING TOTAL DIET STUDY AND 

PROBALISTITC MONTE CARLO 

SIMULATION IN A CADMIUM-POLLUTED 

REGION, JAPAN. F. Kayama 1 , H. Horiguchi 1 , 

S. Nakai 2 , N. Nitta 3 and S. Sasaki 4 . 1 Center for 

Community Medicine, Jichi Medical University, 

Kawachi-Gun, Tochigi, Japan, 2 Yokohama National 

University, Yokohama, Japan, 3 National Institute 

of Environmental Studies, Tsukuba, Japan and 

4 

University of Tokyo, Tokyo, Japan. Sponsor: T. 

Yoshida. 


DETERMINATION OF A SOUTHERN 

CALIFORNIA REGIONAL BACKGROUND 

ARSENIC CONCENTRATION IN SOIL. G. 

Chernoff, W. Bosan and D. Oudiz. Department 

of Toxic Substances Control, California EPA, 



RESEARCH ON TOXIC CHEMICALS IN 

THE GREAT LAKES: DEFINING STUDIES 

TO HELP ENSURE HEALTHY PEOPLE 

IN EVERY STAGE OF LIFE. H. E. Hicks, A. 

Ashizawa and C. T. De Rosa. Division of Toxicology 

and Environmental Medicine, ATSDR/CDC, Atlanta, 

GA. 


9:00 AM to 12:30 PM 

Exhibit Hall 


POSTER SESSION: NANOPARTICLES: INHALATION AND 

RESPIRATORY CELL INJURY 

Chairperson(s): Dale Porter, CDC - NIOSH, Morgantown, WV and 

Jurgen Pauluhn, Bayer Healthcare AG, Wuppertal, Germany. 




AN IN-VITRO ASSESSMENT OF A 

NANOSCALE, REDOX-SENSITIVE 

ANTIOXIDANT DELIVERY SYSTEM’S 

IMPACT ON OXIDATIVE DAMAGE. B. 

S. Lepene and C. D. Thatcher. Department of 

Biomedical and Veterinary Sciences, Virginia- 

Maryland Regional College of Veterinary Medicine, 

Virginia Tech, Blacksburg, VA. Sponsor: M. Ehrich. 

Abstract # 


COMPARISON OF THE BIOLOGICAL 

ACTIVITY BETWEEN ULTRAFINE AND 

FINE TIO2 PARTICLES IN RAW 264.7 CELLS 

ASSOCIATED WITH OXIDATIVE STRESS. 

J. L. Kang 1 , C. Moon 2 , H. S. Lee 3 , H. W. Lee 4 , E. 

Park 5 , H. S. Kim 6 and V. Castranova 7 . 1 Physiology, 

Ewha Womans Univesity, College of Medicine, 

Seoul, South Korea, 2 Physiology, Ewha Womans 

University, Seoul, South Korea, 3 Physiology, 

Ewha Womans University, Seoul, South Korea, 

4 

Physiology, Ewha Womans University, Seoul, South 

Korea, 5 Pharmacology, Ewha Womans University, 

Seoul, South Korea, 6 Neuroscience, Ewha Womans 

University, Seoul, South Korea and 7 Pathology 

and Physiology Research Branch, Health Effects 

Laboratory Division, Morgantown, WV. 


EVALUATION OF IN VITRO CELL CULTURE 

SYSTEMS TO ACCURATELY PREDICT THE 

PULMONARY TOXICITY OF INHALED OR 

INSTILLED FINE OR NANO ZINC OXIDE 

PARTICLES. D. B. Warheit, M. B. Golt, C. M. 

Sayes and K. L. Reed. DuPont Haskell Laboratory, 

Newark, DE. 


ASSESSING THE PULMONARY IMPACTS 

OF TWO SELECTED AMORPHOUS SILICA 

NANOPARTICLE SIZE RANGES IN RATS 

FOLLOWING INHALATION EXPOSURES. 

C. M. Sayes 1 , M. L. Ostraat 2 , K. L. Reed 1 and D. B. 

Warheit 1 . 1 DuPont Haskell Laboratory, Newark, DE 

and 2 DuPont Central Research and Development, 



MECHANISMS OF NANODIAMOND 

PARTICLE INDUCED IL-8 EXPRESSION IN 

HUMAN AIRWAY EPITHELIAL CELLS. R. 

Silbajoris 1 , M. Huang 3 , W. Cheng 5 , L. A. Dailey 1 , 

R. K. Saxena 4 , P. A. Bromberg 2 and J. M. Samet 1 . 

1 

NHEERL, U.S. EPA, Chapel Hill, NC, 2 CEMALB, 

UNC, Chapel Hill, NC, 3 Duke University, Durham, 

NC, 4 School of Life Sciences, Jawaharlal Nehru 

University, New Delhi, India and 5 Environmental 

Sciences and Engineering, UNC, Chapel Hill, NC. 

Sponsor: M. Madden. 


GOLD NANOPARTICLES INDUCE 

OXIDATIVE DAMAGE IN LUNG 

FIBROBLASTS IN VITRO. L. Yung 1 , J. J. Li 2 , L. 

Zou 3 , D. Hartono 1 , C. Ong 3 and B. Bay 2 . 1 Chemical 

& Biomolecular Engineering, National University 

of Singapore, Singapore, Singapore, 2 Anatomy, 


Singapore and 3 Community, Occupational and 

Family Medicine, National University of Singapore, 

Singapore, Singapore. Sponsor: U. Boelsterli. 


PULMONARY RESPONSE TO 

INTRATRACHEAL INSTILLATION OF 

FINE OR ULTRAFINE CARBON BLACK 

OR TITANIUM DIOXIDE: ROLE OF 

SURFACE AREA. T. M. Sager 1,2 , D. Porter 1,2 and 

V. Castranova 1,2 . 1 NIOSH, Morgantown, WV and 

2 

WVU School of Medicine, Morgantown, WV. 

Wednesday 




Wednesday 



ENGINEERED TITANIUM DIOXIDE 

NANOWIRE TOXICITY IN VITRO AND IN 

VIVO. D. W. Porter 1 , A. Holian 3 , K. Sriram 1 , N. Wu 2 , 

M. Wolfarth 1 , R. Hamilton 3 and M. Buford 3 . 1 Health 

Effects Laboratory Division, NIOSH, Morgantown, 

WV, 2 Mechanical & Aerospace Engineering, West 

Virginia University, Morgantown, WV and 3 Center 

for Environmental Health Sciences, University of 

Montana, Missoula, MT. 


COMPARATIVE PULMONARY RESPONSE 

TO INHALED MULTIWALLED CARBON 

NANOTUBES, CARBON BLACK, AND 

ALPHA QUARTZ. J. Pauluhn. Toxicology, Bayer 

HealthCare, Wuppertal, Germany. 


COMBINED EXPOSURE TO CARBON 

NANOTUBES AND BACTERIA ENHANCES 

PULMONARY INFLAMMATION AND 

INFECTIVITY. A. R. Murray 1,2 , E. Kisin 1 , J. 

P. Fabisiak 3 , J. R. Roberts 1,2 , J. M. Antonini 1 , C. 

Kommineni 1 , J. Reynolds 1 , A. Barchowsky 3 , V. 

Castranova 1,2 , V. Kagan 3 and A. A. Shvedova 1,2 . 

1 

PPRB, NIOSH, Morgantown, WV, 2 Physiology 

and Pharmacology, West Virginia University, 

Morgantown, WV and 3 Environmental and 

Occupational Health and Pharmacology, University 

of Pittsburgh, Pittsburgh, PA. 


COMPARATIVE PULMONARY TOXICITY 

STUDY OF 3 DIFFERENT PRIMARY-SIZED 

TIO2 PARTICLES IN RATS. N. Kobayashi, 

M. Naya, S. Endo, K. Yamamoto and J. Nakanishi. 

National Institute of Advanced Industrial Science and 

Technology, Tsukuba, Ibaraki, Japan. 


COMPARATIVE PULMONARY TOXICITY 

STUDY OF 3 DIFFERENT DISPERSIONS 

OF NANO- TIO2 PARTICLES IN RATS. M. 

Naya, N. Kobayasi, S. Endoh, K. Yamamoto and J. 

Nakanishi. National Institute of Advanced Industrial 

Science and Technology, Tsukuba, Ibaraki, Japan. 


INHALATION OF CARBON NANOTUBES 

INDUCES OXIDATIVE STRESS AND 

CYTOKINE RESPONSE CAUSING 

RESPIRATORY IMPAIRMENT AND 

PULMONARY FIBROSIS IN MICE. A. A. 

Shvedova 1,3 , E. Kisin 1 , A. R. Murray 1,3 , V. Johnson 2 , 

O. Gorelik 4 , S. Arepalli 4 , A. F. Hubbs 1 , R. R. 

Mercer 1,3 , S. Stone 1 , D. Frazer 1 , T. Chen 1 , G. Deye 5 , 

A. Maynard 6 , P. Baron 5 , R. Mason 7 , M. Kadiiska 7 , K. 

Stadler 7 , A. Mouithys-Mickalad 9 , V. Castranova 1,3,8 

and V. E. Kagan 8 . 1 PPRB, NIOSH, Morgantown, WV, 

2 

TMBB, NIOSH, Morgantown, WV, 3 Physiology and 

Pharmacology, WVU, Morgantown, WV, 4 NASA- 

JSC, Houston, TX, 5 DART, NIOSH, Cincinnati, OH, 

6 

Woodrow Wilson International Center for Science, 

Washington, DC, 7 NIEHS, Research Triangle Park, 

NC, 8 University of Pittsburgh, Pittsburgh, PA and 

9 

University of Liege, Liege, Belgium. 


CYTOTOXICITY OF NANOSIZED TIO2 AND 

MULTI-WALLED CARBON NANOTUBES 

ON CELL PROLIFERATION IN VITRO. J. 

E. Gibson and J. Masterson. Pharmacology and 

Toxicology, The Brody School of Medicine at East 

Carolina University, Greenville, NC. 


DIRECT FIBROGENIC EFFECTS OF 

DISPERSED SINGLE WALLED CARBON 

NANOTUBES ON HUMAN LUNG 

FIBROBLASTS. L. Wang 1 , V. Castranova 1 , 

Y. Rojanasakul 2 , Y. Lu 2 , J. F. Scabilloni 1 and R. 

R. Mercer 1 . 1 HELD/PPRB, National Institute 

for Occupational Safety and Health (NIOSH), 

Morgantown, WV and 2 Health Sciences Center, West 

Virginia University, Morgantown, WV. 


PULMONARY RESPONSE TO INHALED 

NICKEL NANOPARTICLES. P. Gillespie, G. 

Kang, M. Zhong, A. Gunnison, T. Gordon and L. 

Chen. New York University School of Medicine, 

Tuxedo, NY. 


PULMONARY TOXICITY ASSOCIATED 

WITH NON-DISPERSED TITANIUM 

DIOXIDE NANORODS. J. R. Roberts 1 , D. 

Schwegler-Berry 1 , S. S. Leonard 1 , A. Karim 2 , V. 

Tirumala 2 , J. M. Antonini 1 and V. Castranova 1 . 

1 

HELD/PPRB, NIOSH, Morgantown, WV and 

2 

Polymers Division, NIST, Gaithersburg, MD. 


A NINETY-DAY SUBCHRONIC 

INHALATION TOXICITY STUDY OF SILVER 

NANOPARTICLES IN SPRAGUE DAWLEY 

RATS. J. Sung 1 , J. Ji 2 , J. Park 3 , J. Yoon 4 , D. Kim 4 , 

M. Song 1 , B. Choi 1 , J. Han 5 , Y. Chung 5 , J. Jeong 6 , 

B. Han 6 , J. Chung 7 and I. Yu 1 . 1 Biosafety Evaluation 

Headquarter, KEMTI, Incheon, South Korea, 

2 

Samsung Electronics Co., Suwon, South Korea, 

3 

College of Medicine, Chung-Ang University, Seoul, 

South Korea, 4 HCT Co., Icheon, South Korea, 

5 

Center for Occupational Toxicology, KOSHA, 

Daejeon, South Korea, 6 National Institute of 

Toxicological Research, KFDA, Seoul, South Korea 

and 7 College of Pharmacy, Seoul National University, 

Seoul, South Korea. 


COMPARISON OF HEALTH EFFECTS AND 

COMPOSITION OF BIOGENIC SECONDARY 

ORGANIC AEROSOLS FORMED WITH AND 

WITHOUT SULFUR DIOXIDE. M. Doyle- 

Eisele 1 , J. Seinfeld 2 , A. Rohr 3 , E. Knipping 3 , M. J. 

Campen 1 , J. Seagrave 1 and J. McDonald 1 . 1 Lovelace 

Respiratory Research Institute, Albuquerque, NM, 

2 

California Institute of Technology, Pasadena, CA 

and 3 Electric Power Research Institute, Palo Alto, 

CA. 


TECHNICAL CHALLENGES ASSOCIATED 

WITH ASSESSING THE IN VITRO 

PULMONARY TOXICITY OF CARBON 

NANOTUBES. R. J. Snyder, R. Zucker, R. Jaskot 

and K. Dreher. U.S. Environmental Protection 

Agency, Durham, NC. 


INHALATION EXPOSURE TO 

AEROSOLIZED CARBON NANOTUBES. 

A. K. Madl, S. E. Serrano, T. Guo, S. V. Teague, J. 

Carter, Y. Qu and K. E. Pinkerton. University of 

California, Davis, Davis, CA. 

220 




Abstract # 


MUITIWALL CARBON NANOTUBE 

(MWCNT) EXPOSURE MONITORING 

IN A CNT RESEARCH LABORATORY 

BEFORE AND AFTER IMPROVEMENT OF 

WORKPLACE ENVIRONMENT. J. Han 2 , E. 

Lee 1 , J. Lee 1 , K. So 3 , Y. Lee 3 and I. Yu 1 . 1 Biosafety 

Evaluation Headquarter, KEMTI, Incheon, South 

Korea, 2 Center for Occupational Toxicology, 

KOSHA, Daejeon, South Korea and 3 Departmnet of 

Physics, Sungkyunkwan University, Suwon, South 

Korea. 


INHALED MULTIWALLED CARBON 

NANOTUBES POTENTIATE AIRWAY 

FIBROSIS IN A MURINE MODEL OF 

ALLERGIC ASTHMA. J. P. Ryman-Rasmussen 1,2 , 

E. W. Tewksbury 2 , O. R. Moss 2 , M. F. Cesta 1,2 , 

B. A. Wong 2 and J. C. Bonner 1,2 . 1 Environmental 


University, Raleigh, NC and 2 CIIT at the Hamner 

Institutes, Research Triangle Park, NC. 


THE TOXICITY OF FRESH VERSUS AGED 

NANOPARTICLES. T. Gordon, N. Halzack, M. 

Blaustein, K. Galdanes and L. Chen. New York 



CARBON NANOTUBES AND BACTERIAL 

LIPOPOLYSACCHARIDE (LPS) ACT 

COORDINATELY TO STIMULATE 

PLATELET-DERIVED GROWTH FACTOR 

(PDGF) SIGNALING AND LUNG FIBROSIS 

IN RATS. M. F. Cesta 1,2,3 , J. P. Ryman-Rasmussen 1,2 , 

D. G. Wallace 2 and J. C. Bonner 1,2 . 1 College of 

Agricultural and Life Sciences, North Carolina 

State University, Raleigh, NC, 2 CIIT, The Hamner 

Institutes for Health Sciences, RTP, NC and 3 LEP, 



NANOPARTICLES SELECTIVELY 

STIMULATE NADPH OXIDASE IN RAT 

PULMONARY CELL LINES. E. Rushton 2 , G. 

Oberdörster 2 and J. N. Finkelstein 1,2,3 . 1 Pediatrics, 

University of Rochester, Rochester, NY, 

2 


Rochester, NY and 3 Radiation Oncology, University 



UPTAKE OF FINE AND ULTRA-FINE 

POLYSTYRENE LATEX BEADS IN A549 

CELLS. P. M. Radcliffe 1 , V. A. Wong 1 , O. R. Moss 1 

and D. C. Dorman 2 . 1 Division of Toxicology and 

Preclinical Studies, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 College 

of Veterinary Medicine, North Carolina State 



NANOPARTICLE DEPOSITION 

EFFICIENCY IN RAT AND HUMAN NASAL 

REPLICAS. B. A. Wong, E. W. Tewksbury and 

B. Asgharian. The Hamner Institutes for Health 


Abstract # 


EFFECTS OF CERIUM OXIDE ON RAT 

PRIMARY ALVEOLAR MACROPHAGES. J. 

Y. Ma 1 , H. Zhao 1 , M. Barger 1 , V. Castranova 1 and J. 

K. Ma 2 . 1 NIOSH, Morgantown, WV and 2 School of 

Pharmacy, WVU, Morgantown, WV. 


METHODOLOGY FOR GENERATING 

NANOPARTICLE AEROSOLS- FROM 

BENCHTOP TO INHALATION 

LABORATORY. M. L. Ostraat 2 , K. A. Swain 2 , E. 

McDermott 2 , K. L. Reed 1 , C. M. Sayes 1 and D. B. 

Warheit 1 . 1 DuPont Haskell Laboratory, Newark, DE 

and 2 DuPont Central Research and Development, 



9:00 AM to 12:30 PM 

Exhibit Hall 


POSTER SESSION: DEVELOPMENTAL TOXICOLOGY 

Chairperson(s): Chad Vezina, University of Wisconsin Madison, Madison, 

WI and Robert Ellis-Hutchings, U.S. EPA, Durham, NC. 




2, 3, 7, 8 TETRACHLORODIBENZO-p- 

DIOXIN (TCDD) INHIBITS FIBROBLAST 

GROWTH FACTOR (FGF)10-INDUCIBLE 

PROSTATIC BUDDING IN THE MOUSE 

UROGENITAL SINUS (UGS). C. M. Vezina 1 , R. 

W. Moore 1,2 , S. H. Allgeier 2 and R. E. Peterson 1,2 . 

1 

School of Pharmacy, UW-Madison, Madison, WI 

and 2 Molecular And Environmental Toxicology 

Center, UW-Madison, Madison, WI. 


PROSTATIC BUDDING BY THE 

MOUSE UROGENITAL SINUS (UGS) IS 

INDUCED BY NOTCH SIGNALING; THIS 

EFFECT IS INSENSITIVE TO 2, 3, 7, 8 

TETRACHLORODIBENZO-p-DIOXIN 

(TCDD). R. W. Moore 1,2 , C. M. Vezina 1 , S. H. 

Allgeier 2 and R. E. Peterson 1,2 . 1 School of Pharmacy, 

UW-Madison, Madison, WI and 2 Molecular and 

Environment Toxicology Center, UW-Madison, 

Madison, WI. 


WNT5A REDUCES PROSTATIC BUD 

FORMATION IN THE MOUSE UROGENITAL 

SINUS (UGS) AND INHIBITION OF 

WNT5A RESCUES EFFECTS OF 2, 3, 7, 

8-TETRACHLORODIBENZO-p-DIOXIN 

(TCDD) ON BUD FORMATION IN VITRO. 

S. H. Allgeier 1 , C. M. Vezina 2 , R. W. Moore 1,2 , W. 

A. Fritz 2 and R. E. Peterson 1,2 . 1 Molecular and 

Environmental Toxicology Center, UW-Madison, 

Madison, WI and 2 School of Pharmacy, 

UW-Madison, Madison, WI. 

Wednesday 




Wednesday 



A TERATOLOGY STUDY OF ORAL GAVAGE 

OF LIU-WEI-TI-HUANG-WAN IN RABBITS. 

H. Chen, Y. Yang, C. Chen, H. Ke and L. Lin. 

Development Center for Biotechnology, Taipei, 

Taiwan. 


EFFECTS ON THE CARDIOVASCULAR 

SYSTEM DURING A CONTINUOUS 

INTRAVENOUS INFUSION TERATOLOGY 

STUDY IN THE FEMALE RAT. N. Hebert, L. 

Pouliot and S. Mason. Toxicology, Charles River 

Labs, Preclinical Services Montreal Inc., Senneville, 

QC, Canada. Sponsor: C. Banks. 


VARIATION, LEVELS AND CONGENER 

PROFILES OF POLYBROMINATED 

DIPHENYL ETHERS (PBDES) IN HUMAN 

GESTATIONAL MEMBRANES. M. Miller 1 , 

S. M. Chernyak 1 , M. C. Chames 2 and R. Loch- 

Caruso 1 . 1 Environmental Health Sciences, University 

of Michigan, Ann Arbor, MI and 2 Obstetrics and 

Gynecology, University of Michigan, Ann Arbor, MI. 


MONO-2-ETHYLHEXYL PHTHALATE 

STIMULATES RELEASE OF THE 

PROINFLAMMATORY CYTOKINE 

INTERLEUKIN-6 IN HUMAN GESTATIONAL 

MEMBRANE CULTURES. L. M. Tetz and R. 

Loch-Caruso. Environmental Health Sciences, 

University of Michigan School of Public Health, Ann 

Arbor, MI. 


IN UTERO EXPOSURE TO BENZENE 

CAUSES STRAIN AND GENDER SPECIFIC 

CHANGES IN HEMATOPOIETIC 

PROGENITOR CELLS. H. Badham 1 and L. 

Winn 1,2 . 1 Pharmacology and Toxicology, Queen’s 

University, Kingston, ON, Canada and 2 School 

of Environmental Studies, Queen’s University, 

Kingston, ON, Canada. 


EFFECT OF MATERNAL FOLIC ACID 

SUPPLEMENTATION ON VALPROIC ACID 

INDUCED TERATOGENESIS IN CULTURED 

MOUSE EMBRYOS. E. W. Tung 1 and L. M. 

Winn 1,2 . 1 Pharmacology and Toxicology, Queen’s 





EXPLORING THE DEVELOPMENTAL 

EFFECT OF THALIDOMIDE AND 

IRRADIATION ON LIMB PATTERNING. P. 

Allard 1 , J. Galloway 1 , C. Harris 2 , E. Carney 3 and 

C. J. Tabin 1 . 1 Genetics, Harvard Medical School, 

Boston, MA, 2 Environmental and Industrial Health 

Toxicology, University of Michigan, Ann Arbor, MI 

and 3 Developmental and Reproductive Toxicology, 

The Dow Chemical Company, Midland, MI. 


DEVELOPMENTAL TOXICITY OF 

DIMYRCETOL IN RATS. V. T. Politano 1 , E. M. 

Lewis 2 , A. M. Hoberman 2 , M. S. Christian 3 , R. M. 

Diener 3 and A. Api 1 . 1 Research Institute for Fragrance 

Materials, Inc., Woodcliff Lake, NJ, 2 Charles River 

PCS, Horsham, PA and 3 Argus International, Inc., 

Horsham, PA. 



RISK ASSESSMENT DATA IN 

CYNOMOLGUS MONKEYS OF 

CAMBODIAN, CHINESE, AND INDONESIAN 

ORIGIN. S. Oneda 1 , N. Makori 1 , D. Carwin 1 , 

J. Kenfield 1 , S. Herrin 1 , A. Arima 2 , B. Baker 1 , J. 

Klaassen 1 , S. Meyer 1 and R. Nagata 1,2 . 1 SNBL USA, 

Ltd., Everett, WA and 2 Shin Nippon Biomedical 

Laboratories, Ltd., Kagoshima, Japan. 


DEVELOPMENTAL TOXICITY OF METHYL 

DIHYDROJASMONATE (MDJ) IN RATS. 

S. P. Bhatia 1 , V. T. Politano 1 , E. M. Lewis 2 , A. M. 

Hoberman 2 , M. S. Christian 3 , R. M. Diener 3 and A. 

Api 1 . 1 Research Institute for Fragrance Materials Inc., 

Woodcliff Lake, NJ, 2 Charles River Laboratories 

Preclinical Services, Horsham, PA and 3 Argus 

International, Inc., Horsham, PA. 


EARLY RESPONSE IN GENE 

EXPRESSION PROFILES IN MONKEY 

EMBRYOS FOLLOWING MATERNAL 

EXPOSURE TO THALIDOMIDE DURING 

THE SUSCEPTIBLE PERIOD FOR 

MALFORMATIONS. A. Hirose 1 , H. Kato 2 , R. 

Ise 2 , S. Oneda 3 , M. Hirata-Koizumi 1 , T. Ihara 2 and 

M. Ema 1 . 1 Division of Risk Assessment, National 

Institute of Health Sciences, Tokyo, Japan, 2 Shin 

Nippon Biomedical Laboratories (SNBL), Ltd., 

Kagoshima, Japan and 3 SNBL USA, Ltd., Everett, 

WA. 


DEVELOPMENTAL TOXICITY OF N, 

N-DIMETHYLPROPANAMIDE IN RATS. T. 

Roth 1 , R. Jung 1 and R. Ceccatelli 2 . 1 CPS Toxicology, 

Clariant Produkte (Deutschland) GmbH, Sulzbach 

am Taunus, Germany and 2 RCC Ltd, Fuellinsdorf, 

Switzerland. Sponsor: G. Kennedy. 


ANALYSIS OF ETHANOL-INDUCED 

ABNORMALITIES IN THE MEDIAL 

FOREBRAIN OF FETAL MICE. E. A. Myers 1,2 , 

S. E. Parnell 2 , D. B. Dehart 2 , G. A. Johnson 3 and K. 

K. Sulik 2 . 1 Curriculum in Toxicology, University of 

North Carolina, Chapel Hill, NC, 2 Center for Alcohol 

Studies, University of North Carolina, Chapel Hill, 

NC and 3 Center for In Vivo Microscopy, Duke 



ORAL (GAVAGE) DEVELOPMENTAL 

TOXICITY STUDY OF 

4-TERTBUTYLCYCLOHEXYL ACETATE 

(4-TBCHA) IN RATS. D. McGinty 1 , V. T. 

Politano 1 , E. M. Lewis 2 , A. M. Hoberman 2 , M. 

S. Christian 3 , R. M. Diener 3 and A. Api 1 . 1 RIFM, 

Woodcliff Lake, NJ, 2 Charles River PCS, Horsham, 

PA and 3 Argus International, Horsham, PA. 

222 




Abstract # 


LOW-DOSE TRICHLOROETHYLENE 

EXPOSURE DURING VALVULOSEPTAL 

MORPHOGENESIS CAUSES VENTRICULAR 

SEPTAL DEFECTS IN HATCHED CHICKS. E. 

S. Rufer 1,2 , T. Hacker 3 , J. Lough 4 and S. M. Smith 1,2 . 

1 

Nutritional Sciences, University of Wisconsin - 

Madison, Madison, WI, 2 Molecular & Environmental 

Toxicology Center, University of Wisconsin - 

Madison, Madison, WI, 3 Cardiovascular Research 

Center, University of Wisconsin - Madison, Madison, 

WI and 4 Department of Cell Biology, Medical 

College of Wisconsin, Milwaukee, WI. 


A STUDY OF THE EFFECTS OF GREEN TEA 

CATECHINS (GTC) ON EMBRYO/FETAL 

DEVELOPMENT IN RATS. J. Knapp 1 , J. Moore 1 , 

S. Davis 1 , M. Nemec 1 , O. Morita 2 and Y. Tamaki 2 . 

1 

DART, WIL Research Laboratories, LLC, Ashland, 

OH and 2 Safety Science Research Laboratories, Kao 

Corporation, Haga-Gun TOCHIGI, Japan. Sponsor: 

D. Stump. 


PRENATAL AND POSTNATAL EFFECTS 

IN RATS OF PERFLUORONONANOIC 

ACID EXPOSURE IN UTERO. B. E. Grey, R. 

Ellis-Hutchings, K. Das, J. M. Rogers and C. Lau. 

NHEERL, U.S. EPA, Research Triangle Park, NC. 


EMBRYOTOXICITY OF RETINOIC ACID 

IN POSTIMPLANTATION RAT WHOLE 

EMBRYO CULTURE MONITORED WITH 

GENE EXPRESSION ANALYSIS. V. van 

Beelen 1,2 , M. Luijten 2 , A. Westerman 2 , A. Verhoef 2 , J. 

Pennings 2 , F. van Schooten 1 and A. Piersma 2 . 1 Health 

Risk Analysis & Toxicology, Maatricht University, 

Maastricht, Netherlands and 2 Laboratory for Health 

Protection Research, National Institute for Public 

Health and the Environment (RIVM), Bilthoven, 

Netherlands. Sponsor: H. van Loveren. 


AN EVALUTION OF DEVELOPMENTAL 

LANDMARK, SENSORY AND REFLEX 

TOXICITY TESTING AND CORRELATION 

TO PUP BODY WEIGHT IN CRL:CD(SD) 

RATS. W. Jeng, S. Oldham, C. M. Spencer, D. V. 

Hoover and B. R. Fisher. Covance Laboratories Inc, 

Vienna, VA. 


TWO-GENERATION ASSESSMENT 

OF REPRODUCTIVE TOXICITY AND 

TERATOGENICITY OF A NOVEL CALCIUM/ 

POTASSIUM SALT OF (-)-HYDROXYCITRIC 

ACID. D. Bagchi 1,2 , N. S. Deshmukh 3 and M. 

Bagchi 2 . 1 Department of Pharmacy Sciences, 

Creighton University Medical Center, Omaha, NE, 

2 

InterHealth Research Center, Benicia, CA and 3 Intox 

Pvt. Ltd, Pune, India. 


DEVELOPMENTAL TOXICITY 

ASSESSMENT OF A NOVEL CALCIUM/ 

POTASSIUM SALT OF (-)-HYDROXYCITRIC 

ACID. M. Bagchi 2 , N. S. Deshmukh 3 and D. 

Bagchi 1,2 . 1 Department of Pharmacy Sciences, 

Creighton University Medical Center, Omaha, NE, 

2 

InterHealth Nutraceuticals, Inc, Benicia, CA and 

3 

Intox Pvt. Ltd, Pune, India. 

Abstract # 


POST-TRANSLATIONAL MODIFICATION 

OF P53 DURING STRESS-INDUCED 

RELEASE FROM THE MITOCHONDRION. 

M. Green 1 , M. Pisano 2 , R. Prough 1 , A. Singh 2 

and T. Knudsen 1,2 . 1 Biochemistry and Molecular 

Biology, University of Louisville, Louisville, KY 

and 2 Molecular, Cellular and Craniofacial Biology, 



THE RABBIT IS NOT AN APPROPRIATE 

DEVELOPMENTAL TOXICITY TEST 

SYSTEM FOR BACTERIOSTATIC 

IRRITATIVE COMPOUNDS SUCH AS THE 

FUNGICIDE FOLPET. E. Gordon 1 , B. Neal 2 

and T. Ehrlich 3 . 1 Elliot Gordon Consulting, LLC, 

Princeton Junction, NJ, 2 The Weinberg Group, 

Washington, DC, DC and 3 Makhteshim Chemical 

Works, Ltd., Beer Sheva, Israel. 


EFFECTS OF SUNITINIB, AN 

ANGIOGENESIS INHIBITOR, ON EMBRYO- 

FETAL DEVELOPMENT IN THE RAT 

AND RABBIT. G. Chmielewski 1 , D. Morris 2 , K. 

Freshwater 2 and S. Patyna 3 . 1 Pfizer Global Research 

and Development, Groton, CT, 2 Pfizer Global 

Research and Development, Kalamazoo, MI and 

3 

Pfizer Global Research and Development, La Jolla, 

CA. 


MICROCYSTIN-LR CROSSES THE 

PLACENTA IN CD-1 MICE. A. L. Hall 1 , B. 

M. Tibbetts 1 , K. S. Rein 2 , L. C. Backer 3 and J. M. 

Benson 1 . 1 Toxicology, Lovelace Respiratory Research 

Institute, Albuquerque, NM, 2 Chemistry, Florida 

International University, Miami, FL and 3 National 

Center for Environmental Health, Centers for 

Disease Control and Prevention, Atlanta, GA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: SKIN PENETRATION AND TOXICITY 

Chairperson(s): Vikrant Vijay, North Carolina State University, Raleigh, 

NC and Thomas Kannanayakal, Wright State University, Dayton, OH. 




ROLE OF FERROUS SULFATE IN 

HEXAVALENT CHROMIUM-INDUCED 

CYTOTOXICITY AND APOPTOSIS IN 

HUMAN DERMAL FIBROBLASTS. R. 

Sellamuthu and P. Joseph. NIOSH, Morgantown, 

WV. 

Wednesday 




Wednesday 



REPEATED OPEN APPLICATION TESTS 

FOR ALLERGIC CONTACT DERMATITIS 

USING TWO CHEMICALS CONTAINING 

HEXAVALENT CHROMIUM. J. Gujral 1 , 

J. Fowler 2 , S. Su 3 , D. Morgan 4 and D. Proctor 1 . 

1 

Exponent, Irvine, CA, 2 Dermatology, University of 

Louisville, Louisville, KY, 3 Exponent, New York and 

4 

Forest Products Research Laboratory, Springfield, 

OR. 


VESICANT INJURY INCREASES 

EXPRESSION OF MATRIX DEGRADING 

ENZYMES AND INFLAMMATORY 

MEDIATORS IN A MOUSE EAR MODEL. M. 

Huang 1 , J. P. Gray 2 , A. T. Black 2 , D. R. Gerecke 2 , 

M. K. Gordon 2 , M. A. Gallo 3 , N. D. Heindel 4 , P. J. 

Sinko 5 , R. P. Casillas 6 , R. B. Dyer 7 , C. S. Chung 7 , D. 

L. Laskin 2 , J. D. Laskin 3 and D. E. Heck 7 . 1 Chemical 

Biology, Rutgers University, Piscataway, NJ, 

2 


Piscataway, NJ, 3 Environmental & Occupational 


School, Piscataway, NJ, 4 Chemistry, Lehigh 

University, Bethlehem, PA, 5 Pharmaceutics, Rutgers 

University, Piscataway, NJ, 6 Biomedical Science 

& Technology, Battelle Biomedical Research 

Center, Columbus, OH and 7 Cancer Biology & 

Pharmacology, University of Illinois College of 

Medicine, Peoria, IL. 


DEVELOPMENT OF TOXIC INDUSTRIAL 

CHEMICAL-INDUCED CUTANEOUS 

LESIONS IN SWINE. R. C. Kiser 1 , F. M. Reid 1 , 

E. E. McGuinness 1 , J. Mann 1 , C. T. Olson 1 , R. P. 

Casillas 1 and J. S. Graham 2 . 1 BBRC, Battelle, 

Columbus, OH and 2 USAMRICD, APG, MD. 


SKIN IMMUNOSENESCENCE: 

DECREASED RACK-1 EXPRESSION IS 

ASSOCIATED WITH DEFECTIVE TNF- 

ALPHA PRODUCTION IN RESPONSE 

TO DIFFERENT STIMULI. E. Corsini 1 , C. 

Gregorelli 1 , L. Lucchi 1 , E. Donetti 2 , M. Bedoni 2 , 

M. Marinovich 1 , C. L. Galli 1 and F. Rousset 3 . 

1 

Department of Pharmacological Sciences, University 

of Milan, Milan, Italy, 2 Department of Human 

Morphology, University of Milan, Milan, Italy and 

3 

L’Oreal Advanced Reaserch, Clichy, France. 


MEASUREMENT OF SKIN THICKNESS IN 

CONTROL SD RATS AND BEAGLE DOGS 

FROM TWO SUBCUTANEOUS TOXICITY 

STUDIES. M. Wells 1 , A. Bécret 2 , S. Leuillet 2 , B. 

Palate 2 , M. Lonchampt 3 , V. Boulifard 3 , C. Fisch 3 , 

J. Marsais 3 and P. Picaut 3 . 1 Toxicology/Pathology 

Services Inc., Paris, France, 2 CIT, Evreux, France 

and 3 IPSEN, Les Ulis, France. Sponsor: R. Forster. 


LIGAND ACTIVATION OF PPARb/d 

INHIBITS PROLIFERATION OF HUMAN 

HACAT KERATINOCYTES. M. G. Borland 1 , E. 

E. Girroir 1 , A. N. Billin 2 , T. M. Willson 2 and J. M. 

Peters 1 . 1 Department Vet. and Biomed. Sci., Penn 

State University, University Park, PA and 2 Nuclear 

Receptor Discovery Research, GlaxoSmithKline, 



PERTURBATION OF GLUTATHIONE 

DETOXIFICATION PATHWAYS MAY 

BE INVOLVED IN BUTYLATED 

HYDROXYTOLUENE (BHT) MEDIATED 

POTENTIATION OF 4-TERTIARY 

BUTYLPHENOL (4TBP) TOXICITY IN 

MELANOCYTIC CELLS: IMPLICATIONS 

FOR OCCUPATIONAL VITILIGO. R. 

Sarangarajan, S. Condon, W. Cho, K. Hoey, M. 

Mearn and S. Kerr. Pharmaceutical Sciences, 

Massachusetss College of Pharmacy and Health 

Sciences, Worcester/Boston, MA. 


DIFFERENTIAL RESPONSES 

OF HEMIZYGOUS VERSUS 

HOMOZYGOUS TG.AC MICE TO THE 

PHOTOCARCINOGENIC EFFECT OF ULTRA- 

VIOLET RADIATION. P. C. Howard 1 , N. J. 

Walker 2 and N. V. Gopee 1 . 1 Biochemical Toxicology, 

National Center for Toxicological Research, U.S. 

FDA, Jefferson, AR and 2 National Toxicology 

Program, National Institute of Environmental Health 



DIFFERENTIATION OF DERMAL 

IRRITATION POTENTIAL OF ESTERS FOR 

SKIN CARE PRODUCTS. A. Dang 1 , J. Harbell 2 , 

C. Rodriguez 2 and C. Gomez 1 . 1 Product Safety, Mary 

Kay Inc., Dallas, TX and 2 Clinical and Consumer 

Evaluation, Mary Kay Inc., Dallas, TX. 


METABOLIC ACTIVITY OF SKIN IN VITRO 

SYSTEMS. T. Bernshausen 2 , E. J. Fabian 1 and 

R. Landsiedel 1 . 1 Experimental Toxicology and 

Ecology, BASF, Ludwigshafen am Rhein, Germany 

and 2 Postdoc, c/o BASF, Ludwigshafen am Rhein, 

Germany. 


IN VIVO AND IN VITRO DERMAL 

ABSORPTION OF CREOSOTE. J. H. Butala 1 

and W. J. Fasano 2 . 1 Toxicology Consultants, Inc., 

Gibsonia, PA and 2 Haskell Laboratory, E.I. DuPont 

de Nemours & Co Inc, Newark, DE. 


IN VITRO HUMAN SKIN PENETRATION OF 

THE FRAGRANCE MATERIAL LINALOOL. 

J. Lalko 1 , K. Brain 2 , D. Green 2 and A. Api 1 . 1 Research 

Institute for Fragrance Materials Inc., Woodcliff 

Lake, NJ and 2 An-eX Analytical Services Ltd., 

Cardiff, United Kingdom. 


USE OF A MULTI-FIBER APPROACH 

TO QUANTIFY CHEMICAL MIXTURE 

INTERACTIONS MODULATING DERMAL 

ABSORPTION. M. Imran, R. E. Baynes, X. Xia 

and J. E. Riviere. Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina State 



SOLVATOCHROMATIC INTERACTIONS 

INFLUENCING DERMAL PERMEATION 

OF BIOCIDES IN COMMERCIAL 

CUTTING FLUIDS. V. Vijay and R. E. Baynes. 



Raleigh, NC. 

224 




Abstract # 


IN VITRO STUDIES OF PERCUTANEOUS 

ABSORPTION AND SURFACE-TO-SKIN 

TRANSFER OF D-METHAMPHETAMINE 

HYDROCHLORIDE USING HUMAN 

SKIN. X. Hui 1 , C. Salocks 2 , J. Sanborn 2 and H. 

Maibach 1 . 1 Dermatology, University of California 

San Francisco, San Francisco, CA and 2 Office of 

Environmental Health Hazard Assessment, Cal/EPA, 




SURFACTANTS (SLS AND LAS) ON THE 

DERMAL ABSORPTION OF A SERIES OF 

COMPOUNDS IN ISOLATED PERFUSED 

SKIN. J. E. Riviere and J. D. Brooks. Center 

for Chemical Toxicology Research and 


Raleigh, NC. 


DERMAL EXPOSURE INDUCES KERATIN 

ADDUCTS IN THE SKIN. L. A. Nylander- 

French 1 , J. C. Kang-Sickel 1 , Y. E. Chao 1 , K. Jayaraj 1 , 

A. Gold 1 , D. G. Klapper 2 , L. M. Ball 1 and J. E. 

French 3 . 1 Environmental Sciences and Engineering, 

The University of North Carolina at Chapel Hill, 

Chapel Hill, NC, 2 Microbiology and Immunology, 

The University of North Carolina at Chapel Hill, 

Chapel Hill, NC and 3 Laboratory of Molecular 

Toxicology, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC. 


EFFECT OF BLOCKING THE IL-1 

RECEPTOR ON JP-8-INDUCED GENE 

EXPRESSION IN RAT SKIN. T. J. 

Kannanayakal, C. M. Garrett and J. N. McDougal. 

Pharmacology and Toxicology, Boonshoft School of 

Medicine, Wright State University, Dayton, OH. 


COMPARISON OF GENE EXPRESSION 

IN THE EPIDERMIS AFTER BRIEF 

EXPOSURES TO JP-8 IN HUMAN 

VOLUNTEERS AND RATS. J. N. McDougal, 

R. Simman and C. M. Garrett. Pharmacology and 

Toxicology, Boonshoft School of Medicine, Wright 

State University, Dayton, OH. 


GENE EXPRESSION ANALYSIS OF RAT 

EPIDERMIS AFTER 1 HOUR JP-8 AND JP-8 

COMPONENT EXPOSURES BY REAL- 

TIME PCR. C. M. Garrett and J. N. McDougal. 

Pharmacology and Toxicology, Boonshoft School of 

Medicine, Wright State University, Dayton, OH. 

Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: APPLICATION OF ‘OMICS RESEARCH 

TOOLS IN TOXICOLOGY 

Chairperson(s): Hisham Hamadeh, Amgen, Inc., Thousand Oaks, CA. 




THE SECOND STAGE OF THE 

TOXICOGENOMICS PROJECT IN JAPAN: 

A MULTICENTER VALIDATION STUDY 

OF GENE EXPRESSION IN RAT LIVER. T. 

Urushidani 1,2 , A. Ono 3 , N. Nakatsu 2 , T. Miyagishima 2 

and Y. Ohno 3 . 1 Pathophysiology, Doshisha Women’s 

College of Liberal Arts, Kyotanabe, Kyoto, Japan, 

2 

Toxicogenomics-informatics Project, National 

Institute of Biomedical Innovation, Ibaraki, Osaka, 

Japan and 3 National Institute of Health Sciences, 

Tokyo, Japan. 


ONE-YEAR ASSESSMENT OF AFFYMETRIX 

RAE230 ARRAY PERFORMANCE USING 

MIXED TISSUE RNA REFERENCE 

SAMPLES. T. D. Vo, H. Hamadeh, M. Higgins and 

C. Afshari. Investigative Toxicology, Amgen, Inc, 

Thousand Oaks, CA. 


ANALYSIS OF GLOBAL PATTERNS IN 

MICROARRAY GENE EXPRESSION DUE 

TO LOW DOSE ARSENIC EXPOSURE 

USING CORRELATION AND GENE SET 

ENRICHMENT. T. Hampton 1 , J. C. Davey 1 , J. 

A. Gosse 1 , C. D. Kozul 1 , M. A. Ihnat 2 and J. W. 

Hamilton 1 . 1 Pharmacology Toxicology, Dartmouth 

College, Hanover, NH and 2 Department of Cell 

Biology, University of Oklahoma Health Sciences 

Center, Oklahoma City, OK. 


PROBABILITY FOLD CHANGE 

RANKING: A NOVEL COMPUTATIONAL 

ALGORITHM FOR IDENTIFYING ROBUST 

DIFFERENTIALLY EXPRESSED GENE 

LISTS. X. Deng 1,2 , J. Xu 2 and C. Wang 1,2 . 

1 

Department of Medicine, Cedars-Sinai Medical 

Center, UCLA, Los Angeles, CA and 2 Burns Allen 

Research Institute, Cedars-Sinai Medical Center, Los 

Angeles, CA. 


CHEMICAL TOXICITY PREDICTION FOR 

TOXCAST PHASE I. Z. Li 1 , F. Wright 1 and F. 

Elloumi 2 . 1 Biostatistics, University of North Carolina 

at Chapel Hill, Chapel Hill, NC and 2 National 

Research Council, RTP, NC. 

Wednesday 




Wednesday 



GENE EXPRESSION PROFILING IN RAT 

LIVER TREATED WITH COMPOUNDS 

INDUCING PHOSPHOLIPIDOSIS. M. 

Hirode 1,2 , A. Ono 2 , T. Miyagishima 2 , T. Nagao 2 and 

T. Urushidani 2,3 . 1 Development Research Center, 

Takeda Pharmaceutical Company Limited, Osaka, 

Japan, 2 Toxicogenomics Project, National Institute 

of Biomedical Innovation, Ibaraki, Osaka, Japan and 

3 

Department of Pathophysiology, Doshisha Women’s 

College of Liberal Arts, Kyoto, Japan. 


GENE EXPRESSION PROFILING IN 

TOXICOLOGICAL STUDIES USING FFPE 

TISSUES. P. Hewitt and C. Schmitt. Institute of 

Toxicology, Merck KGaA, Darmstadt, Germany. 

Sponsor: D. Gottschling. 


HEPATIC GENE EXPRESSION DURING 

AGING IN MALE AND FEMALE MICE. M. 

Guo 1 , L. Gong 2 , L. Lehman-McKeeman 2 and Y. 

Wan 1 . 1 Pharmacology, KUMC, Kansas City, KS and 

2 

Bristol-Myers Squibb Company, New York. 


AGE-RELATED HEPATIC GENE 

EXPRESSION ALTERATIONS IN IMMUNE 

SYSTEM PATHWAYS IN THE FISCHER 

RAT. R. Frawley 1 , D. Germolec 1 , E. K. Lobenhofer 2 , 

J. Parker 3 , G. Boorman 1 and R. Irwin 1 . 1 NIEHS, 

Research Triangle Park, NC, 2 Cogenics, Morrisville, 

NC and 3 Expression Analysis, Durham, NC. 


COMPARATIVE HEPATIC GENE 

EXPRESSION ELICITED BY o, p’-DDT IN 

THE RAT AND MOUSE. T. R. Zacharewski 1 , 

J. C. Kwekel 1 , L. D. Burgoon 1 and N. Kiyosawa 1,2 . 

1 

Biochemistry & Molecular Biologyand and National 

Food Safety & Toxicology Center, Michigan State 

University, East Lansing, MI and 2 Medicinal Safety 

Research Labs., Daiichi-Sankyo Co., Ltd., Fukuroi, 

Shizuoka, Japan. 


EARLY MOLECULAR 

MECHANISMS ASSOCIATED WITH 

HEPATOCARCINOGENESIS IN F344 

RATS TREATED WITH GENOTOXIC, 

NONGENOTOXIC OR NONCARCINOGENS. 

R. A. Currie 1 , J. Dow 1 , F. Lim 1 , A. S. Cronin 1 , A. 

Hargreaves 1 , T. Aldridge 1 , W. L. Claire 2 , G. L. 

Julian 2 , C. J. Waterfield 1 and J. Wright 1 . 1 Human 

Safety, Syngenta International Research Centre, 

Bracknell, United Kingdom and 2 Biochemsitry, 

University of Cambridge, Cambridge, United 

Kingdom. Sponsor: R. Peffer. 


THE UTILITY OF TOXICOGENOMICS 

IN THE PRIORITIZATION OF 5-HT6 

RECEPTOR ANTAGONISTS. M. Cooper, M. 

Lorenze, P. Day-Lollini, M. Irwin, H. Stock and K. 

Kolaja. Investigative Toxicology, Roche, Palo Alto, 

CA. 


DETECTION OF UNIQUE TOXIC 

RESPONSES TO CARBON 

TETRACHLORIDE BY COMPREHENSIVE 

GENE EXPRESSION ANALYSIS USING 

CYNOMOLGUS MONKEYS AND RATS. R. 

Ise, Y. Fukiya, H. Izumi and R. Nagata. Shin Nippon 

Biomedical Laboratories (SNBL), Ltd., Tokyo, 

Japan. 


HEPATIC TOXICOGENOMIC PROFILING 

IN RATS AS A PREDICTOR OF 

IDIOSYNCRATIC DRUG-INDUCED LIVER 

INJURY IN HUMANS. B. Hirakawa 1 , M. 

Twamley 1 , B. Lu 2 , M. Lawton 2 , B. Jessen 1 and H. 

Younis 1 . 1 Pfizer Global Research and Development, 

Pfizer, San Diego, CA and 2 Pfizer Global Research 

and Development, Pfizer, Groton, CT. 


TOXICOGENOMIC COMPARISON OF RAT 

LIVER AND PRIMARY HEPATOCYTES 

FOLLOWING COMPOUND EXPOSURE. A. 

Yang and A. Vladimirova. Entelos, Foster City, CA. 


EXPLORING CYTOLETHALITY RESPONSE 

OF COMPOUNDS IN PRIMARY RAT 

HEPATOCYTES USING GENE EXPRESSION 

PATHWAY ANALYSIS. R. A. Jolly 1 , K. M. 

Goldstein 2 , T. K. Baker 1 , X. Zhang 1 , J. P. Stutz 1 , J. C. 

Recknor 1 , G. H. Searfoss 1 , J. L. Stevens 1 and C. E. 

Thomas 1 . 1 Toxicology, Eli Lilly and Co, Greenfiled, 

IN and 2 Integrative Biology, Eli Lilly and Co, 

Greenfield, IN. 


GLOBAL TRANSCRIPTOME CHANGES IN 

HEPG2 CELLS EXPOSED TO COPPER. M. 

Song and J. H. Freedman. LMT, NIEHS, RTP, NC. 


ARSENIC PERTURBATION OF GENE 

NETWORKS DURING VERTEBRATE 

DEVELOPMENT. A. Planchart and C. J. 

Mattingly. Mount Desert Island Biological 

Laboratory, Salisbury Cove, ME. Sponsor: W. 

Toscano. 


D-SERINE EXPOSURE RESULTED IN GENE 

EXPRESSION CHANGES IMPLICATED IN 

NEURODEGENERATIVE DISORDERS AND 

NEURONAL DYSFUNCTION. M. E. Davidson 1 , 

L. Kerepesi 2 , A. Soto 3 and V. T. Chan 3 . 1 ORISE, 

Wpafb, OH, 2 Battelle Memorial Institute, Columbus, 

OH and 3 Applied Biotechnology Branch, Division 

of Biosciences and Protection, Human Effectiveness 

Directorate, Air Force Research Laboratory, Wright 

Patterson Air Force Base, OH. Sponsor: D. Mattie. 


EFFECTS OF ETHANOL ON GENE 

EXPRESSION IN THE BRAIN. M. 

Capparuccini 1 , J. Wolstenholme 2 , K. Archer 1 and 

M. Miles 2 . 1 Biostatistics, VCU, Richmond, VA and 

2 

Pharmacology/Toxicology, VCU, Richmond, VA. 

Sponsor: C. Gennings. 

226 




Abstract # 


GLOBAL GENE EXPRESSION ANALYSIS 

IN A COMMON MARMOSET MODEL 

OF HALOPERIDOL-INDUCED ACUTE 

DYSTONIA. T. Yamada 1 , T. Fukuoka 2 , T. Yoshioka 3 , 

N. Suzuki 3 , K. Saito 3 , C. Higuchi 1 , T. Kimura 1 , T. 

Seki 2 and K. Oeda 3 . 1 Genomic Science Laboratories, 

Dainippon Sumitomo Pharmacology Co., Ltd., 

Osaka, Japan, 2 Safety Research Laboratories, 

Dainippon Sumitomo Pharmacology Co., Ltd., 

Osaka, Japan and 3 Environmental Health Science 

Laboratory, Sumitomo Chemical Co., Ltd., Osaka, 

Japan. 


TRANSCRIPTOMIC ANALYSIS OF 

TOLUENE-EXPOSED BROWN NORWAY 

RAT BRAINS AT DIFFERENT LIFE STAGES. 

J. E. Royland. Neurotoxicology Division, U.S. 

Environmental Protection Agency, Durham, NC. 


EXPRESSION PROFILING OF FIVE RAT 

STRAINS REVEAL TRANSCRIPTIONAL 

MODES IN THE ANTIGEN PROCESSING 

PATHWAY. W. Ward, M. Schladweiler, A. Ledbetter 

and U. Kodavanti. U.S. EPA, RTP, NC. Sponsor: S. 

Hester. 


GENE EXPRESSION PROFILING 

OF NORMAL HUMAN BRONCHIAL 

EPITHELIAL CELLS EXPOSED TO 

TRIVALENT ARSENICALS AND 

DIMETHYLTHIOARSINIC ACID. J. 

Chilakapati 1 , K. Wallace 2 , H. Ren 2 , M. Fricke 3 , K. 

A. Bailey 2 , W. O. Ward 2 , J. C. Corton 2 , J. Creed 3 

and K. T. Kitchin 2 . 1 Curriculum in Toxicology, UNC, 

Chapel Hill, NC, 2 NHEERL, U.S. EPA, RTP, NC and 

3 

NERL, U.S. EPA, Cincinnati, OH. 


CONCORDANCE IN GENOMIC CHANGES 

BETWEEN MOUSE LUNGS AND HUMAN 

AIRWAY EPITHELIAL CELLS EXPOSED TO 

DIESEL EXHAUST PARTICLES. T. Stevens 1 , 

W. Reed 3 , S. Hester 2 , J. Samet 2 and I. Gilmour 2 . 

1 

Toxicology, UNC, carrboro, NC, 2 NHEERL, EPA, 

RTP, NC and 3 CEMALB, Chapel Hill, NC. 


THE URINARY BLADDER EXHIBITS A 

U-SHAPED GENOMIC DOSE-RESPONSE 

FOLLOWING SHORT- AND LONG-TERM 

EXPOSURE OF MICE TO ARSENATE 

IN DRINKING WATER. H. J. Clewell 1 , R. S. 

Thomas 1 , E. M. Kenyon 2 , M. F. Hughes 2 and J. 

W. Yager 3 . 1 The Hamner, RTP, NC, 2 U.S. EPA / 

NHEERL, RTP, NC and 3 EPRI, Palo Alto, CA. 


CONCENTRATIONS DEPENDENT 

TRANSITIONS IN RESPONSES OF RAT 

NASAL EPITHELIUM TO INHALED 

FORMALDEHYDE. M. E. Andersen, H. J. 

Clewell, E. Bermudez, G. A. Wilson and R. S. 

Thomas. The Hamner Institutes for Health Sciences, 


Abstract # 


A TOXICOGENOMIC APPROACH FOR 

IDENTIFYING BIOMARKERS OF DRUG- 

INDUCED PHOSPHOLIPIDOSIS. M. Kanki, 

A. Unami, K. Omura, D. Sasaki, S. Nakatsuji, A. 

Moriguchi, T. Kasuga and J. Seki. Drug Safety 

Research Laboratories, Astellas Pharmacology Inc., 

Osaka, Japan. Sponsor: Y. Miyamae. 


INVESTIGATION OF TOXICOLOGICAL 

MECHANISM FOR RAT CORNEA OPACITY 

INDUCED BY ALKYLALKANOLAMINE. 

T. Fukushima, J. Abe, T. Yamamoto, K. Sawada, 

Y. Hamada and I. Horii. Pfizer Global & Research 

Development, Taketoyo, Japan. Sponsor: M. Kurata. 


TOXICOGENOMICS OF DRUG-INDUCED 

PROXIMAL TUBULAR INJURY BY 

ANALYZING GENE EXPRESSION 

PROFILES IN THE KIDNEY. T. Uehara 1,2 , A. 

Ono 1 , T. Miyagishima 1 , Y. Ohno 1 and T. Urushidani 1 . 

1 

Toxicogenomics Project, National Institute of 

Biomedical Innovation, Ibaraki, Osaka, Japan and 

2 

Drug Safety Evaluation, Shionogi & Co., Ltd., 

Toyonaka, Osaka, Japan. 


EXAMPLE USE OF mRNA PROFILING 

TO ELUCIDATE MECHANISMS OF 

CARDIOTOXICITY FOR COMPOUNDS 

IN PRE-CLINICAL DEVELOPMENT. M. 

J. Liguori 1 , E. A. Blomme 1 , W. W. Wong 2 , A. J. 

Schwartz 2 and J. F. Waring 1 . 1 Cell and Molecular 

Toxicology, Abbott Laboratories, Abbott Park, IL and 

2 

Abbott Bioresearch Center, Abbott Laboratories, 

Worcester, MA. 


DRUG METABOLISM RESPONSE 

EVALUATED BY ANTIBODY PROTEIN 

MICROARRAY IN MALE SPRAGUE- 

DAWLEY RATS EXPOSED TO 

PHENOBARBITAL (PB), 1, 4 DIOXANE (1, 

4-D), TRICHLOROETYLENE (TCE), AND 

ETHANOL (ETOH). D. Geter 1 , L. Kan 1 , D. 

Kaplan 2 , S. Salagrama 3 , H. Kim 2,3 , A. Dombkowski 3 , 

W. Stott 1 and B. Gollapudi 1 . 1 The Dow Chemical 

Company, Midland, MI, 2 Detroit R&D, Detroit, MI 

and 3 Wayne State University, Detroit, MI. 


PROTEOMIC (LC/MS/MS) ANALYSIS 

OF FFPE RAT LIVER TO IDENTIFY 

ATORVASTATIN REGULATED PROTEINS: 

COMPARISON TO FROZEN OCT 

EMBEDDED LIVER TISSUE. M. Scicchitano, 

D. A. Dalmas, R. W. Boyce, K. S. Frazier and H. C. 

Thomas. GlaxoSmithKline, King of Prussia, PA. 


QUANTITATIVE EXPRESSION 

PROTEOMICS-BASED SYSTEMS BIOLOGY 

MODEL OF THE RAT LIVER RESPONSE TO 

PHENOBARBITAL. M. B. Dail 1,2 , L. A. Shack 2 , S. 

C. Burgess 2,3 and J. E. Chambers 1,2 . 1 Ctr for Environ 

Health Sci, Coll. Vet. Med, MS State, MS, 2 Basic 

Sci, Coll. Vet. Med, MS State, MS and 3 MAFES, MS 

State, MS. 

Wednesday 




Wednesday 



PROFILING OF METALLOTHIONEIN 

ISOFORMS IN HUMAN PROSTATE CELLS 

BY MASS SPECTROMETRY. R. Wang 1,2 , D. A. 

Sens 1 , A. Albrecht 1 , S. Garrett 1 , S. Somji 1 , M. Sens 1 

and X. Lu 1,2 . 1 Department of Pathology, University of 

North Dakota, Grand Forks, ND and 2 Proteimics core 

facility, University of North Dakota, Grand Forks, 

ND. 


PROTEOMIC PROFILING OF CULTURED 

HUMAN BLADDER CELLS AFTER 

TRIVALENT ARSENICAL EXPOSURES. P. 

A. Ortiz, K. Wallace and W. Winnik. U.S. EPA, 

Research Triangle Park, NC. Sponsor: K. Kitchin. 


METABOLOMIC PROFILES OF LIVER AND 

PLASMA FOLLOWING WHOLE-LIVER 

IRRADIATION IN MICE. R. Mohney 1 , H. Zhou 2 , 

L. Liu 2 , M. Mitchell 1 and C. Guo 2 . 1 Metabolon, 

Inc., Durham, NC and 2 Department of Radiation 

Oncology, Albert Einstein College of Medicine, 

Bronx, NY. Sponsor: S. Borghoff. 


1H NMR-BASED METABONOMIC 

INVESTIGATIONS OF ACUTE CHOLINE 

AND METHIONINE DEFICIENCY INDUCED 

STEATOSIS IN THE RAT AND MOUSE. T. 

J. Athersuch 1 , R. Cavill 1 , P. H. Chan 1 , L. Lehman- 

McKeeman 2 , J. K. Nicholson 1 , T. M. Ebbels 1 and 

H. C. Keun 1 . 1 Biomolecular Medicine, Imperial 

College London, London, United Kingdom and 

2 

Discovery Toxicology, Bristol-Myers Squibb Co., 

Lawrenceville, NJ. 


PRINCIPAL COMPONENTS AND 

HIERARCHICAL CLUSTER ANALYSES OF 

HPLC/ECD-DERIVED LIVER METABOLITE 

PROFILES IN GLUTAMATE CYSTEINE 

LIGASE TRANSGENIC MICE TREATED 

WITH ACETAMINOPHEN. S. R. Krival, D. 

Botta, C. C. White, I. Mohar, L. A. McConnachie, T. 

J. Kavanagh and C. Simpson. DEOHS, University of 



USE OF METABOLOMICS AS A TOOL TO 

IDENTIFY TOXICOLOGICAL MODES OF 

ACTION. B. van Ravenzwaay 1 , G. Coelho-Palermo 

Cunha 1 , E. Fabian 1 , E. Leibold 2 , R. Looser 2 , W. 

Mellert 1 , A. Prokoudine 2 , V. Strauss 1 , T. Walk 2 and 

J. Wiemer 2 . 1 Experimental Toxicology and Ecology, 

BASF AG, Ludwigshafen, Germany and 2 BASF 

Metanomics, Berlin, Germany. Sponsor: A. Doi. 


A METABOLOMIC ANALYSIS OF NON- 

GENOTOXIC HEPATOCARCINOGENS 

IN THE RAT. C. L. Waterman 1 , L. A. Cottrell 2 , 

J. Dow 2 , R. Currie 2 , A. Hargreaves 2 , T. Aldridge 2 , 

J. Wright 2 , C. J. Waterfield 2 and J. L. Griffin 1 . 

1 

Department of Biochemistry, University of 

Cambridge, Cambridge, United Kingdom and 

2 

Human Safety, Syngenta Jealott’s Hill International 

Research Centre, Bracknell, United Kingdom. 

Sponsor: R. Peffer. 


ION-DIRECTED-SHY APPLIED TO THE 

METABONOMIC ANALYSIS OF BEA 

TOXICITY. J. T. Pearce 1 , M. Coen 1 , E. J. Want 1 , 

A. Campbell 1 , S. Hnatyshyn 2 , P. Shipkova 2 , N. 

Aranibar 2 , M. Sanders 2 , G. H. Cantor 2 , L. D. 

Lehman-McKeeman 2 , H. C. Keun 1 , T. D. Ebbels 1 , 

E. Holmes 1 , J. C. Lindon 1 and J. K. Nicholson 1 . 

1 

Biomolecular Medicine, Imperial College, London, 

United Kingdom and 2 Discovery Toxicology, Bristol- 

Myers Squibb, Lawrenceville, NJ. 


USING GENETIC ALGORITHMS FOR 

SIMULTANEOUS SELECTION OF SAMPLES 

AND VARIABLES TO CLASSIFY TOXICITY 

OF NMR METABOLIC PROFILES. R. 

Cavill, J. K. Nicholson, H. Keun and T. M. Ebbels. 

Biomolecular Medicine, Imperial College London, 

London, United Kingdom. Sponsor: G. Cantor. 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: METALS I 

Chairperson(s): Susan McKarns, NIAID/NIH, Bethesda, MD. 




INTERSPECIES DIFFERENCES IN 

GASTROINTESTINAL REDUCTIVE 

CAPACITY: IMPLICATIONS FOR 

EVALUATING RESULTS OF THE 2007 

NATIONAL TOXICOLOGY PROGRAM 

DRINKING WATER STUDY OF 

HEXAVALENT CHROMIUM. D. HaMai, M. Suh 

and D. M. Proctor. Exponent, Irvine, CA. 


THE CORRELATION OF 

METALLOTHIONEIN ISOFORM 

EXPRESSION WITH THE DEGREE OF 

MALIGNANCY IN A SERIES OF RECENTLY 

DERIVED HUMAN PROSTATE CANCER 

CELL LINES. S. H. Garrett 1 , E. J. Tokar 2 , A. L. 

Albrecht 1 and M. P. Waalkes 2 . 1 Pathology, University 

of North Dakota, Grand Forks, ND and 2 LCC, NCI, 

NIEHS, Research Triangle Park, NC. 


NICKEL INDUCES METALLOTHIONEIN 

IN AIRWAY EPITHELIAL CELLS BY 

INCREASING INTRACELLULAR ZINC. A. A. 

Nemec, S. A. Sandel, G. D. Leikauf, B. R. Pitt and 

A. Barchowsky. Environmental and Occupational 

Health, University of Pittsburgh, Pittsburgh, PA. 


MTF-1 AND CARM1 MAY COOPERATE 

TO REGULATE METALLOTHIONEIN 

EXPRESSION AND METAL HOMEOSTASIS. 

E. Braithwaite and J. Freedman. National Institute of 

Environmental Health Sciences, Research Triangle 

Park, NC. 

228 




Abstract # 


HEAVY METAL RESPONSES OF HUMAN 

METALLOTHIONEIN ISOFORM GENES. 

N. Miura and S. Koizumi. National Institute of 

Occupational Safety and Health, Kawasaki, Japan. 

Sponsor: M. Satoh. 


EMERGENCE OF METHYLMERCURY 

TOXICITY LONG AFTER A PERINATAL 

EXPOSURE IN METALLOTHIONEIN- 

NULL AND ITS WILD-TYPE C57BL MICE 

STRAINS. M. Yoshida 1 , C. Watanabe 2 , M. 

Satoh 3 and A. Yasutake 4 . 1 Hachinohe University, 

Hachinohesi, Aomori, Japan, 2 Graduate School 

of Medicine, University of Tokyo, Tokyo, Japan, 

3 

School of Pharmacy, Aichi Gakuin University, 

Nagoya, Japan and 4 National Institute of Minamata 

Disease, Minamata, Japan. 


RELATIONSHIP BETWEEN PLASMA 

ANTI-METALLOTHIONEIN ANTIBODY 

AND RENAL DYSFUNCTION IN CADMIUM 

EXPOSED WORKERS. T. Jin 1,2,4 , L. Chen 1,2 , B. 

Huang 1,2 , X. Chang 1,2 , L. Lei 1,2 , G. Nordberg 4 and M. 

Nordberg 3 . 1 Occupational Health, Fudan University, 

Shanghai, China, 2 Toxicology, Fudan University, 

Shanghai, China, 3 Environmental Medicine, 

karolinska, Sweden and 4 Public Health and Clinical 

Medicine, Enivironmental Medicine, Umeå, Sweden. 


CAENORHABDITIS ELEGANS GENE, 

NUMR-1, ASSEMBLES INTO NUCLEAR 

STRESS GRANULES AFTER CADMIUM 

TREATMENT. B. Tvermoes 1,2 and J. H. 

Freedman 1,2 . 1 Laboratory of Molecular Toxicology, 

NIEHS, Research Triangle Park, NC and 2 Nicholas 

School of the Environment, Duke University, 

Durham, NC. 


IMMUNOLOCALIZATION OF 

METALLOTHIONEINS IN LIVER AND 

KIDNEY OF WISTAR RATS EXPOSED TO 

CADMIUM. Y. Liang 1 , H. Li 1 , C. Xiang 2 , L. 

Lei 1 , T. Jin 1,4 , M. Nordberg 3 and G. F. Nordberg 4 . 

1 

Department of Occupational Health and Toxicology, 

School of Public Health, Fudan University, Shanghai, 

China, 2 Shanghai Municipal Center For Disease 

Control and Prevention, Shanghai, China, 3 Institute 

Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden and 4 Environmental Medicine, 

Department of Public Health and Clinical Medicine, 

Umeå University, Umeå, Sweden. 


EFFECTS OF LOW LEVEL EXPOSURE TO 

CADMIUM AND ARSENIC ON THE KIDNEY. 

M. Huang, S. Choi, R. Im, N. Kim, B. Choi and J. 

Park. Preventive Medicine, College of Medicine, 

Chung-Ang University, Seoul, South Korea. 


CADMIUM-INDUCED MALIGNANT 

TRANSFORMATION OF HUMAN BREAST 

EPITHELIAL CELLS. L. Benbrahim-Tallaa 1 , J. 

Coppin 1 , J. Liu 1 , B. A. Diwan 1 and M. Waalkes 2 . 1 ICS, 

LCC, NCI at NIEHS, Research Triangle Park, NC 

and 2 SAIC, NCI at Frederick, Frederick, MD. 

Abstract # 


THE INVOLVEMENT OF RENAL IRON 

ACCUMULATION IN THE SUPPRESSION 

OF ERYTHROPOIETIN PRODUCTION 

IN RATS WITH CHRONIC CADMIUM 

INTOXICATION. H. Horiguchi, E. Oguma and 

F. Kayama. Division of Environmental Medicine, 

Center for Community Medicine, Jichi Medical 

University, Shimotsuke, Japan. Sponsor: T. Yoshida. 


STRAIN DIFFERENCES OF CADMIUM 

TOXICITY IN THE LIVER AND TESTES OF 

INBRED WISTAR-IMAMICHI AND FISCHER 

344 RATS. H. Shimada 1 , A. Yasutake 2 , M. Nagano 2 , 

M. P. Waalkes 3 and Y. Imamura 1 . 1 Kumamoto 

University, Kumamoto, Japan, 2 National Institute for 

Minamata Disease, Kumamoto, Japan and 3 NCI at 



CADMIUM INDUCED ALTERATION OF 

CADHERIN EXPRESSION IN THE MT-3 

TRANSFECTED HUMAN PROXIMAL 

TUBULE CELL LINE HK-2. C. Bathula, S. H. 

Garrett, M. Sens, D. A. Sens and S. Somji. Pathology, 

University of North Dakota, Grand Forks, ND. 


LOSS OF GLUTAMATE-CYSTEINE LIGASE 

MODIFIER SUBUNIT SENSITIZES MICE 

TO ACUTE CADMIUM TOXICITY. S. N. 

Schneider, B. Wang, H. G. Shertzer, D. W. Nebert 

and T. P. Dalton. Environmental Health, University 

of Cincinnati Medical Center, Cincinnati, OH. 


ARSENIC SIGNALS THROUGH NADPH 

OXIDASE TO PROMOTE MOUSE LIVER 

SINUSOIDAL ENDOTHELIAL CELL 

DEFENESTRATION AND INCREASED 

PECAM-1 EXPRESSION. A. C. Straub 1 , D. 

B. Stolz 2 , K. A. Clark 2 , A. G. Chandura 1 and A. 

Barchowsky 1 . 1 Environmental and Occupational 

Health, University of Pittsburgh, Pittsburgh, PA 

and 2 Cell Biology and Physiology, University of 

Pittsburgh, Pittsburgh, PA. 


THE ROLE OF FLAVONOIDS IN 

MODULATION OF THE METABOLISM OF 

ARSENIC. Z. Drobna 1 , A. Hernandez-Zavala 2 , F. S. 

Walton 1 , D. J. Thomas 3 and M. Styblo 1,2 . 1 Nutrition, 

UNC Chapel Hill, NC, Chapel Hill, NC, 2 CEMLB, 


3 



CYTOTOXICITY OF COMBINED 

ARSENICALS ON RAT BLADDER 

EPITHELIAL CELLS IN VITRO. S. Suzuki, M. 

Nascimento, S. Kakiuchi-Kiyota, K. L. Pennington, 

L. L. Arnold and S. M. Cohen. Pathology and 

Microbiology, University of Nebraska Medical 

Center, Omaha, NE. 


ARSENIC EXPOSURE DECREASES BETA 

DEFENSIN-1 EXPRESSION. N. Dangleben, D. 

Alexander, M. Smith, C. Hegedus, S. Lim, L. Zhang, 

X. Ren and C. Skibola. School of Public Health, 

University of California, Berkeley, Berkeley, CA. 

Wednesday 




Wednesday 



ARSENIC INDUCED AN INCREASE IN 

ENDOTHELIAL CELL PERMEABILITY: 

INVOLVEMENT OF CYTOSKELETON 

SIGNALING. R. Ward 1,2 , X. Shi 1 , V. Castranova 1 

and Y. Qian 1 . 1 Pathology and Physiology Research 


and Health, Morgantown, WV and 2 The Cancer 

Cell Biology Program, West Virginia University, 



ROLE OF NA/PHOSPHATE 

COTRANSPORTERS IN THE CELL 

MEMBRANE TRANSPORT OF ARSENATE. 

R. Villa-Bellosta 1 , V. Sorribas 1 , M. J. Sancho 1 , P. 

Gaspar 1 and A. Anadon 2 . 1 Toxicology Department, 

University of Zaragoza, Zaragoza, Spain and 

2 





TISSUE DISTRIBUTION OF ARSENIC 

SPECIES IN MICE CHRONICALLY 

EXPOSED TO METHYLARSONOUS ACID. 

D. Paul 1 , A. Hernandez-Zavala 2 , V. Devesa 2 , D. J. 

Thomas 3 and M. Styblo 1,2 . 1 Department of Nutrition, 

University of North Carolina, Chapel Hill, NC, 

2 

Center for Environmental Medicine, Asthma and 

Lung Biology, University of North Carolina, Chapel 

Hill, NC and 3 U.S. EPA, RTP, NC. 


TISSUE DISTRIBUTION AND URINARY 

EXCRETION OF INORGANIC ARSENIC 

AND ITS METHYLATED METABOLITES IN 

C57BL/6 MICE FOLLOWING SUBCHRONIC 

EXPOSURE TO ARSENATE (AS V ) IN 

DRINKING WATER. E. M. Kenyon 1 , M. F. 

Hughes 1 , B. Adair 1 , J. Highfill 1 , E. A. Crecelius 2 , 

H. J. Clewell 3 and J. W. Yager 4 . 1 ORD/NHEERL/ 

ETD, U.S. EPA, RTP, NC, 2 Battelle Marine Sciences 

Laboratory, Sequim, WA, 3 The Hamner Institutes for 

Health Sciences, RTP, NC and 4 EPRI, Palo Alto, CA. 


THE INFLUENCE OF SELENIUM ON 

ARSENIC METABOLISM AND GENOMIC 

METHYLATION OF LEUKOCYTE DNA. 

R. Pilsner 1,2 , X. Liu 3 , H. Ahsan 4 , P. Factor- 

Litvak 4 , J. H. Graziano 2 and M. V. Gamble 2 . 

1 

Epidemiology, University of Michigan, Ann Arbor, 

MI, 2 Environmental Health Sciences, Columbia 

University, New York, 3 Biostatistics, Columbia 

University, New York and 4 Epidemiology, Columbia 

University, New York. 


SORPTION OF ARSENIC BY 

FERRIHYDRITE IN A SIMULATED GI 

MODEL. J. F. Taylor, A. Robinson, N. Johnson, 

A. Marroquin-Cardona, B. Brattin, R. Taylor, E. 

Afriyie-Gyawu and T. Phillips. Veterinary Integrative 

Biosciences, Texas A&M, College Station, TX. 


INCREASED SKIN CARCINOMA 

FORMATION IN ADULT MICE ASSOCIATED 

WITH DISTORTED STEM CELL DYNAMICS 

AFTER IN UTERO ARSENIC EXPOSURE. 

M. Waalkes 1 , J. Liu 1 , D. R. Germolec 2 , J. M. Ward 3 , 

R. E. Cannon 2 , C. S. Trempus 2 , R. W. Tennant 2 and 

B. A. Diwan 4 . 1 Inorganic Carcinogenesis Section, 

LCC, NCI at NIEHS, Research Triangle Park, NC, 

2 

NIEHS, Research Triangle Park, NC, 3 NIAID, 

Bethesda, MD and 4 SAIC, NCI at Frederick, 

Frederick, MD. 


INORGANIC ARSENITE INDUCES 

DELAYED OXIDATIVE DNA DAMAGE 

DEPENDENT ON CELLULAR ABILITY 

TO METHYLATE ARSENIC. C. Kojima 1 , M. 

Waalkes 1 , D. Ramirez 2 and R. Mason 2 . 1 Inorganic 

Carcinogenesis Section, LCC, NCI at NIEHS, 

Research Triangle Park, NC and 2 LPC, NIEHS, 



CYTOTOXICITY, MUTAGENICITY 

AND CELLULAR LOCALIZATION OF 

INSOLUBLE DEPLETED URANIUM IN 

CHO AA8 AND HUMAN LUNG 16HBE14O 

CELLS. V. H. Coryell 1 , M. R. Romanotto 1 , M. 

Yellowhair 2 , R. Lantz 3 and D. M. Stearns 1 . 1 Chemistry 

and Biochemistry, Northern Arizona University, 

Flagstaff, AZ, 2 Pharmacology and Toxicology, 

University of Arizona, Tucson, AZ and 3 Cell Biology 

and Anatomy, University of Arizona, Tucson, AZ. 


BIOMATERIALS AS DECORPORATION 

AGENTS FOR RADIONUCLIDES. T. G. 

Levitskaia, K. D. Thrall and J. Morris. Pacific 

Northwest National Laboratory, Richland, WA. 


TRACE ELEMENT PROFILES IN SINGLE 

STRANDS OF HUMAN HAIR. K. Gellein 1 , P. 

Kaur 2 , T. Flaten 1 and T. Syversen 2 . 1 Department of 

Chemistry, Norwegian University of Science and 

Technology, Trondheim, Norway and 2 Department of 

Neuroscience, Norwegian University of Science and 

Technology, Trondheim, Norway. 


INVESTIGATING METAL 

CONCENTRATIONS IN THE TISSUES AND 

SHELL OF THE BIVALVES CRASSOSTREA 

VIRGINICA AND GEUKENSIA DEMISSA 

IN THE NY HUDSON RIVER ESTUARY 

AND LONG ISLAND SOUND USING 

SYNCHROTRON RADIATION. S. Murray 2 , K. 

Jones 3 and E. J. Catapane 1 . 1 Biology, Medgar Evers 

College, Brooklyn, NY, 2 Biology, Kingsborough 

Community College, Brooklyn, NY and 3 Brookhaven 

National labs, Upton, NY. Sponsor: C. Miller. 


THE CURIOUS HISTORY OF ANTIMONY 

AND ITS RELEVANCE TO HUMAN RISK 

ASSESSMENT. L. Jowa and R. Howd. OEHHA, 

Cal/EPA, Sacramento and Oakland, CA. 

230 




Abstract # 


REDUCING LEAD LEVELS IN 

THE CONTAMINATED SOILS 

BY PHYTOEXTRACTION USING 

SUNFLOWERS. Y. Wei 1 , C. Freeman 2 and M. 

Latimore 3 . 1 Department of Community Medicine, 

Mercer University School of Medicine, Macon, 

GA, 2 Department of Chemistry, Southwest Magnet 

High School and Law Academy, Macon, GA and 

3 

Agricultural Research, Fort Valley State University, 

Fort Valley, GA. 


CARDIOVASCULAR AND OTHER HEALTH 

EFFECTS ASSOCIATED WITH ARSENIC 

EXPOSURE IN INNER MONGOLIA, CHINA. 

J. L. Mumford 1 , Y. Xia 2 , J. Mo 3 , T. Wade 1 , Y. Li 2 , 

K. Wu 2 and W. Sanders 3 . 1 NHEERL/HSD, U.S. 

EPA, Research Triangle Park, NC, 2 Inner Mongolia 

Center for Endemic Disease Control and Research, 

Huhhot, Inner Mongolia, China and 3 Center for 

Environmental Medicine, Asthma and Lung Biology, 

University of North Carolina, Chapel Hill, NC. 

Sponsor: M. Madden. 


NONLINEAR BLOOD LEAD RESPONSE 

OF CHILDREN TO SOIL LEAD: 

TOXICOLOGICAL BASIS FOR HEALTH 

DISPARITIES IN METROPOLITAN NEW 

ORLEANS, LOUISIANA. H. W. Mielke 1,2 , 

C. Gonzales 3 , E. Powell 2 and P. W. Mielke, Jr. 4 . 

1 

Chemistry, Tulane Univesity, New Orleans, LA, 

2 

Center for Bioenvironmental Research, Tulane 

University, New Orleans, LA, 3 Chemistry, Xavier 

University of Louisiana, New Orleans, LA and 

4 

Statistics, Colorado State University, Fort Collins, 

CO. 


GENOTOXIC EFFECTS OF INDIVIDUALS 

EXPOSED TO ARSENIC IN DRINKING 

WATER, IN MORELOS, MEXICO. M. 

Martinez-Pacheco 1 , P. Mussali-Galante 1 , E. Tovar- 

Sanchez 2 , L. Colin-Barenque 3 , P. Bizarro-Nevares 1 , 

A. Gonzalez-Villalva 1 and F. I. Teresa 1 . 1 Biología 

Celular y Tisular, UNAM, Mexico City, Mexico, 

2 

CEAMISH, UAEM, Cuernavaca, Mexico and 

3 

Neuromorfologia, FES Iztacala, Edo. Mexico, 

Mexico. 


ARSENIC EXPOSURE BY DRINKING 

WATER IN MORELOS, MEXICO. P. Mussali- 

Galante 1 , E. Tovar-Sanchez 2 , M. Martinez-Pacheco 1 , 

L. Colin-Barenque 3 , P. Bizarro-Nevares 1 , A. 

Gonzalez-Villalva 1 and F. I. Teresa 1 . 1 Biología 

Celular y Tisular, UNAM, Mexico City, Mexico, 

2 

CEAMISH, UAEM, Cuernavaca, Mexico and 

3 

Neuromorfologia, FES Iztacala, UNAM, Edo. 

Mexico, Mexico. 


URINARY CREATININE: A PREDICTOR 

OF ARSENIC METHYLATION AND OF 

AS-INDUCED PREMALIGNANT SKIN 

LESIONS. M. V. Gamble, X. Liu, R. Pilsner, 

V. Slavkovich and J. H. Graziano. Department 

of Environmental Health Sciences, Columbia 


Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: CARDIOVASCULAR SYSTEM: CARDIAC 

EFFECTS 

Chairperson(s): Jacqueline Wallenborn, University of North Carolina 

Chapel Hill, Chapel Hill, NC and Susan Borghoff, Integrated Lab 

Systems, Research Triangle Park, NC. 




ASSESSMENT OF QTC FORMULAS 

IN CONSCIOUS DOGS WITH PACING- 

INDUCED HEART FAILURE (HF). A. 

Kijtawornrat 1 , Y. Panyasing 1,2 , J. Lolly 1 , J. Schmidt 1 , 

Y. Nishijima 2 , B. Roche 2 and R. Hamlin 1,2 . 1 QTest 

Labs, LLC, Columbus, OH and 2 Department of 

Veterinary Biosciences, The Ohio State University, 

Columbus, OH. Sponsor: M. Hejtmancik. 


ECG ASSESSMENT OF DRUG-INDUCED 

PROARRHYTHMIA IN ADULT ZEBRAFISH. 

D. Park, W. L. Seng, C. Li, X. Tang, L. J. D’Amico 

and P. McGrath. Phylonix, Cambridge, MA. Sponsor: 

C. Zhang. 


EVALUATION OF DRUG-INDUCED QT 

PROLONGATION IN HALOTHANE- 

ANESTHETIZED MONKEYS AND AGED 

MONKEYS: EFFECTS OF SOTALOL. T. 

Ishizaka, Y. Yoshimatsu, M. Ozawa, T. Kimotsuki, S. 

Manabe and M. Yasuda. Medicinal Safety Research 

Laboratories, Daiichi Sankyo Co., Ltd., Fukuroi-shi, 

Shizuoka, Japan. 


INCIDENCE OF SPONTANEOUS CARDIAC 

ALTERATIONS IN CONSCIOUS NAIVE 

CYNOMOLGUS MONKEYS OF MAURITIAN 

ORIGIN. U. Zuehlke 1 , G. Weinbauer 1 and E. 

Schulze-Bahr 2 . 1 Covance Laboratories GmbH, 

Muenster, Germany and 2 Department of Cardiology, 

Hospital of University of Muenster, Muenster, 

Germany. 


COMPARISON OF ANESTHETIC 

PROTOCOLS FOR UNCONSCIOUS 

CARDIOVASCULAR SAFETY 

PHARMACOLOGY IN BEAGLE DOGS. 

S. Fournier 1 , S. Authier 1,2 , F. Chaurand 1 and E. 

Troncy 2 . 1 LAB Research Canada, Laval, QC, Canada 

and 2 GREPAQ, Faculty of Veterinary Medicine, 

University of Montreal, St-Hyacinthe, QC, Canada. 



POTENTIAL IMPORTANCE OF DETECTING 

DRUG-INDUCED ALTERATIONS IN 

REGIOINAL DISTRIBUTION OF CARDIAC 

OUTPUT. R. Hamlin 1,2 , A. Kijtawornrat 1,2 , Y. 

Panyasing 1,2 , J. L. Lolly 2 , J. J. Schmidt 2 , L. Snedden 2 

and D. M. Hamlin 2 . 1 Veterinary Biosciences, The 

Ohio State University, Columbus, OH and 2 QTest 

Labs, Columbus, OH. Sponsor: M. Hejtmancik. 

Wednesday 




Wednesday 



THE IMPORTANCE OF EARLY 

CHARACTERIZATION OF 

METABOLITES TO ASSESS POTENTIAL 

CARDIOVASCULAR EFFECTS. D. L. Misner 1 , 

J. Ly 1 , L. Guo 2 , S. Chanda 1 , S. Platz 1 , R. Weikert 1 

and K. Kolaja 1 . 1 Roche Palo Alto, Palo Alto, CA and 

2 

Roche, Nutley, NJ. 


REPEATED TREATMENTS 

WITH DOXORUBICIN CAUSES 

ELECTROCARDIOGRAM (ECG) CHANGES 

AND INCREASED VENTRICULAR 

PREMATURE BEATS IN WISTAR-KYOTO 

(WKY) RATS. M. S. Hazari 1 , N. Haykal-Coates 2 , 

D. Winsett 2 , A. Carll 1 , D. Costa 2 and A. Farraj 2 . 

1 

Curriculum in Toxicology/ETD, University 

of North Carolina/U.S. EPA, Chapel Hill, NC 

and 2 Experimental Toxicology Division, U.S. 


Park, NC. 


CHARACTERIZATION OF 

CARDIOVASCULAR EFFECTS 

IN ACID SPHINGOMYELINASE 

KNOCKOUT MICE FOLLOWING 

ADMINISTRATION OF RECOMBINANT 

ACID SPHINGOMYELINASE (RHASM). 

A. D’Angona 1 , C. Brown 1 , A. L. D’Angona 1 , J. 

Murray 1 , K. P. Karey 1 , T. G. Hampton 2 and L. 

Andrews 1 . 1 Pharmacology and Toxicology, Genzyme, 

Framingham, MA and 2 Mouse Specifics, Boston, 

MA. 


SUBCHRONIC INHALATION OF ZINC 

SULFATE CAUSES CARDIAC CHANGES IN 

HEALTHY RATS. J. G. Wallenborn 1 , P. Evansky 2 , 

J. H. Shannahan 3 , M. C. Schladweiler 2 , B. Vallanat 4 , 

R. Gottipolu 2 , A. D. Ledbetter 2 , J. Richards 2 , A. 

Nyska 5 and U. P. Kodavanti 2 . 1 SPH, UNC, Chapel 

Hill, NC, 2 NHEERL, ETD, U.S. EPA, Durham, 

NC, 3 Curriculum in Toxicology, UNC, Chapel Hill, 

NC, 4 NHEERL, ECD, U.S. EPA, Durham, NC and 

5 

Toxicologic Pathology, Timrat, Israel. 


MEASUREMENT OF CARDIAC TROPONIN 

T (cTnT) IN RAT SERUM: COMPARING 

TWO ELECTROCHEMILUMINESCENT 

(ECL) PLATFORMS. S. Borghoff 1 , C. Hobbs 1 , K. 

Shepard 1 and G. S. Travlos 2 . 1 ILS, Inc, RTP, NC and 

2 



EXAMINATION OF THE 

CARDIOVASCULAR EFFECTS OF PDE2 

INHIBITORS IN THE NEONATAL AND 

ADULT ISOLATED RABBIT HEART 

(LANGENDROFF) MODEL. P. J. Lapinskas 1 , 

E. Tanhehco 2 , P. Senese 2 , M. Gralinski 2 , P. 

Schafer 1 , D. Stirling 1 and O. Laskin 1 . 1 Exploratory 

Toxicology, Celgene Corporation, Summit, NJ and 

2 

CorDynamics, Inc., Chicago, IL. 


EVALUATION OF SEX DIFFERENCES IN 

ELECTROPHYSIOLOGICAL PROPERTIES 

USING CYNOMOLGUS MONKEY CARDIAC 

MUSCLES. K. Yunomae, A. Suzuki, J. Matsuo, 

M. Ban, M. Haruyama, Y. Arimura, Y. Deguchi, T. 

Kamenosono, H. Tokado, K. Fukuzaki, R. Nagata 

and G. Kito. Drug Safety Research Laboratories, 

Shin Nippon Biomedical Laboratories, (SNBL) Ltd., 

Kagoshima, Japan. 


ADULT ZEBRAFISH EXPOSED TO 2, 3, 7, 


(TCDD) DISPLAY REDUCED MYOCARDIAL 

REGENERATIVE CAPACITY FOLLOWING 

VENTRICULAR RESECTION. V. Mehta 1 , R. 

E. Peterson 1,2 and W. Heideman 1,2 . 1 Molecular and 

Environmental Toxicology Center, University of 

Wisconsin-Madison, Madison, WI and 2 School 

of Pharmacy, University of Wisconsin-Madison, 

Madison, WI. 


A COMMON PATHOLOGICAL AND 

TRANSCRIPTIONAL RESPONSE OF 

ZEBRAFISH EMBRYONIC HEART TO 

VARIOUS STRESSES. J. Chen 1 , C. Struble 2 , R. 

E. Peterson 1 and W. Heideman 1 . 1 Pharmaceutical 

Sciences, University of Wisconsin - Madison, 

Madison, WI and 2 Mathematics, Statistics 

and Computer Sciences, Maquette University, 

Milwaukee, WI. 


A CARDIOVASCULAR SAFETY 

EVALUATION STUDY OF 99M TC SESTAMIBI 

IN DIFFERENT AGED MALE MONGREL 

DOGS DURING REST AND TREADMILL 

EXERCISE. C. Hassler 1 , M. Mistry 2 , S. Robinson 2 , 

M. Hawk 1 , S. Kopp 1 , M. Coffee 1 , R. Lordo 1 , B. 

Wood 1 and T. Vinci 1 . 1 Battelle, Columbus, OH and 

2 

Bristol-Myers Squibb Medical Imaging, N. Billerica, 

MA. Sponsor: M. Hejtmancik. 


ANALYSIS OF SEX- AND AGE-RELATED 

DIFFERENCES IN HEART OF RAT STRAIN 

FISHER 344 USING OLIGONUCLEOTIDE 

MICROARRAYS. T. Han, W. S. Branham, C. L. 

Moland, R. Holland, L. K. Schnackenberg, R. D. 

Beger, R. Jones, R. Edmondson, J. Taylor, W. Tong, 

Y. P. Dragan and J. C. Fuscoe. Division of Systems 

Toxicology, NCTR/FDA, Jefferson, AR. 


INVESTIGATION OF CARDIAC 

SUBENDOCARDIAL PROLIFERATION 

IN THE RAT AND THE RELEVANCY FOR 

HUMAN RISK ASSESSMENT. M. Fielden, P. 

Day-Lollini, C. Riordan, D. Button, R. Martin and 

K. Kyle. Non-Clinical Drug Safety, Roche Palo Alto, 

Palo Alto, CA. 


ANGIOTENSIN II-INDUCED CARDIAC 

APOPTOSIS IS MEDIATED BY P53- 

DEPENDENT MITOCHONDRIAL 

CYTOCHROME C RELEASE PATHWAY. G. 

Zhou and L. Cai. University of Louisville, Louisville, 

KY. 

232 




Abstract # 


CHOLESTEROL SECOALDEHYDE- 

INDUCED APOPTOSIS IN 

CARDIOMYOCYTES: ROLE OF 

HYDROGEN PEROXIDE AND P38 MAP 

KINASE SIGNALING. L. Laynes, A. C. 

Raghavamenon and R. M. Uppu. Environmental 

Toxicology and the Health Research Center, Southern 

University and A & M College, Baton Rouge, LA. 


AKT-DEPENDENT DOWN-REGULATED 

GLYCOGEN SYNTHESIS KINASE-3b 

PLAYS A CRITICAL ROLE IN DIABETES- 

INDUCED INTRAMYOCARDIAL LIPID 

ACCUMULATION AND INFLAMMATION: 

PREVENTION OF METALLOTHIONEIN. Y. 

Wang. Medicine, University of Louisville, Louisville, 

KY. Sponsor: L. Cai. 


FUNCTIONAL STUDY OF CYSTATIN C IN 

CARDIAC EXTRACELLULAR MATRIX 

REMODELING. L. Xie, E. V. Sheveleva, B. Xu 

and Q. M. Chen. University of Arizona, Tucson, AZ. 


EFFECTS OF AGING ON THE 

CARDIOVASCULAR AND 

THERMOREGULATORY RESPONSE TO 

TOLUENE IN THE BROWN NORWAY RAT. 

C. J. Gordon, P. Becker and C. Mack. U.S. EPA, 



9:00 AM to 12:30 PM 

Exhibit Hall 

POSTER SESSION: DNA DAMAGE AND REPAIR: 

MECHANISMS AND AGENTS 

Chairperson(s): Vernon Walker, Lovelace Respiratory Research Institute, 

Albuquerque, NM and Haley Menard, Brown University, Providence, RI. 


Attended: 9:00 AM-11:00 AM 


GROWTH ARREST, DNA REPAIR, AND 

TRANSCRIPTOMIC RESPONSE TO DNA 

DAMAGE IN CAENORHABDITIS ELEGANS. 

J. N. Meyer 1 , W. A. Boyd 2 , T. L. Crocker 1 , D. W. 

Lehmann 2 , A. M. Rodriguez 2 , S. J. McBride 2 , J. 

H. Freedman 2 and B. Van Houten 2 . 1 NSEES, Duke 

University, Durham, NC and 2 NIEHS, RTP, NC. 

Sponsor: R. Di Giulio. 


VALIDITY OF GPT DELTA TRANSGENIC 

RODENT GENOTOXICITY ASSAYS. T. Nohmi. 

Division of Genetics and Mutagenesis, National 

Institute of Health Sciences, Tokyo, Japan. Sponsor: 

A. Nishikawa. 


EXPLORING THE LINK BETWEEN HIF-1 

AND RADIOPROTECTION. I. G. Bebenek 1,3 , 

W. H. McBride 2,3 and O. Hankinson 1,3 . 1 Pathology, 

UCLA, Los Angeles, CA, 2 Radiation Oncology, 

UCLA, Los Angeles, CA and 3 Molecular Toxicology 

Program, UCLA, Los Angeles, CA. 

Abstract # 


REPAIR OF RADIATION INDUCED DNA 

STRAND BREAKS IN P53 DEFICIENT AND 

WILD-TYPE MOUSE HEMATOPOIETIC 

STEM CELLS IS STRAIN DEPENDENT. J. E. 

French and V. I. Parron. Laboratory of Molecular 

Toxicology, NIEHS, NIH, Research Triangle Park, 

NC. 


THE HPRT/SR ASSAY: A NOVEL METHOD 

TO ASSESS STRESS RESPONSE PATHWAY 

ALTERATIONS IN CANCER. D. M. Walker 

and R. J. Albertini. BioMosaics, Burlington, VT. 

Sponsor: V. Walker. 


GENOMIC ARCHITECTURE AND 

INSTABILITY OF HUMAN RIBOSOMAL 

RNA GENE CLUSTERS. D. M. Stults 1,4 , M. W. 

Killen 2,4 , H. H. Pierce 3,4 and A. J. Pierce 2,4,1 . 1 Grad Ctr 

for Toxicology, University of Kentucky, Lexington, 

KY, 2 Microbiology, Immunology, and Molecular 

Genetics, University of Kentucky, Lexington, KY, 

3 

Department of Internal Medicine, University of 

Kentucky, Lexington, KY and 4 Markey Cancer 

Center, University of Kentucky, Lexington, KY. 

Sponsor: M. Vore. 


FORMALDEHYDE INDUCES TOXICITY VIA 

A P53-DEPENDENT SIGNALING PATHWAY. 

H. L. Menard, M. F. Reynolds and A. Zhitkovich. 

Pathology and Laboratory Medicine, Brown 

University, Providence, RI. 


TOXIC ACTIVITIES IN WOOD DUST FROM 

RED OAK. M. Wilson, R. Rando and C. A. Miller. 

Environmental Health Sciences, Tulane University, 

New Orleans, LA. 


ZIDOVUDINE INDUCES APOPTOSIS, 

DELAYS CELL CYCLE PROGRESSION AND 

DECREASES TELOMERASE ACTIVITY IN 

HUMAN HEPATOMA HEPG2 CELLS. J. Fang 

and F. A. Beland. NCTR, Jefferson, AR. Sponsor: T. 

Chen. 


CENTROSOMAL AMPLIFICATION 

INDUCED BY ANTIRETROVIRALS 

COMMONLY USED IN THE THERAPY 

OF HIV. M. Yu, M. C. Poirier and O. A. Olivero. 

Carcinogen-DNA Interactions, National Cancer 

Institute, Bethesda, MD. 


THE END DRAWS NEAR: TELOMERE 

SHORTENING INDUCED BY A QUINONE 

METABOLITE OF PCB3. J. Jacobus 1,2 , A. 

Klingelhutz 3 , L. Robertson 1,2 and G. Ludewig 1,2 . 

1 

OEH, College of Public Health, Univ of Iowa, Iowa 

City, IA, 2 Interdisciplinary Graduate Program in 

Human Toxicology, Univ of Iowa, Iowa City, IA and 

3 

Department of Microbiology, Univ of Iowa, Iowa 

City, IA. 


GENOTOXICITY OF PCB3 METABOLITES 

IN VITRO – WHICH ONE IS THE BAD GUY? 

S. M. Flor and G. Ludewig. Occupational and 


City, IA. 

Wednesday 




Wednesday 



INVESTIGATING GAMMA-H2AX 

EXPRESSION AFTER ACUTE AND IN 

UTERO BENZENE EXPOSURE. A. Lau 1 and L. 

M. Winn 1,2 . 1 Pharmacology and Toxicology, Queen’s 





MUTAGENIC EVALUATION OF THE 

AZO DYE DISPERSE ORANGE-I AND 

DETERMINATION OF THE MECHANISM 

OF DNA DAMAGE. D. P. Oliveira 1 , E. A. Ferraz 1 , 

F. D. Chequer 1 , D. J. Dorta 1 and M. B. Zanoni 2 . 

1 

Clinical, Toxicological and Bromatological analysis, 

University of São Paulo, Ribeirão Preto, São 

Paulo, Brazil and 2 Chemical Institute, Universidade 

Estadual Paulista, Araraquara, São Paulo, Brazil. 


THE GENOTOXICITY AND 

CARCINOGENICITY OF SULFONATED 

AZO-DYES: A STRUCTURE-ACTIVITY 

EVALUATION. S. Robison and C. Strittholt. 

Central Product Safety, Procter & Gamble, 



EFFECTS OF SIDE STREAM TOBACCO 

SMOKE ON MICE DEFICIENT IN THE 

REPAIR OF OXIDATIVE DNA DAMAGE. M. 

L. Yamamoto 1,3 , A. Westbrook 1,3 , J. H. Miller 2,3 and 

R. Schiestl 1,3 . 1 Pathology, University of California, 

Los Angeles, Los Angeles, CA, 2 Microbiology, 

Immunology and Molecular Genetics, University 

of California, Los Angeles, Los Angeles, CA and 

3 

Molecular Toxicology, University of California, Los 

Angeles, Los Angeles, CA. 


EFFECT OF CIGARETTE FILTER 

VENTILATION ON CYTOTOXICITY, 

MUTAGENICITY, INFLAMMATION 

AND FREE RADICALS OF SMOKE 

PARTICULATE MATTER. R. D. Leverette, J. 

T. Hamm, M. Misra and D. C. Middleton. A. W. 

Spears Research Center, Lorillard Tobacco Company, 



DETERMINANTS OF ASBESTOS FIBER- 

INDUCED GENOTOXICITY. M. R. Gwinn, K. 

Z. Guyton, B. Sonawane and D. DeVoney. Office of 

Research & Development, U.S. EPA, Washington, 

DC. 


CHEMICAL SYNTHESIS AND 

IDENTIFICATION OF N3-ADENINE 

ADDUCTS FORMED BY 1- OR 

2-BROMOPROPANE WITH CALF-THYMUS 

DNA AT THE PHYSIOLOGICAL 

CONDITION. H. Choi, P. Thapa, R. Karki, U. 

Thapa, Y. Jahng, T. Jeong and E. Lee. College 

of Pharmacy, Yeungnam University, Kyongsan, 

Kyongbuk, South Korea. 


AN EVALUATION OF THE P53 KNOCKOUT 

MOUSE IN THE EARLY DETECTION OF 

THE CARCINOGENIC POTENTIAL OF 

N-METHYL-N-NITROSUREA. R. W. Lewis, J. 

Wright, J. Noakes and A. Hargreaves. Product Safety, 

Syngenta, Bracknell, United Kingdom. Sponsor: R. 

Peffer. 


DETECTION OF PIG-A MUTANT CELLS 

IN PERIPHERAL BLOOD OF MACACA 

MULATTA. V. N. Dobrovolsky 1 , D. Miura 2 , J. 

G. Shaddock 1 and S. M. Morris 1 . 1 DGRT, NCTR, 

Jefferson, AR and 2 Teijin Pharmacology Limited, 

Tokyo, Japan. Sponsor: T. Chen. 


DETECTION AND QUANTITATION OF 1, 

N 2 -3-METHYLINDOLEDEOXYGUANOSINE 

ADDUCTS AND 1, N 6 -3- 

METHYLINDOLEDEOXYADENOSINE 

ADDUCTS IN HUMAN LUNG EPITHLIAL 

CELLS BY LC/MS. M. Shadid and G. S. Yost. 

Pharmacology & Toxicology, University of Utah, 



9:45 AM to 10:45 AM 


Exhibitor Hosted Session: Drug-Drug Interaction 

Toxicity Screening at a Cellular Level 

Presented by: Hemogenix Inc. 

Drug-drug interactions have focused primarily on the cytochrome P450 

system in hepatocytes. However, virtually every cell contains a P450 

system, thereby potentially contributing to altered pharmacokinetics. The 

lympho-hematopoietic system is probably one of the best model systems 

that can be employed to study and predict toxicity. The HALO ® -384 HT 

(high-throughput) platform can now be used to study both drug-drug 

interactions and toxicity on stem and progenitor cells of the lymphohematopoietic 

system. 


9:45 AM to 10:45 AM 


Exhibitor Hosted Session: Bioanalysis for 

Toxicologists: Everything You Wanted to Know 

but Were Afraid to Ask 

Presented by: Huntingdon Life Sciences 

Bioanalytical data and toxicokinetic reports are critical components of most 

preclinical safety evaluations. Review and understanding of this data can 

be challenging to the toxicologist. This Informational Session will review 

how these data are generated and discuss how to evaluate data validity and 

integrity and identify issues for further investigation. 

234 




Abstract # 


11:00 AM to 12:00 NOON 


Exhibitor Hosted Session: MicroCT Based Virtual 

Histology for Small Animal Imaging 

Presented by: Numira Biosciences 

Numira Biosciences presents Virtual Histology, a microCT based 

methodology allowing high resolution 3D visualization of soft tissue and 

skeletal features for simultaneous, nondestructive quantitative analysis. The 

sensitivity and specificity of Virtual Histology enables accurate detection 

and assessment of both gross and subtle malformations in a wide range of 

animal models and disease conditions. 

WEDNESDAY AFTERNOON 

Wednesday Afternoon, March 19 

12:00 NOON to 1:30 PM 

Sheraton 

Willow Room 

Specialty Section Meeting/Luncheon: 

Comparative and Veterinary 


12:00 NOON to 1:20 PM 

Ballroom 6B 


11:00 AM to 12:00 NOON 


Exhibitor Hosted Session: Utility of 

Hematopoietic Colony Forming Cell (CFC) Assays 

in Drug Development 

Presented by: StemCell Technologies, Inc. 

CFC assays are robust in vitro assays used to detect hematopoietic progenitor 

cells. Using primary cell sources, these clonal assays offer a more 

biologically relevant alternative to many in vitro screening assays. This talk 

outlines how CFC assays can be utilized to learn how compounds stimulate 

or inhibit hematopoietic cells. 

Meet the Directors: A conversation With the 

Directors: THE NIEHS Strategic Plan 

Chairperson: Cheryl Lyn Walker, University of Texas MD Anderson 

Cancer Center, Smithville, TX 

The Meet the Director program is a special 80 minute session that provides 

an opportunity for the leaders of major federal agencies to engage in a 

panel discussion of emerging trends in toxicology research and its funding. 

The session will be a particularly valuable opportunity to update our 

members on the future directions of the Institute and NTP. There will be a 

strong emphasis on change of direction and new initiatives that may impact 

the practice of toxicology in the near and long term. Speakers will identify 

opportunities where non-agency toxicologists may be able to participate in 

initiatives of their agencies, and will answer questions of attendees. 

Cheryl Lyn Walker, University of Texas MD Anderson Cancer Center, 

Smithville, TX 

Wednesday 

Samuel H. Wilson, Director, National Institute of Environmental Health 

Sciences and National Toxicology Program, Research Triangle Park, NC 

William Suk, Deputy Director, National Institute of Environmental Health 

Sciences and National Toxicology Program, Research Triangle Park, NC 

Dennis Lang, Director, Division of Extramural Research and Training 

(NIEHS), Research Triangle Park, NC 






12:00 NOON to 1:20 PM 

South Lobby, Level 4 

SoapBox Session 

12:40 MENTORING GRADUATE STUDENTS: 

TOTO, WE’RE NOT IN KANSAS ANYMORE. 

Katherine Squibb 

1:00 MENTORING BY CHANCE AND CHOICE. 

Reitha Weeks 

Chairpersons: Harvey Clewell, John Morris, and Hollie Swanson 

Each speaker will be allowed to address the audience for up to 10 minutes 

on a topic they have submitted in advance. Topics can reflect either an 

area of continuing concern or an issue that has arisen during the meeting, 

and are expected to be novel, controversial, contrary and/or unpopular. No 

projector or computer slide capability will be provided, but speakers can 

hold up a poster as a visual aid if desired. After each speaker, the audience 

will have up to five minutes to challenge or support the speaker with questions 

or comments. 


12:00 NOON to 1:20 PM 

Room 615 



12:15 PM to 1:15 PM 


Exhibitor Hosted Session: gTox Flow Kit: No-Wash, 

Room-Temperature, Fully Automated Flow 

Cytometric Detection of Murine Peripheral 

Blood Micronucleated Erythrocytes 

Presented by: Beckman Coulter, Inc. 

Beckman Coulter has developed a no-wash, room temperature, and fully 

automated murine peripheral blood flow cytometric micronuclei detection 

application that yields first results in less than 2 hours. Codebar 

sample identification enables automatic data processing and comparison to 

existing flow cytometry tests yields extremely high correlation coefficients 

(R2 > 0.9). 

Wednesday 

INFORMATIONAL SESSION: MENTORING 101—HOW TO 

MENTOR, AND HOW TO BE MENTORED 

Chairperson(s): Carol Auletta, Huntingdon Life Sciences, East Millstone, 

NJ and Rae Benedict, University of Maryland, Solomons, MD. 

Endorsed by: 




Women in Toxicology Special Interest Group* 

A mentor is a teacher or trusted counselor who may play a large role in how 

satisfied a student or colleague is with his/her studies or career. Some individuals 

are natural mentors and excel at this activity. However, for many, 

mentoring skills need to be developed. This session will explore this issue 

and address such questions as: What makes a successful mentor? How does 

a mentor exhibit the empathy, understanding and trustworthiness required 

to form a positive connection? How does a mentor acquire those characteristics? 

Does a mentor know how to listen to goals, help the mentee to 

clarify and understand them and provide appropriate resources or contacts to 

facilitate career advancement? This session is intended for both those scientists 

seeking to improve their mentoring skills and those who want to learn 

more about the potential benefits of receiving mentoring. The ideas fostered 

through this session will positively impact the expanding mentoring activity 

of the Society by providing basic advice on mentoring relationships. 


12:15 PM to 1:15 PM 


Exhibitor Hosted Session: Ocular Drug 

Development Selected Preclinical Topics— 

Pharmacokinetic Barriers to Ocular Drug 

Safety and Considerations in Species Selection 

for Safety Studies 

Presented by: Covance 

Pharmaceutical companies are increasingly looking at ocular diseases as 

opportunities for new drug development or to expand the indications for 

their existing drugs. However, many challenges confront those responsible 

for designing the programs to support these developmental efforts. 

Included in these challenges is a thorough understanding of the pharmacokinetic 

barriers to ocular drug efficacy and species considerations for 

efficacy and safety studies. 

#1690 12:00 MENTORING 101—HOW TO MENTOR, 

HOW TO BE MENTORED. C. S. Auletta 1 and 

R. Benedict 2 . 1 Huntingdon Life Sciences, East 

Millstone, NJ and 2 National Academy of Sciences, 


12:20 ENTERING MENTORING OR HOW I 

BECAME A MENTOR BY DEFAULT. Jim 

Gentile 

236 




Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 


POSTER SESSION: DEVELOPMENTAL NEUROTOXICITY 

Chairperson(s): Joseph Breier, University of North Carolina, Chapel Hill, 

NC. 




ETHANOL INHIBITS CARBACHOL- 

INDUCED AXON OUTGROWTH IN 

HIPPOCAMPAL NEURONS BY INHIBITING 

ERK1/2. K. L. VanDeMark, M. Guizzetti, 

G. Giordano and L. G. Costa. Department of 




MODERATE MATERNAL IRON 

INADEQUACY WORSENS 

NEUROBEHAVIORAL OUTCOMES IN 

A RAT MODEL OF DEVELOPMENTAL 

ETHANOL EXPOSURE. T. Tran 1 , E. S. Rufer 2,3 

and S. M. Smith 2,3 . 1 Department of Psychology, 

East Carolina University, Greenville, NC, 

2 

Department of Nutritional Sciences, University of 

Wisconsin-Madison, Madison, WI and 3 Molecular 

& Environmental Toxicology Center, University of 

Wisconsin-Madison, Madison, WI. 


ETHANOL INHIBITS HIPPOCAMPAL 

NEURON DIFFERENTIATION INDUCED BY 

CARBACHOL-TREATED ASTROCYTES. M. 

Guizzetti, G. Giordano, N. Moore and L. G. Costa. 

Env. Occ. Health Sci., University of Washington, 

Seattle, WA. 


ETHANOL INHIBITS MUSCARINIC 

RECEPTOR-INDUCED RELEASE BY 

ASTROCYTES OF EXTRACELLULAR 

PROTEINS INVOLVED IN NEURONAL 

DEVELOPMENT. N. Moore 1 , M. Guizzetti 1 , 

G. Giordano 1 and L. G. Costa 1,2 . 1 Department of 

Environmental & Occupational Health Sciences, 

University of Washington, Seattle, WA and 

2 

Department of Human Anatomy, Pharmacology 

and Forensic Sciences, University of Parma Medical 

School, Parma, Italy. 


THE ROLE OF NRF2 IN DOMOIC 

ACID-INDUCED EFFECTS ON EARLY 

NEURODEVELOPMENT. Q. H. Le, S. Hong, 

X. Yu and E. M. Faustman. Environmental and 

Occupational Health Sciences, University of 


Abstract # 


THE PROTECTIVE EFFECT OF 

L-CARNITINE ON PHENCYCLIDINE- 

INDUCED CORTICAL APOPTOSIS IN THE 

DEVELOPING RAT. X. Zou 1 , S. Y. Boctor, 1 , N. 

Sadovova 2 , S. Ferguson 1 , M. G. Paule 1 , W. Slikker 1 

and C. Wang 1 . 1 Division of Neurotoxicology, 


Jefferson, AR and 2 Toxicologic Pathology Associates, 


Jefferson, AR. 


FLUORESCENT MOLECULAR 

IMAGING OF TRANSGENIC MICE FOR 

NEUROTOXICITY AND COMPOUND 

SCREENING. L. Zhuo, G. Ho, S. Kumar, 

C. Zhang, X. Min and I. Kng. Institute of 

Bioengineering and Nanotechnology, Singapore, 

Singapore. Sponsor: J. O’Callaghan. 


EVALUATION OF HUMAN NEURAL 

PROGENITOR CELLS FOR 

DEVELOPMENTAL NEUROTOXICITY 

SCREENING: TIME COURSE OF EFFECTS 

ON CELL PROLIFERATION AND 

VIABILITY. J. M. Breier 1,2 and T. J. Shafer 2 . 

1 


Carolina, Chapel Hill, NC and 2 Neurotoxicology, 



COMPARISON OF NEUROSCREEN-1 

AND CEREBELLAR GRANULE CELL 

CULTURES FOR EVALUATING NEURITE 

OUTGROWTH USING THE ARRAYSCAN 

HIGH CONTENT ANALYSIS SYSTEM. N. 

M. Radio, T. M. Freudenrich, B. L. Robinette and 

W. R. Mundy. Neurotoxicology Division, U.S. EPA, 



EFFECTS OF PRENATAL EXPOSURE 

TO 1-BROMOPROPANE ON NEURONAL 

EXCITABILITY IN THE HIPPOCAMPUS OF 

OFFSPRING. Y. Fueta 1 , T. Ishidao 1 , S. Ueno 2 , Y. 

Yoshida 3 and H. Hori 1 . 1 Environmental Management, 

School of Health Sciences, University of 

Occupational and Environmental Health, Kitakyushu, 

Japan, 2 Pharmacology, School of Midicine, 

University of Occupational and Environmental 

Health, Kitakyushu, Japan and 3 Immunology, 

School of Midicine, University of Occupational and 

Environmental Health, Kitakyushu, Japan. Sponsor: 

N. Kunugita. 


RETINOIC ACID AFFECTS CHOLESTEROL 

HOMEOSTASIS IN ASTROCYTES: A NEW 

MECHANISM OF TERATOGENESIS? J. Chen, 

L. G. Costa, K. Dao, J. F. Oram and M. Guizzetti. 

DEOHS, University of Washington, Seattle, WA. 

Wednesday 




Wednesday 



PATHOLOGICAL ASSESSMENT OF THE 

NERVOUS SYSTEM OF RAT OFFSPRING 

EXPOSED TO ACRYLAMIDE DURING THE 

GESTATION AND LACTATION PERIODS – 

A PRELIMINARY STUDY. M. Takahashi 1 , M. 

Shibutani 1,2 , K. Inoue 1 , H. Fujimoto 1 , M. Hirose 1,3 , 

M. Yoshida 1 and A. Nishikawa 1 . 1 Division Pathol., 

National . Inst. Health Sci., Tokyo, Japan, 2 Lab. Vet. 

Pathol., Tokyo University Agricultural Technol., 

Tokyo, Japan and 3 Food Safety Commission, Tokyo, 

Japan. 


DEVELOPMENTAL EXPOSURE TO 

PERCHLORATE ALTERS SYNAPTIC 

TRANSMISSION IN HIPPOCAMPUS OF 

THE ADULT RAT. M. E. Gilbert 1 and L. Sui 1,2 . 

1 


Triangle Park, NC and 2 National Rsearch Council, 



THE ROLE OF N-METHYL-D-ASPARTATE 

RECEPTORS IN POLYCHLORINATED 

BIPHENYL-MEDIATED NEUROTOXICITY. 

N. Leopold and C. Laurie. Community Health, 

University of Northern British Columbia, Prince 

George, BC, Canada. 


POLYCHLORINATED BIPHENYLS (PCBs) 

INFLUENCE DENDRITIC GROWTH IN 

CULTURED HIPPOCAMPAL NEURONS 

VIA RYANODINE RECEPTOR (RYR)- 

DEPENDENT ACTIVATION OF CAM 

KINASE I. V. A. Ledoux 1 , G. A. Wayman 2 , I. N. 

Pessah 3 and P. J. Lein 1 . 1 CROET, Oregon Health 

& Science University, Portland, OR, 2 VCAPP, 

Washington State University, Pullman, WA and 

3 

VM:Molecular Biosciences and CCEH, University 

of California, Davis, CA. 


INDUCTION OF NEUROTOXICITY 

IN FETAL BRAIN AFTER PRENATAL 

EXPOSURE TO VALPROATE. M. Kuwagata 1,2 , 

T. Ogawa 2 , S. Shioda 2 and T. Nagata 1 . 1 Toxicology, 

Hatano Research Institute, Hadano, Japan and 

2 

Department of Anatomy I, Showa University Shool 

of Medicine, Tokyo, Japan. 


IN UTERO AND LACTATIONAL EXPOSURE 

TO A LOW DOSE OF TCDD OR TBDD 

PERTURBS PAIRED ASSOCIATIVE 

LEARNING OF MALE RAT OFFSPRING. 

T. Endo, M. Kakeyama and C. Tohyama. Division 

of Environmental Health Sciences, Center for 

Disease Biology and Integrative Medicine(CDBIM), 

Graduate School of Medicine, The University of 

Tokyo, Bunkyo-ku, Tokyo, Japan. 


HIGHLY BROMINATED DIPHENYL 

ETHERS, PBDE 209, 206 AND 203 AFFECT 

DEVELOPMENTAL MARKER PROTEINS 

IN THE NEONATAL MOUSE BRAIN. H. 

Viberg, N. Johansson and P. Eriksson. Environmental 

Toxicology, Uppsala University, Uppsala, Sweden. 


EXPRESSION AND FUNCTIONAL 

CHARACTERIZATION OF THE ORGANIC 

CATION TRANSPORTER-3 IN MOUSE 

ASTROCYTES. J. Panza 1 , R. Aras 1 , N. Ballatori 1 

and K. Tieu 1,2 . 1 Environmental Medicine, University 

of Rochester, Rochester, NY and 2 Center for 

Aging and Development, University of Rochester, 



PERFLUOROOCTANESULFONATE 


STUDY IN RATS. D. J. Ehresman 1 , A. T. Eveland 2 , 

J. D. Zitzow 2 , J. A. Bjork 3 , D. G. Stump 4 , S. Chang 1 , 

K. B. Wallace 3 and J. L. Butenhoff 1 . 1 3M Company, 

St. Paul, MN, 2 Pace Analytical Services, Inc., 

Minneapolis, MN, 3 University of Minnesota, Duluth, 

MN and 4 WIL Research, Ashland, OH. 


BISPHENOL A IS RELEASED FROM 

POLYCARBONATE DRINKING BOTTLES 

AND MIMICS THE NEUROTOXIC 

ACTIONS OF ESTROGEN IN DEVELOPING 

CEREBELLAR NEURONS. S. M. Belcher, H. 

H. Le, E. M. Carlson and J. P. Chua. Pharmacology, 

University of Cincinnati, Cincinnati, OH. 


HEARING IMPAIRMENT FOLLOWING 

DEVELOPMENTAL EXPOSURE TO PCBs IN 

A RAT MODEL. B. E. Powers, J. J. Sable, P. K. 

Pandya and S. L. Schantz. University of Illinois @ 

U-C, Urbana, IL. 


RDX PILOT FOR DEVELOPMENTAL 

NEUROTOXICITY TEST IN RATS. A. Hess- 

Ruth, L. Crouse and L. Roszell. Directorate of 

Toxicology, U.S. Army Center for Health Promotion 

and Preventive Medicine, Aberdeen Proving Ground, 

MD. 


EFFECTS OF 7-NITROINDAZOLE AND 

MELATONIN ON KETAMINE-INDUCED 

NEUROTOXICITY IN POSTNATAL DAY 3 

(PND-3) MONKEY FRONTAL CORTICAL 

CULTURES. N. Sadovova 1 , T. Patterson 2 , X. Zou 2 , 

X. Zhang 2 , J. Hanig 3 , M. Paule 2 , S. Ali 2 , W. Slikker 2 

and C. Wang 2 . 1 Toxicologic Pathology Associates, 

Jefferson, AR, 2 Division of Neurotoxicology, 

National Center for Toxicological Research/FDA, 

Jefferson, AR and 3 Center for Drug Evaluation and 

Research/FDA, Silver Spring, MD. 


NEUROTOXICITY OF SOME NEW 

ANTICONVULSANT N, N’-SUBSTITUTED 

SPIROHYDANTOINS. R. A. Stephani 1,2 , P. Gutta 1 

and H. Patel 1 . 1 Pharmaceutical Sciences, St. John’s 

University, Jamaica, NY and 2 Chemistry, Saint John’s 

University, Jamaica, NY. 

238 




Abstract # 


TRANSFORMATION OF DEVELOPMENTAL 

NEUROTOXICITY DATA INTO 

STRUCTURE-SEARCHABLE TOXML 

DATABASE. H. W. Broening 1 , K. D. Acuff 1 , K. M. 

Crofton 2 , A. S. Fix 1 , E. Julen 3 , E. J. Matthews 4 , J. F. 

Nash 1 , A. M. Richard 2 , S. A. Tozer 1 and C. Yang 5 . 

1 

Procter & Gamble Company, Cincinnati, OH, 2 ORD, 

U.S. EPA, RTP, NC, 3 ILSI Research Foundation, 

Washington DC, DC, 4 CDER OPS ICSAS, U.S. 

FDA, Silver Spring, MD, MD and 5 Leadscope, inc, 

Columbus, OH. 


BNIP3 INDUCES MITOCHONDRIAL 

DYSFUNCTION AND CELL DEATH 

THROUGH MODULATING ENDOPLASMIC 

RETICULAR AND MITOCHONDRIAL CA2+ 

STORES. L. Zhang, L. Li, X. Zhang, H. Leavesley, 

J. Borowitz and G. Isom. MCMP, Purdue University, 

West Lafayette, IN. 


PROTEOMIC ANALYSIS OF PBDE-99 

EXPOSED IN VIVO CORTEX AND IN VITRO 

CORTICAL CELLS. H. Alm 1 , B. Scholz 1 , A. 

Nilsson 3 , P. E. Andrén 3 , A. Fex-Svenningsen 2 , 

L. Dencker 1 and M. Stigson 1 . 1 Pharmaceutical 

biosciences, Uppsala University, Uppsala, Sweden, 

2 

Department of Neuroscience, Uppsala University, 

Uppsala, Sweden and 3 Laboratory for Medical Mass 

Spectrometry, Uppsala University, Uppsala, Sweden. 


METHAMPHETAMINE RESPONSE IS 

DEPENDENT ON GENOTYPE, AGE, AND 

INITIAL DOSE. R. L. Good and R. A. Radcliffe. 

Department of Pharmaceutical Sciences, University 

of Colorado Health Sciences Center, Denver, CO. 


D-b-HYDROXYBUTYRATE, A 

PRODUCT OF THE KETOGENIC DIET, 

IS NEUROPROTECTIVE IN ANIMAL 

MODELS OF HUNTINGTON’S DISEASE BY 

TARGETING BOTH MITOCHONDRIAL AND 

EPIGENETIC MECHANISMS. M. Blair 1 , S. 

Przedborski 2 and K. Tieu 1 . 1 Environmental Medicine, 

University of Rochester Medical Center, Rochester, 

NY and 2 Neurology, Columbia University, New York. 


BRAIN UPTAKE AND BEHAVIORAL 

CHANGES IN RODENTS FOLLOWING 

NEONATAL EXPOSURE TO THE 

CYANOBACTERIAL TOXIN BMAA (b-N- 

METHYLAMINO-L-ALANINE). O. M. 

Karlsson, E. Roman, N. Lindquist and E. Brittebo. 

Pharmaceutical Biosciences, Uppsala, Sweden. 

Sponsor: M. Stigson. 


ASSESSMENT OF THE IN VIVO 

CONSEQUENCES OF PBDE EXPOSURE 

TO THE DEVELOPING VERTEBRATE 

UTILIZING THE ZEBRAFISH MODEL. F. 

Tilton, V. Pettebone and E. P. Gallagher. Department 



Abstract # 



ASSESSMENT IN ZEBRAFISH: A SURVEY 

OF 200 ENVIRONMENTAL TOXICANTS. L. 

J. D’Amico, C. Li, W. Lin Seng and P. McGrath. 

Phylonix, Cambridge, MA. Sponsor: C. Zhang. 


THE SEQUENTIAL UPREGULATION 

OF CELL CYCLE GENES AND MASH1 

INCREASES THE PROLIFERATION AND 

DIFFERENTIATION OF LATE-BORN 

RETINAL PROGENITOR CELLS (RPC) IN 

GESTATIONALLY LEAD-EXPOSED (GLE) 

MICE. A. Giddabasappa 1 , W. Xiao 1 , B. Xu 1 , S. 

Mukherjee 1 , S. Chaney 1 , R. Hamilton 1 , A. Swaroop 2 

and D. A. Fox 1 . 1 University of Houston, Houston, TX 

and 2 University of Michigan, Ann Arbor, MI. 


NEW NEUROTOXICITY TEST WITH 

ZEBRAFISH EMBRYOS. J. I. Urrutia 1 , J. F. 

Rodriguez 2 , A. Arias 2 , M. Martinez 2 and J. Guinea 2 . 

1 

Canal de Isabel II, Madrid, Spain and 2 ZF Biolabs, 

Tres Cantos, Spain. Sponsor: J. Domingo. 


EFFECT OF GABA AGONISTS ON 

KETAMINE-INDUCED NEUROTOXICITY 

IN PND-3 MONKEY FRONTAL CORTICAL 

CULTURES. C. Wang 1 , N. Sadovova 2 , T. A. 

Patterson1 1 , X. Zou 1 , X. Zhang 1 , J. P. Hanig 1 , M. G. 

Paule 1 and W. Slikker 1 . 1 Division of Neurotoxicology, 

National center for Toxicological research, Jefferson, 

AR and 2 2Toxicologic Pathology Associates, 

National center for Toxicological research, Jefferson, 

AR. 


VOLTAGE-DEPENDENT SODIUM CHANNEL 

GATING MODIFIER TOXINS PRODUCE 

SODIUM INFLUX IN NEOCORTICAL 

NEURONS. Z. Cao 1 , J. George 1 , W. H. Gerwick 2 

and T. F. Murray 1 . 1 Department of Pharmacology, 

Creighton University School of Medicine, Omaha, 

NE and 2 Center for Marine Biotechnology and 

Biomedicine, Scripps Institution of Oceanography, 

San Diego, CA. 


THE ROLE OF NMDA RECEPTOR 

SUBUNITS IN PHENCYCLIDINE (PCP)- 

INDUCED NEURONAL APOPTOSIS IN 

RATS. M. G. Paule 1 , N. Sadovova 2 , X. Zou 1 , X. 

Zhang 1 , W. Slikker 1 and C. Wang 1 . 1 Division of 

Neurotoxicology, National Center for Toxicological 

Research, Jefferson, AR and 2 Toxicologic Pathology 

Associates, National Center for Toxicological 

Research, Jefferson, AR. 


DESIGN CONSIDERATIONS AND 

IMPLICATIONS FOR NEUROBEHAVIORAL 

DATA. M. J. Beck, M. D. Nemec, D. G. Stump and 

J. F. Holson. WIL Research Laboratories, LLC, 

Ashland, OH. 

Wednesday 




Wednesday 



1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: HUMAN BIOMARKERS 

Chairperson(s): Wolfgang Dekant, University of Wuerzburg, Wuerzburg, 

Germany. 




OXIDATIVE DNA DAMAGE AND 

OCCUPATIONAL EXPOSURE TO PAH. H. 

Käfferlein 1 , B. Pesch 1 , B. Marczynski 1 , H. Hahn 3 , R. 

Preuss 2 , S. Rabstein 1 , J. Angerer 2 and T. Brüning 1 . 

1 

BGFA, Ruhr-University, Bochum, Germany, 

2 

Friedrich-Alexander University, Erlangen, Germany 

and 3 BGIA, St. Augustin, Germany. 


BIOMARKERS OF PAH EXPOSURE 

AND GENOTOXIC EFFECTS IN HUMAN 

POPULATIONS. R. A. Lingenfelter 1 , Z. Naufal 1 , 

L. Cizmas 1 , L. He 1 , G. Zhou 1 , T. McDonald 1 , 

A. Mekhtiev 2 , A. Islamzadeh 3 and K. Donnelly 1 . 

1 

TAMU, College Station, TX, 2 Institute of 

Physiology n.a. A.I.Karaev, Baku, Azerbaijan and 

3 

Sumgayit Centre For Environmental Rehabilitation, 

Sumgayit, Azerbaijan. 


BIOMONITORING OF EXPOSURE 

TO POLYCYCLIC AROMATIC 

HYDROCARBONS IN INDIVIDUALS 

LIVING NEAR AN ALUMINUM PLANT 

IN QUEBEC, CANADA. M. Bouchard 1,2 , 

L. Normandin 2 , F. Gagnon 2 and T. Claude 2 . 

1 

Environmental & Occupational Health, Université 

de Montréal, Montreal, QC, Canada and 2 Institut 

national de santé publique du Québec, Montreal, QC, 

Canada. Sponsor: K. Kannan. 


BLOOD URANIUM (U) ISOTOPIC ANALYSIS 

AS A MEASURE OF DU EXPOSURE IN 

U.S. SOLDIERS. K. S. Squibb 1 , T. Todorov 2 , J. 

A. Centeno 2 and M. A. McDiarmid 1 . 1 University of 

Maryland School of Medicine, Baltimore, MD and 

2 

Armed Forces Institute of Pathology, Washington, 

DC. 


HUMAN EXPOSURE TO BISPHENOL A BY 

BIOMONITORING: METHODS, RESULTS 

AND ASSESSMENT OF ENVIRONMENTAL 

EXPOSURES. W. Dekant 1 and W. Völkel 2 . 

1 

Department of Toxicology, University of Würzburg, 

Würzburg, Germany and 2 Environmental Medicine/ 

Biomonitoring, Bavarian Health and Food Safety 

Authority, Munich, Germany. 


THE ROLE OF ESTROGEN METABOLISM 

IN THE INITIATION OF BREAST CANCER: 

DETECTION OF POTENTIAL EARLY 

BIOMARKERS FROM A CASE-CONTROL 

STUDY. L. Yang, E. Rogan and E. Cavalieri. 

Environmental toxicology graduate program, Eppley 

Institute for Research in Cancer and Allied Diseases, 

UNMC, Omaha, NE. 


ANALYSIS OF 1, 2;3, 4 DIEPOXYBUTANE 

SPECIFIC PROTEIN ADDUCT IN 

OCCUPATIONALLY EXPOSED WORKERS, 

PART 2. N. I. Georgieva 1 , G. Boysen 1 , P. Upton 1 , P. 

Vacek 2 , R. Shram 3 , R. Albertini 4 and J. Swenberg 1 . 

1 

ESE, UNC, Chapel Hill, NC, 2 University 

of Vermont, Burlington, VT, 3 Laboratory of 

Genetic Toxicology, Prague, Czech Republic and 

4 

BioMosaics, Inc., Burlington, VT. 


A PILOT STUDY COMPARING 

BIOMARKERS OF EXPOSURE IN SMOKERS 

OF MENTHOL AND NON-MENTHOL 

CIGARETTES. J. D. Heck, K. H. Reinert and P. 

Martin. Scientific Affairs, Lorillard Tobacco Co., 



BIOMARKER IDENTIFICATION AND 

EXPOSURE ESTIMATE FOR PHTHALATES 

IN A PREGNANT POPULATION. X. Yan 1 , M. 

G. Robson 2 , J. C. Smulian 3 , C. V. Ananth 3 and S. 

Lashley 3,4 . 1 Joint Graduate Program in Toxicology, 

Rutgers University/UMDNJ, Piscataway, NJ, 2 New 

Jersey Agricultural Experiment Station, Rutgers 

University, New Brunswick, NJ, 3 Department of 

OBGYN, UMDNJ-Robert Wood Johnson Medical 

School, New Brunswick, NJ and 4 Department of 

OBGYN, University of Virginia, Charlottesville, VA. 


PSTC VXDS#5 KIDNEY INJURY 

MOLECULE-1: A SENSITIVE AND SPECIFIC 

BIOMARKER IN VARIOUS FORMS OF 

ACUTE KIDNEY INJURY IN HUMANS. J. V. 

Bonventre, S. S. Waikar and V. S. Vaidya. Medicine- 

Renal, Brigham and Women’s Hospital, Harvard 



EFFECT OF PCB CONTAMINATED SOILS 

ON SERUM PCB LEVELS IN TRAILER 

PARK RESIDENTS. S. J. Hong 1 , L. Aylward 2 , M. 

Edwards 1 , C. Maltby 1 and M. J. Fedoruk 1 . 1 Health 

and Environmental, Exponent, Inc., Irvine, CA and 

2 

Summit Toxicology, Falls Church, VA. 


EVALUATION OF DIOXIN-LIKE 

COMPOUNDS IN WORKERS FROM A 

PRIMARY MAGNESIUM PRODUCTION 

FACILITY RELATIVE TO LEVELS 

OBSERVED IN THE GENERAL U.S. 

POPULATION. L. Scott 1 , L. Haws 2 , D. F. Staskal 2 , 

M. Harris 1 and B. Finley 3 . 1 ChemRisk, Houston, 

TX, 2 ChemRisk, Austin, TX and 3 ChemRisk, 

SanFrancisco, CA. 


IDENTIFICATION OF BIOMARKERS IN 

ALCOHOLIC LIVER DISEASE AND NON 

ALCOHOLIC STEATOHEPATITIS: PROTEIN 

EXPRESSION STUDIES. K. K. Bhopale 1 , K. V. 

Soman 2 , G. K. Sood 3 , A. Okorodudu 1 , G. Ansari 1 

and B. S. Kaphalia 1 . 1 Pathology, University of Texas 

Medical Branch, Galveston, TX, 2 Department of 

Biochemistry and Molecular Biology, The University 

of Texas Medical Branch, Galveston, TX and 

3 

Internal Medicine, The University of Texas Medical 

Branch, Galveston, TX. 

240 




Abstract # 


PROTEOMIC BIOMARKER DISCOVERY BY 

PARTIAL LEAST SQUARES DISCRIMINANT 

ANALYSIS. M. M. Matzke, S. M. Varnum, B. 

Webb-Robertson, R. D. Smith and J. G. Pounds. 


WA. 


ASSESSMENT OF AUTOANTIBODIES 

TO NERVOUS SYSTEM PROTEINS 

FOLLOWING CHRONIC EXPOSURE 

TO BENZENE. M. Balenga and M. Kabamba. 

University of Kinshasa, Kinshasa, Congo, Dem. Rep. 

Sponsor: J. Mwanza. 


BACKGROUND LEVELS OF HYDROGEN 

CYANIDE IN BREATH. K. Stamyr 1 , O. Vaittinen 2 , 

J. Jaakola 2 , L. Halonen 2 and G. Johanson 1 . 1 Work 

Environment Toxicology, Karolinska Institute, 

Stockholm, Sweden and 2 Laboratory of Physical 

Chemistry, University of Helsinki, Helsinki, Finland. 


THE STABILITY OF THE OXIDATIVE 

STRESS MARKER, URINARY 

8-HYDROXY-2’- DEOXYGUANOSINE 

(8-OHDG). Y. Ogawa 1 , Y. Matsumoto 1 and R. 

Yoshida 2 . 1 Research Planning and Coordination, 

National Institute of Occupational Safety and Health, 

Kawasaki, Kanagawa, Japan and 2 Hazrad Evaluation 

and Epidemiology, National Institute of Occupational 

Safety and Health, Kawasaki, Kanagawa, Japan. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: BIOMARKERS: METHODS 

Chairperson(s): Gunnar Boysen, University of North Carolina Chapel 

Hill, Chapel Hill, NC. 




QUANTIFICATION OF 

3-NITROBENZANTHRONE DNA ADDUCTS 

USING ON-LINE SAMPLE PREPARATION 

AND HPLC-ELECTROSPRAY TANDEM 

MASS SPECTROMETRY. G. Gamboa da Costa 1,3 , 

R. Singh 2 , V. M. Arlt 3 , A. Mirza 4 , M. Richards 4 , T. 

Takamura-Enya 5 , H. H. Schmeiser 6 , P. B. Farmer 2 

and D. H. Phillips 3 . 1 Division of Biochemical 

Toxicology, National Center for Toxicological 

Research, Jefferson, AR, 2 Cancer Biomarkers and 

Prevention Group, Biocentre, University of Leicester, 

Leicester, United Kingdom, 3 Section of Molecular 

Carcinogenesis, Institute of Cancer Research, Sutton, 

United Kingdom, 4 Cancer Research U.K. Centre for 

Cancer Therapeutics, Institute of Cancer Research, 

Sutton, United Kingdom, 5 Department of Applied 

Chemistry, Kanagawa Institute of Technology, 

Atsugi-shi, Japan and 6 Division of Molecular 

Toxicology, German Cancer Research Center, 

Heidelberg, Germany. Sponsor: K. Delclos. 

Abstract # 


MULTI-ADDUCT ANALYSIS OF GLOBIN 

FROM RATS AFTER INHALATION 

EXPOSURE TO 1, 3-BUTADIENE. N. 

Bordeerat 1 , N. I. Georgieva 1 , G. Boysen 1 , P. B. 

Upton 1 , L. Collins 1 , V. Walker 2 and J. A. Swenberg 1 . 

1 

Department of Environmental Sciences and 

Engineering, The University of North Carolina, 

Chapel Hill, NC and 2 Lovelace Respiratory Research 



NOVEL LC-MS/MS METHODS FOR 

THE QUANTIFICATION OF THE 

MAJOR URINARY METABOLITE OF 

PROSTAGLANDIN E2 (PGE-M) AND 

CREATININE IN HUMAN URINE. J. Neale and 

B. Dean. Drug Metabolism, Array BioPharma Inc, 

Boulder, CO. 


DEVELOPMENT OF A NEW SYSTEM 

FOR THE IDENTIFICATION AND 

CLASSIFICATION OF AMPHETAMINE- 

DERIVATIVES ABUSER BY LIQUID 

CHROMATOGRAPHY/TANDEM MASS 

SPECTROMETRY. S. Lee 1 , H. Yoo 1 , N. M. Islam 1 , 

Y. Kim 1 , B. Ko 2 , M. In 2 and D. Kim 1 . 1 Doping control 

center, Korea Institute of Science and Technology, 

Seoul, South Korea and 2 Drug Signature Analysis 

Center, Supreme Prosecutors’ Office, Seoul, South 

Korea. 


METABOLOMIC ANALYSIS OF PLASMA 

AND URINE IN RATS TREATED WITH 

FENOFIBRATE AND PHENOBARBITAL. 

M. Milburn 1 , L. Guo 1 , T. Ohta 2 , N. Masutomi 2 , N. 

Tsutsui 2 , M. Mitchell 1 and J. Ryals 1 . 1 Metabolon, Inc., 

Durham, NC and 2 Mitsubishi Tanabe Pharmacology 

Corporation, Kisarazu, Chiba, Japan. Sponsor: S. 

Borghoff. 


CARBON NANOTUBE-BASED 

ELECTROCHEMICAL SENSOR FOR 

CHOLINESTERASE ENZYME ACTIVITY: 

AN ORGANOPHOSPHORUS INSECTICIDE 

AND NERVE AGENT EXPOSURE MONITOR. 

J. Wang 1 , G. Liu 2 , C. Timchalk 1 and Y. Lin 1 . 1 Pacific 

Northwest National Laboratory, Richland, WA and 

2 

North Dakota State University, Fargo, ND. 


QUANTUM-DOTS-BASED 

ELECTROCHEMICAL IMMUNOASSAY FOR 

THE CHLORPYRIFOS AND TRICHLOPYR 

METABOLITE TRICHLOROPYRIDINOL. G. 

Liu 2 , S. L. Riechers 2 , C. Timchalk 1 and L. Yuehe 1 . 

1 


WA and 2 North Dakota State University, Fargo, ND. 


MOLECULAR DOSIMETRY OF THE VINYL 

CHLORIDE-INDUCED DNA ADDUCT, 

7-OXOETHYLGUANINE. E. Mutlu 1,2 , Y. Jeong 1 , 

G. Boysen 1 , P. B. Upton 1 , L. Collins 1 , M. D. Stout 2 

and J. A. Swenberg 1,2 . 1 Environmental Sciences and 

Engineering, University of North Carolina, Chapel 

Hill, Chapel Hill, NC and 2 Curriculum of Toxicology, 


Wednesday 




Wednesday 



A NOVEL APPROACH FOR ANALYSIS 

OF N-TERMINAL VALINE ADDUCTS 

AS BIOMARKERS FOR EXPOSURE TO 

ALKYLATING COMPOUNDS. G. Boysen, N. 

I. Georgieva, N. Bordeerat, T. R. Gadwal and J. A. 

Swenberg. Environmental Sciences and Engineering, 


Hill, NC. 


CONSTRUCTION OF TISSUE SPECIFIC 

HIGHLY-EXPRESSING GENES DATABASE 

FOR BIOMARKER HUNTING. S. Miyamoto, K. 

Takami and A. Horinouchi. Development Research 

Center, Takeda Pharmaceutical Company Limited, 

Osaka, Japan. 


QUANTITATION OF SELECTED 

CONSTITUENTS IN UNDILUTED 

MAINSTREAM CIGARETTE SMOKE 

GENERATED BY DIRECT PUMP EXPOSURE 

SYSTEMS USING UNFILTERED 2R4FS. B. 

MacIsaac 1 , D. K. Kobayashi 2 , K. M. Lee 1 and K. M. 

Gideon 1 . 1 Toxicology Northwest, Battelle, Richland, 

WA and 2 Division of Pulmonary & Critical Care 

Medicine, Washington University St. Louis School of 

Medicine, St. Louis, MO. 


COMPARATIVE PERFORMANCE OF 

NOVEL MARKERS OF NEPHROTOXICITY 

IN THE RAT. E. Harpur 1 , K. Schuster 2 , G. Betton 3 , 

D. Bounous 4 , D. Ennulat 5 , B. Reifke 6 , L. Mylecraine 6 , 

D. Hoffman 1 , J. Gautier 1 , S. Beushausen 7 and S. 

Pettit 8 . 1 sanofi-aventis, Alnwick, United Kingdom, 

2 

Biotrin, Dublin, Ireland, 3 AstraZeneca, Macclesfield, 

United Kingdom, 4 Bristol-Myers Squibb, Princeton, 

NJ, 5 GlaxoSmithKline, King of Prussia, PA, 6 Bayer, 

Montville, NJ, 7 Pfizer, St. Louis, MO and 8 HESI, 



UPLC-ESI-MS/MS QUANTITATION OF 

CISPLATIN GUANINE INTRASTRAND 

CROSS LINKS IN OVARIAN CARCINOMA 

CELL LINES. I. M. Abraham, G. Boysen, E. Mutlu, 

S. G. Chaney and J. A. Swenberg. Curriculum in 


Hill, NC. 


MATRIX METALLOPROTEINASE-9 (MMP- 

9)-MEDIATED EXTRACELLULAR MATRIX 

REMODELING CAN BE DETECTED USING 

GRATING COUPLED SURFACE PLASMON 

RESONANCE IMAGING. D. Donaldson, G. 

Marusov and M. Lynes. Molecular and Cell Biology, 



A TIME AND DOSE RESPONSE 

METABONOMICS STUDY OF D-SERINE 

TOXICITY IN RATS. N. V. Reo 1 , A. E. Neuforth 1 , 

W. Couch 1 , M. L. Raymer 1,2 , P. Anderson 1,2 , D. 

Mahle 1,3 and N. J. DelRaso 3 . 1 Biochem & Mol 

Biol, Wright St University Dayton, OH, 2 Computer 

Sciences & Eng, Wright St University Dayton, OH 

and 3 AFRL/RHPB, Wright-Patterson AFB, Dayton, 

OH. 


PLASMA VON WILLEBRAND FACTOR 

PROPEPTIDE (VWFPP) IS A POTENTIAL 

PREDICTIVE DRUG-INDUCED VASCULAR 

INJURY (DIVI) BIOMARKER. D. Brott 1 , R. 

Montgomery 2 , H. Thomas 3 , T. Kelly 1 , A. Katein 1 and 

C. Louden 4 . 1 Global Safety Assessment, AstraZeneca 

Pharmaceuticals, Wilmington, DE, 2 Blood Research 

Institute, Milwaukee, WI, 3 Safety Assessment, 

GlaxoSmithKline Pharmaceuticals, King of Prussia, 

PA and 4 Global Safety Assessment, AstraZeneca 

Pharmaceuticals, Alderley Park, United Kingdom. 


CYTOKINE mRNA PROFILING DIRECTLY 

FROM EX VIVO STIMULATED MOUSE 

WHOLE BLOOD. O. N. Diallo, A. Keightley 

and L. LeSauteur. Toxicology, Charles River Labs, 

Preclinical Services Montreal Inc., Senneville, QC, 

Canada. Sponsor: C. Banks. 


AN ELISA MICROARRAY PLATFORM FOR 

USE IN HIGH-THROUGHPUT SCREENS 

OF BIOLOGICAL FLUIDS. R. M. Gonzalez 1 , 

S. L. Servoss 1 , S. M. Varnum 1 , A. M. White 2 , J. 

R. Collett 1 , D. S. Daly 2 and R. C. Zangar 1 . 1 Cell 

Biology & Biochemistry, Pacific Northwest National 

Laboratory, Richland, WA and 2 Computation 

Mathematics, Pacific Northwest National Laboratory, 

Richland, WA. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: JUVENILE TOXICITY 

Chairperson(s): Bhagavatula Moorthy, Baylor College of Medicine, 

Houston, TX. 




EFFECTS OF CIGARETTE SMOKING 

IN PREGNANCY ON THE PLACENTA 

VASCULOSYNCYTIAL MEMBRANE 

THICKNESS. R. Monroy, J. Bourgeois, D. Shaw, 

K. Morrison, S. Atkinson, K. Teo and W. G. Foster. 

McMaster University, Hamilton, ON, Canada. 


THE CONTRIBUTION OF DENTAL 

AMALGAM TO URINARY MERCURY 

EXCRETION IN CHILDREN. P. L. Simmonds 1 , 

M. D. Martin 2 , B. G. Leroux 3 , T. A. DeRouen 3 , J. G. 

Leitão 4 , M. F. Bernardo 4 , H. S. Luis 4 , J. V. Kushleika 1 

and J. S. Woods 1 . 1 Environmental and Occupational 


WA, 2 Oral Medicine, University of Washington, 

Seattle, WA, 3 Dental Public Health Sciences, 

University of Washington, Seattle, WA and 4 Dental 

Medicine, University of Lisbon, Lisbon, Portugal. 

242 




Abstract # 


DIFFERENCES IN ARSENIC METABOLISM 

BETWEEN MEXICAN BOYS AND GIRLS. 

V. M. Rodriguez 1 , L. Torres Sanchez 2 , L. López 

Carrillo 2 , O. Rojas 3 , J. Alatorre 3 , J. L. Rosado 4 , D. 

Ronquillo 4 , M. Caamaño 4 , G. G. García Vargas 5 , 

P. Lopez 6 , K. Kordas 7 , R. J. Stoltzfus 7 , E. Vera 8 

and M. E. Cebrián 8 . 1 MOUNT SINAI SCHOOL 

OF MEDICINE, NY, NY, 2 INSP, Cuernavaca, 

Morelos, Mexico, 3 UNAM, Mexico, Mexico, 

4 

UAQ, Queretaro, Mexico, 5 UJED, Gomez Palacio, 

Mexico, 6 INCMN, Mexico, Mexico, 7 CORNELL 

UNIVERSITY, NY, NY and 8 Toxicology, 

CINVESTAV-IPN, Mexico, Mexico. 


MASS SPECTROSCOPY, AND NUCLEAR 

MAGNETIC RESONANCE SPECTROSCOPY 

ANALYSES OF OXYLIPIDS, LIPIDS, 

AND AMINO ACIDS IN PLASMA OF 

NON-HUMAN PRIMATES EXPOSED TO 

ENVIRONMENTAL TOBACCO SMOKE 

DURING PERI-NATAL DEVELOPMENT. C. 

Hood 1 , J. Lui 1 , S. Data 1 , B. Hammock 1 , O. Fiehn 1 , R. 

Balhorn 2 and K. Pinketon 1 . 1 University of California, 

Davis, Davis, CA and 2 Lawrence Livermore National 

Laboratories, Livermore, CA. 


SUPPRESSION OF PPARg ACTIVITY 

CAUSES INCREASED PROLIFERATION 

AND DECREASED NEUTROPHIL 

ACCUMULATION IN THE LUNGS OF 

NEWBORN MICE EXPOSED TO >95% O2. 

L. K. Rogers 1,2 , T. E. Tipple 1,2 , L. D. Nelin 1,2 and S. 

E. Welty 1,2 . 1 Pediatrics, The Research Institute at 

Nationwide Children’s Hospital, Columbus, OH and 

2 

The Ohio State University, Columbus, OH. 


LOW-DOSE EXPOSURE OF NEONATAL 

RATS TO THE ANTIMALARIAL, 

b-ARTEETHER (bAE), RESULTS IN 

BRAINSTEM PATHOLOGY WITHOUT 

OBVIOUS BEHAVIORAL CHANGES. R. 

I. Erickson, E. B. Defensor, D. R. Middaugh, R. 

Garcia, J. C. Mirsalis and K. L. Steinmetz. SRI 

International, Menlo Park, CA. 


EXPRESSION PROFILE OF THE MAJOR 

CYTOCHROMES P450 IN NEONATAL 

CD-IGS RATS. L. Nguyen, J. Nash, S. Gagnon, L. 

Pinsonneault and K. Robinson. Toxicology, Charles 

River Labs, Preclinical Services Montreal Inc., 

Senneville, QC, Canada. Sponsor: C. Banks. 


RAT AND DOG CLINICAL PATHOLOGY 

HISTORICAL CONTROL DATA FOR 

NEONATAL AND JUVENILE TOXICOLOGY 

STUDIES. L. Pinsonneault, K. Robinson, L. Pouliot, 

S. Barbeau and M. Adamo-Trigiani. Toxicology, 

Charles River Labs, Preclinical Services Montreal 

Inc., Senneville, QC, Canada. Sponsor: C. Banks. 


INHALATION JUVENILE RAT STUDIES 

CAN BE PERFORMED AS EARLY AS AT 

DAY 4 POSTPARTUM. G. Lewin, R. Fuhst, E. 

Berger-Preiss, G. Pohlmann and J. Buschmann. 

Reproductive Toxicology, Fraunhofer Institute of 

Toxicology and Experimental Medicine, Hannover, 

Germany. Sponsor: H. Muhle. 

Abstract # 


ATTENUATION OF HYPEROXIC LUNG 

INJURY BY THE CYTOCHROME P450 

(CYP)1A INDUCER b-NAPHTHOFLAVONE 

(BNF) IN NEONATAL WILD TYPE AND 

CYP1A2-NULL MICE. X. Couroucli, Y. W. Liang, 

W. Jiang and B. Moorthy. Pediatrics, Baylor College 

of Medicine, Houston, TX. 


TRANSPLACENTAL CARCINOGENESIS 

INDUCED BY MATERNAL EXPOSURE TO 

DIBENZO[A, L]PYRENE: THE ROLE OF 

CYP 1B1. D. J. Castro 1,2,3 , C. B. Pereira 3 , F. J. 

Gonzalez 4 and D. E. Williams 1,2,3 . 1 Environmental 

& Molecular Toxicology, Oregon State University, 

Corvallis, OR, 2 Linus Pauling Institute, Oregon State 

University, Corvallis, OR, 3 Environmental Health 

Sciences Center, Oregon State University, Corvallis, 

OR and 4 Laboratory of Metabolism, National Cancer 



1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: RISK ASSESSMENT APPLICATIONS 

Chairperson(s): Julie Goodman, Gradient Corporation, Cambridge, MA 

and Lisa Sweeney, The Sapphire Group, Dayton, OH. 




THE CHEMICAL SECURITY ANALYSIS 

CENTER: ASSESSING THE HAZARD OF 

CHEMICAL TERRORISM. J. Moser 1,2 , S. N. 

Chesler 1,2 and G. R. Famini 1 . 1 Chemical Security 

Analysis Center, Aberdeen Proving Ground, MD 

and 2 Battelle Memorial Institute, Aberdeen Proving 

Ground, MD. 


A REGIONAL ASSESSMENT OF PEDIATRIC 

TOXICANT EXPOSURES OF CURRENT 

CONCERN. M. Sommargren, R. Birdsong, N. 

Beaudet, S. Sathyanarayana and C. Karr. Pediatrics, 

University of Washington, Seattle, WA. Sponsor: E. 

Faustman. 


FUNGAL SPORES – A NEW CRITERIA 

DOCUMENT FROM THE NORDIC EXPERT 

GROUP. G. Johanson 1 and E. Wijnand 2 . 1 Work 

Environment Toxicology, Karolinska Institute, 

Stockholm, Sweden and 2 National Institute of 

Occupational Health, Oslo, Norway. 


APPLICATION OF THE THRESHOLD OF 

TOXICOLOGICAL CONCERN APPROACH 

TO INHALED MYCOTOXINS. B. D. Hardin and 

B. J. Kelman. Veritox, Redmond, WA. 

Wednesday 




Wednesday 



GENOTOXICITY OF PACLITAXEL – RISK 

ASSESSMENT FROM A MEDICAL DEVICE 

PERSPECTIVE. N. S. Goud 1 , E. E. Reverdy 2 and 

I. Purdy 3 . 1 S. Niranjan Goud, Boston Scientific 

Corporation, Spencer, IN, 2 Edward Reverdy, Boston 

Scientific Corporation, Natick, MA and 3 Ian Purdy, 

Boston Scientific Corporation, Galway, Ireland. 


RISK ASSESSMENT OF A SILVER-BASED 

DEODORANT INGREDIENT - A SIMPLE 

APPROACH REPLACING ANIMAL 

TESTING. Z. Akkan and J. R. Plautz. Ciba 

Specialty Chemicals Inc., Basel, Switzerland. 


ASSESSING NASAL TISSUE DOSIMETRY 

OF NAPHTHALENE WITH A HYBRID CFD- 

PBPK MODEL. J. L. Campbell 1 , T. R. Sterner 3 , J. 

B. Morris 2 and H. J. Clewell 1 . 1 Center for Human 

Health Assessment, The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC, 

2 


Dayton, CT and 3 HJF, Wright-Patterson AFB, OH. 


CHRONIC NONCANCER TOXICITY 

REFERENCE VALUES FOR USE IN 

ETHYLBENZENE RISK ASSESSMENTS. L. 

M. Sweeney 1 , C. R. Kirman 2 , M. L. Gargas 1 and M. 

I. Banton 3 . 1 The Sapphire Group, Dayton, OH, 2 The 

Sapphire Group, Beachwood, OH and 3 Lyondell 

Chemical Company, Rotterdam, Netherlands. 


MODE OF ACTION (MOA) 

EVALUATIONS AND DERIVATION OF 

A CANCER REFERENCE VALUE FOR 

ETHYLBENZENE. C. Kirman 1 , L. Sweeney 2 , 

J. Bus 3 and M. Gargas 2 . 1 The Sapphire Group, 

Beachwood, OH, 2 The Sapphire Group, Dayton, OH 

and 3 Dow Chemical Company, Midland, MI. 


A WEIGHT OF EVIDENCE 

METHODOLOGICAL APPROACH FOR 

DERIVING EVIDENCED-BASED RFCS FOR 

GLUTARALDEHYDE: A CASE STUDY. P. J. 

Spencer, C. S. Barrow, L. G. McFadden and N. Ball. 



DETERMINATION OF A DICHLORVOS- 

SPECIFIC ACUTE INTERSPECIES 

UNCERTAINTY FACTOR. L. M. Plunkett 1 , 

J. MacGregor 2 , T. Starr 3 , S. Youngren 4 and A. 

Manley 5 . 1 Integrative Biostrategies LLC, Houston, 

TX, 2 Toxicology Consulting Services, Arnold, MD, 

3 

TBS Associates, Raleigh, NC, 4 The Acta Group, 

Washington, DC and 5 Amvac Chemical Corporation, 

Commerce, CA. 


RECENT STUDIES OF THE HEALTH 

EFFECTS OF MANGANESE AND THE 

IMPLICATIONS FOR THE REFERENCE 

CONCENTRATION (RFC). J. E. Goodman, L. 

A. Bailey and B. D. Beck. Gradient Corporation, 

Cambridge, MA. 


HUMAN SAFETY RISK ASSESSMENT OF A 

NOVEL POLYMERIC MATERIAL. V. M. Silva. 



APPLICATION OF THE 10% MINIMUM 

ELICITATION THRESHOLD TO 

QUANTITATIVE ASSESSMENT OF DERMAL 

SENSITIZATION RISK TO HEXAVALENT 

CHROMIUM USING THE REPEAT OPEN 

APPLICATION TEST IN HUMANS. T. 

McMahon, J. Chen and J. Liccione. U.S. EPA, 



RISK ASSESSMENT OF ALLERGIC 

CONTACT DERMATITIS DUE TO 

DERMAL EXPOSURES TO HEXAVALENT 

CHROMIUM. D. Proctor 1 , S. Su 4 , J. Gujral 1 , 

J. Fowler 2 and D. Morgan 3 . 1 Exponent, Irvine, 

CA, 2 Department of Dermatology, University of 

Louisville, Louisville, KY, 3 FPRL, Springfield, OR 

and 4 Exponent, New York. 


RISK ASSESSMENT FOR ARSENIC ON 

INDOOR SURFACES. C. A. Williams 1 and C. S. 

Perry 2 . 1 Tetra Tech, Inc., Tallahassee, FL and 2 Tetra 

Tech, Inc., Dallas, TX. 


ASSESSMENT OF THE CARCINOGENIC 

RISK ASSOCIATED WITH THE PRESENCE 

OF NITRATES AND NITRITES IN 

DRINKING WATER. S. Chébékoué 1 , D. Phaneuf 2 , 

P. Levallois 2,3 , M. Rodriguez 4 and R. Tardif 1 . 1 Santé 


Montréal, Montreal, QC, Canada, 2 Institut National 

de Santé Publique du Québec, Québec, QC, Canada, 

3 

Médecine Sociale et Préventive, Université 

Laval, Québec, QC, Canada and 4 École Supérieure 

d’Aménagement du Territoire et de Développement 

Régional, Université Laval, Québec, QC, Canada. 


HEALTH RISK ASSESSMENT OF 

BISPHENOL A (BPA) IN DRINKING WATER. 

C. J. McLellan 1 , G. L. Ball 1 and C. Willhite 2 . 1 NSF 

International, Ann Arbor, MI and 2 State of California, 

Berkeley, CA. 


THE POSSIBLE COMMUNITY HEALTH 

HAZARDS POSED BY EMISSIONS FROM 

AUTOMOBILE TRAFFIC TUNNELS: A 

REVIEW OF THE LITERATURE. K. Fehling 1 , 

J. R. Kuykendall 1 , S. Shaw 1 , D. J. Paustenbach 1 and 

D. Collins 2 . 1 ChemRisk Inc., San Francisco, CA and 

2 

Synergetics, Melbourne, VIC, Australia. 


A PROTOCOL FOR DETERMINING CLEAN- 

UP STANDARDS AT SITES CONTAMINATED 

WITH LOW TOXICITY BARITE (BARIUM 

SULFATE). T. McHugh 1 , J. McGinty 2 and E. 

Higgins 1 . 1 GSI Environmental, Houston, TX and 

2 

Hallibutron Energy Services, Houston, TX. 


VAPOR INTRUSION TO INDOOR AIR AT 

A SITE WITH POLYCYCLIC AROMATIC 

HYDROCARBONS IN SHALLOW SOIL. 

T. Taras 1 , A. LaPierre 2 , M. Wade 1 , P. Wong-Yim 1 , 

B. Davis 1 , M. Dalrymple 1 and J. Polisini 1 . 1 Toxic 

Substances Control, California Environmental 

Protection Agency, Sacramento, CA and 2 Iris 

Environmental, Oakland, CA. 

244 




Abstract # 


CHARACTERIZATION OF CANCER 

RISK ASSOCIATED WITH MEASURED 

AIRBORNE BENZENE LEVELS IN THE 

STATE OF FLORIDA. G. T. Johnson, S. C. 

Harbison, J. McCluskey and R. D. Harbison. Center 

for Environmental/Occupational Risk Analysis and 

Management, College of Public Health - University 

of South Florida, Tampa, FL. 


COMPARISON OF CONGENER-SPECIFIC 

AND AROCLOR QUANTITATION 

METHODS FOR ASSURING REMEDIATION 

OF POLYCHLORINATED BIPHENYLS 

AND ASSOCIATED DIBENZOFURANS AT 

A FORMER WASTEWATER TREATMENT 

PLANT. T. L. Copeland 1 , P. Black 2 , P. Duffy 2 , 

D. O’Hehir 3 , A. P. DeCaprio 4 and B. D. Kerger 5 . 

1 

Private Consultant, Agoura Hills, CA, 2 Neptune and 

Company, Lakewood, CO, 3 State University of New 

York, Albany, NY, 4 University of Massachusetts, 

Amherst, MA and 5 Health Science Resource 

Integration, Tallahassee, FL. 


MICROBIAL RISK ASSESSMENT FOR 

RECREATIONAL USE OF CHICAGO AREA 

WATERWAYS. J. K. Tolson 1 , M. DeFlaun 1 , R. 

Lanyon 2 , T. C. Granato 2 , G. Rijal 2 , C. Gerba 3 and C. 

Petropoulou 1 . 1 GeoSyntec Consultants, Tampa, FL, 

2 

Metropolitan Water Reclamation District of Greater 

Chicago, Chicago, IL and 3 University of Arizona, 

Tucson, AZ. 


HUMAN HEALTH RISKS ASSOCIATED 

WITH EXPOSURE TO PATHOGENS IN 

WATERS AND SEDIMENTS OF THE LOWER 

PASSAIC RIVER. D. F. Staskal 1 , E. P. Donovan 2 , 

K. M. Unice 3 , L. C. Haws 1 , J. Roberts 2 , B. Finley 2 

and M. Harris 4 . 1 ChemRisk, Austin, TX, 2 ChemRisk, 

SanFrancisco, CA, 3 ChemRisk, Pittsburgh, PA and 

4 

ChemRisk, Houston, TX. 


IRON DEFICIENCY AS MODE OF ACTION 

FOR RAT ORAL CAVITY NEOPLASMS 

IN 2007 NATIONAL TOXICOLOGY 

PROGRAM DRINKING WATER STUDY 

OF HEXAVALENT CHROMIUM. M. Suh, D. 

Hamai, N. M. Gatto and D. M. Proctor. Exponent, 

Irvine, CA. 


CHRONIC PERCHLOROETHYLENE 

EXPOSURE IN TWO DIFFERENTLY 

SENSITIVE GROUPS: A META-ANALYSIS. 

V. A. Benignus, P. J. Bushnell and W. K. Boyes. 




HEALTH OF CATTLE AND WILDLIFE 

DOWNWIND FROM GAS FACILITIES: THE 

WESTERN CANADA STUDY. T. L. Guidotti 1,2 

and C. Waldner 3,2 . 1 Env & Occ Health, George 

Washington University, Washington, DC, 2 Western 

Interprovincial Scientific Studies Association, 

Calgary, AB, Canada and 3 Western College of 

Veterinary Medicine, University of Saskatchewan, 

Saskatoon, SK, Canada. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: NEUROTOXICITY: MISCELLANEOUS 

COMPOUNDS, MODELS, AND MECHANISMS 

Chairperson(s): Christopher Toscano, National Institutes of Health, 

Bethesda, MD and Mohamed Abou-Donia, Duke University Medical 

Center, Durham, NC. 




CORTICOSTERONE PRETREATMENT 

ATTENUATES NEURODEGENERATION 

AND BLOOD-BRAIN BARRIER 

DISRUPTION FOLLOWING EXCITOTOXIC 

DAMAGE FROM KAINIC ACID. S. A. 

Benkovic, J. P. O’Callaghan and D. B. Miller. 

TMBB, CDC-NIOSH, Morgantown, WV. 


ACUTE NEUROTOXICITY STUDY OF 

1, 2-DICHLOROETHANE (ETHYLENE 

DICHLORIDE; EDC) VIA INHALATION 

IN F344 RATS. A. K. Andrus, J. A. Hotchkiss, 

S. M. Krieger, K. A. Johnson and J. P. Maurissen. 

Toxicology & Environmental Research and 


MI. 


NERAMEXANE LACKS INTERACTION 

WITH DONEPEZIL AND RIVASTIGMINE AT 

THE ACETYLCHOLINESTERASE LEVEL 

IN DISCRETE BRAIN REGIONS. A. Dekundy 1 

and R. C. Gupta 2 . 1 In Vivo Pharmacology, Merz 

Pharmaceuticals GmbH, Frankfurt, Germany and 

2 

Toxicology, Murray State University, Hopkinsville, 

KY. 


PERSISTENT EFFECTS OF REPEATED 

INHALATION OF TOLUENE: 4 WEEKS 

VS. 13 WEEKS. T. E. Samsam 1 , W. K. Boyes 1 , 

L. L. Degn 1 , P. A. Evansky 2 and P. J. Bushnell 1 . 

1 

Neurotoxicology Division, U.S. EPA, RTP, NC and 

2 

Experimental Toxicology Division, U.S. EPA, RTP, 

NC. 


EFFECT OF ACRYLONITRILE 

INTOXICATION ON BRAIN ENERGY 

METABOLISM. F. W. Benz and C. Campian. 


Louisville Medical School, Louisville, KY. Sponsor: 

W. Waddell. 


SCREENING THE ACTIVATION STATE OF 

MULTIPLE PHOSPHOPROTEINS REVEALS 

THE IN VIVO IMPACT OF STRESSORS 

ON BRAIN SIGNALING PATHWAYS 

CONTROLLING CELLULAR STRUCTURE. 

D. B. Miller and J. P. O’Callaghan. HELD, CDC- 

NIOSH, Morgantown, WV. 

Wednesday 




Wednesday 



EFFECTS OF DIETHYL MALEATE 

PRECONDITIONING ON THE EXPRESSION 

OF DNA REPAIR GENES IN MIDBRAIN 

ELICITED BY OCHRATOXIN-A. V. 

Sava 2 , R. D. Harbison 1 and J. Sanchez-Ramos 2 . 

1 

Environmental and Occupational Health, USF- 

COPH, Tampa, FL and 2 Neurology, University of 

South Florida College of Medicine, Tampa, FL. 


EFFECTS OF 4-HYDROXY-2-NONENAL ON 

NEUROTRANSMITTER TRANSPORT AND 

VESICULAR STORAGE IN RAT STRIATAL 

SYNAPTOSOMES. R. LoPachin 1 , B. Geohagen 1 

and T. Gavin 2 . 1 Anesthesiology, Albert Einstein 

College of Medicine, Bronx, NY and 2 Chemistry, 

Iona College, New Rochelle, NY. 


NEUROPROTECTIVE EFFECTS OF MIXED 

TOCOPHEROLS IN ANIMAL MODELS OF 

PARKINSON’S DISEASE. J. Kochar 1 , C. Becker 1 , 

H. Newmark 2 , C. S. Yang 2 and M. Thiruchelvam 1 . 

1 

Environmental & Occupational Medicine, 

Robert Wood Johnson Medical School - UMDNJ, 

Piscataway, NJ and 2 Chemical Biology, Rutgers 

University, Piscataway, NJ. 


PROTEIN MODIFICATION IN RAT 

STRATIAL SYNAPTOSOMES AS A RESULT 

OF THE INHIBITION OF DOPAMINE 

METABOLISM BY PRODUCTS OF 

OXIDATIVE STRESS. J. N. Rees, V. Florang 

and J. A. Doorn. Medicinal and Natural Products 

Chemistry, The University of Iowa, Iowa City, IA. 


HUMAN PROSTAGLANDIN H SYNTHASE 

(hPHS )-1 AND hPHS-2-DEPENDENT 

PROTEIN AND DNA OXIDATION CAUSED 

BY DOPAMINE, ITS PRECURSOR AND 

METABOLITES. A. Ramkissoon 1 and P. G. 

Wells 1,2 . 1 Pharmaceutical Sciences, University of 

Toronto, Toronto, ON, Canada and 2 Pharmacology 

and Toxicology, University of Toronto, Toronto, ON, 

Canada. 


ALTERED GABAERGIC 

NEUROTRANSMISSION IS ASSOCIATED 

WITH INCREASED SUSCEPTIBILITY TO 

NMDA-INDUCED EXCITOTOXICITY IN 

CYCLOOXYGENASE-2 DEFICIENT MICE. 

C. D. Toscano 1 , S. Vicini 2 and F. Bosetti 1 . 1 National 

Institute on Aging/ Brain Physiology and Metabolism 

Section, National Institutes of Health, Bethesda, 

MD and 2 Department of Physiology and Biophysics, 

Georgetown University, Washington, DC. 


PROTEOMIC PROFILING OF PROXIMAL 

MURINE GIANT AXONOPATHY. D. Tshala- 

Katumbay 1,2 , V. Monterroso 3 , R. Kayton 1 , P. 

Spencer 1,2 and M. I. sabri 1,2 . 1 CROET, Oregon Health 

& Science University, Portland, OR, 2 Neurology, 

Oregon Health & Science University, Portland, 

OR and 3 Comparative Medicine, Oregon Health & 

Science University, Portland, OR. 


EFFECT OF 1-BROMOPROPANE 

EXPOSURE ON GENE EXPRESSION OF 

NEUROTRANSMITTER RECEPTORS IN 

RAT. S. Sheik Mohideen 1 , S. Ichihara 2 , F. Liu 1 , K. 

Furuhashi 1 , W. Li 3 and G. Ichihara 1 . 1 Occupational 

and Environmental Health, Nagoya University 

Graduate School of Medicine, Nagoya, Japan, 

2 

Human Functional Genomics, Mie University, Tsu, 

Japan and 3 Shanghai Institute of Planned Parenthood 

Research, Shanghai, China. 


MEASURES OF MPTP BRAIN DOPAMINE 

NEUROTOXICITY. E. F. Domino and L. Ni. 

Pharmacology, University of Michigan, Ann Arbor, 

MI. 


VOODOO WASP TOXINS AND ZOMBIE 

COCKROACHES. C. Banks 1 and M. E. Adams 2,3 . 

1 

Department of Environmental Toxicology, 

University of California Riverside, Riverside, CA, 

2 

Department of Entomology, University of California 

Riverside, Riverside, CA and 3 Department of Cell 

Biology and Neuroscience, University of California 



ACUTE BEHAVIORAL EFFECTS OF 

INHALED PERCHLOROETHYLENE IN 

RATS ARE DIRECTLY RELATED TO ITS 

CONCENTRATION IN THE BRAIN. W. M. 

Oshiro 1 , Q. T. Krantz 2 , E. M. Kenyon 2 and P. J. 

Bushnell 1 . 1 Neurotoxicology Division, U.S. EPA, 

Research Triangle Park, NC and 2 Experimental 

Toxicology Division, U.S. EPA, Research Triangle 

Park, NC. 


ACUTE INHALATION OF 2, 2, 

4-TRIMETHYLPENTANE ALTERS VISUAL 

EVOKED POTENTIALS AND SIGNAL 

DETECTION BEHAVIOR OF RATS. W. K. 

Boyes 1 , L. L. Degn 1 , M. Bercegeay 1 , W. Oshiro 1 , 

T. Krantz 2 and P. J. Bushnell 1 . 1 Neurotoxicology, 

EPA, Research Triangle Park, NC and 2 Experimental 

Toxicology, EPA, Research Triangle Park, NC. 


CIRCADIAN CONTROL OF THE RAPID 

DEVELOPMENT OF TOLERANCE OR 

HYPER-REACTIVITY TO ETHANOL 

INDUCED SLEEP TIME IN RATS. R. L. 

Williams 1,2 and K. F. Soliman 2 . 1 DHHS, Agency for 

Toxic Substances and Disease Registry, Atlanta, GA 

and 2 Florida A&M University College of Pharmacy 

and Pharmaceutical Sciences, Tallahassee, FL. 


TOLERANCE TO ANATOXIN-A AND 

NICOTINE ON OPERANT BEHAVIOR: A 

SEARCH FOR MECHANISMS. K. A. Jarema, J. 

D. Farmer and R. C. MacPhail. NHEERL, U.S. EPA, 


246 




Abstract # 


USE OF AN ORGANOTYPIC CULTURE 

SYSTEM TO STUDY THE ACTIONS 

OF MICROGLIA IN THE PRESENCE 

OF NEURONS EXPRESSING MUTANT 

HUNTINGTIN PROTEIN FRAGMENTS. A. 

D. Kraft 1 , G. J. Turmel 2 , D. C. Lo 2 and G. Harry 1 . 

1 


Research Triangle Park, NC and 2 Duke University, 

Durham, NC. 


MECHANISM AND TREATMENT OF 

SULFIDE-INDUCED COMA: A RAT MODEL. 

T. L. Guidotti 1,2 , A. Almeida 2 and P. N. Nation 2 . 

1 

Env & Occ Health, George Washington University, 

Washington, DC and 2 Public Health Sciences, 

University of Alberta, Edmonton, AB, Canada. 


VALIDATION OF NEW PHOTOBEAM 

ACTIVITY SYSTEM USING ACRYLAMIDE 

IN WISTAR RATS. B. S. Trada, P. B. Deshmukh 

and V. K. Tiwari. Toxicology and Pharmacology, Jai 

Research Foundation, Vapi, Gujarat, India. 


SNC-34 CELLS AS A MODEL OF 

MOTORNEURON EXCITOTOXICITY. K. 

Koski 3,1 , F. Vega 2,1 , R. K. Hajela 1 and B. Atchison 1,3 . 

1 

Pharmacology/Toxicology, Michigan State 

University, East Lansing, MI, 2 RISE Program, 

University of Puerto Rico, Cayey, Cayey, PR and 

3 

College of Veterinary Medicine, Michigan State 



ESTROGEN INCREASES TRANSTHYRETIN 

PRODUCTION IN, BUT NOT SECRETION 

FROM, THE CHOROID PLEXUS. J. S. 

Crossgrove 1 and R. E. Wright 2 . 1 Raabe College 

of Pharmacy, Ohio Northern University, Ada, OH 

and 2 Department of Biological and Allied Health 

Sciences, Ohio Northern University, Ada, OH. 


STANDARDISATION OF A QUANTITATIVE 

METHOD TO ASSESS NEURITE 

ELONGATION IN CULTURED RAT DORSAL 

ROOT GANGLIA (DRG). A. Nicolli 1 , A. Moretto 2 

and M. Lotti 1 . 1 Environmental Medicine and Public 

Health, University of Padova, Padova, Italy and 

2 

Occupational Medicine, University of Milano, 

Milano, Italy. 


UNCOUPLING PROTEIN-2 

UP-REGULATION ENHANCES 


DEPLETION IN CYANIDE-INDUCED 

CYTOTOXICITY. X. Zhang, L. Li, K. 

Prabhakaran, L. Zhang, H. B. Leavesley, J. L. 

Borowitz and G. E. Isom. Medicinal Chemistry and 

Molecular Pharmacology, Purdue University, W 

Lafayette, IN. 


NEUROTOXICITY AND NEPHROTOXICITY 

OF AMPHOTERICIN MONO-METHYL 

ESTER. O. U. Nnodi 1,2 , C. P. Schaffner 3 and K. 

R. Reuhl 1,2 . 1 pharmacology & toxicology, Rutgers 

university piscataway NJ, Piscataway, NJ, 2 JGPT, 

Rutgers, Piscataway, NJ and 3 Waksman Institute of 

Microbiology, Rutgers, Piscataway, NJ. 

Abstract # 


ASTOROGLIAL DYSREGULATION 

OF VEGF EXPRESSION AFTER LPS 

TREATMENT IN DJ-1 KNOCKOUTS. T. 

Katoh 1 , A. K. Ashley 2 , M. E. Legare 1,2 and W. H. 

Hanneman 1,2 . 1 Environmental and Radiological 

Health Sciences, Colorado State University, Fort 

Collins, CO and 2 Cell and Molecular Biology, 



RELEASE OF ENDOGENOUS 

DOPAMINE NEUROTOXIN 3, 

4-DIHYDROXYPHENYLACETALDEHYDE 

(DOPAL) IN METHAMPHETAMINE (METH) 

TREATED PC6-3 CELLS. Y. Jinsmaa, V. Florang 

and J. Doorn. University of Iowa, Iowa City, IA. 


IN VITRO MITOCHONDRIAL PROTEIN 

CARBONYLATION IN DITNC1 CELLS 

EXPOSED TO 1, 3-DINITROBENZENE. S. 

R. Steiner and M. Philbert. University of Michigan 

School of Public Health, Ann Arbor, MI. 


PROTEIN REACTIVITY AND ISOLATION 

OF DOPAMINE OXIDATION PRODUCTS. 

D. G. Anderson, V. R. Florang and J. A. Doorn. 

Medicinal and Natural Products Chemistry, The 



GENE EXPRESS PROFILING MULTIPLEX 

QUANTITATIVE PCR ON AMPLIFIED 

RNA. J. B. Eells. Department of Basic Sciences, 

Mississippi State University, Mississippi State, MS. 

Sponsor: M. Ross. 


NEAR-INFRARED LIGHT TREATMENT 

ATTENUATES THE TOXIC EFFECTS 

OF MPTP IN A RODENT MODEL OF 

PARKINSON’S DISEASE. K. D. DeSmet 1 , E. 

Buchmann 2 , M. Henry 2 , H. T. Whelan 2,1 and J. T. 

Eells 1,2 . 1 Clinical Laboratory Sciences, University 

of Wisconsin-Milwaukee, Milwaukee, WI and 

2 

Neurology, Medical College of Wisconsin, 



NEUROTOXICITY STUDY DESIGN: THE 

ESSENTIAL ELEMENT OF LOCATION. 

R. C. Switzer and C. L. Franssen. NeuroScience 

Associates, Inc., Knoxville, TN. Sponsor: D. Miller. 


DELAYED SYSTEMIC ADMINISTRATION 

OF A NEW-GENERATION FATTY ACID 

AMIDE HYDROLASE INHIBITOR 

IS NEUROPROTECTIVE AGAINST 

EXCITOTOXIC SEIZURES, FUNCTIONAL 

COMPROMISE, AND BRAIN DAMAGE. B. 

A. Bahr 1,2 , D. A. Karanian 1,2 , S. P. Nikas 2 , J. Zhao 2 , 

J. Hwang 1 , R. Kwon 1 , A. Colon 1 , J. E. Manautou 1 

and A. Makriyannis 2 . 1 Department of Pharmaceutical 

Sciences and the Neurosciences Program, University 

of Connecticut, Storrs, CT and 2 Center for Drug 

Discovery, Northeastern University, Boston, MA. 

Wednesday 




Wednesday 



CHANGES IN mRNA EXPRESSION 

PROFILES IN RAT CORTEX AND 

STRIATUM FOLLOWING SUB-CHRONIC 

TOLUENE EXPOSURE. A. F. Johnstone, S. D. 

Hester, W. K. Boyes, P. J. Bushnell, C. A. Meacham 

and T. J. Shafer. NTD, EPA, Durham, NC. 


EVALUATION OF MEMORY FUNCTION IN 

RATS: A COMPARISON OF WATER MAZE 

AND OBJECT RECOGNITION TASKS. P. 

Lainée, A. Lodiot, P. Rousseau, G. Froget and R. 

Forster. CIT, Evreux, France. 


MITOCHONDRIAL RESPIRATORY 

INHIBITORS SENSITIZE ORGANOTYPIC 

HIPPOCAMPAL SLICE CULTURES TO 

EXCITOTOXICITY-INDUCED CELL DEATH. 

R. A. Schuh 1,2 , T. Kristian 3 , C. Matthews 1,2 and P. 

Fishman 1,2 . 1 Research, VA Maryland Health Care 

System, Baltimore, MD, 2 Neurology, University of 

Maryland School of Medicine, Baltimore, MD and 

3 

Anesthesiology, University of Maryland School of 

Medicine, Maryland. 


DISTRIBUTION OF 14C-PARAQUAT IN 

BRAIN AND BODY TISSUES OF C57BL/6 

MICE USING PBPK MODELING AND 

AUTORADIOGRAPHY TOWARD AN 

ANALYSIS OF PARKINSON’S DISEASE- 

PATTERNED NEURODEGENERATION. L. 

McIntosh 1 , A. A. Li 2 and G. L. Kedderis 3 . 1 Exponent, 

Inc., Menlo Park, CA, 2 Exponent, Inc., Oakland, CA 

and 3 Consultant, Chapel Hill, NC. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: METAL NEUROTOXICOLOGY: 

EXPERIMENTAL MODELS AND MECHANISMS 

Chairperson(s): Diana Echeverria, Battelle CPHRE, Seattle, WA and 

Hassan El-Fawal, Mercy College, Dobbs Ferry, NY. 




METHYLMERCURY (MEHG) TOXICITY 

IN POSTNATAL RAT HIPPOCAMPUS IS 

ASSOCIATED WITH ACTIVATION OF THE 

MITOCHONDRIAL APOPTOTIC PATHWAY. 

K. B. Sokolowski 1,2 , A. Falluel-Morel 2 and E. Dicicco- 

Bloom 1,2 . 1 Joint Graduate Program in Toxicology, 

Rutgers, Piscataway, NJ and 2 Neuroscience and Cell 

Biology, Robert Wood Johnson Medical School, 



METHYLMERCURY INDUCES 

ALZHEIMER’S DISEASE-LIKE TAU 

PHOSPHORYLATION IN MOUSE BRAIN. M. 

Fujimura 1 , M. Sawada 1 and A. Takashima 2 . 1 Basic 

Medical Sciences, National Institute for Minamata 

Disease, Minamata, Kumamoto, Japan and 2 Lab for 

Alzheimer’s Disease, RIKEN Brain Science Institute, 

Wako, Saitama, Japan. Sponsor: A. Naganuma. 


ANALYSIS OF NEUROBEHAVIORAL 

DEVELOPMENT EFFECTS ON MICE AFTER 

TREATMENT WITH METHYLMERCURY 

DURING POSTNATAL BRAIN GROWTH 

SPURT. Y. Gao, T. Ying, D. Yu and S. Rong. 

Environmental Health, Shanghai Jiao Tong 

University School of Medicine, Shanghai, China. 


METHYLMERCURY INHIBITS NITRIC 

OXIDE SIGNAL TRANSDUCTION IN 

DEVELOPING MOUSE CEREBELLAR 

CELLS. D. Arias-Salvatierra 1 , L. C. Acosta- 

Saavedra 1 , E. K. Silbergeld 2 and E. S. 

Calderon-Aranda 1 . 1 Toxicologia, Cinvestav, Mexico, 

DF, Mexico and 2 Bloomberg School of Public 

Health, Johns Hopkins University, Baltimore, MD. 


MERCURY MODIFIES LPS-INDUCED GENE 

EXPRESSION IN DEVELOPING MOUSE 

CEREBELLAR CELL CULTURES. E. K. 

Silbergeld 1 , A. E. Jedlika 1 , L. C. Acosta-Saavedra 2 , A. 

S. Scott 1 and E. S. Calderon-Aranda 1,2 . 1 Bloomberg 

School of Public Health, Johns Hopkins University, 

Baltimore, MD and 2 Toxicologia, Cinvestav, Mexico, 

DF, Mexico. 


METHYLMERCURY INCREASES 

N-METHYL-D-ASPARTATE RECEPTORS 

ON SH-SY 5Y NEUROBLASTOMA CELLS 

LEADING TO NEUROTOXICITY. N. Leopold 

and H. Laurie. Community Health, University of 

Northern British Columbia, Prince George, BC, 

Canada. 


METHYLMERCURY DECREASES ERK1/2, 

p38 AND TAK1 PHOSPHORYLATION IN 

DEVELOPING MOUSE CEREBELLAR 

CELLS. B. Luque 1 , D. Arias-Salvatierra 1 , L. C. 

Acosta-Saavedra 1 , E. K. Silbergeld 2 and E. S. 

Calderon-Aranda 1 . 1 Toxicologia, Cinvestav, Mexico, 

DF, Mexico and 2 Bloomberg School of Public 

Health, Johns Hopkins University, Baltimore, MD. 


METHYLMERCURY DECREASES 

NF-kappaB NUCLEAR TRANSLOCATION IN 

CEREBELLAR ORGANOTYPIC CULTURES 

IN VITRO. E. S. Calderon-Aranda 1 , D. Arias- 

Salvatierra 1 , L. C. Acosta-Saavedra 1 and E. K. 

Silbergeld 2 . 1 Toxicologia, Cinvestav, Mexico, DF, 

Mexico and 2 Bloomberg School of Public Health, 




METHYLMERCURY AND TOLUENE ON 

SYNAPTIC TRANSMISSION IN VISUAL 

CORTEX SLICES OF RAT. S. Dasari and Y. 

Yuan. Pharmacology/Toxicology, Neuroscience 

Program, Michigan State University, East Lansing, 

MI. 

248 




Abstract # 


COMPARATIVE GENE EXPRESSION 

ANALYSIS IN C57 MOUSE EMBRYOS 

UNDERGOING NEURULATION EXPOSED 

TO CADMIUM AND METHYLMERCURY. 

J. F. Robinson, X. Yu, S. Hong, R. Beyer and E. M. 

Faustman. Environmental and Occupational Health 

Sciences, University of Washington, Seattle, WA. 


TEMPORAL PATTERN OF INCREASED 

OXIDATIVE DNA DAMAGE IN MURINE 

FETAL BRAIN AFTER IN UTERO 

EXPOSURE TO METHYLMERCURY. K. Lam 1 , 

G. P. McCallum 2 and P. G. Wells 2,1 . 1 Pharmacology 

and Toxicology, University of Toronto, Toronto, ON, 

Canada and 2 Pharmaceutical Sciences, University of 

Toronto, Toronto, ON, Canada. 


METHYLMERCURY NEUROTOXICITY: 

ANALYSIS IN NOVEL GENETIC MODELS 

AND PRIMARY CULTURES. R. M. Nass 1 , T. 

Henry 2 , K. Grimes 1 and K. Braun 3 . 1 Department 

of Pediatrics, Vanderbilt University Medical 

Center, Nashville, TN, 2 Center for Environmental 

Biotechnology, The University of Tennessee, 

Knoxville, TN and 3 Department of Zoology/ 

Developmental Neurobiology, Otto von Guericke 

University, Magdeburg, Germany. 


MATERNAL METHYLMERCURY FROM A 

WILD-CAUGHT WALLEYE DIET INDUCES 

DEVELOPMENTAL ABNORMALITIES IN 

ZEBRAFISH. Q. Liu 1 , M. L. Rise 2,1 , D. Weber 1 , 

M. Dellinger 1 , J. Dellinger 1 , S. L. Gerstenberger 3 

and M. J. Carvan 1 . 1 University of Wisconsin- 

Milwaukee, Milwaukee, WI, 2 Memorial University 

of Newfoundland, St. John’s, NF, Canada and 

3 

University of Nevada Las Vegas, Las Vegas, NV. 


NEUROCHEMICAL BIOMARKERS TO 

ASSESS THE RISKS OF MERCURY IN 

NATURE USING COMPARATIVE AND 

INTEGRATIVE APPROACHES. N. Basu. 

Department of Environmental Health Sciences, 

University of Michigan, Ann Arbor, MI. 


NEUROCHEMICAL EFFECTS OF 

METHYLMERCURY ON GLUTAMATE AND 

GABA RECEPTORS – FROM THE BENCH 

TO THE FIELD. L. Chan 3 , T. Scheuhammer 2 and 

N. Basu 1 . 1 Department of Environmental Health 

Sciences, University of Michigan, Ann Arbor, 

MI, 2 National Wildlife Research Center, Ottawa, 

ON, Canada and 3 University of Northern British 

Columbia, Prince George, BC, Canada. 


DENTAL MERCURY EXPOSURE, 5-HTTLTR 

STATUS, AND ASSOCIATIONS WITH SELF- 

REPORTED SYMPTOMS. N. J. Heyer 1 , D. 

Echeverria 1,2 , J. S. Woods 2 , F. M. Farin 2 and T. Li 2 . 

1 

Center for Public Health Research and Evaluation, 

Battelle CPHRE, Seattle, WA and 2 Department of 

Environmental Health, University of Washington, 

Seattle, WA. 

Abstract # 


MANGANESE EXPOSURE INDUCES 

ALZHEIMER’S–LIKE PATHOLOGY IN 

THE FRONTAL CORTEX OF NON-HUMAN 

PRIMATES. T. Verina 1 , J. S. Schneider 2 and T. R. 

Guilarte 1 . 1 Environmental Health Sciences, Johns 

Hopkins University Bloomberg School of Public 

Health, Baltimore, MD and 2 Pathology, Anatomy 

and Cell Biology, Thomas Jefferson University, 

Philadelphia, PA. 


NEUROIMAGING OF DOPAMINERGIC 

SYNAPSES IN THE STRIATUM OF 

MANGANESE-EXPOSED NON-HUMAN 

PRIMATES. J. L. McGlothan 1 , N. C. Burton 1 , Y. 

Zhou 2 , M. Alexander 2 , D. F. Wong 2 , L. D. Pham 3 , 

M. E. Griswold 3 , T. Syversen 4 , J. S. Schneider 5 

and T. R. Guilarte 1 . 1 Env Hlth Sci, Johns Hopkins 

Bloomberg School of Public Health, Baltimore, MD, 

2 

Radiology, Johns Hopkins Hospital, Baltimore, MD, 

3 

Biostatistics, Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD, 4 Neuroscience, 

Norwegian Univ Sciences & Technol, Trondheim, 

Norway and 5 Pathol, Anat, & Cell Bio, Thomas 

Jefferson University Philadelphia, PA. 


NEUROPATHOLOGICAL ANALYSIS OF 

GLIAL INFLAMMATORY RESPONSES TO 

MANGANESE-INDUCED NEUROTOXICITY 

IN DEVELOPING MICE. K. A. Sullivan 1 , K. 

Streifel 1 , J. A. Moreno 1,2,3 and R. B. Tjalkens 1,2,3 . 

1 

Toxicology Section, Colorado State University, 

Fort Collins, CO, 2 Cellular and Molecular Biology, 


3 




MANGANESE EXPOSURE ALTERS GABA 

AND NOREPINEPHRINE TRANSPORTER 

PROTEIN EXPRESSION IN THE 

DEVELOPING RAT BRAIN. J. Anderson and K. 

Erikson. Nutrition, UNC-Greensboro, Greensboro, 

NC. 


IRON CLEARANCE IN THE 

CEREBROSPINAL (CSF) OF RAT BRAINS AS 

AFFECTED BY MANGANESE EXPOSURE 

BY VENTRICULO-CISTERNAL BRAIN 

PERFUSION. X. Wang 1 , Y. Zhang 2 and W. Zheng 2 . 

1 

Laboratory of Pharmacology and Chemistry, 


Research Triangle Park, NC and 2 Health Sciences, 

Purdue University, West Lafayette, IN. 


MANGANESE DISRUPTION OF 

MITOCHONDRIAL RESPIRATION IN THE 

BIVALVE CRASSOSTREA VIRGINICA AND 

ITS PROTECTION BY P-AMINOSALICYLIC 

ACID. K. Davis 1 , C. Saddler 2 , M. A. Carroll 1 and 

E. J. Catapane 1 . 1 Biology, Medgar Evers College, 

Brooklyn, NY and 2 Biology, Kingsborough 

Community College, Brooklyn, NY. Sponsor: C. 

Miller. 

Wednesday 




Wednesday 



EFFECTS OF BLOCKING AGENTS 

ON MANGANESE AND CADMIUM 

ACCUMULATIONS IN GILL OF THE 

EASTERN OYSTER, CRASSOSTREA 

VIRGINICA. Y. Perdomo, M. Yates, M. A. Carroll 

and E. J. Catapane. Biology, Medgar Evers College, 

Brooklyn, NY. Sponsor: C. Miller. 


ENHANCED PERIPHERAL AND CENTRAL 

INFLAMMATION IN MANGANESE 

EXPOSED MICE THAT WERE 

CHALLENGED WITH LPS. R. B. Pringle 1 , 

D. M. Budreckis 1 , D. Milatovic 3 , M. Aschner 3 , 

L. Bennett 2 and N. M. Filipov 1 . 1 CEHS, Basic 


State, MS, 2 Pathobiology and Population Medicine, 

Mississippi State University, Mississippi State, MS 

and 3 Department of Pediatrics, Vanderbilt University 

Medical Center, Nashville, TN. 


ALZHEIMER’S DISEASE BIOMARKER, 

AMYLOID-BETA, IN THE BLOOD AND 

BRAIN OF DEVELOPMENTALLY LEAD 

EXPOSED MICE. R. S. Dosunmu and N. H. Zawia. 

Biomedical and Pharmaceutical Sciences, University 

of Rhode Island, Kingston, RI. 


LIFETIME EXPOSURE TO LEAD AND 

STRESS: CONSEQUENCES FOR THE HPA 

AXIS AND BRAIN NEUROCHEMISTRY. D. 

A. Cory-Slechta 1 , A. Rossi-George 2 , M. B. Virgolini 2 , 

M. Thiruchelvam 2 , D. Weston 1 and R. Lisek 2 . 

1 

Environmental Medicine, University of Rochester 

School of Medicine and Dentistry, Rochester, NY 

and 2 EOHSI, UMDNJ and Rutgers, Piscataway, NJ. 


LEAD (Pb 2+ ) EXPOSURE ALTERS 

DEVELOPING GLUTAMATERGIC 

SYNAPSES IN CULTURED HIPPOCAMPAL 

NEURONS. A. P. Neal and T. R. Guilarte. 


University Bloomberg School of Public Health, 



HIPPOCAMPAL NEUROGENESIS AND 

BDNF FUNCTION ARE IMPAIRED BY 

CHRONIC LEAD EXPOSURE. S. M. Lasley 1 , 

J. H. Goodman 2 , K. R. Vietti 1 , P. W. Wang 3 , L. 

C. Wang 1 , M. Nudel 2 and M. E. Gilbert 4 . 1 Cancer 

Biology & Pharmacology, University of Illinois 

College of Medicine, Peoria, IL, 2 CNRRR, Helen 

Hayes Hosp., W. Haverstraw, NY, 3 Physics, Bradley 

U., Peoria, IL and 4 Neurotoxicology, U S EPA, RTP, 

NC. 


IDENTIFICATION AND EVALUATION OF 

CHRONIC LOW-LEVEL LEAD TOXICITY 

BIOMARKERS IN NEONATAL RATS. R. U. 

Parikh and M. E. Gillespie. College of Pharmacy 

and Allied Health Professions, St. John’s University, 

Queens, NY. 


CHRONIC LOW-LEVEL LEAD ACETATE 

(PBAC2) EXPOSURE DISRUPTS 

LOCOMOTOR ACTIVITY AND THYROID 

HORMONE LEVELS IN THE MALE 

ALBINO RAT (PRELIMINARY RESULTS). 

V. M. Rodriguez 1 , L. Carrizales 3 , P. Villalobos 2 , 

M. Mendoza 1 , C. Valverde 2 and M. Giordano 1 . 

1 

Behavioral and Cognitive Neurobiology, INB- 

UNAM, Juriquilla, Queretaro, Mexico, 2 Cellular and 

Molecular Neurobiology, INB-UNAM, Juriquilla, 

Queretaro, Mexico and 3 Environmental Toxicology, 

UASLP, San Luis Potosi, Mexico. 


LOW-LEVEL HUMAN EQUIVALENT 

GESTATIONAL LEAD EXPOSURE 

PRODUCES GENDER-SPECIFIC MOTOR 

AND COORDINATION ABNORMALITIES 

AND LATE-ONSET OBESITY IN YEAR-OLD 

MICE. L. Leasure 1 , A. Giddabasappa 1 , S. Chaney 1 , 

J. E. Johnson 2,1 , K. Pothakos 1 , Y. S. Lau 1 and D. 

A. Fox 1 . 1 University of Houston, Houston, TX and 

2 

University of Houston-Downtown, Houston, TX. 


OXIDATIVE STRESS (OS) AND 

NEUROTOXICITY: ANTIBODIES IN 

RATS EXPOSED TO ORGANOMETAL 

ELECTROPHILES. G. Surendran and H. A. 

El-Fawal. Mercy College, Dobbs Ferry, NY. 


MODULATION OF CADMIUM-INDUCED 

OLFACTORY DAMAGE BY CALCIUM IN 

LARVAL ZEBRAFISH. C. Matz and P. Krone. 

Toxicology Group & Anatomy and Cell Biology, 

University of Saskatchewan, Saskatoon, SK, Canada. 


ACUTE SODIUM TUNGSTATE INHALATION 

IS NOT ASSOCIATED WITH DIRECT 

OLFACTORY TRANSPORT OF TUNGSTEN 

(188W) TO THE RAT BRAIN. A. O. Olabisi 1 , 

P. M. Radcliffe 2 , D. J. Wagner 1 , B. A. Wong 2 , M. 

F. Struve 2 , K. M. Attard 2 , E. Tewksbury 2 , P. G. 

Gunasekar 1 , G. D. Chapman 1 and D. C. Dorman 3 . 

1 

Environmental Health Effect Laboratory [EHEL], 

Naval Health Research Center, Wright Patterson 

Air Force Base, OH, 2 CIIT, The Hamner Institutes, 

Research Triangle Park, NC and 3 College of 

Veterinary Medicine, North Carolina State 



NICKEL (NI) NANOPARTICLE (NP)- 

INDUCED OXIDATIVE STRESS (OS) 

AND NEUROANTIBODIES. H. A. El-Fawal 1 , 

P. Gillespie 2 , G. Kang 2 and L. Chen 2 . 1 Health 

Professions, Mercy College, Dobbs Ferry, NY and 

2 

Environmental Medicine, New York University 

School of Medicine, Tuxedo, NY. 


VANADIUM INDUCES NEUROTOXICITY 

IN DOPAMINERGIC NEURONAL CELLS 

VIA PROTEOLYTIC ACTIVATION OF 

PROTEIN KINASE C-DELTA: RELEVANCE 

TO ETIOPATHOGENESIS OF PARKINSON’S 

DISEASE. H. Afeseh Ngwa, A. Kanthasamy, V. 

Anantharam and A. G. Kanthasamy. Biomedical 

Sciences, Iowa State University, Ames, IA. 

250 




Abstract # 


MODERATE PERINATAL ARSENIC HAS 

LONG-TERM AFFECTS ON LEARNING 

AND MEMORY BEHAVIOR AND ERK 

PHOSPHORYLATION. E. J. Martinez 1,2 , J. Liu 2 

and A. M. Allan 1 . 1 Department of Neurosciences, 

University of New Mexico, Albuquerque, NM and 

2 

Department of Toxicology, University of New 

Mexico, Albuquerque, NM. 


INORGANIC ARSENIC METHYLATION 

AND ACCUMULATION IN MOUSE BRAIN 

REGIONS. M. Morales 1 , M. Torres 1 , G. Gutiérrez 

Ospina 2 , C. L. Sánchez-Peña 3 , L. M. Del Razo 3 and 

M. E. Gonsebatt 1 . 1 Medicina Genómica y Toxicología 

Ambiental, IIB, Universidad Nacional Autónoma de 

México, Mexico, D.F., Mexico, 2 Biología Celular 

y Fisiología, IIB, Universidad Nacional Autónoma 

de México, Mexico, D.F., Mexico and 3 Toxicology 

Section, CINVESTAV, Mexico, D.F., Mexico. 


GENE EXPRESSION BIOMARKERS 

ASSOCIATED WITH NEUROTOXICITY 

IN MICE EXPOSED WITH SILVER 

NANOPARTICLES BY INHALATION. H. Lee 1 , 

G. Li 1 , J. Kwon 2 , J. Kim 2,3 , H. Im 2 , M. Cho 2,3 , Y. 

Choi 1 , S. Jang 1 and B. Lee 1 . 1 College of Pharmacy, 

Seoul National University, Seoul, South Korea, 

2 

College of Veterinary Medicine, Seoul National 

University, Seoul, South Korea and 3 Nano Systems 

Institute-National Core Research Center, Seoul 

National University, Seoul, South Korea. 


CHARACTERIZATION OF THE EFFECT OF 

METHYLMERCURY ON CAENORHABDITIS 

ELEGANS. K. J. Helmcke 1,2 , A. Benedetto 3 , 

D. Miller 4 and M. Aschner 1,2,3 . 1 Pharmacology, 

Vanderbilt University, Nashville, TN, 2 Molecular 

Toxicology, Vanderbilt University, Nashville, TN, 

3 

Pediatrics, Vanderbilt University, Nashville, TN 

and 4 Cell and Developmental Biology, Vanderbilt 



INVESTIGATION OF MANGANESE 

TRANSPORT IN C. ELEGANS. C. Au 1 , A. 

Benedetto 2 and M. Aschner 2,3,1 . 1 Center of Molecular 

Neuroscience, Vanderbilt University, Nashville, TN, 

2 

Pediatrics, Vanderbilt University, Nashville, TN and 

3 

Pharmacology, Vanderbilt University, Nashville, TN. 


INVESTIGATION OF MANGANESE 

TOXICITY IN PD GENES DEFICIENT 

C. ELEGANS. A. Benedetto 1 , C. Au 1,2 and M. 

Aschner 1,2,3 . 1 Pediatrics, Vanderbilt University 

Medical Center, Nashville, TN, 2 Center of Molecular 

Neuroscience, Vanderbilt University Medical Center, 

Nashville, TN and 3 Pharmacology, Vanderbilt 

University Medical Center, Nashville, TN. 


METHYLMERCURY INDUCED OXIDATIVE 

INJURY AND INFLAMMATORY RESPONSE 

IN RAT PRIMARY ASTROCYTES: 

ATTENUATION BY ANTIOXIDANTS. M. 

Aschner 1,2 , D. Milatovic 1 and Z. Yin 1 . 1 Pediatrics, 

Vanderbilt University Medical Center, Nashville, TN 

and 2 Pharmacology, Vanderbilt University Medical 

Center, Nashville, TN. 

Abstract # 


EBSELEN ATTENUATES MANGANESE- 

INDUCED OXIDATIVE INJURY IN RAT 

PRIMARY ASTROCYTES. Z. Yin 1 , D. Milatovic 1 , 

J. Rocha 2 and M. Aschner 1 . 1 Vanderbilt University 

Medical Center, Nashville, TN and 2 University of 

Santa Maria, Santa Maria, Brazil. 


ANTIOXIDANTS REDUCE MANGANESE- 

INDUCED MITOCHONDRIAL IMPAIRMENT 

IN CULTURED ASTROCYTES. H. Jiang, Z. Yin 

and M. Aschner. vanderbilt university, Nashville, TN. 


MECHANISMS OF ESTROGEN-MEDIATED 

NEUROPROTECTION IN MANGANESE- 

INDUCED NEUROTOXICITY. E. Y. Lee 1 , H. 

Jiang 2 , Z. Yin 2 , D. Milatovic 2 , A. Benedetto 2 and M. 

Aschner 2 . 1 Neurology, Meharry Medical College, 

Nashville, TN and 2 Pediatrics, Vanderbilt University 

Medical Center, Nashville, TN. 


1:00 PM to 4:30 PM 

Exhibit Hall 

POSTER SESSION: PHARMACEUTICALS 

Chairperson(s): Charlie Zhang, Purdue Pharma, Cranbury, NJ and 

William Brock, Brock Scientific Consulting, LLC, Montgomery Village, 

MD. 




CYTOPROTECTIVE MECHANISMS OF 

DICARBONYL TRAPPING ANTI-DIABETIC 

DRUGS. R. Mehta, L. Wong and P. J. O’Brien. 

Pharmaceutical Sciences, University of Toronto, 

Toronto, ON, Canada. 


PRECLINICAL INVESTIGATION OF 

FIBRODYSPLASIA AND ITS RELEVANCE 

TO HUMAN MUSCULO-SKELETAL 

SYNDROME. M. Coulson 1 , J. D. Tugwood 1 , 

J. Bowyer 2 , D. Waterson 2 , R. A. Roberts 1 , R. C. 

Scott 1 , R. A. Maciewicz 2 and R. Westwood 1 . 1 Safety 

Assessment UK, AstraZeneca, Macclesfield, United 

Kingdom and 2 Respiratory and Inflammation 

Research Area UK, AstraZeneca, Macclesfield, 



DIAGNOSTIC CRITERIA FOR SELECTED 


ACTIVATED RECEPTOR (PPAR) 

AGONIST-INDUCED MESENCHYMAL 

LESIONS IN THE RAT. H. Kolenda-Roberts 1 , J. 

F. Hardisty 1 , M. R. Elwell 2 , H. Ernst 3 , P. Greaves 4 , 

D. Malarkey 5 , P. C. Mann 6 and P. A. Tellier 7 . 1 EPL, 

Inc., RTP, NC, 2 Covance Laboratories, Vienna, VA, 

3 

Fraunhofer Institute of Toxicology and Experimental 

Medicine, Hannover, Germany, 4 University of 

Leicester, Leicester, United Kingdom, 5 NIEHS, RTP, 

NC, 6 EPL Northwest, Seattle, WA and 7 Charles River 

Laboratories, Senneville, QC, Canada. 

Wednesday 




Wednesday 



DIAGNOSTIC CRITERIA FOR SELECTED 


ACTIVATED RECEPTOR (PPAR) 

AGONIST-INDUCED VASCULAR LESIONS 

IN THE MOUSE. J. F. Hardisty 1 , H. Kolenda- 

Roberts 1 , M. R. Elwell 2 , H. Ernst 3 , P. Greaves 4 , D. 

Malarkey 5 , P. C. Mann 6 and P. A. Tellier 7 . 1 EPL, Inc., 

Research Triangle Park, NC, 2 Covance Laboratories, 

Vienna, VA, 3 Fraunhofer Institute of Toxicology 

and Experimental Medicine, Hannover, Germany, 

4 

University of Leicester, Leicester, United Kingdom, 

5 

NIEHS, RTP, NC, 6 EPL Northwest, Seattle, WA and 

7 

Charles River Laboratories, Senneville, QC, Canada. 


STABILITY OF THE MYCOPHENOLIC ACID 

ACYL GLUCURONIDE IN BIOLOGICAL 

MATRICES. D. E. Harbourt 1 , M. S. Joy 2 and P. C. 

Smith 1,2 . 1 Curriculum in Toxicology, UNC-Chapel 

Hill, Chapel Hill, NC and 2 Molecular Pharmaceutics, 

UNC-Chapel Hill, Chapel Hill, NC. Sponsor: M. 

Cordeiro-Stone. 


PHARMACOKINETICS AND TOXICITY 

TO RATS OF SR13668, A NOVEL CANCER 

CHEMOPREVENTIVE AGENT. J. Bakke 1 , A. 

Furimsky 1 , R. Erickson 1 , R. Swezey 1 , L. Jong 1 , I. 

M. Kapetanovic 2 , J. A. Crowell 2 and C. E. Green 1 . 

1 

Toxicology and Metabolism, SRI International, 

Menlo Park, CA and 2 National Cancer Institute, 

Bethesda, MD. 


USING KINASE SELECTIVITY PROFILES 

TO PREDICT IN VITRO AND IN VIVO BONE 

MARROW TOXICITY. M. Hassani, A. Olaharski, 

H. Uppal and K. Kolaja. Investigative Toxicology, 

Roche - Palo Alto, Palo Alto, CA. 


TOLERABILITY OF AN INHALED 

ANTISENSE OLIGONUCLEOTIDE IN 

MOUSE AND MONKEY. R. A. Fey 1 , R. Z. Yu 1 , 

M. D. Reed 2 , J. D. McDonald 2 and S. P. Henry 1 . 

1 

Toxicology/PK, Isis Pharmaceuticals, Carlsbad, CA 

and 2 Toxicology, Lovelace Respiratory Research 



PRECLINICAL SAFETY EVALUATION OF 

INHALED S-NITROSOGLUTATHIONE. G. J. 

Rosenthal 1 , D. Looker 1 , D. Borkhataria 3 , A. Jackson 4 , 

P. Mueller 4 and D. Alexander 2 . 1 N30 Pharmacology, 

LLC, Boulder, CO, 2 DA Nonclinical Safety Ltd, 

Cambridgeshire, United Kingdom, 3 Consultant, 

Hertfordshire, United Kingdom and 4 RCC Ltd, 

Itingen, Switzerland. 


OCCURRENCE AND BEHAVIOR OF ANTI- 

INFLAMMATORY DRUG NAPROXEN IN 

AQUATIC ENVIRONMENT. T. Suzuki 1 , R. 

Kubota 2 and T. Nishimura 2 . 1 Division of Water 

Quality, Tokyo Metropolitan Institute of Public 

Health, Shinjuku, Tokyo, Japan and 2 Division 

of Environmental Chemistry, National Institute 

of Health and Science, Setagaya, Tokyo, Japan. 

Sponsor: M. Ema. 


ROLE OF ENDOCYTIC ARK/PRK KINASES 

IN ADRIAMYCIN RESISTANCE. T. Takahashi 

and A. Naganuma. Tohoku university, Sendai, Japan. 


DRUG INTERFERENCE WITH 

BIOTRANSFORMATION OF BISPHENOL 

A AND NONYLPHENOL IN RATS. M. Verner 

and S. Haddad. Biological sciences, Université du 

Québec à Montréal, Montreal, QC, Canada. 


SPECIES-DEPENDENT 

PHARMACOKINETICS OF CMX001, 

AN ORALLY AVAILABLE PRODRUG 

OF CIDOFOVIR FOR TREATMENT OF 

SMALLPOX. L. C. Trost 1 , M. R. Almond 2 and B. 

M. Lampert 2 . 1 Toxicology, Chimerix, Inc., Durham, 

NC and 2 Chemistry, Chimerix, Inc., Durham, NC. 


OVER-THE-COUNTER ANALGESICS 

NORMALIZE BLOOD GLUCOSE AND BODY 

COMPOSITION IN MICE FED A HIGH 

FAT DIET. H. G. Shertzer 1 , S. N. Schneider 1 , 

E. L. Kendig 1 , D. J. Clegg 2 and M. Genter 1 . 

1 

Environmental Health, University of Cincinnati, 

Cincinnati, OH and 2 Psychiatry, University of 

Cincinnati, Cincinnati, OH. 


ACETAMINOPHEN NORMALIZES 

GLUCOSE HOMEOSTASIS IN MOUSE 

MODELS FOR DIABETES. E. L. Kendig 1 , 

M. Genter 1 , S. N. Schneider 1 , D. J. Clegg 2 , D. A. 

D’Alessio 3 and H. G. Shertzer 1 . 1 Environmental 

Health, University of Cincinnati, Cincinnati, OH, 

2 

Psychiatry, University of Cincinnati, Cincinnati, OH 

and 3 Medicine, University of Cincinnati, Cincinnati, 

OH. 


THE FORMATION OF A QUINONE 

METHIDE FROM NO-ASA AND ITS 

ANALOGS CONTRIBUTES TO THE 

BIOLOGICAL ACTIVITY. T. Dunlap, R. P. 

Chandrasena, Z. Wang, V. Sinha, Z. Wang and G. R. 

Thatcher. Medicinal Chemistry, University of Illinois 

at Chicago, Chicago, IL. Sponsor: G. Thatcher. 


TOPICAL OCULAR MITOMYCIN C 

TREATMENT IN THE PRESENCE OF A 

CORNEAL EPITHELIAL DEFECT CAUSED 

CHANGES IN CORNEAL ENDOTHELIUM. 

B. J. Christian 1 , G. Holley 2,3 , J. Miller 1 , P. Smith 1 , R. 

McCulloh 1 , H. F. Edelhauser 2 , C. J. Murphy 3 , P. E. 

Miller 3 , G. Leatherberry 3 and T. T. Lam 1 . 1 Covance 

Laboratories, Inc., Madison, WI, 2 Emory University, 

Atlanta, GA and 3 Comparative Ophthalmic Research 

Labs, Madison, WI. 


THE QUANTITATIVE EVALUATION OF 

HORMESIS IN ANTICANCER DRUG DOSE- 

RESPONSES. M. A. Nascarella 1 , E. J. Stanek 2 and 

E. J. Calabrese 1 . 1 Environmental Health Sciences 

Program, University of Massachusetts Amherst, 

Amherst, MA and 2 Biostatistics and Epidemiology 

Program, University of Massachusetts Amherst, 

Amherst, MA. 

252 




Abstract # 


4-ANDROSTEN-3, 6, 17-TRIONE (6-OXO) 

DOES NOT HAVE ANDROGENIC OR 

ANABOLIC ACTIVITY IN HERSHBERGER 

ASSAY. K. K. Kabirov and A. V. Lyubimov. 

Pharmacology, Toxicology Research Laboratory, 

University of Illinois at Chicago, Chicago, IL. 


PWT-458 RANGE FINDING STUDY: 

COMPARISON OF ORAL AND 

INTRAVENOUS TOXICITY AFTER ONE 

WEEK OF DOSING IN RATS. A. N. Hayes 1 , 

S. E. Batchelder 1 , N. L. Stedman 1 , J. Bienvenue 2 , 

D. W. Clarke 2 , G. A. Pedneault 1 and M. W. Leach 1 . 

1 

Exploratory Drug Safety, Wyeth Research, Andover, 

MA and 2 Drug Safety & Metabolism, Wyeth 

Research, Chazy, NY. 


NOVEL ASPECTS OF ACQUIRED CANCER 

CELL CHEMO- AND RADIO-RESISTANCE. 

L. Luzhna 1 , V. Tryndyak 2,3 , V. Chekhun 3 , I. Pogribny 2 

and O. Kovalchuk 1 . 1 University of Lethbridge, 

Lethbridge, AB, Canada, 2 NCTR, Jefferson, AR and 

3 

Kavetsky Institute of Experimental Oncology, Kiev, 

Ukraine. 


PRECLINICAL EVALUATION OF ACUTE 

TOXICITY OF DECITABINE (5-AZA- 

2’-DEOXYCYTIDINE). K. K. Kabirov 1 , J. 

DeSimone 2 , R. Labotka 2 and A. V. Lyubimov 1 . 

1 

Pharmacology, Toxicology Research Laboratory, 

University of Illinois at Chicago, Chicago, IL 

and 2 Medicine, Section Hematology/Oncology, 

University of Illinois at Chicago, Chicago, IL. 


ENDOTOXIN ENHANCES 

ACETAMINOPHEN-INDUCED NASAL 

TOXICITY IN MICE. N. Birmingham, D. Ibrahim 

Aibo, J. F. Maddox, S. W. Newport, R. A. Roth, 

P. E. Ganey and J. R. Harkema. Michigan State 



SYNERGISTIC TOXIC EFFECTS OF 

ACETAMINOPHEN AND OZONE ON 

MURINE NASAL EPITHELIUM. D. Ibrahim 

Aibo, N. Birmingham, J. F. Maddox, S. W. Newport, 

R. A. Roth, P. E. Ganey, J. G. Wagner and J. R. 

Harkema. Michigan State University, East Lansing, 

MI. 


AH RECEPTOR – AN UNKNOWN TARGET 

OF IMMUNO-MODULATORY DRUGS? E. 

F. O’Donnell, D. G. Farrer, D. C. Koch, K. S. Saili, 

N. I. Kerkvliet, R. L. Tanguay and S. K. Kolluri. 

Environmental & Molecular Toxicology, Oregon 



NONCLINICAL TOXICOLOGY PROFILE OF 

AMG 517, A NOVEL TRPV1 ANTAGONIST 

CONSIDERED FOR CLINICAL USE AS 

A PAIN THERAPEUTIC. N. B. Ernst, D. N. 

Hovland, S. Surapaneni, A. Back, J. Wisler and M. 

Cosenza. Toxicology, Amgen, Thousand Oaks, CA. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 


PHARMACEUTICAL—LIVER, KIDNEY, IMMUNE SYSTEM 

Chairperson(s): Susan Sumner, RTI International, Research Triangle 

Park, NC and Amy Lambert, Exelixis Inc., South San Francisco, CA. 




A PANEL OF LIVER SPECIFIC PROTEINS 

AS BLOOD BIOMARKERS FOR DRUG 

INDUCED LIVER INJURY. Z. Hu 1 , C. Lausted 1 , 

B. Lin 1 , X. Yan 1 , D. Liu 2 , H. Wen 2 , L. Duan 2 and L. 

Hood 1 . 1 Institute for Systems Biology, Seattle, WA 

and 2 Aviva Systems Biology, San Diego, CA. 


METABOLOMICS: URINARY MARKERS 

OF DRUG-INDUCED LIVER INJURY WITH 

CORRELATION WITH LOBE VARIATIONS 

IN RESPONSE. R. Snyder, J. Burgess, J. Deese- 

Spruill, C. Myers, S. Wu, T. Fennell and S. Sumner. 

RTI International, Research Triangle Park, NC. 


HEPATIC SIDE EFFECTS, IDIOSYNCRATIC 

OR TOXIC MECHANISMS – 

DIFFERENTIATED EVALUATION FOR 

REGULATORY AFFAIRS FOR HERBAL 

REMEDIES. C. P. Siegers and M. Tegtmeier. 

Institute of Experimental and Clinical Pharmacology 

and Toxicology, University of Luebeck, Luebeck, 

Germany. 


MULTI-SITE TECHNICAL VALIDATION OF 

NOVEL PRECLINICAL SERUM ENZYME 

MARKERS OF HEPATOTOXICITY. H. L. 

Jordan 1 , A. Lanevschi-Pietersma 2 , D. Joslin 3 , J. 

Boysza 1 , L. Beattie 2 , B. Gallagher 2 , J. Ozer 4 and S. 

Schomaker 3 . 1 Safety Assessment, GlaxoSmithKline, 

Research Triangle Park, NC, 2 Safety Assessment, 

Astrazeneca, Alderley Park, United Kingdom, 

3 

Drug Safety Assessment, Pfizer, Inc., Groton, CT 

and 4 Safety Assessment, Merck Research Labs, 

Westpoint, PA. 


PREDICTIVE AND MECHANISTIC 

TOXICOLOGY OF NANOPARTICULATE 

CARRIER BY HEPATIC GENE EXPRESSION 

PROFILING IN THE RAT. R. Kravtzoff 1 , O. 

Boutherin-Falson 1 , R. Forster 2 , S. Leuillet 2 , S. 

Arthaud 2 and P. Ancian 2 . 1 Flamel Technologies, 

Venissieux, France and 2 CIT, Evreux, France. 


HEPATIC TRANSCRIPTIONAL PROFILING 

AS AN INDICATOR OF INFLAMMATORY/ 

ACUTE-PHASE RESPONSES. W. Foster 2 and 

T. Van Vleet 1 . 1 Research and Development, Bristol- 

Myers Squibb, Mt. Vernon, IN and 2 Research and 

Development, Bristol-Myers Squibb, Lawrenceville, 

NJ. 

Wednesday 




Wednesday 



DRUG-INDUCED LIPIDOSIS IN THE DOG 

GALLBLADDER: A MECHANISTIC STUDY 

COMBINING CONVENTIONAL AND 

METABONOMIC TOOLS. F. Goldfain-Blanc, 

T. Umbdenstock, H. Bertheux, B. Walther and N. 

Claude. Drug Safety and DMPK Departments, 

Servier, Orleans-Gidy, France. 


THE USE OF PRECISION-CUT LIVER 

SLICES TO ASSESS THE SPECIES SPECIFIC 

TOXICITY OF KINASE INHIBITORS. N. 

Shangari 1 , A. Reising 1 , E. Cruz 1 , F. Pognan 2 and 

A. Wolf 2 . 1 Investigative Toxicology, Novartis 

Pharmaceuticals, East Hanover, NJ and 2 Investigative 

Toxicology, Novartis Pharmacology AG, Basel, 

Switzerland. 


A 28-DAY TOXICITY STUDY OF KRX-0502 

(FERRIC CITRATE) IN RATS BY 

DIETARY ADMINISTRATION. E. Cullen 1 , 

R. Mandella 2 , C. Auletta 2 and R. Niecestro 1 . 

1 

Keryx Biopharmaceuticals, Inc., New York and 

2 

Huntingdon Life Sciences, Inc., East Millstone, NJ. 


EARLY GENTAMICIN TOXICITY URINE 

BIOMARKER IDENTIFICATION IN RATS 

USING AN NMR CHEMOMETRIC AND 

METABOLOMIC APPROACH. A. M. Weljie 1 , L. 

Schnackenberg 2 , P. Espandiari 3 , J. Zhang 3 , D. Chang 1 , 

J. Hanig 3 , J. Newton 1 and R. Beger 2 . 1 Chenomx 

Inc, Edmonton, AB, Canada, 2 National Center for 

Toxicological Research, FDA, Jefferson, AR and 

3 

Center for Drug Evaluation and Research, FDA, 

Silver Spring, MD. 


URINE COLLECTION AND ANALYSIS IN 

REGULATORY TOXICOLOGY STUDIES: A 

CROSS-LABORATORY COMPARISON. D. 

Everett 6 , S. Robinson 1 , K. Chapman 2 , D. Spencer- 

Briggs 3 , R. Hill 4 and A. Danks 5 . 1 AstraZeneca, 

Alderley Edge, United Kingdom, 2 NC3Rs, 

London, United Kingdom, 3 Huntingdon Life 

Sciences, Huntingdon, United Kingdom, 4 Sequani 

Limited, Ledbury, United Kingdom, 5 Charles 

River Laboratories, Tranent, United Kingdom and 

6 

Covance Laboratories Ltd, Harrogate, United 

Kingdom. 


METABONOMIC ANALYSIS OF URINE IN 

CISPLATIN-INDUCED RENAL TOXICITY 

IN RATS AND MICE. R. D. Beger 1 , L. 

Schnackenberg 1 , P. Espandiari 2 , R. Holland 1 , T. 

Schmitt 1 , J. Zhang 2 , K. Nagothu 3 , D. Portilla 3 , 

J. Hanig 2 and N. Sadrieh 2 . 1 National Center for 

Toxicological Research, Jefferson, AR, 2 Center for 

Drug Evaluation and Research, Silver Spring, MD 

and 3 University of Arkansas for Medical Sciences, 

Little Rock, AR. 


PRECLINICAL EVALUATION OF 

IMMUNOMODULATORY ACTIVITY AND 

SAFETY OF RECOMBINANT HUMAN 

INTERLEUKIN-21. K. Van Ness 1 , S. Hughes 1 , R. 

Ponce 1 , S. Laursen 2 and D. Miller 1 . 1 ZymoGenetics, 

Inc., Seattle, WA and 2 Novo Nordisk, Bagsværd, 

Denmark. 


INDUCTION OF IMMUNE TOLERANCE 

TO AMPICILLIN FOLLOWING ORAL 

DOSING IN SPRAGUE-DAWLEY RATS. A. 

Hillegas, C. Genell and C. Maier. Safety Assessment, 

GlaxoSmithKline, King of Prussia, PA. Sponsor: E. 

Gore. 


SAFETY EVALUATION OF A ONE-ARMED 

RECOMBINANT HUMAN ANTIBODY TO 

C-MET (METMAB) IN CYNOMOLGUS 

MONKEYS. T. Gelzleichter 1 , A. Vaidyanathan 1 , K. 

McDorman 1 , R. Kaiser 2 , T. Davancaze 1 , H. Xiang 1 , A. 

Reyes 1 and S. Kaur 1 . 1 Safety Assessment, Genentech, 

South San Francisco, CA and 2 Toxicology, Charles 

River, Reno, NV. 


IDENTIFICATION AND 

CHARACTERIZATION OF NOVEL AHR 

LIGANDS ACROSS SPECIES. C. Sorrentino 1 , W. 

Hu 2 , M. Fielden 3 and M. S. Denison 1 . 1 Environmental 

Toxicology, University of California Davis, Davis, 

CA, 2 Entelos, Foster City, CA and 3 Roche Palo Alto, 

Palo Alto, CA. 


ASSESSMENT OF PRILOCAINE, 

LIDOCAINE, o-TOLUIDINE AND 2, 

6-DIMETHYLANILINE DNA ADDUCTS 

FORMATION IN F344 RATS. J. Duan, A. M. 

Jeffrey and G. M. Williams. Department of Pathology, 

New York Medical College, Valhalla, NY. 


LIVE CELL IN-VITRO SCREEN FOR 

DETECTING OXIDATIVE STRESS. P. A. Billis, 

M. J. Banker and T. H. Jenkinson. Exploratory Safety 

Differentiation, Pfizer, Groton, CT. Sponsor: Y. Will. 


THE EVALUATION OF ATACICEPT ON 

PROTECTIVE IMMUNITY IN THE MOUSE 

STREPTOCOCCAL HOST RESISTANCE 

MODEL. J. Heffernan 1 , F. Burleson 2 , R. Roque 1 , 

K. Waggie 1 , M. Carbonatto 3 and R. Ponce 1 . 

1 

ZymoGenetics, Inc, Seattle, WA, 2 Burleson 

Research Technologies, Morrisville, NC and 3 Merck 

Serono S.A., RBM S.p.A., 10010 Colleretto Giacosa, 

Italy. 


TOXICITY ASSESSMENT WITH KINASE 

INHIBITORS. A. M. Giusti, P. Della Torre, R. 

Castoldi, M. Cattoni and M. Brughera. Accelera 

Preclinical Development, Nerviano Medical 

Sciences, Nerviano (MI), Italy. 


SUBCHRONIC ORAL TOXICITY OF THE 

CORTICOTROPIN-RELEASING HORMONE 

(CRH) RECEPTOR ANTAGONIST, 

ANTALARMIN, IN RHESUS MONKEYS. W. 

D. Johnson 1 , J. Harder 1 , D. L. McCormick 1 , C. J. 

Detrisac 2 , K. Calis 3 , P. W. Gold 3 , K. Rice 3 , H. Manji 3 , 

G. Kunos 3 , M. Heilig 3 , C. Contoreggi 3 , F. Vocci 3 , J. 

Winslow 3 , G. Chrousos 3 , C. Zarate 3 , G. Cizza 3 , E. 

R. Glaze 3 and J. E. Tomaszewski 3 . 1 IIT Research 

Institute, Chicago, IL, 2 Pathology Associates, 

Chicago, IL and 3 National Institutes of Health, 

Bethesda, MD. 

254 




Abstract # 


STRATEGY FOR QUALIFYING 

HUMANIZED MICE AS TOXICITY MODELS 

IN METABOLITE SAFETY ASSESSMENT. M. 

W. Powley 1 , T. H. Rushmore 2 , S. Yu 2 and P. R. Tiller 2 . 

1 

Safety Assessment, Merck Research Laboratories, 

West Point, PA and 2 Drug Metabolism, Merck 

Research Laboratories, West Point, PA. 


THE USE OF OXYGEN AND PH 

SENSITIVE FLUORESCENT PROBES IN 

THE INVESTIGATION OF PERTURBED 

CELLULAR METABOLISM. J. Hynes 2 , T. 

O’Riordan 2 , D. Papkovsky 2 and Y. Will 1 . 1 Drug 

Safety R&D, Pfizer, Inc., San Diego, CA and 2 Luxcel 

Biosciences, Cork, Ireland. 


LACK OF EFFECT OF LACTATE 

DEHYDROGENSASE AND LACTIC ACID 

IN THE ENZYMATIC METHOD FOR 

ETHYL ALCOHOL DETERMINATION. D. H. 

Petroni and W. J. George. Division of Toxicology; 

Pharmacology, Tulane University School of 

Medicine, New Orleans, LA. 


NNC55-0396, A POTENTIALLY SAFE 

THERAPEUTIC T-TYPE CA2+ CHANNEL- 

SPECIFIC ANTAGONIST, DOES NOT 

STRONGLY INHIBIT CYP3A4. P. H. Bui 1,2 , 

A. Quesada 3 , A. Handforth 3 and O. Hankinson 1,2 . 

1 

Pathology and Laboratory Medicine, University 

of California, Los Angeles, Los Angeles, CA, 

2 

Molelcular Toxicology IDP, University of 

California, Los Angles, Los Angeles, CA and 

3 

Neurology and Research Services, Veterans Affairs 

Greater Los Angeles, Los Angeles, CA. 


EVALUATION OF A NOVEL HIGH 

CONTENT BIOLOGY-BASED METHOD TO 

DETECT COMPOUNDS WITH STEATOTIC 

POTENTIAL. J. Milano 1 , P. Ciaccio 1 , J. K. Morelli 1 

and F. Pognan 2 . 1 Safety Assessment, AstraZeneca, 

Wilmington, DE and 2 Current Address: Biological 

and Molecular Toxicology, Novartis Pharmacology 

AG, Schweizerhalle, Switzerland. 


CUTANEOUS CLINICAL ADVERSE DRUG 

REACTIONS IN A TERTIARY CARE 

CENTER. G. Madan Mohana Rao. Dr.Reddy’s 

Medical Centre, Savannalamore, Westmoreland, 

Jamaica. 


MECHANISTIC DIFFERENCES IN 

TOXICOLOGICAL RESPONSE TO 

PHOSPHOLIPOGENICS BY DOG AND 

RAT HEPATOCYTES. J. K. Morelli and P. J. 

Ciaccio. Safety Assessment U.S., AstraZeneca 

Pharmaceuticals, Wilmington, DE. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 


POSTER SESSION: OXIDATIVE INJURY AND REDOX 

BIOLOGY I: IN VIVO 

Chairperson(s): Terrance Kavanagh, University of Washington, Seattle, 

WA and Debra Laskin, Rutgers University, Piscataway, NJ. 




ACETAMINOPHEN-PROTEIN 

ADDUCTS ARE NOT SUFFICIENT FOR 

HEPATOCELLULAR NECROSIS IN MICE: 

MODULATION OF TOXICITY BY GENDER 

AND GLUTAMATE CYSTEINE LIGASE 

MODIFIER SUBUNIT. I. Mohar, C. C. White and 

T. J. Kavanagh. Environmental and Occupational 


WA. 


CHRONIC ETHANOL ADMINISTRATION 

RESULTS IN DOWN REGULATION OF 

PEROXIREDOXIN 6 AND OXIDATIVE 

STRESS. J. Roede, B. J. Stewart and D. R. Petersen. 

Pharmaceutical Sciences, University of Colorado 



THE NATURAL TRITERPENOID 

OLEANOLIC ACID AND A SYNTHETIC 

DERIVATIVE CDDO-IM PROTECT THE 

LIVER FROM HEPATOTOXICANTS 

AND INCREASE ANTIOXIDANT GENES 

THROUGH ACTIVATION OF NRF2. S. A. 

Reisman, L. M. Aleksunes, D. B. Buckley, Y. Tanaka 

and C. D. Klaassen. University of Kansas Medical 



GLUTATHIONE DEPLETION ACTIVATES 

SPECIFIC MITOGEN-ACTIVATED PROTEIN 

KINASE (MAPK) IN MICE. M. E. Gonsebatt 

and J. H. Limón Pacheco. Medicina Genómica y 

Toxicología Ambiental, IIB, Universidad Nacional 

Autónoma de México, Mexico, D.F., Mexico. 


INCREASED SENSITIVITY OF 

GLUTATHIONE S-TRANSFERASE 

P-NULL MICE TO CYCLOPHOSPHAMIDE 

TOXICITY. D. J. Conklin 1 , R. A. Prough 2 and 

A. Bhatnagar 1 . 1 Inst. Mol. Card., University of 

Louisville, Louisville, KY and 2 Biochem., University 

of Louisville, Louisville, KY. 

Wednesday 




Wednesday 



MICE THAT DO NOT EXPRESS 

GLUTATHIONE REDUCTASE ARE MORE 

SUSCEPTIBLE THAN ARE WILD TYPE 

MICE TO INFECTION WITH GROUP B 

STREPTOCOCCUS. M. M. Ralston 1 , K. D. 

Bongiovanni 1 , A. L. Jones 2 and C. V. Smith 1 . 1 Seattle 

Children’s Hospital Research Institute, Center 

for Developmental Therapeutics, Seattle, WA and 

2 

Center for Childhood Infections and Prematurity, 

Seattle Children’s Hospital Research Institute, 

Seattle, WA. 


EXPRESSION AND FUNCTION OF 

ALDEHYDE DEHYDROGENASE 3B1. 

S. A. Marchitti 1 , D. J. Orlicky 2 and V. Vasiliou 1 . 

1 

Pharmaceutical Sciences, University of Colorado 

Health Sciences Center, Denver, CO and 2 Pathology, 

University of Colorado Health Sciences Center at 

Fitzsimmons, Aurora, CO. 


ALDH7A1 IS A NOVEL ALDH THAT 

PROTECTS AGAINST OXIDATIVE 

DAMAGE. C. Brocker 1 , M. Cantore 1 , A. Pappa 1 , N. 

Lassen 1 , T. Estey 1 , S. A. Marchitti 1 , T. Chavakis 2 and 

V. Vasiliou 1 . 1 Pharmaceutical Sciences, University of 

Colorado Health Sciences Center, Denver, CO and 

2 

Experimental Immunology Branch, National Cancer 

Institute, National Institutes of Health, Bethesda, 

MD. 


ORAL ADMINISTRATION OF 

POLAPREZINC, AN ANTI-ULCER DRUG, 

PROTECTS MICE AGAINST ENDOTOXIN 

SHOCK. T. Matsura 1 , C. Moriyama 1 , A. Yamashita 1 , 

H. Morikawa 1 , T. Nishida 1 , S. Ohata 1 , C. Kusumoto 1 , 

J. Nakada 2 and K. Yamada 1 . 1 Medical Biochemistry, 

Tottori University Faculty of Medicine, Yonago, 

Tottori-ken, Japan and 2 Anesthesiology, Aichi Cancer 

Center Hospital, Nagoya, Japan. Sponsor: V. Kagan. 


THE ROLE OF REACTIVE OXYGEN 

SPECIES(ROS)IN AIRWAY HYPER- 

RESPONSIVENESS:THE EFFECTS 

OF 2-CYANO-3, 12-DIOXOOLEANA-1, 

9(11)-DIENE-28-OIC ACID(CDDO). D. 

Hochman 1 , D. Nanyes 3 , S. Schultz 2 and E. Brooks 2 . 

1 

Experimental Pathology, University of Texas 

Medical Branch, Galveston, TX, 2 Pediatrics, 

University of Texas Medical Branch, Galveston, TX 

and 3 The University of Houston, Houston, TX. 


DISTINCT ROLES OF REACTIVE OXYGEN 

AND NITROGEN INTERMEDIATES IN 

ACUTE LUNG INJURY INDUCED BY 

OZONE AND BLEOMYCIN. A. M. Groves 1 , J. 

D. Laskin 2 , A. J. Gow 1 , C. Guo 1 and D. L. Laskin 1 . 

1 

Rutgers University, Piscataway, NJ and 2 UMDNJ- 

RW Johnson Med Sch, Piscataway, NJ. 


DISRUPTION OF ANTIOXIDANT DEFENSE 

AND DNA REPAIR SYSTEMS DURING 

2-ACETYLAMINOFLUORENE-INDUCED 

HEPATOCARCINOGENESIS IN RATS. T. V. 

Bagnyukova 1 , C. L. Powell 2 , B. Montgomery 1 , F. A. 

Beland 1 and I. P. Pogribny 1 . 1 Division of Biochemical 

Toxicology, FDA-National Center for Toxicological 

Research, Jefferson, AR and 2 Department of 

Genetics, University of North Carolina, Chapel Hill, 

NC. 


670 NM PHOTOBIOMODULATION 

NORMALIZES ANTIOXIDANT 

ENZYME ACTIVITIES SUPPRESSED IN 

STREPTOZOTOCIN-INDUCED DIABETIC 

RAT. J. Lim 1 , R. A. Sanders 2 , R. Wilson 3 , A. C. 

Snyder 3 , S. Gopalakrishnan 3 , J. T. Eells 3 , J. B. 

Watkins III 2 and D. S. Henshel 1 . 1 SPEA, Indiana 

University, Bloomington, IN, 2 Medical Sciences, 

Indiana University, Bloomington, IN and 3 Health 

Sciences, University of Wisconsin-Milwaukee, 



SUBCHRONIC TOXICITY OF INHALED 

TOLUENE IN RATS: OXIDATIVE STRESS 

MARKERS IN BRAIN. D. A. Moore-Smith 1,3 , 

J. H. Richards 2 , T. E. Samsam 1 , P. Evansky 2 , P. J. 

Bushnell 1 and P. R. Kodavanti 1 . 1 Neurotoxicology 

Division, U.S. EPA, RTP, NC, 2 Experimental 

Toxicology Division, U.S. EPA, RTP, NC and 

3 

Department of Biology, Livingstone College, 

Salisbury, NC. 


SUPPRESSION OF DFP-INDUCED 

OXIDATIVE INJURY AND DENDRITIC 

DAMAGE IN RAT BRAIN. D. Milatovic 1 , S. 

Zaja-Milatovic 1 , R. C. Gupta 2 and M. Aschner 1 . 

1 

Pediatrics, Vanderbilt University, Nashville, TN 

and 2 Breathitt Vet. Center, Murray State University, 

Hopkinsville, KY. 


A BIOTIN-HYDROXYLAMINE LABELING 

METHOD FOR THE DETECTION 

OF OXIDIZED PROTEINS USING 

WESTERN BLOT ANALYSIS AND MASS 

SPECTROMETRY. W. Chung, C. L. Miranda and 

C. S. Maier. Chemistry, Oregon State University, 



A UPLC/MS/MS PROCEDURE FOR THE 

DETERMINATION OF ISOPROSTANES IN 

HUMAN SERUM. A. R. Molinelli 1 , T. J. Laha 1 , 

M. J. Edenfield 1 and S. M. Sadrzadeh 2 . 1 Laboratory 

Medicine, University of Washington, Seattle, WA and 

2 

Unaffiliated Consultant, Seattle, WA. 


PHOSPHOLIPID PEROXIDATION 

BIOMARKERS OF ALZHEIMER’S DISEASE 

IN THE BRAIN: SELECTIVE OXIDATION 

OF PHOSPHATIDYLSERINE. V. A. Tyurin 1,2 , 

Q. Zhao 1,2 , A. Mnuskin 1,2 , R. L. Hamilton 3 , S. T. 

DeKosky 4 , W. F. Reynolds 5 and V. E. Kagan 1,2 . 1 EOH, 

University of Pittsburgh, Pittsburgh, PA, 2 CFRAH, 

University of Pittsburgh, Pittsburgh, PA, 3 Pathology, 

University of Pittsburgh, Pittsburgh, PA, 4 Neurology, 

University of Pittsburgh, Pittsburgh, PA and 5 Sidney 

Kimmel Cancer Center, San Diego, CA. 

256 




Abstract # 


EVIDENCE OF OXIDATIVE STRESS IN 

LUNG, LIVER AND HEART FROM SHEEP 

EXPOSED TO CHLORINE (CL 2 

) GAS. M. A. 

Dubick, A. I. Batchinsky, J. L. Barr and L. C. Cancio. 

U.S. Army Institute of Surgical Research, San 

Antonio, TX. 


NRF2 PLAYS A PROTECTIVE ROLE IN 

RESPONSE TO PRO-OXIDANT EXPOSURE 

OF ZEBRAFISH EMBRYOS (DANIO RERIO). 

L. Van Tiem, A. Timme-Laragy and R. Di Giulio. 

ITEHP, Duke University, Durham, NC. 


IS OXIDATIVE STRESS A SIGNIFICANT 

FACTOR IN THE SYNERGISTIC 

DEVELOPMENTAL TOXICITY OF MODEL 

PAHS IN ZEBRAFISH? R. Di Giulio, A. 

R. Timme-Laragy, L. Van Tiem and D. Jung. 

Environment, Duke University, Durham, NC. 


1:30 PM to 2:30 PM 


Exhibitor Hosted Session: CellCiphr 

Cytotoxicity Profiling for Investigational 

Safety: Cellular Systems Biology with 

33-features in HepG2 and Primary Rat Hepatocytes 

Presented by: Cellumen Inc. 

Compounds failing Cellumen’s CellCiphr Safety Index fail preclinical 

safety: 100%—no false positives. Recently validated in a 10-pharma 

collaborative evaluation, the 33-feature, CellCiphr profiling panel for 

HepG2 cells has been extended for primary rat hepatocytes. Cellular 

systems biology (CSB) offers a powerful filter for predicting hepatotoxicity 

in investigational safety. 


1:30 PM to 2:30 PM 


Exhibitor Hosted Session: Evaluation of the Use 

of an Unsupervised ECG Classification Tool in 

Cardiovascular Drug Safety Assessment 

Presented by: NOTOCORD Systems 

We will present a new unsupervised ECG beat classification tool (i.e. no 

need of a priori information) for detecting drug-induced cardiac arrhythmias 

in long-term ECG recordings from conscious freely moving dogs and 

non-human primates. Prediction and reliability to classify all beats on-line 

will also be laid out. 

Abstract # 


1:30 PM to 4:15 PM 

Room 6B 

SYMPOSIUM SESSION: ARSENIC AND CARDIOVASCULAR 

DISEASE 

Chairperson(s): J. Christopher States, University of Louisville, Louisville, 

KY and Aaron Barchowsky, University of Pittsburgh, Pittsburgh, PA. 

Endorsed by: 





Epidemiological studies indicate that chronic arsenic ingestion causes 

cardiovascular disease in humans. However, the mechanisms of arsenicinduced 

vascular diseases are unknown. Widespread exposure to arsenic in 

drinking water in the U.S. likely contributes to atherogenesis and death from 

cardiovascular disease. This symposium will address mechanistic studies 

of arsenic-induced vascular disease in experimental mouse models and the 

influence of dietary factors in exposed humans. The presentations will focus 

on atherosclerotic changes in arsenic exposed mice, arsenic induced activation 

of signaling cascades triggering vascular remodeling, prenatal arsenic 

exposure induced epigenetic changes and epidemiological studies of dietary 

modification of arsenic induced cardiovascular disease. 

#1965 1:30 ARSENIC AND CARDIOVASCULAR 

DISEASE. J. States 1 and A. Barchowsky 2 . 

1 

Pharmacology & Toxicology, University of 

Louisville, Louisville, KY and 2 Environmental 

& Occupational Health, University of Pittsburgh, 


#1966 1:35 THE RELATIONSHIPS OF ARSENIC 

EXPOSURE FROM DRINKING WATER 

WITH MOLECULAR, PRECLINICAL, 

AND CLINICAL ENDPOINTS OF 

CARDIOVASCULAR DISEASE IN 

BANGLADESH. Y. Chen 1 , J. H. Graziano 2 , 

F. Parvez 2 , R. M. Santella 2 , P. Factor-Litvak 2 , 

V. Slavkovich 2 , M. G. Kibriya 3 and H. Ahsan 3 . 

1 

Environmental Medicine, New York University 

School of Medicine, New York, 2 Environmental 

Health Science, Columbia University, New York and 

3 

Health Studies, The University of Chicago, Chicago, 

IL. Sponsor: A. Barchowsky. 

#1967 2:15 ARSENIC-INDUCED ATHEROGENESIS: 

CONTRIBUTION OF OXIDATIVE STRESS, 

INFLAMMATION AND UNFOLDED 

PROTEIN RESPONSE. S. Srivastava 1 , P. 

Haberzettl 1 , E. N. Vladykovskaya 1 , S. E. D’Souza 2 

and J. States 3 . 1 Medicine, University of Louisville, 

Louisville, KY, 2 Medicine, University of Louisville, 

Louisville, KY, 3 Medicine, University of Louisville, 

Louisville, KY, 4 Physiology, University of Louisville, 

Louisville, KY and 5 Pharmacology & Toxicology, 


#1968 2:55 PRENATAL ARSENIC EXPOSURE 

ALTERS HEPATIC DEVELOPMENTAL 

PROGRAMMING PREDISPOSING TO 

ATHEROSCLEROSIS. J. States 1 , A. V. Singh 2 , 

H. L. Miller 1 , Y. Piao 4 , M. S. Ko 4 , S. Srivastava 3 

and T. B. Knudsen 2 . 1 Pharmacology & Toxicology, 

U. Louisville, Louisville, KY, 2 Molecular, Cellular 

& Craniofacial Biology, U. Louisville, Louisville, 

KY, 3 Medicine, U. Louisville, Louisville, KY and 

4 

Laboratory of Genetics, National Institute on Aging, 


Wednesday 




Wednesday 


#1969 3:35 SIGNALING MECHANISMS FOR 

VASCULAR RESPONSES TO ARSENIC. A. 

Barchowsky 1 , L. R. Klei 1 , A. C. Straub 1 and D. B. 

Stolz 2 . 1 Environmental and Occupational Health, 

Universtity of Pittsburgh, Pittsburgh, PA and 2 Cell 

Biology, University of Pittsburgh, Pittsburgh, PA. 


1:30 PM to 4:15 PM 

Room 6C 


SYMPOSIUM SESSION: NANOMATERIAL 

PHARMACOKINETICS: WHERE WE ARE AND WHERE WE 

NEED TO GO 

Chairperson(s): Justin Teeguarden, Pacific Northwest National 

Laboratory, Richland, WA and Nigel Walker, NIEHS, Research Triangle 

Park, NC. 

Endorsed by: 


Inhalation and Respiratory Specialty Section 



The rapid development and commercialization of new nanomaterial products 

including catalysts, cosmetics, drug delivery systems, presents an 

urgent need for toxicological assessment of these new submicron particulate 

products. Understanding the unique kinetics of particle uptake, distribution 

and elimination in vivo and particokinetics in vitro are central to the 

safety assessment of nanomaterials. This symposium will present the latest 

findings related to the physiological and biochemical processes controlling 

nanomaterial pharmacokinetics as well as specific data on the portal 

of entry (skin, lung) and systemic kinetics of several important classes of 

nanomaterials including PEBBLEs, polystyrene spheres and quantum dots. 

The session will conclude by bringing together current empirical knowledge 

on the kinetics of nanomaterials with the material property and physiological 

determinants of tissue uptake to develop a framework for developing physiologically 

motivated kinetic models for nanomaterials. 

#1970 1:30 NANOMATERIAL PHARMACOKINETICS 

AND PHARMACOKINETIC MODELING: 

WHERE WE ARE AND WHERE WE 

NEED TO GO. N. Walker. National Institute of 

Environmental Health Sciences, RTP, NC. 

#1971 1:45 PHYSICAL AND BIOLOGICAL BARRIERS 

TO THE ABSORPTION OF NANO-SCALE 

MATERIALS. P. J. Sinko. Pharmaceutics, EM 

School of Pharmacy, Rutgers University, Piscataway, 

NJ. Sponsor: J. Teeguarden. 

#1972 2:15 SYSTEMIC KINETICS AND 

COMPARTMENTAL MODELING OF 

NANOMATERIALS. M. Philbert. Toxicology, 


#1973 2:45 BIODISTRIBUTION OF NANO AND 

MICRON SIZED FLUORESCENT 

POLYSTYRENE LATEX SPHERES 

FOLLOWING PARENTERAL OR LUNG 

EXPOSURE. K. Sarlo. Miami Valley Laboratories, 

Procter & Gamble Company, Cincinnati, OH. 

#1974 3:15 PHARMACOKINETICS AND 


QUANTUM DOTS IN SKIN. J. Riviere. 

Veterinary Medicine, North Carolina State 


#1975 3:45 PHYSIOLOGICAL AND MATERIAL 

PROPERTY DETERMINANTS OF 

NANOMATERIAL KINETICS: A 

PHYSIOLOGICALLY BASED FRAMEWORK 

FOR NANOMATERIAL DOSIMETRY AND 

KINETICS. J. G. Teeguarden 1 , P. M. Hinderliter 1 , 

B. D. Thrall 2 and J. P. Pounds 2 . 1 Biological 

Monitoring and Modeling, Pacific Northwest 

National Laboratory, Richland, WA and 2 Cell 

Biology, Pacific Northwest National Laboratory, 

Richland, WA. 


1:30 PM to 4:15 PM 

Room 608 

WORKSHOP SESSION: ADVANCES IN TECHNOLOGY AND 

INCREASING ACCEPTANCE FOR ZEBRAFISH USE IN DRUG 

DISCOVERY 

Chairperson(s): Michael Carvan, University of Wisconsin Milwaukee, 

Milwaukee, WI and Robert Tanguay, Oregon State University, Corvallis, 

OR. 

Endorsed by: 

Comparative and Veterinary Specialty Section 




Drug discovery is an increasingly expensive and inherently risky process, 

with high rates of attrition often at late stages of R&D primarily due to 

organ toxicity or safety pharmacology issues. High-profile withdrawals of 

drugs from the market due to unforeseen, dangerous side effects have drawn 

extra attention to the difficulties of predicting toxicity using traditional 

methods and the U.S. FDA has also acknowledged a technology deficit in 

toxicity testing at preclinical stages. The zebrafish has emerged as a valuable 

vertebrate model for use by the pharmaceutical industry for expediting the 

process of prioritisation of candidate drugs for development and flagging 

toxicity early in the R&D process. Vast amounts of academic studies over 

the past three decades have shown that zebrafish have conserved genetic 

pathways and that the ease of their genetic manipulation has led to identification 

of numerous mutations that phenocopy human diseases. In addition, 

their small size allows high-throughput screening in microtiter plates using 

minuscule amounts of compounds. This has consequently made the developing 

zebrafish embryo an attractive model vertebrate for use in safety 

pharmacology and drug toxicity testing. These endeavors should help reduce 

the cost of drug discovery, reduce the use of higher vertebrates and decrease 

the risk of advancing potentially toxic compounds towards clinical testing. 

This symposium will focus on recent advances in zebrafish-based technologies 

including automation and screening of transgenics, validation of 

toxicity screens using this zebrafish model that show good concordance with 

mammals, and other novel discoveries made possible due to the zebrafish. 

#1976 1:30 ADVANCES IN TECHNOLOGY AND 

INCREASING ACCEPTANCE FOR 

ZEBRAFISH USE IN DRUG DISCOVERY. 

M. J. Carvan, 1 and R. L. Tanguay 2 . 1 Great Lakes 

WATER Institute, University of Wisconsin- 

Milwaukee, Milwaukee, WI and 2 Department of 

Environmental & Molecular Toxicology, Oregon 


#1977 2:10 ZEBRAFISH USE IN DRUG DISCOVERY. 

A. J. Hill. Biology, Summit plc, Abingdon, Oxon, 


258 




Abstract # 

#1978 2:15 UNRAVELING ENVIRONMENTAL 

BIOLOGICAL INTERACTIONS USING 

ZEBRAFISH. R. L. Tanguay 1,2 , L. K. Mathew 1,2 

and S. L. Harper 1,2 . 1 Environmental and Molecular 

Toxicology, Oregon State University, Corvallis, OR 

and 2 Environmental Health Sciences Center, Oregon 


#1979 2:55 FLUORESCENT ZEBRAFISH ASSAYS FOR 

DRUG DISCOVERY AND TOXICOLOGY. P. 

Eimon. Zygogen LLC, Atlanta, GA. Sponsor: A. Hill. 

#1980 3:35 VALIDATION OF ZEBRAFISH AS A MODEL 

FOR SCREENING TERATOGENICITY. A. 

Gustafson 1 and A. J. Hill 2 . 1 R&D, Safety Assessment, 

AstraZeneca, SE-151 85 Södertälje, Sweden and 

2 

Biology, Summit plc, Abingdon, Oxon, United 

Kingdom. 


1:30 PM to 4:15 PM 

Room 611 

WORKSHOP SESSION: CHLOROTRIAZINE HERBICIDES AND 

THEIR COMMON DEGRADATION PRODUCTS OF CONCERN: 

DISPOSITION AND POTENTIAL HEALTH EFFECTS 

Chairperson(s): Suzanne Fenton, U.S. EPA, Research Triangle Park, NC 

and Amal Mahfouz, U.S. EPA, Washington, DC. 

Endorsed by: 



Since the last atrazine risk assessment in 2002, the EPA Office of Water has 

discussed developing a triazine cumulative risk assessment of the regulated 

parent compounds and their common degradation products of concern in 

drinking water. The chlorotriazine herbicides metabolize/degrade to the 

same subset of residues, which are reported to be biologically active. These 

residues also occur in water as common chlorodegradates of the parent 

compounds. Atrazine is reported to have a short half-life in the rat (less than 

1 day), and is primarily excreted in the urine. Recent studies using acute 

exposures and lower doses (at or lower than the current NOAEL/LOAELs of 

the parent compounds) have shown adverse developmental outcomes in the 

brain, prostate, and mammary gland of rodent models, in addition to those 

effects reported at higher doses. Because of the growing number of health 

effects following chlorotriazine exposure in mammals, analytical tools and 

high quality standards have been developed to measure the metabolites/ 

degradates and their related excretory or conjugated forms. These data can 

be used to determine the disposition of the individual metabolites in the body 

fluids and affected tissues. Furthermore, the measurement of these triazine 

residues in rodent models have only recently been reported in mice, building 

on the limited pharmacokinetic information from male and virgin female 

rats. Post-exposure metabolite/degradate analyses in pregnant and lactating 

rats discovered unique patterns of analytes based on whether the exposure 

was a mixture of residues or the parent compound alone, as well as a dose 

effect. The developmental health effects and the measurement of the chlorotriazine 

metabolites in affected tissues or body fluids in multiple species and 

under varied reproductive/developmental conditions are important data that 

may be used for future risk assessment of these high use herbicide residues. 

This abstract does not necessarily reflect EPA policy. 

#1981 1:30 CHLOROTRIAZINE HERBICIDES AND 

THEIR COMMON DEGRADATION 

PRODUCTS OF CONCERN: DISPOSITION 

AND POTENTIAL HEALTH EFFECTS. S. E. 

Fenton 1 and A. Mahfouz 2 . 1 Reproductive Toxicology 

Division, U.S. EPA, Research Triangle Park, NC and 

2 

Health and Ecological Criteria Division, Office of 

Water, U.S. EPA, Washington, DC. 

Abstract # 

#1982 1:35 WHERE DO WE STAND ON 

CHLOROTRIAZINE RESIDUALS? 

CURRENT STATE OF THE SCIENCE AND 

REGULATION. A. Mahfouz. Health and Ecological 

Criteria Division, Office of Water, U.S. EPA, 


#1983 2:00 ATRAZINE AND DOPAMINE 

NEUROTOXICITY. D. A. Cory-Slechta, V. 

Rodriquez, M. Thiruchelvam, J. Kochar and A. Rossi- 

George. Environmental and Occupational Health 

Sciences Institute, Piscataway, NJ. 

#1984 2:30 COMPLEX PHARMACOKINETIC 

DISPOSITION OF ATRAZINE AND ITS 

CHLORINATED METABOLITES IN THE 

RAT AFTER ORAL ADMINISTRATION. T. 

McMullin 1 , W. H. Hanneman 2 , B. K. Cranmer 2 , J. 

D. Tessari 2 and M. E. Andersen 3 . 1 Toxicology and 


Chemical Company, Midland, MI, 2 Department of 



3 

Computational Biology Division, The Hamner 

Institute, Research Triangle Park, NC. 

#1985 3:00 METABOLISM AND HEALTH EFFECTS OF 

ATRAZINE EXPOSURE IN THE MOUSE. N. 

M. Filipov, M. K. Ross, L. M. Pinchuk, A. Borazjani 

and A. Coban. CEHS, Basic Sciences, Mississippi 

State University, Mississippi State, MS. 

#1986 3:30 DISPOSITION AND HEALTH EFFECTS OF 

CHLOROTRIAZINE METABOLITES IN THE 

PREGNANT RAT AND HER OFFSPRING. S. 

E. Fenton 1 , J. L. Rayner 3,1 , J. P. Stanko 1 and D. L. 

Barr 2 . 1 Reproductive Toxicology Division, U.S. EPA, 

Research Triangle Park, NC, 2 Division of Laboratory 

Sciences, Center for Disease Control & Prevention, 

Atlanta, GA and 3 Oak Ridge National Laboratory, 

Knoxville, TN. 



1:30 PM to 4:15 PM 

Room 6A 

WORKSHOP SESSION: INTERDISCIPLINARY APPROACHES 

FOR IMPROVING CHEMICAL HAZARD TESTING PARADIGMS 

Chairperson(s): Ivan Rusyn, University of North Carolina Chapel Hill, 

Chapel Hill, NC and David Dix, U.S. EPA, Research Triangle Park, NC. 

Endorsed by: 


In Vitro and Alternative Methods Specialty Section* 



Governments, industry and non-governmental organizations are faced 

with the pressing need for evaluating tens of thousands of chemicals (e.g., 

high production volume chemicals, pesticidal inerts, and drinking water 

contaminants) for their potential to cause adverse human health and environmental 

effects. Traditional approaches for toxicological assessment are 

too labor- and cost-intensive to apply to all but a small segment of these 

chemicals. Thus, novel chemical prioritization programs are being actively 

developed with the goal of exploring alternative methods comprising in 

silico modeling, high-throughput screening and toxicogenomic technologies. 

The overall goal of these efforts is to characterize the molecules and/or 

biological processes that are the targets for chemical-biological interactions 

and can serve as predictors of adverse effects. This session presents both the 

scientific approaches being developed, as well as perspectives from various 

stakeholders on applications and promises of novel chemical prioritization 

methods. 

Wednesday 




Wednesday 


#1987 1:30 INTERDISCIPLINARY APPROACHES 

FOR IMPROVING CHEMICAL HAZARD 

TESTING PARADIGMS. I. Rusyn 1 and D. 

Dix 2 . 1 Department of Environmental Sciences 

and Engineering, University of North Carolina at 

Chapel Hill, Chapel Hill, NC and 2 National Center 

for Computational Toxicology, U.S. Environmental 


#1988 1:35 U.S., CANADIAN AND EUROPEAN UNION 

APPROACHES TO PRIORITIZING AND 

IDENTIFYING INDUSTRIAL CHEMICALS OF 

CONCERN. R. A. Denison. Environmental Defense, 

Washington, DC. Sponsor: D. Dix. 

#1989 2:07 APPROACHES FOR PRIORITIZING AND 

TESTING OF CHEMICALS FOR TOXICITY. 

B. Gollapudi. The Dow Chemical Company, 

Midland, MI. 

#1990 2:39 EPA’S TOXCAST PROGRAM FOR 

PREDICTING HAZARD AND PRIORITIZING 

TOXICITY TESTING OF ENVIRONMENTAL 

CHEMICALS. K. Houck. NCCT, U.S. EPA, 

Research Triangle Park, NC. Sponsor: D. Dix. 

#1991 3:11 MODELING TOXICITY FROM HIGH 

THROUGHPUT SCREENING DATA ON 

ENVIRONMENTAL CHEMICALS. A. Tropsha 1 , 

H. Zhu 1 , A. Richard 2 and I. Rusyn 1 . 1 University of 

North Carolina, Chapel Hill, NC and 2 Environmental 


#1992 3:43 REPLACEMENT OF ANIMAL TESTING 

WITH IN VITRO ALTERNATIVES FOR 

CHEMICAL SAFETY SCREENING 

THROUGH TOXICOGENOMICS. J. Kleinjans. 

Health Risk Analysis, Maastricht University, 

Maastricht, Netherlands. Sponsor: D. Dix. 


1:30 PM to 4:15 PM 

Room 6E 

PLATFORM SESSION: APOPTOSIS: CARDIOPULMONARY 

TARGETS 

Chairperson(s): Joseph Cerreta, St. Johns University, Queens, NY and 

Yulia Tyurina, University of Pittsburgh, Pittsburgh, PA. 

#1993 1:30 IMMUNOLOCALIZATION OF GSTA4-4 IN 

ENDOTHELIAL CELLS AND POSSIBLE 

ROLE IN PROTECTION AGAINST 

APOPTOSIS AND ATHEROSCLEROSIS. Y. 

Yang, Y. Xu, V. L. Popov and P. J. Boor. Department 

of Pathology, University of Texas Medical Branch, 

Galveston, TX. 

#1994 1:30 GONIOTHALAMIN INDUCES CORONARY 

ARTERY SMOOTH MUSCLE CELLS 

APOPTOSIS IN P53 DEPENDENT AND NQO1 

INDEPENDENT MANNER. M. K. Chan 1 , N. F. 

Rajab 1 , L. B. Din 1 , D. Siegel 2 , D. Ross 2 and S. H. 

Inayat-Hussain 1 . 1 Environmental Health Programme, 

Faculty of Allied Health Sciences, Universiti 

Kebangsaan Malaysia, Kuala Lumpur, Malaysia and 

2 

Department of Pharmaceutical Sciences, School of 

Pharmacy, University of Colorado at Denver and 


#1995 1:30 PARAQUAT INDUCED APOPTOSIS IN RAT 

PLEURAL MESOTHELIAL CELLS (RPMC) 

INVOLVES RELEASE OF CYTOCHROME C 

AND CASPASE-9 ACTIVATION. K. H. Bijlani, 

H. R. Sukhija, J. O. Cantor and J. M. Cerreta. PHS, 

St. John’s University College of Pharmacy and 

Allied Health Professions, Queens, NY. Sponsor: L. 

Trombetta. 

#1996 1:30 A ROLE FOR CASPASE 8 IN AMIODARONE 

INDUCED APOPTOSIS IN RAT PLEURAL 

MESOTHELIAL CELLS (RPMC). R. Shah, J. O. 

Cantor and J. M. Cerreta. PHS, St. John’s University 

College of Pharmacy and Allied Health Professions, 

Queens, NY. Sponsor: L. Trombetta. 

#1997 1:30 Z-VAD-FMK INHIBITS AMIODARONE 

INDUCED APOPTOSIS IN RAT PLEURAL 

MESOTHELIAL CELLS (RPMC). A. Datwani, 

J. M. Cerreta and J. O. Cantor. PHS, St. John’s 

University College of Pharmacy and Allied Health 

Professions, Queens, NY. Sponsor: L. Trombetta. 

#1998 1:30 Z LEHD FMK AND CYCLOSPORIN 

A INHIBIT APOPTOSIS INDUCED BY 

CADMIUM CHLORIDE IN AT PLEURAL 

MESOTHELIAL CELLS (RPMC). H. R. 

Sukhija, K. H. Biljani, J. O. Cantor and J. M. Cerreta. 

PHS, St. John’s University College of Pharmacy and 

Allied Health Professions, Queens, NY. Sponsor: L. 

Trombetta. 

#1999 1:30 CHOLESTEROL SECOALDEHYDE 

INDUCES APOPTOSIS IN J774 

MACROPHAGES VIA MITOCHONDRIAL 

PATHWAY BUT NOT INVOLVING 

REACTIVE OXYGEN SPECIES AS 

MEDIATORS. X. Gao 1 , A. C. Raghava Menon 1 , 

O. D’Auvergne 2 , K. G. Kousoulas 3 and R. M. 

Uppu 1 . 1 Environmental Toxicology and the Health 

Research Center, Southern University and A & 

M College, Baton Rouge, LA, 2 Department of 

Biological Sciences, Southern University and A 

& M College, Baton Rouge, LA and 3 Department 

of Pathobiological Sciences, School of Veterinary 

Medicine, Louisiana State University, Baton Rouge, 

LA. 

#2000 1:30 OXIDATIVE LIPIDOMICS OF HYPEROXIC 

ACUTE LUNG INJURY. Y. Y. Tyurina 1,2 , K. J. 

Wasserloos 1 , R. C. Stewart 1 , M. S. Stitt 1 , A. Kaynar 1 , 

B. R. Pitt 1 and V. E. Kagan 1,2 . 1 EOH, University 

of Pittsburgh, Pittsburgh, PA and 2 Center for Free 

Radical and Antioxidant Health, University of 


#2001 1:30 3-METHYLINDOLE INDUCED DNA 

DAMAGE PARTITIONS BETWEEN REPAIR 

OR APOPTOSIS IN HUMAN BRONCHIAL 

EPITHELIAL CELLS, DEPENDING ON 

DOSAGE. N. Cutler, J. M. Weems, W. K. Nichols 

and G. S. Yost. Pharmacology & Toxicology, 

University of Utah, Salt Lake City, UT. 

260 




Abstract # 


1:30 PM to 4:15 PM 

Room 602 

PLATFORM SESSION: IMMUNOTOXICOLOGY: T CELLS 

Chairperson(s): Barbara Kaplan, Michigan State University, East 

Lansing, MI and Narendra Singh, University of South Carolina School of 

Medicine, Columbia, SC. 

Abstract # 


1:30 PM to 4:15 PM 

Room 605 

PLATFORM SESSION: ISSUES IN REGULATORY RISK 

ASSESSMENT 

Chairperson(s): George Alexeeff, Cal/EPA, Oakland, CA and Philip 

Bolger, U.S. FDA, College Park, MD. 

#2002 1:30 THE MECHANISM BY WHICH 

CANNABIDIOL, A PLANT-DERIVED 

CANNABINOID, SUPPRESSES IMMUNE 

FUNCTION INVOLVES SUPPRESSION 

OF NUCLEAR FACTOR OF ACTIVATED 

T CELLS (NFAT) TRANSCRIPTIONAL 

ACTIVATION, BUT NOT SUPPRESSION OF 

NFATC1 OR NFATC2 mRNA EXPRESSION. B. 

L. Kaplan and N. E. Kaminski. Center for Integrative 

Toxicology, Pharmacology and Toxicology, Michigan 


#2003 1:58 ATTENUATION OF EXPERIMENTAL 

AUTOIMMUNE HEPATITIS BY 

EXOGENOUS AND ENDOGENOUS 

CANNABINOIDS: INVOLVEMENT OF 

REGULATORY T CELLS. V. L. Hegde, S. Hegde, 

M. Nagarkatti and P. S. Nagarkatti. Pathology, 

Microbiology & Immunology, University of South 

Carolina School of Medicine, Columbia, SC. 

#2004 2:26 C-FLIP PLAYS IMPORTANT ROLE IN 

TCDD (2, 3, 7, 8-TETRACHLORODIBENZO- 

P-DIOXIN)-INDUCED APOPTOSIS IN 

PRIMARY T CELLS AND ESTABLISHED T 

CELL LINE IN VITRO. N. P. Singh, M. Nagarkatti 

and P. Nagarkatti. Pathology, Microbiology, and 

Immunology, University of South Carolina School of 

Medicine, Columbia, SC. 

#2005 2:54 INORGANIC MERCURY MODULATES 

CD95/FAS DEPENDENT CROSS- 

REGULATION OF T-CELL ANTIGEN 

RECEPTOR SIGNAL TRANSDUCTION. 

M. D. Laiosa and M. J. McCabe. Department of 



#2006 3:21 EX-VIVO CHARACTERIZATION OF 

T-REGULATORY TYPE CD4+ T CELLS IN 

MICE EXPOSED TO TCDD. N. B. Marshall 1,3 , 

L. B. Steppan 2 , W. R. Vorachek 2 , D. V. Mourich 1,3 

and N. I. Kerkvliet 2 . 1 Microbiology, Oregon State 

University, Corvallis, OR, 2 Environmental and 

Molecular Toxicology, Oregon State University, 

Corvallis, OR and 3 AVI BioPharma Inc., Corvallis, 

OR. 

#2007 3:48 SUPPRESSION OF T CELL 

CO-STIMULATOR ICOS BY DELTA-9- 

TETRAHYDROCANNABINOL. H. Lu 1,2 , B. L. 

Kaplan 1,2 and N. E. Kaminski 1,2 . 1 Pharmacology and 


MI and 2 Center for Integrative Toxicology, Michigan 


#2008 1:30 CONTAMINANTS AND A GLOBILIZED 

FOOD SUPPLY. P. M. Bolger. Center for Food 

Safety and Applied Nutrition, U.S. FDA, College 

Park, MD. 

#2009 1:49 RISK ASSESSMENT OF ACRYLAMIDE IN 

FOOD CONTACT MATERIALS. S. H. Henry. 

Center for Food Safety and Applied Nutrition, U.S. 

Food and Drug Admin., College Park, MD. 

#2010 2:08 ENVIRONMENTAL FATE OF MEDICINAL 

PRODUCTS: REQUIREMENTS AND 

CASE STUDIES. K. Barrett and D. Kirkpatrick. 

Huntingdon Life Sciences, Huntingdon, Cambs, 

United Kingdom. Sponsor: S. Dean. 

#2011 2:27 COMPUTATIONAL TOXICOLOGY: 

THE PUBLIC HEALTH PERSPECTIVE. 

G. Demchuk, P. Ruiz, H. R. Pohl, J. Wilson, F. 

Scinicariello, M. Mumtaz, M. Fay, M. Hatcher, H. 

Hansen and C. T. De Rosa. Division of Toxicology 

and Environmental Medicine, ATSDR/CDC, Atlanta, 

GA. 

#2012 2:45 DATA-DERIVED UNCERTAINTY FACTOR 

APPROACH IN THE REVISED N-METHYL 

CARBAMATE CUMULATIVE RISK 

ASSESSMENT. A. Lowit 1 , M. E. Reaves 1 , R. W. 

Setzer 2 , V. C. Moser 2 and D. J. Miller 1 . 1 Office of 

Pesticide Programs, U.S. Environmental Protection 

Agency, Washington, DC and 2 Office of Research 

and Development, U.S. Environmental Protection 

Agency, RTP, NC. 

#2013 3:03 POLYCYCLIC AROMATIC HYDROCARBON 

(PAH) MIXTURES: ASSESSMENT OF 

CANCER RISK USING A PROPOSED 

RELATIVE POTENCY FACTOR (RPF) 

APPROACH. L. Flowers 1 , H. Carlson-Lynch 2 , M. 

Gehlhaus 1 , K. Hogan 1 , C. Keshava 1 , P. McClure 2 , 

G. Rice 1 , J. Stickney 2 , J. Strong 1 and L. Teuschler 1 . 

1 

NCEA, U.S. EPA, Washington, DC, DC and 

2 

Syracuse Research Corporation, Syracuse, NY. 

#2014 3:21 MODE OF ACTION FRAMEWORKS FOR 

RISK ASSESSMENT: CHALLENGES AND 

OPPORTUNITIES FOR PROGRESS. K. Z. 

Guyton, S. Barone, R. C. Brown, S. Y. Euling, 

J. Jinot and S. Makris. NCEA, ORD, U.S. EPA, 


#2015 3:39 MUTAGENIC MODE OF ACTION FOR 

CARCINOGENICITY: COMMENTS ON 

EPA’S DRAFT FRAMEWORK. E. L. Hofmann 1 , 

R. S. Schoeny 2 , R. M. Putzrath 1 , M. M. Chu 3 , M. 

C. Cimino 4 , K. L. Dearfield 5 , A. Kligerman 3 , C. 

Keshava 3 , N. Keshava 3 , N. McCarroll 4 and R. 

D. Owen 3 . 1 Office of the Science Advisor, U.S. 

EPA, Washington, DC, 2 Office of Water, U.S. 

EPA, Washington, DC, 3 Office of Research and 

Development, U.S. EPA, Washington, DC, 4 Office 

of Prevention, Pesticides, and Toxic Substances, 

U.S. EPA, Washington, DC and 5 Food Safety and 

Inspection Service, U.S. Department of Agriculture, 


Wednesday 




Wednesday 


#2016 3:57 INTEGRATION OF TOXICOGENOMICS 

DATA INTO MODE OF ACTION ANALYSES 

FOR CANCER RISK ASSESSMENT. C. 

Keshava, N. Keshava and L. Flowers. NCEA, ORD, 



1:30 PM to 4:15 PM 

Room 618 


PLATFORM SESSION: NEW INSIGHTS FOR DEVELOPMENTAL 

TOXICOLOGY 

Chairperson(s): Barbara Abbott, U.S. EPA, Research Triangle Park, NC 

and Evan Gallagher, University of Washington, Seattle, WA. 

#2017 1:30 IS VALPROIC ACID TERATOGENICITY 

DEPENDENT ON HISTONE DEACETYLASE 

INHIBITION? M. Stigson 1 , M. Jergil 1 , M. 

Forsberg 2 , M. Fernandes 3 , H. Nau 3 , A. Gustafson 4 

and L. Dencker 1 . 1 Pharmaceutical Biosciences, 

Uppsala University, Uppsala, Sweden, 2 Medical 

Biochemistry and Microbiology, Uppsala University, 

Uppsala, Sweden, 3 Food Toxicology, Veterinary 

Medical University, Hannover, Germany and 

4 

Safety Assessment, AstraZeneca R&D Södertälje, 

Södertälje, Sweden. 

#2018 1:49 DEVELOPMENTAL TOXICITY OF 

PERFLUOROOCTANE SULFONATE (PFOS) 

IS NOT DEPENDENT ON EXPRESSION 

OF PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR-ALPHA (PPARa) 

IN THE MOUSE. B. D. Abbott, C. J. Wolf, K. 

P. Das and C. Lau. Repro Tox Division U.S. EPA, 


#2019 2:08 HUMAN FETAL LIVER HEMATOPOIETIC 

STEM CELLS AS A TOOL FOR 

UNDERSTANDING IN UTERO INJURY OF 

TRANSPLACENTAL CHEMICALS. E. P. 

Gallagher 1 , J. Shao 1 , S. Tilton 1 and C. Moneypenny 2 . 

1 


University of Washington, Seattle, WA and 

2 

Pathobiology, University of Florida, Gainesville, FL. 

#2020 2:27 PREFERENTIAL EXPRESSION OF 

XENOBIOTIC EFFLUX TRANSPORTERS IN 

MOUSE FETAL MEMBRANES COMPARED 

TO PLACENTA. L. Aleksunes 1 , Y. Cui 1 , J. Hunt 2 

and C. Klaassen 1 . 1 Pharmacology, Toxicology and 


Kansas City, KS and 2 Anatomy and Cell Biology, 


KS. 

#2021 2:45 PARACRINE HH SIGNALING IN 

PROSTATE: STAGE-SPECIFIC EFFECTS 

ON EPITHELIAL PROLIFERATION. M. 

Yu 1,2 , J. Zhang 2 and W. Bushman 2 . 1 Molecular and 

Environmental Toxicology Center, University of 

Wisconsin-Madison, Madison, WI and 2 Surgery, 

University of Wisconsin-Madison, Madison, WI. 

Sponsor: R. Peterson. 

#2022 3:03 ARYL HYDROCARBON RECEPTOR 

REGULATES WILMS’ TUMOR 

SUPPRESSOR GENE FUNCTION DURING 

NEPHROGENESIS. A. Nanez and K. S. Ramos. 

Biochemistry and Molecular Biology, Center for 

Genetics and Molecular Medicine, University of 


#2023 3:21 INVOLVEMENT OF INFLAMMATION- 

RELATED GENES IN TCDD-INDUCED 

HYDRONEPHROSIS IN MALE C57BL/6 

MOUSE PUPS. W. Yoshioka 1 , N. Nishimura 2 , T. 

Akagi 1 and C. Tohyama 1 . 1 Division of Environmental 

Health Sciences, CDBIM, The University of Tokyo 

Graduate School of Medicine, Tokyo, Japan and 

2 

National Institute for Environmental Studies, 

Tsukuba, Japan. 

#2024 3:39 EFFECTS OF 2, 3, 7, 


ON BONE MINERALIZATION IN THE 

GROWING MOUSE. N. Nishimura 1 , I. 

Tomohiko 1 , K. Izumi 2 , H. Fujimaki 1 and H. 

Nishimura 3 . 1 National Institute for Environmental 

Studies, Tsukuba, Ibaraki, Japan, 2 FINETEC, Tokyo, 

Japan and 3 Aichi Mizuho University, Toyota, Japan. 

Sponsor: J. Yonemoto. 

#2025 3:57 ADVERSE HEATH OUTCOMES IN ADULT 

OFFSPRING OF RATS UNDERNOURISHED 

IN UTERO – STRAIN COMPARISON FOR 

USE IN DEVELOPMENTAL ORIGINS 

OF HEALTH AND DISEASE (DOHAD) 

TOXICITY STUDIES. R. Ellis-Hutchings, B. 

Grey, J. Norwood, R. Judy, C. Lau and J. Rogers. 


Park, NC. 


1:30 PM to 4:15 PM 

Room 615 


PLATFORM SESSION: NRF2 INDUCED GENE REGULATION 

Chairperson(s): Heather Kleiner, Louisiana State University-Health 

Sciences Center, Shreveport, LA. 

#2026 1:30 REGULATORY MECHANISM OF NRF2 

ACTIVATION BY HYPOCHLOROUS ACID 

AND CONCOMITANT ACTIVATION OF 

INFLAMMATORY PATHWAYS. C. G. Woods 1,2 , 

Q. Zhang 1 , R. S. Thomas 1 , F. Boellmann 1 , J. 

Wang 3 , C. Wolf 3 , M. E. Andersen 1 and J. Pi 1 . 1 The 

Hamner Institutes for Health Sciences, RTP, NC, 

2 

ExxonMobil Biomedical Sciences, Annandale, NJ 

and 3 Univ of Dundee, Dundee, United Kingdom. 

#2027 1:51 COMPARISON OF CITRUS COUMARINS ON 

CARCINOGEN-DETOXIFYING ENZYMES 

IN NRF2(-/-) VS WILD-TYPE MICE. H. E. 

Kleiner 1,2 , C. Asper 1,2 , K. Itoh 4 , M. Yamamoto 3 

and M. Prince 1,2 . 1 Pharmacology, Louisiana State 

University-Health Sciences Center, Shreveport, LA, 

2 

Feist Weiller Cancer Center, LSUHSC, Shreveport, 

LA, 3 Tohoku University Graduate School of 

Medicine, Sendai, Japan and 4 Hirosaki University 

School of Medicine, Hirosaki, Japan. 

262 




Abstract # 

#2028 2:12 TARGETED DISRUPTION OF THE 

NUCLEAR FACTOR-E2-RELATED 

FACTOR-2 (NRF2) GENE PREVENTS 

FORMATION OF CHOLESTEROL 

GALLSTONES IN MICE. A. Slitt 1 , Q. Cheng 1 , 

H. Jiang 2 , S. Kulkarni 1 , J. Y. Chan 3 and D. Q. Wang 2 . 

1 

Biomedical and Pharmaceutical Sciences, University 

of Rhode Island, Kingston, RI, 2 Department of 

Medicine, Harvard Medical School, Boston, MA and 

3 

Department of Pathology, University of California, 

Irvine, CA. Sponsor: J. Manautou. 

#2029 2:33 HEPATOCYTE-SPECIFIC DELETION OF 

KEAP1 ALTERS EXPRESSION OF HEPATIC 

DRUG METABOLIZING ENZYMES AND 

TRANSPORTERS. Q. Cheng 1 , L. M. Aleksunes 2 , 

J. E. Manautou 2 , N. J. Cherrington 3 , K. Taguchi 4 , 

M. Yamamoto 4 and A. L. Slitt 1 . 1 Biomedical and 

Pharmaceutical Sciences, Univesity of Rhode Island, 

Kingston, RI, 2 Pharmaceutical Sciences, Univerisity 

of Connecticut, Storrs, CT, 3 Pharmacology and 

Toxicology, Univerisity of Arizona, Tucson, AZ 

and 4 Graduate School of Comprehensive Human 

Sciences, Univerisity of Tsukuba, Tennoudai, 


#2030 2:54 THE NRF2 ACTIVATOR OLTIPRAZ 

ALSO ACTIVATES THE CONSTITUTIVE 

ANDROSTANE RECEPTOR. M. D. Merrell 1 , J. 

P. Jackson 1 , L. M. Augustine 1 , C. D. Fisher 1 , A. L. 

Slitt 2 , J. M. Maher 3 , W. Huang 4 , D. D. Moore 4 , C. 

D. Klaassen 5 and N. J. Cherrington 1 . 1 Department 


Arizona, Tucson, AZ, 2 Department of Biomedical 

and Pharmaceutical Sciences, University of Rhode 

Island, Kingston, RI, 3 TARA center, University of 

Tsukuba Tennoudai, Tsukuba-sh, Ibaraki, Japan, 

4 

Department of Molecular and Cellular Biology, 

Baylor College of Medicine, Houston, TX and 

5 

Department of Pharmacology, Toxicology and 



#2031 3:15 ACETYLTRANSFERASE P300/CBP 

REGULATES NRF2-DEPENDENT 

ANTIOXIDANT RESPONSE THROUGH 

ACETYLATION-DEPENDENT AND 

INDEPENDENT MECHANISM. Z. Sun and 

D. D. Zhang. Department of pharmacology & 

toxicology, University of Arizona, Tucson, AZ. 

#2032 3:35 NUCLEAR FACTOR ERYTHROID 

2-RELATED FACTOR 2 (NRF2) INHIBITS 

CYTOKINE PRODUCTION BY ACTIVATED 

MURINE T CELLS. C. E. Rockwell and C. 

D. Klaassen. Pharmacology, Toxicology, and 



#2033 3:55 IDENTIFICATION OF NRF2-DEPENDENT 

AIRWAY EPITHELIAL ADAPTIVE 

RESPONSE TO PROINFLAMMATORY 

OXIDANT-HYPOCHLOROUS ACID (HOCL) 

CHALLENGE BY TRANSCRIPTION 

PROFILING. L. Zhu 1 , J. Pi 1 , S. Wachi 2 , M. E. 

Andersen 1 , R. Wu 2 and Y. Chen 1 . 1 The Hamner 

Institutes, RTP, NC and 2 UC Davis, Davis, CA. 

Abstract # 


1:30 PM to 4:15 PM 

Room 2A 

PLATFORM SESSION: SELECTIVE DOPAMINERGIC 

NEUROTOXICITY: GENETICS AND MECHANISMS 

Chairperson(s): Virgnia Moser, U.S. EPA, Research Triangle Park, NC 

and Lisa Opanashuk, University of Rochester, Rochester, NY. 

#2034 1:30 MUTATION OF THE PARKINSON’S GENE 

DJ-1 INCREASES THE INFLAMMATORY 

RESPONSE IN MOUSE ASTROCYTES. A. K. 

Ashley 1 , T. Katoh 2 , J. A. Moreno 1 , W. H. Hanneman 1,2 

and M. E. Legare 1,2 . 1 Cell and Molecular Biology 

Program, Colorado State University, Fort Collins, 

CO and 2 Environmental and Radiological Health 


CO. 

#2035 1:54 OXIDATIVE STRESS-INDUCED 

PHOSPHORYLATION OF PKD1 

ACTIVATION LOOP IS REGULATED BY 

PROTEIN KINASE C-DELTA PROTEOLYTIC 

ACTIVATION IN CELL CULTURE MODELS 

OF DOPAMINERGIC DEGENERATION. A. 

Asaithambi, A. Kanthasamy, V. Anantharam and A. 

G. Kanthasamy. Biomedical Sciences, Iowa State 

University, Ames, IA. 

#2036 2:18 DEFINING “NEUROINFLAMMATION”: 

LESSONS FROM MPTP- AND 

METHAMPHETAMINE-INDUCED 

NEUROTOXICITY. J. P. O’Callaghan. CDC- 

NIOSH, Morgantown, WV. 

#2037 2:42 PROLYL HYDROXYLASE INHIBITION 

PROTECTS AGAINST MPP+ TOXICITY IN 

VITRO. D. Lee, R. Subramanian and J. K. Andersen. 

Buck Institute for Age Research, Novato, CA. 

#2038 3:06 NUCLEAR FACTOR KAPPA B 

MEDIATES SELECTIVE INDUCTION 

OF NEURONAL NITRIC OXIDE 

SYNTHASE IN ASTROCYTES DURING 

MILD INFLAMMATORY STIMULATION 

WITH 1-METHYL-4-PHENYL-1, 2, 3, 

6-TETRAHYDROPYRADINE. D. L. Carbone 

and R. B. Tjalkens. Environmental and Radiological 

Health Sciences, Colorado State University, Fort 

Collins, CO. 

#2039 3:29 ALTERED DOPAMINE LEVELS AND 

NEURODEGENERATION IN THE 

SUBSTANTIA NIGRA IN RESPONSE TO 

INTRANIGRAL INJECTION OF ROTENONE 

IN MICE. J. Carlsen and J. Eells. Mississippi State 

University, Mississippi State, MS. Sponsor: M. Ross. 

#2040 3:52 CHARACTERIZATION OF THE 

DIFFERENCES IN THE OXIDATIVE 

EVENTS IN PROTEINS IN TWO 

DIFFERENT PESTICIDE MODELS OF PD. 

P. Mastroberardino 1 , A. L. McCormack 3 , D. A. 

Di Monte 3 , G. W. Miller 2 and J. T. Greenamyre 1 . 

1 

Neurology, University of Pittsburgh, Pittsburgh, 

PA, 2 Center for Neurodegenerative Disease, Emory 

University, Atlanta, GA and 3 Basic Research 

Department, The Parkinson’s Institute, Sunnyvale, 

CA. 

Wednesday 





2:45 PM to 3:45 PM 


Abstract # 

discuss regulatory issues and status worldwide, recent toxicological findings, 

relative sources of exposure, biotic and abiotic degradation, and characterization 

of risk and associated data gaps. Finally, a cost-benefit analysis for 

DecaBDE will be evaluated. (This abstract does not represent EPA policy) 

Wednesday 

Exhibitor Hosted Session: An Alternative to 

Animal Use: Today and Prospective 

Presented by: SkinEthic Laboratories 

SkinEthic is devoted to develop and produce reliable and robust in vitro 

alternative methods to animal use in cosmetic, chemical and pharmaceutical 

industries. SkinEthic models provide relevant tools for efficacy and 

safety screening tests in order to support integrated decision making during 

research and development phases. Some screening tests are referenced and 

validated as alternatives to animal use. Others are in the process of validation 

under ECVAM and OECD guidelines. 


2:45 PM to 3:45 PM 


Exhibitor Hosted Session: In Vivo Micro- 

Ultrasound Imaging for Quantification of 

Anatomical, Functional and Molecular 

Biomarkers in Preclinical Imaging 

Presented by: VisualSonics 

This workshop will describe new developments in in vivo micro-imaging 

for Quantification of Anatomical, Functional and Molecular Biomarkers 

in Preclinical Imaging. Specifically, examples of real-time ultrasound 

imaging for performing detailed studies of abdominal and cardiovascular 

phenotypes and analyses as well as assessment of teratogenic effects will 

be reviewed. Possibilities for guided interventional procedures (both therapeutic 

and toxic) will also be discussed. 

#2041 4:30 A CASE STUDY ON THE RISKS AND 

BENEFITS OF DECABDE, A MAJOR 

BROMINATED FLAME RETARDANT. D. 

Staskal. ChemRisk, Austin, TX. 

4:45 TOXICITY OF DECABDE. Linda Birnbaum 

4:58 EXPOSURE TO DECABDE. Tom Webster 

5:11 DEGRADATION OF DECABDE VIA ABIOTIC 

AND BIOTIC PATHWAYS. Heather Stapleton 

5:24 RISK CHARACTERIZATION - 

CONSIDERATIONS FOR BIOAVAILABILITY, 

PHARMACOKINETICS, AND LIMITATIONS 

TO INTERPRETING AVAILABLE TOXICITY 

DATA. Bob Campbell 

5:37 COST BENEFIT ANALYSIS MODEL FOR 

DECABDE AND FIRE SAFETY. Martin van den 

Berg 


4:30 PM to 5:50 PM 

Room 615 

INFORMATIONAL SESSION: IMPLEMENTATION OF THE ICH 

S8 IMMUNOTOXICITY TESTING GUIDELINE 

Chairperson(s): Thomas Kawabata, Pfizer Global Research and 

Development, Groton, CT and Pramila Singh, PPD Industries, Inc., 

Morrisville, NC. 


4:30 PM to 5:50 PM 

Room 608 

ROUNDTABLE SESSION: A CASE STUDY ON THE RISKS AND 

BENEFITS OF DECA-BDE—A MAJOR BROMINATED FLAME 

RETARDANT 

Chairperson(s): Daniele Staskal, ChemRisk, Inc., Austin, TX and 

Linda Birnbaum, U.S. EPA, Research Triangle Park, NC. 

Endorsed by: 



Decabromodiphenyl ether (DecaBDE) is a high production volume chemical 

used as a flame retardant in a variety of consumer products; examples of 

uses in high impact polystyrene and textile applications include housing of 

TVs, audio and video equipment, mobile phones, and upholstery textiles 

(e.g., sofas, office chairs). It is the only polybrominated diphenyl ether 

(PBDE) mixture still used commercially as the other formulations have 

been banned or withdrawn worldwide. However, DecaBDE is the subject 

of intense scientific and regulatory scrutiny given that recent studies have 

suggested that 1) DecaBDE is a potential developmental neurotoxicant 

in rodent models; 2) DecaBDE potentially degrades to lower brominated 

congeners which appear to be more toxic than DecaBDE itself; and 3) levels 

of DecaBDE appear to be increasing in humans, wildlife, and the environment. 

Nonetheless, some scientists suggest that despite these findings, the 

benefits of using DecaBDE as a flame retardant outweigh the potential 

health risks. This scientific roundtable will address these topics. Experts will 

Endorsed by: 


The ICH S8 Guideline, “Immunotoxicity Studies for Human Pharmaceuticals” 

provides recommendations for nonclinical safety testing of low 

molecular weight drugs for potential to induce harmful effects via suppression 

of the immune system. It applies to new drugs; existing drugs in which 

intended indication or label changes may result in unaddressed toxicological 

issues; and drugs in which signs of immunosuppression arise during clinical 

trials or following market approval. Preparation of the S8 guidance document 

progressed through the combined efforts of pharmaceutical industry 

representatives (PhRMA, JPMA, EFPIA) and members from tripartite 

government regulatory agencies (FDA, MHLW, CHMP) who recognized the 

need for globally harmonized regulatory guidance on immunotoxicological 

testing in drug development. Over the years leading up to the adoption of 

the S8 Guideline by regional regulatory agencies (2005-2006), there was 

significant debate and even some confusion over the compulsory versus 

voluntary nature of the testing recommendations and on how to apply the 

guidance in concert with pharmaceutical industry objectives. The purpose 

of this informational seminar is to provide a forum for the discussion of 

the practical implementation of the S8 Guideline including industry case 

examples and questions that remain unanswered. A panel consisting of 

members of the ICH S8 Expert Working Group responsible for creating the 

S8 Guideline and representing the U.S., Europe, and Japan will be available 

to answer questions from the audience. This session is intended to be 

an interactive forum with the expert panel, audience, and selected speakers 

from industry who have comments or questions on the scope and application 

of the S8 Guideline in current industry practice. The session will begin 

with a brief introduction followed by an overview of the development of the 

S8 Guideline and the rationale for the recommendations made. This will be 

followed by two individual oral presentations by industry professionals with 

key opinions to consider about the practical application of the Guideline, an 

open question and answer session, and concluding thoughts. 

264 




Abstract # 

#2042 4:30 IMPLEMENTATION OF THE ICH S8 

IMMUNOTOXICITY TESTING GUIDELINE. 

P. Singh 1 and T. Kawabata 2 . 1 PPD, Morrisville, NC 

and 2 Pfizer, Groton, CT. 

4:35 OVERVIEW AND HISTORY OF THE 

DEVELOPMET OF THE ICH S8 GUIDELINE. 

Jan Willem van der Laan 

5:00 FILLING THE GAP: IMMUNOTOXICITY 

OF BIOTECHNOLOGY PRODUCTS. Daniel 

Wierda 

5:25 GUIDELINE POSITIONS ON ADDITIONAL 

IMMUNOLOGICAL PARAMETERS. Gary 

Burleson 

5:30 CONCLUDING REMARKS. Tom Kawabata 


4:30 PM to 5:50 PM 

Room 6C 

Abstract # 

5:06 AMBIENT PARTICULATE MATTER 

INDUCED ACTIVATION OF COAGULATION. 

Gokhan Mutlu 

5:28 DAMAGE SIGNALING AT THE 

TRANSCRIPTION-TRANSLATION 

INTERFACE. Thomas Begley 

WEDNESDAY EVENING 

Wednesday Evening, March 19 

6:00 PM to 7:30 PM 

Sheraton 

Grand Ballroom A 

Special Interest Group Meeting/Reception: Women 

in Toxicology 


INFORMATIONAL SESSION: NIEHS OUTSTANDING NEW 

ENVIRONMENTAL SCIENTISTS (ONES) AWARDEES 

Chairperson(s): James Mastin, NIEHS, Research Triangle Park, NC and 

Carole Shreffler, NIEHS, Research Triangle Park, NC. 

Endorsed by: 


Concerned with assuring the quality of biomedical research, the National 

Institute of Environmental Health Sciences launched an initiative to support 

the future generation of exceptionally talented and creative new scientists. 

For NIEHS, this involves helping to develop a cadre of talented 

early-career scientists who will further the understanding of the impact of 

environmental exposures on human health through disciplines such as toxicology, 

epidemiology, and clinical research, as well as multi-disciplinary 

translational research. To identify outstanding scientists at the formative 

stages of their career and assist them in launching an innovative research 

program with a defined impact in the environmental health sciences, NIEHS 

has established the ONES program to fund R01 research grants intended 

for researchers who have not received their first R01 research grant. It is 

designed to be highly competitive, each school only being allowed to submit 

one application, with a limited number awarded each year. These R01s are 

distinguished from other R01 research grants in that they provide funding 

for developing necessary resources and for career development activities 

in addition to funding for research expenses. Research programs supported 

by this announcement seek to promote career advancement for new scientists 

who intend to make a long-term career commitment to research in the 

mainstream of the environmental health sciences, and bring innovative, 

ground-breaking research initiatives and thinking to bear on the problems 

of how environmental exposures affect human biology, human pathophysiology 

and human disease. The first round of awardees included researchers 

investigating the effects of air pollution on pulmonary and cardiovascular 

disease, the mechanisms of arsenic carcinogenesis, mechanisms of repair 

of environmentally induced DNA damage, and sensory neuron signaling in 

response to environmental exposures. This session will provide attendees 

the opportunity to hear the exciting, innovative research being conducted 

by these talented new researchers and introduce the recipients of the second 

round of ONES awardees. 

Wednesday Evening, March 19 

6:00 PM to 7:30 PM 


Specialty Section Meetings/Receptions: Dermal 

Toxicology, Immunotoxicology, Mixtures, 

Molecular Biology, And Reproductive and 

Developmental Toxicology 

Wednesday 

#2043 4:30 NIEHS OUTSTANDING NEW 

ENVIRONMENTAL SCIENTISTS (ONES) 

AWARDEES. J. P. Mastin and C. Shreffler. DERT, 


4:44 TRPA1 CHANNELS AS NEURONAL 

SENSORS FOR ENVIRONMENTAL 

TOXICANTS. Sven Eric Jordt 





THURSDAY MORNING 

Thursday Morning, March 20 

7:30 AM to 8:50 AM 

Ballroom 6B 

ISSUES SESSION: 2007 National Research Council- 

National Academy of Sciences Reports: Impact on 

the Future of Toxicology 

Chairpersons: Gerald N. Wogan, Massachusetts Institute of Technology, 

Cambridge, MA and Cheryl Lyn Walker, University of Texas MD 

Anderson Cancer Center, Smithville, TX. 

Endorsed by: SOT Presidential Chain 

This special session has been organized by the 2008 Program Committee 

to introduce SOT members to the 2007 National Research Council reports 

from the National Academy of Science addressing key issues impacting 

our society and profession today. This session will open dialogue on the 

contents of the reports and their implications for the future of Toxicology. 

An Introduction by the Session Chairs will be followed by presentations 

from Chairs of the Committees drafting the three reports to be featured, 

with a facilitated discussion to follow. These reports are: 

Toxicity Testing in the 21 st Century: A Vision and Strategy, Daniel 

Krewski, University of Ottawa, Ontario, Canada 

Applications of Toxicogenomics Technologies to Predictive Toxicology 

and Risk Assessment, David Christiani, Harvard University, Boston, MA 

Models in Environmental Regulatory Decision Making, Chris Whipple, 

ENVIRON Corporation, Emeryville, CA 

combustion, with an emphasis on biodiesel exhaust as one of the better 

studied biofuels. Comparison to emissions from petroleum diesel engines 

will allow assessment as to how similar the emissions may be in terms of 

toxic components, assisting in risk assessment for biodiesel exhaust; 3. to 

present an overview of the known toxicology of biofuel emissions, with 

reference to petroleum diesel exhaust literature, to identify areas where 

assessment of the effects of biofuel emissions exposure should be pursued. 

[This abstract may not reflect EPA policy.] 

#2044 7:30 BIOFUEL COMBUSTION: AN EMERGING 

HEALTH PROBLEM? M. C. Madden 1 and F. 

Cassee 2 . 1 ORD, NHEERL, HSD, Clinical Research 

Branch, U.S. EPA, Chapel Hill, NC and 2 Center of 

Environmental Health Research, National Institute 

for Public Health and Environment, Bilthoven, 

Netherlands. 

7:38 LIQUID BIOFUELS: BIOLOGICAL 

SOURCES, RATIONALE FOR 

DEVELOPMENT, AND THE OUTLOOK 

FOR FUTURE USE IN THE U.S. Christopher 

Somerville 

7:56 COMBUSTION EMISSIONS FROM LIQUID 

BIOFUELS. Robert McCormick 

8:14 THE PRODUCTION AND USE OF LIQUID 

BIOFUELS: SOME OBSERVATIONS FROM A 

EUROPEAN PERSPECTIVE. Flemmee Cassee 

8:32 THE TOXICOLOGY OF BIOFUELS 

COMBUSTION EMISSIONS. Michael Madden 


8:30 AM to 12:00 NOON 

Ballroom 6C & E 

Oxidative Signaling And Redox Biology 

Thursday 


7:30 AM to 8:50 AM 

Room 608 

ROUNDTABLE SESSION: BIOFUEL COMBUSTION: AN 

EMERGING HEALTH PROBLEM? 

Chairperson(s): Michael Madden, U.S. EPA, Chapel Hill, NC and 

Flemming Cassee, National Institute for Public Health & Environment, 

Bilthoven, Netherlands. 

Endorsed by: 



Recently the concept of increasing the production of liquid biofuels for 

energy use in the U.S. and other countries has stirred up debate. Liquid 

biofuels have attracted attention as potential replacements for other liquid 

petroleum-based fuels primarily, but not exclusively, in on-road vehicles. 

Major uncertainties exist as to 1) the best biomass (e.g., corn, soy, etc.) to 

utilize; the net energy balance (gain or loss) in the production and transport 

of liquid biofuels; and 3) the market share liquid biofuels may attain. 

Increased biofuel production has altered land use and created ethical 

concerns, economic changes, and soil sustainability questions. Biofuel 

combustion raises additional issues as to hazard identification of the emissions 

produced under a wide range of conditions, such as fuel types and 

blends, engine types and engine operating conditions, aftertreatments, etc. 

To date few studies have been performed examining the health effects and 

biological responses with exposures to biofuel emissions. The lack of toxicological 

studies with biofuel emissions makes it difficult to assess the toxicity 

of this class of fuel relative to other petroleum-based fuels, or other potential 

fuels, e.g., hydrogen. This discussion session has these goals: 1) to inform 

the audience of the potential for different biomass types being incorporated 

into the global energy structure; 2) describe emission products of biofuel 

POSTER SESSION: OXIDATIVE INJURY AND REDOX 

BIOLOGY II: IN VITRO 

Chairperson(s): Louise Ball, University of North Carolina Chapel Hill, 


Displayed: 8:30 AM–12:00 NOON 



MODULATION OF CELLULAR 

ANTIOXIDANT ENZYMES ACTIVITIES AND 

GLUTATHIONE LEVEL BY THE DRINKING 

WATER CHLORINATION BY-PRODUCT, 

DICHLOROACETATE. E. Hassoun and J. Mehta. 

Pharmacology, The University of Toledo, Toledo, 

OH. 


INCREASED MITOCHONDRIAL 

THIOREDOXIN POTENTIATED 

N-ETHYLMALEIMIDE-INDUCED 

CYTOTOXICITY. Y. Chen 1 , Y. Go 2 , D. P. Jones 2 

and J. Cai 1 . 1 Ophthalmology, Vanderbilt University, 

Nashville, TN and 2 Medicine, Emory University, 

Atlanta, GA. 

266 




Abstract # 


NRF2-DEPENDENT ANTIOXIDANT 

SYSTEM AND PI3 KINASE/AKT 

PATHWAY IN ASTROCYTES EXPOSED TO 

METHYLMERCURY (MEHG). L. Wang 1 , H. 

Jiang 2 , M. Aschner 2 and J. Cai 1 . 1 Ophthalmology, 

Vanderbilt University, Nashville, TN and 2 Pediatrics, 

Vanderbilt University, Nashville, TN. 


MILD ENDOPLASMIC RETICULUM (ER) 

STRESS PRECONDITIONING ATTENUATES 

METHYLMERCURY (MEHG)- 

INTOXICATION IN MYOGENIC CELL 

LINE. F. Usuki. National Institute for Minamata 

Disease, Minamata, Kumamoto, Japan. Sponsor: A. 

Naganuma. 


INCREASED OXYGEN UTILIZATION 

AND OXIDATIVE STRESS IN CHO CELLS 

DURING DIQUAT REDOX CYCLING. K. C. 

Fussell 1 , J. P. Gray 1 , P. Smith 2 , D. E. Heck 3 and J. 

D. Laskin 4 . 1 Pharmacology & Toxicology, Rutgers 

University, Piscataway, NJ, 2 Biocurrents Research 

Center, Marine Biological Laboratory, Woods Hole, 

MA, 3 Cancer Biology & Pharmacology, University 

of Illinois College of Medicine, Peoria, IL and 

4 

Environmental & Occupational Med, UMDNJ- 

Robert Wood Johnson Medical School, Piscataway, 

NJ. 


EFFECT OF TWO NITROSOUREA 

DERIVATIVES ON THE ANTIOXIDATIVE 

DEFENSES OF NEOPLASTIC CELLS. E. 

Skrzydlewska, A. Stankiewicz, A. Bielawska and 

K. Bielawski. Medical University of Bialystok, 

BIalystok, Poland. Sponsor: R. Dixit. 


THE ROLE OF GLUTATHIONE IN 3H-1, 

2-DITHIOLE-3-THIONE-MEDIATED 

CYTOPROTECTION AGAINST ACROLEIN- 

INDUCED NEUROCYTOTOXICITY. Z. 

Jia, H. Zhu, Y. Li and H. P. Misra. Division of 

Biomedical Sciences, Edward Via Virginia College 

of Osteopathic Medicine, Virginia Tech Corporate 

Research Center, Blacksburg, VA. 


OFLOXACIN-INDUCED INJURIES OF 

JUVENILE RABBIT CHONDROCYTES IN 

CULTURE THROUGH OXIDATIVE STRESS. 

S. Peng and Q. Li. Research center for pharmacology 

and toxicology, Beijing Institute of disease control 

and prevention, Beijing, China. 


THE EFFECT OF THE LIPID 

PEROXIDATION PRODUCT 4-HYDROXY- 

2-NONENAL ON ESTERASE AND 

LIPASE ACTIVITIES IN HUMAN THP-1 

MONOCYTES/MACROPHAGES. A. Crow, K. 

Hardin, A. Borazjani and M. K. Ross. Mississippi 

State University, Mississippi State, MS. 

Abstract # 


CYANIDE NEUROTOXICITY: 

INVOLVEMENT OF UCP-2 UPREGULATION, 


DEPLETION AND BNIP3. L. Li, X. Zhang, 

K. Prabhakaran, L. Zhang, H. B. Leavesley, J. L. 

Borowitz and G. E. Isom. Medicinal Chemistry & 

Molecular Pharmacology, Purdue University, West 

Lfayette, IN. 


CATALASE AMELIORATES 

POLYCHLORINATED BIPHENYL-INDUCED 

CYTOTOXICITY IN HUMAN BREAST 

EPITHELIAL CELLS. V. Venkatasubbaiah, S. 

Venkataraman and P. Goswami. Radiation Oncology, 

University of Iowa, Iowa City, IA. Sponsor: G. 

Ludewig. 


PARADOXES OF MNSOD OXIDATIVE 

MODIFICATION: A NEW PROTECTIVE 

FUNCTION AGAINST OXIDATIVE STRESS. 

H. Bayir 1,2 , R. Rafikov 1 , A. Glumac 1,2 , N. Belikova 1 

and V. E. Kagan 1 . 1 Center for Free Radical & 

Antioxidant Health, Department of Environmental 

& Occupational Health, University of Pittsburgh, 

Pittsburgh, PA and 2 Department of Critical Care 

Medicine, University of Pittsburgh, Pittsburgh, PA. 


IDENTIFICATION OF CELLULAR 

PHENOTYPES, MECHANISMS AND 

PATHWAYS OF RADIOSENSITIVITY IN 

HUMAN CELL LINES. S. A. Nahas and R. 

A. Gatti. University of California Los Angeles, 

School of Medicine, Department of Pathology, 

Interdepartmental Ph.D. Program in Molecular 

Toxicology, University of California Los Angeles, 

Los Angeles, CA. Sponsor: O. Hankinson. 


MITOCHONDRIAL MECHANISMS OF ROS 

PRODUCTION AND OXIDATIVE STRESS 

BY REDOX CYCLING HERBICIDES 

IMPLICATED IN PARKINSON’S DISEASE. 

D. Drechsel, K. R. Ryan, L. Liang and M. Patel. 

Department of Pharmaceutical Sciences, University 

of Colorado HSC, Denver, CO. 


ENVIRONMENTAL AND LIPID 

PEROXIDATION DERIVED ALDEHYDES 

INDUCE ENDOPLASMIC RETICULUM 

STRESS AND UNFOLDED PROTEIN 

RESPONSE IN VASCULAR SMOOTH 

MUSCLE AND ENDOTHELIAL CELLS. P. 

Haberzettl 1 , E. N. Vladykovskaya 1 , B. Hill 1 , O. A. 

Barski 1 , S. D. Sithu 2 , S. E. D’Souza 2 , A. Bhatnagar 1 

and S. Srivastava 1 . 1 Inst. Mol. Card., University 

of Louisville, Louisville, KY and 2 Physiology, 



PROCAINAMIDE, BUT NOT 

N-ACETYLPROCAINAMIDE, INDUCES 

PROTEIN RADICAL FORMATION ON 

MYELOPEROXIDASE: A POTENTIAL 

MECHANISM OF AGRANULOCYTOSIS. 

A. Siraki, L. Deterding, M. G. Bonini, J. Jiang, M. 

Ehrenshaft and R. P. Mason. NIEHS, Research 


Thursday 




Thursday 



OXIDANT-INDUCED ARACHIDONIC 

ACID OXIDATION AND RELEASE 

FROM ISOLATED RABBIT RENAL 

MITOCHONDRIA: ROLE OF iPLA 2 

g J. L. 

Blum 1 , G. R. Kinsey 1 , P. Monian 2 , B. S. Cummings 2 

and R. G. Schnellmann 1 . 1 Pharmaceutical and 

Biomedical Sciences, Medical University of South 

Carolina, Charleston, SC and 2 Pharmaceutical and 


GA. 


iPLA 2 

g PREVENTS OXIDANT-INDUCED 

LIPID PEROXIDATION AND Ca 2+ RELEASE 

IN ISOLATED RABBIT KIDNEY CORTEX 

MICROSOMES. A. C. Eaddy and R. G. 

Schnellmann. Pharmaceutical Sciences, Medical 

University of South Carolina, Charleston, SC. 


DEVELOPMENT OF A DOMINANT- 

INHIBITORY MUTANT OF THE CATALYTIC 

SUBUNIT OF GLUTAMATE CYSTEINE 

LIGASE. C. C. Franklin and D. S. Backos. 

Department of Pharmaceutical Sciences, Toxicology 

Graduate Program, University of Colorado Health 

Sciences Center, Denver, CO. 


CATALASE ABROGATES 

POLYCHLORINATED BIPHENYLS- 

INDUCED DELAYS DURING QUIESCENT 

HUMAN BREAST EPITHELIAL CELLS’ 

ENTRY INTO THE PROLIFERATION 

CYCLE. L. Chaudhuri, N. Aykin-Burns, D. R. 

Spitz, A. L. Kalen, E. H. Sarsour and P. C. Goswami. 

Radiation Oncology, University of Iowa, Iowa. 

Sponsor: L. Robertson. 


PROSTAGLANDIN INDUCED GSH EFFLUX 

THROUGH ABCG2. H. M. Leitner 1,2 , E. Min 2 and 

B. J. Day 2,1 . 1 Pharmaceutical Sciences, UCHSC at 

Denver, Denver, CO and 2 Medicine, National Jewish 

Medical and Research Center, Denver, CO. 


ABSENCE OF NITRIC OXIDE SYNTHASE 

IN EXQUISITELY PURE LIVER 

MITOCHONDRIA. P. Venkatakrishnan, E. S. 

Nakayasu, I. C. Almeida and R. T. Miller. Biological 

Sciences, University of Texas at El Paso, El Paso, 

TX. 


ROS AND CHEMOKINE RELEASE IN 

A549 CELLS IN RESPONSE TO FE AND 

SE EXPOSURE. P. A. Potnis, K. S. Squibb and 

A. Elnabawi. Toxicology, University of Maryland, 

Baltimore, Baltimore, MD. 


POLYCHLORINATED BIPHENYL (PCB)- 

INDUCED OXIDATIVE STRESS MEDIATES 

CYTOTOXICITY IN HUMAN BREAST 

EPITHELIAL CELLS. Y. Zhu 1 , N. Aykin- 

Burns 1 , A. L. Kalen 1 , L. Li 1 , H. J. Lehmler 2 , L. 

W. Robertson 2 , P. C. Goswami 1 and D. R. Spitz 1 . 

1 

Radiation Oncology, University of Iowa, Iowa City, 

IA and 2 Occupational and Environmental Health, 



INTERACTIONS OF DINITROBENZENES 

WITH CALMODULIN-FREE NEURONAL 

NOS. C. N. Joshi and T. Miller. Biological Sciences, 

University of Texas at El Paso, El Paso 79968, TX. 


MITOCHONDRIAL PEROXIREDOXIN III 

FUNCTION IN PROTECTION AGAINST 

OXIDATIVE STRESS. R. Xie 1 , J. Dong 2 , S. 

S. Lau 1 and T. J. Monks 1 . 1 Pharmacology and 

Toxicolocy, University of Arizona Health Sciences 

Center, Tucson, AZ and 2 Dow AgroSciences, Beijing, 

China. 


HYPEROXIA ENHANCES LPS-INDUCED 

HMGB1 RELEASE FROM ALVEOLAR 

MACROPHAGES AND EPITHELIAL CELLS. 

M. G. Muralidhar 1 , S. Gangisetti 1 , T. Entezari- 

Zaher 1 , A. R. Pathak 1 , K. Degenhardt 1 , H. Wang 2 , 

K. J. Tracey 2 and L. Mantell 1,2 . 1 Department of 

Pharmaceutical Sciences, St. John’s University 

College, Queens, NY and 2 Cardiopulmonary 

Research, The Feinstein Institute for Medical 

Research, North Shore-LIJ Health System, 

Manhasset, NY. 


MECHANISTIC STUDY OF NRF2 

ACTIVATION BY ARSENIC. X. Wang, Z. Sun 

and D. D. Zhang. U of Arizona, Tucson, AZ. 


MODERATE CONCENTRATIONS OF 

HYDROGEN PEROXIDE RESCUE 

HYPEROXIA-INDUCED MACROPHAGE 

DYSFUNCTION. B. Phan 1 , T. Entezari-Zaher 1 , 

R. Lockshin 2 and L. Mantell 1,3 . 1 Pharmaceutical 

Sciences, St. John’s University College of Pharmacy, 

Queens, NY, 2 Biology Department, St. John’s 

College of Liberal Arts and Sciences, Queens, NY 

and 3 Cardiopulmonary Research, The Feinstein 

Institute for Medical Research, North Shore-Long 

Island Jewish Health System, Manhasset, NY. 


THE IKKb CROSSTALKS WITH THE TGFb 

PATHWAYS IN ARSENIC TOXICITY. Z. 

Peng, Z. Tang and Y. Xia. University of Cincinnati, 



INVESTIGATION OF THE EFFECT 

OF OXIDATIVE STRESS ON THE 

PROTEIN STABILITY OF THE INSULIN 

TRANSCRIPTION FACTOR, MAFA. J. 

Loertscher and M. Giday. Chemistry, Seattle 

University, Seattle, WA. Sponsor: L. White. 


EFFECTS OF SODIUM ARSENITE ON ROS 

PRODUCTION AND CELL PROLIFERATION 

MEDIATED BY C-MYC AND NF-kB 

INDUCTION IN MCF-7 CELLS. R. Ruiz- 

Ramos 1 , M. E. Cebrián 2 , A. De Vizcaya-Ruiz 2 and L. 

T. Lopez-Carrillo 1 . 1 Centro de Investigacion en Salud 

Poblacional, Instituto Nacional de Salud Publica, 

Cuernavaca, Morelos, Mexico and 2 Toxicology, 

Centro de Investigación y de Estudios Avanzados 

del Instituto Politécnico Nacional, Mexico City, DF, 

Mexico. 

268 




Abstract # 


OXIDATIVE POTENTIAL AND CELLULAR 

EFFECTS INDUCED BY PM10 OBTAINED IN 

MEXICO CITY AND AT A RECEPTOR SITE. 

A. R. Osornio-Vargas 1,2 , R. Quintana 1 , V. Gomez 2 , 

J. Serrano 2 , I. Vazquez 1 , G. Flores 1 , J. Miranda 2 , 

E. Vega 3 , H. Ruiz 3 , S. Escalona 3 , B. de Foy 5 , A. de 

Vizcaya 4 , C. Garcia 1 , I. Rosas 2 and L. Tan Molina 6 . 

1 

INCan, Mexico City, DF, Mexico, 2 UNAM, Mexico 

City, DF, Mexico, 3 IMP, Mexico City, DF, Mexico, 

4 

CINVESTAV, Mexico City, DF, Mexico, 5 St. Louis 

University, St. Louis, MO and 6 MCE2, San Diego, 

CA. 


DNA DAMAGE BY A TWO-ELECTRON 

OXIDATION (EPOXIDATION) MECHANISM. 

L. M. Ball 1 , W. Ye 1 , J. E. Olson 1 , K. M. Koshlap 2 , 

K. Jayaraj 1 , G. Boysen 1 , A. Gold 1 and R. Sangaiah 1 . 

1 

Environmental Sciences and Engineering, 


Hill, NC and 2 School of Pharmacy, University of 

North Carolina at Chapel Hill, Chapel Hill, NC. 


OXIDATIVE DNA DAMAGE IN NCI-H292 

CELLS EXPOSED TO CIGARETTE SMOKE 

AT THE AIR-LIQUID INTERFACE. D. 

Thorne, T. Oke, M. McEwan, E. D. Massey and 

M. Gaca. R&D Centre, British American Tobacco, 

Southampton, United Kingdom. Sponsor: J. 

Seagrave. 


UNCONJUGATED BILIRUBIN CAUSES 

CHANGES IN INTRACELLULAR REDOX 

STATUS, CHANGES TO THE DISULFIDE 

PROTEOME, AND UPREGULATION OF 

SEVERAL GENES INVOLVED IN ER 

STRESS. G. H. Oakes 1 , A. Awaysheh 2 , L. B. Dale 3 

and J. R. Bend 1,2 . 1 Physiology and Pharmacology, 

Siebens Drake Medical Research Institute, 

University of Western Ontario, London, ON, Canada, 

2 

Pathology, Siebens-Drake Medical Research 

Insititute, University of Western Ontario, London, 

ON, Canada and 3 Cell Biology Group, Robart’s 

Research Institute, London, ON, Canada. 


MULTI-PARAMETER ANALYSIS OF 

OXIDATIVE STRESS IN INDIVIDUAL 

CELLS USING HIGH CONTENT IMAGING 

AND QUANTITATIVE ANALYSIS. K. K. 

Opperman, B. S. Mandavilli and R. N. Ghosh. 

Research and Development, Thermo Fisher 

Scientific, Rockford, IL. Sponsor: A. Barchowsky. 


APPLICATION OF CONFOCAL 

AUTOFLUORESCENCE SPECTROSCOPY 

FOR ANALYSIS OF NADH STATUS IN THE 

HEPG2 AND THE C6 GLIOMA CELLS AND 

ITS CHANGE UPON EXPOSURE TO CD. M. 

S. Yang 1 , J. Zheng 2 , W. Y. Ng 1 , W. Zheng 2 , T. Lin 1 

and J. Y. Qu 2 . 1 Department of Biology, Hong Kong 

Baptist University, Kowloon, Hong Kong, China and 

2 

Department of Electronic & Computer Engineering, 

Hong Kong University of Science and Technology, 

Kowloon, Hong Kong, China. 

Abstract # 


HUMAN IN VITRO HEMOLYSIS MODEL 

TO ASSESS DRUG-INDUCED HEMOLYTIC 

EFFECTS. A. E. Vickers 1 , R. L. Fisher 2 , J. R. 

Sinclair 1 and S. Morris 1 . 1 Drug Safety Evaluation, 

Allergan Inc, Irvine, CA and 2 Vitron Inc, Tucson, AZ. 


A NEW 405 NM LASER EXCITABLE 

FLUORESCENT PROBE OF 

INTRACELLULAR THIOLS FOR FIXED 

END-POINT IMAGE BASED ASSAYS. Y. Chen, 

R. Aggeler, J. A. Bradford, M. S. Janes, Y. Wu, H. 

Kang and I. Johnson. Molecular Probes, Eugene, OR. 

Sponsor: J. Lin. 


8:30 AM to 12:00 NOON 


POSTER SESSION: METALS II 

Chairperson(s): Steve Lasley, University of Illinois, Peoria, IL. 


Attended: 10:15 AM–12:00 NOON 


ROLE OF METALLOTHIONEIN IN HEPATIC 

TOXICITY CAUSED BY VANADIUM 

COMPOUND IN MICE. T. Hasegawa 1 , M. 

Satoh 2 , A. Shimada 3 and Y. Seko 1 . 1 Environmental 

Biochemistry, Yamanashi Institute of Environmental 

Sciences, Fujiyoshida, Yamanashi, Japan, 2 Aichi 

Gakuin University, Nagoya, Aichi, Japan and 3 Tottori 

University, Tottori, Japan. 


ULTRASTRUCTURAL NUCLEAR CHANGES 

IN LYMPHOCYTES AFTER INHALED 

VANADIUM EXPOSURE. F. I. Teresa 1 , V. 

Rodriguez-Lara 1 , G. Piñon-Zarate 1 , M. Rojas- 

Lemus 1 , L. Colin-Barenque 2 , P. Bizarro-Nevares 1 

and P. Mussali-Galante 1 . 1 Biología Celular y Tisular, 

UNAM, Mexico City, Mexico and 2 Neuromorfologia, 

FES Iztacala, UNAM, Mexico City, Mexico. 


HIF-1a AND COX-2 MEDIATE 

SYNERGISTIC RELEASE OF ANGIOGENIC 

FACTORS FROM HUMAN LUNG 

FIBROBLASTS IN RESPONSE TO NICKEL 

AND MICROBIAL STIMULI. K. A. Brant, R. 

M. Ward and J. P. Fabisiak. Environmental and 

Occupational Health, University of Pittsburgh, 



OVEREXPRESSION OF F-BOX PROTEIN, 

HRT3 OR YLR224W, CONFERS 

RESISTANCE TO METHYLMERCURY IN 

YEAST CELLS. G. Hwang and A. Naganuma. 

Tohoku University, Sendai, Japan. 

Thursday 




Thursday 



THE ROLE OF MRP2 AND GLUT2 

TRANSPORTERS IN THE METABOLISM 

OF ARSENITE BY PRIMARY HUMAN 

HEPATOCYTES. F. S. Walton 1,2 , Z. Drobna 1 and 

M. Styblo 1 . 1 Department of Nutrition, University of 

North Carolina, Chapel Hill, NC and 2 Center for 

Environmental Medicine, Asthma and Lung Biology, 



DNA DAMAGE IN HUMAN LYMPHOCYTES 

IN VITRO EXPOSED TO COMBINED 

METALS; ARSENIC, CADMIUM, COBALT 

AND CHROMIUM. N. Yoshioka, H. Nakashima, 

Y. Sano and K. Omae. Department of Preventive 

Medicine and Public Health, Keio University School 

of Medicine, Tokyo, Japan. 


HETEROLOGOUS EXPRESSION SYSTEM 

IN YEAST REVEALED STRUCTURE- 

FUNCTION RELATIONSHIP IN METAL 

TRANSCRIPTION FACTOR, MTF-1. Y. Jin 1,2 , 

H. Al-Refai 2 and J. Freedman 1,2 . 1 NIEHS, Research 

Triangle Park, NC and 2 Duke University, Durham, 

NC. 


UNDERSTANDING COBALT CHLORIDE- 

INDUCED LUNG INJURY THROUGH 

CYTOMETRIC, METABOLOMIC, 

PROTEOMIC, AND HISTOLOGICAL 

ANALYSIS OF BRONCHIOALVEOLAR 

LAVAGE FLUID (BALF). Y. Saini 1,4 , J. 

Harkema 2,3,4 and J. LaPres 1,3,5 . 1 Genetics, Michigan 

State University, East Lansing, MI, 2 Department of 

Pathobiology and Diagnostic Investigation, Michigan 

State University, East Lansing, MI, 3 The National 

Food Safety and Toxicology Center, Michigan State 

University, East Lansing, MI, 4 Center for Integrative 


MI and 5 Biochemistry and Molecular Biology, 



CHRONIC EXPOSURE TO ZINC 

CHROMATE INDUCES CHROMOSOME 

INSTABILITY IN HUMAN LUNG CELLS. 

A. Holmes 1,2 , Q. Qin 1,2 , J. L. Young 1,2 , K. Joyce 1,2 , 

H. Xie 1,2,3 , T. Cavas 1,2,4 and J. P. Wise 1,2,3 . 1 Wise 

Laboratory of Environmental and Genetic 

Toxicology, University of Southern Maine, 

Portland, ME, 2 Maine Center for Toxicology and 

Environmental Health, University of Southern 

Maine, Portland, ME, 3 Department of Applied 

Medical Science, University of Southern Maine, 

Portland, ME and 4 Department of Biology, Mersin 

University, Mersin, Turkey. 


THE ULTRASTRUCTURAL EFFECTS OF 

COPPER DIMETHYLDITHIOCARBAMATE 

(CDDC) ON MATERNAL AND NEWBORN 

BRAINS OF LONG-EVANS RATS. B. Scharf 1 

and L. D. Trombetta 2,1 . 1 Biology, St. Johns University, 

New York and 2 Pharmaceutical Sciences, St. Johns 



THE EFFECTS OF ZIRAM ON RAT 

HIPPOCAMPAL ASTROCYTES. A. Matei and 

L. D. Trombetta. Pharmaceutical Sciences, St. Johns 



STUDY OF INFLUENCE OF COMBINED 

INTRODUCTION OF MANGANESE AND 

PIRACETAM ON COGNITIVE FUNCTIONS 

IN WHITE RATS. A. N. Petrov. The Institute of 

Toxicology, St-Petersburg, Russian Federation. 


IN VIVO RESPONSE TO SODIUM 

TUNGSTATE: A CYTOGENETIC ANALYSIS 

OF SPLENIC T CELLS AND PROFILE OF 

SYSTEMIC AND LOCALIZED CYTOKINE 

LEVELS. S. L. Prues, H. J. Fullenkamp, K. L. Hess, 

D. J. Wagner, G. D. Chapman and A. O. Olabisi. 

Environmental Health Effect Laboratory [EHEL], 

Naval Health Research Center, Wright Patterson Air 

Force Base, OH. 


PHARMACOKINETICS OF TUNGSTEN 

(188W) FOLLOWING ACUTE SODIUM 

TUNGSTATE INHALATION IN RATS. D. 

J. Wagner 1 , P. M. Radcliffe 2 , A. O. Olabisi 1 , B. A. 

Wong 2 , M. F. Struve 2 , K. M. Attard 2 , E. Tewksbury 2 , 

P. G. Gunasekar 1 , G. D. Chapman 1 and D. C. 

Dorman 3 . 1 Environmental Health Effect Laboratory 

[EHEL], Naval Health Research Center, Wright 

Patterson Air Force Base, OH, 2 CIIT, The Hamner 

Institutes, Research Triangle Park, NC and 3 College 

of Veterinary Medicine, North Carolina State 



TUNGSTATE’S EFFECTS ON IMMUNE 

AND NON-IMMUNE HUMAN CELL TYPES 

WHEN ANALYZED IN VITRO. D. J. Carson 1,2 , 

A. Osterburg 2 , D. J. Wagner 1 , A. O. Olabisi 1 , P. G. 

Gunasekar 1 , G. Babcock 2 and G. D. Chapman 1 . 

1 

Cincinnati Shriner’s Hospital for Children, 

Cincinnati, OH and 2 Environmental Health Effect 

Laboratory [EHEL], Naval Health Research Center, 

Wright Patterson Air Force Base, OH. 


ACUTE AND SUBACUTE TOXICITY 

OF ORALLY ADMINISTERED SODIUM 

TUNGSTATE IN SPRAGUE-DAWLEY 

RATS. W. C. McCain 1 , L. Crouse 1 , M. Thompson 1 , 

A. Hess-Ruth 1 , M. Quinn 1 , M. Bazar 1 , P. Beall 1 , 

K. Mozzachio 2 , H. El-Fawal 3 and G. Leach 1 . 

1 

Toxicology, U.S. Army Center for Health Promotion 

and Preventive Medicine, Aberdeen Proving Ground, 

MD, 2 Biotechnics, Hillsborough, NC and 3 Division 

of Health Professions and Natural Sciences, Mercy 

College, Dobbs Ferry, OH. 


HEALTH EFFECTS OF EMBEDDED 

FRAGMENTS OF TUNGSTEN AND 

TUNGSTEN ALLOYS. L. E. Roszell 1 , A. Hess- 

Ruth 1 , P. Beall 1 and P. Catherine 2 . 1 U.S. Army 

CHPPM, Aberdeen Proving Ground, MD and 

2 

Biotechnics, LLC, Hillsborough, NC. 


REMOVAL OF TISSUE MANGANESE 

BY P-AMINOSALICYLIC ACID (PAS) IN 

MANGANESE-EXPOSED RATS IN VIVO. W. 

Zheng 1 , Y. Zhang 1 , Y. Jiang 2 and W. Jiang 1 . 1 Purdue 

University, West Lafayette, IN and 2 Guangxi Medical 

University, Nanning, Guangxi, China. 

270 




Abstract # 


THE EFFECT OF MANGANESE 

ACCUMULATION ON GLUTATHIONE 

METABOLISM IN RAT LIVER 

SUBCELLULAR FRACTIONS. K. Phillips, P. 

Cooney and K. Erikson. Nutrition, UNC-Greensboro, 



CHARACTERIZATION OF MANGANESE- 

INDUCED PRODUCTION OF REACTIVE 

OXYGEN SPECIES IN MICROGLIA: 

RELEVANCE TO DOPAMINERGIC 

NEURODEGENERATION. B. Liu 1,3 , Y. Liu 1 , G. 

Dutta 1 , D. S. Barber 2 and P. Zhang 1 . 1 Department 

of Pharmacodynamics, University of Florida, 

Gainesville, FL, 2 Department of Physiological 

Sciences, University of Florida, Gainesville, FL and 

3 

McKnight Brain Institute, University of Florida, 



ALTERED COPPER TRANSPORT AT RAT 

BLOOD-CSF BARRIER FOLLOWING 

SUBCHRONIC EXPOSURE TO 

MANGANESE. Y. Zhang and W. Zheng. School of 

Health Sciences, Purdue University, West Lafayette, 

IN. 


COPPER IS REQUIRED FOR HYPOXIA- 

INDUCIBLE FACTOR-1 ACTIVATION. W. 

Feng, F. Ye, Z. Zhou and Y. Kang. Department of 

Medicine, University of Louisville, Louisville, KY. 


COPPER SUPPLEMENTATION REVERSES 

CARDIOMYOCYTE HYPERTROPHY 

THROUGH A DIRECT REDUCTION IN 

THE CELL SIZE. Y. Zhou, Y. Jiang and Y. Kang. 



APOPTOSIS GENE EXPRESSION IN 

HUMAN EPIDERMAL KERATINOCYTES 

TREATED WITH SODIUM ARSENITE 

USING REAL TIME PCR ARRAY. J. Mo 1 , Y. 

Xia 2 and J. L. Mumford 3 . 1 Center for Environmental 

Medicine, Asthma and Lung Biology, University of 

North Carolina, Chapel Hill, NC, 2 Inner Mongolia 

Center for Endemic Disease and Control, Huhhot, 

Inner Mongolia, China and 3 NHEERL/HSD, U.S. 

EPA, Research Triangle Park, NC. Sponsor: M. 

Madden. 


EFFECTS OF GLUTATHIONE AND 

HYDROGEN PEROXIDE ON THE 

STABILITY OF BILIARY METABOLITES OF 

INTRAVENOUSLY INJECTED ARSENITE 

IN RATS. Y. Kobayashi 1 and S. Hirano 2 . 

1 

Environmental Health Sciences Division, National 

Institute for Environmental Studies, Tsukuba, 

Japan and 2 Reserch Center for Environmental 

Risk, National Institute for Environmental Studies, 


Abstract # 


ARSENITE MODIFIES P53-MEDIATED 

RESPONSE TO CISPLATIN-INDUCED DNA 

DAMAGE IN OVARIAN CANCER CELLS. C. 

Muenyi 1 , A. A. Pandit 1 and J. States 1,2 . 1 Pharmacology 

& Toxicology, University of Louisville, Louisville, 

KY and 2 Ctr. Environmental Genomics & Integrative 

Biology, U. Louisville, Louisville, KY. 


EXPOSURE TO ARSENIC DISRUPTS 

VEGF-DIRECTED VASCULOGENESIS 

CAUSING SUBSEQUENT PLACENTAL 

INSUFFICIENCY AND SPONTANEOUS 

ABORTION. J. Coffin 1 , K. Lewis 1 , F. Pereira 1 , D. 

Brooks 1 , W. He 2 and H. D. Beall 1 . 1 CEHS, University 

Montana, Missoula, MT and 2 Env. Health, University 



SENSITIVITY TO SODIUM ARSENITE 

DEPENDS UPON A FUNCTIONAL SPINDLE 

CHECKPOINT. S. C. McNeely 1 , A. C. Belshoff 1 , 

B. F. Taylor 1 , M. J. McCabe 2 and J. States 1 . 

1 

Pharmacology, University of Louisville, Louisville, 

KY and 2 Environmental Medicine, University of 



EXPRESSION OF KERATIN 6A AND 

KERATIN 16 IN ARSENITE AND CADMIUM 

TRANSFORMED UROTSA CELL LINES IS 

INDUCED IN VIVO AND IS ASSOCIATED 

WITH SQUAMOUS DIFFERENTIATION. S. 

Somji, L. Cao, X. Zhou, M. Sens, S. H. Garrett and 

D. A. Sens. Pathology, University of North Dakota, 

Grand Forks, ND. 


CHARACTERIZATION OF TUMOR 

HETEROTRANSPLANTS PRODUCED 

FROM INDEPENDENTLY GENERATED 

CLONES OF ARSENITE AND CADMIUM 

TRANSFORMED HUMAN UROTHELIAL 

CELLS. X. Zhou, S. Somji, S. H. Garrett, M. Sens 

and D. A. Sens. Pathology, University of North 

Dakota, Grand Forks, ND. 


METHYLATED BISMUTH, BUT NOT 

BISMUTH CITRATE OR BISMUTH 

GLUTATHIONE INDUCES CYTO- AND 

GENOTOXIC EFFECTS IN HUMAN CELLS 

IN VITRO. E. Dopp 1 , U. von Recklinghausen 1 , 

L. M. Hartmann 2 , S. Rabieh 2,3 , J. Hippler 2 , A. 

V. Hirner 2 and A. W. Rettenmeier 1 . 1 Institute of 

Hygiene and Occupational Medicine, University of 

Duisburg-Essen, Essen, NRW, Germany, 2 Institute 

of Environmental Analysis, University of Duisburg- 

Essen, Essen, NRW, Germany and 3 Chemical 

Research Department, Matís, Reykjavík, Iceland. 

Sponsor: G. Alink. 


CO-ADMINISTRATION OF COBALT 

CHLORIDE PROTECTS AGAINST 

LIVER INJURY INDUCED BY CADMIUM 

CHLORIDE IN MICE. S. Himeno, K. Nakashima 

and H. Fujishiro. Fac. of Pharmaceutical Sciences, 

Tokushima Bunri University, Tokushima, Japan. 

Sponsor: M. Satoh. 

Thursday 




Thursday 



CELLULAR VITAMIN C INCREASES 

CHROMATE TOXICITY VIA A DEATH 

PROGRAM REQUIRING MISMATCH 

REPAIR BUT NOT P53. M. F. Reynolds and A. 

Zhitkovich. Pathology and Laboratory Medicine, 

Brown University, Providence, RI. 


V-PROLI/NO, A NITRIC OXIDE DONOR 

PRODRUG, PROTECTS LIVER CELLS 

FROM ARSENIC-INDUCED TOXICITY 

AND APOPTOSIS. W. Qu 1 , A. Dill 1 , J. E. 

Saavedra 2 , L. K. Keefer 3 and M. Waalkes 1 . 

1 

Inorganic Carcinogenesis Section, LCC, NCI at 

NIEHS, Research Triangle Park, NC, 2 SAIC, NCI 

at Frederick, Frederick, MD and 3 CS, LCC, NCI at 

Frederick, Frederick, MD. 


ELIMINATION OF THIOL CONJUGATES OF 

INORGANIC MERCURY AND THE ROLE OF 

THE MULTIDRUG RESISTANCE PROTEIN 

2. C. Bridges, R. K. Zalups and L. Joshee. Division 

of Basic Medical Sciences, Mercer University School 

of Medicine, Macon, GA. 


REACTIVE OXYGEN SPECIES 

SCAVENGERS REDUCE 

HYPERPROLIFERATION AND 

ANCHORAGE INDEPENDENT GROWTH OF 

UROTSA CELLS CHRONICALLY EXPOSED 

TO MONOMETHYLARSONOUS ACID. K. E. 

Eblin, S. E. Buffington and A. J. Gandolfi. College 

of Pharmacy-Toxicology, University of Arizona, 

Tucson, AZ. 


ALPHA-TOCOPHEROL AVOIDS 

OVEREXPRESSION OF OCLUDIN AND 

DISORDER PATTERN OF CLAUDIN-2 

LOCATION, AND MANTAINS PROXIMAL 

RENAL FUNCTION IN MICE EXPOSED 

TO DICHROMATE. L. Arreola-Mendoza 1 , J. 

L. Reyes 2 , M. E. Mendoza 2 and L. M. Del Razo 1 . 

1 

Toxicology, Cinvestav-IPN, Mexico D.F, Mexico 

and 2 Physiology & Biophysics, Cinvestav-IPN, 

Mexico D.F., Mexico. 


THE ROLE OF NADPH OXIDASE VERSUS 

MITCHONDRIA IN ARSENIC TRIOXIDE- 

INDUCED APOPTOSIS. K. K. Mann, M. 

Kourelis, Z. Diaz, S. Marcoux and W. H. Miller. 

Lady Davis Institute for Medical Research, McGill 

University, Montreal, QC, Canada. 


8:30 AM to 12:00 NOON 


POSTER SESSION: METHOD DEVELOPMENT, 

AUTOIMMUNITY, AND DISEASE MECHANISMS IN 

IMMUNOTOXICOLOGY 

Chairperson(s): Lin Mantell, St. Johns University, Queens, NY and 

Tai Guo, Virginia Commonwealth University, Richmond, VA. 




EVIDENCE OF AUTOIMMUNE-RELATED 

EFFECTS OF TRICHLOROETHYLENE IN 

STUDIES IN MICE AND HUMANS. G. S. 

Cooper, S. L. Makris and J. Jinot. ORD - NCEA, 



ENHANCED INDUCIBLE NITRIC 

OXIDE SYNTHASE EXPRESSION AND 

NITROTYROSINE FORMATION IN 

TRICHLOROETHENE-MEDIATED 

AUTOIMMUNE RESPONSE. G. Wang, J. 

Wang and M. Khan. Pathology, University of Texas 

Medical Branch, Galveston, TX. 


EVIDENCE FOR POSTNATAL 

AUTOIMMUNE DISEASE FOLLOWING 

DEVELOPMENTAL EXPOSURE TO TCDD 

IN 24 WEEK-0LD C57BL/6 MICE. S. D. 

Holladay 2 , A. Mustafa 1,2 , M. Goff 1,2 , S. Witonsky 1 , 

R. P. Kerr 1,2 , C. D. Reilly 1 , P. Sponenberg 2 and R. 

M. Gogal 1,2 . 1 Center for Molecular Medicine and 

Infectious Disease, VA Tech, Blacksburg, VA and 

2 

Biomedical Sciences and Pathobiology, VA Tech, 

Blacksburg, VA. 


PERINATAL TCDD EXPOSURE 

MODULATES B CELL DEVELOPMENT IN 

JUVENILE C57BL/6 MICE. R. M. Gogal 1,2 , H. 

Groch 1,2 , A. Mustafa 1,2 and S. D. Holladay 2 . 1 Center 

for Molecular Medicine and Infectious Disease, VA 

Tech, Blacksburg, VA and 2 Biomedical Sciences and 

Pathobiology, VA Tech, Blacksburg, VA. 


EXACERBATION OF POSTNATAL 

AUTOIMMUNE DISEASE IN 24 WEEK- 

0LD SNF1 LUPUS NEPHRITIS MICE 

PERINATALLY EXPOSED TO TCDD. A. 

Mustafa 1,2 , S. D. Holladay 2 , M. Goff 1,2 , S. Witonsky 1 , 

R. P. Kerr 1,2 , C. D. Reilly 1,2 , P. Sponenberg 2 and R. 

M. Gogal 1,2 . 1 Center for Molecular Medicine and 

Infectious Disease, VA Tech, Blacksburg, VA and 

2 

Biomedical Sciences and Pathobiology, VA Tech, 

Blacksburg, VA. 

272 




Abstract # 


EFFECTS OF FEED BORNE FUSARIUM 

MYCOTOXINS ON INTESTINE AND 

IMMUNE RESPONSE OF BIRDS INFECTED 

WITH COCCIDIA. G. N. Girgis 1 , T. K. Smith 1 , 

J. R. Barta 2 , S. Sharif 2 and H. J. Boermans 3 . 

1 

Department of Animal and Poultry Science, 

University of Guelph, Guelph, ON, Canada, 

2 

Department of Pathobiology, University of Guelph, 

Guelph, ON, Canada and 3 Department of Biomedical 

Sciences, University of Guelph, Guelph, ON, 

Canada. 


TCDD PREVENTS DIABETES IN NON- 

OBESE DIABETIC (NOD) MICE. D. G. Farrer 1 , 

L. B. Steppan 1 , S. Oda 2 , W. R. Vorachek 1 , D. Pham 1 , 

D. V. Mourich 2 and N. I. Kerkvliet 1 . 1 Environmental 


Corvallis, OR and 2 AVI BioPharma Inc., Corvallis, 

OR. 


GENISTEIN PROTECTS FEMALE 

NONOBESE DIABETIC (NOD) MICE FROM 

DEVELOPING TYPE 1 DIABETES. T. L. Guo 1 , 

D. R. Germolec 2 , W. Auttachoat 1 , J. F. Zheng 1 and 

K. L. White Jr. 1 . 1 Pharmacology and Toxicology, 

Virginia Commonwealth University, Richmond, VA 

and 2 NTP, DIR, NIEHS, RTP, NC. 


EFFECTS OF DEOXYNIVALENOL ON THE 

ANTIBODY FORMATION AGAINST PARVO 

VIRUS VACCCINATION IN MALE MICE. 

S. Jeong, J. Cho, E. Kim, B. Choi, Y. Jean, D. Tark 

and H. Kang. Toxicology, Nat’l Vet Res & Quarant 

Service, Anyang, South Korea. 


THE ROLE OF HMGB1 IN THE 

PATHOGENESIS OF CYSTIC FIBROSIS. 

T. Entezari-Zaher 1 , D. Weiss 3 , S. Gangisetti 1 , K. 

J. Tracey 2 , H. Wang 2 , M. Caryl 1 and L. Mantell 1,2 . 

1 

Pharmaceutical Sciences, St. John’s University, 

Queens, NY, 2 Cardiopulmonary Research, The 

Feinstein Institute for Medical Research, North 

Shore-Long Island Jewish Health System, 

Manhasset, NY and 3 Medicine, University of 

Vermont College of Medicine, Burlington, VT. 


SYSTEMIC AND LOCAL 

IMMUNOMODULATORY 

EFFECTS FOLLOWING A SINGLE 

INTRATRACHEAL EXPOSURE OF 1, 2:5, 

6-DIBENZANTHRACENE (DBA) IN ADULT 

FEMALE B6C3F1 MICE. D. Smith 1,3 , M. J. 

Smith 2 and K. L. White 1 . 1 Pharmacology and 

Toxicology, VCU, Richmond, VA, 2 Biomedical 

Engineering, VCU, Richmond, VA and 3 Philip Morris 

USA, Richmond, VA. 


VALIDATION OF AN IMMUNOTOXICITY 

SCREENING METHOD USING TETANUS 

TOXOID (TT) IN THE CYNOMOLGUS 

MONKEY. S. A. Kirk, S. R. Fraser, D. Gordon 

and A. Templeton. Aptuit Ltd, Edinburgh, United 

Kingdom. 

Abstract # 


ELECTROSPUN NANO-FIBROUS 

TISSUE ENGINEERING SCAFFOLDS 

OF POLYDIOXANONE BLENDED 

WITH ELASTIN: A STUDY OF IN VITRO 

IMMUNOMODULATORY EFFECTS. 

M. J. Smith 1 , D. C. Smith 2,3 , K. L. White 2 and 

G. L. Bowlin 1 . 1 Biomedical Engineering, 

Virginia Commonwealth University, Richmond, 

VA, 2 Pharmacology and Toxicology, Virginia 

Commonwealth University, Richmond, VA and 

3 

Philip Morris USA, Richmond, VA. 


IMMUNOLOGICAL ASSESSMENTS IN 

ONE-YEAR INTRAVENOUS TOXICITY 

STUDY IN MONKEYS WITH ABATACEPT, 

A SELECTIVE COSTIMULATION 

MODULATOR. D. G. Gonchoroff, M. Abbott, T. 

Bigwarfe, L. Phelps, D. DeVona, T. Testorf and H. 

Haggerty. Immunotoxicology, Bristol-Myers Squibb 

Company, East Syracuse, NY. 


CHARACTERIZATION OF THE LONG 

TERM PROINFLAMMATORY EFFECTS OF 

2’MOE GAPMER PHOSPHOROTHIOATE 

OLIGONUCLEOTIDES. T. Machemer, S. Burel, 

H. Zhang, B. Perkins, G. Hung, S. Greenlee and S. 

Henry. ISIS Pharmaceuticals, Inc, Carlsbad, CA. 


IMMUNOTOXICITY ASSESSMENT OF 

YOUNG AND ADULT C57BL/6 MICE FED 

TRIBUTYLTIN CONTAMINATED FISH 

IN THEIR DIET. B. Badiwa Bizowe, M. 

Fortier, S. Pillet, M. Fournier and P. Brousseau. 

Immunotoxicology, INRS-Institut Armand Frappier, 

Pointe Claire, QC, Canada. 


IMMUNOLOGICAL ALTERATIONS 

IN B6C3F1 MICE FOLLOWING ORAL 

EXPOSURE TO A BROMINATED FLAME 

RETARDENT MIXTURE: DE-71. P. A. Fair 1,2 , H. 

Stavros 1 , M. Mollenhauer 2 , D. E. Keil 3 and M. Peden- 

Adams 2 . 1 NOS/NOAA, Charleston, SC, 2 MUSC, 

Charleston, SC and 3 UNLV, Las Vegas, NV. 


EVALUATION OF THE POTENTIAL 

EFFECTS OF ATRAZINE AND ITS 

METABOLITES ON THE IMMUNE 

SYSTEM ROUTINE TOXICITY STUDIES 

CONDUCTED IN RAT, MOUSE AND DOG. T. 

Pastoor 1 , C. Breckenridge 1 and J. Stevens 2 . 1 Syngenta 

Crop Protection, Greensboro, NC and 2 Department 

of Pharmacology, Wake Forest School of Medicine, 

Winston-Salem, NC. 


CHARACTERIZATION OF IMMUNE 

AND ASTHMATIC RESPONSES IN 

CYNOMOLGUS MACAQUES FOLLOWING 

ANTAGONISM OF IL-12/23 ACTIVITY WITH 

USTEKINUMAB (CNTO 1275). C. Sachs 1 , 

J. Benson 1 , P. Smith 2 , A. Schantz 1 , E. Martin 3 , D. 

Graden 1 , Q. Jiao 1 , J. Cornacoff 1 , P. Martin 1 and G. 

Treacy 1 . 1 Centocor R&D, Radnor, PA, 2 Covance 

Laboratories, Madison, WY and 3 Charles River Labs, 

Shrewsbury, MA. 

Thursday 




Thursday 



IMMUNOTOXIC EFFECTS OF 

TRIBUTYLTIN ON SPLENOCYTES 

IN F1 RATS AFTER SUBACUTE 

ADMINISTRATION. M. Tsunoda 1 , M. Tsuji 1,2 , 

Y. Zhang 1,3 , S. Kimura 1,4 , C. Sugaya 1 , Y. Inoue 1 , Y. 

Kudo 1 , T. Satoh 5 , M. Wakasa 6 , T. Tashiro 6 , Y. Sugita- 

Konishi 7 and Y. Aizawa 1 . 1 Preventive Medicine 

and Public Health, Kitasato University School of 

Medicine, Sagamihara, Kanagawa, Japan, 2 Living 

Science, Mejiro University College, Tokyo, Japan, 

3 

Fukushima rehabilitation academy, Asaguchi, 

Okayama, Japan, 4 Kanagawa Prefecture Ken-o 

Livestock Hygiene Station, Atsugi, Kanagawa, Japan, 

5 

Public Health, Kitasato University School of Allied 

Health Sciences, Sagamihara, Kanagawa, Japan, 

6 

Chemistry and Biological Sciences, Aoyama Gakuin 

University School of Science and Engineering, 

Sagamihara, Kanagawa, Japan and 7 Division of 

Microbiology, National Institute of Health Sciences, 

Tokyo, Japan. 


SIMULTANEOUS TIME COURSE AND DOSE 

RESPONSE CHARACTERIZATION OF 2, 3, 7, 

8-TETRACHLORODIBENZO-PARA-DIOXIN 

EFFECTS ON THE IN VIVO LPS-ACTIVATED 

PRIMARY IGM RESPONSE IN FEMALE 

C57BL6 MICE. C. M. North 2,1 , R. B. Crawford 2 , 

H. Lu 2 and N. E. Kaminski 1,2 . 1 Center for Integrative 


MI and 2 Pharmacology and Toxicology, Michigan 



EVALUATION OF THE EFFECTS OF 

ANTISENSE OLIGONUCLEOTIDES 

ON INFLUENZA CLEARANCE AND 

MACROPHAGE FUNCTION IN MOUSE. 

T. Kim 1 , T. Zanardi 1 , S. P. Henry 1 , F. G. Burleson 2 

and G. R. Burleson 2 . 1 ISIS Pharmaceuticals, Inc, 

Carlsbad, CA and 2 Burleson Research Technologies, 

Inc., Morrisville, NC. 


PHENOTYPIC CHARACTERIZATION OF 

LYMPHOCYTE SUBPOPULATIONS IN THE 

MINIPIG. F. Horand, F. Condevaux, J. Briffaux 

and P. Phothirath. MDS Pharmacology Services, St 

Germain sur l’Arbresle, France. 


VALIDATION OF METHOD FOR 

DETERMINATION OF ANTI-DA-3803 

ANTIBODIES IN RAT SERUM USING 

ENZYME LINKED IMMUNOSORBENT 

ASSAY. W. Choi 1 , C. Kim 1 , K. Na 2 , D. Kim 2 and 

W. Koh 1 . 1 Korea Institute of Toxicology, Daejeon, 

South Korea and 2 Research Laboratory, Dong-A 

Pharmaceutical Co. Ltd, Yongin, Kyunggi, South 

Korea. 


DEVELOPMENT OF A SOLID PHASE 

IN VITRO CYTOKINE RELEASE ASSAY 

USING A CUSTOMIZED SUPERAGONIST 

MONOCLONAL ANTIBODY. C. J. Gross 1 , 

J. Min 2 and T. Kawabata 3 . 1 Drug Safety Research 

& Development, Pfizer Inc., Chesterfield, MO, 

2 

Biotherapeutics Center of Emphasis, Pfizer Inc., 

Chesterfield, MO and 3 Drug Safety Research & 

Development, Pfizer Inc., Groton, CT. 


DEVELOPMENT OF IN VITRO MODEL 

TO ASSESS PROINFLAMMATORY 

PROPERTIES OF 2’-MOE 

OLIGONUCLEOTIDES. S. Greenlee, S. Burel, 

T. Machemer, C. Black and S. P. Henry. ISIS 

Pharmaceuticals, Inc, Carlsbad, CA. 


T-CELL DEPENDENT ANTIBODY 

RESPONSE IN CYNOMOLGUS MONKEYS 

FOR IMMUNOTOXICITY EVALUATION. T. 

Nakamura, H. Yamatoya, J. Hayashi, T. Fukuda, N. 

Matsuo, Y. Takahashi, H. Izumi, H. Tokado and R. 

Nagata. Drug Safety Research Laboratories, Shin 

Nippon Biomedical Laboratories, (SNBL) Ltd., 

Kagoshima, Japan. 


ANALYTICAL VALIDATION OF 

SPLEEN, THYMUS, AND MESENTERIC 

AND MANDIBULAR LYMPH NODE 

IMMUNOPHENOTYPING FOR 

CYNOMOLGUS MONKEY. J. E. Arrington, J. 

Fishel and P. Joshi. Covance, Madison, WI. Sponsor: 

P. Thomas. 


EVALUATION OF CIRCULATING IMMUNE 

COMPLEXES (CIC) BIOASSAY ELISA KIT 

TO DETERMINE THE SAFETY PROFILE 

OF MONOCLONAL ANTIBODIES IN MICE. 

M. Ko, A. John-Baptiste, Q. Zong, F. Sace and M. 

Manya. Research & Development, Pfizer Inc, San 

Diego, CA. Sponsor: G. Stevens. 


IMMUNOPHENOTYPING OF CD4 T 

LYMPHOCYTES FROM WHLOLE BLOOD 

OF CYNOMOLGUS MONKEYS BY FLOW 

CYTOMETRY IS IMPROVED BY USAGE 

OF CLONE L200. G. Bannish 1 , M. S. Russell 1 , 

C. S. Page 1 , D. Lanham 2 , B. A. Litzenberger 1 and 

M. Wing 2 . 1 Experimental Biology, Huntingdon Life 

Sciences, East Millstone, NJ and 2 Experimental 

Biology, Huntingdon Life Sciences, Cambridgeshire, 



OPTIMIZATION AND KINETICS OF THE 

PRIMARY AND SECONDARY T CELL 

DEPENDENT ANTIBODY RESPONSE 

MODEL IN WISTAR RATS. C. Dumont, 

S. Corneau, H. Khalil, N. Cristiano, C. Li and 

L. LeSauteur. Toxicology, Charles River Labs, 

Preclinical Services Montreal Inc., Senneville, QC, 

Canada. Sponsor: C. Banks. 


IMMUNOPHENOTYPING OF RAT WHOLE 

BLOOD USING AUTOMATED LYSIS AND 

FIXATION LEADS TO IMPROVED PROCESS 

EFFICIENCY AND PRECISION. C. S. Page 1 , 

G. Bannish 1 , M. S. Russell 1 , D. Lanham 2 , B. A. 

Litzenberger 1 and M. Wing 2 . 1 Experimental Biology, 

Huntingdon Life Sciences, East Millstone, NJ and 

2 

Experimental Biology, Huntingdon Life Sciences, 

Cambridgeshire, United Kingdom. Sponsor: C. 

Auletta. 

274 




Abstract # 


PARTIAL PHENOTYPIC AND FUNCTIONAL 

CHARACTERIZATION OF LEUKOCYTES 

FROM RYR1 R163C MH MICE. S. R. Goth 1,2 , S. 

Tong 2 , B. T. Yuen 2 , P. D. Allen 3 and I. N. Pessah 1,2 . 

1 

Center for Children’s Environmental Health, 

UC Davis, Davis, CA, 2 Department of Molecular 

Biosciences, UC Davis, Davis, CA and 3 Department 

of Anesthesia, Brigham and Women’s Hospital, 

Boston, MA. 


8:30 AM to 12:00 NOON 


POSTER SESSION: AHR MECHANISMS 

Chairperson(s): Richard Pollenz, University of South Florida, Tampa, FL 

and Wade Powell, Kenyon College, Gambier, OH. 




ROLE OF THE CULLIN 4B, E6AP AND 

MDM2 UBIQUITIN E3 LIGASE ENZYMES IN 

LIGAND-DEPENDENT AND INDEPENDENT 

DEGRADATION OF THE AH RECEPTOR. 

R. S. Pollenz. Cell Biology, Microbiology and 

Molecular Biology, University of South Florida, 

Tampa, FL. 


ROLE OF DNA BINDING AND 

DIMERIZATION WITH ARNT IN THE 

LIGAND-INDUCED DEGRADATION OF THE 

AH RECEPTOR. R. Buzzeo, E. J. Dougherty 

and R. S. Pollenz. Cell Biology, Microbiology and 

Molecular Biology, University of South Florida, 

Tampa, FL. 


HSP90 DISPLACEMENT DURING LIGAND- 

DEPENDENT TRANSFORMATION OF 

THE ARYL HYDROCARBON RECEPTOR. 

A. Soshilov and M. S. Denison. Environmental 

Toxicology, UCDavis, Davis, CA. 


IDENTIFICATION OF MURINE AHR 

RESIDUES THAT MAY A PLAY ROLE IN 

SIGNAL TRANSDUCTION THROUGH 

PHOSPHORYLATION. D. P. Vorojeikina, S. K. 

Park and T. A. Gasiewicz. Environmental medicine, 

School of Medicine and Dentistry University of 



EPIDERMAL GROWTH FACTOR 

RECEPTOR PATHWAY BLOCKS ARYL 

HYDROCARBON RECEPTOR-MEDIATED 

TRANSCRIPTION AND DIFFERENTIATION 

IN EPIDERMAL KERATINOCYTES. C. H. 

Sutter 1 , H. Yin 2 , Y. Li 2 , M. S. Jennifer 2 and T. R. 

Sutter 1 . 1 Feinstone Center for Genomic Research, 

University of Memphis, Memphis, TN and 

2 

Bloomberg School of Public Health, Johns Hopkins 

University, Baltimore, MD. 

Abstract # 


SERINE 395, A SITE IMPORTANT FOR 

TRANSCRIPTIONAL ACTIVITY IN THE 

MOUSE ARYL HYDROCARBON RECEPTOR 

(AHR), IS PHOSPHORYLATED BY PROTEIN 

KINASE A. B. Kobielush 1 , G. D. Minsavage 1 , D. 

Vorojeikina 1 , M. L. Easterling 2 , A. Friedman 1 and T. 

A. Gasiewicz 1 . 1 Environmental Medicine, University 

of Rochester, Rochester, NY and 2 Bruker Daltonics, 

Billerica, MA. 


IN VIVO LEFLUNOMIDE EXPOSURE 

MIMICS THE EFFECTS OF TCDD IN AN 

AHR-DEPENDENT MANNER. K. S. Saili, L. K. 

Mathew, S. Sengupta, N. I. Kerkvliet, S. K. Kolluri 

and R. L. Tanguay. Department of Environmental 

& Molecular Toxicology, Environmental Health 

Sciences Center, Oregon State University, Corvallis, 

OR. 


LIGAND-DEPENDENT DIFFERENCES OF 

DNA BINDING BY AHR-ARNT COMPLEXES 

VERSUS AHR-ARNT2 COMPLEXES IN 

VITRO. E. J. Dougherty and R. S. Pollenz. Cell 

Biology, Microbiology and Molecular Biology, 



RELATIVE POTENCIES OF INDIVIDUAL 

DIOXIN-LIKE COMPOUNDS FOR 

IN VITRO CYTOCHROME P450 

1A1 TRANSACTIVATION OF ARYL 

HYDROCARBON RECEPTOR FROM 

BAIKAL SEAL. H. Iwata 1 , E. Kim 1 , T. Suda 1 , 

S. Tanabe 1 and E. A. Petrov 2 . 1 Center for Marine 

Environmental Studies, Ehime University, 

Matsuyama, Japan and 2 The Eastern-Siberian 

Scientific and Production Fisheries Center, Ulan- 

Ude, Russian Federation. 


RESPONSIVENESS OF A XENOPUS LAEVIS 

CELL LINE TO THE ARYL HYDROCARBON 

RECEPTOR LIGAND 6-FORMYLINDOLO[3, 

2-b]CARBAZOLE (FICZ). L. B. Laub 1 , B. D. 

Jones 2 and W. H. Powell 1 . 1 Biology Department, 

Kenyon College, Gambier, OH and 2 Mathematics 

Department, Kenyon College, Gambier, OH. 


DISTINCT REGULATION OF THE ARYL 

HYDROCARBON RECEPTOR ACTIVITY BY 

DIFFERENT LIGANDS. S. Luecke 1 , K. Gradin 2 , 

L. Poellinger 2 , A. Rannug 1 and M. Backlund 1 . 

1 

Institute of Environmental Medicine, Karolinska 

Institutet, Stockholm, Sweden and 2 Department of 

Cell and Molecular Biology, Karolinska Institutet, 



LIGAND SPECIFICITY IN MODULATING 

ARYL HYDROCARBON RECEPTOR DNA 

BINDING. D. DeGroot, Y. Song, S. R. Rushing 

and M. S. Denison. Environmental Toxicology, 

University of California, Davis, Davis, CA. 


NEWSPAPERS AND NEWSPAPER INK 

CONTAIN AGONISTS FOR THE AH 

RECEPTOR. B. Zhao, J. E. Bohonowych, G. He 

and M. S. Denison. Environmental Toxicology, 

University of California, Davis, Davis, CA. 

Thursday 




Thursday 



ARYL-HYDROCARBON RECEPTOR (AHR), 

AGING AND IMMUNITY. L. B. Steppan, D. G. 

Farrer, D. Pham and N. I. Kerkvliet. Environmental 




ARYL HYDROCARBON RECEPTOR (AHR) 

REPRESSES ACUTE PHASE RESPONSE 

GENE EXPRESSION IN A DNA-BINDING 

INDEPENDENT MANNER. R. D. Patel, 

A. Kusnadi, C. A. Flaveny and G. H. Perdew. 

Department of Veterinary & Biomedical Science, The 



COMBINATION OF INFLAMMATORY 

SIGNALING AND AN AHR LIGAND LEADS 

TO SYNERGISTIC INDUCTION OF IL-6. 

B. DiNatale, B. Hollingshead and G. H. Perdew. 

Department of Veterinary & Biomedical Science, The 



8:30 AM to 12:00 NOON 


POSTER SESSION: CHEMOPREVENTION 

Chairperson(s): Silvia Barros, University of Sao Paulo, Sao Paulo, 

Brazil. 




USE OF COMPLEMENTARY AND 

ALTERNATIVE MEDICINES DURING 

BREAST CANCER TREATMENT – 

POTENTIAL INTERACTIONS WITH 

AROMATASE INHIBITORS. M. B. van 

Duursen 1 , P. M. Martines 1 , S. M. Nijmeijer 1 , P. C. 

de Jong 2 and M. van den Berg 1 . 1 Institute for Risk 

Assessment Sciences (IRAS), Utrecht University, 

Utrecht, Netherlands and 2 Department of Internal 

Medicine, St Antonius Hospital, Nieuwegein, 

Netherlands. 


4-NEROLIDYLCATHECOL (4NC), A 

COMPOUND FROM POTHOMORPHE 

UMBELLATA, AS A CYTOTOXIC AGENT 

FOR HUMAN METASTATIC MELANOMA 

CELLS. S. B. Barros, T. C. Sawada, C. A. Brohem, 

R. M. Massaro, D. R. Rivelli, R. L. Almeida, C. D. 

Ropke, V. V. Silva and S. S. Maria-Engler. Clinical 

Chemistry and Toxicology, University of São Paulo, 

São Paulo, SP, Brazil. 


DECREASED INCIDENCES OF NEOPLASMS 

AND NON-NEOPLASTIC LESIONS IN 

F344/N RATS AND B6C3F1 MICE FED MILK 

THISTLE EXTRACTS FOR TWO YEARS. B. 

Singh, A. Nyska, A. Roycroft, D. E. Malarkey and 

J. Dunnick. Environmental Toxicology Program, 




PLATYCODON GRANDIFLORUM INHIBIT 

AP-1 TRANSACTIVATION AND CELL 

TRANSFORMATION IN BEAS-2B HUMAN 

BRONCHIAL EPITHELIAL CELLS. P. Hyejin 1,2 


Kwangju, South Korea and 2 Research Center for 


South Korea. 


EFFECTS OF THE COFFEE DITERPENE 

KAHWEOL ON THE INHIBITION OF 

PROLIFERATION AND INDUCTION 

OF APOPTOSIS IN HUMAN LUNG 

ADENOCARCINOMA A549 CELLS. K. H. 

Hyunggyun 1,2 and H. Jeong 1,2 . 1 Pharmacy, Chosun 

University, Kwangju, South Korea and 2 Research 

Center for Proteineous Materials, Chosun University, 

Gwangju, South Korea. 


SAPONINS ISOLATED FROM THE ROOT 

OF PLATYCODI RADIX INHIBITS THE 

INVASION AND MIGRATION OF HT1080 

HUMAN FIBROSARCOMA CELLS VIA THE 

INHIBITION OF MMP-2 ACTIVATION AND 

DOWN REGULATION OF MMP-9 AND MT1- 

MMP. S. Hwang 1,2 , J. Choi 1,2 , K. Lee 1,2 , Y. Chung 3 


Kwangju, South Korea, 2 Research Center for 


South Korea and 3 Division of Food Science, Jinju 

International University, Jinju, South Korea. 


BIS[3’-(5-BROMOINDOLYL)]METHANE 

INDUCES KRüPPEL-LIKE FACTOR 

4-DEPENDENT ACTIVATION OF P21 IN 

COLON CANCER CELLS EXPRESSING 

WILD-TYPE OR MUTANT P53. S. Liu 1 , S. 

Cho 1 , S. Chintharlapalli 1 , M. Abdelrahim 2,3 , S. 

Papineni 4 , J. Guo 1 , P. Lei 1 and S. Safe 1,4 . 1 Institute 

of Biosciences and Technology, Houston, TX, 2 MD 

Anderson Cancer Center, Orlando, FL, 3 Department 

of Pathology, Orlando Regional Healthcare, Orlando, 

FL and 4 Veterinary Physiology and Pharmacology, 

Texas A&M University, College Station, TX. 


DIHYDROARTEMISININ SUPPRESSES 

PMA-MEDIATED MATRIX 

METALLOPROTEINASE-9 GENE 

ACTIVATION THROUGH DOWN- 

REGULATING NUCLEAR FACTOR-KAPPAB 

AND C-JUN. H. YongPil 1,2 and H. Jeong 1,2 . 

1 




Korea. 


EPIGALLOCATECHIN-3-GALLATE IS A 

NOVEL HSP90 INHIBITOR. Z. Yin, E. Henry 

and T. Gasiewicz. Department of Environmental 

Medicine, University of Rochester Medical Center, 


276 




Abstract # 


METHYL 2-CYANO-3, 11-DIOXO-OLEAN-1, 

12-DIEN-30-OATE (CDODA-ME) IS 

HIGHLY CYTOTOXIC TO PANCREATIC 

CANCER CELLS. I. Jutooru 1 , G. Chadalapaka 1 , 

S. Chintharlapalli 2 , S. Papineni 1 and S. Safe 1,2 . 

1 

Veterinary Physiology and Pharmacology, Texas 

A&M University, College Station, TX and 2 Institute 

of Biosciences and Technology, Texas A&M Health 

Science Center, Houston, TX. 


CURCUMIN INHIBITS BLADDER 

CANCER CELL GROWTH BY TARGETING 

THE SPECIFICITY FACTORS BY 

BOTH PROTEASOME-DEPENDENT 

AND PROTEASOME-INDEPENDENT 

MECHANISMS. G. Chadalapaka 1 , I. Jutooru 1 , 

S. Chintharlapalli 2 , S. Papineni 1 and S. Safe 1,2 . 

1 

Veterinary Physiology and Pharmacology, Texas 

A&M University, College Station, TX and 2 Institute 

of Biosciences and Technology, Texas A&M Health 

Science Center, Houston, TX. 


GUGGULSTERONE, A CONSTITUENT 

OF INDIAN AYURVEDIC MEDICINAL 

PLANT COMMIPHORA MUKUL, INHIBITS 

ANGIOGENESIS IN VITRO AND IN VIVO. S. 

V. Singh and D. Xiao. Pharmacology, University of 



8:30 AM to 12:00 NOON 


POSTER SESSION: FISH ALTERNATIVE MODELS OF 

TOXICITY 

Chairperson(s): Jai Dwivedi, University of Texas Medical Branch, 

Galveston, TX and Sumitra Sengupta, Oregon State University, Corvallis, 

OR. 




MORPHOLINO KNOCKDOWN OF CYP1A 

EXACERBATES CARDIAC DEFORMITIES 

IN b-NAPHTHOFLAVONE DOSED 

FUNDULUS HETEROCLITUS. B. Clark 1 , C. 

Matson 1 , C. Fleming 1 , M. Jenny 2 , M. Hahn 2 and R. Di 

Giulio 1 . 1 Duke University, Durham, NC and 2 Woods 

Hole Oceanographic Institute, Woods Hole, MA. 


LIVER TOXICITY AND REGENERATION: 

THE USE OF A SMALL FISH MODEL – 

JAPANESE MEDAKA. A. J. Bernal, B. Yuen and 

D. Hinton. Integrated Toxicology and Environmental 

Health Program, Nicholas School of Environment 

and Earth Sciences, Duke University, Durham, NC. 

Abstract # 


A MULTIFACETED, MEDIUM- 

THROUGHPUT APPROACH USING 

ZEBRAFISH FOR DETECTING 

DEVELOPMENTAL NEUROTOXICITY. J. 

Cowden, B. Padnos, D. L. Hunter, R. MacPhail, K. 

Jensen and S. Padilla. Neurotoxicology Division, 

U.S. Environmental Protection Agency, Research 



IMPROVED DIFFERENTIAL DISPLAY 

ANALYSIS BASED ON DEGENERATE 

OLIGONUCLEOTIDE-PRIMED PCR. H. 

Teraoka, K. Igarashi, S. Itoh, A. Ogawa, A. Kubota, 

A. M. Elmagd, T. Hiraga and D. Endoh. School of 

Veterinary Medicine, Rakuno Gakuen University, 

Ebetsu, Japan. 


DRUG EFFECTS ON THE LOCOMOTOR 

ACTIVITY OF LARVAL ZEBRAFISH. T. D. 

Irons 2,1 , R. MacPhail 1 , D. L. Hunter 1 and S. Padilla 1 . 

1 

Neurotoxicology Divison, U.S. Environmental 

Protection Agency, Research Triangle Park, NC and 

2 

Curriculum in Toxicology, UNC-CH, Chapel Hill, 

NC. 


CHARACTERIZATION OF LOCOMOTOR 

ACTIVITY OF ZEBRAFISH LARVAE: 

TEMPORAL VARIABILITY AND 

PHOTORESPONSE. J. Brooks 2 , R. MacPhail 1 , 

D. L. Hunter 1 , B. Padnos 1 and S. Padilla 1 . 

1 

Neurotoxicology Division, U.S. EPA, Res Tri Park, 

NC and 2 Division of Science and Mathematics, 

Brevard College, Brevard, NC. 


DIFFERENCES IN THE STRUCTURE 

AND FUNCTION OF FATHEAD MINNOW 

AND HUMAN ERa: IMPLICATIONS FOR 

IN VITRO TESTING OF ENDOCRINE 

DISRUPTING CHEMICALS. C. V. Rider 1,2 , P. C. 

Hartig 2 , M. C. Cardon 2 and V. S. Wilson 2 . 1 Molecular 

Biomedical Sciences, NCSU, Raleigh, NC and 

2 


NHEERL, RTP, NC. 


ZEBRAFISH: A TOOL FOR EXAMINING 

THE EFFECTS OF SUB-ACUTE ALGAL 

TOXIN EXPOSURE IN THE VERTEBRATE 

CNS. K. A. Lefebvre 1 , S. Tilton 2 , T. Bammler 3 , R. 

Beyer 3 , P. Janssen 3 , F. Farin 3 , S. Srinouanprachanh 3 

and E. Gallagher 2 . 1 Environmental Conservation, 

NOAA Fisheries/NWFSC, Seattle, WA, 2 Department 


University of Washington, Seattle, WA and 3 NIEHS 

Center for Ecogenetics and Environmental Health 

Functional Genomics and Bioinformatics Core 

Facilities, University of Washington, Seattle, WA. 

Thursday 




Thursday 



IDENTIFICATION AND COMPARISON OF 

TWO ISOFORMS OF THE FARNESOID X 

RECEPTOR ALPHA IN JAPANESE MEDAKA 

(ORYZIAS LATIPES), A DEVELOPING 

BILIARY TOXICITY MODEL. D. L. Howarth 1,2 , 

D. E. Hinton 1,2 and S. W. Kullman 1,3 . 1 Integrated 

Toxicology and Environmental Health Program, 

Duke University, Durham, NC, 2 Nicholas School 

of the Environment and Earth Sciences, Duke 

University, Durham, NC and 3 Environmental 




MPTP (1-METHYL 4-PHENYL 1, 2, 3, 

6-TETRAHYDROPYRIDINE) INDUCED 

NEURODEGENERATION IN DASYATIS 

SABINA (ATLANTIC STINGRAY). J. Dwivedi 1,2 , 

A. Montalvo 1 and C. Stevens 1 . 1 Preventative 

Medicine and Community Health, University of 

Texas Medical Branch, Galveston, TX and 2 Marine 

Biomedical Technologies Inc., Galveston, TX. 



REPRESSOR (AHRR): MECHANISTIC 

INSIGHTS FROM STUDIES IN 

MAMMALIAN AND NONMAMMALIAN 

MODELS. S. I. Karchner 1 , M. J. Jenny 1 , A. M. 

Tarrant 1 , B. R. Evans 1,2 , X. Yang 2 , D. H. Sherr 2 

and M. E. Hahn 1 . 1 Woods Hole Oceanographic 

Institution, Woods Hole, MA and 2 Boston University, 

Boston, MA. 


REDUCED SOX9B EXPRESSION BY TCDD 

IMPAIRS CRANIOFACIAL CARTILAGE 

GROWTH IN ZEBRAFISH EMBRYOS. K. 

M. Xiong 1 , R. E. Peterson 2 and W. Heideman 2,1 . 

1 

Biomolecular Chemistry, University of Wisconsin 

at Madison, Madison, WI and 2 School of Pharmacy, 

University of Wisconsin at Madison, Madison, WI. 


CHEMICAL GENETICS TO IDENTIFY 

MOLECULAR PATHWAYS CONTROLLING 

TISSUE REGENERATION. S. Sengupta 1,2 , L. K. 

Mathew 1,2 and R. L. Tanguay 1,2 . 1 EMT, Oregon State 

University, Corvallis, OR and 2 EHSC, Oregon State 

University, Corvallis, OR. 


INHIBITOR OF DNA BINDING-1 IS 

REQUIRED FOR NORMAL ZEBRAFISH 

CAUDAL FIN REGENERATION. C. Villano, 

T. Kung and L. White. Biochem and Micro, Rutgers 

University, New Brunswick, NJ. 


ROLES OF ARYL HYDROCARBON 

RECEPTORS (AHR) AND AHR REPRESSORS 

IN DEVELOPMENT AND DEVELOPMENTAL 

TOXICITY OF TCDD. M. J. Jenny, S. I. Karchner, 

D. G. Franks, B. R. Woodin and M. E. Hahn. 

Biology, Woods Hole Oceanographic Institution, 

Woods Hole, MA. 


SELDI PROTEINCHIP-BASED LIVER 

BIOMARKERS IN FUNGICIDE EXPOSED 

ZEBRAFISH. A. Bulman 1 , D. Bencic 2 , A. Biales 2 , 

R. Flick 2 , G. Ross 1 and D. Lattier 2 . 1 LSG, Bio-Rad, 

Hercules, CA and 2 ORD, NERL, EERD, U.S. EPA, 

Cincinnati, OH. Sponsor: T. Reddy. 


8:30 AM to 12:00 NOON 


POSTER SESSION: CARDIOVASCULAR SYSTEM: VASCULAR 

EFFECTS 

Chairperson(s): Bo Jiang, University of Washington, Seattle, WA and 

Judith Zelikoft, New York University School of Medicine, Tuxedo, NY. 




VASCULAR DILATION AND ANEURYSM 

DETECTED BY NONINVASIVE HIGH- 

FREQUENCY ULTRASONOGRAPHY IN 

APOE DEFICIENT MICE INJECTED WITH 

ANGIOTENSIN II. E. Suzuki 1 , N. Shimoji 1 , S. 

Tomioka 1 , H. Kameda 1 , M. Kammueller 2 and Y. 

Nagae 1 . 1 Safety Profiling and Assessment, Novartis 

Pharmacology K.K., Tsukuba, Japan and 2 Safety 

Profiling and Assessment, Novartis Pharmacology 

AG, Basel, Switzerland. 


INFLAMMATORY PROTEIN AND 

GENE EXPRESSION IN MONOCYTES 

AND MACROPHAGES EXPOSED TO 

CHOLESTEROL SECOALDEHYDE: 

IMPLICATIONS TO ATHEROSCLEROTIC 

PLAQUE DEVELOPMENT. A. C. 

Raghavamenon 1 , X. Gao 1 , O. D’Auvergne 2 , K. 

G. Kousoulas 3 and R. M. Uppu 1 . 1 Environmental 

Toxicology and the Health Research Center, Southern 

University and A & M College, Baton Rouge, LA, 

2 

Biological Sciences, Southern University and A & 

M College, Baton Rouge, LA and 3 Pathobilogical 

Sciences, School of Veterinary Medicine, Louisiana 

State University, Baton Rouge, LA. 


EFFECTS OF PRENATAL CIGARETTE 

SMOKE EXPOSURE ON LIPID 

PARAMETERS ASSOCIATED WITH 

OFFSPRING CARDIAC RISK: A STUDY 

IN MICE. J. T. Zelikoff 1 , S. P. Ng 1 , J. Lyon 1 , D. 

D. Bolanowski 2 , D. Conklin 2 and A. Bhatnagar 2 . 

1 

Department of Environmental Medicine, New York 

University School of Medicine, Tuxedo, NY and 

2 

Department of Medicine Division of Cardiology, 


278 




Abstract # 


MECHANISMS OF INHIBITION OF 

VASCULAR CALCIFICATION BY 

PHOSPHONOFORMIC ACID (FOSCARNET) 

IN RAT VASCULAR SMOOTH MUSCLE 

CELLS. V. Sorribas 1 , R. Villa-Bellosta 1 , J. Ducha 1 , 

R. Morales 1 , V. Latorre 1 and A. Anadon 2 . 1 Toxicology 

Department, University of Zaragoza, Zaragoza, Spain 

and 2 Department of Toxicology and Pharmacology, 




ARYL HYDROCARBON RECEPTOR- 

DEPENDENT ALTERATIONS IN HEPATIC 

AND VASCULAR GENE EXPRESSION IN 

ADULT ZEBRAFISH. B. Bugiak 1 and L. P. 

Weber 1,2 . 1 Toxicology, University of Saskatchewan, 

Saskatoon, SK, Canada and 2 Veterinary Biomedical 

Science, University of Saskatchewan, Saskatoon, SK, 

Canada. 


VASCULAR SMOOTH MUSCLE 

DYSFUNCTION INDUCED BY 

GINSENOSIDE RG3, A BIOACTIVE 

COMPONENT OF GINSENG. J. Lee, O. Bae, 

K. Lim, J. Noh and J. Chung. College of Pharmacy, 

Seoul National University, Seoul, South Korea. 


SUBCHRONIC EXPOSURE OF ADULT MICE 

TO 2, 3, 7, 8-TETRACHLORODIBENZO- 

P-DIOXIN (TCDD) INCREASES BLOOD 

PRESSURE AND ALTERS VASCULAR 

REACTIVITY. P. G. Kopf and M. K. Walker. 


NM. 


HYPERTENSIVE HEART DISEASE IN 

OLDER ARYL HYDROCARBON RECEPTOR 

NULL MICE PROGRESSES TO SYMPTOMS 

OF HEART FAILURE. L. Agbor, P. G. Kopf, A. C. 

Aragon, M. T. Walsh, M. Goens and M. K. Walker. 


NM. 


NON-INVASIVE BLOOD PRESSURE 

MONITORING IN THE CYNOMOLGUS 

MONKEY (MACACA FASCICULARIS): 

HIGH DEFINITION OSCILLOMETRY 

VERSUS IMPLANTED TELEMETRIC 

DEVICES. B. Schmelting 1 , M. Niehoff 1 , B. Egner 2 , 

S. Korte 1 and G. Weinbauer 1 . 1 Covance Laboratories 

GmbH, Muenster, Germany and 2 S+B medVet 

GmbH, Babenhausen, Germany. 


EFFECTS OF NO MODULATORS ON 

CARDIOVASCULAR RISK FACTORS IN 

MILD HYPERHOMOCYSTEINEMIC RAT 

MODEL. M. Sharma 1,2 , S. Rai 1 , R. Tiwari 1 , M. 

Tiwari 1 and R. Chandra 1 . 1 Dr. B. R. Ambedkar 

Centre for Biomedical Research University od Delhi, 

University of Delhi, Delhi, India and 2 University 

of Rhode Island, Department of Biomedical 

Pharmaceutical Sciences, Kingston, RI. 

Abstract # 


15-DEOXY-D12, 14 PROSTAGLANDIN J2 

INDUCES PLATELET FORMATION IN A 

HUMAN MEGAKARYOBLASTIC CELL 

LINE. J. J. O’Brien and R. P. Phipps. Environmental 

Medicine, University of Rochester, Rochester, NY. 


AN INVESTIGATION OF PARAOXONASE-1 

(PON1 192 

) ACTIVITIES IN THE SERUM OF 

SOUTHERNERS AS RELATED TO GENDER 

AND RACE. K. A. Davis 1 , H. Chambers 2 , A. Crow 1 

and J. E. Chambers 1 . 1 Ctr Environml Hlth Sci, Coll 

Vet Med, Mississippi State University Mississippi 

State, MS and 2 Entomology and Plant Path, 

Mississippi State University, Mississippi State, MS. 


CHARACTERIZATION OF ENDOTHELIAL 

DYSFUNCTION INDUCED BY 

NUCLEOSIDE REVERSE TRANSCRIPTASE 

INHIBITOR ANALOGUES AND THEIR 

PHOSPHORYLATED METABOLITES. V. Y. 

Hebert, B. Jiang, A. R. Khandelwal and T. R. Dugas. 

Pharmacology, Louisana State University Health 

Sciences Center in Shreveport, Shreveport, LA. 


ANTIRETROVIRALS INDUCE 

ENDOTHELIAL DYSFUNCTION VIA AN 

OXIDANT-DEPENDENT PATHWAY AND 

PROMOTE NEOINTIMAL HYPERPLASIA. B. 

Jiang, J. H. Zavecz and T. R. Dugas. Pharmacology, 

Toxicology and Neuroscience, LSU Health Sciences 

Center in Shreveport, Shreveport, LA. 


MANUFACTURED NANOPARTICLES 

INDUCE ENDOTHELIAL CELL 

INFLAMMATION. C. Deering, S. Cutler, J. 

Veranth and G. Yost. Pharm/Toxicology University of 

Utah, Salt Lake City, UT. 


ENDOTHELIAL CELL CAVEOLAE ARE 

INVOLVED IN ACTIVATION OF ARYL 

HYDROCARBON RECEPTOR PATHWAY 

BY COPLANAR POLYCHLORINATED 

BIPHENYLS. Z. Majkova 1 , E. Lim 2 , E. Smart 3 , M. 

T. Tseng 4 , M. Toborek 5 and B. Hennig 2 . 1 Toxicology, 

University of Kentucky, Lexington, KY, 2 Animal 

Sciences, University of Kentucky, Lexington, KY, 

3 

Pediatrics, University of Kentucky, Lexington, KY, 

4 

Anatomical Sciences, University of Louisville, 

Louisville, KY and 5 Neurosurgery, University of 

Kentucky, Lexington, KY. 


ENVIRONMENTAL PCBs INCREASE 

BLOOD VESSEL FORMATION BY OXIDANT 

SIGNALING. Q. Felty. Environmental & 

Occupational Health, Florida International 

University, Miami, FL. 


ARSENIC SIGNALS THROUGH A GaI- 

COUPLED PATHWAY TO INDUCE 

ANGIOGENIC GENES IN HUMAN 

MICROVASCULAR ENDOTHELIAL CELLS. 

L. R. Klei and A. Barchowsky. Environmental and 

Occupational Health, University of Pittsburgh, 


Thursday 




Thursday 



GENOTOXIC EFFECTS OF 

1-NITROPYRENE IN HUMAN 

ENDOTHELIAL CELLS. H. L. Andersson, E. 

Piras, B. Hellman and E. Brittebo. Pharmaceutical 

Biosciences, Uppsala University, Uppsala, Sweden. 

Sponsor: M. Stigson. 


A NOVEL CXCR4 ANTAGONIST DERIVED 

FROM HUMAN SDF-1, SDF-1P2G, 

STIMULATES ANGIOGENESIS IN A 

MURINE MODEL OF ACUTE HINDLIMB 

ISCHEMIA. Y. Tan 1,2 , X. Li 1 and L. Cai 1,2 . 

1 

Chinese-American Research Institute for Diabetic 

Complications, Wenzhou Medical College, Wenzhou, 

Zhejiang, China and 2 Departments of Medicine, 

Radiation Oncology, and Pharmacological and 



BENZO[A]PYRENE-INDUCED VASCULAR 

ENDOTHELIAL ADHESION MOLECULE 

EXPRESSION CAN BE DISRUPTED BY 

SELECTIVE FLAVONOID TREATMENT. 

E. Oesterling 1 , M. Toborek 3 and B. Hennig 2,1 . 

1 

Toxicology, University of Kentucky, Lexington, 

KY, 2 Animal Sciences, University of Kentucky, 

Lexington, KY and 3 Neurosurgery, University of 

Kentucky, Lexington, KY. 


8:30 AM to 12:00 NOON 


POSTER SESSION: FOOD SAFETY II 

Chairperson(s): Suma Vavilala, University of Maryland Baltimore 

County, Baltimore, MD. 




THE ROLE OF OXIDATIVE STRESS IN THE 

DIFFERENTIAL EFFECTS BETWEEN N-3 

AND N-6 PUFAS AND THE PROTECTIVE 

EFFECTS OF ALGAL AND FISH OIL IN 

COLON CARCINOGENESIS. G. M. Alink 1 , 

V. van Beelen 1 , J. Aarts 1 , R. Bino 3 , D. Bosch 3 , G. 

Hooiveld 4 , H. Mooibroek 2 , M. Muller 4 , A. Reus 1 , 

J. Roeleveld 1 , L. Sijtsma 2 , B. Spenkelink 1 and I. 

Rietjens 1 . 1 Toxicology, Wageningen University, 

Wageningen, Netherlands, 2 Agrotechnology and 

Food Innovations, Wageningen, Netherlands, 3 Plant 

Research International, Wageningen, Netherlands 

and 4 Human Nutrition, Wageningen University, 

Wageningen, Netherlands. 


TOXICOLOGICAL EVALUATION OF 

RESVIDA, A HIGH PURITY TRANS- 

RESVERATROL. L. D. Williams 1 , J. Edwards 2 

and M. Beck 2 . 1 Burdock Group, Vero Beach, FL and 

2 

DSM Nutritional Products, Ltd, Basel, Switzerland. 


IMPLICATION OF MODE OF ACTION 

(MOA) FOR RISK ASSESSMENT OF 

CATECHIN-RICH BEVERAGES. A. Kobayashi, 

R. Ogura, O. Morita, N. Nishiyama and T. 

Kasamatsu. Safety Science Research Laboratories, 

Kao Corporation, Haga-Gun, TOCHIGI, Japan. 

Sponsor: J. Avalos. 


MICROARRAY ANALYSES OF 

VOMITOXIN-INDUCED CHANGES 

IN P53 HETEROZYGOUS AND WILD- 

TYPE MICE: COMPARISION OF GENE 

EXPRESSION CHANGES WITH CLINICAL 

AND HISTOPATHOLOGIC MARKERS OF 

TOXICITY. G. Bondy, A. Nunnikhoven, I. Curran, 

D. Caldwell, L. Coady, S. Gurofsky, C. Armstrong, 

M. Parenteau, S. Aziz, K. Kapal, C. Qiao and R. 

Mehta. Food Directorate, Health Products and Food 

Branch, Health Canada, Ottawa, ON, Canada. 


OPTIMIZATION OF A NEW 

PROCEDURE FOR THE SIMULTANEOUS 

DETERMINATION OF LINCOMYCIN 

AND SPECTINOMYCIN BY LIQUID 

CROMATOGRAPHY-TRIPLE 

QUADRUPOLE-MASS SPECTROMETRY IN 

FOOD. G. Font 1 , E. Ferrer 1 , M. A. Martinez 2 , M. R. 

Martinez-Larrañaga 2 and A. Anadon 2 . 1 Department 

of Bromatology and Toxicology, Faculty of 

Pharmacy, Universitat de Valencia, Valencia, Spain 

and 2 Department of Toxicology and Pharmacology, 




EFFECT OF N-3 AND N-6 

POLYUNSATURATED FATTY ACID 

CONSUMPTION ON DEOXYNIVALENOL- 

INDUCED TISSUE-SPECIFIC IL-6 

EXPRESSION IN MICE. L. L. Vines 1,2 and J. 

J. Pestka 1,2,3 . 1 Food Science and Human Nutrition, 

Michigan State University, East Lansing, MI, 

2 

Center for Integrative Toxicology, Michigan State 

University, East Lansing, MI and 3 Microbiology and 

Molecular Genetics, Michigan State University, East 

Lansing, MI. 


THE FUNGAL METABOLITE, 

PYRROCIDINE A, INDUCES APOPTOSIS IN 

HEPG2 HEPATOCYTES AND PK15 RENAL 

CELLS. W. M. Haschek-Hock 1,2 , S. Hsiao 2 and D. 

T. Wicklow 3 . 1 Pathobiology, University of Illinois, 

Urbana, IL, 2 Veterinary Diagnostic Laboratory, 

University of Illinois, Urbana, IL and 3 ARS/USDA, 

Peoria, IL. 


SAFETY ASSESSMENT OF THE SOYBEAN 

ACETOLACTATE SYNTHASE PROTEIN 

(GM-HRA). C. A. Mathesius 1 , J. F. Barnett 2 , R. F. 

Cressman 3 , T. Davis 1 , J. Ding 1 , C. Finlay 4 , G. Ladics 3 , 

H. Sampson 5 , J. Schmidt 1 , J. Zhang 1 and B. Delaney 1 . 

1 

Pioneer Hi-Bred International, Inc., Johnston, IA, 

2 

Charles River Laboratories, Horsham, PA, 3 DuPont 

Agriculture and Nutrition, Wilmington, DE, 4 DuPont 

Haskell Laboratory, Newark, DE and 5 Department of 

Pediatrics and Immunobiology, Mount Sinai School 

of Medicine, New York. 

280 




Abstract # 


SAFETY ASSESSMENT OF GLYPHOSATE 

ACETYLTRANSFERASE (GAT4601) 

PROTEIN. B. Delaney 1 , J. Zhang 1 , G. Carlson 1 , 

T. Davis 1 , J. Schmidt 1 , B. Stagg 1 , B. Comstock 1 , 

A. Babb 2 , C. Finlay 3 , R. Cressman 4 , G. Ladics 4 , 

A. Cogburn 4 , D. Siehl 5 , L. Bardina 6 , H. Sampson 6 

and Y. Han 7 . 1 Pioneer Hi-Bred International, Inc., 

Johnston, IA, 2 Charles River Laboratories, Redfield, 

AR, 3 DuPont Haskell Laboratory, Newark, DE, 

4 

DuPont Agriculture and Nutrition, Wilmington, DE, 

5 

Pioneer Hi-Bred International, Inc., Verdia Campus, 

Redwood City, CA, 6 Department of Pediatrics and 

Immunobiology, Mount Sinai School of Medicine, 

New York and 7 Sungkyunkwan University School of 

Medicine, Seoul, South Korea. 


SUBCHRONIC DIETARY TOXICITY 

OF HIGH OLEIC SOYBEAN EVENT 

DP-3Ø5423-1 NUTRITIONALLY- 

MODIFIED USING GENE SUPPRESSION 

TECHNOLOGY. C. D. Sanders 1 , L. M. 

Appenzeller 1 , S. M. Munley 2 , L. A. Malley 2 , D. 

Hoban 2 , G. P. Sykes 2 and B. Delaney 1 . 1 Pioneer 

Hi-Bred Int’l., Inc., Johnston, IA and 2 DuPont 

Haskell Laboratory, Newark, DE. 


LOW DOSE DIETARY GENISTEIN 

NEGATES THE THERAPEUTIC EFFECT 

OF TAMOXIFEN. M. Du 1 , J. A. Hartman 2 , H. 

Song 2 , Y. H. Ju 3 and W. G. Helferich 2,1 . 1 Division 

of Nutritional Sciences, University of Illinois at 

Urbana-Champaign, Urbana, IL, 2 Department of 

Food Science and Human Nutrition, University 

of Illinois at Urbana-Champaign, Urbana, IL 

and 3 Department of Human Nutrition, Foods and 

Exercise, Virginia Polytechnic Institute and State 

University, Blacksburg, VA. 


SAFETY AND EFFICACY EVALUATION 

OF PEDIOCOCCUS ACIDILACTICI AS AN 

ORAL PROBIOTIC. B. Magnuson 1 , G. Lala 1 , J. 

Rindos 1 , G. Vo 1 , J. J. Lin 2 and U. Babu 3 . 1 Department 

of Nutr and Food Sci, University of Maryland, 

College Park, MD, 2 Imagilin Technologies, Potomac, 

MD and 3 CFSAN, Food and Drug Administration, 

Beltsville, MD. 


SUBCHRONIC DIETARY TOXICITY 

OF SOYBEAN EVENT DP-356Ø43-5 

GENETICALLY-MODIFIED USING A NOVEL 

GENE SHUFFLING TECHNOLOGY. L. M. 

Appenzeller 1 , R. Essner 1 , S. M. Munley 2 , L. A. 

Malley 2 , D. Hoban 2 , G. P. Sykes 2 and B. Delaney 1 . 

1 

Pioneer Hi-Bred Int’l., Inc., Johnston, IA and 

2 

DuPont Haskell Laboratory, Newark, DE. 


NON-CARIOGENICITY OF 

HYDROGENATED POLYDEXTROSE, 

A SYNTHETIC LOW-CALORIE 

POLYSACCHARIDE SUGAR REPLACER 

IN FOODS. J. C. Griffiths 1 and M. H. Auerbach 2 . 

1 

Burdock Group, Vero Beach, FL and 2 Danisco A/S, 

Elmsford, NY. 

Abstract # 


RAW264.7 MACROPHAGE CELLS - AN 

IN VITRO ALTERNATIVE FOOD SAFETY 

TESTING PLATFORM COMPATIBLE WITH 

VARIOUS FOOD TYPES AND FOOD-BORNE 

TOXINS. W. H. Tolleson 1 and L. S. Jackson 2 . 

1 

Division of Biochemical Toxicology, FDA-NCTR, 

Jefferson, AR and 2 National Center for Food Safety 

and Technology, FDA-CFSAN, Summit-Argo, IL. 


DIETARY FLAVONOIDS SULFATION BY 

HUMAN SULFOTRANSFERASES. C. Huang 

and G. Chen. Physiological Sciences, Oklahoma 



SAFETY ASSESSMENT OF LACTERMIN®, 

A WHEY EXTRACT. A. Dyer 2 , G. Burdock 1 , I. 

Carabin 1 and L. Read 2 . 1 Burdock Group, Orlando, 

FL and 2 TGR BioSciences Pty. Ltd, Thebarton, SA, 

Australia. 


AFLATOXIN EXPOSURE DECREASES 

SERUM LEVELS OF VITAMINS A & E 

IN GHANAIANS AT HIGH RISK FOR 

AFLATOXICOSIS. L. Tang 1 , L. Xu 1 , E. Afriyie- 

Gyawu 2 , P. Wang 1 , Y. Tang 1 , Z. Wang 1 , H. J. 

Huebner 2 , N. A. Ankrah 3 , D. Ofori-Adjei 3 , W. O. 

Ellis 4 , P. E. Jolly 5 , J. H. Williams 6 , J. S. Wang 1 

and T. D. Phillips 2 . 1 Texas Tech University, 

Lubbock, TX, 2 Texas A&M University, College 

Station, TX, 3 University of Ghana, Accra, Ghana, 

4 

KNUST, Kumasi, Ghana, 5 University of Alabama, 

Birmingham, AL and 6 University of Georgia, Griffin, 

GA. 


SEX DIFFERENCES IN APPARENT 

ADAPTATION TO IMMUNOTOXICITY 

OF DEOXYNIVALENOL. X. Wu 1 , M. Kohut 2 , 

J. Cunnick 3 and S. Hendrich 1 . 1 Food Science and 

Human Nutrition, Iowa State University, Ames, IA, 

2 

Kinesiology, Iowa State University, Ames, IA and 

3 

Animal Science, Iowa State University, Ames, IA. 


FUMONISIN B1 EXPOSURE PHENOCOPIES 

CHOLESTEROL DEPRIVATION IN C. 

ELEGANS. M. McElwee 1,2 , A. Wise 1,2 , W. A. Boyd 1 

and J. H. Freedman 1,2 . 1 Laboratory of Molecular 

Toxicology, NIEHS, Research Triangle Park, NC 

and 2 Nicholas School of the Environment, Duke 



THE PI3K/AKT SIGNALING PATHWAY 

MEDIATES THE INDUCTION OF 

CHOLESTEROL BIOSYNTHESIS GENES 

BY a-CHACONINE IN INTESTINAL 

EPITHELIAL CELLS. A. Peijnenburg 1 , T. 

Mandimika 1,2 , H. Baykus 1 , J. Poortman 1 , H. Kuiper 1 

and C. Garza 3 . 1 RIKILT-Institute of Food Safety, 

Wageningen, Netherlands, 2 Division of Nutritional 

Sciences, Cornell University, Ithaca, NY and 3 Office 

of the Provost, Boston College, Chestnut Hill, MA. 

Sponsor: M. Heneweer. 

Thursday 




Thursday 



8:30 AM to 12:00 NOON 


POSTER SESSION: HIGH-THROUGHPUT, HIGH CONTENT 

APPROACHES TO ASSESSING GENOTOXICITY 

Chairperson(s): Andrew Olaharski, Roche Palo Alto, Palo Alto, CA and 

Raymond Kemper, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, 

CT. 




HIGH CONTENT DNA DAMAGE ASSAY: 

SIMULTANEOUS MEASUREMENT OF H2AX 

PHOSPHORYLATION, ATM ACTIVATION, 

AND DNA CONTENT COMBINED WITH 

LIVE CELL ANALYSIS. E. Holden 1 , E. Luther 1 

and Z. Darzynkiewicz 2 . 1 Strategic Research 

Development, CompuCyte Corp., Cambridge, MA 

and 2 Brander Cancer Institute, New York Medical 

College, Valhalla, NY. 


TRACING MICRONUCLEI BY 

FLUORESCENT LIVE CELL IMAGING 

ANALYSIS. M. Honma 1 , Y. Takashima 2 , M. 

Yasui 1 , N. Koyama 1 , T. Koizumi 1 , M. Sakuraba 1 , H. 

Sakamoto 1 , K. Sugimoto 3 and M. Hayashi 1 . 1 Division 

of Genetics and Mutagenesis, National Institute of 

Health Sciences, Tokyo, Japan, 2 Research Center for 

Radiation Emergency Medicine, National Institute of 

Radiological Sciences, Chiba, Japan and 3 Division 

of Biosciences and informatics, Osaka Prefecture 

University, Osaka, Japan. Sponsor: M. Ema. 


IN VITRO MICRONUCLEI SCORED BY 

FLOW CYTOMETRY: AN INTERNATIONAL, 

MULTI-LABORATORY TRIAL. S. Dertinger 1 , S. 

Bryce 1 , S. Avlasevich 1 , J. Bemis 1 , M. Lukamowicz 2 , 

A. Elhajouji 2 , F. Van Goethem 3 , M. De Boeck 3 , D. 

Beerens 3 , H. Aerts 3 , J. Van Gompel 3 , J. Collins 4 , P. 

Ellis 4 , A. White 4 and A. Lynch 4 . 1 Litron Laboratories, 

Rochester, NY, 2 Novartis Pharmacology AG, Basel, 

Switzerland, 3 Johnson & Johnson Pharmaceutical 

R&D, Division of Janssen, Beerse, Belgium and 

4 

GlaxoSmithKline, Ware, Hertfordshire, United 

Kingdom. 


TIME-RELATED PROFILES OF 

MICRONUCLEATED PCES AND NCES IN 

BOTH BLOOD AND BONE MARROW AS 

MEASURED BY MICROSCOPY AND FLOW 

CYTOMETRY. Y. Xu 1 , D. Torous 2 , E. Chacon 1 , 

B. Hsu 1 , K. Butler 1 , C. Marsh 1 , A. Soufal 1 , D. 

Montague 1 , S. Dertinger 2 and T. E. Lawlor 1 . 1 Genetic 

& Molecular Toxicology, Covance Laboratories, 

Vienna, VA and 2 Litron Laboratories, Rochester, NY. 


AUTOMATED FLOW CYTOMETRIC 

DETECTION OF MURINE PERIPHERAL 

BLOOD MICRONUCLEATED 

ERYTHROCYTES USING NO-WASH, 

ROOM-TEMPERATURE GTOX FLOW KIT. 

E. Gautherot, F. Gaille, M. Herbert, A. van Agthoven, 

F. Malergue, F. A. Montero and J. Wolfers. Beckman 

Coulter Immunotech, Marseille, France. Sponsor: J. 

Allen. 


DEVELOPMENT OF AUTOMATED IN VITRO 

MICRONUCLEUS AND CYTOTOXICITY 

SCREENING ASSAYS. Y. Ovechkina, P. 

T. Nguyen, R. Keyser and C. O’Day. MDS 

Pharmacology Services, Bothell, WA. Sponsor: L. 

King. 


ANEUGENIC COMPOUNDS INCREASE 

MICRONUCLEUS FREQUENCIES IN 

MONONUCLEATED CELLS IN THE CB 

MICRONUCLEUS TEST. A. Poth and S. 

Bohnenberger. Genetic Toxicology and Alternative 

Methods, RCC Ltd, Rossdorf, Germany. 


USING KINASE SELECTIVITY PROFILES 

TO PREDICT IN VITRO MICRONUCLEUS 

ASSAY RESULTS. A. J. Olaharski 1 , N. 

Gonzaludo 2 , H. Bitter 2 , S. Kirchner 4 , G. Fischer 4 , D. 

Goldstein 3 and K. Kolaja 1 . 1 Investigative Toxicology, 

Roche, Palo Alto, CA, 2 Group research information, 

Roche, Palo Alto, CA, 3 Medicinal Chemistry, Roche, 

Palo Alto, CA and 4 Non-clinical drug safety, Roche, 

Basel, Switzerland. 


AUTOMATED IN VITRO MICRONUCLEUS 

TESTING OF NATURAL COMPOUNDS 

IN CORRELATION WITH HYDROGEN 

PEROXIDE DETECTION. G. Pappa, T. Woehrle 

and M. Toeroek. R&D Human Nutrition and Health, 

Safety, DSM Nutritional Products Ltd, Basel, 

Switzerland. 


VALIDATION AND OPTIMIZATION OF 

THE IN VITRO MICRONUCLEUS ASSAY IN 

HUMAN LYMPHOCYTES. C. S. Farabaugh, C. 

A. Middendorf, D. J. Roberts and L. F. Stankowski. 

Covance Laboratories, Inc, Vienna, VA. Sponsor: B. 

Fisher. 


AN IMPROVED FLOW CYTOMETRY- 

BASED UNSCHEDULED DNA SYNTHESIS 

(UDS) ASSAY. J. Tao 1 , C. Kirk 1 , L. F. Pratt 1 , G. 

M. Williams 2 and G. L. DeGeorge 1 . 1 MB Research 

Laboratories, Spinnerstown, PA and 2 Department of 

Pathology, NY Medical College, Valhalla, NY. 


HIGH CONTENT SCREENING CELL-BASED 

ASSAYS FOR IN VITRO GENOTOXICITY 

MEASUREMENTS. B. S. Mandavilli and R. N. 

Ghosh. Research and Development, Thermo Fisher 

Scientific, Rockford, IL. Sponsor: A. Barchowsky. 

282 




Abstract # 


GENOTOXICITY SCREENING STEPS 

UP A GEAR: VALIDATION OF HIGHER 

THROUGHPUT PROTOCOLS FOR THE 

GADD45A-GFP GENOTOXICITY ASSAY 

(GREENSCREEN HC). R. Walmsley, A. W. 

Knight and L. Birrell. 46 Grafton Street, Gentronix 

Ltd, Manchester, United Kingdom. 


ASSESSMENT OF THE GENOTOXICITY 

OF METABOLITES GENERATED BY 

HEPATOCYTES AND S9 EXTRACTS USING 

THE GADD45A-GFP GREENSCREEN HC 

ASSAY. C. Jagger, M. Tate, P. Cahill, C. Hughes, 

N. Billinton and R. Walmsley. Gentronix Ltd, 

Manchester, United Kingdom. 


INDEPENDENT VALIDATION OF THE 

GREENSCREEN GADD45-ALPHA 

INDICATOR ASSAY USING ONE HUNDRED 

PROPRIETARY AND NON-PROPRIETARY 

COMPOUNDS. K. Kolaja 1 , M. Hassani 1 , 

H. Uppal 1 , S. Kirchner 2 and A. J. Olaharski 1 . 

1 

Investigative Toxicology, Roche - Palo Alto, Palo 

Alto, CA and 2 Non-clinical Safety, Hoffman-La 

Roche, Basel, Switzerland. 


UTILIZATION OF GENE EXPRESSION 

TECHNOLOGIES IN THE DEVELOPMENT 

OF A PREDICTIVE ASSAY FOR 

GENOTOXICITY. S. Lu 1 , B. Jeffy 2 and B. Jessen 1 . 

1 

Drug safety research and development, Pfizer global 

research and development, San Diego, CA and 

2 

Entelos, Foster City, CA. 


OPTIMIZING A MICROTITER PLATE 

VERSION OF THE YEAST DEL ASSAY 

FOR THE SCREENING OF CHEMICAL 

LIBRARIES. Z. Sobol 1 , N. Hontzeas 1 , K. Hafer 2 

and R. H. Schiestl 1,2 . 1 Pathology, David Geffen 

School of Medicine at UCLA, Los Angeles, CA and 

2 

Radiation Oncology, UCLA, Los Angeles, CA. 


POSITIVE GENOTOXICITY RESULTS DUE 

TO THE FORMATION OF GENOTOXIC 

REACTION-PRODUCTS OF THE SOLVENT 

DMSO WITH CARBOXYLIC/SULFONIC 

ACID HALIDES. A. Amberg, K. Braun, A. Czich, 

H. Kauffmann, H. Spirkl, I. Stammberger and G. 

Troschau. Drug Safety Evaluation, Sanofi-Aventis 

Deutschland GmbH, Frankfurt, Germany. Sponsor: 

M. Bonnefoi. 

Abstract # 


8:30 AM to 12:00 NOON 


POSTER SESSION: PESTICIDE NEUROTOXICITY 

Chairperson(s): Stephanie Padilla, U.S. EPA, Research Triangle Park, 

NC. 




COMPARATIVE IN VITRO 

INHIBITION OF RAT HIPPOCAMPAL 

MONOACYLGLCYEROL LIPASE BY 

CHLORPYRIFOS OXON, PARAOXON AND 

DIISOPROPYLFLUOROPHOSPHATE. A. M. 

Likins, A. Nallapaneni and C. N. Pope. Physiological 

Sciences, Oklahoma State University, Stillwater, OK. 


COMPARISON OF ENZYME 

INHIBITION PATTERNS FOLLOWING 

DEVELOPMENTAL CHLORPYRIFOS 

EXPOSURE USING DIFFERENT 

ADMINISTRATION PARADIGMS. R. L. Carr 

and C. A. Nail. Center for Environmental Health 


State, MS. 


ENHANCED STARTLE RESPONSE IN 

ADULT ZEBRAFISH AFTER EARLY 

DEVELOPMENTAL CHLORPYRIFOS 

EXPOSURE: SENSITIVITY OF A RAPID 

AUTOMATED NEUROBEHAVIORAL 

TEST. E. D. Levin 1 , D. Cerutti 1 , P. Williams 1 and 

E. Linney 2 . 1 Psychiatry and Behavioral Sciences, 

Duke University Medical Center, Durham, NC 

and 2 Molecular Genetics and Microbiology, Duke 

University Medical Center, Durham, NC. 


PRENATAL CHLORPYRIFOS EXPOSURE 

IN MICE IMPAIRS WORKING AND 

REFERENCE MEMORY IN FEMALES 

AS ASSESSED BY A NOVEL FORAGING 

MAZE. S. Agoos 1,2 , D. Butz 2 and W. Porter 2 . 

1 

Duke University, Durham, NC and 2 UW Madison, 

Madison, WI. Sponsor: E. Levin. 


CHLORPYRIFOS-OXON INTERFERES 

WITH AXONOGENESIS IN EMBRYONIC 

ZEBRAFISH. D. Yang 1 , J. Ladu 2 , K. Buels 1 , H. 

Lauridsen 1 , R. Tanguay 2 and P. Lein 1 . 1 CROET, 

Oregon Health & Science University, Portland, 

OR and 2 Environmental & Molecular Toxicology, 

Oregon State University, Corvallis, OR. 


CHORPYRIFOS OXON-INDUCED CHANGES 

IN THIOFLAVIN T BINDING TO THE 

PERIPHERAL ANIONIC SITE OF HUMAN 

ACETYLCHOLINESTERASE. L. Sultatos and 

R. Kaushik. Pharmacology & Physiology, New 

Jersey Medical School, Newark, NJ. 

Thursday 




Thursday 



EXPOSURE OF ZEBRAFISH (DANIO RERIO) 

EMBRYOS TO DELTAMETHRIN RESULTS 

IN ALTERATION OF DOPAMINERGIC 

GENE EXPRESSION AND INCREASED 

ACTIVITY. A. DeMicco 1 , A. Green 1 , K. R. 

Cooper 1 , J. R. Richardson 2 and L. A. White 1 . 

1 

Biochemistry and Microbiology, Rutgers University, 

New Brunswick, NJ and 2 Toxicology Division, 

EOHSI, Piscataway, NJ. 


DEVELOPMENTAL DELTAMETHRIN 

EXPOSURE PRODUCES IMPULSIVE- 

LIKE BEHAVIOR THAT IS REVERSED 

BY METHYLPHENIDATE: RELEVANCE 

TO ADHD. M. Taylor 1 , D. Cory-Slechta 2 and J. 

Richardson 1 . 1 Joint Graduate Program in Toxicology, 

Rutgers University and UMDNJ, Piscataway, NJ and 

2 

Department of Environmental Medicine, University 



DELTAMETHRIN AND ESFENVALERATE 

INHIBIT SPONTANEOUS NETWORK 

ACTIVITY IN RAT CORTICAL NEURONS 

IN VITRO. S. M. Losa 2 , J. E. Baldwin 2 , A. M. 

Johnstone 1 and T. J. Shafer 1 . 1 Neurotoxicology 

Division, NHEERL, ORD, U.S. EPA, Research 

Triangle Park, NC and 2 Meredith College, Raleigh, 

NC. 


MOLECULAR MECHANISMS OF 

DELTAMETHRIN-INDUCED ALTERATIONS 

IN DOPAMINE TRANSPORTER 

EXPRESSION. J. R. Richardson. Environmental 

and Occupational Medicine, Robert Wood Johnson 

Medical School, Piscataway, NJ. 


EFFECT OF ORGANOPHOSPHATE ESTER 

INDUCED DELAYED NEUROPATHY 

(OPIDN) ON THE NEURONAL CELL BODY. 

B. S. Jortner, D. Shabb, S. Hancock, J. Hinckley, 

L. Williams and M. F. Ehrich. Laboratory for 

Neurotoxicity Studies, Virginia Tech, Blacksburg, 

VA. 


EFFECTS OF THE ORGANOCHLORINE 

PESTICIDE DIELDRIN IN THE 

NEUROENDOCRINE BRAIN OF 

LARGEMOUTH BASS (Micropterus salmoides). 

R. E. Weil 1,2 , C. J. Martyniuk 1 , D. S. Barber 1 and N. 

D. Denslow 1 . 1 Center for Environmental and Human 

Toxicology, University of Florida, Gainesville, 

FL and 2 Pharmacology, University of Florida, 



CARBARYL-INDUCED CHOLINESTERASE 

INHIBITION AND DOSIMETRY IN YOUNG 

AND ADULT RATS. V. C. Moser 1 , P. M. Phillips 1 , 

K. L. McDaniel 1 , J. E. Graff 1 , A. B. Lowit 2 , E. 

Reaves 2 , W. Setzer 3 and D. W. Herr 1 . 1 NTD/ 

NHEERL/ORD, U.S. EPA, RTP, NC, 2 OPP/OPPTS, 

U.S. EPA, RTP, NC and 3 NCCT/ORD, U.S. EPA, 

RTP, NC. 


TIME COURSE OF THE 

TRANSCRIPTIONAL RESPONSE OF RAT 

CEREBROCORTICAL TISSUE AFTER 

ACUTE PYRETHROID EXPOSURE IN 

VIVO. J. A. Harrill 1 , Z. Li 2 , F. A. Wright 2 and K. M. 

Crofton 3 . 1 Curriculum in Toxicology, UNC, Chapel 

Hill, NC, 2 Department of Biostatistics & Carolina 

Environmental Bioinformatics Research Center, 

UNC, Chapel Hill, NC and 3 NTD, NHEERL, ORD, 



ACTION OF PYRETHROID INSECTICIDES 

ON RAT Nav1.6 SODIUM CHANNELS 

EXPRESSED IN XENOPUS OOCYTES. J. Tan 1 , 

J. Choi 2 and D. Soderlund 1 . 1 Entomology, Cornell 

University, Geneva, NY and 2 Neurology, Yale 

University, New Haven, CT. 


LONG-TERM NEUROBEHAVIORAL 

CONSEQUENCES OF LOW-LEVEL 

NEONATAL PARATHION EXPOSURE 

IN RATS. O. A. Timofeeva 1 , E. D. Levin 1,2,3 , 

S. Agoos 3 , C. Perraut 1 , F. J. Seidler 2,3 and T. A. 

Slotkin 2,1,3 . 1 Psychiatry and Behavioral Sciences, 

Duke University Medical Center, Durham, NC, 

2 

Pharmacology and Cancer Biology, Duke University 

Medical Center, Durham, NC and 3 Integrated 

Toxicology and Environmental Health Program, 

Duke University, Durham, NC. 


DIISOPROPYLPHOSPHOROFLUORIDATE 

(DFP) INDUCED DIFFERENTIAL mRNA 

EXPRESSION OF BCL2 IS ONE OF 

THE MOLECULAR SYMPTOMS OF 

ORGANOPHOSPHATE INDUCED OPIDN IN 

HENS. T. V. Damodaran and M. B. Abou-Donia. 

Medicine and Pharmacology and Cancer biology, 

Duke University Medical Center, Durham, NC. 


TRANSFER OF NEUROTOXICANTS 

(MALATHION AND LEAD ACETATE) IN 

COMBINATION THROUGH IN VITRO 

BLOOD-BRAIN BARRIER SYSTEMS. P. 

Balbuena, B. Meldrum, K. Fuhrman, B. Wise and 

M. Ehrich. College of Veterinary Medicine, Virginia 

Tech, Blacksburg, VA. 


ORGANOPHOSPHORUS PESTICIDES (OPS) 

DO NOT INTERACT DIRECTLY WITH 

AIRWAY NERVES TO CAUSE NEURONAL 

M2 RECEPTOR DYSFUNCTION. D. Bruun 1 , 

B. Proskocil 2 , A. Fryer 2 and P. J. Lein 1 . 1 CROET, 

Oregon Health & Science University, Portland, OR 

and 2 Physiology and Pharmacology, Oregon Health 

& Science University, Portland, OR. 


SPECTRAL EVALUATION OF 

ELECTROGRAPHIC SEIZURES AFTER 

EXPOSURE TO ORGANOPHOSPHORUS 

COMPOUNDS. M. Furtado 1 , L. Lumley 2 , J. 

Waterhouse 1 , S. Lichtenstein 1 , B. Litwack 1 , T. 

Herbert 1 , K. Clements 1 , C. Robison 2 and D. Yourick 1 . 

1 

Headquarters, Walter Reed Army Institute of 

Research, Silver Spring, MD and 2 U.S. Army 

Medical Research Institute of Chemical Defense, 

Aberdeen Proving Ground, MD. Sponsor: J. Yourick. 

284 




Abstract # 


THE RELATION BETWEEN SPONGY 

CHANGE OF SPINAL CORD AND 

EXPRESSION OF 2’, 3’-CYCLIC 

NUCLEOTIDE 3’-PHOSPHODIESTERASE 

(CNP) INDUCED BY ANILINE IN RATS. T. 

Kanno, T. Kurotaki, Y. Kotani, Y. Wako and M. 

Tsuchitani. Mitsubishi Chemical Safety Institute 

LTD., Kamisu-si, Ibaraki-ken, Japan. 


CYP1A2*1F AND PON1 Q192R GENETIC 

POLYMORPHISMS AS SUSCEPTIBILITY 

DETERMINANTS FOR NEUROLOGICAL 

EFFECTS IN MEXICAN FARMERS 

EXPOSED TO ORGANOPHOSPHOROUS 

PESTICIDES. M. Sánchez-Guerra 1 , N. Pérez- 

Herrera 1 , V. H. Borja-Aburto 2 , J. Alvarado-Mejía 3 , 

G. Elizondo-Azuela 1 and B. Quintanilla-Vega 1 . 

1 

Toxicology Section, CINVESTAV, Mexico City, 

D.F., Mexico, 2 Coordinación Nacional de Salud en el 

Trabajo, IMSS, Mexico City, Mexico and 3 Escuela 

de Medicina, Universidad Autónoma de Yucatán, 

Mérida, Mexico. 


DETERMINATION OF LC50S FOR 

ROUNDUP AND MANZATE IN 

CAENORHABDITIS ELEGANS. D. A. Rudd, 

N. S. Davis, R. Negga and V. A. Fitsanakis. Biology, 

King College, Bristol, TN. 


EFFECTS OF ATRAZINE AND ITS 

METABOLITES ON THE UPTAKE 

OF DOPAMINE INTO RAT STRIATAL 

SYNAPTIC VESICLES AND 

SYNAPTOSOMES. M. M. Hossain and N. M. 

Filipov. CEHS, Basic Sciences, Mississippi State 



LIFESPAN ANALYSIS OF 


MODIFIED PROTEINS FOLLOWING 

ATRAZINE EXPOSURE IN RATS. A. C. Schell 1 , 

G. P. Dooley 1 , W. H. Hanneman 1 and C. D. Foradori 2 . 

1 



2 

Biomedical Sciences, Colorado State University, 



PREVENTION BY ANTIOXIDANTS OR 

NMDA RECEPTOR ANTAGONIST OF 

CARBOFURAN-INDUCED ALTERATIONS IN 

BIOMARKERS OF NEURODEGENERATION 

AND NEUROINFLAMMATION IN RAT 

BRAIN. R. C. Gupta 1 , S. Milatovic 2 , W. Dettbarn 2 

and D. Milatovic 2 . 1 Toxicology, Murray State 

University, Hopkinsville, KY and 2 Vanderbilt 


Abstract # 


PHYSICO-CHEMICAL 

CHARACTERIZATION OF STEALTH 

LIPOSOMES ENCAPSULATING A 

HYDRLYZING ENZYME EMPLOYED IN 

ORGANOPHOSPHORUS ANTAGONISM. 

I. Petrikovics 1 , J. R. Wild 2 , M. Budai 3 , P. Grof 3 , P. 

Chapela 1 and M. E. Wales 2 . 1 Chemistry, Sam Houston 

State University, Huntsville, TX, 2 Biochemistry and 

Biophysics, Texas A&M University, College Station, 

TX and 3 Pharmaceutics, Semmelweis University, 

Budapest, Hungary. 


DECREASE OF DOPAMINE LEVELS AFTER 

GLYPHOSATE HERBICIDE TREATMENT 

IN RATS. A. Anadon, J. Del Pino, M. A. Martinez, 

V. Caballero, I. Nieto, I. Ares and M. R. Martinez- 

Larrañaga. Department of Toxicology and 

Pharmacology, Faculty of Veterinary Medicine, 

Universidad Complutense, Madrid, Spain. 


BRAIN CHOLINESTERASE INHIBITION 

AND DEPRESSION OF THE PHOTIC 

AFTER DISCHARGE (PHAD) OF FLASH 

EVOKED POTENTIALS (FEPS) IN LONG 

EVANS RATS FOLLOWING ACUTE OR 

REPEATED EXPOSURES TO A MIXTURE 

OF CARBARYL AND PROPOXUR. J. Mwanza 1 , 

D. F. Lyke 2 , J. E. Graff 3 and D. W. Herr 3 . 1 NRC, 

Washington, DC, 2 UNC, Chapel Hill, NC and 3 U.S. 

EPA /ORD/NHEERL/NTD, RTP, NC. 


ALDEHYDE DEHYDROGENASE 

INHIBITION BY METABOLITES OF 

MOLINATE, A THIOCARBAMATE 

HERBICIDE. E. M. Gagan 1 , D. G. Anderson 1 , V. R. 

Florang 1 , T. D. Hurley 2 and J. A. Doorn 1 . 1 Medicinal 

and Natural Products Chemistry, University of Iowa, 

Iowa City, IA and 2 Biochemistry and Molecular 

Biology, University of Indiana School of Medicine, 

Indianapolis, IN. 


THE POSSIBLE ROLE OF 

CHLOROACETALDEHYDE IN 

2-CHLOROETHANOL NEUROTOXICITY. Y. 

Chen 1,2 , J. Liao 3 and D. Hung 2 . 1 Veterinary Medicine, 

National Chung Hsing University, Taichung, Taiwan, 

2 

Division of Toxicology, Taichung Veterans General 

Hospital, Taichung, Taiwan and 3 Graduate Institute 

of Veterinary Pathology, National Chung Hsing 

University, Taichung, Taiwan. 


ESTERASE PROFILES AND QSAR 

FOR A SERIES OF DIALKYL-O-(2- 

HYDROPERFLUOROPROP-2-YL) 

PHOSPHATES (PFP). G. F. Makhaeva 1 , O. 

G. Serebryakova 1 , N. B. Boltneva 1 , A. Y. 

Aksinenko 1 , V. B. Sokolov 1 and R. J. Richardson 2 . 

1 

Institute of Physiologically Active Compounds 

RAS, Chernogolovka, Russian Federation and 

2 

Environmental Health Sciences/Toxicology, 


Thursday 




Thursday 



STRUCTURAL INSIGHTS INTO THE 

HUMAN NEUROPATHY TARGET 

ESTERASE (NTE) CATALYTIC DOMAIN 

(NEST). S. J. Wijeyesakere 1 , J. A. Stuckey 2 and R. 

J. Richardson 1 . 1 Environmental Health Sciences/ 

Toxicology, University of Michigan, Ann Arbor, MI 

and 2 Life Sciences Institute, University of Michigan, 

Ann Arbor, MI. 


8:30 AM to 12:00 NOON 



PHARMACEUTICAL—TECHNIQUES, PULMONARY, 

CARDIOVASCULAR 

Chairperson(s): M. Elizabeth Bell, AstraZeneca Pharmaceutical, 

Wilmington, DE and Gary Chmielewski, Pfizer Global Research & 





A REVIEW OF NONCLINICAL 

DEVELOPMENT STRATEGIES USED TO 

SUPPORT PHASE I CLINICAL TRIALS 

WITH INHALED PHARMACEUTICALS. 

A. Gibbs and P. Smith. Programme Management, 

Covance, Harrogate, United Kingdom. Sponsor: C. 

Springall. 


DRUG-INDUCED TOXICITY AND ITS 

REVERSIBILITY IN THE REGULATORY 

NON-CLINICAL STUDIES WITH NEW 

DRUGS IN JAPAN. M. Iijima and T. Eimoto. 

Clinical Pathology, Nagoya City University Graduate 

School of Medical Sciences, Nagoya, Aichi, Japan. 


OPTIMISATION OF PLETHYSMOGRAPHY 

CONDITIONS FOR USE IN REPEAT DOSE 

TOXICITY STUDIES. L. C. Ewart, G. Cullen 

and J. Valentin. AstraZeneca, Macclesfield, United 

Kingdom. 


DETERMINATION OF TIDAL VOLUME 

AND RESPIRATORY RATE BY 

PNEUMOTACHOGRAPHY IN THE 

MARMOSET. S. Korte 1 , B. Schmelting 1 and B. 

Marshall 2 . 1 Covance Laboratories GmbH, Muenster, 

Germany and 2 Covance Laboratories Ltd, Harrogate, 

United Kingdom. Sponsor: G. Weinbauer. 


PULMONARY DELIVERY OF MEASLES 

VACCINE: NON-HUMAN PRIMATE SAFETY 

STUDY. R. Forster 1 , T. Appelqvist 1 , D. Brown 2 , B. 

Cohen 2 , G. Chalonner-Larsson 3 , R. de Swart 4 and 

A. Henao Restrepo 5 . 1 CIT, Evreux, France, 2 Health 

Protection Agency, London, United Kingdom, 

3 

Bioconsult, Ottawa, ON, Canada, 4 Erasmus 

University, Rotterdam, Netherlands and 5 WHO, 

Geneva, Switzerland. 


LONG TERM CONTINUOUS INTRAVENOUS 

INFUSION IN THE ALBINO RAT, BEAGLE 

DOG, CYNOMOLGUS MONKEY AND 

GÖTTINGEN MINI-PIG. A. Patel, L. Armer, M. 

Mus and C. Copeman. Toxicology, Charles River 

Labs, Preclinical Services Montreal Inc., Senneville, 

QC, Canada. Sponsor: C. Banks. 


A METHOD FOR CONTINUOUS 

INTRAVENOUS INFUSION IN GOTTINGEN 

MINI-PIGS. G. Washer, R. Kubaszky, C. Petit- 

Turcotte and S. Authier. LAB Research Canada, 

Laval (Montreal), QC, Canada. 


NEW INITIATIVES TO ENSURE 

AVOIDANCE OF CROSS-CONTAMINATION 

IN THE VIVARIUM. S. Doughty. Covance 

Laboratories Ltd, Harrogate, United Kingdom. 

Sponsor: D. Everett. 


AMBULATORY CONTINUOUS 

INTRAVENOUS INFUSION MODEL FOR 

PREGNANT DUTCH BELTED RABBITS. E. D. 

Sloter 1 , M. Nemec 1 , D. Stump 1 , S. Pritt 2 , M. Beck 1 , T. 

Gleason 1 , W. Miller 1 and J. Holson 1 . 1 WIL Research 

Laboratories, LLC, Ashland, OH and 2 Covance 

Research Products, Inc., Denver, PA. 


OPTIMIZING CELL LINES FOR 

DETECTION OF DRUG-INDUCED 

MITOCHONDRIAL IMPAIRMENT. J. 

Jamieson, L. Marroquin, J. Dykens and Y. Will. Drug 

Safety R&D, Pfizer, Inc., San Diego, CA. 


A NOVEL 

IMMUNOHISTOENZYMOGRAPHY 

APPROACH FOR THE IN SITU 

ASSESSMENT OF DRUG-TARGET 

INTERACTIONS. A. Vicart 1 , B. Greiner 1 , E. G. 

Funhoff 1 , S. Pantano 1 , U. Hassiepen 2 , B. Burkey 3 , 

F. Pognan 1 , S. Busch 1 , S. Chibout 1 , P. Moulin 1 and 

J. G. Moggs 1 . 1 Investigative Toxicology, Safety 

Profiling & Assessment, Novartis Pharmacology 

AG, Basel, Switzerland, 2 CPC/EPP NIBR, Basel, 

Switzerland and 3 Diabetes/Metabolism DA, NIBR 

Inc, Cambridge, MA. 


BEAT-TO-BEAT ELECTRICAL ALTERNANS 

IN GUINEA PIG LANGENDORFF HEARTS 

AS A PREDICTOR OF CARDIOTOXICANTS. 

L. Guo and J. Qian. Non-Clinical Safety, Hoffmann- 

La Roche Inc., Nutley, NJ. 


THIRTEEN-WEEK VEHICLE FEASIBILITY 

STUDY BY CONTINUOUS INTRAVENOUS 

INFUSION IN THE MONKEY. N. Pickersgill, F. 

Bellebeau, H. Contamin, C. Graham, J. Briffaux and 

E. Drevon-Gaillot. MDS Pharmacology Services, St 

Germain sur l’Arbresle, France. 

286 




Abstract # 


A CARDIOVASCULAR SAFETY 

ASSESSMENT PARADIGM FOR THE EARLY 

IDENTIFICATION OF PROARRHYTHMIC 

AND TORSADAGENIC COMPOUNDS. C. 

Frantz 1 , D. Misner 1 , E. Meierhenry 1 , M. Fielden 1 , 

L. Guo 2 , J. Ly 1 , H. Uppal 1 , D. Rotstein 1 , P. Senese 3 , 

M. Albassam 3 , M. Gralinski 3 , S. Chanda 1 , S. Platz 1 

and K. Kolaja 1 . 1 Toxicology, Roche Palo Alto, Palo 

Alto, CA, 2 Roche, Nutley, NJ and 3 CorDynamics, 

Chicago, IL. 


EFFECTS OF INSULIN ON THE QT 

INTERVAL IN ANESTHETIZED DOGS. H. 

Goto 1 , T. Senba 1 , E. Hosoki 1 , K. Morishita 1 and L. 

L. Lanning 2 . 1 Toxicology, Otsuka Pharmaceutical 

Co., Ltd, Tokushima, Japan and 2 Nonclinical Safety 

Evaluation, Otsuka Pharmaceutical Development & 

Commercialization, Inc., Rockville, MD. 


NILOTINIB PRODUCES NO DETECTABLE 

CARDIOTOXICITY AFTER 39 WEEKS OF 

ORAL (GAVAGE) ADMINISTRATION TO 

CYNOMOLGUS MONKEYS. K. Bowenkamp 1 , 

C. Hayden 1 , G. Argentieri 1 , M. Osier 2 , E. Giddens 2 , 

P. Savage 1 , H. Smith 1 and P. Sahota 1 . 1 Novartis 

Pharmaceuticals, East Hanover, NJ and 2 SNBL USA, 

Everett, WA. 


TOXICOLOGICAL EVALUATION OF 

BMS-747158, A PET MYOCARDIAL 

PERFUSION IMAGING AGENT. M. Mistry 1 , 

D. Onthank 1 , J. Green 1 , S. Cicio 1 , D. Casebier 1 , S. 

Robinson 1 , R. Kowalski 2 and T. Baird 2 . 1 Bristol- 

Myers Squibb Medical Imaging, North Billerica, MA 

and 2 MPI Research, Inc, Mattawan, MI. 


TOXICITY OF NORWALK VLP VACCINE 

FOLLOWING REPEATED INTRANASAL 

ADMINISTRATION TO NEW ZEALAND 

WHITE RABBITS. S. Godin 1 , K. Wheeler 1 , 

L. Murphy 1 and R. Sublett 2 . 1 Bridge Global 

Pharmaceutical Services, Inc., Gaithersburg, MD and 

2 

LigoCyte Pharmaceuticals, Inc., Bozeman, MT. 


DRUG-INDUCED PHOSPHOLIPIDOSIS: 

RELATIONSHIPS BETWEEN 

HISTOLOGICAL CHANGE, TISSUE INJURY 

AND DRUG ACCUMULATION. N. Matsumoto, 

Y. Takenobu, K. Shimouchi, H. Yanagi, K. Yamada 

and S. Kim. Ono Pharmaceutical Co., Ltd., Osaka, 

Japan. 


INCREASED EFFICIENCY OF 

PROCONVULSANT SCREENING 

THROUGH STRATEGIC USE OF 

ELECTROCONVULSANT MODELS. M. Bell, 

C. S. Lee and R. A. Bialecki. Safety Assessment, 

AstraZeneca Pharmaceuticals, Wilmington, DE. 

Sponsor: P. Ciaccio. 


TEMPORAL RELATIONSHIP OF 

PHOSPHOLIPIDOSIS AND MITOCHONDRIA 

TOXICITY IN PRIMARY RAT CEREBELLAR 

CULTURES. L. R. Barone and P. J. Ciaccio. Safety 

Assessment, AstraZeneca, Wilmington, DE. 

Abstract # 


14-DAY SODIUM 2, 2-DIMETHYLBUTYRATE 

(ST-20) NEURO/GENOTOXICITY STUDY 

IN RATS. M. Hawk 1 , G. Ritchie 1 , M. Ryan 1 , D. 

Vasconcelos 1 , V. Yildiz 1 , D. Contose 1 , J. D. Johnson 1 , 

S. Perrine 2 , J. Peggins 3 , J. Tomaszewski 3 and P. 

Terse 3 . 1 Battelle, Columbus, OH, 2 Boston University 

School of Medicine, Boston, MA and 3 National 

Cancer Institute, Bethesda, MD. 


PEDIATRIC NON CLINICAL SAFETY 

OF LEVETIRACETAM IN COMPARISON 

TO OTHER AEDS. M. Léonard, S. Dhalluin 

and G. Rose. Non-Clinical Development, UCB 

Pharmacology SA, Braine-l’Alleud, Belgium. 


COLLECTION OF CEREBROSPINAL 

FLUID BY DIRECT PUNCTURE OR BY 

SURGICALLY IMPLANTED PORTS IN 

MONKEYS. J. Perron, Y. Trudel, F. Emond, H. 

Simard, M. Stilianesis and C. Copeman. Toxicology, 

Charles River Labs, Preclinical Services Montreal 

Inc., Senneville, QC, Canada. Sponsor: C. Banks. 


A PERFORMANCE STANDARD FOR 

DEVELOPMENT OF THE MODIFIED IRWIN 

TEST AS PART OF A NEUROLOGICAL 

ASSESSMENT AND A FUNCTIONAL 

OBSERVATIONAL BATTERY (FOB) IN CD-1 

MICE. A. Blackburn, S. Authier, M. Legaspi and G. 

Washer. LAB Research Canada, Laval (Montreal), 

QC, Canada. 


NEUROBEHAVIORAL EFFECTS OF 

D-AMPHETAMINE AND CARBARYL 

IN THE VALIDATION OF SAFETY 

PHARMACOLOGY CENTRAL NERVOUS 

SYSTEM TESTING METHODS IN SPRAGUE 

DAWLEY RATS. S. Bayreuther, S. Wilson, B. 

Countey, C. Eisenhauer and R. Oates. Preclinical 

Services, Charles River Laboratories, Shrewsbury, 

MA. Sponsor: S. Bulera. 


MOTOR ACTIVITY AND FUNCTIONAL 

OBSERVATIONAL BATTERY IN RATS 

TREATED WITH EMD 509847 AND CNS 

REFERENCES. B. C. Gottschling, P. Tempel and 

F. von Landenberg. Institute of Toxicology, Merck 

KGaA, Merck Serono, Darmstadt, Germany. 


THE SIGNIFICANCE OF SKIN 

DISTRIBUTION OF DRUGS FOR THE 

ELICITATION OF PHOTOTOXIC 

REACTION. K. Yamada, A. Akimoto, H. 

Kawashima, N. Matsumoto and S. Kim. Ono 

Pharmaceutical Co., Ltd, Osaka, Japan. 


IN VITRO ASSAYS FOR EVALUATING 

THE ULTRAVIOLET A (UV-A) INDUCED 

DAMAGE IN CULTURED HUMAN RETINAL 

PIGMENT EPITHELIAL CELLS. L. Lee. Pfizer 

Global R&D, San Diego, CA. Sponsor: W. Yvonne. 

Thursday 




Thursday 



TOXICOLOGY STUDIES TO SUPPORT 

CLINICAL DEVELOPMENT OF 

TREMELIMUMAB, A CYTOTOXIC T 

LYMPHOCYTE-ASSOCIATED ANTIGEN 

4 (CTLA4) BLOCKING MONOCLONAL 

ANTIBODY. G. Finch 1 , D. Hanson 1 , F. Wang 1 , D. 

Guyot 2 , L. Morton 1 , T. Kawabata 1 , M. Hurtt 1 and 

J. Gomez-Navarro 1 . 1 Pfizer Global Research and 

Development, Groton/New London, CT and 2 Amgen, 

Thousand Oaks, CA. 


CAECINOGENICITY STUDY OF THE NEW 

PYRAZOLOPYRIMDINONE DERIVATIVE 

K-1089 FOR ERECTILE DYSFUNCTION IN 

F344 RATS. S. Cha, H. Lee, M. Park, E. Jeong, 

K. Lee and S. Han. Korea Institute of Toxicology, 

Daejeon, South Korea. Sponsor: W. Koh. 


DOES ENVIRONMENTAL ENRICHMENT 

AFFECT TUMOUR INCIDENCE IN RATS? 

I. Taylor, L. K. Earl, S. Cook and J. F. Thomas. 

Huntingdon Life Sciences, Alconbury, United 

Kingdom. Sponsor: O. Green. 


TUMORS IN RATS ASSOCIATED 

WITH IMPLANTABLE MICROCHIP 

IDENTIFICATION DEVICES. B. S. Wahle 1 , L. E. 

Elcock 2 , S. G. Lake 1 , B. P. Stuart 1 and L. P. Sheets 1 . 

1 

Toxicology, Bayer CropScience LP, Stilwell, KS and 

2 

Pathology Associates, Inc., Kansas City, MO. 


SPONTANEOUS HIBERNOMAS IN 

SPRAGUE-DAWLEY RATS. R. H. Bruner 2 , 

G. A. Parker 2 , M. N. Novilla 2 , C. A. Picut 2 , J. B. 

Kirkpatrick 1 and T. P. O’Neill 1 . 1 Pathology, WIL 

Research Laboratories, Ashland, OH and 2 Pathology, 

Biotechnics, Hillsborough, NC. 


9:00 AM to 11:45 AM 

Room 615 

Oxidative Signaling and Redox Biology 

SYMPOSIUM SESSION: CELLULAR REDOX STATUS AND ZINC 

SIGNALING 

Chairperson(s): Y. James Kang, University of Louisville, Louisville, KY 

and Dean Jones, Emory University, Atlanta, GA. 

Endorsed by: 




Cellular redox status constantly changes under both physiological and stress 

conditions. The redox change modifies cellular signaling system, leading to 

functional adaptation to the physiological demand or the stress imposition. 

Zinc/cysteine coordination in proteins is sensitive to redox changes and is 

therefore used in redox switches. There are two major classes of redox zinc 

switches: the first are redox sensors that undergo conformational changes 

through zinc release to alter their functions, although the released zinc may 

not have known functions. The second are redox transducers that release 

zinc for the purpose of changing the function of other proteins through the 

released zinc. The function of the redox transducers thus is to convert the 

redox signal to zinc signals. There is virtually no free zinc in the cell under 

physiological conditions and zinc availability is tightly controlled through 

uptake, intracellular sequestration, and controlled trafficking. Metallothionein 

(MT), as a redox transducer, plays a critical role in the redox sensing 

and zinc signaling. Oxidation of the sulfur ligands in MT mobilizes zinc, 

while reduction of the oxidized ligands enhances zinc binding. This MT 

redox cycle provides an excellent control mechanism for the availability 

of intracellular zinc. Many zinc proteins are activated or inactivated after 

receiving zinc under oxidative stress conditions. These zinc proteins are 

the effectors of zinc signaling and involved in signal transduction, energy 

metabolism, mitochondrial function, and gene expression. This symposium 

will present discussions on (1) cellular redox responses under physiological 

and stress conditions; (2) zinc transporters and the regulation of zinc intracellular 

movement in mammalian systems; (3) zinc/cysteine coordination in 

proteins as a sensor to redox signaling and the converting of redox signaling 

to zinc signaling though MT redox cycle; and (4) regulation of gene expression 

by zinc-finger transcription factor. 

#2327 9:00 CELLULAR REDOX STATUS AND ZINC 

SINGALING. Y. Kang. Medicine, University of 

Louisville School of Medicine, Louisville, KY. 

#2328 9:05 REDOX REGULATION OF CELL SIGNAL 

TRANSDUCTION. D. P. Jones. Medicine, Emory 

University, Atlanta, GA. 

#2329 9:45 ZINC TRANSPORTERS AND THE 

REGULATION OF INTRACELLULAR ZINC 

TRAFFICKING. D. Eide. Nutritional Sciences, 

University of Wisconsin-Madison, Madison, WI. 

Sponsor: J. Kang. 

#2330 10:25 METALLOTHIONEIN REDOX CYCLE AND 

ZINC SIGNALING. Y. Kang. Medicine, University 

of Louisville School of Medicine, Louisville, KY. 

#2331 11:05 REGULATION OF METAL-INDUCIBLE 

TRANSCRIPTION BY A ZINC-FINGER 

TRANSCRIPTION FACTOR. J. H. Freedman 1 , 

E. K. Braithwaite 1 and Y. Jin 2 . 1 LMT, NIEHS, NIH, 

DHHS, Research Triangle Park, NC and 2 Duke 



9:00 AM to 11:45 AM 

Room 605 


SYMPOSIUM SESSION: PERINATAL EXPOSURE TO 

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 

(NRTIS) INDUCES TRANSPLACENTAL GENOTOXICITY AND 

MITOCHONDRIAL TOXICITY 

Chairperson(s): Barbara Shane, NIEHS, Research Triangle Park, NC and 

Miriam Poirier, National Institutes of Health, Bethesda, MD. 

Endorsed by: 


Highly active antiretroviral therapy (HAART), containing two NRTIs, 

has been remarkably beneficial in managing HIV-1 infection and AIDS. 

However, increasing evidence suggests that in some HIV-1-uninfected 

children born to HIV-1-infected mothers, perinatal NRTI exposure may 

have long-term genotoxic and mitochondrial consequences. Recent studies, 

compiled in a special issue of Environmental and Molecular Mutagenesis 

(Vol. 48, April/May 2007), support earlier conclusions that AZT is a transplacental 

carcinogen in mice, becomes incorporated into DNA of fetal mice, 

humans and monkeys, and induces mutagenesis (including p53 transversion 

mutations) and micronuclei in mice and humans exposed to NRTIs in 

utero. Currently evidence for increased malignancy in HIV-1-uninfected 

children born to HIV-1-infected mothers who received NRTI therapy during 

pregnancy is lacking, but widespread use of NRTIs in human pregnancy has 

been recommended only since 1994. An additonal area of concern is mitochondrial 

compromise, which occurs in infants exposed to NRITs in utero 

288 




Abstract # 

. Similar morphological and biochemical evidence of NRTI-induced mitochondrial 

damage was found both in human infants born to HIV-1-infected 

mothers and monkey infants born to immunodeficiency virus-free dams 

given human-equivalent NRTI protocols. Therefore, transplacental drug 

treatment alone is able to induce fetal mitochondrial toxicity. Substantial 

morphological and biochemical mitochondrial cardiac damage was also seen 

in the NRTI-exposed infant monkeys, consistent with evidence of a deficiency 

in human cardiac left-ventricular mass reported for HIV-1-uninfected 

infants at 1 and 2 years of age after in utero exposure to NRTIs. This symposium 

will include 4 speakers who will cover topics related to exposures in 

animal models and parallel events in HIV-1-uninfected human infants born 

to HIV-1-infected mothers receiving NRTI therapy during pregnancy. 

#2332 9:00 PERINATAL EXPOSURE TO NUCLEOSIDE 

REVERSE TRANSCRIPTASE INHIBITORS 

(NRTIS) INDUCES TRANSPLACENTAL 

GENOTOXICITY AND MITOCHONDRIAL 

TOXICITY. M. C. Poirier. National Cancer 


#2333 9:05 OVERVIEW OF RODENT 

TRANSPLACENTAL CARCINOGENICITY 

AND GENOTOXICITY STUDIES 

INVOLVING NRTIS. D. M. Walker 1 , V. Walker 2 

and S. M. Torres 2 . 1 Experimental Pathology 

Laboratories, Sterling, VA and 2 Pathophysiology, 

Lovelace Resp Res Inst, Albuquerque, NM. 

#2334 9:45 MUTATIONS IN CANCER GENES IN 

LUNG TUMORS FROM SWISS (CD-1) 

MICE EXPOSED TRANSPLACENTALLY 

TO AZT AFFECT SIMILAR MOLECULAR 

PATHWAYS THAT ARE IMPORTANT IN 

HUMAN LUNG CANCER. R. Sills. NIEHS, 


#2335 10:25 PERINATAL NUCLEOSIDE REVERSE 

TRANSCRIPTASE INHIBITOR (NRTI) 

EXPOSURES CAUSE PERSISTENT 

MITOCHONDRIAL COMPROMISE IN 

MOUSE AND MONKEY OFFSPRING AND 

HUMAN INFANTS. R. L. Division 1 , M. C. 

St. Claire 3 , D. M. Walker 2 , V. E. Walker 2 and M. 

C. Poirier 1 . 1 NCI, NIH, Bethesda, MD, 2 LRRI, 

Albuquerque, NM and 3 BioQual, Rockville, MD. 

#2336 11:05 THE EFFECT OF ART EXPOSURE DURING 

CHILDHOOD ON CARDIOVASCULAR 

STRUCTURE AND FUNCTION IN 

CHILDREN BORN TO HIV INFECTED 

MOTHERS. S. E. Lipshultz. Department of 

Pediatrics, University of Miami, Miami, FL1, Miami, 

FL. Sponsor: V. Walker. 

Abstract # 


9:00 AM to 11:45 AM 

Room 611 

Stem Cell Biology and Toxicology 

SYMPOSIUM SESSION: STEM CELLS IN DEVELOPMENTAL 

AND REPRODUCTIVE BIOLOGY AND TOXICOLOGY 

Chairperson(s): Anne Greenlee, Oregon Health & Sciences University, 

La Grande, OR and Robert Chapin, Pfizer Global Research and 


Endorsed by: 




There is considerable concern that chemical exposures near the time of 

conception or during pregnancy may contribute to the increasing incidence 

of congenital cardiovascular and neurodevelopmental diseases. However, 

most chemicals have not been well characterized because comprehensive 

testing may exceed available resources of time, money and animals. While 

the embryonic stem cell test with morphologic and molecular endpoints 

offers an alternative strategy for screening pharmaceuticals and novel 

compounds, it is just one application of stem cells in toxicology. Adapting 

these cells to high through-put platforms may improve efficiency and offer 

reductions in animal use and costs. This vision is challenged by the longterm 

stability of the pluripotent stem cell populations and standardizing 

conditions for directed differentiation. Resolution of these issues is needed 

to fully capitalize on stem cells in developmental and reproductive toxicology. 

The purpose of this symposium is to provide an overview of stem 

cell biology and convey the current state-of-the-art science of using embryonic 

stem cells in developmental studies and toxicity testing. 

#2337 9:00 STEM CELLS IN DEVELOPMENTAL 

AND REPRODUCTIVE BIOLOGY AND 

TOXICOLOGY - SYMPOSIUM OVERVIEW. 

A. R. Greenlee 1 and R. E. Chapin 2 . 1 School of 

Nursing, Oregon Health & Science University, La 

Grande, OR and 2 Global Research and Development, 

Pfizer, Groton, CT. 

#2338 9:05 STEM CELLS IN REPRODUCTIVE AND 

DEVELOPMENTAL BIOLOGY. D. P. Wolf. 

Oregon National Primate Research Center, Oregon 

Health & Science University, Beaverton, OR. 

Sponsor: A. Greenlee. 

#2339 9:45 METABOLOMICS OF HUMAN 

EMBRYONIC STEM CELLS: INNOVATION 

FOR DISCOVERY OF PREDICTIVE 

BIOMARKERS OF DEVELOPMENTAL 

TOXICITY. G. G. Cezar. Animal Sciences, 

University of Wisconsin, Madison, WI. Sponsor: A. 

Greenlee. 

#2340 10:25 STEM CELLS FOR DEVELOPMENTAL 

TOXICITY TESTING: THE PROMISE AND 

PERILS. D. B. Stedman, J. A. Paquette, R. D. 

Streck, S. W. Krumpf and R. E. Chapin. Global 

Research and Development, Pfizer, Groton, CT. 

#2341 11:05 EGGS AND SPERM FROM EMBRYONIC 

STEM CELLS: EMERGING TOOLS TO 

PREDICT REPRODUCTIVE RISKS? A. R. 

Greenlee 1,2 . 1 School of Nursing, Oregon Health & 

Science University, La Grande, OR and 2 Center 

for Research on Occupational and Environmental 

Toxicology, Oregon Health & Science University, 

Portland, OR. 

Thursday 




Thursday 



9:00 AM to 11:45 AM 

Room 618 

WORKSHOP SESSION: GENOTOXICITY TESTING FROM 

EARLY DISCOVERY THROUGH REGULATORY SUBMISSION: 

A COMPREHENSIVE PRIMER 

Chairperson(s): Ronald Snyder, Schering-Plough Research Institute, 

Summit, NJ and Rob Stachlewitz, Boehringer Ingelheim Pharmaceuticals, 

Inc., Ridgefield, CT. 

Endorsed by: 


A review of the Physician’s Desk Reference (PDR) reveals that 25–30% of 

marketed drugs (excluding those whose mechanism of action is dependent 

on genotoxicity such as some antineoplastics, antivirals, etc) exhibited genotoxicity 

when assessed by the standard battery of bacterial and mammalian 

assays. The majority of these marketed drugs with positive gene-tox findings 

were discovered and developed some years ago in a more relaxed climate 

in which genotoxic liability was balanced against the potential benefit of 

the indication. While this risk/benefit analysis still comes into play today, 

increased drug safety accountability has resulted in a “zero tolerance” situation 

thus mandating better ways to screen for and identify these problematic 

structures as early as possible. Most large pharmaceutical companies with 

active chemistry and/or high throughput combinatorial or compound library 

screening programs have recognized the need for ascertaining the genotoxic 

potential ofnovel molecular scaffolds have genotoxic potential and have 

established biological and in silico strategies to determine this. The goal 

of this workshop will be to provide an assessment of the state of the art of 

genotoxicity evaluation in the drug discovery process, the management of 

genotoxicity issues and regulatory accountabilities. The following topics will 

be discussed: 1) Strengths and limitations of existing traditional and scaleddown 

approaches. 2) Appropriate use of in silico programs for predicting 

genotoxicity including discussion on why these sometimes generate “false 

positives” and “false negatives” and new ways to look at these findings. 

3) Genotoxicity associated with non-covalent drug/DNA interactions. 4) 

high throughput applications. 5) Novel genomics or other molecular-based 

approaches for genotoxicity assessment. 6) Future trends and regulatory 

expectations. 

#2342 9:00 GENOTOXICITY TESTING FROM EARLY 

DISCOVERY THROUGH REGULATORY 

SUBMISSION: A COMPREHENSIVE 

PRIMER. R. Snyder 1 and R. Stachlewitz 2 . 1 Schering- 

Plough, Summit, NJ and 2 Boehringer Ingelheim 

Pharmaceuticals Inc., Ridgefield, CT. 

#2343 9:10 GENETIC TOXICOLOGY TESTING: HOW 

CAN WE IMPROVE ITS UTILITY TO 

INFORM RISK ASSESSMENT? B. Gollapudi. 


#2344 9:40 USING GENETIC TOXICOLOGY 

INFORMATION TO EVALUATE SAFETY 

OF IMPURITIES AND METABOLITES FOR 

PHARMACEUTICALS. J. P. Bercu 1 and K. L. 

Dobo 2 . 1 Toxicology and Drug Disposition, Lilly 

Research Laboratories, a Division of Eli Lilly and 

Company, Greenfield, IN and 2 Drug Safety Research 

and Development, Genetic Toxicology, Pfizer Global 

R & D, Groton, CT. 

#2345 10:10 ICH S2B, A STANDARD BATTERY 

FOR GENOTOXICITY TESTING OF 

PHARMACEUTICALS: A TEN YEAR 

PERSPECTIVE. HOW WELL HAS IT SERVED 

U.S., CAN IT BE IMPROVED? D. Jacobson- 

Kram. CDER, FDA, Silver Spring, MD. 

#2346 10:40 IN SILICO APPROACHES FOR 

ASSESSMENT OF GENOTOXICITY IN 

DRUG DISCOVERY AND DEVELOPMENT. 

R. D. Snyder 2 . 1 Schering-Plough, Summit, NJ and 

2 

Schering-Plough Research Institute, Summit, NJ. 

#2347 11:10 EMERGING SCIENTIFIC APPROACHES IN 

GENETIC TOXICITY TESTING. J. Aubrecht. 

Drug Safety R&D, Pfizer, Inc, Groton, CT. 


9:00 AM to 11:45 AM 

Room 608 

WORKSHOP SESSION: INCORPORATION OF MODE-OF- 

ACTION INTO MECHANISTICALLY-BASED QUANTITATIVE 

MODELS 

Chairperson(s): Nagalakshmi Keshava, U.S. EPA, Research Triangle 

Park, NC and Hisham El-Masri, U.S. EPA, Research Triangle Park, NC. 

Endorsed by: 



The biological processes by which environmental pollutants induce adverse 

health effects is most likely regulated by complex interactions dependent 

upon the route of exposure, dose, kinetics of distribution, and cellular 

responses. To further complicate deciphering these interactions, the majority 

of toxicological data has been developed using in vitro and in vivo models, 

adding to the complexity of extrapolation issues. Quantitative models are 

the next logical step to advance the current toxicological understanding of 

how pollutants induce both cancer and non-cancer health effects. Mechanistically-based 

quantitative modeling represents an avenue of research 

to identify and, in some instances, quantify uncertainties in relationship to 

mode of action (MOA) by which compounds elicit adverse health effects. 

If the MOA for an environmental pollutant is known, a model can be 

constructed utilizing experimentally-derived datasets that quantitatively 

represent the key events in the MOA. Conversely, if the MOA is unknown, 

a hypothesis-driven approach can be utilized to assemble the model and 

inform likely key events within the MOA(s) for which further experimentations 

can be designed to test the MOA hypothesis. An important limitation of 

biologically-based model development is the availability of empirical data to 

construct such models. It is conceivable that this type of approach would 

improve the efficiency of current research strategies by pointing to specific 

research needs and data gaps. Efforts to define the approach for creating 

mechanistically-based models will provide unique and useful tools for 

human health risk assessment. Implementation of such techniques will result 

in the use of science-based derivation of risk posed by exposure to environmental 

pollutants. The following presentations will highlight the current 

state of the science and future directions of biologically-based quantitative 

modeling. (The views expressed in this abstract are those of the authors and 

do not represent the policy of the U.S. Environmental Protection Agency.) 

#2348 9:00 INCORPORATION OF MODE OF ACTION 

INTO MECHANISTICALLY-BASED 

QUANTITATIVE MODELS. N. Keshava and H. 

El-Masri. Office of Research and Development, U.S. 


Park, NC. 

#2349 9:15 USING GENE/PATHWAY/DISEASE 

ANALYSIS TO QUANTIFY CRITICAL 

DISEASE PATHWAYS. C. J. Portier, J. Gohlke 

and R. Thomas. NIEHS, Ressearch Triangle Park, 

NC. 

290 




Abstract # 

#2350 9:45 USING GENOMIC DOSE-RESPONSE 

MODELING TO INFORM KEY EVENTS IN 

A MODE-OF-ACTION RISK ASSESSMENT. 

R. S. Thomas 1 , B. C. Allen 2 , L. Yang 1 , A. Nong 1 , H. J. 

Clewell 1 and M. E. Andersen 1 . 1 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC and 

2 

Bruce Allen Consulting, Chapel Hill, NC. 

#2351 10:15 USE OF (MoA) INFORMATION IN 

BIOLOGICALLY BASED DOSE-RESPONSE 

MODELING FOR INORGANIC ARSENIC: 

DOSE-RESPONSE (DR) AND TIME-COURSE 

(TC) CONSIDERATIONS. R. Conolly. U.S. EPA, 


#2352 10:45 BIOLOGICALLY- BASED DOSE 

RESPONSE (BBDR) MODEL FOR THE 

HYPOTHALAMIC-PITUITARY-THYROID 

(HPT) AXIS. J. Fisher and E. McLanahan. 

Environmental Health Science, University of 


#2353 11:15 CURRENT AND FUTURE USE OF 

MECHANISTICALLY-BASED MODELS AND 

MODE OF ACTION IN HUMAN HEALTH 

RISK ASSESSMENT. R. Sams 1 , N. Keshava 1 and 

H. El-Masri 2 . 1 ORD/NCEA, U.S. Environmental 

Protection Agency, Research Triangle Park, NC and 

2 

ORD/NHEERL, U.S. Environmental Protection 

Agency, Research Triangle Park, NC. 


9:00 AM to 11:45 AM 

Room 6B 


WORKSHOP SESSION: PULMONARY TOXICITY TESTING OF 

NANOPARTICLES 

Chairperson(s): David Lai, U.S. EPA, Washington, DC and David 

Warheit, DuPont Haskell Laboratories, Newark, NJ. 

Endorsed by: 



The unusual physco-chemical properties of engineered nanomaterials raise 

concerns about adverse effects on biological systems and developing testing 

strategies to characterize the hazard potential of increasing number of nanomaterials 

has been a challenge faced by regulatory agencies, academia and 

industries. In 2005, a screening strategy was developed by an International 

Life Sciences Institute (ILSI) workgroup for hazard identification process 

of nanomaterial risk assessment. The ILSI review proposes a comprehensive 

array of in vitro and in vivo assays to investigate the toxicity of diverse 

nanomaterials in routes of entry and target tissues. In vitro tests of toxicity 

can provide a rapid and relatively inexpensive way to assess the potential 

toxicity of large numbers of untested nanoparticles. In vitro studies also 

allow specific biological and mechanistic pathways to be identified and 

tested under controlled conditions to provide initial data on comparative 

toxicity of nanomaterials of diverse size and shape. However, there are a 

number of inherent issues of in vitro test systems resulting in false positives 

and false negatives and recent studies have shown little correlations between 

in vitro and in vivo toxicity of some nanomaterials. Because of their small 

size, aerosolization of respirable nanomaterials is likely, either as singlet 

or as aggregated particles and exposure by the inhalation route is a major 

concern. Whereas inhalation is the preferred method of pulmonary exposure 

for hazard identification, a number of barriers exist for conducting inhalation 

studies with nanomaterials, and alternative exposure methods (e.g., intratracheal 

instillation, intratracheal inhalation, pharyngeal/laryngeal aspiration) 

have been used by various investigators. The purpose of this workshop is 

to bring together experts to discuss the usefulness of in vitro studies for 

Abstract # 

hazard identification of nanomaterials and if alternative pulmonary exposure 

methods can be used to substitute for inhalation studies. 

#2354 9:00 PULMONARY TOXICITY TESTING OF 

NANOPARTICLES. D. Y. Lai. OPPT, U.S. EPA, 


#2355 9:25 COMPARING IN VITRO AND IN VIVO 

PULMONARY TOXICITY OF FINE AND 

NANOPARTICLES. C. Sayes. DuPont Haskell 

Laboratory, Newark, DE. 

#2356 10:00 COMPARISON OF IN VITRO, PHARYNGEAL 

ASPIRATION, AND INHALATION 

RESULTS FOR SINGLE-WALLED CARBON 

NANOTUBES. V. Castranova. NIOSH/CDC, 


#2357 10:35 THE NEED FOR VALIDATION OF 

TOXICITY TESTS OF NANOPARTICLES. G. 

Oberdorster. University of Rochester, Rochester, NY. 

#2358 11:10 PULMONARY TOXICITY STUDIES IN RATS 

WITH THREE FORMS OF ULTRAFINE 

TIO2 PARTICLES BY INTRATRACHEAL 

INSTILLATION AND INHALATION 

EXPOSURES. D. Warheit. DuPont Haskell 

Laboratory, Newark, DE. 


9:00 AM to 11:45 AM 

Room 6A 

INFORMATIONAL SESSION: REACH: IMPLEMENTATION, 

CHEMICAL SAFETY, AND INFORMATION REQUIREMENTS 

Chairperson(s): E. Spencer Williams, ChemRisk, Inc., Houston, TX and 

Susan Borghoff, Integrated Laboratory Systems, Inc., Research Triangle 

Park, NC. 

Endorsed by: 



In December 2006, the REACH Regulation (Registration, Evaluation, 

and Authorisation of Chemicals) was adopted by the European Union. As 

a part of this regulation, manufacturers and importers will be required to 

provide information concerning the safety of their particular chemicals/ 

substances. The goal of this legislation is to compile information on the 

hazards, exposure, and risk from chemicals in commerce. To that end, registration 

of each chemical will require a suite of data on physicochemical and 

toxicological properties. Sharing of data between companies registering the 

same substance will be encouraged for most data, and mandatory for animal 

data. The amount of data compiled for each substance will be based on the 

mass that is manufactured or imported annually in the EU. Those chemicals 

determined to be the most dangerous will be banned from use in the EU. For 

substances manufactured or imported in amounts greater than 10+ tonnes 

per year, hazard and risk assessments are required as part of a Chemical 

Safety Report. These assessments are required for each identified use of the 

substances, and are expected to describe appropriate risk management procedures 

and technology. The identification of uses and exposure scenarios will 

require an unprecedented degree of communication up and down the supply 

chain. Implementation of REACH will require a significant effort on the 

part of the global chemicals industry, with a specific need for expertise in 

toxicology and risk assessment. Pre-registration will begin in June 2008 

and continue until December 2008. Registration of substances manufactured 

or imported in quantities greater than 1000 tonnes per year, as well 

as the substances identified as the most carcinogenic, mutagenic, and toxic 

to reproduction, must be registered by December 2011. Phased deadlines 

for substances in other tonnage bands continue until 2018. The regulatory 

authorities in the EU are developing a comprehensive set of guidance documents, 

called REACH Implementation Projects (RIPs). These documents 

describe the regulatory process and the necessary IT infrastructure, as well 

as provide guidance on how to comply with the regulation. This informa- 

Thursday 




Abstract # 

tion session will focus on details of the REACH regulation as well as the 

REACH Implementation Projects, which will offer guidance to regulatory 

authorities and to industry. 

#2359 9:00 REACH – IMPLEMENTATION, 

CHEMICAL SAFETY, AND INFORMATION 

REQUIREMENTS. E. S. Williams 1 , S. Borghoff 2 

and V. Santa-Cruz 3 . 1 Houston, ChemRisk, Houston, 

TX, 2 ILS, Inc., Durham, NC and 3 Chevron Phillips 

Chemical, Brussels, Belgium. 

#2360 9:10 REACH IMPLEMENTATION PROJECTS: 

GUIDANCE FOR INDUSTRY AND 

REGULATORY AUTHORITIES. E. S. Williams. 

Houston, ChemRisk, Houston, TX. 

#2361 9:45 FULFILLING TECHNICAL 

REQUIREMENTS OF REACH. S. Borghoff. 

Investigative Toxicology, ILS, Inc, Research Triangle 

Park, NC. 

#2362 10:20 REACH’S COMPREHENSIVE APPROACH 

TO CHEMICAL SAFETY. V. Santa-Cruz. 

Chevron-Phillips Chemical, Brussels, Belgium. 

#2363 10:55 REACH EXPOSURE SCENARIOS, 

ASSESSMENT, AND TOOLS. M. Penman. 

H2 Compliance, Brussels, Belgium. Sponsor: E. 

Williams. 


Friday Morning, March 21 

9:00 AM to 3:30 PM 


FRIDAY MORNING 

Satellite Meeting: Perchlorate Exposures, 

Iodine Modulation of Effect, and Epidemiologic 

Associations: Implications for Risk Assessment 

Presented by: The Kleinfelder Group 

Overview: New epidemiologic analyses and experimental results on the 

relationship between perchlorate exposures and thyroid function will be 

presented. Speakers and panelists will consider the role of iodine nutrition 

in determining perchlorate health risks and to address evidence for and 

against the attribution of causality to a given epidemiologic association. 

Ample time for participatory discussion is allotted. 

Program Committee: Gay Goodman (Chair), Michael Dourson, and 

Robert Howd. 

Confirmed Speakers: Yona Amitai, Benjamin Blount, Lewis Braverman, 

John Gibbs, Gay Goodman, Robert Howd, Steven Lamm, and Elizabeth 

Pearce. 

More Information: Telephone Dr. Goodman at (206) 284-4820 or visit 

www.kleinfelder.com/perchlorate.2008.seattle. 

Thursday Afternoon, March 20 

1:00 PM to 4:30 PM 


Satellite Meeting: Perchlorate Exposures, 

Iodine Modulation of Effect, and Epidemiologic 

Associations: Implications for Risk Assessment 

Thursday 

Presented by: The Kleinfelder Group 

Overview: New epidemiologic analyses and experimental results on the 

relationship between perchlorate exposures and thyroid function will be 

presented. Speakers and panelists will consider the role of iodine nutrition 

in determining perchlorate health risks and to address evidence for and 

against the attribution of causality to a given epidemiologic association. 

Ample time for participatory discussion is allotted. 

Program Committee: Gay Goodman (Chair), Michael Dourson, and 

Robert Howd. 

Confirmed Speakers: Yona Amitai, Benjamin Blount, Lewis Braverman, 

John Gibbs, Gay Goodman, Robert Howd, Steven Lamm, and Elizabeth 

Pearce. 

More Information: Telephone Dr. Goodman at (206) 284-4820 or visit 

www.kleinfelder.com/perchlorate.2008.seattle. 

292 



Notes 

up-to-date information at www.toxicology.org 

293


Author Index 

The numerals following the author’s names refer to the abstract numbers. 

The asterisk after the abstract number indicates the author is the first presenter. 

Author Index 

A 

Aardema, M J........................................503 

Aaronson, S A....................................... 25* 

Aarts, J.................................................2221 

Abadin, H G........................................ 933* 

Abbasian, M........................................1201 

Abbott, B D............................... 541, 2018* 

Abbott, M............................................2136 

Abdelrahim, M........................ 1417*, 2178 

Abdel-Rahman, A A......................141, 953 

Abdel-Rahman, S....................................79 

Abe, J...................................................1592 

Abel, E L.............................................. 120* 

Abel, J....................................................578 

Abou-Donia, M B.............. 141*, 953, 2276 

Abou-Hadeed, A H..............................1211 

Aboyade-Cole, A ................................1242 

Abraham, I M.................................... 1759* 

Abraham, W........................................1117 

Abram, F...............................................232 

Abramovitz, D L..................................1123 

Abu-Qare, A W.................................... 953* 

Acosta-Saavedra, L C................ 186*, 1847, 

........................................1848, 1850, 1851 

Acuff, K D...................................330, 1716 

Ada, A O................................................402 

Adair, B...............................................1629 

Adamo-Trigiani, M..............................1772 

Adamou, T........................ 51, 1005, 1016* 

Adams, M E.........................................1819 

Adams, T T..........................................1464 

Adams, T........................................... 1357* 

Addleman, R S..............................140, 435 

Addleman, S........................................1401 

Ade, N.......................................1315, 1456 

Adeshina, F...........925, 926, 927, 928, 929 

Adhikari, P........................................ 1230* 

Adigun, A A...................................... 1319* 

Adler, M.............................................. 528* 

Aeby, P..................................................340 

Aerts, H...............................................2244 

Afeseh Ngwa, H................................ 1879* 

Affonso, S F...........................................183 

Afonin, V............................................1166 

Afriyie-Gyawu, E..................483, 486, 490, 

.............................. 507*, 1478, 1631, 2238 

Afshari, A A....................................... 1099* 

Afshari, C......................................87, 1565 

Agarwal, C....................................151, 678 

Agarwal, R.............................151, 204, 678 

Agbonon, A...........................................716 

Agbor, L............................................. 2207* 

Agca, Y....................................................60 

Aggeler, R ...........................................2084 

Agoos, S................................... 2263*, 2275 

Agostino, Jr., R B...................................876 

Aguilar-Garduño, C............................1473 

Ahmed, G..............................................494 

Ahmed, S.......................................534, 535 

Ahsan, H...................................1630, 1966 

Aidoo, A..............................................1430 

Ainscow, E.............................................619 

Aisaki, K................................................370 

Aizawa, Y............................................2142 

Akagi, T...............................................2023 

Akai, S...................................................218 

Akdemir, C............................................488 

Akgul, Y............................................ 1137* 

Akimoto, A..........................................2320 

Akkan, Z............................................ 1781* 

Aklikokou, K ........................................716 

Aksinenko, A Y...................................2291 

Alatorre, J............................................1767 

Albano, E..............................................844 

Albassam, M........................................2306 

Alberg, T......................................656, 1441 

Albertini, R J.......................................1672 

Albertini, R..........................................1736 

Albrecht, A L.......................................1608 

Albrecht, A..........................................1598 

Albrecht, C............................................440 

Albrecht, R M........................................427 

Alcasey, S...............................................491 

Alden, C L...........................................1222 

Al-Dissi, A........................................... 752* 

Aldridge, T................................1574, 1604 

Aleksunes, L M.....................829, 840, 960, 

..................................................1946, 2029 

Aleksunes, L...................................... 2020* 

Aleo, M D.......................................35*, 36* 

Alexander, D.............................1625, 1898 

Alexander, M......................................1861 

Alexeeff, G V............................... 936*, 938 

Alexeeva, V...........................................294 

Algaier, J W................................. 512*, 814 

Ali, A A................................................ 719* 

Ali, S F.......................................1042, 1043 

Ali, S....................................................1714 

Alink, G M........................................ 2221* 

Alink, G.................................................440 

Alkis, N.................................................404 

Allaben, W T.........................................719 

Allais, L...................................................70 

Allan, A M...........................................1880 

Allard, P............................................ 1524* 

Allen, B C................................ 1175*, 2350 

Allen, B...............................................1007 

Allen, D...............................899, 988, 1455 

Allen, K............................................... 830* 

Allen, P D....................................545, 2155 

Allen, S..................................................738 

Allen-Hoffmann, B...............................372 

Allgeier, S H.................. 1515, 1516, 1517* 

Alm, H............................................... 1718* 

Almeida, A..........................................1825 

Almeida, I C........................................2066 

Almeida, R L.......................................2173 

Almond, M R......................................1902 

Almond, R......................................... 1310* 

Alnouti, Y..............................................943 

Al-Otaiba, A........................................1395 

Alpar, S..................................................402 

Al-Refai, H...........................................2091 

Altman-Hamamdzic, S........................ 381* 

Alvarado-Mejía, J................................2281 

Alvarez-Labastida, G........................... 293* 

Amberg, A................................. 675, 2259* 

Amoruso, M........................................1077 

Amos, A D...........................................1049 

Amuzie, C J......................................... 618* 

Anadon, A................177, 759, 1627, 2203, 

............................................... 2225, 2287* 

Anagnostopoulos, A.............................584 

Ananth, C V........................................1738 

Anantharam, V.........................1879, 2035 

Anaya-Martinez, V................................209 

Ancian, P.............................................1920 

and the ZFIN Staff, ...............................582 

Andersen, J K......................................2037 

Andersen, M E ................994, 1009, 1010, 

.............................1013, 1174, 1175, 1302, 

................... 1590*,1984, 2026, 2033, 2350 

Andersen, M.......................................1162 

Anderson, D G........................ 1835*, 2289 

Anderson, E A.......................................213 

Anderson, J............................... 223, 1863* 

Anderson, P........................................1761 

Anderson, S....................................... 1313* 

Andersson, H L................................. 2218* 

Ando, Y.................................................225 

Andrade, A J.......................................... 57* 

Andrén, P E.........................................1718 

Andrews, G A........................................677 

Andrews, G...........................................129 

Andrews, L..................................321, 1653 

Andringa, K K.......................................843 

Andrus, A K................... 1095, 1142, 1805* 

Andrysik, Z............................................811 

Anestis, D K..........................................450 

Anestis, D..............................................445 

Angel, J M.............................................120 

Angeles-Soto, E.....................................315 

Angerer, J............................................1730 

Aninat, C............................................1202 

Ankley, G T.........................................1231 

Ankrah, N A......................490, 1478, 2238 

Ankrah, N.............................................507 

Ansari, D M...........................................194 

Ansari, G A............................................349 

Ansari, G.............................................1742 

Antonini, J M............... 1081, 1083, 1098*, 

........................................1099, 1494, 1501 

Antonios, D........................................1456 

Antunes Fernandes, E......................... 807* 

Ao, K.....................................................196 

Aoyama, M............................................366 

Aparicio-Fabre, R................................. 780* 

Api, A.....................506, 1453, 1525, 1527, 

..................................................1531, 1555 

Appana, S..............................................497 

Appelqvist, T.......................................2297 

Appenzeller, L M..................... 2230, 2233* 

Applegate, D R......................................622 

Applegate, R D.................................... 900* 

Aragon, A C................................689, 2207 

Arakawa, S.............................................225 

Aranibar, N.................................472, 1605 

Aras, R.................................................1709 

Araújo, A...............................................401 

Araujo, J................................................733 

Archer, K.............................................1583 

Archibong, A E........................ 1143, 1144* 

Arenas-Hernández, R..........................1473 

Areola, S............................................ 1330* 

Arepalli, S....................................441, 1497 

Ares, I..................................................2287 

Argentieri, G.......................................2308 

Arias, A................................................1725 

Arias-Salvatierra, D....... 1847*, 1850, 1851 

Arima, A.................................. 1158*, 1526 

Arima, K..............................................1451 

Arimura, Y...........................................1657 

Arlt, V M.............................................1747 

Armendariz, J......................................1131 

Armer, L..............................................2298 

Armstrong, C......................................2224 

Arnold, K...............................................675 

Arnold, L L..................................520, 1624 

Arnold, S M.........................................1187 

Arocena, M.........................................1169 

Arreola-Mendoza, L.......................... 2121* 

Arrington, J E.................................... 2150* 

Arthaud, S...........................................1920 

Arvidson, K...........................................240 

Arzuaga, X........................................... 813* 

Asaithambi, A................................... 2035* 

Asano, Y............................................ 1135* 

Asare, N.................................................344 

Aschner, M................... 14*, 409, 691, 708, 

................. 1867, 1883, 1884, 1885, 1886*, 

................... 1887, 1888, 1889, 1958, 2047 

Asgharian, B...................... 994, 996*, 1512 

Ashikaga, T...............................1447, 1449 

Ashizawa, A.........................................1484 

Ashley, A K.............................. 1832, 2034* 

Aslam, A S...........................................1080 

Asper, C...............................................2027 

Assaf-Vandecasteele, H.......................1315 

Astroff, A B............................................512 

Atchison, B.........................................1827 

Athersuch, T J................................... 1601* 

Atkins, P I.............................................233 

Atkinson, S..........................................1765 

Attard, K M...............................1877, 2098 

Attardi, B J............................................860 

Attik, G.................................................513 

Au, C....................................... 1884*, 1885 

Aubrecht, J........................................ 2347* 

Auerbach, M H....................................2234 

Auerbach, S S........................................263 

Augustine, L M...................624, 822, 2030 

Auletta, C S....................................... 1690* 

Auletta, C............................................1924 

Ault, J G..............................................1039 

Auriemma, C L...................................1154 

Auslaender, S T................................... 489* 

Austin, C...............................................880 

Authier, S................. 211, 212*, 232, 1649, 

..................................................2299, 2317 

Auttachoat, W.......................... 197*, 2130 

Auyeung-Kim, D.................................1329 

Avants, J K...........................................1196 

Avdalovic, M V.....................................575 

Avila-Costa, M......................................209 

Avlasevich, S.......................................2244 

Awaysheh, A.......................................2080 

Aykin-Burns, N.........................2064, 2068 

Aylward, L L.................... 951*, 1197, 1199 

Aylward, L...........................................1740 

Aze, Y..................................................1215 

Aziz, S..........................................861, 2224 

B 

Babb, A................................................2229 

Babcock, G..........................................2099 

......................................................794, 797 

Babica, P........................................371, 523 

Babiuk, R...............................................584 

Babu, R J................................................335 

Babu, U...............................................2232 

Baccam, M..........................................1437 

Bachman, A N.....................................1182 

Back, A................................................1915 

Backer, L C..........................................1542 

Backhaus, T...........................................107 

Backlund, M........................................2166 

Backos, D S..........................................2063 

Backus, G S.......................................... 913* 

Baden, D G............................................347 

Baden, D........................................... 1117* 

Badger, T M.................................844, 1062 

Badham, H........................................ 1522* 

Badiwa Bizowe, B.............................. 2138* 

Bae, H................................................ 1125* 

Bae, O........................................1045, 2205 

Bagchi, D................................. 1537*, 1538 

Bagchi, M................................ 1537, 1538* 

Bagnyukova, T V............................... 1955* 

Bahar, W...............................................684 

Bahr, B A........................................... 1839* 

Bai, J....................................................1041 

Bailey, K A...........................................1587 

Bailey, L A...........................................1787 

Bailey, S M.............................................843 

Bailey, W J.............................................381 

Bailey, W...............................................380 

Baird, T................................................2309 

Bajt, M..................................................836 

Baken, K.......................................... 64*, 65 

Baker, B...............................................1526 

Baker, C.................................................750 

Baker, D D......................................... 1201* 

Baker, G...............................................1337 

Baker, T K............................................1579 

Baker, T.................................................477 

Bakke, J............................................. 1895* 

Baksi, S..................................................445 

Balani, S K...........................................1222 

Balasubramanian, K............................1398 

Balbuena, P....................................... 2277* 

Baldiris, R............................................ 721* 

Baldock, M M........................................454 

Baldwin, J E.........................................2268 

Baldwin, N J..........................................511 

Baldwin, W S........................................769 

Balenga, M........................................ 1744* 

Balhorn, R...........................................1768 

Ball, A L.................................................327 

Ball, A....................................................328 

Ball, G L..............................................1793 

Ball, L M.......................... 418, 1560, 2078* 

Ball, N...........................................45, 1785 

Ballatori, N..................351, 615, 944, 1709 

Bammler, T.........................................2191 

Ban, M.................................................1657 

Bandiera, S M.....................764*, 804, 809* 

Bandyopadhyay, S.............................. 436* 

Banerjee, A.................................. 846*, 851 

Banerjee, N......................................... 851* 

Banker, M J..........................................1933 

Bankoti, J............................................ 604* 

Banks, C............................................ 1819* 

Bannish, G.............................. 2152*, 2154 

Banton, M I.................................529, 1783 

Baqaar, S..............................................1463 

Barach, J................................................482 

Barbeau, S...........................................1772 

Barber, D S................ 29*, 428, 2104, 2271 

Barber, D.............................................1425 

Barber, J...............................................1205 

Barbier, C............................................1387 

Barcellos-Hoff, M................................ 563* 

Barchowsky, A................1494, 1609, 1622, 

...................................... 1965, 1969*, 2217 

Bardina, L............................................2229 

Barger, M.....................................300, 1513 

Bar-Ilan, O.......................................... 427* 

Barile, F A......................................339, 889 

Barker, D F.......................... 414, 415, 422* 

Barker, M.......................................861, 905 

Barlow, B M...........................................478 

Barnes, J C.............................................258 

Barnes, N...............................................336 

Barnett, J B....................................166, 190 

Barnett, J F..........................................2228 

Barofsky, D F.........................................820 

Baron, P..............................................1497 

Barone, L R........................................ 2313* 

Barone, S.....................................914, 2014 

Barr, D L..............................................1986 

Barr, J L...............................................1962 

Barrett, E G.........................................1071 

Barrett, E...............................................478 

Barrett, K................................1240*, 2010* 

Barrick, C W............................................88 

Barrier, M............................................1109 

Barros, S B......................................... 2173* 

Barrow, C S..........................................1785 

Barrow, P............................................... 70* 

Barry, R C..............................................679 

Barshishat-Kupper, M...........................136 

Barshteyn, N....................................... 379* 

Barski, O A................................ 826*, 2059 

294 



Author Index (Continued) 

Barsoum, J.....................................394, 398 

Barta, J R.............................................2128 

Bartels, M J........................313, 1018, 1429 

Bartels, M.......................................... 1000* 

Bartesaghi, S........................................1046 

Bartlett, M G.........................................947 

Barton, H A....................1011, 1012, 1014, 

................................................ 1374*, 1376 

Barton, H..............................................997 

Basak, S C.................................... 252*, 256 

Basaran, A.............................................488 

Basketter, D A.............................. 46*, 1446 

Basketter, D................................... 41*, 333 

Baskin, S I..............................................162 

Bass, A S.............................................. 647* 

Bassol, S..............................................1473 

Basu, N.................................... 1857*, 1858 

Batchelder, S E....................................1909 

Batchinsky, A I....................................1962 

Bates, T A..............................................949 

Bathula, C......................................... 1620* 

Battelli, L A.........................................1399 

Battle, L............................................. 1243* 

Baucom, C............................................319 

Baud, F J......................................611, 1318 

Baud, F................................................1317 

Bauer, A K.............................................638 

Baum, C J............................................1001 

Bauman, M...........................................230 

Baumeyer, A..........................................698 

Baumgartner, K B..................................413 

Baverel, G............................................ 464* 

Bay, B..................................................1490 

Bayir, H................................... 1036, 2056* 

Baykus, H............................................2241 

Baynes, R E...................... 478*, 1556, 1557 

Bayreuther, S..................................... 2318* 

Bazar, M..............................................2100 

Beach, B C.............................................446 

Beall, H D............................................2111 

Beall, P......................................2100, 2101 

Beattie, L.............................................1919 

Beaudet, N..........................................1777 

Beaumier, P......................................... 230* 

Beauvais, S............................................940 

Bebenek, I G...................................... 1670* 

Beck, B D.........................1188, 1462, 1787 

Beck, M J........................................... 1729* 

Beck, M.....................................2222, 2301 

Becker, C.............................................1812 

Becker, K G............................................259 

Becker, P..............................................1667 

becourt-Lhote, N...................................909 

Bécret, A..............................................1548 

Bedford, M............................................550 

Bednar, A J..........................................1241 

Bedoni, M...........................................1547 

Beedanagari, S R.................................. 782* 

Beerens, D...........................................2244 

Beezhold, D.........................................1313 

Beger, R D........................ 670, 1661, 1927* 

Beger, R.........................................28, 1925 

Beigel, K M............................................162 

Beilke, L D........................................... 833* 

Bekris, L M.......................................... 411* 

Beland, F A........................717, 1676, 1955 

Belcher, S M...................................... 1711* 

Belikova, N..........................................2056 

Bell, D A................................................638 

Bell, M....................................1365*, 2312* 

Bellamine, A..........................................766 

Bellebeau, F.........................................2305 

Bellinger, D......................................... 603* 

Bello, K A..............................................185 

Bello, S M...................................581*, 584* 

Belshoff, A C.......................................2112 

Bemis, J C............................................ 158* 

Bemis, J...............................................2244 

Benbrahim-Tallaa, L.......................... 1617* 

Bencic, D.............................................2199 

Bend, J R.............................................2080 

Bendaly, J.................................... 415, 416* 

Bendová, H......................................... 333* 

Benedetto, A....... 1883, 1884, 1885*, 1889 

Benedict, R..........................................1690 

Benedict, S..........................................1395 

Benignus, V A................................... 1802* 

Benkovic, S A.......................... 1098, 1804* 

Bennett, B.............................................106 

Bennett, E........................................... 255* 

Bennett, F............................................1015 

Bennett, L...........................................1867 

Benninghoff, A D................................ 522* 

Benninghoff, A...................................1238 

Benson, J M.........................................1542 

Benson, J...................................1165, 2141 

Benton, B J.................................. 132, 142* 

Benz, F W.......................................... 1808* 

Benz, R..................................240, 242, 249 

Bercegeay, M.......................................1821 

Bercu, J P........................................... 2344* 

Berdasco, N M......................... 1142, 1187* 

Berdasco, N...........................................465 

Berg, N.............................................. 1452* 

Berger, A................................................907 

Berger, J.................................................169 

Berger-Preiss, E....................................1773 

Bergman, A...........................................803 

Bergwerff, A A.......................................108 

Bermudez, E.................... 508*, 1406, 1590 

Bernal, A J......................................... 2185* 

Bernard, A.............................................588 

Bernardo, M F.....................................1766 

Berner, T O............................................916 

Berner, T........................................917, 918 

Bernshausen, T................................. 1553* 

Berry, J P..............................................1234 

Berry, T..................................................690 

Bertermann, R.......................................307 

Bertheux, H.........................................1922 

Bertrand, R............................................709 

BeruBe, K.............................................1195 

BéruBé, K............................................... 30* 

Bétat, A............................................... 466* 

Betton, G.............................................1758 

Betz, L J.................................................457 

Beushausen, S.....................................1758 

Bevilacqua, V H....................................143 

Beyer, L A................................ 1188, 1462* 

Beyer, R.....................................1853, 2191 

Bhatia, S P......................................... 1527* 

Bhatnagar, A..........826, 1254, 1948, 2059, 

............................................................2202 

Bhattacharya, K.................................. 440* 

Bhave, V S.............................................627 

Bhisitkul, R B........................................ 38* 

Bhopale, K K..................................... 1742* 

Bhusari, S.......................................... 1457* 

Bialecki, R A........................................2312 

Biales, A..............................................2199 

Bidlingmaier, B.....................................675 

Bielawska, A........................................2050 

Bielawski, K.........................................2050 

Bienvenue, J........................................1909 

Bigelow, D J...........................................395 

Bigelow, M M............................ 285*, 1172 

Bigelow-Kern, A....................................477 

Bigley, A......................................859, 1205 

Bigsby, R M.........................................1388 

Bigwarfe, T J..........................................185 

Bigwarfe, T..........................................2136 

Bijlani, K H....................................... 1995* 

Biljani, K H.........................................1998 

Billack, B...............................................713 

Billiard, S...............................................538 

Billin, A N...........................................1549 

Billinton, N.........................................2255 

Billis, P A........................................... 1933* 

Bino, R................................................2221 

Bird, M G............................................1182 

Birdsong, R..........................................1777 

Birmingham, N....................... 1912*, 1913 

Birnbaum, L S.............101, 630, 688, 1178 

Birrell, L..............................................2254 

Bissonnette, S L.....................................609 

Bista, S R...............................................309 

Bistner, S.......................................202, 203 

Biswal, S.............................................. 639* 

Biswas, P.............................................1025 

Bitter, H...............................................2249 

Bizarro-Nevares, P...........1642, 1643, 2086 

Bjork, J A................................... 789*, 1710 

Blaauboer, B J........................................896 

Black, A T.......................... 135, 146*, 1545 

Black, C.......................................319, 2148 

Black, E P..............................................813 

Black, P...............................................1798 

Blackburn, A..................................... 2317* 

Blackburn, K L....................................1355 

Blair, M............................................. 1720* 

Blaisdell, R............................................937 

Blanco-Muñoz, J.................................1473 

Blaschuck, O.......................................1080 

Blaustein, M........................................1508 

Blazer-Yost, B L...................................1049 

Blomme, E A...........847, 1421, 1432, 1594 

Blomme, E G.......................................1208 

Blomme, E............................................250 

Blossom, S....................................... 66, 68* 

Blum, J L........................................... 2061* 

Blystone, C R........................................ 90* 

Bochet, L.............................................1315 

Boctor,, S Y..........................................1696 

Bodwell, J E.........................................1433 

Boehn, S N.......................................... 885* 

Boekelheide, K....................................1154 

Boellmann, F.......................................2026 

Boelsterli, U A..................556, 558*, 1213* 

Boermans, H J.....................................2128 

Bofferding, A.......................................1258 

Bogen, K T............................................. 54* 

Boggs, N T...............................................49 

Boghossian, M......................................464 

Bogue, M A......................................... 585* 

Bohnenberger, S..................................2248 

Bohonowych, J E................................2168 

Boileau, C..............................................232 

Boitier, E........................................675, 676 

Boke, H.................................................523 

Bolanowski, D D.................................2202 

Bolger, P M........................................ 2008* 

Bolmarcich, J........................................895 

Bolt, H M..............................................660 

Bolterstein, E A................................... 372* 

Boltneva, N B......................................2291 

Bolton, J L.......................1057, 1058, 1059 

Bondy, G................................... 861, 2224* 

Bondy, S C............................................733 

Bonefeld-Jørgensen, E.........................1389 

Bongiovanni, K D.......................229, 1949 

Bonini, M G........................................2060 

Bonner, J C................................1507, 1509 

Bonventre, J V..............378, 446, 451, 456, 

.......................................................... 1739* 

Bonventre, J..........................................380 

Booher, L E..........................................1471 

Boor, P J......................................349, 1993 

Boor, P.....................................................79 

Boorman, G........................................1572 

Boote, E.................................................614 

Boraso, M............................................1046 

Borazjani, A.......................301, 1985, 2053 

Bordeerat, N............................ 1748*, 1755 

Borg, D A........................................... 1224* 

Borghoff, S...........465, 1655*, 2359, 2361* 

Borisenko, G G.................................. 1392* 

Borja-Aburto, V H.......................407, 2281 

Borkhataria, D.....................................1898 

Borland, M G.................................... 1549* 

Borowitz, J L.....................149, 1830, 2054 

Borowitz, J..........................................1717 

Bosan, W................................... 942*, 1483 

Bosch, D..............................................2221 

Bose, D................................................ 545* 

Bose, M...............................................1112 

Bose, R.................................................1168 

Bosetti, F.............................................1815 

Botelho, G...............................................57 

Botha, B M............................................796 

Botta, D...............................................1602 

Bottalico, L N...................................... 153* 

Bouchard, M..................................... 1732* 

Boudreau, M D......................................717 

Boulifard, V.........................................1548 

Bounous, D.........................................1758 

Bourdelais, A J.......................................347 

Boureiko, A...........................................524 

Bourgeois, J.........................................1765 

Bourgeois, M M...................................1119 

Bousquet, R.........................................1079 

Boutherin-Falson, O...........................1920 

Boutros, P C................................779, 1110 

Bovee, T................................................803 

Boverhof, D R................. 674, 1314*, 1438 

Boverhof, D...................................673, 852 

Bowe, C.................................................102 

Bowenkamp, K.................................. 2308* 

Bower, D...............................................240 

Bowers, T S..........................................1466 

Bowlin, G L.........................................2135 

Bowman, L..................................354, 1031 

Bowyer, J F..............................................97 

Bowyer, J.............................................1891 

Boyce, R W..........................................1596 

Boyd, J W.............................................. 49* 

Boyd, R................................................1015 

Boyd, W A....................... 878*, 1668, 2240 

Boyd, W..............................................1019 

Boyer, J L...............................................241 

Boyes, W K.......... 1802, 1807, 1821*, 1840 

Boykin, E H....................................... 1442* 

Boykin, E.............................................1038 

Boylstein, R.........................................1099 

Boysen, G...............418, 1166, 1736, 1748, 

............................ 1754, 1755*, 1759, 2078 

Boysza, J..............................................1919 

Brackman, K E.......................................814 

Bradford, B U................................831, 842 

Bradford, B.................................. 221*, 418 

Bradford, J A.......................................2084 

Bradley, L J........................................ 1171* 

Bradley, P..............................................258 

Bradshaw, S G.......................................169 

Brain, K...............................................1555 

Braithwaite, E K..................................2331 

Braithwaite, E.................................... 1610* 

Branco, A..............................................879 

Brandenburg, A.....................................675 

Branham, W S...................710, 1430, 1661 

Branson, K............................................614 

Brant, K A.......................................... 2087* 

Brass, E P...............................................393 

Brattin, B.............................................1631 

Bratton, S B...........................................468 

Braue, C R.............................................152 

Braue, E H........................................... 139* 

Braun, A................................................885 

Braun, K....................................1855, 2259 

Brave Rock, A......................................1094 

Bray, C M............................................1102 

Braydich-Stolle, L K...........423, 424, 1025, 

................................................ 1026, 1053* 

Breckenridge, C...................................2140 

Bredfeldt, T...........................................690 

Brees, D.................................................857 

Breheny, D M...................................... 875* 

Breier, J M................................579*, 1698* 

Breit, T....................................................65 

Brennan, R J........................................ 669* 

Brenneman, D..............................224, 869 

Bresciani, F..........................................1046 

Brezinski, M........................................1094 

Bricker, J................................................864 

Bridges, C.......................................... 2119* 

Bridges, M.............................................501 

Briffaux, J............................70, 2145, 2305 

Briggs, J E..............................................228 

Brimfield, A A..................................... 147* 

Briscoe, D M..........................................847 

Britt, J..................................................1476 

Brittebo, E.................................1721, 2218 

Brocker, C......................................... 1951* 

Brodie, R R............................................949 

Brodzik, A.............................................145 

Broening, H W.................................. 1716* 

Brohem, C A.......................................2173 

Bromberg, P A...........................1073, 1489 

Bronaugh, R L.....................................1032 

Bronaugh, R...................................... 1274* 

Brooks, B W............................................71 

Brooks, C M........................................1144 

Brooks, D............................................2111 

Brooks, E.............................................1953 

Brooks, J D..........................................1559 

Brooks, J............................................ 2189* 

Broomhead, Y.......................................338 

Brott, D..................................... 388, 1762* 

Brousseau, P........................................2138 

Brouwer, K............................................620 

Brown, C C.........................................1196 

Brown, C.............................................1653 

Brown, D.............................................2297 

Brown, J P.............................................938 

Brown, J...................................... 838*, 980 

Brown, K H........................................... 74* 

Brown, K.......................................77, 1313 

Brown, R C..................................914, 2014 

Brown, R D............................................197 

Brown, R P.......................................... 446* 

Brown, R R.......................................... 278* 

Brown, R...............................240, 513, 514 

Brown, W R...........................................203 

Browne, E P......................................... 799* 

Bruce, S...................................................84 

Bruckner, J V.................................947, 955 

Brughera, M................................984, 1935 

Brundage, K M..............................166, 190 

Brundage, R...........................................166 

Bruner, R H....................................... 2326* 

Brüning, T...........................................1730 

Brunnemann, K......................................82 

Brunner, D........................................ 1366* 

Bruno, M E.......................................... 112* 

Brush, E.......................................692, 1334 

Bruun, D........................................... 2278* 

Bryant, B H.........................................1154 

Bryce, S M.............................................158 

Bryce, S...............................................2244 

Bryja, V...............................................1216 

Bucher, J R.....................................515, 516 

Bucher, J..............................................1328 

Buchet, J P.............................................588 

Buchmann, E......................................1837 

Buck, R C............................956, 958, 1163 

Buckalew, A R..........................................85 

Buckalew, A.............................................96 

Buckley, D B........................................1946 

Buckpitt, A..........................................1092 

Budai, M......................................162, 2286 

Budinsky, R A........................................673 

Budinsky, R...................................412, 951 

Budreckis, D M...................................1867 

Budroe, J D.......................................... 934* 

Buels, K...............................................2264 

Buetler, T M........................................ 698* 

Buettner, G R........................................795 

Buffington, S E....................................2120 

Buffington, S....................................... 123* 

Buford, M............................................1492 

Bugiak, B........................................... 2204* 

Author Index 




Author Index 

Bugrim, A..............................................669 

Buhrow, J W........................................1001 

Buhse, L F............................................1023 

Bui, P H............................................. 1940* 

Bull, R J.................................................463 

Bulman, A......................................... 2199* 

Bult, C J.................................................585 

Bunch, J................................................859 

Bunn, W B............................................977 

Burbacher, T M.............................475, 693 

Burback, B.............................................971 

Burcham, P C...................................... 290* 

Burchiel, S...........................................1037 

Burdock, G..........................................2237 

Burel, S............................ 858*, 2137, 2148 

Burgess, J.......................................63, 1917 

Burgess, S C.........................................1597 

Burgher, F..............................................505 

Burgoon, L D............... 11, 50*, 260, 1422, 

..................................................1423, 1573 

Burgoon, L....................................674, 852 

Burgsteden, J.........................................577 

Burkart, D L..........................................584 

Burkey, B.............................................2303 

Burkhard, S.........................................1400 

Burleigh-Flayer, H D...........................1367 

Burleson, F G........................67, 193, 2144 

Burleson, F..........................................1934 

Burleson, G R.............................. 67*, 2144 

Burleson, G...........................................191 

Burnett, D C..........................................132 

Burns Naas, L.............................. 321*, 630 

Burns, T D........................................... 484* 

Burns, T...............................................1455 

Bursian, S..............................................951 

Burton, N C.............................. 707*, 1861 

Burwinkel, K....................................... 773* 

Bus, J...................................................1784 

Busby, A L...........................613, 679, 1375 

Busch, S...............................................2303 

Buschmann, J......................................1773 

Bushman, W.............................1128, 2021 

Bushnell, P J.........1802, 1807, 1820, 1821, 

..................................................1840, 1957 

Bussiere, J L....................................... 1295* 

Bussiere, J....................................321, 1134 

Butala, J H......................................... 1554* 

Butehoff, J L..........................................855 

Butenhoff, J L................98, 542, 789, 1710 

Butler, K..............................................2245 

Butler, W J...........................................1472 

Butterworth, L....................................1313 

Button, D............................................1662 

Butura, A...............................................844 

Butz, D................................................2263 

Buzzeo, R........................................... 2157* 

Byers, C.........................................128, 138 

C 

Caamaño, M.......................................1767 

Cabaleiro, T...........................................177 

Caballero, G..........................................721 

Caballero, V................................759, 2287 

Cabunoc, A......................................... 260* 

Cahill, P..............................................2255 

Cai, B................................................... 352* 

Cai, J............................... 385*, 2046, 2047 

Cai, L.................................461, 1663, 2219 

Cai, Q....................................................701 

Cai, Y............................................735, 744 

Calabrese, E J......................................1907 

Calabro, A R........................................ 339* 

Calderon-Aranda, E S.......186, 1847, 1848, 

................................................ 1850, 1851* 

Caldwell, D J..................................... 1296* 

Caldwell, D.........................................2224 

Cali, J J................................................ 774* 

Calis, K................................................1936 

Calkins, M.............................................580 

Camacho, L......................................... 460* 

Cambron, T...........................................477 

Campbell, A J...................................... 472* 

Campbell, A................................729, 1605 

Campbell, D J.......................................222 

Campbell, J L.................................... 1782* 

Campbell, J.........................................1162 

Campbell, M.........................................474 

Campen, M J.........738*, 739, 1071, 1251*, 

..................................................1256, 1503 

Campen, M.................................737, 1253 

Campian, C.........................................1808 

Campion, S N............................. 624*, 840 

Campion, S......................................... 320* 

Camponovo, R....................................1097 

Camus, A...............................................867 

Cancio, L C.........................................1962 

Cannon, R E........................................1632 

Cantón, R F......................................... 803* 

Cantor, G H................................472, 1605 

Cantor, J O............1995, 1996, 1997, 1998 

Cantore, M..........................................1951 

Cao, L..................................................2113 

Cao, Z................................................ 1727* 

Capaldi, R........................... 902, 905*, 906 

Capparuccini, M............................... 1583* 

Car, B D............................................. 1341* 

Car, B.....................................1268*, 1338* 

Carabin, I............................................2237 

Carbonatto, M....................................1934 

Carbone, D L..................................... 2038* 

Carbone, D............................................704 

Cardellach, F....................................... 295* 

Cardiff, R D...........................................688 

Cardon, M C.................................90, 2190 

Cardona, A..........................................1478 

Cardona, R..........................................1193 

Carey, G J.......................................... 1362* 

Carey, S A..............................................573 

Caride, A...............................................177 

Carll, A P..................................... 748*, 749 

Carll, A................................................1652 

Carlsen, J........................................... 2039* 

Carlson, E A........................................ 817* 

Carlson, E M.......................................1711 

Carlson, G...................................117, 2229 

Carlson-Lynch, H...............................2013 

Carney, E W........................................1142 

Carney, E.............................................1524 

Carpenter, C..........................................958 

Carpenter, T..........................................236 

Carr, G J................................................897 

Carr, G................................................1437 

Carr, M S...............................................974 

Carr, R L............................................ 2261* 

Carratu, M.............................................700 

Carrizales, L........................................1873 

Carroll, D..............................................430 

Carroll, M A............702, 1223, 1865, 1866 

Carson, D J........................................ 2099* 

Carson, J P.............................. 1020*, 1373 

Carson, J...............................................992 

Carter, C A........................................ 1409* 

Carter, J...............................................1505 

Carter, W...............................................385 

Cartwright, I.........................................888 

Carvan, M J.........................................1856 

Carvan,, M J...................................... 1976* 

Carwin, D...........................................1526 

Caryl, M..............................................2132 

Casabar, R C...................................... 1052* 

Casado, F L.......................................... 365* 

Casado, F...............................................367 

Casati, S................................................898 

Cascio, W E.........................................1258 

Casebier, D..........................................2309 

Casillas, R P........135, 146, 155, 683, 1545, 

............................................................1546 

Casper, S....................................1089, 1091 

Cassee, F..............................729, 746, 2044 

Cassis, L A.............................................813 

Casteel, S W.............................. 614*, 1171 

Castellano, V.........................................759 

Casto, B C.............................................873 

Castoldi, R...........................................1935 

Castranova, V....................300, 441, 1031, 

1083, 1099, 1255, 1399, 1486, 1491, 1494, 

........ 1497, 1499, 1501, 1513, 1626, 2356* 

Castro, D J......................................... 1775* 

Catapane, E J..........702, 1223, 1637, 1865, 

............................................................1866 

Catherine, P........................................2101 

Cattoni, M..................................984, 1935 

Catz, P...................................................392 

Caudle, W M.........................................208 

Cavagnaro, J..................................... 1291* 

Cavalieri, E..........................................1735 

Cavas, T..............................................2093 

Cavill, R.................................. 1601, 1606* 

Cawley, T J..........................................1084 

Cebrián, M E.........1419, 1473, 1767, 2076 

Ceccatelli, R........................................1529 

Celius, T.............................................. 779* 

Centeno, J A........................................1733 

Cerreta, J M...........1995, 1996, 1997, 1998 

Certa, H...................................................45 

Cerutti, D............................................2262 

Cerven, D R...................................327, 328 

Cesta, M F............................... 1507, 1509* 

Cezar, G G......................................... 2339* 

Cha, S................................................ 2323* 

Chacon, E...........................................2245 

Chadalapaka, G...................... 2181, 2182* 

Chadwick, C.........................................390 

Chagnon, M..........................................118 

Chai, Y..................................................234 

Chalonner-Larsson, G........................2297 

Chambers, H W....................................133 

Chambers, H.......................................2211 

Chambers, J E.........133, 1481, 1597, 2211 

Chames, M C......................................1520 

Chan, J Y.............................................2028 

Chan, L............................................. 1858* 

Chan, M K........................................ 1994* 

Chan, P H...........................................1601 

Chan, P.......................................720, 1148 

Chan, V T....................................449, 1582 

Chan, V...............................................1431 

Chanda, S..................................1651, 2306 

Chanderbhan, R F.................................253 

Chandra, R..........................................2209 

Chandrasena, R P................................1905 

Chandura, A G....................................1622 

Chaney, S G........................................1759 

Chaney, S..................................1724, 1874 

Chang, C C.........................................1422 

Chang, C...............................371, 751, 877 

Chang, D.............................................1925 

Chang, F...............................................126 

Chang, H...............................................442 

Chang, M............................408, 882, 1057 

Chang, S.............. 98*, 496, 789, 855, 1710 

Chang, X.............................................1613 

Chang, Y..................................... 155, 683* 

Changela, T...........................................430 

Chao, M.............................................. 742* 

Chao, Y E............................................1560 

Chapela, P...........................................2286 

Chapin, R E...............................2337, 2340 

Chapman, G D.....1877, 2097, 2098, 2099 

Chapman, K........................................1926 

Charest-Tardif, G..................................969 

Chaudhary, A........................................881 

Chaudhuri, L.................................... 2064* 

Chaurand, F........................................1649 

Chauvigne, F.......................................1150 

Chavakis, T.........................................1951 

Chébékoué, S.................................... 1792* 

Chekhun, V........................................1910 

Chellman, G J................................... 1294* 

Chen, B T..................................1081, 1255 

Chen, C...............................504, 723, 1518 

Chen, F.................................................300 

Chen, G............................318, 1413, 2236 

Chen, H.................. 504, 525, 1288, 1518* 

Chen, J.........................1659*, 1701*, 1789 

Chen, L........................455, 728, 730, 731, 

................732, 735, 743*, 744, 865*, 1500, 

........................................1508, 1613, 1878 

Chen, M...................................... 468, 670* 

Chen, P....................................... 112, 282* 

Chen, Q M................................1304, 1666 

Chen, Q................................................286 

Chen, T........................... 376*, 1118, 1497 

Chen, X.........................................119, 589 

Chen, Y.......115, 158, 1966*, 2033, 2046*, 

...............................................2084*, 2290* 

Chen, Z............................... 39*, 285, 1172 

Cheng, B...............................................172 

Cheng, Q........................ 317, 2028, 2029* 

Cheng, T............................................. 751* 

Cheng, W............................................1489 

Cheng, X..................................... 824*, 825 

Chequer, F D.......................................1681 

Cherng, T W.......................................1256 

Cherng, T.................................. 737*, 1253 

Chernoff, E A......................................1049 

Chernoff, G....................................... 1483* 

Chernyak, S M....................................1520 

Cherrington, N J........624, 822, 833, 2029, 

............................................................2030 

Chesler, S N.........................................1776 

Cheung, V G..................................... 1282* 

Chhabra, R S.........................................515 

Chiang, P..............................................754 

Chibout, S...........................................2303 

Chilakapati, J.................................... 1587* 

Childress, J............................................162 

Chim, W...............................................714 

Chintalapani, V R................................. 76* 

Chintharlapalli, S......................645, 2178, 

..................................................2181, 2182 

Chipinda, I........................................ 1316* 

Chirtel, S J...........................................1204 

Chiu, A O.......................................... 1380* 

Chiu, N H...........................................1380 

Chiu, W................................................914 

Chmielewski, G................................ 1541* 

Cho, J............................................99, 2131 

Cho, M................................863, 880, 1882 

Cho, S.................................................2178 

Cho, W...............................................1550 

Cho, Y...................................................480 

Choi, B......................99, 1502, 1616, 2131 

Choi, H............................................. 1686* 

Choi, J......1048*, 1106, 1434*, 2177, 2274 

Choi, K..................................................765 

Choi, S................................................1616 

Choi, W............................................ 2146* 

Choi, Y................................................1882 

Choksi, N............................................1455 

Chopra, M...........................................1221 

Chordia, M............................................975 

Chou, C.............................................. 496* 

Chou, S....................................... 931*, 932 

Choudhuri, S........................................825 

Choudhury, H..................................... 921* 

Christensen, D E...................................646 

Christian, B J..................................... 1906* 

Christian, M S.................1525, 1527, 1531 

Chrousos, G........................................1936 

Chu, A C.................................................91 

Chu, H..................................................504 

Chu, I....................................................763 

Chu, J....................................................398 

Chu, M D................................................91 

Chu, M M...........................................2015 

Chu, M....................................................52 

Chu, Y...................................................770 

Chua, J P.............................................1711 

Chuang, M............................................793 

Chung, C S..........................................1545 

Chung, G................................................99 

Chung, J................1045, 1217, 1502, 2205 

Chung, W......................................... 1959* 

Chung, Y.....442, 841, 1106*, 1122, 1439*, 

..................................................1502, 2177 

Ciaccio, P J................................1943, 2313 

Ciaccio, P............................................1941 

Cicio, S................................................2309 

Ciesielski, P N.....................................1021 

Cimino, M C.......................................2015 

Cimino-Reale, G.....................................48 

Cisternino, S.........................................611 

Ciurlionis, R........................................1421 

Cizmas, L............................................1731 

Cizza, G...............................................1936 

Claire, W L..........................................1574 

Clark, A J...............................................974 

Clark, A P......................................512, 814 

Clark, B............................................. 2184* 

Clark, G C...............................................91 

Clark, K A............................................1622 

Clark, K...............................................1036 

Clarke, D W........................................1909 

Clarke, J A...........................................1185 

Clarke, J........................................191, 812 

Clarkson, E............................................139 

Claude, N....................................909, 1922 

Claude, T.............................................1732 

Clausen, J..............................................255 

Clay, C M....................................280, 1321 

Clayton, T A..........................................373 

Clayton, V...........................................1193 

Clegg, D J..................................1903, 1904 

Clegg, D.............................................. 566* 

Clegg, E.................................................887 

Clement, K H........................................157 

Clements, K........................................2279 

Clewell, H J........ 1009, 1010, 1175, 1589*, 

..............................1590, 1629, 1782, 2350 

Clewell, H.................................1007, 1162 

Clewell, R A...................................... 1162* 

Cline, J E...............................................578 

Cloud, J G...............................................74 

Coady, L..............................................2224 

Coban, A.............................................1985 

Cobarrubia, J.........................................348 

Coburn, C.............................................303 

Coburn, M........................................ 1066* 

Cockburn, M S......................................213 

Coelho, A..............................................401 

Coelho-Palermo Cunha, G.................1603 

Coen, M............................ 373*, 397, 1605 

Coffee, M............................................1660 

Coffin, J............................................ 2111* 

Cogburn, A.........................................2229 

Cohen, B.............................................2297 

Cohen, J D........................................ 1412* 

Cohen, S M.................................520, 1624 

Colangelo, J................................ 375*, 384 

Cole, T B.......................................265, 419 

Coleman, B R...................................... 684* 

Coleman, J........................................ 1241* 

Coleman, M..........................................234 

Colin-Barenque, L............209, 1642, 1643, 

............................................................2086 

Collett, J R...........................................1764 

Collette, T W........................................396 

Collier, T...............................................600 

Collings, F B..................................446, 451 

Collins, B J.......................... 516, 517*, 518 

Collins, D............................................1794 

Collins, J F.......................................... 938* 

Collins, J.............................................2244 

Collins, L.........418, 537, 1166, 1748, 1754 

Collins, S.............................................1302 

Collman, G...................................562, 567 

Collotta, A..............................................48 

Colombo, P......................................... 984* 

296 




Colon, A..............................................1839 

Colon, J...............................................1417 

Coluccio, V....................................... 1470* 

Colvin, V L..........................................1027 

Com, E................................................ 676* 

Comstock, B........................................2229 

Conde, P C............................................186 

Condevaux, F......................................2145 

Condon, S...........................................1550 

Conerly, O..........................................1300 

Cong, P Q.............................................733 

Conklin, D J......... 826, 1251, 1254, 1257*, 

.......................................................... 1948* 

Conklin, D..........................................2202 

Conner, E A...........................................587 

Connis, N..............................................148 

Conolly, R....................... 612, 1381, 2351* 

Conrads, T P.......................................1063 

Constantine, L A.................................1228 

Contamin, H.......................................2305 

Contoreggi, C.....................................1936 

Contose, D..........................................2314 

Contrera, J F..................................242, 249 

Cook, C.................................................450 

Cook, D............................... 243, 258*, 724 

Cook, J A...............................................198 

Cook, J C.............................................1228 

Cook, J D...............................................690 

Cook, J................................................1301 

Cook, S................................................2324 

Cooke, G M...........................................861 

Cooney, C.............................................341 

Cooney, P............................................2103 

Cooper, G S..................... 915, 1006, 2123* 

Cooper, K R.........................275, 306, 2266 

Cooper, M......................................... 1575* 

Cooper, R L.............................................85 

Cooper, R..........................94, 95, 96, 1184 

Cooper, S...............................................460 

Copeland, C B.......................................174 

Copeland, N........................................1380 

Copeland, T L................................... 1798* 

Copeman, C..............................2298, 2316 

Coppin, J................................. 1309*, 1617 

Copple, B L......................................... 625* 

Copple, B..............................................830 

Cordier, A..............................................399 

Corey, L M.................................. 176, 750* 

Corley, R.....................................992, 1373 

Cornacoff, J.........................................2141 

Corneau, S..........................................2153 

Corsini, E................................ 1046, 1547* 

Corson, N....................................745, 1404 

Cortes, M M...................................... 1385* 

Corthals, S M...................................... 121* 

Corton, C............................................ 635* 

Corton, J C..............834, 1410, 1428, 1587 

Coryell, V H...................................... 1634* 

Cory-Slechta, D A..................1869*, 1983* 

Cory-Slechta, D...................................2267 

Cosenza, M.........................................1915 

Costa, D L.....................................748, 749 

Costa, D..............................................1652 

Costa, L G.............. 419, 790*, 1691, 1693, 

..................................................1694, 1701 

Costa, L.......................................476, 1396 

Costa, M.................................... 525, 1288* 

Cottrell, L A........................................1604 

Couch, L H.......................................... 965* 

Couch, W............................................1761 

Coulombe, R A............................762, 1075 

Coulson, M....................................... 1891* 

Countey, B..........................................2318 

Courcol, M............................................676 

Couroucli, X............................. 772, 1774* 

Covey-Crump, E M...............................261 

Cowan, D M........................................ 708* 

Cowden, J......................................... 2186* 

Coxen, R...............................................230 

Cox-Ganser, J M..................................1083 

Cozart, C R..........................................1023 

Cozart, C.............................................1403 

Craig, C............................................... 842* 

Crankshaw, D L.................................. 228* 

Cranmer, B K......................................1984 

Crary, V.................................................474 

Crawford, I A........................................949 

Crawford, R B......................................2143 

Crecelius, E A......................................1629 

Creed, J...............................................1587 

Creppy, E E.................................700*, 716* 

Cressman, R F.....................................2228 

Cressman, R........................................2229 

Creutzenberg, O H.............................. 514* 

Creutzenberg, O....................................513 

Cristiano, N........................................2153 

Crittenden, P L............................. 15, 703* 

Crocker, T L........................................1668 

Crofton, K M.............93, 1177, 1716, 2273 

Crofton, K.............................................271 

Cromey, D W........................................122 

Cronin, A S.........................................1574 

Crossgrove, J S.................................. 1828* 

Crouse, L C....................................... 1170* 

Crouse, L...................................1713, 2100 

Croutch, C R.........................................512 

Crow, A................................... 2053*, 2211 

Crowell, J A.................................711, 1895 

Cruz, E................................................1923 

Csanaky, I L................................ 617*, 960 

Csanaky, I.............................................825 

Cui, Y........................................ 829*, 2020 

Cukovic, D............................................673 

Cullen, E........................................... 1924* 

Cullen, G............................................2295 

Culp, S................................................1206 

Cummings, B S...........358, 359, 463, 2061 

Cumpston, J........................................1081 

Cundiff, J A...........................................606 

Cunnick, J...........................................2239 

Cunningham, M...................................627 

Curran, I................................... 862*, 2224 

Curras-Collazo, M.................................303 

Curren, R D...................................323, 325 

Curren, R..............................................883 

Currie, R A........................................ 1574* 

Currie, R..............................................1604 

Currier, A..............................................551 

Curtin, B F............................................156 

Curtin, G M........................................1407 

Curtis, L R.............................................820 

Cutler, N................................. 1044, 2001* 

Cutler, S......................................784, 2214 

Cutruvo, J A..........................................463 

Czich, A..............................................2259 

Czuprynski, C J.......................................69 

Czuprynski, C.......................................610 

D 

D’Agostino, Jr., R B...............................116 

D’Alessio, D A.....................................1904 

d’Argembeau-Thornton, L....................326 

Daamen, F E..........................................807 

Daamen, F.............................................803 

Dabrowski, M J.....................................369 

Dail, M B........................................... 1597* 

Dailey, L A...........................................1489 

Dailey, R N............................................722 

Dalbey, W................................. 254, 1077* 

Dale, L B..............................................2080 

Dalmas, D A........................................1596 

Dalrymple, M......................................1796 

Dalsenter, P.............................................57 

Dalton, T P..........................................1621 

Daly, D S.............................................1764 

D’Amico, L J............................ 1646, 1723* 

Damodaran, T V............................... 2276* 

Dance, S T................................... 116, 876* 

Dang, A..................................... 324, 1552* 

Dangleben, N.................................... 1625* 

D’Angona, A L....................................1653 

D’Angona, A..................................... 1653* 

Danielewska-Nikiel, B.........................1358 

Daniels, M...........................................1038 

D’Anjou, M...........................................232 

Danks, A..............................................1926 

Dao, K.................................................1701 

Dary, C C..............................................269 

Darzynkiewicz, Z..........................82, 2242 

Das, K P...............................................2018 

Das, K..................................................1534 

Dasari, S............................................ 1852* 

Dasmahapatra, A K............................. 881* 

Daston, G P...................................591, 897 

Daston, G....................... 477*, 592*, 1326* 

Data, S.................................................1768 

Datwani, A........................................ 1997* 

Daugherty, A.........................................726 

D’Auvergne, O..........................1999, 2201 

Davancaze, T.......................................1930 

Davey, J C..................... 1308, 1433*, 1566 

Davidson, K A.......................................924 

Davidson, K........................................ 926* 

Davidson, M E.................................. 1582* 

Davies, W............................................1240 

Davis, A P......................................241, 259 

Davis, B J...............................................690 

Davis, B.............................941, 1290, 1796 

Davis, J A........................................... 1183* 

Davis, J W......................................... 1343* 

Davis, K A......................................... 2211* 

Davis, K............................................. 1865* 

Davis, L............................................... 423* 

Davis, M A............................................262 

Davis, M K........................................ 1481* 

Davis, N S............................................2282 

Davis, S..................................... 643*, 1533 

Davis, T A..............................................136 

Davis, T.....................................2228, 2229 

Davison, M.........................................1431 

Dawe, T.................................................230 

Day, B J........................................160, 2065 

Day, N C................................................258 

Day, R M...............................................136 

Day-Lollini, P............................1575, 1662 

de Bie, A T.............................................660 

De Boeck, M........................................2244 

de Bruijne, K............................. 297, 1091* 

de Foy, B..............................................2077 

de Groot, A...........................................794 

de Jong, P C........................................2172 

De Rosa, C T.............................1484, 2011 

De Rosa, C...............................................47 

De Silva, D.......................................... 463* 

de Swart, R..........................................2297 

de Vizcaya, A.......................................2077 

De Vizcaya-Ruiz, A........... 292, 293, 1074*, 

............................................................2076 

De Vooght, V........................................217 

Dean, B...............................................1749 

DeAngelo, A..........................................890 

Dearfield, K L......................................2015 

Dearfield, K...........................................694 

Dearman, R J..................657*, 1310, 1446* 

Dearman, R.........................................1444 

Deb, S....................................................764 

DeBruijne, K.......................................1089 

DeBus, S.............................................. 126* 

DeCaprio, A P...........................1475, 1798 

Decker, E...............................................956 

Deeds, D A........................................ 1369* 

Deering, C E........................................1113 

Deering, C......................................... 2214* 

Deese-Spruill, J....................................1917 

Defensor, E B.......................................1770 

DeFlaun, M.........................................1799 

DeFrees, S..............................................102 

Degenhardt, K.............................299, 2071 

DeGeorge, G L.................... 43*, 338, 2252 

Degitz, S J..............................................103 

Degitz, S................................................106 

Degn, L L..................................1807, 1821 

DeGroot, D M..................................... 577* 

DeGroot, D....................................... 2167* 

Deguchi, Y..........................................1657 

Dehart, D B.........................................1530 

Dekant, W................. 307, 479, 528, 1734* 

DeKosky, S T.......................................1961 

Dekundy, A....................................... 1806* 

Del Pino, J...........................................2287 

Del Razo, L M.............86, 407, 1133, 1881, 

............................................................2121 

Delana, L E............................................355 

Delaney, B........... 2228, 2229*, 2230, 2233 

Delano, D L.........................................1082 

Delatour, T............................................698 

Delclos, K..............................................460 

Delker, D.....................................834, 1428 

Della Torre, P......................................1935 

Dellarco, V L.........................................239 

Dellarco, V..................................238, 1184 

Dellinger, J..........................................1856 

Dellinger, M........................................1856 

DeLong, D.............................................228 

DelRaso, N J................................852, 1761 

DelRaso, N..........................377, 674, 1431 

Demchuk, G...................................... 2011* 

DeMicco, A............................... 275, 2266* 

Dempster, M.........................................321 

Dencker, L.........................364, 1718, 2017 

Dene, H.................................................584 

Deng, X....................................849*, 1567* 

Denison, M S...........91, 1931, 2158, 2167, 

............................................................2168 

Denison, R A..................................... 1988* 

Dennis, W E..........................................103 

Denslow, N D..........428, 1231, 1425, 2271 

Deparade, E.........................................1454 

Dere, E..................................... 1422, 1423* 

Derk, R C.............................................1137 

DeRouen, T A......................................1766 

Deroy, K..............................................1460 

Dertinger, S D.......................................158 

Dertinger, S............................. 2244*, 2245 

Desai, V G................................. 710*, 1430 

Descotes, J........................................... 187* 

Deshmukh, N S.........................1537, 1538 

Deshmukh, P B...................................1826 

DeSilva, A............................................1287 

DeSimone, J........................................1911 

DeSimone, M C.....................................418 

DeSmet, K D...................................... 1837* 

Desmeules, P.......................................1383 

Deterding, L........................................2060 

Determined, T.......................................321 

Detrisac, C J........................................1936 

Dettbarn, W........................................2285 

Devemy, E...........................................1080 

Dever, J T.......................................... 1218* 

Devesa, V............................................1628 

Devi, S S................................................220 

Devine, P J..........................................1383 

DeVito, M J.......93, 952, 1008, 1177, 1178 

DeVito, M.............................100, 271, 612 

Devlin, R B......................1038, 1072, 1258 

Devlin, R.............................................1439 

DeVona, D..........................................2136 

DeVoney, D.........................................1685 

Dewa, Y.........................................113, 519 

DeWitt, J............................................. 174* 

Deye, G...............................................1497 

Dhalluin, S..........................................2315 

Dhand, R...............................................614 

Dhoieam, P......................................... 156* 

Di Giulio, R T........................................538 

Di Giulio, R........ 1235, 1243, 1963, 1964*, 

............................................................2184 

Di Monte, D A....................................2040 

Dial, S L...............................................1118 

Dial, S....................................................383 

Diallo, O N........................................ 1763* 

Diamantakos, E A.................................459 

Diamond, G L........................... 966*, 1006 

Diaz, M J...............................................759 

Diaz, M..................................................253 

Diaz, Z.................................................2122 

DiBartolomeis, M J............................. 981* 

DiBasio, K.............................................941 

Dicicco-Bloom, E................................1844 

Dickhoff, W..........................................600 

Diener, R M.....................1525, 1527, 1531 

Dieterich, C...........................................453 

Dieterle, F............................................ 399* 

Dietert, R R..............................................67 

Dietrich, C..........................................1216 

Dietrich, D R............... 110*, 454, 489, 527 

Dietz, B.....................................1057, 1058 

DiGiovanni, J................................120, 530 

Diliberto, J J..........................................101 

Dill, A..................................................2118 

Dillman, J F.................152, 153, 681, 1105 

Dills, R L................................................287 

Dimond, S S.............................. 970, 1151* 

Din, L B...............................................1994 

DiNatale, B........................................ 2171* 

Ding, J.................................................2228 

Ding, M..................................... 354, 1031* 

Dingemans, M M........................ 794*, 797 

Dingus, C............................................1191 

Ditewig, A C..........................................847 

Ditewig, A...........................................1208 

Divi, R L............................ 206, 770, 2335* 

Diwan, B A................................1617, 1632 

Dix, D J..... 237, 238, 239, 246, 596*, 1323 

Dix, D................................236, 1184, 1987 

Dix, I.....................................................243 

Dix, K J........................................ 311, 945* 

Dobbins, L............................................ 71* 

Dobo, K L............................................2344 

Dobrovolsky, V N............................. 1688* 

Dobson, R.............................................477 

Dodd, D E................................... 508, 510* 

Dodge, D G....................................... 1189* 

Dodge, D...............................................937 

Doerfler, D L.......................................1442 

Doerge, D R........................................... 97* 

Doherty, S P..........................................692 

Doherty, S...........................................1334 

Dohm, M.................................... 207, 210* 

Dolan, D G.............................................. 4* 

Dolinoy, D C..................................... 1408* 

Doll, M A......413, 414, 415, 416, 417, 422 

Dombkowski, A..........................673, 1595 

Domino, E F...................................... 1818* 

Donald, J M..........................................935 

Donaldson, D.................................... 1760* 

Donaldson, K........................................729 

Donatuto, J......................................... 602* 

Donetti, E............................................1547 

Dong, J................................................2070 

Dong, K.................................................495 

Dong, M..............................................1391 

Dong, W..................................... 761*, 867 

Donlin, M...........................................1081 

Donnelly, K C.....................................1249 

Donnelly, K.........................................1731 

Donner, M............................................812 

Donohue, J M..................................... 910* 

Donovan, E P......................................1800 

Donthamsetty, S...................................627 

Dooley, G P.........................................2284 

Dooley, G.................................. 278, 1322* 

Doolittle, D J.......................................1407 

Doorn, J A.......................1813, 1835, 2289 

Doorn, J..............................................1833 

Dopp, E..................................... 440, 2115* 

Dorman, D C........1009, 1511, 1877, 2098 

Dorman, D....................................927, 928 

Dorta, D J............................................1681 

Author Index 




Author Index 

Doss, J.....................................................66 

Dostal, L.................................................. 7* 

Dosunmu, R S................................... 1868* 

Dotson, G................................... 986, 987* 

Doub, W H..........................................1023 

Dougherty, E J......................... 2157, 2163* 

Doughty, S........................................ 2300* 

Dow, J........................................1574, 1604 

Dowd, S...............................................1003 

Doxzon, B F..........................................139 

Doyle, K M............................................194 

Doyle-Eisele, M......................... 738, 1503* 

Dragan, Y P.........................................1661 

Dragan, Y.............................. 23, 28*, 1206 

Draganov, D I...................................... 970* 

Dragomir, A........................................ 839* 

Drechsel, D....................................... 2058* 

Dreher, K L............................................727 

Dreher, K.............................................1504 

Drevon-Gaillot, E................................2305 

Drinkwater, K........................................412 

Driscoll, E..............................................169 

Drobna, Z................................ 1623*, 2089 

Drobná, Z..............................................407 

Drupa, C............................................. 384* 

Druwe, I L........................................... 469* 

D’Souza, S E.................. 1254*, 1967, 2059 

Du, M................................................ 2231* 

Duan, J.............................................. 1932* 

Duan, L...............................................1916 

Duan, M..............................................1311 

Duarte, F V..........................................1035 

Duarte, T.............................................1318 

Dubick, M A...................................... 1962* 

Ducha, J..............................................2203 

Duche, D...............................................661 

Duchesne, M.........................................676 

Duffel, M W..........................................312 

Duffel, M...............................................800 

Duffy, P A.................................. 859, 1205* 

Duffy, P..................................... 497*, 1798 

Dufour, E K...........................................660 

Dugan, C M........................................ 850* 

Dugas, T R.................................2212, 2213 

Duguay, F..............................................232 

Duguchi, Y............................................532 

Duhart, H M.............................1042, 1043 

Duker, G................................................651 

DuMond, J W........................................360 

Dumont, C........................................ 2153* 

Duncan, B...........................................1249 

Dungan, L...........................................1246 

Dunlap, T.......................................... 1905* 

Dunn, A J..............................................938 

Dunn, R T.....................................87, 1134 

Dunnick, J...........................................2174 

Duong, H..............................................380 

Duong, L........................................... 1238* 

Duplany-Conjard, A.............................464 

DuPons, J..............................................583 

Durnford, J M.......................................720 

Dusek, E..............................................1248 

Dutta, D..............................................1401 

Dutta, G..............................................2104 

Dwivedi, J......................................... 2193* 

Dyer, A.............................................. 2237* 

Dyer, M A.......................................... 1260* 

Dyer, R B.............................................1545 

Dykens, J A......................... 902*, 903, 906 

Dykens, J.............................................2302 

E 

Eaddy, A C........................................ 2062* 

Eagle, T M.............................................837 

Eakin, C M.......................................... 646* 

Eakins, J......................................859, 1205 

Earl, L K...............................................2324 

Easterling, M L....................................2161 

Easterling, M R....................................1002 

Easterling, M..................................... 1017* 

Eaton, D L........................... 641*, 760, 768 

Ebata, S.................................................329 

Ebbels, T D..........................................1605 

Ebbels, T M...............................1601, 1606 

Ebersviller, S.................... 297*, 1089, 1091 

Ebihara, T............................................1203 

Eblin, K E.................................. 122, 2120* 

Eblin, K.................................................123 

Ebner, F F..............................................691 

Eby, D M.............................................1024 

Eccleston, H B.......................................843 

Echeverria, D............................ 410*, 1859 

Eckert, M L............................................369 

Eckhert, C...................................544, 1418 

Edelhauser, H F...................................1906 

Edenfield, M J.....................................1960 

Edisiringhe, P D..................................1059 

Edmiston, J S.........................................908 

Edmondson, R..............................28, 1661 

Edwards, B C.........................................954 

Edwards, J................. 378, 458*, 459, 2222 

Edwards, M.........................................1740 

Edwards, P R.........................................809 

Edwards, P...........................................1337 

Edwards, S...........................................1381 

Eells, J B............................................ 1836* 

Eells, J T....................................1837, 1956 

Eells, J..................................................2039 

Eerola, S................................................481 

Egner, B...............................................2208 

Ehrenshaft, M.....................................2060 

Ehresman, D J..................... 98, 855, 1710* 

Ehrich, M F.........................................2270 

Ehrich, M............................................2277 

Ehrlich, T............................................1540 

Eide, D.............................................. 2329* 

Eigler, D..................................................45 

Eiguren-Fernandez, A...........................292 

Eimon, P........................................... 1979* 

Eimoto, T............................................2294 

Einem, T L........................................... 770* 

Einem, T................................................206 

Einstein, D R................... 992, 1020, 1373* 

Eisenbrandt, D L...................................313 

Eisenhauer, C......................................2318 

Eklu-Gadegbeku, K C............................716 

Elaggar, S F............................................272 

Elaine, F M............................................693 

Elcock, L E...........................................2325 

Elcombe, C..........................................1150 

Elder, A...................................... 745*, 1404 

Elfarra, A A..........................305, 379, 1218 

El-Fawal, H A.......................... 1875, 1878* 

El-Fawal, H..........................................2100 

Elhajouji, A.........................................2244 

Elizondo, L............................................120 

Elizondo-Azuela, G.............................2281 

Elleby, A............................................ 1389* 

Ellis, M E........................................... 1104* 

Ellis, P.................................................2244 

Ellis, R............................................... 1165* 

Ellis, W O....................................490, 2238 

Ellis-Hutchings, R................... 1534, 2025* 

Ellison, C............................................. 805* 

Elloumi, F............................................1568 

Elmagd, A M.......................................2187 

El-Masri, H A..................................... 1003* 

El-Masri, H......................1008, 2348, 2353 

Elnabawi, A.........................................2067 

Elsayed, N M....................................... 288* 

El-Tawil, O S...................................... 1211* 

Elwell, M R................................1892, 1893 

Ema, M........... 363, 370, 502, 1056, 1157*, 

............................................................1528 

Emborg, M............................................580 

Emeny, R...............................................178 

Emerce-Tufan, E....................................404 

Emond, F.............................................2316 

Enayetallah, A E....................................420 

Endo, S................................................1495 

Endo, T.............................................. 1707* 

Endo, Y.................................................302 

Endoh, D.............................................2187 

Endoh, S..............................................1496 

Engbring, J............................................860 

Ennulat, D...........................................1758 

Entezari-Zaher, T..............299, 2071, 2073, 

.......................................................... 2132* 

Eppig, J T...............................................584 

Erdely, A.............................................. 740* 

Eremin, S A...........................................190 

Ergle, K D............................................1409 

Erhardt, S E.........................................1000 

Erickson, R I...................................... 1770* 

Erickson, R..........................................1895 

Ericson, J F..........................................1228 

Erikson, K..................................1863, 2103 

Eriksson, P...........................................1708 

Ernst, H.............................514, 1892, 1893 

Ernst, N B.......................................... 1915* 

Ernstgard, L.........................................1005 

Ernstgård, L......................................... 755* 

Escalon, L..............................................130 

Escalona, S..........................................2077 

Esch, H....................................................45 

Eschrich, D..........................................1449 

Escobar, P................................................84 

Esmail, M............................................1152 

Espandiari, P.............................1925, 1927 

Essner, R..............................................2233 

Estes, S...................................................131 

Estey, T................................................1951 

Estrada, I...............................................186 

Euling, S Y...........................................2014 

Eunhee, H........................................... 788* 

Evans, B R...........................................2194 

Evans, J.......................................859, 1205 

Evans, M V..........................................1003 

Evans, P...............................................1203 

Evans, R................................................128 

Evans, S.................................................194 

Evans, T J.............................................. 60* 

Evansky, P A........................................1807 

Evansky, P.................................1654, 1957 

Eveland, A T..........................98, 855, 1710 

Everds, N E............................................201 

Everett, D.......................................... 1926* 

Everitt, J..............................................1079 

Ewart, L C......................................... 2295* 

F 

Fabian, E.............................................1603 

Fabian, E J...........................................1553 

Fabisiak, J P...............................1494, 2087 

Facchi, A.............................................1046 

Factor-Litvak, P.........................1630, 1966 

Fadeel, B.................................. 1036, 1047* 

Fair, P A............................. 169, 198, 2139* 

Fair, S.....................................................942 

Fairchild, D...........................................453 

Faiz, H...................................................464 

Faller, C....................................... 330, 340* 

Falluel-Morel, A..................................1844 

Famini, G R.........................................1776 

Fan, A M............................................. 939* 

Fan, C................................................ 1115* 

Fan, Q...................................................708 

Fan, R....................................................172 

Fan, T..................................................1108 

Fan, Y....................................................343 

Fang, F................................................. 615* 

Fang, H....................................................28 

Fang, J............................................... 1676* 

Fant, P.....................................................70 

Fanucchi, M V.................................... 574* 

Farabaugh, C S.................................. 2251* 

Farin, F M............................................1859 

Farin, F........................................410, 2191 

Farland, W H......................................1178 

Farmer, J D................................1164, 1823 

Farmer, P B..........................................1747 

Farr, S B....................................... 664, 668* 

Farraj, A K................................... 748, 749* 

Farraj, A...............................................1652 

Farrer, D G.................... 1914, 2129*, 2169 

Fasano, W J.........................................1554 

Fasano, W........................................... 957* 

Faustman, E M...........353, 475, 884, 1179, 

....................1190, 1248, 1320, 1695, 1853 

Faustman, E...............................597*, 599* 

Fay, K A............................................... 287* 

Fay, M.................................................2011 

Febbo, E J............................................1232 

Fecher, R...............................................167 

Fechter, L D............................... 215*, 1100 

Fedorowicz, A.....................................1313 

Fedoruk, M J........................... 1476*, 1740 

Fehling, K A........................................1458 

Fehling, K.......................................... 1794* 

Fehrenbacher, C....................................923 

Felter, S P........................................... 1355* 

Felty, Q.............................................. 2216* 

Feng, W..........................473, 1036*, 2106* 

Fennell, T R......................... 403*, 517, 518 

Fennell, T......................................63, 1917 

Fent, G M....................................614, 1171 

Fenton, S E......... 1139, 1155, 1156, 1981*, 

.......................................................... 1986* 

Ferguson, L C.............................. 311*, 945 

Ferguson, S S............................... 319*, 551 

Ferguson, S..................................673, 1696 

Fernandes, M..............................364, 2017 

Fernando, R................................ 517, 518* 

Fernando, T................................167*, 168* 

Ferraz, E A...........................................1681 

Ferrell, B D............................................431 

Ferrell, J...................................................96 

Ferrer, E...............................................2225 

Ferrier, B................................................464 

Fery, Y................................................. 778* 

Festersen, U.........................................1452 

Fetzer, J..................................................254 

Fex-Svenningsen, A............................1718 

Fey, R A............................................. 1897* 

Fey, R.....................................................462 

Fiehn, O..............................................1768 

Fielden, M..................... 1662*, 1931, 2306 

Fifield, L..............................................1401 

Figueira, J R...........................................438 

Filary, M J............................................1084 

Filipov, N M............15*, 703, 1867, 1985*, 

............................................................2283 

Filkowski, J........................................ 1416* 

Financsek, I...........................................723 

Finch, G............................................ 2322* 

Finkelstein, J N........ 391*, 434, 572, 1121, 

............................................................1510 

Finkelstein, J...............................745, 1404 

Finlay, C....................................2228, 2229 

Finley, B L..................... 1185, 1458*, 1468 

Finley, B..........................1178, 1741, 1800 

Firth, M.................................................243 

Fisch, C...............................................1548 

Fischer, G............................................2249 

Fishel, J...............................................2150 

Fisher, A A........................................... 468* 

Fisher, B R...........................................1536 

Fisher, C D................................ 822*, 2030 

Fisher, J W........283, 947, 948, 1013, 1100, 

............................................................1464 

Fisher, J..................................... 463, 2352* 

Fisher, R L.....................................92, 2083 

Fishman, P..........................................1842 

Fitsanakis, V A....................................2282 

Fitzmorris, R........................................1244 

Fitzpatrick, S.........................................988 

Fix, A S................................................1716 

Fix, A.....................................................477 

Flanagan, B F......................................1310 

Flaten, T..............................................1636 

Flaveny, C A........................................2170 

Flaws, J A.........................1153, 1384, 1386 

Fleck, D...............................................1287 

Fleming, C R....................................... 538* 

Fleming, C..........................................2184 

Fleming, E.............................................377 

Flentke, G.............................................350 

Fletcher Claville, M O...........................314 

Flick, R................................................2199 

Flint, M............................................. 1063* 

Flint, O................................................ 766* 

Flor, S M............................................ 1679* 

Florang, V R..............................1835, 2289 

Florang, V.................................1813, 1833 

Flores, G..............................................2077 

Florian, M.............................................721 

Flowers, L................ 912, 913, 2013*, 2016 

Floyd, E.........................................384, 385 

Floyd, H S............................................ 727* 

Fluharty, K..................................406, 1312 

Flynn, C A........................................... 943* 

Flynn, T J............................................1204 

Flynt, K.................................................948 

Fochtman, F W.....................................864 

Foertsch, L..........................................1444 

Foley, C.................................................235 

Follansbee, M........................................917 

Fomby, L M............................................. 2* 

Font, G.............................................. 2225* 

Fontaine, D.........................................1459 

Foo, L.................................................. 137* 

Foradori, C D..........278, 279*, 280, 1321*, 

............................................................2284 

Foradori, C..........................................1322 

Forbes, P D........................ 202, 203, 1169* 

Ford, L...................................................812 

Forgacs, A.................................... 534, 535* 

Foroozesh, M...................................... 776* 

Forsberg, M.........................................2017 

Forster, R........... 5, 466, 1841, 1920, 2297* 

Fort, D J............................................. 1236* 

Fortier, M............................................2138 

Fosdick, A................................................87 

Fossa, A A............................................ 650* 

Foster, W G...............................1146, 1765 

Foster, W........................................... 1921* 

Foureman, G L....................................1183 

Fournier, M.........................................2138 

Fournier, S................................. 212, 1649* 

Fowler, B A.......408, 586, 587*, 589, 1289* 

Fowler, J....................................1544, 1790 

Fox, D A.............1259*, 1261*, 1724, 1874 

Foxenberg, R J..................................... 267* 

Foxenberg, R.......................................1453 

Fraites, M P........................................... 96* 

Frame, S R.............................................542 

Frampton, M.........................................745 

Francke-Carroll, S.................................946 

Francos, V.............................................497 

Franklin, C C.................................... 2063* 

Franks, D G.................................553, 2198 

Franssen, C L......................................1838 

Frantz, C........................................... 2306* 

Fraser, S R............................................2134 

Frasor, J...............................................1057 

Frawley, R.......................................... 1572* 

Frazer, D G......................1081, 1099, 1255 

Frazer, D..............................................1497 

Frazier, K S..........................................1596 

Frazier, K.......................................202, 203 

Frederick, C B........................................381 

Freebern, W J...................................... 185* 

Freedman, J H...... 878, 1019, 1285*, 1580, 

............................ 1614, 1668, 2240, 2331* 

Freedman, J...............................1610, 2091 

Freeman, C..........................................1639 

Freeman, E........................................ 1193* 

Freidig, A...............................................577 

298 




French, J E..........1278, 1279*, 1560, 1671* 

Freshwater, K......................................1541 

Freudenrich, T M................................1699 

Frey, J....................................................377 

Fricke, M.............................................1587 

Frid, A A...................................... 242*, 249 

Friedman, A........................................2161 

Frings, W.............................................1136 

Fritsche, E........................................... 578* 

Fritz, C..................................................375 

Fritz, W A............................................1517 

Froget, G.....................................466, 1841 

Froines, J...............................................292 

Fryer, A................................................2278 

Fryxell, G E...........................................140 

Fu, J.....................................................1302 

Fu, X......................................................460 

Fuchs, A..............................................1136 

Fuchs, H................................................331 

Fuentes-Mattei, E................................ 170* 

Fueta, Y............................................. 1700* 

Fuhrman, K.........................................2277 

Fuhst, R...............................................1773 

Fujii, S.................................................1157 

Fujimaki, H.........................................2024 

Fujimoto, H........................................1702 

Fujimoto, K...........................................225 

Fujimura, M...................................... 1845* 

Fujishiro, H.........................................2116 

Fukiya, Y.............................................1576 

Fukuda, T............................................2149 

Fukuoka, T..........................................1584 

Fukusato, T.........................................1158 

Fukushima, T.................................... 1592* 

Fukuzaki, K.........................................1657 

Fullenkamp, H J..................................2097 

Fullerton, A M..................................... 848* 

Fulton, S................................................215 

Funhoff, E G.......................................2303 

Funk, C...............................................1377 

Furgeson, D Y.......................................427 

Furimsky, A.................................453, 1895 

Furlong, C E..................................265, 419 

Furr, J....................................56, 59, 62, 90 

Furtado, M........................................ 2279* 

Furuhashi, K.............................. 302*, 1817 

Fuscoe, J C..............710, 1118, 1430, 1661 

Fuscoe, J....................................28, 66, 460 

Fussell, K C........................................ 2049* 

Fussell, K...............................................231 

G 

Gaarde, W.............................................858 

Gaca, M.......................................875, 2079 

Gadagbui, B..........................................987 

Gadwal, T R........................................1755 

Gaffney, S H........................................1471 

Gagan, E M....................................... 2289* 

Gagné, M............................................ 969* 

Gagnon, F...................................500, 1732 

Gagnon, S...........................................1771 

Gaido, K........................................58, 1162 

Gaille, F...............................................2246 

Gairola, C..............................................726 

Galal-Gorchev, H..................................910 

Galdanes, K.................................291, 1508 

Galijatovic-Idrizbegovic, A...................381 

Gallagher, B........................................1919 

Gallagher, D..........................................385 

Gallagher, E P.......... 357, 369, 1722, 2019* 

Gallagher, E.................................799, 2191 

Gallagher, J.........................................1474 

Gallegos, R..........................................1222 

Galli, C L...................................1046, 1547 

Gallo, M A...........................................1545 

Galloway, J..........................................1524 

Galloway, N..........................................411 

Gallucci, R........................................... 845* 

Gamble, M V........................... 1630, 1644* 

Gamboa da Costa, G......................... 1747* 

Gamer, A O.........................................1400 

Gan, J....................................................273 

Gan, L.................................................1222 

Gandolfi, A J...............................122, 2120 

Gandolfi, A...........................................123 

Gandy, J................................................801 

Ganey, P E............220, 623, 837, 847, 848, 

...................... 850, 853*, 1208, 1912, 1913 

Ganey, P................................................849 

Gangisetti, S..............................2071, 2132 

Ganguri, A............................................243 

Ganjam, V...............................................60 

Ganter, B........................................... 1123* 

Gao, D.....................................................16 

Gao, H............................................... 1108* 

Gao, S..................................................1103 

Gao, W..................................................865 

Gao, X..................................... 1999*, 2201 

Gao, Y............................................... 1846* 

Gao, Z...........................................311, 945 

García Vargas, G G..............................1767 

Garcia, C.............................................2077 

Garcia, G J........................................... 995* 

Garcia, R......................................209, 1770 

Garcia-Bennett, A...............................1047 

García-Dominguez, R.......................... 292* 

García-Montalvo, E A........................... 86* 

Garcia-Vargas, G G................................407 

Gard, J...................................................754 

Gardner, C R.........................................839 

Gardner, D............................724, 925, 926 

Gardner, R M...................................... 194* 

Garg, N................................................1287 

Gargas, M L.................................957, 1783 

Gargas, M.................................. 967*, 1784 

Garica, R...............................................792 

Garic-Stankovic, A................................350 

Garrabou, G..........................................295 

Garrett, C M.................. 1561, 1562, 1563* 

Garrett, R..............................................367 

Garrett, S H......... 1608*, 1620, 2113, 2114 

Garrett, S.............................................1598 

Garrison, A W.....................................1196 

Garside, H.............................................619 

Garst, J E............................................. 695* 

Garthoff, L H......................................1204 

Garza, C..............................................2241 

Gasiewicz, T A............365, 367, 685, 2159, 

............................................................2161 

Gasiewicz, T........................................2180 

Gaspar, P.............................................1627 

Gassman, P L........................................679 

Gassmann, K.........................................578 

Gatti, R A............................................2057 

Gatto, N M..........................................1801 

Gautherot, E..................................... 2246* 

Gautier, J.....................................676, 1758 

Gavett, S H..........................................1442 

Gavin, T..............................................1811 

Gaylor, D W..........................................801 

Gazarian, D I....................................... 889* 

Gbeassor, M F........................................716 

Ge, Y.....................................................112 

Gear, R..................................................566 

Gearhart, C...........................................215 

Gearhart, J M................................127, 677 

Gearhart, J................................... 128*, 129 

Geary, R S.......................................... 1015* 

Gee, J.....................................................284 

Gehlhaus, M W................................... 919* 

Gehlhaus, M.......................................2013 

Gehman, E............................................887 

Gelatt, R H..........................................1471 

Gelein, R.....................................745, 1404 

Gelineau-van Waes, J B.........................487 

Gellein, K.......................................... 1636* 

Gelzleichter, T................................... 1930* 

Gemzik, B................................ 1341, 1361* 

Genell, C.............................................1929 

Generaux, G T......................................620 

Genet, B................................................676 

Gennings, C..............268, 271, 1165, 1177 

Genter, M...................... 1325*, 1903, 1904 

Gentry, R.................................................51 

Geohagen, B.......................................1811 

George, J.............................................1727 

George, M H.........................................870 

George, M.............................................834 

George, W J.................................959, 1939 

Georgieva, N I............... 1736*, 1748, 1755 

Georgopoulos, P G................................670 

Geraci, C L....................................986, 987 

Gerba, C..............................................1799 

Gerberick, F.........................................1444 

Gerberick, G F.....................................1186 

Gerecke, D R...... 135, 146, 155*, 683, 742, 

............................................................1545 

Gerhold, D....................................380, 381 

Gerken, D K........................................ 720* 

Gerlach, R W.........................................269 

Gerlofs-Nijland, M...................... 729*, 746 

German, T.............................................752 

Germolec, D R..........................1632, 2130 

Germolec, D................................406, 1572 

Gershwin, L J.................................... 1333* 

Gerstenberger, S L...............................1856 

Gerwick, W H.....................................1727 

Gesswein, G..........................................444 

Geter, D R...........................................1429 

Geter, D............................................. 1595* 

Ghantous, H..................................... 1292* 

Ghio, A J..................................... 34*, 1093 

Ghosh, R N..................... 342*, 2081, 2253 

Gibbs, A............................................ 2293* 

Gibson, E..........................................94, 95 

Gibson, J E................................ 347, 1498* 

Giday, M.............................................2075 

Giddabasappa, A..................... 1724*, 1874 

Giddens, E...........................................2308 

Gideon, K M.............................1078, 1757 

Giedzinski, E.......................................1385 

Giesy, J..................................................951 

Gift, J S......................................1183, 1189 

Gigliotti, A P.......................................1071 

Gigliotti, A..........................................1037 

Gilbert, D J..........................................1380 

Gilbert, K.............................................. 66* 

Gilbert, M E............................ 1703*, 1871 

Gilbert, S G....................................... 1479* 

Gill, S.......................................... 861*, 862 

Gillespie, A..........................................1249 

Gillespie, M E......................................1872 

Gillespie, P...................... 728, 1500*, 1878 

Gilliland, F D........................................569 

Gilmour, I...................................652, 1588 

Gilmour, M............................... 654*, 1038 

Gilotti, A C................................. 327*, 328 

Gingell, R..............................................465 

Ginsberg, G...........................................421 

Giordano, G......... 790, 1396*, 1691, 1693, 

............................................................1694 

Giordano, M.......................................1873 

Girgis, G N........................................ 2128* 

Girroir, E E..........................................1549 

Giusti, A M........................................ 1935* 

Glaab, W E............................................381 

Glaise, D..............................................1202 

Glass, D F............................................ 929* 

Glass, K Y.............................................. 80* 

Glaze, E R............................................1936 

Gleason, T...........................................2301 

Glenn, R T...........................................1154 

Glerup, P............................................. 205* 

Glick, J..................................................671 

Glinghammar, B................................. 823* 

Glover, M............................................ 173* 

Glumac, A...........................................2056 

Go, M..................................................1213 

Go, Y...................................................2046 

Goble, R L...............................................52 

Godfrey, V................... 961, 962, 971, 972* 

Godin, C...............................................444 

Godin, S J............................................ 612* 

Godin, S.................................... 102, 2310* 

Goebel, C.......................340, 1167*, 1186* 

Goeddeke, M M....................................974 

Goeden, H........................................... 983* 

Goedken, M J................................624, 829 

Goens, M....................................689, 2207 

Goering, P L........................446, 946, 1048 

Goettel, M........................................... 118* 

Goetz, A K......................................... 1323* 

Goff, K.................................................1192 

Goff, M.....................................2125, 2127 

Gogal, R M.................... 2125, 2126*, 2127 

Gohlke, J M......................................... 259* 

Gohlke, J.....................................366, 2349 

Golbraikh, A.........................................245 

Gold, A..............................418, 1560, 2078 

Gold, P W...........................................1936 

Goldfain-Blanc, F.............................. 1922* 

Goldman, J M....................................... 85* 

Goldsmith, M R.................................. 246* 

Goldsmith, M.......................................247 

Goldstein, D........................................2249 

Goldstein, K M....................................1579 

Goldstein, R..........................................857 

Golias, B M...........................................213 

Gollapudi, B B.................1314, 1429, 1438 

Gollapudi, B........... 412, 673, 1595, 1989*, 

.......................................................... 2343* 

Gollub, J.............................................. 251* 

Golt, M B............................................1487 

Golub, M S............................................935 

Golub, M........................................... 1335* 

Gomez, C.................................. 324*, 1552 

Gomez, V............................................2077 

Gomez-Navarro, J...............................2322 

Gonchoroff, D G............................... 2136* 

Gong, D................................................857 

Gong, L...............................................1571 

Gonsebatt, M E....................... 1881, 1947* 

Gonzales, C.........................................1641 

Gonzalez, F J.......................................1775 

Gonzalez, R M................................... 1764* 

Gonzalez-Villalva, A.................1642, 1643 

Gonzaludo, N.....................................2249 

Good, R L.......................................... 1719* 

Goodman, J E................ 1189, 1462, 1787* 

Goodman, J H.....................................1871 

Goodman, J I........... 26*, 526, 662*, 1407* 

Goodman, P H....................................1467 

Goodrich, G G.................................. 1467* 

Goodsaid, F M........................... 631, 1271* 

Goodwin, S...........................................817 

Gookin, G........................... 732, 734, 753* 

Goon, D J..............................................228 

Gopalakrishnan, S..............................1956 

Gopee, N V........... 965, 1023, 1403*, 1551 

Gopinathan, L.................................... 540* 

Gordon, C J....................................... 1667* 

Gordon, D...........................................2134 

Gordon, E......................................... 1540* 

Gordon, J D........................................... 91* 

Gordon, M K...............155, 683, 742, 1545 

Gordon, R K..........................154, 156, 684 

Gordon, T..... 291, 728, 1082, 1500, 1508* 

Gorelik, O...................................441, 1497 

Gosse, J A........................1308, 1433, 1566 

Goswami, P C...........................2064, 2068 

Goswami, P.........................................2055 

Goth, S R........................................... 2155* 

Goto, H............................................. 2307* 

Gotti, A.........................................48, 1379 

Gottipolu, R........................................1654 

Gottschling, B C............................... 2319* 

Goud, N S.......................................... 1780* 

Gould, N............................................. 160* 

Gow, A J..............................................1954 

Grabiniski, C M....................................423 

Grabowski, J........................................ 692* 

Graden, D.................................1160, 2141 

Gradin, K............................................2166 

Graff, J E....................................2272, 2288 

Graham, C..........................................2305 

Graham, J S.........................134, 681, 1546 

Graham, J....................................680, 1463 

Gralinski, M..............................1656, 2306 

Granato, T C.......................................1799 

Grant, D F.............................................420 

Grant, D M.........................224, 869*, 963* 

Graves, L M.........................................1411 

Graves, S W...........................................720 

Graves, S..................... 961, 962, 971*, 972 

Gray, J P.......... 135, 146, 231*, 1545, 2049 

Gray, L E.......................................... 59*, 90 

Gray, L...............................................56, 62 

Gray, T..................................................254 

Gray, W G.............................................536 

Gray, W.................................................345 

Graziano, J H..................1630, 1644, 1966 

Greathouse, K L.................................. 690* 

Greaves, P.................................1892, 1893 

Green, A.................................... 275*, 2266 

Green, B................................................724 

Green, C E...........................................1895 

Green, C................................................392 

Green, D..............................................1555 

Green, J D............................................... 9* 

Green, J...............................................2309 

Green, M........................................... 1539* 

Green, S.................................................465 

Greenamyre, J T..................................2040 

Greenberg, G I....................................1462 

Greene, A L.........................................1311 

Greene, C..............................................983 

Greenlee, A R.........................2337*, 2341* 

Greenlee, S.............................. 2137, 2148* 

Gregorelli, C.......................................1547 

Greiner, B............................................2303 

Gremminger, J......................................963 

Grenet, O............................................1391 

Grey, B E........................................... 1534* 

Grey, B................................................2025 

Griffin, G..............................................985 

Griffin, J L...........................................1604 

Griffith, W C................. 1179*, 1190, 1248 

Griffiths, B..........................................1203 

Griffiths, J C...................................... 2234* 

Griffiths, J.............................................709 

Griffitt, J.............................................. 428* 

Grimes, K............................................1855 

Grindstaff, R.........................................834 

Grissom, S F..........................................366 

Griswold, M E.....................................1861 

Groch, H.............................................2126 

Grof, P.........................................162, 2286 

Grollman, A P.......................................760 

Groom, C J..........................................1181 

Groopman, J D...................................1214 

Gross, C J.......................................... 2147* 

Gross, E A......................................510, 993 

Gross, S.................................................346 

Grotendorst, G R..................................296 

Groves, A M...................................... 1954* 

Grubb, S C............................................585 

Grue, C E.................................................72 

Gruhler, A.............................................675 

Gu, B...........................................423, 1026 

Gu, J......................................................824 

Gu, M....................................151, 204, 678 

Gu, X.............................................320, 550 

Gu, Y........................................... 473*, 763 

Guerrette, Z......................................... 353* 

Guette, J................................................721 

Gugen-Guillouzo, C............................1202 

Guidotti, T L..........................1803*, 1825* 

Guilarte, T R......... 707, 1259, 1263*, 1860, 

..................................................1861, 1870 

Author Index 




Author Index 

Guillouzo, A........................................1202 

Guinea, J.............................................1725 

Guiney, P D.........................................1236 

Guizzetti, M........ 1691, 1693*, 1694, 1701 

Gujral, J................................... 1544*, 1790 

Gulhan, M............................................402 

Gulledge, W..........................................465 

Gunasekar, P G...............1877, 2098, 2099 

Gundersen, D......................................1244 

Gundert-Remy, U....................................44 

Gunnison, A.......................................1500 

Gunter, M E..........................................294 

Guo, C.......................................1600, 1954 

Guo, G..................................................815 

Guo, J..........................................614, 2178 

Guo, L.......... 376, 383*, 1118, 1651, 1751, 

................................................ 2304*, 2306 

Guo, M.....................................828*, 1571* 

Guo, T L............................................ 2130* 

Guo, T.................................................1505 

Guo-ying, Z......................................... 144* 

Gupta, A K..........................................1341 

Gupta, A................................................766 

Gupta, R C.................... 1806, 1958, 2285* 

Gupta, R K.............................. 1153*, 1384 

Gupta, R................................................633 

Gurer-Orhan, H.................................. 107* 

Gurofsky, S..................................862, 2224 

Gustafson, A........................... 1980*, 2017 

Gute, B..................................................252 

Guthrie, J..............................................946 

Gutiérrez Ospina, G............................1881 

Gutierrez-Valdez, A............................. 209* 

Gutjahr-Gobell, R.................................281 

Gutta, P...............................................1715 

Gutting, B W.........................................677 

Gutting, B.............................................129 

Guy, A................................................. 985* 

Guyot, D.............................................2322 

Guyton, K Z............ 421, 914, 1685, 2014* 

Gwiazda, R............................................589 

Gwinn, M R...................................... 1685* 

H 

Haber, L T............................. 10, 51*, 1189 

Haberzettl, P........................... 1967, 2059* 

Hack, C.................................................677 

Hack, E................................................ 129* 

Hacker, T.............................................1532 

Haddad, S...................... 1016, 1377*, 1901 

Hafer, K...............................................2258 

Hagenbuch, B.......................................943 

Haggblom, M M....................................306 

Haggerty, H G.......................................185 

Haggerty, H.........................................2136 

Hahn, H..............................................1730 

Hahn, M E.........................553, 2194, 2198 

Hahn, M..............................................2184 

Haighton, L A.......................................511 

Hailey, A M...........................................867 

Haines, J L.............................................409 

Hajduk, P J..........................................1432 

Hajela, R K..........................................1827 

Halbert, D N................................251, 1123 

Haley, P.....................................................2 

Halicka, D...............................................82 

Hall, A H...............................................505 

Hall, A L............................................ 1542* 

Hall, K M............................................. 368* 

Hall, M L.............................................1234 

Hall, S J...............................................1154 

Hallmark, C T.......................................483 

Halonen, L..........................................1745 

Halzack, N...........................................1508 

Hamada, Y..........................................1592 

Hamade, A.......................................... 736* 

Hamadeh, H...................... 87, 1339*, 1565 

HaMai, D........................................... 1607* 

Hamai, D.............................................1801 

Hamel, L D.......................................... 547* 

Hamelin, G....................................... 1004* 

Hamers, R J...........................................426 

Hamilton, B........................................1075 

Hamilton, J W.................1308, 1433, 1566 

Hamilton, R L.....................................1961 

Hamilton, R..............................1492, 1724 

Hamilton, T A.......................................192 

Hamlin, D M.......................................1650 

Hamlin, R................................ 1645, 1650* 

Hamm, J T.........................907, 1409, 1684 

Hammerstrom, K........................ 911, 912* 

Hammock, B.......................................1768 

Hammond, B........................................494 

Hammond, C L.....................................351 

Hammond, T G.....................................651 

Hampton, T G.....................................1653 

Hampton, T H...........................1308, 1433 

Hampton, T...................................... 1566* 

Han, B............................... 87, 1134*, 1502 

Han, E H.............................................1436 

Han, E................... 872, 1122*, 1124, 1435 

Han, J...................................... 1502, 1506* 

Han, S................................ 404, 726*, 2323 

Han, T................................. 66, 460, 1661* 

Han, X................................. 616*, 812, 957 

Han, Y.................................................2229 

Hanaki, K............................................1158 

Hancer, F...............................................402 

Hancock, S..........................................2270 

Handa, R J................. 278, 279, 280*, 1321 

Handforth, A.......................................1940 

Haney, L L.............................................814 

Hanig, J P............................................1726 

Hanig, J...........................1714, 1925, 1927 

Hankinson, O...................782, 1670, 1940 

Hanneman, W H.......278, 279, 280, 1321, 

..............................1832, 1984, 2034, 2284 

Hanneman, W....................................1322 

Hannon, D B.........................................540 

Hansen, D.............................................497 

Hansen, H.....................................47, 2011 

Hansen, J S........................656, 1441, 1445 

Hansen, J............................................. 559* 

Hansen, T..............................................514 

Hanson, D...........................................2322 

Hanson, M L....................................... 190* 

Hanson, R G........................................1374 

Hanssen, K A.........................................139 

Hao, J.................................................. 119* 

Harbell, J W...................................... 1352* 

Harbell, J.....................................324, 1552 

Harber, J..............................................1026 

Harbison, R D...........................1797, 1810 

Harbison, S C......................................1797 

Harbourt, D E.................................... 1894* 

Harbourt, D...........................................418 

Hard, G C...................................457*, 465* 

Hardej, D............................................. 713* 

Harder, J..............................................1936 

Hardin, B D....................................... 1779* 

Hardin, K............................................2053 

Hardisty, J F............................. 1892, 1893* 

Hardman, R......................................... 901* 

Hardy, J.................................................693 

Hargreaves, A..................1574, 1604, 1687 

Harkema, J R...... 529, 568, 573*, 618, 718, 

..............................1088, 1474, 1912, 1913 

Harkema, J..........................................2092 

Harper, P A..................................779, 1110 

Harper, S L................................ 433*, 1978 

Harpur, E........................................... 1758* 

Harrill, J A......................................... 2273* 

Harris, C..............................................1524 

Harris, D L........................................... 866* 

Harris, M A................................1178, 1198 

Harris, M......................... 697*, 1741, 1800 

Harris, P A...........................................1229 

Harris, R K.....................................512, 814 

Harris, T R.............................................785 

Harris, W...............................................494 

Harrison, L S.........................................269 

Harrison, R A......................................1003 

Harritos, B.............................................962 

Harry, G J..............................................366 

Harry, G..............................................1824 

Hart, J A........................................ 98, 855* 

Hart, W E..............................................134 

Hartig, P C..........................................2190 

Hartman, J A.......................................2231 

Hartmann, E.........................................531 

Hartmann, L M...................................2115 

Hartono, D................................1398, 1490 

Haruyama, M......................................1657 

Harvey, C N...................................... 1152* 

Harvey, W A..........................................355 

Harvilchuck, J..................................... 117* 

Haschek-Hock, W M......................... 2227* 

Hasegawa, R..........................................502 

Hasegawa, T...................................... 2085* 

Hashimoto, A......................................1215 

Haskell, D............................................1239 

Haskins, J R...........................................894 

Haslam, S..............................................566 

Hassani, M.............................. 1896*, 2256 

Hassett-Sipple, B...................................989 

Hassiepen, U.......................................2303 

Hassler, C.......................................... 1660* 

Hassoun, E........................................ 2045* 

Hasumi, K.............................................519 

Hatcher, M..........................................2011 

Hattan, D..............................................988 

Hattis, D........................................ 52*, 997 

Haux, C...................................................45 

Hawk, M.................................. 1660, 2314* 

Hawkins, B S....................................... 920* 

Haws, L C.............. 697, 1178*, 1198, 1800 

Haws, L...............................................1741 

Hayamizu, K....................................... 493* 

Hayashi, J............................................2149 

Hayashi, M..........................................2243 

Hayashi, T.............................................329 

Hayden, C...........................................2308 

Hayden, P J................................341*, 895* 

Hayden, P.....................326, 334, 335, 883 

Hayes, A N........................................ 1909* 

Hayes, E.................................. 1296, 1301* 

Haykal-Coates, N........727, 748, 749, 1652 

Hayley, G..............................................854 

Haynes, V............................................1311 

Hays, S M................................ 1197, 1199* 

Hayward, D...........................................230 

Hazari, M S................................ 749, 1652* 

He, G...................................................2168 

He, L....................................................1731 

He, W..................................................2111 

He, X.....................................................636 

Heale, J T.................................................92 

Heart, E.................................................231 

Hébert, C D...........................................516 

Hebert, N.......................................... 1519* 

Hebert, V Y....................................... 2212* 

Heck, D E..................................1545, 2049 

Heck, J D........................................... 1737* 

Hedge, J M..............................................93 

Hedtke, B M..........................................311 

Heffernan, J....................................... 1934* 

Heflich, R................................................55 

Hegde, S..............................................2003 

Hegde, V L........................................ 2003* 

Hege, A...................................... 374*, 1280 

Hegedus, C..........................................1625 

Heggland, S J.........................................355 

Heidel, S M................................................9 

Heideman, W...........426, 819, 1161, 1658, 

..................................................1659, 2195 

Heidenfelder, B...................................1474 

Heilig, M.............................................1936 

Hein, D W............413, 414, 415, 416, 417, 

......................................................422, 661 

Heindel, N D.......................................1545 

Heinrichs, J...........................................578 

Heisler, E...............................................331 

Hejtmancik, M R...........................515, 720 

Helferich, W G....................................2231 

Hellman, B..........................................2218 

Helmcke, K J..................................... 1883* 

Helzlsouer, K J..................................... 659* 

Hemmer, M J..................................... 1229* 

Henao Restrepo, A..............................2297 

Henderson, J T......................................226 

Henderson, K A................................. 1418* 

Henderson, K........................................544 

Henderson, M.......................................283 

Henderson, W M...................... 396*, 1196 

Hendrich, S.........................................2239 

Hendry-Hofer, T....................................160 

Heneweer, M.........................................108 

Hennig, B..........................813, 2215, 2220 

Henningsen, G......................................928 

Henry, E..............................................2180 

Henry, M.............................................1837 

Henry, S H......................................... 2009* 

Henry, S P......462, 858, 1015, 1897, 2144, 

............................................................2148 

Henry, S...............................................2137 

Henry, T..............................922, 923, 1855 

Henshel, D S.......................................1956 

Heo, Y............................................... 1440* 

Heravi, N E............................................269 

Herbert, G.............................................296 

Herbert, M...........................................2246 

Herbert, R A..........................................516 

Herbert, T............................................2279 

Heringa, M.......................................... 105* 

Herman, E H.........................................456 

Hermens, J M........................................896 

Hernady, E............................................391 

Hernández Morales, C........................1473 

Hernandez, A........................................973 

Hernandez, J P.................................... 769* 

Hernandez, M.......................................350 

Hernandez, O................................922, 923 

Hernandez, R........................................ 87* 

Hernández-Ochoa, I......................... 1384* 

Hernandez-Zavala, A................1623, 1628 

Herr, D W..................................2272, 2288 

Herrera, L..............................................296 

Herrin, S..............................................1526 

Herseth, J I..........................................1085 

Hess, K L.............................................2097 

Hess-Ruth, A................. 1713*, 2100, 2101 

Hester, S D...................................282, 1840 

Hester, S.............. 1055, 1324*, 1428, 1588 

Hesterberg, T W.................................. 977* 

Hettick, J M.........................................1316 

Heusinkveld, H J................................. 797* 

Heussner, A H............................. 454*, 489 

Hewitt, D............................................1086 

Hewitt, P................................. 1123, 1570* 

Heyde, B................................................754 

Heyer, N J.......................................... 1859* 

Heyer, N................................................410 

Heyliger, S O.........................................286 

Hickman, M........................................1201 

Hicks, H E......................................... 1484* 

Higgins, E............................................1795 

Higgins, M....................................87, 1565 

Highfill, J............................................1629 

Higuchi, C...........................................1584 

Hilberer, A.....................................323, 325 

Hild, S A.............................................. 860* 

Hill, A J................................... 1977*, 1980 

Hill, B..................................................2059 

Hill, J...........................................551, 1246 

Hill, R..................................................1926 

Hillegas, A......................................... 1929* 

Hillegass, J M...................................... 294* 

Himeno, S......................................... 2116* 

Himley, S C......................................... 501* 

Himmelstein, M W..................... 956*, 958 

Hinchcliff, K W.....................................393 

Hinckley, J...........................................2270 

Hinderliter, P M..................................1975 

Hinds, L R...................278, 279, 280, 1321 

Hines, E P...................... 1139, 1155, 1156* 

Hines, R N............................................. 19* 

Hines, R................................................. 18* 

Hiney, J K..............................................274 

Hinkens, D M...................................... 159* 

Hinojosa, J............................................942 

Hinton, D E.........................538, 901, 2192 

Hinton, D............................................2185 

Hippler, J.............................................2115 

Hirabayashi, Y..................................... 361* 

Hiraga, T.............................................2187 

Hirakawa, B............................... 902, 1577* 

Hirano, S.............................................2109 

Hirata-Koizumi, M.......... 502*, 1157, 1528 

Hirner, A V..........................................2115 

Hirode, M.......................................... 1569* 

Hirose, A......................... 502, 1056, 1528* 

Hirose, M....................................480, 1702 

Hirose, Y...............................................532 

Hirvonen, M...............................179, 1096 

Hitchins, V M.....................................1048 

Hixon, M............................................... 61* 

Hnatyshyn, S......................................1605 

Ho, G..................................................1697 

Ho, I K...................................................546 

Ho, J......................................................714 

Ho, M....................................................137 

Ho, S K..................................................226 

Hoban, D..................................2230, 2233 

Hobbs, C.............................................1655 

Hoberman, A M.........202, 203, 270, 1169, 

........................................1525, 1527, 1531 

Hobson, D W.................................... 1354* 

Hobson, D..............................1272*, 1273* 

Hochman, D..................................... 1953* 

Hodgson, E.......................................... 765* 

Hoehle, S I.......................................... 968* 

Hoet, P H..............................................217 

Hoey, K................................................1550 

Hoffman, C.................................692, 1334 

Hoffman, D.........................................1758 

Hoffman, H B................................311, 945 

Hoffmann, E.........................................440 

Hoffmann, J........................................ 331* 

Hofmann, E L................................... 2015* 

Hofmann, M.......................................1053 

Hofmanova, J........................................811 

Hogaboam, J.........................................686 

Hogan, K A.......................................... 914* 

Hogan, K.....................................912, 2013 

Hoke, R A........................................78, 431 

Holcombe, G W....................................103 

Holcombe, G.........................................106 

Holden, E.......................................... 2242* 

Holder, D..............................................380 

Holderman, T........................................236 

Holian, A.....................................555, 1492 

Holladay, S D................ 2125*, 2126, 2127 

Holland, M A......................................1234 

Holland, R.........................670, 1661, 1927 

Hollanders, K........................................337 

Hollebekkers, K.....................................481 

Holley, G.............................................1906 

Hollingshead, B..................................2171 

Holme, J A........................................... 344* 

Holmes, A......................................... 2093* 

Holmes, E....................373, 397, 472, 1605 

Holsapple, M P......................................628 

Holson, J F..........................................1729 

Holson, J.............................................2301 

Holy, J...................................................879 

Holz, J D................................................685 

Holzman, S A...................................... 554* 

Hom, T..................................................600 

Honeggar, M.......................................1044 

300 




Hong, D..............................................1049 

Hong, F.................................................588 

Hong, J................................................ 835* 

Hong, S J........................................... 1740* 

Hong, S K..............................................450 

Hong, S P......................................962, 971 

Hong, S............ 353, 884, 961*, 972, 1320, 

..................................................1695, 1853 

Hong, Y S..............................................373 

Honma, M......................................... 2243* 

Hontzeas, N........................................2258 

Hood, B L............................................1063 

Hood, C............................................. 1768* 

Hood, D B........................................... 691* 

Hood, L...............................................1916 

Hooiveld, G........................................2221 

Hook, S E........................................... 1247* 

Hook, S.............................................. 1232* 

Hooks, S B.............................................359 

Hooks, W N...................................... 1181* 

Hoon, J..................................................832 

Hooper, M............................................. 72* 

Hooth, M J....................512, 516, 517, 518 

Hoover, D V........................................1536 

Hoover, M D.......................................1082 

Hooyberghs, J............................. 337*, 886 

Horand, F.................................... 70, 2145* 

Hori, H................................................1700 

Horiguchi, H........................... 1482, 1618* 

Horii, I.................................................1592 

Horinouchi, A.....................................1756 

Horsmon, J............................................145 

Horsmon, M.........................................145 

Horvath, C............................................321 

Horvath, G............................................474 

Hosako, H......................................... 1109* 

Hosoki, E.............................................2307 

Hosomi, H.............................................218 

Hossain, M M.................................... 2283* 

Hotchkiss, A K..............................62, 1250 

Hotchkiss, J A....... 529, 1084, 1095*, 1314, 

..................................................1438, 1805 

Houck, K A............................................246 

Houck, K........................... 236, 237, 1990* 

Houze, P......................................611, 1318 

Hovland, D N......................................1915 

Howard, G J........................................1378 

Howard, P C.......... 965, 1023, 1403, 1551* 

Howarth, D L.................................... 2192* 

Howatt, D.............................................726 

Howd, R A.....................................938, 939 

Howd, R..............................................1638 

Howdeshell, K L.............................. 56, 62* 

Hoyer, P B.......................1145, 1382, 1383 

Hoyt, S................................................1476 

Hrycay, E...............................................804 

Hsiao, S...............................................2227 

Hsu, B..................................................2245 

Hsu, S....................................................504 

Hu, R.......................................................87 

Hu, T......................................... 883, 1437* 

Hu, W..................................................1931 

Hu, X.....................................................701 

Hu, Y................................................... 754* 

Hu, Z................................................. 1916* 

Hua, I......................................................75 

Huang, B.............................................1613 

Huang, C..........................318*, 793, 2236* 

Huang, M...........1469, 1489, 1545*, 1616* 

Huang, R...............................................880 

Huang, W............................................2030 

Huang, Y...............................................496 

Hubal, E..............................................1474 

Hubbs, A F............1082, 1090, 1255, 1497 

Hudson, C A....................................... 608* 

Hudson, C...............................................16 

Hudson, T C........................................1462 

Hueber-Becker, F...................................660 

Huebner, H J...............................490, 2238 

Huebner, H.........................486, 507, 1478 

Huerta, S.............................................1131 

Huet-Hudson, Y M................................802 

Huggett, D B...................1228, 1230, 1245 

Huggins, T.............................................702 

Hughes, C...........................................2255 

Hughes, M F.... 612, 952, 954*, 1589, 1629 

Hughes, S............................................1928 

Hui, X............................................... 1558* 

Hulderman, T.......................................740 

Hulet, S W........................................... 132* 

Hulet, S.................................................128 

Humphreys, W G..................................766 

Hung, D..............................................2290 

Hung, G....................462, 858, 1015, 2137 

Hung, P J...............................................621 

Hunt, J................................................2020 

Hunter, D L.....................2186, 2188, 2189 

Hurley, K M...........................................607 

Hurley, T D..........................................2289 

Hurst, A.................................................345 

Hurst, C.................................................191 

Hurst, J H..............................................359 

Hurtt, M.................................. 1290*, 2322 

Hussain, S M................................423, 424, 

................... 425, 1024, 1025*, 1026, 1035, 

..............................1042, 1043, 1052, 1053 

Hussain, S...........................................1054 

Huttunen, K........................................1096 

Hwang, G.......................................... 2088* 

Hwang, J.............................................1839 

Hwang, S........................................... 2177* 

Hwang, Y.................................... 725, 872* 

Hyde, D M.......................................... 575* 

Hyder, M.......................................323, 325 

Hyejin, P........................................... 2175* 

Hyepark, J......................................... 1436* 

Hyllner, J...............................................364 

Hymery, N.............................................184 

Hynes, J............................. 902, 904, 1938* 

Hyrien, O..............................................158 

Hyunggyun, K H............................... 2176* 

Hyvärinen, A.........................................179 

I 

Iahara, T..............................................1158 

Ian, C....................................................823 

Iatropoulos, M J.................................. 531* 

Ibrahim Aibo, D...................... 1912, 1913* 

Ichihara, G..................................302, 1817 

Ichihara, S...........................................1817 

Idehara, K................................ 1450*, 1451 

Igarashi, K...................................370, 2187 

Igawa, Y............................................ 1145* 

Ihara, T................................................1528 

Ihnat, M A......................1308, 1433, 1566 

Iijima, M........................................... 2294* 

Ikarashi, Y...........................................1451 

Ikeda, Y.................................................757 

Illa-Bochaca, I.......................................563 

Illouz, K.................................................817 

Im, H...................................................1882 

Im, R.................................442, 1469, 1616 

Imai, N................................................1160 

Imai, T................................................. 480* 

Imamura, Y.........................................1619 

Imanishi, S.......................................... 276* 

Imran, M................................. 1402, 1556* 

In, M...................................................1750 

Inada, K...............................................1076 

Inayat-Hussain, S H............................1994 

Ingelman-Sundberg, M.........................844 

Ingerman, L...................... 931, 932*, 1159 

Inglese, J................................................880 

Ingram, J T............................................722 

Inman, A O............................. 1029, 1030* 

Inoriza, J M...........................................295 

Inoue, A..............................................1427 

Inoue, K..............................188, 214, 1702 

Inoue, N................................................553 

Inoue, T.................................................361 

Inoue, Y......................................757, 2142 

Inouye, K..............................................196 

Irons, R..................................................346 

Irons, T D.......................................... 2188* 

Irvin, C..................................................296 

Irwin, M..............................................1575 

Irwin, R D.............................................263 

Irwin, R...............................................1572 

Iscan, M.............................................. 402* 

Ise, R.............................. 1427, 1528, 1576* 

Ishida, S................................................758 

Ishidao, T............................................1700 

Ishii, N................................................1203 

Ishimura, R....................................... 1111* 

Ishizaka, T......................................... 1647* 

Islam, N M..........................................1750 

Islam, T S............................................ 569* 

Islam, Z I...............................................618 

Islam, Z............................................... 718* 

Islamzadeh, A.....................................1731 

Isom, G E..........................149, 1830, 2054 

Isom, G...............................................1717 

Israel, L................................................1476 

Isse, T.................................. 199*, 200, 783 

Isukapalli, S...........................................670 

Itagaki, H............................................1447 

Itoh, K.................................................2027 

Itoh, S.................................................2187 

Ivanov, V.....................................874, 1394 

Iwata, H..................................... 553, 2164* 

Iyer, P.................................................. 935* 

Iyer, S S.............................................. 1214* 

Izquierdo-Vega, J A........................... 1133* 

Izumi, H....................................1576, 2149 

Izumi, K..............................................2024 

J 

Jaakola, J.............................................1745 

Jackson, A...........................................1898 

Jackson, D A..........................................887 

Jackson, G R..........................................895 

Jackson, J P..........................................2030 

Jackson, L S.........................................2235 

Jackson, P......................................513, 514 

Jacob, H J..............................................583 

Jacob, R E.......................................... 1078* 

Jacobs, A......................................988, 1455 

Jacobs, J M............................................395 

Jacobs, J.......................................436, 1401 

Jacobs, L M............................................968 

Jacobs, R..............................................1373 

Jacobson, P B......................................1234 

Jacobson-Kram, D............................. 2345* 

Jacobus, J................................... 792, 1678* 

Jacocks, H............................................1117 

Jaeho, C H........................................... 841* 

Jaeschke, H W..................... 626, 835, 836* 

Jagannath, D....................................... 930* 

Jagannathan, S......................................243 

Jagger, C............................................ 2255* 

Jahng, Y..............................308, 309, 1686 

Jahns, G L................................... 674*, 852 

Jakubowski, E M...........................125, 138 

Jakubowski, E........................................128 

James, L.................................................632 

James, R A.............................................510 

James, R C............................... 1475*, 1476 

James, S...................................................68 

Jamieson, J D........................................906 

Jamieson, J........................ 902, 903, 2302* 

Jamil, S..................................................231 

Jan, Y................................................... 135* 

Janes, M S............................................2084 

Jang, J......................................................99 

Jang, S.......................................1217, 1882 

Janovitz, E B..........................................390 

Jansen, K L.......................................... 419* 

Janssen, P............................................2191 

Jaramillo, B...........................................721 

Jarema, K A............................. 1164, 1823* 

Jaskot, R H..........................................1074 

Jaskot, R......................................741, 1504 

Jaspers, I............................297, 1089, 1091 

Jayaraj, K...................................1560, 2078 

Jayaram, B.....................................512, 814 

Jayaraman, S.........................................281 

Jean, Y.................................................2131 

Jedlika, A E..........................................1848 

Jefcoate, C R............................................69 

Jefcoate, C.............................................610 

Jeffay, S..............................................94, 95 

Jeffrey, A M.........................................1932 

Jeffries, H..........................297, 1089, 1091 

Jeffy, B D............................................. 250* 

Jeffy, B.........................................251, 2257 

Jégou, B...............................................1150 

Jehannin, B...........................................909 

Jeng, W............................................. 1536* 

Jenkins, A C........................................ 235* 

Jenkinson, T H....................................1933 

Jennifer, M S.......................................2160 

Jenny, M J............................... 2194, 2198* 

Jenny, M..............................................2184 

Jensen, K.............................................2186 

Jensenius, A..........................................145 

Jeong, E...............................................2323 

Jeong, H..................... 310, 725*, 756, 786, 

787, 788, 841, 872, 1106, 1107, 1122, 1124, 

1434, 1435, 1436, 2175, 2176, 2177, 2179 

Jeong, J................................................1502 

Jeong, S......................................99*, 2131* 

Jeong, T..................... 308, 309, 310*, 1686 

Jeong, Y...............................................1754 

Jergil, M.................................... 364*, 2017 

Jernigan, S L............................................68 

Jessen, B............................902, 1577, 2257 

Ji, J.......................................................1502 

Jia, Q.....................................................715 

Jia, Z.................................................. 2051* 

Jiang, B.................................... 2212, 2213* 

Jiang, G C................................ 1458, 1468* 

Jiang, G.................................................871 

Jiang, H............... 1888*, 1889, 2028, 2047 

Jiang, J.......................................1025, 2060 

Jiang, W..........705, 772, 1067, 1774, 2102 

Jiang, Y..............................490, 2102, 2107 

Jiao, J...................................................1168 

Jiao, Q.................................................2141 

Jiao, Z....................................................124 

Jimenez, B D.........................................170 

Jin, G........................................... 171, 606* 

Jin, H.....................................................380 

Jin, M.......................................... 113, 519* 

Jin, P......................................................776 

Jin, T....................... 455, 588, 1613*, 1615 

Jin, X.............730, 731, 732, 735, 743, 744 

Jin, Y....................................... 2091*, 2331 

Jin-hai, W..............................................144 

Jinot, J.......................................2014, 2123 

Jinsmaa, Y......................................... 1833* 

Jírová, D................................................333 

Jirtle, R L..................................... 20*, 1408 

Jo, C......................................................844 

Jo, W J................................................. 882* 

Joad, J P...............................................1332 

Johanning, K M................................ 1246* 

Johanson, G.......... 755, 1005, 1745, 1778* 

Johansson, N......................................1708 

John, A................................................1395 

John, T N........................................98, 855 

John-Baptiste, A..................................2151 

Johns, D...................................... 421*, 997 

Johnson, A M.................................... 1370* 

Johnson, B....................................207, 210 

Johnson, D A........................................864 

Johnson, D J..........................................286 

Johnson, D R.......................................1241 

Johnson, D............................................580 

Johnson, G A......................................1530 

Johnson, G R......................................1024 

Johnson, G T..................................... 1797* 

Johnson, I...........................................2084 

Johnson, J C..........................................269 

Johnson, J D...... 961, 962*, 971, 972, 2314 

Johnson, J E........................................1874 

Johnson, J........................................... 580* 

Johnson, K A.............................1095, 1805 

Johnson, K............................................102 

Johnson, M...........................................672 

Johnson, N M................................... 1478* 

Johnson, N..................483, 486, 507, 1631 

Johnson, S.............................................131 

Johnson, T L.........................................970 

Johnson, V J.............................. 406, 1312* 

Johnson, V..........................................1497 

Johnson, W D........................... 711, 1936* 

Johnston, C J...................................... 572* 

Johnston, C...........................................391 

Johnstone, A F.................................. 1840* 

Johnstone, A M...................................2268 

Jolly, P E......................................490, 2238 

Jolly, P...................................................507 

Jolly, R A................................. 1209, 1579* 

Jones, A L............................................1949 

Jones, B D...........................................2165 

Jones, C............................................... 890* 

Jones, D P................................ 2046, 2328* 

Jones, J..................................................942 

Jones, K...............................................1637 

Jones, L............................................. 1453* 

Jones, R...............................................1661 

Jones, S J...............................................910 

Jones, S.............................................. 1411* 

Jones, T.........................................30, 1195 

Jong, L.................................................1895 

Jonker, M O.........................................1233 

Joo, H....................................................765 

Jordan, H L........................................ 1919* 

Jordan, S.............................................. 709* 

Jortner, B S........................................ 2270* 

Joseph, A...............................................710 

Joseph, L B....................................146, 839 

Joseph, P.............................................1543 

Joshee, L..............................................2119 

Joshi, C N.......................................... 2069* 

Joshi, P................................................2150 

Joslin, D..............................................1919 

Josse, R.............................................. 1202* 

Jowa, L.............................................. 1638* 

Joy, M S...............................................1894 

Joyce, K...............................................2093 

Ju, J......................................................1112 

Ju, Y H.................................................2231 

Judson, R S............................................239 

Judson, R............................. 236*, 237, 238 

Judy, R.................................................2025 

Julen, E................................................1716 

Julian, G L...........................................1574 

Jumanca, O...........................................978 

Jump, D.................................................852 

Jun, E................................................ 1045* 

Jung, D.................................... 1235*, 1964 

Jung, E............................................... 1217* 

Jung, R................................................1529 

Jutooru, I................................. 2181*, 2182 

K 

Kaarakainen, P....................................1096 

Kababick, J............................................723 

Kabamba, M........................................1744 

Kabilan, S............................................1373 

Kabirov, K K...........................1908*, 1911* 

Kadambi, V J.......................................1222 

Kadiiska, M.........................................1497 

Kadry, A M.................................. 911*, 912 

Author Index 




Author Index 

Käfferlein, H...................................... 1730* 

Kagan, V E............1036, 1392, 1497, 1961, 

..................................................2000, 2056 

Kagan, V..............................441, 634, 1494 

Kaiser, R..............................................1930 

Kakeyama, M......................................1707 

Kakiuchi-Kiyota, S.................... 520*, 1624 

Kakuni, M................................. 219, 1200* 

Kalen, A L..................................2064, 2068 

Kalia, K................................................ 705* 

Kallman, M J..................................... 1363* 

Kaluzhny, Y......................... 326, 334, 883* 

Kamberger, K.........................................131 

Kameda, H..........................................2200 

Kamendulis, L M...................109, 121, 124 

Kamendulis, L.......................................521 

Kamenosono, T...................................1657 

Kamerling, S..........................................385 

Kamimura, S.......................................1158 

Kaminski, N E............163, 164, 189, 2002, 

..................................................2007, 2143 

Kammueller, M...................................2200 

Kamp, H G............................................885 

Kampfrath, T....................................... 223* 

Kan, H L..............................................1429 

Kan, L..................................................1595 

Kanagy, N L....................................... 1256* 

Kanagy, N....................................737, 1253 

Kanazawa, Y........................................1451 

Kandarova, H........................326, 333, 334 

Kane, D.................................................888 

Kaneko, H...........................................1443 

Kaneko, I...............................................493 

Kang, G........................... 728*, 1500, 1878 

Kang, H...............................99, 2084, 2131 

Kang, J L............................................ 1486* 

Kang, J.....................................................99 

Kang, M................................308, 309, 310 

Kang, Y...............2106, 2107, 2327*, 2330* 

Kang-Sickel, J C...................................1560 

Kania-Korwel, I.....................................804 

Kanki, M........................................... 1591* 

Kannan, R.............................................614 

Kannanayakal, T J............................. 1561* 

Kanno, J........................................361, 370 

Kanno, T........................................... 2280* 

Kanthasamy, A G......................1879, 2035 

Kanthasamy, A..........................1879, 2035 

Kanwal, R............................................1099 

Kapal, K...............................................2224 

Kapetanovic, I M........................711, 1895 

Kaphalia, B S...............................349, 1742 

Kaplan, B L...................... 164, 2002*, 2007 

Kaplan, D............................................1595 

Kaplan, M.............................................812 

Kapralov, A..........................................1392 

Karahalil, B...........................................404 

Karakaya, A E...................................... 404* 

Karakaya, A......................................... 488* 

Karanian, D A.....................................1839 

Karchner, S I.................... 553, 2194*, 2198 

Karetsky, V............................................883 

Karey, K P............................................1653 

Karim, A..............................................1501 

Karin, N.................................................436 

Karki, R...............................................1686 

Karlsson, O M................................... 1721* 

Karman, B N.......................................1384 

Karr, C.................................................1777 

Kasamatsu, T.......................................2223 

Kashman, J............................................474 

Kashon, M L..........................................406 

Kassa, Z.................................................474 

Kasten-Jolly, J..........................................16 

Kastrati, I........................................... 1059* 

Kasuga, T.............................................1591 

Katein, A................................... 388*, 1762 

Kato, H................................................1528 

Katoh, M...............................................218 

Katoh, T.................................. 1832*, 2034 

Katti, K K...............................................614 

Katti, K..................................................614 

Katz, H E.............................................1041 

Kauffman, J...........................................946 

Kauffmann, H.....................................2259 

Kaufman, D G.....................................1387 

Kaufman, J D................................176, 750 

Kaur, P.................................................1636 

Kaur, S.................................................1930 

Kaushik, R...........................................2265 

Kavanagh, M.........................................861 

Kavanagh, T J.......176, 287, 357, 369, 750, 

..........................................790, 1602, 1944 

Kavanagh, T........................................1396 

Kavlock, R J................................. 237*, 239 

Kavlock, R.............................................236 

Kawabata, T T.......................................338 

Kawabata, T........ 1329*, 2042, 2147, 2322 

Kawada, T.............................................180 

Kawai, M............................................. 113* 

Kawai, R................................................225 

Kawakami, T.......................................1111 

Kawamoto, T....................... 199, 200*, 783 

Kawamura, S.........................................532 

Kawashima, H.....................................2320 

Kay, D....................................................951 

Kayama, F............................... 1482*, 1618 

Kaynar, A............................................2000 

Kayouka, M............................... 611*, 1317 

Kaysen, G............................................1401 

Kayton, R............................................1816 

Ke, H...................................................1518 

Ke, S......................................................550 

Keane, M...............................................441 

Keating, A............................... 1382*, 1383 

Kedderis, G L.......................................1843 

Keefer, L K.................................1397, 2118 

Keenan, J...............................................456 

Keightley, A.........................................1763 

Keil, D E......................................169, 2139 

Keil, D.................................................1194 

Keith, I................................................1101 

Kejlová, K..............................................333 

Keller, D A.............................................664 

Kellert, M............................................ 382* 

Kelley, M A........................................ 1249* 

Kelly, D P............................................1076 

Kelly, T................................................1762 

Kelman, B J.........................................1779 

Kendall, L..............................................963 

Kendig, E L.............................. 1903, 1904* 

Kendrick, C K.................................... 1464* 

Kendrick, C...........................................948 

Kenfield, J...........................................1526 

Kenna, G.............................243, 258, 1206 

Kennedy, G L........................................542 

Kenneke, J F...................... 283, 396, 1196* 

Kensler, T W........................................ 640* 

Kensler, T..............................................635 

Kent, M N.....................................674, 852 

Kenyon, E M................. 1589, 1629*, 1820 

Kerdine-Römer, S......................1315, 1456 

Kerepesi, L...........................................1582 

Kerger, B D.......... 1472*, 1475, 1476, 1798 

Kerkvliet, N I..................1914, 2006, 2129, 

..................................................2162, 2169 

Kern, P................................................1186 

Kerr, R P....................................2125, 2127 

Kerr, S..................................................1550 

Kerzic, P.............................................. 346* 

Keshava, C.... 912, 913, 2013, 2015, 2016* 

Keshava, N.......... 2015, 2016, 2348*, 2353 

Keun, H C.................................1601, 1605 

Keun, H...............................................1606 

Keyser, R.................................. 1207*, 2247 

Khalil, H..............................................2153 

Khambatta, Z S.....................................897 

Khan, F M.....................................349, 772 

Khan, I A...............................................881 

Khan, M................................79, 111, 2124 

Khandelwal, A R.................................2212 

Khim, J..................................................951 

Kibriya, M G.......................................1966 

Kiewitt, M S........................................1423 

Kijtawornrat, A....................... 1645*, 1650 

Kikuchi, K.............................................227 

Kilinc, E............................................... 746* 

Killen, M W........................................1673 

Kilty, C..................................................456 

Kim, C.................................................2146 

Kim, D J.............................................. 530* 

Kim, D.....................308, 1502, 1750, 2146 

Kim, E............... 99, 353, 553*, 2131, 2164 

Kim, G.........................................308, 1063 

Kim, H H........................................... 1107* 

Kim, H S..............................................1486 

Kim, H............................. 756*, 1440, 1595 

Kim, J........ 309*, 310, 438, 442, 442, 1882 

Kim, N.................................................1616 

Kim, S............418*, 543, 798, 1068, 1127*, 

............................ 1422*, 1440, 2311, 2320 

Kim, T............................................... 2144* 

Kim, Y............................... 302, 442*, 1750 

Kimbell, J S.......................... 993*, 994, 995 

Kimber, I....... 42*, 652*, 655*, 1310, 1444, 

............................................................1446 

Kimmel, C.............................................632 

Kimotsuki, T.......................................1647 

Kimura, S............................................2142 

Kimura, T............................................1584 

Kind, J............................................... 1086* 

King Heiden, T C..................................426 

King Heiden, T.................................. 1161* 

King, A L............................................. 843* 

King, B M............................................ 314* 

King, C..................................................702 

King, K A.................................................72 

King, M............................................... 644* 

Kinoshita, D..........................................183 

Kinsey, G R..........................................2061 

Kirby, P A..............................................818 

Kirby, P.............................................. 1079* 

Kirchner, S.................................2249, 2256 

Kirk, C.................................................2252 

Kirk, M................................................ 338* 

Kirk, S A............................................ 2134* 

Kirkpatrick, D T....................................213 

Kirkpatrick, D...........................1240, 2010 

Kirkpatrick, J B....................................2326 

Kirkpatrick, J.........................................494 

Kirman, C R........................................1783 

Kirman, C......................................... 1784* 

Kiser, R C................................... 134, 1546* 

Kisin, E.................. 441*, 1031, 1494, 1497 

Kissling, G E.........457, 515, 516, 517, 518, 

....................................................878, 1002 

Kissling, G...................................406, 1019 

Kitajima, S.............................................370 

Kitchin, K T.........................................1587 

Kito, G.................................................1657 

Kittelson, D...........................................745 

Kiyama, R............................................1427 

Kiyosawa, N........................................1573 

Kjaer, T................................................1452 

Klaassen, C D.......549, 617, 824, 825, 829, 

................................960, 1946, 2030, 2032 

Klaassen, C..........................815, 827, 2020 

Klaassen, J...........................................1526 

Klapper, D G.......................................1560 

Klaunig, J E...........................109, 121, 124 

Klaunig, J..............................................521 

Klausner, M.......326*, 334*, 335, 341, 883, 

..............................................................895 

Kleeberger, S R............... 570*, 638*, 1281* 

Kleeberger, S..........................................115 

Klei, L R................................... 1969, 2217* 

Kleiner, H E............................. 1066, 2027* 

Kleiner, H............................................1065 

Kleinjans, J........................................ 1992* 

Kleinman, M T...................732*, 733*, 753 

Kleinman, M.........................................734 

Kleinow, L.............................................523 

Klevit, R E.............................................646 

Kligerman, A.......................................2015 

Klinefelter, G R...................................1155 

Klinge, C M...........................................414 

Klingelhutz, A.....................................1678 

Klotzbach, J M......................................933 

Klotzback, J...........................................921 

Knaak, J B......................................267, 269 

Knapp, J............................................ 1533* 

Knapton, A............................................456 

Knerr, S.............................................. 1221* 

Kng, I..................................................1697 

Knight, A W........................................2254 

Knighten, B.........................................1040 

Knipping, E.........................................1503 

Knobloch, T J........................................873 

Knowlton, M.........................................584 

Knuckles, T L.................... 738, 739, 1253* 

Knudsen, E............................................343 

Knudsen, G A.............................. 964*, 968 

Knudsen, T B............................. 239*, 1968 

Knudsen, T..................................237, 1539 

Ko, B....................................................1750 

Ko, M S................................................1968 

Ko, M................................................ 2151* 

Kobayashi, A..................................... 2223* 

Kobayashi, D K...................................1757 

Kobayashi, M.................... 180, 757*, 1203 

Kobayashi, N..................................... 1495* 

Kobayashi, T.........................................188 

Kobayashi, Y..................................... 2109* 

Kobayasi, N.........................................1496 

Kobielush, B...................................... 2161* 

Kobylewski, S E................................... 544* 

Kobylewski, S......................................1418 

Kocbach, A..........................................1085 

Kocer, B.................................................404 

Koch, D C...........................................1914 

Kochar, J.................................. 1812*, 1983 

Kock, N D......................................116, 876 

Kodama, Y.............................................361 

Kodavanti, P R..........................1115, 1957 

Kodavanti, P.........................................101 

Kodavanti, U P........741, 1072, 1074, 1654 

Kodavanti, U.......................................1586 

Koduri, S...............................................860 

Kodvanti, U P......................................1038 

Koenig, J Q........................................ 1461* 

Koh, W................................................2146 

Kohut, M.............................................2239 

Kioke, E............................................... 188* 

Koike, E.................................................214 

Koike, M................................................329 

Koizumi, S...........................................1611 

Koizumi, T..........................................2243 

Kojima, C.......................................... 1633* 

Kojima, H.......................................... 1451* 

Kolaja, K L............................... 1338, 1340* 

Kolaja, K.....1266, 1575, 1651, 1896, 2249, 

................................................ 2256*, 2306 

Kolenda-Roberts, H................. 1892*, 1893 

Koller, L.........................................925, 929 

Kolli, V................................................ 485* 

Kolluri, S K................................1914, 2162 

Komissarova, E V................................1306 

Kommineni, C....................................1494 

Komocsar, W J.................................... 193* 

Kondo, Y...............................................362 

Kondraganti, S R............................... 1067* 

Kondraganti, S.................................... 349* 

Konduri, S...........................................1417 

Konduru, N V.....................................1036 

Kong, T............................................... 637* 

Kong, X Q................................... 432, 821* 

Konig, R................................................349 

Konishi, M..........................................1215 

Kono, H.................................................221 

Koo, E.......................................... 102, 444* 

Kopec, A................................................674 

Kopf, P G................................. 2206*, 2207 

Kopp, E............................................... 479* 

Kopp, S................................................1660 

Koppula, S........................................... 345* 

Kopras, E.............................................1189 

Kopylev, L.............................................914 

Kordas, K.............................................1767 

Kornbrust, D J....................................... 40* 

Korourian, S..........................................844 

Korte, J J................................................103 

Korte, J..................................................106 

Korte, S.................................... 2208, 2296* 

Korzeniowski, S H...............956, 958, 1163 

Kosaka, N................................ 1447, 1448* 

Koshlap, K M......................................2078 

Koshlukova, S E.................................. 284* 

Koshy, L............................................ 1195* 

Kosian, P...............................................106 

Koski, K............................................. 1827* 

Koslosky, J.............................................742 

Kosyk, O........................................221, 831 

Kotani, Y.............................................2280 

Kouadio, J H..........................................700 

Kourelis, M..........................................2122 

Kousoulas, K G..........................1999, 2201 

Kovalchuk, O...... 1060, 1064*, 1416, 1910 

Kovochich, M..................................... 437* 

Kowal, M V......................................... 459* 

Kowalski, G...........................................583 

Kowalski, R.........................................2309 

Koyama, N..........................................2243 

Koza-Taylor, P.......................................840 

Kozlovsky, J...........................................243 

Kozubik, A...........................................1216 

Kozul, C D..................... 1308*, 1433, 1566 

Krčmár, P...............................................868 

Kraeling, M E.................................... 1032* 

Kraft, A D.......................................... 1824* 

Kraft, J...................................................131 

Kramer, K..............................................815 

Kramer, N I......................................... 896* 

Kransler, K M...................................... 791* 

Kransler, K.............................................805 

Krantz, Q T.........................................1820 

Krantz, T.............................................1821 

Kravtzoff, R....................................... 1920* 

Kraynie, A.............................................445 

Krcmar, P.............................................1216 

Kreider, M L...................................... 1471* 

Kreiling, R...............................................45 

Krieger, R I..................................285, 1172 

Krieger, S M............ 529, 974, 1084*, 1095, 

............................................................1805 

Krishnan, K..........51, 969, 997, 998, 1004, 

...................................... 1005*, 1016, 1180 

Krishnan, P....................................... 1065* 

Krishnaraj, R..................................... 1344* 

Kristian, T...........................................1842 

Krival, S R.......................................... 1602* 

Krogstad, F.............................. 1190, 1248* 

Krone, P..............................................1876 

Krsmanovic, L S....................................233 

Kruhlak, N L.................................242, 249 

Krumpf, S W.......................................2340 

Kuang, S..............................................1214 

Kubaszky, R.........................................2299 

Kubilus, J...............................................334 

Kubosaki, A...........................................495 

Kubota, A............................................2187 

Kubota, R........................ 363, 1056*, 1899 

Kubota, S.............................................1158 

Kudo, Y...............................................2142 

Kueberuwa, S S.................................... 924* 

Kuester, R K...................................964, 968 

Kuhl, A.................................................. 58* 

Kuhlman, M A....................................1134 

Kuiper, H.............................................2241 

Kuk, R................................................ 1132* 

Kulkarni, S R....................................... 317* 

302 




Kulkarni, S..........................................2028 

Kullman, S W......................................2192 

Kullman, S............................................901 

Kulpa-Eddy, J................................891, 988 

Kumagai, S............................................495 

Kumar, E...............................................523 

Kumar, S..............................................1697 

Kumari, P..............................................763 

Kumsher, D M.......................................103 

Kunak, S C............................................402 

Kung, T...............................................2197 

Kunos, G.............................................1936 

Kunze, G.............................................1167 

Kuo, Y................................................... 75* 

Kuprat, A P................................1020, 1373 

Kuprat, A...............................................992 

Kurotaki, T..........................................2280 

Kurt, B...................................................402 

Kurz, M.................................................675 

Kushida, M............................................532 

Kushleika, J V............................1104, 1766 

Kuskowski, M........................................228 

Kusnadi, A...........................................2170 

Kusumoto, C.......................................1952 

Kutanzi, K............................... 1060*, 1064 

Kuwagata, M..................................... 1706* 

Kuwahara, H.........................................329 

Kuykendall, J R...................................1794 

Kwekel, J C.............................. 1424*, 1573 

Kwitek, A...............................................583 

Kwon, J...............................................1882 

Kwon, R..............................................1839 

Kyle, K.................................................1662 

Kyungjin, L......................................... 786* 

L 

La Merrill, M....................................... 688* 

Labenski, M T.............................468, 1412 

Labotka, R...........................................1911 

Lacasaña, M........................................1473 

Lackey, L.............................................1463 

Lacourse, W R.......................................696 

Ladics, G...................................2228, 2229 

Ladu, J.................................................2264 

LaForge, Y...........................................1201 

Lafuente, A.......................................... 177* 

Låg, M...........................................344, 747 

Lagadic-Gossmann, D...........................344 

Laha, T J..............................................1960 

Lai, D Y............................................. 2354* 

Lai, I.................................................... 234* 

Lai, X...................................................1049 

Lai, Z.....................................................181 

Laine, O................................................179 

Lainée, P.................................... 466, 1841* 

Laiosa, M D....................................... 2005* 

Lake, S G.............................................2325 

Lala, G.................................................2232 

Lalko, J.................................... 1453, 1555* 

Lam, K....................................... 226, 1854* 

Lam, T T..............................................1906 

Lamar, P C.....................................378, 458 

Lamartiniere, C................... 563, 564, 565* 

Lambert, G............................................870 

Lambert, J C..................................257, 921 

Lambert, J D...................................... 1112* 

Lambrechts, N......................................337 

Lambright, C R.......................................62 

Lambright, C S..................................56, 90 

Lammers, J............................................577 

Lampert, B M......................................1902 

Lampi, M A.........................................1232 

Landauer, M R..................................... 136* 

Landenberger, B D..............................1187 

Landolph, J R.........................1284*, 1287* 

Landon, C D....................................... 802* 

Landsiedel, R........... 443, 885, 1400*, 1553 

Landvik, N............................................344 

Lanevschi-Pietersma, A.......................1919 

Langford-Pollard, A D.........................1240 

Langston, J L....................................... 148* 

Langton, K............................................261 

Lanham, D................................2152, 2154 

Lanham, K A....................................... 819* 

Lanning, L L.......................................2307 

Lantz, C...............................................1101 

Lantz, R...............................................1634 

Lanyon, R............................................1799 

LaPierre, A...........................................1796 

Lapin, C A.............................................977 

Lapinskas, P J.......................... 1201, 1656* 

LaPoint, T...........................................1245 

Lappalainen, M H............................... 179* 

LaPres, J J............................................1420 

LaPres, J...............................................2092 

Larangé, A...........................................1456 

Larsen, M..............................................610 

Lash, L H..................................... 447*, 448 

Lashley, S............................................1738 

Laskin, D L........135, 146, 839, 1545, 1954 

Laskin, J D..........135, 146, 231, 683, 1545, 

..................................................1954, 2049 

Laskin, O...................................1201, 1656 

Lasley, S M........................................ 1871* 

Lassen, N.............................................1951 

Last, J A...............................................1087 

Latado, H..............................................698 

Latendresse, J R...............................97, 627 

Latimore, M........................................1639 

Latorre, V............................................2203 

Lattier, D.............................................2199 

Lau, A................................................ 1680* 

Lau, C...........541, 1374, 1428, 1534, 2018, 

............................................................2025 

Lau, S S......................................1412, 2070 

Lau, S.................................. 468, 469, 470* 

Lau, Y S...............................................1874 

Laub, L B........................................... 2165* 

Lau-Cam, C...........................................713 

Lauer, F...............................................1037 

Laulederkind, S.....................................583 

Laumbach, R.........................................742 

Laurent, M..........................................1181 

Lauridsen, H.......................................2264 

Laurie, C.............................................1704 

Laurie, H.............................................1849 

Laursen, S............................................1928 

Lausted, C...........................................1916 

Lawlor, T E..........................................2245 

Lawrence, B.................537, 606, 686, 1147 

Lawrence, C..........................................651 

Lawrence, D A.............................178, 1039 

Lawrence, D..................... 3*, 13*, 16*, 608 

Laws, S C.................................................96 

Laws, S..................................................281 

Lawson-Evi, P S.....................................716 

Lawton, M....... 384, 385, 840, 1267*, 1577 

Laynes, L........................................... 1664* 

Lazaro, C..................................... 323, 325* 

Le Borgne, G.........................................909 

Le, A..............................................346, 981 

Le, H H................................................1711 

Le, H T....................................................49 

Le, K....................................................1097 

Le, Q H.............................................. 1695* 

Leach, G J............................................1170 

Leach, G..............................................2100 

Leach, M W.........................................1909 

Leakey, J E.....................................710, 719 

Leamy, L J.............................................802 

Learn, D B......................... 202, 203*, 1169 

Lease, M................................................380 

Leasure, L.......................................... 1874* 

Leatherberry, G...................................1906 

Leavesley, H B................. 149*, 1830, 2054 

Leavesley, H........................................1717 

LeBaron, M J..................................... 1429* 

LeBlanc, G A.................................89, 1250 

Lebofsky, M...........................................836 

LeCluyse, E L.................................319, 551 

Lecureux, L W..................................... 856* 

Ledbetter, A D............741, 748, 749, 1072, 

..................................................1074, 1654 

Ledbetter, A.........................................1586 

Ledoux, V A...................................... 1705* 

Lee, A W..............................................1423 

Lee, B.........................................1217, 1882 

Lee, C S...............................................2312 

Lee, D................................................ 2037* 

Lee, E Y............................................. 1889* 

Lee, E.................240, 310, 845, 1506, 1686 

Lee, F W..............................................1222 

Lee, H A............................................ 1402* 

Lee, H K...............................................1287 

Lee, H S...............................................1486 

Lee, H W.............................................1486 

Lee, H...................... 783, 798, 1882*, 2323 

Lee, J S....................................... 834*, 1428 

Lee, J............553, 820, 1220*, 1506, 2205* 

Lee, K M......................................395, 1757 

Lee, K P...............................................1076 

Lee, K............ 787*, 841, 1106, 2177, 2323 

Lee, L................................................. 2321* 

Lee, P J................................................ 621* 

Lee, P........................................... 384, 714* 

Lee, S............ 15, 308, 309, 310, 433, 543*, 

.......................613*, 703, 798, 1440, 1750* 

Lee, T...........................88, 710, 1053, 1430 

Lee, Y..................................................1506 

Lefebvre, D E.........................................861 

Lefebvre, K A..................................... 2191* 

Legare, M E.............280, 1321, 1832, 2034 

Legare, M............................................1322 

Legaspi, M...........................211, 212, 2317 

Lehman-McKeeman, L D....................1605 

Lehman-Mckeeman, L D......................390 

Lehman-McKeeman, L D......................856 

Lehman-McKeeman, L........472, 828, 849, 

..................................................1571, 1601 

Lehmann, D W...................................1668 

Lehmann, J R......................................1442 

Lehmann, L........................................ 806* 

Lehmler, H J........................................2068 

Lehmler, H.......................... 312, 804*, 808 

Lei, G.....................................................828 

Lei, L............................... 455*, 1613, 1615 

Lei, P...................................................2178 

Lei, X.....................................................825 

Leibold, E............................................1603 

Leikauf, G D........................................1609 

Leikauf, G...........................................1130 

Lein, P J.....................................1705, 2278 

Lein, P.................................................2264 

Leinweber, B D......................................470 

Leisewitz, A V.....................................1411 

Leitão, J G...........................................1766 

Leitner, H M...................................... 2065* 

Leland, I................................................106 

Lema, S................................................1239 

Lemasters, J J.........................................836 

Lemay, F................................................500 

LeMay, S..............................................1054 

Lemen, J.............................................. 494* 

Lenz, J.................................................1380 

Leonard, J..............................................676 

Léonard, M....................................... 2315* 

Leonard, S S................................300, 1501 

Leonard, S...........................................1031 

Leopold, N.............................1704*, 1849* 

Lepene, B S........................................ 1485* 

Leroux, B G.........................................1766 

Leroux, T...............................................500 

LeSauteur, L..............................1763, 2153 

Letizia, C................................... 506*, 1453 

Leuillet, S..................................1548, 1920 

LeValley, S.............................................392 

Levallois, P..........................................1792 

Leverette, R D................................... 1684* 

Levesque, P C......................................1341 

Levi, N...................................................430 

Levin, E D............................... 2262*, 2275 

Levine, K...............................516, 517, 518 

Levitskaia, T G.................................. 1635* 

Levitt, P.................................................691 

Lew, B j................................................ 537* 

Lewandowski, T A....................950*, 1327* 

Lewin, G........................................... 1773* 

Lewin-Koh, S.........................................262 

Lewis, A............................................. 1188* 

Lewis, E M.......................1525, 1527, 1531 

Lewis, J A............................................. 887* 

Lewis, J................................................1182 

Lewis, K...............................................2111 

Lewis, R W........................................ 1687* 

Lewis, S M.....................................710, 719 

Lewis, T L............................................ 166* 

Li, A A.................................................1843 

Li, A P..................................................1201 

Li, B.....................................................1065 

Li, C I.................................................. 642* 

Li, C...................... 777*, 1646, 1723, 2153 

Li, D............................................583, 1341 

Li, F..................................................... 975* 

Li, G....................................................1882 

Li, H....................................................1615 

Li, J J....................................................1490 

Li, J........................................................580 

Li, L........149, 394, 398, 1396, 1717, 1830, 

................................................ 2054*, 2068 

Li, M............................................ 119, 182* 

Li, N.................................................... 944* 

Li, Q.........180*, 525*, 728, 732, 743, 2052 

Li, Q.................................................... 731* 

Li, R.....................................................1202 

Li, S...................................607, 1138, 1472 

Li, T................................... 400*, 410, 1859 

Li, W....................... 419, 482, 1103*, 1817 

Li, X............................................645, 2219 

Li, Y...... 243, 285, 471, 1172*, 1222, 1640, 

..................................................2051, 2160 

Li, Z......................................... 1568*, 2273 

Liang, L...............................................2058 

Liang, Y W..........................................1774 

Liang, Y............................................. 1615* 

Liao, J..........................................496, 2290 

Liao, W..................................................383 

Liccione, J...........................................1789 

Lichtenstein, S....................................2279 

Lickteig, A J...........................................822 

Lieblong, B............................................471 

Liebsch, M............................................333 

Liguori, M J..................... 847, 1432, 1594* 

Liguori, M...........................................1208 

Likins, A M........................................ 2260* 

Lili, T.....................................................507 

Lim, E..................................................2215 

Lim, F..................................................1574 

Lim, J................................................. 1956* 

Lim, K.......................................1045, 2205 

Lim, P L...............................................1213 

Lim, S..........................................500, 1625 

Lima, A................................................ 401* 

Limoli, C L..........................................1385 

Limón Pacheco, J H............................1947 

Lin Seng, W........................................1723 

Lin, B...................................................1916 

Lin, C....................................................793 

Lin, G....................................................894 

Lin, J J.................................................2232 

Lin, K....................................................690 

Lin, L...................................................1518 

Lin, P................................................... 793* 

Lin, S.....................................................453 

Lin, T...................................................2082 

Lin, W...................................................723 

Lin, X....................................................763 

Lin, Y................................ 348, 679*, 1752 

Lindberg-Livingston, A.................103, 106 

Lindblom, P..........................................823 

Lindenschmidt, R...............................1326 

Lindon, J C.........................373, 472, 1605 

Lindon, J...............................................397 

Lindquist, N........................................1721 

Lindstrom, A B....................................1374 

Lingenfelter, R A............................... 1731* 

Linkov, E...............................................255 

Linkov, I...................................... 255, 438* 

Linn, J...................................................474 

Linney, E.............................................2262 

Lipinski, R J....................................... 1128* 

Lippmann, M................730, 731, 735, 743 

Lipscomb, J................................... 10*, 271 

Lipshultz, S E............................ 456, 2336* 

Lipsky, M M..........................................589 

Lisek, R................................................1869 

Liston, A................................................740 

Liston, V...............................................862 

Little, S B...............................................246 

Little, S..................................................247 

Litwack, B...........................................2279 

Litzenberger, B A.......................2152, 2154 

Liu, B......................................... 119, 2104* 

Liu, C................................................ 1194* 

Liu, D..........................................550, 1916 

Liu, F...................................................1817 

Liu, G.............................. 679, 1752, 1753* 

Liu, J......... 1213, 1303, 1397*, 1617, 1632, 

............................................................1880 

Liu, K.............................................622, 900 

Liu, L.........................................1055, 1600 

Liu, N..................................................1222 

Liu, Q................................................ 1856* 

Liu, R.....................................................383 

Liu, S......................................... 691, 2178* 

Liu, X........................................1630, 1644 

Liu, Y......................312*, 947*, 1148, 2104 

Liukkonen, B.........................................474 

Lo, D C................................................1824 

Loader, J................................................160 

Lobenhofer, E K..................................1572 

Loch-Caruso, R.........................1520, 1521 

Locke, D................................................923 

Lockshin, R.........................................2073 

Lodiot, A.............................................1841 

Loertscher, J...................................... 2075* 

Loftin, S T.............................................446 

Logue, B A.............................................159 

Logue, B................................................161 

Loguinov, A...........................................882 

Loh, H H...............................................546 

Loke, W.................................................137 

Lolly, J L..............................................1650 

Lolly, J.................................................1645 

Lonchampt, M....................................1548 

Long, S................................................1193 

Looker, D............................................1898 

Looser, R.............................................1603 

LoPachin, R....................................... 1811* 

López Carrillo, L.................................1767 

Lopez, P...............................................1767 

Lopez, W L..........................................1237 

Lopez-Carrillo, L T....................1419, 2076 

Lopez-Gonzalez, L................................315 

Lorang, E...............................................989 

Lord, P G.............................................1268 

Lordo, R..............................................1660 

Lorenzana, R.........................................597 

Lorenze, M..........................................1575 

Losa, S M........................................... 2268* 

Lotti, M...............................................1829 

Lou, I...................................................1374 

Lou, S....................................................155 

Louden, C...................................388, 1762 

Lough, J...............................................1532 

Louhead, R............................................462 

Loveday, K............................................444 

Loveless, S E................................542, 1163 

Lovik, M.......................... 656*, 1441, 1445 

Low, L K..............................................1182 

Author Index 




Author Index 

Lowe, E R.................................. 313*, 1000 

Lowe, E................................................1018 

Lowinger, J J..........................................262 

Lowit, A B...........................................2272 

Lowit, A............................................. 2012* 

Lowry, G V..........................................1055 

Lu, B....................................................1577 

Lu, H..............................825*, 2007*, 2143 

Lu, I.......................................................584 

Lu, J.......................................................849 

Lu, S.................................................. 2257* 

Lu, X...................................................1598 

Lu, Y..........................................1031, 1499 

Luben, T................................................989 

Lubinski, J.............................................766 

Lucas, B...............................................1053 

Lucas, S...............................738, 739, 1253 

Lucchi, L.............................................1547 

Lucero, J........................................738, 739 

Luchtel, D L..........................................750 

Luderer, U...........................................1385 

Ludewig, G...........234, 792, 795, 808, 818, 

..................................................1678, 1679 

Luebke, R W................................ 174, 628* 

Luecke, S........................................... 2166* 

Lui, J....................................................1768 

Luijten, M...........................................1535 

Luis, H S..............................................1766 

Lukamowicz, M..................................2244 

Luke, A M.............................................. 83* 

Luke, N S........................................... 1008* 

Luke, N................................................1194 

Lulla, A.............................................. 1129* 

Lumeng, C N................................735, 744 

Lumley, L A...................................125, 148 

Lumley, L.................................. 131*, 2279 

Lumpkin, H L.......................................139 

Lumpkin, M...................................... 1006* 

Lund, A K.................................... 738, 739* 

Lund, A...............................................1253 

Lunstra, D D.......................................1144 

Luo, B.................................................. 420* 

Luo, J.....................................................428 

Luo, W................................................ 277* 

Luque, B............................................ 1850* 

Lust, R M.............................................1258 

Luster, M I...................................406, 1312 

Luthe, G...................................... 792*, 800 

Luther, E.............................................2242 

Lutz, U..................................................382 

Lutz, W K..............................................382 

Luxford, E.............................................512 

Luyendyk, J P...................................... 837* 

Luzhna, L.......................................... 1910* 

Ly, J...........................................1651, 2306 

Lyke, D F.............................................2288 

Lykkesfeldt, A.....................................1389 

Lynch, A..............................................2244 

Lynch, S........................................562, 567 

Lynes, M.............................171, 178, 1760 

Lyon, J.................................................2202 

Lyubimov, A V..........................1908, 1911 

M 

Ma, C....................................................343 

Ma, D....................................................774 

Ma, H.................................................... 79* 

Ma, J K................................................1513 

Ma, J Y............................................... 1513* 

Ma, Q.................................................. 636* 

Ma, T................................................... 546* 

Ma, W...................................................715 

MacAulay, E...................................... 1110* 

MacCoss, M J........................................646 

Macdonald, T........................................975 

MacGregor, J.......................................1786 

Machado, A...........................................210 

Machala, M....................... 811*, 868, 1216 

Machemer, T................... 858, 2137*, 2148 

Machida, K............................................227 

Macias, J..............................................1131 

Maciewicz, R A....................................1891 

MacIsaac, B....................................... 1757* 

Mack, C...............................................1667 

MacKenzie, S A................................... 201* 

Mackman, N.........................................837 

Macmillan-Crow, L.................................66 

MacPhail, R C......................... 1164*, 1823 

MacPhail, R.....................2186, 2188, 2189 

MacPherson, L M................ 533*, 534, 535 

MacPherson, M.....................................294 

MacQueen, B......................................1033 

Madan Mohana Rao, G.................... 1942* 

Maddatu, T P........................................585 

Madden, M C.........629*, 738, 1093, 2044* 

Maddox, C.......................................... 818* 

Maddox, J F.......................837, 1912, 1913 

Maddox, J R..........................................487 

Madhukar, B V.................................. 1413* 

Madl, A K...................... 1458, 1468, 1505* 

Madren-Whalley, J S........................... 143* 

Maejima, T............................................225 

Maekawa, A.........................................1140 

Magnuson, B..................................... 2232* 

Maguire, M...........................................691 

Mahaffey, K R...................................... 590* 

Maher, J M..........................................2030 

Mahfouz, A............................. 1981, 1982* 

Mahle, D.....................................377, 1761 

Ma-Hock, L.........................................1400 

Maibach, H I.........................................505 

Maibach, H.........................................1558 

Maier, A........................... 4, 499*, 986, 987 

Maier, C S............................................1959 

Maier, C..............................................1929 

Maitre, A.............................................1460 

Majkova, Z........................................ 2215* 

Major, M A..........................................1170 

Major, R M............................................949 

Makhaeva, G F.................................. 2291* 

Maki, E................................................1451 

Makin, A...........................................1, 205 

Makley, M K................................ 674, 852* 

Makori, N............................................1526 

Makris, S L..........................................2123 

Makris, S........................... 632*, 914, 2014 

Makriyannis, A...................................1839 

Malarkey, D E......................................2174 

Malarkey, D.............741, 1072, 1892, 1893 

Malergue, F.........................................2246 

Malichky, P E...................................... 864* 

Malladi, S..............................................468 

Mallapati, R...........................................335 

Malle, E.................................................849 

Malley, L A........................201, 2230, 2233 

Mally, A..................................... 528, 1269* 

Maltby, C............................................1740 

Manabe, S...................................225, 1647 

Manautou, J E..............320, 624, 840, 960, 

..................................................1839, 2029 

Mandakas, G.........................................763 

Mandavilli, B S................ 342, 2081, 2253* 

Mandella, R.........................................1924 

Mandimika, T.....................................2241 

Manfred, B............................................454 

Mangham, A.........................................426 

Manion, J S...........................................133 

Manjanatha, M G............................. 1430* 

Manjanatha, M M.................................383 

Manjanatha, M.......................................55 

Manji, H..............................................1936 

Manley, A............................................1786 

Mann, J.......................................134, 1546 

Mann, K K............................... 1305, 2122* 

Mann, P C.................................1892, 1893 

Mannix, M........................................ 1182* 

Mantell, L.............. 299*, 2071, 2073, 2132 

Mantena, S K.........................................843 

Manya, M............................................2151 

Manzan, M A...................................... 163* 

Mar, T F...............................................1461 

Marafante, E............................................48 

Maraganore, D...................................... 22* 

Marchan, R......................................... 351* 

Marchandeau, J.............................675, 676 

Marchant, C A.................................... 261* 

Marchant, C..........................................240 

Marchitti, S A.......................... 1950*, 1951 

Marcoux, S..........................................2122 

Marczynski, B......................................1730 

Marengo, J..........................................1237 

Maresh, J..................................... 207*, 210 

Margolis, J.............................................963 

Maria-Engler, S S.................................2173 

Marien, K............................................ 601* 

Mariën, K..............................................693 

Marini, J..............................................1160 

Marinovich, M..........................1046, 1547 

Marit, J..................................................752 

Marlowe, J.............................................343 

Marriott, M...........................................333 

Marroquin, L D................... 902, 903*, 906 

Marroquin, L.......................................2302 

Marroquin-Cardona, A G................... 483* 

Marroquin-Cardona, A...............486, 1631 

Marsais, J.............................................1548 

Marsden, A..................................859, 1205 

Marsh, C.............................................2245 

Marshall, B..........................................2296 

Marshall, N B.................................... 2006* 

Marshall, S.......................................... 271* 

Martel-Pelletier, J..................................232 

Marti, M J..............................................295 

Martin, C.......................................... 1318* 

Martin, E J......................................... 1480* 

Martin, E.............................................2141 

Martin, G S.........................................1109 

Martin, G..............................................464 

Martin, K............................................. 702* 

Martin, M D........................................1766 

Martin, M T................................ 238*, 239 

Martin, M....................236, 237, 464, 1184 

Martin, P.........................1160, 1737, 2141 

Martin, R C...........................................414 

Martin, R...................................1075, 1662 

Martin, S A...................... 948*, 1100, 1464 

Martines, P M.....................................2172 

Martinez, E J..................................... 1880* 

Martinez, M A...................759, 2225, 2287 

Martinez, M................................759, 1725 

Martinez-Larrañaga, M R......... 759*, 2225, 

............................................................2287 

Martinez-Pacheco, M.............. 1642*, 1643 

Martin-Nims, T...................................1258 

Marty, M A....................................934, 936 

Marty, M.......................................979, 980 

Martyniuk, C J........................ 1231*, 2271 

Marusov, G................................ 178*, 1760 

Marvanová, S........................................868 

Masiello, L M........................................439 

Masiello, L.............................................436 

Mason, R P..........................................2060 

Mason, R...........................634, 1497, 1633 

Mason, S E..................................478, 1402 

Mason, S.............................................1519 

Massa, P T.............................................608 

Massaro, R M......................................2173 

Massey, E D.........................................2079 

Masterson, J........................................1498 

Mastin, J P......................................... 2043* 

Mastin, P J................................... 664, 667* 

Mastroberardino, P........................... 2040* 

Mastrocco, F........................................1301 

Masutomi, N.......................................1751 

Matalonis, S........................................ 102* 

Matei, A............................................ 2095* 

Materna, B............................................981 

Matherly, C M.........................................91 

Mathesius, C A.................................. 2228* 

Matheson, J.........................................1455 

Mathew, L K....................1978, 2162, 2196 

Mathieu, L.......................................... 505* 

Mathis, J M.........................................1066 

Matis, S............................................... 243* 

Matson, C...........................................2184 

Matsumoto, M....................................1157 

Matsumoto, N............... 1215, 2311*, 2320 

Matsumoto, S........................................519 

Matsumoto, Y.....................................1746 

Matsumura, K.......................................219 

Matsuo, J.............................................1657 

Matsuo, N...........................................2149 

Matsuo, T..............................................877 

Matsura, T......................................... 1952* 

Mattes, W B.................................11*, 631* 

Matthews, C........................................1842 

Matthews, E J.................... 242, 249*, 1716 

Matthews, J L.................................... 1002* 

Matthews, J................. 533, 534*, 535, 779 

Mattie, D R..........................424, 425, 1025 

Mattingly, C J..............................259, 1581 

Mattingly, C........................................ 241* 

Mattsson, J L.......................................1018 

Mattuck, R........................................ 1466* 

Matz, C............................................. 1876* 

Matzke, M M..................................... 1743* 

Mauderly, J L............................. 738, 1071* 

Maull, E A................................... 562*, 567 

Maurer, G..............................................399 

Maurissen, J P...........................1095, 1805 

Mauthe, R......................................... 1359* 

Mauzy, C............................................. 377* 

Mawn, M P............................................957 

Mayeno, A N........................... 1021, 1022* 

Mayer, A M....................................... 1234* 

Mayer, G................................... 773, 1414* 

Mayhew, C............................................343 

Maynard, A.........................................1497 

Maynard, M S.......................................277 

Maynard, M........................................ 272* 

Mazur, C S...................................283, 1196 

McAllister, D.......................................1040 

McBride, S J.................................878, 1668 

McBride, S...........................................1019 

McBride, W H.....................................1670 

McCabe, M J.............................2005, 2112 

McCain, W C.................................... 2100* 

McCallister, M M..................................691 

McCallum, G P...................................1854 

McCarley, D..........................................988 

McCarroll, N.......................................2015 

McCart, E A...........................................136 

McCarthy, M.........................................430 

McCartney, A E................................... 355* 

McCarty, J D............................... 270*, 277 

McCash, C L.........................................206 

McCaskill, M..................................... 1242* 

McCausland, D.....................................380 

McClanahan, M............................925, 929 

McClure, P R.......................................1006 

McClure, P..................................913, 2013 

McCluskey, J.......................................1797 

McConnachie, L A..............................1602 

McConnell, E E.....................................927 

McConnell, E........................................925 

McCormack, A L.................................2040 

McCormick, D L....................... 711*, 1936 

McCormick, J M.................................. 306* 

McCoy, K.......................................... 1223* 

McCulloch, C........................................817 

McCulloh, R........................................1906 

McDaniel, K L.....................................2272 

McDermott, E.....................................1514 

McDiarmid, M A.................................1733 

McDonald, J D..........296, 738, 1071, 1897 

McDonald, J..............................1037, 1503 

McDonald, T.............................1249, 1731 

McDonough, J H...................................150 

McDorman, K.....................................1930 

McDougal, A..................................... 1356* 

McDougal, J N.............. 1561, 1562*, 1563 

McDougal, J..........................................680 

McElwee, M...................................... 2240* 

McEwan, M.........................................2079 

McFadden, L G...................................1785 

McFadden, L.......................................1459 

McFarland, R....................................... 891* 

McGarrigle, B P.............................267, 791 

McGarry, H F.......................................1446 

McGaughy, R........................................914 

McGee, J..............................................1074 

McGinnis, P..........................................928 

McGinty, D....................................... 1531* 

McGinty, J...........................................1795 

McGlothan, J L................................. 1861* 

McGovern, V.............................. 664, 666* 

McGrath, J L......................................... 32* 

McGrath, P........................777, 1646, 1723 

McGregor, W........................................417 

McGuinness, E E.........................134, 1546 

McGuire, J M........................................125 

McGuire, J................................... 128, 138* 

McHugh, T E.......................................1479 

McHugh, T........................................ 1795* 

McInally, K........................................ 1080* 

McIntosh, L...................................... 1843* 

Mckarns, S C..................................... 1120* 

McKim, J M...................................892, 893 

McKinney, W J......................................908 

McLanahan, E D............................... 1013* 

McLanahan, E.....................................2352 

McLaughlin, A J..................................1227 

McLaughlin, M................................. 1097* 

McLaurin, K..........................................238 

McLeland, C B.................................. 1051* 

McLeland, S E.....................................1051 

McLellan, C J.................................... 1793* 

McLeod, C.............................................859 

McMahon, T..................................... 1789* 

McMartin, K........................................ 471* 

McMullin, T S.......................................313 

McMullin, T............................ 1000, 1984* 

McNamee, P M.....................................330 

McNeely, S C..................................... 2112* 

McNeil, S E..........................................1050 

McPhail, B T........................................ 955* 

McPherson, C A.................................. 366* 

Meacham, C A....................................1840 

Meacher, D............................732, 734, 753 

Meade, B J...........................................1313 

Meadows, G G.................................. 1348* 

Mearn, M............................................1550 

Medeiros, R...........................................401 

Medvedovic, M...................................1325 

Meek, E C............................................ 133* 

Meerman, J N........................................107 

Mehendale, H M................................. 627* 

Mehling, A............................................ 45* 

Mehta, J..............................................2045 

Mehta, R................. 861, 862, 1890*, 2224 

Mehta, V........................................... 1658* 

Mei, N............................... 376, 383, 1118* 

Meierhenry, E.....................................2306 

Meissner, G...........................................545 

Mekhtiev, A.........................................1731 

Melchior, W B..................................... 682* 

Meldrum, B.........................................2277 

Mellert, W...........................................1603 

Melnick, R L........................................1002 

Melnyk, S................................68, 524, 842 

Menard, H L...................................... 1674* 

Mendez, E...................238, 239, 632, 1184 

Mendoza, M E.....................................2121 

Mendoza, M........................................1873 

Meng, J..................................................124 

Mercado-Feliciano, M....................... 1388* 

Mercer, P...............................................745 

Mercer, R R.................... 1399*, 1497, 1499 

Merrell, M D..................................... 2030* 

304 




Merrill, E A.......................................... 127* 

Merrill, J................................................971 

Mertens-Talcott, S U.............................645 

Metry, K J.................................... 416, 417* 

Metz, K M.............................................426 

Meuling, W J.........................................660 

Meuling, W...........................................661 

Meyer, J N......................................... 1668* 

Meyer, J...............................................1235 

Meyer, S A.............................................130 

Meyer, S..............................................1526 

Meyerhoff, R.......................................1301 

Mi, Y...................................................1477 

Mian, N.................................................243 

Michelliza, S........................................1117 

Michie, M W.......................................1170 

Mickle, B...............................................845 

Middaugh, D R...................................1770 

Middendorf, C A.................................2251 

Middleton, D C...................................1684 

Mielke, H W...................................... 1641* 

Mielke, Jr., P W...................................1641 

Miida, H................................................225 

Milano, J........................................... 1941* 

Milatovic, D.........1867, 1886, 1887, 1889, 

................................................ 1958*, 2285 

Milatovic, S.........................................2285 

Milburn, M....................................... 1751* 

Milchak, L.............................................990 

Milcová, A.............................................868 

Miles, M..............................................1583 

Miles, S L...............................................450 

Milhorn, D.......................................... 192* 

Miller, C A............................... 1364*, 1675 

Miller, D B..................... 1098, 1804, 1809* 

Miller, D J............................................2012 

Miller, D M............................................894 

Miller, D............................145, 1883, 1928 

Miller, E J..............................................299 

Miller, G W.................................208, 2040 

Miller, H L...........................................1968 

Miller, J H............................................1683 

Miller, J M...........................................1024 

Miller, J...............................................1906 

Miller, L A........................................... 571* 

Miller, M G.........................................1149 

Miller, M S................................... 116*, 876 

Miller, M........................... 729, 963, 1520* 

Miller, P E............................................1906 

Miller, R A.............................................510 

Miller, R T...........................................2066 

Miller, T J..............................................946 

Miller, T..............................................2069 

Miller, W H...............................1305, 2122 

Miller, W.............................................2301 

Millner, G C..........................................801 

Millner, L M........................................ 415* 

Mills, L J.............................................. 281* 

Milton, M N........................................1222 

Min, E.................................................2065 

Min, J..................................................2147 

Min, X.................................................1697 

Minami, K.............................................218 

Minard, K R...............................1020, 1078 

Minard, K............................................1373 

Mingoia, R T.........................................616 

Mingoia, R............................................812 

Minsavage, G D..........................153, 2161 

Mioduszewski, R J.................125, 132, 142 

Mioduszewski, R...................................145 

Miranda, C L.......................................1959 

Miranda, J...........................................2077 

Mirkes, P E..........................................1109 

Miro, O.................................................295 

Mirsalis, J C.................................453, 1770 

Mirsalis, J..............................................392 

Mirza, A...............................................1747 

Misner, D L....................................... 1651* 

Misner, D............................................2306 

Misra, H P...........................................2051 

Misra, M......................................907, 1684 

Mistry, M......................... 566, 1660, 2309* 

Mitchell, A............................................235 

Mitchell, H A........................................208 

Mitchell, K A....................................... 630* 

Mitchell, L......................................... 1037* 

Mitchell, M D...............................387, 389 

Mitchell, M...............................1600, 1751 

Mitchell, T R.........................................484 

Mitchell, V L.......................................1333 

Mitsumori, K.................................113, 519 

Miura, D..............................................1688 

Miura, K................................................304 

Miura, N............................................ 1611* 

Miyagishima, T...............1564, 1569, 1593 

Miyajima-Tabata, A............................. 758* 

Miyamoto, S...................................... 1756* 

Miyamoto, Y.........................................196 

Mizushima, K........................................214 

Mnuskin, A.........................................1961 

Mo, J....................................... 1640, 2108* 

Mo, Y..................................................1034 

Mobio, T...............................................700 

Moen, M A........................................ 1228* 

Moffat, I D............................................779 

Moffit, J S.......................................... 1154* 

Mog, S R................................................136 

Moggs, J G...........................................2303 

Mohar, I.................................. 1602, 1944* 

Mohney, R........................................ 1600* 

Mohrman, M......................................1311 

Moland, C L......................710, 1430, 1661 

Molina, L..............................................721 

Molinelli, A R.................................... 1960* 

Mollenhauer, M................ 169, 198*, 2139 

Mondal, T...............................................16 

Moneypenny, C..................................2019 

Mongan, M....................................... 1130* 

Monian, P...........................................2061 

Monier, C..............................................611 

Monks, T J.........468, 469, 470, 1412, 2070 

Monroy, R......................................... 1765* 

Montague, D.......................................2245 

Montalvo, A........................................2193 

Monteiro-Riviere, N A.............1027, 1028, 

...........................1029*, 1030, 1276*, 1402 

Monteiro-Riviere, N..............................332 

Montero, F A.......................................2246 

Monterroso, V.....................................1816 

Montgomery, B...................................1955 

Montgomery, D....................................722 

Montgomery, R...................................1762 

Montine, T J..........................................411 

Mooibroek, H......................................2221 

Moon, C..............................................1486 

Moon, J.................................................625 

Moore, A J........................................... 686* 

Moore, D D.........................................2030 

Moore, J E.....................................116, 876 

Moore, J......................................951, 1533 

Moore, M.............................................. 55* 

Moore, N................................. 1693, 1694* 

Moore, R W................... 1515, 1516*, 1517 

Moore, T...............................................112 

Moore-Smith, D A............................. 1957* 

Moors, M...............................................578 

Moorthy, B...................... 772*, 1067, 1774 

Moos, P J........................................... 1044* 

Morais, R.................................................57 

Moral, R................................................564 

Morales, M M.................................... 1473* 

Morales, M........................................ 1881* 

Morales, R...........................................2203 

Moreau, M............................................232 

Morelli, J K.............................. 1941, 1943* 

Moreno, J A.......................706, 1862, 2034 

Moreno, J............................................ 704* 

Moretto, A...........................................1829 

Morgan, D.......................1079, 1544, 1790 

Mori, T................................................1443 

Moriguchi, A.......................................1591 

Morikawa, H.......................................1952 

Morishita, K........................................2307 

Morita, O..................................1533, 2223 

Moriyama, C.......................................1952 

Morris, D................................. 1342*, 1541 

Morris, J B..................... 1090*, 1092, 1782 

Morris, J..............................................1635 

Morris, R...............................................942 

Morris, S M.........................................1688 

Morris, S R...............................................92 

Morris, S..............................................2083 

Morrison, K.........................................1765 

Morrissey, R L.......................................711 

Morrow, J D..........................................866 

Morry, D................................................979 

Morse, J.................................................286 

Morton, L............................................2322 

Moseley, A...........................................1081 

Moser, J............................................. 1776* 

Moser, V C.............................. 2012, 2272* 

Moser, V................................................268 

Mosley, L J.....................................116, 876 

Moss, O R...................... 1406*, 1507, 1511 

Mossman, B T.......................................294 

Mostowy, J M........................................864 

Mota, L M.............................................769 

Motlagh, S.............................................477 

Motohashi, H........................................196 

Mott, J M...............................................157 

Moudgal, C J....................................... 248* 

Moudgil, B..........................................1401 

Mouithys-Mickalad, A........................1497 

Moukha, S.....................................700, 716 

Mould, A.............................................1134 

Moulin, P............................................2303 

Moulton, M C........................... 425*, 1026 

Mouneir, S M......................................1211 

Mourich, D V............................2006, 2129 

Moye, J K.............................................. 73* 

Moyer, M..............................................890 

Moyer, P................................................983 

Mozzachio, K......................................2100 

Mueller, K..............................................528 

Mueller, P............................................1898 

Mueller, S O..........................................778 

Muenyi, C......................................... 2110* 

Mugica-Alvarez, V.................................292 

Muireann, C..........................................472 

Mukai, M.......................................... 1209* 

Mukerjee, D..........................................917 

Mukherjee, M.......................................719 

Mukherjee, S.......................................1724 

Müller, D.............................................1123 

Müller, G.................................................57 

Muller, M............................................2221 

Mulligan Tuttle, A............................. 1146* 

Mulvey, R..............................................766 

Mumford, J L.......................... 1640*, 2108 

Mumtaz, M................................. 47*, 2011 

Mun, G..........................................323, 325 

Mundy, W R................................579, 1699 

Muniappa, N.........................................380 

Muniz, J G........................................... 888* 

Munley, S M..............................2230, 2233 

Munro, I C........................................ 1358* 

Munsie, L M........................................ 262* 

Munson, A E.......................................1313 

Munz, C............................................ 1346* 

Muralidhar, M G............................... 2071* 

Muralidhara, S..............................947, 955 

Murbach, D M....................................1458 

Murdock, R C.......... 423, 424*, 1025, 1053 

Murk, A J.............................................1233 

Muroi, M...............................................498 

Murono, E P........................................1137 

Murphy, C J........................................1906 

Murphy, C.....................................241, 259 

Murphy, G............................................298 

Murphy, K A..................................... 1415* 

Murphy, L...........................................2310 

Murphy, M.......................................... 474* 

Murr, A S.................................................85 

Murray, A R............................. 1494*, 1497 

Murray, A....................................441, 1031 

Murray, J.....................................254, 1653 

Murray, S........................................... 1637* 

Murray, T F..........................................1727 

Murrell, R N........................................ 347* 

Murty, M...............................................709 

Mus, M................................................2298 

Muse, W................................................145 

Muskhelishvili, L....................................97 

Mussali-Galante, P........ 1642, 1643*, 2086 

Mustafa, A..................... 2125, 2126, 2127* 

Muthiah, K..........................................1067 

Mutlu, E.................................. 1754*, 1759 

Mutter, L........................................... 1350* 

Mwanza, J......................................... 2288* 

Myers, C........................................63, 1917 

Myers, E A......................................... 1530* 

Mylecraine, L......................................1758 

N 

N’jai, A................................................ 610* 

Na, K...................................................2146 

Nabb, D L......................................616, 957 

Nabb, D.................................................812 

Naciff, J M........................................... 897* 

Naciff, J.................................................592 

Nadanaciva, S............. 902, 903, 905, 906* 

Nadas, A..............................................1306 

Nagae, Y..............................................2200 

Nagahori, H..........................................532 

Nagano, M................................ 304*, 1619 

Naganuma, A............................1900, 2088 

Nagao, T..............................................1569 

Nagarkatti, M............................2003, 2004 

Nagarkatti, P S....................................2003 

Nagarkatti, P.......................................2004 

Nagasawa, H T......................................228 

Nagata, R.....1158, 1526, 1576, 1657, 2149 

Nagata, T.............................................1706 

Nagatsuka, S........................................ 219* 

Nagler, J J................................................74 

Nagler, J..................................................77 

Nagothu, K..........................................1927 

Nahas, S A......................................... 2057* 

Nail, C A.............................................2261 

Nakada, J.............................................1952 

Nakagiri, N..........................................1451 

Nakai, S...............................................1482 

Nakajima, M.........................................218 

Nakamura, J............................................83 

Nakamura, T............................. 329, 2149* 

Nakamura, Y..............................492*, 877* 

Nakanishi, J..............................1495, 1496 

Nakashima, H.....................................2090 

Nakashima, K......................................2116 

Nakatsu, N..................................370, 1564 

Nakatsuji, S.........................................1591 

Nakayama, Y.........................................877 

Nakayasu, E S......................................2066 

Nakazawa, K..........................................758 

Nallapaneni, A....................................2260 

Nambiar, M P................................154, 156 

Nambiar, M...........................................684 

Nanez, A............................................ 2022* 

Nanyes, D...........................................1953 

Naragoni, S...........................................536 

Narasimhan, S................................... 1061* 

Narotsky, M G.....................................1191 

Narotsky, M........................................1183 

Nascarella, M A................................. 1907* 

Nascimento, M...........................520, 1624 

Nash, J F............................ 503*, 966, 1716 

Nash, J.................................................1771 

Nass, R M.......................................... 1855* 

Natarajan, R........................................ 256* 

Nation, P N.........................................1825 

Nau, H.........................................364, 2017 

Nau, M..................................................145 

Naufal, Z.............................................1731 

Naughton, B A..............................622, 900 

Naven, R T............................................261 

Navetta, K.............................................384 

Naya, M.................................. 1495, 1496* 

Nazaret, R..............................................464 

Nazridoust, K........................................995 

Neal, A P........................................... 1870* 

Neal, B.................................................1540 

Neale, J.............................................. 1749* 

Neas, L................................................1439 

Nebert, D W........................................1621 

Neca, J...................................................811 

Neff-LaFord, H.................................... 176* 

Negga, R..............................................2282 

Neki, S............................................... 1215* 

Nel, A E.................................................437 

Nel, A....................................................733 

Nelin, L D...........................................1769 

Nelissen, I.....................................337, 886 

Nellemann, C.....................................1389 

Nelson, D M..........................................856 

Nelson, G..............................................870 

Nelson, M R..........................................192 

Nelson, W G.......................................1214 

Nelson-Miller, A....................................215 

Nemec, A A....................................... 1609* 

Nemec, M D........................................1729 

Nemec, M..................................1533, 2301 

Nemery, B.............................................217 

Neradilak, B........................................ 992* 

Nesbit, D...............................................426 

Nesnow, S........ 112, 282, 870*, 1324, 1428 

Ness, D K................................................. 5* 

Neuforth, A E......................................1761 

Neumiller, J J.........................................606 

Nevalainen, A.............................179, 1096 

New, L......................................... 622*, 900 

Newell, O............................................1242 

Newhouse, K....................................... 917* 

Newmark, H........................................1812 

Newport, G D............................1042, 1043 

Newport, S W....................837, 1912, 1913 

Newton, J............................................1925 

Ng, H H............................................... 453* 

Ng, J W................................................1229 

Ng, S P....................................... 181*, 2202 

Ng, W Y................................... 1116*, 2082 

Nguyen, D...........................................1337 

Nguyen, L......................................... 1771* 

Nguyen, N.............................................923 

Nguyen, P T........................................2247 

Nguyen, T A...................................... 1068* 

Ni, L....................................................1818 

Niaz, M S.............................................1144 

Nichols, A C...................................... 1227* 

Nichols, T..............................................129 

Nichols, W K.......................................2001 

Nicholson, J K............373, 397, 472, 1601, 

..................................................1605, 1606 

Nicol, C J........................................... 1069* 

Nicolich, M...........................................254 

Nicolli, A........................................... 1829* 

Niecestro, R.........................................1924 

Niedzwiecki, A.......................... 874, 1394* 

Niehoff, M..........................................2208 

Nieto, I................................................2287 

Nieves, P........................................... 1237* 

Nigam, R...............................................583 

Nijmeijer, S M.....................................2172 

Nikas, S P............................................1839 

Nikolsky, Y............................................669 

Nikolskya, T..........................................669 

Nilles, T...............................................1214 

Nillos, M...............................................273 

Nilsen, A................................... 656, 1441* 

Nilsson, A............................................1718 

Author Index 




Author Index 

Ninomiya, S................................219, 1200 

Nishida, T...........................................1952 

Nishida, Y...........................................1158 

Nishijima, M.........................................498 

Nishijima, Y........................................1645 

Nishikawa, A.....................480, 1140, 1702 

Nishimura, H......................................2024 

Nishimura, J..................................113, 519 

Nishimura, N.......................... 2023, 2024* 

Nishimura, T................... 363*, 1056, 1899 

Nishioka, K.........................................1443 

Nishiyama, N..........329, 1447, 1448, 2223 

Nitschke, K............................................991 

Nitta, N...............................................1482 

Nixon, K............................................ 1262* 

Nnodi, O U....................................... 1831* 

Noakes, J.............................................1687 

Noh, J........................................1045, 2205 

Nohara, K............................................ 196* 

Nohmi, T.......................................... 1669* 

Nohynek, G J...................... 658, 660*, 661 

Nomikos, A P......................................1308 

Nomikos, A.........................................1433 

Nomura, T.............................................227 

Nong, A......................... 1009*, 1175, 2350 

Nony, P..................................... 801*, 1086 

Norbäck, D..........................................1477 

Nordberg, G F........................... 588*, 1615 

Nordberg, G................................455, 1613 

Nordberg, M........... 455, 586*, 1613, 1615 

Normandin, L.....................................1732 

Norstrom, K..........................................800 

North, C M....................................... 2143* 

Norwood, J..........................................2025 

Notch, E G..........................................1414 

Novak*, M J....................................... 1001* 

Novak, R F.............................................673 

Nováková, Z..........................................868 

Novick, R............................................ 305* 

Novilla, M N.......................................2326 

Nudel, M.............................................1871 

Nukada, Y............................... 1447*, 1448 

Nune, S.................................................614 

Nunnikhoven, A.........................862, 2224 

Nurkiewicz, T R................................. 1255* 

Nye, A C................................................801 

Nygaard, U C.......................... 1441, 1445* 

Nygaard, U............................................656 

Nyirabahizi, E................................... 1177* 

Nyland, J F................................ 194, 1041* 

Nylander-French, L A....................... 1560* 

Nyska, A..........516, 741, 1072, 1654, 2174 

O 

O’Brien, J J........................................ 2210* 

O’Brien, P J...............................1210, 1890 

O’Neil, H...............................................160 

O’Riordan, T....................................... 904* 

Oakes, G H........................................ 2080* 

Oates, R...............................................2318 

Oberdorster, G.................................. 2357* 

Oberdörster, G........ 434*, 745, 1404, 1510 

Oberemm, A......................................... 44* 

O’Callaghan, J P.............1098, 1804, 1809, 

.......................................................... 2036* 

Ochalski, R J...................................... 1206* 

Ochoa-Acuña, H.....................................75 

O’Connell, T M.....................................418 

O’Connor, J......................................... 812* 

O’Connor, M A................................... 840* 

Oda, S..................................................2129 

O’Day, C....................................1207, 2247 

O’Donnell, E F.................................. 1914* 

Odusanya, A D.................................... 796* 

Oeda, K...............................................1584 

Oesterling, E..................................... 2220* 

Ofori-Adjei, D...................490, 1478, 2238 

Ogawa, A.............................................2187 

Ogawa, M..............................................302 

Ogawa, T.............................................1706 

Ogawa, Y........................................... 1746* 

Oguma, E............................................1618 

Ogunsola, O A....................................1032 

Ogura, K................................................825 

Ogura, R..............................................2223 

Ohanian, E........................................ 1300* 

Ohata, S..............................................1952 

O’Hehir, D J........................................1475 

O’Hehir, D...........................................1798 

Ohira, T...............................................1068 

Ohno, Y....................................1564, 1593 

Ohsako, S............................................1111 

Ohta, T........................................757, 1751 

Oida, H................................................1215 

Okamoto, S...........................................877 

Okayama, J..........................................1158 

Oke, T.................................................2079 

Okey, A B..............................................779 

Okino, M S............................................269 

Okonkwo, J O.......................................796 

Okorodudu, A.....................................1742 

Okuno, T...............................................362 

Okuno, Y...............................................532 

Olabisi, A O......... 1877*, 2097, 2098, 2099 

Olaharski, A J.......................... 2249*, 2256 

Olaharski, A........................................1896 

Oldham, S...........................................1536 

O’Lenick, C R.................................... 1089* 

Olenick, C...................................297, 1091 

Oliu, G..................................................295 

Oliveira, C.............................................879 

Oliveira, D P..................................... 1681* 

Oliveira, P.............................................879 

Olivero, J T.................................. 853, 854* 

Olivero, J...............................................721 

Olivero, O A........................................1677 

Olmstead, A W............................ 103, 106* 

Olsavsky, K M..................................... 672* 

Olsen, G..................................................12 

Olson, C T...........................................1546 

Olson, G................................................719 

Olson, J A............................................1001 

Olson, J E............................................2078 

Olson, J R......................................267, 791 

Olson, J.................................................805 

Olson, K................................................566 

Olszewski, K........................................1044 

Omae, K..............................................2090 

Omaye, S T............................................492 

Omiecinski, C.......................................672 

Omori, T.............................................1451 

Omura, K............................................1591 

Onda, H................................................584 

Ondovcik, S L..................................... 226* 

Oneda, S........................ 1160, 1526*, 1528 

O’Neill, A............................................ 332* 

O’Neill, T M..........................................814 

O’Neill, T P.........................................2326 

Ong, C.......................................1398, 1490 

Ong, W...............................................1398 

Ono, A.............................1564, 1569, 1593 

Onthank, D.........................................2309 

Opperman, K K................................. 2081* 

Opresko, D M........................................924 

Orak, D............................................... 336* 

Oram, J F.............................................1701 

Ordonez-Librado, J...............................209 

Orehek, M.............................................145 

O’Reilly, M............................................537 

O’Riordan, T.......................................1938 

Orlicky, D J..................................204, 1950 

Orr, G................................................ 1405* 

Ortiz, P A........................................... 1599* 

Orton, C R.......................................... 771* 

Oshiro, W M..................................... 1820* 

Oshiro, W...........................................1821 

Osier, M...............................................2308 

Osnes, J.................................................747 

Osornio-Vargas, A R.......................... 2077* 

Osornio-Vargas, A...............292, 293, 1074 

Ostazeski, S...........................................106 

Osterberg, R E................................... 1351* 

Osterberg, R........................................1272 

Osterburg, A........................................2099 

Ostraat, M L............................ 1488, 1514* 

Ostrowski, M.........................................223 

Ota, M............................................... 1443* 

Otieno, M...........................................1206 

Oudiz, D......................................942, 1483 

Ouellette, S B................................892, 893 

Ourlin, J..............................................1315 

Ovando, B.............................................805 

Ovechkina, Y.......................... 1207, 2247* 

Overmann, G........................................477 

Ovigne, J.............................................1449 

Owen, R D...........................................2015 

Owens, S E.......................................... 409* 

Owumi, S E...........................................121 

Oyama, T..............................................200 

Ozawa, M............................................1647 

Ozawa, S................................................758 

Ozer, J S............................................... 380* 

Ozer, J..................................................1919 

Ozkaya, S..............................................488 

P 

Pacheco, K M........................................945 

Pacurari, M.......................................... 300* 

P?n?íková, K.........................................868 

Pacyniak, E.......................................... 815* 

Paderova, V...........................................811 

Padgett, W T.........................................282 

Padgett, W............................................870 

Padilla, M............................................1457 

Padilla, S.........................2186, 2188, 2189 

Padnos, B..................................2186, 2189 

Padovani, A M.................................. 1305* 

Paepke, O..............................................785 

Pagan, I...............................................1189 

Page, C S................................. 2152, 2154* 

Pal, A................................................... 151* 

Palacios-Gil, Y.......................................266 

Palamanda, J.........................................763 

Palate, B..............................................1548 

Palis, J....................................................158 

Pallardy, M J..............................................3 

Pallardy, M.............................1315*, 1456* 

Palmeira, C M........................... 560*, 1035 

Palucki, D..............................................296 

Pan, X...................................................196 

Pandit, A A..........................................2110 

Pandya, P K.........................................1712 

Panko, J M..........................................1471 

Pansoy, A......................................534, 535 

Pant, K....................................................84 

Pantano, S...........................................2303 

Panter, K................................................724 

Panther, D J.........................................1405 

Panyasing, Y.............................1645, 1650 

Panza, J............................................. 1709* 

Papanayotou, I......................................447 

Papineni, S......................2178, 2181, 2182 

Papkovsky, D...............................904, 1938 

Pappa, A..............................................1951 

Pappa, G............................................ 2250* 

Paquette, J A.......................................2340 

Parent, R A............................................ 12* 

Parenteau, M.......................................2224 

Parent-Massin, D.......................184*, 909* 

Parham, F M.......................................1017 

Parikh, R U........................................ 1872* 

Paris, M....................................... 898*, 899 

Park, C................................................1469 

Park, D.............................................. 1646* 

Park, E.........................................877, 1486 

Park, H.............................................. 1124* 

Park, J............. 371, 442, 523*, 1083, 1469, 

..................................................1502, 1616 

Park, M................................................2323 

Park, S k..............................................2159 

Park, S.................................419, 857, 1129 

Parker, A.............................................. 986* 

Parker, G A................................ 175*, 2326 

Parker, J...............................................1572 

Parker, M S..........................................1248 

Parkerton, T F.....................................1232 

Parkinson, H D.....................................508 

Parmar, M......................................... 1390* 

Parnell, S E..........................................1530 

Parron, V I...........................................1671 

Parsons, B L........................................... 53* 

Parthasarathy, S....................................223 

Parveen, M........................................ 1427* 

Parvez, F..............................................1966 

Parylak, S..............................................131 

Pascal, H............................................ 1317* 

Pastoor, T.......................................... 2140* 

Patel, A.............................................. 2298* 

Patel, H...............................................1715 

Patel, M...............................................2058 

Patel, R D.......................................... 2170* 

Pathak, A R.........................................2071 

Pathak, A...............................................299 

Patiño, A...............................................721 

Patiño, R.............................................1226 

Patlolla, A K...................................... 1040* 

Patlolla, R R...........................................335 

Patricia, G E..........................................854 

Patrone, J B.............................................49 

Patterson, S E........................................228 

Patterson, T A...........................1042, 1043 

Patterson, T.........................................1714 

Patterson1, T A...................................1726 

Patton, G W........................................ 918* 

Patyna, S.............................................1541 

Paul, D.............................................. 1628* 

Paul, I A.................................................546 

Paul, K B................................................ 93* 

Paule, M G.................... 1696, 1726, 1728* 

Paule, M..............................................1714 

Paulos, P..............................................1245 

Paulose, T.......................................... 1386* 

Paulsen, M H.........................................287 

Pauluhn, J......................................... 1493* 

Paustenbach, D J..............697, 1185, 1458, 

..............................1468, 1471, 1472, 1794 

Payer, A F............................................1475 

Payraudeau, V.......................................531 

Peachee, V L........................................ 216* 

Pearce, J T.................................. 472, 1605* 

Pechacek, N...........................................990 

Peck, E C............................................. 760* 

Peckham, J C.........................................515 

Peden, D B..........................................1088 

Peden, D..............................................1439 

Peden-Adams, M............... 169*, 198, 2139 

Pedersen, J A.........................................426 

Pedneault, G A....................................1909 

Peer, C J.................................................190 

Peggins, J.............................................2314 

Pegram, R A.........................................1003 

Peijnenburg, A.................................. 2241* 

Pekkanen, J...........................................179 

Pelletier, J..............................................232 

Pellicore, L............................................497 

Peltonen, K......................................... 481* 

Pencikova, K.........................................811 

Peng, K.................................... 1057*, 1058 

Peng, S.............................................. 2052* 

Peng, Z.................................... 1130, 2074* 

Penman, M....................................... 2363* 

Penn, A.................................................298 

Pennings, J..............................64, 65, 1535 

Pennington, K L..........................520, 1624 

Perdew, G H..............................2170, 2171 

Perdomo, Y....................................... 1866* 

Pereira, C B.........................................1775 

Pereira, F.............................................2111 

Pereira, J................................................564 

Pereira, S............................................. 879* 

Perentes, E.............................................399 

Perez, C F..............................................545 

Pérez-Herrera, N..................................2281 

Pérez-Rivera, A A......................... 330*, 503 

Perez-Tilve, D........................................527 

Perkins, B............................................2137 

Perkins, E J............................................130 

Perraut, C............................................2275 

Perrine, S.............................................2314 

Perron, J............................................ 2316* 

Perry, C S.............................................1791 

Persad, A S........................................... 916* 

Perwaiz, S..............................................709 

Pesch, B...............................................1730 

Pessah, I N..............545, 1114, 1705, 2155 

Pestka, J J.........618, 718, 1125, 1126, 2226 

Pestka, J.................................................182 

Peters, A M.......................................... 894* 

Peters, J M...................................542, 1549 

Peters, M A.......................................... 393* 

Peters, O................................................145 

Petersen, D R.......................................1945 

Petersen, D..........................................1212 

Peterson, N.........................................1069 

Peterson, R E............ 426*, 427, 819, 1161, 

..........1515, 1516, 1517, 1658, 1659, 2195 

Petit-Turcotte, C........................ 211*, 2299 

Petrella, D K..................................892, 893 

Petri, V..................................................583 

Petrikovics, I............................162*, 2286* 

Petrillo, S K....................................... 1383* 

Petroni, D H.............................. 959, 1939* 

Petropoulou, C....................................1799 

Petrov, A N........................................ 2096* 

Petrov, E A...........................................2164 

Petrulis, J...............................................473 

Petry, T................................................ 982* 

Pettebone, V.......................................1722 

Pettit, S................................................1758 

Pevey, C L........................................... 360* 

Pfannkuch, F.........................................631 

Pfau, J C.............................................. 607* 

Pfeifer, K........................................284, 940 

Pfenninger, A........................................675 

Pfister, J.................................................724 

Pfluger, P T............................................527 

Pfuhler, S.............................................1167 

Phadke-Gupta, P.................................1052 

Pham, D....................................2129, 2169 

Pham, L D...........................................1861 

Pham, T.........................................199, 200 

Phan, B.............................................. 2073* 

Phaneuf, D..........................................1792 

Phelka, A D....................................... 1185* 

Phelps, L.............................................2136 

Philbert, M.............................. 1834, 1972* 

Philip, B K........................................... 521* 

Phillips, C S................................. 152, 681* 

Phillips, D H.......................................1747 

Phillips, J L..........................................1405 

Phillips, J M........................ 26, 526*, 1407 

Phillips, K.......................................... 2103* 

Phillips, P M........................................2272 

Phillips, T D..............483, 490, 1478, 2238 

Phillips, T............................486, 507, 1631 

Phipps, R P..........................................2210 

Phipps, R...............................................745 

Phothirath, P......................................2145 

Pi, J............ 1174, 1302*, 1303, 2026, 2033 

Piao, Y.................................................1968 

Picaut, P..............................................1548 

Piccirillo, V J.........................................510 

Piccotti, J R............................................338 

Pichler, E...............................................243 

Pickersgill, N..................................... 2305* 

Picut, C A..........................175, 1141, 2326 

Pidruczny, A........................................1404 

Piegorsch, W W..................................1177 

306 




Piehl, M....................................... 327, 328* 

Pierce, A J............................................1673 

Pierce, H H..........................................1673 

Pierce, W M...................................416, 417 

Piersma, A...................................632, 1535 

Pikkarainen, T.......................................555 

Pillet, S................................................2138 

Pilling, J................................................619 

Pilsner, R................................. 1630*, 1644 

Pinchuk, L M......................................1985 

Pine, M................................................ 274* 

Pinkerton, K E............... 1331, 1332*, 1505 

Pinkerton, M.......................................1457 

Pinketon, K.........................................1768 

Pinney, S M...........................................659 

Piñon-Zarate, G..................................2086 

Pinsonneault, L....................... 1771, 1772* 

Piras, E................................................2218 

Pisano, M............................................1539 

Piskac, A L........................................... 467* 

Pitt, B R.....................................1609, 2000 

Placido, J R.......................................... 712* 

Planchart, A...................................... 1581* 

Platz, S.......................................1651, 2306 

Platzek, T............................................. 663* 

Plautz, J R............................................1781 

Plummer, S........................................ 1150* 

Plunkett, L M.................................... 1786* 

Po, P......................................................742 

Poapolathep, A.....................................495 

Podduturi, J.........................................1066 

Poellinger, L........................................2166 

Poet, T S.......................... 613, 1018*, 1375 

Pognan, F........................1923, 1941, 2303 

Pogribna, M........................................ 717* 

Pogribny, I P........................................1955 

Pogribny, I......524, 842, 1060, 1064, 1416, 

............................................................1910 

Pohjanvirta, R.......................................779 

Pohl, H R.............................................2011 

Pohlmann, G......................................1773 

Poirier, M C............ 206, 770, 1677, 2332*, 

............................................................2335 

Poland, A............................................ 988* 

Polisini, J.............................................1796 

Politano, V T................. 1525*, 1527, 1531 

Politano, V............................................506 

Polk, W W...........................................1104 

Pollard, C E...........................................651 

Pollenz, R S............ 552, 781, 2156*, 2157, 

............................................................2163 

Pollenz, R................................................ 6* 

Polli, J W...............................................620 

Pollisar, N..............................................992 

Ponce, R....................................1928, 1934 

Pooler, M.............................................1055 

Poon, R............................................. 1168* 

Poortman, J.........................................2241 

Pope, C N............................................2260 

Pope, C..............................611, 1317, 1318 

Popov, V L...........................................1993 

Popp, J......................................... 664, 665* 

Poreda, R.............................................1404 

Porter, D W............................. 1255, 1492* 

Porter, D..............................................1491 

Porter, K.............................................. 103* 

Porter, W.............................................2263 

Portier, C J............... 259, 878, 1017, 2349* 

Portier, C.............................................1019 

Portilla, D............................................1927 

Postlethwait, E M..................................573 

Postoyalko, A.................................... 1102* 

Poth, A.............................................. 2248* 

Pothakos, K.........................................1874 

Potnis, P A......................................... 2067* 

Pottenger, L H........................... 529*, 1429 

Potter, P M............................................301 

Poul, J..................................................1202 

Pouliot, L..................................1519, 1772 

Poulton, E M....................................... 768* 

Pounds, J G.......................395, 1405, 1743 

Pounds, J P..........................................1975 

Pounds, J...............................................436 

Powell, C L..................................842, 1955 

Powell, E.............................................1641 

Powell, H................................... 859*, 1205 

Powell, W H................................554, 2165 

Powers, B E........................................ 1712* 

Powers, K W........................................1277 

Powers, K..............................................428 

Powley, M W..................................... 1937* 

Powrie, R...............................................661 

Prabhakaran, K.................149, 1830, 2054 

Prakash, S R.........................................1222 

Prasanna, P G........................................136 

Prather, B..............................................234 

Pratt, C................................................1193 

Pratt, L F..............................................2252 

Pregenzer, J F............................... 892, 893* 

Prenni, J..............................................1322 

Preston, T J............................................226 

Preuss, R..............................................1730 

Price, H...............................................1079 

Price, J................................................. 680* 

Price, K D..............................................185 

Price, L B........................................... 1463* 

Price, O T..............................................996 

Price, P S............................................ 1459* 

Primomo, J..........................................1461 

Prince, M.............................................2027 

Pringle, R B....................................... 1867* 

Pritsos, C A....................................73, 1467 

Pritt, S.................................................2301 

Procter, B G...........................................978 

Proctor, D M.............................1607, 1801 

Proctor, D................................ 1544, 1790* 

Prokoudine, A.....................................1603 

Pronzola, L..........................................1317 

Prophete, C...........................................743 

Proskocil, B.........................................2278 

Prough, R A.........................................1948 

Prough, R............................................1539 

Prozialeck, W C................... 378*, 458, 459 

Prucha, M S....................................... 1425* 

Prud’homme, R...................................1404 

Prues, S L........................................... 2097* 

Pruett, S B................172*, 173, 605, 1347* 

Pryhuber, G S......................................1121 

Przedborski, S......................................1720 

Przybyla, B..............................................66 

Pu, X................................................... 109* 

Puey, A..................................................453 

Puga, A................................................ 343* 

Puijker, L...............................................105 

Pulci, R..................................................984 

Pullen, A...............................................477 

Pumford, N.............................................66 

Purdy, I................................................1780 

Puschner, B.........................................1114 

Putnam, E A........................................1094 

Putney, L F............................................575 

Putt, D A...............................................447 

Putzrath, R M......................................2015 

Puzas, J..................................................685 

Pyatt, D W........................................ 1197* 

Pyrah, I................................................1134 

Pysher, M D...................................... 1304* 

Q 

Qian, J.................................................2304 

Qian, Y................................................1626 

Qiao, C................................................2224 

Qin, Q.................................................2093 

Qin, S.......................................... 394*, 398 

Qu, J Y.................................................2082 

Qu, W............................................... 2118* 

Qu, Y...................................................1505 

Quan, C.............................................. 730* 

Quesada, A..........................................1940 

Quijano, M...........................................477 

Quinn, M............................................2100 

Quinones, O.........................................463 

Quintana, R........................................2077 

Quintanilla-Vega, B.................. 266*, 2281 

Quintero, M..........................................721 

R 

Raabe, H................................323, 325, 336 

Rabieh, S.............................................2115 

Rabinowitz, J R.....................................246 

Rabinowitz, J....................................... 247* 

Rabold, R...............................................736 

Rabstein, S...........................................1730 

Rached, E..............................................528 

Racine, C............................................. 445* 

Radcliffe, P M...... 1406, 1511*, 1877, 2098 

Radcliffe, R A......................................1719 

Radio, N M........................................ 1699* 

Radio, N................................................630 

Radkar, V...............................................713 

Rafikov, R............................................2056 

Rafter, I..................................................823 

Raghava Menon, A C..........................1999 

Raghavamenon, A C....... 316, 1664, 2201* 

Rahaman, A..........................................792 

Rahman, M F.......................... 1042*, 1043 

Rai, S...................................................2209 

Raisbeck, M......................................... 722* 

Rajab, N F............................................1994 

Rajagopalan, S............ 223, 735, 743, 744*, 

.......................................................... 1252* 

Rajamohan, F........................................857 

Ralston, M M...........................229*, 1949* 

Ramabhadran, R.................................1426 

Ramaiah, S K.......................846, 851, 1220 

Raman, P............................................. 164* 

Ramesh, A....................... 866, 1143*, 1144 

Ramirez, D..........................................1633 

Ramkissoon, A.................................. 1814* 

Ramos, K S................................1108, 2022 

Rana, S................................ 151, 204*, 678 

Rancourt, R...........................................160 

Rando, R.............................................1675 

Rankin, G O................................ 445, 450* 

Rannug, A...................................775, 2166 

Rannug, U.............................................775 

Rase, B...................................................604 

Rasmussen, C......................................1452 

Rasoulpour, R.................................... 1142* 

Rasoulpour, T..........................................61 

Rath, M.......................................874, 1394 

Rausch, L L.......................................... 392* 

Rausch, L.............................................1033 

Rawal, S............................................... 762* 

Ray, S D...............................................1390 

Raymer, M L........................................1761 

Raynauld, J............................................232 

Rayner, J L................................. 928*, 1986 

Raza, H.............................................. 1395* 

Re, T A...................................................336 

Read, D S...............................................157 

Read, L................................................2237 

Reagan, W........................................... 857* 

Reardon, K..........................................1322 

Reaves, E.....................................239, 2272 

Reaves, M E............................. 1184*, 2012 

Reaves, M..............................................238 

Rebecca, J............................................1246 

Recknor, J C........................................1579 

Reddy, G..............................................1170 

Reed, C..................................................391 

Reed, G..................................................943 

Reed, J Z................................................258 

Reed, K L.........................1487, 1488, 1514 

Reed, M D.........................738, 1071, 1897 

Reed, N R..............................................284 

Reed, W...............................................1588 

Reel, J R.................................................860 

Rees, J N............................................ 1813* 

Rees, W...............................................1425 

Reeves, B S............................................ 89* 

Reeves, S................................................130 

Refsnes, M.............................................747 

Regal, J F........................................... 1311* 

Regal, R R............................................1311 

Regg, B..................................................477 

Reichling, T D.......................................897 

Reichling, T.........................................1437 

Reid, F M................................... 134*, 1546 

Reid, F...................................................680 

Reif, D............................................... 1474* 

Reifenrath, W G.....................1349*, 1353* 

Reifke, B..............................................1758 

Reilly, C A...........................................1113 

Reilly, C D.................................2125, 2127 

Reilly, L M.............................................143 

Reilly, T P..............................................185 

Reily, M D.....................................373, 397 

Rein, K S..............................................1542 

Reinert, K H........................................1737 

Reinlib, L.......................................562, 567 

Reisfeld, B............................... 1021*, 1022 

Reising, A............................................1923 

Reisman, S A............................. 617, 1946* 

Remick, A K...................................... 1141* 

Ren, H................... 834, 1410*, 1428, 1587 

Ren, X.........................................882, 1625 

Renault, S..............................................464 

Renwick, A G.................................... 1360* 

Reo, N V............................ 674, 852, 1761* 

Rettenmeier, A W................................2115 

Reuhl, K R.................................1112, 1831 

Reus, A................................................2221 

Reverdy, E E........................................1780 

Reyes, A...............................................1930 

Reyes, J L.............................................2121 

Reynolds, J A....................................... 594* 

Reynolds, J S.......................................1312 

Reynolds, J..................................258, 1494 

Reynolds, M F......................... 1674, 2117* 

Reynolds, W F.....................................1961 

Rhode, C M...........................................373 

Rholman, D..........................................410 

Rhomberg, L R........................ 1176*, 1189 

Rice, C...................................................521 

Rice, G E..............................................1191 

Rice, G.................................................2013 

Rice, J R.................................................878 

Rice, J S.................................................143 

Rice, K.................................................1936 

Rice, L M............................................. 619* 

Rich, I....................................................368 

Richard, A M.......................................1716 

Richard, A...................236, 237, 245, 1991 

Richards, I......................................... 1119* 

Richards, J H.............741, 748, 1074, 1957 

Richards, J.................................1072, 1654 

Richards, M.........................................1747 

Richardson, J R............... 275, 2266, 2269* 

Richardson, J.......................................2267 

Richardson, R J.................388, 2291, 2292 

Richardson, V M...................................101 

Richardson, V..................................... 100* 

Richards-Smith, B.................................584 

Richburg, J H........................................348 

Richter, R..............................................265 

Richter-Reichhelm, H B..........................44 

Rick, D L.............................313, 974, 1000 

Rickard, R W.........................................542 

Rider, C V.......................................... 2190* 

Riechers, S L........................................1753 

Rietcheck, R..........................................377 

Rieth, S................................................ 915* 

Rietjens, I............................................2221 

Rigden, M...........................................1168 

Riggs, P K..............................................120 

Rihn, B..................................................513 

Rijal, G................................................1799 

Riley, B J................................................435 

Riley, B................................................1401 

Riley, R T............................................. 487* 

Rinderknecht, A........................ 745, 1404* 

Rindos, J..............................................2232 

Ringham, H N.....................................1049 

Ringwood, A H................................... 430* 

Rintala, H............................................1096 

Riordan, C...........................................1662 

Ríos-Pérez, A D.................................. 1419* 

Rise, M L.............................................1856 

Risede, P................................................611 

Rispin, A................................................988 

Rissel, M................................................344 

Ristagno, E H........................................422 

Ritchie, G............................................2314 

Ritger, S E....................................396, 1196 

Ritger, S............................................... 283* 

Ritieni, A...............................................981 

Rivelli, D R..........................................2173 

Riviere, J E..............478, 1028, 1402, 1556, 

.......................................................... 1559* 

Riviere, J...................................633*, 1974* 

Roberson, S I.......................................1144 

Robert, R A............................................853 

Roberts, D A..........................................330 

Roberts, D J.........................................2251 

Roberts, J R.................... 1098, 1494, 1501* 

Roberts, J.............................................1800 

Roberts, R A........................................1891 

Roberts, R.......................................23*, 24* 

Roberts, S M.................. 1192, 1277*, 1475 

Robertson, D G.....................................373 

Robertson, D.........................................397 

Robertson, J..........................................946 

Robertson, L W............312, 792, 795, 806, 

............................................................2068 

Robertson, L........................234, 800, 1678 

Robertson, T H....................................1373 

Robinette, B L.....................................1699 

Robinson, A............268*, 483, 486*, 1478, 

............................................................1631 

Robinson, J F..................................... 1853* 

Robinson, K..............................1771, 1772 

Robinson, P J........................127, 677, 999 

Robinson, P...................................128, 129 

Robinson, S.....................1660, 1926, 2309 

Robinson, V..........................................300 

Robinson-Gravatt, D......................... 1264* 

Robison, C..........................125, 131, 2279 

Robison, S......................................... 1682* 

Robl, M G............................................1204 

Roblin, S................................................779 

Robson, M G.......................................1738 

Rocha, J...............................................1887 

Roche, B..............................................1645 

Roche, J M...........................................1069 

Rockel, T D............................................578 

Rockwell, C E............................ 164, 2032* 

Rockwood, G A.....................................162 

Roden, D............................................. 648* 

Rodgers, A D....................................... 244* 

Rodriguez, A M...................................1668 

Rodriguez, A...................................... 1149* 

Rodriguez, C E.................................. 1012* 

Rodriguez, C.......................................1552 

Rodriguez, J F......................................1725 

Rodriguez, M.......................................1792 

Rodriguez, V M......................1767*, 1873* 

Rodriguez-Fuentes, G............................303 

Rodriguez-Lara, V...............................2086 

Rodriquez, V.......................................1983 

Roede, J............................................. 1945* 

Roeleveld, J.........................................2221 

Roesh, D................................................197 

Roess, A...............................................1463 

Rogan, E..............................................1735 

Rogers, E N.......................................... 871* 

Rogers, J M......................................7, 1534 

Author Index 




Author Index 

Rogers, J......................................680, 2025 

Rogers, L K........................................ 1769* 

Rogers, R L..........................................1236 

Roggeband, R........................................330 

Roggen, E..................................1437, 1452 

Rohde, C...............................................397 

Rohr, A................................................1503 

Rojanasakul, Y....................................1499 

Rojas, O...............................................1767 

Rojas-Lemus, M..................................2086 

Rollison, D E.........................................659 

Rolo, A P.............................................1035 

Roman, E............................................1721 

Romanotto, M R.................................1634 

Romer, E J.............................................165 

Romer, E..............................................1054 

Romero, A.............................................177 

Rong, S......................................1138, 1846 

Ronis, M J................................. 844*, 1062 

Ronquillo, D.......................................1767 

Roomi, M.................................. 874*, 1394 

Roomi, N.....................................874, 1394 

Rooney, A..............................................919 

Ropke, C D..........................................2173 

Roponen, M.............................. 179, 1096* 

Roque, R..............................................1934 

Rosado, J L..........................................1767 

Rosas, I................................................2077 

Rose, G................................................2315 

Roseman, V C.....................................1141 

Rosemond, Z A................................. 1159* 

Rosemond, Z.........................................932 

Rosen, M.............................................1428 

Rosenblum, I Y...................................1264 

Rosenfeld, M E..............................176, 750 

Rosengren, R J.....................................1393 

Rosenstein, M C............................241, 259 

Rosenthal, F S.......................................708 

Rosenthal, G J................................... 1898* 

Roses, A D............................................. 21* 

Ross, D G......................................612, 952 

Ross, D........................................101, 1994 

Ross, G T...............................516, 517, 518 

Ross, G................................................2199 

Ross, J A................................................870 

Ross, M K........................1481, 1985, 2053 

Ross, M........................................ 301*, 989 

Ross, P K.............................................. 831* 

Ross, P...........................................221, 374 

Rossi-George, A.........................1869, 1983 

Rossman, T G.................................... 1306* 

Roszell, L E........................................ 2101* 

Roszell, L.............................................1713 

Roter, A.................................................251 

Roth, D R..............................................399 

Roth, R A.... 220, 623, 837, 847*, 848, 850, 

........................................1208, 1912, 1913 

Roth, R..................................254, 849, 854 

Roth, T.............................................. 1529* 

Rothe, H.................................. 1186, 1444* 

Rotroff, D..............................................238 

Rotstein, D..........................................2306 

Rouse, R.............................................. 298* 

Rousseau, P.........................................1841 

Rousset, F............................................1547 

Rowan, W H..........................................748 

Rowland, A M..................................... 784* 

Rowlands, J........................412*, 673*, 951 

Roy, R....................................................990 

Roycroft, A..........................................2174 

Royland, J E...................................... 1585* 

Rubin, A L........................................... 940* 

Ruckelshaus, W................................... 598* 

Rudd, D A......................................... 2282* 

Ruddock, W........................................ 978* 

Rufer, E S................................. 1532*, 1692 

Ruff, A L............................................ 1105* 

Ruggles, D I.........................................1204 

Ruiz, H................................................2077 

Ruiz, P...........................................47, 2011 

Ruiz-Ramos, R......................... 1419, 2076* 

Rusch, G M................................. 307, 593* 

Rushing, S R........................................2167 

Rushmore, T H....................................1937 

Rushton, E K.........................................434 

Rushton, E........................................ 1510* 

Russak, M............................................1481 

Russell, M S...............................2152, 2154 

Russo, I H..............................................564 

Russo, J................................................ 564* 

Rusyn, I........221, 244, 245, 374, 418, 524, 

...........831, 842, 1278*, 1280, 1987*, 1991 

Rutherford, M S..................................1311 

Rutherford-Root, K L....................892, 893 

Ryals, J................................................1751 

Ryan, B C................................................62 

Ryan, C................................... 1186, 1449* 

Ryan, E P............................................. 685* 

Ryan, K R............................................2058 

Ryan, M J..............................................720 

Ryan, M...............................................2314 

Ryckman, K K.......................................409 

Ryman-Rasmussen, J P............ 1507*, 1509 

Ryu, D............................................... 1469* 

S 

Saavedra, J E..............................1397, 2118 

Sable, J J..............................................1712 

Sabourin, C C.......................................683 

Sabourin, C L........................................155 

Sabourin, P.......................................... 157* 

sabri, m I.............................................1816 

Sace, F.................................................2151 

Sachdeva, M S..................................... 335* 

Sachs, C..................................1160*, 2141* 

Sack, T J...............................................1196 

Sacksteder, C A.................................... 395* 

Saddler, C............................................1865 

Sadovova, N........ 1696, 1714*, 1726, 1728 

Sadrieh, N....................... 946, 1023*, 1927 

Sadrzadeh, S M....................................1960 

Saegusa, Y.....................................113, 519 

Safe, S H..............................................1109 

Safe, S.......... 645*, 1417, 2178, 2181, 2182 

Sager, T M......................................... 1491* 

Saghir, S A........................................... 974* 

Saghir, S................................................767 

Sahi, J..................................................1246 

Sahlberg, B........................................ 1477* 

Sahota, P.............................................2308 

Sahu, S C........................................... 1204* 

Saik, A Y.............................................. 289* 

Saili, K S.................................. 1914, 2162* 

Saini, Y.............................................. 2092* 

Saito, C................................................ 626* 

Saito, K................................................1584 

Sakaguchi, H...........329, 1447, 1448, 1449 

Sakai, S.............................................. 1076* 

Sakamoto, H.......................................2243 

Sakuraba, M........................................2243 

Sakurai, M.............................................188 

Salagrama, S................................673, 1595 

Salama, G............................................ 649* 

Salazar, K............................. 732, 734*, 753 

Saleh, N...............................................1055 

Salinas, K A.........................................1229 

Salisbury, R.......................................... 165* 

Salmen, R..............................................740 

Salmon, A G..........................................934 

Salmon, A........................... 936, 979, 980* 

Salocks, C............................................1558 

Saltiel, A R.....................................735, 744 

Sambuco, C P.................... 202*, 203, 1169 

Samet, J M.................................1073, 1489 

Samet, J...............................................1588 

Sampayo-Reyes, A............................... 973* 

Sampey, B P....................................... 1387* 

Sampson, H...............................2228, 2229 

Sams, R...................................... 912, 2353* 

Samsam, T E............................ 1807*, 1957 

Samuelsen, M........................................656 

Sanborn, J...........................................1558 

Sánchez-Guerra, M........................... 2281* 

Sanchez-Gutierrez, M.........................1133 

Sánchez-Peña, C L..............................1881 

Sanchez-Ramos, J................................1810 

Sancho, M J.........................................1627 

Sandau, C D........................................1480 

Sandel, S A..........................................1609 

Sanders, C D..................................... 2230* 

Sanders, J M........................................ 515* 

Sanders, M..................................472, 1605 

Sanders, R A........................................1956 

Sanders, W..........................................1640 

Sandrof, M A.......................................1154 

Sandström, T.......................................1085 

Sandusky, C..........................................991 

Sang, S.................................................1112 

Sangaiah, R.........................................2078 

Sangare-Tigori, B...................................700 

Sankella, S........................................... 536* 

Sano, Y................................................2090 

Santa-Cruz, V.......................... 2359, 2362* 

Santella, R M.......................................1966 

Santos Ahmed, J......................................61 

Saperstein, M........................................254 

Saperstein, S...................................... 1121* 

Sarangarajan, R................................. 1550* 

Sarazan, R..............................................235 

Sardão, V...............................................879 

Sardinia, L......................................... 1244* 

Sarigiannis, D A.........................48*, 1379* 

Sarlo, K.......................... 1437, 1444, 1973* 

Sá-Rocha, L C...................................... 183* 

Sá-Rocha, V M.......................................183 

Sarpong, N............................................486 

Sarsour, E H.........................................2064 

Sartor, M A..........................................1325 

Sasaki, D..............................................1591 

Sasaki, S...............................................1482 

Sathyanarayana, S...............................1777 

Sato, K...................................................877 

Satoh, M....................................1612, 2085 

Satoh, T...............................................2142 

Saulsbury, M D.................................... 286* 

Sava, V.............................................. 1810* 

Savage, P.............................................2308 

Sawada, K............................................1592 

Sawada, M...........................................1845 

Sawada, T C........................................2173 

Sawyer, K........................................... 1093* 

Saxena, R K...............................1038, 1489 

Sayes, C M........8*, 78*, 431*, 1487, 1488*, 

............................................................1514 

Sayes, C............................................. 2355* 

Scabilloni, J F............................1399, 1499 

Scarano, L.............................................923 

Schaeublin, N M........... 1024*, 1025, 1026 

Schafer, P............................................1656 

Schafer, R..............................................190 

Schaffner, C P.....................................1831 

Schalger, J............................................1054 

Schank, J R............................................208 

Schantz, A.................................1160, 2141 

Schantz, S L.........................................1712 

Schapiro, B J..........................................162 

Scharf, B............................................ 2094* 

Schatz, A R........................................ 1372* 

Schauss, A........................................... 723* 

Schebler, P J........................................ 814* 

Schecter, A J........................................ 785* 

Scheffler, B............................................761 

Schell, A C......................................... 2284* 

Schellenberg, G D.................................411 

Schenning, A M....................................143 

Scherer, A C........................................ 475* 

Scherer, M...............................................84 

Scheri, R C.......................................... 820* 

Scheuhammer, T.................................1858 

Schiestl, R H........................................2258 

Schiestl, R............................................1683 

Schilter, B..............................................698 

Schins, R...............................................440 

Schisler, M R.......................................1429 

Schladt, L..............................................531 

Schladweiler, M C.......... 741, 1072*, 1074, 

............................................................1654 

Schladweiler, M...................................1586 

Schlager, J J......423, 424, 425, 1024, 1025, 

....................1026, 1042, 1043, 1052, 1053 

Schlenk, D..........................273*, 303*, 780 

Schlezinger, J J....................................1378 

Schlezinger, J....................................... 609* 

Schlierf, T J.......................................... 413* 

Schlosser, P M................................... 1376* 

Schlosser, P..........................................1006 

Schmeiser, H H...................................1747 

Schmelting, B.......................... 2208*, 2296 

Schmid, J E............................................541 

Schmidt, J J.........................................1650 

Schmidt, J.......................1645, 2228, 2229 

Schmidt, K H.........................................552 

Schmitt, C...........................................1570 

Schmitt, T...........................................1927 

Schmuck, G.............................................82 

Schnackenberg, L K....................670, 1661 

Schnackenberg, L................66, 1925, 1927 

Schneider, D J..................................... 677* 

Schneider, D..........................................163 

Schneider, H...................................... 1275* 

Schneider, J S....................707, 1860, 1861 

Schneider, J...........................................566 

Schneider, R..........................................375 

Schneider, S N............... 1621*, 1903, 1904 

Schnellmann, R G.....................2061, 2062 

Schnieders, J.........................................675 

Schnurstein, A......................................331 

Schoeny, R S........................................2015 

Schoeters, E...........................................337 

Schoeters, G..................................337, 886 

Scholten, D......................................... 108* 

Scholz, B.............................................1718 

Schomaker, S.......................................1919 

Schrand, A M.............423, 424, 425, 1025, 

..................................................1026, 1053 

Schreiber, T...........................................578 

Schrenk, D..........................118, 778, 1221 

Schroeder, S...........................................676 

Schroeter, J D.............................. 993, 994* 

Schuck, M E...................................... 1192* 

Schuh, R A........................................ 1842* 

Schulpen, S...........................................577 

Schultz, I R.................74, 77*, 1239*, 1247 

Schultz, I................................... 767*, 1246 

Schultz, S............................................1953 

Schulz, M............................................ 443* 

Schulz, V J.............................................108 

Schulze, J B......................................... 699* 

Schulze-Bahr, E...................................1648 

Schuster, K..........................................1758 

Schuster, P........................................... 307* 

Schutte, K..............................................330 

Schwartz, A J.......................................1594 

Schwartz, R H......................................1120 

Schwarze, P E................................344, 747 

Schwarze, P....................................... 1085* 

Schwegler-Berry, D......................441, 1501 

Schweikart, K........................................392 

Scialis, R J............................................ 960* 

Scian, M J............................................ 908* 

Scicchitano, M.................................. 1596* 

Scinicariello, F........................... 408*, 2011 

Scollon, E J.................................. 612, 952* 

Scott, A S.............................................1848 

Scott, A..................................................102 

Scott, C S...............................................915 

Scott, L F.............................................1198 

Scott, L.............................................. 1741* 

Scott, M T..............................................150 

Scott, P S.............................................1198 

Scott, P................................................1178 

Scott, R C............................................1891 

Scotto, J A.............................................132 

Scuito, A M...........................................156 

Scully, K L...................................175, 1141 

Seabra, V M...........................................401 

Seagrave, J........33*, 296*, 738, 1071, 1503 

Searfoss, G H.............................1209, 1579 

Sedlak, D........................................... 1298* 

Seed, J....................................................923 

Seely, J C...............................................457 

Seidler, F J.................................1319, 2275 

Seifert, J............................................... 264* 

Seiler, A.................................................577 

Seilkop, S K.........................................1071 

Seinfeld, J............................................1503 

Seki, J..................................................1591 

Seki, T..................................................1584 

Seko, Y................................................2085 

Sekowski, J W...................................... 145* 

Selby, P B............................................. 927* 

Selgrade, M K......................................1442 

Sellamuthu, R................................... 1543* 

Selness, S...............................................754 

Sen, N..................................................1382 

Senba, T..............................................2307 

Senese, P...................................1656, 2306 

Seng, W L....................................777, 1646 

Sengupta, S............................. 2162, 2196* 

Sens, D A...............1598, 1620, 2113, 2114 

Sens, M..................1598, 1620, 2113, 2114 

Seo, Y.......................................... 308*, 310 

Sepulveda, M..........................................75 

Serebryakova, O G..............................2291 

Serex, T L.................................. 958*, 1163 

Serrano, J.............................................2077 

Serrano, S E.........................................1505 

Servoss, S L..........................................1764 

Setzer, R W................................1374, 2012 

Setzer, W...........................237, 1011, 2272 

Severson, S............................................819 

Sew, W..................................................137 

Sewald, K...............................................885 

Sexton, K G.......................297, 1089, 1091 

Shabb, D.............................................2270 

Shack, L A...........................................1597 

Shaddock, J G.....................................1688 

Shadid, M.......................................... 1689* 

Shafer, T J...... 576*, 579, 1698, 1840, 2268 

Shah, I.......................................1008, 1323 

Shah, N C..............................................785 

Shah, R R............................................. 263* 

Shah, R.............................................. 1996* 

Shah, S A............................................. 233* 

Shalaby, A A........................................1211 

Shan, Y..................................................477 

Shangari, N....................................... 1923* 

Shangraw, R..........................................767 

Shankar, K.............................................844 

Shannahan, J H...................................1654 

Shannahan, J..............................741, 1072 

Shao, C..................................................865 

Shao, J S................................................357 

Shao, J....................................... 369*, 2019 

Sharif, S...............................................2128 

Sharma, B.......................................... 1226* 

Sharma, M......................................... 2209* 

Shaw, D...............................................1765 

Shaw, M......................................456, 1246 

Shaw, P J.............................. 623*, 847, 848 

Shaw, P................................................1208 

Shaw, S................................................1794 

Shea, D..................................................821 

Shearn, C T......................................... 114* 

Sheasgreen, J.........................................334 

Sheets, L P...........................................2325 

Sheik Mohideen, S............................ 1817* 

Sheikh, K A.........................................1463 

Shelton, S D........................................1430 

308 




Shen, H............................................... 810* 

Shen, L................................................ 462* 

Shen, M.................................................493 

Shen, X.........................................468, 546 

Shepard, K...........................................1655 

Shepherd, D M......................................604 

Sherr, D H.........................609, 1061, 2194 

Shertzer, H G................. 1621, 1903*, 1904 

Sheth, C M.......................................... 195* 

Shetty, A K............................................141 

Sheu, T..................................................685 

Sheveleva, E V.....................................1666 

Shi, J...................................................... 84* 

Shi, L Z.................................................. 69* 

Shi, L.....................................................610 

Shi, W...................................................669 

Shi, X..........................156, 441, 708, 1626 

Shi, Y................................................. 1126* 

Shibaya, Y.............................................225 

Shibutani, M...............................113, 1702 

Shih, T M..............................................125 

Shih, T................................. 131, 148, 150* 

Shilliday, B............................................754 

Shimada, A..........................................2085 

Shimada, H....................................... 1619* 

Shimada, T............................................219 

Shimizu, K...................................363, 1056 

Shimoji, N...........................................2200 

Shimouchi, K......................................2311 

Shimoyama, M................................... 583* 

Shines, C.............................................1079 

Shinohara, M........................................851 

Shioda, S.............................................1706 

Shipkova, P.........................................1605 

Shoufler, D............................................386 

Shram, R.............................................1736 

Shreffler, C..........................................2043 

Shufang, Z...........................................1138 

Shui, G................................................1398 

Shukla, A...............................................294 

Shultz, J.................................................774 

Shultz, M.............................................1337 

Shvedova, A A............... 1036, 1494, 1497* 

Shvedova, A................................441, 1031 

Shymonyak, S.......................................221 

Shyu, C.................................................496 

Sibiril, Y........................................184, 909 

Sieber, T....................................1167, 1186 

Siegel Scott, C.......................................914 

Siegel, D..............................................1994 

Siegel, P D...........................................1316 

Siegers, C P........................................ 1918* 

Siehl, D...............................................2229 

Siemion, R S..........................................722 

Sierra-Santoyo, A........................ 266, 315* 

Sigler, M A.............................................139 

Siitonen, P H.............................1023, 1403 

Sijtsma, L............................................2221 

Silbajoris, R............................. 1073, 1489* 

Silbergeld, E K........194, 1041, 1463, 1847, 

...................................... 1848*, 1850, 1851 

Silkworth, J B.............................. 816*, 817 

Siller, F.............................................. 1131* 

Sills, R................................................ 2334* 

Silva, V M.......................................... 1788* 

Silva, V V............................................2173 

Silverstone, A E.....................................181 

Simard, H............................................2316 

Simeckova, P.........................................811 

Simenstad, C A...................................1248 

Simeonova, P........................................740 

Simman, R..........................................1562 

Simmonds, P L........................ 1104, 1766* 

Simmons, B....................................... 1092* 

Simmons, D..........................................234 

Simmons, J.............................. 1003, 1191* 

Simmons, S....................................... 1426* 

Simões, A M........................................1035 

Simon, G...............................................499 

Simon, R R.......................................... 511* 

Simon, S A...........................................1055 

Simoyi, R H.........................................1316 

Simpson, B.......................................... 254* 

Simpson, C D........................................287 

Simpson, C..........................................1602 

Simpson, P............................................844 

Sinclair, J R.................................. 92*, 2083 

Singh, A V...................................239, 1968 

Singh, A..............................................1539 

Singh, B............................................. 2174* 

Singh, K P................................... 365, 367* 

Singh, K................................................360 

Singh, N P......................................... 2004* 

Singh, P............................................. 2042* 

Singh, R.......................................520, 1747 

Singh, S V.......................................... 2183* 

Singhal, R.......................................... 1062* 

Sinha, V..............................................1905 

Sinko, P J................................. 1545, 1971* 

Sioutas, C..............................................733 

Sipes, I G...............................................964 

Sipes, I...............................968, 1145, 1382 

Siraki, A............................................. 2060* 

Sirica, A E............................................ 222* 

Sistare, F D.............................. 1265, 1283* 

Sistare, F................................................380 

Sit, T L...................................................548 

Sithu, S D..................................1254, 2059 

Siu, W.................................................1213 

Skare, J A............................................. 661* 

Skibola, C............................................1625 

Skirda, K..................................................45 

Skoglund, R S...................................... 990* 

Skomedal, T..........................................747 

Skovira, J W..........................................150 

Skowronek, A J......................................720 

Skrzydlewska, E................................. 2050* 

Skytte, C................................................205 

Slaven, J................................................406 

Slavik, J.................................................811 

Slavkovich, V............................1644, 1966 

Slayton, T M.......................................1462 

Slezak, B P................................. 956, 1163* 

Slikker, W..................... 1328*, 1696, 1714, 

..................................................1726, 1728 

Slitt, A L....................317, 833, 2029, 2030 

Slitt, A............................................... 2028* 

Sloan, C...................................................63 

Sloter, E D......................................... 2301* 

Slotkin, T A...............................1319, 2275 

Sly, J........................................................84 

Smart, D J.............................................. 82* 

Smart, E...............................................2215 

Smartt, A M....................................... 1094* 

Smitasiri, Y............................................723 

Smith, B J..............................................792 

Smith, C L.............................................584 

Smith, C S...........................512, 814, 1403 

Smith, C V........................229, 1159, 1949 

Smith, C........................961, 962, 971, 972 

Smith, D C..........................................2135 

Smith, D.................................... 589, 2133* 

Smith, E................................................236 

Smith, G T.......................................... 949* 

Smith, G................................................478 

Smith, H W......................................... 386* 

Smith, H..............................................2308 

Smith, J.................................................583 

Smith, K......................................330, 1186 

Smith, M J............................... 2133, 2135* 

Smith, M T............................................882 

Smith, M V............................................878 

Smith, M......................... 467, 1019*, 1625 

Smith, N B....................................416, 417 

Smith, P C...........................................1894 

Smith, P J..............................................231 

Smith, P................1906, 2049, 2141, 2293 

Smith, R D..........................................1743 

Smith, R J......................................473, 763 

Smith, S M...................... 350*, 1532, 1692 

Smith, T K...........................................2128 

Smulian, J C........................................1738 

Snajdr, S I..............................................616 

Snajdr, S................................................812 

Snedden, L..........................................1650 

Snellings, W M...................................1084 

Snook, M E....................................482, 484 

Snyder, A C.........................................1956 

Snyder, D W..........................................878 

Snyder, M..............................................988 

Snyder, R D....................... 473, 763, 2346* 

Snyder, R J......................................... 1504* 

Snyder, R W..........................................403 

Snyder, R................63, 1267, 1917*, 2342* 

Snyder, S A............................................463 

So, K....................................................1506 

Sobol, M................................................774 

Sobol, Z............................................. 2258* 

Sobotka, T J.........................................1204 

Soderlund, D.......................................2274 

Söderlund, R.........................................364 

Sokolov, V B........................................2291 

Sokolowski, K B................................. 1844* 

Solanki, A C...................................... 1225* 

Soliman, K F........................................1822 

Solipuram, R.........................................345 

Soman, K V.........................................1742 

Somers-Edgar, T J.............................. 1393* 

Somji, S............... 1598, 1620, 2113*, 2114 

Sommargren, M................................ 1777* 

Sommerville, D R..........................132, 142 

Somps, C A..............................................35 

Somps, C J............................................. 37* 

Somsamayvong, B................................125 

Son, H................................................. 798* 

Sonawane, B R.................................... 997* 

Sonawane, B........................421, 914, 1685 

Sonawane, M...................................... 922* 

Sone, H..................................................276 

Song, H.....................................1138, 2231 

Song, M........................... 442, 1502, 1580* 

Song, P........................................ 825, 827* 

Song, Y................................................2167 

Soni, M G.................................... 493, 658* 

Soni, S...................................................147 

Sonne-Hansen, K................................1389 

Sono, S................................................1447 

Sood, G K............................................1742 

Sorrentino, C.................................... 1931* 

Sorribas, V............................... 1627, 2203* 

Soshilov, A........................................ 2158* 

Soto, A..................................... 1431*, 1582 

Soufal, A..............................................2245 

Sovadinova, I................................371, 523 

Sozu, T................................................1451 

Sparkenbaugh, E............................... 1208* 

Sparks, M..............................................248 

Spencer, C M.......................................1536 

Spencer, P J............................. 1187, 1785* 

Spencer, P............................................1816 

Spencer-Briggs, D................................1926 

Spenkelink, B......................................2221 

Spiller, E................................................333 

Spindel, E R....................................... 1336* 

Spirkl, H..............................................2259 

Spitsbergen, J......................................1161 

Spitz, D R..................................2064, 2068 

Spitz, D.................................................234 

Sponenberg, P...........................2125, 2127 

Sprankle, C............................................988 

Spriggs, D..............................................126 

Spronk, H..............................................746 

Squibb, K S.............................. 1733*, 2067 

Srinouanprachanh, S..........................2191 

Sriram, K...................................1098, 1492 

Srivastava, S........ 1254, 1967*, 1968, 2059 

St. Claire, M C.....................................2335 

Stachlewitz, R......................................2342 

Stadler, K.............................................1497 

Staedtler, F........................................ 1270* 

Stagg, B...............................................2229 

Stammberger, I............................675, 2259 

Stamyr, K........................................... 1745* 

Stanek, E J...........................................1907 

Stanislaus, D J.....................................1132 

Stankiewicz, A.....................................2050 

Stanko, J P........... 1139, 1155*, 1156, 1986 

Stankowski, L F...................................2251 

Stanley, J K.......................................... 429* 

Stapleton, A R..................................... 449* 

Stapleton, H..........................................799 

Stapleton, P L........................................760 

Stark, G V..............................................157 

Starr, J M...............................................952 

Starr, T.................................................1786 

Stashenko, E..........................................721 

Staskal, D F.......... 1178, 1198, 1741, 1800* 

Staskal, D.......................................... 2041* 

States, J..... 414, 415, 416, 417, 871, 1965*, 

............................ 1967, 1968*, 2110, 2112 

Stavros, H............................................2139 

Stearns, D M.......................................1634 

Stebbins, K E.......................................1142 

Stedeford, T...........................................916 

Stedman, D B.................................... 2340* 

Stedman, N L......................................1909 

Steele Fisher, S.......................................324 

Steevens, J A........................................1241 

Steevens, J.............................................438 

Steffen, M C........................................1108 

Steffy, D A...........................................1227 

Stein, J...................................................600 

Steiner, S R........................................ 1834* 

Steinmetz, K L......................... 1033*, 1770 

Steinmetz, K................................392, 1361 

Stemmer, K.................................. 110, 527* 

Stephani, R A.................................... 1715* 

Steppan, L B.................. 2006, 2129, 2169* 

Stern, S T................................. 1050*, 1051 

Sternberg, R M.................................. 1250* 

Sterner, T R............................... 999*, 1782 

Steuerwald, N........................................802 

Stevens, C K..........................................776 

Stevens, C...........................................2193 

Stevens, J L..........................................1579 

Stevens, J.............................................2140 

Stevens, R C........................................ 265* 

Stevens, T.......................................... 1588* 

Stewart, B J..........................................1945 

Stewart, B.......................................... 1212* 

Stewart, J.......................................176, 750 

Stewart, R C........................................2000 

Stickney, J...........................................2013 

Stigson, M....................... 364, 1718, 2017* 

Stilianesis, M.......................................2316 

Stirling, D............................................1656 

Stitt, M S.............................................2000 

Stock, H...............................................1575 

Stohs, S J.............................................1390 

Stoick, K M.......................................... 991* 

Stoker, T................................ 94, 95*, 1184 

Stokes, W.......................47, 891, 898, 899, 

.................................................. 988, 1455* 

Stolper, G......................................341, 895 

Stolte, M................................................675 

Stoltzfus, R J........................................1767 

Stolz, D B........................1036, 1622, 1969 

Stone, P...............................................1103 

Stone, S.....................................1081, 1497 

Stoner, M A...........................................547 

Storaska, A.......................................... 240* 

Storck, M...............................................412 

Storey, J V.......................................... 1245* 

Stork, L..................................................271 

Stott, W...............................................1595 

Stout, M D................ 516*, 517, 518, 1754 

Strader, L F..........................................1155 

Stratmeyer, M E..........................946, 1048 

Straub, A C.............................. 1622*, 1969 

Strauss, V..................................1400, 1603 

Streck, R D..........................................2340 

Strehl, R................................................364 

Streifel, K.............................................1862 

Streit, W J.............................................. 17* 

Strickland, J................................. 898, 899* 

Strittholt, C.........................................1682 

Strom, S.................................................672 

Stromberg, A J.......................................813 

Strong, J..............................911, 919, 2013 

Strouts, B...............................................482 

Struble, C............................................1659 

Strupp, C........................................... 1391* 

Struve, M F................................1877, 2098 

Struve, P S.............................................193 

Strynar, M J.........................................1374 

Stuart, B P...........................................2325 

Stuckey, J A.........................................2292 

Stults, D M........................................ 1673* 

Stump, D G...............................1710, 1729 

Stump, D.............................................2301 

Stutz, J P....................................1209, 1579 

Styblo, M.................407, 1623, 1628, 2089 

Su, J.......................................................701 

Su, S..........................................1544, 1790 

Suarez, J D...........................................1155 

Suárez, J E............................................ 189* 

Sublett, R.............................................2310 

Subramaniam, R...................................914 

Subramanian, R..................................2037 

Suda, T................................................2164 

Suen, T..................................................525 

Sugai, E................................................ 687* 

Sugamori, K S.............................. 224*, 869 

Sugaya, C............................................2142 

Sugimoto, K........................................2243 

Sugita-Konishi, Y.............. 495*, 498, 2142 

Sugiyama, A..........................................757 

Sugiyama, K................................ 495, 498* 

Suh, M..................................... 1607, 1801* 

Suh, Y.................................................. 795* 

Sui, L...................................................1703 

Sukata, T...............................................532 

Sukhija, H R............................ 1995, 1998* 

Sulentic, C E.........................165, 167, 168 

Sulentic, C..........................................1054 

Sulik, K K............................................1530 

Sullivan, K A..................... 704, 706, 1862* 

Sullivan, M R.................................... 1368* 

Sullivan, M............................................619 

Sullivan, R C.........................................671 

Sultatos, L......................................... 2265* 

Sumida, H...........................................1158 

Sumida, K..............................................532 

Summar, M L........................................409 

Summers, C.........................................1205 

Sumner, S J............................................ 63* 

Sumner, S............................................1917 

Sun, B.................................................. 358* 

Sun, D...................................................386 

Sun, G.................................240, 701, 1302 

Sun, N N.............................................1101 

Sun, Q......................... 223, 735*, 743, 744 

Sun, Y................................................ 1303* 

Sun, Z...................................... 2031*, 2072 

Sundaram, S K........................... 435*, 1401 

Sunderland, K.......................................451 

Sung, J............................................... 1502* 

Surapaneni, S......................................1915 

Surendran, G..................................... 1875* 

Sutherland, K......................................1337 

Sutter, C H........................................ 2160* 

Sutter, C................................................816 

Sutter, T R...........................816, 817, 2160 

Sutton, J N..........................................1063 

Sutton, T.................................................75 

Suzen, S H.............................................402 

Suzuki, A.............................................1657 

Suzuki, E........................................... 2200* 

Suzuki, K.............................................1203 

Suzuki, N.............................................1584 

Author Index 




Author Index 

Suzuki, S M...........................................265 

Suzuki, S.................................... 520, 1624* 

Suzuki, T........................................... 1899* 

Suzuki, Y...............................................302 

Svendsen, E.........................................1439 

Svoboda, K K.........................................155 

Swain, K A...........................................1514 

Swann, F B.......................................... 959* 

Swanson, A J.................................892, 893 

Swanson, C L......................................1141 

Swanson, P..........................................1239 

Swaroop, A..........................................1724 

Swartz, C.............................................1055 

Swearengen, J...................................... 976* 

Sweatt, D.............................................1364 

Sweeney, A............................................445 

Sweeney, L M.................................... 1783* 

Sweeney, L..................................967, 1784 

Swenberg, J A.............83, 529, 1166, 1748, 

........................................1754, 1755, 1759 

Swenberg, J.........................................1736 

Swezey, R.....................................453, 1895 

Swinkey, M E.......................................1088 

Switzer, R C....................................... 1838* 

Syed, I.................................................1390 

Sykes, G P..........................201, 2230, 2233 

Sykes, G...............................................1076 

Synhaeve, N..........................................217 

Syversen, T................................1636, 1861 

Szabo, D T........................................... 101* 

Szczublewski, K................................. 1054* 

Szilagyi, M................................... 887, 923* 

Szostek, B......................................509, 957 

T 

Tabin, C J............................................1524 

Tachibana, A.......................................1200 

Tachovsky, J A...................697, 1178, 1198 

Tafazoli, S.......................................... 1210* 

Taguchi, K...........................................2029 

Tahara, M....................................363, 1056 

Tai, T.....................................................875 

Tajuba, J..............................................1055 

Takacs, M L...........................................541 

Takagi, A............................................. 370* 

Takahashi, M..................................... 1702* 

Takahashi, T...................................... 1900* 

Takahashi, Y.............................. 329*, 2149 

Takami, K............................................1756 

Takami, S...............................................480 

Takamura-Enya, T...............................1747 

Takano, H......................................188, 214 

Takasaki, W......................................... 225* 

Takashima, A.......................................1845 

Takashima, Y.......................................2243 

Takenobu, Y........................................2311 

Takeyoshi, M.......................................1451 

Tal, T................................................. 1073* 

Talathi, S...............................................359 

Talatum, S...............................................60 

Tamaki, Y............................................1533 

Tan Molina, L......................................2077 

Tan, J................................................. 2274* 

Tan, S....................................................236 

Tan, Y.................1007, 1010*, 1398, 2219* 

Tan, Z..................................................1130 

Tanabe, S.....................................553, 2164 

Tanaka, A K.........................................1076 

Tanaka, A..............................................877 

Tanaka, M...........................................1451 

Tanaka, Y....................................829, 1946 

Tanamoto, K.........................................498 

Tang, L.... 485, 490, 701, 865, 1478, 2238* 

Tang, X................................................1646 

Tang, Y...................................... 461*, 2238 

Tang, Z................................................2074 

Tanguay, R L......... 433, 1914, 1976, 1978*, 

..................................................2162, 2196 

Tanguay, R.............................6, 1238, 2264 

Tanhehco, E........................................1656 

Tanji, M...............................................1427 

Tankersley, C G.....................................736 

Tanya, M...............................................282 

Tao, J................................................. 2252* 

Tappenden, D M............................... 1420* 

Tarantino, L M.................................. 1082* 

Taras, T...................................... 941, 1796* 

Tarasevich, B J.....................................1405 

Tardif, R.....................969, 997, 1004, 1792 

Tareke, E..................................................97 

Tark, D................................................2131 

Tarrant, A M........................................2194 

Tashiro, N...........................................1203 

Tashiro, T............................................2142 

Tate, M................................................2255 

Tateishi, T...........................................1158 

Tateno, C............................................1200 

Tawde, S............................................ 1465* 

Taylor, B F...........................................2112 

Taylor, G.............................................1079 

Taylor, I................................... 1181, 2324* 

Taylor, J B..............................................933 

Taylor, J F.......................................... 1631* 

Taylor, J T..............................................138 

Taylor, J.....................483, 486, 1478, 1661 

Taylor, M........................................... 2267* 

Taylor, R T................................... 551*, 782 

Taylor, R..............................................1631 

Taylor, T N.......................................... 208* 

Tchounwou, P B..............................80, 356 

Tchounwou, P.....................................1040 

Teague, J E.............................................609 

Teague, S V..........................................1505 

Teeguarden, J G................................. 1975* 

Teeguarden, J..................................8, 1401 

Teesch, L...............................................800 

Tegtmeier, M.......................................1918 

Tekpli, X................................................344 

Tellier, P A.................................1892, 1893 

Tempel, P............................................2319 

Templeton, A......................................2134 

ten Cate, H............................................746 

Tencalla, F R..........................................982 

Tennant, R W......................................1632 

Teo, K..................................................1765 

Teodoro, J P....................................... 1035* 

Teraoka, H......................................... 2187* 

Terasavich, B J.......................................439 

Teresa, F I...................... 1642, 1643, 2086* 

Terneus, M V.........................................452 

Terse, P................................................2314 

Tervonen, T...........................................438 

Tessari, J D...........................................1984 

Tessari, J..............................................1322 

Testorf, T.............................................2136 

Tetz, L M........................................... 1521* 

Teuschler, L K......................................1191 

Teuschler, L.................................271, 2013 

Tewari-Singh, N.................. 151, 204, 678* 

Tewksbury, E W........................1507, 1512 

Tewksbury, E.....................996, 1877, 2098 

Thai, S...........................................282, 890 

Thakur, S A.......................................... 555* 

Thapa, P..............................................1686 

Thapa, U.............................................1686 

Thatcher, C D.....................................1485 

Thatcher, G R........1057, 1058, 1059, 1905 

Theodore, M L........................................49 

Thiemann, A.........................................331 

Thiruchelvam, M............1812, 1869, 1983 

Thomas, C E..............................1209, 1579 

Thomas, D J..............................1623, 1628 

Thomas, H C.......................................1596 

Thomas, H..........................................1762 

Thomas, J F.........................................2324 

Thomas, K C..................................... 1113* 

Thomas, P........................................... 998* 

Thomas, R S......... 591*, 1175, 1420, 1589, 

...................................... 1590, 2026, 2350* 

Thomas, R............... 259, 741*, 1242, 2349 

Thompson, C........................................997 

Thompson, D C.......................... 387, 389* 

Thompson, D................................754, 773 

Thompson, J.........................................114 

Thompson, M.....................................2100 

Thompson, S A.............................892, 893 

Thomson, S A.......................125, 132, 142 

Thomson, S...........................................138 

Thorgeirsson, S S................................... 27* 

Thorne, D.......................................... 2079* 

Thornton, C..................................761, 867 

Thorpe, J E..........................................1433 

Thrall, B D...........................................1975 

Thrall, B...................................... 436, 439* 

Thrall, K D..........................................1635 

Threadgill, D W......................88, 688, 842 

Threadgill, D..................... 374, 418, 1280* 

Thudium, D..........................................380 

Thulin, P...............................................823 

Thuot, R..............................................1460 

Thurston, A...........................................754 

Tian, Q..................................................865 

Tian, Y....................................... 550, 1138* 

Tibbetts, B M.......................................1542 

Tibbetts, B...........................................1165 

Tice, R.................891, 898, 899, 988, 1455 

Tien, L...................................................546 

Tierney, D F...........................................288 

Tiesman, J P..........................................897 

Tieu, K.......................................1709, 1720 

Till, B A.................................................860 

Tiller, P R.............................................1937 

Tilton, F............................................ 1722* 

Tilton, J.................................................230 

Tilton, S C........................................... 357* 

Tilton, S............................799, 2019, 2191 

Timchalk, C.....140, 613, 679, 1018, 1078, 

............................ 1373, 1375*, 1752, 1753 

Timme-Laragy, A R.............................1964 

Timme-Laragy, A.................................1963 

Timofeeva, O A................................. 2275* 

Tipple, T E...........................................1769 

Tirumala, V.........................................1501 

Tita, E F............................................. 1166* 

Tiwari, M.............................................2209 

Tiwari, R..............................................2209 

Tiwari, V K..........................................1826 

Tiwary, A K........................................ 1114* 

Tjalkens, R B.............704, 706, 1862, 2038 

Toal, M C..............................................446 

Toborek, M J.........................................813 

Toborek, M................................2215, 2220 

Todd, D.................................................377 

Todorov, T...........................................1733 

Toeroek, M..........................................2250 

Tohyama, C.....196, 687, 1111, 1707, 2023 

Tokado, H..................................1657, 2149 

Tokar, E J................................. 1307*, 1608 

Tokunaga, H................................363, 1056 

Tollerud, D J........................................1034 

Tolleson, W H........................... 682, 2235* 

Tolson, J K............................... 1192, 1799* 

Tomari, T.....................................757, 1203 

Tomaszewski, J E.................................1936 

Tomaszewski, J............................392, 2314 

Tomczuk, M..........................................584 

Tomi, H.................................................493 

Tomigahara, Y.......................................532 

Tomioka, S..........................................2200 

Tomohiko, I........................................2024 

Tompkins, L M......................................548 

Tong, H................................... 1038*, 1072 

Tong, S................................................2155 

Tong, W...................... 28, 595*, 670, 1661 

Topinka, J............................................ 868* 

Topper, M..............................................380 

Tornero-Velez, R....................269, 612, 952 

Torous, D............................................2245 

Torres Sanchez, L................................1767 

Torres, J............................................... 832* 

Torres, M.............................................1881 

Torres, S M................................ 206*, 2333 

Torres-Hernandez, J A....................... 1039* 

Toscano, C D..................................... 1815* 

Toselli, P..............................................1103 

Totlandsdal, A I................................... 747* 

Tovar-Sanchez, E.......................1642, 1643 

Townsend, A J.......................................116 

Townsend, M................................922, 923 

Tozer, S A.............................................1716 

Tracey, K J.................................2071, 2132 

Trada, B S.......................................... 1826* 

Tran, T............................................... 1692* 

Travlos, G S.................................516, 1655 

Treacy, G...................................1160, 2141 

Tremblay, R T.................. 948, 1100*, 1464 

Trempus, C S.......................................1632 

Trepanier, L.........................................1457 

Trilecová, L...........................................868 

Troesken, E.......................................... 675* 

Trombetta, L D......1224, 1225, 2094, 2095 

Trommer, W E.....................................1391 

Troncy, E................... 211, 212, 232*, 1649 

Tropsha, A......................... 244, 245, 1991* 

Troschau, G.........................................2259 

Trosko, J E.....................361, 371, 523, 877 

Trost, L C.......................................... 1902* 

Troth, S.................................................380 

Troxell, E C...........................................154 

Truchon, G............................................500 

Trudel, Y..............................................2316 

Tryndyak, V........... 524*, 717, 1060, 1064, 

..................................................1416, 1910 

Tsang, A M............................................269 

Tsaprailis, G T.......................................470 

Tschöp, M H.........................................527 

Tseng, C................................................504 

Tseng, J..................................................383 

Tseng, M T..........................................2215 

Tshala-Katumbay, D.......................... 1816* 

Tsuboi, I................................................361 

Tsuchitani, M......................................2280 

Tsuchiya, A................................. 475, 693* 

Tsuchiya, M..........................................842 

Tsuji, M...............................................2142 

Tsunehiro, O.........................................199 

Tsunoda, M....................................... 2142* 

Tsusaki, H............................................1160 

Tsutsui, N..................................1203, 1751 

Tubbs, J...............................................1065 

Tucker, A.............................................1242 

Tugwood, J D......................................1891 

Tung, E W......................................... 1523* 

Turmel, G J..........................................1824 

Tvermoes, B...................................... 1614* 

Twamley, M........................................1577 

Twigger, S..............................................583 

Tyl, R.......................................................63 

Tyler, N K..............................................575 

Tyurin, V A............................. 1392, 1961* 

Tyurina, Y Y............................ 1036, 2000* 

U 

Uddin, A N..........................................1306 

Uehara, T.......................................... 1593* 

Ueng, T............................................. 1148* 

Ueno, S................................................1700 

Ulf, A.....................................................823 

Ulker, O C.............................................488 

Ullmann, L G......................................1454 

Ulrich, R G............................................393 

Umannova, L..............................811, 1216 

Umbdenstock, T.................................1922 

Umbreit, T.......................................... 946* 

Unami, A.............................................1591 

Unfricht, D W.......................................171 

Unice, K M............1178, 1198, 1471, 1800 

Updegraff, M.........................................584 

Upham, B L......................... 371*, 523, 877 

Uppal, H..........................1896, 2256, 2306 

Uppu, R M.... 314, 316*, 1664, 1999, 2201 

Upton, P B................................1748, 1754 

Upton, P..............................................1736 

Urano, K.............................................. 227* 

Urban, J D......................................... 1198* 

Uribe-Ramirez, M..........................292, 293 

Urrutia, J I......................................... 1725* 

Urushidani, T................ 1564*, 1569, 1593 

Usenko, S................................................71 

Usui, T...................................................227 

Usuki, F............................................. 2048* 

Utell, M.................................................745 

Uttamsingh, V....................................1222 

Uwagawa, S...........................................532 

Uzumcu, M.........................................1152 

V 

Vacek, P...............................................1736 

Vahey, M...............................................145 

Vaidya, V S........378, 446, 451*, 456, 664*, 

............................................................1739 

Vaidya, V...............................................380 

Vaidyanathan, A.................................1930 

Vaillancourt, R R.................................1304 

Vailles, R.............................................1463 

Vaittinen, O........................................1745 

Valcke, M.......................................... 1180* 

Valdes, J................................................145 

Valenti, Jr, T W.......................................71 

Valentin, J......................... 647, 651*, 2295 

Valentine, R........................................ 509* 

Valentovic, M............................. 452*, 838 

Valenzuela, O L................................... 407* 

Valerio, L G......................................... 253* 

Vallanat, B..................... 1410, 1428*, 1654 

Valley, M P............................................774 

Vallyathan, V......................300, 406, 1031 

Valverde, C..........................................1873 

van Agthoven, A.................................2246 

van Beelen, V.......................... 1535*, 2221 

van Breemen, R B...............................1058 

Van Cauwenberge, P.............................886 

van den Berg, M...........108, 794, 797, 803, 

..........................................807, 1233, 2172 

Van Den Heuvel, R.......................337, 886 

van der Burg, B.....................................105 

van der Laan, J W............................. 1293* 

van der Linden, S..................................105 

Van Der Merwe, D..............................1465 

van der Vliet, A.....................................294 

van Duursen, M B..... 108, 803, 807, 2172* 

Van Goethem, D L................................531 

Van Goethem, F..................................2244 

Van Gompel, J....................................2244 

Van Houten, B....................................1668 

van Kleef, R G...............................794, 807 

van Loveren, H.......................................64 

Van Loveren, H..................................... 65* 

Van Miller, J..........................................970 

Van Ness, K....................................... 1928* 

van Oerle, R..........................................746 

van Ravenzwaay, B............443, 885, 1400, 

.......................................................... 1603* 

van Schooten, F..................................1535 

Van Scott, M R....................................1258 

van Steeg, H............................................64 

Van Steeg, H............................................65 

Van Tiem, L............................. 1963*, 1964 

Van Vleet, T........................................1921 

Van Winkle, L S............568*, 1331*, 1333, 

.......................................................... 1337* 

Vancza, E M........................................ 291* 

VanDeMark, K L................................ 1691* 

Vanden Heuvel, J P..................... 540, 542* 

Vandenberg, J...............................911, 912 

Vander Wal, R.....................................1037 

310 




Vanoirbeek, J A................................... 217* 

Vanoirbeek, J....................................... 653* 

Varanasi, U.......................................... 600* 

Vargas, J..............................................1097 

Vargas, M..............................................580 

Varnum, S M.............................1743, 1764 

Vasconcelos, D....................................2314 

Vasiliou, V.................................1950, 1951 

Vasquez, M............................................722 

Vassallo, J D................................ 390*, 472 

Vavasour, E............................................861 

Vavilala, S R........................................ 696* 

Vavilikolanu, P............................ 323*, 325 

Vazquez, I............................................2077 

Veenstra, G.............................................45 

Vega, E................................................2077 

Vega, F.................................................1827 

Vega, H........................................285, 1172 

Velez, C...............................................1237 

Venables, B..........................................1230 

Veney, D J.............................................175 

Venkatakrishnan, P........................... 2066* 

Venkatapathy, R....................................499 

Venkataraman, S.................................2055 

Venkatasubbaiah, V.......................... 2055* 

Vennard, T............................................477 

Vera, E.................................................1767 

Veranth, J M.......................................1044 

Veranth, J............................................2214 

Verhoef, A...........................................1535 

Verina, T........................................... 1860* 

Verner, M.......................................... 1901* 

Veronesi, B........................................ 1055* 

Verstraelen, S...................................... 886* 

Vetrano, K...........................................1470 

Vezina, C M.................. 1515*, 1516, 1517 

Viau, C...................................... 500, 1460* 

Viberg, H........................................... 1708* 

Vicart, A............................................ 2303* 

Vicini, S...............................................1815 

Vickers, A E................................. 92, 2083* 

Vicki, D.................................................236 

Vidal, J..................................................631 

Vietti, K R............................................1871 

Vigoren, E M................. 1179, 1190*, 1248 

Vijay, V.............................................. 1557* 

Vijverberg, H P......................................794 

Villa-Bellosta, R....................... 1627*, 2203 

Villalobos, P........................................1873 

Villano, C.......................................... 2197* 

Villeneuve, D......................................1231 

Vinci, T...............................................1660 

Vines, L L.......................................... 2226* 

Vinggaard, A.......................................1389 

Vinnakota, C V................................... 161* 

Virgolini, M B.....................................1869 

Vitalone, A.......................................... 476* 

Viviani, B.......................................... 1046* 

Vladimirova, A..........................1123, 1578 

Vladykovskaya, E N........1254, 1967, 2059 

Vo, G...................................................2232 

Vo, T D.............................................. 1565* 

Vocci, F...............................................1936 

Vodela, J.............................................. 694* 

Völkel, W............................................1734 

von Landenberg, F..............................2319 

von Maltzan, K................................... 605* 

von Recklinghausen, U.......................2115 

Vonderscher, J P................................ 1265* 

Vonderscher, J.......................................399 

Vondrá?ek, J..........................................868 

Vondracek, J.............................. 811, 1216* 

Vora, S...................................................620 

Vorachek, W R..........................2006, 2129 

Vorderstrasse, B A................... 1070*, 1147 

Vorojeikina, D P................................ 2159* 

Vorojeikina, D.....................................2161 

Voss, K A............................. 482*, 484, 487 

Vouros, P...............................................671 

Vrabie, C........................................... 1233* 

Vredevoogd, M................................. 1320* 

Vulimiri, S V....................................... 907* 

Vulpe, C D............................................882 

Vyskocil, A.......................................... 500* 

Vytas, R...............................................1048 

W 

Waalkes, M........... 634*, 1303, 1307, 1309, 

.................. 1397, 1617, 1632*, 1633, 2118 

Waalkes, M P.............................1608, 1619 

Wachi, S..............................................2033 

Wada, Y.................................................398 

Wade, M......................................941, 1796 

Wade, T...............................................1640 

Waggie, K............................................1934 

Wagner, D J......... 1877, 2097, 2098*, 2099 

Wagner, J G..................... 573, 1088*, 1913 

Wagner, J...............................................806 

Wagner, S..............................................382 

Wahle, B S......................................... 2325* 

Waidyanatha, S.....................................418 

Waikar, S S..................................451, 1739 

Wakasa, M...........................................2142 

Wako, Y...............................................2280 

Waldner, C..........................................1803 

Waldrep, J C..........................................614 

Wales, M E..........................................2286 

Walgren, J L................................ 387*, 389 

Walk, T................................................1603 

Walker, B R..........................................1256 

Walker, B...............................................737 

Walker, C C.........................................1229 

Walker, C L...........................................690 

Walker, D M.........206, 1672*, 2333*, 2335 

Walker, G..............................................332 

Walker, H L...........................................694 

Walker, J N..........................................1178 

Walker, M K............ 539, 689*, 2206, 2207 

Walker, N J......................1017, 1403, 1551 

Walker, N.......................................... 1970* 

Walker, S G..........................................1084 

Walker, V E..........................................2335 

Walker, V...........................206, 1748, 2333 

Wallace, A D....................................... 548* 

Wallace, A...........................................1052 

Wallace, D G.......................................1509 

Wallace, K B...................... 557*, 789, 1710 

Wallace, K.........................879, 1587, 1599 

Wallace, M m......................................1220 

Wallace, W............................................441 

Wallenborn, J G................................ 1654* 

Wallenborn, J..............................741, 1072 

Wallis, C................................................992 

Walmsley, R............................ 2254*, 2255 

Walraven, J M.......................................422 

Walsh, D...............................................989 

Walsh, M T..........................................2207 

Walters, D M.........................................115 

Walters, E................................................60 

Walther, B...........................................1922 

Walton, F S.............................. 1623, 2089* 

Wambaugh, J F................................. 1011* 

Wan, R................................................1034 

Wan, Y........................................828, 1571 

Wang, A A........................................... 937* 

Wang, A........................................735, 744 

Wang, B...............................234, 818, 1621 

Wang, C....504*, 1567, 1696, 1714, 1726*, 

............................................................1728 

Wang, D Q..........................................2028 

Wang, E....................................... 473, 763* 

Wang, F...............................................2322 

Wang, G.................. 111, 589, 1289, 2124* 

Wang, H............................679, 2071, 2132 

Wang, J S......... 485, 490, 701*, 1478, 2238 

Wang, J....... 79, 111*, 507, 679, 865, 1042, 

...........................1043*, 1752*, 2026, 2124 

Wang, K................................286, 808, 818 

Wang, L C...........................................1871 

Wang, L............ 761, 766, 772, 867*, 1067, 

...........................1332, 1399, 1499*, 2047* 

Wang, M Z............................................208 

Wang, N Y........................................... 257* 

Wang, N..............................................1048 

Wang, P W..........................................1871 

Wang, P...............................................2238 

Wang, R............................................. 1598* 

Wang, S.................................................194 

Wang, T................................... 1070, 1147* 

Wang, W.............................................1026 

Wang, X.........................638, 1864*, 2072* 

Wang, Y.................................... 939, 1665* 

Wang, Z.........121, 124*, 507, 1057, 1058*, 

............................ 1219*, 1905, 1905, 2238 

Wang-Fan, W.................................... 1454* 

Wangpradit, O.................................... 800* 

Wanner, U...........................................1193 

Want, E J........................... 397*, 472, 1605 

Want, E.................................................373 

Ward, J A.............................................1232 

Ward, J M............................................1632 

Ward, M D..........................................1439 

Ward, R M...........................................2087 

Ward, R............................................. 1626* 

Ward, T.........................................125, 131 

Ward, W O..........................................1587 

Ward, W........ 834, 890, 1055, 1428, 1586* 

Warder, S E..........................................1432 

Warheit, D B............ 78, 431, 1487*, 1488, 

............................................................1514 

Warheit, D........................................ 2358* 

Warholm, M...............................755, 1005 

Waring, J F........... 847, 1208, 1421, 1432*, 

............................................................1594 

Warner, B M.............................. 873*, 1325 

Warner, R.......................................... 1371* 

Warnke, L A..............................1308, 1433 

Warren, S.......................................... 1173* 

Wasdo, S C.................................. 31*, 1277 

Washburn, L L......................................584 

Washer, G...........................1*, 2299*, 2317 

Washington, M K..................................866 

Wasserloos, K J....................................2000 

Watanabe, C.......................................1612 

Watanabe, S..........................................329 

Waterfield, C J...........................1574, 1604 

Waterhouse, J......................................2279 

Waterman, C L.................................. 1604* 

Waters, K M..........................395, 436, 439 

Waterson, D........................................1891 

Waterval, G.........................................1167 

Watkins III, J B....................................1956 

Watkinson, W P....................................748 

Watson, A...........................................1203 

Watson, W H........................................104 

Watterson, T L.................................. 1075* 

Watts, W...............................................745 

Way, W....................................................92 

Wayman, G A.....................................1705 

Weaver, J L............................................946 

Webber, M M......................................1307 

Webb-Robertson, B M...........................435 

Webb-Robertson, B.............................1743 

Weber, D.............................................1856 

Weber, L P...................................752, 2204 

Weber, T J..............................................435 

Weber, T............................................ 1401* 

Weber, W..............................................296 

Webster, L O.........................................620 

Webster, T F...................................... 1378* 

Weed, M................................................ 88* 

Weeks, J A...........................................1236 

Weems, J M................................. 81*, 2001 

Weese, C................................................926 

Wegesser, T C.................................... 1087* 

Weghorst, C M......................................873 

Wehner, N G....................................... 191* 

Wei, Y................................................ 1639* 

Weideman, P A................................. 1367* 

Weikert, R...........................................1651 

Weil, R E............................................ 2271* 

Weimans, S...........................................331 

Weinbauer, G................ 1136*, 1648, 2208 

Weinberg, J T...................................... 213* 

Weiner, M L........................ 272, 277, 491* 

Weinshenker, D....................................208 

Weiss, D..............................................2132 

Welch, K.............................................. 724* 

Weljie, A M....................................... 1925* 

Wells, M............................................ 1548* 

Wells, P G..........................226, 1814, 1854 

Wels, B..................................................234 

Welsh, W J............................................670 

Welty, S E............................................1769 

Wen, H................................................1916 

Wendelin, D..........................................779 

Wendt, M..............................................676 

Wenk, M R..........................................1398 

Wenx, A................................................469 

Werb, Z..................................................563 

Werrlein, R J........................................ 152* 

Wescott, D............................................390 

Westbrook, A......................................1683 

Westerfield, M..................................... 582* 

Westerink, R H......................794, 797, 807 

Westerink, R..........................................577 

Westerman, A.....................................1535 

Westhouse, R A...................................1341 

Westhouse, R........................................766 

Weston, D...........................................1869 

Westwood, R.......................................1891 

Whalen, M........................................ 1345* 

Whalley, C E....................................... 125* 

Whalley, C....................................128, 145 

Wheeler, H M........................................952 

Wheeler, K..........................................2310 

Whelan, H T.......................................1837 

White Jr., K L......................................2130 

White, A M.........................................1764 

White, A..............................................2244 

White, C A....................................947, 955 

White, C C.........176, 287, 357, 369, 1602, 

............................................................1944 

White, C W...................151, 160, 204, 678 

White, G...............................................497 

White, K L.........195, 197, 216, 2133, 2135 

White, L A.................275, 306, 1415, 2266 

White, L D............................................989 

White, L..............................................2197 

White, P................................................914 

White, R................................................254 

White, S S...................... 1139*, 1155, 1156 

White, W..............................................380 

Whiteley, L O................................387, 389 

Whitman, F.........................................1077 

Whittaker, M H......................... 589*, 1289 

Whitten, K A.........................................192 

Wichers, L B..........................................989 

Wicklow, D T......................................2227 

Widner, T E.........................................1471 

Wiecinski, P..........................................426 

Wiegers, T.............................................241 

Wiemer, J............................................1603 

Wiench, K...........................................1400 

Wier, P............................................... 1266* 

Wierda, D......................................193, 386 

Wijeyesakere, S J............................... 2292* 

Wijnand, E..........................................1778 

Wilbanks, M S..................................... 130* 

Wilberding, J.........................................487 

Wild, J R..............................................2286 

Wilga, P C................................... 892*, 893 

Wilke, A................................................523 

Will, Y.......556*, 561*, 902, 903, 904, 905, 

..........................................906, 1938, 2302 

Willett, K L....................................761, 867 

Willett, K.............................................1243 

Willett, P...............................732, 734, 753 

Willhite, C..........................................1793 

Williams, C A.................................... 1791* 

Williams, D E..............................522, 1775 

Williams, E S..................697, 2359*, 2360* 

Williams, G M.............82, 531, 1932, 2252 

Williams, J F..........................................501 

Williams, J H.....................490, 1478, 2238 

Williams, J P.........................................391 

Williams, J.............................................507 

Williams, K J.......................................1424 

Williams, L D.................................... 2222* 

Williams, L..........................................2270 

Williams, P..........................................2262 

Williams, R L..................................... 1822* 

Williams, R T.................................... 1297* 

Williams, R V........................................261 

Willis, J H..............................................905 

Willson, T M.......................................1549 

Wilson, E.............................................1387 

Wilson, G A........................................1590 

Wilson, J D............................202, 203, 955 

Wilson, J.............................................2011 

Wilson, M......................................... 1675* 

Wilson, R............................................1956 

Wilson, S................................... 552*, 2318 

Wilson, V S..................... 56*, 62, 90, 2190 

Wilt, N..................................................336 

Wiltshire, T.........................................1082 

Wincent, E.......................................... 775* 

Wind, M........................................891, 988 

Winder, B.................................... 979*, 980 

Wing, M....................................2152, 2154 

Wingard, C J..................................... 1258* 

Winn, D...................................... 562, 567* 

Winn, L M.................................1523, 1680 

Winn, L...............................................1522 

Winnik, W..........................282, 870, 1599 

Winsett, D W................................748, 749 

Winsett, D...........................................1652 

Winslow, J...........................................1936 

Winters, D.............................................988 

Wintz, H...............................................882 

Wise, A................................................2240 

Wise, B................................................2277 

Wise, J P..............................................2093 

Wisler, J.....................................1134, 1915 

Witasp, E.............................................1047 

Witonsky, S...............................2125, 2127 

Witten, M.................................1097, 1101 

Witters, H......................................337, 886 

Witzmann, F A.................................. 1049* 

Witzmann, F.........................................252 

Wnek, S M.......................................... 122* 

Woehrle, T..........................................2250 

Wohlleben, W.......................................443 

Wokovich, A M...................................1023 

Wolf, A......................................1391, 1923 

Wolf, C J.................................... 541*, 2018 

Wolf, C................................................2026 

Wolf, D P........................................... 2338* 

Wolf, D................................................1381 

Wolf, K K............................................. 620* 

Wolf, M...............................................1117 

Wolfarth, M..............................1083, 1492 

Wolfers, J.............................................2246 

Wolstenholme, J.................................1583 

Wolterbeek, A.......................................577 

Wong, B A.............. 510, 996, 1507, 1512*, 

..................................................1877, 2098 

Wong, D F...........................................1861 

Wong, D................................................912 

Wong, L..............................................1890 

Wong, P................................................882 

Wong, S S................................ 1097, 1101* 

Wong, V A.................................1406, 1511 

Wong, W W........................................1594 

Wong-Yim, P............................. 941*, 1796 

Wood, B..............................................1660 

Wood, C.............................................. 925* 

Wood, J.................................................240 

Woodall, G M........................... 989*, 1183 

Author Index 




Author Index 

Woodburn, K..............................951, 1000 

Woodin, B R........................................2198 

Woodis, K..............................................106 

Woods, C G..................... 831, 1302, 2026* 

Woods, J S.......400, 410, 1104, 1766, 1859 

Woodside, R................................297, 1091 

Woolhiser, M R....................... 1314, 1438* 

Wortelboer, H.......................................577 

Wright, F A..........................................2273 

Wright, F.............................................1568 

Wright, J................1246, 1574, 1604, 1687 

Wright, R E..........................................1828 

Wu, B....................................................102 

Wu, J...................................................1222 

Wu, K..................................................1640 

Wu, M...................................................881 

Wu, N..................................................1492 

Wu, Q..................................................1397 

Wu, R..................................................2033 

Wu, S...................................................1917 

Wu, X................................................ 2239* 

Wu, Y..................................................2084 

Wyman, A.............................................367 

X 

Xi-qiao, X..............................................144 

Xia, C Q............................................ 1222* 

Xia, M................................................. 880* 

Xia, T....................................................437 

Xia, X...................... 432, 821, 1028*, 1556 

Xia, Y.......... 432*, 1130, 1640, 2074, 2108 

Xia, Z.....................................................352 

Xiang, C..............................................1615 

Xiang, H..............................................1930 

Xiao, C..................................................144 

Xiao, D................................................2183 

Xiao, W...............................................1724 

Xiaoming, S........................................1138 

Xie, H..................................................2093 

Xie, L................................................. 1666* 

Xie, R................................................ 2070* 

Xie, S.....................................................301 

Xie, W................................. 550, 808*, 832 

Xie, Y.................................................. 550* 

Xing, R..................................................102 

Xiong, K M............................. 1161, 2195* 

Xu, B.........................................1666, 1724 

Xu, C................................................... 863* 

Xu, F......................................................447 

Xu, J....................................................1567 

Xu, L............... 490*, 507, 701, 1478, 2238 

Xu, Y....................... 124, 875, 1993, 2245* 

Xue, J....................................................269 

Y 

Yager, J D...............................................104 

Yager, J W..................................1589, 1629 

Yahyavi, A G.........................................150 

Yamada, K..................... 1952, 2311, 2320* 

Yamada, T................................532*, 1584* 

Yamagishi, G.......................................1450 

Yamaguchi, N.......................................545 

Yamaguchi, T........................................225 

Yamamoto, K............................1495, 1496 

Yamamoto, M L................................ 1683* 

Yamamoto, M......... 196, 362*, 2027, 2029 

Yamamoto, T.................. 757, 1203*, 1592 

Yamasaki, C.........................................1200 

Yamasaki, H........................................1154 

Yamashita, A.......................................1952 

Yamashita, K.......................................1450 

Yamatoya, H.......................................2149 

Yamauchi, H.........................................587 

Yamazoe, Y............................................219 

Yamoto, T..............................................225 

Yan, K..................................................1065 

Yan, X..................................... 1738*, 1916 

Yanagi, H.............................................2311 

Yanagisawa, R............................. 188, 214* 

Yang, A.............................................. 1578* 

Yang, C S...................................1112, 1812 

Yang, C........................119, 240, 616, 1716 

Yang, D..................................... 413, 2264* 

Yang, L................ 1175, 1420, 1735*, 2350 

Yang, M S................................ 1116, 2082* 

Yang, M............................................... 783* 

Yang, Q.......................................461, 1034 

Yang, R........................................857, 1022 

Yang, S..................................................754 

Yang, X................................................2194 

Yang, Y........250, 504, 1007*, 1421*, 1518, 

.......................................................... 1993* 

Yantasee, W........................................ 140* 

Yao, H H..............................................1153 

Yao, P.................................................. 348* 

Yasuda, M..................................1158, 1647 

Yasui, M..............................................2243 

Yasui, T..................................................553 

Yasutake, A........................304, 1612, 1619 

Yates, M...............................................1866 

Yavanhxay, J.......................................1003 

Ye, F.....................................................2106 

Ye, J...............................................394, 398 

Ye, L......................................................245 

Ye, W...................................................2078 

Yeager, J J............................................ 154* 

Yeager, J.................................................684 

Yeager, R L.............................................617 

Yeatts, K..............................................1439 

Yeatts, S...............................................1177 

Yedjou, C G......................................... 356* 

Yellowhair, M......................................1634 

Yeomans, C......................................... 706* 

Yesupriya, A..........................................408 

Yijun, Z...............................................1138 

Yildiz, V..............................................2314 

Yimam, M A........................................ 715* 

Yin, H..................................................2160 

Yin, X.......................................... 171*, 178 

Yin, Z.......1886, 1887*, 1888, 1889, 2180* 

Ying, T.................................................1846 

Yokoi, T............................................... 218* 

Yonemoto, J..........................................276 

YongPil, H......................................... 2179* 

Yoo, H.................................................1750 

Yoon, B..................................................361 

Yoon, J.................................................1502 

Yoon, M............................................ 1014* 

Yoshida, M...................1140*, 1612*, 1702 

Yoshida, R................................. 405*, 1746 

Yoshida, Y...........................................1700 

Yoshikawa, T.........................................214 

Yoshimatsu, Y.....................................1647 

Yoshimura, I........................................1451 

Yoshimura, M.......................................227 

Yoshino, G............................................493 

Yoshioka, N....................................... 2090* 

Yoshioka, T.................................532, 1584 

Yoshioka, W.............................. 687, 2023* 

Yoshizane, Y........................................1200 

Yost, G S.............81, 771, 784, 1113, 1689, 

............................................................2001 

Yost, G.................................................2214 

Young, J L............................................2093 

Young, S.................................. 1081, 1083* 

Youngchul, C.................................... 1435* 

Younglove, L R......................................475 

Youngren, S.........................................1786 

Younis, H S............................................220 

Younis, H............................................1577 

Yourick, D...........................................2279 

Yu, C.....................................................411 

Yu, D...................................................1846 

Yu, G...................................................1138 

Yu, I...................................442, 1502, 1506 

Yu, K O...................................... 425, 1026* 

Yu, L E............................................... 1398* 

Yu, M......................................1677*, 2021* 

Yu, R Z.................................................1897 

Yu, S....................................................1937 

Yu, W W..............................................1027 

Yu, X............. 353, 884*, 1320, 1695, 1853 

Yu, Y......................................................380 

Yuan, L................................................1058 

Yuan, Y................................................1852 

Yuasa, A...............................................1451 

Yucesoy, B................................. 406*, 1312 

Yuehe, L..............................................1753 

Yuen, B T.............................................2155 

Yuen, B................................................2185 

Yung, L.................................... 1398, 1490* 

Yunomae, K...................................... 1657* 

Z 

Zablotny, C L......................................1142 

Zacharewski, T......................................852 

Zacharewski, T R..........50, 260, 674, 1422, 

...................................... 1423, 1424, 1573* 

Zachow, R............................................1152 

Zaffuto, K..............................................171 

Zahalka, E A..........................................233 

Zairov, G...............................................763 

Zaja-Milatovic, S.................................1958 

Zakharyan, R A.....................................973 

Zalups, R K..........................................2119 

Zanardi, T............................................2144 

Zang, Y................................................ 104* 

Zangar, R C.................................439, 1764 

Zanoni, M B........................................1681 

Zarate, C..............................................1936 

Zarbl, H....................................... 671*, 672 

Zaroogian, G.........................................281 

Zartarian, V G.......................................269 

Zatloukalova, J....................................1216 

Zavecz, J H..........................................2213 

Zaveri, N...............................................392 

Zawia, N H..........................................1868 

Zayas, B...............................................1237 

Zeidler-Erdely, P C.................... 740, 1081* 

Zeise, L..................................................935 

Zelikoff, J T............181, 692, 1334*, 2202* 

Zeller, A...............................................1167 

Zenick, H................................. 1296, 1299* 

ZeRuth, G............................................ 781* 

Zhang, A...............................................588 

Zhang, B................................................119 

Zhang, C.............................................1697 

Zhang, D D...............................2031, 2072 

Zhang, D...............................................766 

Zhang, F..............................................1429 

Zhang, H...................................1348, 2137 

Zhang, J........ 446, 456*, 1472, 1925, 1927, 

........................................2021, 2228, 2229 

Zhang, L W....................................... 1027* 

Zhang, L....... 149, 882, 1625, 1717*, 1830, 

............................................................2054 

Zhang, N............................................. 539* 

Zhang, P..............................................2104 

Zhang, Q...........1034*, 1048, 1174*, 1302, 

............................................................2026 

Zhang, X...................149, 269*, 354, 359*, 

....................... 394, 398, 414*, 1209, 1579, 

........ 1714, 1717, 1726, 1728, 1830*, 2054 

Zhang, Y................. 259, 549*, 1864, 2102, 

................................................ 2105*, 2142 

Zhang, Z................................................222 

Zhao, B.............................................. 2168* 

Zhao, H...............................................1513 

Zhao, J............................. 354*, 1031, 1839 

Zhao, Q...............................................1961 

Zhao, S..........................................416, 417 

Zhao, Y...................115*, 715, 1103, 1381* 

Zheng, J F............................................2130 

Zheng, J.....................................1050, 2082 

Zheng, W.................705, 708, 1864, 2082, 

................................................ 2102*, 2105 

Zheng, X...............................................123 

Zhitkovich, A................ 1286*, 1674, 2117 

Zhivotovsky, B.................................... 322* 

Zhong, M.............728, 730, 731, 735, 743, 

....................................................744, 1500 

Zhong, Q............................................. 448* 

Zhou, D....................................... 394, 398* 

Zhou, G......................... 1249, 1663*, 1731 

Zhou, H...............................................1600 

Zhou, T.................................................930 

Zhou, X................................... 2113, 2114* 

Zhou, Y................................... 1861, 2107* 

Zhou, Z...............................................2106 

Zhu, H..................... 244, 245*, 1991, 2051 

Zhu, L........................................ 115, 2033* 

Zhu, S..................................................1243 

Zhu, Y............................................... 2068* 

Zhuo, L.............................................. 1697* 

Zidek, N..............................................1123 

Ziemann, C................................. 513*, 514 

Zito, S....................................................712 

Zitzow, J D............................98, 855, 1710 

Zolnik, B S...........................................1050 

Zong, Q...............................................2151 

Zopf, D..................................................102 

Zorrilla, L........................................ 94*, 95 

Zou, L..................................................1490 

Zou, W................................................ 220* 

Zou, X................. 1696*, 1714, 1726, 1728 

Zou, Y....................................................708 

Zucker, R.............................................1504 

Zuehlke, U........................................ 1648* 

Zurbrugg, R...........................................117 

Zwiernik, M..........................................951 

Zwingmann, C......................................626 

312 



Notes 


313


Leadership 

2007–2008 Council 

George B. Corcoran 

Kenneth S. Ramos 

Cheryl Lyn Walker 

President 

(2007–2008) 

• Board of Publications, Member, 

Liaison 

• Endowment Fund Board, Member, 

Ex-Officio 

• Finance Committee, Member 

• IUTOX Councilor, Member 

Vice President 

(2007–2008) 

• Board of Publications, Auditor 

• Finance Committee, Member 

• IUTOX Councilor, Liaison 

• Program Committee, Chair, Liaison 

Vice President-elect 

(2007–2008) 

• 50 th Anniversary Year SOT Task 

Force, Liaison 

• Nominating Committee, Liaison 

• Program Committee, 

Co-Chair 

T: (313) 577-1737 F: (313) 577-2033 

corcoran@wayne.edu 

T: (502) 852-7207 F: (502) 852-3659 

kenneth.ramos@louisville.edu 

T: (512) 237-9550 F: (512) 237-2475 

cwalker@odin.mdacc.tmc.edu 

William Slikker, Jr. 

Janice E. Chambers 

Martin A. Philbert 

Treasurer 

(2007–2009) 

• Council Subcommittee for 

Non-SOT and Contemporary 

Concepts in Toxicology Meetings, 

Member 

• Endowment Fund Board, 

Ex-Officio 

• Finance Committee, Chair, Liaison 

• Special Interest Groups, Liaison 

Secretary 

(2006–2008) 

• Communiqué, Editor 




Chair, Liaison 

• Council Subcommittee for Regional 

Chapter Funding, Chair, Liaison 

• Education Committee, Liaison 

• Regional Chapters, Liaison 

Secretary-elect 

(2007–2008) 

• 50 th Anniversary Year SOT Task 

Force, Member 

• Council Subcommittee 

for Regional Chapter Funding, 

Member 

• NIH Funding Task Force, Liaison 

T: (870) 543-7517 F: (870) 543-7576 

wslikker@nctr.fda.gov 

T: (662) 325-1255 F: (662) 325-1031 

chambers@cvm.msstate.edu 

T: (734) 763-4523 F: (734) 763-8095 

philbert@umich.edu 

314 



2007–2008 Council (Continued) 

James A. Popp 

Kim Boekelheide 

Scott W. Burchiel 

Leadership 

Past President 

(2007–2008) 

• Awards Committee, Liaison 

• Endowment Fund Board, 

Member, Liaison 

• IUTOX Councilor, Member 

• Regional Chapter Graduate Student 

Representatives Committee, Liaison 

• Specialty Section Student 

Representatives, Liaison 

• Student Advisory Committee, 

Liaison 

T: (717) 735-3646 F: (717) 293-4470 

popp@stratoxon.com 

Councilor 

(2007–2009) 

• Committee on K–12 Education, 

Liaison 

• Specialty Sections, Liaison 

• World Wide Web Advisory 

Committee, Liaison 

T: (401) 863-1783 F: (401) 863-9008 

kim_boekelheide@brown.edu 

Councilor 

(2006–2008) 

• Continuing Education Committee, 

Liaison 

• Historian, Liaison 

• Membership Committee, Liaison 

• Postdoctoral Assembly, Liaison 

T: (505) 272-0920 F: (505) 272-0704 

sburchiel@salud.unm.edu 

Elaine V. Knight 

Denise E. Robinson Gravatt 

Shawn Douglas Lamb 

Councilor 

(2006–2008) 

• Career Resource and Development 

Committee, Liaison 




Member 

• Regulatory Affairs and Legislative 

Assistance Committee, Liaison 

Councilor 

(2007–2009) 

• Animals in Research Committee, 

Liaison 

• Committee on Diversity Initiatives, 

Liaison 

• Council Subcommittee for Regional 

Chapter Funding, Member 

Executive Director 

• Board of Publications, Staff Liaison 

• Endowment Fund Board, Member, 

Ex-Officio 

• Finance Committee, Staff Liaison 

• IUTOX Councilors, Staff Liaison 

• Nominating Committee, Staff 

Liaison 

T: (908) 704-4344 F: (908) 218-0668 

eknight@prdus.jnj.com 

T: (860) 732-0790 F: (860) 732-7251 

denise.robinson-gravatt@pfizer.com 

T: (703) 438-3115 F: (703) 438-3113 

shawnl@toxicology.org 



Leadership 

Officers and Councilors 


President (2007–2008) 

T: (313) 577-1737 

F: (313) 577-2033 

corcoran@wayne.edu 


Secretary (2006–2008) 

T: (662) 325-1255 

F: (662) 325-1031 

chambers@cvm.msstate.edu 


Councilor (2006–2008) 

T: (505) 272-0920 

F: (505) 272-0704 

sburchiel@salud.unm.edu 


Vice President (2007–2008) 

T: (502) 852-7207 

F: (502) 852-3659 

kenneth.ramos@louisville.edu 

Martin A Philbert 

Secretary–Elect (2007–2008) 

T: (734) 763-4523 

F: (734) 763-8095 

philbert@umich.edu 

Elaine Valerie Knight 


T: (908) 704-4344 

F: (908) 218-0668 

eknight@prdus.jnj.com 

Cheryl Lyn Walker 

Vice President–Elect (2007–2008) 

T: (512) 237-9550 

F: (512) 237-2475 

cwalker@odin.mdacc.tmc.edu 

James A. Popp 

Past President (2007–2008) 

T: (717) 735-3646 

F: (717) 293-4470 

popp@stratoxon.com 

Denise E. Robinson Gravatt 


T: (860) 732-0790 

F: (860) 732-7251 

denise.robinson-gravatt@pfizer.com 


Treasurer (2007–2009) 

T: (870) 543–7517 

F: (870) 543–7576 

wslikker@nctr.fda.gov 

Kim Boekelheide 


T: (401) 863–1783 

F: (401) 863-9008 

kim_boekelheide@brown.edu 

Past Presidents 

1961–1962 Harold C. Hodge* 

1962–1963 C. Boyd Shaffer* 

1963–1964 Paul S. Larson* 

1964–1965 Harry W. Hays* 

1965–1966 Frederick Coulston* 

1966–1967 Verald K. Rowe* 

1967–1968 John A. Zapp, Jr.* 

1968–1969 Carrol S. Weil* 

1969–1970 Ted A. Loomis 

1970–1971 Robert L. Roudabush* 

1971–1972 Wayland J. Hayes, Jr.* 

1972–1973 Victor A. Drill* 

1973–1974 Joseph F. Borzelleca 

1974–1975 Sheldon D. Murphy* 

1975–1976 Seymour L. Friess 

1976–1977 Robert A. Scala 

1977–1978 Harold M. Peck 

1978–1979 Leon Golberg* 

1979–1980 Tom S. Miya 

1980–1981 Perry J. Gehring* 

1981–1982 Robert B. Fowrney* 

1982–1983 Robert L. Dixon* 

1983–1984 Gabriel L. Plaa 

1984–1985 Frederick W. Oehme 

1985–1986 Emil A. Pfitzer* 

1986–1987 John Doull 

1987–1988 Jerry B. Hook 

1988–1989 James E. Gibson 

1989–1990 Roger O. McClellan 

1990–1991 Curtis D. Klaassen 

1991–1992 Donald J. Reed 

1992–1993 John L. Emmerson 

1993–1994 I. Glenn Sipes 

1994–1995 Meryl H. Karol 

1995–1996 Jack H. Dean 

1996–1997 James S. Bus 

1997–1998 R. Michael McClain 

1998–1999 Steven D. Cohen 

1999–2000 Jay I. Goodman 

2000–2001 Daniel Acosta, Jr. 

2001–2002 David L. Eaton 

2002–2003 William F. Greenlee 

2003–2004 Marion F. Ehrich 

2004–2005 Linda S. Birnbaum 

2005–2006 Kendall B. Wallace 

2006–2007 James A. Popp 

*Deceased 

316 



Elected Committees 

Awards 

Melvin E. Andersen, Chair (2007–2008), Member (2006–2008) 

Michael A. Gallo, Member (2007–2009) 

A. Jay Gandolfi, Member (2007–2009) 

Carole A. Kimmel, Member (2006–2008) 

Kenneth Olden, Member (2006–2008) 

Robert A. Roth, Member (2007–2009) 

James A. Swenberg, Member (2007–2009) 

James A. Popp* 

Clarissa Russell Wilson** 


Lawrence R. Curtis, Chair (2007–2008), Member (2005–2008) 

Aaron Barchowsky, Member (2007–2010) 

Susan J. Borghoff, Member (2005–2008) 

Steven G. Gilbert, Member (2006–2009) 

Johnnye L. Lewis, Member (2006–2009) 

Sidhartha D. Ray, Member (2007–2010) 

Kristina D. DeSmet, Student Representative (2007–2008) 

Janice E. Chambers* 

Betty Eidemiller** 

Membership Committee 

David C. Dorman, Chair (2006–2008), Member (2005–2008) 

Russell L. Carr, Member (2006–2009) 

Robert E. Chapin, Member (2007–2010) 

Michael Lee Cunningham, Member (2005–2008) 

Ruth A. Roberts, Member (2006–2009) 

MaryJane K. Selgrade, Member (2007–2010) 

Chrissy J. Schilling, Postdoctoral Representative (2007–2008) 

Adam Straub, Student Representative (2007–2008) 

Scott W. Burchiel* 

Marcia G. Lawson** 

Nominating Committee 

Kendall B. Wallace, Chair (2007–2008), Member (2007–2008) 

Lori A. Dostal, Member (2006–2008) 

David L. Eaton, Member (2007–2009) 

Stephen W. Frantz, Member (2007–2009) 

Mary Beth Genter, Member (2006–2008) 

Carol J. M. Henry, Member (2006–2008) 

Judith T. Zelikoff, Member (2007–2009) 

Cheryl Lyn Walker* 

Shawn Douglas Lamb** 

Leadership 

Appointed Committees 

50 th Year Anniversary SOT Task Force 

Ernest Hodgson, Chair (2006–2012) 

Meryl H. Karol, Past President, Co-Chair (2006–2012) 

Linda S. Birnbaum, Past President (2006–2012) 

Gary P. Carlson, 45th ATF Chair (2006–2012) 

John Doull, Charter Member and Past President (2006–2012) 

David L. Eaton, Past President (2006–2012) 

William C. Hays, Founding Co-Counsel (2006–2012) 

Jack H. Dean, Member (2007–2012) 

Dennis J. Deviln, Member (2007–2012) 

Lisa A. Opanashuk, Member (2007–2012) 

Dennis James Paustenbach, Member (2007–2012) 

Martin A. Philbert, Member (2006–2012) 

Ronald B. Tjalkens, Member (2007–2012) 

Gabriel L. Plaa, Charter Member and Past President 

(2006–2012) 

Robert A. Scala, Past Historian and Past President (2006–2012) 

Cheryl Lyn Walker* 


Animals in Research Committee 

Tracie E. Bunton, Chair (2007–2008), Member (2005–2008) 

Drew A. Badger, Member (2007–2010) 

Nikolay (Nick) M. Filipov, Member (2005–2008) 

Denise E. Fillman-Holliday, Member (2006–2009) 

Timothy P. Reilly, Member (2007–2010) 

Daniel M. Wilson, Member (2006–2009) 

Lisa D. Schmidt, Student Representative (2007–2008) 

Denise E. Robinson Gravatt* 


Board of Publications Committee 

William R. Kelce, Chair (2007–2008), Member (2004–2008) 

A. Jay Gandolfi, Member (2005–2009) 

David Jacobson-Kram, Member (2006–2010) 

Hartmut Jaeschke, Member (2007–2011) 

Lois D. Lehman-McKeeman, ToxSci Editor (2007–2008) 

Kenneth S. Ramos, Auditor (2007–2008) 

George B. Corcoran, Member (2007–2008)* 

Shawn Douglas Lamb ** 


Claude McGowan, Chair (2006–2008), Member (2005–2008) 

B. Bhaskar Gollapudi, Member (2007–2010) 

Robin C. Guy, Member (2006–2008) 

Thomas T. Kawabata, Member (2005–2008) 

Douglas A. Keller, Member (2006–2009) 

Srikanth S. Nadadur, Member (2006–2009) 

Judy L. Raucy, Member (2007–2010) 

Vishal S. Vaidya, Member (2006–2009) 

Richard R. Vaillancourt, Member (2007–2010) 

Christine Palermo, Postdoctoral Representative (2007–2008) 

Prasad Krishnan, Student Representative (2007–2008) 

Elaine Valerie Knight* 


* Council Liaison 

** Staff Liaison 

TBD=To be determined 



Leadership 

Appointed Committees (Continued) 

Committee on Diversity Initiatives (CDI) 

Vicente Santa Cruz, Chair (2006–2008), Member (2005–2008) 

Abraham Dalu, Member (2007–2010) 

Kimberly D. Daniel, Member (2005–2008) 

Lin Mantell, Member (2007–2010) 

Charles A. Miller, III, Member (2005–2008) 

Anthony M. Ndifor, Member (2006–2009) 

Vanessa M. Silva, Member (2006–2009) 

Mari S. Stavanja, Member (2006–2009) 

Jose E. Manautou, ad hoc (2005–2008) 

Patrick J. Shaw, Student Representative (2007–2008) 

Denise E. Robinson Gravatt* 


Committee on K–12 Education 

Vanessa A. Fitsanakis, Chair (2007–2008), Member (2005–2008) 

Dorothy B. Colagiovanni, Member (2007–2010) 

Keith M. Erikson, Member (2007–2009) 

Maureen R. Gwinn, Member (2007–2010) 

Deepa B. Rao, Member (2006–2009) 

Pamela J. Shubat, Member (2005–2008) 

Nicole V. Soucy, Member (2005–2008) 

Katie Sprugel, Member (2006–2009) 

Susanne Brander, Student Representative (2007–2008) 

Kim Boekelheide* 


Continuing Education Committee 

Kok Wah Hew, Chair (2007–2008), Member (2006–2008) 

Stephen E. Bloom, Member (2007–2010) 

David W. Brewster, Member (2006–2009) 

Chris Corton, Member (2006–2009) 

Y. James Kang, Member (2005–2008) 

Thomas A. Lewandowski, Member (2005–2008) 

John C. Lipscomb, Member (2007–2010) 

Barbara J. Mounho, Member (2006–2009) 

Courtney E.W. Sulentic, Member (2007–2010) 

Kylee E. Eblin, Student Representative (2007–2008) 


Nichelle Sankey** 

Council Subcommittee for Non-SOT and 

Contemporary Concepts in Toxicology (CCT) 

Janice E. Chambers, Chair (2007–2008), Member (2005–2008)* 

Elaine Valerie Knight, Member (2007–2008) 

William Slikker, Jr., Member (2007–2008) 


Council Subcommittee for Regional Chapter 

Funding 

Janice E. Chambers, Chair (2007–2008), Member (2005–2008)* 

Martin A. Philbert, Member (2007–2008) 

Denise E. Robinson Gravatt, Member (2007–2008) 


Endowment Fund Board 

Roger O. McClellan, Chair (2006–2008), Member (2005–2008) 

Jon C. Cook, Member (2007–2010) 

Norbert E. Kaminski, Member (2007–2011) 

James E. Klaunig, Member (2006–2009) 

James A. Popp, Member (2006–2009)* 

I. Glenn Sipes, Member (2006–2009) 

Kendall B. Wallace, Member (2006–2008) 

George B. Corcoran, Ex-Officio (2007–2008)* 

William Slikker, Jr., Ex-Officio (2006–2009) 

Shawn Douglas Lamb, Ex-Officio (2007–2008) 


Finance Committee 

William Slikker, Jr., Chair (2007–2008), Member (2006–2009)* 

George B. Corcoran, Member (2006–2008) 

Jeffrey A. Handler, Member (2006–2009) 

Robert W. Kapp, Jr., Member (2007–2010) 

Kenneth S. Ramos, Member (2007–2009) 

Jacqueline H. Smith, Member (2005–2008) 


Historian 

Ernest Hodgson, Chair (2004–2011) 



IUTOX Councilors 

Linda S. Birnbaum, Member (2007–2010) 

George B. Corcoran, Member (2007–2010) 

Jack H. Dean, Member (2007–2010) 

James A. Popp, Member (2007–2010) 

Kenneth S. Ramos, Member (2007–2010)* 


NIH Funding Task Force 

Ronald N. Hines, Chair (2007–2008), Member (2004–2008) 

David L. Eaton, Member (2004–2008) 

Curtis D. Klaassen, Member (2004–2008) 

Serrine S. Lau, Member (2004–2008) 

Jose E. Manautou, Member (2004–2008) 

Alvaro Puga, Member (2004–2008) 

Martin A. Philbert* 


Postdoctoral Assembly Board 

Kristen A. Mitchell, Chair (2007–2008) 

Heather S. Floyd, Vice Chair (2007–2008) 

Heather M. Persson, Councilor (2007–2008) 

Amy M. Skinner, Secretary/Treasurer (2007–2008) 



318 



Appointed Committees (Continued) 

Program Committee 

Kenneth S. Ramos, Chair (2007–2008), Member (2006–2008)* 

Cheryl Lyn Walker, Co-Chair (2007–2008) 

Michael Aschner, Member (2007–2010) 

Matthew S. Bogdanffy, Member (2006–2009) 

William J. Brock, Member (2007–2010) 

Harvey J. Clewell, Member (2006–2009) 

Sally P. Darney, Member (2006–2009) 

Ronald J. Gerson, Member (2005–2008) 

Lynda L. Lanning, Member (2005–2008) 

Charlene A. McQueen, Mem ber (2007–2010) 

John B. Morris, Member (2005–2008) 

Ivan Rusyn, Member (2005–2008) 

Katherine Sarlo, Member (2006–2009) 

Hollie I. Swanson, Member (2007–2010) 

Nichelle Sankey** 

Regional Chapter Graduate Student 

Representative Committee 

Patrick J. Shaw, Chair (2007–2008) 

Kristina D. DeSmet, Co-Chair, Midwest, Education (2007–2008) 

Patricia Gillespie, Secretary, Mid-Atlantic (2007–2008) 

Susanne Brander, Northern California, 

K–12 Education (2007–2008) 

David J. Castro, Pacific Northwest (2007–2008) 

Jennifer D. Cohen, Women in Toxicology (2007–2008) 

Enrique Fuentes-Mattei, Hispanic Organization 

for Toxicologists (2007–2008) 

Natalie M. Johnson, Gulf Coast (2007–2008) 

Prasad Krishnan, South Central, Career Resource and 

Development (2007–2008) 

Ebany J. Martinez, Mountain West (2007–2008) 

Jamie O’Brien, Lake Ontario (2007–2008) 

Melinda Prucha, Southeastern (2007–2008) 

Jennifer N. Rees, Central States (2007–2008) 

Lisa D. Schmidt, Northland, Animals in Research (2007–2008) 

Christopher M. Sheth, National Capital Area (2007–2008) 

Erica M. Sparkenbaugh, Michigan, Regulatory Affairs 

and Legislative Assistance (2007–2008) 

Adam Straub, Allegheny-Erie, Membership (2007–2008) 

Blake Warner, Ohio Valley (2007–2008) 

Melanie B. Weed, North Carolina (2007–2008) 



Specialty Section Graduate Student Representative 

Committee 

Alison Hege, Chair (2007–2008) 

Jaishree Bankoti, Regulatory and Safety Evaluation (2007–2008) 

Lisa D. Beilke, Mechanisms (2007–2008) 

Rebecca A. Clewell, Biological Modeling (2007–2008) 

Edward Dougherty, Molecular Biology (2007–2008) 

Derek A. Drechsel, Neurotoxicology (2007–2008) 

Kylee E. Eblin, Metals (2007–2008) 

Kimberly A. Henderson, Drug Discovery Toxicology (2007–2008) 

Daniel J. Hochman, Ethical, Legal, and Social Issues (2007–2008) 

Thomas J. Kannanayakal, Dermal Toxicology (2007–2008) 

Adrienne L. King, Occupational and Public Health (2007–2008) 

Sheppard Martin, Risk Assessment (2007–2008) 

Sheung P. Ng, Immunotoxicology (2007–2008) 

Prajakta S. Palkar, In Vitro and Alternative Methods (2007–2008) 

Dana C. Upton, Carcinogenesis (2007–2008) 

Elizabeth M. Vancza, Inhalation and Respiratory (2007–2008) 

Wei Zou, Comparative and Veterinary (2007–2008) 


Betty Eidemiller* 


Patrick J. Shaw, President (2007–2008) 

Thomas J. Kannanayakal, President-elect (2007–2008) 

Alison Hege, Secretary/Treaurer (2007–2008) 

Kristina D. DeSmet, Secretary/Treaurer-elect (2007–2008) 

Patricia Gillespie, Member (2007–2008) 

Elizabeth M. Vancza, Member (2007–2008) 


Betty Eidemiller* 

World Wide Web Advisory Committee 

Phil Wexler, Chair (2006–2008), Member (2005–2008) 

Paul Duffy, Member (2007–2010) 

Pertti J. Hakkinen, Member (2006–2009) 

L. Peyton Myers, Member (2005–2009) 

Mark W. Powley, Member (2007–2010) 

Tracy M. Williams, Member (2005–2008) 

Daniel J. Hochman, Student Representative (2007–2008) 

Kim Boekelheide* 

Debbie O’Keefe** 

Leadership 

Regulatory Affairs and Legislative Assistance 

Committee 

Daland R. Juberg, Chair (2007–2008), Member (2006–2009) 

Charles C. Barton, Member (2007–2010) 

Lawrence J. Fischer, Member (2005–2008) 

Larry R. Johnson, Member (2005–2008) 

Joseph R. Landolph, Jr., Member (2007–2010) 

Peter Sausen, Member (2006–2009) 

Jan Oberdoerster, ad hoc 

Jay Vodela, ad hoc 

Erica M. Sparkenbaugh, Student Representative (2007–2008) 

Elaine Valerie Knight* 


* Council Liaison 

** Staff Liaison 

TBD=To be determined 



Leadership 

Regional Chapter—Officers 

Allegheny-Erie (83*) 

Annabelle F. Javier, President 

Jeffrey S. Smith, President-elect 

Aaron Barchowsky, Vice President 

Robin E. Gandley, Secretary 

William James Mackay, Treasurer 

Melanie S. Flint, Past President 

Lori A. Battelli, Councilor 

Jim Scabilloni, Councilor 

Mark Weisberg, Councilor 

Pallavi B. Limaye, Postdoctoral Representative 

Adam Straub, Student Representative 

Central States (273*) 

Gabriele Ludewig, President 

Hartmut Jaeschke, Vice President 

Jonathan A. Doorn, Secretary/Treasurer 

Yu-Jui Yvonne Wan, Past President 

Grace L. Guo, Councilor 

Thu Annelise Nguyen, Councilor 

Richard C. Pleus, Councilor 

Deon Van der Merwe, Councilor 

Jennifer N. Rees, Student Representative 

Gulf Coast (99*) 

Yanan Tian, President 

Sharon A. Petronella, Vice President 

Shashi K. Ramaiah, Vice President-elect 

Mary F. Kanz, Treasurer 

Shawn B. Bratton, Secretary 

Bryan W. Brooks, Past President 

Edward M. Mills, Councilor 

Jeffrey K. Wickliffe, Councilor 

Georgianna G. Gould, Postdoctoral Representative 

Natalie M. Johnson, Student Representative 

Lake Ontario (18*) 

TBD 

Jamie O’Brien, Student Representative 

Michigan (157*) 

Sue Marty, President 

Brad L. Upham, President-elect 

Roseann L. Vorce, Secretary/Treasurer 

Ali Said Faqi, Past President 

Jeanne Y. Domoradzki, Councilor 

Yvonne Frater, Councilor 

Thomas A. Kocarek, Councilor 

Paul M. Stemmer, Councilor 

Erica M. Sparkenbaugh, Student Representative 

Mid-Atlantic (466*) 

John W. Kille, President 

Anthony R. Schatz, Vice President-elect 

Conney W. Berger, Secretary/Treasurer 

Angelique P. J. M. Braen, Past President 

Diann L. Blanset, Councilor 

Patricia Gillespie, Student Representative 

Midwest (214*) 

Don W. Korte, President 

Peter J. Thomford, President-elect 

Jay C. Albretsen, Secretary 

Christina R. Wilson, Treasurer 

Robin C. Guy, Past President 

Jon N. Cammack, Councilor 

Michael DuVall, Councilor 

Janis T. Eells, Councilor 

Molly S. Weiler, Councilor 

Kristina D. DeSmet, Student Representative 

Mountain West (116*) 

Richard R. Vaillancourt, President 

Vasilis Vasiliou, Vice President 

Phillp Moos, Vice President-elect 

N. Shane Cutler, Secretary/Treasurer 

Matthew J. Campen, Past President 

Kevin Welch, Councilor 

Ebany J. Martinez, Student Representative 

National Capital Area (245*) 

Gary J. Burin, President 

Donna Mendrick, Vice President 

Deborah E. Burgin, Secretary 

Jennifer W. Sekowski, Treasurer 

Suzanne Compton Fitzpatrick, Past President 

Thomas J. Flynn, Councilor 

Michael S. Orr, Councilor 

Katherine Squibb, Councilor 

Christopher M. Sheth, Student Representative 

Amy Shaw, Vice Student Representative 

North Carolina (397*) 

Virginia (Ginger) C. Moser, President 

Michael Joseph Santostefano, President-elect 

Brenda Faiola, Vice President 

David J. Thomas, Vice President-elect 

Anthony Bernard DeAngelo, Secretary/Treasurer 

Michael P. Waalkes, Past President 

Greg Falls, Councilor 

Leslie Recio, Councilor 

Melanie B. Weed, Student Representative 

320 



Regional Chapter—Officers (Continued) 

Northeast (248*) 

Douglas J. Ball, President 

Jessica E. Sutherland, President-elect 

Graeme B. J. Smith, Vice President 

Laura Andrews, Secretary/Treasurer 

Joseph V. Rutkowski, Past President 

Phillip M. Bartholomew, Councilor 

Robert F. Stachlewitz, Councilor 

Aldona Karaczyn, Postdoctoral Representative 

Northern California (202*) 

Sanjay Chanda, President 

George R. Clemens, Vice President 

Stephen M. DiZio, Vice President-elect 

Tao Wang, Secretary 

Kent E. Pinkerton, Treasurer 

George V. Alexeeff, Past President 

Sheila M. Healy, Councilor 

Karen L. Steinmetz, Councilor 

Susanne Brander, Student Representative 

Northland (76*) 

Anthony L. Kiorpes, President 

Laura E. Solem, President-elect 

Catherine F. Jacobson, Secretary/Treasurer 

Thomas P. Brunshidle, Past President 

John W. Nichols, Councilor 

Nathan R. Pechacek, Councilor 

Shalene Thomas, Councilor 

Lisa D. Schmidt, Student Representative 

South Central (94*) 

Tammy R. Dugas, President 

Kristine L. Willett, Vice President 

Russell L. Carr, Vice President-elect 

Kartik Shankar, Secretary 

Heather E. Kleiner, Treasurer 

Martin J. Ronis, Past President 

Nikolay (Nick) M. Filipov, Councilor 

Neera V. Gopee, Councilor 

Prasad Krishnan, Student Representative 

Southeastern (90*) 

Essam E. Enan, President 

Carol S. Wood, Secretary/Treasurer 

Gary W. Miller, Past President 

P. Markus Dey, Councilor 

Julie A. Coffield, Councilor 

Melinda Sue Prucha, Student Representative 

Southern California (269*) 

Hisham K. Hamadeh, President 

Husam S. Younis, Vice President 

Anthony M. Ndifor, Secretary 

Tina Leakakos, Treasurer 

David N. Hovland, Past President 

Michelle J. Horner, Councilor 

Gregory J. Stevens, Councilor 

Leadership 

Ohio Valley (152*) 

August V. Wilke, President 

David R. Mattie, President-elect 

Amy L. Roe, Vice President 

Courtney E.W. Sulentic, Secretary 

Lynette K. Rogers, Treasurer 

Charles Vincent Smith, Past President 

Mary Beth Genter, Councilor 

Belinda S. Hawkins, Councilor 

J. Christopher States, Councilor 

Frazier B. Taylor, Student Representative 

Pacific Northwest (151*) 

Bruce J. Kelman, President 

Robert L. Tanguay, Vice President 

Cecile M. Krejsa, Vice President-elect 

Linda L. Carlock, Secretary/Treasurer 

Andrij Holian, Past President 

Evan P. Gallagher, Councilor 

Anne R. Greenlee, Councilor 

Celine A. Beamer, Postdoctoral Representative 

David J. Castro, Student Representative 

* Membership Totals 

Totals reflect as of 

July 26, 2007 



Leadership 

Special Interest Group—Officers 

American Association of Chinese in 

Toxicology (108*) 

Y. James Kang, President 

Jia Sheng Wang, Vice President 

Diana J. Auyeyng-Kim, Secretary 

Charles Y. Wang, Treasurer 

Jhihua (John) Zhang, Past President 

Li-Jie Fu, Councilor 

Zhijie Yang, Councilor 

Li You, Councilor 

Yun Zhang, Councilor 

Association of Scientists of Indian Origin (59*) 

Madhusudan G. Soni, President 

Gopala Krishna, Vice President 

Chellu S. Chetty, Secretary/Treasurer 

Harihara M. Mehendale, Past President 

Sanjay Chanda, Councilor 

Gunda Reddy, Councilor 

Hispanic Organization for Toxicologists (52*) 

Javier Avalos, Interim Executive Committee 

Braulio D. Jimenez-Velez, Interim Executive Committee 

Ofelia A. Olivero, Interim Executive Committee 

Mari Stavanja, Interim Executive Committee 

Enrique Fuentes, Student Representative 

in the Interim Executive Committee 

Korean Toxicologists Association 

in America (23*) 

Ji Eun Lee, President 

Yong Joo Chung, Vice President 

Sookwang Lee, Secretary/Treasurer 

Tae-Won Kim, Past President 

Il Je Yu, Councilor 

Toxicologists of African Origin (20*) 

Abraham Dalu, Head of the Organizing Committee 

Oluwasanmi O. Areola, Organizing Committee 

Bernard K. Gadagbui, Organizing Committee 

Anthony M. Ndifor, Organizing Committee 

Women in Toxicology (317*) 

Maryka Horsting Bhattacharyya, President 

Stacie L. Wild, President-elect 

Laura Andrews, Vice President 

Melissa C. Rhodes, Secretary/Treasurer 

Carol S. Auletta, Past President 

Kristina Dam Chadwick, Councilor 

Katie Sprugel, Councilor 

Julie A. Gosse, Postdoctoral Representative 

Jennifer D. Cohen, Student Representative 

322 



July 26, 2007 



Specialty Section—Officers 

Biological Modeling (108*) 

Sean M. Hays, President 

Craig M. Zwickl, Vice President 

Richard A. Corley, Vice President-elect 

Bradford W. Gutting, Secretary/Treasurer 

Charles Timchalk, Past President 

Cecilia Tan, Councilor 

Justin G. Teeguarden, Councilor 

Rebecca A. Clewell, Student Representative 

Ethical, Legal, and Social Issues (75*) 

Thomas E. McHugh, President 

Mara Seeley, Vice President 

Melinda J. Pomeroy-Black, Vice President-elect 

Lawrence W. Masten, Secretary/Treasurer 

Jacques P. J. Maurissen, Past President 

Michelle C. Catlin, Councilor 

Thomas A. Lewandowski, Councilor 

Daniel J. Hochman, Student Representative 

Leadership 

Carcinogenesis (247*) 

Mark S. Miller, President 

Barbara S. Shane, Vice President 

Charlene A. McQueen, Vice President-elect 

Chris Corton, Secretary/Treasurer 

Michael Lee Cunningham, Past President 

Michelle J. Hooth, Councilor 

Abigail C. Jacobs, Councilor 

Ivan Rusyn, Councilor 

Yu Janet Zang, Postdoctoral Representative 

Dana C. Upton, Student Representative 

Comparative and Veterinary (99*) 

Daniel K. Ness, President 

Jim E. Riviere, Vice President 

Mike J. Murphy, Vice President-elect 

Jay F. Harriman, Secretary/Treasurer 

Wilson Kiiza Rumbeiha, Past President 

Kathleen Gabrielson, Councilor 

Ramesh Chandra Gupta, Councilor 

Sadrih Devi, Postdoctoral Representative 

Wei Zou, Student Representative 

Dermal (129*) 

David W. Hobson, President 

Carol S. Auletta, President-elect 

George DeGeorge, Vice President 

Anne Marie Api, Secretary/Treasurer 

James N. McDougal, Past President 

Robert E. Osterberg, Councilor 

Jeffrey J. Yourick, Councilor 

Adrienne T. Black, Postdoctoral Representative 

Thomas J. Kannanayakal, Student Representative 

Drug Discovery Toxicology (305*) 

Drew A. Badger, President 

Kyle L. Kolaja, Vice President 

John W. Davis, Vice President-Elect 

Mark R. Fielden, Secretary/Treasurer 

James L. Stevens, Councilor 

Kimberly A. Henderson, Student Representative 

Food Safety (138*) 

Bruce G. Hammond, President 

Craig Llewellyn, Vice President 

Jia Sheng Wang, Vice President-elect 

Wu Li, Secretary/Treasurer 

George A. Burdock, Past President 

Genevieve S. Bondy, Councilor 

Bernadene A. Magnuson, Councilor 

Stanley T. Omaye, Councilor 

Jay Vodela, Councilor 

Immunotoxicology (344*) 

Stephen B. Pruett, President 

Jeanine L. Bussiere, Vice President 

Jean F. Regal, Vice President-elect 

Helen V. Ratajczak Edmond, Secretary/Treasurer 

Mitchell D. Cohen, Past President 

Rodney R. Dietert, Councilor 

Danuta J. Herzyk, Councilor 

Stacey E. Anderson, Postdoctoral Representative 

Sheung P. Ng, Student Representative 

In Vitro and Alternative Methods (158*) 

Daniel C. Kemp, President 

Frank A. Barile, Vice President 

David G. Allen, Vice President-elect 

Sue M. Ford, Secretary/Treasurer 

George DeGeorge, Past President 

Renee M. Gardner, Councilor 

Vincent A. Murphy, Councilor 

Sonia R. Miranda, Postdoctoral Representative 

Prajakta S. Palkar, Student Representative 

Ying Fan, Vice Student Representative 

Inhalation and Respiratory (264*) 

Deepak K. Bhalla, President 

Lung-Chi Chen, Vice President 

JeanClare Seagrave, Vice President-elect 

Alison C P Elder, Secretary/Treasurer 

Michael W. Foster, Past President 

Matthew J. Campen, Councilor 

Ilona Jaspers, Councilor 

Jeffrey S. Tepper, Councilor 

James G. Wagner, Councilor 

Elizabeth M. Vancza, Student Representative 




July 26, 2007


Leadership 

Specialty Section—Officers (Continued) 

Mechanisms (316*) 

Dean P. Jones, President 

Gary O. Rankin, Vice President 

Dennis R. Petersen, Vice President-elect 

Joan B. Tarloff, Secretary/Treasurer 

Kenneth S. Ramos, Past President 

Brian J. Day, Councilor 

Terrance J. Kavanagh, Councilor 

Lauren M. Aleksunes, Postdoctoral Representative 

Lisa D. Beilke, Student Representative 

Occupational and Public Health (178*) 

Patricia A. Weideman, President 

David G. Dolan, Vice President 

Angela J. Harris, Vice President-elect 

Tracy A. Kimmel, Secretary/Treasurer 

Harold Zenick, Past President 

Daniel J. Caldwell, Councilor 

Sandra Reiss Murphy, Councilor 

Jianyang Wang, Postdoctoral Representative 

Adrienne L. King, Student Representative 

Metals (156*) 

Kirk T. Kitchin, President 

Y. James Kang, Vice President 

Wei Zheng, Vice President-elect 

Michael F. Hughes, Secretary/Treasurer 

Michael J. McCabe, Past President 

Barbara D. Beck, Councilor 

Walter C. Prozialeck, Councilor 

Kylee E. Eblin, Student Representative 

Mixtures (50*) 

Moiz Mumtaz, President 

Janice E. Chambers, Vice President 

Jane Ellen Simmons, Vice President-elect 

David R. Mattie, Secretary/Treasurer 

Sami Haddad, Councilor 

Cecilia Tan, Councilor 

Molecular Biology (173*) 

Richard S. Pollenz, President 

Thomas R. Sutter, Vice President 

Michael J. Carvan, Vice President-elect 

Kristine L. Willett, Secretary/Treasurer 

Craig Marcus, Past President 

John D. Robertson, Councilor 

Russell S. Thomas, Councilor 

Edward Dougherty, Student Representative 

Nanotoxicology (New Section) 

Annette B. Santamaria, Interim President 

David B. Warheit, Interim Vice President 

Paul C. Howard, Interim Secretray/Treasurer 

Neurotoxicology (344*) 

M. Christopher Newland, President 

Marion F. Ehrich, Vice President 

Susan L. Schantz, Vice President-elect 

Karen L. Steinmetz, Secretary/Treasurer 

Robert C. MacPhail, Past President 

Edward D. Levin, Councilor 

Ronald B. Tjalkens, Councilor 

Derek A. Drechsel, Student Representative 

Regulatory and Safety Evaluation (585*) 

James D. Green, President 

Frank D. Sistare, Vice President 

James C. Lamb, Vice President-elect 

Suzanne Compton Fitzpatrick, Secretary/Treasurer 

James T. MacGregor, Past President 

Vicki L. Dellarco, Councilor 

David Jacobson-Kram, Councilor 

Jaishree Bankoti, Student Representative 

Reproductive and Developmental (306*) 

Rochelle W. Tyl, President 

Lori A. Dostal, Vice President 

Mark E. Hurtt, Vice President-elect 

Ann de Peyster, Secretary/Treasurer 

Jerrold J. Heindel, Past President 

Suzanne E. Fenton, Councilor 

Jodi A. Flaws, Councilor 

Miyun M. Tsai Turton, Postdoctoral Representative 

Sheung P. Ng, Student Representative 

Risk Assessment (523*) 

Jennifer Orme-Zavaleta, President 

Harvey J. Clewell, Vice President 

Edward V. Ohanian, Vice President-elect 

Julie E. Goodman, Secretary/Treasurer 

Michael L. Gargas, Past President 

John C. Lipscomb, Councilor 

Lisa M. Sweeney, Councilor 

Sheppard A. Martin, Student Representative 

Toxicologic and Exploratory Pathology (131*) 

Patrick J. Haley, President 

Karen S. Regan, Vice President 

Charles W. Qualls, Vice President-elect 

Sandra R. Eldridge, Secretary/Treasurer 

Lynda L. Lanning, Past President 

Mark E. Cartwright, Councilor 

Donna M. Dambach, Councilor 

Shashikiran Donthamsetty, Student Representative 



July 26, 2007 

324 



Society of Toxicology Awards and Honors 

In recognition of distinguished toxicologists and students, 

SOT presents Honorary Membership and awards each year. 

In addition to receiving a plaque, recipients are honored at 

a special Awards Ceremony at the SOT Annual Meeting and 

their names are listed in SOT publications. The deadline 

for 2009 Honorary Membership and award nominations is 

October 9, 2008. 

SOT Council reviews nominations for Honorary Membership 

and the Awards Committee reviews applications for SOT 

Awards and most Sponsored Awards. The Best Paper Awards 

are reviewed by the Board of Publications. The Education 

Committee selects the recipients of the Pfizer Undergraduate 

Travel Award and the Committee on Diversity Initiative 

selects the other undergraduate student travel recipients. 

Nominations for most awards must be submitted by a 

sponsor and a seconder who are full members of SOT using 

the On-Line Award Nomination Form. The supporting 

documentation must indicate the candidate’s achievements 

in toxicology and is critical in the review of each application. 

See the award description for the additional requirements for 

some of the awards, including the Sponsored Awards. There 

are specific applications for Fellowships and Graduate 

Travel Support. 

Other graduate student and postdoctoral fellow awards are 

available through Regional Chapters, Specialty Sections, 

and Special Interest Groups. A student or postdoc may apply 

for any award for which he or she is eligible and may apply 

for and receive multiple awards, whether SOT, Regional 

Chapters, Special Interest Groups, or Specialty Sections 

sponsor the awards. Policies related to travel support are 

determined by the sponsor (SOT, Regional Chapter, Special 

Interest Groups, or Specialty Section). Students may only 

receive one SOT National travel award. 

Full descriptions of all awards, awards no longer being 

offered, application procedures, and names of past recipients 

may be found on the SOT Web site at www.toxicology.org. 

reference 

SOT Honor Descriptions 

Honorary Membership 

The Society of Toxicology recognizes non-members who embody outstanding and sustained achievements in the field 

of toxicology with Honorary Membership. Candidates are nominated by two full or associate members of the Society. 

Seconding letters and information regarding career achievements in toxicology should accompany the nomination. A twothirds 

vote of Council determines recipients, with not more than two Honorary Members elected during any one term of 

Council. Nominations should be sent to SOT Headquarters. 

Inductees 

1962 ....... Eugene M.K. Geiling* 

1962 ....... W. F. Von Oettingen* 

1962 ....... Torald H. Sollman* 

1963 ....... Ethel Browning* 

1966 ....... R. Tecwyn Williams* 

1976 ....... Norton Nelson* 

1982 ....... George H. Hitchings* 

1986 ....... Bernard B. Brodie* 

1986 ....... Herbert Remmer* 

1991 ....... Hyman J. Zimmerman* 

1994 ....... Ronald W. Estabrook 

1994 ....... Wendell W. Weber 

1995 ....... Gertrude B. Elion* 

1995 ....... Charles S. Lieber 

1996 ....... Sten G. Orrenius 

1996 ....... Dennis Parke 

1997 ....... John E. Casida 

1997 ....... Roger W. Russell* 

1998 ....... Jud Coon 

1998 ....... Michel Mercier 

1999 ....... William O. Robertson 

1999 ....... Takashi Sugimura 

2000 ....... Findlay Russell 

2001 ....... Herbert Needleman 

2007 ....... Mario Molina 

2008 ....... Lee Hartwell, H. Robert Horvitz 

Indicates an SOT Sponsored Award 

*Deceased 



Reference 

Society of Toxicology Awards and Honors (Continued) 

Awards Descriptions 

Achievement Award 

The Achievement Award is presented to a member of 

the Society of Toxicology who has less than 15 years 

experience since obtaining his/her highest earned degree 

(in the year of the Annual Meeting of the Society of 

Toxicology) and who has made significant contributions 

to toxicology. This award consists of a plaque and a cash 

stipend. 

Award Recipients 

1967 ....... Gabriel L. Plaa 

1968 ....... Allan H. Conney 

1969 ....... Samuel S. Epstein 

1970 ....... Sheldon D. Murphy* 

1971 ....... Yves Alarie 

1972 ....... Robert L. Dixon* 

1973 ....... (No Award) 

1974 ....... Morris F. Cranmer 

1975 ....... Ian C. Munro 

1976 ....... Curtis D. Klaassen 

1977 ....... James E. Gibson 

1978 ....... Raymond D. Harbison 

1979 ....... Michael R. Boyd 

1980 ....... Philip G. Watanabe* 

1981 ....... (No Award) 

1982 ....... Frederick P. Guengerich 

1983 ....... (No Award) 

1984 ....... Melvin E. Andersen 

1985 ....... Alan R. Buckpitt 

1986 ....... Sam Kacew 

1987 ....... James S. Bus 

1988 ....... Jeanne M. Manson 

1989 ....... James P. Kehrer 

1990 ....... Michael P. Waalkes 

1991 ....... Debra Lynn Laskin 

1992 ....... Michael P. Holsapple 

1993 ....... David L. Eaton 

1994 ....... James L. Stevens 

1995 ....... Lucio G. Costa 

1996 ....... Kenneth S. Ramos 

1997 ....... Kevin E. Driscoll 

1998 ....... Rick G. Schnellmann 

1999 ....... Michel Charbonneau 

2000 ....... Christopher Bradfield 

2001 ....... Martin A. Philbert 

2002 ....... Ruth A. Roberts 

2003 ....... Lois D. Lehman-McKeeman 

2004 ....... David C. Dorman 

2005 ....... (No Award) 

2006 ....... Jose E. Manautou 

2007 ....... Jeffrey M. Peters 

2008 ....... Ivan Rusyn 

Arnold J. Lehman Award 

The Arnold J. Lehman Award is presented to recognize an 

individual who has made a major contribution to risk assessment 

and/or the regulation of chemical agents, including 

pharmaceuticals. The contribution may have resulted from 

the application of sound scientific principles to regulation 

and/or from research activities that have significantly 

influenced the regulatory process. The nominee may be 

employed in academia, government, or industry and must 

be a SOT member. This award consists of a plaque and a 

cash stipend. 


1980 ....... Allan H. Conney 


1982 ....... Gary M. Williams 

1983 ....... David P. Rall 

1984 ....... Tibor Balasz 

1985 ....... Frederick Coulston* 

1986 ....... Gerrit Johannes Van Esch 

1987 ....... John P. Frawley 

1988 ....... Kundan S. Khera* 

1989 ....... Richard H. Adamson 

1990 ....... Harold C. Grice 

1991 ....... Bernard A. Schwetz 

1992 ....... Roger O. McClellan 

1993 ....... Thomas W. Clarkson 

1994 ....... Bruce Ames 

1995 ....... Emil A. Pfitzer 

1996 ....... John F. Rosen 

1997 ....... (No Award) 

1998 ....... Helmut Alfred Greim 

1999 ....... (No Award) 

2000 ....... Carole A. Kimmel, Janardan K. Reddy 

2001 ....... Samuel M. Cohen 

2002 ....... Dennis Paustenbach 

2003 ....... Michael L. Dourson 

2004 ....... Melvin E. Andersen 

2005 ....... Rory B. Conolly 

2006 ....... Kathryn R. Mahaffey 

2007 ....... Harvey J. Clewell 

2008 ....... Vicki Dellarco 

326 




Best Postdoctoral Publication 

Awards 

The Best Postdoctoral Publication Awards were created by 

the Postdoctoral Assembly to recognize talented postdoctoral 

researchers who have recently published exceptional 

papers in the field of toxicology. Applications are reviewed 

by the Postdoctoral Assembly Board and outside reviewers 

with appropriate scientific expertise. The review process 

follows NIH conflict of interest, confidentiality, and nondisclosure 

rules. 


2007 ....... Nadine Dragin 

Kristen Mitchell 

Drobna Zuzana 

2008 ....... Joshua P. Gray 

Christie M. Sayes 

Khristy J. Thompson 

Board of Publications Best Paper in 

Toxicological Sciences Award 

The Board of Publications Award for the Best Paper in 

Toxicological Sciences is presented to the author(s) of the 

best paper published in this official SOT publication during 

a 12-month period, terminating with the June issue 

of the calendar year preceding the Annual Meeting at 

which the award is presented. The author(s) need not be a 

member of the Society of Toxicology. Submissions should 

include a one-page summary of the paper’s contribution 

to the science of toxicology and a copy of the article for 

which the nomination is being made. Any member of the 

Society may submit one title for consideration. In addition, 

the titles of no more than six papers to be considered 

are submitted by the editor of Toxicological Sciences. 

All papers submitted will be evaluated by the Board of 

Publications. This award consists of a plaque and a cash 

stipend. (This award was formerly known as the Frank R. 

Blood Award.) 

Best Paper in Toxicological Sciences 

(formerly published as Fundamental and Applied Toxicology) 


1995 ....... J. L. Larson, D. C. Wolf, B. E. Butterworth 

1995 ....... M. I. Luster, C. Portier, D. G. Pait, 

G. J. Rosenthal, D. R. Germolec, E. Corsini, 

B. L. Blaylock, P. Pollock, Y. Kouchi, W. Craig, 

K. L. White, A. E. Munson, C. E. Comment 

1996 ....... B. C. Allen, R. J. Kavlock, C. A. Kimmel, 

E. M. Faustman 

1997 ....... F. L. Fort, H. Ando, T. Suzuki, M. Yamamoto, 

T. Hamashima, S. Sato, T. Kitazaki, 

M. C. Matony, G. D. Hodgen 

1998 ....... D. D. Parrish, M. J. Schlosser, J. C. Kapeghian, 

V. M. Traina 

1999 ....... C. A. Franklin, M. J. Inskip, C. L. Baccanale, 

C. M. Edwards, W. I. Manton, E. Edwards, 

E. J. O’Flaherty 

2000 ....... H.A Boulares, C. Giardina, C.L. Navarro, 

E.A. Khairallah, S.D. Cohen 

2001 ....... Jinqiang Chen, Yunbo Li, Jackie A. Lavigne, 

Michael A. Trush, James D. Yager 

2002 ....... M. J. Bajt, J. A. Lawson, S. L. Vonderfecht, 

J. S. Gujral, H. Jaeschke 

2003 ....... S. Haddad, M. Beliveau, R. Tardif, K. Krishnan 

2004 ....... Abraham Nyska, Carolyn Moyer, Allen 

Ledbetter, David Christiani, Mette Schlasweiler, 

Daniel Costa, Russ Hauser, Urmila Kodavanti, 

2005 ....... Nicole V. Soucy, Michael A. Ihnat, Linda Hess, 

Chandrashekhar D. Kamat, Aaron Barchowsky, 

Mark J. Post, Linda R. Klei, Callie Clark, 

2006 ....... Hiroshi Sawada, Kenji Takami, Satoru Ashai 

2007 ....... Trevor Green, Robert Lee, Sara Lloyd, James 

Noakes, Timothy Pastoor, Richard Peffer, 

Mervyn Robinson, Patrick Rose, Alison 

Toghill, Felix Waechter, Edgar Weber 

2008 ....... Sarah Snykers, Tamara Vanhaecke, Peggy 

Papelue, Aernout Luttun, Yuehua Jiang, Yvan 

Vander Heyden, Catherine Verfaillie, Vera 

Rogiers 

Best Paper in Toxicology and Applied Pharmacology 


1995 ....... M. F. Denny, M. F. Ware, W. D. Atchison 

1996 ....... T. A. Slotkin, C. Lau, E. C. McCook, 

S. E. Lappi, F. J. Seidler 

1997 ....... P. R. S. Kodavanti, T. R. Ward, J. D. McKinney, 

C. L. Waller, H. A. Tilson 

1998 ....... J. S. Landin, S. D. Cohen, E. A. Khairallah 

1999 ....... S. K. Ramaiah, M G. Soni, T. J. Bucci, 

H. M. Mehendale, 

1999 ....... C. L. Zuch, D. J. O’Mara, D. A. Cory-Slechta 

2000 ....... J.E. Staples, N.C. Fiore, D.E. Frazier, Jr., 

T.A. Gasiewicz, A.E. Silverstone 

reference 




Reference 

2001 ....... Barbara J. Mounho, Brian D. Thrall 

2002 ....... G.S. Ratra, S.G. Kamita, J.E. Casida 

2003 ....... J. Doorn, M. Schall, D. Gage, T. Talley, 

C. Thompson, R. Richardson 

Frank R. Blood Award 



1975 ....... Donald J. Ecobichon, G. J. Johnstone, 

O. Hutzinger 

1976 ....... Richard D. Brown 

1977 ....... J. Dedinas, George D. DiVincenzo, C. J. Kaplan 

1978 ....... Perry J. Gehring, E. O. Madrid, 

G. R. McGowan, Philip G. Watanabe 

1979 ....... R. Fradkin, E. J. Ritter, W. J. Scott, 

James G. Wilson 

1980 ....... Jerold A. Last, Peter F. Moore, Otto G. Raabe, 

Brian K. Tarkington 

1981 ....... Yves Alarie, Martin Brady, Christine Dixon, 

Meryl Karol 

1982 ....... Melvin E. Andersen, Michael L. Gargas, 

Lawrence J. Jenkins, Jr., Robert A. Jones 

1983 ....... Henry D. Heck 

1984 ....... Erik Dybing, Sidney Nelson, Erik Soderlund, 

Christer Von Bahr 

1985 ....... Nobumasa Imura, Masae Inokawa, 

Kyoko Miura 

1986 ....... Calvin C. Wilhite, M. I. Dawson, 

K. J. Williams 

1987 ....... John Kao, Frances K. Patterson, Jerry Hall 

1988 ....... Debra L. Laskin, Sungchul Ji, Anne M. Pilaro 

1989 ....... R. G. Cuddihy, W. C. Griffith, 

Rogene F. Henderson, Joe L. Mauderly, 

Roger O. McClellan, M. D. Snipes, 

Ronald K. Wolff 

1990 ....... William P. Beierschmitt, Joseph T. Brady, 

John B. Bartolone, D. Stuart Wyand, 

Edward A. Khairallah, Steven D. Cohen 

1991 ....... Jay Babcock Silkworth, Daryl Cutler, 

LuAnn Antrim, Don Houston, 

Casimir Tumasonis, Laurence S. Kaminsky 

1992 ....... Donald A. Fox, Steve D. Rubinstein, 

Pauline Hsu 

1993 ....... Thomas Mably, Robert W. Moore, 

Robert W. Goy, Richard E. Peterson 

1994 ....... Susan J. Borghoff, William H. Lagarde 

Contributions to Public Awareness 

of the Importance of Animals in 

Toxicology Research Award 

The Contributions to Public Awareness of the Importance 

of Animals in Toxicology Research Award is presented 

annually to an individual (or organization) in recognition 

of the contributions made to the public understanding 

of the role and importance of experimental animals in 

toxicological science. This award may be for either a 

single seminal piece of work or a longer-term contribution 

to public understanding of the necessity of the use of 

animals in toxicological research both to ensure and 

enhance the quality of human and animal health and the 

environment. The award consists of a plaque and a cash 

stipend. 


2000 ....... Allegheny-Erie Chapter 

2001 ....... Massachusetts Society for Medical Research 

2002 ....... George Nethercutt 

2003 ....... Michael Derelanko 

2004 ....... North Carolina Association for Biomedical 

Research (NCABR), Americans for Medical 

Progress (AMP) 

2005 ....... Orrin G. Hatch, Foundation for Biomedical 

Research (FBR) 

2006 ....... Jayne Mackta 


Award 

The Distinguished Toxicology Scholar Award is presented 

to a member of SOT who has made substantial and seminal 

scientific contributions to our understanding of the science 

of toxicology. Nominees should be active scientists involved 

in toxicological research. The prime consideration for this 

award is scientific accomplishments. This award consists of 

a plaque and a cash stipend. (This award was presented in 

2001 as the Scientific Achievement Award.) 


2001 ....... James E. Troska 

2003 ....... Henry C. Pitot 

2004 ....... Gerald N. Wogan 

2005 ....... Daniel Nebert 

2006 ....... Sten G. Orrenius 

2007 ....... Stephen H. Safe 

2008 ....... Toshio Narahashi 

328 





Enhancement of Animal Welfare 

Award 

The Education Award is presented to an individual who is 

distinguished by the teaching and training of toxicologists 

and who has made significant contributions to education 

in the broad field of toxicology. This award consists of a 

plaque and a cash stipend. 


1975 ....... Harold C. Hodge* 

1976 ....... Ted A. Loomis 

1977 ....... Robert B. Forney* 


1980 ....... Herbert H. Cornish* 

1981 ....... Frederick Sperling* 

1982 ....... Lloyd W. Hazleton* 

1983 ....... Julius M. Coon* 

1984 ....... Frank Guthrie, Ernest Hodgson 

1985 ....... William B. Buck 

1986 ....... Robert I. Krieger 


1988 ....... John Autian 

1989 ....... Tom S. Miya 

1990 ....... Charles H. Hine 

1991 ....... Hanspeter R. Witschi 

1992 ....... Dean E. Carter 

1993 ....... Curtis D. Klaassen 

1994 ....... Robert A. Neal 

1995 ....... William Carlton 

1996 ....... Robert Snyder 

1997 ....... Albert E. Munson 

1998 ....... David J. Holbrook 

1999 ....... Jules Brodeur 

2000 ....... Gary Carlson 

2001 ....... Harihara Mehendale 

2002 ....... Joseph Borzelleca 

2003 ....... Frederick W. Oehme 

2004 ....... A. Jay Gandolfi 

2005 ....... Nobuyuki Ito 

2006 ....... Robert A. Schatz 

2007 ....... Torbjörn Malmfors 

2008 ....... Steven Cohen 

The Enhancement of Animal Welfare Award is presented 

annually to a member of the Society in recognition of 

the contribution made to the advancement of toxicological 

science through the development and application 

of methods that replace, refine, or reduce the need for 

experimental animals. This award recognizes outstanding/ 

significant contributions made by members of the Society 

of Toxicology to the sound and responsible use of animals 

in scientific research. The achievement recognized may be 

either a seminal piece of work or a long-term contribution 

to toxicological science and animal welfare. The award 

consists of a plaque and a cash stipend. 



2001 ....... Alan Goldberg 

2002 ....... Gary Williams 

2003 ....... G. Frank Gerberick, Ian Kimber 

2005 ....... Daniel Acosta 

2006 ....... William S. Stokes 

2007 ....... Thomas Hartung 

ENDOWMENT 

Investing in the Future ... 

Founders Award 

The SOT Founders Award is presented to a full or retired full 

member of the Society of Toxicology who has demonstrated 

outstanding leadership in fostering the role of toxicological 

sciences in safety decision-making through the development 

and/or application of state-of-the-art approaches that 

elucidate, with a high degree of confidence, the distinctions 

for humans between safe and unsafe levels of exposures to 

chemical and physical agents. 

Award Recipient 

2008 ....... John Doull 

reference 




Reference 

Graduate Student Travel Support 

Graduate Student Travel Support defrays expenses for 

students presenting platform talks or posters at the SOT 

Annual Meeting. To be eligible, the student must be a SOT 

member (or have submitted a membership application) who 

has not previously received SOT Graduate Student Travel 

Support. 

Merit Award 

The Merit Award is presented to a member of the Society 

of Toxicology in recognition of distinguished contributions 

to toxicology throughout an entire career in areas such as 

research, teaching, regulatory activities, consulting, and 

service to the Society. This award consists of a plaque and 

a cash stipend. The recipient delivers the Merit Awardee 

Lecture at the SOT Annual Meeting. 


1966 ....... Henry F. Smyth, Jr.* 

1967 ....... Arnold J. Lehman* 

1968 ....... R. T. Williams* 

1969 ....... Harold C. Hodge* 

1970 ....... Don D. Irish 

1971 ....... Kenneth P. DuBois 

1972 ....... O. Garth Fitzhugh* 

1973 ....... Herbert E. Stokinger* 

1974 ....... William B. Deichmann* 

1975 ....... Frederick Coulston* 

1976 ....... Verald K. Rowe* 

1977 ....... Harry W. Hays* 

1978 ....... Julius M. Coon* 

1979 ....... David W. Fassett* 

1980 ....... Bernard L. Oser 

1981 ....... John H. Weisburger 

1982 ....... Harold M. Peck 

1983 ....... Perry J. Gehring* 

1984 ....... Tom S. Miya 

1985 ....... Carrol S. Weil* 

1986 ....... Ted A. Loomis 

1987 ....... Bo Holmstedt 

1988 ....... Seymour L. Friess 

1989 ....... Wayland J. Hayes, Jr.* 


1991 ...... Toshio Narahashi 

1992 ....... W. Norman Aldridge 

1993 ....... John Doull 

1994 ....... Ernest Hodgson 

1995 ....... Robert A. Scala 


1997 ....... Mary O. Amdur* 

1998 ....... John A. Thomas 

1999 ....... Thomas Clarkson 

2000 ....... Philippe Shubik* 

2001 ....... Donald Reed 

2002 ....... Bernard Schwetz 

2003 ....... M.W. Anders 

2004 ....... Robert Goyer 

2005 ....... Roger McClellan 

2006 ....... A. Wallace Hayes 

2007 ....... James A. Swenberg 

2008 ....... Hanspeter Witschi 

Minority Undergraduate Student 

and Advisor Awards 

The Minority Undergraduate Student and Advisor 

Awards provide support for awardees to participate in the 

Undergraduate Education Program at the SOT Annual 

Meeting. This program is an introduction to the discipline 

of toxicology for undergraduate science majors and includes 

an orientation, a special poster session with scientists, and 

activities with a SOT mentor. The travel awards are for 

those from races and ethnic groups underrepresented in the 

sciences (African American, American Indian, or Hispanic 

American) and for their advisors. The advisors are eligible 

regardless of racial or ethnic background. Meeting registration 

and support for travel, lodging, and meals are provided 

for students and advisors who are not local to the meeting 

site. Students and advisors from local institutions receive 

meeting and program registration and meals. In the past, 

the program has been supported in part by NIH-MARC, 

Pfizer, Johnson & Johnson, Covance, and other supporters. 

The recipient list is available on the Web site. 

330 




Public Communications Award 

SOT/AstraZeneca IUTOX Fellowship 

The Public Communications Award is presented by the 

Society of Toxicology to recognize an individual who 

has made a major contribution to broadening the awareness 

of the general public on toxicological issues through 

any aspect of public communications. The award should 

reflect accomplishments made over a significant period of 

time. Examples of qualifying media in which the nominated 

communication may appear are as follows: books, 

brochures, continuing education courses, data bases, extension 

bulletins, magazines, newspapers (local or national), 

outreach, public presentations, public forums, radio and 

television scripts, and workshops. The award consists of a 

plaque and a cash stipend. 

Awards Recipients 

1994 ....... Michael A. Kamrin 

1995 ....... Philip Abelson* 

1996 ....... Bruce N. Ames 

1997 ....... Audrey Gotsch 

1999 ....... Ann de Peyster 

2001 ....... Anna Shvedova 

2002 ....... Sam Kacew 

2003 ....... Charlene A. McQueen 

2004 ....... Kenneth Olden 

2005 ....... Robert Kreiger 

2007 ....... Linda S. Birnbaum 

The AstraZeneca, Ltd. and SOT sponsor travel fellowship 

awards annually, which are administered by IUTOX. 

Awards are available to senior scientists from a country 

where toxicology is underrepresented to assist with travel 

to attend the Society of Toxicology Annual Meeting. 


2002 ....... Christophor Dishovsky (Bulgaria), 

Zoltan Gregus (Hungary), 

Maritza Rojas Martini (Venezuela), 

Choon-Nam Ong (Singapore), 

W. Wasowicz (Poland), 

Ping-kun Zhou (China) 

2003 ....... Jian-Hui Liang (China), 

Marjan G. Vracko (Slovenia), 

Eman A. Seif (Egypt) 

2004 ....... Cristina Bolaton (Phillipines), 

P.K. Gupta (India), 

Salmaan Inayat-Hussain (Malaysia), 

Xianping Ying (China) 

2005 ....... Diana B. Apostolova (Bulgaria), 

Marite Arija Bake (Latvia), 

Teresa I. Fortuoul (Mexico), 

Mary Gulumian (South Africa), 

He Jiliang (China), 

Khalidya Khamidulina (Russia), 

L. Orish Orisakwe (Nigeria), 

Songsak Srianujata (Thailand), 

Sinan Suzen (Turkey) 

2006 ....... Olanike Adeyemo (Nigeria), 

Deepak Argwal (India), 

Carlos Colangelo (Argentina), 

Sandra Demichelis (Argentina), 

Mumtaz Iscan (Turkey), 

Karolina Lyubomirova (Bulgaria), 

Osman Aly Osman (Egypt), 

Shuang-Qing Peng (China), 

Julia Radenkova-Saeva (Bulgaria) 

2007 ....... Hatem Ahmed (Egypt), 

Jiri Bajgar (Czech Republic), 

Ismet Çok (Turkey), 

Carlos Garcia (Peru), 

Wenceslao Kiat (Philippines), 

Calivarathan Latchoumycandane (Singapore), 

Fateheya Metwally (Egypt), 

Hilmi Orhan (Turkey), 

Nwoha Umunna (Nigeria) 

reference 




Reference 

2008 ....... Jin-Ho Chung (Korea), 

Lyndy McGaw (South Africa), 

Kemal Buyukguzel (Turkey), 

Hande Gurer-Orhan (Turkey), 

Phillip Burcham (Australia), 

Sayed Bakry (Egypt), 

Zdravko Paskalev (Bulgaria), 

Gafer Rageh Ahmed (Egypt) 

Undergraduate Toxicology 


The Undergraduate Toxicology Education Awards provide 

support for awardees to participate in the Undergraduate 

Education Program at the SOT Annual Meeting. This 

program is an introduction to the discipline of toxicology 

for undergraduate science majors and includes an orientation, 

a special poster session with scientists, and activities 

with a SOT mentor. The travel awards are for those from 

institutions that receive a limited amount of Federal 

funding in science and technology (list is available on the 

Web site). Preference in selection will be students who are 

first generation college attendees (that is, neither parent 

graduated from a four-year academic institution). 

Meeting registration and support for travel, lodging, and 

meals are provided for students who are not local to the 

meeting site. Students from local institutions receive registration, 

meeting materials, and an expense stipend. The 

recipient list is available on the Web site. 

SOT Special Interest Group Awards 

SOT Special Interest Groups provide awards to recognize 

outstanding students, postdoctoral fellows, or scientists 

throughout their career. Application requirements and deadlines 

vary. For more details refer to the Award descriptions 

on the SOT Web site at www.toxicology.org, under Special 

Interest Groups or the Awards and Fellowships section. 

SOT Specialty Section Student 

Awards 

Most SOT Specialty Sections provide awards to recognize 


throughout their career at the SOT Annual Meeting. 

Application requirements and deadlines vary. For more 

details refer to the Award descriptions on the SOT Web site 

at www.toxicology.org, under Specialty Sections or the 

Awards and Fellowships section. 

SOT Regional Chapter Awards 

Most SOT Regional Chapters provide awards to recognize 


throughout their career. Application requirements and deadlines 

vary. For more details refer to the Award descriptions 

on the SOT Web site at www.toxicology.org, under 

Regional Chapters or the Awards and Fellowships section. 

332 



Sponsored Award Descriptions 

AstraZeneca Traveling 

Lectureship Awards 

The AstraZeneca Traveling Lectureship Awards are 

presented through the Society of Toxicology to recognize 

excellence in research and service in toxicology. 

AstraZeneca, Ltd., provides one or two awards annually to 

promote greater collaboration between European and North 

American toxicologists and to enable North American 

toxicologists to undertake a three-four week lecture tour of 

Europe. The awards are intended to familiarize recipients 

with research and regulatory issues in Europe as well as 

bring a North American perspective to these issues. 

Candidates for these awards should be established, midcareer 

North American scientists who are members of the 

Society and who demonstrate the ability to develop collaborative 

relationships with European colleagues. The awards 

are given each year in the amount of $6,000 each. 


1990 ....... Robert I. Krieger, Joseph R. Landolph 

1991 ....... Sam Kacew 

1992 ....... Charles V. Smith, Jerold A. Last 

1993 ....... Terrence James Monks, Harihara H. Mehendale 

1995 ....... David L. Eaton, Hanspeter R. Witschi 

1996 ....... Rick G. Schnellmann, James P. Kehrer 

1997 ....... Lucio G. Costa, Durisala Desaiah 

1998 ....... Syed F. Ali, Curtis J. Omiecinski 

1999 ....... Alvaro Pugo 

2000 ....... Kenneth Ramos, Garold Yost 

2001 ....... Ronald Hines, Richard Seegal 

2003 ....... William D. Atchison 

2004 ....... Charlene A. McQueen 

2005 ....... Kevin M. Crofton 

2006 ....... Robert A. Roth 

2007 ....... Michael S. Denison 

2008 ....... José E. Manautou 

Colgate-Palmolive Grants for Alternative 

Research 

The Colgate-Palmolive Grants for Alternative Research will 

identify and support efforts that promote, develop, refine, or 

validate scientifically acceptable animal alternative methods 

to facilitate the safety assessment of new chemicals and 

formulations. Scientists at any stage of career progression 

may submit a proposal. 

High priority will be given to projects that use in vitro or 

non-animal models, reproductive and developmental toxicology, 

neurotoxicology, systemic toxicology, sensitization, 

and acute toxicity. 

The maximum award is $40,000. Awards are made as 

a single lump payment. An expert panel from the SOT 

In Vitro and Alternative Methods Specialty Section will 

recommend a prioritized list of applicants for funding, with 

the final awards designated by the SOT Awards Committee. 

Awardees can apply again for funding. 


2006 ....... Rola Barhoumi, Abby Benninghoff, Jodie Flaws, 

Courtney Sulentic, Xiaouzhong Yu 

2007 ....... Rita L. Caruso, Daniel R. Cerven, 

Anne R. Greenlee, Glenn M. Walker 

2008 ....... Daniel R. Cerven, Duncan C. Ferguson, 

Shashi K. Ramaiah 

reference 



Sponsored Award Descriptions (Continued) 

Reference 

Colgate-Palmolive Postdoctoral Fellowship 

Award in In Vitro Toxicology 

The Colgate-Palmolive Company sponsors the Colgate- 

Palmolive Postdoctoral Fellowship Award in In Vitro 

Toxicology through the Society of Toxicology to advance 

the development of alternatives to animal testing in toxicological 

research. The award is given in alternate years and 

includes stipend and research-related costs (up to $38,500) 

for one year. The award may be extended for an additional 

year upon agreement between Colgate-Palmolive and the 

postdoctoral fellow. The award is available to postdoctoral 

trainees employed by academic institutions, federal/national 

laboratories, or research institutes worldwide. Preference 

will be given to applicants in their first year of postdoctoral 

study. Applications are due in even calendar years and the 

fellowship is awarded for the following year. The next application 

deadline: October 9, 2008. 


1988 ....... Ernest Bloom 

1989 ....... Gin Hsieh 

1990 ....... Dennis E. Chapman 

1991 ....... Anne Walsh 

1992 ....... Qin Chen 

1993 ....... Erika Cretton 

1994 ....... William Chan 

1995 ....... Bob Van de Water 

1997 ....... Alan Parrish 

1999 ....... Russell Thomas 

2001 ....... Kevin Kerzee, Christopher Reilly 

2002 ....... Kevin Kerzee 

2003 ....... Kimberly Miller 

2004 ....... Kimberly Miller 

2005 ....... Francis Tukov 

2007 ....... Aaron Rowland 

Colgate-Palmolive Awards for Student 

Research Training in Alternative Methods 

The purpose of the Colgate-Palmolive Awards for Student 

Research Training in Alternative Methods is to enhance 

student research training using in vitro methods or alternative 

techniques to reduce, replace or refine use of animals in 

toxicological research. The Awards Committee will present 

the awards to graduate students. Up to five awards, at $3,500 

each, are available. Deadlines for applications are February 

15, June 15, and October 9. 

Graduate Students: The award is for expenses for training 

consistent with the goal of this award program. The training 

may include, but is not limited to, use of in vitro and ex vivo 

procedures, non-mammalian animal models, computer 

modeling, and structure-activity relationships. Graduate 

students may propose to develop expertise in relevant 

methodologies at 1) a laboratory away from their home 

institution; 2) a laboratory at their home institution that 

would not be available to them otherwise; or 3) approved 

workshops, symposia, or continuing education programs 

where hands-on training will be received. The training 

should help toxicology graduate students enhance their 

thesis or dissertation research. The overall goal is to support 

the replacement, reduction, or refinement of currently used 

animal models in toxicology research and testing. Awards 

of up to $3,500 per student will defray travel, per diem, and 

training expenses. 


2000 ....... Jason Gross 

2001 ....... Jason Biggs, Victoria Richards 

2002 ....... Kartik Shankar, Chad M. Vezina, Ryan L. 

Williams 

2003 ....... Sachin Devi, Midhun Korrapati, Pallavi Limaye 

2004 ....... Jaya Chilakapati 

2005 ....... Vishaka Bhave, Ankur Dnyanmote, Johnathan 

Maher 

2006 ....... Mary Hassani, Prajakta Palkar 

2007 ....... Renee Gardner, Prajakta Palkar, Rohit Singhal, 

René Vinas 

2008 ....... Kimberly A. Hays, Haitian Lu 

334 




Colgate-Palmolive Traveling Lectureship in 

Alternative Methods in Toxicology Award 

The Colgate-Palmolive Company sponsors the Colgate- 

Palmolive Traveling Lectureship in Alternative Methods 

in Toxicology Award annually through the Society of 

Toxicology. This award covers expenses for an individual 

scholar to visit institution(s) for the dissemination of knowledge 

and for stimulating research that takes advantage of 

modern in vitro toxicology approaches. The overall goal 

of this program is to make scientists aware of the benefits 

of modern in vitro toxicology approaches and to stimulate 

research for the replacement, reduction, or refinement of 

currently used animal models. 

Lecturing scholars should be established, mid-career 

through late-career scientists who are members of SOT and 

who are developing collaborative relationships with scientists 

at other institutions. 

Requests for funds can be made by the individual scholar 

or by a host from an academic institution, SOT Regional 

Chapter, SOT Special Interest Group, SOT Specialty 

Section, or another toxicology organization. Up to $15,000 is 

available for all the awards. The Awards Committee reviews 

the applications, which must be accompanied by a statement 

detailing the applicants expertise in alternative methods, 

a brief overview of the techniques to be discussed in the 

lecture, the budget request, and a letter from the host indicating 

interest in serving as host and the potential benefits to 

the institution. 

1998 ....... San Diego State University 

Visiting Professor: Leigh Ann Burns-Naas 

1999 ....... San Diego State University 

Visiting Professor: Robert Chapin 

2000 ....... Yale University, School of Medicine 

Visiting Professor: Narendre Singh 

2001 ....... Medical College of Wisconsin 

Visiting Professor: Garold Yost 

2003 ....... Washington State University 

Visiting Professor: Marc W. Fariss 

2004 ....... Snorri S. Thorgeirsson 

Institution to be Visited: University of 

Louisiana at Monroe 

2008 ....... George Michalopoulos 

Institution to be Visited: University of 

Louisiana at Monroe 

reference 


1996 ....... University of Mississippi Medical Center 

Visiting Professor: Tetsuo Satoh 

1996 ....... University of Illinois at Urbana 

Visiting Professor: Julio Davila 

1996 ....... Mississippi State University 

Visiting Professor: Michael Holsapple 

1996 ....... Washington State University 

Visiting Professor: Daniel Acosta 

1997 ....... Indiana University School of Medicine 

Visiting Professor: A. Jay Gandolfi 

1997 ....... University of Arizona Health Science Center 

Visiting Professor: Kevin E. Driscoll 

1997 ....... University of New Mexico Health 

Sciences Center 

Visiting Professor: Sam Kacew 

1997 ....... University of Illinois 

Visiting Professor: Michael Denison 

1998 ....... University of Washington 

Visiting Professor: Bruce Fowler 




Reference 

Graduate Student Fellowship Award — 

Novartis Award 

The Graduate Student Fellowship—Novartis Award is available 

for student members of the SOT engaged in full-time 

graduate study towards a Ph.D. degree in toxicology. The 

major professor must be a SOT member. The evaluation is 

based primarily on originality of the dissertation research, 

research productivity, relevance to toxicology, scholastic 

achievement, and letters of recommendation. Finalists 

are interviewed at the Annual Meeting and receive travel 

support. 


1989 ....... Timothy Zacharewski 

1990 ....... Mary Suzanne Stefaniak 

1991 ....... Donald Bjerke 

1992 ....... Lhanoo Gunawardhana 

1993 ....... Christopher Martenson 

1994 ....... Nyla Harper 

1995 ....... Heather E. Kleiner 

1996 ....... Russell Thomas 

1997 ....... Melva Rios-Blancos 

1998 ....... Kent Carlson 

1999 ....... Mark Hickman 

2000 ....... Jeffrey Moran 

2001 ....... Vishal Vaidya 

2002 ....... Kartik Shankar 

2003 ....... Sachin Devi 

2004 ....... James Luyendyk 

2005 ....... Andrea W. Wong 

2006 ....... Sheung P. Ng 

2007 ....... Atrayee Banerjee 

Pfizer Undergraduate Student Travel Award 

Pfizer Undergraduate Student Travel Awards are presented 

through the Society of Toxicology to foster an interest in 

graduate studies in the field of toxicology by bringing promising 

undergraduate students to the SOT Annual Meetings. 

Pfizer, Inc. will provide up to five awards per year to undergraduate 

students presenting research at the Annual Meeting. 

Awardees will be selected by the Education Committee 

based on the quality of the submitted abstract and the 

advisor’s supporting recommendation. Those selected will 

receive travel assistance for the Meeting, a plaque presented 

at the annual Awards Ceremony, and recognition at a special 

Pfizer function. Awardees will be matched with a graduate 

student and a Pfizer scientist to mentor them during the 

Annual Meeting, and will have the opportunity to attend the 

Society of Toxicology Undergraduate Education Program 

on the Sunday of the SOT Annual Meeting. 

Awards Recipients 

2006 ...... Shawntay Chaney, Theresa M. Eagle, 

Natalie Malek, Adeliada Segarra, Ryan Vaughan 

2007 ....... Kay Gonsalves, Lisa Koselke, Basharat Sanni, 

Sonia Talathi, Anna Zimmerman 

2008 ....... Amy DeMicco, Tharu Fernando, Yamel 

Perdomo, Amy Yi Hsan Saik, and Kelly 

Sullivan 

(Recipients of Graduate Fellowship Awards no longer 

offered may be found on the SOT Web site at 

www.toxicology.org.) 

336 



Toxicology Specialists 

The Society of Toxicology has established a Toxicology Specialists Program to assist journalists and members of 

the public in identifying or locating expert toxicologists who can provide factual information on issues of public 

concern. These Toxicology Specialists provide information based on their own credentials and do not represent the 

views of the Society of Toxicology. For further information, please contact SOT Headquarters at (703) 438-3115 or 

e-mail: sothq@toxicology.org. 

Specialties: 

Carcinogenesis 

Jane A. S. Allen 

James A. Bond 

Richard J. Bull 

Yvonne P. Dragan 

David L. Eaton 

James E. Klaunig 

Michael McClain 

Charlene A. McQueen 

Henry C. Pitot 

James A. Popp 

Jacqueline H. Smith 

Cheryl L. Walker 

Comparative and 

Veterinary 

Roger O. McClellan 

Epidemiology 

Ellen K. Silbergeld 

General Toxicology 


Linda S. Birnbaum 




Sidney Green 


Robert I. Krieger 

Michael McClain 

Kendall B. Wallace 

Genetic Toxicology 


Sidney Green 


Charlene A. McQueen 

(environmental) 


Immunotoxicology 


Jack H. Dean 

A. Jay Gandolfi 

(hypersensitivity) 

Norbert E. Kaminski 

Nancy I. Kerkvliet 

Kathleen E. Rodgers 

Mary Jane Selgrade 

In Vitro 

Daniel Acosta, Jr. 




Rick G. Schnellmann 


Inhalation/Pulmonary 

Barbara D. Beck 

James A. Bond 

Gary A. Boorman 

(pulmonary pathology) 


John B. Morris 

Robert F. Phalen 

Gary S. Yost 

Kidney Toxicity 

William O. Berndt 

Steven D. Cohen 

Mary E. Davis 

Ernest C. Foulkes 


Robin S. Goldstein 

Lois D. Lehman- 

McKeeman 


Liver Toxicity 



Mary E. Davis 



Robin S. Goldstein 


Jose E. Manautou 

Hari M. Mehendale 

James A. Popp 

Mechanisms 


Daniel Acosta, Jr. 



Gary P. Carlson 


Ann de Peyster 


Elaine M. Faustman 

Jay Gandolfi 



McKeeman 

Jose E. Manautou 

Hari M. Mehendale 

James A. Popp 


Stephen H. Safe 




Gary S. Yost 

Metabolism/ 

Toxicokinetics 




McKeeman 

Raymond F. Novak 

Molecular 


William F. Greenlee 


Raymond Novak 

(cell signaling, 

gene expression) 

Henry C. Pitot 


Robert Rubin 


Gary S. Yost 

Neurotoxicity 

Marion F. Ehrich 


Joel L. Mattsson 



Hugh A. Tilson 

Regulatory Toxicology/ 

Regulatory Affairs/ 

Safety Evaluation 

Daniel Acosta, Jr. (drugs/ 

addictive agents) 


Gregory Allgood 


Jack H. Dean (drugs) 

Michael L. Dourson 

Robin S. Goldstein (drugs) 

Robert A. Kuna 

James C. Lamb (pesticides 

and industrial chemicals) 

Michael McClain (drugs) 


(drugs) 

Robert Rubin 

reference 



Toxicology Specialists (Continued) 

Reference 

Reproductive/ 

Developmental 

Robert E. Chapin 

George P. Daston 



Carole A. Kimmel 

James C. Lamb 


(developmental 

neurotoxicology) 

Risk Assessmen 


Michael Bolger 

James A. Bond 


John P. Christopher 

Rory B. Conolly 


Jay I. Goodman 

Carole A. Kimmel 


James C. Lamb 


Robert Rubin 


Issues: 

Air Pollution 

James A. Bond 


(air quality standardsenvironmental 

and 

occupational) 

John B. Morris 



Animal Studies/ 

Animals in Research 


Stephen M. DiZio 


Biotechnology/ 

Biopharmaceutical 



Chemical-Chemical 

Interactions 



Chlorine-Based 

Compounds 



A. Jay Gandolfi (also 

fluorine compounds) 


H. B. Matthews 

Hugh A. Tilson (PCBs) 

Dioxins/PCBs 











Endocrine Disrupters 



James S. Bus 

Robert E. Chapin 


Michael A. Gallo 


James C. Lamb 


Food Additives/ 

Food Safety/ 

Food Toxins 



David L. Eaton (especially 

aflatoxins) 


Robert Rubin 

Free Radicals/Oxidative 

Stress/Antioxidants 


James P. Kehrer 



Industrial Chemical 


James S. Bus 

Michael P. Holsapple 



Medical Devices 




Metals 




Ernest C. Foulkes 


Hugh A. Tilson (lead, 

methyl mercury) 

Natural Toxins 


Joel L. Mattsson 

Pesticides 

James S. Bus 

Marion F. Ehrich 


James C. Lamb 




Radiation 

Gary A. Boorman (EMF 

exposure) 


Solvents 

Mary E. Davis 


Validation of Alternative 

Methods 

Sidney Green 

Water Pollution 


Regional 

Distribution: 

Allegheny-Erie 

Mary E. Davis (WV) 

Central States 

William O. Berndt (NE) 

Gulf Coast (Texas) 





Michigan 

James S. Bus 


Jay I. Goodman 


Joel Mattsson 

Raymond F. Novak 

338 



Toxicology Specialists (Continued) 

Mid-Atlantic 

Michael A. Gallo (NJ) 

Robin S. Goldstein (NJ) 

Robert A. Kuna (NJ) 

Michael McClain (NJ) 

James A. Popp (PA) 

Jacqueline H. Smith (MD) 

Midwest 

Yvonne Dragan (DE) 

James E. Klaunig (IN) 

Henry C. Pitot (WI) 

Kendall B. Wallace (MN) 

Northeast 

Barbara D. Beck (MA) 

Robert E. Chapin (CT) 

Steven D. Cohen (MA) 

Lois D. Lehman-McKeeman 

(NJ) 

Jose E. Manautou (CT) 

John B. Morris (CT) 

James A. Popp (CT) 

Northern California 

John P. Christopher 

Stephen M. DiZio 

reference 

Mountain West 

Scott W. Burchiel (NM) 

Jack H. Dean (AZ) 

A. Jay Gandolfi (AZ) 

Roger O. McClellan (NM) 

Charlene A. McQueen (AZ) 

Gary S. Yost (UT) 

National Capital 

Michael Bolger (DC) 

Marion F. Ehrich (VA) 

Sidney Green (DC) 

Michael P. Holsapple (DC) 

Carole A. Kimmel (MD) 

James C. Lamb (DC) 

Robert Rubin (MD) 

Ellen K. Silbergeld (MD) 

North Carolina 


James A. Bond 





Roger McClellan 



Ohio Valley 

Daniel Acosta, Jr. (OH) 

George P. Daston (OH) 

Michael L. Dourson (OH) 

Ernest C. Foulkes (OH) 

Pacific Northwest 

Richard J. Bull (WA) 

David L. Eaton (WA) 

Elaine M. Faustman (WA) 

Nancy I. Kerkvliet (OR) 

South Central 

Janice E. Chambers (MS) 

Yvonne P. Dragan (AR) 

Hari M. Mehendale (LA) 

Southeastern 

Bruce A. Fowler (GA) 

Rick G. Schnellmann (SC) 

Southern California 







SOT Affiliates 

Abbott Laboratories 

Abbott Park, Illinois 

Chevron Energy Technology Company 

Richmond, California 

Honeywell International, Inc. 

Morristown, New Jersey 

Reference 

The AEgis Technologies Group 

Orlando, Florida 

Agilent Technologies, Inc. 

Wilmington, Delaware 

Alcon Research LTD 

Fort Worth, Texas 

American Chemistry Council 

Arlington, Virginia 

American Petroleum Institute 

Washington, D.C. 

Ani Lytics, Inc. 

Gaithersburg, Maryland 

AstraZeneca R&D 

Södertälje, Sweden 

B.I.K. Industries 

Mumbai, India 

BASi Evansville 

Mount Vernon, Indiana 

Bayer 

Stilwell, Kansas 

Bayer HealthCare Pharmaceuticals 

Montville, New Jersey 

Biogen Idec, Inc. 

Cambridge, Massachusetts 

Boehringer Ingelheim 

Pharmaceuticals, Inc. 

Ridgefield, Connecticut 

Bristol-Myers Squibb Company 

Princeton, New Jersey 

CANTOX 

Mississauga, Ontario, Canada 

Charles River Laboratories 

Wilmington, Massachusetts 

Chevron Phillips Chemical Company, LP 

The Woodlands, Texas 

Chlorine Chemistry Division 

Arlington, Virginia 

Colgate-Palmolive Company 

Piscataway, New Jersey 

Covance Laboratories, Inc. 

Madison, Wisconsin 

Daiichi Sankyo Company Limited 

Shizuoka, Japan 

The Dial Corporation 

A Henkel Company 

Scottsdale, Arizona 

The Dow Chemical Company, 

Midland, Michigan 

Dow Corning Corporation 

Midland, Michigan 

The DuPont Company 

Newark, Delaware 

Eastman Chemical Company 

Kingsport, Tennessee 

ExxonMobil Biomedical Sciences, Inc. 

Annandale, New Jersey 

Genentech, Inc. 

South San Francisco, California 

GlaxoSmithKline 

King of Prussia, Pennsylvania 

The Hamner Institutes for Health 

Sciences 

Research Triangle Park, North Carolina 

Harlan/RCC 

Indianapolis, Indiana 

Hoffmann-La Roche, Inc. 

Nutley, New Jersey 

J&J Pharma R&D Companies 

(Centocor, J&JPRD, Tibotec) 

Raritan, New Jersey 

Lilly Research Laboratories 

Indianapolis, Indiana 

Merck & Co., Inc. 

West Point, Pennsylvania 

Millennium Pharmaceuticals, Inc. 

Cambridge, Massachusetts 

MPI Research 

Mattawan, Michigan 

Novartis Pharmaceuticals Corporation 

East Hanover, New Jersey 

Pfizer, Inc. 

Groton, Connecticut 

Procter & Gamble Company 

Cincinnati, Ohio 

RTC Research Toxicology Centre 

S.P.A. 

Pomezia, Italy 

sanofi-aventis 

Bridgewater, New Jersey 

Schering-Plough Research Institute 

Kenilworth, New Jersey 

Sequani, Ltd. 

Ledbury, Herefordshire, United Kingdom 

Southern Research Institute 

Birmingham, Alabama 

WIL Research Laboratories, LLC. 

Ashland, Ohio 

Wyeth Research 

Collegeville, Pennsylvania 

340 



Headquarters Staff 

Society of Toxicology Headquarters 

1821 Michael Faraday Drive, Suite 300, Reston, Virgina 20190 

Tel: (703) 438-3115 • Fax: (703) 438-3113 • E-mail: sothq@toxicology.org; • Web site: www.toxicology.org 

Staff Contact Extension E-mail Activity 

Shawn Douglas Lamb 1444 shawnl@toxicology.org Executive Director 

Clarissa Russell Wilson 1455 clarissa@toxicology.org Deputy Executive Director 

Awards 

Endowment 

Rosibel Alvarenga 1432 rosibel@toxicology.org Member Services 

Regional Chapters, Specialty Sections 

Special Interest Groups 

Allison Branco 1437 allison@toxicology.org Member Services 



Donna Breskin 1440 donna@toxicology.org Administration 

Chris Cerniglia 1445 chris@toxicology.org Publications/World Wide Web 

Sue Curran 1445 suec@toxicology.org Publications/World Wide Web 

Jim Dailey 1428 jimd@toxicology.org Registration 

Betty Eidemiller 1430 bettye@toxicology.org Animals in Research 

Awards/Student Progams 

Education, Student, and Postdoctoral Programs 

Veronica Fisher 1450 vfisher@toxicology.org Financials 

Krystle Gulley 1436 krystle@toxicology.org Administration 

Ed Jennings 1453 ejennings@aim-hq.com Administration 

Liz Kasabian 1454 liz@toxicology.org Exhibits 

Colleen Kelley-Vaquerano 1434 colleen@toxicology.org Publications/World Wide Web 

Phillip Larson 1438 phil@toxicology.org Awards/Education Coordinator 

Marcia Lawson 1446 marcia@toxicology.org Career Resource and Development 

Member Services 

Regulatory Affairs and Legislative Assistance 



Tonia Masson 1433 tonia@toxicology.org Administration 

Mia McDaniel 1423 sothq@toxicology.org Administration 

Tim McKinney 1439 tim@toxicology.org Administration 

Catherine Michaels 1443 catherine@toxicology.org Meetings/Administration 

Tierre Miller 1451 tierre@toxicology.org Administration 

Katie Moore 1403 katie@toxicology.org Administration/Meetings 

Debbie O’Keefe 1441 debbie@toxicology.org Publications/World Wide Web 

Sue Pitsch 1442 sue@toxicology.org Administration 

Heidi Prange 1424 heidi@toxicology.org Meetings 

Kristy Rand 1429 kristy@toxicology.org Career Resource and Development 

Member Services 

Becca Rhame 1447 becca@toxicology.org Administration 

Nichelle Sankey 1431 nichelle@toxicology.org Continuing Education/Program Committee 

Devin Yates 1434 devin@toxicology.org Publications/World Wide Web 

reference 


Creating a Safer and Healthier 

World by Advancing the Science of 


As an SOT member you can . . . 

Stay connected at www.toxicology.org 

Access member restricted information and services on 

the SOT Web site. Keep informed of breaking news in 

toxicology, updated meeting and program information, 

funding opportunities, and other resources. 

Receive SOT Publications 

Members* receive the electronic publications The 

Toxicologist on CD-ROM, Communiqué newsletter, 

and Toxicological Sciences. Members are eligible for 

the reduced-rate subscriptions to the print version of 

Toxicological Sciences and other toxicology journals. 

Members also receive other printed publications of the 

Society including the Annual Meeting Program and the 

Membership Directory. 

*Graduate Student, Postdoctoral, and Retired Members 

subscribe to Toxicological Sciences (web or print) at reduced 

rates. 

Utilize the On-Line Directory 

Members have said this is one of their most-used 

resources. You can search by organization name, city, 

state, country, Specialty Section, Special Interest Group, 

or Regional Chapter, as well as member name. 

Join a Specialty Section 

Choose from 21 SOT Specialty Sections, which provide 

forums for networking and exchanging information with 

peers who share an interest in your area of toxicology. 

The annual receptions and meetings of the Specialty 

Sections at the Annual Meeting are ideal opportunities to 

network with colleagues. Dues for each Specialty Section 

membership are $15. Student and postdoctoral members 

receive the first Specialty Section at no cost. 

Choose a Special Interest Group 

SOT is committed to increasing the diversity and 

inclusiveness of the Society. Join one of six established 

groups that provide forums for networking, education, 

and recognition of achievement. Dues for each Special 

Interest Group are $15. Student and postdoctoral 

members receive the first Special Interest Group at no 

cost. 

Special Offer to Non-Member SOT 2008 Annual 

Meeting Attendees: 

• Apply for SOT membership between January 2, 2008, 

and the May 1, 2008 deadline, and if accepted, 

SOT will waive your 2008 dues. 

• Applications must be complete and sponsor letters 

received by the deadline. 

Participate in Your Regional SOT Chapter 

Join one of 18 Regional Chapters that foster scientific 

exchange at a local level, organize regular meetings 

throughout the year, and sponsor awards. Most 

chapters have a Web site, which is accessible at 

www.toxicology.org. 

Utilize Career Resource and Development 

Services 

Take advantage of SOT’s on-line Job Bank service from 

the SOT Web site at www.toxicology.org. This Job 

Bank provides a year-round mechanism for linking job 

seekers with employment positions in toxicology and 

related biological sciences. The SOT Annual Meeting Job 

Bank Center also can help facilitate interviews at the 

meeting. 

Nominate for Awards 

Consider nominating a fellow toxicologist or student for 

an award. SOT has simplified the process of nominating 

candidates for SOT Sponsored Awards through the 

Awards Nomination On-Line System. 

Demonstrate your Leadership Skills—Volunteer 

Opportunities range from serving on an SOT Committee 

to helping with programs and special events. 

Nominations for SOT Councilors and Officers come 

from those who have served on committees or as 

Specialty Section, Special Interest Group, or Regional 

Chapter officers. 

Find Products and Services Easily 

Visit www.toxexpo.com, the year-round resource for 

all your scientific product and service needs. 

Receive Reduced Registration Costs for SOT 

Annual Meetings 

The Annual Meeting fosters collegial exchange of the 

latest scientific findings among the more than 6,000 

participants. 

Membership Fees: 

Full Membership______________________________ $135 

Associate Membership________________________ $135 

Postdoctoral Membership______________________ $35 

Student Membership___________________________ $20 

Retired Membership____________________________ $0 

Easy on-line membership application takes 

approximately 15 minutes to complete. 

Visit www.toxicology.org 

(select Membership) for 

full details. 

Membership 

For complete information about membership in the Society of 

Toxicology, visit the SOT Web site at www.toxicology.org, 

and select Member Information. 


March 16–20, 2008 

342 



Notes 


343


Notes 

344 



Notes 


345


Notes 

346 



Notes 


347


Notes 

348 



Notes 


349


Notes 

350 



Notes 


351


Society of Toxicology Sponsorship 

Reference 

Sponsorship opportunities are available for the Annual Meeting. Your 

sponsorship serves as visible evidence of your organization’s commitment to the science of 

toxicology. In addition, your sponsorship provides an opportunity for you to increase overall 

awareness of your company to SOT members and 6,000 Annual Meeting attendees. As a 

sponsor, your company will be featured in post-meeting newsletters, the ToxExpo TM Directory, 

pre-meeting publications, on-site meeting registration materials, and the SOT Web site. In 

addition, acknowledgement signs will group sponsors by levels of giving and will be displayed 

at many of the SOT functions during the Annual Meeting. 

Your sponsorship will help offset the cost of the following functions: Undergraduate Program, 

Student/Postdoctoral Fellow Mixer, Continuing Education Program Refreshments, and the 

Welcoming Reception. If you are interested in SOT Sponsorship, contact Liz Kasabian at SOT 

Headquarters: (703) 438–3115 or E-mail: sothq@toxicology.org. 

There are five levels 

of sponsorship 

available: 

Diamond 

(over $10,000) 

Platinum 

($5,000–$9,999) 

Gold 

($2,500–$4,999) 

Silver 

($1,000–$2,499) 

Contributor 

(under $999) 

Deadline for Proposals for SOT 2009 

Annual Meeting Sessions: April 30, 2008 

WHY SUBMIT A PROPOSAL? 

1. To present new developments in toxicology. 

2. To provide attendees an opportunity to learn about 

state-of-the-art technology and how it applies to 

toxicological research. 

3. To provide attendees an opportunity to learn about the 

emerging fields and how they apply to toxicology. 

2009 Thematic Approach 

The Program Committee will carry forward the 

thematic approach for the 2009 Annual Meeting. 

All proposal submissions will be reviewed for their 

relevance under the following themes—Biomarkers, 

Epigenetics, Inflammation and Disease, and 

Neurodegenerative Disease. Due to the timeliness of the 

Nanotechnology theme, it will again be highlighted for 

the 2009 meeting. Please refer to the Scientific Program 

Overview on the fold-out cover for a list of 2008 

sessions highlighted under the thematic approach. 

Session Types 

Continuing Education—Emphasis on quality 

presentations of generally accepted, state-of-the-art 

knowledge in toxicology 

Note: CE Courses will be held on Sunday. 

Symposia—“Cutting-edge” science; new areas, 

concepts, or data 

Workshops—State-of-the-art knowledge in toxicology 

Roundtables—Controversial subjects 

Historical Highlights—Review of a historical 

body of science that has impacted toxicology 

Informational Sessions—Scientific planning or 

membership development 

You can now submit your proposal on-line at www.toxicology.org 

352 


Annual Meeting Sponsors 

(As 

of January 10, 2008) 

Diamond: (over $10,000) 

AstraZeneca Pharmaceuticals 

Huntingdon Life Sciences 

Boehringer Ingelheim 

Pharmaceuticals, Inc. 

J&J Pharma R&D Companies 

(Centocor, J&JPRD, Tibotec) 

Bridge 

Merck Research Laboratories 

Bristol-Myers Squibb Company 

MPI Research 

Charles River Laboratories 

Colgate-Palmolive Company 

Covance 

GlaxoSmithKline 

Hoffmann-La Roche, Inc. 

National Toxicology Program 

(NTP) 

NIH-MARC 

Novartis 

Pfizer Global Research & 

Development 

Southern Research 

47 th Annual Meeting 

& ToxExpo 

Society of Toxicology 

1821 Michael Faraday Drive, Suite 300 • Reston, VA 20190 

T: (703) 438-3115 • F: (703) 438-3113 • E-mail: sothq@toxicology.org 

www.toxicology.org 

Cert no. XXX-XXX-XXXX 

We are proud to print this publication entirely on Forest Stewardship Council certified paper. 

FSC certification ensures that the paper in this publication contains fiber from well-managed 

and responsibly harvested forests that meet strict environmental and socioeconomic standards. 

SOT saved the following resources: 33.6 trees preserved for the future • 23,800,000 BTUs energy not consumed • 3,109 lbs net greenhouse gases prevented • 

• 14,272 gallons wastewater flow saved • 97.02 lbs waterborne waste not created • 1,579 lbs solid waste not generated

Annual Meeting Sponsors 

(as 

of January 10, 2008) 

Platinum: ($5,000–$9,999) 

Allergan, Inc. 

Ani Lytics, Inc. 

Burroughs Wellcome Fund 

Eli Lilly and Company 

Genentech, Inc. 

Harlan/RCC/Safepharm 

Millennium Pharmaceuticals, Inc. 

Schering-Plough Research Institute 

ToxServices, LLC 

Veritox, Inc. 

Wyeth Research 

Gold: ($2,500–$4,999) 

BioReliance ® 

CANTOX HEALTH SCIENCES INTERNATIONAL 

Daiichi Sankyo Co., Ltd. 

Eastman Charitable Foundation 

LAB Research, Inc. 

Meso Scale Discovery 

Novartis Vaccines and Diagnostics 

WEINBERG GROUP, THE 

WIL Research Laboratories, LLC 

Silver: ($1,000–$2,499) 

Abbott Laboratories 

BASi (Bioanalytical 

Systems, Inc.) 

Brock Scientific Consulting, 

LLC 

Calvert Laboratories, Inc. 

Chevron Corporation 

Data Science 

International (DSI) 

DuPont Haskell Laboratories 

Environmental Mutagen 

Society 

EPL, Inc. (Experimental 

Pathology Laboratories) 

Exxon Mobil Corporation 

Gradient Corporation 

Hamner Institutes 

for Health Sciences, The 

Pharma Algorithms 

Research Institute for 

Fragrance Materials 

SafeBridge Consultants, Inc. 

Safety Pharmacology Society 

Sapphire Group, Inc., The 

Society of Toxicologic 

Pathology 

Teratology Society, The 

Toxicology Excellence for Risk 

Assessment 

Contributor: (under $999) 

Systems Pathology Company, LLC

SOT Resource Pavilion 

One-Stop Resources—SOT Information 

in One Centralized Location 

Visit the special SOT Exhibit in the Skybridge 

between the ToxExpo Exhibit Halls. 

Members and non-members will find displays staffed 

by SOT members, including: 

• Animals in Research 

• Endowment Fund 

• K–12 and Public Outreach Materials 

• Membership 

• Regulatory Affairs and Legislative Assistance 

Connection to important resources 

and people in toxicology 

48 th Annual 

Meeting and 

ToxExpo 

2009 

Baltimore, 

Maryland 

March 15–19, 2009 

Baltimore Convention Center 

Photos courtesy of Baltimore Area Convention and Visitors Association

Annual Meeting Program - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?